sentence	label
In defects of BC6ENTG , BC6OTHER is transformed to BC6OTHER , resulting in high levels of BC6ENTC in the body.	False
Once formed, the molecule can be converted to BC6ENTC by BC6ENTG ( BC6OTHER ).	CPR:9
Once formed, the molecule can be converted to BC6ENTC by BC6OTHER - BC6OTHER aminotransferase ( BC6ENTG ).	CPR:9
Once formed, the molecule can be converted to BC6OTHER by BC6ENTC - BC6OTHER aminotransferase ( BC6ENTG ).	False
Once formed, the molecule can be converted to BC6OTHER by BC6OTHER - BC6ENTC aminotransferase ( BC6ENTG ).	False
In defects of BC6ENTG , BC6ENTC is transformed to BC6OTHER , resulting in high levels of BC6OTHER in the body.	False
BC6ENTC kinase inhibitors are BC6OTHER - derived, low molecular weight synthetic molecules that can block the intracellular BC6ENTG of several receptors, including BC6OTHER , BC6OTHER , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling.	False
BC6ENTC kinase inhibitors are BC6OTHER - derived, low molecular weight synthetic molecules that can block the intracellular BC6OTHER of several receptors, including BC6ENTG , BC6OTHER , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling.	False
BC6ENTC kinase inhibitors are BC6OTHER - derived, low molecular weight synthetic molecules that can block the intracellular BC6OTHER of several receptors, including BC6OTHER , BC6ENTG , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling.	False
BC6ENTC kinase inhibitors are BC6OTHER - derived, low molecular weight synthetic molecules that can block the intracellular BC6OTHER of several receptors, including BC6OTHER , BC6OTHER , and BC6ENTG , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling.	False
BC6ENTC kinase inhibitors are BC6OTHER - derived, low molecular weight synthetic molecules that can block the intracellular BC6OTHER of several receptors, including BC6OTHER , BC6OTHER , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6ENTG signaling.	False
BC6ENTG inhibitors are BC6ENTC - derived, low molecular weight synthetic molecules that can block the intracellular BC6OTHER of several receptors, including BC6OTHER , BC6OTHER , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling.	CPR:4
BC6OTHER inhibitors are BC6ENTC - derived, low molecular weight synthetic molecules that can block the intracellular BC6ENTG of several receptors, including BC6OTHER , BC6OTHER , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling.	CPR:4
BC6OTHER inhibitors are BC6ENTC - derived, low molecular weight synthetic molecules that can block the intracellular BC6OTHER of several receptors, including BC6ENTG , BC6OTHER , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling.	CPR:4
BC6OTHER inhibitors are BC6ENTC - derived, low molecular weight synthetic molecules that can block the intracellular BC6OTHER of several receptors, including BC6OTHER , BC6ENTG , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling.	CPR:4
BC6OTHER inhibitors are BC6ENTC - derived, low molecular weight synthetic molecules that can block the intracellular BC6OTHER of several receptors, including BC6OTHER , BC6OTHER , and BC6ENTG , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling.	CPR:4
BC6OTHER inhibitors are BC6ENTC - derived, low molecular weight synthetic molecules that can block the intracellular BC6OTHER of several receptors, including BC6OTHER , BC6OTHER , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6ENTG signaling.	CPR:4
BC6ENTG inhibitors are BC6OTHER - derived, low molecular weight synthetic molecules that can block the intracellular BC6ENTC kinase domain of several receptors, including BC6OTHER , BC6OTHER , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling.	False
BC6OTHER inhibitors are BC6OTHER - derived, low molecular weight synthetic molecules that can block the intracellular BC6ENTC kinase domain of several receptors, including BC6ENTG , BC6OTHER , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling.	False
BC6OTHER inhibitors are BC6OTHER - derived, low molecular weight synthetic molecules that can block the intracellular BC6ENTC kinase domain of several receptors, including BC6OTHER , BC6ENTG , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling.	False
BC6OTHER inhibitors are BC6OTHER - derived, low molecular weight synthetic molecules that can block the intracellular BC6ENTC kinase domain of several receptors, including BC6OTHER , BC6OTHER , and BC6ENTG , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling.	False
BC6OTHER inhibitors are BC6OTHER - derived, low molecular weight synthetic molecules that can block the intracellular BC6ENTC kinase domain of several receptors, including BC6OTHER , BC6OTHER , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6ENTG signaling.	False
Preincubation with 1 microM of the BC6ENTG ( BC6OTHER ) activator BC6OTHER ( BC6ENTC ) caused a small but significant decrease in BC6OTHER - induced E(max), indicating activated BC6OTHER - mediated heterologous BC6OTHER desensitization.	CPR:3
Preincubation with 1 microM of the BC6OTHER ( BC6ENTG ) activator BC6OTHER ( BC6ENTC ) caused a small but significant decrease in BC6OTHER - induced E(max), indicating activated BC6OTHER - mediated heterologous BC6OTHER desensitization.	CPR:3
Preincubation with 1 microM of the BC6OTHER ( BC6OTHER ) activator BC6OTHER ( BC6ENTC ) caused a small but significant decrease in BC6OTHER - induced E(max), indicating activated BC6ENTG - mediated heterologous BC6OTHER desensitization.	CPR:3
Preincubation with 1 microM of the BC6OTHER ( BC6OTHER ) activator BC6OTHER ( BC6ENTC ) caused a small but significant decrease in BC6OTHER - induced E(max), indicating activated BC6OTHER - mediated heterologous BC6ENTG desensitization.	CPR:4
Preincubation with 1 microM of the BC6ENTG ( BC6OTHER ) activator BC6OTHER ( BC6OTHER ) caused a small but significant decrease in BC6ENTC - induced E(max), indicating activated BC6OTHER - mediated heterologous BC6OTHER desensitization.	False
Preincubation with 1 microM of the BC6OTHER ( BC6ENTG ) activator BC6OTHER ( BC6OTHER ) caused a small but significant decrease in BC6ENTC - induced E(max), indicating activated BC6OTHER - mediated heterologous BC6OTHER desensitization.	False
Preincubation with 1 microM of the BC6OTHER ( BC6OTHER ) activator BC6OTHER ( BC6OTHER ) caused a small but significant decrease in BC6ENTC - induced E(max), indicating activated BC6ENTG - mediated heterologous BC6OTHER desensitization.	False
Preincubation with 1 microM of the BC6OTHER ( BC6OTHER ) activator BC6OTHER ( BC6OTHER ) caused a small but significant decrease in BC6ENTC - induced E(max), indicating activated BC6OTHER - mediated heterologous BC6ENTG desensitization.	CPR:5
To investigate the capacity of activated BC6ENTG to regulate homologous desensitization, we incubated the smooth muscle strips with the combination of both 1 microM PMA and 1 microM BC6ENTC .	False
Moreover, the specific BC6ENTG - inhibitor BC6ENTC ( BC6OTHER ) markedly increased the potency and E(max) of BC6OTHER for all conditions used, including control conditions, and the synergistic effects of BC6OTHER and BC6OTHER were completely prevented.	CPR:4
Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of BC6ENTC decreased BC6OTHER - induced maximal relaxation (E(max)) of BC6OTHER - contracted preparations in a concentration dependent fashion, indicating desensitization of the BC6ENTG .	CPR:4
Moreover, the specific BC6ENTG - inhibitor BC6OTHER ( BC6ENTC ) markedly increased the potency and E(max) of BC6OTHER for all conditions used, including control conditions, and the synergistic effects of BC6OTHER and BC6OTHER were completely prevented.	CPR:4
Moreover, the specific BC6ENTG - inhibitor BC6OTHER ( BC6OTHER ) markedly increased the potency and E(max) of BC6ENTC for all conditions used, including control conditions, and the synergistic effects of BC6OTHER and BC6OTHER were completely prevented.	False
Moreover, the specific BC6ENTG - inhibitor BC6OTHER ( BC6OTHER ) markedly increased the potency and E(max) of BC6OTHER for all conditions used, including control conditions, and the synergistic effects of BC6ENTC and BC6OTHER were completely prevented.	False
Moreover, the specific BC6ENTG - inhibitor BC6OTHER ( BC6OTHER ) markedly increased the potency and E(max) of BC6OTHER for all conditions used, including control conditions, and the synergistic effects of BC6OTHER and BC6ENTC were completely prevented.	False
Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of BC6OTHER decreased BC6ENTC - induced maximal relaxation (E(max)) of BC6OTHER - contracted preparations in a concentration dependent fashion, indicating desensitization of the BC6ENTG .	CPR:5
Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of BC6OTHER decreased BC6OTHER - induced maximal relaxation (E(max)) of BC6ENTC - contracted preparations in a concentration dependent fashion, indicating desensitization of the BC6ENTG .	False
Preincubation with 1 microM of the BC6ENTG ( BC6OTHER ) activator BC6ENTC ( BC6OTHER ) caused a small but significant decrease in BC6OTHER - induced E(max), indicating activated BC6OTHER - mediated heterologous BC6OTHER desensitization.	CPR:3
Preincubation with 1 microM of the BC6OTHER ( BC6ENTG ) activator BC6ENTC ( BC6OTHER ) caused a small but significant decrease in BC6OTHER - induced E(max), indicating activated BC6OTHER - mediated heterologous BC6OTHER desensitization.	CPR:3
Preincubation with 1 microM of the BC6OTHER ( BC6OTHER ) activator BC6ENTC ( BC6OTHER ) caused a small but significant decrease in BC6OTHER - induced E(max), indicating activated BC6ENTG - mediated heterologous BC6OTHER desensitization.	CPR:3
Preincubation with 1 microM of the BC6OTHER ( BC6OTHER ) activator BC6ENTC ( BC6OTHER ) caused a small but significant decrease in BC6OTHER - induced E(max), indicating activated BC6OTHER - mediated heterologous BC6ENTG desensitization.	CPR:4
UNLABELLED: Apparent muscarinic BC6OTHER (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6OTHER , a relatively selective BC6ENTG antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ).	False
UNLABELLED: Apparent BC6ENTG occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6OTHER , a relatively selective BC6OTHER antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ).	False
UNLABELLED: Apparent muscarinic BC6ENTC (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6OTHER , a relatively selective BC6ENTG antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
UNLABELLED: Apparent muscarinic BC6OTHER (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6OTHER , a relatively selective BC6ENTG antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ).	False
UNLABELLED: Apparent BC6ENTG occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6OTHER , a relatively selective BC6OTHER antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ).	False
UNLABELLED: Apparent muscarinic BC6OTHER (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6OTHER , a relatively selective BC6ENTG antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ).	False
UNLABELLED: Apparent BC6ENTG occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6OTHER , a relatively selective BC6OTHER antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ).	False
Both radioligands labeled BC6ENTG in these brain regions, and the relative regional distributions of the specific binding of BC6ENTC in vivo paralleled the distribution of BC6OTHER .	False
Both radioligands labeled BC6OTHER in these brain regions, and the relative regional distributions of the specific binding of BC6ENTC in vivo paralleled the distribution of BC6ENTG .	False
A similar discrepancy in sensitivity to competitors between BC6ENTC and BC6OTHER was also observed when BC6OTHER was used as a competitor, indicating that binding to different subtypes of the BC6ENTG could not account for the observed differences in sensitivity to competition.	False
A similar discrepancy in sensitivity to competitors between BC6OTHER and BC6ENTC was also observed when BC6OTHER was used as a competitor, indicating that binding to different subtypes of the BC6ENTG could not account for the observed differences in sensitivity to competition.	False
A similar discrepancy in sensitivity to competitors between BC6OTHER and BC6OTHER was also observed when BC6ENTC was used as a competitor, indicating that binding to different subtypes of the BC6ENTG could not account for the observed differences in sensitivity to competition.	False
UNLABELLED: Apparent muscarinic BC6OTHER (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6ENTC , an antagonist, and BC6OTHER , a relatively selective BC6ENTG antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
UNLABELLED: Apparent BC6ENTG occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6ENTC , an antagonist, and BC6OTHER , a relatively selective BC6OTHER antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	CPR:6
This finding, together with the more favorable accumulation of BC6ENTC in cerebral cortex, hippocampus, and striatum, leads us to conclude that BC6OTHER , or its positron emitting counterpart, should be the more favorable radiotracer for the estimation of BC6ENTG occupancy by cholinergic drugs in the brain.	False
This finding, together with the more favorable accumulation of BC6OTHER in cerebral cortex, hippocampus, and striatum, leads us to conclude that BC6ENTC , or its positron emitting counterpart, should be the more favorable radiotracer for the estimation of BC6ENTG occupancy by cholinergic drugs in the brain.	False
UNLABELLED: Apparent muscarinic BC6OTHER (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6ENTC , a relatively selective BC6ENTG antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	CPR:6
UNLABELLED: Apparent BC6ENTG occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6ENTC , a relatively selective BC6OTHER antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
KEYWORDS: BC6ENTG , BC6ENTC , BC6OTHER , in vivo, mouse.	False
KEYWORDS: BC6ENTG , BC6OTHER , BC6ENTC , in vivo, mouse.	False
UNLABELLED: Apparent muscarinic BC6OTHER (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6OTHER , a relatively selective BC6ENTG antagonist, was estimated with competitive binding studies using two different radioligands: BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
UNLABELLED: Apparent BC6ENTG occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6OTHER , a relatively selective BC6OTHER antagonist, was estimated with competitive binding studies using two different radioligands: BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
BC6OTHER is an BC6OTHER which is metabolised to BC6ENTC and which binds selectively to the BC6ENTG BC6OTHER and BC6OTHER .	False
BC6OTHER is an BC6OTHER which is metabolised to BC6ENTC and which binds selectively to the BC6OTHER receptors BC6ENTG and BC6OTHER .	False
BC6OTHER is an BC6OTHER which is metabolised to BC6ENTC and which binds selectively to the BC6OTHER receptors BC6OTHER and BC6ENTG .	False
BC6ENTC is an BC6OTHER which is metabolised to BC6OTHER and which binds selectively to the BC6ENTG BC6OTHER and BC6OTHER .	False
BC6ENTC is an BC6OTHER which is metabolised to BC6OTHER and which binds selectively to the BC6OTHER receptors BC6ENTG and BC6OTHER .	False
BC6ENTC is an BC6OTHER which is metabolised to BC6OTHER and which binds selectively to the BC6OTHER receptors BC6OTHER and BC6ENTG .	False
BC6OTHER is an BC6OTHER which is metabolised to BC6OTHER and which binds selectively to the BC6ENTC receptors BC6ENTG and BC6OTHER .	False
BC6OTHER is an BC6OTHER which is metabolised to BC6OTHER and which binds selectively to the BC6ENTC receptors BC6OTHER and BC6ENTG .	False
BC6OTHER is an BC6ENTC which is metabolised to BC6OTHER and which binds selectively to the BC6ENTG BC6OTHER and BC6OTHER .	False
BC6OTHER is an BC6ENTC which is metabolised to BC6OTHER and which binds selectively to the BC6OTHER receptors BC6ENTG and BC6OTHER .	False
BC6OTHER is an BC6ENTC which is metabolised to BC6OTHER and which binds selectively to the BC6OTHER receptors BC6OTHER and BC6ENTG .	False
Potency switch between BC6OTHER and BC6ENTG : Discovery of BC6ENTC - and BC6OTHER - based BC6OTHER inhibitors.	CPR:4
Potency switch between BC6OTHER and BC6OTHER : Discovery of BC6ENTC - and BC6OTHER - based BC6ENTG inhibitors.	CPR:4
Potency switch between BC6ENTG and BC6OTHER : Discovery of BC6ENTC - and BC6OTHER - based BC6OTHER inhibitors.	CPR:4
Potency switch between BC6OTHER and BC6ENTG : Discovery of BC6OTHER - and BC6ENTC - based BC6OTHER inhibitors.	CPR:4
Potency switch between BC6OTHER and BC6OTHER : Discovery of BC6OTHER - and BC6ENTC - based BC6ENTG inhibitors.	CPR:4
Potency switch between BC6ENTG and BC6OTHER : Discovery of BC6OTHER - and BC6ENTC - based BC6OTHER inhibitors.	CPR:4
Both BC6ENTC and BC6ENTG attenuated the parameters increased by acid - induced lung injury in rats.	False
We examined the effects of the high dose of BC6ENTG ( BC6OTHER ), which is capable of increasing peripheral neutrophils, and a specific BC6OTHER inhibitor ( BC6ENTC ) on acid lung injury in rats.	False
We examined the effects of the high dose of BC6OTHER ( BC6ENTG ), which is capable of increasing peripheral neutrophils, and a specific BC6OTHER inhibitor ( BC6ENTC ) on acid lung injury in rats.	False
We examined the effects of the high dose of BC6OTHER ( BC6OTHER ), which is capable of increasing peripheral neutrophils, and a specific BC6ENTG inhibitor ( BC6ENTC ) on acid lung injury in rats.	CPR:4
Thirty minutes before BC6ENTC instillation, BC6ENTG (150 microg kg( - 1)) was injected subcutaneously or BC6OTHER (10 mg kg( - 1) h( - 1)) was infused continuously into the right jugular vein.	False
Thirty minutes before BC6OTHER instillation, BC6ENTG (150 microg kg( - 1)) was injected subcutaneously or BC6ENTC (10 mg kg( - 1) h( - 1)) was infused continuously into the right jugular vein.	False
Effects of BC6ENTG ( BC6OTHER ) and BC6OTHER inhibitor ( BC6ENTC ) on acid - induced lung injury in rats.	CPR:4
Effects of BC6OTHER ( BC6ENTG ) and BC6OTHER inhibitor ( BC6ENTC ) on acid - induced lung injury in rats.	CPR:4
Effects of BC6OTHER ( BC6OTHER ) and BC6ENTG inhibitor ( BC6ENTC ) on acid - induced lung injury in rats.	CPR:4
Complexes of BC6ENTG with a range of anions ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER )) have been studied in the gas phase by both experimental and theoretical methods.	False
Complexes of BC6ENTG with a range of anions ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER )) have been studied in the gas phase by both experimental and theoretical methods.	False
Complexes of BC6ENTG with a range of anions ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER )) have been studied in the gas phase by both experimental and theoretical methods.	False
Complexes of BC6ENTG with a range of anions ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER )) have been studied in the gas phase by both experimental and theoretical methods.	False
Structure and energetics of gas phase BC6ENTC - bonding in BC6ENTG as studied by BIRD.	False
Complexes of BC6ENTG with a range of anions ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ( BC6OTHER )) have been studied in the gas phase by both experimental and theoretical methods.	False
Complexes of BC6ENTG with a range of anions ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ( BC6OTHER )) have been studied in the gas phase by both experimental and theoretical methods.	False
Complexes of BC6ENTG with a range of anions ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ( BC6OTHER )) have been studied in the gas phase by both experimental and theoretical methods.	False
Complexes of BC6ENTG with a range of anions ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6ENTC )) have been studied in the gas phase by both experimental and theoretical methods.	False
An increase in the energy required to remove the same anion from the BC6ENTG when compared to the BC6OTHER is explained as being due to the increase in BC6ENTC bonding interactions.	False
An increase in the energy required to remove the same anion from the BC6OTHER when compared to the BC6ENTG is explained as being due to the increase in BC6ENTC bonding interactions.	False
The present study was initiated to evaluate the safety and efficacy of Haemate - P (Humate - P in North America) (anti - hemophilic BC6ENTG / BC6OTHER complex [human] dried, pasteurized) dosed in BC6ENTC cofactor units (VWF:RCo) in the treatment of von Willebrand disease (VWD) patients in Canada.	False
The present study was initiated to evaluate the safety and efficacy of Haemate - P (Humate - P in North America) (anti - hemophilic BC6OTHER / BC6ENTG complex [human] dried, pasteurized) dosed in BC6ENTC cofactor units (VWF:RCo) in the treatment of von Willebrand disease (VWD) patients in Canada.	False
Efficacy and safety of the BC6OTHER / BC6ENTG concentrate, haemate - P / humate - P: BC6ENTC cofactor unit dosing in patients with von Willebrand disease.	False
Efficacy and safety of the BC6ENTG / BC6OTHER concentrate, haemate - P / humate - P: BC6ENTC cofactor unit dosing in patients with von Willebrand disease.	False
Neonatal epileptic encephalopathy caused by mutations in the BC6ENTG gene encoding BC6ENTC oxidase.	False
Cerebrospinal fluid and urine analyses indicated reduced activity of BC6ENTG and other BC6ENTC - dependent enzymes.	False
Seizures ceased with the administration of BC6ENTC , having been resistant to treatment with CHEM, suggesting a defect of BC6ENTG ( BC6OTHER ).	False
Seizures ceased with the administration of BC6ENTC , having been resistant to treatment with CHEM, suggesting a defect of BC6OTHER oxidase ( BC6ENTG ).	False
Seizures ceased with the administration of BC6OTHER , having been resistant to treatment with CHEM, suggesting a defect of BC6ENTC oxidase ( BC6ENTG ).	False
Expression studies in Chinese hamster ovary cells showed that the splice site (IVS3 - 1 BC6ENTG ) and stop codon (X262Q) mutations were null activity mutations and that the missense mutation ( BC6OTHER ) markedly reduced BC6ENTC oxidase activity.	False
Expression studies in Chinese hamster ovary cells showed that the splice site (IVS3 - 1 BC6OTHER ) and stop codon (X262Q) mutations were null activity mutations and that the missense mutation ( BC6ENTG ) markedly reduced BC6ENTC oxidase activity.	False
BC6ENTG - induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of BC6ENTC by driving BC6OTHER - dependent BC6OTHER expression, which, in turn, drives fibroblast proliferation. - Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., Tager, A. M. BC6OTHER - induced cytoskeleton reorganization drives fibrosis through BC6OTHER - dependent fibroblast proliferation.	False
BC6OTHER - induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of BC6ENTC by driving BC6ENTG - dependent BC6OTHER expression, which, in turn, drives fibroblast proliferation. - Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., Tager, A. M. BC6OTHER - induced cytoskeleton reorganization drives fibrosis through BC6OTHER - dependent fibroblast proliferation.	False
BC6OTHER - induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of BC6ENTC by driving BC6OTHER - dependent BC6ENTG expression, which, in turn, drives fibroblast proliferation. - Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., Tager, A. M. BC6OTHER - induced cytoskeleton reorganization drives fibrosis through BC6OTHER - dependent fibroblast proliferation.	CPR:3
BC6OTHER - induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of BC6ENTC by driving BC6OTHER - dependent BC6OTHER expression, which, in turn, drives fibroblast proliferation. - Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., Tager, A. M. BC6ENTG - induced cytoskeleton reorganization drives fibrosis through BC6OTHER - dependent fibroblast proliferation.	False
BC6OTHER - induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of BC6ENTC by driving BC6OTHER - dependent BC6OTHER expression, which, in turn, drives fibroblast proliferation. - Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., Tager, A. M. BC6OTHER - induced cytoskeleton reorganization drives fibrosis through BC6ENTG - dependent fibroblast proliferation.	False
There has been much recent interest in BC6OTHER ( BC6OTHER ) signaling through one of its receptors, BC6OTHER , in fibrotic diseases, but the mechanisms by which BC6ENTC - BC6ENTG signaling promotes pathological fibrosis remain to be fully elucidated.	False
There has been much recent interest in BC6OTHER ( BC6OTHER ) signaling through one of its receptors, BC6ENTG , in fibrotic diseases, but the mechanisms by which BC6ENTC - BC6OTHER signaling promotes pathological fibrosis remain to be fully elucidated.	False
Using a mouse peritoneal fibrosis model, we demonstrate central roles for BC6ENTC and BC6ENTG in fibroblast proliferation.	False
There has been much recent interest in BC6ENTC ( BC6OTHER ) signaling through one of its receptors, BC6OTHER , in fibrotic diseases, but the mechanisms by which BC6OTHER - BC6ENTG signaling promotes pathological fibrosis remain to be fully elucidated.	False
There has been much recent interest in BC6ENTC ( BC6OTHER ) signaling through one of its receptors, BC6ENTG , in fibrotic diseases, but the mechanisms by which BC6OTHER - BC6OTHER signaling promotes pathological fibrosis remain to be fully elucidated.	False
There has been much recent interest in BC6OTHER ( BC6ENTC ) signaling through one of its receptors, BC6OTHER , in fibrotic diseases, but the mechanisms by which BC6OTHER - BC6ENTG signaling promotes pathological fibrosis remain to be fully elucidated.	False
There has been much recent interest in BC6OTHER ( BC6ENTC ) signaling through one of its receptors, BC6ENTG , in fibrotic diseases, but the mechanisms by which BC6OTHER - BC6OTHER signaling promotes pathological fibrosis remain to be fully elucidated.	False
BC6ENTG of the BC6OTHER ( BC6ENTC - ) subtype are tetrameric allosteric and BC6OTHER .	False
BC6OTHER receptors of the BC6OTHER ( BC6ENTC - ) subtype are tetrameric allosteric and BC6ENTG .	False
 BC6ENTC receptors are not alone: dynamic regulation of BC6OTHER structure and function by BC6OTHER and BC6ENTG leads to disease - specific nuances of BC6OTHER - signalling.	False
 BC6ENTC receptors are not alone: dynamic regulation of BC6ENTG structure and function by BC6OTHER and transient BC6OTHER - rich membrane domains leads to disease - specific nuances of BC6OTHER - signalling.	False
 BC6ENTC receptors are not alone: dynamic regulation of BC6OTHER structure and function by BC6ENTG and transient BC6OTHER - rich membrane domains leads to disease - specific nuances of BC6OTHER - signalling.	False
 BC6ENTG are not alone: dynamic regulation of BC6OTHER structure and function by BC6OTHER and transient BC6ENTC - rich membrane domains leads to disease - specific nuances of BC6OTHER - signalling.	False
 BC6OTHER are not alone: dynamic regulation of BC6ENTG structure and function by BC6OTHER and transient BC6ENTC - rich membrane domains leads to disease - specific nuances of BC6OTHER - signalling.	False
 BC6OTHER are not alone: dynamic regulation of BC6OTHER structure and function by BC6ENTG and transient BC6ENTC - rich membrane domains leads to disease - specific nuances of BC6OTHER - signalling.	False
 BC6ENTG are not alone: dynamic regulation of BC6OTHER structure and function by BC6OTHER and transient BC6OTHER - rich membrane domains leads to disease - specific nuances of BC6ENTC - signalling.	False
 BC6OTHER are not alone: dynamic regulation of BC6OTHER structure and function by BC6OTHER and BC6ENTG leads to disease - specific nuances of BC6ENTC - signalling.	False
 BC6OTHER are not alone: dynamic regulation of BC6ENTG structure and function by BC6OTHER and transient BC6OTHER - rich membrane domains leads to disease - specific nuances of BC6ENTC - signalling.	False
 BC6OTHER are not alone: dynamic regulation of BC6OTHER structure and function by BC6ENTG and transient BC6OTHER - rich membrane domains leads to disease - specific nuances of BC6ENTC - signalling.	False
 BC6ENTG are not alone: dynamic regulation of BC6ENTC receptor structure and function by BC6OTHER and transient BC6OTHER - rich membrane domains leads to disease - specific nuances of BC6OTHER - signalling.	False
 BC6OTHER are not alone: dynamic regulation of BC6ENTC receptor structure and function by BC6OTHER and BC6ENTG leads to disease - specific nuances of BC6OTHER - signalling.	False
 BC6OTHER are not alone: dynamic regulation of BC6ENTC receptor structure and function by BC6ENTG and transient BC6OTHER - rich membrane domains leads to disease - specific nuances of BC6OTHER - signalling.	False
BC6ENTC receptors of the BC6OTHER ( BC6OTHER - ) subtype are tetrameric allosteric and BC6ENTG .	False
This fundamental significance of BC6ENTG - related excitotoxicity is discussed in the context of the developing clinical success of BC6ENTC , but moreover set into relation to various proteomic and genetic markers of said diseases.	False
The very complex localisational and functional regulation of BC6ENTC receptors appears to be dependent on BC6ENTG and receptor BC6OTHER kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6OTHER ).	False
The very complex localisational and functional regulation of BC6ENTC receptors appears to be dependent on BC6OTHER and BC6ENTG in BC6OTHER - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6OTHER ).	False
The very complex localisational and functional regulation of BC6ENTC receptors appears to be dependent on BC6OTHER and receptor BC6OTHER kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6ENTG ( BC6OTHER ).	False
The very complex localisational and functional regulation of BC6ENTC receptors appears to be dependent on BC6OTHER and receptor BC6OTHER kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6ENTG ).	False
The very complex localisational and functional regulation of BC6ENTG appears to be dependent on BC6OTHER and receptor BC6ENTC kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6OTHER ).	False
The very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6ENTG and receptor BC6ENTC kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6OTHER ).	False
The very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6OTHER and receptor BC6ENTC kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6ENTG ( BC6OTHER ).	False
The very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6OTHER and receptor BC6ENTC kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6ENTG ).	False
The very complex localisational and functional regulation of BC6ENTG appears to be dependent on BC6OTHER and receptor BC6OTHER kinases in BC6ENTC - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6OTHER ).	False
The very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6ENTG and receptor BC6OTHER kinases in BC6ENTC - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6OTHER ).	False
The very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6OTHER and BC6ENTG in BC6ENTC - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6OTHER ).	False
The very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6OTHER and receptor BC6OTHER kinases in BC6ENTC - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6ENTG ( BC6OTHER ).	False
The very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6OTHER and receptor BC6OTHER kinases in BC6ENTC - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6ENTG ).	False
The very complex localisational and functional regulation of BC6ENTG appears to be dependent on BC6OTHER and receptor BC6OTHER kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6ENTC - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6OTHER ).	False
The very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6ENTG and receptor BC6OTHER kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6ENTC - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6OTHER ).	False
The very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6OTHER and BC6ENTG in BC6OTHER - rich membrane domains (lipid rafts), BC6ENTC - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6OTHER ).	False
The very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6OTHER and receptor BC6OTHER kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6ENTC - related mitochondrial feedback - loops and subsynaptic structural elements like BC6ENTG ( BC6OTHER ).	False
The very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6OTHER and receptor BC6OTHER kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6ENTC - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6ENTG ).	False
BC6ENTG of the BC6ENTC ( BC6OTHER - ) subtype are tetrameric allosteric and BC6OTHER .	False
BC6OTHER receptors of the BC6ENTC ( BC6OTHER - ) subtype are tetrameric allosteric and BC6ENTG .	False
On the structural level BC6ENTC receptors have an enormous flexibility due to seven genes ( BC6ENTG , BC6OTHER and BC6OTHER ), alternative splicing, RNA - editing and extensive posttranslational modifications, like phosphorylation and glycosylation.	False
On the structural level BC6ENTC receptors have an enormous flexibility due to seven genes ( BC6OTHER , BC6ENTG and BC6OTHER ), alternative splicing, RNA - editing and extensive posttranslational modifications, like phosphorylation and glycosylation.	False
On the structural level BC6ENTC receptors have an enormous flexibility due to seven genes ( BC6OTHER , BC6OTHER and BC6ENTG ), alternative splicing, RNA - editing and extensive posttranslational modifications, like phosphorylation and glycosylation.	False
The availability of the BC6OTHER prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that BC6ENTG , the activating enzyme for BC6ENTC , is expressed at a higher level in tumor tissue compared with normal tissue counterparts.	CPR:9
BC6ENTC synthase ( BC6ENTG ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis.	False
BC6ENTG ( BC6OTHER ) continues to be a critical target for BC6ENTC ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis.	False
BC6OTHER ( BC6ENTG ) continues to be a critical target for BC6ENTC ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis.	False
BC6ENTG ( BC6OTHER ) continues to be a critical target for BC6OTHER ( BC6ENTC ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis.	False
BC6OTHER ( BC6ENTG ) continues to be a critical target for BC6OTHER ( BC6ENTC ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis.	False
BC6ENTG ( BC6OTHER ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6ENTC / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis.	False
BC6OTHER ( BC6ENTG ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6ENTC / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis.	False
BC6ENTG ( BC6OTHER ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis.	False
BC6OTHER ( BC6ENTG ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis.	False
BC6ENTG ( BC6OTHER ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis.	False
BC6OTHER ( BC6ENTG ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis.	False
BC6ENTG ( BC6OTHER ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis.	False
BC6OTHER ( BC6ENTG ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis.	False
BC6ENTG ( BC6OTHER ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis.	False
BC6OTHER ( BC6ENTG ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis.	False
While BC6ENTC antimetabolites have other sites of action, antifolates BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) are more specific and potent BC6ENTG inhibitors.	False
BC6ENTG ( BC6OTHER ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis.	False
BC6OTHER ( BC6ENTG ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis.	False
BC6ENTG ( BC6OTHER ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6ENTC , a precursor for DNA synthesis.	CPR:9
BC6OTHER ( BC6ENTG ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6ENTC , a precursor for DNA synthesis.	CPR:9
While BC6OTHER antimetabolites have other sites of action, antifolates BC6ENTC ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) are more specific and potent BC6ENTG inhibitors.	CPR:4
While BC6OTHER antimetabolites have other sites of action, antifolates BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER ) are more specific and potent BC6ENTG inhibitors.	CPR:4
While BC6OTHER antimetabolites have other sites of action, antifolates BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER ) are more specific and potent BC6ENTG inhibitors.	CPR:4
While BC6OTHER antimetabolites have other sites of action, antifolates BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTC ( BC6OTHER ) are more specific and potent BC6ENTG inhibitors.	CPR:4
While BC6OTHER antimetabolites have other sites of action, antifolates BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC ) are more specific and potent BC6ENTG inhibitors.	CPR:4
The availability of the BC6ENTC prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that BC6ENTG , the activating enzyme for BC6OTHER , is expressed at a higher level in tumor tissue compared with normal tissue counterparts.	False
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6ENTG receptor agonists BC6OTHER , BC6OTHER and BC6ENTC in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6OTHER , BC6OTHER and BC6OTHER receptors.	False
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6OTHER receptor agonists BC6OTHER , BC6OTHER and BC6ENTC in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6ENTG , BC6OTHER and BC6OTHER receptors.	False
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6OTHER receptor agonists BC6OTHER , BC6OTHER and BC6ENTC in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6OTHER , BC6ENTG and BC6OTHER receptors.	False
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6OTHER receptor agonists BC6OTHER , BC6OTHER and BC6ENTC in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6OTHER , BC6OTHER and BC6ENTG receptors.	False
In vitro studies showed that all three BC6ENTC are high affinity, full agonists at BC6ENTG receptors, but that BC6OTHER is functionally less potent as a BC6OTHER agonist than BC6OTHER and BC6OTHER .	False
In vitro studies showed that all three BC6ENTC are high affinity, full agonists at BC6OTHER receptors, but that BC6OTHER is functionally less potent as a BC6ENTG agonist than BC6OTHER and BC6OTHER .	False
In vitro studies showed that all three BC6OTHER are high affinity, full agonists at BC6ENTG receptors, but that BC6ENTC is functionally less potent as a BC6OTHER agonist than BC6OTHER and BC6OTHER .	False
In vitro studies showed that all three BC6OTHER are high affinity, full agonists at BC6OTHER receptors, but that BC6ENTC is functionally less potent as a BC6ENTG agonist than BC6OTHER and BC6OTHER .	False
In vitro studies showed that all three BC6OTHER are high affinity, full agonists at BC6ENTG receptors, but that BC6OTHER is functionally less potent as a BC6OTHER agonist than BC6ENTC and BC6OTHER .	False
In vitro studies showed that all three BC6OTHER are high affinity, full agonists at BC6OTHER receptors, but that BC6OTHER is functionally less potent as a BC6ENTG agonist than BC6ENTC and BC6OTHER .	False
In vitro studies showed that all three BC6OTHER are high affinity, full agonists at BC6ENTG receptors, but that BC6OTHER is functionally less potent as a BC6OTHER agonist than BC6OTHER and BC6ENTC .	False
In vitro studies showed that all three BC6OTHER are high affinity, full agonists at BC6OTHER receptors, but that BC6OTHER is functionally less potent as a BC6ENTG agonist than BC6OTHER and BC6ENTC .	False
 The observation that BC6ENTC and BC6OTHER produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional BC6ENTG receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg / kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg / kg i.v. BC6OTHER is likely due to its weaker functional BC6OTHER receptor agonist potency than BC6OTHER and BC6OTHER , rather than lower brain levels, consistent with CHEM's fivefold lower potency after intracerebral administration.	False
 The observation that BC6ENTC and BC6OTHER produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional BC6OTHER receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg / kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg / kg i.v. BC6OTHER is likely due to its weaker functional BC6ENTG receptor agonist potency than BC6OTHER and BC6OTHER , rather than lower brain levels, consistent with CHEM's fivefold lower potency after intracerebral administration.	False
 The observation that BC6OTHER and BC6ENTC produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional BC6ENTG receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg / kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg / kg i.v. BC6OTHER is likely due to its weaker functional BC6OTHER receptor agonist potency than BC6OTHER and BC6OTHER , rather than lower brain levels, consistent with CHEM's fivefold lower potency after intracerebral administration.	False
 The observation that BC6OTHER and BC6ENTC produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional BC6OTHER receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg / kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg / kg i.v. BC6OTHER is likely due to its weaker functional BC6ENTG receptor agonist potency than BC6OTHER and BC6OTHER , rather than lower brain levels, consistent with CHEM's fivefold lower potency after intracerebral administration.	False
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6ENTG receptor agonists BC6ENTC , BC6OTHER and BC6OTHER in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6OTHER , BC6OTHER and BC6OTHER receptors.	False
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6OTHER receptor agonists BC6ENTC , BC6OTHER and BC6OTHER in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6ENTG , BC6OTHER and BC6OTHER receptors.	False
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6OTHER receptor agonists BC6ENTC , BC6OTHER and BC6OTHER in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6OTHER , BC6ENTG and BC6OTHER receptors.	False
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6OTHER receptor agonists BC6ENTC , BC6OTHER and BC6OTHER in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6OTHER , BC6OTHER and BC6ENTG receptors.	False
 The observation that BC6OTHER and BC6OTHER produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional BC6ENTG receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg / kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg / kg i.v. BC6ENTC is likely due to its weaker functional BC6OTHER receptor agonist potency than BC6OTHER and BC6OTHER , rather than lower brain levels, consistent with CHEM's fivefold lower potency after intracerebral administration.	False
 The observation that BC6OTHER and BC6OTHER produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional BC6OTHER receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg / kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg / kg i.v. BC6ENTC is likely due to its weaker functional BC6ENTG receptor agonist potency than BC6OTHER and BC6OTHER , rather than lower brain levels, consistent with CHEM's fivefold lower potency after intracerebral administration.	False
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6ENTG receptor agonists BC6OTHER , BC6ENTC and BC6OTHER in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6OTHER , BC6OTHER and BC6OTHER receptors.	False
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6OTHER receptor agonists BC6OTHER , BC6ENTC and BC6OTHER in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6ENTG , BC6OTHER and BC6OTHER receptors.	False
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6OTHER receptor agonists BC6OTHER , BC6ENTC and BC6OTHER in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6OTHER , BC6ENTG and BC6OTHER receptors.	False
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6OTHER receptor agonists BC6OTHER , BC6ENTC and BC6OTHER in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6OTHER , BC6OTHER and BC6ENTG receptors.	False
 The observation that BC6OTHER and BC6OTHER produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional BC6ENTG receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg / kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg / kg i.v. BC6OTHER is likely due to its weaker functional BC6OTHER receptor agonist potency than BC6ENTC and BC6OTHER , rather than lower brain levels, consistent with CHEM's fivefold lower potency after intracerebral administration.	False
 The observation that BC6OTHER and BC6OTHER produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional BC6OTHER receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg / kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg / kg i.v. BC6OTHER is likely due to its weaker functional BC6ENTG receptor agonist potency than BC6ENTC and BC6OTHER , rather than lower brain levels, consistent with CHEM's fivefold lower potency after intracerebral administration.	False
 The observation that BC6OTHER and BC6OTHER produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional BC6ENTG receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg / kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg / kg i.v. BC6OTHER is likely due to its weaker functional BC6OTHER receptor agonist potency than BC6OTHER and BC6ENTC , rather than lower brain levels, consistent with CHEM's fivefold lower potency after intracerebral administration.	False
 The observation that BC6OTHER and BC6OTHER produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional BC6OTHER receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg / kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg / kg i.v. BC6OTHER is likely due to its weaker functional BC6ENTG receptor agonist potency than BC6OTHER and BC6ENTC , rather than lower brain levels, consistent with CHEM's fivefold lower potency after intracerebral administration.	False
In addition, we examined the ability of BC6OTHER ; a BC6ENTC antidepressant that is devoid of BC6OTHER reuptake inhibitory properties on BC6ENTG production.	False
In addition, we examined the ability of BC6OTHER ; a BC6OTHER antidepressant that is devoid of BC6ENTC reuptake inhibitory properties on BC6ENTG production.	False
In this study, antidepressants with selectivity for the BC6ENTC transporter ( BC6OTHER and BC6OTHER ), or the BC6ENTG ( BC6OTHER and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6OTHER phenotype in human blood.	False
In this study, antidepressants with selectivity for the BC6ENTC transporter ( BC6OTHER and BC6OTHER ), or the BC6OTHER transporter ( BC6OTHER and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6ENTG phenotype in human blood.	False
All of the antidepressants suppressed BC6ENTG production in the 10 - 50 microM concentration range, irrespective of their preference for BC6ENTC or BC6OTHER transporters.	False
In this study, antidepressants with selectivity for the BC6OTHER ( BC6ENTC and BC6OTHER ), or the BC6ENTG ( BC6OTHER and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6OTHER phenotype in human blood.	False
In this study, antidepressants with selectivity for the BC6OTHER ( BC6ENTC and BC6OTHER ), or the BC6OTHER transporter ( BC6OTHER and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6ENTG phenotype in human blood.	False
In this study, antidepressants with selectivity for the BC6ENTG ( BC6ENTC and BC6OTHER ), or the BC6OTHER transporter ( BC6OTHER and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6OTHER phenotype in human blood.	False
All of the antidepressants suppressed BC6ENTG production in the 10 - 50 microM concentration range, irrespective of their preference for CHEM or BC6ENTC transporters.	False
In this study, antidepressants with selectivity for the BC6OTHER ( BC6OTHER and BC6ENTC ), or the BC6ENTG ( BC6OTHER and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6OTHER phenotype in human blood.	False
In this study, antidepressants with selectivity for the BC6OTHER ( BC6OTHER and BC6ENTC ), or the BC6OTHER transporter ( BC6OTHER and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6ENTG phenotype in human blood.	False
In this study, antidepressants with selectivity for the BC6ENTG ( BC6OTHER and BC6ENTC ), or the BC6OTHER transporter ( BC6OTHER and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6OTHER phenotype in human blood.	False
Antidepressants suppress production of the Th1 BC6ENTG BC6OTHER , independent of BC6ENTC transporter blockade.	False
Antidepressants suppress production of the Th1 BC6OTHER BC6ENTG , independent of BC6ENTC transporter blockade.	False
The fact that BC6ENTC also suppressed BC6ENTG production and T - cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of BC6OTHER reuptake.	CPR:4
In this study, antidepressants with selectivity for the BC6OTHER ( BC6OTHER and BC6OTHER ), or the BC6ENTC transporter ( BC6OTHER and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6ENTG phenotype in human blood.	False
In this study, antidepressants with selectivity for the BC6ENTG ( BC6OTHER and BC6OTHER ), or the BC6ENTC transporter ( BC6OTHER and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6OTHER phenotype in human blood.	False
The fact that BC6OTHER also suppressed BC6ENTG production and T - cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of BC6ENTC reuptake.	False
In this study, antidepressants with selectivity for the BC6OTHER ( BC6OTHER and BC6OTHER ), or the BC6ENTG ( BC6ENTC and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6OTHER phenotype in human blood.	False
In this study, antidepressants with selectivity for the BC6OTHER ( BC6OTHER and BC6OTHER ), or the BC6OTHER transporter ( BC6ENTC and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6ENTG phenotype in human blood.	False
In this study, antidepressants with selectivity for the BC6ENTG ( BC6OTHER and BC6OTHER ), or the BC6OTHER transporter ( BC6ENTC and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6OTHER phenotype in human blood.	False
Interestingly, exposure to a lower concentration (1 microM) of the antidepressants tended to increase T - cell - derived BC6ENTG production, with significant effects elicited by the BC6ENTC reuptake inhibitors BC6OTHER and BC6OTHER .	False
Interestingly, exposure to a lower concentration (1 microM) of the antidepressants tended to increase T - cell - derived BC6ENTG production, with significant effects elicited by the BC6OTHER reuptake inhibitors BC6ENTC and BC6OTHER .	False
Interestingly, exposure to a lower concentration (1 microM) of the antidepressants tended to increase T - cell - derived BC6ENTG production, with significant effects elicited by the BC6OTHER reuptake inhibitors BC6OTHER and BC6ENTC .	False
In this study, antidepressants with selectivity for the BC6OTHER ( BC6OTHER and BC6OTHER ), or the BC6ENTG ( BC6OTHER and BC6ENTC ) were examined in terms of their ability to promote an anti - inflammatory BC6OTHER phenotype in human blood.	False
In this study, antidepressants with selectivity for the BC6OTHER ( BC6OTHER and BC6OTHER ), or the BC6OTHER transporter ( BC6OTHER and BC6ENTC ) were examined in terms of their ability to promote an anti - inflammatory BC6ENTG phenotype in human blood.	False
In this study, antidepressants with selectivity for the BC6ENTG ( BC6OTHER and BC6OTHER ), or the BC6OTHER transporter ( BC6OTHER and BC6ENTC ) were examined in terms of their ability to promote an anti - inflammatory BC6OTHER phenotype in human blood.	False
In addition, we examined the ability of BC6ENTC ; a BC6OTHER antidepressant that is devoid of BC6OTHER reuptake inhibitory properties on BC6ENTG production.	False
CONCLUSION: Our results did not lend strong support to the view that the genetic variation of the BC6ENTG gene plays a major role in the individually variable adverse effect induced by BC6ENTC , at least in Chinese patients with schizophrenia.	False
In this study, we evaluate the role BC6ENTG plays in BC6ENTC - induced EPS in schizophrenic patients.	False
METHODS: We identified seven SNP(single BC6ENTC polymorphism) ( - 141Cins>del, CHEM, TaqID, BC6ENTG , rs6275, rs6277 and TaqIA) in the BC6OTHER gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson - Angus Scale) treated with BC6OTHER after 8 weeks.	False
METHODS: We identified seven SNP(single BC6ENTC polymorphism) ( - 141Cins>del, CHEM, TaqID, BC6OTHER , rs6275, rs6277 and TaqIA) in the BC6ENTG gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson - Angus Scale) treated with BC6OTHER after 8 weeks.	False
METHODS: We identified seven SNP(single BC6OTHER polymorphism) ( - 141Cins>del, CHEM, TaqID, BC6ENTG , rs6275, rs6277 and TaqIA) in the BC6OTHER gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson - Angus Scale) treated with BC6ENTC after 8 weeks.	False
METHODS: We identified seven SNP(single BC6OTHER polymorphism) ( - 141Cins>del, CHEM, TaqID, BC6OTHER , rs6275, rs6277 and TaqIA) in the BC6ENTG gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson - Angus Scale) treated with BC6ENTC after 8 weeks.	False
Association of BC6ENTG polymorphisms and BC6ENTC - induced extrapyramidal syndrome in Chinese schizophrenic patients.	False
BC6ENTG level in plasma and mesenteric arteries in BC6ENTC group was significantly lower than that in BC6OTHER group (P<0.05).	CPR:4
BC6ENTG level in plasma and mesenteric arteries in BC6OTHER group was significantly lower than that in BC6ENTC group (P<0.05).	CPR:3
The BC6ENTG absorbed light value / BC6OTHER absorbed light value of mesenteric arteries in the SHR group was 0.850+ / - 0.015, which was significantly higher than that in the WKY, BC6ENTC , and BC6OTHER groups (0.582+ / - 0.013, 0.743+ / - 0.012, and 0.789+ / - 0.013, respectively, P<0.01), and was significantly lower in BC6OTHER group than in BC6OTHER group (P<0.05).	CPR:3
The BC6OTHER absorbed light value / BC6ENTG absorbed light value of mesenteric arteries in the SHR group was 0.850+ / - 0.015, which was significantly higher than that in the WKY, BC6ENTC , and BC6OTHER groups (0.582+ / - 0.013, 0.743+ / - 0.012, and 0.789+ / - 0.013, respectively, P<0.01), and was significantly lower in BC6OTHER group than in BC6OTHER group (P<0.05).	CPR:3
The BC6ENTG absorbed light value / BC6OTHER absorbed light value of mesenteric arteries in the SHR group was 0.850+ / - 0.015, which was significantly higher than that in the WKY, BC6OTHER , and BC6ENTC groups (0.582+ / - 0.013, 0.743+ / - 0.012, and 0.789+ / - 0.013, respectively, P<0.01), and was significantly lower in BC6OTHER group than in BC6OTHER group (P<0.05).	CPR:3
The BC6OTHER absorbed light value / BC6ENTG absorbed light value of mesenteric arteries in the SHR group was 0.850+ / - 0.015, which was significantly higher than that in the WKY, BC6OTHER , and BC6ENTC groups (0.582+ / - 0.013, 0.743+ / - 0.012, and 0.789+ / - 0.013, respectively, P<0.01), and was significantly lower in BC6OTHER group than in BC6OTHER group (P<0.05).	CPR:3
The BC6ENTG absorbed light value / BC6OTHER absorbed light value of mesenteric arteries in the SHR group was 0.850+ / - 0.015, which was significantly higher than that in the WKY, BC6OTHER , and BC6OTHER groups (0.582+ / - 0.013, 0.743+ / - 0.012, and 0.789+ / - 0.013, respectively, P<0.01), and was significantly lower in BC6ENTC group than in BC6OTHER group (P<0.05).	False
The BC6OTHER absorbed light value / BC6ENTG absorbed light value of mesenteric arteries in the SHR group was 0.850+ / - 0.015, which was significantly higher than that in the WKY, BC6OTHER , and BC6OTHER groups (0.582+ / - 0.013, 0.743+ / - 0.012, and 0.789+ / - 0.013, respectively, P<0.01), and was significantly lower in BC6ENTC group than in BC6OTHER group (P<0.05).	False
The BC6ENTG absorbed light value / BC6OTHER absorbed light value of mesenteric arteries in the SHR group was 0.850+ / - 0.015, which was significantly higher than that in the WKY, BC6OTHER , and BC6OTHER groups (0.582+ / - 0.013, 0.743+ / - 0.012, and 0.789+ / - 0.013, respectively, P<0.01), and was significantly lower in BC6OTHER group than in BC6ENTC group (P<0.05).	False
The BC6OTHER absorbed light value / BC6ENTG absorbed light value of mesenteric arteries in the SHR group was 0.850+ / - 0.015, which was significantly higher than that in the WKY, BC6OTHER , and BC6OTHER groups (0.582+ / - 0.013, 0.743+ / - 0.012, and 0.789+ / - 0.013, respectively, P<0.01), and was significantly lower in BC6OTHER group than in BC6ENTC group (P<0.05).	False
CONCLUSION: BC6ENTC and BC6OTHER can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of BC6ENTG , BC6OTHER in SHR.	CPR:4
CONCLUSION: BC6ENTC and BC6OTHER can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of BC6OTHER , BC6ENTG in SHR.	CPR:4
CONCLUSION: BC6OTHER and BC6ENTC can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of BC6ENTG , BC6OTHER in SHR.	CPR:4
CONCLUSION: BC6OTHER and BC6ENTC can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of BC6OTHER , BC6ENTG in SHR.	CPR:4
BC6ENTC ( BC6ENTG ) level in plasma and mesenteric arteries was measured by radioimmunoassay.	False
BC6ENTG ( BC6ENTC ) level in plasma and mesenteric arteries was measured by radioimmunoassay.	False
AIM: To investigate the remodeling of mesenteric artery and the expression of BC6ENTG , BC6OTHER in mesenteric artery and effects of BC6ENTC and BC6OTHER on the remodeling in spontaneously hypertensive rats (SHR).	False
AIM: To investigate the remodeling of mesenteric artery and the expression of BC6OTHER , BC6ENTG in mesenteric artery and effects of BC6ENTC and BC6OTHER on the remodeling in spontaneously hypertensive rats (SHR).	False
BC6ENTG level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in BC6ENTC group and lower in BC6OTHER group.	CPR:3
BC6ENTG level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in BC6OTHER group and lower in BC6ENTC group.	CPR:4
AIM: To investigate the remodeling of mesenteric artery and the expression of BC6ENTG , BC6OTHER in mesenteric artery and effects of BC6OTHER and BC6ENTC on the remodeling in spontaneously hypertensive rats (SHR).	False
AIM: To investigate the remodeling of mesenteric artery and the expression of BC6OTHER , BC6ENTG in mesenteric artery and effects of BC6OTHER and BC6ENTC on the remodeling in spontaneously hypertensive rats (SHR).	False
The ratio of BC6ENTG absorbed light value to BC6OTHER absorbed light value in the SHR group was 0.887+ / - 0.019, which was significantly higher than that in WKY group, BC6ENTC group, and BC6OTHER group with the ratios of 0.780+ / - 0.018, 0.803+ / - 0.005, and 0.847+ / - 0.017, respectively (P<0.01).	CPR:3
The ratio of BC6OTHER absorbed light value to BC6ENTG absorbed light value in the SHR group was 0.887+ / - 0.019, which was significantly higher than that in WKY group, BC6ENTC group, and BC6OTHER group with the ratios of 0.780+ / - 0.018, 0.803+ / - 0.005, and 0.847+ / - 0.017, respectively (P<0.01).	CPR:3
The ratio of BC6ENTG absorbed light value to BC6OTHER absorbed light value in the SHR group was 0.887+ / - 0.019, which was significantly higher than that in WKY group, BC6OTHER group, and BC6ENTC group with the ratios of 0.780+ / - 0.018, 0.803+ / - 0.005, and 0.847+ / - 0.017, respectively (P<0.01).	CPR:3
The ratio of BC6OTHER absorbed light value to BC6ENTG absorbed light value in the SHR group was 0.887+ / - 0.019, which was significantly higher than that in WKY group, BC6OTHER group, and BC6ENTC group with the ratios of 0.780+ / - 0.018, 0.803+ / - 0.005, and 0.847+ / - 0.017, respectively (P<0.01).	CPR:3
In overexpressing cell lines, BC6ENTG - and BC6OTHER - mediated BC6ENTC uptake and BC6OTHER - mediated BC6OTHER uptake were inhibited by most of the CHEM BC6OTHER investigated.	CPR:9
In overexpressing cell lines, BC6OTHER - and BC6ENTG - mediated BC6ENTC uptake and BC6OTHER - mediated BC6OTHER uptake were inhibited by most of the CHEM BC6OTHER investigated.	CPR:9
In overexpressing cell lines, BC6OTHER - and BC6OTHER - mediated BC6ENTC uptake and BC6ENTG - mediated BC6OTHER uptake were inhibited by most of the CHEM BC6OTHER investigated.	False
In overexpressing cell lines, BC6ENTG - and BC6OTHER - mediated BC6OTHER uptake and BC6OTHER - mediated BC6ENTC uptake were inhibited by most of the CHEM BC6OTHER investigated.	False
In overexpressing cell lines, BC6OTHER - and BC6ENTG - mediated BC6OTHER uptake and BC6OTHER - mediated BC6ENTC uptake were inhibited by most of the CHEM BC6OTHER investigated.	False
In overexpressing cell lines, BC6OTHER - and BC6OTHER - mediated BC6OTHER uptake and BC6ENTG - mediated BC6ENTC uptake were inhibited by most of the CHEM BC6OTHER investigated.	CPR:9
In overexpressing cell lines, BC6ENTG - and BC6OTHER - mediated BC6OTHER uptake and BC6OTHER - mediated BC6OTHER uptake were inhibited by most of the CHEM BC6ENTC investigated.	CPR:4
In overexpressing cell lines, BC6OTHER - and BC6ENTG - mediated BC6OTHER uptake and BC6OTHER - mediated BC6OTHER uptake were inhibited by most of the CHEM BC6ENTC investigated.	CPR:4
In overexpressing cell lines, BC6OTHER - and BC6OTHER - mediated BC6OTHER uptake and BC6ENTG - mediated BC6OTHER uptake were inhibited by most of the CHEM BC6ENTC investigated.	CPR:4
BC6ENTG - , BC6OTHER - , and BC6OTHER - mediated substrate transport was inhibited efficiently by CHEM (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), BC6ENTC (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), BC6OTHER (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and BC6OTHER (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).	CPR:4
BC6OTHER - , BC6ENTG - , and BC6OTHER - mediated substrate transport was inhibited efficiently by CHEM (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), BC6ENTC (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), BC6OTHER (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and BC6OTHER (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).	CPR:4
BC6OTHER - , BC6OTHER - , and BC6ENTG - mediated substrate transport was inhibited efficiently by CHEM (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), BC6ENTC (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), BC6OTHER (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and BC6OTHER (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).	CPR:4
Interaction of CHEM BC6ENTC with BC6ENTG .	False
BC6ENTG - , BC6OTHER - , and BC6OTHER - mediated substrate transport was inhibited efficiently by CHEM (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), BC6OTHER (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), BC6ENTC (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and BC6OTHER (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).	CPR:4
BC6OTHER - , BC6ENTG - , and BC6OTHER - mediated substrate transport was inhibited efficiently by CHEM (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), BC6OTHER (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), BC6ENTC (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and BC6OTHER (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).	CPR:4
BC6OTHER - , BC6OTHER - , and BC6ENTG - mediated substrate transport was inhibited efficiently by CHEM (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), BC6OTHER (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), BC6ENTC (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and BC6OTHER (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).	CPR:4
BC6ENTG - , BC6OTHER - , and BC6OTHER - mediated substrate transport was inhibited efficiently by CHEM (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), BC6OTHER (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), BC6OTHER (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and BC6ENTC (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).	CPR:4
BC6OTHER - , BC6ENTG - , and BC6OTHER - mediated substrate transport was inhibited efficiently by CHEM (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), BC6OTHER (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), BC6OTHER (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and BC6ENTC (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).	CPR:4
BC6OTHER - , BC6OTHER - , and BC6ENTG - mediated substrate transport was inhibited efficiently by CHEM (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), BC6OTHER (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), BC6OTHER (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and BC6ENTC (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).	CPR:4
Furthermore, CHEM, BC6ENTC , and BC6OTHER (100 µM) significantly inhibited BC6ENTG - mediated BC6OTHER and BC6OTHER uptake into human hepatocytes.	CPR:4
Furthermore, CHEM, BC6OTHER , and BC6ENTC (100 µM) significantly inhibited BC6ENTG - mediated BC6OTHER and BC6OTHER uptake into human hepatocytes.	CPR:4
Furthermore, CHEM, BC6OTHER , and BC6OTHER (100 µM) significantly inhibited BC6ENTG - mediated BC6ENTC and BC6OTHER uptake into human hepatocytes.	CPR:9
Furthermore, CHEM, BC6OTHER , and BC6OTHER (100 µM) significantly inhibited BC6ENTG - mediated BC6OTHER and BC6ENTC uptake into human hepatocytes.	CPR:9
The extent of CHEM - drug interactions depends on BC6ENTG isoform specificity and concentrations of BC6ENTC at the site of drug transport.	False
Higher than customary doses of CHEM, or formulations with improved bioavailability, may increase the risk of BC6ENTC interactions with BC6ENTG substrates in patients.	False
The present study examined the effect of CHEM BC6ENTC on BC6ENTG - , BC6OTHER - , and BC6OTHER - mediated transport in cell lines stably expressing these transporters and in human hepatocytes.	False
The present study examined the effect of CHEM BC6ENTC on BC6OTHER - , BC6ENTG - , and BC6OTHER - mediated transport in cell lines stably expressing these transporters and in human hepatocytes.	False
The present study examined the effect of CHEM BC6ENTC on BC6OTHER - , BC6OTHER - , and BC6ENTG - mediated transport in cell lines stably expressing these transporters and in human hepatocytes.	False
An inhibitor of BC6ENTG ( BC6OTHER ), BC6ENTC ( BC6OTHER ), was reported to have neuroprotective activity, but clinical trials failed to confirm it.	CPR:4
An inhibitor of type B BC6OTHER oxidase ( BC6ENTG ), BC6ENTC ( BC6OTHER ), was reported to have neuroprotective activity, but clinical trials failed to confirm it.	CPR:4
An inhibitor of BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6ENTC ), was reported to have neuroprotective activity, but clinical trials failed to confirm it.	CPR:4
An inhibitor of type B BC6OTHER oxidase ( BC6ENTG ), BC6OTHER ( BC6ENTC ), was reported to have neuroprotective activity, but clinical trials failed to confirm it.	CPR:4
BC6ENTC prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic BC6ENTG and a BC6OTHER , BC6OTHER ( BC6OTHER ).	CPR:3
BC6ENTC prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic BC6OTHER and a BC6ENTG , BC6OTHER ( BC6OTHER ).	CPR:3
BC6ENTC prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic BC6OTHER and a BC6OTHER , BC6ENTG ( BC6OTHER ).	CPR:3
BC6ENTC prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic BC6OTHER and a BC6OTHER , BC6OTHER ( BC6ENTG ).	CPR:3
Long - term administration of BC6ENTC to rats increased the activities of antioxidative enzymes BC6ENTG ( BC6OTHER ) and BC6OTHER in the brain regions containing BC6OTHER neurons.	CPR:3
Long - term administration of BC6ENTC to rats increased the activities of antioxidative enzymes BC6OTHER dismutase ( BC6ENTG ) and BC6OTHER in the brain regions containing BC6OTHER neurons.	CPR:3
Long - term administration of BC6ENTC to rats increased the activities of antioxidative enzymes BC6OTHER dismutase ( BC6OTHER ) and BC6ENTG in the brain regions containing BC6OTHER neurons.	CPR:3
Long - term administration of BC6OTHER to rats increased the activities of antioxidative enzymes BC6ENTC dismutase ( BC6ENTG ) and BC6OTHER in the brain regions containing BC6OTHER neurons.	False
Long - term administration of BC6OTHER to rats increased the activities of antioxidative enzymes BC6ENTC dismutase ( BC6OTHER ) and BC6ENTG in the brain regions containing BC6OTHER neurons.	False
Long - term administration of BC6OTHER to rats increased the activities of antioxidative enzymes BC6ENTG ( BC6OTHER ) and BC6OTHER in the brain regions containing BC6ENTC neurons.	False
Long - term administration of BC6OTHER to rats increased the activities of antioxidative enzymes BC6OTHER dismutase ( BC6ENTG ) and BC6OTHER in the brain regions containing BC6ENTC neurons.	False
Long - term administration of BC6OTHER to rats increased the activities of antioxidative enzymes BC6OTHER dismutase ( BC6OTHER ) and BC6ENTG in the brain regions containing BC6ENTC neurons.	False
An inhibitor of type B BC6ENTC oxidase ( BC6ENTG ), BC6OTHER ( BC6OTHER ), was reported to have neuroprotective activity, but clinical trials failed to confirm it.	False
The induction of BC6ENTG by CHEM was inhibited by BC6ENTC but not by BC6OTHER , BC6OTHER , nor BC6OTHER .	CPR:4
The induction of BC6ENTG by CHEM was inhibited by BC6OTHER but not by BC6ENTC , BC6OTHER , nor BC6OTHER .	False
The induction of BC6ENTG by CHEM was inhibited by BC6OTHER but not by BC6OTHER , BC6ENTC , nor BC6OTHER .	False
The induction of BC6ENTG by CHEM was inhibited by BC6OTHER but not by BC6OTHER , BC6OTHER , nor BC6ENTC .	False
Most importantly, administration of EIH significantly reduced not only increase in blood BC6ENTG , BC6OTHER BC6OTHER , BUN, BC6ENTC levels but also decrease macrophage infiltrate in the liver of septic mice, which were reversed by CHEM, a BC6OTHER inhibitor.	False
Most importantly, administration of EIH significantly reduced not only increase in blood BC6OTHER , BC6ENTG BC6OTHER , BUN, BC6ENTC levels but also decrease macrophage infiltrate in the liver of septic mice, which were reversed by CHEM, a BC6OTHER inhibitor.	False
Most importantly, administration of EIH significantly reduced not only increase in blood BC6OTHER , BC6OTHER BC6ENTG , BUN, BC6ENTC levels but also decrease macrophage infiltrate in the liver of septic mice, which were reversed by CHEM, a BC6OTHER inhibitor.	False
Most importantly, administration of EIH significantly reduced not only increase in blood BC6OTHER , BC6OTHER BC6OTHER , BUN, BC6ENTC levels but also decrease macrophage infiltrate in the liver of septic mice, which were reversed by CHEM, a BC6ENTG inhibitor.	False
We recently proposed that BC6ENTC oxygenase - 1 ( BC6ENTG ) negatively regulates BC6OTHER in inflammatory conditions.	False
We recently proposed that BC6ENTC oxygenase - 1 ( BC6OTHER ) negatively regulates BC6ENTG in inflammatory conditions.	False
We investigated whether BC6ENTC extract of Inula helenium L. (EIH) activates BC6ENTG BC6OTHER / BC6OTHER / BC6OTHER pathways in RAW264.7 cells and reduces inflammation in CLP - induced septic mice.	False
We investigated whether BC6ENTC extract of Inula helenium L. (EIH) activates BC6OTHER BC6ENTG / BC6OTHER / BC6OTHER pathways in RAW264.7 cells and reduces inflammation in CLP - induced septic mice.	False
We investigated whether BC6ENTC extract of Inula helenium L. (EIH) activates BC6OTHER BC6OTHER / BC6ENTG / BC6OTHER pathways in RAW264.7 cells and reduces inflammation in CLP - induced septic mice.	False
We investigated whether BC6ENTC extract of Inula helenium L. (EIH) activates BC6OTHER BC6OTHER / BC6OTHER / BC6ENTG pathways in RAW264.7 cells and reduces inflammation in CLP - induced septic mice.	False
Induction of BC6ENTG through BC6OTHER BC6OTHER / BC6OTHER signaling pathway by BC6ENTC extract of Inula helenium L. reduces inflammation in LPS - activated RAW 264.7 cells and CLP - induced septic mice.	CPR:3
Induction of BC6OTHER through BC6ENTG BC6OTHER / BC6OTHER signaling pathway by BC6ENTC extract of Inula helenium L. reduces inflammation in LPS - activated RAW 264.7 cells and CLP - induced septic mice.	CPR:3
Induction of BC6OTHER through BC6OTHER BC6ENTG / BC6OTHER signaling pathway by BC6ENTC extract of Inula helenium L. reduces inflammation in LPS - activated RAW 264.7 cells and CLP - induced septic mice.	CPR:3
Induction of BC6OTHER through BC6OTHER BC6OTHER / BC6ENTG signaling pathway by BC6ENTC extract of Inula helenium L. reduces inflammation in LPS - activated RAW 264.7 cells and CLP - induced septic mice.	False
A novel missense mutation, BC6ENTG , in exon 5 of the erythroid - specific BC6OTHER synthase gene ( BC6OTHER ) was identified in a Japanese male with BC6ENTC - responsive sideroblastic anemia.	False
A novel missense mutation, BC6OTHER , in exon 5 of the BC6ENTG gene ( BC6OTHER ) was identified in a Japanese male with BC6ENTC - responsive sideroblastic anemia.	False
A novel missense mutation, BC6OTHER , in exon 5 of the erythroid - specific BC6OTHER synthase gene ( BC6ENTG ) was identified in a Japanese male with BC6ENTC - responsive sideroblastic anemia.	False
Activity of the mutant BC6ENTG protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of BC6ENTC , consistent with the clinical response of the patient to BC6OTHER treatment.	CPR:3
Activity of the mutant BC6ENTG protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of BC6OTHER , consistent with the clinical response of the patient to BC6ENTC treatment.	False
A novel missense mutation, BC6ENTG , in exon 5 of the erythroid - specific BC6ENTC synthase gene ( BC6OTHER ) was identified in a Japanese male with BC6OTHER - responsive sideroblastic anemia.	False
A novel missense mutation, BC6OTHER , in exon 5 of the erythroid - specific BC6ENTC synthase gene ( BC6ENTG ) was identified in a Japanese male with BC6OTHER - responsive sideroblastic anemia.	False
A novel mutation of the BC6ENTG gene in a patient with non - inherited BC6ENTC - responsive sideroblastic anemia.	False
BC6ENTC receptor ( BC6OTHER ) antagonists are valuable in the treatment of BC6ENTG - positive human breast cancer.	False
BC6ENTC receptor ( BC6ENTG ) antagonists are valuable in the treatment of BC6OTHER - positive human breast cancer.	False
In this study, we designed and synthesized nine new derivatives of BC6ENTC (E2) with a bulky side chain attached to its C - 7α position, and determined their BC6ENTG antagonistic activity using in vitro bioassays.	False
Computational docking analysis was conducted to model the interaction of these antagonists with the BC6ENTG and showed that they could tightly bind to the BC6OTHER in a manner similar to that of BC6ENTC , a pure BC6OTHER antagonist.	False
Computational docking analysis was conducted to model the interaction of these antagonists with the BC6OTHER and showed that they could tightly bind to the BC6ENTG in a manner similar to that of BC6ENTC , a pure BC6OTHER antagonist.	False
Computational docking analysis was conducted to model the interaction of these antagonists with the BC6OTHER and showed that they could tightly bind to the BC6OTHER in a manner similar to that of BC6ENTC , a pure BC6ENTG antagonist.	CPR:6
These results provide an example that attachment of a bulky side chain to the CHEM position of E2 can produce BC6ENTG antagonists with BC6OTHER affinity comparable to that of BC6ENTC .	False
These results provide an example that attachment of a bulky side chain to the CHEM position of E2 can produce BC6OTHER antagonists with BC6ENTG affinity comparable to that of BC6ENTC .	CPR:6
When dual angiogenic growth factors (GFs), such as BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), are encapsulated separately in the core and shell domains, respectively, the BC6OTHER release rate is much greater than that of BC6OTHER , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6ENTC and more than 45% with HMW core BC6OTHER .	False
When dual angiogenic growth factors (GFs), such as BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ), are encapsulated separately in the core and shell domains, respectively, the BC6OTHER release rate is much greater than that of BC6OTHER , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6ENTC and more than 45% with HMW core BC6OTHER .	False
When dual angiogenic growth factors (GFs), such as BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), are encapsulated separately in the core and shell domains, respectively, the BC6OTHER release rate is much greater than that of BC6OTHER , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6ENTC and more than 45% with HMW core BC6OTHER .	False
When dual angiogenic growth factors (GFs), such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ), are encapsulated separately in the core and shell domains, respectively, the BC6OTHER release rate is much greater than that of BC6OTHER , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6ENTC and more than 45% with HMW core BC6OTHER .	False
When dual angiogenic growth factors (GFs), such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), are encapsulated separately in the core and shell domains, respectively, the BC6ENTG release rate is much greater than that of BC6OTHER , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6ENTC and more than 45% with HMW core BC6OTHER .	CPR:3
When dual angiogenic growth factors (GFs), such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), are encapsulated separately in the core and shell domains, respectively, the BC6OTHER release rate is much greater than that of BC6ENTG , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6ENTC and more than 45% with HMW core BC6OTHER .	CPR:3
When dual angiogenic growth factors (GFs), such as BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), are encapsulated separately in the core and shell domains, respectively, the BC6OTHER release rate is much greater than that of BC6OTHER , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6OTHER and more than 45% with HMW core BC6ENTC .	False
When dual angiogenic growth factors (GFs), such as BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ), are encapsulated separately in the core and shell domains, respectively, the BC6OTHER release rate is much greater than that of BC6OTHER , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6OTHER and more than 45% with HMW core BC6ENTC .	False
When dual angiogenic growth factors (GFs), such as BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), are encapsulated separately in the core and shell domains, respectively, the BC6OTHER release rate is much greater than that of BC6OTHER , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6OTHER and more than 45% with HMW core BC6ENTC .	False
When dual angiogenic growth factors (GFs), such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ), are encapsulated separately in the core and shell domains, respectively, the BC6OTHER release rate is much greater than that of BC6OTHER , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6OTHER and more than 45% with HMW core BC6ENTC .	False
When dual angiogenic growth factors (GFs), such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), are encapsulated separately in the core and shell domains, respectively, the BC6ENTG release rate is much greater than that of BC6OTHER , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6OTHER and more than 45% with HMW core BC6ENTC .	CPR:3
When dual angiogenic growth factors (GFs), such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), are encapsulated separately in the core and shell domains, respectively, the BC6OTHER release rate is much greater than that of BC6ENTG , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6OTHER and more than 45% with HMW core BC6ENTC .	CPR:3
CSF production in wildtype mice was (in microl / min) 0.37 + / - 0.04 microl / min (control), 0.16 + / - 0.03 microl / min ( BC6ENTC - treated) and 1.14 + / - 0.15 microl / min ( BC6OTHER - treated), and reduced by up to 25% in BC6ENTG null mice.	False
CSF production in wildtype mice was (in microl / min) 0.37 + / - 0.04 microl / min (control), 0.16 + / - 0.03 microl / min ( BC6OTHER - treated) and 1.14 + / - 0.15 microl / min ( BC6ENTC - treated), and reduced by up to 25% in BC6ENTG null mice.	False
BACKGROUND & AIMS: Sensitization of Kupffer cells (KCs) to lipopolysaccharide (LPS) and overproduction of BC6ENTG are critical for progression of BC6ENTC liver injury.	False
CONCLUSIONS: These results collectively indicate that BC6ENTC prevents alcoholic liver injury through suppression of BC6ENTG production and abolishment of KC sensitization.	CPR:4
BC6ENTC has been shown to suppress BC6ENTG production from macrophages.	CPR:4
KCs were isolated after 4 weeks of BC6ENTC treatment and intracellular BC6OTHER ([ BC6OTHER ]i) was measured using fura - 2, whereas BC6ENTG was evaluated by reverse - transcription polymerase chain reaction and enzyme - linked immunosorbent assay.	False
KCs were isolated after 4 weeks of BC6OTHER treatment and intracellular BC6ENTC ([ BC6OTHER ]i) was measured using fura - 2, whereas BC6ENTG was evaluated by reverse - transcription polymerase chain reaction and enzyme - linked immunosorbent assay.	False
KCs were isolated after 4 weeks of BC6OTHER treatment and intracellular BC6OTHER ([ BC6ENTC ]i) was measured using fura - 2, whereas BC6ENTG was evaluated by reverse - transcription polymerase chain reaction and enzyme - linked immunosorbent assay.	False
 BC6ENTC prevents BC6OTHER liver injury in rats through suppression of Kupffer cell sensitization and BC6ENTG production.	CPR:4
 BC6OTHER prevents BC6ENTC liver injury in rats through suppression of Kupffer cell sensitization and BC6ENTG production.	False
Furthermore, BC6ENTC abolished the LPS - induced increase in BC6ENTG expression and [ BC6OTHER ]i elevation in KCs.	CPR:4
Furthermore, BC6OTHER abolished the LPS - induced increase in BC6ENTG expression and [ BC6ENTC ]i elevation in KCs.	False
Moreover, BC6ENTC reduced the LPS - induced BC6ENTG production by KCs by decreasing BC6OTHER messenger RNA.	CPR:4
Moreover, BC6ENTC reduced the LPS - induced BC6OTHER production by KCs by decreasing BC6ENTG messenger RNA.	CPR:4
BC6ENTC between CHEM(183) and CHEM(191) are necessary for proper BC6ENTG activation, but additional sequence between CHEM(195) and CHEM(197) or between CHEM(260) and CHEM(265) is required for complete restoration of activation.	False
To identify key BC6ENTC involved in BC6ENTG activation, recombinant BC6OTHER proteins containing BC6OTHER substitutions for wild - type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay.	False
To identify key BC6ENTC involved in BC6OTHER activation, recombinant BC6ENTG proteins containing BC6OTHER substitutions for wild - type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay.	False
To identify key BC6OTHER involved in BC6ENTG activation, recombinant BC6OTHER proteins containing BC6ENTC substitutions for wild - type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay.	False
To identify key BC6OTHER involved in BC6OTHER activation, recombinant BC6ENTG proteins containing BC6ENTC substitutions for wild - type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay.	False
Substitutions for CHEM and CHEM at the BC6ENTC terminus and for CHEM at the BC6OTHER terminus of the BC6ENTG markedly decreased BC6OTHER coagulant activity.	False
Substitutions for CHEM and CHEM at the BC6ENTC terminus and for CHEM at the BC6OTHER terminus of the BC6OTHER markedly decreased BC6ENTG coagulant activity.	False
Substitutions for CHEM and CHEM at the BC6OTHER terminus and for CHEM at the BC6ENTC terminus of the BC6ENTG markedly decreased BC6OTHER coagulant activity.	False
Substitutions for CHEM and CHEM at the BC6OTHER terminus and for CHEM at the BC6ENTC terminus of the BC6OTHER markedly decreased BC6ENTG coagulant activity.	False
Identification of BC6ENTC in the BC6ENTG required for activation of BC6OTHER .	False
Identification of BC6ENTC in the BC6OTHER required for activation of BC6ENTG .	False
The current comprehensive BC6OTHER clinical end - point programme (4 large scale morbidity / mortality trials) should provide evidence regarding the efficacy of direct blockade of the BC6ENTG with BC6OTHER compared to standard therapy: 1) The BC6OTHER Heart Failure Survival Study - ELITE II, 2) The BC6OTHER Post - Myocardial Infarction Survival Study - OPTIMAAL, 3) The BC6ENTC Hypertension Survival Study - LIFE and 4) The BC6OTHER Renal Protection Study - RENAAL.	False
The current comprehensive BC6OTHER clinical end - point programme (4 large scale morbidity / mortality trials) should provide evidence regarding the efficacy of direct blockade of the BC6ENTG with BC6OTHER compared to standard therapy: 1) The BC6OTHER Heart Failure Survival Study - ELITE II, 2) The BC6OTHER Post - Myocardial Infarction Survival Study - OPTIMAAL, 3) The BC6OTHER Hypertension Survival Study - LIFE and 4) The BC6ENTC Renal Protection Study - RENAAL.	False
Since all of the BC6ENTC antagonists are selective for the BC6ENTG , these drugs should exhibit similar cardiovascular effects.	False
BC6ENTC (parent compound), has moderate affinity for the BC6ENTG (competitive inhibition).	False
BC6ENTC is well - absorbed orally as an active drug and is rapidly converted via oxidation in the human liver to a more potent metabolite (designated E3174) with an affinity 20 - to 30 - times greater for the BC6ENTG (non - competitive inhibition).	CPR:4
 BC6ENTC : a selective BC6ENTG antagonist for the treatment of heart failure.	CPR:6
BC6ENTC ( BC6OTHER ) is the prototype of a new class of potent and selective BC6ENTG antagonists with the largest published preclinical and clinical data base.	CPR:6
BC6OTHER ( BC6ENTC ) is the prototype of a new class of potent and selective BC6ENTG antagonists with the largest published preclinical and clinical data base.	CPR:6
Clinical experience in heart failure is growing, and recent data suggest an improved survival with BC6ENTC versus BC6OTHER , a drug from the BC6ENTG inhibitor class with proven benefit in this population.	CPR:4
Clinical experience in heart failure is growing, and recent data suggest an improved survival with BC6OTHER versus BC6ENTC , a drug from the BC6ENTG inhibitor class with proven benefit in this population.	CPR:4
The current comprehensive BC6ENTC clinical end - point programme (4 large scale morbidity / mortality trials) should provide evidence regarding the efficacy of direct blockade of the BC6ENTG with BC6OTHER compared to standard therapy: 1) The BC6OTHER Heart Failure Survival Study - ELITE II, 2) The BC6OTHER Post - Myocardial Infarction Survival Study - OPTIMAAL, 3) The BC6OTHER Hypertension Survival Study - LIFE and 4) The BC6OTHER Renal Protection Study - RENAAL.	False
The current comprehensive BC6OTHER clinical end - point programme (4 large scale morbidity / mortality trials) should provide evidence regarding the efficacy of direct blockade of the BC6ENTG with BC6ENTC compared to standard therapy: 1) The BC6OTHER Heart Failure Survival Study - ELITE II, 2) The BC6OTHER Post - Myocardial Infarction Survival Study - OPTIMAAL, 3) The BC6OTHER Hypertension Survival Study - LIFE and 4) The BC6OTHER Renal Protection Study - RENAAL.	CPR:4
The current comprehensive BC6OTHER clinical end - point programme (4 large scale morbidity / mortality trials) should provide evidence regarding the efficacy of direct blockade of the BC6ENTG with BC6OTHER compared to standard therapy: 1) The BC6ENTC Heart Failure Survival Study - ELITE II, 2) The BC6OTHER Post - Myocardial Infarction Survival Study - OPTIMAAL, 3) The BC6OTHER Hypertension Survival Study - LIFE and 4) The BC6OTHER Renal Protection Study - RENAAL.	False
The current comprehensive BC6OTHER clinical end - point programme (4 large scale morbidity / mortality trials) should provide evidence regarding the efficacy of direct blockade of the BC6ENTG with BC6OTHER compared to standard therapy: 1) The BC6OTHER Heart Failure Survival Study - ELITE II, 2) The BC6ENTC Post - Myocardial Infarction Survival Study - OPTIMAAL, 3) The BC6OTHER Hypertension Survival Study - LIFE and 4) The BC6OTHER Renal Protection Study - RENAAL.	False
Since 10( - 3)M BC6OTHER oxidises BC6OTHER and BC6OTHER residues in proteins, we examined BC6ENTC binding to BC6ENTG in the presence and absence of BC6OTHER utilising (45) BC6OTHER .	False
Since 10( - 3)M BC6OTHER oxidises BC6OTHER and BC6OTHER residues in proteins, we examined BC6OTHER binding to BC6ENTG in the presence and absence of BC6ENTC utilising (45) BC6OTHER .	False
Since 10( - 3)M BC6OTHER oxidises BC6OTHER and BC6OTHER residues in proteins, we examined BC6OTHER binding to BC6ENTG in the presence and absence of BC6OTHER utilising (45) BC6ENTC .	False
The results showed that all four BC6ENTC atoms exchanged per molecule of BC6ENTG .	False
Since oxidised BC6ENTG looses its ability to activate BC6ENTC ATPase, enzyme activities were followed in full skin biopsies from lesional skin of patients with acute vitiligo (n=6) and healthy controls (n=6).	False
Computer simulation of native and oxidised BC6ENTG confirmed the loss of all four BC6ENTC ions from their specific BC6OTHER .	False
Computer simulation of native and oxidised BC6OTHER confirmed the loss of all four BC6ENTC ions from their specific BC6ENTG .	False
 BC6ENTC - mediated oxidative stress disrupts BC6OTHER binding on BC6ENTG : more evidence for oxidative stress in vitiligo.	False
 BC6OTHER - mediated oxidative stress disrupts BC6ENTC binding on BC6ENTG : more evidence for oxidative stress in vitiligo.	False
Taken together BC6ENTC - mediated oxidation affects BC6OTHER binding in BC6ENTG leading to perturbed BC6OTHER homeostasis and perturbed BC6OTHER - uptake in the epidermis of acute vitiligo.	False
Patients with acute vitiligo have low epidermal BC6ENTG expression / activities and accumulate 10( - 3) M BC6ENTC .	CPR:9
Taken together BC6OTHER - mediated oxidation affects BC6ENTC binding in BC6ENTG leading to perturbed BC6OTHER homeostasis and perturbed BC6OTHER - uptake in the epidermis of acute vitiligo.	False
Taken together BC6OTHER - mediated oxidation affects BC6OTHER binding in BC6ENTG leading to perturbed BC6ENTC homeostasis and perturbed BC6OTHER - uptake in the epidermis of acute vitiligo.	False
Taken together BC6OTHER - mediated oxidation affects BC6OTHER binding in BC6ENTG leading to perturbed BC6OTHER homeostasis and perturbed BC6ENTC - uptake in the epidermis of acute vitiligo.	False
Since 10( - 3)M BC6ENTC oxidises BC6OTHER and BC6OTHER residues in proteins, we examined BC6OTHER binding to BC6ENTG in the presence and absence of BC6OTHER utilising (45) BC6OTHER .	False
Since 10( - 3)M BC6OTHER oxidises BC6ENTC and BC6OTHER residues in proteins, we examined BC6OTHER binding to BC6ENTG in the presence and absence of BC6OTHER utilising (45) BC6OTHER .	False
Since 10( - 3)M BC6OTHER oxidises BC6OTHER and BC6ENTC residues in proteins, we examined BC6OTHER binding to BC6ENTG in the presence and absence of BC6OTHER utilising (45) BC6OTHER .	False
The transport BC6ENTC - sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to BC6OTHER - BC6OTHER exchange ( BC6ENTG isoform).	False
The transport BC6OTHER - sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to BC6ENTC - BC6OTHER exchange ( BC6ENTG isoform).	CPR:9
The transport BC6OTHER - sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to BC6OTHER - BC6ENTC exchange ( BC6ENTG isoform).	CPR:9
The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective BC6ENTG inhibitor 15b ( BC6ENTC ) are described.	CPR:4
In this initial report, preliminary structure - activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation BC6ENTG inhibitor 4 ( BC6ENTC ).	CPR:4
Synthesis, structure - activity relationships, and in vivo efficacy of the novel potent and selective BC6ENTG ( BC6OTHER ) inhibitor BC6ENTC ( BC6OTHER ) currently in phase 1 and phase 2 clinical trials.	False
Synthesis, structure - activity relationships, and in vivo efficacy of the novel potent and selective BC6OTHER ( BC6ENTG ) inhibitor BC6ENTC ( BC6OTHER ) currently in phase 1 and phase 2 clinical trials.	False
Synthesis, structure - activity relationships, and in vivo efficacy of the novel potent and selective BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER ( BC6ENTC ) currently in phase 1 and phase 2 clinical trials.	False
Synthesis, structure - activity relationships, and in vivo efficacy of the novel potent and selective BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER ( BC6ENTC ) currently in phase 1 and phase 2 clinical trials.	False
This process was reduced by a protonophore, BC6ENTC , and a typical BC6ENTG ( BC6OTHER ) inhibitor, BC6OTHER , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6OTHER .	False
This process was reduced by a protonophore, BC6ENTC , and a typical BC6OTHER ( BC6ENTG ) inhibitor, BC6OTHER , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6OTHER .	False
This process was reduced by a protonophore, BC6ENTC , and a typical BC6OTHER ( BC6OTHER ) inhibitor, BC6OTHER , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6ENTG .	False
This process was reduced by a protonophore, BC6OTHER , and a typical BC6ENTC transporter ( BC6ENTG ) inhibitor, BC6OTHER , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6OTHER .	False
This process was reduced by a protonophore, BC6OTHER , and a typical BC6ENTC transporter ( BC6OTHER ) inhibitor, BC6OTHER , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6ENTG .	False
This process was reduced by a protonophore, BC6OTHER , and a typical BC6ENTG ( BC6OTHER ) inhibitor, BC6ENTC , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6OTHER .	CPR:4
This process was reduced by a protonophore, BC6OTHER , and a typical BC6OTHER ( BC6ENTG ) inhibitor, BC6ENTC , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6OTHER .	CPR:4
This process was reduced by a protonophore, BC6OTHER , and a typical BC6OTHER ( BC6OTHER ) inhibitor, BC6ENTC , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6ENTG .	False
This process was reduced by a protonophore, BC6OTHER , and a typical BC6ENTG ( BC6OTHER ) inhibitor, BC6OTHER , suggesting that BC6ENTC uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6OTHER .	False
This process was reduced by a protonophore, BC6OTHER , and a typical BC6OTHER ( BC6ENTG ) inhibitor, BC6OTHER , suggesting that BC6ENTC uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6OTHER .	False
This process was reduced by a protonophore, BC6OTHER , and a typical BC6OTHER ( BC6OTHER ) inhibitor, BC6OTHER , suggesting that BC6ENTC uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6ENTG .	CPR:9
This process was reduced by a protonophore, BC6OTHER , and a typical BC6ENTG ( BC6OTHER ) inhibitor, BC6OTHER , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6ENTC - coupled BC6OTHER .	False
This process was reduced by a protonophore, BC6OTHER , and a typical BC6OTHER ( BC6ENTG ) inhibitor, BC6OTHER , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6ENTC - coupled BC6OTHER .	False
This process was reduced by a protonophore, BC6OTHER , and a typical BC6OTHER ( BC6OTHER ) inhibitor, BC6OTHER , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6ENTC - coupled BC6ENTG .	False
This process was reduced by a protonophore, BC6OTHER , and a typical BC6ENTG ( BC6OTHER ) inhibitor, BC6OTHER , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6ENTC transport system.	False
This process was reduced by a protonophore, BC6OTHER , and a typical BC6OTHER ( BC6ENTG ) inhibitor, BC6OTHER , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6ENTC transport system.	False
Because BC6ENTC reduced to 67% of the BC6OTHER uptake even at 10mM, it is unlikely that BC6OTHER uptake in rat astrocytes is mediated by BC6ENTG and / or BC6OTHER .	False
Because BC6ENTC reduced to 67% of the BC6OTHER uptake even at 10mM, it is unlikely that BC6OTHER uptake in rat astrocytes is mediated by BC6OTHER and / or BC6ENTG .	False
Because BC6OTHER reduced to 67% of the BC6ENTC uptake even at 10mM, it is unlikely that BC6OTHER uptake in rat astrocytes is mediated by BC6ENTG and / or BC6OTHER .	False
Because BC6OTHER reduced to 67% of the BC6ENTC uptake even at 10mM, it is unlikely that BC6OTHER uptake in rat astrocytes is mediated by BC6OTHER and / or BC6ENTG .	False
Because BC6OTHER reduced to 67% of the BC6OTHER uptake even at 10mM, it is unlikely that BC6ENTC uptake in rat astrocytes is mediated by BC6ENTG and / or BC6OTHER .	CPR:9
Because BC6OTHER reduced to 67% of the BC6OTHER uptake even at 10mM, it is unlikely that BC6ENTC uptake in rat astrocytes is mediated by BC6OTHER and / or BC6ENTG .	CPR:9
These results provide biochemical evidence of a BC6ENTC - coupled and saturable transport system, presumed to be a BC6ENTG BC6OTHER or other unknown BC6OTHER - coupled BC6OTHER transport system, for BC6OTHER in rat cerebrocortical astrocytes.	False
These results provide biochemical evidence of a BC6ENTC - coupled and saturable transport system, presumed to be a low - affinity BC6OTHER transporter BC6ENTG or other unknown BC6OTHER - coupled BC6OTHER transport system, for BC6OTHER in rat cerebrocortical astrocytes.	False
These results provide biochemical evidence of a BC6ENTC - coupled and saturable transport system, presumed to be a low - affinity BC6OTHER transporter BC6OTHER or other unknown BC6ENTG , for BC6OTHER in rat cerebrocortical astrocytes.	False
These results provide biochemical evidence of a BC6OTHER - coupled and saturable transport system, presumed to be a low - affinity BC6ENTC transporter BC6ENTG or other unknown BC6OTHER - coupled BC6OTHER transport system, for BC6OTHER in rat cerebrocortical astrocytes.	False
These results provide biochemical evidence of a BC6OTHER - coupled and saturable transport system, presumed to be a low - affinity BC6ENTC transporter BC6OTHER or other unknown BC6ENTG , for BC6OTHER in rat cerebrocortical astrocytes.	False
These results provide biochemical evidence of a BC6OTHER - coupled and saturable transport system, presumed to be a BC6ENTG BC6OTHER or other unknown BC6ENTC - coupled BC6OTHER transport system, for BC6OTHER in rat cerebrocortical astrocytes.	False
These results provide biochemical evidence of a BC6OTHER - coupled and saturable transport system, presumed to be a low - affinity BC6OTHER transporter BC6ENTG or other unknown BC6ENTC - coupled BC6OTHER transport system, for BC6OTHER in rat cerebrocortical astrocytes.	False
These results provide biochemical evidence of a BC6OTHER - coupled and saturable transport system, presumed to be a BC6ENTG BC6OTHER or other unknown BC6OTHER - coupled BC6ENTC transport system, for BC6OTHER in rat cerebrocortical astrocytes.	False
These results provide biochemical evidence of a BC6OTHER - coupled and saturable transport system, presumed to be a low - affinity BC6OTHER transporter BC6ENTG or other unknown BC6OTHER - coupled BC6ENTC transport system, for BC6OTHER in rat cerebrocortical astrocytes.	False
These results provide biochemical evidence of a BC6OTHER - coupled and saturable transport system, presumed to be a BC6ENTG BC6OTHER or other unknown BC6OTHER - coupled BC6OTHER transport system, for BC6ENTC in rat cerebrocortical astrocytes.	CPR:9
These results provide biochemical evidence of a BC6OTHER - coupled and saturable transport system, presumed to be a low - affinity BC6OTHER transporter BC6ENTG or other unknown BC6OTHER - coupled BC6OTHER transport system, for BC6ENTC in rat cerebrocortical astrocytes.	CPR:9
These results provide biochemical evidence of a BC6OTHER - coupled and saturable transport system, presumed to be a low - affinity BC6OTHER transporter BC6OTHER or other unknown BC6ENTG , for BC6ENTC in rat cerebrocortical astrocytes.	CPR:9
 BC6ENTC , the first prostate - selective BC6ENTG antagonist.	CPR:6
Treatment options for DUB are: combined oral contraceptives (COCs), BC6ENTC , non CHEM anti inflammatory drugs (NSAIDs), BC6OTHER (anti - fibrinolytic), BC6ENTG analogues, BC6OTHER and BC6OTHER releasing intra uterine system (LNG IUS).	False
Treatment options for DUB are: combined oral contraceptives (COCs), BC6OTHER , non CHEM anti inflammatory drugs (NSAIDs), BC6ENTC (anti - fibrinolytic), BC6ENTG analogues, BC6OTHER and BC6OTHER releasing intra uterine system (LNG IUS).	False
Treatment options for DUB are: combined oral contraceptives (COCs), BC6OTHER , non CHEM anti inflammatory drugs (NSAIDs), BC6OTHER (anti - fibrinolytic), BC6ENTG analogues, BC6ENTC and BC6OTHER releasing intra uterine system (LNG IUS).	False
Treatment options for DUB are: combined oral contraceptives (COCs), BC6OTHER , non CHEM anti inflammatory drugs (NSAIDs), BC6OTHER (anti - fibrinolytic), BC6ENTG analogues, BC6OTHER and BC6ENTC releasing intra uterine system (LNG IUS).	False
The phosphorylations of BC6ENTG and endothelial BC6OTHER synthase ( BC6OTHER ) as well as the level of BC6ENTC were measured to confirm the effect of BC6OTHER on BC6OTHER signaling pathway.	False
The phosphorylations of BC6OTHER and BC6ENTG ( BC6OTHER ) as well as the level of BC6ENTC were measured to confirm the effect of BC6OTHER on BC6OTHER signaling pathway.	False
The phosphorylations of BC6OTHER and endothelial BC6OTHER synthase ( BC6ENTG ) as well as the level of BC6ENTC were measured to confirm the effect of BC6OTHER on BC6OTHER signaling pathway.	False
The phosphorylations of BC6OTHER and endothelial BC6OTHER synthase ( BC6OTHER ) as well as the level of BC6ENTC were measured to confirm the effect of BC6ENTG on BC6OTHER signaling pathway.	False
The phosphorylations of BC6OTHER and endothelial BC6OTHER synthase ( BC6OTHER ) as well as the level of BC6ENTC were measured to confirm the effect of BC6OTHER on BC6ENTG signaling pathway.	False
The preventive effect of uncarboxylated BC6OTHER against BC6OTHER - induced endothelial apoptosis through the activation of BC6ENTC 3 - kinase / BC6ENTG signaling pathway: BC6OTHER and endothelial apoptosis.	False
The preventive effect of uncarboxylated BC6OTHER against BC6OTHER - induced endothelial apoptosis through the activation of BC6ENTC 3 - kinase / BC6OTHER signaling pathway: BC6ENTG and endothelial apoptosis.	False
The preventive effect of uncarboxylated BC6ENTG against BC6OTHER - induced endothelial apoptosis through the activation of BC6ENTC 3 - kinase / BC6OTHER signaling pathway: BC6OTHER and endothelial apoptosis.	False
The preventive effect of uncarboxylated BC6OTHER against BC6ENTC - induced endothelial apoptosis through the activation of BC6ENTG / BC6OTHER signaling pathway: BC6OTHER and endothelial apoptosis.	False
The preventive effect of uncarboxylated BC6OTHER against BC6ENTC - induced endothelial apoptosis through the activation of BC6OTHER / BC6ENTG signaling pathway: BC6OTHER and endothelial apoptosis.	False
The preventive effect of uncarboxylated BC6OTHER against BC6ENTC - induced endothelial apoptosis through the activation of BC6OTHER / BC6OTHER signaling pathway: BC6ENTG and endothelial apoptosis.	False
The preventive effect of uncarboxylated BC6ENTG against BC6ENTC - induced endothelial apoptosis through the activation of BC6OTHER / BC6OTHER signaling pathway: BC6OTHER and endothelial apoptosis.	False
RESULTS: Pretreatment of BC6ENTG (30ng / ml) prevented LA - induced apoptosis in BC6OTHER - stimulated endothelial cells; effects were abolished by pretreatment with the BC6ENTC 3 - kinase ( BC6OTHER ) inhibitor, BC6OTHER .	False
RESULTS: Pretreatment of BC6OTHER (30ng / ml) prevented LA - induced apoptosis in BC6ENTG - stimulated endothelial cells; effects were abolished by pretreatment with the BC6ENTC 3 - kinase ( BC6OTHER ) inhibitor, BC6OTHER .	False
RESULTS: Pretreatment of BC6OTHER (30ng / ml) prevented LA - induced apoptosis in BC6OTHER - stimulated endothelial cells; effects were abolished by pretreatment with the BC6ENTC 3 - kinase ( BC6ENTG ) inhibitor, BC6OTHER .	False
RESULTS: Pretreatment of BC6ENTG (30ng / ml) prevented LA - induced apoptosis in BC6OTHER - stimulated endothelial cells; effects were abolished by pretreatment with the BC6OTHER 3 - kinase ( BC6OTHER ) inhibitor, BC6ENTC .	False
RESULTS: Pretreatment of BC6OTHER (30ng / ml) prevented LA - induced apoptosis in BC6ENTG - stimulated endothelial cells; effects were abolished by pretreatment with the BC6OTHER 3 - kinase ( BC6OTHER ) inhibitor, BC6ENTC .	False
RESULTS: Pretreatment of BC6OTHER (30ng / ml) prevented LA - induced apoptosis in BC6OTHER - stimulated endothelial cells; effects were abolished by pretreatment with the BC6ENTG ( BC6OTHER ) inhibitor, BC6ENTC .	CPR:4
RESULTS: Pretreatment of BC6OTHER (30ng / ml) prevented LA - induced apoptosis in BC6OTHER - stimulated endothelial cells; effects were abolished by pretreatment with the BC6OTHER 3 - kinase ( BC6ENTG ) inhibitor, BC6ENTC .	CPR:4
Treatment of BC6ENTG (ranged from 0.3 to 30ng / ml) significantly increased the phosphorylation of BC6OTHER and BC6OTHER and BC6ENTC secretion from endothelial cells in a BC6OTHER dependent manner.	False
Treatment of BC6OTHER (ranged from 0.3 to 30ng / ml) significantly increased the phosphorylation of BC6ENTG and BC6OTHER and BC6ENTC secretion from endothelial cells in a BC6OTHER dependent manner.	False
Treatment of BC6OTHER (ranged from 0.3 to 30ng / ml) significantly increased the phosphorylation of BC6OTHER and BC6ENTG and BC6ENTC secretion from endothelial cells in a BC6OTHER dependent manner.	False
Treatment of BC6OTHER (ranged from 0.3 to 30ng / ml) significantly increased the phosphorylation of BC6OTHER and BC6OTHER and BC6ENTC secretion from endothelial cells in a BC6ENTG dependent manner.	False
Apoptosis was evaluated using various methods including a terminal BC6ENTC transferase - mediated BC6OTHER nick - end labeling analysis kit and Western blotting for cleaved BC6ENTG , cleaved BC6OTHER polymerase and BC6OTHER .	False
Apoptosis was evaluated using various methods including a terminal BC6ENTC transferase - mediated BC6OTHER nick - end labeling analysis kit and Western blotting for cleaved BC6OTHER , cleaved BC6ENTG and BC6OTHER .	False
Apoptosis was evaluated using various methods including a terminal BC6ENTC transferase - mediated BC6OTHER nick - end labeling analysis kit and Western blotting for cleaved BC6OTHER , cleaved BC6OTHER polymerase and BC6ENTG .	False
Apoptosis was evaluated using various methods including a terminal BC6ENTG - mediated BC6ENTC nick - end labeling analysis kit and Western blotting for cleaved BC6OTHER , cleaved BC6OTHER polymerase and BC6OTHER .	False
Apoptosis was evaluated using various methods including a terminal BC6OTHER transferase - mediated BC6ENTC nick - end labeling analysis kit and Western blotting for cleaved BC6ENTG , cleaved BC6OTHER polymerase and BC6OTHER .	False
Apoptosis was evaluated using various methods including a terminal BC6OTHER transferase - mediated BC6ENTC nick - end labeling analysis kit and Western blotting for cleaved BC6OTHER , cleaved BC6ENTG and BC6OTHER .	False
Apoptosis was evaluated using various methods including a terminal BC6OTHER transferase - mediated BC6ENTC nick - end labeling analysis kit and Western blotting for cleaved BC6OTHER , cleaved BC6OTHER polymerase and BC6ENTG .	False
Apoptosis was evaluated using various methods including a terminal BC6ENTG - mediated BC6OTHER nick - end labeling analysis kit and Western blotting for cleaved BC6OTHER , cleaved BC6ENTC polymerase and BC6OTHER .	False
Apoptosis was evaluated using various methods including a terminal BC6OTHER transferase - mediated BC6OTHER nick - end labeling analysis kit and Western blotting for cleaved BC6ENTG , cleaved BC6ENTC polymerase and BC6OTHER .	False
Apoptosis was evaluated using various methods including a terminal BC6OTHER transferase - mediated BC6OTHER nick - end labeling analysis kit and Western blotting for cleaved BC6OTHER , cleaved BC6ENTC polymerase and BC6ENTG .	False
The phosphorylations of BC6ENTG and endothelial BC6ENTC synthase ( BC6OTHER ) as well as the level of BC6OTHER were measured to confirm the effect of BC6OTHER on BC6OTHER signaling pathway.	False
The phosphorylations of BC6OTHER and endothelial BC6ENTC synthase ( BC6ENTG ) as well as the level of BC6OTHER were measured to confirm the effect of BC6OTHER on BC6OTHER signaling pathway.	False
The phosphorylations of BC6OTHER and endothelial BC6ENTC synthase ( BC6OTHER ) as well as the level of BC6OTHER were measured to confirm the effect of BC6ENTG on BC6OTHER signaling pathway.	False
The phosphorylations of BC6OTHER and endothelial BC6ENTC synthase ( BC6OTHER ) as well as the level of BC6OTHER were measured to confirm the effect of BC6OTHER on BC6ENTG signaling pathway.	False
In the present study, age - related changes of BC6OTHER ( BC6OTHER ) synthesizing enzymes, BC6OTHER kinase ( BC6ENTG ) and BC6ENTC oxidase ( BC6OTHER ), their protein contents and activities were examined in the gerbil hippocampus proper.	False
In the present study, age - related changes of BC6OTHER ( BC6OTHER ) synthesizing enzymes, BC6OTHER kinase ( BC6OTHER ) and BC6ENTC oxidase ( BC6ENTG ), their protein contents and activities were examined in the gerbil hippocampus proper.	False
In the present study, age - related changes of BC6OTHER ( BC6OTHER ) synthesizing enzymes, BC6ENTG ( BC6OTHER ) and BC6ENTC oxidase ( BC6OTHER ), their protein contents and activities were examined in the gerbil hippocampus proper.	False
Therefore, decreases of BC6ENTG and BC6OTHER in the hippocampal CA1 region of aged brains may be involved in aging processes related with BC6ENTC ( BC6OTHER ) function.	CPR:4
Therefore, decreases of BC6OTHER and BC6ENTG in the hippocampal CA1 region of aged brains may be involved in aging processes related with BC6ENTC ( BC6OTHER ) function.	CPR:4
Therefore, decreases of BC6ENTG and BC6OTHER in the hippocampal CA1 region of aged brains may be involved in aging processes related with BC6OTHER ( BC6ENTC ) function.	CPR:4
Therefore, decreases of BC6OTHER and BC6ENTG in the hippocampal CA1 region of aged brains may be involved in aging processes related with BC6OTHER ( BC6ENTC ) function.	CPR:4
In the present study, age - related changes of BC6ENTC ( BC6OTHER ) synthesizing enzymes, BC6OTHER kinase ( BC6ENTG ) and BC6OTHER oxidase ( BC6OTHER ), their protein contents and activities were examined in the gerbil hippocampus proper.	CPR:9
In the present study, age - related changes of BC6ENTC ( BC6OTHER ) synthesizing enzymes, BC6OTHER kinase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), their protein contents and activities were examined in the gerbil hippocampus proper.	CPR:9
In the present study, age - related changes of BC6ENTC ( BC6OTHER ) synthesizing enzymes, BC6OTHER kinase ( BC6OTHER ) and BC6OTHER oxidase ( BC6ENTG ), their protein contents and activities were examined in the gerbil hippocampus proper.	CPR:9
In the present study, age - related changes of BC6ENTC ( BC6OTHER ) synthesizing enzymes, BC6ENTG ( BC6OTHER ) and BC6OTHER oxidase ( BC6OTHER ), their protein contents and activities were examined in the gerbil hippocampus proper.	CPR:9
In the present study, age - related changes of BC6OTHER ( BC6ENTC ) synthesizing enzymes, BC6OTHER kinase ( BC6ENTG ) and BC6OTHER oxidase ( BC6OTHER ), their protein contents and activities were examined in the gerbil hippocampus proper.	CPR:9
In the present study, age - related changes of BC6OTHER ( BC6ENTC ) synthesizing enzymes, BC6OTHER kinase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), their protein contents and activities were examined in the gerbil hippocampus proper.	CPR:9
In the present study, age - related changes of BC6OTHER ( BC6ENTC ) synthesizing enzymes, BC6OTHER kinase ( BC6OTHER ) and BC6OTHER oxidase ( BC6ENTG ), their protein contents and activities were examined in the gerbil hippocampus proper.	CPR:9
In the present study, age - related changes of BC6OTHER ( BC6ENTC ) synthesizing enzymes, BC6ENTG ( BC6OTHER ) and BC6OTHER oxidase ( BC6OTHER ), their protein contents and activities were examined in the gerbil hippocampus proper.	CPR:9
In the present study, age - related changes of BC6OTHER ( BC6OTHER ) synthesizing enzymes, BC6ENTC kinase ( BC6ENTG ) and BC6OTHER oxidase ( BC6OTHER ), their protein contents and activities were examined in the gerbil hippocampus proper.	False
In the present study, age - related changes of BC6OTHER ( BC6OTHER ) synthesizing enzymes, BC6ENTC kinase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), their protein contents and activities were examined in the gerbil hippocampus proper.	False
In the present study, age - related changes of BC6OTHER ( BC6OTHER ) synthesizing enzymes, BC6ENTC kinase ( BC6OTHER ) and BC6OTHER oxidase ( BC6ENTG ), their protein contents and activities were examined in the gerbil hippocampus proper.	False
BC6OTHER ( BC6OTHER ) enzymes or BC6OTHER are a family of BC6ENTG BC6ENTC ) deacetylases.	False
BC6ENTG ( BC6OTHER ) enzymes or BC6OTHER are a family of BC6OTHER - dependent protein BC6OTHER ( BC6ENTC ) deacetylases.	False
BC6OTHER ( BC6ENTG ) enzymes or BC6OTHER are a family of BC6OTHER - dependent protein BC6OTHER ( BC6ENTC ) deacetylases.	False
BC6OTHER ( BC6OTHER ) enzymes or BC6ENTG are a family of BC6OTHER - dependent protein BC6OTHER ( BC6ENTC ) deacetylases.	False
BC6ENTG ( BC6OTHER ) enzymes or BC6OTHER are a family of BC6ENTC - dependent protein BC6OTHER ( BC6OTHER ) deacetylases.	False
BC6OTHER ( BC6ENTG ) enzymes or BC6OTHER are a family of BC6ENTC - dependent protein BC6OTHER ( BC6OTHER ) deacetylases.	False
BC6OTHER ( BC6OTHER ) enzymes or BC6ENTG are a family of BC6ENTC - dependent protein BC6OTHER ( BC6OTHER ) deacetylases.	False
BC6ENTG ( BC6OTHER ) enzymes or BC6OTHER are a family of BC6OTHER - dependent protein BC6ENTC ( BC6OTHER ) deacetylases.	False
BC6OTHER ( BC6ENTG ) enzymes or BC6OTHER are a family of BC6OTHER - dependent protein BC6ENTC ( BC6OTHER ) deacetylases.	False
BC6OTHER ( BC6OTHER ) enzymes or BC6ENTG are a family of BC6OTHER - dependent protein BC6ENTC ( BC6OTHER ) deacetylases.	False
The anticonvulsant action of BC6OTHER or BC6OTHER was significantly counteracted by a selective BC6OTHER antagonist BC6ENTC , suggesting that the anticonvulsant action of BC6OTHER or BC6OTHER is, at least in part, related to BC6ENTG - activated modulation of BC6OTHER transcription factors.	False
The anticonvulsant action of BC6OTHER or BC6OTHER was significantly counteracted by a selective BC6OTHER antagonist BC6ENTC , suggesting that the anticonvulsant action of BC6OTHER or BC6OTHER is, at least in part, related to BC6OTHER - activated modulation of BC6ENTG transcription factors.	False
The anticonvulsant action of BC6OTHER or BC6OTHER was significantly counteracted by a selective BC6ENTG antagonist BC6ENTC , suggesting that the anticonvulsant action of BC6OTHER or BC6OTHER is, at least in part, related to BC6OTHER - activated modulation of BC6OTHER transcription factors.	CPR:6
BC6ENTC pre - treatment also attenuated the BC6OTHER - induced increases in BC6ENTG / BC6OTHER expression, BC6OTHER DNA - binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.	CPR:4
BC6ENTC pre - treatment also attenuated the BC6OTHER - induced increases in BC6OTHER / BC6ENTG expression, BC6OTHER DNA - binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.	CPR:4
BC6ENTC pre - treatment also attenuated the BC6OTHER - induced increases in BC6OTHER / BC6OTHER expression, BC6ENTG DNA - binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.	CPR:4
BC6OTHER pre - treatment also attenuated the BC6ENTC - induced increases in BC6ENTG / BC6OTHER expression, BC6OTHER DNA - binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.	CPR:3
BC6OTHER pre - treatment also attenuated the BC6ENTC - induced increases in BC6OTHER / BC6ENTG expression, BC6OTHER DNA - binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.	CPR:3
BC6OTHER pre - treatment also attenuated the BC6ENTC - induced increases in BC6OTHER / BC6OTHER expression, BC6ENTG DNA - binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.	CPR:3
The anticonvulsant action of BC6OTHER or BC6OTHER was significantly counteracted by a selective BC6OTHER antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6ENTC or BC6OTHER is, at least in part, related to BC6ENTG - activated modulation of BC6OTHER transcription factors.	False
The anticonvulsant action of BC6OTHER or BC6OTHER was significantly counteracted by a selective BC6OTHER antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6ENTC or BC6OTHER is, at least in part, related to BC6OTHER - activated modulation of BC6ENTG transcription factors.	False
The anticonvulsant action of BC6OTHER or BC6OTHER was significantly counteracted by a selective BC6ENTG antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6ENTC or BC6OTHER is, at least in part, related to BC6OTHER - activated modulation of BC6OTHER transcription factors.	False
The anticonvulsant action of BC6ENTC or BC6OTHER was significantly counteracted by a selective BC6OTHER antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6OTHER or BC6OTHER is, at least in part, related to BC6ENTG - activated modulation of BC6OTHER transcription factors.	False
The anticonvulsant action of BC6ENTC or BC6OTHER was significantly counteracted by a selective BC6OTHER antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6OTHER or BC6OTHER is, at least in part, related to BC6OTHER - activated modulation of BC6ENTG transcription factors.	False
The anticonvulsant action of BC6ENTC or BC6OTHER was significantly counteracted by a selective BC6ENTG antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6OTHER or BC6OTHER is, at least in part, related to BC6OTHER - activated modulation of BC6OTHER transcription factors.	False
The anticonvulsant action of BC6OTHER or BC6ENTC was significantly counteracted by a selective BC6OTHER antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6OTHER or BC6OTHER is, at least in part, related to BC6ENTG - activated modulation of BC6OTHER transcription factors.	False
The anticonvulsant action of BC6OTHER or BC6ENTC was significantly counteracted by a selective BC6OTHER antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6OTHER or BC6OTHER is, at least in part, related to BC6OTHER - activated modulation of BC6ENTG transcription factors.	False
The anticonvulsant action of BC6OTHER or BC6ENTC was significantly counteracted by a selective BC6ENTG antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6OTHER or BC6OTHER is, at least in part, related to BC6OTHER - activated modulation of BC6OTHER transcription factors.	False
The BC6OTHER analog BC6OTHER attenuates CHEM - induced seizures via BC6ENTG activation: comparison with the effects of BC6ENTC .	False
The BC6OTHER analog BC6ENTC attenuates CHEM - induced seizures via BC6ENTG activation: comparison with the effects of BC6OTHER .	CPR:3
The BC6ENTC analog BC6OTHER attenuates CHEM - induced seizures via BC6ENTG activation: comparison with the effects of BC6OTHER .	CPR:3
The anticonvulsant action of BC6OTHER or BC6OTHER was significantly counteracted by a selective BC6OTHER antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6OTHER or BC6ENTC is, at least in part, related to BC6ENTG - activated modulation of BC6OTHER transcription factors.	False
The anticonvulsant action of BC6OTHER or BC6OTHER was significantly counteracted by a selective BC6OTHER antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6OTHER or BC6ENTC is, at least in part, related to BC6OTHER - activated modulation of BC6ENTG transcription factors.	False
The anticonvulsant action of BC6OTHER or BC6OTHER was significantly counteracted by a selective BC6ENTG antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6OTHER or BC6ENTC is, at least in part, related to BC6OTHER - activated modulation of BC6OTHER transcription factors.	False
BC6ENTC and BC6OTHER are high - affinity ligands at BC6ENTG .	False
BC6OTHER and BC6ENTC are high - affinity ligands at BC6ENTG .	False
The expression of key genes important in BC6OTHER metabolism, such as BC6ENTG , BC6OTHER - BC6OTHER methyltransferase and BC6ENTC BC6OTHER - methyltransferase, were suppressed.	False
The expression of key genes important in BC6OTHER metabolism, such as BC6OTHER adenosyltransferase - 1a, BC6ENTG and BC6ENTC BC6OTHER - methyltransferase, were suppressed.	False
The expression of key genes important in BC6OTHER metabolism, such as BC6ENTG , BC6OTHER - BC6OTHER methyltransferase and CHEM BC6ENTC - methyltransferase, were suppressed.	False
The expression of key genes important in BC6OTHER metabolism, such as BC6OTHER adenosyltransferase - 1a, BC6ENTG and CHEM BC6ENTC - methyltransferase, were suppressed.	False
Several genes involved with BC6ENTC metabolism also showed remarkable expression changes, including increased expression of BC6ENTG ( BC6OTHER ; involved in BC6OTHER production) and decreased expression of BC6OTHER (involved in BC6OTHER production).	False
Several genes involved with BC6ENTC metabolism also showed remarkable expression changes, including increased expression of BC6OTHER ( BC6ENTG ; involved in BC6OTHER production) and decreased expression of BC6OTHER (involved in BC6OTHER production).	False
Several genes involved with BC6ENTC metabolism also showed remarkable expression changes, including increased expression of BC6OTHER ( BC6OTHER ; involved in BC6OTHER production) and decreased expression of BC6ENTG (involved in BC6OTHER production).	False
Various genes controlled by BC6ENTC , including BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and small BC6OTHER - rich protein - 2A, were dramatically over - expressed.	CPR:3
Various genes controlled by BC6ENTC , including BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and small BC6OTHER - rich protein - 2A, were dramatically over - expressed.	CPR:3
Various genes controlled by BC6ENTC , including BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and small BC6OTHER - rich protein - 2A, were dramatically over - expressed.	CPR:3
Various genes controlled by BC6ENTC , including BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and small BC6OTHER - rich protein - 2A, were dramatically over - expressed.	CPR:3
Various genes controlled by BC6ENTC , including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and small BC6OTHER - rich protein - 2A, were dramatically over - expressed.	CPR:3
Various genes controlled by BC6ENTC , including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG , were dramatically over - expressed.	CPR:3
Various genes controlled by BC6OTHER , including BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and small BC6ENTC - rich protein - 2A, were dramatically over - expressed.	False
Various genes controlled by BC6OTHER , including BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and small BC6ENTC - rich protein - 2A, were dramatically over - expressed.	False
Various genes controlled by BC6OTHER , including BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and small BC6ENTC - rich protein - 2A, were dramatically over - expressed.	False
Various genes controlled by BC6OTHER , including BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and small BC6ENTC - rich protein - 2A, were dramatically over - expressed.	False
Various genes controlled by BC6OTHER , including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and small BC6ENTC - rich protein - 2A, were dramatically over - expressed.	False
BC6ENTC - regulated genes including BC6OTHER and BC6ENTG were over - expressed, although BC6OTHER was suppressed.	CPR:3
BC6ENTC - regulated genes including BC6OTHER and BC6OTHER were over - expressed, although BC6ENTG was suppressed.	CPR:4
BC6ENTC - regulated genes including BC6ENTG and BC6OTHER were over - expressed, although BC6OTHER was suppressed.	CPR:3
Several genes involved with BC6OTHER metabolism also showed remarkable expression changes, including increased expression of BC6ENTC dehydrogenase - 7 ( BC6ENTG ; involved in BC6OTHER production) and decreased expression of BC6OTHER (involved in BC6OTHER production).	False
Several genes involved with BC6OTHER metabolism also showed remarkable expression changes, including increased expression of BC6ENTC dehydrogenase - 7 ( BC6OTHER ; involved in BC6OTHER production) and decreased expression of BC6ENTG (involved in BC6OTHER production).	False
Several genes involved with BC6OTHER metabolism also showed remarkable expression changes, including increased expression of BC6ENTG ( BC6OTHER ; involved in BC6ENTC production) and decreased expression of BC6OTHER (involved in BC6OTHER production).	CPR:9
Several genes involved with BC6OTHER metabolism also showed remarkable expression changes, including increased expression of BC6OTHER ( BC6ENTG ; involved in BC6ENTC production) and decreased expression of BC6OTHER (involved in BC6OTHER production).	CPR:9
Several genes involved with BC6OTHER metabolism also showed remarkable expression changes, including increased expression of BC6OTHER ( BC6OTHER ; involved in BC6ENTC production) and decreased expression of BC6ENTG (involved in BC6OTHER production).	False
Several genes involved with BC6OTHER metabolism also showed remarkable expression changes, including increased expression of BC6ENTG ( BC6OTHER ; involved in BC6OTHER production) and decreased expression of BC6OTHER (involved in BC6ENTC production).	False
Several genes involved with BC6OTHER metabolism also showed remarkable expression changes, including increased expression of BC6OTHER ( BC6ENTG ; involved in BC6OTHER production) and decreased expression of BC6OTHER (involved in BC6ENTC production).	False
Several genes involved with BC6OTHER metabolism also showed remarkable expression changes, including increased expression of BC6OTHER ( BC6OTHER ; involved in BC6OTHER production) and decreased expression of BC6ENTG (involved in BC6ENTC production).	CPR:9
The expression of key genes important in BC6ENTC metabolism, such as BC6ENTG , BC6OTHER - BC6OTHER methyltransferase and CHEM BC6OTHER - methyltransferase, were suppressed.	CPR:9
The expression of key genes important in BC6ENTC metabolism, such as BC6OTHER adenosyltransferase - 1a, BC6ENTG and CHEM BC6OTHER - methyltransferase, were suppressed.	CPR:9
The expression of key genes important in BC6ENTC metabolism, such as BC6OTHER adenosyltransferase - 1a, BC6OTHER - BC6OTHER methyltransferase and BC6ENTG , were suppressed.	CPR:9
The expression of key genes important in BC6OTHER metabolism, such as BC6ENTC adenosyltransferase - 1a, BC6ENTG and CHEM BC6OTHER - methyltransferase, were suppressed.	False
The expression of key genes important in BC6OTHER metabolism, such as BC6ENTC adenosyltransferase - 1a, BC6OTHER - BC6OTHER methyltransferase and BC6ENTG , were suppressed.	False
The expression of key genes important in BC6OTHER metabolism, such as BC6ENTG , BC6ENTC - BC6OTHER methyltransferase and CHEM BC6OTHER - methyltransferase, were suppressed.	False
The expression of key genes important in BC6OTHER metabolism, such as BC6OTHER adenosyltransferase - 1a, BC6ENTC - BC6OTHER methyltransferase and BC6ENTG , were suppressed.	False
The expression of key genes important in BC6OTHER metabolism, such as BC6ENTG , BC6OTHER - BC6ENTC methyltransferase and CHEM BC6OTHER - methyltransferase, were suppressed.	False
The expression of key genes important in BC6OTHER metabolism, such as BC6OTHER adenosyltransferase - 1a, BC6OTHER - BC6ENTC methyltransferase and BC6ENTG , were suppressed.	False
 The BC6OTHER BC6OTHER kinase is important for BC6OTHER - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6ENTC kinase that is activated in response to BC6ENTG ( BC6OTHER ) stimulation.	False
 The BC6OTHER BC6OTHER kinase is important for BC6ENTG - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6ENTC kinase that is activated in response to BC6OTHER ( BC6OTHER ) stimulation.	False
 The BC6ENTG BC6OTHER kinase is important for BC6OTHER - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6ENTC kinase that is activated in response to BC6OTHER ( BC6OTHER ) stimulation.	False
 The BC6OTHER BC6ENTG is important for BC6OTHER - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6ENTC kinase that is activated in response to BC6OTHER ( BC6OTHER ) stimulation.	False
 The BC6OTHER BC6OTHER kinase is important for BC6OTHER - induced BC6ENTG phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6ENTC kinase that is activated in response to BC6OTHER ( BC6OTHER ) stimulation.	False
 The BC6OTHER BC6OTHER kinase is important for BC6OTHER - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6ENTG is a cytoplasmic BC6ENTC kinase that is activated in response to BC6OTHER ( BC6OTHER ) stimulation.	False
 The BC6OTHER BC6OTHER kinase is important for BC6OTHER - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6ENTC kinase that is activated in response to BC6OTHER ( BC6ENTG ) stimulation.	False
 In the present report, we show that BC6ENTG associates with the activated BC6OTHER ( BC6OTHER ) through multiple autophosphorylation sites, i.e. BC6ENTC 579, BC6OTHER 581, BC6OTHER 740 and BC6OTHER 1021.	False
 In the present report, we show that BC6OTHER associates with the activated BC6ENTG ( BC6OTHER ) through multiple autophosphorylation sites, i.e. BC6ENTC 579, BC6OTHER 581, BC6OTHER 740 and BC6OTHER 1021.	False
 In the present report, we show that BC6OTHER associates with the activated BC6OTHER ( BC6ENTG ) through multiple autophosphorylation sites, i.e. BC6ENTC 579, BC6OTHER 581, BC6OTHER 740 and BC6OTHER 1021.	False
 In the present report, we show that BC6ENTG associates with the activated BC6OTHER ( BC6OTHER ) through multiple autophosphorylation sites, i.e. BC6OTHER 579, BC6ENTC 581, BC6OTHER 740 and BC6OTHER 1021.	False
 In the present report, we show that BC6OTHER associates with the activated BC6ENTG ( BC6OTHER ) through multiple autophosphorylation sites, i.e. BC6OTHER 579, BC6ENTC 581, BC6OTHER 740 and BC6OTHER 1021.	False
 In the present report, we show that BC6OTHER associates with the activated BC6OTHER ( BC6ENTG ) through multiple autophosphorylation sites, i.e. BC6OTHER 579, BC6ENTC 581, BC6OTHER 740 and BC6OTHER 1021.	False
 In the present report, we show that BC6ENTG associates with the activated BC6OTHER ( BC6OTHER ) through multiple autophosphorylation sites, i.e. BC6OTHER 579, BC6OTHER 581, BC6ENTC 740 and BC6OTHER 1021.	False
 In the present report, we show that BC6OTHER associates with the activated BC6ENTG ( BC6OTHER ) through multiple autophosphorylation sites, i.e. BC6OTHER 579, BC6OTHER 581, BC6ENTC 740 and BC6OTHER 1021.	False
 In the present report, we show that BC6OTHER associates with the activated BC6OTHER ( BC6ENTG ) through multiple autophosphorylation sites, i.e. BC6OTHER 579, BC6OTHER 581, BC6ENTC 740 and BC6OTHER 1021.	False
 In the present report, we show that BC6ENTG associates with the activated BC6OTHER ( BC6OTHER ) through multiple autophosphorylation sites, i.e. BC6OTHER 579, BC6OTHER 581, BC6OTHER 740 and BC6ENTC 1021.	False
 In the present report, we show that BC6OTHER associates with the activated BC6ENTG ( BC6OTHER ) through multiple autophosphorylation sites, i.e. BC6OTHER 579, BC6OTHER 581, BC6OTHER 740 and BC6ENTC 1021.	False
 In the present report, we show that BC6OTHER associates with the activated BC6OTHER ( BC6ENTG ) through multiple autophosphorylation sites, i.e. BC6OTHER 579, BC6OTHER 581, BC6OTHER 740 and BC6ENTC 1021.	False
 The BC6OTHER BC6ENTC kinase is important for BC6OTHER - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6ENTG that is activated in response to BC6OTHER ( BC6OTHER ) stimulation.	False
 The BC6OTHER BC6ENTC kinase is important for BC6OTHER - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6OTHER kinase that is activated in response to BC6ENTG ( BC6OTHER ) stimulation.	False
 The BC6OTHER BC6ENTC kinase is important for BC6ENTG - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6OTHER kinase that is activated in response to BC6OTHER ( BC6OTHER ) stimulation.	False
 The BC6ENTG BC6ENTC kinase is important for BC6OTHER - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6OTHER kinase that is activated in response to BC6OTHER ( BC6OTHER ) stimulation.	False
 The BC6OTHER BC6ENTC kinase is important for BC6OTHER - induced BC6ENTG phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6OTHER kinase that is activated in response to BC6OTHER ( BC6OTHER ) stimulation.	False
 The BC6OTHER BC6ENTC kinase is important for BC6OTHER - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6ENTG is a cytoplasmic BC6OTHER kinase that is activated in response to BC6OTHER ( BC6OTHER ) stimulation.	False
 The BC6OTHER BC6ENTC kinase is important for BC6OTHER - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6OTHER kinase that is activated in response to BC6OTHER ( BC6ENTG ) stimulation.	False
 Other ligands (e.g. BC6OTHER for BC6ENTG ; BC6OTHER , BC6OTHER , BC6ENTC for BC6OTHER ) were found to have subtype - selective intrinsic efficacy.	False
 Other ligands (e.g. BC6OTHER for BC6OTHER ; BC6OTHER , BC6OTHER , BC6ENTC for BC6ENTG ) were found to have subtype - selective intrinsic efficacy.	False
EXPERIMENTAL APPROACH: Stable clonal CHO - K1 cell lines, transfected with either the BC6ENTG , were used, and whole - cell BC6ENTC radioligand binding and BC6OTHER accumulation were measured.	False
EXPERIMENTAL APPROACH: Stable clonal CHO - K1 cell lines, transfected with either the BC6ENTG , were used, and whole - cell BC6OTHER radioligand binding and BC6ENTC accumulation were measured.	False
 KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. BC6ENTC and BC6OTHER , for the BC6ENTG over the BC6OTHER or BC6OTHER ), while others (e.g. BC6OTHER ) had little affinity - selectivity.	CPR:5
 KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. BC6ENTC and BC6OTHER , for the BC6OTHER over the BC6ENTG or BC6OTHER ), while others (e.g. BC6OTHER ) had little affinity - selectivity.	CPR:5
 KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. BC6ENTC and BC6OTHER , for the BC6OTHER over the BC6OTHER or BC6ENTG ), while others (e.g. BC6OTHER ) had little affinity - selectivity.	False
 KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. BC6OTHER and BC6ENTC , for the BC6ENTG over the BC6OTHER or BC6OTHER ), while others (e.g. BC6OTHER ) had little affinity - selectivity.	CPR:5
 KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. BC6OTHER and BC6ENTC , for the BC6OTHER over the BC6ENTG or BC6OTHER ), while others (e.g. BC6OTHER ) had little affinity - selectivity.	False
 KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. BC6OTHER and BC6ENTC , for the BC6OTHER over the BC6OTHER or BC6ENTG ), while others (e.g. BC6OTHER ) had little affinity - selectivity.	CPR:5
 KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. BC6OTHER and BC6OTHER , for the BC6ENTG over the BC6OTHER or BC6OTHER ), while others (e.g. BC6ENTC ) had little affinity - selectivity.	CPR:5
 KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. BC6OTHER and BC6OTHER , for the BC6OTHER over the BC6ENTG or BC6OTHER ), while others (e.g. BC6ENTC ) had little affinity - selectivity.	CPR:5
 KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. BC6OTHER and BC6OTHER , for the BC6OTHER over the BC6OTHER or BC6ENTG ), while others (e.g. BC6ENTC ) had little affinity - selectivity.	CPR:5
 Other ligands (e.g. BC6ENTC for BC6ENTG ; BC6OTHER , BC6OTHER , BC6OTHER for BC6OTHER ) were found to have subtype - selective intrinsic efficacy.	False
 Other ligands (e.g. BC6ENTC for BC6OTHER ; BC6OTHER , BC6OTHER , BC6OTHER for BC6ENTG ) were found to have subtype - selective intrinsic efficacy.	False
 Other ligands (e.g. BC6OTHER for BC6ENTG ; BC6ENTC , BC6OTHER , BC6OTHER for BC6OTHER ) were found to have subtype - selective intrinsic efficacy.	False
 Other ligands (e.g. BC6OTHER for BC6OTHER ; BC6ENTC , BC6OTHER , BC6OTHER for BC6ENTG ) were found to have subtype - selective intrinsic efficacy.	False
 Other ligands (e.g. BC6OTHER for BC6ENTG ; BC6OTHER , BC6ENTC , BC6OTHER for BC6OTHER ) were found to have subtype - selective intrinsic efficacy.	False
 Other ligands (e.g. BC6OTHER for BC6OTHER ; BC6OTHER , BC6ENTC , BC6OTHER for BC6ENTG ) were found to have subtype - selective intrinsic efficacy.	False
BC6OTHER was crystallized with the ligand - binding domain of BC6ENTG , and the structure revealed a complex containing BC6ENTC at the CHEM binding site.	False
BC6ENTC locks the BC6ENTG in an open form, consistent with a pharmacological action as competitive antagonist of BC6OTHER .	CPR:4
BC6ENTC locks the BC6OTHER in an open form, consistent with a pharmacological action as competitive antagonist of BC6ENTG .	CPR:6
Studies on an BC6OTHER BC6ENTG antagonist BC6ENTC : asymmetric synthesis, neuroactivity, and structural characterization.	CPR:6
Studies on an BC6ENTC BC6ENTG antagonist BC6OTHER : asymmetric synthesis, neuroactivity, and structural characterization.	False
BC6ENTC was developed and identified as a member of a new class of heterotricyclic BC6OTHER analogues that act as BC6ENTG - selective antagonists.	CPR:6
BC6ENTC was crystallized with the ligand - binding domain of BC6ENTG , and the structure revealed a complex containing BC6OTHER at the CHEM binding site.	False
BC6OTHER was developed and identified as a member of a new class of heterotricyclic BC6ENTC analogues that act as BC6ENTG - selective antagonists.	CPR:6
The influence of candidate gene polymorphisms involved in BC6ENTC and BC6OTHER or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6OTHER , BC6OTHER , and BC6ENTG [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6ENTC and BC6OTHER or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6OTHER , BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6ENTG ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6ENTC and BC6OTHER or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6ENTG , BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6ENTC and BC6OTHER or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6OTHER , BC6ENTG , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6OTHER and BC6ENTC or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6OTHER , BC6OTHER , and BC6ENTG [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6OTHER and BC6ENTC or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6OTHER , BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6ENTG ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6OTHER and BC6ENTC or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6ENTG , BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6OTHER and BC6ENTC or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6OTHER , BC6ENTG , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6ENTC BC6OTHER - methyltransferase, BC6OTHER , BC6OTHER , and BC6ENTG [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6ENTC BC6OTHER - methyltransferase, BC6OTHER , BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6ENTG ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6ENTC BC6OTHER - methyltransferase, BC6ENTG , BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6ENTC BC6OTHER - methyltransferase, BC6OTHER , BC6ENTG , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6OTHER BC6ENTC - methyltransferase, BC6OTHER , BC6OTHER , and BC6ENTG [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6OTHER BC6ENTC - methyltransferase, BC6OTHER , BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6ENTG ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6OTHER BC6ENTC - methyltransferase, BC6ENTG , BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6OTHER BC6ENTC - methyltransferase, BC6OTHER , BC6ENTG , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6ENTC binding protein beta polypeptide 3, BC6OTHER , and BC6ENTG [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6ENTC binding protein beta polypeptide 3, BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6ENTG ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6ENTC binding protein beta polypeptide 3, BC6ENTG , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6OTHER , BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6ENTC ] member 4 [homo sapiens] [ BC6ENTG ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6ENTG , BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6ENTC ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated.	False
The influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6OTHER , BC6ENTG , and solute carrier family 6 [neurotransmitter transporter, BC6ENTC ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated.	False
The BC6ENTC group showed significant retardation in gastric emptying of solids (P = .03), reduced maximum tolerated volume (P = .03), and increased postprandial BC6ENTG compared with the placebo group.	CPR:3
The LS / SS genotype of the promoter for BC6ENTG was associated with enhanced weight loss with BC6ENTC .	False
CONCLUSIONS: Weight reduction with BC6ENTC is associated with altered gastric functions and increased BC6ENTG and is significantly associated with BC6OTHER genotype.	CPR:3
CONCLUSIONS: Weight reduction with BC6ENTC is associated with altered gastric functions and increased BC6OTHER and is significantly associated with BC6ENTG genotype.	False
The role of genetic variation in BC6ENTG on weight loss in response to BC6ENTC deserves further study.	False
BC6ENTG treatment of complex IV prevented trimer formation in the absence of BC6ENTC .	False
We have examined the effectiveness of two novel BC6ENTG selective inhibitors, BC6ENTC and BC6OTHER , in a panel of melanoma cell lines and normal cell types.	CPR:4
We have examined the effectiveness of two novel BC6ENTG selective inhibitors, BC6OTHER and BC6ENTC , in a panel of melanoma cell lines and normal cell types.	CPR:4
CONTEXT: BC6ENTC is a novel BC6ENTG and BC6OTHER selective agonist recently approved for insomnia treatment.	CPR:5
CONTEXT: BC6ENTC is a novel BC6OTHER and BC6ENTG selective agonist recently approved for insomnia treatment.	CPR:5
BACKGROUND: A mutation in the cardiac BC6ENTC channel gene ( BC6ENTG ) has been described in patients with the syndrome of right bundle branch block, ST - segment elevation in leads V1 to V3, and sudden death (Brugada syndrome).	False
METHODS AND RESULTS: The effect of intravenous BC6ENTC (1 mg / kg), BC6OTHER (10 mg / kg), or BC6OTHER (2 mg / kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a BC6ENTG mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C).	False
METHODS AND RESULTS: The effect of intravenous BC6OTHER (1 mg / kg), BC6ENTC (10 mg / kg), or BC6OTHER (2 mg / kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a BC6ENTG mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C).	False
METHODS AND RESULTS: The effect of intravenous BC6OTHER (1 mg / kg), BC6OTHER (10 mg / kg), or BC6ENTC (2 mg / kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a BC6ENTG mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C).	False
BC6ENTC is a potent and selective BC6ENTG antagonist.	CPR:6
respectively) for the BC6ENTG in receptor binding and in functional studies (42 - and 29 - fold, respectively) measuring BC6ENTC changes using a cell - based luciferase reporter gene assay.	False
These findings demonstrate that the addition of spacer linkages to bivalent BC6ENTC molecules provides a successful approach to the development of ligands that are potent and highly selective for the BC6ENTG .	False
Initial studies showed that BC6ENTC was about 4 - and 15 - fold more selective for the BC6ENTG in comparison with the BC6OTHER , respectively.	False
Initial studies showed that BC6ENTC was about 4 - and 15 - fold more selective for the BC6OTHER in comparison with the BC6ENTG , respectively.	False
To improve on this BC6ENTG subtype selectivity, a series of BC6ENTC dimers (varying from n = 2 to 24 spacer atoms) were prepared and evaluated for receptor binding on BC6OTHER subtypes expressed in Chinese hamster ovary cells.	False
To improve on this BC6OTHER subtype selectivity, a series of BC6ENTC dimers (varying from n = 2 to 24 spacer atoms) were prepared and evaluated for receptor binding on BC6ENTG subtypes expressed in Chinese hamster ovary cells.	False
Each dimeric analog showed higher affinities for BC6ENTG versus the BC6OTHER ; and BC6ENTC dimers with spacers of n = 2, 3, 4, 18, and 24 exhibited selectivity for the BC6OTHER .	False
Each dimeric analog showed higher affinities for BC6OTHER versus the BC6ENTG ; and BC6ENTC dimers with spacers of n = 2, 3, 4, 18, and 24 exhibited selectivity for the BC6OTHER .	False
Each dimeric analog showed higher affinities for BC6OTHER versus the BC6OTHER ; and BC6ENTC dimers with spacers of n = 2, 3, 4, 18, and 24 exhibited selectivity for the BC6ENTG .	False
 BC6ENTC dimers exhibiting selectivity for the BC6ENTG subtype.	False
Striatal BC6ENTG protein ( - 25 to - 46%) and BC6OTHER ( - 17 to - 22%) were reduced, whereas BC6OTHER determined by BC6ENTC binding was normal.	False
Striatal BC6OTHER protein ( - 25 to - 46%) and BC6ENTG ( - 17 to - 22%) were reduced, whereas BC6OTHER determined by BC6ENTC binding was normal.	False
Striatal BC6OTHER protein ( - 25 to - 46%) and BC6OTHER ( - 17 to - 22%) were reduced, whereas BC6ENTG determined by BC6ENTC binding was normal.	False
In conclusion, our data suggest that chronic BC6ENTC use is associated with modestly reduced levels of striatal BC6OTHER and the BC6ENTG in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug.	CPR:4
In conclusion, our data suggest that chronic BC6OTHER use is associated with modestly reduced levels of striatal BC6ENTC and the BC6ENTG in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug.	False
Striatal BC6OTHER , BC6ENTC transporter, and BC6ENTG in chronic BC6OTHER users.	False
Striatal BC6OTHER , BC6ENTG , and vesicular BC6ENTC transporter in chronic BC6OTHER users.	False
Striatal BC6OTHER , BC6ENTG , and vesicular BC6OTHER transporter in chronic BC6ENTC users.	False
Striatal BC6OTHER , BC6OTHER , and BC6ENTG in chronic BC6ENTC users.	False
Striatal BC6ENTC , BC6ENTG , and vesicular BC6OTHER transporter in chronic BC6OTHER users.	False
Striatal BC6ENTC , BC6OTHER , and BC6ENTG in chronic BC6OTHER users.	False
We measured levels of BC6ENTC , as well as two BC6OTHER nerve terminal indices, namely, the BC6ENTG ( BC6OTHER ) and the vesicular BC6OTHER transporter ( BC6OTHER ) in autopsied brain of 12 chronic BC6OTHER users.	False
We measured levels of BC6ENTC , as well as two BC6OTHER nerve terminal indices, namely, the BC6OTHER transporter ( BC6ENTG ) and the vesicular BC6OTHER transporter ( BC6OTHER ) in autopsied brain of 12 chronic BC6OTHER users.	False
We measured levels of BC6ENTC , as well as two BC6OTHER nerve terminal indices, namely, the BC6OTHER transporter ( BC6OTHER ) and the BC6ENTG ( BC6OTHER ) in autopsied brain of 12 chronic BC6OTHER users.	False
We measured levels of BC6ENTC , as well as two BC6OTHER nerve terminal indices, namely, the BC6OTHER transporter ( BC6OTHER ) and the vesicular BC6OTHER transporter ( BC6ENTG ) in autopsied brain of 12 chronic BC6OTHER users.	False
We measured levels of BC6OTHER , as well as two BC6ENTC nerve terminal indices, namely, the BC6ENTG ( BC6OTHER ) and the vesicular BC6OTHER transporter ( BC6OTHER ) in autopsied brain of 12 chronic BC6OTHER users.	False
We measured levels of BC6OTHER , as well as two BC6ENTC nerve terminal indices, namely, the BC6OTHER transporter ( BC6ENTG ) and the vesicular BC6OTHER transporter ( BC6OTHER ) in autopsied brain of 12 chronic BC6OTHER users.	False
We measured levels of BC6OTHER , as well as two BC6ENTC nerve terminal indices, namely, the BC6OTHER transporter ( BC6OTHER ) and the BC6ENTG ( BC6OTHER ) in autopsied brain of 12 chronic BC6OTHER users.	False
We measured levels of BC6OTHER , as well as two BC6ENTC nerve terminal indices, namely, the BC6OTHER transporter ( BC6OTHER ) and the vesicular BC6OTHER transporter ( BC6ENTG ) in autopsied brain of 12 chronic BC6OTHER users.	False
We measured levels of BC6OTHER , as well as two BC6OTHER nerve terminal indices, namely, the BC6ENTC transporter ( BC6ENTG ) and the vesicular BC6OTHER transporter ( BC6OTHER ) in autopsied brain of 12 chronic BC6OTHER users.	False
We measured levels of BC6OTHER , as well as two BC6OTHER nerve terminal indices, namely, the BC6ENTC transporter ( BC6OTHER ) and the BC6ENTG ( BC6OTHER ) in autopsied brain of 12 chronic BC6OTHER users.	False
We measured levels of BC6OTHER , as well as two BC6OTHER nerve terminal indices, namely, the BC6ENTC transporter ( BC6OTHER ) and the vesicular BC6OTHER transporter ( BC6ENTG ) in autopsied brain of 12 chronic BC6OTHER users.	False
We measured levels of BC6OTHER , as well as two BC6OTHER nerve terminal indices, namely, the BC6ENTG ( BC6OTHER ) and the vesicular BC6ENTC transporter ( BC6OTHER ) in autopsied brain of 12 chronic BC6OTHER users.	False
We measured levels of BC6OTHER , as well as two BC6OTHER nerve terminal indices, namely, the BC6OTHER transporter ( BC6ENTG ) and the vesicular BC6ENTC transporter ( BC6OTHER ) in autopsied brain of 12 chronic BC6OTHER users.	False
We measured levels of BC6OTHER , as well as two BC6OTHER nerve terminal indices, namely, the BC6OTHER transporter ( BC6OTHER ) and the vesicular BC6ENTC transporter ( BC6ENTG ) in autopsied brain of 12 chronic BC6OTHER users.	False
We measured levels of BC6OTHER , as well as two BC6OTHER nerve terminal indices, namely, the BC6ENTG ( BC6OTHER ) and the vesicular BC6OTHER transporter ( BC6OTHER ) in autopsied brain of 12 chronic BC6ENTC users.	False
We measured levels of BC6OTHER , as well as two BC6OTHER nerve terminal indices, namely, the BC6OTHER transporter ( BC6ENTG ) and the vesicular BC6OTHER transporter ( BC6OTHER ) in autopsied brain of 12 chronic BC6ENTC users.	False
We measured levels of BC6OTHER , as well as two BC6OTHER nerve terminal indices, namely, the BC6OTHER transporter ( BC6OTHER ) and the BC6ENTG ( BC6OTHER ) in autopsied brain of 12 chronic BC6ENTC users.	False
We measured levels of BC6OTHER , as well as two BC6OTHER nerve terminal indices, namely, the BC6OTHER transporter ( BC6OTHER ) and the vesicular BC6OTHER transporter ( BC6ENTG ) in autopsied brain of 12 chronic BC6ENTC users.	False
The expression of BC6ENTG and BC6OTHER was induced by BC6OTHER , as well as BC6OTHER and BC6ENTC , which are ligands of the BC6OTHER BC6OTHER / BC6OTHER .	CPR:3
The expression of BC6OTHER and BC6ENTG was induced by BC6OTHER , as well as BC6OTHER and BC6ENTC , which are ligands of the BC6OTHER BC6OTHER / BC6OTHER .	CPR:3
The expression of BC6OTHER and BC6OTHER was induced by BC6OTHER , as well as BC6OTHER and BC6ENTC , which are ligands of the BC6ENTG BC6OTHER / BC6OTHER .	False
The expression of BC6OTHER and BC6OTHER was induced by BC6OTHER , as well as BC6OTHER and BC6ENTC , which are ligands of the BC6OTHER BC6ENTG / BC6OTHER .	False
The expression of BC6OTHER and BC6OTHER was induced by BC6OTHER , as well as BC6OTHER and BC6ENTC , which are ligands of the BC6OTHER BC6OTHER / BC6ENTG .	False
When the expression of BC6ENTG and BC6OTHER was induced, BC6ENTC efflux was stimulated in the presence of BC6OTHER ( BC6OTHER ), whereas BC6OTHER was not an efficient acceptor.	False
When the expression of BC6OTHER and BC6ENTG was induced, BC6ENTC efflux was stimulated in the presence of BC6OTHER ( BC6OTHER ), whereas BC6OTHER was not an efficient acceptor.	False
When the expression of BC6OTHER and BC6OTHER was induced, BC6ENTC efflux was stimulated in the presence of BC6ENTG ( BC6OTHER ), whereas BC6OTHER was not an efficient acceptor.	False
When the expression of BC6OTHER and BC6OTHER was induced, BC6ENTC efflux was stimulated in the presence of BC6OTHER ( BC6ENTG ), whereas BC6OTHER was not an efficient acceptor.	False
When the expression of BC6OTHER and BC6OTHER was induced, BC6ENTC efflux was stimulated in the presence of BC6OTHER ( BC6OTHER ), whereas BC6ENTG was not an efficient acceptor.	False
To confirm the role of each transporter, we analyzed HEK293 cells stably expressing BC6OTHER or BC6OTHER ; we clearly observed BC6ENTC efflux in the presence of BC6ENTG , whereas efflux in the presence of BC6OTHER was marginal.	False
To confirm the role of each transporter, we analyzed HEK293 cells stably expressing BC6OTHER or BC6OTHER ; we clearly observed BC6ENTC efflux in the presence of BC6OTHER , whereas efflux in the presence of BC6ENTG was marginal.	False
To confirm the role of each transporter, we analyzed HEK293 cells stably expressing BC6ENTG or BC6OTHER ; we clearly observed BC6ENTC efflux in the presence of BC6OTHER , whereas efflux in the presence of BC6OTHER was marginal.	CPR:9
To confirm the role of each transporter, we analyzed HEK293 cells stably expressing BC6OTHER or BC6ENTG ; we clearly observed BC6ENTC efflux in the presence of BC6OTHER , whereas efflux in the presence of BC6OTHER was marginal.	CPR:9
 BC6ENTC is actively eliminated from neuronal cells by BC6ENTG .	CPR:9
Furthermore, the treatment of primary cerebral neurons with BC6ENTG / BC6OTHER ligands suppressed the toxicity of BC6ENTC .	False
Furthermore, the treatment of primary cerebral neurons with BC6OTHER / BC6ENTG ligands suppressed the toxicity of BC6ENTC .	False
These results suggest that BC6ENTG actively eliminates BC6ENTC in the presence of BC6OTHER as a lipid acceptor and protects neuronal cells.	CPR:9
These results suggest that BC6OTHER actively eliminates BC6ENTC in the presence of BC6ENTG as a lipid acceptor and protects neuronal cells.	False
Because BC6ENTC ( BC6OTHER ), produced by BC6ENTG , induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells.	CPR:9
Because BC6OTHER ( BC6ENTC ), produced by BC6ENTG , induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells.	CPR:9
Here, using differentiated SH - SY5Y neuron - like cells as a model, we examined whether BC6ENTC is actively eliminated via BC6ENTG induced by its accumulation.	False
The expression of BC6ENTG and BC6OTHER was induced by BC6ENTC , as well as BC6OTHER and BC6OTHER , which are ligands of the BC6OTHER BC6OTHER / BC6OTHER .	CPR:3
The expression of BC6OTHER and BC6ENTG was induced by BC6ENTC , as well as BC6OTHER and BC6OTHER , which are ligands of the BC6OTHER BC6OTHER / BC6OTHER .	CPR:3
The expression of BC6OTHER and BC6OTHER was induced by BC6ENTC , as well as BC6OTHER and BC6OTHER , which are ligands of the BC6ENTG BC6OTHER / BC6OTHER .	False
The expression of BC6OTHER and BC6OTHER was induced by BC6ENTC , as well as BC6OTHER and BC6OTHER , which are ligands of the BC6OTHER BC6ENTG / BC6OTHER .	False
The expression of BC6OTHER and BC6OTHER was induced by BC6ENTC , as well as BC6OTHER and BC6OTHER , which are ligands of the BC6OTHER BC6OTHER / BC6ENTG .	False
The expression of BC6ENTG and BC6OTHER was induced by BC6OTHER , as well as BC6ENTC and BC6OTHER , which are ligands of the BC6OTHER BC6OTHER / BC6OTHER .	CPR:3
The expression of BC6OTHER and BC6ENTG was induced by BC6OTHER , as well as BC6ENTC and BC6OTHER , which are ligands of the BC6OTHER BC6OTHER / BC6OTHER .	CPR:3
The expression of BC6OTHER and BC6OTHER was induced by BC6OTHER , as well as BC6ENTC and BC6OTHER , which are ligands of the BC6ENTG BC6OTHER / BC6OTHER .	False
The expression of BC6OTHER and BC6OTHER was induced by BC6OTHER , as well as BC6ENTC and BC6OTHER , which are ligands of the BC6OTHER BC6ENTG / BC6OTHER .	False
The expression of BC6OTHER and BC6OTHER was induced by BC6OTHER , as well as BC6ENTC and BC6OTHER , which are ligands of the BC6OTHER BC6OTHER / BC6ENTG .	False
High BC6ENTC turnover catalyzed by BC6ENTG is essential for neural functions, especially learning.	CPR:9
BC6ENTG conjugated with BC6OTHER ( BC6OTHER - HIS) has been used for the demonstration of BC6ENTC receptors on human platelets.	False
BC6OTHER conjugated with BC6OTHER ( BC6ENTG - HIS) has been used for the demonstration of BC6ENTC receptors on human platelets.	False
The binding of BC6ENTG - HIS was inhibited on 35 - 79% of the platelets by the BC6ENTC H1 receptor antagonists BC6OTHER and BC6OTHER .	False
The binding of BC6ENTG - HIS was inhibited on 35 - 79% of the platelets by the BC6OTHER H1 receptor antagonists BC6ENTC and BC6OTHER .	CPR:4
The binding of BC6OTHER - HIS was inhibited on 35 - 79% of the platelets by the BC6ENTG antagonists BC6ENTC and BC6OTHER .	CPR:6
The binding of BC6ENTG - HIS was inhibited on 35 - 79% of the platelets by the BC6OTHER H1 receptor antagonists BC6OTHER and BC6ENTC .	CPR:4
The binding of BC6OTHER - HIS was inhibited on 35 - 79% of the platelets by the BC6ENTG antagonists BC6OTHER and BC6ENTC .	CPR:6
The BC6ENTC H2 receptor antagonist BC6OTHER blocked the BC6ENTG - HIS binding on 14 - 37% of the platelets.	False
The BC6ENTG antagonist BC6ENTC blocked the BC6OTHER - HIS binding on 14 - 37% of the platelets.	CPR:6
The BC6OTHER H2 receptor antagonist BC6ENTC blocked the BC6ENTG - HIS binding on 14 - 37% of the platelets.	CPR:4
BC6ENTG conjugated with BC6ENTC ( BC6OTHER - HIS) has been used for the demonstration of BC6OTHER receptors on human platelets.	False
BC6OTHER conjugated with BC6ENTC ( BC6OTHER - HIS) has been used for the demonstration of BC6ENTG on human platelets.	False
BC6OTHER conjugated with BC6ENTC ( BC6ENTG - HIS) has been used for the demonstration of BC6OTHER receptors on human platelets.	False
It is concluded that BC6ENTC H1 as well as BC6ENTG occur on human platelets but the receptors are not equally distributed in the platelet population.	False
Blood pressure was increased in rats exposed to IH, and treatment with the BC6ENTG inhibitor BC6ENTC [ BC6OTHER ] (33 mg / day) lowered blood pressure in IH but not sham group rats.	CPR:4
Blood pressure was increased in rats exposed to IH, and treatment with the BC6ENTG inhibitor BC6OTHER [ BC6ENTC ] (33 mg / day) lowered blood pressure in IH but not sham group rats.	CPR:4
mRNA levels for BC6ENTG , BC6OTHER and BC6OTHER , the BC6OTHER for BC6ENTC , decreased during activation of freshly isolated HSC even with BC6OTHER supplementation.	False
mRNA levels for BC6OTHER , BC6ENTG and BC6OTHER , the BC6OTHER for BC6ENTC , decreased during activation of freshly isolated HSC even with BC6OTHER supplementation.	False
mRNA levels for BC6OTHER , BC6OTHER and BC6ENTG , the BC6OTHER for BC6ENTC , decreased during activation of freshly isolated HSC even with BC6OTHER supplementation.	False
mRNA levels for BC6OTHER , BC6OTHER and BC6OTHER , the BC6ENTG for BC6ENTC , decreased during activation of freshly isolated HSC even with BC6OTHER supplementation.	False
mRNA levels for BC6ENTG , BC6OTHER and BC6OTHER , the BC6OTHER for BC6OTHER , decreased during activation of freshly isolated HSC even with BC6ENTC supplementation.	CPR:4
mRNA levels for BC6OTHER , BC6ENTG and BC6OTHER , the BC6OTHER for BC6OTHER , decreased during activation of freshly isolated HSC even with BC6ENTC supplementation.	CPR:4
mRNA levels for BC6OTHER , BC6OTHER and BC6ENTG , the BC6OTHER for BC6OTHER , decreased during activation of freshly isolated HSC even with BC6ENTC supplementation.	CPR:4
mRNA levels for BC6OTHER , BC6OTHER and BC6OTHER , the BC6ENTG for BC6OTHER , decreased during activation of freshly isolated HSC even with BC6ENTC supplementation.	CPR:4
BC6OTHER , BC6OTHER and BC6ENTG mRNA and BC6OTHER protein was undetectable in chronically activated HSC and remained absent after BC6ENTC supplementation.	False
BC6OTHER , BC6OTHER and BC6OTHER mRNA and BC6ENTG protein was undetectable in chronically activated HSC and remained absent after BC6ENTC supplementation.	False
BC6ENTG , BC6OTHER and BC6OTHER mRNA and BC6OTHER protein was undetectable in chronically activated HSC and remained absent after BC6ENTC supplementation.	False
BC6OTHER , BC6ENTG and BC6OTHER mRNA and BC6OTHER protein was undetectable in chronically activated HSC and remained absent after BC6ENTC supplementation.	False
Many stimuli cause HSC to activate, lose their BC6ENTC and produce BC6ENTG .	False
We also determine if BC6ENTC : (1) reverse HSC activation; (2) maintain / restore HSC intracellular BC6OTHER levels; (3) maintain expression of HSC BC6ENTG ( BC6OTHER ) in HSC that are becoming activated or are chronically activated.	False
We also determine if BC6ENTC : (1) reverse HSC activation; (2) maintain / restore HSC intracellular BC6OTHER levels; (3) maintain expression of HSC nuclear receptors for BC6OTHER ( BC6ENTG ) in HSC that are becoming activated or are chronically activated.	False
We also determine if BC6OTHER : (1) reverse HSC activation; (2) maintain / restore HSC intracellular BC6ENTC levels; (3) maintain expression of HSC BC6ENTG ( BC6OTHER ) in HSC that are becoming activated or are chronically activated.	False
We also determine if BC6OTHER : (1) reverse HSC activation; (2) maintain / restore HSC intracellular BC6ENTC levels; (3) maintain expression of HSC nuclear receptors for BC6OTHER ( BC6ENTG ) in HSC that are becoming activated or are chronically activated.	False
We also determine if BC6OTHER : (1) reverse HSC activation; (2) maintain / restore HSC intracellular BC6OTHER levels; (3) maintain expression of HSC nuclear receptors for BC6ENTC ( BC6ENTG ) in HSC that are becoming activated or are chronically activated.	False
"Using computer analysis, we recently identified nuclear BC6ENTG ( BC6OTHER ) binding sites termed "" BC6ENTC response elements"" ( BC6OTHER ) in the 5' - untranslated region (5' - UTR) of BC6OTHER BC6OTHER (Accession No."	False
"Using computer analysis, we recently identified nuclear BC6OTHER receptor ( BC6ENTG ) binding sites termed "" BC6ENTC response elements"" ( BC6OTHER ) in the 5' - untranslated region (5' - UTR) of BC6OTHER BC6OTHER (Accession No."	False
"Using computer analysis, we recently identified nuclear BC6OTHER receptor ( BC6OTHER ) binding sites termed "" BC6ENTC response elements"" ( BC6ENTG ) in the 5' - untranslated region (5' - UTR) of BC6OTHER BC6OTHER (Accession No."	False
"Using computer analysis, we recently identified nuclear BC6OTHER receptor ( BC6OTHER ) binding sites termed "" BC6ENTC response elements"" ( BC6OTHER ) in the 5' - untranslated region (5' - UTR) of BC6ENTG BC6OTHER (Accession No."	False
"Using computer analysis, we recently identified nuclear BC6OTHER receptor ( BC6OTHER ) binding sites termed "" BC6ENTC response elements"" ( BC6OTHER ) in the 5' - untranslated region (5' - UTR) of BC6OTHER BC6ENTG (Accession No."	False
As these regulatory motifs mediate regulation of target genes by BC6ENTG agonists including BC6ENTC and BC6OTHER , we have systematically investigated the effect of both contaminants on functional BC6OTHER transport activity in primary bovine mammary epithelial cells.	CPR:5
As these regulatory motifs mediate regulation of target genes by BC6OTHER agonists including BC6ENTC and BC6OTHER , we have systematically investigated the effect of both contaminants on functional BC6ENTG transport activity in primary bovine mammary epithelial cells.	False
As these regulatory motifs mediate regulation of target genes by BC6ENTG agonists including BC6OTHER and BC6ENTC , we have systematically investigated the effect of both contaminants on functional BC6OTHER transport activity in primary bovine mammary epithelial cells.	CPR:5
As these regulatory motifs mediate regulation of target genes by BC6OTHER agonists including BC6OTHER and BC6ENTC , we have systematically investigated the effect of both contaminants on functional BC6ENTG transport activity in primary bovine mammary epithelial cells.	False
BC6ENTC or BC6OTHER doubled BC6ENTG - mediated BC6OTHER secretion.	False
BC6OTHER or BC6ENTC doubled BC6ENTG - mediated BC6OTHER secretion.	False
BC6OTHER or BC6OTHER doubled BC6ENTG - mediated BC6ENTC secretion.	CPR:9
This effect was almost completely reversed by specific BC6ENTG inhibitor BC6ENTC .	CPR:4
Fungicide BC6ENTC and environmental pollutant BC6OTHER induce the BC6OTHER transporter in bovine mammary epithelial cells by the BC6ENTG signaling pathway.	False
Fungicide BC6ENTC and environmental pollutant BC6OTHER induce the BC6ENTG transporter in bovine mammary epithelial cells by the BC6OTHER signaling pathway.	CPR:3
Fungicide BC6OTHER and environmental pollutant BC6OTHER induce the BC6ENTG transporter in bovine mammary epithelial cells by the BC6ENTC receptor signaling pathway.	False
Fungicide BC6OTHER and environmental pollutant BC6ENTC induce the BC6OTHER transporter in bovine mammary epithelial cells by the BC6ENTG signaling pathway.	False
Fungicide BC6OTHER and environmental pollutant BC6ENTC induce the BC6ENTG transporter in bovine mammary epithelial cells by the BC6OTHER signaling pathway.	CPR:3
Receptor binding was significantly reduced by specific BC6ENTG antagonist BC6ENTC .	CPR:6
Induction of BC6ENTG by BC6ENTC and BC6OTHER resulted in a time - and dose - dependent increase of BC6OTHER gene expression and transporter protein levels.	CPR:3
Induction of BC6OTHER by BC6ENTC and BC6OTHER resulted in a time - and dose - dependent increase of BC6ENTG gene expression and transporter protein levels.	CPR:3
Induction of BC6ENTG by BC6OTHER and BC6ENTC resulted in a time - and dose - dependent increase of BC6OTHER gene expression and transporter protein levels.	CPR:3
Induction of BC6OTHER by BC6OTHER and BC6ENTC resulted in a time - and dose - dependent increase of BC6ENTG gene expression and transporter protein levels.	CPR:3
Through identification of mammary BC6ENTG as a novel target gene of pesticide BC6ENTC and BC6OTHER , our results may therefore help to improve the protection of breast - feeding infants and the consumer of dairy products.	False
Through identification of mammary BC6ENTG as a novel target gene of pesticide BC6OTHER and BC6ENTC , our results may therefore help to improve the protection of breast - feeding infants and the consumer of dairy products.	False
"Using computer analysis, we recently identified nuclear BC6ENTC receptor ( BC6ENTG ) binding sites termed "" BC6OTHER "" ( BC6OTHER ) in the 5' - untranslated region (5' - UTR) of BC6OTHER BC6OTHER (Accession No."	False
"Using computer analysis, we recently identified nuclear BC6ENTC receptor ( BC6OTHER ) binding sites termed "" BC6ENTG "" ( BC6OTHER ) in the 5' - untranslated region (5' - UTR) of BC6OTHER BC6OTHER (Accession No."	False
"Using computer analysis, we recently identified nuclear BC6ENTC receptor ( BC6OTHER ) binding sites termed "" BC6OTHER "" ( BC6ENTG ) in the 5' - untranslated region (5' - UTR) of BC6OTHER BC6OTHER (Accession No."	False
"Using computer analysis, we recently identified nuclear BC6ENTC receptor ( BC6OTHER ) binding sites termed "" BC6OTHER "" ( BC6OTHER ) in the 5' - untranslated region (5' - UTR) of BC6ENTG BC6OTHER (Accession No."	False
"Using computer analysis, we recently identified nuclear BC6ENTC receptor ( BC6OTHER ) binding sites termed "" BC6OTHER "" ( BC6OTHER ) in the 5' - untranslated region (5' - UTR) of BC6OTHER BC6ENTG (Accession No."	False
Physicians should consider using low - dose BC6ENTC and BC6ENTG activated in the treatment of patients who have vasopressor - dependent septic shock with persistent signs of hypoperfusion, organ dysfunction, or hypotension.	False
This article summarizes the current knowledge on the benefit / risk profile from the use of low - dose BC6ENTC and BC6ENTG in treating septic shock.	False
 BC6ENTC and BC6ENTG for septic shock.	False
MATERIALS AND METHODS: Methylation of BC6ENTC sulfotransferase pi ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) genes was studied using methylation sensitive PCR (MS - PCR).	False
MATERIALS AND METHODS: Methylation of BC6ENTC sulfotransferase pi ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) genes was studied using methylation sensitive PCR (MS - PCR).	False
MATERIALS AND METHODS: Methylation of BC6ENTC sulfotransferase pi ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) genes was studied using methylation sensitive PCR (MS - PCR).	False
We postulate that this conserved BC6ENTC residue provides a flexible hinge within the BC6ENTG catalytic pocket to facilitate linker dynamics and the structural alterations that accompany drug binding of the covalent enzyme - DNA intermediate.	False
BC6ENTG is the cellular target of the anti - cancer drug BC6ENTC ( BC6OTHER ), which reversibly stabilizes a covalent enzyme - DNA intermediate.	False
BC6ENTG is the cellular target of the anti - cancer drug BC6OTHER ( BC6ENTC ), which reversibly stabilizes a covalent enzyme - DNA intermediate.	False
BC6ENTG clamps around duplex DNA, wherein the core and BC6ENTC - terminal domains are connected by extended BC6OTHER ( BC6OTHER ), which position the active site BC6OTHER of the BC6OTHER - terminal domain within the catalytic pocket.	False
BC6OTHER clamps around duplex DNA, wherein the core and BC6ENTC - terminal domains are connected by extended BC6ENTG ( BC6OTHER ), which position the active site BC6OTHER of the BC6OTHER - terminal domain within the catalytic pocket.	False
BC6OTHER clamps around duplex DNA, wherein the core and BC6ENTC - terminal domains are connected by extended BC6OTHER ( BC6ENTG ), which position the active site BC6OTHER of the BC6OTHER - terminal domain within the catalytic pocket.	False
We report that mutation of this conserved BC6ENTC in BC6ENTG alters enzyme sensitivity to BC6OTHER .	False
BC6ENTG clamps around duplex DNA, wherein the core and BC6OTHER - terminal domains are connected by extended BC6OTHER ( BC6OTHER ), which position the active site BC6ENTC of the BC6OTHER - terminal domain within the catalytic pocket.	False
BC6OTHER clamps around duplex DNA, wherein the core and BC6OTHER - terminal domains are connected by extended BC6ENTG ( BC6OTHER ), which position the active site BC6ENTC of the BC6OTHER - terminal domain within the catalytic pocket.	False
BC6OTHER clamps around duplex DNA, wherein the core and BC6OTHER - terminal domains are connected by extended BC6OTHER ( BC6ENTG ), which position the active site BC6ENTC of the BC6OTHER - terminal domain within the catalytic pocket.	False
BC6ENTG clamps around duplex DNA, wherein the core and BC6OTHER - terminal domains are connected by extended BC6OTHER ( BC6OTHER ), which position the active site BC6OTHER of the BC6ENTC - terminal domain within the catalytic pocket.	False
BC6OTHER clamps around duplex DNA, wherein the core and BC6OTHER - terminal domains are connected by extended BC6ENTG ( BC6OTHER ), which position the active site BC6OTHER of the BC6ENTC - terminal domain within the catalytic pocket.	False
BC6OTHER clamps around duplex DNA, wherein the core and BC6OTHER - terminal domains are connected by extended BC6OTHER ( BC6ENTG ), which position the active site BC6OTHER of the BC6ENTC - terminal domain within the catalytic pocket.	False
The physical connection of the linker with the BC6ENTG clamp as well as linker flexibility affect enzyme sensitivity to BC6ENTC .	False
Crystallographic data reveal that a conserved BC6ENTC residue (located at the juncture between the linker and BC6OTHER - terminal domains) is at one end of a short BC6ENTG , which extends to the active site BC6OTHER covalently linked to the DNA.	False
Crystallographic data reveal that a conserved BC6OTHER residue (located at the juncture between the linker and BC6ENTC - terminal domains) is at one end of a short BC6ENTG , which extends to the active site BC6OTHER covalently linked to the DNA.	False
Crystallographic data reveal that a conserved BC6OTHER residue (located at the juncture between the linker and BC6OTHER - terminal domains) is at one end of a short BC6ENTG , which extends to the active site BC6ENTC covalently linked to the DNA.	False
In the presence of drug, the linker is rigid and this BC6ENTG extends to include BC6ENTC and the preceding BC6OTHER .	False
In the presence of drug, the linker is rigid and this BC6ENTG extends to include BC6OTHER and the preceding BC6ENTC .	False
Mutation of CHEM721 alters BC6ENTG active site architecture and sensitivity to BC6ENTC .	False
We report that mutation of this conserved BC6OTHER in BC6ENTG alters enzyme sensitivity to BC6ENTC .	False
Of the antihypertensive agents, CHEM is now rarely prescribed and adverse effects are reported infrequently, whereas cases of liver injury associated with the BC6ENTC receptor and BC6ENTG inhibitors are increasingly reported.	False
Of the antidiabetic agents, BC6ENTC , BC6OTHER , BC6OTHER , and BC6ENTG have been implicated in causing liver injury.	False
Of the antidiabetic agents, BC6OTHER , BC6ENTC , BC6OTHER , and BC6ENTG have been implicated in causing liver injury.	False
Of the antidiabetic agents, BC6OTHER , BC6OTHER , BC6ENTC , and BC6ENTG have been implicated in causing liver injury.	False
Rice with high BC6ENTC content in seed endosperm has been developed by insertion of BC6ENTG gene under the control of the endosperm specific BC6OTHER into the genome of indica rice line IR68144.	False
Rice with high BC6ENTC content in seed endosperm has been developed by insertion of BC6OTHER gene under the control of the endosperm specific BC6ENTG into the genome of indica rice line IR68144.	False
 BC6ENTC prevents cardiac hypertrophy and overexpression of BC6ENTG and BC6OTHER in pressure - overloaded rat heart.	CPR:4
 BC6ENTC prevents cardiac hypertrophy and overexpression of BC6OTHER and BC6ENTG in pressure - overloaded rat heart.	CPR:4
Treatment with BC6ENTC , BC6OTHER , or BC6OTHER did not significantly affect BC6ENTG and BC6OTHER proteins expression in the banding groups.	False
Treatment with BC6ENTC , BC6OTHER , or BC6OTHER did not significantly affect BC6OTHER and BC6ENTG proteins expression in the banding groups.	False
Treatment with BC6OTHER , BC6ENTC , or BC6OTHER did not significantly affect BC6ENTG and BC6OTHER proteins expression in the banding groups.	False
Treatment with BC6OTHER , BC6ENTC , or BC6OTHER did not significantly affect BC6OTHER and BC6ENTG proteins expression in the banding groups.	False
Treatment with BC6OTHER , BC6OTHER , or BC6ENTC did not significantly affect BC6ENTG and BC6OTHER proteins expression in the banding groups.	False
Treatment with BC6OTHER , BC6OTHER , or BC6ENTC did not significantly affect BC6OTHER and BC6ENTG proteins expression in the banding groups.	False
Treatment with BC6ENTC reversed both protein and mRNA of BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER to the baseline values.	CPR:4
Treatment with BC6ENTC reversed both protein and mRNA of BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER to the baseline values.	CPR:4
Treatment with BC6ENTC reversed both protein and mRNA of BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER to the baseline values.	CPR:4
Treatment with BC6ENTC reversed both protein and mRNA of BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG to the baseline values.	CPR:3
Increased immunohistochemical labeling of BC6ENTG , BC6OTHER , and BC6OTHER in the ventricular myocardium was observed in the banding group and BC6ENTC again normalized the labeling.	CPR:4
Increased immunohistochemical labeling of BC6OTHER , BC6ENTG , and BC6OTHER in the ventricular myocardium was observed in the banding group and BC6ENTC again normalized the labeling.	CPR:4
Increased immunohistochemical labeling of BC6OTHER , BC6OTHER , and BC6ENTG in the ventricular myocardium was observed in the banding group and BC6ENTC again normalized the labeling.	CPR:4
Treatment with BC6ENTC is associated with a reversal of abnormal regulation of BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER in the hypertrophic myocardium.	CPR:4
Treatment with BC6ENTC is associated with a reversal of abnormal regulation of BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER in the hypertrophic myocardium.	CPR:4
Treatment with BC6ENTC is associated with a reversal of abnormal regulation of BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER in the hypertrophic myocardium.	CPR:4
Treatment with BC6ENTC is associated with a reversal of abnormal regulation of BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG in the hypertrophic myocardium.	False
To evaluate the effect of BC6ENTC on both myocardial BC6ENTG expression and cardiac hypertrophy, infra - renal aortic banding was performed for 4 weeks in adult Sprague - Dawley rats to induce cardiac hypertrophy.	False
Furthermore, the activation of the FRET biosensor also confirms the endothelial cell apoptosis induced by the abnormal pulsatile shear stress and high BC6ENTC concentration is through BC6ENTG pathway.	False
A double - labeling fluorescent technique ( BC6ENTC and BC6OTHER ) was used to validate the findings revealed by the FRET - based BC6ENTG sensor.	False
A double - labeling fluorescent technique ( BC6OTHER and BC6ENTC ) was used to validate the findings revealed by the FRET - based BC6ENTG sensor.	False
BC6ENTG ( BC6OTHER ) salvages BC6ENTC by releasing BC6OTHER from BC6OTHER and is often deleted in mesothelioma.	False
BC6OTHER phosphorylase ( BC6ENTG ) salvages BC6ENTC by releasing BC6OTHER from BC6OTHER and is often deleted in mesothelioma.	False
BC6ENTG ( BC6OTHER ) salvages BC6OTHER by releasing BC6ENTC from BC6OTHER and is often deleted in mesothelioma.	CPR:9
BC6OTHER phosphorylase ( BC6ENTG ) salvages BC6OTHER by releasing BC6ENTC from BC6OTHER and is often deleted in mesothelioma.	CPR:9
BC6ENTG ( BC6OTHER ) salvages BC6OTHER by releasing BC6OTHER from BC6ENTC and is often deleted in mesothelioma.	CPR:9
BC6OTHER phosphorylase ( BC6ENTG ) salvages BC6OTHER by releasing BC6OTHER from BC6ENTC and is often deleted in mesothelioma.	CPR:9
The current study addresses the effect of BC6ENTG on BC6ENTC activity using a highly potent transition state inhibitor of BC6OTHER , MT - DADMe - Immucillin A (ImmA; K(i) = 86 pmol / L) in the BC6OTHER (+) NCI - H28 and BC6OTHER ( - ) NCI - H2052 mesothelioma cell lines.	False
The current study addresses the effect of BC6OTHER on BC6ENTC activity using a highly potent transition state inhibitor of BC6ENTG , MT - DADMe - Immucillin A (ImmA; K(i) = 86 pmol / L) in the BC6OTHER (+) NCI - H28 and BC6OTHER ( - ) NCI - H2052 mesothelioma cell lines.	False
The current study addresses the effect of BC6OTHER on BC6ENTC activity using a highly potent transition state inhibitor of BC6OTHER , MT - DADMe - Immucillin A (ImmA; K(i) = 86 pmol / L) in the BC6ENTG (+) NCI - H28 and BC6OTHER ( - ) NCI - H2052 mesothelioma cell lines.	False
The current study addresses the effect of BC6OTHER on BC6ENTC activity using a highly potent transition state inhibitor of BC6OTHER , MT - DADMe - Immucillin A (ImmA; K(i) = 86 pmol / L) in the BC6OTHER (+) NCI - H28 and BC6ENTG ( - ) NCI - H2052 mesothelioma cell lines.	False
CHEM is a new - generation antifolate inhibitor of BC6ENTC synthase ( BC6OTHER ) and a weaker inhibitor of BC6ENTG ( BC6OTHER ) required for de novo BC6OTHER synthesis.	False
CHEM is a new - generation antifolate inhibitor of BC6ENTC synthase ( BC6OTHER ) and a weaker inhibitor of BC6OTHER transformylase ( BC6ENTG ) required for de novo BC6OTHER synthesis.	False
CHEM is a new - generation antifolate inhibitor of BC6ENTC synthase ( BC6ENTG ) and a weaker inhibitor of BC6OTHER transformylase ( BC6OTHER ) required for de novo BC6OTHER synthesis.	False
Based on selective CHEM protection, BC6ENTG was found to be the primary BC6ENTC target in both cell lines with BC6OTHER inhibition requiring 20 - to 30 - fold higher BC6OTHER concentrations.	False
Based on selective CHEM protection, BC6OTHER was found to be the primary BC6ENTC target in both cell lines with BC6ENTG inhibition requiring 20 - to 30 - fold higher BC6OTHER concentrations.	False
Based on selective CHEM protection, BC6ENTG was found to be the primary BC6OTHER target in both cell lines with BC6OTHER inhibition requiring 20 - to 30 - fold higher BC6ENTC concentrations.	False
Based on selective CHEM protection, BC6OTHER was found to be the primary BC6OTHER target in both cell lines with BC6ENTG inhibition requiring 20 - to 30 - fold higher BC6ENTC concentrations.	CPR:4
ImmA had no effect on BC6ENTC activity but, when BC6OTHER was added, the BC6OTHER IC(50) decreased by a factor of approximately 3 in BC6ENTG (+) H28 cells with no effect in BC6OTHER ( - ) H2052 cells.	False
ImmA had no effect on BC6ENTC activity but, when BC6OTHER was added, the BC6OTHER IC(50) decreased by a factor of approximately 3 in BC6OTHER (+) H28 cells with no effect in BC6ENTG ( - ) H2052 cells.	False
ImmA had no effect on BC6OTHER activity but, when BC6ENTC was added, the BC6OTHER IC(50) decreased by a factor of approximately 3 in BC6ENTG (+) H28 cells with no effect in BC6OTHER ( - ) H2052 cells.	False
ImmA had no effect on BC6OTHER activity but, when BC6ENTC was added, the BC6OTHER IC(50) decreased by a factor of approximately 3 in BC6OTHER (+) H28 cells with no effect in BC6ENTG ( - ) H2052 cells.	False
ImmA had no effect on BC6OTHER activity but, when BC6OTHER was added, the BC6ENTC IC(50) decreased by a factor of approximately 3 in BC6ENTG (+) H28 cells with no effect in BC6OTHER ( - ) H2052 cells.	False
ImmA had no effect on BC6OTHER activity but, when BC6OTHER was added, the BC6ENTC IC(50) decreased by a factor of approximately 3 in BC6OTHER (+) H28 cells with no effect in BC6ENTG ( - ) H2052 cells.	False
Conversely, the transfection of BC6ENTG into H2052 cells increased the BC6ENTC IC(50) by nearly 3 - fold but only in the presence of BC6OTHER ; this was reversed by ImmA.	False
The effect of a novel transition state inhibitor of BC6ENTG on BC6ENTC activity.	False
CHEM is a new - generation antifolate inhibitor of BC6OTHER ( BC6OTHER ) and a weaker inhibitor of BC6ENTC transformylase ( BC6ENTG ) required for de novo BC6OTHER synthesis.	False
CHEM is a new - generation antifolate inhibitor of BC6ENTG ( BC6OTHER ) and a weaker inhibitor of BC6ENTC transformylase ( BC6OTHER ) required for de novo BC6OTHER synthesis.	False
CHEM is a new - generation antifolate inhibitor of BC6OTHER ( BC6ENTG ) and a weaker inhibitor of BC6ENTC transformylase ( BC6OTHER ) required for de novo BC6OTHER synthesis.	False
Conversely, the transfection of BC6ENTG into H2052 cells increased the BC6OTHER IC(50) by nearly 3 - fold but only in the presence of BC6ENTC ; this was reversed by ImmA.	False
An BC6ENTG - specific short interfering RNA produced a 2 - fold decrease in BC6ENTC IC(50) in BC6OTHER (+) HeLa cells in the presence of BC6OTHER .	False
An BC6OTHER - specific short interfering RNA produced a 2 - fold decrease in BC6ENTC IC(50) in BC6ENTG (+) HeLa cells in the presence of BC6OTHER .	False
An BC6ENTG - specific short interfering RNA produced a 2 - fold decrease in BC6OTHER IC(50) in BC6OTHER (+) HeLa cells in the presence of BC6ENTC .	False
An BC6OTHER - specific short interfering RNA produced a 2 - fold decrease in BC6OTHER IC(50) in BC6ENTG (+) HeLa cells in the presence of BC6ENTC .	False
These data indicate that suppression of constitutive BC6ENTG has no effect on BC6ENTC activity when the primary target is BC6OTHER .	False
These data indicate that suppression of constitutive BC6OTHER has no effect on BC6ENTC activity when the primary target is BC6ENTG .	False
There is a modest salutary effect when the BC6ENTC target is BC6ENTG alone.	False
CHEM is a new - generation antifolate inhibitor of BC6OTHER ( BC6OTHER ) and a weaker inhibitor of BC6ENTG ( BC6OTHER ) required for de novo BC6ENTC synthesis.	False
CHEM is a new - generation antifolate inhibitor of BC6OTHER ( BC6OTHER ) and a weaker inhibitor of BC6OTHER transformylase ( BC6ENTG ) required for de novo BC6ENTC synthesis.	False
CHEM is a new - generation antifolate inhibitor of BC6ENTG ( BC6OTHER ) and a weaker inhibitor of BC6OTHER transformylase ( BC6OTHER ) required for de novo BC6ENTC synthesis.	False
CHEM is a new - generation antifolate inhibitor of BC6OTHER ( BC6ENTG ) and a weaker inhibitor of BC6OTHER transformylase ( BC6OTHER ) required for de novo BC6ENTC synthesis.	False
BC6ENTC phosphorylase ( BC6ENTG ) salvages BC6OTHER by releasing BC6OTHER from BC6OTHER and is often deleted in mesothelioma.	False
The purpose of this study was to compare viability assessments determined with the CHEM, BC6ENTC dehydrogenase ( BC6ENTG ), BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6OTHER , and to define the LOAEL for these xenobiotics in this system.	False
The purpose of this study was to compare viability assessments determined with the CHEM, BC6ENTC dehydrogenase ( BC6OTHER ), BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6ENTG , and to define the LOAEL for these xenobiotics in this system.	False
The purpose of this study was to compare viability assessments determined with the CHEM, BC6ENTG ( BC6OTHER ), BC6ENTC , BC6OTHER ( BC6OTHER ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6OTHER , and to define the LOAEL for these xenobiotics in this system.	False
The purpose of this study was to compare viability assessments determined with the CHEM, BC6OTHER ( BC6ENTG ), BC6ENTC , BC6OTHER ( BC6OTHER ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6OTHER , and to define the LOAEL for these xenobiotics in this system.	False
The purpose of this study was to compare viability assessments determined with the CHEM, BC6OTHER ( BC6OTHER ), BC6ENTC , BC6OTHER ( BC6OTHER ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6ENTG , and to define the LOAEL for these xenobiotics in this system.	False
The purpose of this study was to compare viability assessments determined with the CHEM, BC6ENTG ( BC6OTHER ), BC6OTHER , BC6ENTC ( BC6OTHER ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6OTHER , and to define the LOAEL for these xenobiotics in this system.	False
The purpose of this study was to compare viability assessments determined with the CHEM, BC6OTHER ( BC6ENTG ), BC6OTHER , BC6ENTC ( BC6OTHER ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6OTHER , and to define the LOAEL for these xenobiotics in this system.	False
The purpose of this study was to compare viability assessments determined with the CHEM, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6ENTC ( BC6OTHER ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6ENTG , and to define the LOAEL for these xenobiotics in this system.	False
The purpose of this study was to compare viability assessments determined with the CHEM, BC6ENTG ( BC6OTHER ), BC6OTHER , BC6OTHER ( BC6ENTC ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6OTHER , and to define the LOAEL for these xenobiotics in this system.	False
The purpose of this study was to compare viability assessments determined with the CHEM, BC6OTHER ( BC6ENTG ), BC6OTHER , BC6OTHER ( BC6ENTC ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6OTHER , and to define the LOAEL for these xenobiotics in this system.	False
The purpose of this study was to compare viability assessments determined with the CHEM, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER ( BC6ENTC ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6ENTG , and to define the LOAEL for these xenobiotics in this system.	False
The purpose of this study was to compare viability assessments determined with the CHEM, BC6ENTG ( BC6OTHER ), BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6OTHER , and to define the LOAEL for these xenobiotics in this system.	False
The purpose of this study was to compare viability assessments determined with the CHEM, BC6OTHER ( BC6ENTG ), BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6OTHER , and to define the LOAEL for these xenobiotics in this system.	False
The purpose of this study was to compare viability assessments determined with the CHEM, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6ENTG , and to define the LOAEL for these xenobiotics in this system.	False
BC6ENTC also decreased viability as measured by the BC6ENTG , BC6OTHER and BC6OTHER assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the BC6OTHER assay.	False
BC6OTHER , BC6OTHER and BC6OTHER inhibit the BC6ENTG ( BC6OTHER ) which transports BC6ENTC into bile.	CPR:9
BC6OTHER , BC6OTHER and BC6OTHER inhibit the BC6OTHER ( BC6ENTG ) which transports BC6ENTC into bile.	CPR:9
BC6ENTC , BC6OTHER and BC6OTHER inhibit the BC6ENTG ( BC6OTHER ) which transports BC6OTHER into bile.	CPR:4
BC6ENTC , BC6OTHER and BC6OTHER inhibit the BC6OTHER ( BC6ENTG ) which transports BC6OTHER into bile.	CPR:4
BC6OTHER also decreased viability as measured by the BC6ENTG , BC6ENTC and BC6OTHER assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the BC6OTHER assay.	False
BC6OTHER also decreased viability as measured by the BC6ENTG , BC6OTHER and BC6ENTC assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the BC6OTHER assay.	False
BC6OTHER also decreased viability as measured by the BC6ENTG , BC6OTHER and BC6OTHER assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the BC6ENTC assay.	False
Based on the results of this study, the BC6ENTG or BC6ENTC assays would be the methods of choice to assess viability in sandwich - cultured rat hepatocytes after xenobiotic exposure.	False
BC6OTHER , BC6ENTC and BC6OTHER inhibit the BC6ENTG ( BC6OTHER ) which transports BC6OTHER into bile.	CPR:4
BC6OTHER , BC6ENTC and BC6OTHER inhibit the BC6OTHER ( BC6ENTG ) which transports BC6OTHER into bile.	CPR:4
Sandwich - cultured rat hepatocytes maintain functional BC6ENTC co - transporting polypeptide and BC6ENTG transport proteins, and may be useful to study inhibition of transport by xenobiotics at concentrations below the lowest observable adverse effect level (LOAEL).	False
BC6OTHER , BC6OTHER and BC6ENTC inhibit the BC6ENTG ( BC6OTHER ) which transports BC6OTHER into bile.	CPR:4
BC6OTHER , BC6OTHER and BC6ENTC inhibit the BC6OTHER ( BC6ENTG ) which transports BC6OTHER into bile.	CPR:4
For the BC6ENTG antagonist BC6OTHER , none of the receptor constructs were able to provide a binding with higher affinity than the starting BC6ENTC V2 receptor.	False
In contrast, the binding of BC6ENTC was significantly improved when the transmembrane domains 1 and 2 were transferred from the BC6OTHER receptor to the BC6ENTG .	False
We have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6ENTC V1A / CHEM receptor antagonist BC6OTHER and the agonists BC6ENTG and BC6OTHER .	False
We have analyzed binding domains of the BC6ENTG for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6ENTC V1A / CHEM receptor antagonist BC6OTHER and the agonists BC6OTHER and BC6OTHER .	False
We have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6ENTG antagonist, in comparison to the combined BC6ENTC V1A / CHEM receptor antagonist BC6OTHER and the agonists BC6OTHER and BC6OTHER .	False
In contrast, the binding of BC6OTHER was significantly improved when the transmembrane domains 1 and 2 were transferred from the BC6ENTC receptor to the BC6ENTG .	False
The binding domain of BC6ENTC differs from the binding domain of the agonists and the nonselective BC6ENTG antagonist CHEM BC6OTHER that has been used in previous studies.	False
The binding domain of BC6ENTC differs from the binding domain of the agonists and the nonselective BC6OTHER antagonist CHEM BC6ENTG that has been used in previous studies.	False
The binding domain of BC6OTHER differs from the binding domain of the agonists and the nonselective BC6ENTC receptor antagonist CHEM BC6ENTG that has been used in previous studies.	False
The binding domain of BC6OTHER differs from the binding domain of the agonists and the nonselective BC6ENTG antagonist BC6ENTC that has been used in previous studies.	CPR:6
We have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6ENTG antagonist BC6ENTC and the agonists BC6OTHER and BC6OTHER .	CPR:6
We have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6OTHER antagonist BC6ENTC and the agonists BC6ENTG and BC6OTHER .	False
We have analyzed binding domains of the BC6ENTG for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6OTHER antagonist BC6ENTC and the agonists BC6OTHER and BC6OTHER .	False
We have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6ENTG antagonist, in comparison to the combined BC6OTHER antagonist BC6ENTC and the agonists BC6OTHER and BC6OTHER .	False
In displacement studies with 10 chimeric receptor constructs, the binding profile of BC6OTHER was compared with the binding profiles of the ligands BC6OTHER , [Arg8] BC6ENTG , BC6ENTC , and BC6OTHER .	False
In displacement studies with 10 chimeric receptor constructs, the binding profile of BC6OTHER was compared with the binding profiles of the ligands BC6ENTG , [Arg8] BC6OTHER , BC6ENTC , and BC6OTHER .	False
We have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6ENTG antagonist BC6OTHER and the agonists BC6ENTC and BC6OTHER .	CPR:5
We have analyzed binding domains of the BC6ENTG for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6ENTC and BC6OTHER .	False
We have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6ENTG antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6ENTC and BC6OTHER .	False
We have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6ENTG antagonist BC6OTHER and the agonists BC6OTHER and BC6ENTC .	CPR:5
We have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6ENTG and BC6ENTC .	False
We have analyzed binding domains of the BC6ENTG for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6OTHER and BC6ENTC .	False
We have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6ENTG antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6OTHER and BC6ENTC .	False
We have analyzed binding domains of the BC6ENTC receptor for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6ENTG antagonist BC6OTHER and the agonists BC6OTHER and BC6OTHER .	False
We have analyzed binding domains of the BC6ENTC receptor for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6ENTG and BC6OTHER .	False
We have analyzed binding domains of the BC6ENTC receptor for BC6OTHER , a highly selective BC6ENTG antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6OTHER and BC6OTHER .	False
These recombinant receptors have been produced by transfer of domains from the BC6ENTC receptor into the related BC6ENTG and have already been successfully employed for the identification of ligand binding domains at the BC6OTHER (Postina, R., Kojro, E., Fahrenholz, F., 1996.	False
These recombinant receptors have been produced by transfer of domains from the BC6ENTC receptor into the related BC6OTHER and have already been successfully employed for the identification of ligand binding domains at the BC6ENTG (Postina, R., Kojro, E., Fahrenholz, F., 1996.	False
These recombinant receptors have been produced by transfer of domains from the BC6ENTG into the related BC6ENTC V2 receptor and have already been successfully employed for the identification of ligand binding domains at the BC6OTHER (Postina, R., Kojro, E., Fahrenholz, F., 1996.	False
These recombinant receptors have been produced by transfer of domains from the BC6OTHER into the related BC6ENTC V2 receptor and have already been successfully employed for the identification of ligand binding domains at the BC6ENTG (Postina, R., Kojro, E., Fahrenholz, F., 1996.	False
These recombinant receptors have been produced by transfer of domains from the BC6ENTG into the related BC6OTHER and have already been successfully employed for the identification of ligand binding domains at the BC6ENTC receptor (Postina, R., Kojro, E., Fahrenholz, F., 1996.	False
These recombinant receptors have been produced by transfer of domains from the BC6OTHER into the related BC6ENTG and have already been successfully employed for the identification of ligand binding domains at the BC6ENTC receptor (Postina, R., Kojro, E., Fahrenholz, F., 1996.	False
We have analyzed binding domains of the BC6OTHER for BC6ENTC , a highly selective BC6OTHER antagonist, in comparison to the combined BC6ENTG antagonist BC6OTHER and the agonists BC6OTHER and BC6OTHER .	False
We have analyzed binding domains of the BC6OTHER for BC6ENTC , a highly selective BC6OTHER antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6ENTG and BC6OTHER .	False
We have analyzed binding domains of the BC6ENTG for BC6ENTC , a highly selective BC6OTHER antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6OTHER and BC6OTHER .	False
We have analyzed binding domains of the BC6OTHER for BC6ENTC , a highly selective BC6ENTG antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6OTHER and BC6OTHER .	CPR:6
Separate agonist and peptide antagonist binding sites of the BC6ENTC receptor defined by their transfer into the BC6ENTG .	False
In displacement studies with 10 chimeric receptor constructs, the binding profile of BC6OTHER was compared with the binding profiles of the ligands BC6OTHER , [Arg8] BC6ENTG , BC6OTHER , and BC6ENTC .	False
In displacement studies with 10 chimeric receptor constructs, the binding profile of BC6OTHER was compared with the binding profiles of the ligands BC6ENTG , [Arg8] BC6OTHER , BC6OTHER , and BC6ENTC .	False
Separate agonist and peptide antagonist binding sites of the BC6ENTG defined by their transfer into the V2 BC6ENTC receptor.	False
In displacement studies with 10 chimeric receptor constructs, the binding profile of BC6ENTC was compared with the binding profiles of the ligands BC6OTHER , [Arg8] BC6ENTG , BC6OTHER , and BC6OTHER .	False
In displacement studies with 10 chimeric receptor constructs, the binding profile of BC6ENTC was compared with the binding profiles of the ligands BC6ENTG , [Arg8] BC6OTHER , BC6OTHER , and BC6OTHER .	False
We have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6ENTC receptor antagonist, in comparison to the combined BC6ENTG antagonist BC6OTHER and the agonists BC6OTHER and BC6OTHER .	False
We have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6ENTC receptor antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6ENTG and BC6OTHER .	False
We have analyzed binding domains of the BC6ENTG for BC6OTHER , a highly selective BC6ENTC receptor antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6OTHER and BC6OTHER .	False
In displacement studies with 10 chimeric receptor constructs, the binding profile of BC6OTHER was compared with the binding profiles of the ligands BC6ENTC , [Arg8] BC6ENTG , BC6OTHER , and BC6OTHER .	False
In displacement studies with 10 chimeric receptor constructs, the binding profile of BC6OTHER was compared with the binding profiles of the ligands BC6ENTG , BC6ENTC , BC6OTHER , and BC6OTHER .	False
Binding domains of the BC6ENTG for the selective BC6OTHER antagonist BC6OTHER in comparison to the agonists BC6ENTC and BC6OTHER .	False
Binding domains of the BC6OTHER for the selective BC6ENTG antagonist BC6OTHER in comparison to the agonists BC6ENTC and BC6OTHER .	CPR:5
Binding domains of the BC6OTHER for the selective BC6OTHER antagonist BC6OTHER in comparison to the agonists BC6ENTG and BC6ENTC .	False
Binding domains of the BC6ENTG for the selective BC6OTHER antagonist BC6OTHER in comparison to the agonists BC6OTHER and BC6ENTC .	False
Binding domains of the BC6OTHER for the selective BC6ENTG antagonist BC6OTHER in comparison to the agonists BC6OTHER and BC6ENTC .	CPR:5
Binding domains of the BC6ENTC receptor for the selective BC6OTHER antagonist BC6OTHER in comparison to the agonists BC6ENTG and BC6OTHER .	False
Binding domains of the BC6ENTC receptor for the selective BC6ENTG antagonist BC6OTHER in comparison to the agonists BC6OTHER and BC6OTHER .	False
Binding domains of the BC6OTHER for the selective BC6ENTC receptor antagonist BC6OTHER in comparison to the agonists BC6ENTG and BC6OTHER .	False
Binding domains of the BC6ENTG for the selective BC6ENTC receptor antagonist BC6OTHER in comparison to the agonists BC6OTHER and BC6OTHER .	False
Binding domains of the BC6OTHER for the selective BC6OTHER antagonist BC6ENTC in comparison to the agonists BC6ENTG and BC6OTHER .	False
Binding domains of the BC6ENTG for the selective BC6OTHER antagonist BC6ENTC in comparison to the agonists BC6OTHER and BC6OTHER .	False
Binding domains of the BC6OTHER for the selective BC6ENTG antagonist BC6ENTC in comparison to the agonists BC6OTHER and BC6OTHER .	CPR:6
The binding profiles for the agonists BC6ENTG and BC6ENTC were found to be similar.	False
For both agonists, important binding domains were the extracellular BC6ENTC - terminus (=E1) and the extracellular loops E2 and E3 from the BC6ENTG .	False
For the BC6ENTC V1A / BC6OTHER receptor antagonist BC6OTHER , none of the receptor constructs were able to provide a binding with higher affinity than the starting BC6ENTG .	False
For the BC6OTHER V1A / BC6ENTC receptor antagonist BC6OTHER , none of the receptor constructs were able to provide a binding with higher affinity than the starting BC6ENTG .	False
For the BC6ENTG antagonist BC6ENTC , none of the receptor constructs were able to provide a binding with higher affinity than the starting BC6OTHER .	CPR:6
For the BC6OTHER V1A / BC6OTHER receptor antagonist BC6ENTC , none of the receptor constructs were able to provide a binding with higher affinity than the starting BC6ENTG .	False
Block of BC6ENTG with BC6ENTC after channel activation was voltage dependent.	CPR:4
At - 20 mV, 10 nM BC6ENTC reduced BC6ENTG tail - current amplitude by 5%, whereas, at + 20 mV, the tail - current amplitude was reduced by 45% (n = 4 cells).	CPR:4
Blockage of the BC6ENTG by the gastrointestinal prokinetic agent BC6ENTC .	CPR:4
We conclude that BC6ENTC is a potent blocker of BC6ENTG channels expressed in HEK293 cells.	CPR:4
The BC6ENTG ( BC6OTHER ), which encodes the rapidly activating delayed rectifier BC6ENTC current and is important in cardiac repolarization, may serve as a target for the action of BC6OTHER .	False
The BC6OTHER ( BC6ENTG ), which encodes the rapidly activating delayed rectifier BC6ENTC current and is important in cardiac repolarization, may serve as a target for the action of BC6OTHER .	False
The BC6ENTG ( BC6OTHER ), which encodes the rapidly activating delayed rectifier BC6OTHER current and is important in cardiac repolarization, may serve as a target for the action of BC6ENTC .	False
The BC6OTHER ( BC6ENTG ), which encodes the rapidly activating delayed rectifier BC6OTHER current and is important in cardiac repolarization, may serve as a target for the action of BC6ENTC .	False
We tested the hypothesis that BC6ENTC blocks BC6ENTG .	CPR:4
Under voltage - clamp conditions, BC6ENTC block of BC6ENTG is dose dependent with a half - maximal inhibitory concentration of 6.5 nM at 22 degrees C (n = 25 cells).	CPR:4
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6OTHER ( BC6ENTC ) transporter ( BC6ENTG ) function, we chronically antagonized BC6OTHER by a range of doses of BC6OTHER [ BC6OTHER ], which blocks the BC6OTHER reuptake process.	False
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6OTHER ( BC6ENTC ) transporter ( BC6OTHER ) function, we chronically antagonized BC6ENTG by a range of doses of BC6OTHER [ BC6OTHER ], which blocks the BC6OTHER reuptake process.	False
CONCLUSIONS: These findings suggest that the degree of BC6ENTG blockade can be assessed with the plasma or urine BC6ENTC / BC6OTHER ratio and the pressor effect of CHEM.	False
CONCLUSIONS: These findings suggest that the degree of BC6ENTG blockade can be assessed with the plasma or urine BC6OTHER / BC6ENTC ratio and the pressor effect of CHEM.	False
Also, the BC6ENTC / BC6OTHER ratio is more sensitive at the lower end of BC6ENTG inhibition, whereas CHEM exhibits a linear relation, with BC6OTHER inhibition commencing at a higher dose.	False
Also, the BC6ENTC / BC6OTHER ratio is more sensitive at the lower end of BC6OTHER inhibition, whereas CHEM exhibits a linear relation, with BC6ENTG inhibition commencing at a higher dose.	False
Also, the BC6OTHER / BC6ENTC ratio is more sensitive at the lower end of BC6ENTG inhibition, whereas CHEM exhibits a linear relation, with BC6OTHER inhibition commencing at a higher dose.	False
Also, the BC6OTHER / BC6ENTC ratio is more sensitive at the lower end of BC6OTHER inhibition, whereas CHEM exhibits a linear relation, with BC6ENTG inhibition commencing at a higher dose.	False
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6ENTG ( BC6OTHER ) function, we chronically antagonized BC6OTHER by a range of doses of BC6ENTC [ BC6OTHER ], which blocks the BC6OTHER reuptake process.	False
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6OTHER ( BC6OTHER ) transporter ( BC6ENTG ) function, we chronically antagonized BC6OTHER by a range of doses of BC6ENTC [ BC6OTHER ], which blocks the BC6OTHER reuptake process.	False
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6OTHER ( BC6OTHER ) transporter ( BC6OTHER ) function, we chronically antagonized BC6ENTG by a range of doses of BC6ENTC [ BC6OTHER ], which blocks the BC6OTHER reuptake process.	CPR:6
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6ENTG ( BC6OTHER ) function, we chronically antagonized BC6OTHER by a range of doses of BC6OTHER [ BC6ENTC ], which blocks the BC6OTHER reuptake process.	False
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6OTHER ( BC6OTHER ) transporter ( BC6ENTG ) function, we chronically antagonized BC6OTHER by a range of doses of BC6OTHER [ BC6ENTC ], which blocks the BC6OTHER reuptake process.	False
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6OTHER ( BC6OTHER ) transporter ( BC6OTHER ) function, we chronically antagonized BC6ENTG by a range of doses of BC6OTHER [ BC6ENTC ], which blocks the BC6OTHER reuptake process.	CPR:6
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6ENTG ( BC6OTHER ) function, we chronically antagonized BC6OTHER by a range of doses of BC6OTHER [ BC6OTHER ], which blocks the BC6ENTC reuptake process.	False
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6OTHER ( BC6OTHER ) transporter ( BC6ENTG ) function, we chronically antagonized BC6OTHER by a range of doses of BC6OTHER [ BC6OTHER ], which blocks the BC6ENTC reuptake process.	False
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6OTHER ( BC6OTHER ) transporter ( BC6OTHER ) function, we chronically antagonized BC6ENTG by a range of doses of BC6OTHER [ BC6OTHER ], which blocks the BC6ENTC reuptake process.	CPR:9
Plasma from BC6ENTC - treated subjects (ex vivo effect) dose - dependently decreased radioligand binding to BC6ENTG (maximum inhibition was 60%) (P=0.02).	False
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6ENTC ( BC6OTHER ) transporter ( BC6ENTG ) function, we chronically antagonized BC6OTHER by a range of doses of BC6OTHER [ BC6OTHER ], which blocks the BC6OTHER reuptake process.	False
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6ENTC ( BC6OTHER ) transporter ( BC6OTHER ) function, we chronically antagonized BC6ENTG by a range of doses of BC6OTHER [ BC6OTHER ], which blocks the BC6OTHER reuptake process.	False
Moreover, activation of transfected cells and porcine PBMC by BC6ENTG ligands was inhibited by BC6ENTC indicating the requirement of endosomal / lysosomal acidification for activation of the receptors.	CPR:4
Both BC6ENTG and BC6OTHER proteins were expressed in cell lines and were BC6ENTC - glycosylated.	False
Both BC6OTHER and BC6ENTG proteins were expressed in cell lines and were BC6ENTC - glycosylated.	False
Two BC6ENTC molecules, BC6OTHER and BC6OTHER , markedly activated both BC6ENTG and BC6OTHER whereas only BC6OTHER , but not BC6OTHER , was activated by the ligands.	CPR:3
Two BC6ENTC molecules, BC6OTHER and BC6OTHER , markedly activated both BC6OTHER and BC6ENTG whereas only BC6OTHER , but not BC6OTHER , was activated by the ligands.	CPR:3
Two BC6ENTC molecules, BC6OTHER and BC6OTHER , markedly activated both BC6OTHER and BC6OTHER whereas only BC6ENTG , but not BC6OTHER , was activated by the ligands.	CPR:3
Two BC6ENTC molecules, BC6OTHER and BC6OTHER , markedly activated both BC6OTHER and BC6OTHER whereas only BC6OTHER , but not BC6ENTG , was activated by the ligands.	False
Two BC6OTHER molecules, BC6ENTC and BC6OTHER , markedly activated both BC6ENTG and BC6OTHER whereas only BC6OTHER , but not BC6OTHER , was activated by the ligands.	CPR:3
Two BC6OTHER molecules, BC6ENTC and BC6OTHER , markedly activated both BC6OTHER and BC6ENTG whereas only BC6OTHER , but not BC6OTHER , was activated by the ligands.	CPR:3
Two BC6OTHER molecules, BC6ENTC and BC6OTHER , markedly activated both BC6OTHER and BC6OTHER whereas only BC6ENTG , but not BC6OTHER , was activated by the ligands.	CPR:3
Two BC6OTHER molecules, BC6ENTC and BC6OTHER , markedly activated both BC6OTHER and BC6OTHER whereas only BC6OTHER , but not BC6ENTG , was activated by the ligands.	False
Two BC6OTHER molecules, BC6OTHER and BC6ENTC , markedly activated both BC6ENTG and BC6OTHER whereas only BC6OTHER , but not BC6OTHER , was activated by the ligands.	CPR:3
Two BC6OTHER molecules, BC6OTHER and BC6ENTC , markedly activated both BC6OTHER and BC6ENTG whereas only BC6OTHER , but not BC6OTHER , was activated by the ligands.	CPR:3
Two BC6OTHER molecules, BC6OTHER and BC6ENTC , markedly activated both BC6OTHER and BC6OTHER whereas only BC6ENTG , but not BC6OTHER , was activated by the ligands.	CPR:3
Two BC6OTHER molecules, BC6OTHER and BC6ENTC , markedly activated both BC6OTHER and BC6OTHER whereas only BC6OTHER , but not BC6ENTG , was activated by the ligands.	False
Porcine BC6OTHER and BC6ENTG are both activated by a selective BC6OTHER ligand, BC6ENTC .	CPR:3
Porcine BC6OTHER and BC6OTHER are both activated by a selective BC6ENTG ligand, BC6ENTC .	False
Porcine BC6ENTG and BC6OTHER are both activated by a selective BC6OTHER ligand, BC6ENTC .	CPR:3
The BC6ENTC lipase ( BC6ENTG ) inhibitor BC6OTHER produces antinociceptive and anti - inflammatory effects.	False
The BC6OTHER ( BC6ENTG ) inhibitor BC6ENTC produces antinociceptive and anti - inflammatory effects.	CPR:4
The BC6ENTG ( BC6OTHER ) inhibitor BC6ENTC produces antinociceptive and anti - inflammatory effects.	CPR:4
Mice given daily injections of high dose BC6ENTC (≥16 mg / kg) for six days displayed decreased BC6ENTG receptor density and function in brain, as assessed in BC6OTHER binding and BC6OTHER - stimulated [ BC6OTHER ]GTPγS binding assays, respectively.	CPR:4
Mice given daily injections of high dose BC6OTHER (≥16 mg / kg) for six days displayed decreased BC6ENTG receptor density and function in brain, as assessed in BC6ENTC binding and BC6OTHER - stimulated [ BC6OTHER ]GTPγS binding assays, respectively.	False
Mice given daily injections of high dose BC6OTHER (≥16 mg / kg) for six days displayed decreased BC6ENTG receptor density and function in brain, as assessed in BC6OTHER binding and BC6ENTC - stimulated [ BC6OTHER ]GTPγS binding assays, respectively.	False
Mice given daily injections of high dose BC6OTHER (≥16 mg / kg) for six days displayed decreased BC6ENTG receptor density and function in brain, as assessed in BC6OTHER binding and BC6OTHER - stimulated [ BC6ENTC ]GTPγS binding assays, respectively.	False
Repeated Low Dose Administration of the BC6ENTC Lipase Inhibitor BC6OTHER Retains BC6ENTG Receptor Mediated Antinociceptive and Gastroprotective Effects.	False
Repeated Low Dose Administration of the BC6ENTG Inhibitor BC6ENTC Retains BC6OTHER Receptor Mediated Antinociceptive and Gastroprotective Effects.	CPR:4
Repeated Low Dose Administration of the BC6OTHER Inhibitor BC6ENTC Retains BC6ENTG Receptor Mediated Antinociceptive and Gastroprotective Effects.	False
In contrast, normal BC6ENTG receptor expression and function were maintained following repeated administration of low dose BC6ENTC (≤8 mg / kg).	False
However, repeated administration of high dose BC6ENTC (40 mg / kg) causes dependence, antinociceptive tolerance, cross - tolerance to the pharmacological effects of BC6ENTG agonists, and BC6OTHER receptor downregulation and desensitization.	False
However, repeated administration of high dose BC6ENTC (40 mg / kg) causes dependence, antinociceptive tolerance, cross - tolerance to the pharmacological effects of BC6OTHER agonists, and BC6ENTG receptor downregulation and desensitization.	False
BC6ENTC crystals stimulate monocytes and macrophages to release BC6OTHER through the BC6ENTG component of the inflammasome.	False
BC6ENTC crystals stimulate monocytes and macrophages to release BC6ENTG through the BC6OTHER component of the inflammasome.	CPR:3
The effectiveness of BC6ENTG inhibition was first evaluated in a mouse model of BC6ENTC crystal - induced inflammation.	False
Effect of BC6ENTC on lipid peroxidation, BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6ENTC on lipid peroxidation, BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6ENTC on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6ENTC on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6ENTC on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6ENTC on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6OTHER on lipid peroxidation, BC6ENTC oxygenase 1( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6OTHER on lipid peroxidation, BC6ENTC oxygenase 1( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6OTHER on lipid peroxidation, BC6ENTC oxygenase 1( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6OTHER on lipid peroxidation, BC6ENTC oxygenase 1( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6OTHER on lipid peroxidation, BC6ENTC oxygenase 1( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6OTHER on lipid peroxidation, BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6OTHER on lipid peroxidation, BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6OTHER on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6OTHER on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6OTHER on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6OTHER on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6ENTC ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6OTHER on lipid peroxidation, BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6OTHER on lipid peroxidation, BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6OTHER on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6OTHER on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6OTHER on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
Effect of BC6OTHER on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6ENTC ) and expression of cell adhesion molecules (CAM) is summarized stepwise.	False
In vitro metabolism of the BC6ENTG receptor antagonist BC6ENTC .	CPR:6
BC6ENTG has shown to be an essential component in BC6OTHER catalyzed BC6ENTC formation and provides insights on the disconnect between human liver microsomes data and that of BC6OTHER .	False
BC6OTHER has shown to be an essential component in BC6ENTG catalyzed BC6ENTC formation and provides insights on the disconnect between human liver microsomes data and that of BC6OTHER .	CPR:9
BC6OTHER has shown to be an essential component in BC6OTHER catalyzed BC6ENTC formation and provides insights on the disconnect between human liver microsomes data and that of BC6ENTG .	False
The metabolism of BC6ENTC has been examined in vitro using hepatic microsomes from human and recombinant heterologously expressed BC6ENTG ( BC6OTHER ).	False
The metabolism of BC6ENTC has been examined in vitro using hepatic microsomes from human and recombinant heterologously expressed BC6OTHER ( BC6ENTG ).	False
The BC6ENTG data was normalized relative to the levels of each BC6OTHER form in native human liver microsomes to better assess the contribution of each BC6OTHER in the metabolism of BC6ENTC .	False
The BC6OTHER data was normalized relative to the levels of each BC6ENTG form in native human liver microsomes to better assess the contribution of each BC6OTHER in the metabolism of BC6ENTC .	False
The BC6OTHER data was normalized relative to the levels of each BC6OTHER form in native human liver microsomes to better assess the contribution of each BC6ENTG in the metabolism of BC6ENTC .	CPR:9
 BC6ENTG regulates BC6ENTC - induced BC6OTHER gene expression.	False
 BC6OTHER regulates BC6ENTC - induced BC6ENTG gene expression.	CPR:3
However, none of the BC6ENTG in that region were required for promoter activation by BC6ENTC .	False
Furthermore, knockdown of BC6ENTG significantly attenuated BC6ENTC - induced BC6OTHER expression.	False
Furthermore, knockdown of BC6OTHER significantly attenuated BC6ENTC - induced BC6ENTG expression.	CPR:3
Thus, our findings indicate that the expression of BC6ENTG depends on BC6OTHER activity and contributes to BC6OTHER induction by BC6ENTC .	False
Thus, our findings indicate that the expression of BC6OTHER depends on BC6ENTG activity and contributes to BC6OTHER induction by BC6ENTC .	False
Thus, our findings indicate that the expression of BC6OTHER depends on BC6OTHER activity and contributes to BC6ENTG induction by BC6ENTC .	CPR:3
For example, involvement of BC6ENTG in LHβ induction by BC6ENTC has been discovered.	False
BC6ENTC caused a sustained increase in nuclear BC6ENTG levels, which was significantly reduced CHEM BC6OTHER - terminal kinase ( BC6OTHER ) inhibition.	CPR:3
BC6ENTC caused a sustained increase in nuclear BC6OTHER levels, which was significantly reduced by BC6ENTG ( BC6OTHER ) inhibition.	False
BC6ENTC caused a sustained increase in nuclear BC6OTHER levels, which was significantly reduced CHEM BC6OTHER - terminal kinase ( BC6ENTG ) inhibition.	False
The regulation of BC6ENTG synthesis by BC6ENTC plays an essential role in the neuroendocrine control of reproduction.	False
BC6ENTG caused a sustained increase in nuclear BC6OTHER levels, which was significantly reduced by c - Jun BC6ENTC - terminal kinase ( BC6OTHER ) inhibition.	False
BC6OTHER caused a sustained increase in nuclear BC6ENTG levels, which was significantly reduced by c - Jun BC6ENTC - terminal kinase ( BC6OTHER ) inhibition.	False
BC6OTHER caused a sustained increase in nuclear BC6OTHER levels, which was significantly reduced by c - Jun BC6ENTC - terminal kinase ( BC6ENTG ) inhibition.	False
Small interfering RNA - mediated knockdown of BC6ENTG mRNA demonstrated that induction of BC6OTHER mRNA by BC6ENTC depended on BC6OTHER and that regulation of BC6OTHER by BC6OTHER occurred independently of the BC6OTHER - BC6OTHER pathway.	False
Small interfering RNA - mediated knockdown of BC6OTHER mRNA demonstrated that induction of BC6ENTG mRNA by BC6ENTC depended on BC6OTHER and that regulation of BC6OTHER by BC6OTHER occurred independently of the BC6OTHER - BC6OTHER pathway.	CPR:3
Small interfering RNA - mediated knockdown of BC6OTHER mRNA demonstrated that induction of BC6OTHER mRNA by BC6ENTC depended on BC6ENTG and that regulation of BC6OTHER by BC6OTHER occurred independently of the BC6OTHER - BC6OTHER pathway.	False
Small interfering RNA - mediated knockdown of BC6OTHER mRNA demonstrated that induction of BC6OTHER mRNA by BC6ENTC depended on BC6OTHER and that regulation of BC6ENTG by BC6OTHER occurred independently of the BC6OTHER - BC6OTHER pathway.	False
Small interfering RNA - mediated knockdown of BC6OTHER mRNA demonstrated that induction of BC6OTHER mRNA by BC6ENTC depended on BC6OTHER and that regulation of BC6OTHER by BC6ENTG occurred independently of the BC6OTHER - BC6OTHER pathway.	False
Small interfering RNA - mediated knockdown of BC6OTHER mRNA demonstrated that induction of BC6OTHER mRNA by BC6ENTC depended on BC6OTHER and that regulation of BC6OTHER by BC6OTHER occurred independently of the BC6ENTG - BC6OTHER pathway.	False
Small interfering RNA - mediated knockdown of BC6OTHER mRNA demonstrated that induction of BC6OTHER mRNA by BC6ENTC depended on BC6OTHER and that regulation of BC6OTHER by BC6OTHER occurred independently of the BC6OTHER - BC6ENTG pathway.	False
In LβT2 cells transfected with BC6ENTG luciferase fusion constructs, BC6ENTC responsiveness was conferred by the proximal promoter ( - 944 / - 1) and was markedly decreased by BC6OTHER knockdown.	False
In LβT2 cells transfected with BC6OTHER luciferase fusion constructs, BC6ENTC responsiveness was conferred by the proximal promoter ( - 944 / - 1) and was markedly decreased by BC6ENTG knockdown.	False
Of the compounds active in the present assay system, the most potent compound 7, BC6ENTC , significantly suppressed the induction of BC6OTHER ( BC6OTHER and BC6ENTG ( BC6OTHER ) protein expression, and inhibited adipocyte differentiation induced by BC6OTHER , a BC6OTHER agonist.	CPR:4
Of the compounds active in the present assay system, the most potent compound 7, BC6ENTC , significantly suppressed the induction of BC6OTHER ( BC6OTHER and BC6OTHER ( BC6ENTG ) protein expression, and inhibited adipocyte differentiation induced by BC6OTHER , a BC6OTHER agonist.	CPR:4
Of the compounds active in the present assay system, the most potent compound 7, BC6ENTC , significantly suppressed the induction of BC6OTHER ( BC6OTHER and BC6OTHER ( BC6OTHER ) protein expression, and inhibited adipocyte differentiation induced by BC6OTHER , a BC6ENTG agonist.	False
Of the compounds active in the present assay system, the most potent compound 7, BC6ENTC , significantly suppressed the induction of BC6ENTG ( BC6OTHER and BC6OTHER ( BC6OTHER ) protein expression, and inhibited adipocyte differentiation induced by BC6OTHER , a BC6OTHER agonist.	CPR:4
Of the compounds active in the present assay system, the most potent compound 7, BC6ENTC , significantly suppressed the induction of BC6OTHER ( BC6ENTG and BC6OTHER ( BC6OTHER ) protein expression, and inhibited adipocyte differentiation induced by BC6OTHER , a BC6OTHER agonist.	CPR:4
Of the compounds active in the present assay system, the most potent compound 7, BC6OTHER , significantly suppressed the induction of BC6OTHER ( BC6OTHER and BC6ENTG ( BC6OTHER ) protein expression, and inhibited adipocyte differentiation induced by BC6ENTC , a BC6OTHER agonist.	False
Of the compounds active in the present assay system, the most potent compound 7, BC6OTHER , significantly suppressed the induction of BC6OTHER ( BC6OTHER and BC6OTHER ( BC6ENTG ) protein expression, and inhibited adipocyte differentiation induced by BC6ENTC , a BC6OTHER agonist.	False
Of the compounds active in the present assay system, the most potent compound 7, BC6OTHER , significantly suppressed the induction of BC6OTHER ( BC6OTHER and BC6OTHER ( BC6OTHER ) protein expression, and inhibited adipocyte differentiation induced by BC6ENTC , a BC6ENTG agonist.	CPR:5
Of the compounds active in the present assay system, the most potent compound 7, BC6OTHER , significantly suppressed the induction of BC6ENTG ( BC6OTHER and BC6OTHER ( BC6OTHER ) protein expression, and inhibited adipocyte differentiation induced by BC6ENTC , a BC6OTHER agonist.	False
Of the compounds active in the present assay system, the most potent compound 7, BC6OTHER , significantly suppressed the induction of BC6OTHER ( BC6ENTG and BC6OTHER ( BC6OTHER ) protein expression, and inhibited adipocyte differentiation induced by BC6ENTC , a BC6OTHER agonist.	False
A selective BC6ENTG agonist BC6ENTC ( BC6OTHER , BC6OTHER ) inhibits angiogenesis and metastasis in solid tumours.	CPR:5
A selective BC6ENTG agonist BC6OTHER ( BC6ENTC , BC6OTHER ) inhibits angiogenesis and metastasis in solid tumours.	CPR:5
A selective BC6ENTG agonist BC6OTHER ( BC6OTHER , BC6ENTC ) inhibits angiogenesis and metastasis in solid tumours.	CPR:5
Analysis of tumour - conditioned medium indicated that BC6ENTC decreased the secretion of angiogenic factors and BC6ENTG and increased the tissue inhibitor of BC6OTHER .	CPR:4
Analysis of tumour - conditioned medium indicated that BC6ENTC decreased the secretion of angiogenic factors and BC6OTHER and increased the tissue inhibitor of BC6ENTG .	CPR:3
The ability of BC6ENTC to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner BC6ENTG .	CPR:3
In vivo angiogenesis assay utilising CHEM sponges, BC6ENTC reduced angiogenesis in sponges containing BC6ENTG , BC6OTHER and basic BC6OTHER to various extent.	False
In vivo angiogenesis assay utilising CHEM sponges, BC6ENTC reduced angiogenesis in sponges containing BC6OTHER , BC6ENTG and basic BC6OTHER to various extent.	False
In vivo angiogenesis assay utilising CHEM sponges, BC6ENTC reduced angiogenesis in sponges containing BC6OTHER , BC6OTHER and basic BC6ENTG to various extent.	False
The present study determined the influence of a BC6ENTG agonist BC6ENTC on angiogenesis and metastasis in solid tumours.	CPR:5
BC6ENTC acting on BC6ENTG at the central nervous system appears to have an important role in these modulatory processes.	False
BC6ENTG acting on BC6ENTC AT1 receptors at the central nervous system appears to have an important role in these modulatory processes.	False
We investigated the effect of BC6ENTG blockade in the NTS on the response to stimulation of HDA in anaesthetised rats treated with the neuromuscular blocking agent BC6ENTC .	CPR:4
 BC6ENTG antagonist BC6ENTC and the defence reaction in the anaesthetised rat.	CPR:6
This review will try to enlighten on the BC6ENTG as a molecular link between dietary BC6ENTC and reproductive diseases in women.	False
BC6ENTG and BC6OTHER are nuclear receptors activated by BC6ENTC , oxidized derivatives of BC6OTHER .	CPR:3
BC6OTHER and BC6ENTG are nuclear receptors activated by BC6ENTC , oxidized derivatives of BC6OTHER .	CPR:3
BC6ENTG and BC6OTHER are nuclear receptors activated by BC6OTHER , oxidized derivatives of BC6ENTC .	False
BC6OTHER and BC6ENTG are nuclear receptors activated by BC6OTHER , oxidized derivatives of BC6ENTC .	False
Since their discovery, the role of BC6ENTG in the control of BC6ENTC homeostasis has been widely described.	False
INTRODUCTION: BC6OTHER ( BC6ENTC ) induces BC6OTHER ( BC6OTHER ) - positive and BC6OTHER ( BC6ENTG ) - positive ductal invasive mammary carcinomas in BALB / c mice.	CPR:3
INTRODUCTION: BC6OTHER ( BC6ENTC ) induces BC6ENTG ( BC6OTHER ) - positive and BC6OTHER ( BC6OTHER ) - positive ductal invasive mammary carcinomas in BALB / c mice.	CPR:3
INTRODUCTION: BC6OTHER ( BC6ENTC ) induces BC6OTHER ( BC6ENTG ) - positive and BC6OTHER ( BC6OTHER ) - positive ductal invasive mammary carcinomas in BALB / c mice.	CPR:3
INTRODUCTION: BC6OTHER ( BC6ENTC ) induces BC6OTHER ( BC6OTHER ) - positive and BC6ENTG ( BC6OTHER ) - positive ductal invasive mammary carcinomas in BALB / c mice.	False
Within this experimental setting, we studied the carcinogenic effects of BC6OTHER , the morphologic changes in mammary glands that are induced by BC6ENTC and BC6OTHER , and the levels of BC6ENTG and BC6OTHER expression in BC6OTHER - treated and BC6OTHER - treated mammary glands.	False
Within this experimental setting, we studied the carcinogenic effects of BC6OTHER , the morphologic changes in mammary glands that are induced by BC6ENTC and BC6OTHER , and the levels of BC6OTHER and BC6ENTG expression in BC6OTHER - treated and BC6OTHER - treated mammary glands.	False
Within this experimental setting, we studied the carcinogenic effects of BC6OTHER , the morphologic changes in mammary glands that are induced by BC6OTHER and BC6ENTC , and the levels of BC6ENTG and BC6OTHER expression in BC6OTHER - treated and BC6OTHER - treated mammary glands.	False
Within this experimental setting, we studied the carcinogenic effects of BC6OTHER , the morphologic changes in mammary glands that are induced by BC6OTHER and BC6ENTC , and the levels of BC6OTHER and BC6ENTG expression in BC6OTHER - treated and BC6OTHER - treated mammary glands.	False
Within this experimental setting, we studied the carcinogenic effects of BC6OTHER , the morphologic changes in mammary glands that are induced by BC6OTHER and BC6OTHER , and the levels of BC6ENTG and BC6OTHER expression in BC6ENTC - treated and BC6OTHER - treated mammary glands.	False
Within this experimental setting, we studied the carcinogenic effects of BC6OTHER , the morphologic changes in mammary glands that are induced by BC6OTHER and BC6OTHER , and the levels of BC6OTHER and BC6ENTG expression in BC6ENTC - treated and BC6OTHER - treated mammary glands.	False
Within this experimental setting, we studied the carcinogenic effects of BC6OTHER , the morphologic changes in mammary glands that are induced by BC6OTHER and BC6OTHER , and the levels of BC6ENTG and BC6OTHER expression in BC6OTHER - treated and BC6ENTC - treated mammary glands.	False
Within this experimental setting, we studied the carcinogenic effects of BC6OTHER , the morphologic changes in mammary glands that are induced by BC6OTHER and BC6OTHER , and the levels of BC6OTHER and BC6ENTG expression in BC6OTHER - treated and BC6ENTC - treated mammary glands.	False
INTRODUCTION: BC6OTHER ( BC6OTHER ) induces BC6ENTC receptor ( BC6OTHER ) - positive and BC6OTHER ( BC6ENTG ) - positive ductal invasive mammary carcinomas in BALB / c mice.	False
INTRODUCTION: BC6OTHER ( BC6OTHER ) induces BC6ENTC receptor ( BC6ENTG ) - positive and BC6OTHER ( BC6OTHER ) - positive ductal invasive mammary carcinomas in BALB / c mice.	False
INTRODUCTION: BC6OTHER ( BC6OTHER ) induces BC6ENTC receptor ( BC6OTHER ) - positive and BC6ENTG ( BC6OTHER ) - positive ductal invasive mammary carcinomas in BALB / c mice.	False
In addition, BALB / c and C57BL / 6 females were treated with BC6ENTC or BC6OTHER for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of BC6ENTG and BC6OTHER .	False
In addition, BALB / c and C57BL / 6 females were treated with BC6ENTC or BC6OTHER for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of BC6OTHER and BC6ENTG .	False
In addition, BALB / c and C57BL / 6 females were treated with BC6OTHER or BC6ENTC for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of BC6ENTG and BC6OTHER .	False
In addition, BALB / c and C57BL / 6 females were treated with BC6OTHER or BC6ENTC for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of BC6OTHER and BC6ENTG .	False
INTRODUCTION: BC6OTHER ( BC6OTHER ) induces BC6OTHER ( BC6OTHER ) - positive and BC6ENTC receptor ( BC6ENTG ) - positive ductal invasive mammary carcinomas in BALB / c mice.	False
INTRODUCTION: BC6OTHER ( BC6OTHER ) induces BC6ENTG ( BC6OTHER ) - positive and BC6ENTC receptor ( BC6OTHER ) - positive ductal invasive mammary carcinomas in BALB / c mice.	False
INTRODUCTION: BC6OTHER ( BC6OTHER ) induces BC6OTHER ( BC6ENTG ) - positive and BC6ENTC receptor ( BC6OTHER ) - positive ductal invasive mammary carcinomas in BALB / c mice.	False
Association of BC6ENTC receptor - alpha and BC6ENTG A expression with hormonal mammary carcinogenesis: role of the host microenvironment.	False
Association of BC6ENTG and BC6ENTC receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment.	False
INTRODUCTION: BC6ENTC ( BC6OTHER ) induces BC6OTHER ( BC6OTHER ) - positive and BC6OTHER ( BC6ENTG ) - positive ductal invasive mammary carcinomas in BALB / c mice.	CPR:3
INTRODUCTION: BC6ENTC ( BC6OTHER ) induces BC6ENTG ( BC6OTHER ) - positive and BC6OTHER ( BC6OTHER ) - positive ductal invasive mammary carcinomas in BALB / c mice.	CPR:3
INTRODUCTION: BC6ENTC ( BC6OTHER ) induces BC6OTHER ( BC6ENTG ) - positive and BC6OTHER ( BC6OTHER ) - positive ductal invasive mammary carcinomas in BALB / c mice.	CPR:3
INTRODUCTION: BC6ENTC ( BC6OTHER ) induces BC6OTHER ( BC6OTHER ) - positive and BC6ENTG ( BC6OTHER ) - positive ductal invasive mammary carcinomas in BALB / c mice.	CPR:3
The expression of BC6ENTG and BC6OTHER in virgin mice was surprisingly much higher in BALB / c than in C57BL / 6 mammary glands, and both receptors were downregulated in BC6ENTC - treated BALB / c mice (P < 0.05).	CPR:4
The expression of BC6OTHER and BC6ENTG in virgin mice was surprisingly much higher in BALB / c than in C57BL / 6 mammary glands, and both receptors were downregulated in BC6ENTC - treated BALB / c mice (P < 0.05).	CPR:4
BC6ENTG levels were low in virgin control mice and increased after BC6ENTC treatment in both strains.	CPR:3
Within this experimental setting, we studied the carcinogenic effects of BC6ENTC , the morphologic changes in mammary glands that are induced by BC6OTHER and BC6OTHER , and the levels of BC6ENTG and BC6OTHER expression in BC6OTHER - treated and BC6OTHER - treated mammary glands.	False
Within this experimental setting, we studied the carcinogenic effects of BC6ENTC , the morphologic changes in mammary glands that are induced by BC6OTHER and BC6OTHER , and the levels of BC6OTHER and BC6ENTG expression in BC6OTHER - treated and BC6OTHER - treated mammary glands.	False
The radioactivity was rapidly and widely distributed throughout the body, and remained detectable in all tissues investigated at later time points (24 and 48 hours for [ BC6ENTC ] - BC6ENTG and [ BC6OTHER ] - SSB siRNA, respectively).	False
The radioactivity was rapidly and widely distributed throughout the body, and remained detectable in all tissues investigated at later time points (24 and 48 hours for [ BC6OTHER ] - BC6ENTG and [ BC6ENTC ] - SSB siRNA, respectively).	False
Instead, radiolabeled BC6ENTC resulting from BC6ENTG hydrolysis were observed.	CPR:9
Expression of pituitary BC6ENTG and BC6OTHER , under the control of pulsatile BC6ENTC , is essential for fertility.	False
Expression of pituitary BC6OTHER and BC6ENTG , under the control of pulsatile BC6ENTC , is essential for fertility.	False
A BC6ENTG ( BC6OTHER ) reduced BC6ENTC - stimulated BC6OTHER and markedly decreased BC6OTHER stimulation of BC6OTHER mRNA and BC6OTHER LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway.	False
A BC6OTHER ( BC6ENTG ) reduced BC6ENTC - stimulated BC6OTHER and markedly decreased BC6OTHER stimulation of BC6OTHER mRNA and BC6OTHER LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway.	False
A BC6OTHER ( BC6OTHER ) reduced BC6ENTC - stimulated BC6ENTG and markedly decreased BC6OTHER stimulation of BC6OTHER mRNA and BC6OTHER LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway.	CPR:3
A BC6OTHER ( BC6OTHER ) reduced BC6ENTC - stimulated BC6OTHER and markedly decreased BC6ENTG stimulation of BC6OTHER mRNA and BC6OTHER LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway.	False
A BC6OTHER ( BC6OTHER ) reduced BC6ENTC - stimulated BC6OTHER and markedly decreased BC6OTHER stimulation of BC6ENTG mRNA and BC6OTHER LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway.	False
A BC6OTHER ( BC6OTHER ) reduced BC6ENTC - stimulated BC6OTHER and markedly decreased BC6OTHER stimulation of BC6OTHER mRNA and BC6ENTG LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway.	False
A BC6OTHER ( BC6OTHER ) reduced BC6ENTC - stimulated BC6OTHER and markedly decreased BC6OTHER stimulation of BC6OTHER mRNA and BC6OTHER LUC activity, but had little effect on BC6ENTG LUC activity, indicating relative specificity of this pathway.	False
A BC6ENTG ( BC6OTHER ) reduced BC6OTHER - stimulated BC6OTHER and markedly decreased BC6ENTC stimulation of BC6OTHER mRNA and BC6OTHER LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway.	False
A BC6OTHER ( BC6ENTG ) reduced BC6OTHER - stimulated BC6OTHER and markedly decreased BC6ENTC stimulation of BC6OTHER mRNA and BC6OTHER LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway.	False
A BC6OTHER ( BC6OTHER ) reduced BC6ENTG - stimulated BC6OTHER and markedly decreased BC6ENTC stimulation of BC6OTHER mRNA and BC6OTHER LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway.	False
A BC6OTHER ( BC6OTHER ) reduced BC6OTHER - stimulated BC6ENTG and markedly decreased BC6ENTC stimulation of BC6OTHER mRNA and BC6OTHER LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway.	False
A BC6OTHER ( BC6OTHER ) reduced BC6OTHER - stimulated BC6OTHER and markedly decreased BC6ENTC stimulation of BC6ENTG mRNA and BC6OTHER LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway.	CPR:3
A BC6OTHER ( BC6OTHER ) reduced BC6OTHER - stimulated BC6OTHER and markedly decreased BC6ENTC stimulation of BC6OTHER mRNA and BC6ENTG LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway.	CPR:3
A BC6OTHER ( BC6OTHER ) reduced BC6OTHER - stimulated BC6OTHER and markedly decreased BC6ENTC stimulation of BC6OTHER mRNA and BC6OTHER LUC activity, but had little effect on BC6ENTG LUC activity, indicating relative specificity of this pathway.	False
In perifusion studies, BC6ENTG mRNA levels and BC6OTHER LUC activities were increased by pulsatile BC6ENTC , with significantly greater increases at low compared with high pulse frequencies.	CPR:3
In perifusion studies, BC6OTHER mRNA levels and BC6ENTG LUC activities were increased by pulsatile BC6ENTC , with significantly greater increases at low compared with high pulse frequencies.	CPR:3
 BC6ENTC pulse frequency - dependent stimulation of BC6OTHER transcription is mediated via activation of BC6OTHER and BC6ENTG .	CPR:3
 BC6ENTC pulse frequency - dependent stimulation of BC6ENTG transcription is mediated via activation of BC6OTHER and BC6OTHER .	CPR:3
 BC6ENTC pulse frequency - dependent stimulation of BC6OTHER transcription is mediated via activation of BC6ENTG and BC6OTHER .	CPR:3
BC6ENTC response element - binding protein ( BC6ENTG ) has been implicated in the regulation of BC6OTHER gene expression, but the molecular mechanisms by which pulsatile BC6OTHER regulates BC6OTHER activation remain poorly understood.	False
BC6ENTC response element - binding protein ( BC6OTHER ) has been implicated in the regulation of BC6ENTG gene expression, but the molecular mechanisms by which pulsatile BC6OTHER regulates BC6OTHER activation remain poorly understood.	False
BC6ENTC response element - binding protein ( BC6OTHER ) has been implicated in the regulation of BC6OTHER gene expression, but the molecular mechanisms by which pulsatile BC6ENTG regulates BC6OTHER activation remain poorly understood.	False
BC6ENTC response element - binding protein ( BC6OTHER ) has been implicated in the regulation of BC6OTHER gene expression, but the molecular mechanisms by which pulsatile BC6OTHER regulates BC6ENTG activation remain poorly understood.	False
BC6ENTG markedly reduced these BC6ENTC - stimulated BC6OTHER responses at both low and high pulse frequencies.	False
BC6OTHER markedly reduced these BC6ENTC - stimulated BC6ENTG responses at both low and high pulse frequencies.	CPR:3
Correlating with BC6ENTG activation, both BC6OTHER activity and levels of BC6OTHER were increased to a greater extent by low compared with high BC6ENTC pulse frequencies, and the induction of BC6OTHER was also attenuated by overexpression of BC6OTHER at both low and high pulse frequencies.	CPR:3
Correlating with BC6OTHER activation, both BC6ENTG activity and levels of BC6OTHER were increased to a greater extent by low compared with high BC6ENTC pulse frequencies, and the induction of BC6OTHER was also attenuated by overexpression of BC6OTHER at both low and high pulse frequencies.	CPR:3
Correlating with BC6OTHER activation, both BC6OTHER activity and levels of BC6ENTG were increased to a greater extent by low compared with high BC6ENTC pulse frequencies, and the induction of BC6OTHER was also attenuated by overexpression of BC6OTHER at both low and high pulse frequencies.	CPR:3
Correlating with BC6OTHER activation, both BC6OTHER activity and levels of BC6OTHER were increased to a greater extent by low compared with high BC6ENTC pulse frequencies, and the induction of BC6ENTG was also attenuated by overexpression of BC6OTHER at both low and high pulse frequencies.	CPR:3
Correlating with BC6OTHER activation, both BC6OTHER activity and levels of BC6OTHER were increased to a greater extent by low compared with high BC6ENTC pulse frequencies, and the induction of BC6OTHER was also attenuated by overexpression of BC6ENTG at both low and high pulse frequencies.	False
Taken together, these data indicate that a BC6ENTG - mediated signaling pathway mediates BC6ENTC activation of BC6OTHER at low - pulse frequencies, playing a significant role in the decoding of the hypothalamic BC6OTHER signal to result in frequency - dependent BC6OTHER activation.	False
Taken together, these data indicate that a BC6OTHER - mediated signaling pathway mediates BC6ENTC activation of BC6ENTG at low - pulse frequencies, playing a significant role in the decoding of the hypothalamic BC6OTHER signal to result in frequency - dependent BC6OTHER activation.	CPR:3
Taken together, these data indicate that a BC6OTHER - mediated signaling pathway mediates BC6ENTC activation of BC6OTHER at low - pulse frequencies, playing a significant role in the decoding of the hypothalamic BC6ENTG signal to result in frequency - dependent BC6OTHER activation.	False
Taken together, these data indicate that a BC6OTHER - mediated signaling pathway mediates BC6ENTC activation of BC6OTHER at low - pulse frequencies, playing a significant role in the decoding of the hypothalamic BC6OTHER signal to result in frequency - dependent BC6ENTG activation.	False
Taken together, these data indicate that a BC6ENTG - mediated signaling pathway mediates BC6OTHER activation of BC6OTHER at low - pulse frequencies, playing a significant role in the decoding of the hypothalamic BC6ENTC signal to result in frequency - dependent BC6OTHER activation.	False
Taken together, these data indicate that a BC6OTHER - mediated signaling pathway mediates BC6ENTG activation of BC6OTHER at low - pulse frequencies, playing a significant role in the decoding of the hypothalamic BC6ENTC signal to result in frequency - dependent BC6OTHER activation.	False
Taken together, these data indicate that a BC6OTHER - mediated signaling pathway mediates BC6OTHER activation of BC6ENTG at low - pulse frequencies, playing a significant role in the decoding of the hypothalamic BC6ENTC signal to result in frequency - dependent BC6OTHER activation.	False
Taken together, these data indicate that a BC6OTHER - mediated signaling pathway mediates BC6OTHER activation of BC6OTHER at low - pulse frequencies, playing a significant role in the decoding of the hypothalamic BC6ENTC signal to result in frequency - dependent BC6ENTG activation.	CPR:3
BC6ENTG ( BC6OTHER ) has been implicated in the regulation of BC6OTHER gene expression, but the molecular mechanisms by which pulsatile BC6ENTC regulates BC6OTHER activation remain poorly understood.	False
BC6OTHER response element - binding protein ( BC6ENTG ) has been implicated in the regulation of BC6OTHER gene expression, but the molecular mechanisms by which pulsatile BC6ENTC regulates BC6OTHER activation remain poorly understood.	False
BC6OTHER response element - binding protein ( BC6OTHER ) has been implicated in the regulation of BC6ENTG gene expression, but the molecular mechanisms by which pulsatile BC6ENTC regulates BC6OTHER activation remain poorly understood.	False
BC6OTHER response element - binding protein ( BC6OTHER ) has been implicated in the regulation of BC6OTHER gene expression, but the molecular mechanisms by which pulsatile BC6ENTC regulates BC6ENTG activation remain poorly understood.	CPR:3
We hypothesized that BC6ENTG is activated by a distinct signaling pathway in response to pulsatile BC6ENTC in a frequency - dependent manner to dictate the BC6OTHER transcriptional response.	CPR:3
We hypothesized that BC6OTHER is activated by a distinct signaling pathway in response to pulsatile BC6ENTC in a frequency - dependent manner to dictate the BC6ENTG transcriptional response.	False
BC6ENTC stimulation of BC6ENTG phosphorylation ( BC6OTHER ) in the gonadotrope - derived LβT2 cell line was attenuated by a BC6OTHER ( BC6OTHER ) inhibitor, BC6OTHER .	CPR:3
BC6ENTC stimulation of BC6OTHER phosphorylation ( BC6ENTG ) in the gonadotrope - derived LβT2 cell line was attenuated by a BC6OTHER ( BC6OTHER ) inhibitor, BC6OTHER .	CPR:3
BC6ENTC stimulation of BC6OTHER phosphorylation ( BC6OTHER ) in the gonadotrope - derived LβT2 cell line was attenuated by a BC6ENTG ( BC6OTHER ) inhibitor, BC6OTHER .	False
BC6ENTC stimulation of BC6OTHER phosphorylation ( BC6OTHER ) in the gonadotrope - derived LβT2 cell line was attenuated by a BC6OTHER ( BC6ENTG ) inhibitor, BC6OTHER .	False
BC6ENTG stimulation of BC6OTHER phosphorylation ( BC6OTHER ) in the gonadotrope - derived LβT2 cell line was attenuated by a BC6OTHER ( BC6OTHER ) inhibitor, BC6ENTC .	False
BC6OTHER stimulation of BC6ENTG phosphorylation ( BC6OTHER ) in the gonadotrope - derived LβT2 cell line was attenuated by a BC6OTHER ( BC6OTHER ) inhibitor, BC6ENTC .	CPR:4
BC6OTHER stimulation of BC6OTHER phosphorylation ( BC6ENTG ) in the gonadotrope - derived LβT2 cell line was attenuated by a BC6OTHER ( BC6OTHER ) inhibitor, BC6ENTC .	CPR:4
BC6OTHER stimulation of BC6OTHER phosphorylation ( BC6OTHER ) in the gonadotrope - derived LβT2 cell line was attenuated by a BC6ENTG ( BC6OTHER ) inhibitor, BC6ENTC .	CPR:4
BC6OTHER stimulation of BC6OTHER phosphorylation ( BC6OTHER ) in the gonadotrope - derived LβT2 cell line was attenuated by a BC6OTHER ( BC6ENTG ) inhibitor, BC6ENTC .	CPR:4
In humans, BC6ENTG deficiency results in the accumulation of BC6ENTC at the expense of BC6OTHER derivatives required for BC6OTHER and BC6OTHER biosynthesis.	CPR:9
In humans, BC6ENTG deficiency results in the accumulation of BC6OTHER at the expense of BC6ENTC derivatives required for BC6OTHER and BC6OTHER biosynthesis.	False
In humans, BC6ENTG deficiency results in the accumulation of BC6OTHER at the expense of BC6OTHER derivatives required for BC6ENTC and BC6OTHER biosynthesis.	False
In humans, BC6ENTG deficiency results in the accumulation of BC6OTHER at the expense of BC6OTHER derivatives required for BC6OTHER and BC6ENTC biosynthesis.	False
This model is a hypomorph, with reduced BC6ENTG activity, thus avoiding the lethality associated with the absence of BC6ENTC synthase activity.	False
We have constructed a mouse model with a gene trap insertion in the BC6ENTG gene specifying BC6ENTC synthase reductase, an enzyme essential for the activity of BC6OTHER .	False
We have constructed a mouse model with a gene trap insertion in the BC6OTHER gene specifying BC6ENTC synthase reductase, an enzyme essential for the activity of BC6ENTG .	False
We have constructed a mouse model with a gene trap insertion in the BC6ENTG gene specifying BC6OTHER , an enzyme essential for the activity of BC6ENTC synthase.	False
We have constructed a mouse model with a gene trap insertion in the BC6OTHER gene specifying BC6ENTG , an enzyme essential for the activity of BC6ENTC synthase.	False
This model is a hypomorph, with reduced BC6ENTC synthase reductase activity, thus avoiding the lethality associated with the absence of BC6ENTG activity.	False
Metabolic derangement of BC6ENTC and BC6OTHER metabolism in mice deficient in BC6ENTG .	False
Metabolic derangement of BC6OTHER and BC6ENTC metabolism in mice deficient in BC6ENTG .	False
BC6ENTG (gt / gt) mice have increased plasma BC6ENTC , decreased plasma BC6OTHER , and increased tissue BC6OTHER .	False
BC6ENTG (gt / gt) mice have increased plasma BC6OTHER , decreased plasma BC6ENTC , and increased tissue BC6OTHER .	False
BC6ENTG (gt / gt) mice have increased plasma BC6OTHER , decreased plasma BC6OTHER , and increased tissue BC6ENTC .	False
Unexpectedly, BC6ENTG (gt / gt) mice do not show decreases in the BC6ENTC / BC6OTHER ratio in most tissues.	False
Unexpectedly, BC6ENTG (gt / gt) mice do not show decreases in the BC6OTHER / BC6ENTC ratio in most tissues.	False
BC6ENTC had no effect on resting intracellular [ BC6OTHER ] or BC6ENTG - induced increase in BC6OTHER mobilization.	False
BC6OTHER had no effect on resting intracellular [ BC6ENTC ] or BC6ENTG - induced increase in BC6OTHER mobilization.	False
BC6OTHER had no effect on resting intracellular [ BC6OTHER ] or BC6ENTG - induced increase in BC6ENTC mobilization.	False
Addition of the inhibitors of endothelial BC6ENTC synthase or BC6ENTG did not alter the protective effect of BC6OTHER .	False
Addition of the inhibitors of BC6ENTG or BC6ENTC receptor did not alter the protective effect of BC6OTHER .	False
Addition of the inhibitors of BC6ENTG or BC6OTHER did not alter the protective effect of BC6ENTC .	False
Addition of the inhibitors of endothelial BC6OTHER synthase or BC6ENTG did not alter the protective effect of BC6ENTC .	False
BC6ENTG inhibitor blocked the protective effect of BC6ENTC on endothelial permeability and also ablated BC6OTHER - induced BC6OTHER - phosphorylation in ECs.	False
BC6OTHER inhibitor blocked the protective effect of BC6ENTC on endothelial permeability and also ablated BC6ENTG - induced BC6OTHER - phosphorylation in ECs.	False
BC6OTHER inhibitor blocked the protective effect of BC6ENTC on endothelial permeability and also ablated BC6OTHER - induced BC6ENTG - phosphorylation in ECs.	False
CHEM BC6ENTC protects against endothelial barrier dysfunction in vascular endothelial cells through BC6ENTG - mediated suppression of BC6OTHER signaling.	False
CHEM BC6ENTC protects against endothelial barrier dysfunction in vascular endothelial cells through BC6OTHER - mediated suppression of BC6ENTG signaling.	False
Inhibition of BC6ENTG significantly attenuated the effect of BC6ENTC on BC6OTHER - induced EC permeability, BC6OTHER phosphorylation, and BC6OTHER membrane translocation in ECs.	False
Inhibition of BC6OTHER significantly attenuated the effect of BC6ENTC on BC6ENTG - induced EC permeability, BC6OTHER phosphorylation, and BC6OTHER membrane translocation in ECs.	False
Inhibition of BC6OTHER significantly attenuated the effect of BC6ENTC on BC6OTHER - induced EC permeability, BC6ENTG phosphorylation, and BC6OTHER membrane translocation in ECs.	False
Inhibition of BC6OTHER significantly attenuated the effect of BC6ENTC on BC6OTHER - induced EC permeability, BC6OTHER phosphorylation, and BC6ENTG membrane translocation in ECs.	False
Furthermore, BC6ENTG diminished BC6ENTC production in ECs, which were prevented by treatment with BC6OTHER .	False
Furthermore, BC6ENTG diminished BC6OTHER production in ECs, which were prevented by treatment with BC6ENTC .	CPR:4
These findings demonstrated that BC6ENTC improves BC6ENTG - induced endothelial barrier dysfunction in ECs through BC6OTHER - mediated suppression of BC6OTHER signaling.	False
These findings demonstrated that BC6ENTC improves BC6OTHER - induced endothelial barrier dysfunction in ECs through BC6ENTG - mediated suppression of BC6OTHER signaling.	False
These findings demonstrated that BC6ENTC improves BC6OTHER - induced endothelial barrier dysfunction in ECs through BC6OTHER - mediated suppression of BC6ENTG signaling.	False
Here, we report that BC6ENTC at physiologically relevant concentrations (0.1 - 10 μM) significantly inhibited BC6ENTG - induced increase in endothelial monolayer permeability.	CPR:4
BC6ENTC also reduced the formation of stress fibers by BC6ENTG and suppressed BC6OTHER - induced phosphorylation of BC6OTHER ( BC6OTHER ) on BC6OTHER (19) / BC6OTHER (18) in endothelial cells (ECs).	CPR:4
BC6ENTC also reduced the formation of stress fibers by BC6OTHER and suppressed BC6ENTG - induced phosphorylation of BC6OTHER ( BC6OTHER ) on BC6OTHER (19) / BC6OTHER (18) in endothelial cells (ECs).	CPR:4
BC6ENTC also reduced the formation of stress fibers by BC6OTHER and suppressed BC6OTHER - induced phosphorylation of BC6ENTG ( BC6OTHER ) on BC6OTHER (19) / BC6OTHER (18) in endothelial cells (ECs).	CPR:4
BC6ENTC also reduced the formation of stress fibers by BC6OTHER and suppressed BC6OTHER - induced phosphorylation of BC6OTHER ( BC6ENTG ) on BC6OTHER (19) / BC6OTHER (18) in endothelial cells (ECs).	CPR:4
BC6OTHER also reduced the formation of stress fibers by BC6ENTG and suppressed BC6OTHER - induced phosphorylation of BC6OTHER ( BC6OTHER ) on BC6ENTC (19) / BC6OTHER (18) in endothelial cells (ECs).	False
BC6OTHER also reduced the formation of stress fibers by BC6OTHER and suppressed BC6ENTG - induced phosphorylation of BC6OTHER ( BC6OTHER ) on BC6ENTC (19) / BC6OTHER (18) in endothelial cells (ECs).	False
BC6OTHER also reduced the formation of stress fibers by BC6OTHER and suppressed BC6OTHER - induced phosphorylation of BC6ENTG ( BC6OTHER ) on BC6ENTC (19) / BC6OTHER (18) in endothelial cells (ECs).	False
BC6OTHER also reduced the formation of stress fibers by BC6OTHER and suppressed BC6OTHER - induced phosphorylation of BC6OTHER ( BC6ENTG ) on BC6ENTC (19) / BC6OTHER (18) in endothelial cells (ECs).	False
BC6OTHER also reduced the formation of stress fibers by BC6ENTG and suppressed BC6OTHER - induced phosphorylation of BC6OTHER ( BC6OTHER ) on BC6OTHER (19) / BC6ENTC (18) in endothelial cells (ECs).	False
BC6OTHER also reduced the formation of stress fibers by BC6OTHER and suppressed BC6ENTG - induced phosphorylation of BC6OTHER ( BC6OTHER ) on BC6OTHER (19) / BC6ENTC (18) in endothelial cells (ECs).	False
BC6OTHER also reduced the formation of stress fibers by BC6OTHER and suppressed BC6OTHER - induced phosphorylation of BC6ENTG ( BC6OTHER ) on BC6OTHER (19) / BC6ENTC (18) in endothelial cells (ECs).	False
BC6OTHER also reduced the formation of stress fibers by BC6OTHER and suppressed BC6OTHER - induced phosphorylation of BC6OTHER ( BC6ENTG ) on BC6OTHER (19) / BC6ENTC (18) in endothelial cells (ECs).	False
In the absence of BC6ENTG (in BC6OTHER Δ mutant strain) sensitivity to the essential oil and BC6OTHER increased indicating that this oil and BC6ENTC are generating reactive BC6OTHER species (ROS).	False
In the absence of BC6OTHER dismutase (in BC6ENTG Δ mutant strain) sensitivity to the essential oil and BC6OTHER increased indicating that this oil and BC6ENTC are generating reactive BC6OTHER species (ROS).	False
In the absence of BC6ENTG (in BC6OTHER Δ mutant strain) sensitivity to the essential oil and BC6OTHER increased indicating that this oil and BC6OTHER are generating reactive BC6ENTC species (ROS).	False
In the absence of BC6OTHER dismutase (in BC6ENTG Δ mutant strain) sensitivity to the essential oil and BC6OTHER increased indicating that this oil and BC6OTHER are generating reactive BC6ENTC species (ROS).	False
The ROS production was confirmed by BC6ENTC probing assay in BC6ENTG - deficient strains.	False
Our results revealed an important role of base excision repair (BER) as the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER mutants showed pronounced sensitivity to essential oil and BC6ENTC .	False
Our results revealed an important role of base excision repair (BER) as the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER mutants showed pronounced sensitivity to essential oil and BC6ENTC .	False
Our results revealed an important role of base excision repair (BER) as the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER mutants showed pronounced sensitivity to essential oil and BC6ENTC .	False
Our results revealed an important role of base excision repair (BER) as the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG mutants showed pronounced sensitivity to essential oil and BC6ENTC .	False
In the absence of BC6ENTC dismutase (in BC6ENTG Δ mutant strain) sensitivity to the essential oil and BC6OTHER increased indicating that this oil and BC6OTHER are generating reactive BC6OTHER species (ROS).	False
In the absence of BC6ENTG (in BC6OTHER Δ mutant strain) sensitivity to the essential oil and BC6ENTC increased indicating that this oil and BC6OTHER are generating reactive BC6OTHER species (ROS).	False
In the absence of BC6OTHER dismutase (in BC6ENTG Δ mutant strain) sensitivity to the essential oil and BC6ENTC increased indicating that this oil and BC6OTHER are generating reactive BC6OTHER species (ROS).	False
The suppression of BC6ENTG activation by inhibition of the BC6OTHER contributes to the well - known anti - inflammatory and immunosuppressive effects of BC6ENTC .	CPR:4
The suppression of BC6OTHER activation by inhibition of the BC6ENTG contributes to the well - known anti - inflammatory and immunosuppressive effects of BC6ENTC .	CPR:4
Various drugs used in the treatment of IBD, such as glucocorticoids, BC6ENTC , and BC6OTHER , interfere with BC6ENTG / BC6OTHER signaling.	False
Various drugs used in the treatment of IBD, such as glucocorticoids, BC6ENTC , and BC6OTHER , interfere with BC6OTHER / BC6ENTG signaling.	False
Various drugs used in the treatment of IBD, such as glucocorticoids, BC6OTHER , and BC6ENTC , interfere with BC6ENTG / BC6OTHER signaling.	False
Various drugs used in the treatment of IBD, such as glucocorticoids, BC6OTHER , and BC6ENTC , interfere with BC6OTHER / BC6ENTG signaling.	False
The aim of this study was to define the molecular mechanism by which BC6ENTC inhibits BC6ENTG activation.	CPR:4
METHODS: The effects of BC6ENTC and its moieties on BC6ENTG signaling were evaluated using electromobility shift, transfection, and immune complex kinase assays.	False
The direct effect of BC6ENTC on BC6ENTG ( BC6OTHER ) activity was investigated using purified recombinant BC6OTHER proteins.	False
The direct effect of BC6ENTC on BC6OTHER ( BC6ENTG ) activity was investigated using purified recombinant BC6OTHER proteins.	False
The direct effect of BC6ENTC on BC6OTHER ( BC6OTHER ) activity was investigated using purified recombinant BC6ENTG proteins.	False
RESULTS: BC6ENTG / BC6OTHER activity induced by BC6OTHER , BC6ENTC , or overexpression of BC6OTHER , BC6OTHER , BC6OTHER , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6OTHER .	CPR:3
RESULTS: BC6OTHER / BC6ENTG activity induced by BC6OTHER , BC6ENTC , or overexpression of BC6OTHER , BC6OTHER , BC6OTHER , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6OTHER .	CPR:3
RESULTS: BC6OTHER / BC6OTHER activity induced by BC6ENTG , BC6ENTC , or overexpression of BC6OTHER , BC6OTHER , BC6OTHER , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6OTHER .	False
RESULTS: BC6OTHER / BC6OTHER activity induced by BC6OTHER , BC6ENTC , or overexpression of BC6ENTG , BC6OTHER , BC6OTHER , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6OTHER .	False
RESULTS: BC6OTHER / BC6OTHER activity induced by BC6OTHER , BC6ENTC , or overexpression of BC6OTHER , BC6ENTG , BC6OTHER , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6OTHER .	False
RESULTS: BC6OTHER / BC6OTHER activity induced by BC6OTHER , BC6ENTC , or overexpression of BC6OTHER , BC6OTHER , BC6ENTG , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6OTHER .	False
RESULTS: BC6OTHER / BC6OTHER activity induced by BC6OTHER , BC6ENTC , or overexpression of BC6OTHER , BC6OTHER , BC6OTHER , or constitutively active BC6ENTG and BC6OTHER mutants was inhibited dose dependently by BC6OTHER .	False
RESULTS: BC6OTHER / BC6OTHER activity induced by BC6OTHER , BC6ENTC , or overexpression of BC6OTHER , BC6OTHER , BC6OTHER , or constitutively active BC6OTHER and BC6ENTG mutants was inhibited dose dependently by BC6OTHER .	False
RESULTS: BC6ENTG / BC6OTHER activity induced by BC6OTHER , BC6OTHER , or overexpression of BC6OTHER , BC6OTHER , BC6OTHER , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6ENTC .	CPR:4
RESULTS: BC6OTHER / BC6ENTG activity induced by BC6OTHER , BC6OTHER , or overexpression of BC6OTHER , BC6OTHER , BC6OTHER , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6ENTC .	CPR:4
RESULTS: BC6OTHER / BC6OTHER activity induced by BC6ENTG , BC6OTHER , or overexpression of BC6OTHER , BC6OTHER , BC6OTHER , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6ENTC .	False
RESULTS: BC6OTHER / BC6OTHER activity induced by BC6OTHER , BC6OTHER , or overexpression of BC6ENTG , BC6OTHER , BC6OTHER , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6ENTC .	CPR:4
RESULTS: BC6OTHER / BC6OTHER activity induced by BC6OTHER , BC6OTHER , or overexpression of BC6OTHER , BC6ENTG , BC6OTHER , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6ENTC .	CPR:4
RESULTS: BC6OTHER / BC6OTHER activity induced by BC6OTHER , BC6OTHER , or overexpression of BC6OTHER , BC6OTHER , BC6ENTG , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6ENTC .	CPR:4
RESULTS: BC6OTHER / BC6OTHER activity induced by BC6OTHER , BC6OTHER , or overexpression of BC6OTHER , BC6OTHER , BC6OTHER , or constitutively active BC6ENTG and BC6OTHER mutants was inhibited dose dependently by BC6ENTC .	CPR:4
RESULTS: BC6OTHER / BC6OTHER activity induced by BC6OTHER , BC6OTHER , or overexpression of BC6OTHER , BC6OTHER , BC6OTHER , or constitutively active BC6OTHER and BC6ENTG mutants was inhibited dose dependently by BC6ENTC .	CPR:4
BC6ENTC inhibited BC6ENTG - induced activation of endogenous BC6OTHER in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified BC6OTHER and BC6OTHER in vitro.	CPR:4
BC6ENTC inhibited BC6OTHER - induced activation of endogenous BC6ENTG in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified BC6OTHER and BC6OTHER in vitro.	CPR:4
BC6ENTC inhibited BC6OTHER - induced activation of endogenous BC6OTHER in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified BC6ENTG and BC6OTHER in vitro.	CPR:4
BC6ENTC inhibited BC6OTHER - induced activation of endogenous BC6OTHER in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified BC6OTHER and BC6ENTG in vitro.	CPR:4
Suppression of BC6ENTG activity by BC6ENTC is mediated by direct inhibition of BC6OTHER .	CPR:4
Suppression of BC6OTHER activity by BC6ENTC is mediated by direct inhibition of BC6ENTG .	False
Activation of BC6ENTG , c - Jun - BC6ENTC - terminal kinase (JNK) 1, and BC6OTHER was unaffected by BC6OTHER .	False
Activation of BC6OTHER , c - Jun - BC6ENTC - terminal kinase (JNK) 1, and BC6ENTG was unaffected by BC6OTHER .	False
Activation of BC6ENTG , c - Jun - BC6OTHER - terminal kinase (JNK) 1, and BC6OTHER was unaffected by BC6ENTC .	False
Activation of BC6OTHER , BC6ENTG , and BC6OTHER was unaffected by BC6ENTC .	False
Activation of BC6OTHER , c - Jun - BC6OTHER - terminal kinase (JNK) 1, and BC6ENTG was unaffected by BC6ENTC .	False
The decrease in substrate phosphorylation by BC6ENTG is associated with a decrease in autophosphorylation of BC6OTHER and can be antagonized by excess BC6ENTC .	False
The decrease in substrate phosphorylation by BC6OTHER is associated with a decrease in autophosphorylation of BC6ENTG and can be antagonized by excess BC6ENTC .	CPR:4
CONCLUSIONS: These data identify BC6ENTC as a direct inhibitor of BC6ENTG by antagonizing BC6OTHER binding.	False
CONCLUSIONS: These data identify BC6OTHER as a direct inhibitor of BC6ENTG by antagonizing BC6ENTC binding.	False
Inhibition of the BC6ENTG BC6ENTC channel by BC6OTHER : affinity for open and inactivated states.	False
Inhibition of the BC6ENTG BC6OTHER channel by BC6ENTC : affinity for open and inactivated states.	CPR:4
6 In conclusion, BC6ENTG channel inhibition by BC6ENTC exhibits features consistent with open and inactivated state binding and is sensitive to external BC6OTHER concentration.	CPR:4
6 In conclusion, BC6ENTG channel inhibition by BC6OTHER exhibits features consistent with open and inactivated state binding and is sensitive to external BC6ENTC concentration.	False
2 In a chronic transfection model using CHO - K1 cells, BC6ENTC inhibited BC6ENTG tail currents after a step to +25 mV with similar potency at room and physiological temperatures (IC50 16.	CPR:4
When combined, BC6OTHER antagonized the effects of the full BC6ENTG agonists in BC6ENTC assays and reduced the stimulation of BC6OTHER BC6OTHER and BC6OTHER phosphorylation by BC6OTHER .	False
When combined, BC6OTHER antagonized the effects of the full BC6OTHER agonists in BC6ENTC assays and reduced the stimulation of BC6ENTG BC6OTHER and BC6OTHER phosphorylation by BC6OTHER .	False
When combined, BC6OTHER antagonized the effects of the full BC6OTHER agonists in BC6ENTC assays and reduced the stimulation of BC6OTHER BC6ENTG and BC6OTHER phosphorylation by BC6OTHER .	False
When combined, BC6OTHER antagonized the effects of the full BC6OTHER agonists in BC6ENTC assays and reduced the stimulation of BC6OTHER BC6OTHER and BC6ENTG phosphorylation by BC6OTHER .	False
When combined, BC6OTHER antagonized the effects of the full BC6OTHER agonists in BC6ENTC assays and reduced the stimulation of BC6OTHER BC6OTHER and BC6OTHER phosphorylation by BC6ENTG .	False
We previously reported that BC6ENTC antidepressants act as agonists at distinct BC6ENTG .	CPR:5
When combined, BC6OTHER antagonized the effects of the full BC6ENTG agonists in BC6OTHER assays and reduced the stimulation of BC6OTHER BC6OTHER and BC6OTHER phosphorylation by BC6ENTC .	False
When combined, BC6OTHER antagonized the effects of the full BC6OTHER agonists in BC6OTHER assays and reduced the stimulation of BC6ENTG BC6OTHER and BC6OTHER phosphorylation by BC6ENTC .	CPR:3
When combined, BC6OTHER antagonized the effects of the full BC6OTHER agonists in BC6OTHER assays and reduced the stimulation of BC6OTHER BC6ENTG and BC6OTHER phosphorylation by BC6ENTC .	CPR:3
When combined, BC6OTHER antagonized the effects of the full BC6OTHER agonists in BC6OTHER assays and reduced the stimulation of BC6OTHER BC6OTHER and BC6ENTG phosphorylation by BC6ENTC .	False
CONCLUSIONS AND IMPLICATIONS: In different cell systems, BC6ENTC directly activates BC6ENTG , displaying partial agonist activity at brain receptors.	CPR:5
Here, we investigated the effect of the atypical antidepressant BC6ENTC at cloned and native BC6ENTG .	False
EXPERIMENTAL APPROACH: Effects of BC6ENTC were examined in CHO cells transfected with BC6ENTG , C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of BC6OTHER binding and BC6OTHER phosphorylation.	False
EXPERIMENTAL APPROACH: Effects of BC6ENTC were examined in CHO cells transfected with BC6OTHER , C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of BC6OTHER binding and BC6ENTG phosphorylation.	False
EXPERIMENTAL APPROACH: Effects of BC6OTHER were examined in CHO cells transfected with BC6ENTG , C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of BC6ENTC binding and BC6OTHER phosphorylation.	False
EXPERIMENTAL APPROACH: Effects of BC6OTHER were examined in CHO cells transfected with BC6OTHER , C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of BC6ENTC binding and BC6ENTG phosphorylation.	False
KEY RESULTS: BC6ENTC displayed 12 - and 18 - fold higher affinity for BC6ENTG respectively.	False
In BC6ENTC assays, BC6OTHER selectively activated BC6ENTG .	False
In BC6OTHER assays, BC6ENTC selectively activated BC6ENTG .	CPR:3
BC6ENTC and BC6OTHER increased BC6ENTG phosphorylation in CHO cells expressing BC6OTHER and C6 cells, and these effects were antagonized by BC6OTHER .	False
BC6ENTC and BC6OTHER increased BC6OTHER phosphorylation in CHO cells expressing BC6ENTG and C6 cells, and these effects were antagonized by BC6OTHER .	False
The agonist activity was antagonized by the selective BC6ENTG blocker BC6ENTC ( BC6OTHER ).	CPR:6
The agonist activity was antagonized by the selective BC6ENTG blocker BC6OTHER ( BC6ENTC ).	CPR:6
The BC6ENTC analogue BC6OTHER also displayed BC6ENTG agonist activity.	CPR:5
The BC6OTHER analogue BC6ENTC also displayed BC6ENTG agonist activity.	CPR:5
The atypical antidepressant BC6ENTC exhibits agonist activity at BC6ENTG .	CPR:5
BC6OTHER and BC6ENTC increased BC6ENTG phosphorylation in CHO cells expressing BC6OTHER and C6 cells, and these effects were antagonized by BC6OTHER .	False
BC6OTHER and BC6ENTC increased BC6OTHER phosphorylation in CHO cells expressing BC6ENTG and C6 cells, and these effects were antagonized by BC6OTHER .	False
BC6OTHER and BC6OTHER increased BC6ENTG phosphorylation in CHO cells expressing BC6OTHER and C6 cells, and these effects were antagonized by BC6ENTC .	False
BC6OTHER and BC6OTHER increased BC6OTHER phosphorylation in CHO cells expressing BC6ENTG and C6 cells, and these effects were antagonized by BC6ENTC .	False
In rat striatum and nucleus accumbens, BC6ENTC stimulated BC6OTHER binding in a BC6OTHER - sensitive manner with maximal effects lower than those of the full BC6ENTG agonists BC6OTHER and BC6OTHER .	False
In rat striatum and nucleus accumbens, BC6ENTC stimulated BC6OTHER binding in a BC6OTHER - sensitive manner with maximal effects lower than those of the full BC6OTHER agonists BC6OTHER and BC6ENTG .	False
In rat striatum and nucleus accumbens, BC6OTHER stimulated BC6ENTC binding in a BC6OTHER - sensitive manner with maximal effects lower than those of the full BC6ENTG agonists BC6OTHER and BC6OTHER .	False
In rat striatum and nucleus accumbens, BC6OTHER stimulated BC6ENTC binding in a BC6OTHER - sensitive manner with maximal effects lower than those of the full BC6OTHER agonists BC6OTHER and BC6ENTG .	False
In rat striatum and nucleus accumbens, BC6OTHER stimulated BC6OTHER binding in a BC6ENTC - sensitive manner with maximal effects lower than those of the full BC6ENTG agonists BC6OTHER and BC6OTHER .	False
In rat striatum and nucleus accumbens, BC6OTHER stimulated BC6OTHER binding in a BC6ENTC - sensitive manner with maximal effects lower than those of the full BC6OTHER agonists BC6OTHER and BC6ENTG .	False
In rat striatum and nucleus accumbens, BC6OTHER stimulated BC6OTHER binding in a BC6OTHER - sensitive manner with maximal effects lower than those of the full BC6ENTG agonists BC6ENTC and BC6OTHER .	CPR:5
In rat striatum and nucleus accumbens, BC6OTHER stimulated BC6OTHER binding in a BC6OTHER - sensitive manner with maximal effects lower than those of the full BC6OTHER agonists BC6ENTC and BC6ENTG .	False
In rat striatum and nucleus accumbens, BC6OTHER stimulated BC6OTHER binding in a BC6OTHER - sensitive manner with maximal effects lower than those of the full BC6ENTG agonists BC6OTHER and BC6ENTC .	CPR:5
When combined, BC6ENTC antagonized the effects of the full BC6ENTG agonists in BC6OTHER assays and reduced the stimulation of BC6OTHER BC6OTHER and BC6OTHER phosphorylation by BC6OTHER .	CPR:6
When combined, BC6ENTC antagonized the effects of the full BC6OTHER agonists in BC6OTHER assays and reduced the stimulation of BC6ENTG BC6OTHER and BC6OTHER phosphorylation by BC6OTHER .	CPR:4
When combined, BC6ENTC antagonized the effects of the full BC6OTHER agonists in BC6OTHER assays and reduced the stimulation of BC6OTHER BC6ENTG and BC6OTHER phosphorylation by BC6OTHER .	CPR:4
When combined, BC6ENTC antagonized the effects of the full BC6OTHER agonists in BC6OTHER assays and reduced the stimulation of BC6OTHER BC6OTHER and BC6ENTG phosphorylation by BC6OTHER .	False
When combined, BC6ENTC antagonized the effects of the full BC6OTHER agonists in BC6OTHER assays and reduced the stimulation of BC6OTHER BC6OTHER and BC6OTHER phosphorylation by BC6ENTG .	False
Fluorescence of the reporter dye is turned on by rapid removal of the BC6OTHER quencher, an event that immediately occurs only after highly selective, two - electron reduction of the sterically and conformationally restricted BC6ENTC substrate by the cancer - associated BC6ENTG ( BC6OTHER ).	CPR:9
Fluorescence of the reporter dye is turned on by rapid removal of the BC6OTHER quencher, an event that immediately occurs only after highly selective, two - electron reduction of the sterically and conformationally restricted BC6ENTC substrate by the cancer - associated human CHEM: BC6OTHER oxidoreductase isozyme 1 ( BC6ENTG ).	CPR:9
Fluorescence of the reporter dye is turned on by rapid removal of the BC6OTHER quencher, an event that immediately occurs only after highly selective, two - electron reduction of the sterically and conformationally restricted BC6OTHER substrate by the cancer - associated human CHEM: BC6ENTC oxidoreductase isozyme 1 ( BC6ENTG ).	False
Fluorescence of the reporter dye is turned on by rapid removal of the BC6ENTC quencher, an event that immediately occurs only after highly selective, two - electron reduction of the sterically and conformationally restricted BC6OTHER substrate by the cancer - associated BC6ENTG ( BC6OTHER ).	False
Fluorescence of the reporter dye is turned on by rapid removal of the BC6ENTC quencher, an event that immediately occurs only after highly selective, two - electron reduction of the sterically and conformationally restricted BC6OTHER substrate by the cancer - associated human CHEM: BC6OTHER oxidoreductase isozyme 1 ( BC6ENTG ).	False
BC6ENTG required BC6OTHER and BC6ENTC - tRNA([Ser]Sec) as substrates to generate BC6OTHER - tRNA([Ser]Sec).	CPR:9
BC6ENTG required BC6OTHER and BC6OTHER - tRNA([Ser]Sec) as substrates to generate BC6ENTC - tRNA([Ser]Sec).	CPR:9
Moreover, it was found that BC6ENTC was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER .	False
Moreover, it was found that BC6ENTC was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER .	False
Moreover, it was found that BC6ENTC was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER .	False
Moreover, it was found that BC6ENTC was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG .	False
Moreover, it was found that BC6ENTG was synthesized on the tRNA scaffold from BC6ENTC , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6ENTC , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6ENTC , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6ENTC , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6ENTC , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG .	False
Moreover, it was found that BC6ENTG was synthesized on the tRNA scaffold from BC6OTHER , BC6ENTC , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6ENTC , and BC6OTHER using tRNA([Ser]Sec), BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6ENTC , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6ENTC , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6ENTC , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG .	False
Moreover, it was found that BC6ENTG was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6ENTC using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6ENTC using tRNA([Ser]Sec), BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6ENTC using tRNA([Ser]Sec), BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6ENTC using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6ENTC using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG .	False
Moreover, it was found that BC6ENTG was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6ENTC - tRNA synthetase, BC6OTHER , BC6OTHER , and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6ENTC - tRNA synthetase, BC6ENTG , BC6OTHER , and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6ENTC - tRNA synthetase, BC6OTHER , BC6ENTG , and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6ENTC - tRNA synthetase, BC6OTHER , BC6OTHER , and BC6ENTG .	False
Moreover, it was found that BC6ENTG was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6ENTC - tRNA([Ser]Sec) kinase, BC6OTHER , and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6ENTG , BC6ENTC - tRNA([Ser]Sec) kinase, BC6OTHER , and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6ENTC - tRNA([Ser]Sec) kinase, BC6ENTG , and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6ENTC - tRNA([Ser]Sec) kinase, BC6OTHER , and BC6ENTG .	False
Moreover, it was found that BC6ENTG was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6ENTC synthetase, and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6ENTG , BC6OTHER , BC6ENTC synthetase, and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6ENTG , BC6ENTC synthetase, and BC6OTHER .	False
Moreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6ENTC synthetase, and BC6ENTG .	False
By identifying the pathway of BC6ENTC biosynthesis in mammals, this study not only functionally characterized BC6ENTG but also assigned the function of the BC6OTHER .	False
By identifying the pathway of BC6ENTC biosynthesis in mammals, this study not only functionally characterized BC6OTHER but also assigned the function of the BC6ENTG .	False
BC6ENTC ( BC6OTHER ) is cotranslationally inserted into protein in response to BC6ENTG codons and is the 21st BC6OTHER in the genetic code.	False
By identifying the pathway of BC6OTHER biosynthesis in mammals, this study not only functionally characterized BC6ENTG but also assigned the function of the BC6ENTC - tRNA([Ser]Sec) kinase.	False
In addition, we found that BC6ENTC synthetase 2 could synthesize BC6OTHER in vitro but BC6ENTG could not.	False
In addition, we found that BC6OTHER could synthesize BC6ENTC in vitro but BC6ENTG could not.	False
In addition, we found that BC6ENTG could synthesize BC6ENTC in vitro but BC6OTHER synthetase 1 could not.	CPR:9
In addition, we found that BC6ENTG could synthesize BC6OTHER in vitro but BC6ENTC synthetase 1 could not.	False
BC6OTHER ( BC6OTHER ) is cotranslationally inserted into protein in response to BC6ENTG codons and is the 21st BC6ENTC in the genetic code.	False
BC6OTHER ( BC6ENTC ) is cotranslationally inserted into protein in response to BC6ENTG codons and is the 21st BC6OTHER in the genetic code.	False
Herein, comparative genomics and experimental analyses revealed that the mammalian BC6ENTC synthase ( BC6ENTG ) is the previously identified BC6OTHER - containing protein known as the BC6OTHER .	False
Herein, comparative genomics and experimental analyses revealed that the mammalian BC6ENTC synthase ( BC6OTHER ) is the previously identified BC6OTHER - containing protein known as the BC6ENTG .	False
Herein, comparative genomics and experimental analyses revealed that the BC6ENTG ( BC6OTHER ) is the previously identified BC6ENTC - containing protein known as the BC6OTHER .	False
Herein, comparative genomics and experimental analyses revealed that the mammalian BC6OTHER synthase ( BC6ENTG ) is the previously identified BC6ENTC - containing protein known as the BC6OTHER .	False
Herein, comparative genomics and experimental analyses revealed that the mammalian BC6OTHER synthase ( BC6OTHER ) is the previously identified BC6ENTC - containing protein known as the BC6ENTG .	False
BC6ENTG required BC6ENTC and BC6OTHER - tRNA([Ser]Sec) as substrates to generate BC6OTHER - tRNA([Ser]Sec).	CPR:9
Among 12 BC6OTHER with linear BC6OTHER chains ranging in length from C1 to C12, BC6ENTC (C7) and BC6OTHER (C5) showed the most potent BC6ENTG and BC6OTHER agonistic activity in the order of 10CHEM, respectively, and the activities decreased in a stepwise manner as the CHEM chain was shortened to C1 or lengthened to C12.	CPR:5
Among 12 BC6OTHER with linear BC6OTHER chains ranging in length from C1 to C12, BC6ENTC (C7) and BC6OTHER (C5) showed the most potent BC6OTHER and BC6ENTG agonistic activity in the order of 10CHEM, respectively, and the activities decreased in a stepwise manner as the CHEM chain was shortened to C1 or lengthened to C12.	CPR:5
Among 12 BC6OTHER with linear BC6OTHER chains ranging in length from C1 to C12, BC6OTHER (C7) and BC6ENTC (C5) showed the most potent BC6ENTG and BC6OTHER agonistic activity in the order of 10CHEM, respectively, and the activities decreased in a stepwise manner as the CHEM chain was shortened to C1 or lengthened to C12.	CPR:5
Among 12 BC6OTHER with linear BC6OTHER chains ranging in length from C1 to C12, BC6OTHER (C7) and BC6ENTC (C5) showed the most potent BC6OTHER and BC6ENTG agonistic activity in the order of 10CHEM, respectively, and the activities decreased in a stepwise manner as the CHEM chain was shortened to C1 or lengthened to C12.	CPR:5
Most BC6ENTC showing estrogenic activity exhibited BC6ENTG - agonistic activity at lower concentrations than those inducing BC6OTHER - agonistic activity.	CPR:5
Most BC6ENTC showing estrogenic activity exhibited BC6OTHER - agonistic activity at lower concentrations than those inducing BC6ENTG - agonistic activity.	CPR:5
The estrogenic activity of BC6ENTC was markedly decreased by incubation with rat liver microsomes, and the decrease of activity was blocked by a BC6ENTG inhibitor.	False
Comparative study on transcriptional activity of 17 BC6OTHER mediated by BC6ENTG and BC6ENTC receptor.	False
Comparative study on transcriptional activity of 17 BC6ENTC mediated by BC6OTHER and BC6ENTG .	False
Comparative study on transcriptional activity of 17 BC6ENTC mediated by BC6ENTG and BC6OTHER .	False
Comparative study on transcriptional activity of 17 BC6OTHER mediated by BC6ENTC receptor α and β and BC6ENTG .	False
These results indicate that BC6ENTC are selective agonists for BC6ENTG over BC6OTHER ; their interactions with BC6OTHER are dependent on the size and bulkiness of the BC6OTHER groups; and they are metabolized by BC6OTHER , leading to attenuation of their estrogenic activity.	CPR:5
These results indicate that BC6ENTC are selective agonists for BC6OTHER over BC6ENTG ; their interactions with BC6OTHER are dependent on the size and bulkiness of the BC6OTHER groups; and they are metabolized by BC6OTHER , leading to attenuation of their estrogenic activity.	CPR:5
These results indicate that BC6ENTC are selective agonists for BC6OTHER over BC6OTHER ; their interactions with BC6ENTG are dependent on the size and bulkiness of the BC6OTHER groups; and they are metabolized by BC6OTHER , leading to attenuation of their estrogenic activity.	False
These results indicate that BC6ENTC are selective agonists for BC6OTHER over BC6OTHER ; their interactions with BC6OTHER are dependent on the size and bulkiness of the BC6OTHER groups; and they are metabolized by BC6ENTG , leading to attenuation of their estrogenic activity.	CPR:9
These results indicate that BC6OTHER are selective agonists for BC6ENTG over BC6OTHER ; their interactions with BC6OTHER are dependent on the size and bulkiness of the BC6ENTC groups; and they are metabolized by BC6OTHER , leading to attenuation of their estrogenic activity.	False
These results indicate that BC6OTHER are selective agonists for BC6OTHER over BC6ENTG ; their interactions with BC6OTHER are dependent on the size and bulkiness of the BC6ENTC groups; and they are metabolized by BC6OTHER , leading to attenuation of their estrogenic activity.	False
These results indicate that BC6OTHER are selective agonists for BC6OTHER over BC6OTHER ; their interactions with BC6ENTG are dependent on the size and bulkiness of the BC6ENTC groups; and they are metabolized by BC6OTHER , leading to attenuation of their estrogenic activity.	False
These results indicate that BC6OTHER are selective agonists for BC6OTHER over BC6OTHER ; their interactions with BC6OTHER are dependent on the size and bulkiness of the BC6ENTC groups; and they are metabolized by BC6ENTG , leading to attenuation of their estrogenic activity.	False
The structure - activity relationships of BC6OTHER which are widely used as preservatives for transcriptional activities mediated by human BC6ENTC receptor α ( BC6ENTG ), BC6OTHER and BC6OTHER receptor ( BC6OTHER ) were investigated.	False
The structure - activity relationships of BC6OTHER which are widely used as preservatives for transcriptional activities mediated by human BC6ENTC receptor α ( BC6OTHER ), BC6ENTG and BC6OTHER receptor ( BC6OTHER ) were investigated.	False
The structure - activity relationships of BC6OTHER which are widely used as preservatives for transcriptional activities mediated by human BC6ENTC receptor α ( BC6OTHER ), BC6OTHER and BC6ENTG ( BC6OTHER ) were investigated.	False
The structure - activity relationships of BC6OTHER which are widely used as preservatives for transcriptional activities mediated by human BC6ENTC receptor α ( BC6OTHER ), BC6OTHER and BC6OTHER receptor ( BC6ENTG ) were investigated.	False
The structure - activity relationships of BC6OTHER which are widely used as preservatives for transcriptional activities mediated by BC6ENTG ( BC6OTHER ), BC6OTHER and BC6ENTC receptor ( BC6OTHER ) were investigated.	False
The structure - activity relationships of BC6OTHER which are widely used as preservatives for transcriptional activities mediated by human BC6OTHER receptor α ( BC6ENTG ), BC6OTHER and BC6ENTC receptor ( BC6OTHER ) were investigated.	False
The structure - activity relationships of BC6OTHER which are widely used as preservatives for transcriptional activities mediated by human BC6OTHER receptor α ( BC6OTHER ), BC6ENTG and BC6ENTC receptor ( BC6OTHER ) were investigated.	False
The structure - activity relationships of BC6OTHER which are widely used as preservatives for transcriptional activities mediated by human BC6OTHER receptor α ( BC6OTHER ), BC6OTHER and BC6ENTC receptor ( BC6ENTG ) were investigated.	False
Fourteen of 17 BC6ENTC exhibited BC6ENTG and / or BC6OTHER agonistic activity at concentrations of ⩽1×10( - 5)M, whereas none of the 17 BC6OTHER showed BC6OTHER agonistic or antagonistic activity.	CPR:5
Fourteen of 17 BC6ENTC exhibited BC6OTHER and / or BC6ENTG agonistic activity at concentrations of ⩽1×10( - 5)M, whereas none of the 17 BC6OTHER showed BC6OTHER agonistic or antagonistic activity.	CPR:5
Fourteen of 17 BC6ENTC exhibited BC6OTHER and / or BC6OTHER agonistic activity at concentrations of ⩽1×10( - 5)M, whereas none of the 17 BC6OTHER showed BC6ENTG agonistic or antagonistic activity.	False
Fourteen of 17 BC6OTHER exhibited BC6ENTG and / or BC6OTHER agonistic activity at concentrations of ⩽1×10( - 5)M, whereas none of the 17 BC6ENTC showed BC6OTHER agonistic or antagonistic activity.	False
Fourteen of 17 BC6OTHER exhibited BC6OTHER and / or BC6ENTG agonistic activity at concentrations of ⩽1×10( - 5)M, whereas none of the 17 BC6ENTC showed BC6OTHER agonistic or antagonistic activity.	False
Fourteen of 17 BC6OTHER exhibited BC6OTHER and / or BC6OTHER agonistic activity at concentrations of ⩽1×10( - 5)M, whereas none of the 17 BC6ENTC showed BC6ENTG agonistic or antagonistic activity.	False
The structure - activity relationships of BC6ENTC which are widely used as preservatives for transcriptional activities mediated by BC6ENTG ( BC6OTHER ), BC6OTHER and BC6OTHER receptor ( BC6OTHER ) were investigated.	False
The structure - activity relationships of BC6ENTC which are widely used as preservatives for transcriptional activities mediated by human BC6OTHER receptor α ( BC6ENTG ), BC6OTHER and BC6OTHER receptor ( BC6OTHER ) were investigated.	False
The structure - activity relationships of BC6ENTC which are widely used as preservatives for transcriptional activities mediated by human BC6OTHER receptor α ( BC6OTHER ), BC6ENTG and BC6OTHER receptor ( BC6OTHER ) were investigated.	False
The structure - activity relationships of BC6ENTC which are widely used as preservatives for transcriptional activities mediated by human BC6OTHER receptor α ( BC6OTHER ), BC6OTHER and BC6ENTG ( BC6OTHER ) were investigated.	False
The structure - activity relationships of BC6ENTC which are widely used as preservatives for transcriptional activities mediated by human BC6OTHER receptor α ( BC6OTHER ), BC6OTHER and BC6OTHER receptor ( BC6ENTG ) were investigated.	False
Among 12 BC6ENTC with linear BC6OTHER chains ranging in length from C1 to C12, BC6OTHER (C7) and BC6OTHER (C5) showed the most potent BC6ENTG and BC6OTHER agonistic activity in the order of 10CHEM, respectively, and the activities decreased in a stepwise manner as the CHEM chain was shortened to C1 or lengthened to C12.	CPR:5
Among 12 BC6ENTC with linear BC6OTHER chains ranging in length from C1 to C12, BC6OTHER (C7) and BC6OTHER (C5) showed the most potent BC6OTHER and BC6ENTG agonistic activity in the order of 10CHEM, respectively, and the activities decreased in a stepwise manner as the CHEM chain was shortened to C1 or lengthened to C12.	CPR:5
Among 12 BC6OTHER with linear BC6ENTC chains ranging in length from C1 to C12, BC6OTHER (C7) and BC6OTHER (C5) showed the most potent BC6ENTG and BC6OTHER agonistic activity in the order of 10CHEM, respectively, and the activities decreased in a stepwise manner as the CHEM chain was shortened to C1 or lengthened to C12.	CPR:5
Among 12 BC6OTHER with linear BC6ENTC chains ranging in length from C1 to C12, BC6OTHER (C7) and BC6OTHER (C5) showed the most potent BC6OTHER and BC6ENTG agonistic activity in the order of 10CHEM, respectively, and the activities decreased in a stepwise manner as the CHEM chain was shortened to C1 or lengthened to C12.	CPR:5
"A novel membrane sensor for BC6ENTG antagonist "" BC6ENTC ""."	CPR:6
The relative potency of compounds in displacing BC6OTHER binding to BC6ENTG receptor was: domoate > BC6OTHER > BC6OTHER = BC6OTHER > BC6OTHER ( BC6OTHER ) = BC6OTHER > BC6OTHER > BC6ENTC > BC6OTHER .	False
The relative potency of compounds in displacing BC6OTHER binding to BC6ENTG receptor was: domoate > BC6OTHER > BC6OTHER = BC6OTHER > BC6OTHER ( BC6OTHER ) = BC6OTHER > BC6OTHER > BC6OTHER > BC6ENTC .	False
This cDNA clone, designated BC6ENTG , shares a 90% BC6ENTC identity with the previously reported BC6OTHER cDNA splice variant and differed from BC6OTHER in the BC6OTHER and BC6OTHER terminal regions.	False
This cDNA clone, designated BC6OTHER , shares a 90% BC6ENTC identity with the previously reported BC6ENTG cDNA splice variant and differed from BC6OTHER in the BC6OTHER and BC6OTHER terminal regions.	False
This cDNA clone, designated BC6OTHER , shares a 90% BC6ENTC identity with the previously reported BC6OTHER cDNA splice variant and differed from BC6ENTG in the BC6OTHER and BC6OTHER terminal regions.	False
This cDNA clone, designated BC6ENTG , shares a 90% BC6OTHER identity with the previously reported BC6OTHER cDNA splice variant and differed from BC6OTHER in the BC6ENTC and BC6OTHER terminal regions.	False
This cDNA clone, designated BC6OTHER , shares a 90% BC6OTHER identity with the previously reported BC6ENTG cDNA splice variant and differed from BC6OTHER in the BC6ENTC and BC6OTHER terminal regions.	False
This cDNA clone, designated BC6OTHER , shares a 90% BC6OTHER identity with the previously reported BC6OTHER cDNA splice variant and differed from BC6ENTG in the BC6ENTC and BC6OTHER terminal regions.	False
This cDNA clone, designated BC6ENTG , shares a 90% BC6OTHER identity with the previously reported BC6OTHER cDNA splice variant and differed from BC6OTHER in the BC6OTHER and BC6ENTC terminal regions.	False
This cDNA clone, designated BC6OTHER , shares a 90% BC6OTHER identity with the previously reported BC6ENTG cDNA splice variant and differed from BC6OTHER in the BC6OTHER and BC6ENTC terminal regions.	False
This cDNA clone, designated BC6OTHER , shares a 90% BC6OTHER identity with the previously reported BC6OTHER cDNA splice variant and differed from BC6ENTG in the BC6OTHER and BC6ENTC terminal regions.	False
Cell lines stably expressing BC6ENTG protein formed homomeric BC6OTHER responsive, in order of decreasing affinity to domoate, BC6ENTC , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
Cell lines stably expressing BC6OTHER protein formed homomeric BC6ENTG responsive, in order of decreasing affinity to domoate, BC6ENTC , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
Cell lines stably expressing BC6ENTG protein formed homomeric BC6OTHER responsive, in order of decreasing affinity to domoate, BC6OTHER , BC6ENTC and BC6OTHER ( BC6OTHER ).	False
Cell lines stably expressing BC6OTHER protein formed homomeric BC6ENTG responsive, in order of decreasing affinity to domoate, BC6OTHER , BC6ENTC and BC6OTHER ( BC6OTHER ).	False
Cell lines stably expressing BC6ENTG protein formed homomeric BC6OTHER responsive, in order of decreasing affinity to domoate, BC6OTHER , BC6OTHER and BC6ENTC ( BC6OTHER ).	False
Cell lines stably expressing BC6OTHER protein formed homomeric BC6ENTG responsive, in order of decreasing affinity to domoate, BC6OTHER , BC6OTHER and BC6ENTC ( BC6OTHER ).	False
Cell lines stably expressing BC6ENTG protein formed homomeric BC6OTHER responsive, in order of decreasing affinity to domoate, BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTC ).	False
Cell lines stably expressing BC6OTHER protein formed homomeric BC6ENTG responsive, in order of decreasing affinity to domoate, BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTC ).	False
Ligand binding studies with the recombinant BC6ENTG receptor expressed in mammalian cells indicated a high affinity BC6ENTC binding site (Kd = 120 + / - 15.0 nM).	False
BC6ENTC - evoked currents showed partial desensitization that was reduced on incubation with BC6ENTG ( BC6OTHER ) but not BC6OTHER and were attenuated by the non CHEM ( BC6OTHER ) receptor antagonist BC6OTHER ( BC6OTHER ).	False
BC6ENTC - evoked currents showed partial desensitization that was reduced on incubation with BC6OTHER ( BC6ENTG ) but not BC6OTHER and were attenuated by the non CHEM ( BC6OTHER ) receptor antagonist BC6OTHER ( BC6OTHER ).	False
BC6ENTC - evoked currents showed partial desensitization that was reduced on incubation with BC6OTHER ( BC6OTHER ) but not BC6OTHER and were attenuated by the non - BC6ENTG antagonist BC6OTHER ( BC6OTHER ).	False
BC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6ENTG ( BC6OTHER ) but not BC6ENTC and were attenuated by the non CHEM ( BC6OTHER ) receptor antagonist BC6OTHER ( BC6OTHER ).	False
BC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6OTHER ( BC6ENTG ) but not BC6ENTC and were attenuated by the non CHEM ( BC6OTHER ) receptor antagonist BC6OTHER ( BC6OTHER ).	False
BC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6OTHER ( BC6OTHER ) but not BC6ENTC and were attenuated by the non - BC6ENTG antagonist BC6OTHER ( BC6OTHER ).	False
BC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6ENTG ( BC6OTHER ) but not BC6OTHER and were attenuated by the BC6ENTC (CHEM) receptor antagonist BC6OTHER ( BC6OTHER ).	False
BC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6OTHER ( BC6ENTG ) but not BC6OTHER and were attenuated by the BC6ENTC (CHEM) receptor antagonist BC6OTHER ( BC6OTHER ).	False
BC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6ENTG ( BC6OTHER ) but not BC6OTHER and were attenuated by the non CHEM ( BC6ENTC ) receptor antagonist BC6OTHER ( BC6OTHER ).	False
BC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6OTHER ( BC6ENTG ) but not BC6OTHER and were attenuated by the non CHEM ( BC6ENTC ) receptor antagonist BC6OTHER ( BC6OTHER ).	False
BC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6ENTG ( BC6OTHER ) but not BC6OTHER and were attenuated by the non CHEM ( BC6OTHER ) receptor antagonist BC6ENTC ( BC6OTHER ).	False
BC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6OTHER ( BC6ENTG ) but not BC6OTHER and were attenuated by the non CHEM ( BC6OTHER ) receptor antagonist BC6ENTC ( BC6OTHER ).	False
BC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6OTHER ( BC6OTHER ) but not BC6OTHER and were attenuated by the non - BC6ENTG antagonist BC6ENTC ( BC6OTHER ).	CPR:6
BC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6ENTG ( BC6OTHER ) but not BC6OTHER and were attenuated by the non CHEM ( BC6OTHER ) receptor antagonist BC6OTHER ( BC6ENTC ).	False
BC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6OTHER ( BC6ENTG ) but not BC6OTHER and were attenuated by the non CHEM ( BC6OTHER ) receptor antagonist BC6OTHER ( BC6ENTC ).	False
BC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6OTHER ( BC6OTHER ) but not BC6OTHER and were attenuated by the non - BC6ENTG antagonist BC6OTHER ( BC6ENTC ).	CPR:6
BC6ENTC and BC6OTHER activated the heteromeric channel with significantly higher affinities than observed for BC6ENTG alone.	False
BC6OTHER and BC6ENTC activated the heteromeric channel with significantly higher affinities than observed for BC6ENTG alone.	False
cDNA cloning and functional properties of human BC6ENTC receptor BC6ENTG ( BC6OTHER ) in homomeric and heteromeric configuration.	False
cDNA cloning and functional properties of human BC6ENTC receptor BC6OTHER ( BC6ENTG ) in homomeric and heteromeric configuration.	False
The relative potency of compounds in displacing BC6ENTC binding to BC6ENTG receptor was: domoate > BC6OTHER > BC6OTHER = BC6OTHER > BC6OTHER ( BC6OTHER ) = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER .	False
The relative potency of compounds in displacing BC6OTHER binding to BC6ENTG receptor was: domoate > BC6ENTC > BC6OTHER = BC6OTHER > BC6OTHER ( BC6OTHER ) = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER .	False
The relative potency of compounds in displacing BC6OTHER binding to BC6ENTG receptor was: domoate > BC6OTHER > BC6ENTC = BC6OTHER > BC6OTHER ( BC6OTHER ) = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER .	False
The relative potency of compounds in displacing BC6OTHER binding to BC6ENTG receptor was: domoate > BC6OTHER > BC6OTHER = BC6ENTC > BC6OTHER ( BC6OTHER ) = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER .	False
The relative potency of compounds in displacing BC6OTHER binding to BC6ENTG receptor was: domoate > BC6OTHER > BC6OTHER = BC6OTHER > BC6ENTC ( BC6OTHER ) = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER .	False
The relative potency of compounds in displacing BC6OTHER binding to BC6ENTG receptor was: domoate > BC6OTHER > BC6OTHER = BC6OTHER > BC6OTHER ( BC6ENTC ) = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER .	False
The relative potency of compounds in displacing BC6OTHER binding to BC6ENTG receptor was: domoate > BC6OTHER > BC6OTHER = BC6OTHER > BC6OTHER ( BC6OTHER ) = BC6ENTC > BC6OTHER > BC6OTHER > BC6OTHER .	False
The relative potency of compounds in displacing BC6OTHER binding to BC6ENTG receptor was: domoate > BC6OTHER > BC6OTHER = BC6OTHER > BC6OTHER ( BC6OTHER ) = BC6OTHER > BC6ENTC > BC6OTHER > BC6OTHER .	False
To investigate the recognition sites of BC6OTHER tRNA for BC6ENTG from an extreme hyperthermophilic archaeon, Aeropyrum pernix K1, we examined histidylation activities by using overexpressed BC6ENTC - tRNA synthetase and various BC6OTHER tRNA transcripts that were prepared by in vitro transcription system.	False
To investigate the recognition sites of BC6OTHER tRNA for BC6OTHER from an extreme hyperthermophilic archaeon, Aeropyrum pernix K1, we examined histidylation activities by using overexpressed BC6ENTG and various BC6ENTC tRNA transcripts that were prepared by in vitro transcription system.	False
To investigate the recognition sites of BC6OTHER tRNA for BC6ENTG from an extreme hyperthermophilic archaeon, Aeropyrum pernix K1, we examined histidylation activities by using overexpressed BC6OTHER and various BC6ENTC tRNA transcripts that were prepared by in vitro transcription system.	False
To investigate the recognition sites of BC6ENTC tRNA for BC6OTHER from an extreme hyperthermophilic archaeon, Aeropyrum pernix K1, we examined histidylation activities by using overexpressed BC6ENTG and various BC6OTHER tRNA transcripts that were prepared by in vitro transcription system.	False
To investigate the recognition sites of BC6ENTC tRNA for BC6ENTG from an extreme hyperthermophilic archaeon, Aeropyrum pernix K1, we examined histidylation activities by using overexpressed BC6OTHER and various BC6OTHER tRNA transcripts that were prepared by in vitro transcription system.	False
Results indicated that anticodon was not recognized by the BC6ENTG similar to that of Escherichia coli BC6ENTC tRNA recognition system.	False
Molecular recognition of BC6ENTC tRNA by BC6ENTG from hyperthermophilic archaeon, Aeropyrum pernix K1.	False
In this study the neuromuscular blocking drug BC6OTHER and the controls BC6OTHER and BC6OTHER slowed the rate of BC6OTHER induced BC6OTHER dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6OTHER (125 nM), BC6OTHER 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6OTHER (21 nM), BC6OTHER 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6ENTC (21 nM), BC6OTHER 0.36+ / - 0.03+blocker 0.03+ / - 0.01).	False
In this study the neuromuscular blocking drug BC6OTHER and the controls BC6OTHER and BC6OTHER slowed the rate of BC6OTHER induced BC6OTHER dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6OTHER (125 nM), BC6OTHER 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6OTHER (21 nM), BC6OTHER 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6OTHER (21 nM), BC6ENTC 0.36+ / - 0.03+blocker 0.03+ / - 0.01).	False
These data indicate that BC6ENTC , BC6OTHER and BC6OTHER interact with an allosteric site on the BC6ENTG (located on the heart) and this may explain some of their cardiac side effects.	False
These data indicate that BC6OTHER , BC6ENTC and BC6OTHER interact with an allosteric site on the BC6ENTG (located on the heart) and this may explain some of their cardiac side effects.	False
These data indicate that BC6OTHER , BC6OTHER and BC6ENTC interact with an allosteric site on the BC6ENTG (located on the heart) and this may explain some of their cardiac side effects.	False
Allosteric interaction of the neuromuscular blockers BC6ENTC and BC6OTHER with recombinant BC6ENTG .	False
Allosteric interaction of the neuromuscular blockers BC6OTHER and BC6ENTC with recombinant BC6ENTG .	False
In this study the neuromuscular blocking drug BC6ENTC and the controls BC6OTHER and BC6OTHER slowed the rate of BC6OTHER induced BC6OTHER dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6OTHER (125 nM), BC6OTHER 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6OTHER (21 nM), BC6OTHER 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6OTHER (21 nM), BC6OTHER 0.36+ / - 0.03+blocker 0.03+ / - 0.01).	CPR:4
In this study the neuromuscular blocking drug BC6OTHER and the controls BC6ENTC and BC6OTHER slowed the rate of BC6OTHER induced BC6OTHER dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6OTHER (125 nM), BC6OTHER 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6OTHER (21 nM), BC6OTHER 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6OTHER (21 nM), BC6OTHER 0.36+ / - 0.03+blocker 0.03+ / - 0.01).	CPR:4
In this study the neuromuscular blocking drug BC6OTHER and the controls BC6OTHER and BC6ENTC slowed the rate of BC6OTHER induced BC6OTHER dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6OTHER (125 nM), BC6OTHER 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6OTHER (21 nM), BC6OTHER 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6OTHER (21 nM), BC6OTHER 0.36+ / - 0.03+blocker 0.03+ / - 0.01).	CPR:4
In this study the neuromuscular blocking drug BC6OTHER and the controls BC6OTHER and BC6OTHER slowed the rate of BC6ENTC induced BC6OTHER dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6OTHER (125 nM), BC6OTHER 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6OTHER (21 nM), BC6OTHER 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6OTHER (21 nM), BC6OTHER 0.36+ / - 0.03+blocker 0.03+ / - 0.01).	False
In this study the neuromuscular blocking drug BC6OTHER and the controls BC6OTHER and BC6OTHER slowed the rate of BC6OTHER induced BC6ENTC dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6OTHER (125 nM), BC6OTHER 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6OTHER (21 nM), BC6OTHER 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6OTHER (21 nM), BC6OTHER 0.36+ / - 0.03+blocker 0.03+ / - 0.01).	False
In this study the neuromuscular blocking drug BC6OTHER and the controls BC6OTHER and BC6OTHER slowed the rate of BC6OTHER induced BC6OTHER dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6ENTC (125 nM), BC6OTHER 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6OTHER (21 nM), BC6OTHER 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6OTHER (21 nM), BC6OTHER 0.36+ / - 0.03+blocker 0.03+ / - 0.01).	False
In this study the neuromuscular blocking drug BC6OTHER and the controls BC6OTHER and BC6OTHER slowed the rate of BC6OTHER induced BC6OTHER dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6OTHER (125 nM), BC6ENTC 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6OTHER (21 nM), BC6OTHER 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6OTHER (21 nM), BC6OTHER 0.36+ / - 0.03+blocker 0.03+ / - 0.01).	False
In this study the neuromuscular blocking drug BC6OTHER and the controls BC6OTHER and BC6OTHER slowed the rate of BC6OTHER induced BC6OTHER dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6OTHER (125 nM), BC6OTHER 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6ENTC (21 nM), BC6OTHER 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6OTHER (21 nM), BC6OTHER 0.36+ / - 0.03+blocker 0.03+ / - 0.01).	False
In this study the neuromuscular blocking drug BC6OTHER and the controls BC6OTHER and BC6OTHER slowed the rate of BC6OTHER induced BC6OTHER dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6OTHER (125 nM), BC6OTHER 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6OTHER (21 nM), BC6ENTC 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6OTHER (21 nM), BC6OTHER 0.36+ / - 0.03+blocker 0.03+ / - 0.01).	False
The smooth muscle relaxant, BC6OTHER , which is believed relatively specific in inhibiting the BC6ENTC - BC6ENTG interaction, depressed hyposmolarity - induced BC6OTHER secretion in a dose - dependent manner (r = - 0.991, p less than 0.01).	False
The smooth muscle relaxant, BC6OTHER , which is believed relatively specific in inhibiting the BC6ENTC - BC6OTHER interaction, depressed hyposmolarity - induced BC6ENTG secretion in a dose - dependent manner (r = - 0.991, p less than 0.01).	False
The above drugs also blocked or decreased high BC6ENTC - induced secretion, but had much less effect on BC6ENTG - induced secretion.	False
Secretion induced by BC6ENTG , hyposmolarity, or high BC6ENTC was optimal at pH 7.3 - 7.65 and was significantly depressed at pH 6.0 or 8.0, indicating that release of hormone induced by all 3 stimuli is due to an active cell process requiring a physiologic extracellular pH and is not produced by nonspecific cell toxicity.	False
Role of extracellular BC6OTHER and BC6ENTG in BC6OTHER secretion induced by hyposmolarity, BC6OTHER , and high BC6ENTC in GH4C1 cells.	False
Role of extracellular BC6OTHER and BC6OTHER in BC6ENTG secretion induced by hyposmolarity, BC6OTHER , and high BC6ENTC in GH4C1 cells.	False
Role of extracellular BC6OTHER and BC6OTHER in BC6OTHER secretion induced by hyposmolarity, BC6ENTG , and high BC6ENTC in GH4C1 cells.	False
Role of extracellular BC6ENTC and BC6ENTG in BC6OTHER secretion induced by hyposmolarity, BC6OTHER , and high BC6OTHER in GH4C1 cells.	False
Role of extracellular BC6ENTC and BC6OTHER in BC6ENTG secretion induced by hyposmolarity, BC6OTHER , and high BC6OTHER in GH4C1 cells.	False
Role of extracellular BC6ENTC and BC6OTHER in BC6OTHER secretion induced by hyposmolarity, BC6ENTG , and high BC6OTHER in GH4C1 cells.	False
The data suggest hyposmolarity and high BC6ENTC may share some similarities in their mechanism of stimulating secretion, which is different from that of BC6ENTG .	False
The mechanism by which 30% medium hyposmolarity induces BC6OTHER secretion by GH4C1 cells was compared with that induced by 100 nmol / l BC6ENTG or 30 mmol / l BC6ENTC .	False
The mechanism by which 30% medium hyposmolarity induces BC6ENTG secretion by GH4C1 cells was compared with that induced by 100 nmol / l BC6OTHER or 30 mmol / l BC6ENTC .	False
Removing medium BC6ENTC , blocking BC6ENTG with 50 mumol / l BC6OTHER , or inhibiting BC6OTHER activation with 20 mumol / l BC6OTHER , 10 mumol / l BC6OTHER or 10 mumol / l BC6OTHER almost completely blocked hyposmolarity - induced secretion.	False
Removing medium BC6ENTC , blocking BC6OTHER channels with 50 mumol / l BC6OTHER , or inhibiting BC6ENTG activation with 20 mumol / l BC6OTHER , 10 mumol / l BC6OTHER or 10 mumol / l BC6OTHER almost completely blocked hyposmolarity - induced secretion.	False
Removing medium BC6OTHER , blocking BC6ENTC channels with 50 mumol / l BC6OTHER , or inhibiting BC6ENTG activation with 20 mumol / l BC6OTHER , 10 mumol / l BC6OTHER or 10 mumol / l BC6OTHER almost completely blocked hyposmolarity - induced secretion.	False
Removing medium BC6OTHER , blocking BC6ENTG with 50 mumol / l BC6ENTC , or inhibiting BC6OTHER activation with 20 mumol / l BC6OTHER , 10 mumol / l BC6OTHER or 10 mumol / l BC6OTHER almost completely blocked hyposmolarity - induced secretion.	CPR:4
Removing medium BC6OTHER , blocking BC6OTHER channels with 50 mumol / l BC6ENTC , or inhibiting BC6ENTG activation with 20 mumol / l BC6OTHER , 10 mumol / l BC6OTHER or 10 mumol / l BC6OTHER almost completely blocked hyposmolarity - induced secretion.	False
Removing medium BC6OTHER , blocking BC6ENTG with 50 mumol / l BC6OTHER , or inhibiting BC6OTHER activation with 20 mumol / l BC6ENTC , 10 mumol / l BC6OTHER or 10 mumol / l BC6OTHER almost completely blocked hyposmolarity - induced secretion.	False
Removing medium BC6OTHER , blocking BC6OTHER channels with 50 mumol / l BC6OTHER , or inhibiting BC6ENTG activation with 20 mumol / l BC6ENTC , 10 mumol / l BC6OTHER or 10 mumol / l BC6OTHER almost completely blocked hyposmolarity - induced secretion.	CPR:4
Removing medium BC6OTHER , blocking BC6ENTG with 50 mumol / l BC6OTHER , or inhibiting BC6OTHER activation with 20 mumol / l BC6OTHER , 10 mumol / l BC6ENTC or 10 mumol / l BC6OTHER almost completely blocked hyposmolarity - induced secretion.	False
Removing medium BC6OTHER , blocking BC6OTHER channels with 50 mumol / l BC6OTHER , or inhibiting BC6ENTG activation with 20 mumol / l BC6OTHER , 10 mumol / l BC6ENTC or 10 mumol / l BC6OTHER almost completely blocked hyposmolarity - induced secretion.	CPR:4
Removing medium BC6OTHER , blocking BC6ENTG with 50 mumol / l BC6OTHER , or inhibiting BC6OTHER activation with 20 mumol / l BC6OTHER , 10 mumol / l BC6OTHER or 10 mumol / l BC6ENTC almost completely blocked hyposmolarity - induced secretion.	False
Removing medium BC6OTHER , blocking BC6OTHER channels with 50 mumol / l BC6OTHER , or inhibiting BC6ENTG activation with 20 mumol / l BC6OTHER , 10 mumol / l BC6OTHER or 10 mumol / l BC6ENTC almost completely blocked hyposmolarity - induced secretion.	CPR:4
The smooth muscle relaxant, BC6ENTC , which is believed relatively specific in inhibiting the BC6OTHER - BC6ENTG interaction, depressed hyposmolarity - induced BC6OTHER secretion in a dose - dependent manner (r = - 0.991, p less than 0.01).	False
The smooth muscle relaxant, BC6ENTC , which is believed relatively specific in inhibiting the BC6OTHER - BC6OTHER interaction, depressed hyposmolarity - induced BC6ENTG secretion in a dose - dependent manner (r = - 0.991, p less than 0.01).	CPR:4
BC6ENTC has an advantage over the indirect BC6ENTG inhibitors, unfractionated heparin and low - molecular - weight heparin, in that it inhibits free and BC6OTHER - bound BC6OTHER .	CPR:4
BC6ENTC has an advantage over the indirect BC6OTHER inhibitors, unfractionated heparin and low - molecular - weight heparin, in that it inhibits free and BC6ENTG - bound BC6OTHER .	CPR:4
BC6ENTC has an advantage over the indirect BC6OTHER inhibitors, unfractionated heparin and low - molecular - weight heparin, in that it inhibits free and BC6OTHER - bound BC6ENTG .	CPR:4
 The reversible binding of BC6ENTC may provide safer and more predictable anticoagulant treatment than seen with irreversible, non - covalent BC6ENTG inhibitors, e.g. hirudin.	CPR:4
 BC6ENTG inhibitors, e.g. BC6ENTC and BC6OTHER , are potent, oral direct inhibitors of BC6OTHER - bound, clot - associated or free BC6OTHER .	CPR:4
 BC6OTHER inhibitors, e.g. BC6ENTC and BC6OTHER , are potent, oral direct inhibitors of BC6ENTG - bound, clot - associated or free BC6OTHER .	CPR:4
 BC6OTHER inhibitors, e.g. BC6ENTC and BC6OTHER , are potent, oral direct inhibitors of BC6OTHER - bound, clot - associated or free BC6ENTG .	CPR:4
 BC6ENTG inhibitors, e.g. BC6OTHER and BC6ENTC , are potent, oral direct inhibitors of BC6OTHER - bound, clot - associated or free BC6OTHER .	CPR:4
 BC6OTHER inhibitors, e.g. BC6OTHER and BC6ENTC , are potent, oral direct inhibitors of BC6ENTG - bound, clot - associated or free BC6OTHER .	CPR:4
 BC6OTHER inhibitors, e.g. BC6OTHER and BC6ENTC , are potent, oral direct inhibitors of BC6OTHER - bound, clot - associated or free BC6ENTG .	CPR:4
Since both are substrates, co - administration of BC6ENTC and BC6OTHER with strong BC6ENTG and BC6OTHER ( BC6OTHER ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong BC6OTHER and BC6OTHER inducers.	False
Since both are substrates, co - administration of BC6ENTC and BC6OTHER with strong BC6OTHER and BC6ENTG ( BC6OTHER ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong BC6OTHER and BC6OTHER inducers.	False
Since both are substrates, co - administration of BC6ENTC and BC6OTHER with strong BC6OTHER and BC6OTHER ( BC6ENTG ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong BC6OTHER and BC6OTHER inducers.	False
Since both are substrates, co - administration of BC6ENTC and BC6OTHER with strong BC6OTHER and BC6OTHER ( BC6OTHER ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong BC6ENTG and BC6OTHER inducers.	False
Since both are substrates, co - administration of BC6ENTC and BC6OTHER with strong BC6OTHER and BC6OTHER ( BC6OTHER ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong BC6OTHER and BC6ENTG inducers.	False
Since both are substrates, co - administration of BC6OTHER and BC6ENTC with strong BC6ENTG and BC6OTHER ( BC6OTHER ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong BC6OTHER and BC6OTHER inducers.	False
Since both are substrates, co - administration of BC6OTHER and BC6ENTC with strong BC6OTHER and BC6ENTG ( BC6OTHER ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong BC6OTHER and BC6OTHER inducers.	False
Since both are substrates, co - administration of BC6OTHER and BC6ENTC with strong BC6OTHER and BC6OTHER ( BC6ENTG ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong BC6OTHER and BC6OTHER inducers.	False
Since both are substrates, co - administration of BC6OTHER and BC6ENTC with strong BC6OTHER and BC6OTHER ( BC6OTHER ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong BC6ENTG and BC6OTHER inducers.	False
Since both are substrates, co - administration of BC6OTHER and BC6ENTC with strong BC6OTHER and BC6OTHER ( BC6OTHER ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong BC6OTHER and BC6ENTG inducers.	False
Although parenteral oral direct BC6ENTG inhibitors (DTIs), such as BC6ENTC and CHEM, have been on the market for years, DTIs such as BC6OTHER are novel synthetic BC6OTHER antagonists.	CPR:4
Although parenteral oral direct BC6OTHER inhibitors (DTIs), such as BC6ENTC and CHEM, have been on the market for years, DTIs such as BC6OTHER are novel synthetic BC6ENTG antagonists.	False
Although parenteral oral direct BC6ENTG inhibitors (DTIs), such as BC6OTHER and CHEM, have been on the market for years, DTIs such as BC6ENTC are novel synthetic BC6OTHER antagonists.	False
Although parenteral oral direct BC6OTHER inhibitors (DTIs), such as BC6OTHER and CHEM, have been on the market for years, DTIs such as BC6ENTC are novel synthetic BC6ENTG antagonists.	CPR:6
One is that the binding of BC6ENTC to nuclear BC6ENTG ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6OTHER .	False
One is that the binding of BC6ENTC to nuclear BC6OTHER receptors ( BC6ENTG ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6OTHER .	False
One is that the binding of BC6ENTC to nuclear BC6OTHER receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6ENTG , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6OTHER .	False
One is that the binding of BC6ENTC to nuclear BC6OTHER receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6ENTG in preference to BC6OTHER .	False
One is that the binding of BC6ENTC to nuclear BC6OTHER receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6ENTG .	False
One is that the binding of BC6OTHER to nuclear BC6ENTC receptors ( BC6ENTG ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6OTHER .	False
One is that the binding of BC6OTHER to nuclear BC6ENTC receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6ENTG , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6OTHER .	False
One is that the binding of BC6OTHER to nuclear BC6ENTC receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6ENTG in preference to BC6OTHER .	False
One is that the binding of BC6OTHER to nuclear BC6ENTC receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6ENTG .	False
One is that the binding of BC6OTHER to nuclear BC6ENTG ( BC6OTHER ) does not match their therapeutic efficacy: BC6ENTC activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6OTHER .	False
One is that the binding of BC6OTHER to nuclear BC6OTHER receptors ( BC6ENTG ) does not match their therapeutic efficacy: BC6ENTC activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6OTHER .	False
One is that the binding of BC6OTHER to nuclear BC6OTHER receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6ENTC activates the three receptor subtypes, BC6ENTG , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6OTHER .	False
One is that the binding of BC6OTHER to nuclear BC6OTHER receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6ENTC activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6ENTG in preference to BC6OTHER .	False
One is that the binding of BC6OTHER to nuclear BC6OTHER receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6ENTC activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6ENTG .	False
One is that the binding of BC6OTHER to nuclear BC6ENTG ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6ENTC preferentially binds to and activates BC6OTHER in preference to BC6OTHER .	False
One is that the binding of BC6OTHER to nuclear BC6OTHER receptors ( BC6ENTG ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6ENTC preferentially binds to and activates BC6OTHER in preference to BC6OTHER .	False
One is that the binding of BC6OTHER to nuclear BC6OTHER receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6ENTG , without measurable receptor binding, whereas BC6ENTC preferentially binds to and activates BC6OTHER in preference to BC6OTHER .	False
One is that the binding of BC6OTHER to nuclear BC6OTHER receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6ENTC preferentially binds to and activates BC6ENTG in preference to BC6OTHER .	False
One is that the binding of BC6OTHER to nuclear BC6OTHER receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6ENTC preferentially binds to and activates BC6OTHER in preference to BC6ENTG .	CPR:3
The octanoylation of BC6OTHER is critical for its orexigenic functions and is dependent upon ghrelin BC6ENTC - acyltransferase ( BC6ENTG ) catalyzation.	False
The octanoylation of BC6ENTG is critical for its orexigenic functions and is dependent upon ghrelin BC6ENTC - acyltransferase ( BC6OTHER ) catalyzation.	False
Protein BC6ENTC phosphatase 1B ( BC6OTHER ) is an important factor in non - BC6ENTG - dependent diabetes mellitus (type - 2 diabetes), and a promising target for treatment of diabetes and obesity.	False
Protein BC6ENTC phosphatase 1B ( BC6ENTG ) is an important factor in non - BC6OTHER - dependent diabetes mellitus (type - 2 diabetes), and a promising target for treatment of diabetes and obesity.	False
 BC6ENTG inhibitory effect by BC6OTHER - type BC6OTHER from hydrolyzate of total Gynostemma pentaphyllum BC6ENTC .	CPR:4
 BC6ENTG inhibitory effect by BC6ENTC - type BC6OTHER from hydrolyzate of total Gynostemma pentaphyllum BC6OTHER .	CPR:4
 BC6ENTG inhibitory effect by BC6OTHER - type BC6ENTC from hydrolyzate of total Gynostemma pentaphyllum BC6OTHER .	CPR:4
BC6ENTC blocks BC6ENTG activation without modifying BC6OTHER synthesis.	CPR:4
BC6OTHER blocks BC6ENTG activation without modifying BC6ENTC synthesis.	False
They include BC6ENTC antagonists, dopaminergic agonists, BC6OTHER , BC6OTHER , BC6ENTG analogs and BC6OTHER .	False
They include BC6OTHER antagonists, dopaminergic agonists, BC6ENTC , BC6OTHER , BC6ENTG analogs and BC6OTHER .	False
They include BC6OTHER antagonists, dopaminergic agonists, BC6OTHER , BC6ENTC , BC6ENTG analogs and BC6OTHER .	False
They include BC6OTHER antagonists, dopaminergic agonists, BC6OTHER , BC6OTHER , BC6ENTG analogs and BC6ENTC .	False
BC6ENTC markedly increased postprandial plasma BC6OTHER release (P<0.001) while distinctly reducing postprandial BC6ENTG levels (P<0.01) as compared to placebo.	CPR:4
BC6ENTC markedly increased postprandial plasma BC6ENTG release (P<0.001) while distinctly reducing postprandial BC6OTHER levels (P<0.01) as compared to placebo.	CPR:3
The study demonstrates for the first time the marked gastrokinetic properties of the new BC6ENTG antagonist BC6ENTC in humans.	CPR:6
We studied the role of endogenous BC6ENTG in the emptying of a solid / liquid meal administering the new, highly specific and potent BC6OTHER antagonist BC6ENTC .	False
We studied the role of endogenous BC6OTHER in the emptying of a solid / liquid meal administering the new, highly specific and potent BC6ENTG antagonist BC6ENTC .	CPR:6
Effect of BC6ENTC , a new BC6ENTG antagonist, on gastric emptying of a solid - liquid meal in humans.	CPR:6
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6ENTG ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6ENTC ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	CPR:9
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6ENTG ( BC6OTHER ) from BC6ENTC ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	CPR:9
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6ENTG ) from BC6ENTC ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	CPR:9
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6ENTG ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6ENTC ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	CPR:9
Interestingly, the inhibitory effect of BC6OTHER on BC6ENTG activation was reversed by the transient transfection with BC6OTHER siRNA, but was mimicked by either BC6OTHER gene transfection or treatment with BC6ENTC ( BC6OTHER ), an end product of BC6OTHER .	False
Interestingly, the inhibitory effect of BC6OTHER on BC6OTHER activation was reversed by the transient transfection with BC6ENTG siRNA, but was mimicked by either BC6OTHER gene transfection or treatment with BC6ENTC ( BC6OTHER ), an end product of BC6OTHER .	False
Interestingly, the inhibitory effect of BC6OTHER on BC6OTHER activation was reversed by the transient transfection with BC6OTHER siRNA, but was mimicked by either BC6ENTG gene transfection or treatment with BC6ENTC ( BC6OTHER ), an end product of BC6OTHER .	False
Interestingly, the inhibitory effect of BC6OTHER on BC6OTHER activation was reversed by the transient transfection with BC6OTHER siRNA, but was mimicked by either BC6OTHER gene transfection or treatment with BC6ENTC ( BC6OTHER ), an end product of BC6ENTG .	CPR:9
Interestingly, the inhibitory effect of BC6OTHER on BC6ENTG activation was reversed by the transient transfection with BC6OTHER siRNA, but was mimicked by either BC6OTHER gene transfection or treatment with BC6OTHER ( BC6ENTC ), an end product of BC6OTHER .	False
Interestingly, the inhibitory effect of BC6OTHER on BC6OTHER activation was reversed by the transient transfection with BC6ENTG siRNA, but was mimicked by either BC6OTHER gene transfection or treatment with BC6OTHER ( BC6ENTC ), an end product of BC6OTHER .	False
Interestingly, the inhibitory effect of BC6OTHER on BC6OTHER activation was reversed by the transient transfection with BC6OTHER siRNA, but was mimicked by either BC6ENTG gene transfection or treatment with BC6OTHER ( BC6ENTC ), an end product of BC6OTHER .	False
Interestingly, the inhibitory effect of BC6OTHER on BC6OTHER activation was reversed by the transient transfection with BC6OTHER siRNA, but was mimicked by either BC6OTHER gene transfection or treatment with BC6OTHER ( BC6ENTC ), an end product of BC6ENTG .	CPR:9
BC6ENTC treatment also inhibited LPS - induced BC6OTHER production and BC6ENTG expression via its inactivation of BC6OTHER .	CPR:4
BC6ENTC treatment also inhibited LPS - induced BC6OTHER production and BC6OTHER expression via its inactivation of BC6ENTG .	CPR:4
BC6OTHER treatment also inhibited LPS - induced BC6ENTC production and BC6ENTG expression via its inactivation of BC6OTHER .	CPR:9
BC6OTHER treatment also inhibited LPS - induced BC6ENTC production and BC6OTHER expression via its inactivation of BC6ENTG .	False
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6ENTG ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6ENTC ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	CPR:9
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6ENTG ( BC6OTHER ) from BC6OTHER ( BC6ENTC ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	CPR:9
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6ENTG ) from BC6OTHER ( BC6ENTC ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	CPR:9
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6ENTG ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6ENTC ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	CPR:9
BC6OTHER ( BC6ENTC ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6ENTG ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	CPR:9
BC6OTHER ( BC6ENTC ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6ENTG ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	CPR:9
BC6OTHER ( BC6ENTC ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6ENTG ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	CPR:9
BC6OTHER ( BC6ENTC ), a regulatory gaseous molecule that is endogenously synthesized by BC6ENTG ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	CPR:9
Collectively, our results suggest that BC6ENTC can inhibit BC6OTHER production and BC6ENTG activation in LPS - stimulated macrophages through a mechanism that involves the action of BC6OTHER / BC6OTHER .	CPR:4
Collectively, our results suggest that BC6ENTC can inhibit BC6OTHER production and BC6OTHER activation in LPS - stimulated macrophages through a mechanism that involves the action of BC6ENTG / BC6OTHER .	False
Collectively, our results suggest that BC6OTHER can inhibit BC6ENTC production and BC6ENTG activation in LPS - stimulated macrophages through a mechanism that involves the action of BC6OTHER / BC6OTHER .	False
Collectively, our results suggest that BC6OTHER can inhibit BC6ENTC production and BC6OTHER activation in LPS - stimulated macrophages through a mechanism that involves the action of BC6ENTG / BC6OTHER .	False
Collectively, our results suggest that BC6OTHER can inhibit BC6OTHER production and BC6ENTG activation in LPS - stimulated macrophages through a mechanism that involves the action of BC6OTHER / BC6ENTC .	False
Collectively, our results suggest that BC6OTHER can inhibit BC6OTHER production and BC6OTHER activation in LPS - stimulated macrophages through a mechanism that involves the action of BC6ENTG / BC6ENTC .	CPR:9
BC6ENTC ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6ENTG ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	CPR:9
BC6ENTC ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6ENTG ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	CPR:9
BC6ENTC ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6ENTG ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	CPR:9
BC6ENTC ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6ENTG ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	CPR:9
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6ENTG ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6ENTC ( BC6OTHER ) production is unexplored.	False
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6ENTG ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6ENTC ( BC6OTHER ) production is unexplored.	False
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6ENTG ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6ENTC ( BC6OTHER ) production is unexplored.	False
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6ENTG ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6ENTC ( BC6OTHER ) production is unexplored.	False
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6ENTG ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6ENTC ) production is unexplored.	False
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6ENTG ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6ENTC ) production is unexplored.	False
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6ENTG ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6ENTC ) production is unexplored.	False
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6ENTG ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6ENTC ) production is unexplored.	False
Here, we show that at noncytotoxic concentrations, BC6ENTC was able to inhibit BC6OTHER production and BC6ENTG ( BC6OTHER ) expression via BC6OTHER ( BC6OTHER ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	CPR:4
Here, we show that at noncytotoxic concentrations, BC6ENTC was able to inhibit BC6OTHER production and inducible BC6OTHER synthase ( BC6ENTG ) expression via BC6OTHER ( BC6OTHER ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	CPR:4
Here, we show that at noncytotoxic concentrations, BC6ENTC was able to inhibit BC6OTHER production and inducible BC6OTHER synthase ( BC6OTHER ) expression via BC6ENTG ( BC6OTHER ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	False
Here, we show that at noncytotoxic concentrations, BC6ENTC was able to inhibit BC6OTHER production and inducible BC6OTHER synthase ( BC6OTHER ) expression via BC6OTHER ( BC6ENTG ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	False
Here, we show that at noncytotoxic concentrations, BC6OTHER was able to inhibit BC6ENTC production and BC6ENTG ( BC6OTHER ) expression via BC6OTHER ( BC6OTHER ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	CPR:9
Here, we show that at noncytotoxic concentrations, BC6OTHER was able to inhibit BC6ENTC production and inducible BC6OTHER synthase ( BC6ENTG ) expression via BC6OTHER ( BC6OTHER ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	CPR:9
Here, we show that at noncytotoxic concentrations, BC6OTHER was able to inhibit BC6ENTC production and inducible BC6OTHER synthase ( BC6OTHER ) expression via BC6ENTG ( BC6OTHER ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	False
Here, we show that at noncytotoxic concentrations, BC6OTHER was able to inhibit BC6ENTC production and inducible BC6OTHER synthase ( BC6OTHER ) expression via BC6OTHER ( BC6ENTG ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	False
Here, we show that at noncytotoxic concentrations, BC6OTHER was able to inhibit BC6OTHER production and inducible BC6ENTC synthase ( BC6ENTG ) expression via BC6OTHER ( BC6OTHER ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	False
Here, we show that at noncytotoxic concentrations, BC6OTHER was able to inhibit BC6OTHER production and inducible BC6ENTC synthase ( BC6OTHER ) expression via BC6ENTG ( BC6OTHER ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	False
Here, we show that at noncytotoxic concentrations, BC6OTHER was able to inhibit BC6OTHER production and inducible BC6ENTC synthase ( BC6OTHER ) expression via BC6OTHER ( BC6ENTG ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	False
Both BC6ENTC solution prepared by bubbling pure BC6OTHER gas and BC6OTHER , a BC6OTHER donor, dose dependently induced BC6ENTG expression through the activation of the BC6OTHER ( BC6OTHER ).	CPR:3
Both BC6ENTC solution prepared by bubbling pure BC6OTHER gas and BC6OTHER , a BC6OTHER donor, dose dependently induced BC6OTHER expression through the activation of the BC6ENTG ( BC6OTHER ).	CPR:3
Both BC6ENTC solution prepared by bubbling pure BC6OTHER gas and BC6OTHER , a BC6OTHER donor, dose dependently induced BC6OTHER expression through the activation of the BC6OTHER ( BC6ENTG ).	CPR:3
Both BC6OTHER solution prepared by bubbling pure BC6ENTC gas and BC6OTHER , a BC6OTHER donor, dose dependently induced BC6ENTG expression through the activation of the BC6OTHER ( BC6OTHER ).	False
Both BC6OTHER solution prepared by bubbling pure BC6ENTC gas and BC6OTHER , a BC6OTHER donor, dose dependently induced BC6OTHER expression through the activation of the BC6ENTG ( BC6OTHER ).	False
Both BC6OTHER solution prepared by bubbling pure BC6ENTC gas and BC6OTHER , a BC6OTHER donor, dose dependently induced BC6OTHER expression through the activation of the BC6OTHER ( BC6ENTG ).	False
Both BC6OTHER solution prepared by bubbling pure BC6OTHER gas and BC6ENTC , a BC6OTHER donor, dose dependently induced BC6ENTG expression through the activation of the BC6OTHER ( BC6OTHER ).	False
Both BC6OTHER solution prepared by bubbling pure BC6OTHER gas and BC6ENTC , a BC6OTHER donor, dose dependently induced BC6OTHER expression through the activation of the BC6ENTG ( BC6OTHER ).	False
Both BC6OTHER solution prepared by bubbling pure BC6OTHER gas and BC6ENTC , a BC6OTHER donor, dose dependently induced BC6OTHER expression through the activation of the BC6OTHER ( BC6ENTG ).	False
Both BC6OTHER solution prepared by bubbling pure BC6OTHER gas and BC6OTHER , a BC6ENTC donor, dose dependently induced BC6ENTG expression through the activation of the BC6OTHER ( BC6OTHER ).	False
Both BC6OTHER solution prepared by bubbling pure BC6OTHER gas and BC6OTHER , a BC6ENTC donor, dose dependently induced BC6OTHER expression through the activation of the BC6ENTG ( BC6OTHER ).	False
Both BC6OTHER solution prepared by bubbling pure BC6OTHER gas and BC6OTHER , a BC6ENTC donor, dose dependently induced BC6OTHER expression through the activation of the BC6OTHER ( BC6ENTG ).	False
Pretreatment with BC6ENTC or BC6OTHER significantly inhibited LPS - induced BC6ENTG expression and BC6OTHER production.	CPR:4
Moreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6OTHER mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6OTHER , but enhanced by the selective BC6ENTG inhibitor BC6ENTC but not by the BC6OTHER inhibitor BC6OTHER .	CPR:4
Moreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6OTHER mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6OTHER , but enhanced by the selective BC6OTHER inhibitor BC6ENTC but not by the BC6ENTG inhibitor BC6OTHER .	False
Moreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6ENTG mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6OTHER , but enhanced by the selective BC6OTHER inhibitor BC6ENTC but not by the BC6OTHER inhibitor BC6OTHER .	False
Pretreatment with BC6OTHER or BC6ENTC significantly inhibited LPS - induced BC6ENTG expression and BC6OTHER production.	CPR:4
Pretreatment with BC6OTHER or BC6OTHER significantly inhibited LPS - induced BC6ENTG expression and BC6ENTC production.	CPR:9
Moreover, BC6ENTC production in LPS - stimulated macrophages that are expressing BC6OTHER mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6OTHER , but enhanced by the selective BC6ENTG inhibitor BC6OTHER but not by the BC6OTHER inhibitor BC6OTHER .	False
Moreover, BC6ENTC production in LPS - stimulated macrophages that are expressing BC6OTHER mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6OTHER , but enhanced by the selective BC6OTHER inhibitor BC6OTHER but not by the BC6ENTG inhibitor BC6OTHER .	False
Moreover, BC6ENTC production in LPS - stimulated macrophages that are expressing BC6ENTG mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6OTHER , but enhanced by the selective BC6OTHER inhibitor BC6OTHER but not by the BC6OTHER inhibitor BC6OTHER .	False
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6ENTC gamma - lyase ( BC6ENTG ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	False
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6ENTC gamma - lyase ( BC6OTHER ) and / or BC6ENTG ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	False
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6ENTC gamma - lyase ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6ENTG ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	False
Moreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6OTHER mRNA was significantly reduced by the addition of BC6ENTC , a substrate for BC6OTHER , but enhanced by the selective BC6ENTG inhibitor BC6OTHER but not by the BC6OTHER inhibitor BC6OTHER .	False
Moreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6OTHER mRNA was significantly reduced by the addition of BC6ENTC , a substrate for BC6OTHER , but enhanced by the selective BC6OTHER inhibitor BC6OTHER but not by the BC6ENTG inhibitor BC6OTHER .	False
Moreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6ENTG mRNA was significantly reduced by the addition of BC6ENTC , a substrate for BC6OTHER , but enhanced by the selective BC6OTHER inhibitor BC6OTHER but not by the BC6OTHER inhibitor BC6OTHER .	CPR:9
Moreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6OTHER mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6ENTC , but enhanced by the selective BC6ENTG inhibitor BC6OTHER but not by the BC6OTHER inhibitor BC6OTHER .	False
Moreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6OTHER mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6ENTC , but enhanced by the selective BC6OTHER inhibitor BC6OTHER but not by the BC6ENTG inhibitor BC6OTHER .	False
Moreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6ENTG mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6ENTC , but enhanced by the selective BC6OTHER inhibitor BC6OTHER but not by the BC6OTHER inhibitor BC6OTHER .	False
 BC6ENTC inhibits BC6OTHER production and BC6ENTG via BC6OTHER expression in RAW264.7 macrophages stimulated with lipopolysaccharide.	CPR:4
 BC6ENTC inhibits BC6OTHER production and BC6OTHER via BC6ENTG expression in RAW264.7 macrophages stimulated with lipopolysaccharide.	False
 BC6OTHER inhibits BC6ENTC production and BC6ENTG via BC6OTHER expression in RAW264.7 macrophages stimulated with lipopolysaccharide.	False
 BC6OTHER inhibits BC6ENTC production and BC6OTHER via BC6ENTG expression in RAW264.7 macrophages stimulated with lipopolysaccharide.	False
Moreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6OTHER mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6OTHER , but enhanced by the selective BC6ENTG inhibitor BC6OTHER but not by the BC6OTHER inhibitor BC6ENTC .	False
Moreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6OTHER mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6OTHER , but enhanced by the selective BC6OTHER inhibitor BC6OTHER but not by the BC6ENTG inhibitor BC6ENTC .	CPR:4
Moreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6ENTG mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6OTHER , but enhanced by the selective BC6OTHER inhibitor BC6OTHER but not by the BC6OTHER inhibitor BC6ENTC .	False
While either blockage of BC6ENTG activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6ENTC on BC6OTHER expression and BC6OTHER production, BC6OTHER overexpression produced the same inhibitory effects of BC6OTHER .	False
While either blockage of BC6OTHER activity by the BC6ENTG inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6ENTC on BC6OTHER expression and BC6OTHER production, BC6OTHER overexpression produced the same inhibitory effects of BC6OTHER .	False
While either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6ENTG expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6ENTC on BC6OTHER expression and BC6OTHER production, BC6OTHER overexpression produced the same inhibitory effects of BC6OTHER .	False
While either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6ENTG small interfering RNA (siRNA) reversed the inhibitory effects of BC6ENTC on BC6OTHER expression and BC6OTHER production, BC6OTHER overexpression produced the same inhibitory effects of BC6OTHER .	False
While either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6ENTC on BC6ENTG expression and BC6OTHER production, BC6OTHER overexpression produced the same inhibitory effects of BC6OTHER .	CPR:4
While either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6ENTC on BC6OTHER expression and BC6OTHER production, BC6ENTG overexpression produced the same inhibitory effects of BC6OTHER .	False
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6ENTG ) and / or BC6ENTC beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	False
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6ENTC beta - synthase ( BC6ENTG ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	False
BC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6ENTG ( BC6OTHER ) and / or BC6ENTC beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored.	False
While either blockage of BC6ENTG activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6OTHER expression and BC6ENTC production, BC6OTHER overexpression produced the same inhibitory effects of BC6OTHER .	False
While either blockage of BC6OTHER activity by the BC6ENTG inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6OTHER expression and BC6ENTC production, BC6OTHER overexpression produced the same inhibitory effects of BC6OTHER .	False
While either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6ENTG expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6OTHER expression and BC6ENTC production, BC6OTHER overexpression produced the same inhibitory effects of BC6OTHER .	False
While either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6ENTG small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6OTHER expression and BC6ENTC production, BC6OTHER overexpression produced the same inhibitory effects of BC6OTHER .	False
While either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6ENTG expression and BC6ENTC production, BC6OTHER overexpression produced the same inhibitory effects of BC6OTHER .	CPR:9
While either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6OTHER expression and BC6ENTC production, BC6ENTG overexpression produced the same inhibitory effects of BC6OTHER .	False
While either blockage of BC6ENTG activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6OTHER expression and BC6OTHER production, BC6OTHER overexpression produced the same inhibitory effects of BC6ENTC .	False
While either blockage of BC6OTHER activity by the BC6ENTG inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6OTHER expression and BC6OTHER production, BC6OTHER overexpression produced the same inhibitory effects of BC6ENTC .	False
While either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6ENTG expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6OTHER expression and BC6OTHER production, BC6OTHER overexpression produced the same inhibitory effects of BC6ENTC .	False
While either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6ENTG small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6OTHER expression and BC6OTHER production, BC6OTHER overexpression produced the same inhibitory effects of BC6ENTC .	False
While either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6ENTG expression and BC6OTHER production, BC6OTHER overexpression produced the same inhibitory effects of BC6ENTC .	False
While either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6OTHER expression and BC6OTHER production, BC6ENTG overexpression produced the same inhibitory effects of BC6ENTC .	False
In addition, LPS - induced nuclear factor BC6ENTG activation was diminished in RAW264.7 macrophages preincubated with BC6ENTC .	CPR:4
Interestingly, the inhibitory effect of BC6ENTC on BC6ENTG activation was reversed by the transient transfection with BC6OTHER siRNA, but was mimicked by either BC6OTHER gene transfection or treatment with BC6OTHER ( BC6OTHER ), an end product of BC6OTHER .	CPR:4
Interestingly, the inhibitory effect of BC6ENTC on BC6OTHER activation was reversed by the transient transfection with BC6ENTG siRNA, but was mimicked by either BC6OTHER gene transfection or treatment with BC6OTHER ( BC6OTHER ), an end product of BC6OTHER .	False
Interestingly, the inhibitory effect of BC6ENTC on BC6OTHER activation was reversed by the transient transfection with BC6OTHER siRNA, but was mimicked by either BC6ENTG gene transfection or treatment with BC6OTHER ( BC6OTHER ), an end product of BC6OTHER .	False
Interestingly, the inhibitory effect of BC6ENTC on BC6OTHER activation was reversed by the transient transfection with BC6OTHER siRNA, but was mimicked by either BC6OTHER gene transfection or treatment with BC6OTHER ( BC6OTHER ), an end product of BC6ENTG .	False
BC6ENTG is expressed in differentiating osteoclast - like cells and the BC6OTHER mutation selectively impairs the BC6OTHER - BC6OTHER interaction in co - immunoprecipitations, which molecular modelling indicates results from effects on critical BC6ENTC bonds required to stabilise the BC6OTHER - BC6OTHER complex.	False
BC6OTHER is expressed in differentiating osteoclast - like cells and the BC6ENTG mutation selectively impairs the BC6OTHER - BC6OTHER interaction in co - immunoprecipitations, which molecular modelling indicates results from effects on critical BC6ENTC bonds required to stabilise the BC6OTHER - BC6OTHER complex.	False
BC6OTHER is expressed in differentiating osteoclast - like cells and the BC6OTHER mutation selectively impairs the BC6ENTG - BC6OTHER interaction in co - immunoprecipitations, which molecular modelling indicates results from effects on critical BC6ENTC bonds required to stabilise the BC6OTHER - BC6OTHER complex.	False
BC6OTHER is expressed in differentiating osteoclast - like cells and the BC6OTHER mutation selectively impairs the BC6OTHER - BC6ENTG interaction in co - immunoprecipitations, which molecular modelling indicates results from effects on critical BC6ENTC bonds required to stabilise the BC6OTHER - BC6OTHER complex.	False
BC6OTHER is expressed in differentiating osteoclast - like cells and the BC6OTHER mutation selectively impairs the BC6OTHER - BC6OTHER interaction in co - immunoprecipitations, which molecular modelling indicates results from effects on critical BC6ENTC bonds required to stabilise the BC6ENTG - BC6OTHER complex.	False
BC6OTHER is expressed in differentiating osteoclast - like cells and the BC6OTHER mutation selectively impairs the BC6OTHER - BC6OTHER interaction in co - immunoprecipitations, which molecular modelling indicates results from effects on critical BC6ENTC bonds required to stabilise the BC6OTHER - BC6ENTG complex.	False
Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme BC6ENTG , as compared to the standard tyrosinase inhibitors BC6ENTC (IC50=16.67 microM) and BC6OTHER (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes.	CPR:4
Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme BC6ENTG , as compared to the standard tyrosinase inhibitors BC6OTHER (IC50=16.67 microM) and BC6ENTC (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes.	CPR:4
Patients treated with BC6ENTC - based chemotherapy, carrying the BC6ENTG BC6OTHER genotype had significantly decreased time - to - tumor recurrence (TTR) in univariate analysis and multivariate analysis (hazard ratio (HR) 2.47; 95% confidence interval (CI) 1.16 - 5.29; P=0.019).	False
Patients treated with BC6ENTC - based chemotherapy, carrying the BC6OTHER BC6ENTG genotype had significantly decreased time - to - tumor recurrence (TTR) in univariate analysis and multivariate analysis (hazard ratio (HR) 2.47; 95% confidence interval (CI) 1.16 - 5.29; P=0.019).	False
The BC6OTHER ( BC6ENTG ) BC6OTHER polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant BC6ENTC - based chemotherapy.	False
The BC6OTHER ( BC6OTHER ) BC6ENTG polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant BC6ENTC - based chemotherapy.	False
The BC6ENTG ( BC6OTHER ) BC6OTHER polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant BC6ENTC - based chemotherapy.	False
Filtering and analysis of data identified three oncogenic pathways interfered by BC6ENTC : BC6ENTG / BC6OTHER pathway, cell adhesion and BC6OTHER / BC6OTHER signaling.	False
Filtering and analysis of data identified three oncogenic pathways interfered by BC6ENTC : BC6OTHER / BC6ENTG pathway, cell adhesion and BC6OTHER / BC6OTHER signaling.	False
Filtering and analysis of data identified three oncogenic pathways interfered by BC6ENTC : BC6OTHER / BC6OTHER pathway, cell adhesion and BC6ENTG / BC6OTHER signaling.	False
Filtering and analysis of data identified three oncogenic pathways interfered by BC6ENTC : BC6OTHER / BC6OTHER pathway, cell adhesion and BC6OTHER / BC6ENTG signaling.	False
BC6ENTG emerged as a consensus target of BC6ENTC , orchestrating these pathways.	False
Moreover, BC6ENTC treatment restored membranous expression of adhesion molecules BC6ENTG and BC6OTHER .	CPR:3
Moreover, BC6ENTC treatment restored membranous expression of adhesion molecules BC6OTHER and BC6ENTG .	CPR:3
 BC6ENTC modulates intercellular adhesion through inhibition of BC6ENTG .	CPR:4
BC6ENTG expression was elevated in APC(min) polyps and BC6ENTC treatment reduced its expression.	CPR:4
Our data demonstrates novel pharmacological mechanism of BC6ENTC in modulation of cell adhesion and role of BC6ENTG in APC(min) polyposis.	False
We propose that inhibition of BC6ENTG expression by BC6ENTC can impede with neoplastic progression in colorectal carcinogenesis.	CPR:4
The mechanism of BC6ENTG inhibition and induction of membranous translocation of adhesion proteins by BC6ENTC might be independent of its known anti - inflammatory action.	CPR:4
Strain - dependent down - regulation of several key one - BC6ENTC metabolism genes, including BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6ENTC metabolism genes, including BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6ENTC metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6ENTC metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6ENTC metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6ENTC metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6ENTC metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6ENTC metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6ENTC metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6ENTC metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTC adenosyltransferase 1α ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTC adenosyltransferase 1α ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTC adenosyltransferase 1α ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTC adenosyltransferase 1α ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTC adenosyltransferase 1α ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTC adenosyltransferase 1α ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTC adenosyltransferase 1α ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTC adenosyltransferase 1α ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTC adenosyltransferase 1α ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTG ( BC6OTHER ), BC6ENTC - β - synthase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6ENTG ), BC6ENTC - β - synthase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTC - β - synthase ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTC - β - synthase ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTC - β - synthase ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTC - β - synthase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTC - β - synthase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTC - β - synthase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTC - β - synthase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6ENTG ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC - homocysteinase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC - homocysteinase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC - homocysteinase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6ENTC - homocysteinase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6ENTC - homocysteinase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6ENTC - homocysteinase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC - homocysteinase ( BC6ENTG ), and BC6OTHER ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC - homocysteinase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC - homocysteinase ( BC6OTHER ), and BC6OTHER ( BC6ENTG ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC dehydrogenase 1 ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC dehydrogenase 1 ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC dehydrogenase 1 ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC dehydrogenase 1 ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC dehydrogenase 1 ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and BC6ENTC dehydrogenase 1 ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6ENTC dehydrogenase 1 ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), and BC6ENTC dehydrogenase 1 ( BC6OTHER ), was observed.	False
Strain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC dehydrogenase 1 ( BC6ENTG ), was observed.	False
In contrast, the BC6ENTG sequence showed well - defined structure only near its BC6ENTC - terminal residues.	False
The BC6ENTG of the BC6ENTC (1) receptor have not yet been conclusively resolved, and bear limited sequence identity to known structures.	False
This study involved development of a peptide to characterize the intrinsic structure of the BC6ENTC (1) BC6ENTG second BC6OTHER .	False
This study involved development of a peptide to characterize the intrinsic structure of the BC6ENTC (1) BC6OTHER second BC6ENTG .	False
The loop was embedded between two helices that assemble into a BC6ENTG , which served as a receptor - mimetic folding constraint ( BC6ENTC (1) - CC - BC6OTHER peptide).	False
The loop was embedded between two helices that assemble into a BC6OTHER , which served as a receptor - mimetic folding constraint ( BC6ENTC (1) - CC - BC6ENTG peptide).	False
Acute and chronic BC6OTHER administration increase brain BC6OTHER levels, an effect due, at least in part, to an inhibition of the activity of the BC6OTHER metabolizing enzyme, BC6ENTC transaminase ( BC6ENTG ).	False
As with BC6ENTC , the metabolism of BC6OTHER involves a BC6ENTG .	False
As with BC6OTHER , the metabolism of BC6ENTC involves a BC6ENTG .	CPR:9
In the study reported here, the effects of acute BC6ENTC treatment on the levels of various BC6OTHER , some of which are also metabolized by BC6ENTG were compared in rat whole brain.	False
In the study reported here, the effects of acute BC6OTHER treatment on the levels of various BC6ENTC , some of which are also metabolized by BC6ENTG were compared in rat whole brain.	CPR:9
In addition, we also showed that the elevation in BC6ENTC levels and the inhibition of BC6ENTG in the brain are retained after 14 days of BC6OTHER treatment, and that BC6OTHER produces a marked increase in extracellular levels of BC6OTHER .	CPR:9
The elevation in brain BC6ENTC levels could be explained, at least in part, by a time - and dose - dependent inhibitory effect of BC6OTHER on BC6ENTG ( BC6OTHER ), although as with BC6OTHER the increases are higher than expected from the degree of enzyme inhibition produced.	CPR:9
The elevation in brain BC6ENTC levels could be explained, at least in part, by a time - and dose - dependent inhibitory effect of BC6OTHER on BC6OTHER ( BC6ENTG ), although as with BC6OTHER the increases are higher than expected from the degree of enzyme inhibition produced.	CPR:9
Acute and chronic BC6ENTC administration increase brain BC6OTHER levels, an effect due, at least in part, to an inhibition of the activity of the BC6OTHER metabolizing enzyme, BC6ENTG ( BC6OTHER ).	CPR:4
Acute and chronic BC6ENTC administration increase brain BC6OTHER levels, an effect due, at least in part, to an inhibition of the activity of the BC6OTHER metabolizing enzyme, BC6OTHER ( BC6ENTG ).	CPR:4
The elevation in brain BC6OTHER levels could be explained, at least in part, by a time - and dose - dependent inhibitory effect of BC6ENTC on BC6ENTG ( BC6OTHER ), although as with BC6OTHER the increases are higher than expected from the degree of enzyme inhibition produced.	CPR:4
The elevation in brain BC6OTHER levels could be explained, at least in part, by a time - and dose - dependent inhibitory effect of BC6ENTC on BC6OTHER ( BC6ENTG ), although as with BC6OTHER the increases are higher than expected from the degree of enzyme inhibition produced.	CPR:4
The elevation in brain BC6OTHER levels could be explained, at least in part, by a time - and dose - dependent inhibitory effect of BC6OTHER on BC6ENTC transaminase ( BC6ENTG ), although as with BC6OTHER the increases are higher than expected from the degree of enzyme inhibition produced.	False
The elevation in brain BC6OTHER levels could be explained, at least in part, by a time - and dose - dependent inhibitory effect of BC6OTHER on BC6ENTG ( BC6ENTC - T), although as with BC6OTHER the increases are higher than expected from the degree of enzyme inhibition produced.	False
The elevation in brain BC6OTHER levels could be explained, at least in part, by a time - and dose - dependent inhibitory effect of BC6OTHER on BC6ENTG ( BC6OTHER ), although as with BC6ENTC the increases are higher than expected from the degree of enzyme inhibition produced.	False
The elevation in brain BC6OTHER levels could be explained, at least in part, by a time - and dose - dependent inhibitory effect of BC6OTHER on BC6OTHER ( BC6ENTG ), although as with BC6ENTC the increases are higher than expected from the degree of enzyme inhibition produced.	False
Effects of the antidepressant / antipanic drug BC6ENTC on BC6OTHER and BC6ENTG in rat brain.	False
Effects of the antidepressant / antipanic drug BC6OTHER on BC6ENTC and BC6ENTG in rat brain.	False
Acute and chronic BC6OTHER administration increase brain BC6ENTC levels, an effect due, at least in part, to an inhibition of the activity of the BC6OTHER metabolizing enzyme, BC6ENTG ( BC6OTHER ).	False
Acute and chronic BC6OTHER administration increase brain BC6ENTC levels, an effect due, at least in part, to an inhibition of the activity of the BC6OTHER metabolizing enzyme, BC6OTHER ( BC6ENTG ).	False
In addition, we also showed that the elevation in BC6OTHER levels and the inhibition of BC6ENTG in the brain are retained after 14 days of BC6ENTC treatment, and that BC6OTHER produces a marked increase in extracellular levels of BC6OTHER .	CPR:4
In addition, we also showed that the elevation in BC6OTHER levels and the inhibition of BC6ENTG in the brain are retained after 14 days of BC6OTHER treatment, and that BC6ENTC produces a marked increase in extracellular levels of BC6OTHER .	False
In addition, we also showed that the elevation in BC6OTHER levels and the inhibition of BC6ENTG in the brain are retained after 14 days of BC6OTHER treatment, and that BC6OTHER produces a marked increase in extracellular levels of BC6ENTC .	False
Acute and chronic BC6OTHER administration increase brain BC6OTHER levels, an effect due, at least in part, to an inhibition of the activity of the BC6ENTC metabolizing enzyme, BC6ENTG ( BC6OTHER ).	CPR:9
Acute and chronic BC6OTHER administration increase brain BC6OTHER levels, an effect due, at least in part, to an inhibition of the activity of the BC6ENTC metabolizing enzyme, BC6OTHER ( BC6ENTG ).	CPR:9
BC6ENTC 11 ( BC6OTHER ) was synthesized and evaluated as BC6OTHER (also known as BC6ENTG or BC6OTHER ) inhibitor.	CPR:4
BC6ENTC 11 ( BC6OTHER ) was synthesized and evaluated as BC6OTHER (also known as BC6OTHER or BC6ENTG ) inhibitor.	CPR:4
BC6ENTC 11 ( BC6OTHER ) was synthesized and evaluated as BC6ENTG (also known as BC6OTHER or BC6OTHER ) inhibitor.	CPR:4
BC6OTHER 11 ( BC6ENTC ) was synthesized and evaluated as BC6OTHER (also known as BC6ENTG or BC6OTHER ) inhibitor.	CPR:4
BC6OTHER 11 ( BC6ENTC ) was synthesized and evaluated as BC6OTHER (also known as BC6OTHER or BC6ENTG ) inhibitor.	CPR:4
BC6OTHER 11 ( BC6ENTC ) was synthesized and evaluated as BC6ENTG (also known as BC6OTHER or BC6OTHER ) inhibitor.	CPR:4
Discovery of BC6ENTC ( BC6OTHER ): a potent and selective BC6ENTG inhibitor as a topical drug for alopecia.	CPR:4
Discovery of BC6OTHER ( BC6ENTC ): a potent and selective BC6ENTG inhibitor as a topical drug for alopecia.	CPR:4
BC6OTHER ( BC6ENTC ), a widely used drug to lower elevated plasma lipid levels, induced BC6ENTG enzyme activity in white adipose tissue of mice.	CPR:3
BC6ENTG ( BC6OTHER ) catalyses the conversion of BC6OTHER to BC6ENTC and plays an important role in hepatic detoxification reactions.	CPR:9
BC6OTHER BC6OTHER - methyltransferase ( BC6ENTG ) catalyses the conversion of BC6OTHER to BC6ENTC and plays an important role in hepatic detoxification reactions.	CPR:9
Adipose tissue as a source of BC6ENTG and BC6ENTC .	False
BC6ENTC BC6OTHER - methyltransferase ( BC6ENTG ) catalyses the conversion of BC6OTHER to BC6OTHER and plays an important role in hepatic detoxification reactions.	False
These data support the concept that adipose tissue BC6ENTG contributes to the increased plasma BC6ENTC levels in patients treated with BC6OTHER .	CPR:9
These data support the concept that adipose tissue BC6ENTG contributes to the increased plasma BC6OTHER levels in patients treated with BC6ENTC .	False
BC6OTHER BC6ENTC - methyltransferase ( BC6ENTG ) catalyses the conversion of BC6OTHER to BC6OTHER and plays an important role in hepatic detoxification reactions.	False
BC6ENTC , the atherogenic product of the BC6ENTG - catalyzed reaction, was secreted from 3T3 - L1 cells or adipose tissue cultures.	CPR:9
BC6ENTC release increased during 3T3 - L1 differentiation and was reduced when adipose tissue was treated with the BC6ENTG inhibitor BC6OTHER .	False
BC6ENTG ( BC6OTHER ) catalyses the conversion of BC6ENTC to BC6OTHER and plays an important role in hepatic detoxification reactions.	CPR:9
BC6OTHER BC6OTHER - methyltransferase ( BC6ENTG ) catalyses the conversion of BC6ENTC to BC6OTHER and plays an important role in hepatic detoxification reactions.	CPR:9
BC6OTHER release increased during 3T3 - L1 differentiation and was reduced when adipose tissue was treated with the BC6ENTG inhibitor BC6ENTC .	CPR:4
BC6ENTC ( BC6OTHER ), a widely used drug to lower elevated plasma lipid levels, induced BC6ENTG enzyme activity in white adipose tissue of mice.	CPR:3
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6ENTG ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6ENTC and BC6OTHER , respectively.	False
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6ENTG ( BC6OTHER ) to produce BC6ENTC and BC6OTHER , respectively.	CPR:9
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6ENTG ) to produce BC6ENTC and BC6OTHER , respectively.	CPR:9
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by BC6ENTG BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6ENTC and BC6OTHER , respectively.	False
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6ENTG ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6ENTC , respectively.	False
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6ENTG ( BC6OTHER ) to produce BC6OTHER and BC6ENTC , respectively.	CPR:9
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6ENTG ) to produce BC6OTHER and BC6ENTC , respectively.	CPR:9
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by BC6ENTG BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6ENTC , respectively.	False
During BC6OTHER catabolism, BC6ENTC and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6ENTG ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively.	CPR:9
During BC6OTHER catabolism, BC6ENTC and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6ENTG ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively.	False
During BC6OTHER catabolism, BC6ENTC and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6ENTG ) to produce BC6OTHER and BC6OTHER , respectively.	False
During BC6OTHER catabolism, BC6ENTC and BC6OTHER are first acetylated by BC6ENTG BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively.	CPR:9
In attempting to clone the BC6ENTG involved in this back - conversion pathway, we encountered an BC6OTHER that preferentially cleaves BC6ENTC in the absence of prior acetylation by BC6OTHER .	False
In attempting to clone the BC6OTHER involved in this back - conversion pathway, we encountered an BC6ENTG that preferentially cleaves BC6ENTC in the absence of prior acetylation by BC6OTHER .	False
In attempting to clone the BC6OTHER involved in this back - conversion pathway, we encountered an BC6OTHER that preferentially cleaves BC6ENTC in the absence of prior acetylation by BC6ENTG .	CPR:9
During BC6OTHER catabolism, BC6OTHER and BC6ENTC are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6ENTG ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively.	CPR:9
During BC6OTHER catabolism, BC6OTHER and BC6ENTC are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6ENTG ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively.	False
During BC6OTHER catabolism, BC6OTHER and BC6ENTC are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6ENTG ) to produce BC6OTHER and BC6OTHER , respectively.	False
During BC6OTHER catabolism, BC6OTHER and BC6ENTC are first acetylated by BC6ENTG BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively.	CPR:9
A BLAST search using BC6ENTG sequences identified homologous mammalian cDNAs derived from human hepatoma and mouse mammary carcinoma: the encoded proteins differed by 20 BC6ENTC .	False
Substrate specificity using lysates of BC6OTHER - transfected HEK - 293 cells revealed that the newly identified BC6OTHER strongly favoured BC6OTHER over BC6OTHER and that it failed to act on BC6ENTC , BC6OTHER or the preferred BC6ENTG substrate, BC6OTHER .	False
Substrate specificity using lysates of BC6ENTG - transfected HEK - 293 cells revealed that the newly identified BC6OTHER strongly favoured BC6OTHER over BC6OTHER and that it failed to act on BC6ENTC , BC6OTHER or the preferred BC6OTHER substrate, BC6OTHER .	False
Substrate specificity using lysates of BC6OTHER - transfected HEK - 293 cells revealed that the newly identified BC6ENTG strongly favoured BC6OTHER over BC6OTHER and that it failed to act on BC6ENTC , BC6OTHER or the preferred BC6OTHER substrate, BC6OTHER .	False
During BC6ENTC catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6ENTG ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively.	CPR:9
During BC6ENTC catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6ENTG ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively.	False
During BC6ENTC catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6ENTG ) to produce BC6OTHER and BC6OTHER , respectively.	False
During BC6ENTC catabolism, BC6OTHER and BC6OTHER are first acetylated by BC6ENTG BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively.	CPR:9
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by BC6ENTC / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6ENTG ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively.	False
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by BC6ENTC / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6ENTG ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively.	False
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by BC6ENTC / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6ENTG ) to produce BC6OTHER and BC6OTHER , respectively.	False
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6ENTC BC6OTHER (1) - acetyltransferase ( BC6ENTG ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively.	False
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6ENTC BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6ENTG ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively.	False
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6ENTC BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6ENTG ) to produce BC6OTHER and BC6OTHER , respectively.	False
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6ENTC (1) - acetyltransferase ( BC6ENTG ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively.	False
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6ENTC (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6ENTG ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively.	False
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6ENTC (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6ENTG ) to produce BC6OTHER and BC6OTHER , respectively.	False
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by BC6ENTG BC6ENTC (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively.	False
Substrate specificity using lysates of BC6OTHER - transfected HEK - 293 cells revealed that the newly identified BC6OTHER strongly favoured BC6ENTC over BC6OTHER and that it failed to act on BC6OTHER , BC6OTHER or the preferred BC6ENTG substrate, BC6OTHER .	False
Substrate specificity using lysates of BC6ENTG - transfected HEK - 293 cells revealed that the newly identified BC6OTHER strongly favoured BC6ENTC over BC6OTHER and that it failed to act on BC6OTHER , BC6OTHER or the preferred BC6OTHER substrate, BC6OTHER .	False
Substrate specificity using lysates of BC6OTHER - transfected HEK - 293 cells revealed that the newly identified BC6ENTG strongly favoured BC6ENTC over BC6OTHER and that it failed to act on BC6OTHER , BC6OTHER or the preferred BC6OTHER substrate, BC6OTHER .	CPR:9
Substrate specificity using lysates of BC6OTHER - transfected HEK - 293 cells revealed that the newly identified BC6OTHER strongly favoured BC6OTHER over BC6ENTC and that it failed to act on BC6OTHER , BC6OTHER or the preferred BC6ENTG substrate, BC6OTHER .	False
Substrate specificity using lysates of BC6ENTG - transfected HEK - 293 cells revealed that the newly identified BC6OTHER strongly favoured BC6OTHER over BC6ENTC and that it failed to act on BC6OTHER , BC6OTHER or the preferred BC6OTHER substrate, BC6OTHER .	False
Substrate specificity using lysates of BC6OTHER - transfected HEK - 293 cells revealed that the newly identified BC6ENTG strongly favoured BC6OTHER over BC6ENTC and that it failed to act on BC6OTHER , BC6OTHER or the preferred BC6OTHER substrate, BC6OTHER .	CPR:9
Identification and characterization of a novel BC6ENTC - containing BC6ENTG of mammalian cell origin.	False
Substrate specificity using lysates of BC6OTHER - transfected HEK - 293 cells revealed that the newly identified BC6OTHER strongly favoured BC6OTHER over BC6OTHER and that it failed to act on BC6OTHER , BC6ENTC or the preferred BC6ENTG substrate, BC6OTHER .	False
Substrate specificity using lysates of BC6ENTG - transfected HEK - 293 cells revealed that the newly identified BC6OTHER strongly favoured BC6OTHER over BC6OTHER and that it failed to act on BC6OTHER , BC6ENTC or the preferred BC6OTHER substrate, BC6OTHER .	False
Substrate specificity using lysates of BC6OTHER - transfected HEK - 293 cells revealed that the newly identified BC6ENTG strongly favoured BC6OTHER over BC6OTHER and that it failed to act on BC6OTHER , BC6ENTC or the preferred BC6OTHER substrate, BC6OTHER .	False
Substrate specificity using lysates of BC6OTHER - transfected HEK - 293 cells revealed that the newly identified BC6OTHER strongly favoured BC6OTHER over BC6OTHER and that it failed to act on BC6OTHER , BC6OTHER or the preferred BC6ENTG substrate, BC6ENTC .	CPR:9
Substrate specificity using lysates of BC6ENTG - transfected HEK - 293 cells revealed that the newly identified BC6OTHER strongly favoured BC6OTHER over BC6OTHER and that it failed to act on BC6OTHER , BC6OTHER or the preferred BC6OTHER substrate, BC6ENTC .	False
Substrate specificity using lysates of BC6OTHER - transfected HEK - 293 cells revealed that the newly identified BC6ENTG strongly favoured BC6OTHER over BC6OTHER and that it failed to act on BC6OTHER , BC6OTHER or the preferred BC6OTHER substrate, BC6ENTC .	False
The BC6ENTG inhibitor, BC6ENTC , only partially blocked oxidation of BC6OTHER while a previously reported BC6OTHER substrate, BC6OTHER , potently inhibited the reaction.	CPR:4
The BC6OTHER inhibitor, BC6ENTC , only partially blocked oxidation of BC6OTHER while a previously reported BC6ENTG substrate, BC6OTHER , potently inhibited the reaction.	False
The BC6ENTG inhibitor, BC6OTHER , only partially blocked oxidation of BC6ENTC while a previously reported BC6OTHER substrate, BC6OTHER , potently inhibited the reaction.	False
The BC6OTHER inhibitor, BC6OTHER , only partially blocked oxidation of BC6ENTC while a previously reported BC6ENTG substrate, BC6OTHER , potently inhibited the reaction.	False
The BC6ENTG inhibitor, BC6OTHER , only partially blocked oxidation of BC6OTHER while a previously reported BC6OTHER substrate, BC6ENTC , potently inhibited the reaction.	False
The BC6OTHER inhibitor, BC6OTHER , only partially blocked oxidation of BC6OTHER while a previously reported BC6ENTG substrate, BC6ENTC , potently inhibited the reaction.	CPR:9
Overall, the data indicate that the enzyme represents a novel BC6ENTG which, on the basis of substrate specificity, we have designated BC6ENTC oxidase in order to distinguish it from the BC6OTHER involved in BC6OTHER back - conversion.	False
Overall, the data indicate that the enzyme represents a novel BC6OTHER which, on the basis of substrate specificity, we have designated BC6ENTC oxidase in order to distinguish it from the BC6ENTG involved in BC6OTHER back - conversion.	False
Overall, the data indicate that the enzyme represents a novel BC6ENTG which, on the basis of substrate specificity, we have designated BC6OTHER oxidase in order to distinguish it from the BC6OTHER involved in BC6ENTC back - conversion.	False
Overall, the data indicate that the enzyme represents a novel BC6OTHER which, on the basis of substrate specificity, we have designated BC6ENTG in order to distinguish it from the BC6OTHER involved in BC6ENTC back - conversion.	False
Overall, the data indicate that the enzyme represents a novel BC6OTHER which, on the basis of substrate specificity, we have designated BC6OTHER oxidase in order to distinguish it from the BC6ENTG involved in BC6ENTC back - conversion.	False
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6ENTG ) and subsequently oxidized by BC6ENTC oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively.	False
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6ENTC oxidase ( BC6ENTG ) to produce BC6OTHER and BC6OTHER , respectively.	False
During BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by BC6ENTG BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6ENTC oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively.	False
In BC6OTHER - treated situation, cell viability was not different before and after administration of either BC6ENTG siRNA or BC6ENTC whereas it was lessened after co - administration of BC6OTHER siRNA and BC6OTHER .	False
In BC6OTHER - treated situation, cell viability was not different before and after administration of either BC6OTHER siRNA or BC6ENTC whereas it was lessened after co - administration of BC6ENTG siRNA and BC6OTHER .	False
In BC6OTHER - treated situation, cell viability was not different before and after administration of either BC6ENTG siRNA or BC6OTHER whereas it was lessened after co - administration of BC6OTHER siRNA and BC6ENTC .	False
In BC6OTHER - treated situation, cell viability was not different before and after administration of either BC6OTHER siRNA or BC6OTHER whereas it was lessened after co - administration of BC6ENTG siRNA and BC6ENTC .	False
Compared to BC6ENTC treatment alone, cell viability was reduced with BC6ENTG plasmid but it was unchanged with BC6OTHER siRNA.	False
Compared to BC6ENTC treatment alone, cell viability was reduced with BC6OTHER plasmid but it was unchanged with BC6ENTG siRNA.	False
 BC6ENTG sensitizes to BC6ENTC by modulating BC6OTHER and BC6OTHER / BC6OTHER signal pathway in FRO anaplastic thyroid carcinoma cells.	False
 BC6OTHER sensitizes to BC6ENTC by modulating BC6ENTG and BC6OTHER / BC6OTHER signal pathway in FRO anaplastic thyroid carcinoma cells.	False
 BC6OTHER sensitizes to BC6ENTC by modulating BC6OTHER and BC6ENTG / BC6OTHER signal pathway in FRO anaplastic thyroid carcinoma cells.	False
 BC6OTHER sensitizes to BC6ENTC by modulating BC6OTHER and BC6OTHER / BC6ENTG signal pathway in FRO anaplastic thyroid carcinoma cells.	False
While BC6ENTG plasmid transfection diminished BC6OTHER and BC6ENTC - Akt protein levels, BC6OTHER siRNA transfection did not alter the protein levels.	False
While BC6OTHER plasmid transfection diminished BC6ENTG and BC6ENTC - Akt protein levels, BC6OTHER siRNA transfection did not alter the protein levels.	False
While BC6OTHER plasmid transfection diminished BC6OTHER and BC6ENTC - Akt protein levels, BC6ENTG siRNA transfection did not alter the protein levels.	False
In conclusion, these results suggest that BC6ENTG may sensitize FRO ATC cells to BC6ENTC thereby inhibiting cell survival by modulating BC6OTHER and BC6OTHER / BC6OTHER signal pathway.	False
In conclusion, these results suggest that BC6OTHER may sensitize FRO ATC cells to BC6ENTC thereby inhibiting cell survival by modulating BC6ENTG and BC6OTHER / BC6OTHER signal pathway.	False
In conclusion, these results suggest that BC6OTHER may sensitize FRO ATC cells to BC6ENTC thereby inhibiting cell survival by modulating BC6OTHER and BC6ENTG / BC6OTHER signal pathway.	False
In conclusion, these results suggest that BC6OTHER may sensitize FRO ATC cells to BC6ENTC thereby inhibiting cell survival by modulating BC6OTHER and BC6OTHER / BC6ENTG signal pathway.	False
Furthermore, these findings imply that BC6ENTG may be a possible candidate as the chemosensitizing factor for induction of cytotoxicity in ATC cells exposed to BC6ENTC .	False
In the present study, we evaluated the effects of BC6ENTC on cell survival, BC6ENTG , and BC6OTHER / BC6OTHER signal pathway in FRO anaplastic thyroid carcinoma (ATC) cells.	False
In the present study, we evaluated the effects of BC6ENTC on cell survival, BC6OTHER , and BC6ENTG / BC6OTHER signal pathway in FRO anaplastic thyroid carcinoma (ATC) cells.	False
In the present study, we evaluated the effects of BC6ENTC on cell survival, BC6OTHER , and BC6OTHER / BC6ENTG signal pathway in FRO anaplastic thyroid carcinoma (ATC) cells.	False
Moreover, we investigated the roles of BC6ENTG in cell survival under condition of BC6ENTC treatment in FRO ATC cells.	False
After BC6ENTC treatment, cell viability, BC6ENTG , and BC6OTHER protein levels were not changed.	False
After BC6ENTC treatment, cell viability, BC6OTHER , and BC6ENTG protein levels were not changed.	False
In BC6ENTC - treated situation, cell viability was not different before and after administration of either BC6ENTG siRNA or BC6OTHER whereas it was lessened after co - administration of BC6OTHER siRNA and BC6OTHER .	False
In BC6ENTC - treated situation, cell viability was not different before and after administration of either BC6OTHER siRNA or BC6OTHER whereas it was lessened after co - administration of BC6ENTG siRNA and BC6OTHER .	False
RESULTS: In the BC6ENTC - injured brain, the BC6ENTG mRNA, and protein expression were upregulated, and the receptor was mainly localized in the neurons and not in the astrocytes.	CPR:3
BC6ENTC , BC6OTHER and BC6OTHER decreased BC6OTHER - induced injury; BC6OTHER (0.1 mg / kg) and BC6OTHER inhibited the upregulated expression of the BC6ENTG .	False
BC6OTHER , BC6ENTC and BC6OTHER decreased BC6OTHER - induced injury; BC6OTHER (0.1 mg / kg) and BC6OTHER inhibited the upregulated expression of the BC6ENTG .	False
BC6OTHER , BC6OTHER and BC6ENTC decreased BC6OTHER - induced injury; BC6OTHER (0.1 mg / kg) and BC6OTHER inhibited the upregulated expression of the BC6ENTG .	False
BC6OTHER , BC6OTHER and BC6OTHER decreased BC6ENTC - induced injury; BC6OTHER (0.1 mg / kg) and BC6OTHER inhibited the upregulated expression of the BC6ENTG .	False
BC6OTHER , BC6OTHER and BC6OTHER decreased BC6OTHER - induced injury; BC6ENTC (0.1 mg / kg) and BC6OTHER inhibited the upregulated expression of the BC6ENTG .	CPR:4
BC6OTHER , BC6OTHER and BC6OTHER decreased BC6OTHER - induced injury; BC6OTHER (0.1 mg / kg) and BC6ENTC inhibited the upregulated expression of the BC6ENTG .	CPR:4
AIM: To determine whether BC6ENTG ( BC6OTHER ) is involved in BC6ENTC ( BC6OTHER ) - induced excitotoxic injury in the mouse brain.	False
AIM: To determine whether BC6OTHER receptor 1 ( BC6ENTG ) is involved in BC6ENTC ( BC6OTHER ) - induced excitotoxic injury in the mouse brain.	False
CONCLUSION: BC6OTHER expression in neurons is upregulated after BC6ENTC injection, and BC6OTHER - induced responses are inhibited by BC6ENTG antagonists, indicating that the increased BC6OTHER is involved in BC6OTHER excitotoxicity.	False
CONCLUSION: BC6OTHER expression in neurons is upregulated after BC6ENTC injection, and BC6OTHER - induced responses are inhibited by BC6OTHER antagonists, indicating that the increased BC6ENTG is involved in BC6OTHER excitotoxicity.	False
CONCLUSION: BC6ENTG expression in neurons is upregulated after BC6ENTC injection, and BC6OTHER - induced responses are inhibited by BC6OTHER antagonists, indicating that the increased BC6OTHER is involved in BC6OTHER excitotoxicity.	CPR:3
CONCLUSION: BC6OTHER expression in neurons is upregulated after BC6OTHER injection, and BC6ENTC - induced responses are inhibited by BC6ENTG antagonists, indicating that the increased BC6OTHER is involved in BC6OTHER excitotoxicity.	False
CONCLUSION: BC6OTHER expression in neurons is upregulated after BC6OTHER injection, and BC6ENTC - induced responses are inhibited by BC6OTHER antagonists, indicating that the increased BC6ENTG is involved in BC6OTHER excitotoxicity.	False
CONCLUSION: BC6ENTG expression in neurons is upregulated after BC6OTHER injection, and BC6ENTC - induced responses are inhibited by BC6OTHER antagonists, indicating that the increased BC6OTHER is involved in BC6OTHER excitotoxicity.	False
CONCLUSION: BC6OTHER expression in neurons is upregulated after BC6OTHER injection, and BC6OTHER - induced responses are inhibited by BC6ENTG antagonists, indicating that the increased BC6OTHER is involved in BC6ENTC excitotoxicity.	False
CONCLUSION: BC6OTHER expression in neurons is upregulated after BC6OTHER injection, and BC6OTHER - induced responses are inhibited by BC6OTHER antagonists, indicating that the increased BC6ENTG is involved in BC6ENTC excitotoxicity.	CPR:3
CONCLUSION: BC6ENTG expression in neurons is upregulated after BC6OTHER injection, and BC6OTHER - induced responses are inhibited by BC6OTHER antagonists, indicating that the increased BC6OTHER is involved in BC6ENTC excitotoxicity.	False
 BC6ENTG is involved in BC6ENTC - mediated neuronal injury in mice.	False
AIM: To determine whether BC6ENTG ( BC6OTHER ) is involved in BC6OTHER ( BC6ENTC ) - induced excitotoxic injury in the mouse brain.	False
AIM: To determine whether BC6OTHER receptor 1 ( BC6ENTG ) is involved in BC6OTHER ( BC6ENTC ) - induced excitotoxic injury in the mouse brain.	False
AIM: To determine whether BC6ENTC receptor 1 ( BC6ENTG ) is involved in BC6OTHER ( BC6OTHER ) - induced excitotoxic injury in the mouse brain.	False
The changes in BC6ENTG expression 24 h after BC6ENTC injection and the effects of a BC6OTHER antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6OTHER receptor antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed.	False
The changes in BC6OTHER expression 24 h after BC6ENTC injection and the effects of a BC6ENTG antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6OTHER receptor antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed.	False
The changes in BC6OTHER expression 24 h after BC6ENTC injection and the effects of a BC6OTHER antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6ENTG antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed.	False
The changes in BC6ENTG expression 24 h after BC6OTHER injection and the effects of a BC6OTHER antagonist, BC6ENTC (0.01 and 0.1 mg / kg), an BC6OTHER receptor antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed.	False
The changes in BC6OTHER expression 24 h after BC6OTHER injection and the effects of a BC6ENTG antagonist, BC6ENTC (0.01 and 0.1 mg / kg), an BC6OTHER receptor antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed.	CPR:6
The changes in BC6OTHER expression 24 h after BC6OTHER injection and the effects of a BC6OTHER antagonist, BC6ENTC (0.01 and 0.1 mg / kg), an BC6ENTG antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed.	False
The changes in BC6ENTG expression 24 h after BC6OTHER injection and the effects of a BC6OTHER antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6ENTC receptor antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed.	False
The changes in BC6OTHER expression 24 h after BC6OTHER injection and the effects of a BC6ENTG antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6ENTC receptor antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed.	False
The changes in BC6ENTG expression 24 h after BC6OTHER injection and the effects of a BC6OTHER antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6OTHER receptor antagonist, BC6ENTC (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed.	False
The changes in BC6OTHER expression 24 h after BC6OTHER injection and the effects of a BC6ENTG antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6OTHER receptor antagonist, BC6ENTC (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed.	False
The changes in BC6OTHER expression 24 h after BC6OTHER injection and the effects of a BC6OTHER antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6ENTG antagonist, BC6ENTC (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed.	CPR:6
The changes in BC6ENTG expression 24 h after BC6OTHER injection and the effects of a BC6OTHER antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6OTHER receptor antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6ENTC (9 mg / kg) were observed.	False
The changes in BC6OTHER expression 24 h after BC6OTHER injection and the effects of a BC6ENTG antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6OTHER receptor antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6ENTC (9 mg / kg) were observed.	False
The changes in BC6OTHER expression 24 h after BC6OTHER injection and the effects of a BC6OTHER antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6ENTG antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6ENTC (9 mg / kg) were observed.	False
BC6ENTC treatment for 4weeks led to marked liver fibrosis as assessed by serum biochemistry, histopathological examination, and hepatic lipid peroxidation and BC6ENTG content.	False
CK significantly inhibited BC6ENTC - induced increases in serum BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, fibrosis score, and hepatic BC6OTHER and BC6OTHER content.	CPR:3
CK significantly inhibited BC6ENTC - induced increases in serum BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, fibrosis score, and hepatic BC6OTHER and BC6OTHER content.	CPR:3
CK significantly inhibited BC6ENTC - induced increases in serum BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, fibrosis score, and hepatic BC6OTHER and BC6OTHER content.	CPR:3
CK significantly inhibited BC6ENTC - induced increases in serum BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, fibrosis score, and hepatic BC6OTHER and BC6OTHER content.	CPR:3
CK significantly inhibited BC6ENTC - induced increases in serum BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, fibrosis score, and hepatic BC6OTHER and BC6ENTG content.	CPR:3
CK significantly inhibited BC6OTHER - induced increases in serum BC6ENTC aminotransferase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, fibrosis score, and hepatic BC6OTHER and BC6OTHER content.	False
CK significantly inhibited BC6OTHER - induced increases in serum BC6ENTC aminotransferase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, fibrosis score, and hepatic BC6OTHER and BC6OTHER content.	False
CK significantly inhibited BC6OTHER - induced increases in serum BC6ENTC aminotransferase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, fibrosis score, and hepatic BC6OTHER and BC6OTHER content.	False
CK significantly inhibited BC6OTHER - induced increases in serum BC6ENTC aminotransferase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, fibrosis score, and hepatic BC6OTHER and BC6ENTG content.	False
CK significantly inhibited BC6OTHER - induced increases in serum BC6ENTG ( BC6OTHER ) and BC6ENTC aminotransferase ( BC6OTHER ) activities, fibrosis score, and hepatic BC6OTHER and BC6OTHER content.	False
CK significantly inhibited BC6OTHER - induced increases in serum BC6OTHER ( BC6ENTG ) and BC6ENTC aminotransferase ( BC6OTHER ) activities, fibrosis score, and hepatic BC6OTHER and BC6OTHER content.	False
CK significantly inhibited BC6OTHER - induced increases in serum BC6OTHER ( BC6OTHER ) and BC6ENTC aminotransferase ( BC6ENTG ) activities, fibrosis score, and hepatic BC6OTHER and BC6OTHER content.	False
CK significantly inhibited BC6OTHER - induced increases in serum BC6OTHER ( BC6OTHER ) and BC6ENTC aminotransferase ( BC6OTHER ) activities, fibrosis score, and hepatic BC6OTHER and BC6ENTG content.	False
CK significantly inhibited BC6OTHER - induced increases in serum BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, fibrosis score, and hepatic BC6ENTC and BC6OTHER content.	False
CK significantly inhibited BC6OTHER - induced increases in serum BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, fibrosis score, and hepatic BC6ENTC and BC6OTHER content.	False
CK significantly inhibited BC6OTHER - induced increases in serum BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, fibrosis score, and hepatic BC6ENTC and BC6OTHER content.	False
CK significantly inhibited BC6OTHER - induced increases in serum BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, fibrosis score, and hepatic BC6ENTC and BC6OTHER content.	False
CK significantly inhibited BC6OTHER - induced increases in serum BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, fibrosis score, and hepatic BC6ENTC and BC6ENTG content.	False
Reverse transcription polymerase chain reaction (RT - PCR) and western blot analyses revealed that CK inhibited BC6ENTC - induced increases in BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) mRNA, and BC6OTHER and BC6OTHER protein.	CPR:3
Reverse transcription polymerase chain reaction (RT - PCR) and western blot analyses revealed that CK inhibited BC6ENTC - induced increases in BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) mRNA, and BC6OTHER and BC6OTHER protein.	CPR:3
Reverse transcription polymerase chain reaction (RT - PCR) and western blot analyses revealed that CK inhibited BC6ENTC - induced increases in BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) mRNA, and BC6OTHER and BC6OTHER protein.	CPR:3
Reverse transcription polymerase chain reaction (RT - PCR) and western blot analyses revealed that CK inhibited BC6ENTC - induced increases in BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), and BC6OTHER ( BC6OTHER ) mRNA, and BC6OTHER and BC6OTHER protein.	CPR:3
Reverse transcription polymerase chain reaction (RT - PCR) and western blot analyses revealed that CK inhibited BC6ENTC - induced increases in BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) mRNA, and BC6OTHER and BC6OTHER protein.	CPR:3
Reverse transcription polymerase chain reaction (RT - PCR) and western blot analyses revealed that CK inhibited BC6ENTC - induced increases in BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG ) mRNA, and BC6OTHER and BC6OTHER protein.	CPR:3
Reverse transcription polymerase chain reaction (RT - PCR) and western blot analyses revealed that CK inhibited BC6ENTC - induced increases in BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) mRNA, and BC6ENTG and BC6OTHER protein.	CPR:3
Reverse transcription polymerase chain reaction (RT - PCR) and western blot analyses revealed that CK inhibited BC6ENTC - induced increases in BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) mRNA, and BC6OTHER and BC6ENTG protein.	CPR:3
BC6ENTC - induced BC6OTHER ( BC6OTHER ) expression and BC6ENTG ( BC6OTHER ) activation was reduced by CK treatment.	CPR:3
BC6ENTC - induced BC6OTHER ( BC6OTHER ) expression and BC6OTHER ( BC6ENTG ) activation was reduced by CK treatment.	CPR:3
BC6ENTC - induced BC6ENTG ( BC6OTHER ) expression and BC6OTHER ( BC6OTHER ) activation was reduced by CK treatment.	CPR:3
BC6ENTC - induced BC6OTHER ( BC6ENTG ) expression and BC6OTHER ( BC6OTHER ) activation was reduced by CK treatment.	CPR:3
Platycodi Radix attenuates BC6ENTC - induced liver fibrosis in rats by inducing BC6ENTG - mediated antioxidant enzymes.	False
Furthermore, CK induced activation of BC6ENTG ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTC synthetase ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6ENTG ) - mediated antioxidant enzymes such as BC6ENTC synthetase ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTC synthetase ( BC6ENTG ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTC synthetase ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTC synthetase ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6ENTG ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTC synthetase ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTC synthetase ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6ENTG ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTC synthetase ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTC synthetase ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6ENTG ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6ENTG ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTC oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6ENTG ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTC oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTG ( BC6OTHER ), BC6ENTC oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6ENTG ), BC6ENTC oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTC oxygenase - 1 ( BC6ENTG ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTC oxygenase - 1 ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTC oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6ENTG ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTC oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTC oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6ENTG ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6ENTG ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6ENTC BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6ENTG ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6ENTC BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTG ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6ENTC BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6ENTG ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6ENTC BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6ENTC BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6ENTG ), BC6ENTC BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6ENTC BC6OTHER oxidoreductase 1 ( BC6ENTG ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6ENTC BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6ENTC BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6ENTG ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6ENTG ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6ENTC oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6ENTG ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6ENTC oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTG ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6ENTC oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6ENTG ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6ENTC oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER BC6ENTC oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6ENTG ), BC6OTHER BC6ENTC oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6ENTC oxidoreductase 1 ( BC6ENTG ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6ENTC oxidoreductase 1 ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6ENTC oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6ENTG ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6ENTG ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6ENTG ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTG ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6ENTG ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6ENTG ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6ENTG ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6ENTG ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6ENTG ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6ENTC - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6ENTG ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6ENTC - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTG ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6ENTC - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6ENTG ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6ENTC - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6ENTC - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6ENTG ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6ENTC - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER - BC6ENTC - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6ENTG ), and BC6OTHER - BC6ENTC - transferase ( BC6OTHER ) in HepG2 cells.	False
Furthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6ENTC - transferase ( BC6ENTG ) in HepG2 cells.	False
These results demonstrated that CK attenuates BC6ENTC - induced liver fibrosis through the activation of BC6ENTG - mediated antioxidant enzymes.	False
METHODS: The effect of BC6OTHER and the BC6ENTC receptor antagonist, BC6OTHER ( BC6OTHER ) on the regulation of BC6ENTG gene expression and BC6OTHER secretion were observed in human airway NCI - H292 epithelial cells.	False
METHODS: The effect of BC6OTHER and the BC6ENTC receptor antagonist, BC6OTHER ( BC6OTHER ) on the regulation of BC6OTHER gene expression and BC6ENTG secretion were observed in human airway NCI - H292 epithelial cells.	False
METHODS: The effect of BC6OTHER and the BC6ENTG antagonist, BC6ENTC ( BC6OTHER ) on the regulation of BC6OTHER gene expression and BC6OTHER secretion were observed in human airway NCI - H292 epithelial cells.	CPR:6
METHODS: The effect of BC6OTHER and the BC6OTHER antagonist, BC6ENTC ( BC6OTHER ) on the regulation of BC6ENTG gene expression and BC6OTHER secretion were observed in human airway NCI - H292 epithelial cells.	False
METHODS: The effect of BC6OTHER and the BC6OTHER antagonist, BC6ENTC ( BC6OTHER ) on the regulation of BC6OTHER gene expression and BC6ENTG secretion were observed in human airway NCI - H292 epithelial cells.	False
METHODS: The effect of BC6OTHER and the BC6ENTG antagonist, BC6OTHER ( BC6ENTC ) on the regulation of BC6OTHER gene expression and BC6OTHER secretion were observed in human airway NCI - H292 epithelial cells.	CPR:6
METHODS: The effect of BC6OTHER and the BC6OTHER antagonist, BC6OTHER ( BC6ENTC ) on the regulation of BC6ENTG gene expression and BC6OTHER secretion were observed in human airway NCI - H292 epithelial cells.	False
METHODS: The effect of BC6OTHER and the BC6OTHER antagonist, BC6OTHER ( BC6ENTC ) on the regulation of BC6OTHER gene expression and BC6ENTG secretion were observed in human airway NCI - H292 epithelial cells.	False
RESULTS: BC6ENTC upregulated BC6ENTG gene expression and BC6OTHER secretion in a dose dependent pattern.	CPR:3
RESULTS: BC6ENTC upregulated BC6OTHER gene expression and BC6ENTG secretion in a dose dependent pattern.	CPR:3
The inhibitory effect of the BC6ENTC receptor antagonist on BC6OTHER - induced BC6OTHER gene expression and BC6ENTG secretion in human airway epithelial cells.	False
The inhibitory effect of the BC6ENTC receptor antagonist on BC6OTHER - induced BC6ENTG gene expression and BC6OTHER secretion in human airway epithelial cells.	False
The inhibitory effect of the BC6OTHER antagonist on BC6ENTC - induced BC6OTHER gene expression and BC6ENTG secretion in human airway epithelial cells.	CPR:3
The inhibitory effect of the BC6ENTG antagonist on BC6ENTC - induced BC6OTHER gene expression and BC6OTHER secretion in human airway epithelial cells.	False
The inhibitory effect of the BC6OTHER antagonist on BC6ENTC - induced BC6ENTG gene expression and BC6OTHER secretion in human airway epithelial cells.	CPR:3
BC6ENTC ( BC6OTHER , 100 microM) downregulated the BC6OTHER - induced BC6ENTG gene expression and BC6OTHER secretion.	CPR:4
BC6ENTC ( BC6OTHER , 100 microM) downregulated the BC6OTHER - induced BC6OTHER gene expression and BC6ENTG secretion.	CPR:4
BC6OTHER ( BC6ENTC , 100 microM) downregulated the BC6OTHER - induced BC6ENTG gene expression and BC6OTHER secretion.	CPR:4
BC6OTHER ( BC6ENTC , 100 microM) downregulated the BC6OTHER - induced BC6OTHER gene expression and BC6ENTG secretion.	CPR:4
BC6OTHER ( BC6OTHER , 100 microM) downregulated the BC6ENTC - induced BC6ENTG gene expression and BC6OTHER secretion.	CPR:3
BC6OTHER ( BC6OTHER , 100 microM) downregulated the BC6ENTC - induced BC6OTHER gene expression and BC6ENTG secretion.	CPR:3
CONCLUSION: These results suggest that the BC6ENTC receptor system is one of the mechanisms related to BC6ENTG gene expression and BC6OTHER secretion in the human airway epithelium.	False
CONCLUSION: These results suggest that the BC6ENTC receptor system is one of the mechanisms related to BC6OTHER gene expression and BC6ENTG secretion in the human airway epithelium.	False
BC6ENTG , lipopolysaccharides and other inflammatory mediators such as BC6ENTC and BC6OTHER are related to the secretion and production of BC6OTHER .	False
BC6OTHER , lipopolysaccharides and other inflammatory mediators such as BC6ENTC and BC6OTHER are related to the secretion and production of BC6ENTG .	False
BC6ENTG , lipopolysaccharides and other inflammatory mediators such as BC6OTHER and BC6ENTC are related to the secretion and production of BC6OTHER .	False
BC6OTHER , lipopolysaccharides and other inflammatory mediators such as BC6OTHER and BC6ENTC are related to the secretion and production of BC6ENTG .	False
However, the relationship of BC6ENTC with BC6ENTG genes expression is not clear.	False
The aim of this study is to evaluate BC6ENTG gene expression and BC6OTHER secretion by the BC6ENTC receptor in human airway epithelial cells.	False
The aim of this study is to evaluate BC6OTHER gene expression and BC6ENTG secretion by the BC6ENTC receptor in human airway epithelial cells.	False
METHODS: The effect of BC6ENTC and the BC6ENTG antagonist, BC6OTHER ( BC6OTHER ) on the regulation of BC6OTHER gene expression and BC6OTHER secretion were observed in human airway NCI - H292 epithelial cells.	False
METHODS: The effect of BC6ENTC and the BC6OTHER antagonist, BC6OTHER ( BC6OTHER ) on the regulation of BC6ENTG gene expression and BC6OTHER secretion were observed in human airway NCI - H292 epithelial cells.	False
METHODS: The effect of BC6ENTC and the BC6OTHER antagonist, BC6OTHER ( BC6OTHER ) on the regulation of BC6OTHER gene expression and BC6ENTG secretion were observed in human airway NCI - H292 epithelial cells.	False
The pleiotropic effects of BC6ENTC are exerted mainly by one active metabolite, BC6OTHER ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6ENTG ( BC6OTHER , BC6OTHER and BC6OTHER ), polymorphic BC6OTHER (RA) response elements and multiple coregulators.	False
The pleiotropic effects of BC6ENTC are exerted mainly by one active metabolite, BC6OTHER ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6ENTG , BC6OTHER and BC6OTHER ), polymorphic BC6OTHER (RA) response elements and multiple coregulators.	False
The pleiotropic effects of BC6ENTC are exerted mainly by one active metabolite, BC6OTHER ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6ENTG and BC6OTHER ), polymorphic BC6OTHER (RA) response elements and multiple coregulators.	False
The pleiotropic effects of BC6ENTC are exerted mainly by one active metabolite, BC6OTHER ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6OTHER and BC6ENTG ), polymorphic BC6OTHER (RA) response elements and multiple coregulators.	False
The pleiotropic effects of BC6ENTC are exerted mainly by one active metabolite, BC6OTHER ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6OTHER and BC6OTHER ), BC6ENTG and multiple coregulators.	False
The pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6ENTC ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6ENTG ( BC6OTHER , BC6OTHER and BC6OTHER ), polymorphic BC6OTHER (RA) response elements and multiple coregulators.	CPR:3
The pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6ENTC ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6ENTG , BC6OTHER and BC6OTHER ), polymorphic BC6OTHER (RA) response elements and multiple coregulators.	CPR:3
The pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6ENTC ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6ENTG and BC6OTHER ), polymorphic BC6OTHER (RA) response elements and multiple coregulators.	CPR:3
The pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6ENTC ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6OTHER and BC6ENTG ), polymorphic BC6OTHER (RA) response elements and multiple coregulators.	False
The pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6ENTC ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6OTHER and BC6OTHER ), BC6ENTG and multiple coregulators.	CPR:3
The pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6OTHER ( BC6ENTC ), which regulates the expression of a battery of target genes through several families of BC6ENTG ( BC6OTHER , BC6OTHER and BC6OTHER ), polymorphic BC6OTHER (RA) response elements and multiple coregulators.	CPR:3
The pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6OTHER ( BC6ENTC ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6ENTG , BC6OTHER and BC6OTHER ), polymorphic BC6OTHER (RA) response elements and multiple coregulators.	CPR:3
The pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6OTHER ( BC6ENTC ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6ENTG and BC6OTHER ), polymorphic BC6OTHER (RA) response elements and multiple coregulators.	CPR:3
The pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6OTHER ( BC6ENTC ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6OTHER and BC6ENTG ), polymorphic BC6OTHER (RA) response elements and multiple coregulators.	False
The pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6OTHER ( BC6ENTC ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6OTHER and BC6OTHER ), BC6ENTG and multiple coregulators.	CPR:3
The pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6OTHER ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6ENTG ( BC6OTHER , BC6OTHER and BC6OTHER ), polymorphic BC6ENTC (RA) response elements and multiple coregulators.	False
The pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6OTHER ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6ENTG , BC6OTHER and BC6OTHER ), polymorphic BC6ENTC (RA) response elements and multiple coregulators.	False
The pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6OTHER ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6ENTG and BC6OTHER ), polymorphic BC6ENTC (RA) response elements and multiple coregulators.	False
The pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6OTHER ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6OTHER and BC6ENTG ), polymorphic BC6ENTC (RA) response elements and multiple coregulators.	False
However, BC6ENTC itself proved recently to be active and BC6ENTG to be present in the cytosol to regulate translation and cell plasticity.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTG , were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the BC6ENTG , the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTG , the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
BC6ENTC , a putative BC6ENTG agonist, and BC6OTHER , a putative BC6OTHER / BC6OTHER agonist, also bound to this receptor with Ki values of 120 nM.	CPR:5
BC6ENTC , a putative BC6OTHER agonist, and BC6OTHER , a putative BC6ENTG / BC6OTHER agonist, also bound to this receptor with Ki values of 120 nM.	False
BC6ENTC , a putative BC6OTHER agonist, and BC6OTHER , a putative BC6OTHER / BC6ENTG agonist, also bound to this receptor with Ki values of 120 nM.	False
BC6OTHER , a putative BC6ENTG agonist, and BC6ENTC , a putative BC6OTHER / BC6OTHER agonist, also bound to this receptor with Ki values of 120 nM.	False
BC6OTHER , a putative BC6OTHER agonist, and BC6ENTC , a putative BC6ENTG / BC6OTHER agonist, also bound to this receptor with Ki values of 120 nM.	CPR:5
BC6OTHER , a putative BC6OTHER agonist, and BC6ENTC , a putative BC6OTHER / BC6ENTG agonist, also bound to this receptor with Ki values of 120 nM.	CPR:5
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTG , were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the BC6ENTG , the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTG , the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the BC6ENTG and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTG , were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the BC6ENTG , the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the BC6ENTG and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
The two receptors were discriminated by BC6ENTC , BC6OTHER and BC6OTHER that bound to the BC6ENTG receptor but not to the BC6OTHER receptor, and by BC6OTHER that bound to the BC6OTHER but not to the BC6OTHER receptor.	False
The two receptors were discriminated by BC6ENTC , BC6OTHER and BC6OTHER that bound to the BC6OTHER receptor but not to the BC6ENTG receptor, and by BC6OTHER that bound to the BC6OTHER but not to the BC6OTHER receptor.	False
The two receptors were discriminated by BC6ENTC , BC6OTHER and BC6OTHER that bound to the BC6OTHER receptor but not to the BC6OTHER receptor, and by BC6OTHER that bound to the BC6ENTG but not to the BC6OTHER receptor.	False
The two receptors were discriminated by BC6ENTC , BC6OTHER and BC6OTHER that bound to the BC6OTHER receptor but not to the BC6OTHER receptor, and by BC6OTHER that bound to the BC6OTHER but not to the BC6ENTG receptor.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTG , were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the BC6ENTG , the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTG , the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
The two receptors were discriminated by BC6OTHER , BC6ENTC and BC6OTHER that bound to the BC6ENTG receptor but not to the BC6OTHER receptor, and by BC6OTHER that bound to the BC6OTHER but not to the BC6OTHER receptor.	False
The two receptors were discriminated by BC6OTHER , BC6ENTC and BC6OTHER that bound to the BC6OTHER receptor but not to the BC6ENTG receptor, and by BC6OTHER that bound to the BC6OTHER but not to the BC6OTHER receptor.	False
The two receptors were discriminated by BC6OTHER , BC6ENTC and BC6OTHER that bound to the BC6OTHER receptor but not to the BC6OTHER receptor, and by BC6OTHER that bound to the BC6ENTG but not to the BC6OTHER receptor.	False
The two receptors were discriminated by BC6OTHER , BC6ENTC and BC6OTHER that bound to the BC6OTHER receptor but not to the BC6OTHER receptor, and by BC6OTHER that bound to the BC6OTHER but not to the BC6ENTG receptor.	False
The two receptors were discriminated by BC6OTHER , BC6OTHER and BC6ENTC that bound to the BC6ENTG receptor but not to the BC6OTHER receptor, and by BC6OTHER that bound to the BC6OTHER but not to the BC6OTHER receptor.	False
The two receptors were discriminated by BC6OTHER , BC6OTHER and BC6ENTC that bound to the BC6OTHER receptor but not to the BC6ENTG receptor, and by BC6OTHER that bound to the BC6OTHER but not to the BC6OTHER receptor.	False
The two receptors were discriminated by BC6OTHER , BC6OTHER and BC6ENTC that bound to the BC6OTHER receptor but not to the BC6OTHER receptor, and by BC6OTHER that bound to the BC6ENTG but not to the BC6OTHER receptor.	False
The two receptors were discriminated by BC6OTHER , BC6OTHER and BC6ENTC that bound to the BC6OTHER receptor but not to the BC6OTHER receptor, and by BC6OTHER that bound to the BC6OTHER but not to the BC6ENTG receptor.	False
The two receptors were discriminated by BC6OTHER , BC6OTHER and BC6OTHER that bound to the BC6ENTG receptor but not to the BC6OTHER receptor, and by BC6ENTC that bound to the BC6OTHER but not to the BC6OTHER receptor.	False
The two receptors were discriminated by BC6OTHER , BC6OTHER and BC6OTHER that bound to the BC6OTHER receptor but not to the BC6ENTG receptor, and by BC6ENTC that bound to the BC6OTHER but not to the BC6OTHER receptor.	False
The two receptors were discriminated by BC6OTHER , BC6OTHER and BC6OTHER that bound to the BC6OTHER receptor but not to the BC6OTHER receptor, and by BC6ENTC that bound to the BC6ENTG but not to the BC6OTHER receptor.	False
The two receptors were discriminated by BC6OTHER , BC6OTHER and BC6OTHER that bound to the BC6OTHER receptor but not to the BC6OTHER receptor, and by BC6ENTC that bound to the BC6OTHER but not to the BC6ENTG receptor.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTG , were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the BC6ENTG , the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG , the BC6ENTC ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor and the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor and the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
The BC6ENTG receptor showed the broadest binding profile, and bound BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , in addition to BC6OTHER and BC6OTHER , with Ki values of 0.6 - 3.7 nM.	False
The BC6ENTG receptor showed the broadest binding profile, and bound BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , in addition to BC6OTHER and BC6OTHER , with Ki values of 0.6 - 3.7 nM.	False
The BC6ENTG receptor showed the broadest binding profile, and bound BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , in addition to BC6OTHER and BC6OTHER , with Ki values of 0.6 - 3.7 nM.	False
The BC6ENTG receptor showed the broadest binding profile, and bound BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , in addition to BC6OTHER and BC6OTHER , with Ki values of 0.6 - 3.7 nM.	False
The BC6ENTG receptor showed the broadest binding profile, and bound BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , in addition to BC6OTHER and BC6OTHER , with Ki values of 0.6 - 3.7 nM.	False
The BC6ENTG receptor showed the broadest binding profile, and bound BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC , in addition to BC6OTHER and BC6OTHER , with Ki values of 0.6 - 3.7 nM.	False
The BC6ENTG receptor bound BC6ENTC , BC6OTHER and BC6OTHER in addition to BC6OTHER and BC6OTHER , with Ki values of 14 - 36 nM.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTG , were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the BC6ENTG , the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6ENTC ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor and the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor and the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor and the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
The BC6ENTG receptor showed the broadest binding profile, and bound BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , in addition to BC6ENTC and BC6OTHER , with Ki values of 0.6 - 3.7 nM.	False
The BC6ENTG receptor showed the broadest binding profile, and bound BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , in addition to BC6OTHER and BC6ENTC , with Ki values of 0.6 - 3.7 nM.	False
In addition, three BC6ENTC ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6ENTG ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6OTHER , respectively.	False
In addition, three BC6ENTC ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6ENTG and BC6OTHER , respectively.	False
In addition, three BC6ENTC ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6ENTG , respectively.	False
In addition, three BC6ENTG ligands, BC6ENTC , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6OTHER , respectively.	False
In addition, three BC6OTHER ligands, BC6ENTC , BC6OTHER and BC6OTHER , and one BC6ENTG ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6OTHER , respectively.	False
In addition, three BC6OTHER ligands, BC6ENTC , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6ENTG and BC6OTHER , respectively.	False
In addition, three BC6OTHER ligands, BC6ENTC , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6ENTG , respectively.	False
In addition, three BC6ENTG ligands, BC6OTHER , BC6ENTC and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6OTHER , respectively.	False
In addition, three BC6OTHER ligands, BC6OTHER , BC6ENTC and BC6OTHER , and one BC6ENTG ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6OTHER , respectively.	False
In addition, three BC6OTHER ligands, BC6OTHER , BC6ENTC and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6ENTG and BC6OTHER , respectively.	False
In addition, three BC6OTHER ligands, BC6OTHER , BC6ENTC and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6ENTG , respectively.	False
In addition, three BC6ENTG ligands, BC6OTHER , BC6OTHER and BC6ENTC , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6OTHER , respectively.	False
In addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6ENTC , and one BC6ENTG ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6OTHER , respectively.	False
In addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6ENTC , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6ENTG and BC6OTHER , respectively.	False
In addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6ENTC , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6ENTG , respectively.	False
In addition, three BC6ENTG ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6ENTC ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6OTHER , respectively.	False
In addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6ENTC ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6ENTG and BC6OTHER , respectively.	False
In addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6ENTC ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6ENTG , respectively.	False
In addition, three BC6ENTG ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6ENTC , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6OTHER , respectively.	False
In addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6ENTG ligand, BC6ENTC , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6OTHER , respectively.	False
In addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6ENTC , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6ENTG and BC6OTHER , respectively.	False
In addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6ENTC , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6ENTG , respectively.	False
In addition, three BC6ENTG ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6ENTC and BC6OTHER , respectively.	False
In addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6ENTG ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6ENTC and BC6OTHER , respectively.	False
In addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6ENTC and BC6ENTG , respectively.	False
The BC6ENTG receptor bound BC6OTHER , BC6ENTC and BC6OTHER in addition to BC6OTHER and BC6OTHER , with Ki values of 14 - 36 nM.	False
In addition, three BC6ENTG ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6ENTC receptors, respectively.	False
In addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6ENTG ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6ENTC receptors, respectively.	False
In addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6ENTG and BC6ENTC receptors, respectively.	False
BC6ENTC alpha showed only weak binding to the BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG receptor at 10 microM concentration.	False
BC6ENTC alpha showed only weak binding to the BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER receptor at 10 microM concentration.	False
BC6ENTC alpha showed only weak binding to the BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER receptor at 10 microM concentration.	False
BC6ENTC alpha showed only weak binding to the BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER receptor at 10 microM concentration.	False
BC6ENTC alpha showed only weak binding to the BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER receptor at 10 microM concentration.	False
BC6OTHER alpha showed only weak binding to the BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG receptor at 10 microM concentration.	False
BC6OTHER alpha showed only weak binding to the BC6ENTC , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER receptor at 10 microM concentration.	False
BC6OTHER alpha showed only weak binding to the BC6ENTC , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER receptor at 10 microM concentration.	False
BC6OTHER alpha showed only weak binding to the BC6ENTC , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER receptor at 10 microM concentration.	False
BC6OTHER alpha showed only weak binding to the BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6ENTG receptor at 10 microM concentration.	False
BC6OTHER alpha showed only weak binding to the BC6ENTG , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER receptor at 10 microM concentration.	False
BC6OTHER alpha showed only weak binding to the BC6OTHER , BC6ENTC , BC6ENTG , BC6OTHER and BC6OTHER receptor at 10 microM concentration.	False
BC6OTHER alpha showed only weak binding to the BC6OTHER , BC6ENTC , BC6OTHER , BC6ENTG and BC6OTHER receptor at 10 microM concentration.	False
BC6OTHER alpha showed only weak binding to the BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6ENTG receptor at 10 microM concentration.	False
BC6OTHER alpha showed only weak binding to the BC6ENTG , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER receptor at 10 microM concentration.	False
BC6OTHER alpha showed only weak binding to the BC6OTHER , BC6ENTG , BC6ENTC , BC6OTHER and BC6OTHER receptor at 10 microM concentration.	False
BC6OTHER alpha showed only weak binding to the BC6OTHER , BC6OTHER , BC6ENTC , BC6ENTG and BC6OTHER receptor at 10 microM concentration.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG subtypes of the BC6ENTC receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the BC6ENTG , the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTC receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTC receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTC receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTC receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTC receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTC receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER subtypes of the BC6ENTC receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER subtypes of the BC6ENTC receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6ENTC receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6ENTC receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTG , were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6ENTC receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6ENTC receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6ENTC receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6ENTC receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6ENTC receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6ENTC receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6ENTC receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
The BC6ENTC , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6ENTC , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6ENTC , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6ENTC , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6ENTC , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG .	False
The BC6ENTG , BC6ENTC and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6ENTC and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6ENTC and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6ENTC and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6ENTC and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG .	False
The BC6ENTG receptor bound BC6OTHER , BC6OTHER and BC6ENTC in addition to BC6OTHER and BC6OTHER , with Ki values of 14 - 36 nM.	False
The BC6ENTG , BC6OTHER and BC6ENTC receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6ENTG and BC6ENTC receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6ENTC receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6ENTC receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6ENTC receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG .	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTG , were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the BC6ENTG , the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTC ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
The BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6ENTC , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG .	False
The BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6ENTC and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG .	False
The BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6ENTC for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG .	False
The BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG .	False
The BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG .	False
The BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG .	False
The BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG .	False
The BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG .	False
The BC6ENTG receptor bound BC6OTHER , BC6OTHER and BC6OTHER in addition to BC6ENTC and BC6OTHER , with Ki values of 14 - 36 nM.	False
The BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6ENTC , BC6OTHER and BC6OTHER for BC6ENTG .	False
The BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6ENTC and BC6OTHER for BC6ENTG .	False
The BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER .	False
The BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6ENTC for BC6ENTG .	False
The BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC .	False
The BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC .	False
The BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC .	False
The BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC .	False
The BC6ENTG bound BC6ENTC alpha and BC6OTHER with Ki values of 3 - 4 nM.	False
The BC6ENTG bound BC6OTHER alpha and BC6ENTC with Ki values of 3 - 4 nM.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTG , were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the BC6ENTG , the BC6OTHER ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6ENTC ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
Eight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells.	False
The BC6ENTG receptor bound BC6OTHER , BC6OTHER and BC6OTHER in addition to BC6OTHER and BC6ENTC , with Ki values of 14 - 36 nM.	False
BC6ENTC and two putative BC6ENTG antagonists, BC6OTHER and BC6OTHER , did not show any significant binding to this receptor.	False
BC6OTHER and two putative BC6ENTG antagonists, BC6ENTC and BC6OTHER , did not show any significant binding to this receptor.	CPR:6
BC6OTHER and two putative BC6ENTG antagonists, BC6OTHER and BC6ENTC , did not show any significant binding to this receptor.	CPR:6
These data indicate that a BC6ENTC binding assay using BC6ENTG membranes may help identify compounds that prolong the QT interval.	False
 BC6ENTC binding to BC6ENTG transfected membranes: a potential high throughput preclinical screen.	False
The pharmacological characteristics of BC6OTHER binding were examined in membranes prepared from human embryonic kidney (HEK293) cells stably expressing BC6ENTG BC6ENTC channels.	False
The pharmacological characteristics of BC6ENTC binding were examined in membranes prepared from human embryonic kidney (HEK293) cells stably expressing BC6ENTG BC6OTHER channels.	False
Exploring the effect of BC6OTHER - substitution in BC6ENTC on the interaction with BC6ENTG : discovery of a potential clinical candidate for treatment of BC6OTHER abuse.	False
A series of BC6ENTC - substituted BC6OTHER analogues was synthesized and evaluated for their BC6OTHER binding affinity at the BC6ENTG and for their inhibition of vesicular BC6OTHER uptake.	False
A series of BC6OTHER - substituted BC6OTHER analogues was synthesized and evaluated for their BC6OTHER binding affinity at the BC6ENTG and for their inhibition of vesicular BC6ENTC uptake.	CPR:9
A series of BC6OTHER - substituted BC6ENTC analogues was synthesized and evaluated for their BC6OTHER binding affinity at the BC6ENTG and for their inhibition of vesicular BC6OTHER uptake.	False
A series of BC6OTHER - substituted BC6OTHER analogues was synthesized and evaluated for their BC6ENTC binding affinity at the BC6ENTG and for their inhibition of vesicular BC6OTHER uptake.	False
Exploring the effect of BC6OTHER - substitution in BC6OTHER on the interaction with BC6ENTG : discovery of a potential clinical candidate for treatment of BC6ENTC abuse.	False
Exploring the effect of BC6ENTC - substitution in BC6OTHER on the interaction with BC6ENTG : discovery of a potential clinical candidate for treatment of BC6OTHER abuse.	False
The tocolytic agent BC6ENTC acts on the BC6ENTG and is an effective treatment option for preterm labor.	False
Importantly, expression of the acute - phase reactant BC6ENTG ( BC6OTHER ) significantly increased after BC6ENTC injection, with values indicating the largest fold - change.	CPR:3
Importantly, expression of the acute - phase reactant BC6OTHER ( BC6ENTG ) significantly increased after BC6ENTC injection, with values indicating the largest fold - change.	CPR:3
This large increase in blood BC6OTHER levels serves as a more sensitive biomarker than conventional liver enzymes, such as BC6ENTC aminotransferase and BC6ENTG .	False
This large increase in blood BC6ENTG levels serves as a more sensitive biomarker than conventional liver enzymes, such as BC6ENTC aminotransferase and BC6OTHER aminotransferase.	False
 BC6ENTG upsurge precedes standard biomarkers of hepatotoxicity in BC6ENTC - injected mice.	CPR:3
This large increase in blood BC6OTHER levels serves as a more sensitive biomarker than conventional liver enzymes, such as BC6ENTG and BC6ENTC aminotransferase.	False
This large increase in blood BC6ENTG levels serves as a more sensitive biomarker than conventional liver enzymes, such as BC6OTHER and BC6ENTC aminotransferase.	False
The increase in BC6ENTG expression is specific to BC6ENTC - induced liver damage, because BC6OTHER expression was not induced by other hepatotoxic drugs such as BC6OTHER , BC6OTHER , or BC6OTHER .	CPR:3
The increase in BC6OTHER expression is specific to BC6ENTC - induced liver damage, because BC6ENTG expression was not induced by other hepatotoxic drugs such as BC6OTHER , BC6OTHER , or BC6OTHER .	False
The increase in BC6ENTG expression is specific to BC6OTHER - induced liver damage, because BC6OTHER expression was not induced by other hepatotoxic drugs such as BC6ENTC , BC6OTHER , or BC6OTHER .	False
The increase in BC6OTHER expression is specific to BC6OTHER - induced liver damage, because BC6ENTG expression was not induced by other hepatotoxic drugs such as BC6ENTC , BC6OTHER , or BC6OTHER .	False
The increase in BC6ENTG expression is specific to BC6OTHER - induced liver damage, because BC6OTHER expression was not induced by other hepatotoxic drugs such as BC6OTHER , BC6ENTC , or BC6OTHER .	False
The increase in BC6OTHER expression is specific to BC6OTHER - induced liver damage, because BC6ENTG expression was not induced by other hepatotoxic drugs such as BC6OTHER , BC6ENTC , or BC6OTHER .	False
The increase in BC6ENTG expression is specific to BC6OTHER - induced liver damage, because BC6OTHER expression was not induced by other hepatotoxic drugs such as BC6OTHER , BC6OTHER , or BC6ENTC .	False
The increase in BC6OTHER expression is specific to BC6OTHER - induced liver damage, because BC6ENTG expression was not induced by other hepatotoxic drugs such as BC6OTHER , BC6OTHER , or BC6ENTC .	False
Our in vitro studies showed that BC6ENTC ( BC6OTHER ) accumulation was not a primary cause of the BC6OTHER - induced BC6ENTG increase.	False
Our in vitro studies showed that BC6OTHER ( BC6ENTC ) accumulation was not a primary cause of the BC6OTHER - induced BC6ENTG increase.	False
Our in vitro studies showed that BC6OTHER ( BC6OTHER ) accumulation was not a primary cause of the BC6ENTC - induced BC6ENTG increase.	CPR:3
Postoperative concentrations of BC6ENTG were decreased significantly in the BC6ENTC group (P < 0.001).	CPR:4
The altered genes associated with BC6ENTC - induced cleft palate included BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER but the magnitude of the change was relatively small (1.5 - to 2 - fold).	False
The altered genes associated with BC6ENTC - induced cleft palate included BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER but the magnitude of the change was relatively small (1.5 - to 2 - fold).	False
The altered genes associated with BC6ENTC - induced cleft palate included BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER but the magnitude of the change was relatively small (1.5 - to 2 - fold).	False
The altered genes associated with BC6ENTC - induced cleft palate included BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER but the magnitude of the change was relatively small (1.5 - to 2 - fold).	False
The altered genes associated with BC6ENTC - induced cleft palate included BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER but the magnitude of the change was relatively small (1.5 - to 2 - fold).	False
The altered genes associated with BC6ENTC - induced cleft palate included BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG but the magnitude of the change was relatively small (1.5 - to 2 - fold).	False
The altered genes associated with BC6ENTC - induced cleft palate included BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER but the magnitude of the change was relatively small (1.5 - to 2 - fold).	False
BACKGROUND: The effects of BC6ENTG antagonist BC6ENTC on rat palate development were characterized following in utero exposure.	CPR:6
Effects of the BC6ENTG antagonist BC6ENTC on rat fetal palate development.	CPR:6
We found that this interaction is highly specific, requires the BC6ENTC - UBP domain of BC6ENTG , and is disrupted by the inactivating BC6OTHER mutation within BC6OTHER .	False
We found that this interaction is highly specific, requires the BC6ENTC - UBP domain of BC6OTHER , and is disrupted by the inactivating BC6ENTG mutation within BC6OTHER .	False
We found that this interaction is highly specific, requires the BC6ENTC - UBP domain of BC6OTHER , and is disrupted by the inactivating BC6OTHER mutation within BC6ENTG .	False
Moreover, we show that BC6ENTG is acetylated on multiple BC6ENTC residues and that alteration of a single BC6OTHER (K129) within the BC6OTHER - UBP domain is sufficient to alter interaction of the BC6OTHER with the core BC6OTHER complex.	False
Moreover, we show that BC6OTHER is acetylated on multiple BC6ENTC residues and that alteration of a single BC6OTHER (K129) within the BC6ENTG is sufficient to alter interaction of the BC6OTHER with the core BC6OTHER complex.	False
Moreover, we show that BC6OTHER is acetylated on multiple BC6ENTC residues and that alteration of a single BC6OTHER (K129) within the BC6OTHER - UBP domain is sufficient to alter interaction of the BC6ENTG with the core BC6OTHER complex.	False
Moreover, we show that BC6OTHER is acetylated on multiple BC6ENTC residues and that alteration of a single BC6OTHER (K129) within the BC6OTHER - UBP domain is sufficient to alter interaction of the BC6OTHER with the core BC6ENTG complex.	False
Moreover, we show that BC6ENTG is acetylated on multiple BC6OTHER residues and that alteration of a single BC6ENTC (K129) within the BC6OTHER - UBP domain is sufficient to alter interaction of the BC6OTHER with the core BC6OTHER complex.	False
Moreover, we show that BC6OTHER is acetylated on multiple BC6OTHER residues and that alteration of a single BC6ENTC (K129) within the BC6ENTG is sufficient to alter interaction of the BC6OTHER with the core BC6OTHER complex.	False
Moreover, we show that BC6OTHER is acetylated on multiple BC6OTHER residues and that alteration of a single BC6ENTC (K129) within the BC6OTHER - UBP domain is sufficient to alter interaction of the BC6ENTG with the core BC6OTHER complex.	False
Moreover, we show that BC6OTHER is acetylated on multiple BC6OTHER residues and that alteration of a single BC6ENTC (K129) within the BC6OTHER - UBP domain is sufficient to alter interaction of the BC6OTHER with the core BC6ENTG complex.	False
Moreover, we show that BC6ENTG is acetylated on multiple BC6OTHER residues and that alteration of a single BC6OTHER (K129) within the BC6ENTC - UBP domain is sufficient to alter interaction of the BC6OTHER with the core BC6OTHER complex.	False
Moreover, we show that BC6OTHER is acetylated on multiple BC6OTHER residues and that alteration of a single BC6OTHER (K129) within the BC6ENTC - UBP domain is sufficient to alter interaction of the BC6ENTG with the core BC6OTHER complex.	False
Moreover, we show that BC6OTHER is acetylated on multiple BC6OTHER residues and that alteration of a single BC6OTHER (K129) within the BC6ENTC - UBP domain is sufficient to alter interaction of the BC6OTHER with the core BC6ENTG complex.	False
These findings suggest that the mechanism of antiproliferative toxicity of BC6OTHER is at least partly due to BC6ENTG inhibitory activity of its active metabolite BC6OTHER ( BC6ENTC ).	CPR:4
Monitoring of plasma BC6ENTC concentrations have the potential to help clinicians to guide scheduling of BC6OTHER or other BC6ENTG inhibitors in clinical trials.	False
Monitoring of plasma BC6OTHER concentrations have the potential to help clinicians to guide scheduling of BC6ENTC or other BC6ENTG inhibitors in clinical trials.	False
Clinical studies in cancer patients treated with the new BC6ENTC analogue BC6OTHER ( BC6OTHER ) have shown that plasma BC6OTHER was significantly elevated after 1 week of treatment, consistent with inhibition of BC6ENTG ( BC6OTHER ).	CPR:4
Clinical studies in cancer patients treated with the new BC6ENTC analogue BC6OTHER ( BC6OTHER ) have shown that plasma BC6OTHER was significantly elevated after 1 week of treatment, consistent with inhibition of BC6OTHER synthase ( BC6ENTG ).	CPR:4
Clinical studies in cancer patients treated with the new BC6OTHER analogue BC6ENTC ( BC6OTHER ) have shown that plasma BC6OTHER was significantly elevated after 1 week of treatment, consistent with inhibition of BC6ENTG ( BC6OTHER ).	CPR:4
Clinical studies in cancer patients treated with the new BC6OTHER analogue BC6ENTC ( BC6OTHER ) have shown that plasma BC6OTHER was significantly elevated after 1 week of treatment, consistent with inhibition of BC6OTHER synthase ( BC6ENTG ).	CPR:4
Clinical studies in cancer patients treated with the new BC6OTHER analogue BC6OTHER ( BC6ENTC ) have shown that plasma BC6OTHER was significantly elevated after 1 week of treatment, consistent with inhibition of BC6ENTG ( BC6OTHER ).	CPR:4
Clinical studies in cancer patients treated with the new BC6OTHER analogue BC6OTHER ( BC6ENTC ) have shown that plasma BC6OTHER was significantly elevated after 1 week of treatment, consistent with inhibition of BC6OTHER synthase ( BC6ENTG ).	CPR:4
Clinical studies in cancer patients treated with the new BC6OTHER analogue BC6OTHER ( BC6OTHER ) have shown that plasma BC6ENTC was significantly elevated after 1 week of treatment, consistent with inhibition of BC6ENTG ( BC6OTHER ).	CPR:4
Clinical studies in cancer patients treated with the new BC6OTHER analogue BC6OTHER ( BC6OTHER ) have shown that plasma BC6ENTC was significantly elevated after 1 week of treatment, consistent with inhibition of BC6OTHER synthase ( BC6ENTG ).	CPR:4
Clinical studies in cancer patients treated with the new BC6OTHER analogue BC6OTHER ( BC6OTHER ) have shown that plasma BC6OTHER was significantly elevated after 1 week of treatment, consistent with inhibition of BC6ENTC synthase ( BC6ENTG ).	False
These findings suggest that the mechanism of antiproliferative toxicity of BC6ENTC is at least partly due to BC6ENTG inhibitory activity of its active metabolite BC6OTHER ( BC6OTHER ).	CPR:4
These findings suggest that the mechanism of antiproliferative toxicity of BC6OTHER is at least partly due to BC6ENTG inhibitory activity of its active metabolite BC6ENTC ( BC6OTHER ).	CPR:4
Using surface biotinylation, we observed that treatment of CHEM - 38 neurons with BC6OTHER or with a membrane impermeant BC6ENTC elevated plasma membrane BC6ENTG protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane.	CPR:3
Insertion of BC6ENTG was blocked by the BC6OTHER antagonist BC6ENTC or with the BC6OTHER ( BC6OTHER ) pathway inhibitor BC6OTHER ( BC6OTHER ).	CPR:4
Insertion of BC6OTHER was blocked by the BC6ENTG antagonist BC6ENTC or with the BC6OTHER ( BC6OTHER ) pathway inhibitor BC6OTHER ( BC6OTHER ).	CPR:6
Insertion of BC6OTHER was blocked by the BC6OTHER antagonist BC6ENTC or with the BC6ENTG ( BC6OTHER ) pathway inhibitor BC6OTHER ( BC6OTHER ).	False
Insertion of BC6OTHER was blocked by the BC6OTHER antagonist BC6ENTC or with the BC6OTHER ( BC6ENTG ) pathway inhibitor BC6OTHER ( BC6OTHER ).	False
Insertion of BC6ENTG was blocked by the BC6OTHER antagonist BC6OTHER or with the BC6OTHER ( BC6OTHER ) pathway inhibitor BC6ENTC ( BC6OTHER ).	CPR:4
Insertion of BC6OTHER was blocked by the BC6ENTG antagonist BC6OTHER or with the BC6OTHER ( BC6OTHER ) pathway inhibitor BC6ENTC ( BC6OTHER ).	False
Insertion of BC6OTHER was blocked by the BC6OTHER antagonist BC6OTHER or with the BC6ENTG ( BC6OTHER ) pathway inhibitor BC6ENTC ( BC6OTHER ).	CPR:4
Insertion of BC6OTHER was blocked by the BC6OTHER antagonist BC6OTHER or with the BC6OTHER ( BC6ENTG ) pathway inhibitor BC6ENTC ( BC6OTHER ).	CPR:4
Insertion of BC6ENTG was blocked by the BC6OTHER antagonist BC6OTHER or with the BC6OTHER ( BC6OTHER ) pathway inhibitor BC6OTHER ( BC6ENTC ).	CPR:4
Insertion of BC6OTHER was blocked by the BC6ENTG antagonist BC6OTHER or with the BC6OTHER ( BC6OTHER ) pathway inhibitor BC6OTHER ( BC6ENTC ).	False
Insertion of BC6OTHER was blocked by the BC6OTHER antagonist BC6OTHER or with the BC6ENTG ( BC6OTHER ) pathway inhibitor BC6OTHER ( BC6ENTC ).	CPR:4
Insertion of BC6OTHER was blocked by the BC6OTHER antagonist BC6OTHER or with the BC6OTHER ( BC6ENTG ) pathway inhibitor BC6OTHER ( BC6ENTC ).	CPR:4
Downstream membrane - initiated signaling was confirmed by BC6ENTC activation of BC6ENTG ( BC6OTHER ) and the release of intracellular CHEM.	False
Downstream membrane - initiated signaling was confirmed by BC6ENTC activation of BC6OTHER ( BC6ENTG ) and the release of intracellular CHEM.	False
These results indicate that membrane BC6ENTG levels in N - 38 neurons are dynamically autoregulated by BC6ENTC .	CPR:3
Regulation of sexual reproduction by BC6ENTC involves the activation of BC6ENTG ( BC6OTHER ) in the hypothalamus.	CPR:3
Regulation of sexual reproduction by BC6ENTC involves the activation of BC6OTHER receptors ( BC6ENTG ) in the hypothalamus.	CPR:3
Regulation of sexual reproduction by BC6OTHER involves the activation of BC6ENTC receptors ( BC6ENTG ) in the hypothalamus.	False
Using surface biotinylation, we observed that treatment of CHEM - 38 neurons with BC6ENTC or with a membrane impermeant BC6OTHER elevated plasma membrane BC6ENTG protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane.	CPR:3
BC6ENTC inhibited BC6OTHER activity stimulated by this specific heptapeptide but did not block BC6OTHER binding or induce BC6ENTG expression.	False
BC6ENTC inhibited BC6ENTG activity stimulated by this specific heptapeptide but did not block BC6OTHER binding or induce BC6OTHER expression.	CPR:4
 BC6ENTC and BC6OTHER bind to BC6ENTG ( BC6OTHER ) and inhibit its BC6OTHER activity in human fibroblasts.	False
 BC6ENTC and BC6OTHER bind to BC6OTHER ( BC6ENTG ) and inhibit its BC6OTHER activity in human fibroblasts.	False
 BC6ENTC and BC6OTHER bind to BC6OTHER ( BC6OTHER ) and inhibit its BC6ENTG activity in human fibroblasts.	CPR:4
 BC6OTHER and BC6ENTC bind to BC6ENTG ( BC6OTHER ) and inhibit its BC6OTHER activity in human fibroblasts.	False
 BC6OTHER and BC6ENTC bind to BC6OTHER ( BC6ENTG ) and inhibit its BC6OTHER activity in human fibroblasts.	False
 BC6OTHER and BC6ENTC bind to BC6OTHER ( BC6OTHER ) and inhibit its BC6ENTG activity in human fibroblasts.	CPR:4
BC6OTHER inhibited BC6OTHER activity stimulated by this specific heptapeptide but did not block BC6ENTC binding or induce BC6ENTG expression.	False
BC6OTHER inhibited BC6ENTG activity stimulated by this specific heptapeptide but did not block BC6ENTC binding or induce BC6OTHER expression.	False
These results indicate that BC6ENTC bind specifically to the polypeptide binding site of BC6ENTG in human cells that may interfere with folding and transport of proteins important in inflammation.	False
The Kd values of BC6ENTC binding to crude extract and to recombinant BC6ENTG were 45.2 and 54.6 microM, respectively.	False
BC6ENTG is a BC6OTHER containing a polypeptide binding site recognizing specific BC6OTHER and an BC6ENTC binding site.	False
BC6OTHER is a BC6ENTG containing a polypeptide binding site recognizing specific BC6OTHER and an BC6ENTC binding site.	False
BC6OTHER is a BC6OTHER containing a polypeptide binding site recognizing specific BC6ENTG and an BC6ENTC binding site.	False
Although BC6ENTC exerts local antioxidant activity with beneficial effects on lung tissue, this BC6ENTG inhibitor intensifies the blast overpressure caused hemodynamic insufficiency.	CPR:4
 One group of experimental animals was treated with BC6ENTG ( BC6OTHER ) inhibitor, BC6ENTC ( BC6OTHER , Sigma, St. Louis, Missouri) (50 mg / kg, i.v.), immediately before blast.	CPR:4
 One group of experimental animals was treated with BC6OTHER ( BC6ENTG ) inhibitor, BC6ENTC ( BC6OTHER , Sigma, St. Louis, Missouri) (50 mg / kg, i.v.), immediately before blast.	CPR:4
 One group of experimental animals was treated with BC6ENTG ( BC6OTHER ) inhibitor, BC6OTHER ( BC6ENTC , Sigma, St. Louis, Missouri) (50 mg / kg, i.v.), immediately before blast.	CPR:4
 One group of experimental animals was treated with BC6OTHER ( BC6ENTG ) inhibitor, BC6OTHER ( BC6ENTC , Sigma, St. Louis, Missouri) (50 mg / kg, i.v.), immediately before blast.	CPR:4
BC6ENTC is a reversible, competitive BC6OTHER ( BC6OTHER ) inhibitor and allosteric potentiating ligand of BC6ENTG ( BC6OTHER - APL) that shares many common structural elements with BC6OTHER - based opioids.	False
BC6ENTC is a reversible, competitive BC6OTHER ( BC6OTHER ) inhibitor and allosteric potentiating ligand of nicotinic BC6OTHER receptors ( BC6ENTG - APL) that shares many common structural elements with BC6OTHER - based opioids.	False
BC6ENTC is a reversible, competitive BC6ENTG ( BC6OTHER ) inhibitor and allosteric potentiating ligand of nicotinic BC6OTHER receptors ( BC6OTHER - APL) that shares many common structural elements with BC6OTHER - based opioids.	CPR:4
BC6ENTC is a reversible, competitive BC6OTHER ( BC6ENTG ) inhibitor and allosteric potentiating ligand of nicotinic BC6OTHER receptors ( BC6OTHER - APL) that shares many common structural elements with BC6OTHER - based opioids.	CPR:4
BC6OTHER is a reversible, competitive BC6OTHER ( BC6OTHER ) inhibitor and allosteric potentiating ligand of nicotinic BC6ENTC receptors ( BC6ENTG - APL) that shares many common structural elements with BC6OTHER - based opioids.	False
BC6OTHER is a reversible, competitive BC6ENTG ( BC6OTHER ) inhibitor and allosteric potentiating ligand of nicotinic BC6ENTC receptors ( BC6OTHER - APL) that shares many common structural elements with BC6OTHER - based opioids.	False
BC6OTHER is a reversible, competitive BC6OTHER ( BC6ENTG ) inhibitor and allosteric potentiating ligand of nicotinic BC6ENTC receptors ( BC6OTHER - APL) that shares many common structural elements with BC6OTHER - based opioids.	False
BC6OTHER is a reversible, competitive BC6OTHER ( BC6OTHER ) inhibitor and allosteric potentiating ligand of BC6ENTG ( BC6OTHER - APL) that shares many common structural elements with BC6ENTC - based opioids.	False
BC6OTHER is a reversible, competitive BC6OTHER ( BC6OTHER ) inhibitor and allosteric potentiating ligand of nicotinic BC6OTHER receptors ( BC6ENTG - APL) that shares many common structural elements with BC6ENTC - based opioids.	False
BC6OTHER is a reversible, competitive BC6ENTG ( BC6OTHER ) inhibitor and allosteric potentiating ligand of nicotinic BC6OTHER receptors ( BC6OTHER - APL) that shares many common structural elements with BC6ENTC - based opioids.	False
BC6OTHER is a reversible, competitive BC6OTHER ( BC6ENTG ) inhibitor and allosteric potentiating ligand of nicotinic BC6OTHER receptors ( BC6OTHER - APL) that shares many common structural elements with BC6ENTC - based opioids.	False
The structurally diverse opioids BC6ENTC and BC6OTHER , like BC6OTHER , are also BC6ENTG - APL that have greatly diminished affinity for BC6OTHER , representing potential lead compounds for selective BC6OTHER - APL development.	False
The structurally diverse opioids BC6ENTC and BC6OTHER , like BC6OTHER , are also BC6OTHER - APL that have greatly diminished affinity for BC6ENTG , representing potential lead compounds for selective BC6OTHER - APL development.	False
The structurally diverse opioids BC6ENTC and BC6OTHER , like BC6OTHER , are also BC6OTHER - APL that have greatly diminished affinity for BC6OTHER , representing potential lead compounds for selective BC6ENTG - APL development.	False
The structurally diverse opioids BC6OTHER and BC6ENTC , like BC6OTHER , are also BC6ENTG - APL that have greatly diminished affinity for BC6OTHER , representing potential lead compounds for selective BC6OTHER - APL development.	False
The structurally diverse opioids BC6OTHER and BC6ENTC , like BC6OTHER , are also BC6OTHER - APL that have greatly diminished affinity for BC6ENTG , representing potential lead compounds for selective BC6OTHER - APL development.	False
The structurally diverse opioids BC6OTHER and BC6ENTC , like BC6OTHER , are also BC6OTHER - APL that have greatly diminished affinity for BC6OTHER , representing potential lead compounds for selective BC6ENTG - APL development.	False
The structurally diverse opioids BC6OTHER and BC6OTHER , like BC6ENTC , are also BC6ENTG - APL that have greatly diminished affinity for BC6OTHER , representing potential lead compounds for selective BC6OTHER - APL development.	False
The structurally diverse opioids BC6OTHER and BC6OTHER , like BC6ENTC , are also BC6OTHER - APL that have greatly diminished affinity for BC6ENTG , representing potential lead compounds for selective BC6OTHER - APL development.	False
The structurally diverse opioids BC6OTHER and BC6OTHER , like BC6ENTC , are also BC6OTHER - APL that have greatly diminished affinity for BC6OTHER , representing potential lead compounds for selective BC6ENTG - APL development.	False
The Schild plots for the competitive antagonists BC6OTHER and BC6OTHER against BC6ENTG - selective agonist BC6ENTC - induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 + / - 0.07 (n = 5) for BC6OTHER and 9.09 + / - 0.05 (n = 3) for BC6OTHER .	CPR:5
The Schild plots for the competitive antagonists BC6OTHER and BC6OTHER against BC6ENTG - selective agonist BC6OTHER - induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 + / - 0.07 (n = 5) for BC6ENTC and 9.09 + / - 0.05 (n = 3) for BC6OTHER .	CPR:6
The Schild plots for the competitive antagonists BC6OTHER and BC6OTHER against BC6ENTG - selective agonist BC6OTHER - induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 + / - 0.07 (n = 5) for BC6OTHER and 9.09 + / - 0.05 (n = 3) for BC6ENTC .	CPR:6
Computer - assisted analysis of these curvilinear Schild plots in a two - receptor system indicated that BC6ENTG populations responsible for the constrictive response are predominantly (approximately 80 - 90%) low affinity sites for the two antagonists (pKd approximately 8.1 for BC6ENTC and pKd approximately 7.1 for BC6OTHER ) and a small population (approximately 10 - 20%) are high affinity sites (pKd approximately 9.1 for both BC6OTHER and BC6OTHER ), which was in good agreement with radioligand binding studies.	CPR:6
Computer - assisted analysis of these curvilinear Schild plots in a two - receptor system indicated that BC6ENTG populations responsible for the constrictive response are predominantly (approximately 80 - 90%) low affinity sites for the two antagonists (pKd approximately 8.1 for BC6OTHER and pKd approximately 7.1 for BC6ENTC ) and a small population (approximately 10 - 20%) are high affinity sites (pKd approximately 9.1 for both BC6OTHER and BC6OTHER ), which was in good agreement with radioligand binding studies.	CPR:6
Computer - assisted analysis of these curvilinear Schild plots in a two - receptor system indicated that BC6ENTG populations responsible for the constrictive response are predominantly (approximately 80 - 90%) low affinity sites for the two antagonists (pKd approximately 8.1 for BC6OTHER and pKd approximately 7.1 for BC6OTHER ) and a small population (approximately 10 - 20%) are high affinity sites (pKd approximately 9.1 for both BC6ENTC and BC6OTHER ), which was in good agreement with radioligand binding studies.	False
Computer - assisted analysis of these curvilinear Schild plots in a two - receptor system indicated that BC6ENTG populations responsible for the constrictive response are predominantly (approximately 80 - 90%) low affinity sites for the two antagonists (pKd approximately 8.1 for BC6OTHER and pKd approximately 7.1 for BC6OTHER ) and a small population (approximately 10 - 20%) are high affinity sites (pKd approximately 9.1 for both BC6OTHER and BC6ENTC ), which was in good agreement with radioligand binding studies.	False
The BC6ENTG alkylating agent CEC selectively inhibited the phasic component of the BC6ENTC - induced contractile response, with little effect on the tonic component.	False
The BC6ENTG occupancy - response relationship defined by the BC6ENTC inactivation method was rectangular hyperbolic for the tonic response, whereas that for the phasic response was linear, indicating the different degree of receptor reserve for the two responses.	False
Using the BC6ENTG subtype - selective antagonists BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6ENTC , we have examined the possible heterogeneity in the BC6OTHER populations in rabbit aorta.	CPR:6
Using the BC6OTHER subtype - selective antagonists BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6ENTC , we have examined the possible heterogeneity in the BC6ENTG populations in rabbit aorta.	False
Using the BC6ENTG subtype - selective antagonists BC6ENTC ( BC6OTHER ), BC6OTHER , and BC6OTHER , we have examined the possible heterogeneity in the BC6OTHER populations in rabbit aorta.	CPR:6
Using the BC6OTHER subtype - selective antagonists BC6ENTC ( BC6OTHER ), BC6OTHER , and BC6OTHER , we have examined the possible heterogeneity in the BC6ENTG populations in rabbit aorta.	False
Radioligand binding studies with the nonselective BC6ENTG antagonist radioligand BC6ENTC showed that 73 - 87% of the binding sites in rabbit aorta are BC6OTHER sensitive and they are predominantly low affinity sites both for BC6OTHER (pKd = 8.1) and for BC6OTHER (pKd = 7.1).	CPR:6
Using the BC6ENTG subtype - selective antagonists BC6OTHER ( BC6ENTC ), BC6OTHER , and BC6OTHER , we have examined the possible heterogeneity in the BC6OTHER populations in rabbit aorta.	CPR:6
Using the BC6OTHER subtype - selective antagonists BC6OTHER ( BC6ENTC ), BC6OTHER , and BC6OTHER , we have examined the possible heterogeneity in the BC6ENTG populations in rabbit aorta.	False
Radioligand binding studies with the nonselective BC6ENTG antagonist radioligand BC6OTHER showed that 73 - 87% of the binding sites in rabbit aorta are BC6ENTC sensitive and they are predominantly low affinity sites both for BC6OTHER (pKd = 8.1) and for BC6OTHER (pKd = 7.1).	False
Using the BC6ENTG subtype - selective antagonists BC6OTHER ( BC6OTHER ), BC6ENTC , and BC6OTHER , we have examined the possible heterogeneity in the BC6OTHER populations in rabbit aorta.	CPR:6
Using the BC6OTHER subtype - selective antagonists BC6OTHER ( BC6OTHER ), BC6ENTC , and BC6OTHER , we have examined the possible heterogeneity in the BC6ENTG populations in rabbit aorta.	False
Radioligand binding studies with the nonselective BC6ENTG antagonist radioligand BC6OTHER showed that 73 - 87% of the binding sites in rabbit aorta are BC6OTHER sensitive and they are predominantly low affinity sites both for BC6ENTC (pKd = 8.1) and for BC6OTHER (pKd = 7.1).	False
Radioligand binding studies with the nonselective BC6ENTG antagonist radioligand BC6OTHER showed that 73 - 87% of the binding sites in rabbit aorta are BC6OTHER sensitive and they are predominantly low affinity sites both for BC6OTHER (pKd = 8.1) and for BC6ENTC (pKd = 7.1).	False
Two pharmacologically distinct BC6ENTG subtypes in the contraction of rabbit aorta: each subtype couples with a different BC6ENTC signalling mechanism and plays a different physiological role.	False
Moreover, BC6OTHER - mediated BC6ENTC ( BC6OTHER ) hydrolysis was BC6OTHER sensitive, and fractional inactivation of BC6ENTG with BC6OTHER showed equivalent increments in the reduction of BC6OTHER hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6OTHER - sensitive receptor sites.	False
Moreover, BC6ENTG - mediated BC6ENTC ( BC6OTHER ) hydrolysis was BC6OTHER sensitive, and fractional inactivation of BC6OTHER with BC6OTHER showed equivalent increments in the reduction of BC6OTHER hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6OTHER - sensitive receptor sites.	False
Moreover, BC6OTHER - mediated BC6OTHER ( BC6ENTC ) hydrolysis was BC6OTHER sensitive, and fractional inactivation of BC6ENTG with BC6OTHER showed equivalent increments in the reduction of BC6OTHER hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6OTHER - sensitive receptor sites.	False
Moreover, BC6ENTG - mediated BC6OTHER ( BC6ENTC ) hydrolysis was BC6OTHER sensitive, and fractional inactivation of BC6OTHER with BC6OTHER showed equivalent increments in the reduction of BC6OTHER hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6OTHER - sensitive receptor sites.	False
Moreover, BC6OTHER - mediated BC6OTHER ( BC6OTHER ) hydrolysis was BC6ENTC sensitive, and fractional inactivation of BC6ENTG with BC6OTHER showed equivalent increments in the reduction of BC6OTHER hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6OTHER - sensitive receptor sites.	False
Moreover, BC6ENTG - mediated BC6OTHER ( BC6OTHER ) hydrolysis was BC6ENTC sensitive, and fractional inactivation of BC6OTHER with BC6OTHER showed equivalent increments in the reduction of BC6OTHER hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6OTHER - sensitive receptor sites.	False
Moreover, BC6OTHER - mediated BC6OTHER ( BC6OTHER ) hydrolysis was BC6OTHER sensitive, and fractional inactivation of BC6ENTG with BC6ENTC showed equivalent increments in the reduction of BC6OTHER hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6OTHER - sensitive receptor sites.	False
Moreover, BC6ENTG - mediated BC6OTHER ( BC6OTHER ) hydrolysis was BC6OTHER sensitive, and fractional inactivation of BC6OTHER with BC6ENTC showed equivalent increments in the reduction of BC6OTHER hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6OTHER - sensitive receptor sites.	False
Moreover, BC6OTHER - mediated BC6OTHER ( BC6OTHER ) hydrolysis was BC6OTHER sensitive, and fractional inactivation of BC6ENTG with BC6OTHER showed equivalent increments in the reduction of BC6ENTC hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6OTHER - sensitive receptor sites.	False
Moreover, BC6ENTG - mediated BC6OTHER ( BC6OTHER ) hydrolysis was BC6OTHER sensitive, and fractional inactivation of BC6OTHER with BC6OTHER showed equivalent increments in the reduction of BC6ENTC hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6OTHER - sensitive receptor sites.	False
Moreover, BC6OTHER - mediated BC6OTHER ( BC6OTHER ) hydrolysis was BC6OTHER sensitive, and fractional inactivation of BC6ENTG with BC6OTHER showed equivalent increments in the reduction of BC6OTHER hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6ENTC - sensitive receptor sites.	False
Moreover, BC6ENTG - mediated BC6OTHER ( BC6OTHER ) hydrolysis was BC6OTHER sensitive, and fractional inactivation of BC6OTHER with BC6OTHER showed equivalent increments in the reduction of BC6OTHER hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6ENTC - sensitive receptor sites.	False
The Schild plots for the competitive antagonists BC6ENTC and BC6OTHER against BC6ENTG - selective agonist BC6OTHER - induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 + / - 0.07 (n = 5) for BC6OTHER and 9.09 + / - 0.05 (n = 3) for BC6OTHER .	CPR:6
The Schild plots for the competitive antagonists BC6OTHER and BC6ENTC against BC6ENTG - selective agonist BC6OTHER - induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 + / - 0.07 (n = 5) for BC6OTHER and 9.09 + / - 0.05 (n = 3) for BC6OTHER .	CPR:6
In a search for less flexible analogues of BC6OTHER (1), a BC6OTHER BC6ENTC endowed with an interesting BC6ENTG affinity profile, we discovered compound 2, in which the terminal BC6OTHER groups of 1 have been incorporated into a BC6OTHER system.	False
 BC6ENTC derivatives as BC6ENTG inhibitors.	CPR:4
In a search for less flexible analogues of BC6OTHER (1), a BC6OTHER BC6OTHER endowed with an interesting BC6ENTG affinity profile, we discovered compound 2, in which the terminal BC6ENTC groups of 1 have been incorporated into a BC6OTHER system.	False
In a search for less flexible analogues of BC6OTHER (1), a BC6OTHER BC6OTHER endowed with an interesting BC6ENTG affinity profile, we discovered compound 2, in which the terminal BC6OTHER groups of 1 have been incorporated into a BC6ENTC system.	False
Since this compound retains good BC6ENTG inhibitory activity and its BC6ENTC moiety is reminiscent of the BC6OTHER (3), we have designed and synthesized BC6OTHER 4 - 6, and their biological evaluation has been assessed in vitro against BC6OTHER and BC6OTHER .	CPR:4
Since this compound retains good BC6OTHER inhibitory activity and its BC6ENTC moiety is reminiscent of the BC6OTHER (3), we have designed and synthesized BC6OTHER 4 - 6, and their biological evaluation has been assessed in vitro against BC6ENTG and BC6OTHER .	False
Since this compound retains good BC6OTHER inhibitory activity and its BC6ENTC moiety is reminiscent of the BC6OTHER (3), we have designed and synthesized BC6OTHER 4 - 6, and their biological evaluation has been assessed in vitro against BC6OTHER and BC6ENTG .	False
Since this compound retains good BC6ENTG inhibitory activity and its BC6OTHER moiety is reminiscent of the BC6ENTC (3), we have designed and synthesized BC6OTHER 4 - 6, and their biological evaluation has been assessed in vitro against BC6OTHER and BC6OTHER .	CPR:4
Since this compound retains good BC6OTHER inhibitory activity and its BC6OTHER moiety is reminiscent of the BC6ENTC (3), we have designed and synthesized BC6OTHER 4 - 6, and their biological evaluation has been assessed in vitro against BC6ENTG and BC6OTHER .	False
Since this compound retains good BC6OTHER inhibitory activity and its BC6OTHER moiety is reminiscent of the BC6ENTC (3), we have designed and synthesized BC6OTHER 4 - 6, and their biological evaluation has been assessed in vitro against BC6OTHER and BC6ENTG .	False
In a search for less flexible analogues of BC6ENTC (1), a BC6OTHER BC6OTHER endowed with an interesting BC6ENTG affinity profile, we discovered compound 2, in which the terminal BC6OTHER groups of 1 have been incorporated into a BC6OTHER system.	False
Since this compound retains good BC6ENTG inhibitory activity and its BC6OTHER moiety is reminiscent of the BC6OTHER (3), we have designed and synthesized BC6ENTC 4 - 6, and their biological evaluation has been assessed in vitro against BC6OTHER and BC6OTHER .	False
Since this compound retains good BC6OTHER inhibitory activity and its BC6OTHER moiety is reminiscent of the BC6OTHER (3), we have designed and synthesized BC6ENTC 4 - 6, and their biological evaluation has been assessed in vitro against BC6ENTG and BC6OTHER .	False
Since this compound retains good BC6OTHER inhibitory activity and its BC6OTHER moiety is reminiscent of the BC6OTHER (3), we have designed and synthesized BC6ENTC 4 - 6, and their biological evaluation has been assessed in vitro against BC6OTHER and BC6ENTG .	False
In a search for less flexible analogues of BC6OTHER (1), a BC6ENTC BC6OTHER endowed with an interesting BC6ENTG affinity profile, we discovered compound 2, in which the terminal BC6OTHER groups of 1 have been incorporated into a BC6OTHER system.	False
BC6ENTC was found to be a time - dependent inhibitor of the rat enzyme, with the lowest inhibition constant (Ki* = 0.77 nM) determined so far for BC6ENTG .	CPR:4
Another inhibitor, BC6ENTC was previously reported to be a slow - binding inhibitor of the BC6ENTG [W. Knecht, M. Loffler, Species - related inhibition of human and rat BC6OTHER dehydrogenase by immunosuppressive BC6OTHER and BC6OTHER derivatives, Biochem.	CPR:4
Another inhibitor, BC6ENTC was previously reported to be a slow - binding inhibitor of the human BC6OTHER dehydrogenase [W. Knecht, M. Loffler, Species - related inhibition of BC6ENTG by immunosuppressive BC6OTHER and BC6OTHER derivatives, Biochem.	False
Another inhibitor, BC6OTHER was previously reported to be a slow - binding inhibitor of the human BC6ENTC dehydrogenase [W. Knecht, M. Loffler, Species - related inhibition of BC6ENTG by immunosuppressive BC6OTHER and BC6OTHER derivatives, Biochem.	False
Another inhibitor, BC6OTHER was previously reported to be a slow - binding inhibitor of the BC6ENTG [W. Knecht, M. Loffler, Species - related inhibition of human and rat BC6ENTC dehydrogenase by immunosuppressive BC6OTHER and BC6OTHER derivatives, Biochem.	False
Another inhibitor, BC6OTHER was previously reported to be a slow - binding inhibitor of the BC6ENTG [W. Knecht, M. Loffler, Species - related inhibition of human and rat BC6OTHER dehydrogenase by immunosuppressive BC6ENTC and BC6OTHER derivatives, Biochem.	False
Another inhibitor, BC6OTHER was previously reported to be a slow - binding inhibitor of the human BC6OTHER dehydrogenase [W. Knecht, M. Loffler, Species - related inhibition of BC6ENTG by immunosuppressive BC6ENTC and BC6OTHER derivatives, Biochem.	CPR:4
Another inhibitor, BC6OTHER was previously reported to be a slow - binding inhibitor of the BC6ENTG [W. Knecht, M. Loffler, Species - related inhibition of human and rat BC6OTHER dehydrogenase by immunosuppressive BC6OTHER and BC6ENTC derivatives, Biochem.	False
Another inhibitor, BC6OTHER was previously reported to be a slow - binding inhibitor of the human BC6OTHER dehydrogenase [W. Knecht, M. Loffler, Species - related inhibition of BC6ENTG by immunosuppressive BC6OTHER and BC6ENTC derivatives, Biochem.	CPR:4
Mitochondrially - bound BC6ENTC dehydrogenase ( BC6ENTG ) catalyzes the fourth sequential step in the de novo synthesis of BC6OTHER .	False
With respect to the substrate BC6ENTC , BC6OTHER was an uncompetitive inhibitor of BC6ENTG (Kiu = 11.6 microM) and a non - competitive inhibitor of the rat enzyme (Kiu = 905 / Kic = 1,012 nM).	CPR:4
With respect to the substrate BC6OTHER , BC6ENTC was an uncompetitive inhibitor of BC6ENTG (Kiu = 11.6 microM) and a non - competitive inhibitor of the rat enzyme (Kiu = 905 / Kic = 1,012 nM).	CPR:4
Kinetics of inhibition of BC6ENTG by BC6OTHER , BC6OTHER derivatives, BC6ENTC and BC6OTHER .	CPR:4
Kinetics of inhibition of BC6ENTG by BC6OTHER , BC6OTHER derivatives, BC6OTHER and BC6ENTC .	CPR:4
Kinetics of inhibition of BC6ENTG by BC6ENTC , BC6OTHER derivatives, BC6OTHER and BC6OTHER .	CPR:4
Kinetics of inhibition of BC6ENTG by BC6OTHER , BC6ENTC derivatives, BC6OTHER and BC6OTHER .	CPR:4
With respect to the BC6ENTC co - substrate of the BC6ENTG , BC6OTHER (Kic = 2.7 microM) and BC6OTHER (Kic = 9.8 nM) were shown to be competitive inhibitors of human BC6OTHER dehydrogenase.	CPR:9
With respect to the BC6ENTC co - substrate of the BC6OTHER dehydrogenase, BC6OTHER (Kic = 2.7 microM) and BC6OTHER (Kic = 9.8 nM) were shown to be competitive inhibitors of BC6ENTG .	False
With respect to the BC6OTHER co - substrate of the BC6ENTC dehydrogenase, BC6OTHER (Kic = 2.7 microM) and BC6OTHER (Kic = 9.8 nM) were shown to be competitive inhibitors of BC6ENTG .	False
With respect to the BC6OTHER co - substrate of the BC6ENTG , BC6ENTC (Kic = 2.7 microM) and BC6OTHER (Kic = 9.8 nM) were shown to be competitive inhibitors of human BC6OTHER dehydrogenase.	False
With respect to the BC6OTHER co - substrate of the BC6OTHER dehydrogenase, BC6ENTC (Kic = 2.7 microM) and BC6OTHER (Kic = 9.8 nM) were shown to be competitive inhibitors of BC6ENTG .	CPR:4
With respect to the BC6OTHER co - substrate of the BC6ENTG , BC6OTHER (Kic = 2.7 microM) and BC6ENTC (Kic = 9.8 nM) were shown to be competitive inhibitors of human BC6OTHER dehydrogenase.	False
With respect to the BC6OTHER co - substrate of the BC6OTHER dehydrogenase, BC6OTHER (Kic = 2.7 microM) and BC6ENTC (Kic = 9.8 nM) were shown to be competitive inhibitors of BC6ENTG .	CPR:4
Mitochondrially - bound BC6ENTG ( BC6OTHER ) catalyzes the fourth sequential step in the de novo synthesis of BC6ENTC .	CPR:9
Mitochondrially - bound BC6OTHER ( BC6ENTG ) catalyzes the fourth sequential step in the de novo synthesis of BC6ENTC .	CPR:9
With respect to the BC6OTHER co - substrate of the BC6ENTG , BC6OTHER (Kic = 2.7 microM) and BC6OTHER (Kic = 9.8 nM) were shown to be competitive inhibitors of human BC6ENTC dehydrogenase.	False
Synthesis and in - silico studies of some BC6ENTC derivatives as potential BC6ENTG inhibitors.	CPR:4
Since pathologies are often related to inflammation, an inflammatory HUVEC culture condition with BC6ENTG stimulation has been introduced and suggested to be widely applied for studying nanocarriers, since cellular uptake in this assay was clearly increased for BC6ENTC contents ⩾20mol.%.	False
Transgenic expression of the human BC6ENTC receptor ( BC6ENTG ) in the duodenum of BC6OTHER - null mice attenuates the age - dependent decline in BC6OTHER absorption.	False
Transgenic expression of the human BC6ENTC receptor ( BC6OTHER ) in the duodenum of BC6ENTG - null mice attenuates the age - dependent decline in BC6OTHER absorption.	False
In conclusion, transgenic BC6OTHER in the proximal small intestine of BC6ENTG + / BC6OTHER - null mice was transcriptionally active and regulated BC6ENTC absorption, but BC6OTHER actions elsewhere in the intestine are probably necessary to support adequate BC6OTHER homeostasis.	False
In conclusion, transgenic BC6OTHER in the proximal small intestine of BC6OTHER + / BC6ENTG - null mice was transcriptionally active and regulated BC6ENTC absorption, but BC6OTHER actions elsewhere in the intestine are probably necessary to support adequate BC6OTHER homeostasis.	False
In conclusion, transgenic BC6OTHER in the proximal small intestine of BC6OTHER + / BC6OTHER - null mice was transcriptionally active and regulated BC6ENTC absorption, but BC6ENTG actions elsewhere in the intestine are probably necessary to support adequate BC6OTHER homeostasis.	False
In conclusion, transgenic BC6ENTG in the proximal small intestine of BC6OTHER + / BC6OTHER - null mice was transcriptionally active and regulated BC6ENTC absorption, but BC6OTHER actions elsewhere in the intestine are probably necessary to support adequate BC6OTHER homeostasis.	False
In conclusion, transgenic BC6OTHER in the proximal small intestine of BC6ENTG + / BC6OTHER - null mice was transcriptionally active and regulated BC6OTHER absorption, but BC6OTHER actions elsewhere in the intestine are probably necessary to support adequate BC6ENTC homeostasis.	False
In conclusion, transgenic BC6OTHER in the proximal small intestine of BC6OTHER + / BC6ENTG - null mice was transcriptionally active and regulated BC6OTHER absorption, but BC6OTHER actions elsewhere in the intestine are probably necessary to support adequate BC6ENTC homeostasis.	False
In conclusion, transgenic BC6OTHER in the proximal small intestine of BC6OTHER + / BC6OTHER - null mice was transcriptionally active and regulated BC6OTHER absorption, but BC6ENTG actions elsewhere in the intestine are probably necessary to support adequate BC6ENTC homeostasis.	False
In conclusion, transgenic BC6ENTG in the proximal small intestine of BC6OTHER + / BC6OTHER - null mice was transcriptionally active and regulated BC6OTHER absorption, but BC6OTHER actions elsewhere in the intestine are probably necessary to support adequate BC6ENTC homeostasis.	False
In addition, BC6ENTG + / BC6OTHER - null mice responded better to the late rescue diet suggesting that expression of BC6OTHER in the proximal small intestine protected the BC6ENTC absorbing machinery from age - dependent decline.	False
In addition, BC6OTHER + / BC6ENTG - null mice responded better to the late rescue diet suggesting that expression of BC6OTHER in the proximal small intestine protected the BC6ENTC absorbing machinery from age - dependent decline.	False
In addition, BC6OTHER + / BC6OTHER - null mice responded better to the late rescue diet suggesting that expression of BC6ENTG in the proximal small intestine protected the BC6ENTC absorbing machinery from age - dependent decline.	False
To determine if BC6ENTG 's actions in the proximal small intestine can sufficiently restore BC6ENTC homeostasis, we generated transgenic mice expressing BC6OTHER exclusively in the duodenum of BC6OTHER - null mice by using the BC6OTHER deaminase enhancer ( BC6OTHER + / BC6OTHER - null).	False
To determine if BC6OTHER 's actions in the proximal small intestine can sufficiently restore BC6ENTC homeostasis, we generated transgenic mice expressing BC6ENTG exclusively in the duodenum of BC6OTHER - null mice by using the BC6OTHER deaminase enhancer ( BC6OTHER + / BC6OTHER - null).	False
To determine if BC6OTHER 's actions in the proximal small intestine can sufficiently restore BC6ENTC homeostasis, we generated transgenic mice expressing BC6OTHER exclusively in the duodenum of BC6ENTG - null mice by using the BC6OTHER deaminase enhancer ( BC6OTHER + / BC6OTHER - null).	False
To determine if BC6OTHER 's actions in the proximal small intestine can sufficiently restore BC6ENTC homeostasis, we generated transgenic mice expressing BC6OTHER exclusively in the duodenum of BC6OTHER - null mice by using the BC6ENTG ( BC6OTHER + / BC6OTHER - null).	False
To determine if BC6OTHER 's actions in the proximal small intestine can sufficiently restore BC6ENTC homeostasis, we generated transgenic mice expressing BC6OTHER exclusively in the duodenum of BC6OTHER - null mice by using the BC6OTHER deaminase enhancer ( BC6ENTG + / BC6OTHER - null).	False
To determine if BC6OTHER 's actions in the proximal small intestine can sufficiently restore BC6ENTC homeostasis, we generated transgenic mice expressing BC6OTHER exclusively in the duodenum of BC6OTHER - null mice by using the BC6OTHER deaminase enhancer ( BC6OTHER + / BC6ENTG - null).	False
To determine if BC6ENTG 's actions in the proximal small intestine can sufficiently restore BC6OTHER homeostasis, we generated transgenic mice expressing BC6OTHER exclusively in the duodenum of BC6OTHER - null mice by using the BC6ENTC deaminase enhancer ( BC6OTHER + / BC6OTHER - null).	False
To determine if BC6OTHER 's actions in the proximal small intestine can sufficiently restore BC6OTHER homeostasis, we generated transgenic mice expressing BC6ENTG exclusively in the duodenum of BC6OTHER - null mice by using the BC6ENTC deaminase enhancer ( BC6OTHER + / BC6OTHER - null).	False
To determine if BC6OTHER 's actions in the proximal small intestine can sufficiently restore BC6OTHER homeostasis, we generated transgenic mice expressing BC6OTHER exclusively in the duodenum of BC6ENTG - null mice by using the BC6ENTC deaminase enhancer ( BC6OTHER + / BC6OTHER - null).	False
To determine if BC6OTHER 's actions in the proximal small intestine can sufficiently restore BC6OTHER homeostasis, we generated transgenic mice expressing BC6OTHER exclusively in the duodenum of BC6OTHER - null mice by using the BC6ENTC deaminase enhancer ( BC6ENTG + / BC6OTHER - null).	False
To determine if BC6OTHER 's actions in the proximal small intestine can sufficiently restore BC6OTHER homeostasis, we generated transgenic mice expressing BC6OTHER exclusively in the duodenum of BC6OTHER - null mice by using the BC6ENTC deaminase enhancer ( BC6OTHER + / BC6ENTG - null).	False
However, when 90 - day - old rachitic mice were fed a rescue diet, serum BC6ENTC improved in BC6ENTG + / BC6OTHER - null mice, but not in BC6OTHER - null mice.	False
However, when 90 - day - old rachitic mice were fed a rescue diet, serum BC6ENTC improved in BC6OTHER + / BC6ENTG - null mice, but not in BC6OTHER - null mice.	False
However, when 90 - day - old rachitic mice were fed a rescue diet, serum BC6ENTC improved in BC6OTHER + / BC6OTHER - null mice, but not in BC6ENTG - null mice.	False
Transgenic expression of the BC6ENTG ( BC6OTHER ) in the duodenum of BC6OTHER - null mice attenuates the age - dependent decline in BC6ENTC absorption.	False
Transgenic expression of the human BC6OTHER receptor ( BC6ENTG ) in the duodenum of BC6OTHER - null mice attenuates the age - dependent decline in BC6ENTC absorption.	False
Transgenic expression of the human BC6OTHER receptor ( BC6OTHER ) in the duodenum of BC6ENTG - null mice attenuates the age - dependent decline in BC6ENTC absorption.	False
In general, the rats treated with BC6ENTC alone did not exhibit any pronounced alteration in memory compared with controls in the MWM, and in many cases BC6ENTG did not induce any alteration.	False
In conclusion, BC6ENTG improves spatial memory in intact rats and can reverse certain effects induced by anabolic androgenic BC6ENTC .	False
In this study we report the effects of BC6ENTG on learning and memory in intact rats pretreated with the anabolic androgenic BC6ENTC BC6OTHER .	False
In this study we report the effects of BC6ENTG on learning and memory in intact rats pretreated with the anabolic androgenic BC6OTHER BC6ENTC .	False
Male Wistar rats received BC6ENTC (15 mg / kg) or peanut oil every third day for 3 weeks and were subsequently treated with recombinant BC6ENTG (1.0 IU / kg) or saline for 10 consecutive days.	False
In addition, BC6ENTG was demonstrated to increase the body weight gain and was able to attenuate the reduced body weight seen in BC6ENTC - treated animals.	False
Similar to the pharmacological characteristics of the BC6ENTG site defined by BC6OTHER , compounds most active at inhibiting 15 mM BC6OTHER - stimulated release of BC6OTHER were BC6OTHER = BC6OTHER BC6OTHER = BC6OTHER greater than BC6OTHER greater than BC6ENTC .	False
A correlation analysis of selective BC6ENTG compounds comparing the pKD for displacement of BC6ENTC vs. the IC50 for inhibition of BC6OTHER release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6OTHER and the BC6OTHER site defined by BC6OTHER binding in spinal cord synaptosomes (r = 0.791, P = .0193).	False
A correlation analysis of selective BC6OTHER compounds comparing the pKD for displacement of BC6ENTC vs. the IC50 for inhibition of BC6OTHER release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6ENTG and the BC6OTHER site defined by BC6OTHER binding in spinal cord synaptosomes (r = 0.791, P = .0193).	False
A correlation analysis of selective BC6OTHER compounds comparing the pKD for displacement of BC6ENTC vs. the IC50 for inhibition of BC6OTHER release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6OTHER and the BC6ENTG site defined by BC6OTHER binding in spinal cord synaptosomes (r = 0.791, P = .0193).	False
The aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the BC6ENTG defined by BC6ENTC BC6OTHER binding and the BC6OTHER defined by inhibition of BC6OTHER release.	False
The aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the BC6OTHER defined by BC6ENTC BC6OTHER binding and the BC6ENTG defined by inhibition of BC6OTHER release.	False
A correlation analysis of selective BC6ENTG compounds comparing the pKD for displacement of BC6OTHER vs. the IC50 for inhibition of BC6ENTC release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6OTHER and the BC6OTHER site defined by BC6OTHER binding in spinal cord synaptosomes (r = 0.791, P = .0193).	False
A correlation analysis of selective BC6OTHER compounds comparing the pKD for displacement of BC6OTHER vs. the IC50 for inhibition of BC6ENTC release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6ENTG and the BC6OTHER site defined by BC6OTHER binding in spinal cord synaptosomes (r = 0.791, P = .0193).	False
A correlation analysis of selective BC6OTHER compounds comparing the pKD for displacement of BC6OTHER vs. the IC50 for inhibition of BC6ENTC release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6OTHER and the BC6ENTG site defined by BC6OTHER binding in spinal cord synaptosomes (r = 0.791, P = .0193).	False
A correlation analysis of selective BC6ENTG compounds comparing the pKD for displacement of BC6OTHER vs. the IC50 for inhibition of BC6OTHER release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6ENTC autoreceptor and the BC6OTHER site defined by BC6OTHER binding in spinal cord synaptosomes (r = 0.791, P = .0193).	False
A correlation analysis of selective BC6OTHER compounds comparing the pKD for displacement of BC6OTHER vs. the IC50 for inhibition of BC6OTHER release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6ENTC autoreceptor and the BC6ENTG site defined by BC6OTHER binding in spinal cord synaptosomes (r = 0.791, P = .0193).	False
A correlation analysis of selective BC6ENTG compounds comparing the pKD for displacement of BC6OTHER vs. the IC50 for inhibition of BC6OTHER release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6OTHER and the BC6ENTC receptor site defined by BC6OTHER binding in spinal cord synaptosomes (r = 0.791, P = .0193).	False
A correlation analysis of selective BC6OTHER compounds comparing the pKD for displacement of BC6OTHER vs. the IC50 for inhibition of BC6OTHER release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6ENTG and the BC6ENTC receptor site defined by BC6OTHER binding in spinal cord synaptosomes (r = 0.791, P = .0193).	False
A correlation analysis of selective BC6ENTG compounds comparing the pKD for displacement of BC6OTHER vs. the IC50 for inhibition of BC6OTHER release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6OTHER and the BC6OTHER site defined by BC6ENTC binding in spinal cord synaptosomes (r = 0.791, P = .0193).	False
A correlation analysis of selective BC6OTHER compounds comparing the pKD for displacement of BC6OTHER vs. the IC50 for inhibition of BC6OTHER release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6ENTG and the BC6OTHER site defined by BC6ENTC binding in spinal cord synaptosomes (r = 0.791, P = .0193).	False
A correlation analysis of selective BC6OTHER compounds comparing the pKD for displacement of BC6OTHER vs. the IC50 for inhibition of BC6OTHER release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6OTHER and the BC6ENTG site defined by BC6ENTC binding in spinal cord synaptosomes (r = 0.791, P = .0193).	False
The aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the BC6ENTG defined by BC6OTHER BC6ENTC binding and the BC6OTHER defined by inhibition of BC6OTHER release.	False
The aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the BC6OTHER defined by BC6OTHER BC6ENTC binding and the BC6ENTG defined by inhibition of BC6OTHER release.	False
Similar to the pharmacological characteristics of the BC6ENTG site defined by BC6ENTC , compounds most active at inhibiting 15 mM BC6OTHER - stimulated release of BC6OTHER were BC6OTHER = BC6OTHER BC6OTHER = BC6OTHER greater than BC6OTHER greater than BC6OTHER .	False
The aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the BC6ENTG defined by BC6OTHER BC6OTHER binding and the BC6ENTC autoreceptor defined by inhibition of BC6OTHER release.	False
The aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the BC6ENTC (5 - HT)1B receptor defined by BC6OTHER BC6OTHER binding and the BC6ENTG defined by inhibition of BC6OTHER release.	False
These results point out that BC6ENTC identifies the BC6ENTG receptor, and affinity of compounds for this site predicts action at the BC6OTHER autoreceptor.	False
These results point out that BC6ENTC identifies the BC6OTHER receptor, and affinity of compounds for this site predicts action at the BC6ENTG autoreceptor.	False
The aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the BC6ENTG defined by BC6OTHER BC6OTHER binding and the BC6OTHER defined by inhibition of BC6ENTC release.	False
The aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the BC6OTHER defined by BC6OTHER BC6OTHER binding and the BC6ENTG defined by inhibition of BC6ENTC release.	False
Similar to the pharmacological characteristics of the BC6ENTG site defined by BC6OTHER , compounds most active at inhibiting 15 mM BC6ENTC - stimulated release of BC6OTHER were BC6OTHER = BC6OTHER BC6OTHER = BC6OTHER greater than BC6OTHER greater than BC6OTHER .	False
BC6ENTC binding was not altered by compounds with activity at BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER or alpha - 2 receptor sites.	False
BC6ENTC binding was not altered by compounds with activity at BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER or alpha - 2 receptor sites.	False
BC6ENTC binding was not altered by compounds with activity at BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER or alpha - 2 receptor sites.	False
BC6ENTC binding was not altered by compounds with activity at BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG or alpha - 2 receptor sites.	False
Characterization of BC6ENTG receptors in rat spinal cord via BC6OTHER binding and inhibition of BC6ENTC release.	False
Characterization of BC6ENTG receptors in rat spinal cord via BC6ENTC binding and inhibition of BC6OTHER release.	False
Similar to the pharmacological characteristics of the BC6ENTG site defined by BC6OTHER , compounds most active at inhibiting 15 mM BC6OTHER - stimulated release of BC6ENTC were BC6OTHER = BC6OTHER BC6OTHER = BC6OTHER greater than BC6OTHER greater than BC6OTHER .	False
Similar to the pharmacological characteristics of the BC6ENTG site defined by BC6OTHER , compounds most active at inhibiting 15 mM BC6OTHER - stimulated release of BC6OTHER were BC6ENTC = BC6OTHER BC6OTHER = BC6OTHER greater than BC6OTHER greater than BC6OTHER .	False
Similar to the pharmacological characteristics of the BC6ENTG site defined by BC6OTHER , compounds most active at inhibiting 15 mM BC6OTHER - stimulated release of BC6OTHER were BC6OTHER = BC6ENTC BC6OTHER = BC6OTHER greater than BC6OTHER greater than BC6OTHER .	False
Similar to the pharmacological characteristics of the BC6ENTG site defined by BC6OTHER , compounds most active at inhibiting 15 mM BC6OTHER - stimulated release of BC6OTHER were BC6OTHER = BC6OTHER BC6ENTC = BC6OTHER greater than BC6OTHER greater than BC6OTHER .	False
Similar to the pharmacological characteristics of the BC6ENTG site defined by BC6OTHER , compounds most active at inhibiting 15 mM BC6OTHER - stimulated release of BC6OTHER were BC6OTHER = BC6OTHER BC6OTHER = BC6ENTC greater than BC6OTHER greater than BC6OTHER .	False
Similar to the pharmacological characteristics of the BC6ENTG site defined by BC6OTHER , compounds most active at inhibiting 15 mM BC6OTHER - stimulated release of BC6OTHER were BC6OTHER = BC6OTHER BC6OTHER = BC6OTHER greater than BC6ENTC greater than BC6OTHER .	False
Reductions in striatal BC6ENTC and BC6ENTG content were also less pronounced with BC6OTHER treatment.	False
Reductions in striatal BC6OTHER and BC6ENTG content were also less pronounced with BC6ENTC treatment.	CPR:3
The neuroinflammatory response to BC6ENTC was markedly attenuated, and indices of oxidative stress and BC6ENTG activation were significantly prevented with BC6OTHER .	False
The neuroinflammatory response to BC6OTHER was markedly attenuated, and indices of oxidative stress and BC6ENTG activation were significantly prevented with BC6ENTC .	CPR:4
In cultured primary microglia and astrocytes, BC6ENTC had a direct anti - inflammatory effect demonstrated by repression of lipopolysaccharide - induced BC6ENTG activation, BC6OTHER induction, and BC6OTHER production.	CPR:4
In cultured primary microglia and astrocytes, BC6ENTC had a direct anti - inflammatory effect demonstrated by repression of lipopolysaccharide - induced BC6OTHER activation, BC6ENTG induction, and BC6OTHER production.	CPR:4
In cultured primary microglia and astrocytes, BC6OTHER had a direct anti - inflammatory effect demonstrated by repression of lipopolysaccharide - induced BC6ENTG activation, BC6OTHER induction, and BC6ENTC production.	False
In cultured primary microglia and astrocytes, BC6OTHER had a direct anti - inflammatory effect demonstrated by repression of lipopolysaccharide - induced BC6OTHER activation, BC6ENTG induction, and BC6ENTC production.	False
Additionally, in SH - SY5Y cells, BC6ENTC - induced demethylation of BC6ENTG ( BC6OTHER ), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by BC6OTHER .	CPR:4
Additionally, in SH - SY5Y cells, BC6ENTC - induced demethylation of BC6OTHER ( BC6ENTG ), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by BC6OTHER .	CPR:4
Additionally, in SH - SY5Y cells, BC6OTHER - induced demethylation of BC6ENTG ( BC6OTHER ), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by BC6ENTC .	CPR:3
Additionally, in SH - SY5Y cells, BC6OTHER - induced demethylation of BC6OTHER ( BC6ENTG ), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by BC6ENTC .	CPR:3
These findings indicate that the neuroprotective effect of BC6ENTC against BC6OTHER is through several mechanisms including its anti - inflammatory and antioxidant activities as well as its ability to modulate the methylation and hence activity of BC6ENTG .	False
These findings indicate that the neuroprotective effect of BC6OTHER against BC6ENTC is through several mechanisms including its anti - inflammatory and antioxidant activities as well as its ability to modulate the methylation and hence activity of BC6ENTG .	False
One of these compounds is BC6ENTC ( BC6OTHER ), which ameliorates the phenotype of BC6ENTG transgenic mice associated with decreased protein aggregation and phosphorylation, improved neuronal integrity and reduced neuroinflammation.	False
One of these compounds is BC6OTHER ( BC6ENTC ), which ameliorates the phenotype of BC6ENTG transgenic mice associated with decreased protein aggregation and phosphorylation, improved neuronal integrity and reduced neuroinflammation.	False
In a genome - wide meta - analysis of a population - based discovery cohort (n = 33 533), rs838133 in BC6ENTG (19q13.33), rs197273 near BC6OTHER ( BC6OTHER ) (2p24.2), and rs10163409 in BC6OTHER (16q12.2) were among the top associations (P < 10( - 5)) for percentage of total caloric intake from protein and BC6ENTC .	False
In a genome - wide meta - analysis of a population - based discovery cohort (n = 33 533), rs838133 in BC6OTHER (19q13.33), rs197273 near BC6ENTG ( BC6OTHER ) (2p24.2), and rs10163409 in BC6OTHER (16q12.2) were among the top associations (P < 10( - 5)) for percentage of total caloric intake from protein and BC6ENTC .	False
In a genome - wide meta - analysis of a population - based discovery cohort (n = 33 533), rs838133 in BC6OTHER (19q13.33), rs197273 near BC6OTHER ( BC6ENTG ) (2p24.2), and rs10163409 in BC6OTHER (16q12.2) were among the top associations (P < 10( - 5)) for percentage of total caloric intake from protein and BC6ENTC .	False
In a genome - wide meta - analysis of a population - based discovery cohort (n = 33 533), rs838133 in BC6OTHER (19q13.33), rs197273 near BC6OTHER ( BC6OTHER ) (2p24.2), and rs10163409 in BC6ENTG (16q12.2) were among the top associations (P < 10( - 5)) for percentage of total caloric intake from protein and BC6ENTC .	False
To examine receptor mediation of BC6ENTC effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6OTHER or the BC6OTHER - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6OTHER ( BC6ENTG KO) were compared to WT littermates.	False
To examine receptor mediation of BC6ENTC effects, Ovx mice replaced for 2 days with either the BC6ENTG - selective agonist BC6OTHER or the BC6OTHER - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates.	False
To examine receptor mediation of BC6ENTC effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6OTHER or the BC6ENTG - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates.	False
To examine receptor mediation of BC6ENTC effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6OTHER or the BC6OTHER - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6ENTG ( BC6OTHER KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates.	False
To examine receptor mediation of BC6ENTC effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6OTHER or the BC6OTHER - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6OTHER ( BC6ENTG KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates.	False
To examine receptor mediation of BC6ENTC effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6OTHER or the BC6OTHER - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6ENTG ( BC6OTHER KO) were compared to WT littermates.	False
To examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6ENTC or the BC6OTHER - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6OTHER ( BC6ENTG KO) were compared to WT littermates.	False
To examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6ENTG - selective agonist BC6ENTC or the BC6OTHER - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates.	CPR:5
To examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6ENTC or the BC6ENTG - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates.	False
To examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6ENTC or the BC6OTHER - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6ENTG ( BC6OTHER KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates.	False
To examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6ENTC or the BC6OTHER - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6OTHER ( BC6ENTG KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates.	False
To examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6ENTC or the BC6OTHER - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6ENTG ( BC6OTHER KO) were compared to WT littermates.	False
To examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6OTHER or the BC6OTHER - selective agonist BC6ENTC were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6OTHER ( BC6ENTG KO) were compared to WT littermates.	False
To examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6ENTG - selective agonist BC6OTHER or the BC6OTHER - selective agonist BC6ENTC were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates.	False
To examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6OTHER or the BC6ENTG - selective agonist BC6ENTC were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates.	CPR:5
To examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6OTHER or the BC6OTHER - selective agonist BC6ENTC were compared to Sham mice, and mice lacking either BC6ENTG ( BC6OTHER KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates.	False
To examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6OTHER or the BC6OTHER - selective agonist BC6ENTC were compared to Sham mice, and mice lacking either BC6OTHER ( BC6ENTG KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates.	False
To examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6OTHER or the BC6OTHER - selective agonist BC6ENTC were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6ENTG ( BC6OTHER KO) were compared to WT littermates.	False
 BC6ENTC replacement enhances BC6OTHER - stimulated locomotion in female C57BL / 6 mice through BC6ENTG .	False
 BC6OTHER replacement enhances BC6ENTC - stimulated locomotion in female C57BL / 6 mice through BC6ENTG .	False
BC6ENTG KO mice displayed modestly attenuated behavioral responses to novelty and BC6ENTC compared to αWT littermates, but no behavioral differences were found between BC6OTHER KO and βWT mice.	False
BC6OTHER KO mice displayed modestly attenuated behavioral responses to novelty and BC6ENTC compared to αWT littermates, but no behavioral differences were found between BC6ENTG KO and βWT mice.	False
These results suggest that E2 enhances BC6ENTC - stimulated locomotion in mice predominantly through BC6ENTG .	False
BC6ENTC - induced changes were blocked with the BC6ENTG antagonist cetuximab, which suggested direct involvement of BC6OTHER in this process.	False
BC6ENTC - induced changes were blocked with the BC6OTHER antagonist cetuximab, which suggested direct involvement of BC6ENTG in this process.	CPR:3
Western blot analysis of cells incubated with BC6ENTC demonstrated activation of BC6ENTG and downstream signaling that was reduced by inhibition of BC6OTHER ( BC6OTHER ) and BC6OTHER , but not BC6OTHER / BC6OTHER .	CPR:3
Western blot analysis of cells incubated with BC6ENTC demonstrated activation of BC6OTHER and downstream signaling that was reduced by inhibition of BC6ENTG ( BC6OTHER ) and BC6OTHER , but not BC6OTHER / BC6OTHER .	False
Western blot analysis of cells incubated with BC6ENTC demonstrated activation of BC6OTHER and downstream signaling that was reduced by inhibition of BC6OTHER ( BC6ENTG ) and BC6OTHER , but not BC6OTHER / BC6OTHER .	False
Western blot analysis of cells incubated with BC6ENTC demonstrated activation of BC6OTHER and downstream signaling that was reduced by inhibition of BC6OTHER ( BC6OTHER ) and BC6ENTG , but not BC6OTHER / BC6OTHER .	False
Western blot analysis of cells incubated with BC6ENTC demonstrated activation of BC6OTHER and downstream signaling that was reduced by inhibition of BC6OTHER ( BC6OTHER ) and BC6OTHER , but not BC6ENTG / BC6OTHER .	False
Western blot analysis of cells incubated with BC6ENTC demonstrated activation of BC6OTHER and downstream signaling that was reduced by inhibition of BC6OTHER ( BC6OTHER ) and BC6OTHER , but not BC6OTHER / BC6ENTG .	False
An in vitro BC6OTHER assay showed that BC6ENTC did not directly affect BC6OTHER BC6ENTG activity, suggesting involvement of BC6OTHER - activating molecules.	False
An in vitro BC6OTHER assay showed that BC6ENTC did not directly affect BC6OTHER BC6OTHER activity, suggesting involvement of BC6ENTG - activating molecules.	False
An in vitro BC6ENTG assay showed that BC6ENTC did not directly affect BC6OTHER BC6OTHER activity, suggesting involvement of BC6OTHER - activating molecules.	False
An in vitro BC6OTHER assay showed that BC6ENTC did not directly affect BC6ENTG BC6OTHER activity, suggesting involvement of BC6OTHER - activating molecules.	False
Induction of BC6ENTG and activation of BC6OTHER in BC6ENTC - treated squamous carcinoma cells.	False
Induction of BC6OTHER and activation of BC6ENTG in BC6ENTC - treated squamous carcinoma cells.	CPR:3
BC6ENTC is a BC6OTHER kinase inhibitor of the BC6OTHER , BC6OTHER ( BC6ENTG ), and BC6OTHER BC6OTHER .	CPR:4
BC6ENTC is a BC6OTHER kinase inhibitor of the BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTG BC6OTHER .	CPR:4
BC6ENTC is a BC6OTHER kinase inhibitor of the BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER BC6ENTG .	CPR:4
BC6ENTC is a BC6ENTG inhibitor of the BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER BC6OTHER .	CPR:4
BC6ENTC is a BC6OTHER kinase inhibitor of the BC6ENTG , BC6OTHER ( BC6OTHER ), and BC6OTHER BC6OTHER .	CPR:4
BC6ENTC is a BC6OTHER kinase inhibitor of the BC6OTHER , BC6ENTG ( BC6OTHER ), and BC6OTHER BC6OTHER .	CPR:4
Inhibitors and neutralizing antibodies against BC6ENTG ( BC6OTHER ), and to a lesser extent BC6OTHER , reduced BC6ENTC - mediated BC6OTHER ( BC6OTHER ) activation.	False
Inhibitors and neutralizing antibodies against BC6OTHER ( BC6ENTG ), and to a lesser extent BC6OTHER , reduced BC6ENTC - mediated BC6OTHER ( BC6OTHER ) activation.	False
Inhibitors and neutralizing antibodies against BC6OTHER ( BC6OTHER ), and to a lesser extent BC6ENTG , reduced BC6ENTC - mediated BC6OTHER ( BC6OTHER ) activation.	False
Inhibitors and neutralizing antibodies against BC6OTHER ( BC6OTHER ), and to a lesser extent BC6OTHER , reduced BC6ENTC - mediated BC6ENTG ( BC6OTHER ) activation.	CPR:3
Inhibitors and neutralizing antibodies against BC6OTHER ( BC6OTHER ), and to a lesser extent BC6OTHER , reduced BC6ENTC - mediated BC6OTHER ( BC6ENTG ) activation.	CPR:3
BC6ENTC stimulated the rapid release of soluble BC6ENTG and the subsequent induction of membrane - bound BC6OTHER , which correlated with biphasic BC6OTHER activation.	CPR:3
BC6ENTC stimulated the rapid release of soluble BC6OTHER and the subsequent induction of membrane - bound BC6ENTG , which correlated with biphasic BC6OTHER activation.	CPR:3
BC6ENTC stimulated the rapid release of soluble BC6OTHER and the subsequent induction of membrane - bound BC6OTHER , which correlated with biphasic BC6ENTG activation.	CPR:3
Together, these results suggested that BC6ENTC affects BC6ENTG activation and signaling pathways through rapid release and increased expression of endogenous BC6OTHER - activating ligands.	False
Together, these results suggested that BC6ENTC affects BC6OTHER activation and signaling pathways through rapid release and increased expression of endogenous BC6ENTG - activating ligands.	CPR:3
Although, BC6ENTC primarily inhibits BC6ENTG , it also stimulates the activity of BC6OTHER BC6OTHER kinase in head and neck squamous tumors.	CPR:4
Although, BC6ENTC primarily inhibits BC6OTHER , it also stimulates the activity of BC6ENTG BC6OTHER kinase in head and neck squamous tumors.	CPR:3
Although, BC6ENTC primarily inhibits BC6OTHER , it also stimulates the activity of BC6OTHER BC6ENTG in head and neck squamous tumors.	CPR:3
Although, BC6OTHER primarily inhibits BC6ENTG , it also stimulates the activity of BC6OTHER BC6ENTC kinase in head and neck squamous tumors.	False
Although, BC6OTHER primarily inhibits BC6OTHER , it also stimulates the activity of BC6ENTG BC6ENTC kinase in head and neck squamous tumors.	False
BC6OTHER is a BC6ENTC kinase inhibitor of the BC6OTHER , BC6OTHER ( BC6ENTG ), and BC6OTHER BC6OTHER .	False
BC6OTHER is a BC6ENTC kinase inhibitor of the BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTG BC6OTHER .	False
BC6OTHER is a BC6ENTC kinase inhibitor of the BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER BC6ENTG .	False
BC6OTHER is a BC6ENTC kinase inhibitor of the BC6ENTG , BC6OTHER ( BC6OTHER ), and BC6OTHER BC6OTHER .	False
BC6OTHER is a BC6ENTC kinase inhibitor of the BC6OTHER , BC6ENTG ( BC6OTHER ), and BC6OTHER BC6OTHER .	False
Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of BC6ENTC - induced changes in cell morphology and growth similar to changes associated with BC6ENTG ( BC6OTHER ) activation.	CPR:3
Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of BC6ENTC - induced changes in cell morphology and growth similar to changes associated with BC6OTHER ( BC6ENTG ) activation.	CPR:3
For some, pharmacologic inhibitors are available, including BC6ENTC for BC6ENTG , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors.	CPR:4
For some, pharmacologic inhibitors are available, including BC6ENTC for BC6OTHER , BC6ENTG inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6ENTC for BC6OTHER , BC6OTHER inhibitors for BC6ENTG , BC6OTHER for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6ENTC for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6ENTG / BC6OTHER , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6ENTC for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6ENTG , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6ENTC for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6OTHER analogues for BC6ENTG , and agents that inhibit either BC6OTHER or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6ENTC for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6ENTG or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6OTHER for BC6ENTG , BC6OTHER inhibitors for BC6OTHER , BC6ENTC for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6ENTG inhibitors for BC6OTHER , BC6ENTC for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6ENTG , BC6ENTC for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6ENTC for BC6ENTG / BC6OTHER , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors.	CPR:4
For some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6ENTC for BC6OTHER / BC6ENTG , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors.	CPR:4
For some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6ENTC for BC6OTHER / BC6OTHER , BC6OTHER analogues for BC6ENTG , and agents that inhibit either BC6OTHER or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6ENTC for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6ENTG or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6OTHER for BC6ENTG , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6ENTC analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6ENTG inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6ENTC analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6ENTG , BC6OTHER for BC6OTHER / BC6OTHER , BC6ENTC analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6ENTG / BC6OTHER , BC6ENTC analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6ENTG , BC6ENTC analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6ENTC analogues for BC6ENTG , and agents that inhibit either BC6OTHER or its receptors.	CPR:4
For some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6ENTC analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6ENTG or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6OTHER for BC6ENTG , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6ENTC , and agents that inhibit either BC6OTHER or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6ENTG inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6ENTC , and agents that inhibit either BC6OTHER or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6ENTG , BC6OTHER for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6ENTC , and agents that inhibit either BC6OTHER or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6ENTG / BC6OTHER , BC6OTHER analogues for mammalian target of BC6ENTC , and agents that inhibit either BC6OTHER or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6ENTG , BC6OTHER analogues for mammalian target of BC6ENTC , and agents that inhibit either BC6OTHER or its receptors.	False
For some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6ENTC , and agents that inhibit either BC6ENTG or its receptors.	False
In this study, we compared the effects of BC6OTHER and BC6ENTC on regulating serum BC6OTHER and BC6ENTG , and also the expression of BC6OTHER , BC6OTHER , and BC6OTHER mRNA.	False
In this study, we compared the effects of BC6OTHER and BC6ENTC on regulating serum BC6OTHER and BC6OTHER , and also the expression of BC6ENTG , BC6OTHER , and BC6OTHER mRNA.	False
In this study, we compared the effects of BC6OTHER and BC6ENTC on regulating serum BC6OTHER and BC6OTHER , and also the expression of BC6OTHER , BC6ENTG , and BC6OTHER mRNA.	False
In this study, we compared the effects of BC6OTHER and BC6ENTC on regulating serum BC6OTHER and BC6OTHER , and also the expression of BC6OTHER , BC6OTHER , and BC6ENTG mRNA.	False
In this study, we compared the effects of BC6OTHER and BC6OTHER on regulating serum BC6ENTC and BC6ENTG , and also the expression of BC6OTHER , BC6OTHER , and BC6OTHER mRNA.	False
In this study, we compared the effects of BC6OTHER and BC6OTHER on regulating serum BC6ENTC and BC6OTHER , and also the expression of BC6ENTG , BC6OTHER , and BC6OTHER mRNA.	False
In this study, we compared the effects of BC6OTHER and BC6OTHER on regulating serum BC6ENTC and BC6OTHER , and also the expression of BC6OTHER , BC6ENTG , and BC6OTHER mRNA.	False
In this study, we compared the effects of BC6OTHER and BC6OTHER on regulating serum BC6ENTC and BC6OTHER , and also the expression of BC6OTHER , BC6OTHER , and BC6ENTG mRNA.	False
Both drugs at the tested doses (0.042 - 0.33 mug / kg) suppressed BC6ENTG mRNA expression and serum BC6OTHER effectively in the 5 / 6 NX rats, but BC6ENTC was less potent in raising serum BC6OTHER than BC6OTHER .	CPR:4
Both drugs at the tested doses (0.042 - 0.33 mug / kg) suppressed BC6OTHER mRNA expression and serum BC6ENTG effectively in the 5 / 6 NX rats, but BC6ENTC was less potent in raising serum BC6OTHER than BC6OTHER .	CPR:4
Both drugs at the tested doses (0.042 - 0.33 mug / kg) suppressed BC6ENTG mRNA expression and serum BC6OTHER effectively in the 5 / 6 NX rats, but BC6OTHER was less potent in raising serum BC6ENTC than BC6OTHER .	False
Both drugs at the tested doses (0.042 - 0.33 mug / kg) suppressed BC6OTHER mRNA expression and serum BC6ENTG effectively in the 5 / 6 NX rats, but BC6OTHER was less potent in raising serum BC6ENTC than BC6OTHER .	False
Both drugs at the tested doses (0.042 - 0.33 mug / kg) suppressed BC6ENTG mRNA expression and serum BC6OTHER effectively in the 5 / 6 NX rats, but BC6OTHER was less potent in raising serum BC6OTHER than BC6ENTC .	CPR:4
Both drugs at the tested doses (0.042 - 0.33 mug / kg) suppressed BC6OTHER mRNA expression and serum BC6ENTG effectively in the 5 / 6 NX rats, but BC6OTHER was less potent in raising serum BC6OTHER than BC6ENTC .	CPR:4
In pig parathyroid cells, BC6ENTC and the active form of BC6OTHER induced BC6OTHER translocation from the cytoplasm into the nucleus, suppressed BC6OTHER mRNA expression and inhibited cell proliferation in a similar manner, although BC6OTHER induced the expression of BC6ENTG mRNA more effectively.	False
In pig parathyroid cells, BC6ENTC and the active form of BC6OTHER induced BC6ENTG translocation from the cytoplasm into the nucleus, suppressed BC6OTHER mRNA expression and inhibited cell proliferation in a similar manner, although BC6OTHER induced the expression of BC6OTHER mRNA more effectively.	False
In pig parathyroid cells, BC6ENTC and the active form of BC6OTHER induced BC6OTHER translocation from the cytoplasm into the nucleus, suppressed BC6ENTG mRNA expression and inhibited cell proliferation in a similar manner, although BC6OTHER induced the expression of BC6OTHER mRNA more effectively.	CPR:4
In pig parathyroid cells, BC6OTHER and the active form of BC6ENTC induced BC6OTHER translocation from the cytoplasm into the nucleus, suppressed BC6OTHER mRNA expression and inhibited cell proliferation in a similar manner, although BC6OTHER induced the expression of BC6ENTG mRNA more effectively.	False
In pig parathyroid cells, BC6OTHER and the active form of BC6ENTC induced BC6ENTG translocation from the cytoplasm into the nucleus, suppressed BC6OTHER mRNA expression and inhibited cell proliferation in a similar manner, although BC6OTHER induced the expression of BC6OTHER mRNA more effectively.	False
In pig parathyroid cells, BC6OTHER and the active form of BC6ENTC induced BC6OTHER translocation from the cytoplasm into the nucleus, suppressed BC6ENTG mRNA expression and inhibited cell proliferation in a similar manner, although BC6OTHER induced the expression of BC6OTHER mRNA more effectively.	CPR:4
BC6ENTC receptor agonists (VDRAs) directly suppress BC6ENTG ( BC6OTHER ) mRNA expression.	False
BC6ENTC receptor agonists (VDRAs) directly suppress BC6OTHER ( BC6ENTG ) mRNA expression.	False
In pig parathyroid cells, BC6OTHER and the active form of BC6OTHER induced BC6OTHER translocation from the cytoplasm into the nucleus, suppressed BC6OTHER mRNA expression and inhibited cell proliferation in a similar manner, although BC6ENTC induced the expression of BC6ENTG mRNA more effectively.	CPR:3
In pig parathyroid cells, BC6OTHER and the active form of BC6OTHER induced BC6ENTG translocation from the cytoplasm into the nucleus, suppressed BC6OTHER mRNA expression and inhibited cell proliferation in a similar manner, although BC6ENTC induced the expression of BC6OTHER mRNA more effectively.	False
In pig parathyroid cells, BC6OTHER and the active form of BC6OTHER induced BC6OTHER translocation from the cytoplasm into the nucleus, suppressed BC6ENTG mRNA expression and inhibited cell proliferation in a similar manner, although BC6ENTC induced the expression of BC6OTHER mRNA more effectively.	False
The multiple effects of VDRAs on modulating serum BC6ENTC , parathyroid cell proliferation, and the expression of BC6ENTG and BC6OTHER mRNA reflect the complex involvement of the BC6OTHER axis in regulating the mineral homeostasis system.	False
The multiple effects of VDRAs on modulating serum BC6ENTC , parathyroid cell proliferation, and the expression of BC6OTHER and BC6ENTG mRNA reflect the complex involvement of the BC6OTHER axis in regulating the mineral homeostasis system.	False
The multiple effects of VDRAs on modulating serum BC6OTHER , parathyroid cell proliferation, and the expression of BC6ENTG and BC6OTHER mRNA reflect the complex involvement of the BC6ENTC axis in regulating the mineral homeostasis system.	False
The multiple effects of VDRAs on modulating serum BC6OTHER , parathyroid cell proliferation, and the expression of BC6OTHER and BC6ENTG mRNA reflect the complex involvement of the BC6ENTC axis in regulating the mineral homeostasis system.	False
Different VDRAs are known to have differential effects on serum BC6ENTC ( BC6OTHER ), which may also affect serum BC6ENTG levels since serum BC6OTHER regulates BC6OTHER secretion mediated by the BC6OTHER - sensing receptor ( BC6OTHER ).	False
Different VDRAs are known to have differential effects on serum BC6ENTC ( BC6OTHER ), which may also affect serum BC6OTHER levels since serum BC6OTHER regulates BC6ENTG secretion mediated by the BC6OTHER - sensing receptor ( BC6OTHER ).	False
Different VDRAs are known to have differential effects on serum BC6ENTC ( BC6OTHER ), which may also affect serum BC6OTHER levels since serum BC6OTHER regulates BC6OTHER secretion mediated by the BC6ENTG ( BC6OTHER ).	False
Different VDRAs are known to have differential effects on serum BC6ENTC ( BC6OTHER ), which may also affect serum BC6OTHER levels since serum BC6OTHER regulates BC6OTHER secretion mediated by the BC6OTHER - sensing receptor ( BC6ENTG ).	False
Different VDRAs are known to have differential effects on serum BC6OTHER ( BC6ENTC ), which may also affect serum BC6ENTG levels since serum BC6OTHER regulates BC6OTHER secretion mediated by the BC6OTHER - sensing receptor ( BC6OTHER ).	False
Different VDRAs are known to have differential effects on serum BC6OTHER ( BC6ENTC ), which may also affect serum BC6OTHER levels since serum BC6OTHER regulates BC6ENTG secretion mediated by the BC6OTHER - sensing receptor ( BC6OTHER ).	False
Different VDRAs are known to have differential effects on serum BC6OTHER ( BC6ENTC ), which may also affect serum BC6OTHER levels since serum BC6OTHER regulates BC6OTHER secretion mediated by the BC6ENTG ( BC6OTHER ).	False
Different VDRAs are known to have differential effects on serum BC6OTHER ( BC6ENTC ), which may also affect serum BC6OTHER levels since serum BC6OTHER regulates BC6OTHER secretion mediated by the BC6OTHER - sensing receptor ( BC6ENTG ).	False
Different VDRAs are known to have differential effects on serum BC6OTHER ( BC6OTHER ), which may also affect serum BC6ENTG levels since serum BC6ENTC regulates BC6OTHER secretion mediated by the BC6OTHER - sensing receptor ( BC6OTHER ).	False
Different VDRAs are known to have differential effects on serum BC6OTHER ( BC6OTHER ), which may also affect serum BC6OTHER levels since serum BC6ENTC regulates BC6ENTG secretion mediated by the BC6OTHER - sensing receptor ( BC6OTHER ).	CPR:3
Different VDRAs are known to have differential effects on serum BC6OTHER ( BC6OTHER ), which may also affect serum BC6OTHER levels since serum BC6ENTC regulates BC6OTHER secretion mediated by the BC6ENTG ( BC6OTHER ).	False
Different VDRAs are known to have differential effects on serum BC6OTHER ( BC6OTHER ), which may also affect serum BC6OTHER levels since serum BC6ENTC regulates BC6OTHER secretion mediated by the BC6OTHER - sensing receptor ( BC6ENTG ).	False
Different VDRAs are known to have differential effects on serum BC6OTHER ( BC6OTHER ), which may also affect serum BC6ENTG levels since serum BC6OTHER regulates BC6OTHER secretion mediated by the BC6ENTC - sensing receptor ( BC6OTHER ).	False
Different VDRAs are known to have differential effects on serum BC6OTHER ( BC6OTHER ), which may also affect serum BC6OTHER levels since serum BC6OTHER regulates BC6ENTG secretion mediated by the BC6ENTC - sensing receptor ( BC6OTHER ).	False
Different VDRAs are known to have differential effects on serum BC6OTHER ( BC6OTHER ), which may also affect serum BC6OTHER levels since serum BC6OTHER regulates BC6OTHER secretion mediated by the BC6ENTC - sensing receptor ( BC6ENTG ).	False
In this study, we compared the effects of BC6ENTC and BC6OTHER on regulating serum BC6OTHER and BC6ENTG , and also the expression of BC6OTHER , BC6OTHER , and BC6OTHER mRNA.	False
In this study, we compared the effects of BC6ENTC and BC6OTHER on regulating serum BC6OTHER and BC6OTHER , and also the expression of BC6ENTG , BC6OTHER , and BC6OTHER mRNA.	False
In this study, we compared the effects of BC6ENTC and BC6OTHER on regulating serum BC6OTHER and BC6OTHER , and also the expression of BC6OTHER , BC6ENTG , and BC6OTHER mRNA.	False
In this study, we compared the effects of BC6ENTC and BC6OTHER on regulating serum BC6OTHER and BC6OTHER , and also the expression of BC6OTHER , BC6OTHER , and BC6ENTG mRNA.	False
The existence of multiple affinity states for the opiate receptor in neuroblastoma x glioma NG108 - 15 hybrid cells has been demonstrated by competition binding studies with BC6OTHER and [D - Ala2, D - Leu5] BC6ENTG ( BC6ENTC ).	False
However, in the presence of 100 mM BC6ENTC , which is required for opiate inhibition of BC6ENTG activity, analysis of competition binding data revealed three sites: the first, consisting of 17.5% of total receptor population has a Kd = 0.38 + / - 0.18 nM; the second, 50.6% of the population, has a Kd = 6.8 + / - 2.2 nM; and the third, 31.9% of the population, has a Kd of 410 + / - 110 nM.	CPR:4
These multiple affinity states of receptor in the hybrid cells are agonist - specific, and the percentage of total BC6ENTG in high affinity state is relatively constant in various concentrations of BC6ENTC .	False
Multiple affinity states of BC6ENTG can be demonstrated further by Scatchard analysis of saturation binding studies with BC6ENTC .	False
The existence of multiple affinity states for the opiate receptor in neuroblastoma x glioma NG108 - 15 hybrid cells has been demonstrated by competition binding studies with BC6ENTC and [D - Ala2, D - Leu5] BC6ENTG ( BC6OTHER ).	False
PURPOSE: BC6ENTC has (R) - and CHEM, which exhibit different pharmacokinetics (PK) among patients with BC6ENTG genotype groups.	CPR:9
The BC6ENTC hydroxylation index reflects BC6ENTG activity in healthy Japanese volunteers.	CPR:9
Additionally, there was a significant difference in plasma concentrations of BC6ENTC among BC6ENTG genotype groups, whereas no significant differences were observed in that of BC6OTHER .	CPR:9
Additionally, there was a significant difference in plasma concentrations of BC6OTHER among BC6ENTG genotype groups, whereas no significant differences were observed in that of BC6ENTC .	CPR:9
CONCLUSION: Our findings demonstrate that BC6ENTC HI correlated better with BC6ENTG genotype groups than BC6OTHER HI, and these results may be useful for classification among patients in BC6OTHER genotype groups prior to CHEM treatment.	CPR:9
CONCLUSION: Our findings demonstrate that BC6ENTC HI correlated better with BC6OTHER genotype groups than BC6OTHER HI, and these results may be useful for classification among patients in BC6ENTG genotype groups prior to CHEM treatment.	False
CONCLUSION: Our findings demonstrate that BC6OTHER HI correlated better with BC6ENTG genotype groups than BC6ENTC HI, and these results may be useful for classification among patients in BC6OTHER genotype groups prior to CHEM treatment.	CPR:9
CONCLUSION: Our findings demonstrate that BC6OTHER HI correlated better with BC6OTHER genotype groups than BC6ENTC HI, and these results may be useful for classification among patients in BC6ENTG genotype groups prior to CHEM treatment.	False
The aim of this study was to investigate whether the 1 - point, 4 - h postdose BC6ENTC hydroxylation index (HI) of BC6OTHER reflects the three BC6ENTG genotype groups in Japanese individuals.	False
The aim of this study was to investigate whether the 1 - point, 4 - h postdose BC6OTHER hydroxylation index (HI) of BC6ENTC reflects the three BC6ENTG genotype groups in Japanese individuals.	False
Compounds 16 and 19 were more active than the positive control BC6ENTC , a known inhibitor of the BC6ENTG signaling pathway.	False
The cytosolic fraction obtained from pancreatic islets obtained from BC6ENTC - treated rats had an increased BC6ENTG level compared to the levels obtained from the pancreatic islets of control rats.	CPR:3
To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of BC6ENTC ( BC6OTHER ), we focused on the role of BC6ENTG ( BC6OTHER ) in islet BC6OTHER synthesis.	False
To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of BC6ENTC ( BC6OTHER ), we focused on the role of BC6OTHER ( BC6ENTG ) in islet BC6OTHER synthesis.	False
To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of BC6ENTC ( BC6OTHER ), we focused on the role of BC6OTHER ( BC6OTHER ) in islet BC6ENTG synthesis.	False
To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of BC6OTHER ( BC6ENTC ), we focused on the role of BC6ENTG ( BC6OTHER ) in islet BC6OTHER synthesis.	False
To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of BC6OTHER ( BC6ENTC ), we focused on the role of BC6OTHER ( BC6ENTG ) in islet BC6OTHER synthesis.	False
To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of BC6OTHER ( BC6ENTC ), we focused on the role of BC6OTHER ( BC6OTHER ) in islet BC6ENTG synthesis.	False
In the present study, BC6ENTC - stimulated BC6ENTG secretion was significantly increased in BC6OTHER - treated rats compared to controls.	CPR:3
In the present study, BC6OTHER - stimulated BC6ENTG secretion was significantly increased in BC6ENTC - treated rats compared to controls.	CPR:3
Levels of mRNA encoding BC6ENTG , BC6OTHER , and BC6OTHER were increased in the pancreatic islets of BC6ENTC - treated rats.	CPR:3
Levels of mRNA encoding BC6OTHER , BC6ENTG , and BC6OTHER were increased in the pancreatic islets of BC6ENTC - treated rats.	CPR:3
Levels of mRNA encoding BC6OTHER , BC6OTHER , and BC6ENTG were increased in the pancreatic islets of BC6ENTC - treated rats.	False
When the BC6ENTG in BC6OTHER mRNA was incubated with the islet cytosolic fraction, the RNA - protein complex level was increased in the cytosolic fraction obtained from BC6ENTC - treated rats compared to the level in control rats.	CPR:3
When the BC6OTHER in BC6ENTG mRNA was incubated with the islet cytosolic fraction, the RNA - protein complex level was increased in the cytosolic fraction obtained from BC6ENTC - treated rats compared to the level in control rats.	CPR:3
BC6ENTC , a BC6ENTG inhibitor and anti - inflammatory compound used in traditional Chinese medicine, also decreased BC6OTHER - induced phosphorylation of BC6OTHER and BC6OTHER , and suppressed basal, BC6OTHER - and BC6OTHER ( BC6OTHER ) - induced BC6OTHER reporter gene activity.	CPR:4
BC6ENTC , a BC6OTHER inhibitor and anti - inflammatory compound used in traditional Chinese medicine, also decreased BC6ENTG - induced phosphorylation of BC6OTHER and BC6OTHER , and suppressed basal, BC6OTHER - and BC6OTHER ( BC6OTHER ) - induced BC6OTHER reporter gene activity.	CPR:4
BC6ENTC , a BC6OTHER inhibitor and anti - inflammatory compound used in traditional Chinese medicine, also decreased BC6OTHER - induced phosphorylation of BC6ENTG and BC6OTHER , and suppressed basal, BC6OTHER - and BC6OTHER ( BC6OTHER ) - induced BC6OTHER reporter gene activity.	CPR:4
BC6ENTC , a BC6OTHER inhibitor and anti - inflammatory compound used in traditional Chinese medicine, also decreased BC6OTHER - induced phosphorylation of BC6OTHER and BC6ENTG , and suppressed basal, BC6OTHER - and BC6OTHER ( BC6OTHER ) - induced BC6OTHER reporter gene activity.	CPR:4
BC6ENTC , a BC6OTHER inhibitor and anti - inflammatory compound used in traditional Chinese medicine, also decreased BC6OTHER - induced phosphorylation of BC6OTHER and BC6OTHER , and suppressed basal, BC6ENTG - and BC6OTHER ( BC6OTHER ) - induced BC6OTHER reporter gene activity.	CPR:4
BC6ENTC , a BC6OTHER inhibitor and anti - inflammatory compound used in traditional Chinese medicine, also decreased BC6OTHER - induced phosphorylation of BC6OTHER and BC6OTHER , and suppressed basal, BC6OTHER - and BC6ENTG ( BC6OTHER ) - induced BC6OTHER reporter gene activity.	CPR:4
BC6ENTC , a BC6OTHER inhibitor and anti - inflammatory compound used in traditional Chinese medicine, also decreased BC6OTHER - induced phosphorylation of BC6OTHER and BC6OTHER , and suppressed basal, BC6OTHER - and BC6OTHER ( BC6ENTG ) - induced BC6OTHER reporter gene activity.	False
BC6ENTC , a BC6OTHER inhibitor and anti - inflammatory compound used in traditional Chinese medicine, also decreased BC6OTHER - induced phosphorylation of BC6OTHER and BC6OTHER , and suppressed basal, BC6OTHER - and BC6OTHER ( BC6OTHER ) - induced BC6ENTG reporter gene activity.	CPR:4
BC6ENTC also inhibited cell proliferation, while increasing sub - G0 DNA fragmentation and BC6ENTG markers of apoptosis.	CPR:3
BC6ENTC highlights the therapeutic potential of agents targeting BC6ENTG as a key node in this pro - oncogenic BC6OTHER - BC6OTHER signal pathway.	CPR:4
BC6ENTC highlights the therapeutic potential of agents targeting BC6OTHER as a key node in this pro - oncogenic BC6ENTG - BC6OTHER signal pathway.	False
BC6ENTC highlights the therapeutic potential of agents targeting BC6OTHER as a key node in this pro - oncogenic BC6OTHER - BC6ENTG signal pathway.	False
BC6ENTC and BC6OTHER , but not BC6OTHER , caused a dose - dependent reduction in plasma BC6ENTG , an effect that correlated with BC6OTHER - induced bone effects.	CPR:4
BC6OTHER and BC6ENTC , but not BC6OTHER , caused a dose - dependent reduction in plasma BC6ENTG , an effect that correlated with BC6OTHER - induced bone effects.	CPR:4
BC6OTHER and BC6OTHER , but not BC6ENTC , caused a dose - dependent reduction in plasma BC6ENTG , an effect that correlated with BC6OTHER - induced bone effects.	CPR:4
BC6OTHER and BC6OTHER , but not BC6OTHER , caused a dose - dependent reduction in plasma BC6ENTG , an effect that correlated with BC6ENTC - induced bone effects.	False
In contrast, serum BC6ENTG was elevated in animals dosed with BC6ENTC or BC6OTHER but not in those dose with BC6OTHER .	CPR:3
In contrast, serum BC6ENTG was elevated in animals dosed with BC6OTHER or BC6ENTC but not in those dose with BC6OTHER .	CPR:3
In contrast, serum BC6ENTG was elevated in animals dosed with BC6OTHER or BC6OTHER but not in those dose with BC6ENTC .	False
Hence, plasma BC6ENTG is a better predictor of BC6ENTC - induced bone effects than serum BC6OTHER .	False
Hence, plasma BC6OTHER is a better predictor of BC6ENTC - induced bone effects than serum BC6ENTG .	False
The BC6ENTC had no effect on BC6ENTG times of animals fed the supplemented diet.	False
When BC6ENTC was omitted from the diet, however, BC6OTHER - dosed animals had elevated BC6ENTG times.	False
When BC6OTHER was omitted from the diet, however, BC6ENTC - dosed animals had elevated BC6ENTG times.	CPR:3
BC6ENTC - dosed animals showed no change in BC6ENTG times.	False
In the high - dose BC6ENTC group, there was a twofold increase in BC6ENTG times but only after prolonged dosing.	CPR:3
For all BC6ENTC - dosed groups maintained on the purified diet, changes in BC6ENTG times occured as early as 1 week.	False
The order of effect was BC6ENTC greater than BC6OTHER greater than BC6OTHER , with increases in BC6ENTG times correlating with increases in hemorrhagic deaths.	CPR:3
The order of effect was BC6OTHER greater than BC6ENTC greater than BC6OTHER , with increases in BC6ENTG times correlating with increases in hemorrhagic deaths.	CPR:3
The order of effect was BC6OTHER greater than BC6OTHER greater than BC6ENTC , with increases in BC6ENTG times correlating with increases in hemorrhagic deaths.	CPR:3
This effect was reverted in the presence of BC6ENTC ( BC6OTHER ; 0.1 microM), which blocks the pre - synaptic BC6ENTG .	CPR:4
This effect was reverted in the presence of BC6OTHER ( BC6ENTC ; 0.1 microM), which blocks the pre - synaptic BC6ENTG .	CPR:4
After that, a wide range of concentrations of drugs, concomitantly with BC6ENTC (0.1 microM), was studied in the presence of BC6OTHER ( BC6OTHER ; 0.01 microM), a BC6ENTG antagonist.	False
After that, a wide range of concentrations of drugs, concomitantly with BC6OTHER (0.1 microM), was studied in the presence of BC6ENTC ( BC6OTHER ; 0.01 microM), a BC6ENTG antagonist.	CPR:6
After that, a wide range of concentrations of drugs, concomitantly with BC6OTHER (0.1 microM), was studied in the presence of BC6OTHER ( BC6ENTC ; 0.01 microM), a BC6ENTG antagonist.	CPR:6
 BC6ENTG potentiator drugs, huprine X and BC6ENTC , increase BC6OTHER release by blocking BC6OTHER activity but not acting on BC6OTHER .	False
 BC6OTHER potentiator drugs, huprine X and BC6ENTC , increase BC6OTHER release by blocking BC6OTHER activity but not acting on BC6ENTG .	False
 BC6OTHER potentiator drugs, huprine X and BC6ENTC , increase BC6OTHER release by blocking BC6ENTG activity but not acting on BC6OTHER .	CPR:4
 BC6ENTG potentiator drugs, huprine X and BC6OTHER , increase BC6ENTC release by blocking BC6OTHER activity but not acting on BC6OTHER .	False
 BC6OTHER potentiator drugs, huprine X and BC6OTHER , increase BC6ENTC release by blocking BC6OTHER activity but not acting on BC6ENTG .	False
 BC6OTHER potentiator drugs, huprine X and BC6OTHER , increase BC6ENTC release by blocking BC6ENTG activity but not acting on BC6OTHER .	False
To test the role of BC6ENTG in the drugs' effects on BC6ENTC release, BC6OTHER ( BC6OTHER ) 100 microM was used to block such receptors.	False
To test the role of BC6ENTG in the drugs' effects on BC6OTHER release, BC6ENTC ( BC6OTHER ) 100 microM was used to block such receptors.	CPR:4
To test the role of BC6ENTG in the drugs' effects on BC6OTHER release, BC6OTHER ( BC6ENTC ) 100 microM was used to block such receptors.	CPR:4
The main goal of the present study was to analyse the effects of (+ / - ) - huprine X ((+ / - ) - HX) and CHEM (CHEM), with potentiating action on BC6ENTG , and CHEM (CHEM), devoid of nicotinic activity, on BC6ENTC ( BC6OTHER ) release in striatal slices of rat brain.	False
The main goal of the present study was to analyse the effects of (+ / - ) - huprine X ((+ / - ) - HX) and CHEM (CHEM), with potentiating action on BC6ENTG , and CHEM (CHEM), devoid of nicotinic activity, on BC6OTHER ( BC6ENTC ) release in striatal slices of rat brain.	False
Results showed that BC6ENTC increased nuclear levels of BC6ENTG , and both BC6OTHER and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F).	CPR:3
Results showed that BC6ENTC increased nuclear levels of BC6OTHER , and both BC6OTHER and adenovirus - mediated overexpression of BC6ENTG (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F).	False
Results showed that BC6ENTC increased nuclear levels of BC6OTHER , and both BC6OTHER and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6ENTG ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F).	False
Results showed that BC6ENTC increased nuclear levels of BC6OTHER , and both BC6OTHER and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F).	False
Results showed that BC6ENTC increased nuclear levels of BC6OTHER , and both BC6OTHER and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6ENTG ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F).	False
Results showed that BC6ENTC increased nuclear levels of BC6OTHER , and both BC6OTHER and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6ENTG ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F).	False
Results showed that BC6ENTC increased nuclear levels of BC6OTHER , and both BC6OTHER and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTG and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F).	False
Results showed that BC6ENTC increased nuclear levels of BC6OTHER , and both BC6OTHER and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6ENTG expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F).	False
Results showed that BC6ENTC increased nuclear levels of BC6OTHER , and both BC6OTHER and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6ENTG - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F).	False
Results showed that BC6OTHER increased nuclear levels of BC6ENTG , and both BC6ENTC and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F).	False
Results showed that BC6OTHER increased nuclear levels of BC6OTHER , and both BC6ENTC and adenovirus - mediated overexpression of BC6ENTG (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F).	CPR:3
Results showed that BC6OTHER increased nuclear levels of BC6OTHER , and both BC6ENTC and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6ENTG ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F).	False
Results showed that BC6OTHER increased nuclear levels of BC6OTHER , and both BC6ENTC and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F).	CPR:4
Results showed that BC6OTHER increased nuclear levels of BC6OTHER , and both BC6ENTC and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6ENTG ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F).	CPR:4
Results showed that BC6OTHER increased nuclear levels of BC6OTHER , and both BC6ENTC and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6ENTG ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F).	CPR:4
Results showed that BC6OTHER increased nuclear levels of BC6OTHER , and both BC6ENTC and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTG and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F).	CPR:4
Results showed that BC6OTHER increased nuclear levels of BC6OTHER , and both BC6ENTC and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6ENTG expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F).	CPR:4
Results showed that BC6OTHER increased nuclear levels of BC6OTHER , and both BC6ENTC and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6ENTG - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F).	False
Additionally, BC6ENTC and Ad - BC6ENTG repressed BC6OTHER - stimulated BC6OTHER activity by inhibiting BC6OTHER phosphorylation, which was restored by siRNA - mediated knockdown of BC6OTHER expression.	False
Additionally, BC6ENTC and Ad - BC6OTHER repressed BC6ENTG - stimulated BC6OTHER activity by inhibiting BC6OTHER phosphorylation, which was restored by siRNA - mediated knockdown of BC6OTHER expression.	CPR:4
Additionally, BC6ENTC and Ad - BC6OTHER repressed BC6OTHER - stimulated BC6ENTG activity by inhibiting BC6OTHER phosphorylation, which was restored by siRNA - mediated knockdown of BC6OTHER expression.	CPR:4
Additionally, BC6ENTC and Ad - BC6OTHER repressed BC6OTHER - stimulated BC6OTHER activity by inhibiting BC6ENTG phosphorylation, which was restored by siRNA - mediated knockdown of BC6OTHER expression.	CPR:4
Additionally, BC6ENTC and Ad - BC6OTHER repressed BC6OTHER - stimulated BC6OTHER activity by inhibiting BC6OTHER phosphorylation, which was restored by siRNA - mediated knockdown of BC6ENTG expression.	False
 BC6ENTC attenuates renal fibrosis via BC6OTHER - mediated inhibition of BC6OTHER / BC6ENTG signaling.	CPR:4
 BC6ENTC attenuates renal fibrosis via BC6ENTG - mediated inhibition of BC6OTHER / BC6OTHER signaling.	False
 BC6ENTC attenuates renal fibrosis via BC6OTHER - mediated inhibition of BC6ENTG / BC6OTHER signaling.	CPR:4
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6ENTG , BC6OTHER and BC6ENTC BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6ENTG and BC6ENTC BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6ENTC BC6OTHER - transferase ( BC6ENTG ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6ENTC BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6ENTG - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6ENTC BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6ENTG - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6ENTG ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6ENTC BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6ENTG ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6ENTC BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6ENTG target genes such as BC6OTHER , BC6OTHER and BC6ENTC BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6ENTG , BC6OTHER and BC6OTHER BC6ENTC - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6ENTG and BC6OTHER BC6ENTC - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6ENTC - transferase ( BC6ENTG ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6ENTC - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6ENTG - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6ENTC - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6ENTG - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6ENTG ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6ENTC - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6ENTG ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6ENTC - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6ENTG target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6ENTC - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6ENTG , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6ENTC on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6ENTG and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6ENTC on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ) did not reverse the inhibitory effect of BC6ENTC on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6ENTG ) did not reverse the inhibitory effect of BC6ENTC on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6ENTC on BC6ENTG - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	CPR:4
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6ENTC on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6ENTG - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6ENTG ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6ENTC on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6ENTG ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6ENTC on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6ENTG target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6ENTC on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6ENTG , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6ENTC .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6ENTG and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6ENTC .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6ENTC .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6ENTG ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6ENTC .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6ENTG - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6ENTC .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6ENTG - independent anti - fibrotic activity of BC6ENTC .	False
However, downregulation of the BC6ENTG ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6ENTC .	False
However, downregulation of the BC6OTHER ( BC6ENTG ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6ENTC .	False
However, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6ENTG target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6ENTC .	False
Finally, BC6ENTC suppressed unilateral ureteral obstruction (UUO) - induced renal fibrosis and BC6ENTG , BC6OTHER and BC6OTHER expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of BC6OTHER and BC6OTHER , respectively.	CPR:4
Finally, BC6ENTC suppressed unilateral ureteral obstruction (UUO) - induced renal fibrosis and BC6OTHER , BC6ENTG and BC6OTHER expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of BC6OTHER and BC6OTHER , respectively.	CPR:4
Finally, BC6ENTC suppressed unilateral ureteral obstruction (UUO) - induced renal fibrosis and BC6OTHER , BC6OTHER and BC6ENTG expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of BC6OTHER and BC6OTHER , respectively.	CPR:4
Finally, BC6ENTC suppressed unilateral ureteral obstruction (UUO) - induced renal fibrosis and BC6OTHER , BC6OTHER and BC6OTHER expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of BC6ENTG and BC6OTHER , respectively.	CPR:3
Finally, BC6ENTC suppressed unilateral ureteral obstruction (UUO) - induced renal fibrosis and BC6OTHER , BC6OTHER and BC6OTHER expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of BC6OTHER and BC6ENTG , respectively.	CPR:4
In summary, BC6ENTC attenuated renal fibrosis via the BC6ENTG - mediated inhibition of BC6OTHER / BC6OTHER signaling in an BC6OTHER - independent manner, suggesting that BC6OTHER could be used to treat renal fibrosis.	False
In summary, BC6ENTC attenuated renal fibrosis via the BC6OTHER - mediated inhibition of BC6ENTG / BC6OTHER signaling in an BC6OTHER - independent manner, suggesting that BC6OTHER could be used to treat renal fibrosis.	CPR:4
In summary, BC6ENTC attenuated renal fibrosis via the BC6OTHER - mediated inhibition of BC6OTHER / BC6ENTG signaling in an BC6OTHER - independent manner, suggesting that BC6OTHER could be used to treat renal fibrosis.	CPR:4
In summary, BC6ENTC attenuated renal fibrosis via the BC6OTHER - mediated inhibition of BC6OTHER / BC6OTHER signaling in an BC6ENTG - independent manner, suggesting that BC6OTHER could be used to treat renal fibrosis.	False
In summary, BC6OTHER attenuated renal fibrosis via the BC6ENTG - mediated inhibition of BC6OTHER / BC6OTHER signaling in an BC6OTHER - independent manner, suggesting that BC6ENTC could be used to treat renal fibrosis.	False
In summary, BC6OTHER attenuated renal fibrosis via the BC6OTHER - mediated inhibition of BC6ENTG / BC6OTHER signaling in an BC6OTHER - independent manner, suggesting that BC6ENTC could be used to treat renal fibrosis.	False
In summary, BC6OTHER attenuated renal fibrosis via the BC6OTHER - mediated inhibition of BC6OTHER / BC6ENTG signaling in an BC6OTHER - independent manner, suggesting that BC6ENTC could be used to treat renal fibrosis.	False
In summary, BC6OTHER attenuated renal fibrosis via the BC6OTHER - mediated inhibition of BC6OTHER / BC6OTHER signaling in an BC6ENTG - independent manner, suggesting that BC6ENTC could be used to treat renal fibrosis.	False
This study examines whether BC6ENTC ( BC6OTHER ), which stimulates BC6ENTG , prevents renal fibrosis via the BC6OTHER - mediated suppression of BC6OTHER signaling.	False
This study examines whether BC6ENTC ( BC6OTHER ), which stimulates BC6OTHER , prevents renal fibrosis via the BC6ENTG - mediated suppression of BC6OTHER signaling.	False
This study examines whether BC6ENTC ( BC6OTHER ), which stimulates BC6OTHER , prevents renal fibrosis via the BC6OTHER - mediated suppression of BC6ENTG signaling.	False
This study examines whether BC6OTHER ( BC6ENTC ), which stimulates BC6ENTG , prevents renal fibrosis via the BC6OTHER - mediated suppression of BC6OTHER signaling.	False
This study examines whether BC6OTHER ( BC6ENTC ), which stimulates BC6OTHER , prevents renal fibrosis via the BC6ENTG - mediated suppression of BC6OTHER signaling.	False
This study examines whether BC6OTHER ( BC6ENTC ), which stimulates BC6OTHER , prevents renal fibrosis via the BC6OTHER - mediated suppression of BC6ENTG signaling.	False
SAR beyond protein - ligand interactions: By combining structure - affinity relationships, protein - ligand modeling studies, and quantum mechanical calculations, we show that ligand conformational energies and basicity play critical roles in ligand binding to the BC6ENTC H4 receptor, a BC6ENTG that plays a key role in inflammation.	False
Using BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6ENTC analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	CPR:6
Using BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6ENTC analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	False
Using BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6ENTC ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	CPR:6
Using BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6ENTC ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	False
Using BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6ENTC ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	CPR:6
Using BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6ENTC ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	False
Using BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6ENTC , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	CPR:6
Using BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6ENTC , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	False
BC6OTHER ( BC6OTHER ) is a recently introduced antagonist of the human BC6ENTC and BC6OTHER transporters ( BC6ENTG and BC6OTHER , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	False
BC6OTHER ( BC6OTHER ) is a recently introduced antagonist of the human BC6ENTC and BC6OTHER transporters ( BC6OTHER and BC6ENTG , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	False
Using BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6ENTC analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	CPR:6
Using BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6ENTC analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	False
Using BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6ENTC ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	CPR:6
Using BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6ENTC ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	False
Using BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6ENTC ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	CPR:6
Using BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6ENTC ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	False
Using BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6ENTC , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	False
Using BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6ENTC , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	CPR:6
Using BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6ENTC , BC6OTHER antidepressants, and BC6OTHER .	False
Using BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6ENTC , BC6OTHER antidepressants, and BC6OTHER .	CPR:6
BC6ENTC ( BC6OTHER ) is a recently introduced antagonist of the human BC6OTHER and BC6OTHER transporters ( BC6ENTG and BC6OTHER , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	CPR:6
BC6ENTC ( BC6OTHER ) is a recently introduced antagonist of the human BC6OTHER and BC6OTHER transporters ( BC6OTHER and BC6ENTG , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	CPR:6
BC6ENTC ( BC6OTHER ) is a recently introduced antagonist of the BC6ENTG BC6OTHER transporters ( BC6OTHER and BC6OTHER , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	False
Using BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6ENTC antidepressants, and BC6OTHER .	False
Using BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6ENTC antidepressants, and BC6OTHER .	CPR:6
BC6OTHER ( BC6OTHER ) is a recently introduced antagonist of the human BC6OTHER and BC6ENTC transporters ( BC6ENTG and BC6OTHER , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	False
BC6OTHER ( BC6OTHER ) is a recently introduced antagonist of the human BC6OTHER and BC6ENTC transporters ( BC6OTHER and BC6ENTG , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	False
BC6OTHER ( BC6OTHER ) is a recently introduced antagonist of the BC6ENTG BC6ENTC transporters ( BC6OTHER and BC6OTHER , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	False
Using BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6ENTC .	False
Using BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6ENTC .	CPR:6
 BC6ENTC identifies novel antagonist binding determinants in the BC6ENTG .	CPR:6
In an initial search for molecular features that differentially define antagonist binding determinants, we document that CHEM148 in BC6ENTG selectively disrupts BC6ENTC binding but not that of DVS.	False
BC6OTHER ( BC6ENTC ) is a recently introduced antagonist of the human BC6OTHER and BC6OTHER transporters ( BC6ENTG and BC6OTHER , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	CPR:6
BC6OTHER ( BC6ENTC ) is a recently introduced antagonist of the human BC6OTHER and BC6OTHER transporters ( BC6OTHER and BC6ENTG , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	CPR:6
BC6OTHER ( BC6ENTC ) is a recently introduced antagonist of the BC6ENTG BC6OTHER transporters ( BC6OTHER and BC6OTHER , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	False
Initial evaluation of the pharmacological properties of BC6ENTC (J Pharmacol Exp CHEM 318:657 - 665, 2006) revealed significantly reduced potency for the BC6ENTG expressed in membranes compared with whole cells when competing for BC6OTHER ( BC6OTHER ) binding.	False
Initial evaluation of the pharmacological properties of BC6OTHER (J Pharmacol Exp CHEM 318:657 - 665, 2006) revealed significantly reduced potency for the BC6ENTG expressed in membranes compared with whole cells when competing for BC6ENTC ( BC6OTHER ) binding.	False
Initial evaluation of the pharmacological properties of BC6OTHER (J Pharmacol Exp CHEM 318:657 - 665, 2006) revealed significantly reduced potency for the BC6ENTG expressed in membranes compared with whole cells when competing for BC6OTHER ( BC6ENTC ) binding.	False
Using BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6ENTC at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	False
Using BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6ENTC at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	False
Using BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6ENTC was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	False
Using BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6ENTC was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	False
Using BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6ENTC , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	CPR:6
Using BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6ENTC , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER .	False
Parenteral administration of selective agonists of the BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER and BC6OTHER ), and BC6OTHER ( BC6ENTC ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively.	False
Parenteral administration of selective agonists of the BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER and BC6OTHER ), and BC6OTHER ( BC6ENTC ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively.	False
Parenteral administration of selective agonists of the BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER and BC6OTHER ), and BC6ENTG ( BC6ENTC ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively.	CPR:5
Parenteral administration of selective agonists of the BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER and BC6OTHER ), and BC6OTHER ( BC6OTHER ) produced dose - related inhibition of BC6ENTC - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively.	False
Parenteral administration of selective agonists of the BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER and BC6OTHER ), and BC6OTHER ( BC6OTHER ) produced dose - related inhibition of BC6ENTC - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively.	False
Parenteral administration of selective agonists of the BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER and BC6OTHER ), and BC6ENTG ( BC6OTHER ) produced dose - related inhibition of BC6ENTC - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively.	False
 The nonselective BC6ENTG antagonist, BC6ENTC (3 mg / kg, i.m.), attenuated the antitussive effects of BC6OTHER or BC6OTHER , indicating that the antitussive activity of both compounds is BC6OTHER - mediated.	CPR:6
 The nonselective BC6OTHER antagonist, BC6ENTC (3 mg / kg, i.m.), attenuated the antitussive effects of BC6OTHER or BC6OTHER , indicating that the antitussive activity of both compounds is BC6ENTG - mediated.	False
 The nonselective BC6ENTG antagonist, BC6OTHER (3 mg / kg, i.m.), attenuated the antitussive effects of BC6ENTC or BC6OTHER , indicating that the antitussive activity of both compounds is BC6OTHER - mediated.	CPR:5
 The nonselective BC6OTHER antagonist, BC6OTHER (3 mg / kg, i.m.), attenuated the antitussive effects of BC6ENTC or BC6OTHER , indicating that the antitussive activity of both compounds is BC6ENTG - mediated.	CPR:5
 The nonselective BC6ENTG antagonist, BC6OTHER (3 mg / kg, i.m.), attenuated the antitussive effects of BC6OTHER or BC6ENTC , indicating that the antitussive activity of both compounds is BC6OTHER - mediated.	CPR:5
 The nonselective BC6OTHER antagonist, BC6OTHER (3 mg / kg, i.m.), attenuated the antitussive effects of BC6OTHER or BC6ENTC , indicating that the antitussive activity of both compounds is BC6ENTG - mediated.	CPR:5
The BC6ENTG antagonist, BC6ENTC (10 mg / kg, i.p.	CPR:6
In contrast, combined pretreatment with BC6ENTC ( BC6OTHER antagonist; 20 mg / kg, s.c.) and BC6OTHER ( BC6OTHER antagonist; 20 mg / kg, s.c.), at doses that inhibited the antitussive activity of BC6ENTG agonists, respectively, was without effect on the antitussive response of BC6OTHER (20 mg / kg, i.p.).	False
In contrast, combined pretreatment with BC6ENTC ( BC6ENTG antagonist; 20 mg / kg, s.c.) and BC6OTHER ( BC6OTHER antagonist; 20 mg / kg, s.c.), at doses that inhibited the antitussive activity of BC6OTHER agonists, respectively, was without effect on the antitussive response of BC6OTHER (20 mg / kg, i.p.).	CPR:6
In contrast, combined pretreatment with BC6ENTC ( BC6OTHER antagonist; 20 mg / kg, s.c.) and BC6OTHER ( BC6ENTG antagonist; 20 mg / kg, s.c.), at doses that inhibited the antitussive activity of BC6OTHER agonists, respectively, was without effect on the antitussive response of BC6OTHER (20 mg / kg, i.p.).	False
In this study, the activity of the BC6ENTG subtype - selective agonist, BC6ENTC , was investigated in a guinea pig model of BC6OTHER - induced cough.	CPR:5
In contrast, combined pretreatment with BC6OTHER ( BC6OTHER antagonist; 20 mg / kg, s.c.) and BC6ENTC ( BC6OTHER antagonist; 20 mg / kg, s.c.), at doses that inhibited the antitussive activity of BC6ENTG agonists, respectively, was without effect on the antitussive response of BC6OTHER (20 mg / kg, i.p.).	False
In contrast, combined pretreatment with BC6OTHER ( BC6ENTG antagonist; 20 mg / kg, s.c.) and BC6ENTC ( BC6OTHER antagonist; 20 mg / kg, s.c.), at doses that inhibited the antitussive activity of BC6OTHER agonists, respectively, was without effect on the antitussive response of BC6OTHER (20 mg / kg, i.p.).	False
In contrast, combined pretreatment with BC6OTHER ( BC6OTHER antagonist; 20 mg / kg, s.c.) and BC6ENTC ( BC6ENTG antagonist; 20 mg / kg, s.c.), at doses that inhibited the antitussive activity of BC6OTHER agonists, respectively, was without effect on the antitussive response of BC6OTHER (20 mg / kg, i.p.).	CPR:6
In contrast, combined pretreatment with BC6OTHER ( BC6OTHER antagonist; 20 mg / kg, s.c.) and BC6OTHER ( BC6OTHER antagonist; 20 mg / kg, s.c.), at doses that inhibited the antitussive activity of BC6ENTG agonists, respectively, was without effect on the antitussive response of BC6ENTC (20 mg / kg, i.p.).	False
In contrast, combined pretreatment with BC6OTHER ( BC6ENTG antagonist; 20 mg / kg, s.c.) and BC6OTHER ( BC6OTHER antagonist; 20 mg / kg, s.c.), at doses that inhibited the antitussive activity of BC6OTHER agonists, respectively, was without effect on the antitussive response of BC6ENTC (20 mg / kg, i.p.).	False
In contrast, combined pretreatment with BC6OTHER ( BC6OTHER antagonist; 20 mg / kg, s.c.) and BC6OTHER ( BC6ENTG antagonist; 20 mg / kg, s.c.), at doses that inhibited the antitussive activity of BC6OTHER agonists, respectively, was without effect on the antitussive response of BC6ENTC (20 mg / kg, i.p.).	False
The BC6ENTG antagonist BC6ENTC (3 mg / kg, i.p.)	CPR:6
In this study, the activity of the BC6ENTG subtype - selective agonist, BC6OTHER , was investigated in a guinea pig model of BC6ENTC - induced cough.	False
These studies provide compelling evidence that the antitussive effects of BC6ENTC in this guinea pig cough model are mediated by agonist activity at the BC6ENTG .	CPR:5
Parenteral administration of selective agonists of the BC6ENTG ( BC6ENTC ), BC6OTHER ( BC6OTHER and BC6OTHER ), and BC6OTHER ( BC6OTHER ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively.	CPR:5
Parenteral administration of selective agonists of the BC6OTHER ( BC6ENTC ), BC6ENTG ( BC6OTHER and BC6OTHER ), and BC6OTHER ( BC6OTHER ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively.	False
Parenteral administration of selective agonists of the BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER and BC6OTHER ), and BC6ENTG ( BC6OTHER ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively.	False
Parenteral administration of selective agonists of the BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6ENTC and BC6OTHER ), and BC6OTHER ( BC6OTHER ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively.	False
Parenteral administration of selective agonists of the BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6ENTC and BC6OTHER ), and BC6OTHER ( BC6OTHER ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively.	CPR:5
Parenteral administration of selective agonists of the BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC and BC6OTHER ), and BC6ENTG ( BC6OTHER ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively.	False
Parenteral administration of selective agonists of the BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER and BC6ENTC ), and BC6OTHER ( BC6OTHER ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively.	False
Parenteral administration of selective agonists of the BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER and BC6ENTC ), and BC6OTHER ( BC6OTHER ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively.	CPR:5
Parenteral administration of selective agonists of the BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER and BC6ENTC ), and BC6ENTG ( BC6OTHER ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively.	False
Finally, the involvement of BC6ENTG and BC6OTHER was also studied, and we showed that both play a role in the antinociceptive mechanism of BC6ENTC .	False
Finally, the involvement of BC6OTHER and BC6ENTG was also studied, and we showed that both play a role in the antinociceptive mechanism of BC6ENTC .	False
Conclusion The results of this work contribute information regarding the antinociceptive properties of BC6ENTC on acute pain and show that, at least in part, BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER participate in BC6OTHER 's antinociceptive mechanism.	False
Conclusion The results of this work contribute information regarding the antinociceptive properties of BC6ENTC on acute pain and show that, at least in part, BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER participate in BC6OTHER 's antinociceptive mechanism.	False
Conclusion The results of this work contribute information regarding the antinociceptive properties of BC6ENTC on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER participate in BC6OTHER 's antinociceptive mechanism.	False
Conclusion The results of this work contribute information regarding the antinociceptive properties of BC6ENTC on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER participate in BC6OTHER 's antinociceptive mechanism.	False
Conclusion The results of this work contribute information regarding the antinociceptive properties of BC6ENTC on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER participate in BC6OTHER 's antinociceptive mechanism.	False
Conclusion The results of this work contribute information regarding the antinociceptive properties of BC6ENTC on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG participate in BC6OTHER 's antinociceptive mechanism.	False
Conclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC receptors, BC6OTHER and BC6OTHER participate in BC6OTHER 's antinociceptive mechanism.	False
Conclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC receptors, BC6OTHER and BC6OTHER participate in BC6OTHER 's antinociceptive mechanism.	False
Conclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC receptors, BC6OTHER and BC6OTHER participate in BC6OTHER 's antinociceptive mechanism.	False
Conclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC receptors, BC6ENTG and BC6OTHER participate in BC6OTHER 's antinociceptive mechanism.	False
Conclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC receptors, BC6OTHER and BC6ENTG participate in BC6OTHER 's antinociceptive mechanism.	False
Conclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER participate in BC6ENTC 's antinociceptive mechanism.	False
Conclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER participate in BC6ENTC 's antinociceptive mechanism.	False
Conclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER participate in BC6ENTC 's antinociceptive mechanism.	False
Conclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER participate in BC6ENTC 's antinociceptive mechanism.	False
Conclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER participate in BC6ENTC 's antinociceptive mechanism.	False
Conclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG participate in BC6ENTC 's antinociceptive mechanism.	False
Methods The BC6ENTC - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism.	False
Methods The BC6ENTC - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism.	False
Methods The BC6ENTC - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism.	False
Methods The BC6ENTC - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER in its antinociceptive mechanism.	False
Methods The BC6ENTC - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER in its antinociceptive mechanism.	False
Methods The BC6ENTC - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG in its antinociceptive mechanism.	False
Methods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6ENTC and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism.	False
Methods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6ENTC and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism.	False
Methods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6ENTC and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism.	False
Methods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6ENTC and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER in its antinociceptive mechanism.	False
Methods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6ENTC and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER in its antinociceptive mechanism.	False
Methods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6ENTC and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG in its antinociceptive mechanism.	False
Methods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6ENTC , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism.	False
Methods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6ENTC , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism.	False
Methods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6ENTC , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism.	False
Methods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6ENTC , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER in its antinociceptive mechanism.	False
Methods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6ENTC , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER in its antinociceptive mechanism.	False
Methods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6ENTC , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG in its antinociceptive mechanism.	False
Methods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6ENTC and to determine the involvement of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism.	False
Methods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6ENTC and to determine the involvement of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism.	False
Methods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6ENTC and to determine the involvement of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism.	False
Methods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6ENTC and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER in its antinociceptive mechanism.	False
Methods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6ENTC and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER in its antinociceptive mechanism.	False
Methods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6ENTC and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG in its antinociceptive mechanism.	False
 BC6ENTG mediate the antinociceptive effect of BC6ENTC .	False
In an investigation into the participation of BC6ENTG and BC6OTHER in BC6ENTC 's antinociceptive mechanism, we used BC6OTHER (2.2μg / paw), BC6OTHER (10mmol / paw), BC6OTHER (1.2mmol / paw) and acidified saline (2% BC6OTHER , pH 1.98).	False
In an investigation into the participation of BC6OTHER and BC6ENTG in BC6ENTC 's antinociceptive mechanism, we used BC6OTHER (2.2μg / paw), BC6OTHER (10mmol / paw), BC6OTHER (1.2mmol / paw) and acidified saline (2% BC6OTHER , pH 1.98).	False
In an investigation into the participation of BC6ENTG and BC6OTHER in BC6OTHER 's antinociceptive mechanism, we used BC6ENTC (2.2μg / paw), BC6OTHER (10mmol / paw), BC6OTHER (1.2mmol / paw) and acidified saline (2% BC6OTHER , pH 1.98).	False
In an investigation into the participation of BC6OTHER and BC6ENTG in BC6OTHER 's antinociceptive mechanism, we used BC6ENTC (2.2μg / paw), BC6OTHER (10mmol / paw), BC6OTHER (1.2mmol / paw) and acidified saline (2% BC6OTHER , pH 1.98).	False
In an investigation into the participation of BC6ENTG and BC6OTHER in BC6OTHER 's antinociceptive mechanism, we used BC6OTHER (2.2μg / paw), BC6ENTC (10mmol / paw), BC6OTHER (1.2mmol / paw) and acidified saline (2% BC6OTHER , pH 1.98).	False
In an investigation into the participation of BC6OTHER and BC6ENTG in BC6OTHER 's antinociceptive mechanism, we used BC6OTHER (2.2μg / paw), BC6ENTC (10mmol / paw), BC6OTHER (1.2mmol / paw) and acidified saline (2% BC6OTHER , pH 1.98).	False
In an investigation into the participation of BC6ENTG and BC6OTHER in BC6OTHER 's antinociceptive mechanism, we used BC6OTHER (2.2μg / paw), BC6OTHER (10mmol / paw), BC6ENTC (1.2mmol / paw) and acidified saline (2% BC6OTHER , pH 1.98).	False
In an investigation into the participation of BC6OTHER and BC6ENTG in BC6OTHER 's antinociceptive mechanism, we used BC6OTHER (2.2μg / paw), BC6OTHER (10mmol / paw), BC6ENTC (1.2mmol / paw) and acidified saline (2% BC6OTHER , pH 1.98).	False
In an investigation into the participation of BC6ENTG and BC6OTHER in BC6OTHER 's antinociceptive mechanism, we used BC6OTHER (2.2μg / paw), BC6OTHER (10mmol / paw), BC6OTHER (1.2mmol / paw) and acidified saline (2% BC6ENTC , pH 1.98).	False
In an investigation into the participation of BC6OTHER and BC6ENTG in BC6OTHER 's antinociceptive mechanism, we used BC6OTHER (2.2μg / paw), BC6OTHER (10mmol / paw), BC6OTHER (1.2mmol / paw) and acidified saline (2% BC6ENTC , pH 1.98).	False
BC6ENTC promotes dissociation of BC6OTHER - BC6ENTG BC6OTHER complexes both in the absence and the presence of unlabeled BC6OTHER .	False
BC6ENTC promotes dissociation of BC6OTHER - BC6OTHER BC6ENTG complexes both in the absence and the presence of unlabeled BC6OTHER .	False
BC6ENTC promotes dissociation of BC6OTHER - BC6OTHER BC6OTHER complexes both in the absence and the presence of unlabeled BC6ENTG .	False
BC6OTHER promotes dissociation of BC6ENTC - BC6ENTG BC6OTHER complexes both in the absence and the presence of unlabeled BC6OTHER .	False
BC6OTHER promotes dissociation of BC6ENTC - BC6OTHER BC6ENTG complexes both in the absence and the presence of unlabeled BC6OTHER .	False
BC6OTHER promotes dissociation of BC6ENTC - BC6OTHER BC6OTHER complexes both in the absence and the presence of unlabeled BC6ENTG .	False
It has no influence on the rate of association of BC6ENTC - BC6ENTG to BC6OTHER .	False
It has no influence on the rate of association of BC6ENTC - BC6OTHER to BC6ENTG .	False
BC6ENTC do not promote dissociation of BC6OTHER - BC6ENTG BC6OTHER complexes.	False
BC6ENTC do not promote dissociation of BC6OTHER - BC6OTHER BC6ENTG complexes.	False
BC6OTHER do not promote dissociation of BC6ENTC - BC6ENTG BC6OTHER complexes.	False
BC6OTHER do not promote dissociation of BC6ENTC - BC6OTHER BC6ENTG complexes.	False
 BC6ENTC and BC6OTHER inhibit endothelin BC6ENTG by an allosteric type of mechanism.	False
 BC6OTHER and BC6ENTC inhibit endothelin BC6ENTG by an allosteric type of mechanism.	False
It is concluded that BC6ENTC are allosteric inhibitors of BC6ENTG .	False
The results also suggest that: 1) irreversible BC6ENTG binding probably limits actions of receptor antagonists in vivo, and 2) an association of BC6ENTC and BC6OTHER antagonists should be used to evaluate the physiopathological role of BC6OTHER and may be of therapeutic interest in the treatment of ischemic heart disease.	False
The results also suggest that: 1) irreversible BC6OTHER binding probably limits actions of receptor antagonists in vivo, and 2) an association of BC6ENTC and BC6ENTG antagonists should be used to evaluate the physiopathological role of BC6OTHER and may be of therapeutic interest in the treatment of ischemic heart disease.	False
The results also suggest that: 1) irreversible BC6OTHER binding probably limits actions of receptor antagonists in vivo, and 2) an association of BC6ENTC and BC6OTHER antagonists should be used to evaluate the physiopathological role of BC6ENTG and may be of therapeutic interest in the treatment of ischemic heart disease.	False
This study shows that BC6ENTC and BC6OTHER , its major blood metabolite, reverse contractile actions of BC6ENTG ( BC6OTHER ) in isolated rat aorta and human mammary arteries.	False
This study shows that BC6ENTC and BC6OTHER , its major blood metabolite, reverse contractile actions of BC6OTHER ( BC6ENTG ) in isolated rat aorta and human mammary arteries.	False
This study shows that BC6OTHER and BC6ENTC , its major blood metabolite, reverse contractile actions of BC6ENTG ( BC6OTHER ) in isolated rat aorta and human mammary arteries.	False
This study shows that BC6OTHER and BC6ENTC , its major blood metabolite, reverse contractile actions of BC6OTHER ( BC6ENTG ) in isolated rat aorta and human mammary arteries.	False
They also prevent the intracellular BC6ENTC mobilizing action of BC6ENTG in cultured endothelial cells but not those of BC6OTHER or CHEM.	False
They also prevent the intracellular BC6ENTC mobilizing action of BC6OTHER in cultured endothelial cells but not those of BC6ENTG or CHEM.	False
Inhibition of the actions of BC6ENTG by BC6ENTC is apparently competitive.	CPR:4
BC6ENTC inhibit BC6OTHER - BC6ENTG binding to recombinant BC6OTHER .	False
BC6ENTC inhibit BC6OTHER - BC6OTHER binding to recombinant BC6ENTG .	False
BC6OTHER inhibit BC6ENTC - BC6ENTG binding to recombinant BC6OTHER .	False
BC6OTHER inhibit BC6ENTC - BC6OTHER binding to recombinant BC6ENTG .	False
Changes in BC6ENTG mRNA occur in parallel with modifications in the levels of free BC6ENTC , which are reduced in lactation and are upregulated due to weaning or fasting.	False
Conversely, when mice are fed a high - fat diet after parturition, the downregulation of BC6ENTG mRNA and BC6OTHER protein levels due to lactation is partially reversed, as is the reduction in serum free BC6ENTC levels.	False
Conversely, when mice are fed a high - fat diet after parturition, the downregulation of BC6OTHER mRNA and BC6ENTG protein levels due to lactation is partially reversed, as is the reduction in serum free BC6ENTC levels.	False
Impaired expression of the BC6OTHER gene in skeletal muscle during lactation: CHEM and BC6ENTC reverse lactation - induced downregulation of the BC6ENTG gene.	CPR:3
Impaired expression of the BC6ENTG gene in skeletal muscle during lactation: CHEM and BC6ENTC reverse lactation - induced downregulation of the BC6OTHER gene.	False
Treatment of lactating mice with a single injection of BC6ENTC , an activator of the BC6ENTG ( BC6OTHER ), raises BC6OTHER mRNA in skeletal muscle to levels similar to those in virgin mice.	CPR:3
Treatment of lactating mice with a single injection of BC6ENTC , an activator of the BC6OTHER ( BC6ENTG ), raises BC6OTHER mRNA in skeletal muscle to levels similar to those in virgin mice.	CPR:3
Treatment of lactating mice with a single injection of BC6ENTC , an activator of the BC6OTHER ( BC6OTHER ), raises BC6ENTG mRNA in skeletal muscle to levels similar to those in virgin mice.	CPR:3
BC6ENTC ( BC6OTHER ), a specific ligand of the BC6ENTG subtype, causes the most dramatic increase in BC6OTHER mRNA, whereas BC6OTHER , a specific activator of BC6OTHER , also significantly increases BC6OTHER mRNA abundance in skeletal muscle of lactating mice.	False
BC6ENTC ( BC6OTHER ), a specific ligand of the BC6OTHER subtype, causes the most dramatic increase in BC6ENTG mRNA, whereas BC6OTHER , a specific activator of BC6OTHER , also significantly increases BC6OTHER mRNA abundance in skeletal muscle of lactating mice.	CPR:3
BC6ENTC ( BC6OTHER ), a specific ligand of the BC6OTHER subtype, causes the most dramatic increase in BC6OTHER mRNA, whereas BC6OTHER , a specific activator of BC6ENTG , also significantly increases BC6OTHER mRNA abundance in skeletal muscle of lactating mice.	False
BC6ENTC ( BC6OTHER ), a specific ligand of the BC6OTHER subtype, causes the most dramatic increase in BC6OTHER mRNA, whereas BC6OTHER , a specific activator of BC6OTHER , also significantly increases BC6ENTG mRNA abundance in skeletal muscle of lactating mice.	False
BC6OTHER ( BC6ENTC ), a specific ligand of the BC6ENTG subtype, causes the most dramatic increase in BC6OTHER mRNA, whereas BC6OTHER , a specific activator of BC6OTHER , also significantly increases BC6OTHER mRNA abundance in skeletal muscle of lactating mice.	False
BC6OTHER ( BC6ENTC ), a specific ligand of the BC6OTHER subtype, causes the most dramatic increase in BC6ENTG mRNA, whereas BC6OTHER , a specific activator of BC6OTHER , also significantly increases BC6OTHER mRNA abundance in skeletal muscle of lactating mice.	CPR:3
BC6OTHER ( BC6ENTC ), a specific ligand of the BC6OTHER subtype, causes the most dramatic increase in BC6OTHER mRNA, whereas BC6OTHER , a specific activator of BC6ENTG , also significantly increases BC6OTHER mRNA abundance in skeletal muscle of lactating mice.	False
BC6OTHER ( BC6ENTC ), a specific ligand of the BC6OTHER subtype, causes the most dramatic increase in BC6OTHER mRNA, whereas BC6OTHER , a specific activator of BC6OTHER , also significantly increases BC6ENTG mRNA abundance in skeletal muscle of lactating mice.	False
BC6OTHER ( BC6OTHER ), a specific ligand of the BC6ENTG subtype, causes the most dramatic increase in BC6OTHER mRNA, whereas BC6ENTC , a specific activator of BC6OTHER , also significantly increases BC6OTHER mRNA abundance in skeletal muscle of lactating mice.	False
BC6OTHER ( BC6OTHER ), a specific ligand of the BC6OTHER subtype, causes the most dramatic increase in BC6ENTG mRNA, whereas BC6ENTC , a specific activator of BC6OTHER , also significantly increases BC6OTHER mRNA abundance in skeletal muscle of lactating mice.	False
BC6OTHER ( BC6OTHER ), a specific ligand of the BC6OTHER subtype, causes the most dramatic increase in BC6OTHER mRNA, whereas BC6ENTC , a specific activator of BC6ENTG , also significantly increases BC6OTHER mRNA abundance in skeletal muscle of lactating mice.	CPR:3
BC6OTHER ( BC6OTHER ), a specific ligand of the BC6OTHER subtype, causes the most dramatic increase in BC6OTHER mRNA, whereas BC6ENTC , a specific activator of BC6OTHER , also significantly increases BC6ENTG mRNA abundance in skeletal muscle of lactating mice.	CPR:3
However, in virgin mice, BC6ENTC and BC6OTHER do not significantly affect BC6ENTG mRNA expression, whereas BC6OTHER is at least as effective as it is in lactating dams.	False
However, in virgin mice, BC6OTHER and BC6ENTC do not significantly affect BC6ENTG mRNA expression, whereas BC6OTHER is at least as effective as it is in lactating dams.	False
However, in virgin mice, BC6OTHER and BC6OTHER do not significantly affect BC6ENTG mRNA expression, whereas BC6ENTC is at least as effective as it is in lactating dams.	False
It is proposed that the BC6ENTG gene is regulated in skeletal muscle during lactation in response to changes in circulating free BC6ENTC by mechanisms involving activation of BC6OTHER .	False
It is proposed that the BC6OTHER gene is regulated in skeletal muscle during lactation in response to changes in circulating free BC6ENTC by mechanisms involving activation of BC6ENTG .	CPR:3
The impaired expression of the BC6ENTG gene is consistent with the involvement of BC6OTHER gene regulation in the reduction of the use of BC6ENTC as fuel by the skeletal muscle and in impaired adaptative thermogenesis, both of which are major metabolic adaptations that occur during lactation.	False
The impaired expression of the BC6OTHER gene is consistent with the involvement of BC6ENTG gene regulation in the reduction of the use of BC6ENTC as fuel by the skeletal muscle and in impaired adaptative thermogenesis, both of which are major metabolic adaptations that occur during lactation.	False
Oligomeric BC6OTHER - (POG - ) peptides, wherein the BC6ENTG is supported by BC6ENTC - terminal capping, exhibit BC6OTHER precipitation properties (CHEM, BC6OTHER = BC6OTHER ).	False
Hence, BC6ENTC - enclosed BC6ENTG have promising perspectives as composite materials.	False
Oligomeric BC6ENTC - (POG - ) peptides, wherein the BC6ENTG is supported by BC6OTHER - terminal capping, exhibit BC6OTHER precipitation properties (CHEM, BC6OTHER = BC6OTHER ).	False
Oligomeric BC6OTHER - (POG - ) peptides, wherein the BC6ENTG is supported by BC6OTHER - terminal capping, exhibit BC6ENTC precipitation properties (CHEM, BC6OTHER = BC6OTHER ).	False
Oligomeric BC6OTHER - (POG - ) peptides, wherein the BC6ENTG is supported by BC6OTHER - terminal capping, exhibit BC6OTHER precipitation properties (CHEM, BC6ENTC = BC6OTHER ).	False
Oligomeric BC6OTHER - (POG - ) peptides, wherein the BC6ENTG is supported by BC6OTHER - terminal capping, exhibit BC6OTHER precipitation properties (CHEM, BC6OTHER = BC6ENTC ).	False
As quantified by a molybdate assay, the length of the covalently tethered BC6ENTG (number of POG units) determines the amount of amorphous BC6ENTC obtained from BC6OTHER solution.	False
As quantified by a molybdate assay, the length of the covalently tethered BC6ENTG (number of POG units) determines the amount of amorphous BC6OTHER obtained from BC6ENTC solution.	False
Although lacking charged side chains, the synthetic BC6ENTG precipitate large quantities of BC6ENTC resulting in micrometer - sized spheres of varying surface morphologies as analyzed by scanning electron microscopy.	False
The selective BC6ENTG inhibitor BC6ENTC ( BC6OTHER ) inhibits B cell signaling and function in vitro and in vivo and augments the activity of BC6OTHER in chronic lymphocytic leukemia.	CPR:4
The selective BC6ENTG inhibitor BC6OTHER ( BC6ENTC ) inhibits B cell signaling and function in vitro and in vivo and augments the activity of BC6OTHER in chronic lymphocytic leukemia.	CPR:4
BC6ENTC (also known as BC6OTHER ) is a novel, highly selective, and orally bioavailable small molecule BC6ENTG inhibitor ( BC6OTHER IC(50) = 1 nM) with anti - BC6OTHER activity that is at least 80 - fold greater than its affinity for other BC6OTHER .	CPR:4
BC6ENTC (also known as BC6OTHER ) is a novel, highly selective, and orally bioavailable small molecule BC6OTHER inhibitor ( BC6ENTG IC(50) = 1 nM) with anti - BC6OTHER activity that is at least 80 - fold greater than its affinity for other BC6OTHER .	CPR:4
BC6ENTC (also known as BC6OTHER ) is a novel, highly selective, and orally bioavailable small molecule BC6OTHER inhibitor ( BC6OTHER IC(50) = 1 nM) with anti - BC6ENTG activity that is at least 80 - fold greater than its affinity for other BC6OTHER .	CPR:4
BC6ENTC (also known as BC6OTHER ) is a novel, highly selective, and orally bioavailable small molecule BC6OTHER inhibitor ( BC6OTHER IC(50) = 1 nM) with anti - BC6OTHER activity that is at least 80 - fold greater than its affinity for other BC6ENTG .	False
BC6OTHER (also known as BC6ENTC ) is a novel, highly selective, and orally bioavailable small molecule BC6ENTG inhibitor ( BC6OTHER IC(50) = 1 nM) with anti - BC6OTHER activity that is at least 80 - fold greater than its affinity for other BC6OTHER .	CPR:4
BC6OTHER (also known as BC6ENTC ) is a novel, highly selective, and orally bioavailable small molecule BC6OTHER inhibitor ( BC6ENTG IC(50) = 1 nM) with anti - BC6OTHER activity that is at least 80 - fold greater than its affinity for other BC6OTHER .	CPR:4
BC6OTHER (also known as BC6ENTC ) is a novel, highly selective, and orally bioavailable small molecule BC6OTHER inhibitor ( BC6OTHER IC(50) = 1 nM) with anti - BC6ENTG activity that is at least 80 - fold greater than its affinity for other BC6OTHER .	CPR:4
BC6OTHER (also known as BC6ENTC ) is a novel, highly selective, and orally bioavailable small molecule BC6OTHER inhibitor ( BC6OTHER IC(50) = 1 nM) with anti - BC6OTHER activity that is at least 80 - fold greater than its affinity for other BC6ENTG .	False
BC6ENTG ( BC6OTHER ) associated BC6OTHER including spleen BC6ENTC kinase ( BC6OTHER ) contribute to the pathogenesis of B - cell malignancies.	False
BC6OTHER ( BC6ENTG ) associated BC6OTHER including spleen BC6ENTC kinase ( BC6OTHER ) contribute to the pathogenesis of B - cell malignancies.	False
BC6OTHER ( BC6OTHER ) associated BC6ENTG including spleen BC6ENTC kinase ( BC6OTHER ) contribute to the pathogenesis of B - cell malignancies.	False
BC6OTHER ( BC6OTHER ) associated BC6OTHER including spleen BC6ENTC kinase ( BC6ENTG ) contribute to the pathogenesis of B - cell malignancies.	False
BC6ENTC successfully inhibited BC6ENTG - mediated BC6OTHER signaling and decreased cell viability in NHL and CLL.	CPR:4
BC6ENTC successfully inhibited BC6OTHER - mediated BC6ENTG signaling and decreased cell viability in NHL and CLL.	CPR:4
The selective BC6ENTG inhibitor BC6OTHER ( BC6OTHER ) inhibits B cell signaling and function in vitro and in vivo and augments the activity of BC6ENTC in chronic lymphocytic leukemia.	False
Recent studies have demonstrated the importance of the BC6ENTC / BC6OTHER / BC6OTHER ( BC6ENTG ) pathway to the process of learning and memory.	False
Recent studies have demonstrated the importance of the BC6ENTC / BC6OTHER / BC6ENTG ( BC6OTHER ) pathway to the process of learning and memory.	False
Recent studies have demonstrated the importance of the BC6OTHER / BC6ENTC / BC6OTHER ( BC6ENTG ) pathway to the process of learning and memory.	False
Recent studies have demonstrated the importance of the BC6OTHER / BC6ENTC / BC6ENTG ( BC6OTHER ) pathway to the process of learning and memory.	False
Recent studies have demonstrated the importance of the BC6OTHER / BC6OTHER / BC6ENTC - responsive element - binding protein ( BC6ENTG ) pathway to the process of learning and memory.	False
BC6OTHER ( BC6ENTG ) mediates the degradation of BC6ENTC in a variety of tissues including brain.	CPR:9
BC6ENTG ( BC6OTHER ) mediates the degradation of BC6ENTC in a variety of tissues including brain.	CPR:9
Synthesis of BC6ENTC derivatives: discovery of a potent and selective BC6ENTG inhibitor for the treatment of Alzheimer's disease.	CPR:4
Within the BC6ENTC scaffold, either electronic or steric perturbations to the central BC6OTHER ring led to a loss of selective M(1) allosteric agonism and afforded pan - BC6ENTG antagonism, which was demonstrated to be mediated via the orthosteric site.	CPR:6
Within the BC6OTHER scaffold, either electronic or steric perturbations to the central BC6ENTC ring led to a loss of selective M(1) allosteric agonism and afforded pan - BC6ENTG antagonism, which was demonstrated to be mediated via the orthosteric site.	CPR:6
Additional SAR around a related M(1) allosteric agonist family ( BC6ENTC ) identified similar, subtle 'molecular switches' that modulated modes of pharmacology from allosteric agonism to pan - BC6ENTG orthosteric antagonism.	CPR:6
Unlike BC6ENTC , BC6ENTG activates BC6OTHER pathways, and BC6OTHER pathways can substitute for BC6OTHER signaling for BC6OTHER generation.	False
Unlike BC6ENTC , BC6OTHER activates BC6ENTG pathways, and BC6OTHER pathways can substitute for BC6OTHER signaling for BC6OTHER generation.	False
Unlike BC6ENTC , BC6OTHER activates BC6OTHER pathways, and BC6ENTG pathways can substitute for BC6OTHER signaling for BC6OTHER generation.	False
Unlike BC6ENTC , BC6OTHER activates BC6OTHER pathways, and BC6OTHER pathways can substitute for BC6ENTG signaling for BC6OTHER generation.	False
Unlike BC6OTHER , BC6ENTG activates BC6OTHER pathways, and BC6OTHER pathways can substitute for BC6OTHER signaling for BC6ENTC generation.	False
Unlike BC6OTHER , BC6OTHER activates BC6ENTG pathways, and BC6OTHER pathways can substitute for BC6OTHER signaling for BC6ENTC generation.	False
Unlike BC6OTHER , BC6OTHER activates BC6OTHER pathways, and BC6ENTG pathways can substitute for BC6OTHER signaling for BC6ENTC generation.	False
Unlike BC6OTHER , BC6OTHER activates BC6OTHER pathways, and BC6OTHER pathways can substitute for BC6ENTG signaling for BC6ENTC generation.	False
We found that BC6ENTG was activated downstream of both BC6OTHER and BC6OTHER - mediated pathways, and both BC6ENTC - and AYPGKF - induced BC6OTHER generation was significantly diminished in BC6OTHER - deficient platelets.	False
We found that BC6OTHER was activated downstream of both BC6ENTG and BC6OTHER - mediated pathways, and both BC6ENTC - and AYPGKF - induced BC6OTHER generation was significantly diminished in BC6OTHER - deficient platelets.	False
We found that BC6OTHER was activated downstream of both BC6OTHER and BC6ENTG - mediated pathways, and both BC6ENTC - and AYPGKF - induced BC6OTHER generation was significantly diminished in BC6OTHER - deficient platelets.	False
We found that BC6OTHER was activated downstream of both BC6OTHER and BC6OTHER - mediated pathways, and both BC6ENTC - and AYPGKF - induced BC6OTHER generation was significantly diminished in BC6ENTG - deficient platelets.	False
We found that BC6ENTG was activated downstream of both BC6OTHER and BC6OTHER - mediated pathways, and both BC6OTHER - and AYPGKF - induced BC6ENTC generation was significantly diminished in BC6OTHER - deficient platelets.	False
We found that BC6OTHER was activated downstream of both BC6ENTG and BC6OTHER - mediated pathways, and both BC6OTHER - and AYPGKF - induced BC6ENTC generation was significantly diminished in BC6OTHER - deficient platelets.	False
We found that BC6OTHER was activated downstream of both BC6OTHER and BC6ENTG - mediated pathways, and both BC6OTHER - and AYPGKF - induced BC6ENTC generation was significantly diminished in BC6OTHER - deficient platelets.	False
We found that BC6OTHER was activated downstream of both BC6OTHER and BC6OTHER - mediated pathways, and both BC6OTHER - and AYPGKF - induced BC6ENTC generation was significantly diminished in BC6ENTG - deficient platelets.	False
In addition, BC6ENTC generation induced by co - stimulation of BC6OTHER and BC6ENTG pathways, which is dependent on BC6OTHER signaling, was inhibited by blocking BC6OTHER .	False
In addition, BC6ENTC generation induced by co - stimulation of BC6OTHER and BC6OTHER pathways, which is dependent on BC6ENTG signaling, was inhibited by blocking BC6OTHER .	False
In addition, BC6ENTC generation induced by co - stimulation of BC6OTHER and BC6OTHER pathways, which is dependent on BC6OTHER signaling, was inhibited by blocking BC6ENTG .	False
In addition, BC6ENTC generation induced by co - stimulation of BC6ENTG and BC6OTHER pathways, which is dependent on BC6OTHER signaling, was inhibited by blocking BC6OTHER .	False
Distinct role of BC6ENTG in mediating BC6ENTC generation downstream of both BC6OTHER and BC6OTHER in platelets.	False
Distinct role of BC6OTHER in mediating BC6ENTC generation downstream of both BC6ENTG and BC6OTHER in platelets.	False
Distinct role of BC6OTHER in mediating BC6ENTC generation downstream of both BC6OTHER and BC6ENTG in platelets.	False
BC6ENTC - rich BC6OTHER kinase 2 ( BC6ENTG ) is activated by various agonists in platelets.	False
Furthermore, inhibition of BC6ENTC - induced BC6OTHER generation by BC6ENTG antagonist was not rescued by co - stimulation of BC6OTHER pathways in the presence of BC6OTHER inhibitor.	False
Furthermore, inhibition of BC6ENTC - induced BC6OTHER generation by BC6OTHER antagonist was not rescued by co - stimulation of BC6ENTG pathways in the presence of BC6OTHER inhibitor.	False
Furthermore, inhibition of BC6ENTC - induced BC6OTHER generation by BC6OTHER antagonist was not rescued by co - stimulation of BC6OTHER pathways in the presence of BC6ENTG inhibitor.	False
Furthermore, inhibition of BC6OTHER - induced BC6ENTC generation by BC6ENTG antagonist was not rescued by co - stimulation of BC6OTHER pathways in the presence of BC6OTHER inhibitor.	False
Furthermore, inhibition of BC6OTHER - induced BC6ENTC generation by BC6OTHER antagonist was not rescued by co - stimulation of BC6ENTG pathways in the presence of BC6OTHER inhibitor.	False
Furthermore, inhibition of BC6OTHER - induced BC6ENTC generation by BC6OTHER antagonist was not rescued by co - stimulation of BC6OTHER pathways in the presence of BC6ENTG inhibitor.	False
BC6OTHER - rich BC6ENTC kinase 2 ( BC6ENTG ) is activated by various agonists in platelets.	False
We conclude that BC6ENTG is a common signaling effector downstream of both BC6OTHER and BC6OTHER signaling which contributes to BC6ENTC generation.	False
We conclude that BC6OTHER is a common signaling effector downstream of both BC6ENTG and BC6OTHER signaling which contributes to BC6ENTC generation.	False
We conclude that BC6OTHER is a common signaling effector downstream of both BC6OTHER and BC6ENTG signaling which contributes to BC6ENTC generation.	False
We found that platelet aggregation and secretion in response to BC6ENTC and AYPGKF were diminished in the presence of BC6ENTG inhibitors or in BC6OTHER - deficient platelets, suggesting that BC6OTHER plays a positive regulatory role in platelet functional responses.	False
We found that platelet aggregation and secretion in response to BC6ENTC and AYPGKF were diminished in the presence of BC6OTHER inhibitors or in BC6ENTG - deficient platelets, suggesting that BC6OTHER plays a positive regulatory role in platelet functional responses.	False
We found that platelet aggregation and secretion in response to BC6ENTC and AYPGKF were diminished in the presence of BC6OTHER inhibitors or in BC6OTHER - deficient platelets, suggesting that BC6ENTG plays a positive regulatory role in platelet functional responses.	False
It has been shown that BC6ENTC - , but not BC6ENTG - , induced BC6OTHER ( BC6OTHER ) generation depends on BC6OTHER signaling.	False
It has been shown that BC6ENTC - , but not BC6OTHER - , induced BC6OTHER ( BC6OTHER ) generation depends on BC6ENTG signaling.	False
It has been shown that BC6OTHER - , but not BC6ENTG - , induced BC6ENTC ( BC6OTHER ) generation depends on BC6OTHER signaling.	False
It has been shown that BC6OTHER - , but not BC6OTHER - , induced BC6ENTC ( BC6OTHER ) generation depends on BC6ENTG signaling.	False
It has been shown that BC6OTHER - , but not BC6ENTG - , induced BC6OTHER ( BC6ENTC ) generation depends on BC6OTHER signaling.	False
It has been shown that BC6OTHER - , but not BC6OTHER - , induced BC6OTHER ( BC6ENTC ) generation depends on BC6ENTG signaling.	False
A series of structurally novel BC6OTHER was derived from optimization of the HTS lead as selective BC6ENTC H3 receptor ( BC6ENTG ) antagonists.	False
A series of structurally novel BC6ENTC was derived from optimization of the HTS lead as selective BC6ENTG ( BC6OTHER ) antagonists.	CPR:6
A series of structurally novel BC6ENTC was derived from optimization of the HTS lead as selective BC6OTHER ( BC6ENTG ) antagonists.	CPR:6
Discovery of BC6ENTC and BC6OTHER as potent and selective BC6ENTG antagonists for the treatment of obesity (Part I).	CPR:6
Discovery of BC6OTHER and BC6ENTC as potent and selective BC6ENTG antagonists for the treatment of obesity (Part I).	CPR:6
The objective of this study was to determine the influence of BC6ENTC administration (15 mg / kg intraperitoneally twice daily for 8 days) on liver expression of BC6ENTG , transporters, and DMEs in rats.	False
Induction of BC6ENTG , transporters, and drug metabolizing enzymes by BC6ENTC .	False
Therefore, a series of transactivation / translocation assays were conducted to determine whether the observed changes of transporters / DMEs are mediated by direct activation of BC6ENTG , BC6OTHER , or BC6OTHER by BC6ENTC or its major metabolites ( BC6OTHER and BC6OTHER ).	False
Therefore, a series of transactivation / translocation assays were conducted to determine whether the observed changes of transporters / DMEs are mediated by direct activation of BC6OTHER , BC6ENTG , or BC6OTHER by BC6ENTC or its major metabolites ( BC6OTHER and BC6OTHER ).	False
Therefore, a series of transactivation / translocation assays were conducted to determine whether the observed changes of transporters / DMEs are mediated by direct activation of BC6OTHER , BC6OTHER , or BC6ENTG by BC6ENTC or its major metabolites ( BC6OTHER and BC6OTHER ).	False
Therefore, a series of transactivation / translocation assays were conducted to determine whether the observed changes of transporters / DMEs are mediated by direct activation of BC6ENTG , BC6OTHER , or BC6OTHER by BC6OTHER or its major metabolites ( BC6ENTC and BC6OTHER ).	False
Therefore, a series of transactivation / translocation assays were conducted to determine whether the observed changes of transporters / DMEs are mediated by direct activation of BC6OTHER , BC6ENTG , or BC6OTHER by BC6OTHER or its major metabolites ( BC6ENTC and BC6OTHER ).	False
Therefore, a series of transactivation / translocation assays were conducted to determine whether the observed changes of transporters / DMEs are mediated by direct activation of BC6OTHER , BC6OTHER , or BC6ENTG by BC6OTHER or its major metabolites ( BC6ENTC and BC6OTHER ).	False
Therefore, a series of transactivation / translocation assays were conducted to determine whether the observed changes of transporters / DMEs are mediated by direct activation of BC6ENTG , BC6OTHER , or BC6OTHER by BC6OTHER or its major metabolites ( BC6OTHER and BC6ENTC ).	False
Therefore, a series of transactivation / translocation assays were conducted to determine whether the observed changes of transporters / DMEs are mediated by direct activation of BC6OTHER , BC6ENTG , or BC6OTHER by BC6OTHER or its major metabolites ( BC6OTHER and BC6ENTC ).	False
Therefore, a series of transactivation / translocation assays were conducted to determine whether the observed changes of transporters / DMEs are mediated by direct activation of BC6OTHER , BC6OTHER , or BC6ENTG by BC6OTHER or its major metabolites ( BC6OTHER and BC6ENTC ).	False
Neither BC6ENTC nor its metabolites activated BC6ENTG , BC6OTHER , or BC6OTHER .	False
Neither BC6ENTC nor its metabolites activated BC6OTHER , BC6ENTG , or BC6OTHER .	False
Neither BC6ENTC nor its metabolites activated BC6OTHER , BC6OTHER , or BC6ENTG .	False
Taken together, these findings identify a signature hepatic gene - network associated with repeated BC6ENTC administration in rats and demonstrate that BC6OTHER alters the expression of many transporters and DMEs (without direct activation of BC6ENTG , BC6OTHER , and BC6OTHER ), which could lead to undesirable DDIs after coadministration of substrates of these transporters / DMEs with BC6OTHER .	False
Taken together, these findings identify a signature hepatic gene - network associated with repeated BC6ENTC administration in rats and demonstrate that BC6OTHER alters the expression of many transporters and DMEs (without direct activation of BC6OTHER , BC6ENTG , and BC6OTHER ), which could lead to undesirable DDIs after coadministration of substrates of these transporters / DMEs with BC6OTHER .	False
Taken together, these findings identify a signature hepatic gene - network associated with repeated BC6ENTC administration in rats and demonstrate that BC6OTHER alters the expression of many transporters and DMEs (without direct activation of BC6OTHER , BC6OTHER , and BC6ENTG ), which could lead to undesirable DDIs after coadministration of substrates of these transporters / DMEs with BC6OTHER .	False
Taken together, these findings identify a signature hepatic gene - network associated with repeated BC6OTHER administration in rats and demonstrate that BC6ENTC alters the expression of many transporters and DMEs (without direct activation of BC6ENTG , BC6OTHER , and BC6OTHER ), which could lead to undesirable DDIs after coadministration of substrates of these transporters / DMEs with BC6OTHER .	False
Taken together, these findings identify a signature hepatic gene - network associated with repeated BC6OTHER administration in rats and demonstrate that BC6ENTC alters the expression of many transporters and DMEs (without direct activation of BC6OTHER , BC6ENTG , and BC6OTHER ), which could lead to undesirable DDIs after coadministration of substrates of these transporters / DMEs with BC6OTHER .	False
Taken together, these findings identify a signature hepatic gene - network associated with repeated BC6OTHER administration in rats and demonstrate that BC6ENTC alters the expression of many transporters and DMEs (without direct activation of BC6OTHER , BC6OTHER , and BC6ENTG ), which could lead to undesirable DDIs after coadministration of substrates of these transporters / DMEs with BC6OTHER .	False
Taken together, these findings identify a signature hepatic gene - network associated with repeated BC6OTHER administration in rats and demonstrate that BC6OTHER alters the expression of many transporters and DMEs (without direct activation of BC6ENTG , BC6OTHER , and BC6OTHER ), which could lead to undesirable DDIs after coadministration of substrates of these transporters / DMEs with BC6ENTC .	False
Taken together, these findings identify a signature hepatic gene - network associated with repeated BC6OTHER administration in rats and demonstrate that BC6OTHER alters the expression of many transporters and DMEs (without direct activation of BC6OTHER , BC6ENTG , and BC6OTHER ), which could lead to undesirable DDIs after coadministration of substrates of these transporters / DMEs with BC6ENTC .	False
Taken together, these findings identify a signature hepatic gene - network associated with repeated BC6OTHER administration in rats and demonstrate that BC6OTHER alters the expression of many transporters and DMEs (without direct activation of BC6OTHER , BC6OTHER , and BC6ENTG ), which could lead to undesirable DDIs after coadministration of substrates of these transporters / DMEs with BC6ENTC .	False
Many transporters and DMEs are regulated by BC6ENTG [ BC6OTHER ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6ENTC receptor ( BC6OTHER ), and BC6OTHER receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER .	False
Many transporters and DMEs are regulated by BC6OTHER [ BC6ENTG ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6ENTC receptor ( BC6OTHER ), and BC6OTHER receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER .	False
Many transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6ENTG ( BC6OTHER ), constitutive BC6ENTC receptor ( BC6OTHER ), and BC6OTHER receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER .	False
Many transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6OTHER ( BC6ENTG ), constitutive BC6ENTC receptor ( BC6OTHER ), and BC6OTHER receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER .	False
Many transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6ENTC receptor ( BC6ENTG ), and BC6OTHER receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER .	False
Many transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6ENTC receptor ( BC6OTHER ), and BC6ENTG ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER .	False
Many transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6ENTC receptor ( BC6OTHER ), and BC6OTHER receptor ( BC6ENTG )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER .	False
Many transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6ENTC receptor ( BC6OTHER ), and BC6OTHER receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6ENTG .	False
Many transporters and DMEs are regulated by BC6ENTG [ BC6OTHER ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6OTHER receptor ( BC6OTHER ), and BC6ENTC receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER .	False
Many transporters and DMEs are regulated by BC6OTHER [ BC6ENTG ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6OTHER receptor ( BC6OTHER ), and BC6ENTC receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER .	False
Many transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6ENTG ( BC6OTHER ), constitutive BC6OTHER receptor ( BC6OTHER ), and BC6ENTC receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER .	False
Many transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6OTHER ( BC6ENTG ), constitutive BC6OTHER receptor ( BC6OTHER ), and BC6ENTC receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER .	False
Many transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6ENTC receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER .	False
Many transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6OTHER receptor ( BC6ENTG ), and BC6ENTC receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER .	False
Many transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6OTHER receptor ( BC6OTHER ), and BC6ENTC receptor ( BC6ENTG )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER .	False
Many transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6OTHER receptor ( BC6OTHER ), and BC6ENTC receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6ENTG .	False
CHEM BC6ENTC (PPS) has been shown to exert antitumor activity by antagonizing the binding of BC6ENTG to cell surface receptors.	CPR:6
In summary, BC6ENTC and BC6OTHER increase BC6ENTG activity and phosphorylation in the isolated heart.	CPR:3
In summary, BC6OTHER and BC6ENTC increase BC6ENTG activity and phosphorylation in the isolated heart.	CPR:3
BC6ENTG ( BC6OTHER ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6OTHER ]) or the BC6ENTC - to - BC6OTHER ratio ( BC6OTHER / BC6OTHER ).	False
BC6OTHER ( BC6ENTG ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6OTHER ]) or the BC6ENTC - to - BC6OTHER ratio ( BC6OTHER / BC6OTHER ).	False
BC6ENTG ( BC6OTHER ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6OTHER ]) or the BC6OTHER - to - BC6ENTC ratio ( BC6OTHER / BC6OTHER ).	False
BC6OTHER ( BC6ENTG ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6OTHER ]) or the BC6OTHER - to - BC6ENTC ratio ( BC6OTHER / BC6OTHER ).	False
The increase in BC6ENTG activity was always preceded by and correlated with increased cytosolic [ BC6ENTC ].	False
BC6ENTG ( BC6OTHER ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6OTHER ]) or the BC6OTHER - to - BC6OTHER ratio ( BC6ENTC / BC6OTHER ).	False
BC6OTHER ( BC6ENTG ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6OTHER ]) or the BC6OTHER - to - BC6OTHER ratio ( BC6ENTC / BC6OTHER ).	False
BC6ENTC - activated protein kinase ( BC6ENTG ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6OTHER ]) or the BC6OTHER - to - BC6OTHER ratio ( BC6OTHER / BC6OTHER ).	False
BC6ENTG ( BC6OTHER ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6OTHER ]) or the BC6OTHER - to - BC6OTHER ratio ( BC6OTHER / BC6ENTC ).	False
BC6OTHER ( BC6ENTG ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6OTHER ]) or the BC6OTHER - to - BC6OTHER ratio ( BC6OTHER / BC6ENTC ).	False
Cytosolic [ BC6ENTC ] reported metabolically active BC6OTHER , which triggered increased BC6ENTG activity, but measures of total BC6OTHER did not.	False
Cytosolic [ BC6OTHER ] reported metabolically active BC6ENTC , which triggered increased BC6ENTG activity, but measures of total BC6OTHER did not.	CPR:3
BC6ENTC and BC6OTHER , which are BC6OTHER , have been reported to increase BC6ENTG activity without increasing BC6OTHER / BC6OTHER .	CPR:3
Cytosolic [ BC6OTHER ] reported metabolically active BC6OTHER , which triggered increased BC6ENTG activity, but measures of total BC6ENTC did not.	False
BC6OTHER and BC6ENTC , which are BC6OTHER , have been reported to increase BC6ENTG activity without increasing BC6OTHER / BC6OTHER .	CPR:3
BC6OTHER and BC6OTHER , which are BC6ENTC , have been reported to increase BC6ENTG activity without increasing BC6OTHER / BC6OTHER .	CPR:3
BC6OTHER and BC6OTHER , which are BC6OTHER , have been reported to increase BC6ENTG activity without increasing BC6ENTC / BC6OTHER .	False
BC6OTHER and BC6OTHER , which are BC6OTHER , have been reported to increase BC6ENTG activity without increasing BC6OTHER / BC6ENTC .	False
This study tests the hypothesis that these BC6ENTC increase BC6ENTG activity in the heart by increasing cytosolic [ BC6OTHER ].	False
BC6ENTG ( BC6OTHER ) acts as a cellular energy sensor: it responds to an increase in BC6ENTC concentration ([ BC6OTHER ]) or the BC6OTHER - to - BC6OTHER ratio ( BC6OTHER / BC6OTHER ).	False
BC6OTHER ( BC6ENTG ) acts as a cellular energy sensor: it responds to an increase in BC6ENTC concentration ([ BC6OTHER ]) or the BC6OTHER - to - BC6OTHER ratio ( BC6OTHER / BC6OTHER ).	False
This study tests the hypothesis that these BC6OTHER increase BC6ENTG activity in the heart by increasing cytosolic [ BC6ENTC ].	False
At various times, hearts were freeze - clamped and assayed for BC6ENTG activity, phosphorylation of CHEM(172) on BC6OTHER , and phosphorylation of CHEM(79) on BC6ENTC carboxylase, an BC6OTHER target.	False
At various times, hearts were freeze - clamped and assayed for BC6OTHER activity, phosphorylation of CHEM(172) on BC6ENTG , and phosphorylation of CHEM(79) on BC6ENTC carboxylase, an BC6OTHER target.	False
At various times, hearts were freeze - clamped and assayed for BC6OTHER activity, phosphorylation of CHEM(172) on BC6OTHER , and phosphorylation of CHEM(79) on BC6ENTC carboxylase, an BC6ENTG target.	False
In hearts treated with BC6ENTC for 18 min and then perfused for 20 min with Krebs - Henseleit buffer, [ BC6OTHER ] began to increase at 26 min and BC6ENTG activity was elevated at 36 min.	CPR:3
In hearts treated with BC6OTHER for 18 min and then perfused for 20 min with Krebs - Henseleit buffer, [ BC6ENTC ] began to increase at 26 min and BC6ENTG activity was elevated at 36 min.	False
In hearts treated with BC6ENTC , [ BC6OTHER ] was increased at 50 min and BC6ENTG activity, phosphorylated BC6OTHER , and phosphorylated BC6OTHER carboxylase were elevated at 61 min.	CPR:3
In hearts treated with BC6ENTC , [ BC6OTHER ] was increased at 50 min and BC6OTHER activity, phosphorylated BC6ENTG , and phosphorylated BC6OTHER carboxylase were elevated at 61 min.	CPR:3
In hearts treated with BC6ENTC , [ BC6OTHER ] was increased at 50 min and BC6OTHER activity, phosphorylated BC6OTHER , and BC6ENTG were elevated at 61 min.	CPR:3
 BC6ENTC and BC6OTHER activate BC6ENTG in the heart by increasing cytosolic BC6OTHER concentration.	CPR:3
 BC6OTHER and BC6OTHER activate BC6ENTG in the heart by increasing cytosolic BC6ENTC concentration.	False
 BC6OTHER and BC6ENTC activate BC6ENTG in the heart by increasing cytosolic BC6OTHER concentration.	CPR:3
In hearts treated with BC6OTHER , [ BC6ENTC ] was increased at 50 min and BC6ENTG activity, phosphorylated BC6OTHER , and phosphorylated BC6OTHER carboxylase were elevated at 61 min.	False
In hearts treated with BC6OTHER , [ BC6ENTC ] was increased at 50 min and BC6OTHER activity, phosphorylated BC6ENTG , and phosphorylated BC6OTHER carboxylase were elevated at 61 min.	False
In hearts treated with BC6OTHER , [ BC6ENTC ] was increased at 50 min and BC6OTHER activity, phosphorylated BC6OTHER , and BC6ENTG were elevated at 61 min.	False
In hearts treated with BC6OTHER , [ BC6OTHER ] was increased at 50 min and BC6ENTG activity, phosphorylated BC6OTHER , and phosphorylated BC6ENTC carboxylase were elevated at 61 min.	False
In hearts treated with BC6OTHER , [ BC6OTHER ] was increased at 50 min and BC6OTHER activity, phosphorylated BC6ENTG , and phosphorylated BC6ENTC carboxylase were elevated at 61 min.	False
BC6ENTG ( BC6OTHER ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6ENTC ]) or the BC6OTHER - to - BC6OTHER ratio ( BC6OTHER / BC6OTHER ).	False
BC6OTHER ( BC6ENTG ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6ENTC ]) or the BC6OTHER - to - BC6OTHER ratio ( BC6OTHER / BC6OTHER ).	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6ENTC - requiring enzymes of BC6OTHER biosynthesis, BC6ENTG , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6ENTC - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6ENTG , and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6ENTC - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6ENTG , to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6ENTC - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTG and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6ENTC - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6ENTG .	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6ENTC and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6ENTG , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6ENTC and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6ENTG , and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6ENTC and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6ENTG , to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6ENTC and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTG and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6ENTC and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6ENTG .	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6ENTC in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6ENTG , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6ENTC in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6ENTG , and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6ENTC in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6ENTG , to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6ENTC in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTG and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6ENTC in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6ENTG .	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6ENTC biosynthesis, BC6ENTG , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6ENTC biosynthesis, BC6OTHER , BC6ENTG , and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6ENTC biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6ENTG , to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6ENTC biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTG and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6ENTC biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6ENTG .	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6ENTG , BC6ENTC synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6ENTC synthase, and BC6ENTG , to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6ENTC synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTG and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6ENTC synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6ENTG .	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6ENTG , BC6OTHER synthase, and BC6ENTC synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6ENTG , and BC6ENTC synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6ENTC synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTG and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6ENTC synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6ENTG .	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6ENTG , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6ENTC biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6ENTG , and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6ENTC biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6ENTG , to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6ENTC biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6ENTC biosynthetic enzymes, BC6ENTG and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6ENTC biosynthetic enzymes, BC6OTHER synthase II and BC6ENTG .	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6ENTG , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTC synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6ENTG , and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTC synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6ENTG , to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTC synthase II and BC6OTHER synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTC synthase II and BC6ENTG .	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6ENTG , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6ENTC synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6ENTG , and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6ENTC synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6ENTG , to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6ENTC synthase.	False
At 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTG and BC6ENTC synthase.	False
BC6ENTC dismutase 1 ( BC6OTHER ) maturation within the cell is mainly accomplished with the BC6OTHER , BC6ENTG , a dimeric protein with three distinct domains in each monomer.	False
BC6ENTC dismutase 1 ( BC6ENTG ) maturation within the cell is mainly accomplished with the BC6OTHER , BC6OTHER , a dimeric protein with three distinct domains in each monomer.	False
BC6ENTC dismutase 1 ( BC6OTHER ) maturation within the cell is mainly accomplished with the BC6ENTG , BC6OTHER , a dimeric protein with three distinct domains in each monomer.	False
We recently showed that the first domain of BC6ENTG ( BC6OTHER ) is responsible for BC6ENTC transfer to its protein partner, BC6OTHER ( BC6OTHER ).	False
We recently showed that the first domain of BC6OTHER ( BC6ENTG ) is responsible for BC6ENTC transfer to its protein partner, BC6OTHER ( BC6OTHER ).	False
We recently showed that the first domain of BC6OTHER ( BC6OTHER ) is responsible for BC6ENTC transfer to its protein partner, BC6ENTG ( BC6OTHER ).	False
We recently showed that the first domain of BC6OTHER ( BC6OTHER ) is responsible for BC6ENTC transfer to its protein partner, BC6OTHER ( BC6ENTG ).	False
The NMR solution structure of the BC6ENTC - loaded form of BC6ENTG reported here contributes further to characterization of the CHEM - transfer mechanism to BC6OTHER .	False
The NMR solution structure of the BC6ENTC - loaded form of BC6OTHER reported here contributes further to characterization of the CHEM - transfer mechanism to BC6ENTG .	False
NMR spectroscopy was also used to examine the BC6ENTG mutants BC6OTHER , BC6OTHER , and BC6OTHER / BC6OTHER , which are unable to form the structurally conserved BC6ENTC bond in BC6OTHER , in order to investigate the role of these BC6OTHER during BC6OTHER CHEM acquisition.	False
NMR spectroscopy was also used to examine the BC6OTHER mutants BC6ENTG , BC6OTHER , and BC6OTHER / BC6OTHER , which are unable to form the structurally conserved BC6ENTC bond in BC6OTHER , in order to investigate the role of these BC6OTHER during BC6OTHER CHEM acquisition.	False
NMR spectroscopy was also used to examine the BC6OTHER mutants BC6OTHER , BC6ENTG , and BC6OTHER / BC6OTHER , which are unable to form the structurally conserved BC6ENTC bond in BC6OTHER , in order to investigate the role of these BC6OTHER during BC6OTHER CHEM acquisition.	False
NMR spectroscopy was also used to examine the BC6OTHER mutants BC6OTHER , BC6OTHER , and BC6ENTG / BC6OTHER , which are unable to form the structurally conserved BC6ENTC bond in BC6OTHER , in order to investigate the role of these BC6OTHER during BC6OTHER CHEM acquisition.	False
NMR spectroscopy was also used to examine the BC6OTHER mutants BC6OTHER , BC6OTHER , and BC6OTHER / BC6ENTG , which are unable to form the structurally conserved BC6ENTC bond in BC6OTHER , in order to investigate the role of these BC6OTHER during BC6OTHER CHEM acquisition.	False
NMR spectroscopy was also used to examine the BC6OTHER mutants BC6OTHER , BC6OTHER , and BC6OTHER / BC6OTHER , which are unable to form the structurally conserved BC6ENTC bond in BC6ENTG , in order to investigate the role of these BC6OTHER during BC6OTHER CHEM acquisition.	False
NMR spectroscopy was also used to examine the BC6OTHER mutants BC6OTHER , BC6OTHER , and BC6OTHER / BC6OTHER , which are unable to form the structurally conserved BC6ENTC bond in BC6OTHER , in order to investigate the role of these BC6OTHER during BC6ENTG CHEM acquisition.	False
NMR spectroscopy was also used to examine the BC6ENTG mutants BC6OTHER , BC6OTHER , and BC6OTHER / BC6OTHER , which are unable to form the structurally conserved BC6OTHER bond in BC6OTHER , in order to investigate the role of these BC6ENTC during BC6OTHER CHEM acquisition.	False
NMR spectroscopy was also used to examine the BC6OTHER mutants BC6ENTG , BC6OTHER , and BC6OTHER / BC6OTHER , which are unable to form the structurally conserved BC6OTHER bond in BC6OTHER , in order to investigate the role of these BC6ENTC during BC6OTHER CHEM acquisition.	False
NMR spectroscopy was also used to examine the BC6OTHER mutants BC6OTHER , BC6ENTG , and BC6OTHER / BC6OTHER , which are unable to form the structurally conserved BC6OTHER bond in BC6OTHER , in order to investigate the role of these BC6ENTC during BC6OTHER CHEM acquisition.	False
NMR spectroscopy was also used to examine the BC6OTHER mutants BC6OTHER , BC6OTHER , and BC6ENTG / BC6OTHER , which are unable to form the structurally conserved BC6OTHER bond in BC6OTHER , in order to investigate the role of these BC6ENTC during BC6OTHER CHEM acquisition.	False
NMR spectroscopy was also used to examine the BC6OTHER mutants BC6OTHER , BC6OTHER , and BC6OTHER / BC6ENTG , which are unable to form the structurally conserved BC6OTHER bond in BC6OTHER , in order to investigate the role of these BC6ENTC during BC6OTHER CHEM acquisition.	False
NMR spectroscopy was also used to examine the BC6OTHER mutants BC6OTHER , BC6OTHER , and BC6OTHER / BC6OTHER , which are unable to form the structurally conserved BC6OTHER bond in BC6ENTG , in order to investigate the role of these BC6ENTC during BC6OTHER CHEM acquisition.	False
NMR spectroscopy was also used to examine the BC6OTHER mutants BC6OTHER , BC6OTHER , and BC6OTHER / BC6OTHER , which are unable to form the structurally conserved BC6OTHER bond in BC6OTHER , in order to investigate the role of these BC6ENTC during BC6ENTG CHEM acquisition.	False
Together, the information on both BC6ENTG and BC6OTHER , along with a sequence analysis of eukaryotic BC6OTHER , allows us to propose important mechanistic aspects regarding the BC6ENTC - transfer process from BC6OTHER to BC6OTHER .	False
Together, the information on both BC6OTHER and BC6ENTG , along with a sequence analysis of eukaryotic BC6OTHER , allows us to propose important mechanistic aspects regarding the BC6ENTC - transfer process from BC6OTHER to BC6OTHER .	False
Together, the information on both BC6OTHER and BC6OTHER , along with a sequence analysis of eukaryotic BC6ENTG , allows us to propose important mechanistic aspects regarding the BC6ENTC - transfer process from BC6OTHER to BC6OTHER .	False
Together, the information on both BC6OTHER and BC6OTHER , along with a sequence analysis of eukaryotic BC6OTHER , allows us to propose important mechanistic aspects regarding the BC6ENTC - transfer process from BC6ENTG to BC6OTHER .	False
Together, the information on both BC6OTHER and BC6OTHER , along with a sequence analysis of eukaryotic BC6OTHER , allows us to propose important mechanistic aspects regarding the BC6ENTC - transfer process from BC6OTHER to BC6ENTG .	False
Mechanistic Aspects of BC6OTHER Maturation from the Solution Structure of BC6OTHER - Loaded BC6OTHER and Analysis of BC6ENTC - Free BC6ENTG Mutants.	False
Mechanistic Aspects of BC6ENTG Maturation from the Solution Structure of BC6OTHER - Loaded BC6OTHER and Analysis of BC6ENTC - Free BC6OTHER Mutants.	False
Mechanistic Aspects of BC6OTHER Maturation from the Solution Structure of BC6OTHER - Loaded BC6ENTG and Analysis of BC6ENTC - Free BC6OTHER Mutants.	False
Mechanistic Aspects of BC6OTHER Maturation from the Solution Structure of BC6ENTC - Loaded BC6OTHER and Analysis of BC6OTHER - Free BC6ENTG Mutants.	False
Mechanistic Aspects of BC6ENTG Maturation from the Solution Structure of BC6ENTC - Loaded BC6OTHER and Analysis of BC6OTHER - Free BC6OTHER Mutants.	False
Mechanistic Aspects of BC6OTHER Maturation from the Solution Structure of BC6ENTC - Loaded BC6ENTG and Analysis of BC6OTHER - Free BC6OTHER Mutants.	False
The mRNA expression of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) was not reduced by BC6ENTC .	False
The mRNA expression of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) was not reduced by BC6ENTC .	False
The mRNA expression of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) was not reduced by BC6ENTC .	False
The mRNA expression of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) was not reduced by BC6ENTC .	False
Similarly, the BC6ENTG enzyme level did not change after BC6ENTC exposure but BC6OTHER could not be probed with the antibody available currently.	False
Similarly, the BC6OTHER enzyme level did not change after BC6ENTC exposure but BC6ENTG could not be probed with the antibody available currently.	False
BC6OTHER ( BC6OTHER ) ( BC6OTHER ) and BC6ENTC are competitive inhibitors of BC6OTHER by binding to the BC6ENTG ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) ( BC6OTHER ) and BC6ENTC are competitive inhibitors of BC6OTHER by binding to the BC6OTHER ( BC6ENTG ).	False
BC6OTHER ( BC6OTHER ) ( BC6OTHER ) and BC6OTHER are competitive inhibitors of BC6ENTC by binding to the BC6ENTG ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) ( BC6OTHER ) and BC6OTHER are competitive inhibitors of BC6ENTC by binding to the BC6OTHER ( BC6ENTG ).	False
BC6OTHER ( BC6OTHER ) ( BC6OTHER ) and BC6OTHER are competitive inhibitors of BC6OTHER by binding to the BC6ENTC receptor ( BC6ENTG ).	False
BC6ENTC and BC6OTHER are the most potent pure antiestrogens and BC6OTHER has the highest affinity of all antiestrogens to BC6ENTG .	False
BC6OTHER and BC6ENTC are the most potent pure antiestrogens and BC6OTHER has the highest affinity of all antiestrogens to BC6ENTG .	False
BC6OTHER and BC6OTHER are the most potent pure antiestrogens and BC6ENTC has the highest affinity of all antiestrogens to BC6ENTG .	False
BC6ENTC ( BC6OTHER ) ( BC6OTHER ) and BC6OTHER are competitive inhibitors of BC6OTHER by binding to the BC6ENTG ( BC6OTHER ).	False
BC6ENTC ( BC6OTHER ) ( BC6OTHER ) and BC6OTHER are competitive inhibitors of BC6OTHER by binding to the BC6OTHER ( BC6ENTG ).	False
BC6OTHER ( BC6ENTC ) ( BC6OTHER ) and BC6OTHER are competitive inhibitors of BC6OTHER by binding to the BC6ENTG ( BC6OTHER ).	False
BC6OTHER ( BC6ENTC ) ( BC6OTHER ) and BC6OTHER are competitive inhibitors of BC6OTHER by binding to the BC6OTHER ( BC6ENTG ).	False
BC6OTHER ( BC6OTHER ) ( BC6ENTC ) and BC6OTHER are competitive inhibitors of BC6OTHER by binding to the BC6ENTG ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) ( BC6ENTC ) and BC6OTHER are competitive inhibitors of BC6OTHER by binding to the BC6OTHER ( BC6ENTG ).	False
We used the patch - clamp technique and BC6ENTC flux assays to determine the role of these drugs in BC6ENTG (K( BC6OTHER )) regulation in cell lines expressing the cloned components of K( BC6OTHER ) and the current natively expressed in vascular smooth muscle cells (VSMCs).	False
We used the patch - clamp technique and BC6ENTC flux assays to determine the role of these drugs in CHEM - sensitive BC6OTHER channel ( BC6ENTG ) regulation in cell lines expressing the cloned components of K( BC6OTHER ) and the current natively expressed in vascular smooth muscle cells (VSMCs).	False
We used the patch - clamp technique and BC6ENTC flux assays to determine the role of these drugs in CHEM - sensitive BC6OTHER channel (K( BC6OTHER )) regulation in cell lines expressing the cloned components of BC6ENTG and the current natively expressed in vascular smooth muscle cells (VSMCs).	False
We used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in BC6ENTC - sensitive BC6OTHER channel ( BC6ENTG ) regulation in cell lines expressing the cloned components of K( BC6OTHER ) and the current natively expressed in vascular smooth muscle cells (VSMCs).	False
We used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in BC6ENTC - sensitive BC6OTHER channel (K( BC6OTHER )) regulation in cell lines expressing the cloned components of BC6ENTG and the current natively expressed in vascular smooth muscle cells (VSMCs).	False
We used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in CHEM - sensitive BC6ENTC channel ( BC6ENTG ) regulation in cell lines expressing the cloned components of K( BC6OTHER ) and the current natively expressed in vascular smooth muscle cells (VSMCs).	False
We used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in CHEM - sensitive BC6ENTC channel (K( BC6OTHER )) regulation in cell lines expressing the cloned components of BC6ENTG and the current natively expressed in vascular smooth muscle cells (VSMCs).	False
We used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in BC6ENTG ( BC6ENTC ( BC6OTHER )) regulation in cell lines expressing the cloned components of K( BC6OTHER ) and the current natively expressed in vascular smooth muscle cells (VSMCs).	False
We used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in CHEM - sensitive BC6OTHER channel ( BC6ENTC ( BC6OTHER )) regulation in cell lines expressing the cloned components of BC6ENTG and the current natively expressed in vascular smooth muscle cells (VSMCs).	False
We used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in BC6ENTG (K( BC6ENTC )) regulation in cell lines expressing the cloned components of K( BC6OTHER ) and the current natively expressed in vascular smooth muscle cells (VSMCs).	False
We used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in CHEM - sensitive BC6OTHER channel (K( BC6ENTC )) regulation in cell lines expressing the cloned components of BC6ENTG and the current natively expressed in vascular smooth muscle cells (VSMCs).	False
The BC6OTHER , BC6OTHER and BC6ENTC , are used in the treatment of type II diabetes mellitus, as well as being routinely used in studies investigating BC6ENTG activity.	False
We used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in BC6ENTG (K( BC6OTHER )) regulation in cell lines expressing the cloned components of BC6ENTC ( BC6OTHER ) and the current natively expressed in vascular smooth muscle cells (VSMCs).	False
We used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in CHEM - sensitive BC6OTHER channel ( BC6ENTG ) regulation in cell lines expressing the cloned components of BC6ENTC ( BC6OTHER ) and the current natively expressed in vascular smooth muscle cells (VSMCs).	False
We used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in BC6ENTG (K( BC6OTHER )) regulation in cell lines expressing the cloned components of K( BC6ENTC ) and the current natively expressed in vascular smooth muscle cells (VSMCs).	False
We used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in CHEM - sensitive BC6OTHER channel ( BC6ENTG ) regulation in cell lines expressing the cloned components of K( BC6ENTC ) and the current natively expressed in vascular smooth muscle cells (VSMCs).	False
The BC6ENTC , BC6OTHER and BC6OTHER , are used in the treatment of type II diabetes mellitus, as well as being routinely used in studies investigating BC6ENTG activity.	False
BC6ENTC but not BC6OTHER inhibits a number of variants of BC6ENTG including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ).	CPR:4
BC6ENTC but not BC6OTHER inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6ENTG / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ).	CPR:4
BC6ENTC but not BC6OTHER inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6ENTG and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ).	CPR:4
BC6ENTC but not BC6OTHER inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ).	CPR:4
BC6ENTC but not BC6OTHER inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6ENTG ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ).	CPR:4
BC6ENTC but not BC6OTHER inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6ENTG / BC6OTHER ).	CPR:4
BC6ENTC but not BC6OTHER inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6ENTG ).	CPR:4
BC6OTHER but not BC6ENTC inhibits a number of variants of BC6ENTG including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ).	False
BC6OTHER but not BC6ENTC inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6ENTG / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ).	False
BC6OTHER but not BC6ENTC inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6ENTG and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ).	False
BC6OTHER but not BC6ENTC inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ).	False
BC6OTHER but not BC6ENTC inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6ENTG ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ).	False
BC6OTHER but not BC6ENTC inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6ENTG / BC6OTHER ).	False
BC6OTHER but not BC6ENTC inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6ENTG ).	False
BC6OTHER but not BC6OTHER inhibits a number of variants of BC6ENTC ( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6ENTG / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ).	False
BC6OTHER but not BC6OTHER inhibits a number of variants of BC6ENTC ( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6ENTG and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ).	False
BC6OTHER but not BC6OTHER inhibits a number of variants of BC6ENTC ( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ).	False
BC6OTHER but not BC6OTHER inhibits a number of variants of BC6ENTC ( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6ENTG ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ).	False
BC6OTHER but not BC6OTHER inhibits a number of variants of BC6ENTC ( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6ENTG / BC6OTHER ).	False
BC6OTHER but not BC6OTHER inhibits a number of variants of BC6ENTC ( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6ENTG ).	False
BC6OTHER but not BC6OTHER inhibits a number of variants of K( BC6ENTC ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6ENTG / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ).	False
BC6OTHER but not BC6OTHER inhibits a number of variants of K( BC6ENTC ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6ENTG and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ).	False
BC6OTHER but not BC6OTHER inhibits a number of variants of K( BC6ENTC ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ).	False
BC6OTHER but not BC6OTHER inhibits a number of variants of K( BC6ENTC ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6ENTG ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ).	False
BC6OTHER but not BC6OTHER inhibits a number of variants of K( BC6ENTC ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6ENTG / BC6OTHER ).	False
BC6OTHER but not BC6OTHER inhibits a number of variants of K( BC6ENTC ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6ENTG ).	False
 BC6ENTC has a direct inhibitory effect on the BC6ENTG .	CPR:4
The extent and rate of inhibition are similar to that seen with the known BC6ENTG blocker BC6ENTC .	CPR:4
Additionally, BC6ENTC inhibited the current elicited through the BC6ENTG (functional without BC6OTHER ) channel with an IC50 of 1.78 mM.	CPR:4
Additionally, BC6ENTC inhibited the current elicited through the BC6OTHER (functional without BC6ENTG ) channel with an IC50 of 1.78 mM.	False
BC6ENTC reduced the open probability of BC6ENTG / BC6OTHER channels by approximately 90% in inside - out patches.	CPR:4
BC6ENTC reduced the open probability of BC6OTHER / BC6ENTG channels by approximately 90% in inside - out patches.	CPR:4
These findings suggest that BC6ENTC interacts directly with the pore - forming BC6ENTG subunit however the BC6OTHER receptor is able to significantly modulate the affinity.	False
These findings suggest that BC6ENTC interacts directly with the pore - forming BC6OTHER subunit however the BC6ENTG is able to significantly modulate the affinity.	False
These findings suggest that BC6OTHER interacts directly with the pore - forming BC6ENTG subunit however the BC6ENTC receptor is able to significantly modulate the affinity.	False
The BC6OTHER , BC6ENTC and BC6OTHER , are used in the treatment of type II diabetes mellitus, as well as being routinely used in studies investigating BC6ENTG activity.	False
We have previously isolated from human hemofiltrate an BC6ENTC - terminally truncated form of the BC6OTHER ( BC6OTHER ), and characterized BC6OTHER as a strong agonist of BC6OTHER , BC6OTHER , and to a lower extent BC6ENTG .	False
We have previously isolated from human hemofiltrate an BC6ENTC - terminally truncated form of the BC6ENTG ( BC6OTHER ), and characterized BC6OTHER as a strong agonist of BC6OTHER , BC6OTHER , and to a lower extent BC6OTHER .	False
We have previously isolated from human hemofiltrate an BC6ENTC - terminally truncated form of the BC6OTHER ( BC6ENTG ), and characterized BC6OTHER as a strong agonist of BC6OTHER , BC6OTHER , and to a lower extent BC6OTHER .	False
We have previously isolated from human hemofiltrate an BC6ENTC - terminally truncated form of the BC6OTHER ( BC6OTHER ), and characterized BC6ENTG as a strong agonist of BC6OTHER , BC6OTHER , and to a lower extent BC6OTHER .	False
We have previously isolated from human hemofiltrate an BC6ENTC - terminally truncated form of the BC6OTHER ( BC6OTHER ), and characterized BC6OTHER as a strong agonist of BC6ENTG , BC6OTHER , and to a lower extent BC6OTHER .	False
We have previously isolated from human hemofiltrate an BC6ENTC - terminally truncated form of the BC6OTHER ( BC6OTHER ), and characterized BC6OTHER as a strong agonist of BC6OTHER , BC6ENTG , and to a lower extent BC6OTHER .	False
BC6ENTC (1) reduced the pro - inflammatory factor such as BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	CPR:4
BC6ENTC (1) reduced the pro - inflammatory factor such as BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	CPR:4
BC6OTHER (1) reduced the pro - inflammatory factor such as BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
BC6OTHER (1) reduced the pro - inflammatory factor such as BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
BC6OTHER (1) reduced the pro - inflammatory factor such as BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
BC6OTHER (1) reduced the pro - inflammatory factor such as BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
BC6OTHER (1) reduced the pro - inflammatory factor such as BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
BC6OTHER (1) reduced the pro - inflammatory factor such as BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
BC6OTHER (1) reduced the pro - inflammatory factor such as BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and BC6ENTG ( BC6OTHER ).	False
BC6OTHER (1) reduced the pro - inflammatory factor such as BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6ENTG ).	False
An BC6ENTC dehydrogenase ( BC6ENTG ) activity has been localized in the rat kidney by a histochemical technique which links BC6OTHER metabolism with the production of a color reaction.	False
These results demonstrate the presence of a BC6ENTG activity separate from the BC6ENTC ( BC6OTHER ) - dependent BC6OTHER recently purified and cloned from rat liver.	False
These results demonstrate the presence of a BC6OTHER activity separate from the BC6ENTC ( BC6OTHER ) - dependent BC6ENTG recently purified and cloned from rat liver.	False
These results demonstrate the presence of a BC6ENTG activity separate from the BC6OTHER ( BC6ENTC ) - dependent BC6OTHER recently purified and cloned from rat liver.	False
These results demonstrate the presence of a BC6OTHER activity separate from the BC6OTHER ( BC6ENTC ) - dependent BC6ENTG recently purified and cloned from rat liver.	False
These results demonstrate the presence of a BC6ENTG activity separate from the BC6OTHER ( BC6OTHER ) - dependent BC6ENTC dehydrogenase recently purified and cloned from rat liver.	False
We have named this activity BC6ENTG to distinguish it from the BC6ENTC - dependent BC6OTHER .	False
We have named this activity BC6OTHER to distinguish it from the BC6ENTC - dependent BC6ENTG .	False
An BC6ENTG ( BC6OTHER ) activity has been localized in the rat kidney by a histochemical technique which links BC6ENTC metabolism with the production of a color reaction.	False
An BC6OTHER ( BC6ENTG ) activity has been localized in the rat kidney by a histochemical technique which links BC6ENTC metabolism with the production of a color reaction.	False
Possible BC6ENTG involvement in BC6ENTC metabolism in insects was evaluated using BC6OTHER - expressing and BC6OTHER - deficient Drosophila, but no differences were found in BC6OTHER nitroreduction or sensitivity between the two strains.	CPR:9
Possible BC6OTHER involvement in BC6ENTC metabolism in insects was evaluated using BC6ENTG - expressing and BC6OTHER - deficient Drosophila, but no differences were found in BC6OTHER nitroreduction or sensitivity between the two strains.	CPR:9
Possible BC6OTHER involvement in BC6ENTC metabolism in insects was evaluated using BC6OTHER - expressing and BC6ENTG - deficient Drosophila, but no differences were found in BC6OTHER nitroreduction or sensitivity between the two strains.	False
Possible BC6ENTG involvement in BC6OTHER metabolism in insects was evaluated using BC6OTHER - expressing and BC6OTHER - deficient Drosophila, but no differences were found in BC6ENTC nitroreduction or sensitivity between the two strains.	False
Possible BC6OTHER involvement in BC6OTHER metabolism in insects was evaluated using BC6ENTG - expressing and BC6OTHER - deficient Drosophila, but no differences were found in BC6ENTC nitroreduction or sensitivity between the two strains.	False
Possible BC6OTHER involvement in BC6OTHER metabolism in insects was evaluated using BC6OTHER - expressing and BC6ENTG - deficient Drosophila, but no differences were found in BC6ENTC nitroreduction or sensitivity between the two strains.	False
This is the first study to establish the in vivo relevance of BC6ENTG in BC6ENTC metabolism in mammals and one of the first for xenobiotics in general.	CPR:9
Currently, the most important insecticides are BC6ENTC , which are metabolized in vitro by BC6ENTG on reduction of the BC6OTHER group and by BC6OTHER via oxidation reactions.	CPR:9
Currently, the most important insecticides are BC6ENTC , which are metabolized in vitro by BC6OTHER on reduction of the BC6OTHER group and by BC6ENTG via oxidation reactions.	CPR:9
Currently, the most important insecticides are BC6OTHER , which are metabolized in vitro by BC6ENTG on reduction of the BC6ENTC group and by BC6OTHER via oxidation reactions.	CPR:9
Currently, the most important insecticides are BC6OTHER , which are metabolized in vitro by BC6OTHER on reduction of the BC6ENTC group and by BC6ENTG via oxidation reactions.	False
The procedure was to reduce liver BC6ENTG activity by providing BC6ENTC or BC6OTHER in the drinking water or to use the BC6OTHER - deficient DBA / 2 mouse strain.	CPR:4
The procedure was to reduce liver BC6OTHER activity by providing BC6ENTC or BC6OTHER in the drinking water or to use the BC6ENTG - deficient DBA / 2 mouse strain.	False
The procedure was to reduce liver BC6ENTG activity by providing BC6OTHER or BC6ENTC in the drinking water or to use the BC6OTHER - deficient DBA / 2 mouse strain.	CPR:4
The procedure was to reduce liver BC6OTHER activity by providing BC6OTHER or BC6ENTC in the drinking water or to use the BC6ENTG - deficient DBA / 2 mouse strain.	False
Liver BC6ENTG activity was reduced by 45% with BC6ENTC and 61% with BC6OTHER and 81% in BC6OTHER - deficient mice relative to controls.	CPR:4
Liver BC6OTHER activity was reduced by 45% with BC6ENTC and 61% with BC6OTHER and 81% in BC6ENTG - deficient mice relative to controls.	False
Liver BC6ENTG activity was reduced by 45% with BC6OTHER and 61% with BC6ENTC and 81% in BC6OTHER - deficient mice relative to controls.	CPR:4
Liver BC6OTHER activity was reduced by 45% with BC6OTHER and 61% with BC6ENTC and 81% in BC6ENTG - deficient mice relative to controls.	False
When mice were treated ip with the major neonicotinoid BC6ENTC ( BC6OTHER ), metabolism by BC6OTHER oxidation reactions was not appreciably affected, whereas the BC6ENTG - generated BC6OTHER metabolite was decreased by 30% with BC6OTHER and 56% with BC6OTHER and 86% in the BC6OTHER - deficient mice.	False
When mice were treated ip with the major neonicotinoid BC6ENTC ( BC6OTHER ), metabolism by BC6OTHER oxidation reactions was not appreciably affected, whereas the BC6OTHER - generated BC6OTHER metabolite was decreased by 30% with BC6OTHER and 56% with BC6OTHER and 86% in the BC6ENTG - deficient mice.	False
When mice were treated ip with the major neonicotinoid BC6ENTC ( BC6OTHER ), metabolism by BC6ENTG oxidation reactions was not appreciably affected, whereas the BC6OTHER - generated BC6OTHER metabolite was decreased by 30% with BC6OTHER and 56% with BC6OTHER and 86% in the BC6OTHER - deficient mice.	False
BC6ENTC oxidase ( BC6OTHER ) metabolizes many xenobiotics in vitro, but its importance in vivo is usually unknown relative to BC6ENTG ( BC6OTHER ) and other detoxification systems.	False
BC6ENTC oxidase ( BC6OTHER ) metabolizes many xenobiotics in vitro, but its importance in vivo is usually unknown relative to BC6OTHER ( BC6ENTG ) and other detoxification systems.	False
BC6ENTC oxidase ( BC6ENTG ) metabolizes many xenobiotics in vitro, but its importance in vivo is usually unknown relative to BC6OTHER ( BC6OTHER ) and other detoxification systems.	False
When mice were treated ip with the major neonicotinoid BC6OTHER ( BC6ENTC ), metabolism by BC6OTHER oxidation reactions was not appreciably affected, whereas the BC6ENTG - generated BC6OTHER metabolite was decreased by 30% with BC6OTHER and 56% with BC6OTHER and 86% in the BC6OTHER - deficient mice.	False
When mice were treated ip with the major neonicotinoid BC6OTHER ( BC6ENTC ), metabolism by BC6OTHER oxidation reactions was not appreciably affected, whereas the BC6OTHER - generated BC6OTHER metabolite was decreased by 30% with BC6OTHER and 56% with BC6OTHER and 86% in the BC6ENTG - deficient mice.	False
When mice were treated ip with the major neonicotinoid BC6OTHER ( BC6ENTC ), metabolism by BC6ENTG oxidation reactions was not appreciably affected, whereas the BC6OTHER - generated BC6OTHER metabolite was decreased by 30% with BC6OTHER and 56% with BC6OTHER and 86% in the BC6OTHER - deficient mice.	False
 BC6ENTG importance in vivo in xenobiotic metabolism: BC6ENTC nitroreduction in mice.	False
When mice were treated ip with the major neonicotinoid BC6OTHER ( BC6OTHER ), metabolism by BC6OTHER oxidation reactions was not appreciably affected, whereas the BC6ENTG - generated BC6ENTC metabolite was decreased by 30% with BC6OTHER and 56% with BC6OTHER and 86% in the BC6OTHER - deficient mice.	CPR:9
When mice were treated ip with the major neonicotinoid BC6OTHER ( BC6OTHER ), metabolism by BC6OTHER oxidation reactions was not appreciably affected, whereas the BC6OTHER - generated BC6ENTC metabolite was decreased by 30% with BC6OTHER and 56% with BC6OTHER and 86% in the BC6ENTG - deficient mice.	False
When mice were treated ip with the major neonicotinoid BC6OTHER ( BC6OTHER ), metabolism by BC6ENTG oxidation reactions was not appreciably affected, whereas the BC6OTHER - generated BC6ENTC metabolite was decreased by 30% with BC6OTHER and 56% with BC6OTHER and 86% in the BC6OTHER - deficient mice.	False
When mice were treated ip with the major neonicotinoid BC6OTHER ( BC6OTHER ), metabolism by BC6OTHER oxidation reactions was not appreciably affected, whereas the BC6ENTG - generated BC6OTHER metabolite was decreased by 30% with BC6ENTC and 56% with BC6OTHER and 86% in the BC6OTHER - deficient mice.	CPR:4
When mice were treated ip with the major neonicotinoid BC6OTHER ( BC6OTHER ), metabolism by BC6OTHER oxidation reactions was not appreciably affected, whereas the BC6OTHER - generated BC6OTHER metabolite was decreased by 30% with BC6ENTC and 56% with BC6OTHER and 86% in the BC6ENTG - deficient mice.	False
When mice were treated ip with the major neonicotinoid BC6OTHER ( BC6OTHER ), metabolism by BC6ENTG oxidation reactions was not appreciably affected, whereas the BC6OTHER - generated BC6OTHER metabolite was decreased by 30% with BC6ENTC and 56% with BC6OTHER and 86% in the BC6OTHER - deficient mice.	False
When mice were treated ip with the major neonicotinoid BC6OTHER ( BC6OTHER ), metabolism by BC6OTHER oxidation reactions was not appreciably affected, whereas the BC6ENTG - generated BC6OTHER metabolite was decreased by 30% with BC6OTHER and 56% with BC6ENTC and 86% in the BC6OTHER - deficient mice.	CPR:4
When mice were treated ip with the major neonicotinoid BC6OTHER ( BC6OTHER ), metabolism by BC6OTHER oxidation reactions was not appreciably affected, whereas the BC6OTHER - generated BC6OTHER metabolite was decreased by 30% with BC6OTHER and 56% with BC6ENTC and 86% in the BC6ENTG - deficient mice.	False
When mice were treated ip with the major neonicotinoid BC6OTHER ( BC6OTHER ), metabolism by BC6ENTG oxidation reactions was not appreciably affected, whereas the BC6OTHER - generated BC6OTHER metabolite was decreased by 30% with BC6OTHER and 56% with BC6ENTC and 86% in the BC6OTHER - deficient mice.	False
The other BC6ENTC nitroreduction metabolite, desnitro - BC6OTHER , was decreased by 55%, 65%, and 81% with BC6OTHER , BC6OTHER , and in the BC6ENTG - deficient mice, respectively.	False
The other BC6OTHER nitroreduction metabolite, desnitro - BC6ENTC , was decreased by 55%, 65%, and 81% with BC6OTHER , BC6OTHER , and in the BC6ENTG - deficient mice, respectively.	False
The other BC6OTHER nitroreduction metabolite, desnitro - BC6OTHER , was decreased by 55%, 65%, and 81% with BC6ENTC , BC6OTHER , and in the BC6ENTG - deficient mice, respectively.	False
The other BC6OTHER nitroreduction metabolite, desnitro - BC6OTHER , was decreased by 55%, 65%, and 81% with BC6OTHER , BC6ENTC , and in the BC6ENTG - deficient mice, respectively.	False
Thus, decreasing liver BC6ENTG activity by three quite different procedures gave a corresponding decrease for in vivo reductive metabolites in the liver of BC6ENTC - treated mice.	CPR:9
Here we tested the effect of chronic supplementation with a mineral extract from red marine algae - rich in BC6ENTC (34%), BC6OTHER , BC6OTHER , BC6OTHER and other trace minerals - in a clinically relevant model of spontaneous enterocolitis, BC6ENTG ( - / - ) mice.	False
Here we tested the effect of chronic supplementation with a mineral extract from red marine algae - rich in BC6OTHER (34%), BC6ENTC , BC6OTHER , BC6OTHER and other trace minerals - in a clinically relevant model of spontaneous enterocolitis, BC6ENTG ( - / - ) mice.	False
Here we tested the effect of chronic supplementation with a mineral extract from red marine algae - rich in BC6OTHER (34%), BC6OTHER , BC6ENTC , BC6OTHER and other trace minerals - in a clinically relevant model of spontaneous enterocolitis, BC6ENTG ( - / - ) mice.	False
Here we tested the effect of chronic supplementation with a mineral extract from red marine algae - rich in BC6OTHER (34%), BC6OTHER , BC6OTHER , BC6ENTC and other trace minerals - in a clinically relevant model of spontaneous enterocolitis, BC6ENTG ( - / - ) mice.	False
In vitro binding affinities of BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and some of their metabolites for BC6ENTG , BC6OTHER in rat brain were previously reported from our laboratories.	False
In vitro binding affinities of BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and some of their metabolites for BC6OTHER D2 receptors, BC6ENTG in rat brain were previously reported from our laboratories.	False
BC6OTHER , BC6ENTC , and their metabolites had 5 - 30 times higher binding affinities for BC6ENTG than BC6OTHER , BC6OTHER and their metabolites.	False
BC6OTHER , BC6OTHER , and their metabolites had 5 - 30 times higher binding affinities for BC6ENTG than BC6ENTC , BC6OTHER and their metabolites.	False
In vitro binding affinities of BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and some of their metabolites for BC6ENTG , BC6OTHER in rat brain were previously reported from our laboratories.	False
In vitro binding affinities of BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and some of their metabolites for BC6OTHER D2 receptors, BC6ENTG in rat brain were previously reported from our laboratories.	False
BC6OTHER , BC6OTHER , and their metabolites had 5 - 30 times higher binding affinities for BC6ENTG than BC6OTHER , BC6ENTC and their metabolites.	False
BC6ENTC was the most potent and BC6OTHER the least potent of the four drugs in BC6ENTG binding.	False
BC6OTHER was the most potent and BC6ENTC the least potent of the four drugs in BC6ENTG binding.	False
BC6ENTC , BC6OTHER and BC6OTHER had only 10% of the potency of the parent drug in BC6ENTG binding, while the BC6OTHER - metabolites of BC6OTHER and BC6OTHER had about 75% of the potency of the parent drug in this binding system.	False
In vitro binding affinities of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and some of their metabolites for BC6ENTG , BC6OTHER in rat brain were previously reported from our laboratories.	False
In vitro binding affinities of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and some of their metabolites for BC6OTHER D2 receptors, BC6ENTG in rat brain were previously reported from our laboratories.	False
BC6OTHER , BC6ENTC and BC6OTHER had only 10% of the potency of the parent drug in BC6ENTG binding, while the BC6OTHER - metabolites of BC6OTHER and BC6OTHER had about 75% of the potency of the parent drug in this binding system.	False
BC6OTHER , BC6OTHER and BC6ENTC had only 10% of the potency of the parent drug in BC6ENTG binding, while the BC6OTHER - metabolites of BC6OTHER and BC6OTHER had about 75% of the potency of the parent drug in this binding system.	False
BC6OTHER , BC6OTHER and BC6OTHER had only 10% of the potency of the parent drug in BC6ENTG binding, while the BC6ENTC - metabolites of BC6OTHER and BC6OTHER had about 75% of the potency of the parent drug in this binding system.	False
BC6OTHER , BC6OTHER and BC6OTHER had only 10% of the potency of the parent drug in BC6ENTG binding, while the BC6OTHER - metabolites of BC6ENTC and BC6OTHER had about 75% of the potency of the parent drug in this binding system.	False
BC6OTHER , BC6OTHER and BC6OTHER had only 10% of the potency of the parent drug in BC6ENTG binding, while the BC6OTHER - metabolites of BC6OTHER and BC6ENTC had about 75% of the potency of the parent drug in this binding system.	False
Muscarinic cholinergic and BC6ENTG binding of BC6ENTC drug metabolites.	False
Their BC6ENTG binding affinities indicate that metabolites may contribute to the sedative effects of BC6ENTC and BC6OTHER .	False
Their BC6ENTG binding affinities indicate that metabolites may contribute to the sedative effects of BC6OTHER and BC6ENTC .	False
In vitro binding affinities of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and some of their metabolites for BC6ENTC D2 receptors, BC6ENTG in rat brain were previously reported from our laboratories.	False
In vitro binding affinities of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and some of their metabolites for BC6ENTG , BC6OTHER in rat brain were previously reported from our laboratories.	False
In vitro binding affinities of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and some of their metabolites for BC6OTHER D2 receptors, BC6ENTG in rat brain were previously reported from our laboratories.	False
The present study reports the in vitro binding affinities of the same compounds for BC6ENTG and for BC6ENTC H1 receptors in rat brain, using BC6OTHER and BC6OTHER as radioligands.	False
The present study reports the in vitro binding affinities of the same compounds for BC6ENTG and for BC6OTHER H1 receptors in rat brain, using BC6ENTC and BC6OTHER as radioligands.	False
The present study reports the in vitro binding affinities of the same compounds for BC6OTHER and for BC6ENTG in rat brain, using BC6ENTC and BC6OTHER as radioligands.	False
The present study reports the in vitro binding affinities of the same compounds for BC6ENTG and for BC6OTHER H1 receptors in rat brain, using BC6OTHER and BC6ENTC as radioligands.	False
The present study reports the in vitro binding affinities of the same compounds for BC6OTHER and for BC6ENTG in rat brain, using BC6OTHER and BC6ENTC as radioligands.	False
BC6ENTC , BC6OTHER , and their metabolites had 5 - 30 times higher binding affinities for BC6ENTG than BC6OTHER , BC6OTHER and their metabolites.	False
BC6ENTG activates platelets through 2 pathways: one is through BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC - mediated induction of aggregation; the other is through BC6OTHER - mediated aggregation and agglutination.	False
BC6OTHER activates platelets through 2 pathways: one is through BC6ENTG , BC6OTHER ( BC6OTHER ), BC6ENTC - mediated induction of aggregation; the other is through BC6OTHER - mediated aggregation and agglutination.	False
BC6OTHER activates platelets through 2 pathways: one is through BC6OTHER , BC6ENTG ( BC6OTHER ), BC6ENTC - mediated induction of aggregation; the other is through BC6OTHER - mediated aggregation and agglutination.	False
BC6OTHER activates platelets through 2 pathways: one is through BC6OTHER , BC6OTHER ( BC6ENTG ), BC6ENTC - mediated induction of aggregation; the other is through BC6OTHER - mediated aggregation and agglutination.	False
BC6OTHER activates platelets through 2 pathways: one is through BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC - mediated induction of aggregation; the other is through BC6ENTG - mediated aggregation and agglutination.	False
BC6ENTG - induced platelet aggregation was independent of BC6ENTC formation and BC6OTHER secretion but enhanced by feedback stimulation through these pathways.	False
BC6ENTG - induced platelet aggregation was independent of BC6OTHER formation and BC6ENTC secretion but enhanced by feedback stimulation through these pathways.	False
Treatments that raised BC6ENTC ( BC6OTHER ), sequestered BC6OTHER ( BC6OTHER ) or prevented BC6ENTG - platelet interaction (sRAGE, BC6OTHER [ BC6OTHER ]) induced almost complete inhibition.	False
Treatments that raised BC6ENTC ( BC6OTHER ), sequestered BC6OTHER ( BC6OTHER ) or prevented BC6OTHER - platelet interaction (sRAGE, BC6ENTG [ BC6OTHER ]) induced almost complete inhibition.	False
Treatments that raised BC6ENTC ( BC6OTHER ), sequestered BC6OTHER ( BC6OTHER ) or prevented BC6OTHER - platelet interaction (sRAGE, BC6OTHER [ BC6ENTG ]) induced almost complete inhibition.	False
Treatments that raised BC6OTHER ( BC6ENTC ), sequestered BC6OTHER ( BC6OTHER ) or prevented BC6ENTG - platelet interaction (sRAGE, BC6OTHER [ BC6OTHER ]) induced almost complete inhibition.	False
Treatments that raised BC6OTHER ( BC6ENTC ), sequestered BC6OTHER ( BC6OTHER ) or prevented BC6OTHER - platelet interaction (sRAGE, BC6ENTG [ BC6OTHER ]) induced almost complete inhibition.	False
Treatments that raised BC6OTHER ( BC6ENTC ), sequestered BC6OTHER ( BC6OTHER ) or prevented BC6OTHER - platelet interaction (sRAGE, BC6OTHER [ BC6ENTG ]) induced almost complete inhibition.	False
Treatments that raised BC6OTHER ( BC6OTHER ), sequestered BC6ENTC ( BC6OTHER ) or prevented BC6ENTG - platelet interaction (sRAGE, BC6OTHER [ BC6OTHER ]) induced almost complete inhibition.	False
Treatments that raised BC6OTHER ( BC6OTHER ), sequestered BC6ENTC ( BC6OTHER ) or prevented BC6OTHER - platelet interaction (sRAGE, BC6ENTG [ BC6OTHER ]) induced almost complete inhibition.	False
Treatments that raised BC6OTHER ( BC6OTHER ), sequestered BC6ENTC ( BC6OTHER ) or prevented BC6OTHER - platelet interaction (sRAGE, BC6OTHER [ BC6ENTG ]) induced almost complete inhibition.	False
Treatments that raised BC6OTHER ( BC6OTHER ), sequestered BC6OTHER ( BC6ENTC ) or prevented BC6ENTG - platelet interaction (sRAGE, BC6OTHER [ BC6OTHER ]) induced almost complete inhibition.	False
Treatments that raised BC6OTHER ( BC6OTHER ), sequestered BC6OTHER ( BC6ENTC ) or prevented BC6OTHER - platelet interaction (sRAGE, BC6ENTG [ BC6OTHER ]) induced almost complete inhibition.	False
Treatments that raised BC6OTHER ( BC6OTHER ), sequestered BC6OTHER ( BC6ENTC ) or prevented BC6OTHER - platelet interaction (sRAGE, BC6OTHER [ BC6ENTG ]) induced almost complete inhibition.	False
Modulation of the function of BC6ENTG (CD36 - / - mice), BC6OTHER ( BC6OTHER ) ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER , 6D1 antibody) induced approximately 50% inhibition.	False
Modulation of the function of BC6OTHER (CD36 - / - mice), BC6ENTG ( BC6OTHER ) ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER , 6D1 antibody) induced approximately 50% inhibition.	CPR:4
Modulation of the function of BC6OTHER (CD36 - / - mice), BC6OTHER ( BC6ENTG ) ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER , 6D1 antibody) induced approximately 50% inhibition.	CPR:4
Modulation of the function of BC6OTHER (CD36 - / - mice), BC6OTHER ( BC6OTHER ) ( BC6ENTC ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER , 6D1 antibody) induced approximately 50% inhibition.	False
Modulation of the function of BC6OTHER (CD36 - / - mice), BC6OTHER ( BC6OTHER ) ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER , 6D1 antibody) induced approximately 50% inhibition.	False
Modulation of the function of BC6OTHER (CD36 - / - mice), BC6OTHER ( BC6OTHER ) ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG , 6D1 antibody) induced approximately 50% inhibition.	False
Modulation of the function of BC6ENTG (CD36 - / - mice), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER , 6D1 antibody) induced approximately 50% inhibition.	False
Modulation of the function of BC6OTHER (CD36 - / - mice), BC6ENTG ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER , 6D1 antibody) induced approximately 50% inhibition.	False
Modulation of the function of BC6OTHER (CD36 - / - mice), BC6OTHER ( BC6ENTG ) ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER , 6D1 antibody) induced approximately 50% inhibition.	False
Modulation of the function of BC6OTHER (CD36 - / - mice), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6ENTG ( BC6ENTC ), and BC6OTHER ( BC6OTHER , 6D1 antibody) induced approximately 50% inhibition.	CPR:4
Modulation of the function of BC6OTHER (CD36 - / - mice), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6ENTG ( BC6OTHER , 6D1 antibody) induced approximately 50% inhibition.	False
Modulation of the function of BC6OTHER (CD36 - / - mice), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6ENTG , 6D1 antibody) induced approximately 50% inhibition.	False
We identified BC6ENTC as a compound that binds to BC6ENTG and showed that it inhibits SIRT5 BC6OTHER - dependent deacetylase activity with an IC(50) value of 22 microM.	False
We identified BC6ENTC as a compound that binds to BC6OTHER and showed that it inhibits BC6ENTG activity with an IC(50) value of 22 microM.	CPR:4
We identified BC6OTHER as a compound that binds to BC6ENTG and showed that it inhibits SIRT5 BC6ENTC - dependent deacetylase activity with an IC(50) value of 22 microM.	False
To provide insights into how sirtuin function is altered by inhibitors, we determined two crystal structures of BC6ENTG , one in complex with BC6ENTC - CHEM, the other bound to BC6OTHER .	False
To provide insights into how sirtuin function is altered by inhibitors, we determined two crystal structures of BC6ENTG , one in complex with BC6OTHER - CHEM, the other bound to BC6ENTC .	False
Our structural studies provide a view of a synthetic inhibitory compound in a BC6ENTG active site revealing that BC6ENTC binds into the BC6OTHER , the product, and the substrate - binding site.	False
Our structural studies provide a view of a synthetic inhibitory compound in a BC6ENTG active site revealing that BC6OTHER binds into the BC6ENTC , the product, and the substrate - binding site.	False
Structural basis of inhibition of the BC6ENTG by BC6ENTC .	CPR:4
Inhibition of BC6ENTG pathway of BC6OTHER metabolism in human neutrophils by BC6OTHER and BC6ENTC .	CPR:4
Inhibition of BC6ENTG pathway of BC6ENTC metabolism in human neutrophils by BC6OTHER and BC6OTHER .	CPR:9
Inhibition of BC6ENTG pathway of BC6OTHER metabolism in human neutrophils by BC6ENTC and BC6OTHER .	CPR:4
Interference with BC6ENTG enzymes, rather than a BC6ENTC - like inhibition of BC6OTHER release from intracellular CHEM, seems to be the mode of action.	CPR:4
Interference with BC6ENTG enzymes, rather than a BC6OTHER - like inhibition of BC6ENTC release from intracellular CHEM, seems to be the mode of action.	CPR:9
RESULTS: In contrast to immune stimulatory sequence ISS 1018, BCG DNA spontaneously formed nanoparticulate structures and induced BC6ENTG polymerization as did synthetic BC6ENTC nanoparticles.	False
CHEM - incubation with BC6ENTC nanoparticles amplified the responsiveness of macrophages toward the BC6ENTG ligand ISS 1018.	False
The activation of BC6ENTG was induced by BC6ENTC nanoparticles as well as BCG DNA and is suggested as the critical signaling event inducing both cytoskeleton changes as well as inflammatory cell activation.	CPR:3
BC6ENTG polymerization was measured by BC6ENTC - BC6OTHER staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay ( BC6OTHER induction), and pull - down assays ( BC6OTHER BC6OTHER ).	False
BC6OTHER polymerization was measured by BC6ENTC - BC6OTHER staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay ( BC6ENTG induction), and pull - down assays ( BC6OTHER BC6OTHER ).	False
BC6OTHER polymerization was measured by BC6ENTC - BC6OTHER staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay ( BC6OTHER induction), and pull - down assays ( BC6ENTG BC6OTHER ).	False
BC6OTHER polymerization was measured by BC6ENTC - BC6OTHER staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay ( BC6OTHER induction), and pull - down assays ( BC6OTHER BC6ENTG ).	False
BC6ENTG polymerization was measured by BC6OTHER - BC6ENTC staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay ( BC6OTHER induction), and pull - down assays ( BC6OTHER BC6OTHER ).	False
BC6OTHER polymerization was measured by BC6OTHER - BC6ENTC staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay ( BC6ENTG induction), and pull - down assays ( BC6OTHER BC6OTHER ).	False
BC6OTHER polymerization was measured by BC6OTHER - BC6ENTC staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay ( BC6OTHER induction), and pull - down assays ( BC6ENTG BC6OTHER ).	False
BC6OTHER polymerization was measured by BC6OTHER - BC6ENTC staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay ( BC6OTHER induction), and pull - down assays ( BC6OTHER BC6ENTG ).	False
Circulating levels of BC6OTHER and BC6ENTG reflect the nutritional state of animals and elicit regulatory responses in the liver that maintain BC6ENTC and lipid homeostasis.	False
Circulating levels of BC6ENTG and BC6OTHER reflect the nutritional state of animals and elicit regulatory responses in the liver that maintain BC6ENTC and lipid homeostasis.	False
Introduction of the acetylation - mimicking ( BC6ENTG ) or - deficient ( BC6OTHER ) mutations promotes or inhibits BC6OTHER activity, respectively, and adenoviral expression of BC6OTHER - BC6OTHER augments expression of genes involved in BC6ENTC oxidation and ketogenesis.	False
Introduction of the acetylation - mimicking ( BC6OTHER ) or - deficient ( BC6ENTG ) mutations promotes or inhibits BC6OTHER activity, respectively, and adenoviral expression of BC6OTHER - BC6OTHER augments expression of genes involved in BC6ENTC oxidation and ketogenesis.	False
Introduction of the acetylation - mimicking ( BC6OTHER ) or - deficient ( BC6OTHER ) mutations promotes or inhibits BC6ENTG activity, respectively, and adenoviral expression of BC6OTHER - BC6OTHER augments expression of genes involved in BC6ENTC oxidation and ketogenesis.	False
Introduction of the acetylation - mimicking ( BC6OTHER ) or - deficient ( BC6OTHER ) mutations promotes or inhibits BC6OTHER activity, respectively, and adenoviral expression of BC6ENTG - BC6OTHER augments expression of genes involved in BC6ENTC oxidation and ketogenesis.	False
Introduction of the acetylation - mimicking ( BC6OTHER ) or - deficient ( BC6OTHER ) mutations promotes or inhibits BC6OTHER activity, respectively, and adenoviral expression of BC6OTHER - BC6ENTG augments expression of genes involved in BC6ENTC oxidation and ketogenesis.	False
"Female precocious puberty may require hyperactivity of both BC6ENTG axes because of the ""two - cell' arrangement required for ovarian BC6ENTC production."	False
 BC6ENTC ( BC6OTHER ), an activator of BC6OTHER ( BC6OTHER ), induces by several routes a profound anti - viral and anti - tumor effect in vivo. Physiologically, the immune system is using BC6ENTG - containing granules of cytotoxic T lymphocytes (CTL) towards the same biological purpose.	False
 BC6ENTC ( BC6OTHER ), an activator of BC6ENTG ( BC6OTHER ), induces by several routes a profound anti - viral and anti - tumor effect in vivo. Physiologically, the immune system is using BC6OTHER - containing granules of cytotoxic T lymphocytes (CTL) towards the same biological purpose.	CPR:3
 BC6ENTC ( BC6OTHER ), an activator of BC6OTHER ( BC6ENTG ), induces by several routes a profound anti - viral and anti - tumor effect in vivo. Physiologically, the immune system is using BC6OTHER - containing granules of cytotoxic T lymphocytes (CTL) towards the same biological purpose.	CPR:3
BC6ENTG release from peripheral blood CTLs after CHEM / CHEM - stimulation was not influenced significantly by BC6ENTC .	False
Thus, the biological activity of BC6ENTC appears to exceed its previously known functions, inasmuch as it boosts up significantly the BC6ENTG - granule system.	CPR:3
 BC6OTHER ( BC6ENTC ), an activator of BC6OTHER ( BC6OTHER ), induces by several routes a profound anti - viral and anti - tumor effect in vivo. Physiologically, the immune system is using BC6ENTG - containing granules of cytotoxic T lymphocytes (CTL) towards the same biological purpose.	False
 BC6OTHER ( BC6ENTC ), an activator of BC6ENTG ( BC6OTHER ), induces by several routes a profound anti - viral and anti - tumor effect in vivo. Physiologically, the immune system is using BC6OTHER - containing granules of cytotoxic T lymphocytes (CTL) towards the same biological purpose.	CPR:3
 BC6OTHER ( BC6ENTC ), an activator of BC6OTHER ( BC6ENTG ), induces by several routes a profound anti - viral and anti - tumor effect in vivo. Physiologically, the immune system is using BC6OTHER - containing granules of cytotoxic T lymphocytes (CTL) towards the same biological purpose.	CPR:3
This functional synergism prompted our current experiments addressing the question whether BC6ENTC may influence BC6ENTG - release and / or induce BC6OTHER in CTLs in vitro.	False
This functional synergism prompted our current experiments addressing the question whether BC6ENTC may influence BC6OTHER - release and / or induce BC6ENTG in CTLs in vitro.	False
In peripheral lymphocytes of healthy and diseased subjects, BC6ENTC induced a significant increase of BC6ENTG (+) CTLs within 12h in all experiments performed.	CPR:3
This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal BC6ENTG expression: as compared to BC6OTHER (+) CTLs detected at time point zero (100%), up to 270% of BC6OTHER (+) CTLs were induced by 2.5 microg / ml [corrected] BC6ENTC .	False
This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal BC6OTHER expression: as compared to BC6ENTG (+) CTLs detected at time point zero (100%), up to 270% of BC6OTHER (+) CTLs were induced by 2.5 microg / ml [corrected] BC6ENTC .	False
This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal BC6OTHER expression: as compared to BC6OTHER (+) CTLs detected at time point zero (100%), up to 270% of BC6ENTG (+) CTLs were induced by 2.5 microg / ml [corrected] BC6ENTC .	CPR:3
 BC6ENTC , a BC6ENTG agonist, induces BC6OTHER in cytotoxic T lymphocytes in vitro.	CPR:5
 BC6ENTC , a BC6OTHER agonist, induces BC6ENTG in cytotoxic T lymphocytes in vitro.	CPR:3
Blockade of the BC6ENTG - BC6OTHER system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by BC6ENTC throughout the cardiovascular and renal continua.	False
Blockade of the BC6OTHER - BC6ENTG system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by BC6ENTC throughout the cardiovascular and renal continua.	False
Blockade of the BC6ENTG - BC6ENTC system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by BC6OTHER throughout the cardiovascular and renal continua.	False
Blockade of the BC6OTHER - BC6ENTC system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by BC6ENTG throughout the cardiovascular and renal continua.	False
BC6ENTC is an BC6ENTG blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure.	CPR:4
BC6OTHER triggered strong induction of BC6ENTG , which was prevented by 1 micro g / mL BC6ENTC ( BC6OTHER ).	CPR:4
BC6OTHER triggered strong induction of BC6ENTG , which was prevented by 1 micro g / mL BC6OTHER ( BC6ENTC ).	CPR:4
 BC6ENTC caused cell loss and increased cell death with features of apoptosis, i.e. CHEM - mediated CHEM nick - end labelling (TUNEL) reaction and BC6ENTG activation.	CPR:3
Induction of BC6ENTG ( BC6OTHER ) by BC6ENTC in cultured astrocytes and reduction of BC6OTHER - induced cell death.	CPR:3
Induction of BC6OTHER ( BC6ENTG ) by BC6ENTC in cultured astrocytes and reduction of BC6OTHER - induced cell death.	CPR:3
Induction of BC6ENTG ( BC6OTHER ) by BC6OTHER in cultured astrocytes and reduction of BC6ENTC - induced cell death.	False
Induction of BC6OTHER ( BC6ENTG ) by BC6OTHER in cultured astrocytes and reduction of BC6ENTC - induced cell death.	False
Pre - treatment with CHEM increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) phosphorylation after BC6ENTC .	False
Pre - treatment with CHEM increased BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) phosphorylation after BC6ENTC .	CPR:3
Pre - treatment with CHEM increased BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) phosphorylation after BC6ENTC .	CPR:3
Pre - treatment with CHEM increased BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) phosphorylation after BC6ENTC .	False
However, while BC6ENTG phosphorylation was prevented by CHX, BC6OTHER phosphorylation was further enhanced by BC6ENTC .	CPR:4
However, while BC6OTHER phosphorylation was prevented by CHX, BC6ENTG phosphorylation was further enhanced by BC6ENTC .	False
The results show that transient BC6ENTC pre - treatment induces BC6ENTG , BC6OTHER and, to a lesser extent, BC6OTHER ; it reduces BC6OTHER - induced astrocyte death; and it causes selective activation of BC6OTHER following BC6OTHER .	CPR:3
The results show that transient BC6ENTC pre - treatment induces BC6OTHER , BC6ENTG and, to a lesser extent, BC6OTHER ; it reduces BC6OTHER - induced astrocyte death; and it causes selective activation of BC6OTHER following BC6OTHER .	CPR:3
The results show that transient BC6ENTC pre - treatment induces BC6OTHER , BC6OTHER and, to a lesser extent, BC6ENTG ; it reduces BC6OTHER - induced astrocyte death; and it causes selective activation of BC6OTHER following BC6OTHER .	CPR:3
The results show that transient BC6ENTC pre - treatment induces BC6OTHER , BC6OTHER and, to a lesser extent, BC6OTHER ; it reduces BC6OTHER - induced astrocyte death; and it causes selective activation of BC6ENTG following BC6OTHER .	CPR:3
The results show that transient BC6OTHER pre - treatment induces BC6ENTG , BC6OTHER and, to a lesser extent, BC6OTHER ; it reduces BC6ENTC - induced astrocyte death; and it causes selective activation of BC6OTHER following BC6OTHER .	False
The results show that transient BC6OTHER pre - treatment induces BC6OTHER , BC6ENTG and, to a lesser extent, BC6OTHER ; it reduces BC6ENTC - induced astrocyte death; and it causes selective activation of BC6OTHER following BC6OTHER .	False
The results show that transient BC6OTHER pre - treatment induces BC6OTHER , BC6OTHER and, to a lesser extent, BC6ENTG ; it reduces BC6ENTC - induced astrocyte death; and it causes selective activation of BC6OTHER following BC6OTHER .	False
The results show that transient BC6OTHER pre - treatment induces BC6OTHER , BC6OTHER and, to a lesser extent, BC6OTHER ; it reduces BC6ENTC - induced astrocyte death; and it causes selective activation of BC6ENTG following BC6OTHER .	False
The results show that transient BC6OTHER pre - treatment induces BC6ENTG , BC6OTHER and, to a lesser extent, BC6OTHER ; it reduces BC6OTHER - induced astrocyte death; and it causes selective activation of BC6OTHER following BC6ENTC .	False
The results show that transient BC6OTHER pre - treatment induces BC6OTHER , BC6ENTG and, to a lesser extent, BC6OTHER ; it reduces BC6OTHER - induced astrocyte death; and it causes selective activation of BC6OTHER following BC6ENTC .	False
The results show that transient BC6OTHER pre - treatment induces BC6OTHER , BC6OTHER and, to a lesser extent, BC6ENTG ; it reduces BC6OTHER - induced astrocyte death; and it causes selective activation of BC6OTHER following BC6ENTC .	False
The results show that transient BC6OTHER pre - treatment induces BC6OTHER , BC6OTHER and, to a lesser extent, BC6OTHER ; it reduces BC6OTHER - induced astrocyte death; and it causes selective activation of BC6ENTG following BC6ENTC .	CPR:3
It is suggested that BC6ENTG expression at the time of BC6ENTC exposure protects astrocytes from oxidative injury and apoptotic cell death by means of pro - survival BC6OTHER .	False
It is suggested that BC6OTHER expression at the time of BC6ENTC exposure protects astrocytes from oxidative injury and apoptotic cell death by means of pro - survival BC6ENTG .	False
BC6ENTC triggered strong induction of BC6ENTG , which was prevented by 1 micro g / mL BC6OTHER ( BC6OTHER ).	CPR:3
A novel potent compound, BC6ENTC (12c), which binds BC6ENTG with an IC(50) value of 54 nM was obtained.	CPR:4
We have previously reported a nanomolar inhibitor of antiapoptotic BC6ENTG protein, BC6ENTC (S1).	CPR:4
Fragment - based design, synthesis, and biological evaluation of BC6ENTC derivatives as novel BC6ENTG inhibitors.	CPR:4
 Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6ENTC , BC6OTHER , BC6OTHER , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6ENTG ( BC6OTHER ) and of the inducible form ( BC6OTHER ).	False
 Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6ENTC , BC6OTHER , BC6OTHER , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6OTHER CHEM synthase - 1 ( BC6ENTG ) and of the inducible form ( BC6OTHER ).	False
 Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6ENTC , BC6OTHER , BC6OTHER , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6OTHER CHEM synthase - 1 ( BC6OTHER ) and of the inducible form ( BC6ENTG ).	False
Activation of cytoprotective BC6ENTG by BC6ENTC as a possible explanation for its hair growth - stimulating effect.	CPR:3
 Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6ENTC , BC6OTHER , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6ENTG ( BC6OTHER ) and of the inducible form ( BC6OTHER ).	False
 Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6ENTC , BC6OTHER , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6OTHER CHEM synthase - 1 ( BC6ENTG ) and of the inducible form ( BC6OTHER ).	False
 Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6ENTC , BC6OTHER , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6OTHER CHEM synthase - 1 ( BC6OTHER ) and of the inducible form ( BC6ENTG ).	False
 Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6OTHER , BC6ENTC , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6ENTG ( BC6OTHER ) and of the inducible form ( BC6OTHER ).	False
 Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6OTHER , BC6ENTC , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6OTHER CHEM synthase - 1 ( BC6ENTG ) and of the inducible form ( BC6OTHER ).	False
 Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6OTHER , BC6ENTC , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6OTHER CHEM synthase - 1 ( BC6OTHER ) and of the inducible form ( BC6ENTG ).	False
 Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTC , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6ENTG ( BC6OTHER ) and of the inducible form ( BC6OTHER ).	False
 Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTC , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6OTHER CHEM synthase - 1 ( BC6ENTG ) and of the inducible form ( BC6OTHER ).	False
 Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTC , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6OTHER CHEM synthase - 1 ( BC6OTHER ) and of the inducible form ( BC6ENTG ).	False
 Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of CHEM synthase - 1 ( BC6ENTG ) and of the inducible form ( BC6OTHER ).	False
 Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of CHEM synthase - 1 ( BC6OTHER ) and of the inducible form ( BC6ENTG ).	False
 We thus speculated that activation of BC6ENTG might be a mechanism by which BC6ENTC ( BC6OTHER ) stimulates hair growth in vivo. We demonstrate here that BC6OTHER is a potent activator of purified BC6OTHER (AC50 = 80 microM), as assayed by BC6OTHER consumption and CHEM production.	CPR:3
 We thus speculated that activation of BC6OTHER might be a mechanism by which BC6ENTC ( BC6OTHER ) stimulates hair growth in vivo. We demonstrate here that BC6OTHER is a potent activator of purified BC6ENTG (AC50 = 80 microM), as assayed by BC6OTHER consumption and CHEM production.	False
 We thus speculated that activation of BC6ENTG might be a mechanism by which BC6OTHER ( BC6ENTC ) stimulates hair growth in vivo. We demonstrate here that BC6OTHER is a potent activator of purified BC6OTHER (AC50 = 80 microM), as assayed by BC6OTHER consumption and CHEM production.	CPR:3
 We thus speculated that activation of BC6OTHER might be a mechanism by which BC6OTHER ( BC6ENTC ) stimulates hair growth in vivo. We demonstrate here that BC6OTHER is a potent activator of purified BC6ENTG (AC50 = 80 microM), as assayed by BC6OTHER consumption and CHEM production.	False
 We thus speculated that activation of BC6ENTG might be a mechanism by which BC6OTHER ( BC6OTHER ) stimulates hair growth in vivo. We demonstrate here that BC6ENTC is a potent activator of purified BC6OTHER (AC50 = 80 microM), as assayed by BC6OTHER consumption and CHEM production.	False
 We thus speculated that activation of BC6OTHER might be a mechanism by which BC6OTHER ( BC6OTHER ) stimulates hair growth in vivo. We demonstrate here that BC6ENTC is a potent activator of purified BC6ENTG (AC50 = 80 microM), as assayed by BC6OTHER consumption and CHEM production.	CPR:3
 We thus speculated that activation of BC6ENTG might be a mechanism by which BC6OTHER ( BC6OTHER ) stimulates hair growth in vivo. We demonstrate here that BC6OTHER is a potent activator of purified BC6OTHER (AC50 = 80 microM), as assayed by BC6ENTC consumption and CHEM production.	False
 We thus speculated that activation of BC6OTHER might be a mechanism by which BC6OTHER ( BC6OTHER ) stimulates hair growth in vivo. We demonstrate here that BC6OTHER is a potent activator of purified BC6ENTG (AC50 = 80 microM), as assayed by BC6ENTC consumption and CHEM production.	False
"In rat kidney the ""secretory"" isoform of the BC6ENTC - BC6OTHER - BC6OTHER cotransporter ( BC6ENTG ) localizes to the basolateral membrane of the alpha - intercalated cell."	False
"In rat kidney the ""secretory"" isoform of the CHEM - BC6ENTC - BC6OTHER cotransporter ( BC6ENTG ) localizes to the basolateral membrane of the alpha - intercalated cell."	False
"In rat kidney the ""secretory"" isoform of the BC6ENTG BC6ENTC cotransporter ( BC6OTHER ) localizes to the basolateral membrane of the alpha - intercalated cell."	False
"In rat kidney the ""secretory"" isoform of the CHEM - BC6OTHER - BC6ENTC cotransporter ( BC6ENTG ) localizes to the basolateral membrane of the alpha - intercalated cell."	False
BC6ENTC - sensitive BC6OTHER secretion was dependent on extracellular BC6OTHER and either BC6OTHER or BC6OTHER , consistent with the ion dependency of BC6ENTG - mediated BC6OTHER transport.	False
In conclusion, OMCD tubules from BC6ENTC - treated rats secrete BC6OTHER into the luminal fluid through BC6ENTG - mediated BC6OTHER uptake across the basolateral membrane in series with BC6OTHER efflux across the apical membrane.	False
BC6OTHER - sensitive BC6ENTC secretion was dependent on extracellular BC6OTHER and either BC6OTHER or BC6OTHER , consistent with the ion dependency of BC6ENTG - mediated BC6OTHER transport.	False
BC6OTHER - sensitive BC6OTHER secretion was dependent on extracellular BC6ENTC and either BC6OTHER or BC6OTHER , consistent with the ion dependency of BC6ENTG - mediated BC6OTHER transport.	False
BC6OTHER - sensitive BC6OTHER secretion was dependent on extracellular BC6OTHER and either BC6ENTC or BC6OTHER , consistent with the ion dependency of BC6ENTG - mediated BC6OTHER transport.	False
BC6OTHER - sensitive BC6OTHER secretion was dependent on extracellular BC6OTHER and either BC6OTHER or BC6ENTC , consistent with the ion dependency of BC6ENTG - mediated BC6OTHER transport.	False
BC6OTHER - sensitive BC6OTHER secretion was dependent on extracellular BC6OTHER and either BC6OTHER or BC6OTHER , consistent with the ion dependency of BC6ENTG - mediated BC6ENTC transport.	CPR:9
Contribution of the BC6ENTC - BC6OTHER - BC6OTHER cotransporter BC6ENTG to BC6OTHER secretion in rat OMCD.	False
Contribution of the CHEM - BC6ENTC - BC6OTHER cotransporter BC6ENTG to BC6OTHER secretion in rat OMCD.	False
Contribution of the BC6ENTG BC6ENTC cotransporter BC6OTHER to BC6OTHER secretion in rat OMCD.	False
Contribution of the CHEM - BC6OTHER - BC6ENTC cotransporter BC6ENTG to BC6OTHER secretion in rat OMCD.	False
Contribution of the BC6ENTG BC6OTHER cotransporter BC6OTHER to BC6ENTC secretion in rat OMCD.	CPR:9
Contribution of the CHEM - BC6OTHER - BC6OTHER cotransporter BC6ENTG to BC6ENTC secretion in rat OMCD.	CPR:9
In conclusion, OMCD tubules from BC6OTHER - treated rats secrete BC6ENTC into the luminal fluid through BC6ENTG - mediated BC6OTHER uptake across the basolateral membrane in series with BC6OTHER efflux across the apical membrane.	CPR:9
In conclusion, OMCD tubules from BC6OTHER - treated rats secrete BC6OTHER into the luminal fluid through BC6ENTG - mediated BC6ENTC uptake across the basolateral membrane in series with BC6OTHER efflux across the apical membrane.	CPR:9
In conclusion, OMCD tubules from BC6OTHER - treated rats secrete BC6OTHER into the luminal fluid through BC6ENTG - mediated BC6OTHER uptake across the basolateral membrane in series with BC6ENTC efflux across the apical membrane.	CPR:9
The physiological role of BC6ENTG - mediated BC6ENTC uptake remains to be determined.	CPR:9
The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes BC6ENTC and whether transepithelial BC6OTHER transport occurs, in part, through BC6OTHER uptake across the basolateral membrane mediated by BC6ENTG in series with BC6OTHER efflux across the apical membrane.	False
The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes BC6OTHER and whether transepithelial BC6ENTC transport occurs, in part, through BC6OTHER uptake across the basolateral membrane mediated by BC6ENTG in series with BC6OTHER efflux across the apical membrane.	False
The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes BC6OTHER and whether transepithelial BC6OTHER transport occurs, in part, through BC6ENTC uptake across the basolateral membrane mediated by BC6ENTG in series with BC6OTHER efflux across the apical membrane.	CPR:9
The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes BC6OTHER and whether transepithelial BC6OTHER transport occurs, in part, through BC6OTHER uptake across the basolateral membrane mediated by BC6ENTG in series with BC6ENTC efflux across the apical membrane.	CPR:9
Loss of agonist binding was observed on intact human embryonic kidney 293 cells expressing the BC6ENTG receptor, conditions where high BC6OTHER levels are present; however, high affinity binding BC6ENTC was observed in broken cell preparations washed free of BC6OTHER .	False
Unlike the majority of BC6ENTG , the BC6OTHER ( BC6ENTC ) BC6OTHER 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of BC6OTHER ( BC6OTHER ).	False
Loss of agonist binding was observed on intact human embryonic kidney 293 cells expressing the BC6ENTG receptor, conditions where high BC6OTHER levels are present; however, high affinity binding BC6OTHER was observed in broken cell preparations washed free of BC6ENTC .	False
The BC6ENTC binding of BC6ENTG in broken cell membrane fractions was inhibited by addition of BC6OTHER (IC(50) 21 ± 1.8 nM).	False
Unlike the majority of BC6ENTG , the BC6OTHER ( BC6OTHER ) BC6ENTC 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of BC6OTHER ( BC6OTHER ).	False
Unlike the majority of BC6OTHER , the BC6ENTG BC6ENTC 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of BC6OTHER ( BC6OTHER ).	False
The BC6OTHER binding of BC6ENTG in broken cell membrane fractions was inhibited by addition of BC6ENTC (IC(50) 21 ± 1.8 nM).	False
 BC6ENTG modulates BC6ENTC sensitivity of the BC6OTHER .	False
 BC6OTHER modulates BC6ENTC sensitivity of the BC6ENTG .	False
 BC6ENTG modulates BC6OTHER sensitivity of the BC6ENTC EP3 receptor.	False
Moreover, mutation of BC6ENTG can alter this coupled equilibrium from BC6ENTC - insensitive agonist binding to more conventional BC6OTHER - sensitive binding.	False
Moreover, mutation of BC6ENTG can alter this coupled equilibrium from BC6OTHER - insensitive agonist binding to more conventional BC6ENTC - sensitive binding.	False
This suggests that for the mutant receptors, BC6ENTG plays a critical role in linking the agonist bound receptor conformation to the BC6OTHER BC6ENTC bound state.	False
This suggests that for the mutant receptors, BC6OTHER plays a critical role in linking the agonist bound receptor conformation to the BC6ENTG BC6ENTC bound state.	False
Unlike the majority of BC6ENTG , the BC6OTHER ( BC6OTHER ) BC6OTHER 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of BC6ENTC ( BC6OTHER ).	False
Unlike the majority of BC6OTHER , the BC6ENTG BC6OTHER 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of BC6ENTC ( BC6OTHER ).	False
Unlike the majority of BC6ENTG , the BC6OTHER ( BC6OTHER ) BC6OTHER 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of BC6OTHER ( BC6ENTC ).	False
Unlike the majority of BC6OTHER , the BC6ENTG BC6OTHER 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of BC6OTHER ( BC6ENTC ).	False
Seven point mutations were introduced into the conserved motif in the BC6ENTG ( BC6OTHER ) of BC6OTHER , resulting in acquisition of BC6ENTC - sensitive agonist binding.	False
Seven point mutations were introduced into the conserved motif in the BC6OTHER ( BC6ENTG ) of BC6OTHER , resulting in acquisition of BC6ENTC - sensitive agonist binding.	False
Seven point mutations were introduced into the conserved motif in the BC6OTHER ( BC6OTHER ) of BC6ENTG , resulting in acquisition of BC6ENTC - sensitive agonist binding.	False
Unlike the majority of BC6ENTG , the BC6ENTC ( BC6OTHER ) BC6OTHER 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of BC6OTHER ( BC6OTHER ).	False
Loss of agonist binding was observed on intact human embryonic kidney 293 cells expressing the BC6ENTG receptor, conditions where high BC6ENTC levels are present; however, high affinity binding BC6OTHER was observed in broken cell preparations washed free of BC6OTHER .	False
Binding and transactivation assays were used to compare affinities and transcriptional activities of BC6OTHER and BC6ENTC for the BC6ENTG , BC6OTHER ( BC6OTHER ).	False
Binding and transactivation assays were used to compare affinities and transcriptional activities of BC6OTHER and BC6ENTC for the BC6OTHER , BC6ENTG ( BC6OTHER ).	False
Binding and transactivation assays were used to compare affinities and transcriptional activities of BC6OTHER and BC6ENTC for the BC6OTHER , BC6OTHER ( BC6ENTG ).	False
Binding and transactivation assays were used to compare affinities and transcriptional activities of BC6OTHER and BC6OTHER for the BC6ENTG , BC6ENTC receptors ( BC6OTHER ).	False
Binding and transactivation assays were used to compare affinities and transcriptional activities of BC6OTHER and BC6OTHER for the BC6OTHER , BC6ENTC receptors ( BC6ENTG ).	False
The BC6ENTG BC6OTHER and BC6OTHER mediate the BC6ENTC activity of BC6OTHER .	False
The BC6OTHER BC6ENTG and BC6OTHER mediate the BC6ENTC activity of BC6OTHER .	False
The BC6OTHER BC6OTHER and BC6ENTG mediate the BC6ENTC activity of BC6OTHER .	False
The BC6ENTG BC6OTHER and BC6OTHER mediate the BC6OTHER activity of BC6ENTC .	False
The BC6OTHER BC6ENTG and BC6OTHER mediate the BC6OTHER activity of BC6ENTC .	False
The BC6OTHER BC6OTHER and BC6ENTG mediate the BC6OTHER activity of BC6ENTC .	False
Binding and transactivation assays were used to compare affinities and transcriptional activities of BC6ENTC and BC6OTHER for the BC6ENTG , BC6OTHER ( BC6OTHER ).	False
Binding and transactivation assays were used to compare affinities and transcriptional activities of BC6ENTC and BC6OTHER for the BC6OTHER , BC6ENTG ( BC6OTHER ).	False
Binding and transactivation assays were used to compare affinities and transcriptional activities of BC6ENTC and BC6OTHER for the BC6OTHER , BC6OTHER ( BC6ENTG ).	False
All tested compounds proved to be potent BC6ENTG receptor and BC6ENTC transporter protein ( BC6OTHER ) ligands.	False
All tested compounds proved to be potent BC6OTHER receptor and BC6ENTC transporter protein ( BC6ENTG ) ligands.	False
Accordingly, docking of different BC6ENTG inhibitors, including selective and non - selective ligands: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER were undertaken using the AMBER program.	CPR:4
Accordingly, docking of different BC6ENTG inhibitors, including selective and non - selective ligands: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER were undertaken using the AMBER program.	CPR:4
Accordingly, docking of different BC6ENTG inhibitors, including selective and non - selective ligands: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER were undertaken using the AMBER program.	CPR:4
Accordingly, docking of different BC6ENTG inhibitors, including selective and non - selective ligands: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC were undertaken using the AMBER program.	CPR:4
Non - BC6OTHER anti - inflammatory drugs (NSAIDs) are competitive inhibitors of BC6ENTG ( BC6OTHER ), the enzyme that mediates biosynthesis of BC6ENTC and BC6OTHER from BC6OTHER .	CPR:9
Non - BC6OTHER anti - inflammatory drugs (NSAIDs) are competitive inhibitors of BC6OTHER ( BC6ENTG ), the enzyme that mediates biosynthesis of BC6ENTC and BC6OTHER from BC6OTHER .	CPR:9
Non - BC6OTHER anti - inflammatory drugs (NSAIDs) are competitive inhibitors of BC6ENTG ( BC6OTHER ), the enzyme that mediates biosynthesis of BC6OTHER and BC6ENTC from BC6OTHER .	CPR:9
Non - BC6OTHER anti - inflammatory drugs (NSAIDs) are competitive inhibitors of BC6OTHER ( BC6ENTG ), the enzyme that mediates biosynthesis of BC6OTHER and BC6ENTC from BC6OTHER .	CPR:9
Non - BC6OTHER anti - inflammatory drugs (NSAIDs) are competitive inhibitors of BC6ENTG ( BC6OTHER ), the enzyme that mediates biosynthesis of BC6OTHER and BC6OTHER from BC6ENTC .	CPR:9
Non - BC6OTHER anti - inflammatory drugs (NSAIDs) are competitive inhibitors of BC6OTHER ( BC6ENTG ), the enzyme that mediates biosynthesis of BC6OTHER and BC6OTHER from BC6ENTC .	CPR:9
Non - BC6ENTC anti - inflammatory drugs (NSAIDs) are competitive inhibitors of BC6ENTG ( BC6OTHER ), the enzyme that mediates biosynthesis of BC6OTHER and BC6OTHER from BC6OTHER .	CPR:4
Non - BC6ENTC anti - inflammatory drugs (NSAIDs) are competitive inhibitors of BC6OTHER ( BC6ENTG ), the enzyme that mediates biosynthesis of BC6OTHER and BC6OTHER from BC6OTHER .	CPR:4
Accordingly, docking of different BC6ENTG inhibitors, including selective and non - selective ligands: BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER were undertaken using the AMBER program.	CPR:4
Accordingly, docking of different BC6ENTG inhibitors, including selective and non - selective ligands: BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER were undertaken using the AMBER program.	CPR:4
Accordingly, docking of different BC6ENTG inhibitors, including selective and non - selective ligands: BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER were undertaken using the AMBER program.	CPR:4
Accordingly, docking of different BC6ENTG inhibitors, including selective and non - selective ligands: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER were undertaken using the AMBER program.	CPR:4
Utilizing agonist - stimulated BC6OTHER autoradiography, we analyzed the ability of BC6ENTG to stimulate BC6ENTC binding in adult rat brain.	False
Taken together, these findings support the view that (1) BC6ENTG is the only BC6OTHER peptide that binds to and activates the BC6OTHER receptor and (2) BC6OTHER does not bind or stimulate BC6ENTC binding in cells expressing the BC6OTHER .	False
Taken together, these findings support the view that (1) BC6OTHER is the only BC6ENTG peptide that binds to and activates the BC6OTHER receptor and (2) BC6OTHER does not bind or stimulate BC6ENTC binding in cells expressing the BC6OTHER .	False
Taken together, these findings support the view that (1) BC6OTHER is the only BC6OTHER peptide that binds to and activates the BC6ENTG receptor and (2) BC6OTHER does not bind or stimulate BC6ENTC binding in cells expressing the BC6OTHER .	False
Taken together, these findings support the view that (1) BC6OTHER is the only BC6OTHER peptide that binds to and activates the BC6OTHER receptor and (2) BC6ENTG does not bind or stimulate BC6ENTC binding in cells expressing the BC6OTHER .	False
Taken together, these findings support the view that (1) BC6OTHER is the only BC6OTHER peptide that binds to and activates the BC6OTHER receptor and (2) BC6OTHER does not bind or stimulate BC6ENTC binding in cells expressing the BC6ENTG .	False
BC6ENTG ( BC6OTHER ) stimulated BC6ENTC binding in a pattern similar to that described for [ BC6OTHER ] - BC6OTHER at the endogenous BC6OTHER .	False
BC6OTHER ( BC6ENTG ) stimulated BC6ENTC binding in a pattern similar to that described for [ BC6OTHER ] - BC6OTHER at the endogenous BC6OTHER .	False
BC6OTHER ( BC6OTHER ) stimulated BC6ENTC binding in a pattern similar to that described for [ BC6OTHER ] - BC6ENTG at the endogenous BC6OTHER .	False
BC6OTHER ( BC6OTHER ) stimulated BC6ENTC binding in a pattern similar to that described for [ BC6OTHER ] - BC6OTHER at the endogenous BC6ENTG .	False
BC6ENTG ( BC6OTHER ) stimulated BC6OTHER binding in a pattern similar to that described for [ BC6ENTC ] - BC6OTHER at the endogenous BC6OTHER .	False
BC6OTHER ( BC6ENTG ) stimulated BC6OTHER binding in a pattern similar to that described for [ BC6ENTC ] - BC6OTHER at the endogenous BC6OTHER .	False
BC6OTHER ( BC6OTHER ) stimulated BC6OTHER binding in a pattern similar to that described for [ BC6ENTC ] - BC6ENTG at the endogenous BC6OTHER .	False
BC6OTHER ( BC6OTHER ) stimulated BC6OTHER binding in a pattern similar to that described for [ BC6ENTC ] - BC6OTHER at the endogenous BC6ENTG .	False
Utilizing agonist - stimulated BC6ENTC autoradiography, we analyzed the ability of BC6ENTG to stimulate BC6OTHER binding in adult rat brain.	False
Unlike BC6ENTG , high concentrations of its BC6ENTC - terminal extension, BC6OTHER , stimulated BC6OTHER binding in a BC6OTHER - like distribution and the effect was blocked by BC6OTHER .	False
Unlike BC6OTHER , high concentrations of its BC6ENTC - terminal extension, BC6ENTG , stimulated BC6OTHER binding in a BC6OTHER - like distribution and the effect was blocked by BC6OTHER .	False
Unlike BC6OTHER , high concentrations of its BC6ENTC - terminal extension, BC6OTHER , stimulated BC6OTHER binding in a BC6ENTG - like distribution and the effect was blocked by BC6OTHER .	False
Unlike BC6ENTG , high concentrations of its BC6OTHER - terminal extension, BC6OTHER , stimulated BC6ENTC binding in a BC6OTHER - like distribution and the effect was blocked by BC6OTHER .	False
Unlike BC6OTHER , high concentrations of its BC6OTHER - terminal extension, BC6ENTG , stimulated BC6ENTC binding in a BC6OTHER - like distribution and the effect was blocked by BC6OTHER .	False
Unlike BC6OTHER , high concentrations of its BC6OTHER - terminal extension, BC6OTHER , stimulated BC6ENTC binding in a BC6ENTG - like distribution and the effect was blocked by BC6OTHER .	False
Unlike BC6ENTG , high concentrations of its BC6OTHER - terminal extension, BC6OTHER , stimulated BC6OTHER binding in a BC6OTHER - like distribution and the effect was blocked by BC6ENTC .	False
Unlike BC6OTHER , high concentrations of its BC6OTHER - terminal extension, BC6ENTG , stimulated BC6OTHER binding in a BC6OTHER - like distribution and the effect was blocked by BC6ENTC .	False
Unlike BC6OTHER , high concentrations of its BC6OTHER - terminal extension, BC6OTHER , stimulated BC6OTHER binding in a BC6ENTG - like distribution and the effect was blocked by BC6ENTC .	False
Binding and BC6ENTC autoradiographic analysis of BC6OTHER products at the BC6ENTG and BC6OTHER .	False
Binding and BC6ENTC autoradiographic analysis of BC6OTHER products at the BC6OTHER and BC6ENTG .	False
Binding and BC6ENTC autoradiographic analysis of BC6ENTG products at the BC6OTHER and BC6OTHER .	False
We provide evidence that defective BC6ENTC catabolism promotes the development of fasting hypoglycemia in BC6ENTG - / - mice by limiting gluconeogenic substrate availability.	False
BC6ENTG - / - liver and skeletal muscle show markedly reduced mRNA expression of BC6ENTC - degrading enzymes.	False
Furthermore, the enzymatic activity of BC6ENTC aminotransferase ( BC6ENTG ), which converts the critical gluconeogenic BC6OTHER BC6OTHER into BC6OTHER , is decreased (approximately 50%) in BC6OTHER - / - hepatocytes.	False
Furthermore, the enzymatic activity of BC6ENTC aminotransferase ( BC6OTHER ), which converts the critical gluconeogenic BC6OTHER BC6OTHER into BC6OTHER , is decreased (approximately 50%) in BC6ENTG - / - hepatocytes.	False
Furthermore, the enzymatic activity of BC6ENTG ( BC6OTHER ), which converts the critical gluconeogenic BC6ENTC BC6OTHER into BC6OTHER , is decreased (approximately 50%) in BC6OTHER - / - hepatocytes.	CPR:9
Furthermore, the enzymatic activity of BC6OTHER aminotransferase ( BC6ENTG ), which converts the critical gluconeogenic BC6ENTC BC6OTHER into BC6OTHER , is decreased (approximately 50%) in BC6OTHER - / - hepatocytes.	CPR:9
Furthermore, the enzymatic activity of BC6OTHER aminotransferase ( BC6OTHER ), which converts the critical gluconeogenic BC6ENTC BC6OTHER into BC6OTHER , is decreased (approximately 50%) in BC6ENTG - / - hepatocytes.	False
Furthermore, the enzymatic activity of BC6ENTG ( BC6OTHER ), which converts the critical gluconeogenic BC6OTHER BC6ENTC into BC6OTHER , is decreased (approximately 50%) in BC6OTHER - / - hepatocytes.	CPR:9
Furthermore, the enzymatic activity of BC6OTHER aminotransferase ( BC6ENTG ), which converts the critical gluconeogenic BC6OTHER BC6ENTC into BC6OTHER , is decreased (approximately 50%) in BC6OTHER - / - hepatocytes.	CPR:9
Furthermore, the enzymatic activity of BC6OTHER aminotransferase ( BC6OTHER ), which converts the critical gluconeogenic BC6OTHER BC6ENTC into BC6OTHER , is decreased (approximately 50%) in BC6ENTG - / - hepatocytes.	False
Furthermore, the enzymatic activity of BC6ENTG ( BC6OTHER ), which converts the critical gluconeogenic BC6OTHER BC6OTHER into BC6ENTC , is decreased (approximately 50%) in BC6OTHER - / - hepatocytes.	CPR:9
Furthermore, the enzymatic activity of BC6OTHER aminotransferase ( BC6ENTG ), which converts the critical gluconeogenic BC6OTHER BC6OTHER into BC6ENTC , is decreased (approximately 50%) in BC6OTHER - / - hepatocytes.	CPR:9
Furthermore, the enzymatic activity of BC6OTHER aminotransferase ( BC6OTHER ), which converts the critical gluconeogenic BC6OTHER BC6OTHER into BC6ENTC , is decreased (approximately 50%) in BC6ENTG - / - hepatocytes.	False
Consistent with this observation, intraperitoneal injection of BC6ENTC , but not BC6OTHER , rescues fasting hypoglycemia in BC6ENTG - / - mice.	False
Consistent with this observation, intraperitoneal injection of BC6OTHER , but not BC6ENTC , rescues fasting hypoglycemia in BC6ENTG - / - mice.	False
This was the first study to investigate platelet BC6ENTC binding in BC6OTHER - dependent and age - matched control subjects in relation to the BC6ENTG genotype.	False
This was the first study to investigate platelet BC6OTHER binding in BC6ENTC - dependent and age - matched control subjects in relation to the BC6ENTG genotype.	False
No differences concerning BC6ENTG - alleles were found in these groups Furthermore, no significant interaction between these parameters and impulsivity was shown in BC6ENTC - dependent subjects.	False
These results do not support previous results of altered BC6ENTC binding sites in CHEM - dependent subjects or BC6ENTG S - allele carriers.	False
BC6ENTG S - genotype carriers in both BC6ENTC - dependent and control subjects were expected to show significantly fewer binding sites and a lower dissociation constant.	False
The aim of this study was to investigate BC6ENTC binding and impulsivity in BC6OTHER - dependent and age - matched control subjects in relation to a 5' - promoter region BC6ENTG ( BC6OTHER ) polymorphism ( BC6OTHER ).	False
The aim of this study was to investigate BC6ENTC binding and impulsivity in BC6OTHER - dependent and age - matched control subjects in relation to a 5' - promoter region BC6OTHER transporter ( BC6ENTG ) polymorphism ( BC6OTHER ).	False
The aim of this study was to investigate BC6ENTC binding and impulsivity in BC6OTHER - dependent and age - matched control subjects in relation to a 5' - promoter region BC6OTHER transporter ( BC6OTHER ) polymorphism ( BC6ENTG ).	False
Blood samples were taken from both BC6OTHER - dependent and control subjects to determine BC6ENTG genotypes using PCR of lymphocyte DNA, and to perform platelet BC6ENTC binding (binding capacity: B(max); and dissociation constant: K(D)).	False
The aim of this study was to investigate BC6OTHER binding and impulsivity in BC6ENTC - dependent and age - matched control subjects in relation to a 5' - promoter region BC6ENTG ( BC6OTHER ) polymorphism ( BC6OTHER ).	False
The aim of this study was to investigate BC6OTHER binding and impulsivity in BC6ENTC - dependent and age - matched control subjects in relation to a 5' - promoter region BC6OTHER transporter ( BC6ENTG ) polymorphism ( BC6OTHER ).	False
The aim of this study was to investigate BC6OTHER binding and impulsivity in BC6ENTC - dependent and age - matched control subjects in relation to a 5' - promoter region BC6OTHER transporter ( BC6OTHER ) polymorphism ( BC6ENTG ).	False
Blood samples were taken from both BC6ENTC - dependent and control subjects to determine BC6ENTG genotypes using PCR of lymphocyte DNA, and to perform platelet BC6OTHER binding (binding capacity: B(max); and dissociation constant: K(D)).	False
 BC6ENTC transporter gene regulatory region polymorphism ( BC6ENTG ), BC6OTHER binding in healthy control subjects and CHEM - dependent patients and their relationships to impulsivity.	False
 BC6ENTG gene regulatory region polymorphism ( BC6OTHER ), BC6ENTC binding in healthy control subjects and CHEM - dependent patients and their relationships to impulsivity.	False
 BC6OTHER gene regulatory region polymorphism ( BC6ENTG ), BC6ENTC binding in healthy control subjects and CHEM - dependent patients and their relationships to impulsivity.	False
The aim of this study was to investigate BC6OTHER binding and impulsivity in BC6OTHER - dependent and age - matched control subjects in relation to a 5' - promoter region BC6ENTC transporter ( BC6ENTG ) polymorphism ( BC6OTHER ).	False
The aim of this study was to investigate BC6OTHER binding and impulsivity in BC6OTHER - dependent and age - matched control subjects in relation to a 5' - promoter region BC6ENTC transporter ( BC6OTHER ) polymorphism ( BC6ENTG ).	False
Novel CHEM analogues as potent BC6ENTG inhibitors.	CPR:4
Finally, BC6ENTC treatment caused a significant increase in the level of BC6ENTG .	CPR:3
Our results show that BC6ENTC directly inhibits stomach BC6OTHER production and secretion through BC6ENTG .	False
Our results show that BC6ENTC directly inhibits stomach BC6ENTG production and secretion through BC6OTHER .	CPR:4
BC6ENTC treatment is also associated with lower circulating levels of the BC6ENTG BC6OTHER .	CPR:4
BC6ENTC treatment is also associated with lower circulating levels of the BC6OTHER BC6ENTG .	CPR:4
 BC6ENTC directly inhibits BC6ENTG secretion through BC6OTHER in rat primary gastric cells.	CPR:4
 BC6ENTC directly inhibits BC6OTHER secretion through BC6ENTG in rat primary gastric cells.	False
 BC6OTHER directly inhibits BC6ENTG secretion through BC6ENTC - activated protein kinase in rat primary gastric cells.	False
To test whether BC6ENTC directly affects BC6ENTG cells, rat primary stomach cells were treated with BC6OTHER and the levels of BC6OTHER secretion, BC6OTHER gene expression and activation of BC6OTHER - activated protein kinase ( BC6OTHER ) were examined.	False
To test whether BC6ENTC directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6OTHER and the levels of BC6ENTG secretion, BC6OTHER gene expression and activation of BC6OTHER - activated protein kinase ( BC6OTHER ) were examined.	False
To test whether BC6ENTC directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6OTHER and the levels of BC6OTHER secretion, BC6ENTG gene expression and activation of BC6OTHER - activated protein kinase ( BC6OTHER ) were examined.	False
To test whether BC6ENTC directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6OTHER and the levels of BC6OTHER secretion, BC6OTHER gene expression and activation of BC6ENTG ( BC6OTHER ) were examined.	False
To test whether BC6ENTC directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6OTHER and the levels of BC6OTHER secretion, BC6OTHER gene expression and activation of BC6OTHER - activated protein kinase ( BC6ENTG ) were examined.	False
To test whether BC6OTHER directly affects BC6ENTG cells, rat primary stomach cells were treated with BC6ENTC and the levels of BC6OTHER secretion, BC6OTHER gene expression and activation of BC6OTHER - activated protein kinase ( BC6OTHER ) were examined.	False
To test whether BC6OTHER directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6ENTC and the levels of BC6ENTG secretion, BC6OTHER gene expression and activation of BC6OTHER - activated protein kinase ( BC6OTHER ) were examined.	False
To test whether BC6OTHER directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6ENTC and the levels of BC6OTHER secretion, BC6ENTG gene expression and activation of BC6OTHER - activated protein kinase ( BC6OTHER ) were examined.	False
To test whether BC6OTHER directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6ENTC and the levels of BC6OTHER secretion, BC6OTHER gene expression and activation of BC6ENTG ( BC6OTHER ) were examined.	False
To test whether BC6OTHER directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6ENTC and the levels of BC6OTHER secretion, BC6OTHER gene expression and activation of BC6OTHER - activated protein kinase ( BC6ENTG ) were examined.	False
To test whether BC6OTHER directly affects BC6ENTG cells, rat primary stomach cells were treated with BC6OTHER and the levels of BC6OTHER secretion, BC6OTHER gene expression and activation of BC6ENTC - activated protein kinase ( BC6OTHER ) were examined.	False
To test whether BC6OTHER directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6OTHER and the levels of BC6ENTG secretion, BC6OTHER gene expression and activation of BC6ENTC - activated protein kinase ( BC6OTHER ) were examined.	False
To test whether BC6OTHER directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6OTHER and the levels of BC6OTHER secretion, BC6ENTG gene expression and activation of BC6ENTC - activated protein kinase ( BC6OTHER ) were examined.	False
To test whether BC6OTHER directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6OTHER and the levels of BC6OTHER secretion, BC6OTHER gene expression and activation of BC6ENTC - activated protein kinase ( BC6ENTG ) were examined.	False
BC6ENTC significantly reduced BC6ENTG secretion and BC6OTHER mRNA production and both these effects were blocked by co - incubation with the BC6OTHER inhibitor BC6OTHER .	CPR:4
BC6ENTC significantly reduced BC6OTHER secretion and BC6ENTG mRNA production and both these effects were blocked by co - incubation with the BC6OTHER inhibitor BC6OTHER .	CPR:4
BC6ENTC significantly reduced BC6OTHER secretion and BC6OTHER mRNA production and both these effects were blocked by co - incubation with the BC6ENTG inhibitor BC6OTHER .	False
BC6OTHER significantly reduced BC6ENTG secretion and BC6OTHER mRNA production and both these effects were blocked by co - incubation with the BC6OTHER inhibitor BC6ENTC .	CPR:3
BC6OTHER significantly reduced BC6OTHER secretion and BC6ENTG mRNA production and both these effects were blocked by co - incubation with the BC6OTHER inhibitor BC6ENTC .	CPR:3
BC6OTHER significantly reduced BC6OTHER secretion and BC6OTHER mRNA production and both these effects were blocked by co - incubation with the BC6ENTG inhibitor BC6ENTC .	CPR:4
Furthermore, the BC6ENTG activator BC6ENTC ( BC6OTHER ) significantly inhibited BC6OTHER secretion.	CPR:3
Furthermore, the BC6OTHER activator BC6ENTC ( BC6OTHER ) significantly inhibited BC6ENTG secretion.	False
Furthermore, the BC6ENTG activator BC6OTHER ( BC6ENTC ) significantly inhibited BC6OTHER secretion.	CPR:3
Furthermore, the BC6OTHER activator BC6OTHER ( BC6ENTC ) significantly inhibited BC6ENTG secretion.	CPR:4
Among the various enzymes, BC6OTHER inhibitable cytosolic BC6ENTG ( BC6OTHER ) was shown to catalyse bioreductive activation of BC6ENTC leading to cross - linking of the DNA and cytotoxicity.	CPR:9
Among the various enzymes, BC6OTHER inhibitable cytosolic BC6OTHER : BC6OTHER oxidoreductase1 ( BC6ENTG ) was shown to catalyse bioreductive activation of BC6ENTC leading to cross - linking of the DNA and cytotoxicity.	CPR:9
However, the role of BC6ENTG in metabolic activation of BC6ENTC has been disputed.	CPR:9
In this report, we present cellular and animal models to demonstrate that BC6ENTG may play only a minor role in metabolic activation of BC6ENTC .	CPR:9
We further demonstrate that bioreductive activation of BC6ENTC is catalysed by a unique cytosolic activity which is related but distinct from BC6ENTG .	False
A unique cytosolic activity related but distinct from BC6ENTG catalyses metabolic activation of BC6ENTC .	CPR:9
The cytosolic fractions from liver and colon tissues of BC6ENTG - / - mice showed similar amounts of DNA cross - linking upon exposure to BC6ENTC , as observed in BC6OTHER + / + mice.	False
The cytosolic fractions from liver and colon tissues of BC6OTHER - / - mice showed similar amounts of DNA cross - linking upon exposure to BC6ENTC , as observed in BC6ENTG + / + mice.	False
The unique cytosolic activity that activated BC6ENTC in cytosolic fractions of liver and colon tissues of BC6ENTG - / - mice was designated as cytosolic BC6OTHER reductase.	False
The unique cytosolic activity that activated BC6ENTC in cytosolic fractions of liver and colon tissues of BC6OTHER - / - mice was designated as cytosolic BC6ENTG .	False
Among the various enzymes, BC6ENTC inhibitable cytosolic BC6ENTG ( BC6OTHER ) was shown to catalyse bioreductive activation of BC6OTHER leading to cross - linking of the DNA and cytotoxicity.	CPR:4
Among the various enzymes, BC6ENTC inhibitable cytosolic BC6OTHER : BC6OTHER oxidoreductase1 ( BC6ENTG ) was shown to catalyse bioreductive activation of BC6OTHER leading to cross - linking of the DNA and cytotoxicity.	CPR:4
The unique cytosolic activity that activated BC6OTHER in cytosolic fractions of liver and colon tissues of BC6ENTG - / - mice was designated as cytosolic BC6ENTC reductase.	False
This activity, like BC6ENTG , was inhibited by BC6ENTC and immunologically related to BC6OTHER .	CPR:4
This activity, like BC6OTHER , was inhibited by BC6ENTC and immunologically related to BC6ENTG .	False
Among the various enzymes, BC6OTHER inhibitable cytosolic BC6ENTC : BC6OTHER oxidoreductase1 ( BC6ENTG ) was shown to catalyse bioreductive activation of BC6OTHER leading to cross - linking of the DNA and cytotoxicity.	False
Among the various enzymes, BC6OTHER inhibitable cytosolic BC6OTHER : BC6ENTC oxidoreductase1 ( BC6ENTG ) was shown to catalyse bioreductive activation of BC6OTHER leading to cross - linking of the DNA and cytotoxicity.	False
By using pharmacological and genetic manipulation of BC6ENTG ( BC6OTHER ), we demonstrate that compartmentalized BC6OTHER and BC6OTHER are responsible for selectively modulating the concentration of BC6ENTC in individual subcellular compartments.	False
By using pharmacological and genetic manipulation of BC6OTHER ( BC6ENTG ), we demonstrate that compartmentalized BC6OTHER and BC6OTHER are responsible for selectively modulating the concentration of BC6ENTC in individual subcellular compartments.	False
By using pharmacological and genetic manipulation of BC6OTHER ( BC6OTHER ), we demonstrate that compartmentalized BC6ENTG and BC6OTHER are responsible for selectively modulating the concentration of BC6ENTC in individual subcellular compartments.	CPR:9
By using pharmacological and genetic manipulation of BC6OTHER ( BC6OTHER ), we demonstrate that compartmentalized BC6OTHER and BC6ENTG are responsible for selectively modulating the concentration of BC6ENTC in individual subcellular compartments.	CPR:9
We propose a model whereby compartmentalized BC6ENTG , rather than representing an enzymatic barrier to BC6ENTC diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different BC6OTHER concentrations irrespective of their distance from the site of BC6OTHER synthesis.	False
We propose a model whereby compartmentalized BC6ENTG , rather than representing an enzymatic barrier to BC6OTHER diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different BC6ENTC concentrations irrespective of their distance from the site of BC6OTHER synthesis.	CPR:9
We propose a model whereby compartmentalized BC6ENTG , rather than representing an enzymatic barrier to BC6OTHER diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different BC6OTHER concentrations irrespective of their distance from the site of BC6ENTC synthesis.	CPR:9
Such organization results in the local activation of BC6ENTG subsets through the generation of confined intracellular gradients of BC6ENTC , but the mechanisms responsible for limiting the diffusion of BC6OTHER largely remain to be clarified.	CPR:3
Such organization results in the local activation of BC6ENTG subsets through the generation of confined intracellular gradients of BC6OTHER , but the mechanisms responsible for limiting the diffusion of BC6ENTC largely remain to be clarified.	False
There is a growing appreciation that the BC6ENTC ( BC6OTHER ) - BC6ENTG ( BC6OTHER ) signaling pathway is organized to form transduction units that function to deliver specific messages.	False
There is a growing appreciation that the BC6ENTC ( BC6OTHER ) - BC6OTHER ( BC6ENTG ) signaling pathway is organized to form transduction units that function to deliver specific messages.	False
There is a growing appreciation that the BC6OTHER ( BC6ENTC ) - BC6ENTG ( BC6OTHER ) signaling pathway is organized to form transduction units that function to deliver specific messages.	False
There is a growing appreciation that the BC6OTHER ( BC6ENTC ) - BC6OTHER ( BC6ENTG ) signaling pathway is organized to form transduction units that function to deliver specific messages.	False
In BC6ENTC hydratase deficiency (mutations in BC6ENTG ), it derives from BC6OTHER degradation.	False
In BC6ENTG deficiency (mutations in BC6OTHER ), it derives from BC6ENTC degradation.	False
In BC6OTHER hydratase deficiency (mutations in BC6ENTG ), it derives from BC6ENTC degradation.	False
It had higher levels of BC6ENTC ( BC6OTHER ), a nutraceutical compound exerting actions against BC6ENTG and BC6OTHER ( BC6OTHER ).	False
It had higher levels of BC6ENTC ( BC6OTHER ), a nutraceutical compound exerting actions against BC6OTHER and BC6ENTG ( BC6OTHER ).	False
It had higher levels of BC6ENTC ( BC6OTHER ), a nutraceutical compound exerting actions against BC6OTHER and BC6OTHER ( BC6ENTG ).	False
It had higher levels of BC6OTHER ( BC6ENTC ), a nutraceutical compound exerting actions against BC6ENTG and BC6OTHER ( BC6OTHER ).	False
It had higher levels of BC6OTHER ( BC6ENTC ), a nutraceutical compound exerting actions against BC6OTHER and BC6ENTG ( BC6OTHER ).	False
It had higher levels of BC6OTHER ( BC6ENTC ), a nutraceutical compound exerting actions against BC6OTHER and BC6OTHER ( BC6ENTG ).	False
Its head - space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the BC6ENTG ( BC6OTHER ) - pathway (one having as precursors the BC6ENTC containing a BC6OTHER system).	CPR:9
Its head - space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the BC6OTHER ( BC6ENTG ) - pathway (one having as precursors the BC6ENTC containing a BC6OTHER system).	CPR:9
Its head - space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the BC6ENTG ( BC6OTHER ) - pathway (one having as precursors the BC6OTHER containing a BC6ENTC system).	CPR:9
Its head - space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the BC6OTHER ( BC6ENTG ) - pathway (one having as precursors the BC6OTHER containing a BC6ENTC system).	CPR:9
We demonstrate that activation of BC6ENTG BC6ENTC - 727 and BC6OTHER - 705 phosphorylations is promoted by BC6OTHER ( BC6OTHER ) activity and that the BC6OTHER is dependent on a BC6OTHER consensus - site for BC6OTHER - mediated activation.	False
We demonstrate that activation of BC6OTHER BC6ENTC - 727 and BC6OTHER - 705 phosphorylations is promoted by BC6ENTG ( BC6OTHER ) activity and that the BC6OTHER is dependent on a BC6OTHER consensus - site for BC6OTHER - mediated activation.	False
We demonstrate that activation of BC6OTHER BC6ENTC - 727 and BC6OTHER - 705 phosphorylations is promoted by BC6OTHER ( BC6ENTG ) activity and that the BC6OTHER is dependent on a BC6OTHER consensus - site for BC6OTHER - mediated activation.	False
We demonstrate that activation of BC6OTHER BC6ENTC - 727 and BC6OTHER - 705 phosphorylations is promoted by BC6OTHER ( BC6OTHER ) activity and that the BC6ENTG is dependent on a BC6OTHER consensus - site for BC6OTHER - mediated activation.	False
We demonstrate that activation of BC6OTHER BC6ENTC - 727 and BC6OTHER - 705 phosphorylations is promoted by BC6OTHER ( BC6OTHER ) activity and that the BC6OTHER is dependent on a BC6ENTG consensus - site for BC6OTHER - mediated activation.	False
We demonstrate that activation of BC6OTHER BC6ENTC - 727 and BC6OTHER - 705 phosphorylations is promoted by BC6OTHER ( BC6OTHER ) activity and that the BC6OTHER is dependent on a BC6OTHER consensus - site for BC6ENTG - mediated activation.	False
We demonstrate that activation of BC6ENTG BC6OTHER - 727 and BC6ENTC - 705 phosphorylations is promoted by BC6OTHER ( BC6OTHER ) activity and that the BC6OTHER is dependent on a BC6OTHER consensus - site for BC6OTHER - mediated activation.	False
We demonstrate that activation of BC6OTHER BC6OTHER - 727 and BC6ENTC - 705 phosphorylations is promoted by BC6ENTG ( BC6OTHER ) activity and that the BC6OTHER is dependent on a BC6OTHER consensus - site for BC6OTHER - mediated activation.	False
We demonstrate that activation of BC6OTHER BC6OTHER - 727 and BC6ENTC - 705 phosphorylations is promoted by BC6OTHER ( BC6ENTG ) activity and that the BC6OTHER is dependent on a BC6OTHER consensus - site for BC6OTHER - mediated activation.	False
We demonstrate that activation of BC6OTHER BC6OTHER - 727 and BC6ENTC - 705 phosphorylations is promoted by BC6OTHER ( BC6OTHER ) activity and that the BC6ENTG is dependent on a BC6OTHER consensus - site for BC6OTHER - mediated activation.	False
We demonstrate that activation of BC6OTHER BC6OTHER - 727 and BC6ENTC - 705 phosphorylations is promoted by BC6OTHER ( BC6OTHER ) activity and that the BC6OTHER is dependent on a BC6ENTG consensus - site for BC6OTHER - mediated activation.	False
We demonstrate that activation of BC6OTHER BC6OTHER - 727 and BC6ENTC - 705 phosphorylations is promoted by BC6OTHER ( BC6OTHER ) activity and that the BC6OTHER is dependent on a BC6OTHER consensus - site for BC6ENTG - mediated activation.	False
Alleles of BC6ENTG ( BC6OTHER ) with elevated slippage rates were identified among BC6ENTC - sensitive mutants and were also isolated using a slippage - dependent reporter gene.	False
Alleles of BC6OTHER ( BC6ENTG ) with elevated slippage rates were identified among BC6ENTC - sensitive mutants and were also isolated using a slippage - dependent reporter gene.	False
BC6ENTC receptors in postmortem human spinal cord were analyzed using BC6OTHER ligand binding and immunoblotting with BC6ENTG subunit - specific antibodies.	False
BC6ENTG in postmortem human spinal cord were analyzed using BC6OTHER ligand binding and immunoblotting with BC6ENTC receptor subunit - specific antibodies.	False
None of these parameters were affected by postmortem intervals up to 72 h. Immunoblotting of native BC6ENTC receptors showed that BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER subunits could all be found in the human spinal cord of which BC6OTHER was preferentially located to the dorsal half.	False
None of these parameters were affected by postmortem intervals up to 72 h. Immunoblotting of native BC6ENTC receptors showed that BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER subunits could all be found in the human spinal cord of which BC6OTHER was preferentially located to the dorsal half.	False
None of these parameters were affected by postmortem intervals up to 72 h. Immunoblotting of native BC6ENTC receptors showed that BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER subunits could all be found in the human spinal cord of which BC6OTHER was preferentially located to the dorsal half.	False
None of these parameters were affected by postmortem intervals up to 72 h. Immunoblotting of native BC6ENTC receptors showed that BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG subunits could all be found in the human spinal cord of which BC6OTHER was preferentially located to the dorsal half.	False
None of these parameters were affected by postmortem intervals up to 72 h. Immunoblotting of native BC6ENTC receptors showed that BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER subunits could all be found in the human spinal cord of which BC6ENTG was preferentially located to the dorsal half.	False
BC6ENTG in postmortem human spinal cord were analyzed using BC6ENTC ligand binding and immunoblotting with BC6OTHER receptor subunit - specific antibodies.	False
BC6OTHER receptors in postmortem human spinal cord were analyzed using BC6ENTC ligand binding and immunoblotting with BC6ENTG subunit - specific antibodies.	False
Immunoprecipitation of solubilized receptors revealed that BC6ENTG , BC6OTHER , and BC6OTHER subunits coprecipitated with the BC6OTHER subunit, indicating that native human spinal cord BC6ENTC receptors are BC6OTHER receptors assembled by at least three different receptor subunits.	False
Immunoprecipitation of solubilized receptors revealed that BC6OTHER , BC6ENTG , and BC6OTHER subunits coprecipitated with the BC6OTHER subunit, indicating that native human spinal cord BC6ENTC receptors are BC6OTHER receptors assembled by at least three different receptor subunits.	False
Immunoprecipitation of solubilized receptors revealed that BC6OTHER , BC6OTHER , and BC6ENTG subunits coprecipitated with the BC6OTHER subunit, indicating that native human spinal cord BC6ENTC receptors are BC6OTHER receptors assembled by at least three different receptor subunits.	False
Immunoprecipitation of solubilized receptors revealed that BC6OTHER , BC6OTHER , and BC6OTHER subunits coprecipitated with the BC6ENTG subunit, indicating that native human spinal cord BC6ENTC receptors are BC6OTHER receptors assembled by at least three different receptor subunits.	False
Immunoprecipitation of solubilized receptors revealed that BC6OTHER , BC6OTHER , and BC6OTHER subunits coprecipitated with the BC6OTHER subunit, indicating that native human spinal cord BC6ENTC receptors are BC6ENTG assembled by at least three different receptor subunits.	False
Immunoprecipitation of solubilized receptors revealed that BC6ENTG , BC6OTHER , and BC6OTHER subunits coprecipitated with the BC6OTHER subunit, indicating that native human spinal cord BC6OTHER receptors are BC6ENTC receptors assembled by at least three different receptor subunits.	False
Immunoprecipitation of solubilized receptors revealed that BC6OTHER , BC6ENTG , and BC6OTHER subunits coprecipitated with the BC6OTHER subunit, indicating that native human spinal cord BC6OTHER receptors are BC6ENTC receptors assembled by at least three different receptor subunits.	False
Immunoprecipitation of solubilized receptors revealed that BC6OTHER , BC6OTHER , and BC6ENTG subunits coprecipitated with the BC6OTHER subunit, indicating that native human spinal cord BC6OTHER receptors are BC6ENTC receptors assembled by at least three different receptor subunits.	False
Immunoprecipitation of solubilized receptors revealed that BC6OTHER , BC6OTHER , and BC6OTHER subunits coprecipitated with the BC6ENTG subunit, indicating that native human spinal cord BC6OTHER receptors are BC6ENTC receptors assembled by at least three different receptor subunits.	False
Immunoprecipitation of solubilized receptors revealed that BC6OTHER , BC6OTHER , and BC6OTHER subunits coprecipitated with the BC6OTHER subunit, indicating that native human spinal cord BC6ENTG are BC6ENTC receptors assembled by at least three different receptor subunits.	False
Thus, the formation of BC6ENTC bonds in BC6ENTG is a potentially important reversible mechanism for alterations in the rates of sulfation of both endogenous and xenobiotic substrates.	False
We have examined the hypothesis that the formation of BC6ENTC bonds in BC6ENTG can reversibly regulate the catalytic function of the enzyme.	False
Three BC6ENTC oxidants were used as model compounds to investigate their effects on homogeneous preparations of BC6ENTG : BC6OTHER , BC6OTHER , and BC6OTHER ) ( BC6OTHER ).	False
Three BC6OTHER oxidants were used as model compounds to investigate their effects on homogeneous preparations of BC6ENTG : BC6ENTC , BC6OTHER , and BC6OTHER ) ( BC6OTHER ).	False
Three BC6OTHER oxidants were used as model compounds to investigate their effects on homogeneous preparations of BC6ENTG : BC6OTHER , BC6ENTC , and BC6OTHER ) ( BC6OTHER ).	False
Three BC6OTHER oxidants were used as model compounds to investigate their effects on homogeneous preparations of BC6ENTG : BC6OTHER , BC6OTHER , and BC6ENTC ) ( BC6OTHER ).	False
Three BC6OTHER oxidants were used as model compounds to investigate their effects on homogeneous preparations of BC6ENTG : BC6OTHER , BC6OTHER , and BC6OTHER ) ( BC6ENTC ).	False
Studies on the kinetics of the BC6ENTG - catalyzed sulfation of BC6ENTC ( BC6OTHER ) showed the effects of BC6OTHER bond formation on the substrate inhibition characteristics of the enzyme.	CPR:9
Modification of the Catalytic Function of BC6ENTG by Formation of BC6ENTC Bonds.	False
Studies on the kinetics of the BC6ENTG - catalyzed sulfation of BC6OTHER ( BC6ENTC ) showed the effects of BC6OTHER bond formation on the substrate inhibition characteristics of the enzyme.	CPR:9
Studies on the kinetics of the BC6ENTG - catalyzed sulfation of BC6OTHER ( BC6OTHER ) showed the effects of BC6ENTC bond formation on the substrate inhibition characteristics of the enzyme.	False
The BC6ENTG catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous BC6ENTC and BC6OTHER .	CPR:9
The BC6ENTG catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous BC6OTHER and BC6ENTC .	CPR:9
BC6OTHER ( BC6OTHER , BC6OTHER ) is a small molecule BC6ENTG inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6ENTC kinases from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families.	False
BC6OTHER ( BC6OTHER , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6ENTC kinases from the BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families.	False
BC6OTHER ( BC6OTHER , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6ENTC kinases from the BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) families.	False
BC6OTHER ( BC6OTHER , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6ENTC kinases from the BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) families.	False
BC6OTHER ( BC6OTHER , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6ENTC kinases from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) families.	False
We investigated the efficacy of BC6ENTC at inhibiting mutants of the BC6ENTG BC6OTHER , BC6OTHER , and BC6OTHER , which are implicated in the pathogenesis of myeloid malignancies.	CPR:4
We investigated the efficacy of BC6ENTC at inhibiting mutants of the receptor BC6OTHER kinases BC6ENTG , BC6OTHER , and BC6OTHER , which are implicated in the pathogenesis of myeloid malignancies.	CPR:4
We investigated the efficacy of BC6ENTC at inhibiting mutants of the receptor BC6OTHER kinases BC6OTHER , BC6ENTG , and BC6OTHER , which are implicated in the pathogenesis of myeloid malignancies.	CPR:4
We investigated the efficacy of BC6ENTC at inhibiting mutants of the receptor BC6OTHER kinases BC6OTHER , BC6OTHER , and BC6ENTG , which are implicated in the pathogenesis of myeloid malignancies.	CPR:4
We investigated the efficacy of BC6OTHER at inhibiting mutants of the receptor BC6ENTC kinases BC6ENTG , BC6OTHER , and BC6OTHER , which are implicated in the pathogenesis of myeloid malignancies.	False
We investigated the efficacy of BC6OTHER at inhibiting mutants of the receptor BC6ENTC kinases BC6OTHER , BC6ENTG , and BC6OTHER , which are implicated in the pathogenesis of myeloid malignancies.	False
We investigated the efficacy of BC6OTHER at inhibiting mutants of the receptor BC6ENTC kinases BC6OTHER , BC6OTHER , and BC6ENTG , which are implicated in the pathogenesis of myeloid malignancies.	False
DESIGN AND METHODS: We tested the effect of BC6ENTC on the proliferation of hematopoietic cells transformed by BC6ENTG - BC6OTHER , BC6OTHER with an internal tandem duplication or BC6OTHER point mutation, and the BC6OTHER ( BC6OTHER ) mutant.	False
DESIGN AND METHODS: We tested the effect of BC6ENTC on the proliferation of hematopoietic cells transformed by BC6OTHER - BC6ENTG , BC6OTHER with an internal tandem duplication or BC6OTHER point mutation, and the BC6OTHER ( BC6OTHER ) mutant.	False
DESIGN AND METHODS: We tested the effect of BC6ENTC on the proliferation of hematopoietic cells transformed by BC6OTHER - BC6OTHER , BC6ENTG with an internal tandem duplication or BC6OTHER point mutation, and the BC6OTHER ( BC6OTHER ) mutant.	False
DESIGN AND METHODS: We tested the effect of BC6ENTC on the proliferation of hematopoietic cells transformed by BC6OTHER - BC6OTHER , BC6OTHER with an internal tandem duplication or BC6ENTG point mutation, and the BC6OTHER ( BC6OTHER ) mutant.	False
DESIGN AND METHODS: We tested the effect of BC6ENTC on the proliferation of hematopoietic cells transformed by BC6OTHER - BC6OTHER , BC6OTHER with an internal tandem duplication or BC6OTHER point mutation, and the BC6ENTG ( BC6OTHER ) mutant.	False
DESIGN AND METHODS: We tested the effect of BC6ENTC on the proliferation of hematopoietic cells transformed by BC6OTHER - BC6OTHER , BC6OTHER with an internal tandem duplication or BC6OTHER point mutation, and the BC6OTHER ( BC6ENTG ) mutant.	False
The direct effect of BC6ENTC on the activity of these BC6ENTG and their downstream signaling was tested using BC6OTHER - specific antibodies.	False
The ability of BC6ENTC to inhibit oncogenic BC6ENTG and BC6OTHER mutants and overcome resistance to other small molecule inhibitors.	CPR:4
The ability of BC6ENTC to inhibit oncogenic BC6OTHER and BC6ENTG mutants and overcome resistance to other small molecule inhibitors.	CPR:4
The direct effect of BC6OTHER on the activity of these BC6ENTG and their downstream signaling was tested using BC6ENTC - specific antibodies.	False
RESULTS: We show that BC6ENTC is a potent inhibitor of BC6ENTG - BC6OTHER and BC6OTHER mutants, including some of the mutants that confer resistance to PKC412 and other BC6OTHER inhibitors.	CPR:4
RESULTS: We show that BC6ENTC is a potent inhibitor of BC6OTHER - BC6ENTG and BC6OTHER mutants, including some of the mutants that confer resistance to PKC412 and other BC6OTHER inhibitors.	CPR:4
RESULTS: We show that BC6ENTC is a potent inhibitor of BC6OTHER - BC6OTHER and BC6ENTG mutants, including some of the mutants that confer resistance to PKC412 and other BC6OTHER inhibitors.	CPR:4
RESULTS: We show that BC6ENTC is a potent inhibitor of BC6OTHER - BC6OTHER and BC6OTHER mutants, including some of the mutants that confer resistance to PKC412 and other BC6ENTG inhibitors.	CPR:4
BC6ENTC induced a cell cycle block and apoptosis in the acute myeloid leukemia cell lines MV4 - 11 and MOLM - 13, both expressing BC6ENTG with an internal tandem duplication, whereas no effect was observed on four other acute myeloid leukemia cell lines.	CPR:4
The BC6ENTC - resistant BC6ENTG ( BC6OTHER ) mutant, associated with systemic mastocytosis, was found to be resistant to BC6OTHER .	False
The BC6ENTC - resistant BC6OTHER ( BC6ENTG ) mutant, associated with systemic mastocytosis, was found to be resistant to BC6OTHER .	False
The BC6OTHER - resistant BC6ENTG ( BC6OTHER ) mutant, associated with systemic mastocytosis, was found to be resistant to BC6ENTC .	False
The BC6OTHER - resistant BC6OTHER ( BC6ENTG ) mutant, associated with systemic mastocytosis, was found to be resistant to BC6ENTC .	False
BC6ENTC ( BC6OTHER , BC6OTHER ) is a small molecule BC6ENTG inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families.	CPR:4
BC6ENTC ( BC6OTHER , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against BC6ENTG from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families.	False
BC6ENTC ( BC6OTHER , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families.	False
BC6ENTC ( BC6OTHER , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) families.	False
BC6ENTC ( BC6OTHER , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) families.	False
BC6ENTC ( BC6OTHER , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) families.	False
INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of BC6ENTC for the treatment of myeloid malignancies expressing activated forms of BC6ENTG and BC6OTHER .	CPR:4
INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of BC6ENTC for the treatment of myeloid malignancies expressing activated forms of BC6OTHER and BC6ENTG .	CPR:4
BC6OTHER ( BC6ENTC , BC6OTHER ) is a small molecule BC6ENTG inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families.	CPR:4
BC6OTHER ( BC6ENTC , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against BC6ENTG from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families.	False
BC6OTHER ( BC6ENTC , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families.	False
BC6OTHER ( BC6ENTC , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) families.	False
BC6OTHER ( BC6ENTC , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) families.	False
BC6OTHER ( BC6ENTC , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) families.	False
BC6OTHER ( BC6OTHER , BC6ENTC ) is a small molecule BC6ENTG inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families.	CPR:4
BC6OTHER ( BC6OTHER , BC6ENTC ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against BC6ENTG from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families.	False
BC6OTHER ( BC6OTHER , BC6ENTC ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families.	False
BC6OTHER ( BC6OTHER , BC6ENTC ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) families.	False
BC6OTHER ( BC6OTHER , BC6ENTC ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) families.	False
BC6OTHER ( BC6OTHER , BC6ENTC ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) families.	False
It is a state of relative water excess due to stimulated BC6ENTG ( BC6ENTC ) and fluid intake greater than obligatory losses.	False
However, several promising nonpeptide, BC6ENTG antagonists have been described; these agents are BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER .	CPR:6
However, several promising nonpeptide, BC6ENTG antagonists have been described; these agents are BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER .	CPR:6
However, several promising nonpeptide, BC6ENTG antagonists have been described; these agents are BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER .	CPR:6
However, several promising nonpeptide, BC6ENTG antagonists have been described; these agents are BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER .	CPR:6
However, several promising nonpeptide, BC6ENTG antagonists have been described; these agents are BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), and BC6OTHER .	CPR:6
However, several promising nonpeptide, BC6ENTG antagonists have been described; these agents are BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER .	CPR:6
However, several promising nonpeptide, BC6ENTG antagonists have been described; these agents are BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC .	CPR:6
It is a state of relative water excess due to stimulated BC6ENTC ( BC6ENTG ) and fluid intake greater than obligatory losses.	False
A series of BC6ENTC , designed as mimics of a cationic high energy intermediate in the BC6OTHER cyclase(1) ( BC6ENTG ) - mediated cyclization of BC6OTHER to BC6OTHER was prepared from BC6OTHER .	False
A series of BC6ENTC , designed as mimics of a cationic high energy intermediate in the BC6ENTG ( BC6OTHER ) - mediated cyclization of BC6OTHER to BC6OTHER was prepared from BC6OTHER .	False
A series of BC6OTHER , designed as mimics of a cationic high energy intermediate in the BC6OTHER cyclase(1) ( BC6ENTG ) - mediated cyclization of BC6ENTC to BC6OTHER was prepared from BC6OTHER .	CPR:9
A series of BC6OTHER , designed as mimics of a cationic high energy intermediate in the BC6ENTG ( BC6OTHER ) - mediated cyclization of BC6ENTC to BC6OTHER was prepared from BC6OTHER .	CPR:9
A series of BC6OTHER , designed as mimics of a cationic high energy intermediate in the BC6OTHER cyclase(1) ( BC6ENTG ) - mediated cyclization of BC6OTHER to BC6ENTC was prepared from BC6OTHER .	CPR:9
A series of BC6OTHER , designed as mimics of a cationic high energy intermediate in the BC6ENTG ( BC6OTHER ) - mediated cyclization of BC6OTHER to BC6ENTC was prepared from BC6OTHER .	CPR:9
A series of BC6OTHER , designed as mimics of a cationic high energy intermediate in the BC6OTHER cyclase(1) ( BC6ENTG ) - mediated cyclization of BC6OTHER to BC6OTHER was prepared from BC6ENTC .	False
A series of BC6OTHER , designed as mimics of a cationic high energy intermediate in the BC6ENTG ( BC6OTHER ) - mediated cyclization of BC6OTHER to BC6OTHER was prepared from BC6ENTC .	False
A BC6ENTC derivative showed promising inhibition of BC6ENTG in combination with low cytotoxicity, and showed significant reduction of BC6OTHER biosynthesis in a human cell line.	CPR:4
A BC6OTHER derivative showed promising inhibition of BC6ENTG in combination with low cytotoxicity, and showed significant reduction of BC6ENTC biosynthesis in a human cell line.	CPR:9
A series of BC6OTHER , designed as mimics of a cationic high energy intermediate in the BC6ENTC cyclase(1) ( BC6ENTG ) - mediated cyclization of BC6OTHER to BC6OTHER was prepared from BC6OTHER .	False
 BC6ENTC derived from BC6OTHER as a novel chemotype of BC6ENTG inhibitors.	CPR:4
 BC6OTHER derived from BC6ENTC as a novel chemotype of BC6ENTG inhibitors.	CPR:4
A series of substituted BC6ENTC has been synthesised and tested in vitro as potential pro - apoptotic BC6ENTG - inhibitory anticancer agents.	CPR:4
Active compounds, such as the BC6ENTC analogue 6c, were found to exhibit sub - micromolar IC50 values in BC6ENTG expressing human cancer cell lines.	CPR:4
Synthesis and evaluation of BC6ENTC as BC6ENTG inhibitory anticancer agents.	CPR:4
The development of specific BC6ENTG inhibitors and further experience with the dual enzyme inhibitor BC6ENTC will improve understanding of the aetiology of AD and should lead to a wider variety of potent treatment options.	CPR:4
BC6OTHER ( BC6ENTG ) predominates in the healthy brain, with BC6OTHER ( BC6OTHER ) considered to play a minor role in regulating brain BC6ENTC ( BC6OTHER ) levels.	CPR:9
BC6OTHER ( BC6OTHER ) predominates in the healthy brain, with BC6ENTG ( BC6OTHER ) considered to play a minor role in regulating brain BC6ENTC ( BC6OTHER ) levels.	CPR:9
BC6OTHER ( BC6OTHER ) predominates in the healthy brain, with BC6OTHER ( BC6ENTG ) considered to play a minor role in regulating brain BC6ENTC ( BC6OTHER ) levels.	CPR:9
BC6ENTG ( BC6OTHER ) predominates in the healthy brain, with BC6OTHER ( BC6OTHER ) considered to play a minor role in regulating brain BC6ENTC ( BC6OTHER ) levels.	CPR:9
BC6OTHER ( BC6ENTG ) predominates in the healthy brain, with BC6OTHER ( BC6OTHER ) considered to play a minor role in regulating brain BC6OTHER ( BC6ENTC ) levels.	CPR:9
BC6OTHER ( BC6OTHER ) predominates in the healthy brain, with BC6ENTG ( BC6OTHER ) considered to play a minor role in regulating brain BC6OTHER ( BC6ENTC ) levels.	CPR:9
BC6OTHER ( BC6OTHER ) predominates in the healthy brain, with BC6OTHER ( BC6ENTG ) considered to play a minor role in regulating brain BC6OTHER ( BC6ENTC ) levels.	CPR:9
BC6ENTG ( BC6OTHER ) predominates in the healthy brain, with BC6OTHER ( BC6OTHER ) considered to play a minor role in regulating brain BC6OTHER ( BC6ENTC ) levels.	CPR:9
Experimental evidence from the use of agents with enhanced selectivity for BC6ENTG ( BC6ENTC analogues, BC6OTHER ) and the dual inhibitor of both BC6OTHER and BC6OTHER , BC6OTHER , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6OTHER in AD and related dementias.	False
Experimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6ENTC analogues, BC6OTHER ) and the dual inhibitor of both BC6ENTG and BC6OTHER , BC6OTHER , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6OTHER in AD and related dementias.	False
Experimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6ENTC analogues, BC6OTHER ) and the dual inhibitor of both BC6OTHER and BC6ENTG , BC6OTHER , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6OTHER in AD and related dementias.	False
Experimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6ENTC analogues, BC6OTHER ) and the dual inhibitor of both BC6OTHER and BC6OTHER , BC6OTHER , indicates potential therapeutic benefits of inhibiting both BC6ENTG and BC6OTHER in AD and related dementias.	False
Experimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6ENTC analogues, BC6OTHER ) and the dual inhibitor of both BC6OTHER and BC6OTHER , BC6OTHER , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6ENTG in AD and related dementias.	False
Experimental evidence from the use of agents with enhanced selectivity for BC6ENTG ( BC6OTHER analogues, BC6ENTC ) and the dual inhibitor of both BC6OTHER and BC6OTHER , BC6OTHER , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6OTHER in AD and related dementias.	False
Experimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6OTHER analogues, BC6ENTC ) and the dual inhibitor of both BC6ENTG and BC6OTHER , BC6OTHER , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6OTHER in AD and related dementias.	False
Experimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6OTHER analogues, BC6ENTC ) and the dual inhibitor of both BC6OTHER and BC6ENTG , BC6OTHER , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6OTHER in AD and related dementias.	False
Experimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6OTHER analogues, BC6ENTC ) and the dual inhibitor of both BC6OTHER and BC6OTHER , BC6OTHER , indicates potential therapeutic benefits of inhibiting both BC6ENTG and BC6OTHER in AD and related dementias.	False
Experimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6OTHER analogues, BC6ENTC ) and the dual inhibitor of both BC6OTHER and BC6OTHER , BC6OTHER , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6ENTG in AD and related dementias.	False
Experimental evidence from the use of agents with enhanced selectivity for BC6ENTG ( BC6OTHER analogues, BC6OTHER ) and the dual inhibitor of both BC6OTHER and BC6OTHER , BC6ENTC , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6OTHER in AD and related dementias.	False
Experimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6OTHER analogues, BC6OTHER ) and the dual inhibitor of both BC6ENTG and BC6OTHER , BC6ENTC , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6OTHER in AD and related dementias.	CPR:4
Experimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6OTHER analogues, BC6OTHER ) and the dual inhibitor of both BC6OTHER and BC6ENTG , BC6ENTC , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6OTHER in AD and related dementias.	CPR:4
Experimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6OTHER analogues, BC6OTHER ) and the dual inhibitor of both BC6OTHER and BC6OTHER , BC6ENTC , indicates potential therapeutic benefits of inhibiting both BC6ENTG and BC6OTHER in AD and related dementias.	CPR:4
Experimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6OTHER analogues, BC6OTHER ) and the dual inhibitor of both BC6OTHER and BC6OTHER , BC6ENTC , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6ENTG in AD and related dementias.	CPR:4
The discovery of a BC6OTHER ( BC6OTHER ) led to the search for compounds that could selectively inhibit BC6ENTG in humans while sparing BC6ENTC formation from BC6OTHER .	False
The discovery of a BC6OTHER ( BC6OTHER ) led to the search for compounds that could selectively inhibit BC6OTHER in humans while sparing BC6ENTC formation from BC6ENTG .	CPR:9
The discovery of a BC6ENTG ( BC6OTHER ) led to the search for compounds that could selectively inhibit BC6OTHER in humans while sparing BC6ENTC formation from BC6OTHER .	False
The discovery of a BC6OTHER ( BC6ENTG ) led to the search for compounds that could selectively inhibit BC6OTHER in humans while sparing BC6ENTC formation from BC6OTHER .	False
We report here the pharmacological properties of a third selective BC6ENTG inhibitor, BC6ENTC , which is the most potent and in vitro selective of the marketed BC6OTHER inhibitors that we have studied.	CPR:4
We report here the pharmacological properties of a third selective BC6OTHER inhibitor, BC6ENTC , which is the most potent and in vitro selective of the marketed BC6ENTG inhibitors that we have studied.	CPR:4
BC6ENTC potently inhibits recombinant BC6ENTG , with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for BC6OTHER , 0.5 microM for BC6OTHER , and 5 microM for BC6OTHER .	CPR:4
BC6OTHER potently inhibits recombinant BC6ENTG , with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for BC6ENTC , 0.5 microM for BC6OTHER , and 5 microM for BC6OTHER .	CPR:4
BC6OTHER potently inhibits recombinant BC6ENTG , with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for BC6OTHER , 0.5 microM for BC6ENTC , and 5 microM for BC6OTHER .	CPR:4
BC6OTHER potently inhibits recombinant BC6ENTG , with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for BC6OTHER , 0.5 microM for BC6OTHER , and 5 microM for BC6ENTC .	CPR:4
Unique binding interactions of BC6OTHER with BC6ENTG translate into a fast rate of inactivation of BC6OTHER (110,000 M / s compared with 7000 M / s for BC6ENTC and 80 M / s for BC6OTHER ).	False
Unique binding interactions of BC6OTHER with BC6OTHER translate into a fast rate of inactivation of BC6ENTG (110,000 M / s compared with 7000 M / s for BC6ENTC and 80 M / s for BC6OTHER ).	False
Unique binding interactions of BC6ENTC with BC6ENTG translate into a fast rate of inactivation of BC6OTHER (110,000 M / s compared with 7000 M / s for BC6OTHER and 80 M / s for BC6OTHER ).	False
Unique binding interactions of BC6ENTC with BC6OTHER translate into a fast rate of inactivation of BC6ENTG (110,000 M / s compared with 7000 M / s for BC6OTHER and 80 M / s for BC6OTHER ).	CPR:4
 BC6ENTC : assessment of BC6ENTG potency and selectivity.	False
Unique binding interactions of BC6OTHER with BC6ENTG translate into a fast rate of inactivation of BC6OTHER (110,000 M / s compared with 7000 M / s for BC6OTHER and 80 M / s for BC6ENTC ).	False
Unique binding interactions of BC6OTHER with BC6OTHER translate into a fast rate of inactivation of BC6ENTG (110,000 M / s compared with 7000 M / s for BC6OTHER and 80 M / s for BC6ENTC ).	False
The overall saturation binding affinity for BC6ENTG of BC6ENTC is 2.6 nM (compared with 1.6 nM for BC6OTHER , 51 nM for BC6OTHER , and 260 nM for BC6OTHER ), with a slow off - rate (t(1 / 2) approximately 98 min).	False
The overall saturation binding affinity for BC6ENTG of BC6OTHER is 2.6 nM (compared with 1.6 nM for BC6ENTC , 51 nM for BC6OTHER , and 260 nM for BC6OTHER ), with a slow off - rate (t(1 / 2) approximately 98 min).	False
The overall saturation binding affinity for BC6ENTG of BC6OTHER is 2.6 nM (compared with 1.6 nM for BC6OTHER , 51 nM for BC6ENTC , and 260 nM for BC6OTHER ), with a slow off - rate (t(1 / 2) approximately 98 min).	False
The overall saturation binding affinity for BC6ENTG of BC6OTHER is 2.6 nM (compared with 1.6 nM for BC6OTHER , 51 nM for BC6OTHER , and 260 nM for BC6ENTC ), with a slow off - rate (t(1 / 2) approximately 98 min).	False
BC6ENTC inhibits BC6ENTG in a competitive fashion only at very high concentrations (IC(50) = 150 microM).	CPR:4
Collectively, these data provide a mechanistic basis for the potency and in vitro selectivity of BC6ENTC for BC6ENTG .	False
BC6ENTC showed similar activity in the BC6ENTG assay ( BC6OTHER IC(50) = 0.24 microM; BC6OTHER IC(50) = 21.9 microM).	CPR:4
BC6ENTC showed similar activity in the BC6OTHER assay ( BC6ENTG IC(50) = 0.24 microM; BC6OTHER IC(50) = 21.9 microM).	CPR:4
BC6ENTC showed similar activity in the BC6OTHER assay ( BC6OTHER IC(50) = 0.24 microM; BC6ENTG IC(50) = 21.9 microM).	CPR:4
These characteristics of the bound BC6ENTC suggest that BC6ENTG catalysis is not facilitated by forming the resonance - stabilized structure of the BC6OTHER as seen in BC6OTHER .	False
These characteristics of the bound BC6ENTC suggest that BC6OTHER catalysis is not facilitated by forming the resonance - stabilized structure of the BC6OTHER as seen in BC6ENTG .	False
These characteristics of the bound BC6OTHER suggest that BC6ENTG catalysis is not facilitated by forming the resonance - stabilized structure of the BC6ENTC as seen in BC6OTHER .	False
These characteristics of the bound BC6OTHER suggest that BC6OTHER catalysis is not facilitated by forming the resonance - stabilized structure of the BC6ENTC as seen in BC6ENTG .	False
BC6ENTG ( BC6OTHER dehydratase, BC6OTHER ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6ENTC to yield BC6OTHER and BC6OTHER .	CPR:9
BC6OTHER ( BC6OTHER dehydratase, BC6ENTG ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6ENTC to yield BC6OTHER and BC6OTHER .	CPR:9
BC6OTHER BC6ENTG , BC6OTHER ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6ENTC to yield BC6OTHER and BC6OTHER .	CPR:9
Formation of BC6ENTC by BC6ENTG is a two - step reaction in which the BC6OTHER group of BC6OTHER is cleaved to produce BC6OTHER , and then the BC6OTHER is deaminated by nonenzymatic hydrolysis to produce BC6OTHER .	CPR:9
Formation of BC6OTHER by BC6ENTG is a two - step reaction in which the BC6ENTC group of BC6OTHER is cleaved to produce BC6OTHER , and then the BC6OTHER is deaminated by nonenzymatic hydrolysis to produce BC6OTHER .	False
Formation of BC6OTHER by BC6ENTG is a two - step reaction in which the BC6OTHER group of BC6ENTC is cleaved to produce BC6OTHER , and then the BC6OTHER is deaminated by nonenzymatic hydrolysis to produce BC6OTHER .	False
Formation of BC6OTHER by BC6ENTG is a two - step reaction in which the BC6OTHER group of BC6OTHER is cleaved to produce BC6ENTC , and then the BC6OTHER is deaminated by nonenzymatic hydrolysis to produce BC6OTHER .	CPR:9
Formation of BC6OTHER by BC6ENTG is a two - step reaction in which the BC6OTHER group of BC6OTHER is cleaved to produce BC6OTHER , and then the BC6ENTC is deaminated by nonenzymatic hydrolysis to produce BC6OTHER .	False
Formation of BC6OTHER by BC6ENTG is a two - step reaction in which the BC6OTHER group of BC6OTHER is cleaved to produce BC6OTHER , and then the BC6OTHER is deaminated by nonenzymatic hydrolysis to produce BC6ENTC .	CPR:9
BC6ENTG ( BC6ENTC dehydratase, BC6OTHER ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6OTHER .	False
BC6OTHER ( BC6ENTC dehydratase, BC6ENTG ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6OTHER .	False
BC6ENTG ( BC6OTHER dehydratase, BC6OTHER ) catalyzes the BC6ENTC ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6OTHER .	False
BC6OTHER ( BC6OTHER dehydratase, BC6ENTG ) catalyzes the BC6ENTC ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6OTHER .	False
BC6OTHER BC6ENTG , BC6OTHER ) catalyzes the BC6ENTC ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6OTHER .	False
The BC6ENTG crystallized with BC6ENTC ( BC6OTHER ) was also determined at 2.6 A resolution by molecular replacement.	False
BC6ENTG ( BC6OTHER dehydratase, BC6OTHER ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6ENTC and BC6OTHER .	CPR:9
BC6OTHER ( BC6OTHER dehydratase, BC6ENTG ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6ENTC and BC6OTHER .	CPR:9
BC6OTHER BC6ENTG , BC6OTHER ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6ENTC and BC6OTHER .	CPR:9
The BC6ENTG crystallized with BC6OTHER ( BC6ENTC ) was also determined at 2.6 A resolution by molecular replacement.	False
BC6ENTG ( BC6OTHER dehydratase, BC6OTHER ) catalyzes the BC6OTHER ( BC6ENTC ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6OTHER .	False
BC6OTHER ( BC6OTHER dehydratase, BC6ENTG ) catalyzes the BC6OTHER ( BC6ENTC ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6OTHER .	False
BC6OTHER BC6ENTG , BC6OTHER ) catalyzes the BC6OTHER ( BC6ENTC ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6OTHER .	False
The BC6ENTG contained CHEM - OMS BC6ENTC in the active site, indicating that BC6OTHER can form the BC6OTHER linkage with BC6OTHER , but the subsequent dehydration did not occur.	False
The BC6ENTG contained CHEM - OMS BC6OTHER in the active site, indicating that BC6ENTC can form the BC6OTHER linkage with BC6OTHER , but the subsequent dehydration did not occur.	False
The BC6ENTG contained CHEM - OMS BC6OTHER in the active site, indicating that BC6OTHER can form the BC6ENTC linkage with BC6OTHER , but the subsequent dehydration did not occur.	False
The BC6ENTG contained CHEM - OMS BC6OTHER in the active site, indicating that BC6OTHER can form the BC6OTHER linkage with BC6ENTC , but the subsequent dehydration did not occur.	False
The CHEM group of BC6ENTC is surrounded by a characteristic BC6ENTG ((168) BC6OTHER (172)) and forms BC6OTHER bonds with the BC6OTHER groups of those BC6OTHER residues, suggesting that the BC6OTHER group can be protonated.	False
The CHEM group of BC6ENTC is surrounded by a characteristic BC6OTHER ((168) BC6ENTG (172)) and forms BC6OTHER bonds with the BC6OTHER groups of those BC6OTHER residues, suggesting that the BC6OTHER group can be protonated.	False
The CHEM group of BC6OTHER is surrounded by a characteristic BC6ENTG ((168) BC6ENTC (172)) and forms BC6OTHER bonds with the BC6OTHER groups of those BC6OTHER residues, suggesting that the BC6OTHER group can be protonated.	False
The CHEM group of BC6OTHER is surrounded by a characteristic BC6ENTG ((168) BC6OTHER (172)) and forms BC6ENTC bonds with the BC6OTHER groups of those BC6OTHER residues, suggesting that the BC6OTHER group can be protonated.	False
The CHEM group of BC6OTHER is surrounded by a characteristic BC6OTHER ((168) BC6ENTG (172)) and forms BC6ENTC bonds with the BC6OTHER groups of those BC6OTHER residues, suggesting that the BC6OTHER group can be protonated.	False
The CHEM group of BC6OTHER is surrounded by a characteristic BC6ENTG ((168) BC6OTHER (172)) and forms BC6OTHER bonds with the BC6ENTC groups of those BC6OTHER residues, suggesting that the BC6OTHER group can be protonated.	False
The CHEM group of BC6OTHER is surrounded by a characteristic BC6OTHER ((168) BC6ENTG (172)) and forms BC6OTHER bonds with the BC6ENTC groups of those BC6OTHER residues, suggesting that the BC6OTHER group can be protonated.	False
The CHEM group of BC6OTHER is surrounded by a characteristic BC6ENTG ((168) BC6OTHER (172)) and forms BC6OTHER bonds with the BC6OTHER groups of those BC6ENTC residues, suggesting that the BC6OTHER group can be protonated.	False
The CHEM group of BC6OTHER is surrounded by a characteristic BC6OTHER ((168) BC6ENTG (172)) and forms BC6OTHER bonds with the BC6OTHER groups of those BC6ENTC residues, suggesting that the BC6OTHER group can be protonated.	False
BC6ENTG ( BC6OTHER dehydratase, BC6OTHER ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6ENTC .	CPR:9
BC6OTHER ( BC6OTHER dehydratase, BC6ENTG ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6ENTC .	CPR:9
BC6OTHER BC6ENTG , BC6OTHER ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6ENTC .	CPR:9
The CHEM group of BC6OTHER is surrounded by a characteristic BC6ENTG ((168) BC6OTHER (172)) and forms BC6OTHER bonds with the BC6OTHER groups of those BC6OTHER residues, suggesting that the BC6ENTC group can be protonated.	False
The CHEM group of BC6OTHER is surrounded by a characteristic BC6OTHER ((168) BC6ENTG (172)) and forms BC6OTHER bonds with the BC6OTHER groups of those BC6OTHER residues, suggesting that the BC6ENTC group can be protonated.	False
In addition, BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG .	False
In addition, BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG .	False
In addition, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG .	False
In addition, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG .	False
In addition, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG .	False
In addition, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG .	False
In addition, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG .	False
A total of 68 chemicals including derivatives of BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were examined for their abilities to interact with BC6ENTG .	False
In addition, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG .	False
In addition, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG .	False
BC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values.	CPR:4
In addition, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG .	False
In addition, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC were found to induce a Type I spectral change only with BC6ENTG .	False
A total of 68 chemicals including derivatives of BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER were examined for their abilities to interact with BC6ENTG .	False
BC6ENTC 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values.	CPR:9
BC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values.	CPR:4
BC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values.	CPR:4
BC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values.	CPR:4
A total of 68 chemicals including derivatives of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER were examined for their abilities to interact with BC6ENTG .	False
BC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values.	CPR:4
BC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values.	CPR:4
BC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values.	CPR:4
BC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values.	CPR:4
A total of 68 chemicals including derivatives of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER were examined for their abilities to interact with BC6ENTG .	False
BC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values.	CPR:4
BC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values.	CPR:4
BC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values.	CPR:4
BC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values.	CPR:4
BC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ; these chemicals induced Type I spectral changes with low Ks values.	CPR:4
A total of 68 chemicals including derivatives of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC were examined for their abilities to interact with BC6ENTG .	False
Fifty - one of these 68 chemicals induced stronger Type I binding spectra ( BC6ENTC low - to high - spin state shift) with BC6ENTG than those seen with BC6OTHER , i.e., the spectral binding intensities (ΔAmax / Ks ratio) determined with these chemicals were always higher for BC6OTHER .	False
Fifty - one of these 68 chemicals induced stronger Type I binding spectra ( BC6ENTC low - to high - spin state shift) with BC6OTHER than those seen with BC6ENTG , i.e., the spectral binding intensities (ΔAmax / Ks ratio) determined with these chemicals were always higher for BC6OTHER .	False
Fifty - one of these 68 chemicals induced stronger Type I binding spectra ( BC6ENTC low - to high - spin state shift) with BC6OTHER than those seen with BC6OTHER , i.e., the spectral binding intensities (ΔAmax / Ks ratio) determined with these chemicals were always higher for BC6ENTG .	False
In addition, BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG .	False
A total of 68 chemicals including derivatives of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were examined for their abilities to interact with BC6ENTG .	False
Inhibitors based on a BC6OTHER scaffold were discovered for BC6ENTC ( BC6OTHER ) desaturase 1 ( BC6ENTG ) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model.	False
Discovery of liver - targeted inhibitors of BC6ENTC desaturase ( BC6ENTG ).	False
Inhibitors based on a BC6OTHER scaffold were discovered for CHEM - CHEM ( BC6ENTC ) desaturase 1 ( BC6ENTG ) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model.	False
Inhibitors based on a BC6ENTC scaffold were discovered for CHEM - CHEM ( BC6OTHER ) desaturase 1 ( BC6ENTG ) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model.	CPR:4
Inhibitors based on a BC6ENTC scaffold were discovered for BC6ENTG ( BC6OTHER ) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model.	CPR:4
We have reported that BC6ENTG clones are sensitive to reactive BC6ENTC species (ROS) treatment by inducing autophagic cell death.	False
BC6ENTG is one of four major classes of BC6ENTC / BC6OTHER phosphatases.	False
BC6ENTG is one of four major classes of BC6OTHER / BC6ENTC phosphatases.	False
The BC6ENTG / BC6OTHER ratio increased and BC6OTHER expression decreased in MIN6 cells after BC6ENTC stimulation.	CPR:3
The BC6OTHER / BC6ENTG ratio increased and BC6OTHER expression decreased in MIN6 cells after BC6ENTC stimulation.	CPR:3
The BC6OTHER / BC6OTHER ratio increased and BC6ENTG expression decreased in MIN6 cells after BC6ENTC stimulation.	CPR:4
Additionally, treatment with BC6ENTC / BC6OTHER showed a higher BC6ENTG activity.	CPR:3
Additionally, treatment with BC6OTHER / BC6ENTC showed a higher BC6ENTG activity.	CPR:3
Effects of High BC6ENTC and BC6OTHER Concentrations over the Relative Expression of BC6ENTG , BC6OTHER , and BC6OTHER in MIN6 Cells.	False
Effects of High BC6ENTC and BC6OTHER Concentrations over the Relative Expression of BC6OTHER , BC6ENTG , and BC6OTHER in MIN6 Cells.	False
Effects of High BC6ENTC and BC6OTHER Concentrations over the Relative Expression of BC6OTHER , BC6OTHER , and BC6ENTG in MIN6 Cells.	False
Effects of High BC6OTHER and BC6ENTC Concentrations over the Relative Expression of BC6ENTG , BC6OTHER , and BC6OTHER in MIN6 Cells.	False
Effects of High BC6OTHER and BC6ENTC Concentrations over the Relative Expression of BC6OTHER , BC6ENTG , and BC6OTHER in MIN6 Cells.	False
Effects of High BC6OTHER and BC6ENTC Concentrations over the Relative Expression of BC6OTHER , BC6OTHER , and BC6ENTG in MIN6 Cells.	False
Our study revealed that high BC6ENTC / BC6OTHER concentrations in MIN6 cells induced an increase of the BC6ENTG / BC6OTHER ratio, an indicator of increased cell apoptosis.	CPR:3
Our study revealed that high BC6ENTC / BC6OTHER concentrations in MIN6 cells induced an increase of the BC6OTHER / BC6ENTG ratio, an indicator of increased cell apoptosis.	CPR:3
Our study revealed that high BC6OTHER / BC6ENTC concentrations in MIN6 cells induced an increase of the BC6ENTG / BC6OTHER ratio, an indicator of increased cell apoptosis.	CPR:3
Our study revealed that high BC6OTHER / BC6ENTC concentrations in MIN6 cells induced an increase of the BC6OTHER / BC6ENTG ratio, an indicator of increased cell apoptosis.	CPR:3
The purpose of this study was to describe the effect of different BC6ENTC and / or BC6OTHER concentrations over BC6ENTG , BC6OTHER , and BC6OTHER expressions in a β - pancreatic cell line (MIN6 cells).	False
The purpose of this study was to describe the effect of different BC6ENTC and / or BC6OTHER concentrations over BC6OTHER , BC6ENTG , and BC6OTHER expressions in a β - pancreatic cell line (MIN6 cells).	False
The purpose of this study was to describe the effect of different BC6ENTC and / or BC6OTHER concentrations over BC6OTHER , BC6OTHER , and BC6ENTG expressions in a β - pancreatic cell line (MIN6 cells).	False
The purpose of this study was to describe the effect of different BC6OTHER and / or BC6ENTC concentrations over BC6ENTG , BC6OTHER , and BC6OTHER expressions in a β - pancreatic cell line (MIN6 cells).	False
The purpose of this study was to describe the effect of different BC6OTHER and / or BC6ENTC concentrations over BC6OTHER , BC6ENTG , and BC6OTHER expressions in a β - pancreatic cell line (MIN6 cells).	False
The purpose of this study was to describe the effect of different BC6OTHER and / or BC6ENTC concentrations over BC6OTHER , BC6OTHER , and BC6ENTG expressions in a β - pancreatic cell line (MIN6 cells).	False
MIN6 cells were pre - incubated with different BC6ENTC and / or BC6OTHER concentrations, and the relative mRNA abundance of the BC6ENTG / BC6OTHER ratio and of BC6OTHER genes was measured by qRT - PCR.	False
MIN6 cells were pre - incubated with different BC6ENTC and / or BC6OTHER concentrations, and the relative mRNA abundance of the BC6OTHER / BC6ENTG ratio and of BC6OTHER genes was measured by qRT - PCR.	False
MIN6 cells were pre - incubated with different BC6ENTC and / or BC6OTHER concentrations, and the relative mRNA abundance of the BC6OTHER / BC6OTHER ratio and of BC6ENTG genes was measured by qRT - PCR.	False
MIN6 cells were pre - incubated with different BC6OTHER and / or BC6ENTC concentrations, and the relative mRNA abundance of the BC6ENTG / BC6OTHER ratio and of BC6OTHER genes was measured by qRT - PCR.	False
MIN6 cells were pre - incubated with different BC6OTHER and / or BC6ENTC concentrations, and the relative mRNA abundance of the BC6OTHER / BC6ENTG ratio and of BC6OTHER genes was measured by qRT - PCR.	False
MIN6 cells were pre - incubated with different BC6OTHER and / or BC6ENTC concentrations, and the relative mRNA abundance of the BC6OTHER / BC6OTHER ratio and of BC6ENTG genes was measured by qRT - PCR.	False
BC6ENTG ( BC6OTHER ) activity, BC6ENTC uptake, BC6OTHER dismutase activity, and BC6OTHER content were also determined.	False
BC6OTHER ( BC6ENTG ) activity, BC6ENTC uptake, BC6OTHER dismutase activity, and BC6OTHER content were also determined.	False
BC6OTHER ( BC6OTHER ) activity, BC6ENTC uptake, BC6ENTG activity, and BC6OTHER content were also determined.	False
BC6ENTG ( BC6OTHER ) activity, BC6OTHER uptake, BC6ENTC dismutase activity, and BC6OTHER content were also determined.	False
BC6OTHER ( BC6ENTG ) activity, BC6OTHER uptake, BC6ENTC dismutase activity, and BC6OTHER content were also determined.	False
BC6ENTG ( BC6OTHER ) activity, BC6OTHER uptake, BC6OTHER dismutase activity, and BC6ENTC content were also determined.	False
BC6OTHER ( BC6ENTG ) activity, BC6OTHER uptake, BC6OTHER dismutase activity, and BC6ENTC content were also determined.	False
BC6OTHER ( BC6OTHER ) activity, BC6OTHER uptake, BC6ENTG activity, and BC6ENTC content were also determined.	False
The L - type BC6OTHER channel ( BC6ENTG ) isoforms BC6OTHER and BC6OTHER display similar BC6OTHER ( BC6ENTC ) binding properties and are both expressed in mammalian brain.	False
The BC6ENTG ( BC6OTHER ) isoforms BC6OTHER and BC6OTHER display similar BC6OTHER ( BC6ENTC ) binding properties and are both expressed in mammalian brain.	False
The L - type BC6OTHER channel ( BC6OTHER ) isoforms BC6ENTG and BC6OTHER display similar BC6OTHER ( BC6ENTC ) binding properties and are both expressed in mammalian brain.	False
The L - type BC6OTHER channel ( BC6OTHER ) isoforms BC6OTHER and BC6ENTG display similar BC6OTHER ( BC6ENTC ) binding properties and are both expressed in mammalian brain.	False
The L - type BC6ENTC channel ( BC6ENTG ) isoforms BC6OTHER and BC6OTHER display similar BC6OTHER ( BC6OTHER ) binding properties and are both expressed in mammalian brain.	False
The L - type BC6ENTC channel ( BC6OTHER ) isoforms BC6ENTG and BC6OTHER display similar BC6OTHER ( BC6OTHER ) binding properties and are both expressed in mammalian brain.	False
The L - type BC6ENTC channel ( BC6OTHER ) isoforms BC6OTHER and BC6ENTG display similar BC6OTHER ( BC6OTHER ) binding properties and are both expressed in mammalian brain.	False
Inhibition of BC6ENTC binding to BC6ENTG DHP( - / - ) (predominantly BC6OTHER ) and wild - type (predominantly BC6OTHER ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6OTHER and BC6OTHER for the BC6OTHER binding pocket, a finding further confirmed with heterologously expressed channels.	False
Inhibition of BC6ENTC binding to BC6OTHER DHP( - / - ) (predominantly BC6ENTG ) and wild - type (predominantly BC6OTHER ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6OTHER and BC6OTHER for the BC6OTHER binding pocket, a finding further confirmed with heterologously expressed channels.	False
Inhibition of BC6ENTC binding to BC6OTHER DHP( - / - ) (predominantly BC6OTHER ) and wild - type (predominantly BC6ENTG ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6OTHER and BC6OTHER for the BC6OTHER binding pocket, a finding further confirmed with heterologously expressed channels.	False
Inhibition of BC6ENTC binding to BC6OTHER DHP( - / - ) (predominantly BC6OTHER ) and wild - type (predominantly BC6OTHER ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6OTHER and BC6OTHER for the BC6ENTG binding pocket, a finding further confirmed with heterologously expressed channels.	False
Inhibition of BC6OTHER binding to BC6ENTG DHP( - / - ) (predominantly BC6OTHER ) and wild - type (predominantly BC6OTHER ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6ENTC and BC6OTHER for the BC6OTHER binding pocket, a finding further confirmed with heterologously expressed channels.	False
Inhibition of BC6OTHER binding to BC6OTHER DHP( - / - ) (predominantly BC6ENTG ) and wild - type (predominantly BC6OTHER ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6ENTC and BC6OTHER for the BC6OTHER binding pocket, a finding further confirmed with heterologously expressed channels.	False
Inhibition of BC6OTHER binding to BC6OTHER DHP( - / - ) (predominantly BC6OTHER ) and wild - type (predominantly BC6ENTG ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6ENTC and BC6OTHER for the BC6OTHER binding pocket, a finding further confirmed with heterologously expressed channels.	False
Inhibition of BC6OTHER binding to BC6OTHER DHP( - / - ) (predominantly BC6OTHER ) and wild - type (predominantly BC6OTHER ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6ENTC and BC6OTHER for the BC6ENTG binding pocket, a finding further confirmed with heterologously expressed channels.	False
Inhibition of BC6OTHER binding to BC6ENTG DHP( - / - ) (predominantly BC6OTHER ) and wild - type (predominantly BC6OTHER ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6OTHER and BC6ENTC for the BC6OTHER binding pocket, a finding further confirmed with heterologously expressed channels.	False
Inhibition of BC6OTHER binding to BC6OTHER DHP( - / - ) (predominantly BC6ENTG ) and wild - type (predominantly BC6OTHER ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6OTHER and BC6ENTC for the BC6OTHER binding pocket, a finding further confirmed with heterologously expressed channels.	False
Inhibition of BC6OTHER binding to BC6OTHER DHP( - / - ) (predominantly BC6OTHER ) and wild - type (predominantly BC6ENTG ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6OTHER and BC6ENTC for the BC6OTHER binding pocket, a finding further confirmed with heterologously expressed channels.	False
Inhibition of BC6OTHER binding to BC6OTHER DHP( - / - ) (predominantly BC6OTHER ) and wild - type (predominantly BC6OTHER ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6OTHER and BC6ENTC for the BC6ENTG binding pocket, a finding further confirmed with heterologously expressed channels.	False
It is also unknown to what extent BC6ENTG and BC6OTHER contribute to L - type - specific BC6ENTC binding activity in brain.	False
It is also unknown to what extent BC6OTHER and BC6ENTG contribute to L - type - specific BC6ENTC binding activity in brain.	False
BC6ENTC binding to BC6ENTG DHP( - / - ) and BC6OTHER - DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that BC6OTHER accounts for 10.7% of brain BC6OTHER .	False
BC6ENTC binding to BC6OTHER DHP( - / - ) and BC6ENTG - DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that BC6OTHER accounts for 10.7% of brain BC6OTHER .	False
BC6ENTC binding to BC6OTHER DHP( - / - ) and BC6OTHER - DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that BC6ENTG accounts for 10.7% of brain BC6OTHER .	False
BC6ENTC binding to BC6OTHER DHP( - / - ) and BC6OTHER - DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that BC6OTHER accounts for 10.7% of brain BC6ENTG .	False
The L - type BC6OTHER channel ( BC6ENTG ) isoforms BC6OTHER and BC6OTHER display similar BC6ENTC ( BC6OTHER ) binding properties and are both expressed in mammalian brain.	False
The BC6ENTG ( BC6OTHER ) isoforms BC6OTHER and BC6OTHER display similar BC6ENTC ( BC6OTHER ) binding properties and are both expressed in mammalian brain.	False
The L - type BC6OTHER channel ( BC6OTHER ) isoforms BC6ENTG and BC6OTHER display similar BC6ENTC ( BC6OTHER ) binding properties and are both expressed in mammalian brain.	False
The L - type BC6OTHER channel ( BC6OTHER ) isoforms BC6OTHER and BC6ENTG display similar BC6ENTC ( BC6OTHER ) binding properties and are both expressed in mammalian brain.	False
Expression and BC6ENTC - binding properties of brain BC6ENTG isoforms.	False
BC6ENTG - mediated signaling also modulates the BC6ENTC response.	False
Anti - BC6ENTC (AEs) and BC6ENTG inhibitors (AIs) are used clinically to arrest the BC6OTHER - dependent growth of BC.	False
Anti - BC6OTHER (AEs) and BC6ENTG inhibitors (AIs) are used clinically to arrest the BC6ENTC - dependent growth of BC.	False
BC6ENTC effects are mediated not only through nuclear BC6ENTG but also through cytoplasmic / membrane BC6OTHER and BC6OTHER - coupled BC6OTHER .	False
BC6ENTC effects are mediated not only through nuclear BC6OTHER but also through cytoplasmic / membrane BC6ENTG and BC6OTHER - coupled BC6OTHER .	False
BC6ENTC effects are mediated not only through nuclear BC6OTHER but also through cytoplasmic / membrane BC6OTHER and BC6ENTG - coupled BC6OTHER .	False
BC6ENTC effects are mediated not only through nuclear BC6OTHER but also through cytoplasmic / membrane BC6OTHER and BC6OTHER - coupled BC6ENTG .	False
In breast cancer (BC) epithelial cells, the mitogenic action of BC6ENTC is transduced through binding to two receptors, BC6ENTG and BC6OTHER , which act as transcription factors.	False
In breast cancer (BC) epithelial cells, the mitogenic action of BC6ENTC is transduced through binding to two receptors, BC6OTHER and BC6ENTG , which act as transcription factors.	False
The partners of extra - nuclear BC6ENTG include BC6OTHER and the BC6ENTC kinase BC6OTHER .	False
The partners of extra - nuclear BC6OTHER include BC6ENTG and the BC6ENTC kinase BC6OTHER .	False
The partners of extra - nuclear BC6OTHER include BC6OTHER and the BC6ENTC kinase BC6ENTG .	False
Further investigation demonstrated that 8k reduced BC6ENTC - induced activation of mitochondrial apoptosis by inhibiting the expression of BC6ENTG and elevating the expression of BC6OTHER .	CPR:3
Further investigation demonstrated that 8k reduced BC6ENTC - induced activation of mitochondrial apoptosis by inhibiting the expression of BC6OTHER and elevating the expression of BC6ENTG .	CPR:4
To evaluate the BC6ENTG balance and enzymatic alterations induced by environmental pesticide exposure during pregnancy, this transversal study explored placentas derived from non - exposed women (control group - CG), and from women living in a rural area (rural group - RG), collected during intensive BC6ENTC (OP) pesticide spraying season (RG - SS) and during non - spraying season (RG - NSS).	False
BC6ENTG and BC6ENTC decarboxylase ( BC6OTHER ) enzymes were induced in syncytiotrophoblast and endothelial cells.	False
BC6OTHER and BC6ENTC decarboxylase ( BC6ENTG ) enzymes were induced in syncytiotrophoblast and endothelial cells.	False
Environmental pesticide exposure modulates BC6ENTG , BC6OTHER and BC6ENTC decarboxylase expression in human placenta.	False
Environmental pesticide exposure modulates BC6OTHER , BC6ENTG and BC6ENTC decarboxylase expression in human placenta.	False
In the present studies, the BC6ENTG inverse agonist BC6OTHER ( BC6OTHER ) and the BC6OTHER neutral antagonist BC6ENTC were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6OTHER .	False
In the present studies, the BC6OTHER inverse agonist BC6OTHER ( BC6OTHER ) and the BC6ENTG neutral antagonist BC6ENTC were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6OTHER .	CPR:6
In the present studies, the BC6OTHER inverse agonist BC6OTHER ( BC6OTHER ) and the BC6OTHER neutral antagonist BC6ENTC were compared for their ability to modify BC6ENTG - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6OTHER .	False
In the present studies, the BC6OTHER inverse agonist BC6OTHER ( BC6OTHER ) and the BC6OTHER neutral antagonist BC6ENTC were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6ENTG full agonist BC6OTHER .	False
In the present studies, the BC6ENTG inverse agonist BC6OTHER ( BC6OTHER ) and the BC6OTHER neutral antagonist BC6OTHER were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6ENTC .	False
In the present studies, the BC6OTHER inverse agonist BC6OTHER ( BC6OTHER ) and the BC6ENTG neutral antagonist BC6OTHER were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6ENTC .	False
In the present studies, the BC6OTHER inverse agonist BC6OTHER ( BC6OTHER ) and the BC6OTHER neutral antagonist BC6OTHER were compared for their ability to modify BC6ENTG - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6ENTC .	False
In the present studies, the BC6OTHER inverse agonist BC6OTHER ( BC6OTHER ) and the BC6OTHER neutral antagonist BC6OTHER were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6ENTG full agonist BC6ENTC .	CPR:5
Results indicate that BC6ENTC serves as an effective BC6ENTG discriminative stimulus, with an onset and time course of action comparable with that of the BC6OTHER agonist BC6OTHER , and that the inverse agonist BC6OTHER and the neutral antagonist BC6OTHER produce dose - related rightward shifts in the BC6OTHER dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6OTHER .	CPR:3
Results indicate that BC6ENTC serves as an effective BC6OTHER discriminative stimulus, with an onset and time course of action comparable with that of the BC6ENTG agonist BC6OTHER , and that the inverse agonist BC6OTHER and the neutral antagonist BC6OTHER produce dose - related rightward shifts in the BC6OTHER dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6OTHER .	False
Results indicate that BC6OTHER serves as an effective BC6ENTG discriminative stimulus, with an onset and time course of action comparable with that of the BC6OTHER agonist BC6ENTC , and that the inverse agonist BC6OTHER and the neutral antagonist BC6OTHER produce dose - related rightward shifts in the BC6OTHER dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6OTHER .	False
Results indicate that BC6OTHER serves as an effective BC6OTHER discriminative stimulus, with an onset and time course of action comparable with that of the BC6ENTG agonist BC6ENTC , and that the inverse agonist BC6OTHER and the neutral antagonist BC6OTHER produce dose - related rightward shifts in the BC6OTHER dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6OTHER .	CPR:5
Results indicate that BC6OTHER serves as an effective BC6ENTG discriminative stimulus, with an onset and time course of action comparable with that of the BC6OTHER agonist BC6OTHER , and that the inverse agonist BC6ENTC and the neutral antagonist BC6OTHER produce dose - related rightward shifts in the BC6OTHER dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6OTHER .	False
Results indicate that BC6OTHER serves as an effective BC6OTHER discriminative stimulus, with an onset and time course of action comparable with that of the BC6ENTG agonist BC6OTHER , and that the inverse agonist BC6ENTC and the neutral antagonist BC6OTHER produce dose - related rightward shifts in the BC6OTHER dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6OTHER .	CPR:5
 BC6ENTC discrimination and antagonism by BC6ENTG neutral and inverse agonist antagonists.	False
BC6ENTC receptor 1 ( BC6ENTG ) inverse agonists (e.g., BC6OTHER ) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications.	False
Results indicate that BC6OTHER serves as an effective BC6ENTG discriminative stimulus, with an onset and time course of action comparable with that of the BC6OTHER agonist BC6OTHER , and that the inverse agonist BC6OTHER and the neutral antagonist BC6ENTC produce dose - related rightward shifts in the BC6OTHER dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6OTHER .	False
Results indicate that BC6OTHER serves as an effective BC6OTHER discriminative stimulus, with an onset and time course of action comparable with that of the BC6ENTG agonist BC6OTHER , and that the inverse agonist BC6OTHER and the neutral antagonist BC6ENTC produce dose - related rightward shifts in the BC6OTHER dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6OTHER .	CPR:6
Results indicate that BC6OTHER serves as an effective BC6ENTG discriminative stimulus, with an onset and time course of action comparable with that of the BC6OTHER agonist BC6OTHER , and that the inverse agonist BC6OTHER and the neutral antagonist BC6OTHER produce dose - related rightward shifts in the BC6ENTC dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6OTHER .	False
Results indicate that BC6OTHER serves as an effective BC6OTHER discriminative stimulus, with an onset and time course of action comparable with that of the BC6ENTG agonist BC6OTHER , and that the inverse agonist BC6OTHER and the neutral antagonist BC6OTHER produce dose - related rightward shifts in the BC6ENTC dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6OTHER .	CPR:5
Results indicate that BC6OTHER serves as an effective BC6ENTG discriminative stimulus, with an onset and time course of action comparable with that of the BC6OTHER agonist BC6OTHER , and that the inverse agonist BC6OTHER and the neutral antagonist BC6OTHER produce dose - related rightward shifts in the BC6OTHER dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6ENTC .	False
Results indicate that BC6OTHER serves as an effective BC6OTHER discriminative stimulus, with an onset and time course of action comparable with that of the BC6ENTG agonist BC6OTHER , and that the inverse agonist BC6OTHER and the neutral antagonist BC6OTHER produce dose - related rightward shifts in the BC6OTHER dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6ENTC .	CPR:5
In the present studies, the BC6ENTG inverse agonist BC6ENTC ( BC6OTHER ) and the BC6OTHER neutral antagonist BC6OTHER were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6OTHER .	CPR:5
In the present studies, the BC6OTHER inverse agonist BC6ENTC ( BC6OTHER ) and the BC6ENTG neutral antagonist BC6OTHER were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6OTHER .	False
In the present studies, the BC6OTHER inverse agonist BC6ENTC ( BC6OTHER ) and the BC6OTHER neutral antagonist BC6OTHER were compared for their ability to modify BC6ENTG - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6OTHER .	False
In the present studies, the BC6OTHER inverse agonist BC6ENTC ( BC6OTHER ) and the BC6OTHER neutral antagonist BC6OTHER were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6ENTG full agonist BC6OTHER .	False
In the present studies, the BC6ENTG inverse agonist BC6OTHER ( BC6ENTC ) and the BC6OTHER neutral antagonist BC6OTHER were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6OTHER .	CPR:5
In the present studies, the BC6OTHER inverse agonist BC6OTHER ( BC6ENTC ) and the BC6ENTG neutral antagonist BC6OTHER were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6OTHER .	False
In the present studies, the BC6OTHER inverse agonist BC6OTHER ( BC6ENTC ) and the BC6OTHER neutral antagonist BC6OTHER were compared for their ability to modify BC6ENTG - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6OTHER .	False
In the present studies, the BC6OTHER inverse agonist BC6OTHER ( BC6ENTC ) and the BC6OTHER neutral antagonist BC6OTHER were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6ENTG full agonist BC6OTHER .	False
BC6ENTG ( BC6OTHER ) inverse agonists (e.g., BC6ENTC ) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications.	CPR:5
BC6OTHER receptor 1 ( BC6ENTG ) inverse agonists (e.g., BC6ENTC ) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications.	CPR:5
Several in vitro studies were conducted to evaluate the effect of BC6ENTC on 4 primary enzymes of the pathways of BC6OTHER metabolism, BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER .	False
Several in vitro studies were conducted to evaluate the effect of BC6ENTC on 4 primary enzymes of the pathways of BC6OTHER metabolism, BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER .	False
Several in vitro studies were conducted to evaluate the effect of BC6ENTC on 4 primary enzymes of the pathways of BC6OTHER metabolism, BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER .	False
Several in vitro studies were conducted to evaluate the effect of BC6ENTC on 4 primary enzymes of the pathways of BC6OTHER metabolism, BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG .	False
Several in vitro studies were conducted to evaluate the effect of BC6OTHER on 4 primary enzymes of the pathways of BC6ENTC metabolism, BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER .	False
Several in vitro studies were conducted to evaluate the effect of BC6OTHER on 4 primary enzymes of the pathways of BC6ENTC metabolism, BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER .	False
Several in vitro studies were conducted to evaluate the effect of BC6OTHER on 4 primary enzymes of the pathways of BC6ENTC metabolism, BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER .	False
Several in vitro studies were conducted to evaluate the effect of BC6OTHER on 4 primary enzymes of the pathways of BC6ENTC metabolism, BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG .	False
BC6ENTC inhibited both BC6ENTG and BC6OTHER with IC - 50 values of 43 microM and 227 microM, respectively.	CPR:4
BC6ENTC inhibited both BC6OTHER and BC6ENTG with IC - 50 values of 43 microM and 227 microM, respectively.	CPR:4
BC6ENTC also inhibited BC6ENTG with an IC - 50 of 43 microM.	CPR:4
The BC6ENTG was similarly inhibited by BC6ENTC with an IC - 50 of 61 microM.	CPR:4
Hence, BC6ENTC has the ability to inhibit both the BC6ENTG and BC6OTHER pathways of BC6OTHER metabolism with similar efficacy.	CPR:4
Hence, BC6ENTC has the ability to inhibit both the BC6OTHER and BC6ENTG pathways of BC6OTHER metabolism with similar efficacy.	CPR:4
Hence, BC6OTHER has the ability to inhibit both the BC6ENTG and BC6OTHER pathways of BC6ENTC metabolism with similar efficacy.	CPR:9
Hence, BC6OTHER has the ability to inhibit both the BC6OTHER and BC6ENTG pathways of BC6ENTC metabolism with similar efficacy.	CPR:9
In cell culture experiments, it was found that BC6ENTC inhibited BC6ENTG induced BC6OTHER production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations.	CPR:4
In cell culture experiments, it was found that BC6OTHER inhibited BC6ENTG induced BC6ENTC production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations.	CPR:9
The effect of a peripheral block on inflammation - induced BC6ENTC and BC6ENTG expression in rats.	False
Systemic BC6ENTC did not modify either the hyperalgesia and local inflammation or BC6ENTG expression.	False
BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord BC6ENTG ( BC6OTHER ), with a subsequent increase in central BC6ENTC ( BC6OTHER ) levels associated with the development of hyperalgesia.	CPR:9
BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord BC6OTHER ( BC6ENTG ), with a subsequent increase in central BC6ENTC ( BC6OTHER ) levels associated with the development of hyperalgesia.	CPR:9
BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord BC6ENTG ( BC6OTHER ), with a subsequent increase in central BC6OTHER ( BC6ENTC ) levels associated with the development of hyperalgesia.	CPR:9
BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord BC6OTHER ( BC6ENTG ), with a subsequent increase in central BC6OTHER ( BC6ENTC ) levels associated with the development of hyperalgesia.	CPR:9
In this study, we evaluated the effect of BC6ENTC administered via a nerve block or via a systemic route on the spinal expression of BC6OTHER and BC6ENTG in a model of peripheral inflammation in rats.	False
In this study, we evaluated the effect of BC6OTHER administered via a nerve block or via a systemic route on the spinal expression of BC6ENTC and BC6ENTG in a model of peripheral inflammation in rats.	False
Local edema, thermal, and mechanical hyperalgesia as well as cerebrospinal fluid BC6ENTC concentration and BC6ENTG and BC6OTHER expression in the spinal cord in dorsal root ganglions were measured.	False
Local edema, thermal, and mechanical hyperalgesia as well as cerebrospinal fluid BC6ENTC concentration and BC6OTHER and BC6ENTG expression in the spinal cord in dorsal root ganglions were measured.	False
Exchange protein directly activated by BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) are two intracellular receptors that mediate the effects of the prototypic second messenger BC6ENTC .	False
Exchange protein directly activated by BC6OTHER ( BC6OTHER ) and BC6OTHER - dependent protein kinase ( BC6ENTG ) are two intracellular receptors that mediate the effects of the prototypic second messenger BC6ENTC .	False
BC6ENTG ( BC6OTHER ) and BC6OTHER - dependent protein kinase ( BC6OTHER ) are two intracellular receptors that mediate the effects of the prototypic second messenger BC6ENTC .	False
Exchange protein directly activated by BC6OTHER ( BC6ENTG ) and BC6OTHER - dependent protein kinase ( BC6OTHER ) are two intracellular receptors that mediate the effects of the prototypic second messenger BC6ENTC .	False
Herein, we report the identification and characterization of BC6ENTC ( BC6OTHER ), a novel noncyclic BC6OTHER BC6ENTG antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells.	CPR:6
Herein, we report the identification and characterization of BC6ENTC ( BC6OTHER ), a novel noncyclic BC6OTHER BC6OTHER antagonist that is capable of specifically blocking intracellular BC6ENTG - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells.	CPR:4
Herein, we report the identification and characterization of BC6ENTC ( BC6OTHER ), a novel noncyclic BC6OTHER BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6ENTG activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells.	CPR:4
Herein, we report the identification and characterization of BC6ENTC ( BC6OTHER ), a novel noncyclic BC6OTHER BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6ENTG phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells.	CPR:4
Herein, we report the identification and characterization of BC6ENTC ( BC6OTHER ), a novel noncyclic BC6OTHER BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6ENTG - mediated BC6OTHER secretion in pancreatic β cells.	CPR:4
Herein, we report the identification and characterization of BC6ENTC ( BC6OTHER ), a novel noncyclic BC6OTHER BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6ENTG secretion in pancreatic β cells.	CPR:4
Exchange protein directly activated by BC6ENTC ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) are two intracellular receptors that mediate the effects of the prototypic second messenger BC6OTHER .	False
Exchange protein directly activated by BC6ENTC ( BC6OTHER ) and BC6OTHER - dependent protein kinase ( BC6ENTG ) are two intracellular receptors that mediate the effects of the prototypic second messenger BC6OTHER .	False
Exchange protein directly activated by BC6ENTC ( BC6ENTG ) and BC6OTHER - dependent protein kinase ( BC6OTHER ) are two intracellular receptors that mediate the effects of the prototypic second messenger BC6OTHER .	False
Herein, we report the identification and characterization of BC6OTHER ( BC6ENTC ), a novel noncyclic BC6OTHER BC6ENTG antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells.	CPR:6
Herein, we report the identification and characterization of BC6OTHER ( BC6ENTC ), a novel noncyclic BC6OTHER BC6OTHER antagonist that is capable of specifically blocking intracellular BC6ENTG - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells.	CPR:4
Herein, we report the identification and characterization of BC6OTHER ( BC6ENTC ), a novel noncyclic BC6OTHER BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6ENTG activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells.	CPR:4
Herein, we report the identification and characterization of BC6OTHER ( BC6ENTC ), a novel noncyclic BC6OTHER BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6ENTG phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells.	CPR:4
Herein, we report the identification and characterization of BC6OTHER ( BC6ENTC ), a novel noncyclic BC6OTHER BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6ENTG - mediated BC6OTHER secretion in pancreatic β cells.	CPR:4
Herein, we report the identification and characterization of BC6OTHER ( BC6ENTC ), a novel noncyclic BC6OTHER BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6ENTG secretion in pancreatic β cells.	CPR:4
Herein, we report the identification and characterization of BC6OTHER ( BC6OTHER ), a novel noncyclic BC6ENTC BC6ENTG antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells.	CPR:6
Herein, we report the identification and characterization of BC6OTHER ( BC6OTHER ), a novel noncyclic BC6ENTC BC6OTHER antagonist that is capable of specifically blocking intracellular BC6ENTG - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells.	CPR:4
Herein, we report the identification and characterization of BC6OTHER ( BC6OTHER ), a novel noncyclic BC6ENTC BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6ENTG activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells.	CPR:4
Herein, we report the identification and characterization of BC6OTHER ( BC6OTHER ), a novel noncyclic BC6ENTC BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6ENTG phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells.	CPR:4
Herein, we report the identification and characterization of BC6OTHER ( BC6OTHER ), a novel noncyclic BC6ENTC BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6ENTG - mediated BC6OTHER secretion in pancreatic β cells.	CPR:4
Herein, we report the identification and characterization of BC6OTHER ( BC6OTHER ), a novel noncyclic BC6ENTC BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6ENTG secretion in pancreatic β cells.	CPR:4
Exchange protein directly activated by BC6OTHER ( BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6ENTG ) are two intracellular receptors that mediate the effects of the prototypic second messenger BC6OTHER .	False
BC6ENTG ( BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) are two intracellular receptors that mediate the effects of the prototypic second messenger BC6OTHER .	False
Exchange protein directly activated by BC6OTHER ( BC6ENTG ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) are two intracellular receptors that mediate the effects of the prototypic second messenger BC6OTHER .	False
We examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6OTHER , BC6OTHER ( BC6ENTC ) a BC6OTHER , and BC6OTHER a BC6OTHER , modulate expression of BC6ENTG ( BC6OTHER ), an enzyme pivotal to skin inflammation and reparation.	False
We examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6OTHER , BC6OTHER ( BC6ENTC ) a BC6OTHER , and BC6OTHER a BC6OTHER , modulate expression of BC6OTHER ( BC6ENTG ), an enzyme pivotal to skin inflammation and reparation.	False
We examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6OTHER , BC6OTHER ( BC6OTHER ) a BC6ENTC , and BC6OTHER a BC6OTHER , modulate expression of BC6ENTG ( BC6OTHER ), an enzyme pivotal to skin inflammation and reparation.	False
We examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6OTHER , BC6OTHER ( BC6OTHER ) a BC6ENTC , and BC6OTHER a BC6OTHER , modulate expression of BC6OTHER ( BC6ENTG ), an enzyme pivotal to skin inflammation and reparation.	False
We examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6OTHER , BC6OTHER ( BC6OTHER ) a BC6OTHER , and BC6ENTC a BC6OTHER , modulate expression of BC6ENTG ( BC6OTHER ), an enzyme pivotal to skin inflammation and reparation.	False
We examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6OTHER , BC6OTHER ( BC6OTHER ) a BC6OTHER , and BC6ENTC a BC6OTHER , modulate expression of BC6OTHER ( BC6ENTG ), an enzyme pivotal to skin inflammation and reparation.	False
We examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6OTHER , BC6OTHER ( BC6OTHER ) a BC6OTHER , and BC6OTHER a BC6ENTC , modulate expression of BC6ENTG ( BC6OTHER ), an enzyme pivotal to skin inflammation and reparation.	False
We examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6OTHER , BC6OTHER ( BC6OTHER ) a BC6OTHER , and BC6OTHER a BC6ENTC , modulate expression of BC6OTHER ( BC6ENTG ), an enzyme pivotal to skin inflammation and reparation.	False
We demonstrate that only treatment of HaCaT with BC6ENTC and BC6OTHER or a BC6ENTG ligand ( BC6OTHER ), induced BC6OTHER expression (protein and mRNA).	False
We demonstrate that only treatment of HaCaT with BC6ENTC and BC6OTHER or a BC6OTHER ligand ( BC6OTHER ), induced BC6ENTG expression (protein and mRNA).	CPR:3
We demonstrate that only treatment of HaCaT with BC6OTHER and BC6ENTC or a BC6ENTG ligand ( BC6OTHER ), induced BC6OTHER expression (protein and mRNA).	False
We demonstrate that only treatment of HaCaT with BC6OTHER and BC6ENTC or a BC6OTHER ligand ( BC6OTHER ), induced BC6ENTG expression (protein and mRNA).	CPR:3
We demonstrate that only treatment of HaCaT with BC6OTHER and BC6OTHER or a BC6ENTG ligand ( BC6ENTC ), induced BC6OTHER expression (protein and mRNA).	False
We demonstrate that only treatment of HaCaT with BC6OTHER and BC6OTHER or a BC6OTHER ligand ( BC6ENTC ), induced BC6ENTG expression (protein and mRNA).	CPR:3
Moreover stimulation of BC6ENTG activity was increased by those BC6ENTC or BC6OTHER .	CPR:3
Moreover stimulation of BC6ENTG activity was increased by those BC6OTHER or BC6ENTC .	CPR:3
The inhibitory effects of BC6ENTC and BC6OTHER ( BC6ENTG antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6OTHER suggest that BC6OTHER is implicated in BC6OTHER induction.	CPR:6
The inhibitory effects of BC6ENTC and BC6OTHER ( BC6OTHER antagonists), on BC6ENTG expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6OTHER suggest that BC6OTHER is implicated in BC6OTHER induction.	False
The inhibitory effects of BC6ENTC and BC6OTHER ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6ENTG activity by BC6OTHER and BC6OTHER suggest that BC6OTHER is implicated in BC6OTHER induction.	False
The inhibitory effects of BC6ENTC and BC6OTHER ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6OTHER suggest that BC6ENTG is implicated in BC6OTHER induction.	False
The inhibitory effects of BC6ENTC and BC6OTHER ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6OTHER suggest that BC6OTHER is implicated in BC6ENTG induction.	False
The inhibitory effects of BC6OTHER and BC6ENTC ( BC6ENTG antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6OTHER suggest that BC6OTHER is implicated in BC6OTHER induction.	CPR:6
The inhibitory effects of BC6OTHER and BC6ENTC ( BC6OTHER antagonists), on BC6ENTG expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6OTHER suggest that BC6OTHER is implicated in BC6OTHER induction.	False
The inhibitory effects of BC6OTHER and BC6ENTC ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6ENTG activity by BC6OTHER and BC6OTHER suggest that BC6OTHER is implicated in BC6OTHER induction.	False
The inhibitory effects of BC6OTHER and BC6ENTC ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6OTHER suggest that BC6ENTG is implicated in BC6OTHER induction.	False
The inhibitory effects of BC6OTHER and BC6ENTC ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6OTHER suggest that BC6OTHER is implicated in BC6ENTG induction.	False
The inhibitory effects of BC6OTHER and BC6OTHER ( BC6ENTG antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6ENTC and BC6OTHER suggest that BC6OTHER is implicated in BC6OTHER induction.	False
The inhibitory effects of BC6OTHER and BC6OTHER ( BC6OTHER antagonists), on BC6ENTG expression and on stimulation of BC6OTHER activity by BC6ENTC and BC6OTHER suggest that BC6OTHER is implicated in BC6OTHER induction.	False
The inhibitory effects of BC6OTHER and BC6OTHER ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6ENTG activity by BC6ENTC and BC6OTHER suggest that BC6OTHER is implicated in BC6OTHER induction.	False
The inhibitory effects of BC6OTHER and BC6OTHER ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6ENTC and BC6OTHER suggest that BC6ENTG is implicated in BC6OTHER induction.	False
The inhibitory effects of BC6OTHER and BC6OTHER ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6ENTC and BC6OTHER suggest that BC6OTHER is implicated in BC6ENTG induction.	False
The inhibitory effects of BC6OTHER and BC6OTHER ( BC6ENTG antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6ENTC suggest that BC6OTHER is implicated in BC6OTHER induction.	False
The inhibitory effects of BC6OTHER and BC6OTHER ( BC6OTHER antagonists), on BC6ENTG expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6ENTC suggest that BC6OTHER is implicated in BC6OTHER induction.	False
The inhibitory effects of BC6OTHER and BC6OTHER ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6ENTG activity by BC6OTHER and BC6ENTC suggest that BC6OTHER is implicated in BC6OTHER induction.	False
The inhibitory effects of BC6OTHER and BC6OTHER ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6ENTC suggest that BC6ENTG is implicated in BC6OTHER induction.	False
The inhibitory effects of BC6OTHER and BC6OTHER ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6ENTC suggest that BC6OTHER is implicated in BC6ENTG induction.	False
Finally, BC6OTHER inhibitor CHEM BC6ENTC blocked the BC6OTHER effects on BC6OTHER induction, promoter activity and BC6OTHER mobilization suggesting involvement of BC6OTHER metabolites in BC6ENTG activation.	False
Finally, BC6ENTG inhibitor CHEM BC6ENTC blocked the BC6OTHER effects on BC6OTHER induction, promoter activity and BC6OTHER mobilization suggesting involvement of BC6OTHER metabolites in BC6OTHER activation.	CPR:4
Finally, BC6OTHER inhibitor CHEM BC6ENTC blocked the BC6OTHER effects on BC6ENTG induction, promoter activity and BC6OTHER mobilization suggesting involvement of BC6OTHER metabolites in BC6OTHER activation.	CPR:4
Finally, BC6OTHER inhibitor CHEM BC6OTHER blocked the BC6ENTC effects on BC6OTHER induction, promoter activity and BC6OTHER mobilization suggesting involvement of BC6OTHER metabolites in BC6ENTG activation.	False
Finally, BC6ENTG inhibitor CHEM BC6OTHER blocked the BC6ENTC effects on BC6OTHER induction, promoter activity and BC6OTHER mobilization suggesting involvement of BC6OTHER metabolites in BC6OTHER activation.	False
Finally, BC6OTHER inhibitor CHEM BC6OTHER blocked the BC6ENTC effects on BC6ENTG induction, promoter activity and BC6OTHER mobilization suggesting involvement of BC6OTHER metabolites in BC6OTHER activation.	False
Finally, BC6OTHER inhibitor CHEM BC6OTHER blocked the BC6OTHER effects on BC6OTHER induction, promoter activity and BC6ENTC mobilization suggesting involvement of BC6OTHER metabolites in BC6ENTG activation.	False
Finally, BC6ENTG inhibitor CHEM BC6OTHER blocked the BC6OTHER effects on BC6OTHER induction, promoter activity and BC6ENTC mobilization suggesting involvement of BC6OTHER metabolites in BC6OTHER activation.	False
Finally, BC6OTHER inhibitor CHEM BC6OTHER blocked the BC6OTHER effects on BC6ENTG induction, promoter activity and BC6ENTC mobilization suggesting involvement of BC6OTHER metabolites in BC6OTHER activation.	False
 BC6ENTC induce the expression of BC6ENTG via BC6OTHER activation in human keratinocyte HaCaT cells.	CPR:3
 BC6ENTC induce the expression of BC6OTHER via BC6ENTG activation in human keratinocyte HaCaT cells.	CPR:3
Finally, BC6OTHER inhibitor CHEM BC6OTHER blocked the BC6OTHER effects on BC6OTHER induction, promoter activity and BC6OTHER mobilization suggesting involvement of BC6ENTC metabolites in BC6ENTG activation.	CPR:3
Finally, BC6ENTG inhibitor CHEM BC6OTHER blocked the BC6OTHER effects on BC6OTHER induction, promoter activity and BC6OTHER mobilization suggesting involvement of BC6ENTC metabolites in BC6OTHER activation.	False
Finally, BC6OTHER inhibitor CHEM BC6OTHER blocked the BC6OTHER effects on BC6ENTG induction, promoter activity and BC6OTHER mobilization suggesting involvement of BC6ENTC metabolites in BC6OTHER activation.	False
These findings demonstrate that BC6ENTC increased BC6ENTG activity is necessary for the BC6OTHER induction in HaCaT human keratinocyte cells.	CPR:3
These findings demonstrate that BC6ENTC increased BC6OTHER activity is necessary for the BC6ENTG induction in HaCaT human keratinocyte cells.	CPR:3
Given the anti - inflammatory properties of BC6ENTC , we suggest that induction of BC6ENTG in keratinocytes may be important in the anti - inflammatory and protective mechanism of action of BC6OTHER or n - 6.	False
Given the anti - inflammatory properties of BC6OTHER , we suggest that induction of BC6ENTG in keratinocytes may be important in the anti - inflammatory and protective mechanism of action of BC6ENTC or n - 6.	CPR:3
We examined in HaCaT keratinocyte cell line whether BC6ENTC ( BC6OTHER ) a BC6OTHER , BC6OTHER ( BC6OTHER ) a BC6OTHER , and BC6OTHER a BC6OTHER , modulate expression of BC6ENTG ( BC6OTHER ), an enzyme pivotal to skin inflammation and reparation.	False
We examined in HaCaT keratinocyte cell line whether BC6ENTC ( BC6OTHER ) a BC6OTHER , BC6OTHER ( BC6OTHER ) a BC6OTHER , and BC6OTHER a BC6OTHER , modulate expression of BC6OTHER ( BC6ENTG ), an enzyme pivotal to skin inflammation and reparation.	False
We examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6ENTC ) a BC6OTHER , BC6OTHER ( BC6OTHER ) a BC6OTHER , and BC6OTHER a BC6OTHER , modulate expression of BC6ENTG ( BC6OTHER ), an enzyme pivotal to skin inflammation and reparation.	False
We examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6ENTC ) a BC6OTHER , BC6OTHER ( BC6OTHER ) a BC6OTHER , and BC6OTHER a BC6OTHER , modulate expression of BC6OTHER ( BC6ENTG ), an enzyme pivotal to skin inflammation and reparation.	False
We examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6ENTC , BC6OTHER ( BC6OTHER ) a BC6OTHER , and BC6OTHER a BC6OTHER , modulate expression of BC6ENTG ( BC6OTHER ), an enzyme pivotal to skin inflammation and reparation.	False
We examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6ENTC , BC6OTHER ( BC6OTHER ) a BC6OTHER , and BC6OTHER a BC6OTHER , modulate expression of BC6OTHER ( BC6ENTG ), an enzyme pivotal to skin inflammation and reparation.	False
We examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6OTHER , BC6ENTC ( BC6OTHER ) a BC6OTHER , and BC6OTHER a BC6OTHER , modulate expression of BC6ENTG ( BC6OTHER ), an enzyme pivotal to skin inflammation and reparation.	False
We examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6OTHER , BC6ENTC ( BC6OTHER ) a BC6OTHER , and BC6OTHER a BC6OTHER , modulate expression of BC6OTHER ( BC6ENTG ), an enzyme pivotal to skin inflammation and reparation.	False
Here, we report that the transcription factor BC6ENTG ( BC6OTHER ) is essential for coupling BC6ENTC to BC6OTHER inhibition and subsequent neurite growth promotion in neurons.	False
Here, we report that the transcription factor BC6OTHER ( BC6ENTG ) is essential for coupling BC6ENTC to BC6OTHER inhibition and subsequent neurite growth promotion in neurons.	False
Here, we report that the transcription factor BC6OTHER ( BC6OTHER ) is essential for coupling BC6ENTC to BC6ENTG inhibition and subsequent neurite growth promotion in neurons.	CPR:4
BC6ENTC activates BC6ENTG in neuron - like PC12 and B104 cells.	CPR:3
A molecular mechanism for BC6ENTC - mediated BC6ENTG inhibition in neurons.	CPR:4
BC6ENTC is a nonsteroidal anti - inflammatory drug widely used to relieve pain and inflammation in many disorders via inhibition of BC6ENTG .	CPR:4
Activation of BC6OTHER with traditional agonists mimics the BC6ENTG - inhibiting properties of BC6ENTC in PC12 cells and, like BC6OTHER , promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors.	CPR:4
Activation of BC6ENTG with traditional agonists mimics the BC6OTHER - inhibiting properties of BC6ENTC in PC12 cells and, like BC6OTHER , promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors.	False
Activation of BC6OTHER with traditional agonists mimics the BC6ENTG - inhibiting properties of BC6OTHER in PC12 cells and, like BC6ENTC , promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors.	False
Activation of BC6ENTG with traditional agonists mimics the BC6OTHER - inhibiting properties of BC6OTHER in PC12 cells and, like BC6ENTC , promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors.	False
Moreover, the effect of BC6ENTC on BC6ENTG activity and neurite growth in neuronal cultures is prevented by selective BC6OTHER inhibition.	False
Moreover, the effect of BC6ENTC on BC6OTHER activity and neurite growth in neuronal cultures is prevented by selective BC6ENTG inhibition.	False
These findings support that BC6ENTG plays an essential role in mediating the BC6OTHER - inhibiting effect of BC6ENTC .	False
These findings support that BC6OTHER plays an essential role in mediating the BC6ENTG - inhibiting effect of BC6ENTC .	CPR:4
Elucidation of the novel molecular mechanisms linking BC6ENTC to BC6ENTG inhibition may provide additional therapeutic targets to the disorders characterized by BC6OTHER activation, including spinal cord injuries and Alzheimer's disease.	CPR:4
Elucidation of the novel molecular mechanisms linking BC6ENTC to BC6OTHER inhibition may provide additional therapeutic targets to the disorders characterized by BC6ENTG activation, including spinal cord injuries and Alzheimer's disease.	False
Recently, we have demonstrated that BC6ENTC inhibits intracellular signaling of BC6ENTG and promotes significant axonal growth and functional recovery following spinal cord lesions in rodents.	CPR:4
In addition, another study suggests that BC6ENTC reduces generation of BC6ENTG peptide via inactivation of BC6OTHER signaling, although it may also regulate BC6OTHER formation by direct inhibition of the BC6OTHER .	CPR:4
In addition, another study suggests that BC6ENTC reduces generation of BC6OTHER peptide via inactivation of BC6ENTG signaling, although it may also regulate BC6OTHER formation by direct inhibition of the BC6OTHER .	CPR:4
In addition, another study suggests that BC6ENTC reduces generation of BC6OTHER peptide via inactivation of BC6OTHER signaling, although it may also regulate BC6ENTG formation by direct inhibition of the BC6OTHER .	CPR:3
In addition, another study suggests that BC6ENTC reduces generation of BC6OTHER peptide via inactivation of BC6OTHER signaling, although it may also regulate BC6OTHER formation by direct inhibition of the BC6ENTG .	CPR:4
The molecular mechanisms by which BC6ENTC inhibits the BC6ENTG signal in neurons, however, remain unclear.	CPR:4
BC6OTHER ( BC6ENTC , BC6OTHER ) is a novel antiallergic / BC6ENTG antagonistic drug that was synthesized and evaluated in our laboratories.	CPR:6
BC6OTHER ( BC6OTHER , BC6ENTC ) is a novel antiallergic / BC6ENTG antagonistic drug that was synthesized and evaluated in our laboratories.	CPR:6
BC6ENTC is a selective BC6ENTG antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as BC6OTHER and BC6OTHER from human polymorphonuclear leukocytes and eosinophils.	CPR:6
BC6OTHER is a selective BC6ENTG antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as BC6ENTC and BC6OTHER from human polymorphonuclear leukocytes and eosinophils.	False
BC6OTHER is a selective BC6ENTG antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as BC6OTHER and BC6ENTC from human polymorphonuclear leukocytes and eosinophils.	False
BC6ENTC exerted no significant effects on action potential duration in isolated guinea pig ventricular myocytes, myocardium and BC6ENTG .	False
BC6ENTC ( BC6OTHER , BC6OTHER ) is a novel antiallergic / BC6ENTG antagonistic drug that was synthesized and evaluated in our laboratories.	CPR:6
This study compared the sedative profiles of the second - generation BC6ENTC , BC6OTHER and BC6OTHER , using 3 different criteria: subjective sleepiness evaluated by the Stanford Sleepiness Scale, objective psychomotor tests (simple and choice reaction time tests and visual discrimination tests at 4 different exposure durations), and measurement of BC6ENTG occupancy (H1RO) in the brain.	False
This study compared the sedative profiles of the second - generation BC6OTHER , BC6ENTC and BC6OTHER , using 3 different criteria: subjective sleepiness evaluated by the Stanford Sleepiness Scale, objective psychomotor tests (simple and choice reaction time tests and visual discrimination tests at 4 different exposure durations), and measurement of BC6ENTG occupancy (H1RO) in the brain.	False
This study compared the sedative profiles of the second - generation BC6OTHER , BC6OTHER and BC6ENTC , using 3 different criteria: subjective sleepiness evaluated by the Stanford Sleepiness Scale, objective psychomotor tests (simple and choice reaction time tests and visual discrimination tests at 4 different exposure durations), and measurement of BC6ENTG occupancy (H1RO) in the brain.	False
BC6ENTG ( BC6OTHER ) antagonists, or BC6ENTC , often induce sedative side effects when used for the treatment of allergic disorders.	CPR:6
BC6OTHER ( BC6ENTG ) antagonists, or BC6ENTC , often induce sedative side effects when used for the treatment of allergic disorders.	CPR:6
BC6ENTC H1 - receptor ( BC6ENTG ) antagonists, or BC6OTHER , often induce sedative side effects when used for the treatment of allergic disorders.	False
Central effects of BC6OTHER and BC6OTHER : measurement of psychomotor performance, subjective sleepiness, and brain BC6ENTG occupancy using BC6ENTC positron emission tomography.	False
Central effects of BC6ENTC and BC6OTHER : measurement of psychomotor performance, subjective sleepiness, and brain BC6ENTG occupancy using BC6OTHER positron emission tomography.	False
Central effects of BC6OTHER and BC6ENTC : measurement of psychomotor performance, subjective sleepiness, and brain BC6ENTG occupancy using BC6OTHER positron emission tomography.	False
 These data directly demonstrate that BC6ENTG is the major BC6ENTC uptake mechanism across the basolateral membrane of acinar cells and is critical for driving saliva secretion in vivo.	CPR:9
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of BC6ENTC / BC6OTHER / BC6OTHER cotransporter isoform 1 ( BC6ENTG ), the gene encoding the salivary CHEM / BC6OTHER / BC6OTHER cotransporter.	False
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of BC6ENTC / BC6OTHER / BC6OTHER cotransporter isoform 1 ( BC6OTHER ), the gene encoding the salivary BC6ENTG BC6OTHER cotransporter.	False
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of CHEM / BC6ENTC / BC6OTHER cotransporter isoform 1 ( BC6ENTG ), the gene encoding the salivary CHEM / BC6OTHER / BC6OTHER cotransporter.	False
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of CHEM / BC6ENTC / BC6OTHER cotransporter isoform 1 ( BC6OTHER ), the gene encoding the salivary BC6ENTG BC6OTHER cotransporter.	False
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of BC6ENTG BC6ENTC cotransporter isoform 1 ( BC6OTHER ), the gene encoding the salivary CHEM / BC6OTHER / BC6OTHER cotransporter.	False
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of CHEM / BC6OTHER / BC6ENTC cotransporter isoform 1 ( BC6ENTG ), the gene encoding the salivary CHEM / BC6OTHER / BC6OTHER cotransporter.	False
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of CHEM / BC6OTHER / BC6ENTC cotransporter isoform 1 ( BC6OTHER ), the gene encoding the salivary BC6ENTG BC6OTHER cotransporter.	False
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of BC6ENTG BC6OTHER cotransporter isoform 1 ( BC6OTHER ), the gene encoding the salivary BC6ENTC / BC6OTHER / BC6OTHER cotransporter.	False
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of CHEM / BC6OTHER / BC6OTHER cotransporter isoform 1 ( BC6ENTG ), the gene encoding the salivary BC6ENTC / BC6OTHER / BC6OTHER cotransporter.	False
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of BC6ENTG BC6OTHER cotransporter isoform 1 ( BC6OTHER ), the gene encoding the salivary CHEM / BC6ENTC / BC6OTHER cotransporter.	False
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of CHEM / BC6OTHER / BC6OTHER cotransporter isoform 1 ( BC6ENTG ), the gene encoding the salivary CHEM / BC6ENTC / BC6OTHER cotransporter.	False
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of BC6ENTG BC6OTHER cotransporter isoform 1 ( BC6OTHER ), the gene encoding the salivary CHEM / BC6OTHER / BC6ENTC cotransporter.	False
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of CHEM / BC6OTHER / BC6OTHER cotransporter isoform 1 ( BC6ENTG ), the gene encoding the salivary CHEM / BC6OTHER / BC6ENTC cotransporter.	False
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of CHEM / BC6OTHER / BC6OTHER cotransporter isoform 1 ( BC6OTHER ), the gene encoding the salivary BC6ENTG BC6ENTC cotransporter.	False
The salivary fluid secretory mechanism is thought to require BC6ENTG BC6ENTC cotransporter - mediated BC6OTHER uptake.	False
The salivary fluid secretory mechanism is thought to require BC6ENTG BC6OTHER cotransporter - mediated BC6ENTC uptake.	CPR:9
Consistent with defective BC6ENTC uptake, a loss of BC6OTHER - sensitive BC6OTHER influx was observed in parotid acinar cells from mice lacking BC6ENTG .	False
Consistent with defective BC6OTHER uptake, a loss of BC6ENTC - sensitive BC6OTHER influx was observed in parotid acinar cells from mice lacking BC6ENTG .	False
Consistent with defective BC6OTHER uptake, a loss of BC6OTHER - sensitive BC6ENTC influx was observed in parotid acinar cells from mice lacking BC6ENTG .	False
BC6ENTC / BC6OTHER exchanger activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking BC6ENTG is associated with anion exchanger - dependent BC6OTHER uptake.	False
Cl( - ) / BC6ENTC exchanger activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking BC6ENTG is associated with anion exchanger - dependent BC6OTHER uptake.	False
Severe impairment of salivation in BC6ENTC / BC6OTHER / BC6OTHER cotransporter ( BC6ENTG ) - deficient mice.	False
Severe impairment of salivation in CHEM / BC6ENTC / BC6OTHER cotransporter ( BC6ENTG ) - deficient mice.	False
Severe impairment of salivation in BC6ENTG BC6ENTC cotransporter ( BC6OTHER ) - deficient mice.	False
Severe impairment of salivation in CHEM / BC6OTHER / BC6ENTC cotransporter ( BC6ENTG ) - deficient mice.	False
Cl( - ) / BC6OTHER exchanger activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking BC6ENTG is associated with anion exchanger - dependent BC6ENTC uptake.	False
BC6ENTG activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking BC6OTHER is associated with anion exchanger - dependent BC6ENTC uptake.	False
Indeed, expression of the BC6ENTC / BC6OTHER exchanger BC6ENTG was enhanced suggesting that this transporter compensates for the loss of functional BC6OTHER / BC6OTHER / BC6OTHER cotransporter.	False
Indeed, expression of the BC6ENTC / BC6OTHER exchanger BC6OTHER was enhanced suggesting that this transporter compensates for the loss of functional BC6ENTG BC6OTHER cotransporter.	False
Indeed, expression of the BC6OTHER / BC6ENTC exchanger BC6ENTG was enhanced suggesting that this transporter compensates for the loss of functional BC6OTHER / BC6OTHER / BC6OTHER cotransporter.	False
Indeed, expression of the BC6OTHER / BC6ENTC exchanger BC6OTHER was enhanced suggesting that this transporter compensates for the loss of functional BC6ENTG BC6OTHER cotransporter.	False
Indeed, expression of the BC6ENTG BC6OTHER was enhanced suggesting that this transporter compensates for the loss of functional BC6ENTC / BC6OTHER / BC6OTHER cotransporter.	False
Indeed, expression of the BC6OTHER / BC6OTHER exchanger BC6ENTG was enhanced suggesting that this transporter compensates for the loss of functional BC6ENTC / BC6OTHER / BC6OTHER cotransporter.	False
Indeed, expression of the BC6ENTG BC6OTHER was enhanced suggesting that this transporter compensates for the loss of functional BC6OTHER / BC6ENTC / BC6OTHER cotransporter.	False
Indeed, expression of the BC6OTHER / BC6OTHER exchanger BC6ENTG was enhanced suggesting that this transporter compensates for the loss of functional BC6OTHER / BC6ENTC / BC6OTHER cotransporter.	False
Indeed, expression of the BC6ENTG BC6OTHER was enhanced suggesting that this transporter compensates for the loss of functional BC6OTHER / BC6OTHER / BC6ENTC cotransporter.	False
Indeed, expression of the BC6OTHER / BC6OTHER exchanger BC6ENTG was enhanced suggesting that this transporter compensates for the loss of functional BC6OTHER / BC6OTHER / BC6ENTC cotransporter.	False
Indeed, expression of the BC6OTHER / BC6OTHER exchanger BC6OTHER was enhanced suggesting that this transporter compensates for the loss of functional BC6ENTG BC6ENTC cotransporter.	False
Furthermore, the ability of the parotid gland to conserve BC6ENTC was abolished in BC6ENTG - deficient mice.	False
We examined the effect of the highly lipophilic CHEM, BC6OTHER ( BC6OTHER ), in causing (1) inhibition of nuclear translocation of BC6ENTG ( BC6OTHER ), and (2) blockade of BC6OTHER ( BC6ENTC ) synthesis in isolated human eosinophils in vitro.	False
We examined the effect of the highly lipophilic CHEM, BC6OTHER ( BC6OTHER ), in causing (1) inhibition of nuclear translocation of BC6OTHER ( BC6ENTG ), and (2) blockade of BC6OTHER ( BC6ENTC ) synthesis in isolated human eosinophils in vitro.	False
Eosinophils were isolated from peripheral blood, treated with either buffer or 10( - )10 M to 10( - )6 M BC6ENTC in the presence of 10 pg / ml BC6ENTG ( BC6OTHER ) and activated with BC6OTHER ( BC6OTHER ) + BC6OTHER ( BC6OTHER ).	False
Eosinophils were isolated from peripheral blood, treated with either buffer or 10( - )10 M to 10( - )6 M BC6ENTC in the presence of 10 pg / ml BC6OTHER ( BC6ENTG ) and activated with BC6OTHER ( BC6OTHER ) + BC6OTHER ( BC6OTHER ).	False
Eosinophils were isolated from peripheral blood, treated with either buffer or 10( - )10 M to 10( - )6 M BC6OTHER in the presence of 10 pg / ml BC6ENTG ( BC6OTHER ) and activated with BC6ENTC ( BC6OTHER ) + BC6OTHER ( BC6OTHER ).	False
Eosinophils were isolated from peripheral blood, treated with either buffer or 10( - )10 M to 10( - )6 M BC6OTHER in the presence of 10 pg / ml BC6OTHER ( BC6ENTG ) and activated with BC6ENTC ( BC6OTHER ) + BC6OTHER ( BC6OTHER ).	False
Eosinophils were isolated from peripheral blood, treated with either buffer or 10( - )10 M to 10( - )6 M BC6OTHER in the presence of 10 pg / ml BC6ENTG ( BC6OTHER ) and activated with BC6OTHER ( BC6ENTC ) + BC6OTHER ( BC6OTHER ).	False
Eosinophils were isolated from peripheral blood, treated with either buffer or 10( - )10 M to 10( - )6 M BC6OTHER in the presence of 10 pg / ml BC6OTHER ( BC6ENTG ) and activated with BC6OTHER ( BC6ENTC ) + BC6OTHER ( BC6OTHER ).	False
Eosinophils were isolated from peripheral blood, treated with either buffer or 10( - )10 M to 10( - )6 M BC6OTHER in the presence of 10 pg / ml BC6ENTG ( BC6OTHER ) and activated with BC6OTHER ( BC6OTHER ) + BC6ENTC ( BC6OTHER ).	False
Eosinophils were isolated from peripheral blood, treated with either buffer or 10( - )10 M to 10( - )6 M BC6OTHER in the presence of 10 pg / ml BC6OTHER ( BC6ENTG ) and activated with BC6OTHER ( BC6OTHER ) + BC6ENTC ( BC6OTHER ).	False
Eosinophils were isolated from peripheral blood, treated with either buffer or 10( - )10 M to 10( - )6 M BC6OTHER in the presence of 10 pg / ml BC6ENTG ( BC6OTHER ) and activated with BC6OTHER ( BC6OTHER ) + BC6OTHER ( BC6ENTC ).	False
Eosinophils were isolated from peripheral blood, treated with either buffer or 10( - )10 M to 10( - )6 M BC6OTHER in the presence of 10 pg / ml BC6OTHER ( BC6ENTG ) and activated with BC6OTHER ( BC6OTHER ) + BC6OTHER ( BC6ENTC ).	False
We examined the effect of the highly lipophilic CHEM, BC6ENTC ( BC6OTHER ), in causing (1) inhibition of nuclear translocation of BC6ENTG ( BC6OTHER ), and (2) blockade of BC6OTHER ( BC6OTHER ) synthesis in isolated human eosinophils in vitro.	False
We examined the effect of the highly lipophilic CHEM, BC6ENTC ( BC6OTHER ), in causing (1) inhibition of nuclear translocation of BC6OTHER ( BC6ENTG ), and (2) blockade of BC6OTHER ( BC6OTHER ) synthesis in isolated human eosinophils in vitro.	False
By contrast, membrane expression of BC6ENTG , which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10( - )10 M BC6ENTC , and inhibition of BC6OTHER synthesis was reversed by exogenous BC6OTHER ( BC6OTHER ).	False
BC6ENTC / BC6OTHER - stimulated translocation of BC6ENTG to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by BC6OTHER .	False
BC6OTHER / BC6ENTC - stimulated translocation of BC6ENTG to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by BC6OTHER .	False
We examined the effect of the highly lipophilic CHEM, BC6OTHER ( BC6ENTC ), in causing (1) inhibition of nuclear translocation of BC6ENTG ( BC6OTHER ), and (2) blockade of BC6OTHER ( BC6OTHER ) synthesis in isolated human eosinophils in vitro.	False
We examined the effect of the highly lipophilic CHEM, BC6OTHER ( BC6ENTC ), in causing (1) inhibition of nuclear translocation of BC6OTHER ( BC6ENTG ), and (2) blockade of BC6OTHER ( BC6OTHER ) synthesis in isolated human eosinophils in vitro.	False
BC6OTHER / BC6OTHER - stimulated translocation of BC6ENTG to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by BC6ENTC .	CPR:4
Inhibition of BC6ENTG translocation and BC6ENTC secretion by BC6OTHER in exogenously activated human eosinophils.	False
Inhibition of BC6ENTG translocation and BC6OTHER secretion by BC6ENTC in exogenously activated human eosinophils.	CPR:4
By contrast, membrane expression of BC6ENTG , which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10( - )10 M BC6OTHER , and inhibition of BC6ENTC synthesis was reversed by exogenous BC6OTHER ( BC6OTHER ).	False
By contrast, membrane expression of BC6ENTG , which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10( - )10 M BC6OTHER , and inhibition of BC6OTHER synthesis was reversed by exogenous BC6ENTC ( BC6OTHER ).	False
By contrast, membrane expression of BC6ENTG , which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10( - )10 M BC6OTHER , and inhibition of BC6OTHER synthesis was reversed by exogenous BC6OTHER ( BC6ENTC ).	False
We find that BC6ENTC causes a decrease in stimulated eosinophil secretion of BC6OTHER that is regulated by BC6ENTG ( BC6OTHER ).	CPR:4
We find that BC6ENTC causes a decrease in stimulated eosinophil secretion of BC6OTHER that is regulated by BC6OTHER ( BC6ENTG ).	False
We find that BC6OTHER causes a decrease in stimulated eosinophil secretion of BC6ENTC that is regulated by BC6ENTG ( BC6OTHER ).	CPR:9
We find that BC6OTHER causes a decrease in stimulated eosinophil secretion of BC6ENTC that is regulated by BC6OTHER ( BC6ENTG ).	CPR:9
Inhibition of BC6ENTC synthesis precedes the global cytotoxic effects of BC6OTHER as indicated by the simultaneous upregulation of BC6ENTG expression.	False
Inhibition of BC6OTHER synthesis precedes the global cytotoxic effects of BC6ENTC as indicated by the simultaneous upregulation of BC6ENTG expression.	CPR:3
We examined the effect of the highly lipophilic CHEM, BC6OTHER ( BC6OTHER ), in causing (1) inhibition of nuclear translocation of BC6ENTG ( BC6OTHER ), and (2) blockade of BC6ENTC ( BC6OTHER ) synthesis in isolated human eosinophils in vitro.	False
We examined the effect of the highly lipophilic CHEM, BC6OTHER ( BC6OTHER ), in causing (1) inhibition of nuclear translocation of BC6OTHER ( BC6ENTG ), and (2) blockade of BC6ENTC ( BC6OTHER ) synthesis in isolated human eosinophils in vitro.	False
 To clarify if the behavioral interaction between BC6OTHER and BC6ENTG reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTC agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p.	False
There was no escape of i.c.v. - administered BC6OTHER from brain to the peripheral circulation ruling out a peripheral and supporting a central mechanism of BC6ENTC - BC6ENTG interaction.	False
 To clarify if the behavioral interaction between BC6OTHER and BC6OTHER reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTG agonists, BC6ENTC ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p.	CPR:5
 To clarify if the behavioral interaction between BC6OTHER and BC6ENTG reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6OTHER agonists, BC6ENTC ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p.	False
 To clarify if the behavioral interaction between BC6OTHER and BC6OTHER reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTG agonists, BC6OTHER ( BC6ENTC ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p.	CPR:5
 To clarify if the behavioral interaction between BC6OTHER and BC6ENTG reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6OTHER agonists, BC6OTHER ( BC6ENTC ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p.	False
 To clarify if the behavioral interaction between BC6OTHER and BC6OTHER reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTG agonists, BC6OTHER ( BC6OTHER ), BC6ENTC , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p.	CPR:5
 To clarify if the behavioral interaction between BC6OTHER and BC6ENTG reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6OTHER agonists, BC6OTHER ( BC6OTHER ), BC6ENTC , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p.	False
 To clarify if the behavioral interaction between BC6OTHER and BC6OTHER reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTG agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6ENTC , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p.	CPR:5
 To clarify if the behavioral interaction between BC6OTHER and BC6ENTG reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6OTHER agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6ENTC , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p.	False
 To clarify if the behavioral interaction between BC6OTHER and BC6OTHER reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTG agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6ENTC and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p.	CPR:6
 To clarify if the behavioral interaction between BC6OTHER and BC6ENTG reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6OTHER agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6ENTC and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p.	False
 To clarify if the behavioral interaction between BC6OTHER and BC6OTHER reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTG agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6ENTC as well as BC6OTHER on BC6OTHER - (i.p.	CPR:6
 To clarify if the behavioral interaction between BC6OTHER and BC6ENTG reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6OTHER agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6ENTC as well as BC6OTHER on BC6OTHER - (i.p.	False
 To clarify if the behavioral interaction between BC6OTHER and BC6OTHER reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTG agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6ENTC on BC6OTHER - (i.p.	CPR:6
 To clarify if the behavioral interaction between BC6OTHER and BC6ENTG reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6OTHER agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6ENTC on BC6OTHER - (i.p.	False
BC6OTHER , a weak BC6ENTG antagonist but potent inhibitor of BC6OTHER , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6OTHER - BC6ENTC interactions.	False
BC6OTHER , a weak BC6OTHER antagonist but potent inhibitor of BC6ENTG , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6OTHER - BC6ENTC interactions.	False
BC6OTHER , a weak BC6OTHER antagonist but potent inhibitor of BC6OTHER , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6ENTG mechanism(s) in BC6OTHER - BC6ENTC interactions.	False
 To clarify if the behavioral interaction between BC6OTHER and BC6OTHER reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTG agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6ENTC - (i.p.	False
 To clarify if the behavioral interaction between BC6OTHER and BC6ENTG reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6OTHER agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6ENTC - (i.p.	False
BC6ENTC agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6OTHER - induced motor incoordination, thereby suggesting a central mechanism of BC6ENTG modulation of this effect of BC6OTHER and confirmed our previous reports in which BC6OTHER agonists and antagonists were given i.p.	False
BC6ENTC agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6OTHER - induced motor incoordination, thereby suggesting a central mechanism of BC6OTHER modulation of this effect of BC6OTHER and confirmed our previous reports in which BC6ENTG agonists and antagonists were given i.p.	False
 To clarify if the behavioral interaction between BC6ENTC and BC6OTHER reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTG agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p.	False
 To clarify if the behavioral interaction between BC6ENTC and BC6ENTG reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6OTHER agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p.	False
BC6ENTG agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6ENTC - induced motor incoordination, thereby suggesting a central mechanism of BC6OTHER modulation of this effect of BC6OTHER and confirmed our previous reports in which BC6OTHER agonists and antagonists were given i.p.	False
BC6OTHER agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6ENTC - induced motor incoordination, thereby suggesting a central mechanism of BC6ENTG modulation of this effect of BC6OTHER and confirmed our previous reports in which BC6OTHER agonists and antagonists were given i.p.	False
BC6OTHER agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6ENTC - induced motor incoordination, thereby suggesting a central mechanism of BC6OTHER modulation of this effect of BC6OTHER and confirmed our previous reports in which BC6ENTG agonists and antagonists were given i.p.	False
 To clarify if the behavioral interaction between BC6OTHER and BC6ENTC reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTG agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p.	False
BC6ENTG agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6OTHER - induced motor incoordination, thereby suggesting a central mechanism of BC6ENTC modulation of this effect of BC6OTHER and confirmed our previous reports in which BC6OTHER agonists and antagonists were given i.p.	False
BC6OTHER agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6OTHER - induced motor incoordination, thereby suggesting a central mechanism of BC6ENTC modulation of this effect of BC6OTHER and confirmed our previous reports in which BC6ENTG agonists and antagonists were given i.p.	False
BC6ENTG agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6OTHER - induced motor incoordination, thereby suggesting a central mechanism of BC6OTHER modulation of this effect of BC6ENTC and confirmed our previous reports in which BC6OTHER agonists and antagonists were given i.p.	False
BC6OTHER agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6OTHER - induced motor incoordination, thereby suggesting a central mechanism of BC6ENTG modulation of this effect of BC6ENTC and confirmed our previous reports in which BC6OTHER agonists and antagonists were given i.p.	False
BC6OTHER agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6OTHER - induced motor incoordination, thereby suggesting a central mechanism of BC6OTHER modulation of this effect of BC6ENTC and confirmed our previous reports in which BC6ENTG agonists and antagonists were given i.p.	False
BC6ENTG agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6OTHER - induced motor incoordination, thereby suggesting a central mechanism of BC6OTHER modulation of this effect of BC6OTHER and confirmed our previous reports in which BC6ENTC agonists and antagonists were given i.p.	False
BC6OTHER agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6OTHER - induced motor incoordination, thereby suggesting a central mechanism of BC6ENTG modulation of this effect of BC6OTHER and confirmed our previous reports in which BC6ENTC agonists and antagonists were given i.p.	False
BC6ENTC , a weak BC6OTHER antagonist but potent inhibitor of BC6OTHER , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6OTHER - BC6ENTG interactions.	False
BC6ENTC , a weak BC6ENTG antagonist but potent inhibitor of BC6OTHER , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6OTHER - BC6OTHER interactions.	CPR:6
BC6ENTC , a weak BC6OTHER antagonist but potent inhibitor of BC6ENTG , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6OTHER - BC6OTHER interactions.	CPR:4
BC6ENTC , a weak BC6OTHER antagonist but potent inhibitor of BC6OTHER , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6ENTG mechanism(s) in BC6OTHER - BC6OTHER interactions.	False
BC6OTHER , a weak BC6ENTC antagonist but potent inhibitor of BC6OTHER , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6OTHER - BC6ENTG interactions.	False
BC6OTHER , a weak BC6ENTC antagonist but potent inhibitor of BC6ENTG , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6OTHER - BC6OTHER interactions.	False
BC6OTHER , a weak BC6ENTC antagonist but potent inhibitor of BC6OTHER , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6ENTG mechanism(s) in BC6OTHER - BC6OTHER interactions.	False
Results from R - PIA and BC6ENTC experiments showed nearly a 40 - fold greater potency of R - vs. CHEM, suggesting predominance of BC6ENTG subtype.	False
BC6OTHER , a weak BC6OTHER antagonist but potent inhibitor of BC6ENTC phosphodiesterase, did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6OTHER - BC6ENTG interactions.	False
BC6OTHER , a weak BC6ENTG antagonist but potent inhibitor of BC6ENTC phosphodiesterase, did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6OTHER - BC6OTHER interactions.	False
BC6OTHER , a weak BC6OTHER antagonist but potent inhibitor of BC6ENTC phosphodiesterase, did not alter CHEM's motor incoordination, further supporting involvement of brain BC6ENTG mechanism(s) in BC6OTHER - BC6OTHER interactions.	False
BC6OTHER , a weak BC6OTHER antagonist but potent inhibitor of BC6OTHER , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6ENTC - BC6ENTG interactions.	False
BC6OTHER , a weak BC6ENTG antagonist but potent inhibitor of BC6OTHER , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6ENTC - BC6OTHER interactions.	False
BC6OTHER , a weak BC6OTHER antagonist but potent inhibitor of BC6ENTG , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6ENTC - BC6OTHER interactions.	False
BC6OTHER , a weak BC6OTHER antagonist but potent inhibitor of BC6OTHER , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6ENTG mechanism(s) in BC6ENTC - BC6OTHER interactions.	False
However, BC6ENTC data indicate complexity of the mechanism(s) and point toward an additional involvement of a yet unknown subtype of BC6ENTG .	False
No effect of CHEM on blood or brain levels of BC6ENTC was noted and sufficient amount of the latter entered the brain to suggest BC6ENTG activation adequate to produce behavioral interaction with BC6OTHER .	False
No effect of CHEM on blood or brain levels of BC6OTHER was noted and sufficient amount of the latter entered the brain to suggest BC6ENTG activation adequate to produce behavioral interaction with BC6ENTC .	False
There was no escape of i.c.v. - administered BC6ENTC from brain to the peripheral circulation ruling out a peripheral and supporting a central mechanism of BC6OTHER - BC6ENTG interaction.	False
Unlike bacterial BC6ENTG , the human isomerase reaction is stimulated by BC6ENTC ( BC6OTHER , BC6OTHER ).	False
Unlike bacterial BC6ENTG , the human isomerase reaction is stimulated by BC6OTHER ( BC6ENTC , BC6OTHER ).	False
Unlike bacterial BC6ENTG , the human isomerase reaction is stimulated by BC6OTHER ( BC6OTHER , BC6ENTC ).	False
The affinity labeling BC6ENTC analog, BC6OTHER ( BC6OTHER ), inactivates the BC6ENTG and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2 - 0.6 mM).	CPR:4
The affinity labeling BC6OTHER analog, BC6ENTC ( BC6OTHER ), inactivates the BC6ENTG and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2 - 0.6 mM).	CPR:4
The affinity labeling BC6OTHER analog, BC6OTHER ( BC6ENTC ), inactivates the BC6ENTG and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2 - 0.6 mM).	CPR:4
Analysis of coenzyme binding by BC6ENTG and BC6OTHER using BC6ENTC , an affinity labeling cofactor analog.	False
Analysis of coenzyme binding by human placental BC6OTHER dehydrogenase and BC6ENTG using BC6ENTC , an affinity labeling cofactor analog.	False
Analysis of coenzyme binding by human placental BC6ENTC dehydrogenase and BC6ENTG using BC6OTHER , an affinity labeling cofactor analog.	False
BC6ENTC dehydrogenase and BC6ENTG copurify as a single, homogeneous protein from human placental microsomes.	False
FSA is a cofactor site - directed reagent that binds with similar affinity as a competitive inhibitor of BC6ENTC reduction by BC6ENTG (Ki = 162 microM) or as a stimulator of isomerase (Km = 153 microM).	False
The BC6ENTC substrate, BC6OTHER , protects isomerase as well as BC6ENTG from inactivation by BC6OTHER .	False
The BC6OTHER substrate, BC6ENTC , protects isomerase as well as BC6ENTG from inactivation by BC6OTHER .	False
The BC6OTHER substrate, BC6OTHER , protects isomerase as well as BC6ENTG from inactivation by BC6ENTC .	CPR:4
Affinity alkylation with 2 BC6ENTC suggests that the BC6ENTG and isomerase substrate BC6OTHER bind at different sites on the same protein.	False
Affinity alkylation with 2 BC6OTHER suggests that the BC6ENTG and isomerase substrate BC6ENTC bind at different sites on the same protein.	CPR:9
Moreover, treatment of high - fat - diet - fed BC6ENTG - knockout mice with a selective BC6OTHER inhibitor, BC6ENTC , improved vascular function, and also attenuated obesity.	False
Moreover, treatment of high - fat - diet - fed BC6OTHER - knockout mice with a selective BC6ENTG inhibitor, BC6ENTC , improved vascular function, and also attenuated obesity.	CPR:4
Increased BC6ENTC / BC6OTHER - exchanger ( BC6ENTG ) and altered BC6OTHER ( BC6OTHER ) responses are observed in failing human heart.	False
Increased BC6ENTC / BC6OTHER - exchanger ( BC6OTHER ) and altered BC6ENTG ( BC6OTHER ) responses are observed in failing human heart.	False
Increased BC6ENTC / BC6OTHER - exchanger ( BC6OTHER ) and altered BC6OTHER ( BC6ENTG ) responses are observed in failing human heart.	False
Increased CHEM / BC6ENTC - exchanger ( BC6ENTG ) and altered BC6OTHER ( BC6OTHER ) responses are observed in failing human heart.	False
Increased CHEM / BC6ENTC - exchanger ( BC6OTHER ) and altered BC6ENTG ( BC6OTHER ) responses are observed in failing human heart.	False
Increased CHEM / BC6ENTC - exchanger ( BC6OTHER ) and altered BC6OTHER ( BC6ENTG ) responses are observed in failing human heart.	False
Responses to BC6ENTC were largely mediated through the BC6ENTG in control myocytes.	False
Adenovirally - mediated overexpression of BC6ENTG , at levels, which did not alter basal contraction of myocytes, markedly depressed the BC6ENTC concentration - response curve.	False
Responses to BC6ENTC could be restored to normal by BC6ENTG blockade, suggesting a BC6OTHER - mediated inhibition of BC6OTHER signalling.	False
Responses to BC6ENTC could be restored to normal by BC6OTHER blockade, suggesting a BC6ENTG - mediated inhibition of BC6OTHER signalling.	False
Responses to BC6ENTC could be restored to normal by BC6OTHER blockade, suggesting a BC6OTHER - mediated inhibition of BC6ENTG signalling.	False
BC6ENTG normalised BC6ENTC responses in BC6OTHER cells, indicating that BC6OTHER effects were mediated by BC6OTHER .	False
BC6OTHER normalised BC6ENTC responses in BC6ENTG cells, indicating that BC6OTHER effects were mediated by BC6OTHER .	False
BC6OTHER normalised BC6ENTC responses in BC6OTHER cells, indicating that BC6ENTG effects were mediated by BC6OTHER .	False
BC6OTHER normalised BC6ENTC responses in BC6OTHER cells, indicating that BC6OTHER effects were mediated by BC6ENTG .	False
Loss of BC6ENTG response in myocytes overexpressing the BC6ENTC / BC6OTHER - exchanger.	False
Loss of BC6ENTG response in myocytes overexpressing the BC6OTHER / BC6ENTC - exchanger.	False
Selective inhibition of BC6ENTG spares renal function and BC6ENTC synthesis in cirrhotic rats with ascites.	CPR:9
RESULTS: Administration of BC6OTHER to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective BC6ENTG / BC6OTHER inhibitor, BC6OTHER , resulted in a marked reduction in urine volume, urinary excretion of BC6ENTC , and glomerular filtration rate and in a significant impairment in renal water metabolism.	CPR:9
RESULTS: Administration of BC6OTHER to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective BC6OTHER / BC6ENTG inhibitor, BC6OTHER , resulted in a marked reduction in urine volume, urinary excretion of BC6ENTC , and glomerular filtration rate and in a significant impairment in renal water metabolism.	CPR:9
The current study evaluates the effects of a selective BC6ENTG inhibitor ( BC6ENTC ) on renal function in cirrhotic rats with ascites.	CPR:4
RESULTS: Administration of BC6ENTC to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective BC6ENTG / BC6OTHER inhibitor, BC6OTHER , resulted in a marked reduction in urine volume, urinary excretion of BC6OTHER , and glomerular filtration rate and in a significant impairment in renal water metabolism.	False
RESULTS: Administration of BC6ENTC to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective BC6OTHER / BC6ENTG inhibitor, BC6OTHER , resulted in a marked reduction in urine volume, urinary excretion of BC6OTHER , and glomerular filtration rate and in a significant impairment in renal water metabolism.	False
RESULTS: Administration of BC6OTHER to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective BC6ENTG / BC6OTHER inhibitor, BC6ENTC , resulted in a marked reduction in urine volume, urinary excretion of BC6OTHER , and glomerular filtration rate and in a significant impairment in renal water metabolism.	CPR:4
RESULTS: Administration of BC6OTHER to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective BC6OTHER / BC6ENTG inhibitor, BC6ENTC , resulted in a marked reduction in urine volume, urinary excretion of BC6OTHER , and glomerular filtration rate and in a significant impairment in renal water metabolism.	CPR:4
Furthermore, BC6ENTC , a specific BC6ENTG phosphorylation - inducing agent, increased BC6OTHER and BC6OTHER expression in the presence of VA.	CPR:3
Furthermore, BC6ENTC , a specific BC6OTHER phosphorylation - inducing agent, increased BC6ENTG and BC6OTHER expression in the presence of VA.	CPR:3
Furthermore, BC6ENTC , a specific BC6OTHER phosphorylation - inducing agent, increased BC6OTHER and BC6ENTG expression in the presence of VA.	CPR:3
Therefore, we examined whether BC6ENTC (VA) sensitize BC6ENTG - induced apoptosis in cancer cells by induction of ER stress.	False
 BC6ENTC sensitizes BC6ENTG - induced apoptosis via the upregulation of BC6OTHER in an BC6OTHER / BC6OTHER - dependent manner.	False
 BC6ENTC sensitizes BC6OTHER - induced apoptosis via the upregulation of BC6ENTG in an BC6OTHER / BC6OTHER - dependent manner.	CPR:3
 BC6ENTC sensitizes BC6OTHER - induced apoptosis via the upregulation of BC6OTHER in an BC6ENTG / BC6OTHER - dependent manner.	CPR:3
 BC6ENTC sensitizes BC6OTHER - induced apoptosis via the upregulation of BC6OTHER in an BC6OTHER / BC6ENTG - dependent manner.	CPR:3
BC6ENTC receptor - alpha ( BC6ENTG ) antagonists have been widely used for breast cancer therapy.	False
With the CHEM linked through the C7alpha position of BC6ENTC , the resulting PROTAC shows the most effective BC6ENTG degradation and highest affinity for the BC6OTHER receptor.	CPR:4
With the CHEM linked through the C7alpha position of BC6ENTC , the resulting PROTAC shows the most effective BC6OTHER degradation and highest affinity for the BC6ENTG .	False
With the CHEM linked through the C7alpha position of BC6OTHER , the resulting PROTAC shows the most effective BC6ENTG degradation and highest affinity for the BC6ENTC receptor.	False
This result provides an opportunity to develop a novel type of BC6ENTG antagonist that may overcome the resistance of breast tumors to conventional drugs such as BC6ENTC and BC6OTHER ( BC6OTHER ).	False
This result provides an opportunity to develop a novel type of BC6ENTG antagonist that may overcome the resistance of breast tumors to conventional drugs such as BC6OTHER and BC6ENTC ( BC6OTHER ).	False
This result provides an opportunity to develop a novel type of BC6ENTG antagonist that may overcome the resistance of breast tumors to conventional drugs such as BC6OTHER and BC6OTHER ( BC6ENTC ).	False
Recent studies indicate that BC6ENTC initially acts as an antagonist, but later functions as an BC6ENTG agonist, promoting tumor growth.	CPR:6
The BC6ENTG - targeting PROTACs are composed of an BC6ENTC on one end and a BC6OTHER ( BC6OTHER ) - derived synthetic CHEM on the other.	False
The BC6OTHER - targeting PROTACs are composed of an BC6ENTC on one end and a BC6ENTG ( BC6OTHER ) - derived synthetic CHEM on the other.	False
The BC6OTHER - targeting PROTACs are composed of an BC6ENTC on one end and a BC6OTHER ( BC6ENTG ) - derived synthetic CHEM on the other.	False
Altogether, our results prove the importance of BC6ENTC homeostasis in the BC6ENTG - effector system and suggest a possible mechanism by which this vitamin may regulate the neuronal cell survival in the adult hippocampus.	False
We previously demonstrated that the somatostatinergic system, implicated in neuronal survival control, can be modulated by BC6ENTC in the rat dentate gyrus, increasing BC6ENTG phosphorylation.	CPR:3
To gain a better understanding of the molecular actions of BC6ENTC and examine the link among BC6OTHER , BC6ENTG and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of BC6OTHER on the BC6OTHER signaling pathway and neuronal survival in the rat hippocampus.	False
To gain a better understanding of the molecular actions of BC6ENTC and examine the link among BC6OTHER , BC6OTHER and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of BC6OTHER on the BC6ENTG signaling pathway and neuronal survival in the rat hippocampus.	False
To gain a better understanding of the molecular actions of BC6OTHER and examine the link among BC6ENTC , BC6ENTG and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of BC6OTHER on the BC6OTHER signaling pathway and neuronal survival in the rat hippocampus.	False
To gain a better understanding of the molecular actions of BC6OTHER and examine the link among BC6ENTC , BC6OTHER and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of BC6OTHER on the BC6ENTG signaling pathway and neuronal survival in the rat hippocampus.	False
To gain a better understanding of the molecular actions of BC6OTHER and examine the link among BC6OTHER , BC6ENTC and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of BC6OTHER on the BC6ENTG signaling pathway and neuronal survival in the rat hippocampus.	False
To gain a better understanding of the molecular actions of BC6OTHER and examine the link among BC6OTHER , BC6ENTG and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of BC6ENTC on the BC6OTHER signaling pathway and neuronal survival in the rat hippocampus.	False
To gain a better understanding of the molecular actions of BC6OTHER and examine the link among BC6OTHER , BC6OTHER and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of BC6ENTC on the BC6ENTG signaling pathway and neuronal survival in the rat hippocampus.	False
To gain a better understanding of the molecular actions of BC6OTHER and examine the link among BC6OTHER , BC6ENTG and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of BC6OTHER on the BC6ENTC signaling pathway and neuronal survival in the rat hippocampus.	False
No changes in BC6ENTG expression were detected in BC6ENTC - deficient rats.	False
These rats, however, showed a significant increase in the BC6ENTC receptor density and dissociation constant, which correlated with a significant increase in the protein levels of BC6ENTG .	False
 BC6ENTC deficiency impairs the BC6ENTG - effector system and leads to BC6OTHER overactivation and cell death in the rat hippocampus.	False
 BC6ENTC deficiency impairs the BC6OTHER - effector system and leads to BC6ENTG overactivation and cell death in the rat hippocampus.	False
 BC6OTHER deficiency impairs the BC6ENTG - effector system and leads to BC6ENTC phosphatase overactivation and cell death in the rat hippocampus.	False
These rats, however, showed a significant increase in the BC6ENTG density and dissociation constant, which correlated with a significant increase in the protein levels of BC6ENTC receptors.	False
Nevertheless, BC6ENTC deficiency impaired the ability of the BC6ENTG to couple to the effectors BC6OTHER cyclase and BC6OTHER phosphatase by diminishing BC6OTHER functionality.	False
Nevertheless, BC6ENTC deficiency impaired the ability of the BC6OTHER receptors to couple to the effectors BC6OTHER cyclase and BC6ENTG by diminishing BC6OTHER functionality.	False
Nevertheless, BC6ENTC deficiency impaired the ability of the BC6OTHER receptors to couple to the effectors BC6OTHER cyclase and BC6OTHER phosphatase by diminishing BC6ENTG functionality.	False
Nevertheless, BC6OTHER deficiency impaired the ability of the BC6ENTC receptors to couple to the effectors BC6OTHER cyclase and BC6ENTG by diminishing BC6OTHER functionality.	False
Nevertheless, BC6OTHER deficiency impaired the ability of the BC6ENTC receptors to couple to the effectors BC6OTHER cyclase and BC6OTHER phosphatase by diminishing BC6ENTG functionality.	False
Nevertheless, BC6OTHER deficiency impaired the ability of the BC6ENTG to couple to the effectors BC6ENTC cyclase and BC6OTHER phosphatase by diminishing BC6OTHER functionality.	False
Nevertheless, BC6OTHER deficiency impaired the ability of the BC6OTHER receptors to couple to the effectors BC6ENTC cyclase and BC6ENTG by diminishing BC6OTHER functionality.	False
Nevertheless, BC6OTHER deficiency impaired the ability of the BC6OTHER receptors to couple to the effectors BC6ENTC cyclase and BC6OTHER phosphatase by diminishing BC6ENTG functionality.	False
Nevertheless, BC6OTHER deficiency impaired the ability of the BC6ENTG to couple to the effectors BC6OTHER cyclase and BC6ENTC phosphatase by diminishing BC6OTHER functionality.	False
Nevertheless, BC6OTHER deficiency impaired the ability of the BC6OTHER receptors to couple to the effectors BC6OTHER cyclase and BC6ENTC phosphatase by diminishing BC6ENTG functionality.	False
Furthermore, BC6ENTC deficiency significantly increased BC6ENTG activity and BC6OTHER expression, as well as BC6OTHER activation, and decreased BC6OTHER phosphorylation.	False
Furthermore, BC6ENTC deficiency significantly increased BC6OTHER phosphatase activity and BC6ENTG expression, as well as BC6OTHER activation, and decreased BC6OTHER phosphorylation.	False
Furthermore, BC6ENTC deficiency significantly increased BC6OTHER phosphatase activity and BC6OTHER expression, as well as BC6ENTG activation, and decreased BC6OTHER phosphorylation.	False
Furthermore, BC6ENTC deficiency significantly increased BC6OTHER phosphatase activity and BC6OTHER expression, as well as BC6OTHER activation, and decreased BC6ENTG phosphorylation.	False
Furthermore, BC6OTHER deficiency significantly increased BC6ENTC phosphatase activity and BC6ENTG expression, as well as BC6OTHER activation, and decreased BC6OTHER phosphorylation.	False
Furthermore, BC6OTHER deficiency significantly increased BC6ENTC phosphatase activity and BC6OTHER expression, as well as BC6ENTG activation, and decreased BC6OTHER phosphorylation.	False
Furthermore, BC6OTHER deficiency significantly increased BC6ENTC phosphatase activity and BC6OTHER expression, as well as BC6OTHER activation, and decreased BC6ENTG phosphorylation.	False
This study was designed to determine the gastroprotective properties of BC6ENTC ( BC6OTHER ), a novel prokinetic BC6OTHER derivative agonist of BC6ENTG and BC6OTHER receptors and BC6OTHER antagonist, on mucosal injury produced by 50% (v / v) BC6OTHER .	CPR:5
This study was designed to determine the gastroprotective properties of BC6ENTC ( BC6OTHER ), a novel prokinetic BC6OTHER derivative agonist of BC6OTHER and BC6ENTG receptors and BC6OTHER antagonist, on mucosal injury produced by 50% (v / v) BC6OTHER .	CPR:5
This study was designed to determine the gastroprotective properties of BC6ENTC ( BC6OTHER ), a novel prokinetic BC6OTHER derivative agonist of BC6OTHER and BC6OTHER receptors and BC6ENTG antagonist, on mucosal injury produced by 50% (v / v) BC6OTHER .	CPR:6
This study was designed to determine the gastroprotective properties of BC6OTHER ( BC6OTHER ), a novel prokinetic BC6ENTC derivative agonist of BC6ENTG and BC6OTHER receptors and BC6OTHER antagonist, on mucosal injury produced by 50% (v / v) BC6OTHER .	CPR:5
This study was designed to determine the gastroprotective properties of BC6OTHER ( BC6OTHER ), a novel prokinetic BC6ENTC derivative agonist of BC6OTHER and BC6ENTG receptors and BC6OTHER antagonist, on mucosal injury produced by 50% (v / v) BC6OTHER .	CPR:5
This study was designed to determine the gastroprotective properties of BC6OTHER ( BC6OTHER ), a novel prokinetic BC6ENTC derivative agonist of BC6OTHER and BC6OTHER receptors and BC6ENTG antagonist, on mucosal injury produced by 50% (v / v) BC6OTHER .	CPR:6
On the contrary, pretreatment with BC6ENTC worsened BC6OTHER - induced erosions, however, did not affect gastric mucus secretion, BC6ENTG content or BC6OTHER levels, although the non - protein BC6OTHER fraction was significantly decreased.	False
This study was designed to determine the gastroprotective properties of BC6OTHER ( BC6ENTC ), a novel prokinetic BC6OTHER derivative agonist of BC6ENTG and BC6OTHER receptors and BC6OTHER antagonist, on mucosal injury produced by 50% (v / v) BC6OTHER .	CPR:5
This study was designed to determine the gastroprotective properties of BC6OTHER ( BC6ENTC ), a novel prokinetic BC6OTHER derivative agonist of BC6OTHER and BC6ENTG receptors and BC6OTHER antagonist, on mucosal injury produced by 50% (v / v) BC6OTHER .	CPR:5
This study was designed to determine the gastroprotective properties of BC6OTHER ( BC6ENTC ), a novel prokinetic BC6OTHER derivative agonist of BC6OTHER and BC6OTHER receptors and BC6ENTG antagonist, on mucosal injury produced by 50% (v / v) BC6OTHER .	CPR:6
On the contrary, pretreatment with BC6OTHER worsened BC6ENTC - induced erosions, however, did not affect gastric mucus secretion, BC6ENTG content or BC6OTHER levels, although the non - protein BC6OTHER fraction was significantly decreased.	False
On the contrary, pretreatment with BC6OTHER worsened BC6OTHER - induced erosions, however, did not affect gastric mucus secretion, BC6ENTG content or BC6ENTC levels, although the non - protein BC6OTHER fraction was significantly decreased.	False
On the contrary, pretreatment with BC6OTHER worsened BC6OTHER - induced erosions, however, did not affect gastric mucus secretion, BC6ENTG content or BC6OTHER levels, although the non - protein BC6ENTC fraction was significantly decreased.	False
We suggest that BC6ENTC dependent mechanisms through BC6ENTG receptor blockade and BC6OTHER receptor activation could be also involved.	False
We suggest that BC6ENTC dependent mechanisms through BC6OTHER receptor blockade and BC6ENTG receptor activation could be also involved.	False
This study was designed to determine the gastroprotective properties of BC6OTHER ( BC6OTHER ), a novel prokinetic BC6OTHER derivative agonist of BC6ENTG and BC6OTHER receptors and BC6OTHER antagonist, on mucosal injury produced by 50% (v / v) BC6ENTC .	False
This study was designed to determine the gastroprotective properties of BC6OTHER ( BC6OTHER ), a novel prokinetic BC6OTHER derivative agonist of BC6OTHER and BC6ENTG receptors and BC6OTHER antagonist, on mucosal injury produced by 50% (v / v) BC6ENTC .	False
This study was designed to determine the gastroprotective properties of BC6OTHER ( BC6OTHER ), a novel prokinetic BC6OTHER derivative agonist of BC6OTHER and BC6OTHER receptors and BC6ENTG antagonist, on mucosal injury produced by 50% (v / v) BC6ENTC .	False
 Synthesis, biological evaluation, and molecular modeling of BC6OTHER derivatives as potent BC6ENTG inhibitors with anti - heart - failure activity in vivo. Novel BC6OTHER (GL) derivatives were designed and synthesized by introducing various BC6OTHER or BC6OTHER residues into the BC6ENTC chain and at C - 30.	False
 Synthesis, biological evaluation, and molecular modeling of BC6OTHER derivatives as potent BC6ENTG inhibitors with anti - heart - failure activity in vivo. Novel BC6ENTC (GL) derivatives were designed and synthesized by introducing various BC6OTHER or BC6OTHER residues into the BC6OTHER chain and at C - 30.	False
 Synthesis, biological evaluation, and molecular modeling of BC6OTHER derivatives as potent BC6ENTG inhibitors with anti - heart - failure activity in vivo. Novel BC6OTHER (GL) derivatives were designed and synthesized by introducing various BC6ENTC or BC6OTHER residues into the BC6OTHER chain and at C - 30.	False
 Synthesis, biological evaluation, and molecular modeling of BC6OTHER derivatives as potent BC6ENTG inhibitors with anti - heart - failure activity in vivo. Novel BC6OTHER (GL) derivatives were designed and synthesized by introducing various BC6OTHER or BC6ENTC residues into the BC6OTHER chain and at C - 30.	False
 Synthesis, biological evaluation, and molecular modeling of BC6ENTC derivatives as potent BC6ENTG inhibitors with anti - heart - failure activity in vivo. Novel BC6OTHER (GL) derivatives were designed and synthesized by introducing various BC6OTHER or BC6OTHER residues into the BC6OTHER chain and at C - 30.	CPR:4
The purpose of this investigation was to determine whether this pH - dependent uptake represents BC6OTHER / BC6ENTC cotransport via a BC6ENTG - like transport system.	False
The BC6ENTG cDNA was isolated (2296bp including both 5' and 3' untranslated regions and BC6OTHER and the BC6OTHER codes for a protein of 475 BC6ENTC (92% identity to BC6OTHER ).	False
The BC6OTHER cDNA was isolated (2296bp including both 5' and 3' untranslated regions and BC6ENTG and the BC6OTHER codes for a protein of 475 BC6ENTC (92% identity to BC6OTHER ).	False
The BC6OTHER cDNA was isolated (2296bp including both 5' and 3' untranslated regions and BC6OTHER and the BC6ENTG codes for a protein of 475 BC6ENTC (92% identity to BC6OTHER ).	False
The BC6OTHER cDNA was isolated (2296bp including both 5' and 3' untranslated regions and BC6OTHER and the BC6OTHER codes for a protein of 475 BC6ENTC (92% identity to BC6ENTG ).	False
When expressed heterologously in a mammalian cell line, BC6ENTG mediates pH - dependent, BC6ENTC - independent uptake of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
When expressed heterologously in a mammalian cell line, BC6ENTG mediates pH - dependent, BC6OTHER - independent uptake of BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER .	CPR:9
When expressed heterologously in a mammalian cell line, BC6ENTG mediates pH - dependent, BC6OTHER - independent uptake of BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER .	CPR:9
When expressed heterologously in a mammalian cell line, BC6ENTG mediates pH - dependent, BC6OTHER - independent uptake of BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER .	CPR:9
When expressed heterologously in a mammalian cell line, BC6ENTG mediates pH - dependent, BC6OTHER - independent uptake of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC .	CPR:9
Isolation and function of the BC6ENTC transporter PAT1 ( BC6OTHER ) from rabbit and discrimination between transport via BC6ENTG and BC6OTHER in renal brush - border membrane vesicles.	False
Isolation and function of the BC6ENTC transporter PAT1 ( BC6OTHER ) from rabbit and discrimination between transport via BC6OTHER and BC6ENTG in renal brush - border membrane vesicles.	False
Isolation and function of the BC6ENTC transporter PAT1 ( BC6ENTG ) from rabbit and discrimination between transport via BC6OTHER and BC6OTHER in renal brush - border membrane vesicles.	False
In the presence of BC6ENTC and under conditions in which BC6ENTG transport function was suppressed, a second BC6OTHER uptake system was detected that exhibited functional characteristics similar to those of the BC6OTHER .	False
In the presence of BC6ENTC and under conditions in which BC6OTHER transport function was suppressed, a second BC6OTHER uptake system was detected that exhibited functional characteristics similar to those of the BC6ENTG .	False
In the presence of BC6OTHER and under conditions in which BC6ENTG transport function was suppressed, a second BC6ENTC uptake system was detected that exhibited functional characteristics similar to those of the BC6OTHER .	CPR:9
In the presence of BC6OTHER and under conditions in which BC6OTHER transport function was suppressed, a second BC6ENTC uptake system was detected that exhibited functional characteristics similar to those of the BC6ENTG .	False
The functional characteristics of BC6ENTG in either mammalian cells or renal BBMV suggest that BC6OTHER is the low - affinity transporter of BC6ENTC , BC6OTHER and BC6OTHER believed to be defective in patients with iminoglycinuria.	False
The functional characteristics of BC6OTHER in either mammalian cells or renal BBMV suggest that BC6ENTG is the low - affinity transporter of BC6ENTC , BC6OTHER and BC6OTHER believed to be defective in patients with iminoglycinuria.	CPR:9
The functional characteristics of BC6ENTG in either mammalian cells or renal BBMV suggest that BC6OTHER is the low - affinity transporter of BC6OTHER , BC6ENTC and BC6OTHER believed to be defective in patients with iminoglycinuria.	False
The functional characteristics of BC6OTHER in either mammalian cells or renal BBMV suggest that BC6ENTG is the low - affinity transporter of BC6OTHER , BC6ENTC and BC6OTHER believed to be defective in patients with iminoglycinuria.	CPR:9
The functional characteristics of BC6ENTG in either mammalian cells or renal BBMV suggest that BC6OTHER is the low - affinity transporter of BC6OTHER , BC6OTHER and BC6ENTC believed to be defective in patients with iminoglycinuria.	False
The functional characteristics of BC6OTHER in either mammalian cells or renal BBMV suggest that BC6ENTG is the low - affinity transporter of BC6OTHER , BC6OTHER and BC6ENTC believed to be defective in patients with iminoglycinuria.	CPR:9
The purpose of this investigation was to determine whether this pH - dependent uptake represents BC6ENTC / BC6OTHER cotransport via a BC6ENTG - like transport system.	False
CHEM - incubation with BC6ENTG or BC6OTHER but not BC6OTHER protected BC6OTHER from BC6ENTC .	False
CHEM - incubation with BC6OTHER or BC6OTHER but not BC6OTHER protected BC6ENTG from BC6ENTC .	False
Inhibition of testicular BC6ENTG from laboratory animals and man by BC6ENTC and its isomers.	CPR:4
CHEM inhibited BC6ENTG prepared from the testes of the mouse greater than rabbit greater than human greater than rat greater than hamster.	CPR:4
The inhibitory effect of BC6ENTC and BC6OTHER upon testicular cytosolic BC6ENTG was measured in vitro.	CPR:4
BC6ENTG activity measured in vitro in serum of men and hamsters was unaffected by BC6ENTC .	False
BC6ENTC and its isomers were non - competitive inhibitors of BC6ENTG with respect to the coenzyme BC6OTHER , competitive inhibitors of BC6OTHER and noncompetitive - competitive inhibitors of BC6OTHER with respect to the substrate BC6OTHER .	CPR:4
BC6ENTC and its isomers were non - competitive inhibitors of BC6OTHER with respect to the coenzyme BC6OTHER , competitive inhibitors of BC6ENTG and noncompetitive - competitive inhibitors of BC6OTHER with respect to the substrate BC6OTHER .	False
BC6ENTC and its isomers were non - competitive inhibitors of BC6OTHER with respect to the coenzyme BC6OTHER , competitive inhibitors of BC6OTHER and noncompetitive - competitive inhibitors of BC6ENTG with respect to the substrate BC6OTHER .	False
The inhibitory effect of BC6OTHER and BC6ENTC upon testicular cytosolic BC6ENTG was measured in vitro.	CPR:4
BC6OTHER and its isomers were non - competitive inhibitors of BC6ENTG with respect to the coenzyme BC6ENTC , competitive inhibitors of BC6OTHER and noncompetitive - competitive inhibitors of BC6OTHER with respect to the substrate BC6OTHER .	False
BC6OTHER and its isomers were non - competitive inhibitors of BC6OTHER with respect to the coenzyme BC6ENTC , competitive inhibitors of BC6ENTG and noncompetitive - competitive inhibitors of BC6OTHER with respect to the substrate BC6OTHER .	CPR:4
BC6OTHER and its isomers were non - competitive inhibitors of BC6OTHER with respect to the coenzyme BC6ENTC , competitive inhibitors of BC6OTHER and noncompetitive - competitive inhibitors of BC6ENTG with respect to the substrate BC6OTHER .	False
BC6OTHER and its isomers were non - competitive inhibitors of BC6ENTG with respect to the coenzyme BC6OTHER , competitive inhibitors of BC6OTHER and noncompetitive - competitive inhibitors of BC6OTHER with respect to the substrate BC6ENTC .	False
BC6OTHER and its isomers were non - competitive inhibitors of BC6OTHER with respect to the coenzyme BC6OTHER , competitive inhibitors of BC6ENTG and noncompetitive - competitive inhibitors of BC6OTHER with respect to the substrate BC6ENTC .	False
BC6OTHER and its isomers were non - competitive inhibitors of BC6OTHER with respect to the coenzyme BC6OTHER , competitive inhibitors of BC6OTHER and noncompetitive - competitive inhibitors of BC6ENTG with respect to the substrate BC6ENTC .	CPR:9
CHEM - incubation with BC6ENTG or BC6ENTC but not BC6OTHER protected BC6OTHER from BC6OTHER .	False
CHEM - incubation with BC6OTHER or BC6ENTC but not BC6OTHER protected BC6ENTG from BC6OTHER .	False
CHEM - incubation with BC6ENTG or BC6OTHER but not BC6ENTC protected BC6OTHER from BC6OTHER .	False
CHEM - incubation with BC6OTHER or BC6OTHER but not BC6ENTC protected BC6ENTG from BC6OTHER .	False
These include intestinal alkalizing agents, oral antibiotics, enzyme inducers, BC6ENTG ( BC6OTHER ) inhibitors, BC6OTHER ( BC6OTHER ) inhibitors, BC6OTHER ( BC6OTHER ) inhibitors, or blockers of biliary excretion of BC6ENTC .	False
These include intestinal alkalizing agents, oral antibiotics, enzyme inducers, BC6OTHER ( BC6ENTG ) inhibitors, BC6OTHER ( BC6OTHER ) inhibitors, BC6OTHER ( BC6OTHER ) inhibitors, or blockers of biliary excretion of BC6ENTC .	False
These include intestinal alkalizing agents, oral antibiotics, enzyme inducers, BC6OTHER ( BC6OTHER ) inhibitors, BC6ENTG ( BC6OTHER ) inhibitors, BC6OTHER ( BC6OTHER ) inhibitors, or blockers of biliary excretion of BC6ENTC .	False
These include intestinal alkalizing agents, oral antibiotics, enzyme inducers, BC6OTHER ( BC6OTHER ) inhibitors, BC6OTHER ( BC6ENTG ) inhibitors, BC6OTHER ( BC6OTHER ) inhibitors, or blockers of biliary excretion of BC6ENTC .	False
These include intestinal alkalizing agents, oral antibiotics, enzyme inducers, BC6OTHER ( BC6OTHER ) inhibitors, BC6OTHER ( BC6OTHER ) inhibitors, BC6ENTG ( BC6OTHER ) inhibitors, or blockers of biliary excretion of BC6ENTC .	False
These include intestinal alkalizing agents, oral antibiotics, enzyme inducers, BC6OTHER ( BC6OTHER ) inhibitors, BC6OTHER ( BC6OTHER ) inhibitors, BC6OTHER ( BC6ENTG ) inhibitors, or blockers of biliary excretion of BC6ENTC .	False
BC6OTHER ( BC6OTHER , BC6ENTC ) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting BC6ENTG ( BC6OTHER ).	CPR:4
BC6OTHER ( BC6OTHER , BC6ENTC ) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting BC6OTHER ( BC6ENTG ).	CPR:4
Early - onset diarrhea is observed immediately after BC6ENTC infusion and probably due to the inhibition of BC6ENTG activity, which can be eliminated by administration of BC6OTHER .	CPR:4
Early - onset diarrhea is observed immediately after BC6OTHER infusion and probably due to the inhibition of BC6ENTG activity, which can be eliminated by administration of BC6ENTC .	CPR:3
Late - onset diarrhea appears to be associated with intestinal exposure to BC6ENTC ( BC6OTHER ), the major active metabolite of BC6OTHER , which may bind to BC6ENTG and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa.	False
Late - onset diarrhea appears to be associated with intestinal exposure to BC6OTHER ( BC6ENTC ), the major active metabolite of BC6OTHER , which may bind to BC6ENTG and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa.	False
BC6ENTC ( BC6OTHER , BC6OTHER ) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting BC6ENTG ( BC6OTHER ).	CPR:4
BC6ENTC ( BC6OTHER , BC6OTHER ) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting BC6OTHER ( BC6ENTG ).	CPR:4
Late - onset diarrhea appears to be associated with intestinal exposure to BC6OTHER ( BC6OTHER ), the major active metabolite of BC6ENTC , which may bind to BC6ENTG and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa.	False
BC6ENTC and BC6OTHER may also stimulate the production of pro - inflammatory BC6ENTG and BC6OTHER ( BC6OTHER ), thus inducing the secretion of BC6OTHER and BC6OTHER .	CPR:3
BC6OTHER and BC6ENTC may also stimulate the production of pro - inflammatory BC6ENTG and BC6OTHER ( BC6OTHER ), thus inducing the secretion of BC6OTHER and BC6OTHER .	CPR:3
BC6OTHER ( BC6ENTC , BC6OTHER ) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting BC6ENTG ( BC6OTHER ).	CPR:4
BC6OTHER ( BC6ENTC , BC6OTHER ) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting BC6OTHER ( BC6ENTG ).	CPR:4
BC6OTHER and BC6OTHER may also stimulate the production of pro - inflammatory BC6ENTG and BC6ENTC ( BC6OTHER ), thus inducing the secretion of BC6OTHER and BC6OTHER .	False
BC6OTHER and BC6OTHER may also stimulate the production of pro - inflammatory BC6ENTG and BC6OTHER ( BC6ENTC ), thus inducing the secretion of BC6OTHER and BC6OTHER .	False
BC6OTHER and BC6OTHER may also stimulate the production of pro - inflammatory BC6ENTG and BC6OTHER ( BC6OTHER ), thus inducing the secretion of BC6ENTC and BC6OTHER .	False
BC6OTHER and BC6OTHER may also stimulate the production of pro - inflammatory BC6ENTG and BC6OTHER ( BC6OTHER ), thus inducing the secretion of BC6OTHER and BC6ENTC .	False
Proteins BC6ENTG and BC6OTHER were not found to be involved in BC6ENTC import.	False
Proteins BC6OTHER and BC6ENTG were not found to be involved in BC6ENTC import.	False
The presence of BC6ENTC hormones most probably causes the degradation of the BC6ENTG permease and impairment of BC6OTHER import.	CPR:4
The presence of BC6OTHER hormones most probably causes the degradation of the BC6ENTG permease and impairment of BC6ENTC import.	False
The expression of the osteoblast markers BC6OTHER ( BC6ENTG ) and BC6OTHER was decreased, while BC6OTHER ( BC6OTHER ) was augmented in BC6OTHER ( - / - ) and BC6ENTC - RANTES - treated mice.	CPR:4
The expression of the osteoblast markers BC6OTHER ( BC6OTHER ) and BC6ENTG was decreased, while BC6OTHER ( BC6OTHER ) was augmented in BC6OTHER ( - / - ) and BC6ENTC - RANTES - treated mice.	CPR:4
The expression of the osteoblast markers BC6OTHER ( BC6OTHER ) and BC6OTHER was decreased, while BC6ENTG ( BC6OTHER ) was augmented in BC6OTHER ( - / - ) and BC6ENTC - RANTES - treated mice.	CPR:3
The expression of the osteoblast markers BC6OTHER ( BC6OTHER ) and BC6OTHER was decreased, while BC6OTHER ( BC6ENTG ) was augmented in BC6OTHER ( - / - ) and BC6ENTC - RANTES - treated mice.	CPR:3
The expression of the osteoblast markers BC6OTHER ( BC6OTHER ) and BC6OTHER was decreased, while BC6OTHER ( BC6OTHER ) was augmented in BC6ENTG ( - / - ) and BC6ENTC - RANTES - treated mice.	False
The expression of the osteoblast markers BC6ENTG ( BC6OTHER ) and BC6OTHER was decreased, while BC6OTHER ( BC6OTHER ) was augmented in BC6OTHER ( - / - ) and BC6ENTC - RANTES - treated mice.	CPR:4
Our results showed that bone remodeling was significantly decreased in BC6ENTG ( - / - ) and BC6OTHER ( - / - ) mice and in animals treated with BC6ENTC - RANTES (an antagonist of BC6OTHER and BC6OTHER ).	False
Our results showed that bone remodeling was significantly decreased in BC6OTHER ( - / - ) and BC6ENTG ( - / - ) mice and in animals treated with BC6ENTC - RANTES (an antagonist of BC6OTHER and BC6OTHER ).	False
Our results showed that bone remodeling was significantly decreased in BC6OTHER ( - / - ) and BC6OTHER ( - / - ) mice and in animals treated with BC6ENTC - RANTES (an antagonist of BC6ENTG and BC6OTHER ).	CPR:6
Our results showed that bone remodeling was significantly decreased in BC6OTHER ( - / - ) and BC6OTHER ( - / - ) mice and in animals treated with BC6ENTC - RANTES (an antagonist of BC6OTHER and BC6ENTG ).	CPR:6
mRNA levels of BC6ENTG ( BC6OTHER ), its ligand BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER / BC6OTHER ( BC6OTHER ) ratio were diminished in the periodontium of BC6OTHER ( - / - ) mice and in the group treated with BC6ENTC - RANTES.	CPR:4
mRNA levels of BC6OTHER ( BC6ENTG ), its ligand BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER / BC6OTHER ( BC6OTHER ) ratio were diminished in the periodontium of BC6OTHER ( - / - ) mice and in the group treated with BC6ENTC - RANTES.	CPR:4
mRNA levels of BC6OTHER ( BC6OTHER ), its ligand BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER / BC6OTHER ( BC6OTHER ) ratio were diminished in the periodontium of BC6OTHER ( - / - ) mice and in the group treated with BC6ENTC - RANTES.	CPR:4
mRNA levels of BC6OTHER ( BC6OTHER ), its ligand BC6OTHER , BC6ENTG ( BC6OTHER ) and BC6OTHER / BC6OTHER ( BC6OTHER ) ratio were diminished in the periodontium of BC6OTHER ( - / - ) mice and in the group treated with BC6ENTC - RANTES.	CPR:4
mRNA levels of BC6OTHER ( BC6OTHER ), its ligand BC6OTHER , BC6OTHER ( BC6ENTG ) and BC6OTHER / BC6OTHER ( BC6OTHER ) ratio were diminished in the periodontium of BC6OTHER ( - / - ) mice and in the group treated with BC6ENTC - RANTES.	CPR:4
mRNA levels of BC6OTHER ( BC6OTHER ), its ligand BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTG / BC6OTHER ( BC6OTHER ) ratio were diminished in the periodontium of BC6OTHER ( - / - ) mice and in the group treated with BC6ENTC - RANTES.	CPR:4
mRNA levels of BC6OTHER ( BC6OTHER ), its ligand BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER / BC6ENTG ( BC6OTHER ) ratio were diminished in the periodontium of BC6OTHER ( - / - ) mice and in the group treated with BC6ENTC - RANTES.	CPR:4
mRNA levels of BC6OTHER ( BC6OTHER ), its ligand BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER / BC6OTHER ( BC6ENTG ) ratio were diminished in the periodontium of BC6OTHER ( - / - ) mice and in the group treated with BC6ENTC - RANTES.	CPR:4
mRNA levels of BC6OTHER ( BC6OTHER ), its ligand BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER / BC6OTHER ( BC6OTHER ) ratio were diminished in the periodontium of BC6ENTG ( - / - ) mice and in the group treated with BC6ENTC - RANTES.	False
BC6ENTC - RANTES treatment also reduced the levels of BC6ENTG and BC6OTHER ( BC6OTHER ).	CPR:4
BC6ENTC - RANTES treatment also reduced the levels of BC6OTHER and BC6ENTG ( BC6OTHER ).	CPR:4
BC6ENTC - RANTES treatment also reduced the levels of BC6OTHER and BC6OTHER ( BC6ENTG ).	CPR:4
To elucidate the target genes regulated by these compounds, we treated Zucker diabetic CHEM (ZDF) for 15 days with a BC6ENTG - specific compound, BC6ENTC , a BC6OTHER - specific ligand, BC6OTHER , and a BC6OTHER coagonist, BC6OTHER , and measured the levels of several messenger RNAs (mRNAs) in liver by real - time polymerase chain reaction.	False
To elucidate the target genes regulated by these compounds, we treated Zucker diabetic CHEM (ZDF) for 15 days with a BC6OTHER - specific compound, BC6ENTC , a BC6ENTG - specific ligand, BC6OTHER , and a BC6OTHER coagonist, BC6OTHER , and measured the levels of several messenger RNAs (mRNAs) in liver by real - time polymerase chain reaction.	False
To elucidate the target genes regulated by these compounds, we treated Zucker diabetic CHEM (ZDF) for 15 days with a BC6OTHER - specific compound, BC6ENTC , a BC6OTHER - specific ligand, BC6OTHER , and a BC6ENTG coagonist, BC6OTHER , and measured the levels of several messenger RNAs (mRNAs) in liver by real - time polymerase chain reaction.	False
To elucidate the target genes regulated by these compounds, we treated Zucker diabetic CHEM (ZDF) for 15 days with a BC6ENTG - specific compound, BC6OTHER , a BC6OTHER - specific ligand, BC6ENTC , and a BC6OTHER coagonist, BC6OTHER , and measured the levels of several messenger RNAs (mRNAs) in liver by real - time polymerase chain reaction.	False
To elucidate the target genes regulated by these compounds, we treated Zucker diabetic CHEM (ZDF) for 15 days with a BC6OTHER - specific compound, BC6OTHER , a BC6ENTG - specific ligand, BC6ENTC , and a BC6OTHER coagonist, BC6OTHER , and measured the levels of several messenger RNAs (mRNAs) in liver by real - time polymerase chain reaction.	False
To elucidate the target genes regulated by these compounds, we treated Zucker diabetic CHEM (ZDF) for 15 days with a BC6OTHER - specific compound, BC6OTHER , a BC6OTHER - specific ligand, BC6ENTC , and a BC6ENTG coagonist, BC6OTHER , and measured the levels of several messenger RNAs (mRNAs) in liver by real - time polymerase chain reaction.	False
To elucidate the target genes regulated by these compounds, we treated Zucker diabetic CHEM (ZDF) for 15 days with a BC6ENTG - specific compound, BC6OTHER , a BC6OTHER - specific ligand, BC6OTHER , and a BC6OTHER coagonist, BC6ENTC , and measured the levels of several messenger RNAs (mRNAs) in liver by real - time polymerase chain reaction.	False
To elucidate the target genes regulated by these compounds, we treated Zucker diabetic CHEM (ZDF) for 15 days with a BC6OTHER - specific compound, BC6OTHER , a BC6ENTG - specific ligand, BC6OTHER , and a BC6OTHER coagonist, BC6ENTC , and measured the levels of several messenger RNAs (mRNAs) in liver by real - time polymerase chain reaction.	False
To elucidate the target genes regulated by these compounds, we treated Zucker diabetic CHEM (ZDF) for 15 days with a BC6OTHER - specific compound, BC6OTHER , a BC6OTHER - specific ligand, BC6OTHER , and a BC6ENTG coagonist, BC6ENTC , and measured the levels of several messenger RNAs (mRNAs) in liver by real - time polymerase chain reaction.	False
BC6ENTC and BC6OTHER induced expression of BC6ENTG and BC6OTHER and reduced BC6OTHER and BC6OTHER mRNAs.	CPR:3
BC6ENTC and BC6OTHER induced expression of CHEM ( BC6OTHER ) oxidase and BC6ENTG and reduced BC6OTHER and BC6OTHER mRNAs.	CPR:3
BC6ENTC and BC6OTHER induced expression of CHEM ( BC6OTHER ) oxidase and BC6OTHER and reduced BC6ENTG and BC6OTHER mRNAs.	CPR:4
BC6ENTC and BC6OTHER induced expression of CHEM ( BC6OTHER ) oxidase and BC6OTHER and reduced BC6OTHER and BC6ENTG mRNAs.	CPR:4
BC6OTHER and BC6ENTC induced expression of BC6ENTG and BC6OTHER and reduced BC6OTHER and BC6OTHER mRNAs.	CPR:3
BC6OTHER and BC6ENTC induced expression of CHEM ( BC6OTHER ) oxidase and BC6ENTG and reduced BC6OTHER and BC6OTHER mRNAs.	CPR:3
BC6OTHER and BC6ENTC induced expression of CHEM ( BC6OTHER ) oxidase and BC6OTHER and reduced BC6ENTG and BC6OTHER mRNAs.	CPR:4
BC6OTHER and BC6ENTC induced expression of CHEM ( BC6OTHER ) oxidase and BC6OTHER and reduced BC6OTHER and BC6ENTG mRNAs.	CPR:4
BC6OTHER and BC6OTHER induced expression of BC6ENTC ( BC6OTHER ) oxidase and BC6ENTG and reduced BC6OTHER and BC6OTHER mRNAs.	False
BC6OTHER and BC6OTHER induced expression of BC6ENTC ( BC6OTHER ) oxidase and BC6OTHER and reduced BC6ENTG and BC6OTHER mRNAs.	False
BC6OTHER and BC6OTHER induced expression of BC6ENTC ( BC6OTHER ) oxidase and BC6OTHER and reduced BC6OTHER and BC6ENTG mRNAs.	False
BC6OTHER and BC6OTHER induced expression of CHEM ( BC6ENTC ) oxidase and BC6ENTG and reduced BC6OTHER and BC6OTHER mRNAs.	False
BC6OTHER and BC6OTHER induced expression of CHEM ( BC6ENTC ) oxidase and BC6OTHER and reduced BC6ENTG and BC6OTHER mRNAs.	False
BC6OTHER and BC6OTHER induced expression of CHEM ( BC6ENTC ) oxidase and BC6OTHER and reduced BC6OTHER and BC6ENTG mRNAs.	False
BC6OTHER and BC6OTHER induced expression of BC6ENTG and BC6ENTC hydratase and reduced BC6OTHER and BC6OTHER mRNAs.	False
BC6OTHER and BC6OTHER induced expression of CHEM ( BC6OTHER ) oxidase and BC6ENTC hydratase and reduced BC6ENTG and BC6OTHER mRNAs.	False
BC6OTHER and BC6OTHER induced expression of CHEM ( BC6OTHER ) oxidase and BC6ENTC hydratase and reduced BC6OTHER and BC6ENTG mRNAs.	False
BC6OTHER and BC6OTHER induced expression of BC6ENTG and BC6OTHER and reduced BC6OTHER and BC6ENTC carboxykinase mRNAs.	False
BC6OTHER and BC6OTHER induced expression of CHEM ( BC6OTHER ) oxidase and BC6ENTG and reduced BC6OTHER and BC6ENTC carboxykinase mRNAs.	False
BC6OTHER and BC6OTHER induced expression of CHEM ( BC6OTHER ) oxidase and BC6OTHER and reduced BC6ENTG and BC6ENTC carboxykinase mRNAs.	False
BC6ENTC modestly increased BC6OTHER mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of BC6ENTG and BC6OTHER carboxykinase in adipose tissue.	CPR:3
BC6ENTC modestly increased BC6OTHER mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of BC6OTHER transporter 4 and BC6ENTG in adipose tissue.	CPR:3
BC6ENTC modestly increased BC6ENTG mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of BC6OTHER transporter 4 and BC6OTHER carboxykinase in adipose tissue.	CPR:3
BC6OTHER modestly increased BC6OTHER mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of BC6ENTC transporter 4 and BC6ENTG in adipose tissue.	False
BC6OTHER modestly increased BC6ENTG mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of BC6ENTC transporter 4 and BC6OTHER carboxykinase in adipose tissue.	False
BC6OTHER modestly increased BC6OTHER mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of BC6ENTG and BC6ENTC carboxykinase in adipose tissue.	False
BC6OTHER modestly increased BC6ENTG mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of BC6OTHER transporter 4 and BC6ENTC carboxykinase in adipose tissue.	False
BC6ENTC bind to the BC6ENTG , and BC6OTHER are ligands of BC6OTHER .	False
BC6ENTC bind to the BC6OTHER , and BC6OTHER are ligands of BC6ENTG .	False
The results of these studies suggest that activation of BC6ENTG as well as BC6OTHER in therapy for type 2 diabetes will enhance BC6ENTC and BC6OTHER control by combining actions in hepatic and peripheral tissues.	False
The results of these studies suggest that activation of BC6OTHER as well as BC6ENTG in therapy for type 2 diabetes will enhance BC6ENTC and BC6OTHER control by combining actions in hepatic and peripheral tissues.	False
The results of these studies suggest that activation of BC6ENTG as well as BC6OTHER in therapy for type 2 diabetes will enhance BC6OTHER and BC6ENTC control by combining actions in hepatic and peripheral tissues.	False
The results of these studies suggest that activation of BC6OTHER as well as BC6ENTG in therapy for type 2 diabetes will enhance BC6OTHER and BC6ENTC control by combining actions in hepatic and peripheral tissues.	False
BC6OTHER bind to the BC6ENTG , and BC6ENTC are ligands of BC6OTHER .	False
BC6OTHER bind to the BC6OTHER , and BC6ENTC are ligands of BC6ENTG .	False
We report the discovery of novel series of highly potent BC6ENTG agonists based on BC6OTHER , 1 and 2 by introducing and optimizing various BC6ENTC onto the BC6OTHER (9) - position of the BC6OTHER moiety.	CPR:5
We report the discovery of novel series of highly potent BC6ENTG agonists based on BC6OTHER , 1 and 2 by introducing and optimizing various BC6OTHER onto the BC6ENTC (9) - position of the BC6OTHER moiety.	CPR:5
We report the discovery of novel series of highly potent BC6ENTG agonists based on BC6OTHER , 1 and 2 by introducing and optimizing various BC6OTHER onto the BC6OTHER (9) - position of the BC6ENTC moiety.	CPR:5
The introduction of the BC6ENTC group resulted in not only improved water solubility but also enhanced BC6ENTG agonistic activity.	CPR:5
We report the discovery of novel series of highly potent BC6ENTG agonists based on BC6ENTC , 1 and 2 by introducing and optimizing various BC6OTHER onto the BC6OTHER (9) - position of the BC6OTHER moiety.	CPR:5
Synthesis and evaluation of BC6ENTC derivatives as potent BC6ENTG agonists with high water solubility.	CPR:5
Finally, the three drugs were compared with the BC6ENTG inhibitor BC6ENTC .	CPR:4
The goal of the present study was to compare the effects of three potent reference BC6ENTG inhibitors ( BC6ENTC , BC6OTHER , and BC6OTHER ) in BC6OTHER - depleted normotensive squirrel monkeys.	CPR:4
The goal of the present study was to compare the effects of three potent reference BC6ENTG inhibitors ( BC6OTHER , BC6ENTC , and BC6OTHER ) in BC6OTHER - depleted normotensive squirrel monkeys.	CPR:4
The goal of the present study was to compare the effects of three potent reference BC6ENTG inhibitors ( BC6OTHER , BC6OTHER , and BC6ENTC ) in BC6OTHER - depleted normotensive squirrel monkeys.	CPR:4
One possible explanation is that, in our model, BC6ENTC in contrast to BC6OTHER and BC6OTHER is able to inhibit BC6ENTG in a functionally important extraplasmatic compartment.	CPR:4
One possible explanation is that, in our model, BC6OTHER in contrast to BC6ENTC and BC6OTHER is able to inhibit BC6ENTG in a functionally important extraplasmatic compartment.	CPR:4
One possible explanation is that, in our model, BC6OTHER in contrast to BC6OTHER and BC6ENTC is able to inhibit BC6ENTG in a functionally important extraplasmatic compartment.	CPR:4
The goal of the present study was to compare the effects of three potent reference BC6ENTG inhibitors ( BC6OTHER , BC6OTHER , and BC6OTHER ) in BC6ENTC - depleted normotensive squirrel monkeys.	False
BC6OTHER ( BC6OTHER ) accumulates in tissues and fluids of patients with Smith - Lemli - Opitz syndrome (SLOS), which is caused by mutations in the gene encoding BC6ENTC - Δ(7) - reductase ( BC6ENTG ).	False
BC6OTHER ( BC6ENTC ) accumulates in tissues and fluids of patients with Smith - Lemli - Opitz syndrome (SLOS), which is caused by mutations in the gene encoding BC6ENTG ( BC6OTHER ).	False
BC6OTHER ( BC6ENTC ) accumulates in tissues and fluids of patients with Smith - Lemli - Opitz syndrome (SLOS), which is caused by mutations in the gene encoding BC6OTHER ( BC6ENTG ).	False
As the high oxidizability of BC6ENTC may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a BC6ENTG - KO mouse model of SLOS, including BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) that are formed from the oxidation of BC6OTHER , BC6OTHER and BC6OTHER , respectively.	False
As the high oxidizability of BC6OTHER may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a BC6ENTG - KO mouse model of SLOS, including BC6ENTC , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) that are formed from the oxidation of BC6OTHER , BC6OTHER and BC6OTHER , respectively.	False
As the high oxidizability of BC6OTHER may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a BC6ENTG - KO mouse model of SLOS, including BC6OTHER , BC6ENTC ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) that are formed from the oxidation of BC6OTHER , BC6OTHER and BC6OTHER , respectively.	False
As the high oxidizability of BC6OTHER may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a BC6ENTG - KO mouse model of SLOS, including BC6OTHER , BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER ) that are formed from the oxidation of BC6OTHER , BC6OTHER and BC6OTHER , respectively.	False
As the high oxidizability of BC6OTHER may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a BC6ENTG - KO mouse model of SLOS, including BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTC ( BC6OTHER ) that are formed from the oxidation of BC6OTHER , BC6OTHER and BC6OTHER , respectively.	False
BC6ENTC ( BC6OTHER ) accumulates in tissues and fluids of patients with Smith - Lemli - Opitz syndrome (SLOS), which is caused by mutations in the gene encoding BC6ENTG ( BC6OTHER ).	False
BC6ENTC ( BC6OTHER ) accumulates in tissues and fluids of patients with Smith - Lemli - Opitz syndrome (SLOS), which is caused by mutations in the gene encoding BC6OTHER ( BC6ENTG ).	False
As the high oxidizability of BC6OTHER may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a BC6ENTG - KO mouse model of SLOS, including BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTC ) that are formed from the oxidation of BC6OTHER , BC6OTHER and BC6OTHER , respectively.	False
As the high oxidizability of BC6OTHER may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a BC6ENTG - KO mouse model of SLOS, including BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) that are formed from the oxidation of BC6ENTC , BC6OTHER and BC6OTHER , respectively.	False
As the high oxidizability of BC6OTHER may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a BC6ENTG - KO mouse model of SLOS, including BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) that are formed from the oxidation of BC6OTHER , BC6ENTC and BC6OTHER , respectively.	False
As the high oxidizability of BC6OTHER may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a BC6ENTG - KO mouse model of SLOS, including BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) that are formed from the oxidation of BC6OTHER , BC6OTHER and BC6ENTC , respectively.	False
In addition to a previously described BC6ENTC , BC6OTHER ( BC6OTHER ), we provide evidence for the chemical structures of three new BC6OTHER in the brain and / or liver tissue of BC6ENTG - KO mice, two of which were quantified.	False
In addition to a previously described BC6OTHER , BC6ENTC ( BC6OTHER ), we provide evidence for the chemical structures of three new BC6OTHER in the brain and / or liver tissue of BC6ENTG - KO mice, two of which were quantified.	False
In addition to a previously described BC6OTHER , BC6OTHER ( BC6ENTC ), we provide evidence for the chemical structures of three new BC6OTHER in the brain and / or liver tissue of BC6ENTG - KO mice, two of which were quantified.	False
In addition to a previously described BC6OTHER , BC6OTHER ( BC6OTHER ), we provide evidence for the chemical structures of three new BC6ENTC in the brain and / or liver tissue of BC6ENTG - KO mice, two of which were quantified.	False
We find that levels of BC6ENTC and BC6OTHER are also elevated in brain and / or liver tissues of BC6ENTG - KO mice relative to matching WT mice.	False
We find that levels of BC6OTHER and BC6ENTC are also elevated in brain and / or liver tissues of BC6ENTG - KO mice relative to matching WT mice.	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6ENTC .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6ENTC .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER .	False
The expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
The expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER .	False
BC6ENTG showed a high similarity in the primary structure to other vertebrate counterparts, BC6OTHER contained additional sequences of 21 and 28 BC6ENTC , respectively, as in the case of other teleost fish species when compared with African clawed frog counterparts.	False
BC6OTHER showed a high similarity in the primary structure to other vertebrate counterparts, BC6ENTG contained additional sequences of 21 and 28 BC6ENTC , respectively, as in the case of other teleost fish species when compared with African clawed frog counterparts.	False
The transcriptional activity of torafugu BC6ENTG was enhanced 4.5 - and 11.5 - fold by BC6ENTC and BC6OTHER ( BC6OTHER ) each at 10 microM, respectively, whereas that of BC6OTHER , 4.5 - and 7.3 - fold at the same concentration of the respective ligands, respectively.	CPR:3
The transcriptional activity of torafugu BC6OTHER was enhanced 4.5 - and 11.5 - fold by BC6ENTC and BC6OTHER ( BC6OTHER ) each at 10 microM, respectively, whereas that of BC6ENTG , 4.5 - and 7.3 - fold at the same concentration of the respective ligands, respectively.	CPR:3
The transcriptional activity of torafugu BC6ENTG was enhanced 4.5 - and 11.5 - fold by BC6OTHER and BC6ENTC ( BC6OTHER ) each at 10 microM, respectively, whereas that of BC6OTHER , 4.5 - and 7.3 - fold at the same concentration of the respective ligands, respectively.	CPR:3
The transcriptional activity of torafugu BC6OTHER was enhanced 4.5 - and 11.5 - fold by BC6OTHER and BC6ENTC ( BC6OTHER ) each at 10 microM, respectively, whereas that of BC6ENTG , 4.5 - and 7.3 - fold at the same concentration of the respective ligands, respectively.	CPR:3
The transcriptional activity of torafugu BC6ENTG was enhanced 4.5 - and 11.5 - fold by BC6OTHER and BC6OTHER ( BC6ENTC ) each at 10 microM, respectively, whereas that of BC6OTHER , 4.5 - and 7.3 - fold at the same concentration of the respective ligands, respectively.	CPR:3
The transcriptional activity of torafugu BC6OTHER was enhanced 4.5 - and 11.5 - fold by BC6OTHER and BC6OTHER ( BC6ENTC ) each at 10 microM, respectively, whereas that of BC6ENTG , 4.5 - and 7.3 - fold at the same concentration of the respective ligands, respectively.	CPR:3
The activities of torafugu BC6ENTG were also enhanced 5.6 - and 6.3 - fold by BC6ENTC at 1 microM, respectively, but not by BC6OTHER at this concentration.	False
The activities of torafugu BC6ENTG were also enhanced 5.6 - and 6.3 - fold by BC6OTHER at 1 microM, respectively, but not by BC6ENTC at this concentration.	False
Furthermore, the activities of the two BC6ENTG were enhanced 4.3 - and 7.6 - fold by BC6ENTC , 4.4 - and 5.2 - fold by BC6OTHER , and 6.7 - and 8.0 - fold by BC6OTHER each at 50 microM, respectively.	CPR:3
Furthermore, the activities of the two BC6ENTG were enhanced 4.3 - and 7.6 - fold by BC6OTHER , 4.4 - and 5.2 - fold by BC6ENTC , and 6.7 - and 8.0 - fold by BC6OTHER each at 50 microM, respectively.	CPR:3
Furthermore, the activities of the two BC6ENTG were enhanced 4.3 - and 7.6 - fold by BC6OTHER , 4.4 - and 5.2 - fold by BC6OTHER , and 6.7 - and 8.0 - fold by BC6ENTC each at 50 microM, respectively.	CPR:3
On the other hand, the activities of BC6ENTG were not changed by BC6ENTC , BC6OTHER , BC6OTHER , nor CHEM.	False
On the other hand, the activities of BC6ENTG were not changed by BC6OTHER , BC6ENTC , BC6OTHER , nor CHEM.	False
On the other hand, the activities of BC6ENTG were not changed by BC6OTHER , BC6OTHER , BC6ENTC , nor CHEM.	False
Structural and functional properties were investigated for four BC6OTHER ( BC6ENTG ), BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the BC6ENTC oxidase PPAR response element.	False
Structural and functional properties were investigated for four BC6OTHER ( BC6OTHER ), BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER , from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the BC6ENTC oxidase PPAR response element.	False
Structural and functional properties were investigated for four BC6OTHER ( BC6OTHER ), BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER , from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the BC6ENTC oxidase PPAR response element.	False
Structural and functional properties were investigated for four BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER , from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the BC6ENTC oxidase PPAR response element.	False
Structural and functional properties were investigated for four BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG , from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the BC6ENTC oxidase PPAR response element.	False
Structural and functional properties were investigated for four BC6ENTG ( BC6OTHER ), BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the BC6ENTC oxidase PPAR response element.	False
We found a strong interaction of baseline FEV(1) with the BC6ENTG ( BC6ENTC ) polymorphism in predicting bronchodilator response.	False
Genetic variants at the BC6ENTG ( BC6OTHER ) may modify asthma severity and BC6ENTC responsiveness.	False
Genetic variants at the BC6OTHER ( BC6ENTG ) may modify asthma severity and BC6ENTC responsiveness.	False
We tested the association of BC6ENTG genotypes with asthma severity and bronchodilator response to BC6ENTC in Puerto Ricans and Mexicans with asthma.	False
METHODS: We used both family - based and cross - sectional tests of association with 8 BC6ENTG single BC6ENTC polymorphisms in 684 Puerto Rican and Mexican families.	False
We developed a computational model of the hypothalamic - pituitary - gonadal (HPG) axis in female fathead minnows to predict dose - response and time - course (DRTC) behaviors for endocrine effects of the BC6ENTG inhibitor, BC6ENTC ( BC6OTHER ).	CPR:4
We developed a computational model of the hypothalamic - pituitary - gonadal (HPG) axis in female fathead minnows to predict dose - response and time - course (DRTC) behaviors for endocrine effects of the BC6ENTG inhibitor, BC6OTHER ( BC6ENTC ).	CPR:4
For model development, we used plasma BC6ENTC (E2) concentrations and ovarian BC6ENTG mRNA data from two time - course experiments, each of which included both an exposure and a depuration phase, and plasma E2 data from a third 4 - day study.	False
The model accurately predicted BC6ENTG mRNA fold changes for controls and three BC6ENTC doses (0, 0.5, and 3 µg / l) and plasma E2 dose response from the 4 - day study.	False
BC6ENTG is a transmembrane glycoprotein that mediates BC6ENTC - dependent interactions between adjacent epithelial cells.	False
BC6ENTC was the most potent BC6OTHER analog tested in BC6ENTG functional BC6OTHER turnover assays in the following cell types: human ciliary muscle (EC50 = 1.4 nM), human trabecular meshwork (EC50 = 3.6 nM), and mouse fibroblasts and rat aortic smooth muscle cells (EC50 = 2.6 nM).	False
BC6OTHER was the most potent BC6ENTC analog tested in BC6ENTG functional BC6OTHER turnover assays in the following cell types: human ciliary muscle (EC50 = 1.4 nM), human trabecular meshwork (EC50 = 3.6 nM), and mouse fibroblasts and rat aortic smooth muscle cells (EC50 = 2.6 nM).	False
BC6OTHER was the most potent BC6OTHER analog tested in BC6ENTG functional BC6ENTC turnover assays in the following cell types: human ciliary muscle (EC50 = 1.4 nM), human trabecular meshwork (EC50 = 3.6 nM), and mouse fibroblasts and rat aortic smooth muscle cells (EC50 = 2.6 nM).	False
Although BC6ENTC exhibited a relatively high affinity for the BC6ENTG (Ki = 98 nM), it had significant functional activity at BC6OTHER (EC50 = 32 - 124 nM) and BC6OTHER (EC50 = 119 nM) receptors.	False
Although BC6ENTC exhibited a relatively high affinity for the BC6OTHER (Ki = 98 nM), it had significant functional activity at BC6ENTG (EC50 = 32 - 124 nM) and BC6OTHER (EC50 = 119 nM) receptors.	False
Although BC6ENTC exhibited a relatively high affinity for the BC6OTHER (Ki = 98 nM), it had significant functional activity at BC6OTHER (EC50 = 32 - 124 nM) and BC6ENTG (EC50 = 119 nM) receptors.	False
BC6ENTC was less selective, exhibiting a relatively high affinity for the BC6ENTG (Ki = 83 nM), BC6OTHER (Ki = 95 nM), and BC6OTHER (Ki = 387 nM) receptors.	False
BC6ENTC was less selective, exhibiting a relatively high affinity for the BC6OTHER (Ki = 83 nM), BC6ENTG (Ki = 95 nM), and BC6OTHER (Ki = 387 nM) receptors.	False
BC6ENTC was less selective, exhibiting a relatively high affinity for the BC6OTHER (Ki = 83 nM), BC6OTHER (Ki = 95 nM), and BC6ENTG (Ki = 387 nM) receptors.	False
Ocular hypotensive FP BC6OTHER ( BC6OTHER ) analogs: BC6OTHER subtype binding affinities and selectivities, and agonist potencies at BC6ENTG and other BC6ENTC receptors in cultured cells.	False
Ocular hypotensive FP BC6OTHER ( BC6OTHER ) analogs: BC6ENTG subtype binding affinities and selectivities, and agonist potencies at BC6OTHER and other BC6ENTC receptors in cultured cells.	False
Ocular hypotensive FP BC6ENTC ( BC6OTHER ) analogs: BC6OTHER subtype binding affinities and selectivities, and agonist potencies at BC6ENTG and other BC6OTHER in cultured cells.	False
Ocular hypotensive FP BC6ENTC ( BC6OTHER ) analogs: BC6OTHER subtype binding affinities and selectivities, and agonist potencies at BC6OTHER and other BC6ENTG in cultured cells.	False
Ocular hypotensive FP BC6ENTC ( BC6OTHER ) analogs: BC6ENTG subtype binding affinities and selectivities, and agonist potencies at BC6OTHER and other BC6OTHER in cultured cells.	False
Ocular hypotensive FP BC6OTHER ( BC6ENTC ) analogs: BC6OTHER subtype binding affinities and selectivities, and agonist potencies at BC6ENTG and other BC6OTHER in cultured cells.	False
Ocular hypotensive FP BC6OTHER ( BC6ENTC ) analogs: BC6OTHER subtype binding affinities and selectivities, and agonist potencies at BC6OTHER and other BC6ENTG in cultured cells.	False
Ocular hypotensive FP BC6OTHER ( BC6ENTC ) analogs: BC6ENTG subtype binding affinities and selectivities, and agonist potencies at BC6OTHER and other BC6OTHER in cultured cells.	False
Ocular hypotensive FP BC6OTHER ( BC6OTHER ) analogs: BC6ENTC receptor subtype binding affinities and selectivities, and agonist potencies at BC6ENTG and other BC6OTHER in cultured cells.	False
Ocular hypotensive FP BC6OTHER ( BC6OTHER ) analogs: BC6ENTC receptor subtype binding affinities and selectivities, and agonist potencies at BC6OTHER and other BC6ENTG in cultured cells.	False
BC6ENTC exhibited functional activity at the BC6ENTG (EC50 = 2.7 nM) and BC6OTHER (EC50 = 2.8 - 3.8 nM in most cells) receptors.	False
BC6ENTC exhibited functional activity at the BC6OTHER (EC50 = 2.7 nM) and BC6ENTG (EC50 = 2.8 - 3.8 nM in most cells) receptors.	False
BC6ENTC (nonhydrolyzed CHEM) also behaved as an BC6ENTG agonist at the cloned BC6OTHER (EC50 = 681 nM), in h - TM (EC50 = 3245 nM) and other cell types.	False
BC6ENTC (nonhydrolyzed CHEM) also behaved as an BC6OTHER agonist at the cloned BC6ENTG (EC50 = 681 nM), in h - TM (EC50 = 3245 nM) and other cell types.	False
BC6ENTC and BC6OTHER bound with low affinity (Ki = 5.9 microM to > 22 microM) to the BC6ENTG , were not selective, but activated the BC6OTHER .	False
BC6ENTC and BC6OTHER bound with low affinity (Ki = 5.9 microM to > 22 microM) to the BC6OTHER , were not selective, but activated the BC6ENTG .	False
BC6OTHER and BC6ENTC bound with low affinity (Ki = 5.9 microM to > 22 microM) to the BC6ENTG , were not selective, but activated the BC6OTHER .	False
BC6OTHER and BC6ENTC bound with low affinity (Ki = 5.9 microM to > 22 microM) to the BC6OTHER , were not selective, but activated the BC6ENTG .	False
In conclusion, BC6ENTC has the highest affinity, the highest BC6ENTG - selectivity, and the highest potency at the BC6OTHER as compared to the other ocular hypotensive PG analogs known so far, including BC6OTHER .	False
In conclusion, BC6ENTC has the highest affinity, the highest BC6OTHER - selectivity, and the highest potency at the BC6ENTG as compared to the other ocular hypotensive PG analogs known so far, including BC6OTHER .	False
In conclusion, BC6OTHER has the highest affinity, the highest BC6ENTG - selectivity, and the highest potency at the BC6OTHER as compared to the other ocular hypotensive PG analogs known so far, including BC6ENTC .	False
In conclusion, BC6OTHER has the highest affinity, the highest BC6OTHER - selectivity, and the highest potency at the BC6ENTG as compared to the other ocular hypotensive PG analogs known so far, including BC6ENTC .	False
BC6ENTC ( BC6OTHER ) was the most BC6ENTG - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors.	False
BC6ENTC ( BC6OTHER ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6ENTG , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors.	False
BC6ENTC ( BC6OTHER ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6ENTG (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors.	False
BC6ENTC ( BC6OTHER ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6ENTG (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors.	False
BC6ENTC ( BC6OTHER ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6ENTG (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors.	False
BC6ENTC ( BC6OTHER ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6ENTG (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors.	False
BC6ENTC ( BC6OTHER ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6ENTG (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors.	False
BC6ENTC ( BC6OTHER ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6ENTG (Ki = 121,000 nM) receptors.	False
BC6OTHER ( BC6ENTC ) was the most BC6ENTG - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors.	False
BC6OTHER ( BC6ENTC ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6ENTG , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors.	False
BC6OTHER ( BC6ENTC ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6ENTG (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors.	False
BC6OTHER ( BC6ENTC ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6ENTG (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors.	False
BC6OTHER ( BC6ENTC ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6ENTG (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors.	False
BC6OTHER ( BC6ENTC ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6ENTG (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors.	False
BC6OTHER ( BC6ENTC ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6ENTG (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors.	False
BC6OTHER ( BC6ENTC ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6ENTG (Ki = 121,000 nM) receptors.	False
DNA damage is accepted as a consequence of BC6ENTC deprivation induced by chemotherapeutic inhibitors of BC6ENTG ( BC6OTHER ), but the types of damage and signaling responses remain incompletely understood.	CPR:9
DNA damage is accepted as a consequence of BC6ENTC deprivation induced by chemotherapeutic inhibitors of BC6OTHER synthase ( BC6ENTG ), but the types of damage and signaling responses remain incompletely understood.	CPR:9
When BC6ENTG , which is a central component of HR, was depleted by siRNA cells were sensitized to BC6ENTC ( BC6OTHER ), which specifically inhibits BC6OTHER .	False
When BC6OTHER , which is a central component of HR, was depleted by siRNA cells were sensitized to BC6ENTC ( BC6OTHER ), which specifically inhibits BC6ENTG .	False
When BC6ENTG , which is a central component of HR, was depleted by siRNA cells were sensitized to BC6OTHER ( BC6ENTC ), which specifically inhibits BC6OTHER .	False
When BC6OTHER , which is a central component of HR, was depleted by siRNA cells were sensitized to BC6OTHER ( BC6ENTC ), which specifically inhibits BC6ENTG .	CPR:4
To our knowledge, this is the first demonstration in mammalian cells that depletion of BC6ENTG causes sensitivity to BC6ENTC deprivation.	False
DNA damage is accepted as a consequence of BC6OTHER deprivation induced by chemotherapeutic inhibitors of BC6ENTC synthase ( BC6ENTG ), but the types of damage and signaling responses remain incompletely understood.	False
Phosphorylation of BC6ENTG ( BC6OTHER subunit) and formation of damage - induced foci were strikingly evident following IC(50) doses of BC6ENTC .	False
Phosphorylation of BC6OTHER ( BC6ENTG subunit) and formation of damage - induced foci were strikingly evident following IC(50) doses of BC6ENTC .	False
BC6ENTC treatment also induced foci of BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER , although the extent of co - localization with BC6OTHER foci varied.	CPR:3
BC6ENTC treatment also induced foci of BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER , although the extent of co - localization with BC6OTHER foci varied.	CPR:3
BC6ENTC treatment also induced foci of BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER , although the extent of co - localization with BC6OTHER foci varied.	CPR:3
BC6ENTC treatment also induced foci of BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG , although the extent of co - localization with BC6OTHER foci varied.	CPR:3
BC6ENTC treatment also induced foci of BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , although the extent of co - localization with BC6ENTG foci varied.	False
OBJECTIVETo 1) determine if plasma BC6OTHER ( BC6OTHER ) concentrations differ among obese youth with normal BC6OTHER tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6OTHER and in vivo BC6ENTG sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6OTHER concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6ENTC tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6OTHER sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively.	False
OBJECTIVETo 1) determine if plasma BC6OTHER ( BC6OTHER ) concentrations differ among obese youth with normal BC6OTHER tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6OTHER concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6ENTC tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6ENTG sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively.	False
OBJECTIVETo 1) determine if plasma BC6OTHER ( BC6ENTC ) concentrations differ among obese youth with normal BC6OTHER tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6OTHER and in vivo BC6ENTG sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6OTHER concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6OTHER tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6OTHER sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively.	False
OBJECTIVETo 1) determine if plasma BC6OTHER ( BC6ENTC ) concentrations differ among obese youth with normal BC6OTHER tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6OTHER concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6OTHER tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6ENTG sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively.	False
Furthermore, there was no association between BC6ENTC and in vivo BC6ENTG sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups.	False
Furthermore, there was no association between BC6ENTC and in vivo BC6OTHER sensitivity or β - cell function relative to BC6ENTG sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups.	False
Furthermore, there was no association between BC6ENTC and in vivo BC6OTHER sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6ENTG sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups.	False
Furthermore, there was no association between BC6ENTC and in vivo BC6OTHER sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function relative to BC6ENTG sensitivity in any of the groups.	False
OBJECTIVETo 1) determine if plasma BC6OTHER ( BC6OTHER ) concentrations differ among obese youth with normal BC6ENTC tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6OTHER and in vivo BC6ENTG sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6OTHER concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6OTHER tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6OTHER sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively.	False
OBJECTIVETo 1) determine if plasma BC6OTHER ( BC6OTHER ) concentrations differ among obese youth with normal BC6ENTC tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6OTHER concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6OTHER tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6ENTG sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively.	False
Furthermore, there was no association between BC6OTHER and in vivo BC6ENTG sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6ENTC concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups.	False
Furthermore, there was no association between BC6OTHER and in vivo BC6OTHER sensitivity or β - cell function relative to BC6ENTG sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6ENTC concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups.	False
Furthermore, there was no association between BC6OTHER and in vivo BC6OTHER sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6ENTC concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6ENTG sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups.	False
Furthermore, there was no association between BC6OTHER and in vivo BC6OTHER sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6ENTC concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function relative to BC6ENTG sensitivity in any of the groups.	False
Furthermore, there was no association between BC6OTHER and in vivo BC6ENTG sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6ENTC tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups.	False
Furthermore, there was no association between BC6OTHER and in vivo BC6OTHER sensitivity or β - cell function relative to BC6ENTG sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6ENTC tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups.	False
Furthermore, there was no association between BC6OTHER and in vivo BC6OTHER sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6ENTC tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6ENTG sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups.	False
Furthermore, there was no association between BC6OTHER and in vivo BC6OTHER sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6ENTC tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function relative to BC6ENTG sensitivity in any of the groups.	False
Furthermore, there was no association between BC6OTHER and in vivo BC6ENTG sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6ENTC and in vivo BC6OTHER sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups.	False
Furthermore, there was no association between BC6OTHER and in vivo BC6OTHER sensitivity or β - cell function relative to BC6ENTG sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6ENTC and in vivo BC6OTHER sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups.	False
Furthermore, there was no association between BC6OTHER and in vivo BC6OTHER sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6ENTC and in vivo BC6ENTG sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups.	False
Furthermore, there was no association between BC6OTHER and in vivo BC6OTHER sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6ENTC and in vivo BC6OTHER sensitivity and β - cell function relative to BC6ENTG sensitivity in any of the groups.	False
OBJECTIVETo 1) determine if plasma BC6OTHER ( BC6OTHER ) concentrations differ among obese youth with normal BC6OTHER tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6ENTC and in vivo BC6ENTG sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6OTHER concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6OTHER tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6OTHER sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively.	False
OBJECTIVETo 1) determine if plasma BC6OTHER ( BC6OTHER ) concentrations differ among obese youth with normal BC6OTHER tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6ENTC and in vivo BC6OTHER sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6OTHER concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6OTHER tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6ENTG sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively.	False
OBJECTIVETo 1) determine if plasma BC6OTHER ( BC6OTHER ) concentrations differ among obese youth with normal BC6OTHER tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6OTHER and in vivo BC6ENTG sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6ENTC concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6OTHER tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6OTHER sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively.	False
OBJECTIVETo 1) determine if plasma BC6OTHER ( BC6OTHER ) concentrations differ among obese youth with normal BC6OTHER tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6ENTC concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6OTHER tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6ENTG sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively.	False
OBJECTIVETo 1) determine if plasma BC6ENTC ( BC6OTHER ) concentrations differ among obese youth with normal BC6OTHER tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6OTHER and in vivo BC6ENTG sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6OTHER concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6OTHER tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6OTHER sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively.	False
OBJECTIVETo 1) determine if plasma BC6ENTC ( BC6OTHER ) concentrations differ among obese youth with normal BC6OTHER tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6OTHER concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6OTHER tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6ENTG sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively.	False
The unusual { BC6ENTC }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6OTHER BC6ENTG (termed {ES - BC6OTHER }7) is a result of the BC6OTHER coordination of BC6OTHER in the BC6OTHER - bound BC6OTHER active site.	False
The unusual { BC6ENTC }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6OTHER BC6OTHER (termed {ES - BC6OTHER }7) is a result of the BC6OTHER coordination of BC6OTHER in the BC6OTHER - bound BC6ENTG active site.	False
The unusual { BC6OTHER }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6ENTC BC6ENTG (termed {ES - BC6OTHER }7) is a result of the BC6OTHER coordination of BC6OTHER in the BC6OTHER - bound BC6OTHER active site.	False
The unusual { BC6OTHER }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6ENTC BC6OTHER (termed {ES - BC6OTHER }7) is a result of the BC6OTHER coordination of BC6OTHER in the BC6OTHER - bound BC6ENTG active site.	False
The unusual { BC6OTHER }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6OTHER BC6ENTG (termed {ES - BC6ENTC }7) is a result of the BC6OTHER coordination of BC6OTHER in the BC6OTHER - bound BC6OTHER active site.	False
The unusual { BC6OTHER }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6OTHER BC6OTHER (termed {ES - BC6ENTC }7) is a result of the BC6OTHER coordination of BC6OTHER in the BC6OTHER - bound BC6ENTG active site.	False
The unusual { BC6OTHER }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6OTHER BC6ENTG (termed {ES - BC6OTHER }7) is a result of the BC6ENTC coordination of BC6OTHER in the BC6OTHER - bound BC6OTHER active site.	False
The unusual { BC6OTHER }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6OTHER BC6OTHER (termed {ES - BC6OTHER }7) is a result of the BC6ENTC coordination of BC6OTHER in the BC6OTHER - bound BC6ENTG active site.	False
Mammalian BC6ENTC dioxygenase ( BC6ENTG ) is a non - CHEM BC6OTHER metalloenzyme that catalyzes the first committed step in oxidative BC6OTHER catabolism.	False
The unusual { BC6OTHER }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6OTHER BC6ENTG (termed {ES - BC6OTHER }7) is a result of the BC6OTHER coordination of BC6ENTC in the BC6OTHER - bound BC6OTHER active site.	False
The unusual { BC6OTHER }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6OTHER BC6OTHER (termed {ES - BC6OTHER }7) is a result of the BC6OTHER coordination of BC6ENTC in the BC6OTHER - bound BC6ENTG active site.	False
The unusual { BC6OTHER }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6OTHER BC6ENTG (termed {ES - BC6OTHER }7) is a result of the BC6OTHER coordination of BC6OTHER in the BC6ENTC - bound BC6OTHER active site.	False
The unusual { BC6OTHER }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6OTHER BC6OTHER (termed {ES - BC6OTHER }7) is a result of the BC6OTHER coordination of BC6OTHER in the BC6ENTC - bound BC6ENTG active site.	False
The active site coordination of BC6ENTG comprises a mononuclear BC6ENTC ligated by the Nepsilon atoms of three protein - derived BC6OTHER , thus representing a new variant on the CHEM ( BC6OTHER ) facial triad motif.	False
The active site coordination of BC6OTHER comprises a mononuclear BC6ENTC ligated by the Nepsilon atoms of three protein - derived BC6OTHER , thus representing a new variant on the BC6ENTG .	False
The DFT - predicted geometric parameters for {ES - BC6ENTC }7 are in good agreement with the crystallographically determined substrate - bound active site configuration of BC6ENTG and are consistent with known BC6OTHER model complexes.	False
The DFT - predicted geometric parameters for {ES - BC6OTHER }7 are in good agreement with the crystallographically determined substrate - bound active site configuration of BC6ENTG and are consistent with known BC6ENTC model complexes.	False
Moreover, the computed EPR parameters (g and A values) are in excellent agreement with experimental results for this BC6ENTG species and those obtained from comparable synthetic { BC6ENTC }7 (S = 1 / 2) BC6OTHER complexes.	False
Moreover, the computed EPR parameters (g and A values) are in excellent agreement with experimental results for this BC6ENTG species and those obtained from comparable synthetic { BC6OTHER }7 (S = 1 / 2) BC6ENTC complexes.	False
The active site coordination of BC6ENTG comprises a mononuclear BC6OTHER ligated by the Nepsilon atoms of three protein - derived BC6ENTC , thus representing a new variant on the CHEM ( BC6OTHER ) facial triad motif.	False
The active site coordination of BC6OTHER comprises a mononuclear BC6OTHER ligated by the Nepsilon atoms of three protein - derived BC6ENTC , thus representing a new variant on the BC6ENTG .	False
The active site coordination of BC6ENTG comprises a mononuclear BC6OTHER ligated by the Nepsilon atoms of three protein - derived BC6OTHER , thus representing a new variant on the BC6ENTC ( BC6OTHER ) facial triad motif.	False
The active site coordination of BC6ENTG comprises a mononuclear BC6OTHER ligated by the Nepsilon atoms of three protein - derived BC6OTHER , thus representing a new variant on the CHEM ( BC6ENTC ) facial triad motif.	False
However, upon addition of BC6ENTC to BC6ENTG in the presence of substrate BC6OTHER , a low - spin { BC6OTHER }7 (S = 1 / 2) signal that accounts for approximately 85% of the BC6OTHER within the enzyme develops.	False
BC6ENTG ( BC6OTHER ) is a non - CHEM BC6ENTC metalloenzyme that catalyzes the first committed step in oxidative BC6OTHER catabolism.	False
Mammalian BC6OTHER dioxygenase ( BC6ENTG ) is a non - CHEM BC6ENTC metalloenzyme that catalyzes the first committed step in oxidative BC6OTHER catabolism.	False
In these experiments, BC6ENTG exhibits an ordered binding of BC6ENTC prior to BC6OTHER (and presumably BC6OTHER ) similar to that observed for the 2H1C class of non - CHEM BC6OTHER enzymes.	False
In these experiments, BC6OTHER exhibits an ordered binding of BC6ENTC prior to BC6OTHER (and presumably BC6OTHER ) similar to that observed for the BC6ENTG .	False
In these experiments, BC6ENTG exhibits an ordered binding of BC6OTHER prior to BC6ENTC (and presumably BC6OTHER ) similar to that observed for the 2H1C class of non - CHEM BC6OTHER enzymes.	False
In these experiments, BC6OTHER exhibits an ordered binding of BC6OTHER prior to BC6ENTC (and presumably BC6OTHER ) similar to that observed for the BC6ENTG .	False
In these experiments, BC6ENTG exhibits an ordered binding of BC6OTHER prior to BC6OTHER (and presumably BC6ENTC ) similar to that observed for the 2H1C class of non - CHEM BC6OTHER enzymes.	False
In these experiments, BC6OTHER exhibits an ordered binding of BC6OTHER prior to BC6OTHER (and presumably BC6ENTC ) similar to that observed for the BC6ENTG .	False
In these experiments, BC6ENTG exhibits an ordered binding of BC6OTHER prior to BC6OTHER (and presumably BC6OTHER ) similar to that observed for the BC6ENTC class of non - CHEM BC6OTHER enzymes.	False
In these experiments, BC6ENTG exhibits an ordered binding of BC6OTHER prior to BC6OTHER (and presumably BC6OTHER ) similar to that observed for the 2H1C class of non - CHEM BC6ENTC enzymes.	False
Moreover, the BC6ENTG active site is essentially unreactive toward BC6ENTC in the absence of substrate, suggesting an obligate ordered binding of BC6OTHER prior to BC6OTHER .	False
Moreover, the BC6ENTG active site is essentially unreactive toward BC6OTHER in the absence of substrate, suggesting an obligate ordered binding of BC6ENTC prior to BC6OTHER .	False
However, upon addition of BC6OTHER to BC6ENTG in the presence of substrate BC6ENTC , a low - spin { BC6OTHER }7 (S = 1 / 2) signal that accounts for approximately 85% of the BC6OTHER within the enzyme develops.	CPR:9
Moreover, the BC6ENTG active site is essentially unreactive toward BC6OTHER in the absence of substrate, suggesting an obligate ordered binding of BC6OTHER prior to BC6ENTC .	False
Characterization of the BC6ENTC adduct of substrate - bound BC6ENTG by electron paramagnetic resonance: electronic structure of the active site and mechanistic implications.	False
However, upon addition of BC6OTHER to BC6ENTG in the presence of substrate BC6OTHER , a low - spin { BC6ENTC }7 (S = 1 / 2) signal that accounts for approximately 85% of the BC6OTHER within the enzyme develops.	False
BC6ENTG ( BC6OTHER ) is a non - CHEM BC6OTHER metalloenzyme that catalyzes the first committed step in oxidative BC6ENTC catabolism.	CPR:9
Mammalian BC6OTHER dioxygenase ( BC6ENTG ) is a non - CHEM BC6OTHER metalloenzyme that catalyzes the first committed step in oxidative BC6ENTC catabolism.	CPR:9
However, upon addition of BC6OTHER to BC6ENTG in the presence of substrate BC6OTHER , a low - spin { BC6OTHER }7 (S = 1 / 2) signal that accounts for approximately 85% of the BC6ENTC within the enzyme develops.	False
The binding of the antipsychotic drugs BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER was studied at the subtypes of the BC6ENTG .	False
The binding of the antipsychotic drugs BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER was studied at the subtypes of the BC6ENTG .	False
The binding of the antipsychotic drugs BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER was studied at the subtypes of the BC6ENTG .	False
Binding of antipsychotic drugs at BC6OTHER : BC6ENTC is selective for the BC6ENTG .	False
Binding of antipsychotic drugs at BC6ENTG : BC6ENTC is selective for the BC6OTHER .	False
With the exception of BC6ENTC , all the antipsychotic drugs tested failed to show selectivity for either of the BC6ENTG subtypes.	False
The binding of the antipsychotic drugs BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER was studied at the subtypes of the BC6ENTG .	False
BC6ENTC was 120 - fold more selective for the BC6ENTG with respect to the BC6OTHER (Ki values: 2.3 + / - 1.2 nM and 283.6 + / - 174.1 nM respectively).	False
BC6ENTC was 120 - fold more selective for the BC6OTHER with respect to the BC6ENTG (Ki values: 2.3 + / - 1.2 nM and 283.6 + / - 174.1 nM respectively).	False
The binding of the antipsychotic drugs BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC was studied at the subtypes of the BC6ENTG .	False
Saturation experiments showed that BC6ENTC labelled a single population of binding sites in the spleen ( BC6ENTG ) and hippocampus ( BC6OTHER and BC6OTHER ) (dissociation constants (KD): 0.26 nM and 0.14 nM respectively).	False
Saturation experiments showed that BC6ENTC labelled a single population of binding sites in the spleen ( BC6OTHER ) and hippocampus ( BC6ENTG and BC6OTHER ) (dissociation constants (KD): 0.26 nM and 0.14 nM respectively).	False
Saturation experiments showed that BC6ENTC labelled a single population of binding sites in the spleen ( BC6OTHER ) and hippocampus ( BC6OTHER and BC6ENTG ) (dissociation constants (KD): 0.26 nM and 0.14 nM respectively).	False
The binding of the antipsychotic drugs BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER was studied at the subtypes of the BC6ENTG .	False
The binding of the antipsychotic drugs BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER was studied at the subtypes of the BC6ENTG .	False
PURPOSE: BC6ENTG deficiency is a recently described inborn error of BC6ENTC pathway.	False
It was concluded that the presence of the BC6ENTG in these isoforms is not relevant for the formation of the BC6OTHER / BC6OTHER complex in the absence of BC6ENTC , that is the interaction of BC6OTHER with inactive BC6OTHER .	False
It was concluded that the presence of the BC6OTHER in these isoforms is not relevant for the formation of the BC6ENTG / BC6OTHER complex in the absence of BC6ENTC , that is the interaction of BC6OTHER with inactive BC6OTHER .	False
It was concluded that the presence of the BC6OTHER in these isoforms is not relevant for the formation of the BC6OTHER / BC6ENTG complex in the absence of BC6ENTC , that is the interaction of BC6OTHER with inactive BC6OTHER .	False
It was concluded that the presence of the BC6OTHER in these isoforms is not relevant for the formation of the BC6OTHER / BC6OTHER complex in the absence of BC6ENTC , that is the interaction of BC6ENTG with inactive BC6OTHER .	False
It was concluded that the presence of the BC6OTHER in these isoforms is not relevant for the formation of the BC6OTHER / BC6OTHER complex in the absence of BC6ENTC , that is the interaction of BC6OTHER with inactive BC6ENTG .	False
Multiple BC6ENTG forms are produced by distinct starting points and alternative splicing of the BC6ENTC - terminal exons.	False
The kinetics of onset of BC6OTHER ( BC6OTHER ) receptor desensitization by BC6OTHER , and the extent of attenuation of BC6ENTG desensitization by BC6ENTC , showed pronounced cell - to - cell variation in cultures of rat hippocampal neurons.	False
The kinetics of onset of BC6OTHER BC6ENTG desensitization by BC6OTHER , and the extent of attenuation of BC6OTHER receptor desensitization by BC6ENTC , showed pronounced cell - to - cell variation in cultures of rat hippocampal neurons.	False
The kinetics of onset of BC6ENTC ( BC6OTHER ) receptor desensitization by BC6OTHER , and the extent of attenuation of BC6ENTG desensitization by BC6OTHER , showed pronounced cell - to - cell variation in cultures of rat hippocampal neurons.	False
The kinetics of onset of BC6ENTC BC6ENTG desensitization by BC6OTHER , and the extent of attenuation of BC6OTHER receptor desensitization by BC6OTHER , showed pronounced cell - to - cell variation in cultures of rat hippocampal neurons.	False
The kinetics of onset of BC6OTHER ( BC6ENTC ) receptor desensitization by BC6OTHER , and the extent of attenuation of BC6ENTG desensitization by BC6OTHER , showed pronounced cell - to - cell variation in cultures of rat hippocampal neurons.	False
The complex patterns of sensitivity to BC6ENTC seen in hippocampal neurons could be reconstituted by assembly of recombinant BC6ENTG subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the BC6OTHER and BC6OTHER subunits.	False
The complex patterns of sensitivity to BC6ENTC seen in hippocampal neurons could be reconstituted by assembly of recombinant BC6OTHER subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the BC6ENTG and BC6OTHER subunits.	False
The complex patterns of sensitivity to BC6ENTC seen in hippocampal neurons could be reconstituted by assembly of recombinant BC6OTHER subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the BC6OTHER and BC6ENTG subunits.	False
 BC6ENTG heterogeneity in rat hippocampal neurons revealed by differential sensitivity to BC6ENTC .	False
The complex patterns of sensitivity to BC6OTHER seen in hippocampal neurons could be reconstituted by assembly of recombinant BC6ENTC receptor subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the BC6ENTG and BC6OTHER subunits.	False
The complex patterns of sensitivity to BC6OTHER seen in hippocampal neurons could be reconstituted by assembly of recombinant BC6ENTC receptor subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the BC6OTHER and BC6ENTG subunits.	False
Recovery from modulation by BC6ENTC was slower for BC6ENTG and BC6OTHER than for BC6OTHER and BC6OTHER .	False
Recovery from modulation by BC6ENTC was slower for BC6OTHER and BC6ENTG than for BC6OTHER and BC6OTHER .	False
Recovery from modulation by BC6ENTC was slower for BC6OTHER and BC6OTHER than for BC6ENTG and BC6OTHER .	False
Recovery from modulation by BC6ENTC was slower for BC6OTHER and BC6OTHER than for BC6OTHER and BC6ENTG .	False
The kinetics of onset of BC6OTHER ( BC6OTHER ) receptor desensitization by BC6ENTC , and the extent of attenuation of BC6ENTG desensitization by BC6OTHER , showed pronounced cell - to - cell variation in cultures of rat hippocampal neurons.	False
The kinetics of onset of BC6OTHER BC6ENTG desensitization by BC6ENTC , and the extent of attenuation of BC6OTHER receptor desensitization by BC6OTHER , showed pronounced cell - to - cell variation in cultures of rat hippocampal neurons.	False
Coexpression of the flip and flop splice variants of BC6ENTG , in the absence of BC6OTHER , revealed that heteromeric BC6ENTC receptors with intermediate sensitivity to BC6OTHER , similar to responses observed for the combinations BC6OTHER or BC6OTHER , could be generated independently of the presence of the BC6OTHER subunit.	False
Coexpression of the flip and flop splice variants of BC6OTHER , in the absence of BC6ENTG , revealed that heteromeric BC6ENTC receptors with intermediate sensitivity to BC6OTHER , similar to responses observed for the combinations BC6OTHER or BC6OTHER , could be generated independently of the presence of the BC6OTHER subunit.	False
Coexpression of the flip and flop splice variants of BC6OTHER , in the absence of BC6OTHER , revealed that heteromeric BC6ENTC receptors with intermediate sensitivity to BC6OTHER , similar to responses observed for the combinations BC6ENTG or BC6OTHER , could be generated independently of the presence of the BC6OTHER subunit.	False
Coexpression of the flip and flop splice variants of BC6OTHER , in the absence of BC6OTHER , revealed that heteromeric BC6ENTC receptors with intermediate sensitivity to BC6OTHER , similar to responses observed for the combinations BC6OTHER or BC6ENTG , could be generated independently of the presence of the BC6OTHER subunit.	False
Coexpression of the flip and flop splice variants of BC6OTHER , in the absence of BC6OTHER , revealed that heteromeric BC6ENTC receptors with intermediate sensitivity to BC6OTHER , similar to responses observed for the combinations BC6OTHER or BC6OTHER , could be generated independently of the presence of the BC6ENTG subunit.	False
Coexpression of the flip and flop splice variants of BC6ENTG , in the absence of BC6OTHER , revealed that heteromeric BC6OTHER receptors with intermediate sensitivity to BC6ENTC , similar to responses observed for the combinations BC6OTHER or BC6OTHER , could be generated independently of the presence of the BC6OTHER subunit.	False
Coexpression of the flip and flop splice variants of BC6OTHER , in the absence of BC6ENTG , revealed that heteromeric BC6OTHER receptors with intermediate sensitivity to BC6ENTC , similar to responses observed for the combinations BC6OTHER or BC6OTHER , could be generated independently of the presence of the BC6OTHER subunit.	False
Coexpression of the flip and flop splice variants of BC6OTHER , in the absence of BC6OTHER , revealed that heteromeric BC6ENTG with intermediate sensitivity to BC6ENTC , similar to responses observed for the combinations BC6OTHER or BC6OTHER , could be generated independently of the presence of the BC6OTHER subunit.	False
Coexpression of the flip and flop splice variants of BC6OTHER , in the absence of BC6OTHER , revealed that heteromeric BC6OTHER receptors with intermediate sensitivity to BC6ENTC , similar to responses observed for the combinations BC6ENTG or BC6OTHER , could be generated independently of the presence of the BC6OTHER subunit.	False
Coexpression of the flip and flop splice variants of BC6OTHER , in the absence of BC6OTHER , revealed that heteromeric BC6OTHER receptors with intermediate sensitivity to BC6ENTC , similar to responses observed for the combinations BC6OTHER or BC6ENTG , could be generated independently of the presence of the BC6OTHER subunit.	False
Coexpression of the flip and flop splice variants of BC6OTHER , in the absence of BC6OTHER , revealed that heteromeric BC6OTHER receptors with intermediate sensitivity to BC6ENTC , similar to responses observed for the combinations BC6OTHER or BC6OTHER , could be generated independently of the presence of the BC6ENTG subunit.	False
The kinetics of onset of BC6OTHER BC6ENTG desensitization by BC6OTHER , and the extent of attenuation of BC6ENTC receptor desensitization by BC6OTHER , showed pronounced cell - to - cell variation in cultures of rat hippocampal neurons.	False
However, recovery from modulation by BC6ENTC was twofold slower for BC6ENTG than for homomeric BC6OTHER , indicating that the BC6OTHER and BC6OTHER subunits are not functionally equivalent in controlling sensitivity to BC6OTHER .	False
However, recovery from modulation by BC6ENTC was twofold slower for BC6OTHER than for homomeric BC6ENTG , indicating that the BC6OTHER and BC6OTHER subunits are not functionally equivalent in controlling sensitivity to BC6OTHER .	False
However, recovery from modulation by BC6ENTC was twofold slower for BC6OTHER than for homomeric BC6OTHER , indicating that the BC6ENTG and BC6OTHER subunits are not functionally equivalent in controlling sensitivity to BC6OTHER .	False
However, recovery from modulation by BC6ENTC was twofold slower for BC6OTHER than for homomeric BC6OTHER , indicating that the BC6OTHER and BC6ENTG subunits are not functionally equivalent in controlling sensitivity to BC6OTHER .	False
However, recovery from modulation by BC6OTHER was twofold slower for BC6ENTG than for homomeric BC6OTHER , indicating that the BC6OTHER and BC6OTHER subunits are not functionally equivalent in controlling sensitivity to BC6ENTC .	False
However, recovery from modulation by BC6OTHER was twofold slower for BC6OTHER than for homomeric BC6ENTG , indicating that the BC6OTHER and BC6OTHER subunits are not functionally equivalent in controlling sensitivity to BC6ENTC .	False
However, recovery from modulation by BC6OTHER was twofold slower for BC6OTHER than for homomeric BC6OTHER , indicating that the BC6ENTG and BC6OTHER subunits are not functionally equivalent in controlling sensitivity to BC6ENTC .	False
However, recovery from modulation by BC6OTHER was twofold slower for BC6OTHER than for homomeric BC6OTHER , indicating that the BC6OTHER and BC6ENTG subunits are not functionally equivalent in controlling sensitivity to BC6ENTC .	False
The juvenile visceral steatosis (jvs) mouse, having a mutation in the BC6ENTC transporter gene BC6ENTG , is a model of primary systemic BC6OTHER deficiency in humans (SCD, CHEM).	CPR:9
The juvenile visceral steatosis (jvs) mouse, having a mutation in the BC6OTHER transporter gene BC6ENTG , is a model of primary systemic BC6ENTC deficiency in humans (SCD, CHEM).	False
 BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6ENTG , which have no demonstrable general anesthetic activity in vivo. In this study, BC6ENTC ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6OTHER ), was used to characterize the BC6OTHER and BC6OTHER sites on the desensitized Torpedo californica BC6OTHER and to investigate if these sites interact.	False
 BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6OTHER , which have no demonstrable general anesthetic activity in vivo. In this study, BC6ENTC ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6OTHER ), was used to characterize the BC6OTHER and BC6OTHER sites on the desensitized Torpedo californica BC6ENTG and to investigate if these sites interact.	False
 BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6ENTG , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6ENTC ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6OTHER ), was used to characterize the BC6OTHER and BC6OTHER sites on the desensitized Torpedo californica BC6OTHER and to investigate if these sites interact.	False
 BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6OTHER , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6ENTC ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6OTHER ), was used to characterize the BC6OTHER and BC6OTHER sites on the desensitized Torpedo californica BC6ENTG and to investigate if these sites interact.	False
 BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6ENTG , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6ENTC ( BC6OTHER ), was used to characterize the BC6OTHER and BC6OTHER sites on the desensitized Torpedo californica BC6OTHER and to investigate if these sites interact.	False
 BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6OTHER , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6ENTC ( BC6OTHER ), was used to characterize the BC6OTHER and BC6OTHER sites on the desensitized Torpedo californica BC6ENTG and to investigate if these sites interact.	False
 BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6ENTG , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6ENTC ), was used to characterize the BC6OTHER and BC6OTHER sites on the desensitized Torpedo californica BC6OTHER and to investigate if these sites interact.	False
 BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6OTHER , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6ENTC ), was used to characterize the BC6OTHER and BC6OTHER sites on the desensitized Torpedo californica BC6ENTG and to investigate if these sites interact.	False
 BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6ENTG , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6OTHER ), was used to characterize the BC6ENTC and BC6OTHER sites on the desensitized Torpedo californica BC6OTHER and to investigate if these sites interact.	False
 BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6OTHER , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6OTHER ), was used to characterize the BC6ENTC and BC6OTHER sites on the desensitized Torpedo californica BC6ENTG and to investigate if these sites interact.	False
 BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6ENTG , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6OTHER ), was used to characterize the BC6OTHER and BC6ENTC sites on the desensitized Torpedo californica BC6OTHER and to investigate if these sites interact.	False
 BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6OTHER , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6OTHER ), was used to characterize the BC6OTHER and BC6ENTC sites on the desensitized Torpedo californica BC6ENTG and to investigate if these sites interact.	False
BC6ENTC are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral BC6ENTG ( BC6OTHER ) by binding to one or more specific sites on the BC6OTHER .	CPR:4
BC6ENTC are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic BC6OTHER receptor ( BC6ENTG ) by binding to one or more specific sites on the BC6OTHER .	False
BC6ENTC are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic BC6OTHER receptor ( BC6OTHER ) by binding to one or more specific sites on the BC6ENTG .	False
 BC6ENTC and BC6OTHER sites on the BC6ENTG and their allosteric interaction.	False
 BC6OTHER and BC6ENTC sites on the BC6ENTG and their allosteric interaction.	False
BC6OTHER are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic BC6ENTC receptor ( BC6ENTG ) by binding to one or more specific sites on the BC6OTHER .	False
BC6OTHER are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic BC6ENTC receptor ( BC6OTHER ) by binding to one or more specific sites on the BC6ENTG .	False
 BC6ENTC are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6ENTG , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6OTHER ), was used to characterize the BC6OTHER and BC6OTHER sites on the desensitized Torpedo californica BC6OTHER and to investigate if these sites interact.	CPR:4
 BC6ENTC are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6OTHER , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6OTHER ), was used to characterize the BC6OTHER and BC6OTHER sites on the desensitized Torpedo californica BC6ENTG and to investigate if these sites interact.	False
AIM: This study seeks to determine the role of the BC6ENTC transferases M1 and T1 null genotypes ( BC6ENTG *0 and BC6OTHER *0) in individual susceptibility to bladder cancer in a Tunisian population.	False
AIM: This study seeks to determine the role of the BC6ENTC transferases M1 and T1 null genotypes ( BC6OTHER *0 and BC6ENTG *0) in individual susceptibility to bladder cancer in a Tunisian population.	False
BC6ENTC was fortuitously found to be a novel, potent inhibitor of the BC6ENTG .	CPR:4
It showed high rat lymphoma growth - inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of BC6ENTG - - mediated BC6ENTC uptake, in contrast to its colonic metabolites, BC6OTHER and BC6OTHER .	CPR:9
It showed high rat lymphoma growth - inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of BC6ENTG - - mediated BC6OTHER uptake, in contrast to its colonic metabolites, BC6ENTC and BC6OTHER .	CPR:4
It showed high rat lymphoma growth - inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of BC6ENTG - - mediated BC6OTHER uptake, in contrast to its colonic metabolites, BC6OTHER and BC6ENTC .	CPR:4
 BC6ENTC , a potent suppressor of lymphoma growth by inhibition of the BC6ENTG : a new action for an old drug.	CPR:4
The BC6ENTG represents a novel target for BC6ENTC - like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular BC6OTHER .	False
The BC6ENTG represents a novel target for BC6OTHER - like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular BC6ENTC .	CPR:9
We recently showed that BC6OTHER is metabolized in vitro by BC6OTHER catabolic enzyme BC6ENTC / BC6OTHER - N(1) - acetyltransferase ( BC6ENTG ) and by BC6OTHER ( BC6OTHER ) to its monoacetylated derivative (MAT).	False
We recently showed that BC6OTHER is metabolized in vitro by BC6OTHER catabolic enzyme BC6ENTC / BC6OTHER - N(1) - acetyltransferase ( BC6OTHER ) and by BC6ENTG ( BC6OTHER ) to its monoacetylated derivative (MAT).	False
We recently showed that BC6OTHER is metabolized in vitro by BC6OTHER catabolic enzyme BC6ENTC / BC6OTHER - N(1) - acetyltransferase ( BC6OTHER ) and by BC6OTHER ( BC6ENTG ) to its monoacetylated derivative (MAT).	False
We recently showed that BC6OTHER is metabolized in vitro by BC6OTHER catabolic enzyme CHEM / CHEM - acetyltransferase ( BC6ENTG ) and by BC6OTHER ( BC6OTHER ) to its monoacetylated derivative (MAT).	False
We recently showed that BC6OTHER is metabolized in vitro by BC6OTHER catabolic enzyme CHEM / CHEM - acetyltransferase ( BC6OTHER ) and by BC6ENTG ( BC6OTHER ) to its monoacetylated derivative (MAT).	False
We recently showed that BC6OTHER is metabolized in vitro by BC6OTHER catabolic enzyme CHEM / CHEM - acetyltransferase ( BC6OTHER ) and by BC6OTHER ( BC6ENTG ) to its monoacetylated derivative (MAT).	False
We recently showed that BC6OTHER is metabolized in vitro by BC6OTHER catabolic enzyme BC6ENTG ( BC6OTHER ) and by BC6ENTC acetyltransferase ( BC6OTHER ) to its monoacetylated derivative (MAT).	False
We recently showed that BC6OTHER is metabolized in vitro by BC6OTHER catabolic enzyme CHEM / BC6OTHER - N(1) - acetyltransferase ( BC6ENTG ) and by BC6ENTC acetyltransferase ( BC6OTHER ) to its monoacetylated derivative (MAT).	False
We recently showed that BC6OTHER is metabolized in vitro by BC6OTHER catabolic enzyme CHEM / BC6OTHER - N(1) - acetyltransferase ( BC6OTHER ) and by BC6ENTC acetyltransferase ( BC6ENTG ) to its monoacetylated derivative (MAT).	False
The acetylation of BC6ENTC is increased in BC6ENTG - overexpressing mice compared with wild - type mice.	CPR:9
However, BC6ENTG - deficient mice metabolize BC6ENTC at the same rate as the wild - type mice, indicating the existence of another BC6OTHER respons 2ible for its metabolism in mice.	False
However, BC6OTHER - deficient mice metabolize BC6ENTC at the same rate as the wild - type mice, indicating the existence of another BC6ENTG respons 2ible for its metabolism in mice.	CPR:9
Here, we show that siRNA - mediated knockdown of BC6ENTG in HEPG2 cells and in primary hepatocytes from the BC6OTHER - deficient or wild - type mice reduced the metabolism of BC6ENTC to MAT.	CPR:9
Here, we show that siRNA - mediated knockdown of BC6OTHER in HEPG2 cells and in primary hepatocytes from the BC6ENTG - deficient or wild - type mice reduced the metabolism of BC6ENTC to MAT.	False
By contrast, BC6ENTC ( BC6OTHER ), a charge - deficient BC6OTHER analog, was an extremely poor substrate of BC6OTHER and was metabolized by BC6ENTG in HEPG2 cells and in wild - type primary hepatocytes.	CPR:9
By contrast, BC6ENTC ( BC6OTHER ), a charge - deficient BC6OTHER analog, was an extremely poor substrate of BC6ENTG and was metabolized by BC6OTHER in HEPG2 cells and in wild - type primary hepatocytes.	CPR:9
By contrast, BC6OTHER ( BC6ENTC ), a charge - deficient BC6OTHER analog, was an extremely poor substrate of BC6OTHER and was metabolized by BC6ENTG in HEPG2 cells and in wild - type primary hepatocytes.	CPR:9
By contrast, BC6OTHER ( BC6ENTC ), a charge - deficient BC6OTHER analog, was an extremely poor substrate of BC6ENTG and was metabolized by BC6OTHER in HEPG2 cells and in wild - type primary hepatocytes.	CPR:9
By contrast, BC6OTHER ( BC6OTHER ), a charge - deficient BC6ENTC analog, was an extremely poor substrate of BC6OTHER and was metabolized by BC6ENTG in HEPG2 cells and in wild - type primary hepatocytes.	CPR:9
By contrast, BC6OTHER ( BC6OTHER ), a charge - deficient BC6ENTC analog, was an extremely poor substrate of BC6ENTG and was metabolized by BC6OTHER in HEPG2 cells and in wild - type primary hepatocytes.	CPR:9
Metabolism of BC6OTHER and BC6OTHER by the BC6ENTG and BC6ENTC acetyltransferase.	False
Metabolism of BC6ENTC and BC6OTHER by the CHEM / BC6OTHER - N(1) - acetyltransferase and BC6ENTG .	CPR:9
Metabolism of BC6ENTC and BC6OTHER by the BC6ENTG and BC6OTHER .	CPR:9
Metabolism of BC6OTHER and BC6ENTC by the CHEM / BC6OTHER - N(1) - acetyltransferase and BC6ENTG .	CPR:9
Metabolism of BC6OTHER and BC6ENTC by the BC6ENTG and BC6OTHER .	CPR:9
Metabolism of BC6OTHER and BC6OTHER by the BC6ENTC / BC6OTHER - N(1) - acetyltransferase and BC6ENTG .	False
Metabolism of BC6OTHER and BC6OTHER by the CHEM / CHEM - acetyltransferase and BC6ENTG .	False
Thus, despite the similar structures of BC6ENTC and BC6OTHER , BC6ENTG is the main acetylator of BC6OTHER , whereas BC6OTHER is primarily acetylated by BC6OTHER .	False
Thus, despite the similar structures of BC6ENTC and BC6OTHER , BC6OTHER is the main acetylator of BC6OTHER , whereas BC6OTHER is primarily acetylated by BC6ENTG .	False
Thus, despite the similar structures of BC6OTHER and BC6ENTC , BC6ENTG is the main acetylator of BC6OTHER , whereas BC6OTHER is primarily acetylated by BC6OTHER .	False
Thus, despite the similar structures of BC6OTHER and BC6ENTC , BC6OTHER is the main acetylator of BC6OTHER , whereas BC6OTHER is primarily acetylated by BC6ENTG .	False
Thus, despite the similar structures of BC6OTHER and BC6OTHER , BC6ENTG is the main acetylator of BC6ENTC , whereas BC6OTHER is primarily acetylated by BC6OTHER .	CPR:9
Thus, despite the similar structures of BC6OTHER and BC6OTHER , BC6OTHER is the main acetylator of BC6ENTC , whereas BC6OTHER is primarily acetylated by BC6ENTG .	False
Thus, despite the similar structures of BC6OTHER and BC6OTHER , BC6ENTG is the main acetylator of BC6OTHER , whereas BC6ENTC is primarily acetylated by BC6OTHER .	False
Thus, despite the similar structures of BC6OTHER and BC6OTHER , BC6OTHER is the main acetylator of BC6OTHER , whereas BC6ENTC is primarily acetylated by BC6ENTG .	CPR:9
We recently showed that BC6ENTC is metabolized in vitro by BC6OTHER catabolic enzyme BC6ENTG ( BC6OTHER ) and by BC6OTHER ( BC6OTHER ) to its monoacetylated derivative (MAT).	CPR:9
We recently showed that BC6ENTC is metabolized in vitro by BC6OTHER catabolic enzyme CHEM / BC6OTHER - N(1) - acetyltransferase ( BC6ENTG ) and by BC6OTHER ( BC6OTHER ) to its monoacetylated derivative (MAT).	CPR:9
We recently showed that BC6ENTC is metabolized in vitro by BC6OTHER catabolic enzyme CHEM / BC6OTHER - N(1) - acetyltransferase ( BC6OTHER ) and by BC6ENTG ( BC6OTHER ) to its monoacetylated derivative (MAT).	CPR:9
We recently showed that BC6ENTC is metabolized in vitro by BC6OTHER catabolic enzyme CHEM / BC6OTHER - N(1) - acetyltransferase ( BC6OTHER ) and by BC6OTHER ( BC6ENTG ) to its monoacetylated derivative (MAT).	CPR:9
We recently showed that BC6OTHER is metabolized in vitro by BC6ENTC catabolic enzyme BC6ENTG ( BC6OTHER ) and by BC6OTHER ( BC6OTHER ) to its monoacetylated derivative (MAT).	CPR:9
We recently showed that BC6OTHER is metabolized in vitro by BC6ENTC catabolic enzyme CHEM / BC6OTHER - N(1) - acetyltransferase ( BC6ENTG ) and by BC6OTHER ( BC6OTHER ) to its monoacetylated derivative (MAT).	CPR:9
We recently showed that BC6OTHER is metabolized in vitro by BC6ENTC catabolic enzyme CHEM / BC6OTHER - N(1) - acetyltransferase ( BC6OTHER ) and by BC6ENTG ( BC6OTHER ) to its monoacetylated derivative (MAT).	False
We recently showed that BC6OTHER is metabolized in vitro by BC6ENTC catabolic enzyme CHEM / BC6OTHER - N(1) - acetyltransferase ( BC6OTHER ) and by BC6OTHER ( BC6ENTG ) to its monoacetylated derivative (MAT).	False
This direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6ENTG of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6ENTC to be released from BC6OTHER .	False
This direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6ENTG suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6ENTC to be released from BC6OTHER .	False
This direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6ENTG , causes BC6ENTC to be released from BC6OTHER .	False
This direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6ENTC to be released from BC6ENTG .	False
The CHEM - sensitive BC6ENTC (CHEM) channels in pancreatic beta cells are critical in the regulation of BC6OTHER - induced BC6ENTG secretion.	False
Although electrophysiological studies provide clues to the complex control of BC6ENTG by BC6ENTC , BC6OTHER , and pharmacological agents, the molecular mechanism of BC6OTHER regulation remains unclear.	False
Although electrophysiological studies provide clues to the complex control of BC6OTHER by BC6ENTC , BC6OTHER , and pharmacological agents, the molecular mechanism of BC6ENTG regulation remains unclear.	False
Although electrophysiological studies provide clues to the complex control of BC6ENTG by BC6OTHER , BC6ENTC , and pharmacological agents, the molecular mechanism of BC6OTHER regulation remains unclear.	False
Although electrophysiological studies provide clues to the complex control of BC6OTHER by BC6OTHER , BC6ENTC , and pharmacological agents, the molecular mechanism of BC6ENTG regulation remains unclear.	False
The BC6ENTG is a heterooligomeric complex of BC6OTHER subunits of the BC6ENTC - binding - cassette superfamily with two BC6OTHER ( BC6OTHER and BC6OTHER ) and the pore - forming BC6OTHER subunits.	False
The BC6OTHER is a heterooligomeric complex of BC6ENTG subunits of the BC6ENTC - binding - cassette superfamily with two BC6OTHER ( BC6OTHER and BC6OTHER ) and the pore - forming BC6OTHER subunits.	False
The BC6OTHER is a heterooligomeric complex of BC6OTHER subunits of the BC6ENTC - binding - cassette superfamily with two BC6ENTG ( BC6OTHER and BC6OTHER ) and the pore - forming BC6OTHER subunits.	False
The BC6OTHER is a heterooligomeric complex of BC6OTHER subunits of the BC6ENTC - binding - cassette superfamily with two BC6OTHER ( BC6ENTG and BC6OTHER ) and the pore - forming BC6OTHER subunits.	False
The BC6OTHER is a heterooligomeric complex of BC6OTHER subunits of the BC6ENTC - binding - cassette superfamily with two BC6OTHER ( BC6OTHER and BC6ENTG ) and the pore - forming BC6OTHER subunits.	False
The BC6OTHER is a heterooligomeric complex of BC6OTHER subunits of the BC6ENTC - binding - cassette superfamily with two BC6OTHER ( BC6OTHER and BC6OTHER ) and the pore - forming BC6ENTG subunits.	False
The BC6ENTG is a heterooligomeric complex of BC6OTHER subunits of the BC6OTHER - binding - cassette superfamily with two BC6ENTC - binding folds ( BC6OTHER and BC6OTHER ) and the pore - forming BC6OTHER subunits.	False
The BC6OTHER is a heterooligomeric complex of BC6ENTG subunits of the BC6OTHER - binding - cassette superfamily with two BC6ENTC - binding folds ( BC6OTHER and BC6OTHER ) and the pore - forming BC6OTHER subunits.	False
The BC6OTHER is a heterooligomeric complex of BC6OTHER subunits of the BC6OTHER - binding - cassette superfamily with two BC6ENTC - binding folds ( BC6ENTG and BC6OTHER ) and the pore - forming BC6OTHER subunits.	False
The BC6OTHER is a heterooligomeric complex of BC6OTHER subunits of the BC6OTHER - binding - cassette superfamily with two BC6ENTC - binding folds ( BC6OTHER and BC6ENTG ) and the pore - forming BC6OTHER subunits.	False
The BC6OTHER is a heterooligomeric complex of BC6OTHER subunits of the BC6OTHER - binding - cassette superfamily with two BC6ENTC - binding folds ( BC6OTHER and BC6OTHER ) and the pore - forming BC6ENTG subunits.	False
The BC6ENTC - sensitive BC6OTHER (CHEM) channels in pancreatic beta cells are critical in the regulation of BC6OTHER - induced BC6ENTG secretion.	False
Here, we report that BC6ENTC and BC6OTHER , but not the BC6OTHER salt of BC6OTHER , stabilize the binding of prebound BC6OTHER to BC6ENTG .	False
Here, we report that BC6OTHER and BC6ENTC , but not the BC6OTHER salt of BC6OTHER , stabilize the binding of prebound BC6OTHER to BC6ENTG .	False
Here, we report that BC6OTHER and BC6OTHER , but not the BC6ENTC salt of BC6OTHER , stabilize the binding of prebound BC6OTHER to BC6ENTG .	False
The CHEM - sensitive BC6OTHER (CHEM) channels in pancreatic beta cells are critical in the regulation of BC6ENTC - induced BC6ENTG secretion.	CPR:3
The BC6ENTG in pancreatic beta cells are critical in the regulation of BC6ENTC - induced BC6OTHER secretion.	False
Here, we report that BC6OTHER and BC6OTHER , but not the BC6OTHER salt of BC6ENTC , stabilize the binding of prebound BC6OTHER to BC6ENTG .	False
Here, we report that BC6OTHER and BC6OTHER , but not the BC6OTHER salt of BC6OTHER , stabilize the binding of prebound BC6ENTC to BC6ENTG .	False
Mutation in the BC6ENTG of BC6OTHER of BC6OTHER abolished this stabilizing effect of BC6ENTC .	False
Mutation in the BC6OTHER of BC6ENTG of BC6OTHER abolished this stabilizing effect of BC6ENTC .	False
Mutation in the BC6OTHER of BC6OTHER of BC6ENTG abolished this stabilizing effect of BC6ENTC .	False
These results suggest that BC6ENTG binds BC6ENTC strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6OTHER .	False
These results suggest that BC6OTHER binds BC6ENTC strongly at BC6ENTG and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6OTHER .	False
These results suggest that BC6OTHER binds BC6ENTC strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6ENTG or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6OTHER .	False
These results suggest that BC6OTHER binds BC6ENTC strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6ENTG , stabilizes prebound BC6OTHER binding at BC6OTHER .	False
These results suggest that BC6OTHER binds BC6ENTC strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6ENTG .	False
These results suggest that BC6ENTG binds BC6OTHER strongly at BC6OTHER and that BC6ENTC , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6OTHER .	False
These results suggest that BC6OTHER binds BC6OTHER strongly at BC6ENTG and that BC6ENTC , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6OTHER .	False
These results suggest that BC6OTHER binds BC6OTHER strongly at BC6OTHER and that BC6ENTC , either by direct binding to BC6ENTG or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6OTHER .	False
These results suggest that BC6OTHER binds BC6OTHER strongly at BC6OTHER and that BC6ENTC , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6ENTG , stabilizes prebound BC6OTHER binding at BC6OTHER .	False
These results suggest that BC6OTHER binds BC6OTHER strongly at BC6OTHER and that BC6ENTC , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6ENTG .	False
These results suggest that BC6ENTG binds BC6OTHER strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6ENTC at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6OTHER .	False
These results suggest that BC6OTHER binds BC6OTHER strongly at BC6ENTG and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6ENTC at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6OTHER .	False
These results suggest that BC6OTHER binds BC6OTHER strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6ENTG or by hydrolysis of bound BC6ENTC at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6OTHER .	False
These results suggest that BC6OTHER binds BC6OTHER strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6ENTC at BC6ENTG , stabilizes prebound BC6OTHER binding at BC6OTHER .	CPR:9
These results suggest that BC6OTHER binds BC6OTHER strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6ENTC at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6ENTG .	False
These results suggest that BC6ENTG binds BC6OTHER strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6ENTC binding at BC6OTHER .	False
These results suggest that BC6OTHER binds BC6OTHER strongly at BC6ENTG and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6ENTC binding at BC6OTHER .	False
These results suggest that BC6OTHER binds BC6OTHER strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6ENTG or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6ENTC binding at BC6OTHER .	False
These results suggest that BC6OTHER binds BC6OTHER strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6ENTG , stabilizes prebound BC6ENTC binding at BC6OTHER .	False
These results suggest that BC6OTHER binds BC6OTHER strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6ENTC binding at BC6ENTG .	False
The BC6ENTC caused release of prebound BC6OTHER from BC6ENTG in the presence of BC6OTHER or BC6OTHER in a concentration - dependent manner.	False
Cooperative binding of BC6ENTC and BC6OTHER in the BC6ENTG is modulated by BC6OTHER .	False
Cooperative binding of BC6OTHER and BC6ENTC in the BC6ENTG is modulated by BC6OTHER .	False
The BC6OTHER caused release of prebound BC6ENTC from BC6ENTG in the presence of BC6OTHER or BC6OTHER in a concentration - dependent manner.	False
Cooperative binding of BC6OTHER and BC6OTHER in the BC6ENTG is modulated by BC6ENTC .	False
The BC6OTHER caused release of prebound BC6OTHER from BC6ENTG in the presence of BC6ENTC or BC6OTHER in a concentration - dependent manner.	False
The BC6OTHER caused release of prebound BC6OTHER from BC6ENTG in the presence of BC6OTHER or BC6ENTC in a concentration - dependent manner.	False
This direct biochemical evidence of cooperative interaction in BC6ENTC binding of the two BC6ENTG of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6OTHER .	False
This direct biochemical evidence of cooperative interaction in BC6ENTC binding of the two BC6OTHER of BC6ENTG suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6OTHER .	False
This direct biochemical evidence of cooperative interaction in BC6ENTC binding of the two BC6OTHER of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6ENTG , causes BC6OTHER to be released from BC6OTHER .	False
This direct biochemical evidence of cooperative interaction in BC6ENTC binding of the two BC6OTHER of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6ENTG .	False
This direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6ENTG of BC6OTHER suggests that BC6ENTC both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6OTHER .	False
This direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6ENTG suggests that BC6ENTC both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6OTHER .	False
This direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6OTHER suggests that BC6ENTC both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6ENTG , causes BC6OTHER to be released from BC6OTHER .	False
This direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6OTHER suggests that BC6ENTC both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6ENTG .	False
This direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6ENTG of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6ENTC and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6OTHER .	False
This direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6ENTG suggests that BC6OTHER both blocks this cooperative binding of BC6ENTC and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6OTHER .	False
This direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6ENTC and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6ENTG , causes BC6OTHER to be released from BC6OTHER .	False
This direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6ENTC and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6ENTG .	False
This direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6ENTG of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6ENTC and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6OTHER .	False
This direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6ENTG suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6ENTC and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6OTHER .	False
This direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6ENTC and, in cooperation with the BC6OTHER bound at BC6ENTG , causes BC6OTHER to be released from BC6OTHER .	False
This direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6ENTC and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6ENTG .	False
This direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6ENTG of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6ENTC bound at BC6OTHER , causes BC6OTHER to be released from BC6OTHER .	False
This direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6ENTG suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6ENTC bound at BC6OTHER , causes BC6OTHER to be released from BC6OTHER .	False
This direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6ENTC bound at BC6ENTG , causes BC6OTHER to be released from BC6OTHER .	False
This direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6ENTC bound at BC6OTHER , causes BC6OTHER to be released from BC6ENTG .	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6ENTG ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6ENTG ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6ENTG ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6ENTG ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6ENTG ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6ENTG ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6ENTG ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6ENTG ) and BC6ENTC ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6ENTG ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6ENTG ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6ENTC ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6ENTG ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6ENTG ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) levels and increased BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6ENTG ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6ENTG ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Compared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
BC6ENTG hyperphosphorylation (PHF - 1 epitope) shown by SAMP8 mice at this age was also decreased in the hippocampus of BC6ENTC - treated mice, an effect probably related to a decrease in BC6OTHER expression.	False
BC6OTHER hyperphosphorylation (PHF - 1 epitope) shown by SAMP8 mice at this age was also decreased in the hippocampus of BC6ENTC - treated mice, an effect probably related to a decrease in BC6ENTG expression.	False
Interestingly, BC6ENTC also phosphorylated BC6ENTG in SAMP8 mice, which was associated with an increase of BC6OTHER phosphorylation, contributing therefore to the reductions in BC6OTHER hyperphosphorylation.	False
Interestingly, BC6ENTC also phosphorylated BC6OTHER in SAMP8 mice, which was associated with an increase of BC6ENTG phosphorylation, contributing therefore to the reductions in BC6OTHER hyperphosphorylation.	False
Interestingly, BC6ENTC also phosphorylated BC6OTHER in SAMP8 mice, which was associated with an increase of BC6OTHER phosphorylation, contributing therefore to the reductions in BC6ENTG hyperphosphorylation.	False
Synaptic pathology in SAMP8 mice, as shown by decreases in BC6ENTG and BC6OTHER , was also counteracted by BC6ENTC treatment.	False
Synaptic pathology in SAMP8 mice, as shown by decreases in BC6OTHER and BC6ENTG , was also counteracted by BC6ENTC treatment.	False
In the present study we tested whether BC6ENTC , a BC6ENTG antagonist commonly used as antihypertensive drug, could ameliorate the cognitive impairments and increases in AD - related markers shown by the senescence - accelerated mouse prone - 8 (SAMP8).	CPR:6
 BC6ENTC restores cognitive deficits and improves BC6ENTG and BC6OTHER pathologies in a senescence - accelerated mouse model.	False
 BC6ENTC restores cognitive deficits and improves BC6OTHER and BC6ENTG pathologies in a senescence - accelerated mouse model.	False
Cell proliferation and apoptosis rate were measured in HDMVEC by BC6ENTC ( BC6OTHER ) incorporation and BC6ENTG and BC6OTHER activity, respectively.	False
Cell proliferation and apoptosis rate were measured in HDMVEC by BC6ENTC ( BC6OTHER ) incorporation and BC6OTHER and BC6ENTG activity, respectively.	False
Cell proliferation and apoptosis rate were measured in HDMVEC by BC6OTHER ( BC6ENTC ) incorporation and BC6ENTG and BC6OTHER activity, respectively.	False
Cell proliferation and apoptosis rate were measured in HDMVEC by BC6OTHER ( BC6ENTC ) incorporation and BC6OTHER and BC6ENTG activity, respectively.	False
Fasting serum BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.5 ± 15.2 years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter).	False
Fasting serum BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.5 ± 15.2 years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter).	False
Fasting serum BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC , as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.5 ± 15.2 years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter).	False
Fasting serum BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC , as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.5 ± 15.2 years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter).	False
Fasting serum BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC , as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.5 ± 15.2 years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter).	False
More robust BC6ENTG secretion and microparticle generation with BC6OTHER - AP was attributable to stronger and more sustained phosphorylation of myosin light chain at BC6ENTC 19 and BC6OTHER 18.	False
More robust BC6OTHER secretion and microparticle generation with BC6ENTG - AP was attributable to stronger and more sustained phosphorylation of myosin light chain at BC6ENTC 19 and BC6OTHER 18.	False
More robust BC6ENTG secretion and microparticle generation with BC6OTHER - AP was attributable to stronger and more sustained phosphorylation of myosin light chain at BC6OTHER 19 and BC6ENTC 18.	False
More robust BC6OTHER secretion and microparticle generation with BC6ENTG - AP was attributable to stronger and more sustained phosphorylation of myosin light chain at BC6OTHER 19 and BC6ENTC 18.	False
Inhibited BC6ENTG undergoes aging to release BC6ENTC and BC6OTHER .	False
Inhibited BC6ENTG undergoes aging to release BC6OTHER and BC6ENTC .	False
Mass spectral analysis of BC6ENTC - inhibited BC6ENTG digested with BC6OTHER - C showed an BC6OTHER adduct (+106amu) on BC6OTHER 499, a residue far from the active site, but not on BC6OTHER - 438.	CPR:4
Mass spectral analysis of BC6OTHER - inhibited BC6ENTG digested with BC6ENTC - C showed an BC6OTHER adduct (+106amu) on BC6OTHER 499, a residue far from the active site, but not on BC6OTHER - 438.	False
Mass spectral analysis of BC6OTHER - inhibited BC6ENTG digested with BC6OTHER - C showed an BC6ENTC adduct (+106amu) on BC6OTHER 499, a residue far from the active site, but not on BC6OTHER - 438.	False
Mass spectral analysis of BC6OTHER - inhibited BC6ENTG digested with BC6OTHER - C showed an BC6OTHER adduct (+106amu) on BC6ENTC 499, a residue far from the active site, but not on BC6OTHER - 438.	False
Mass spectral analysis of BC6OTHER - inhibited BC6ENTG digested with BC6OTHER - C showed an BC6OTHER adduct (+106amu) on BC6OTHER 499, a residue far from the active site, but not on BC6ENTC - 438.	False
 BC6ENTC makes multiple adducts on free BC6OTHER , but does not form an adduct on BC6OTHER 438 of BC6ENTG .	False
 BC6OTHER makes multiple adducts on free BC6OTHER , but does not form an adduct on BC6ENTC 438 of BC6ENTG .	False
 BC6OTHER makes multiple adducts on free BC6ENTC , but does not form an adduct on BC6OTHER 438 of BC6ENTG .	False
BC6ENTC irreversibly inhibits BC6ENTG ( BC6OTHER ) in human plasma by forming adducts on the active site BC6OTHER ( BC6OTHER - 198).	CPR:4
BC6ENTC irreversibly inhibits BC6OTHER ( BC6ENTG ) in human plasma by forming adducts on the active site BC6OTHER ( BC6OTHER - 198).	CPR:4
BC6OTHER irreversibly inhibits BC6ENTG ( BC6OTHER ) in human plasma by forming adducts on the active site BC6ENTC ( BC6OTHER - 198).	False
BC6OTHER irreversibly inhibits BC6OTHER ( BC6ENTG ) in human plasma by forming adducts on the active site BC6ENTC ( BC6OTHER - 198).	False
BC6OTHER irreversibly inhibits BC6ENTG ( BC6OTHER ) in human plasma by forming adducts on the active site BC6OTHER ( BC6ENTC - 198).	False
BC6OTHER irreversibly inhibits BC6OTHER ( BC6ENTG ) in human plasma by forming adducts on the active site BC6OTHER ( BC6ENTC - 198).	False
BC6ENTC receptor ( BC6ENTG ) signaling is essential for prostate cancer (PCa) development in humans.	False
Furthermore, we demonstrated that BC6ENTG binds to both the BC6ENTC - terminal domain and the ligand - binding domain of BC6OTHER , and the BC6OTHER of BC6OTHER is required for the interaction of BC6OTHER and BC6OTHER proteins.	False
Furthermore, we demonstrated that BC6OTHER binds to both the BC6ENTC - terminal domain and the ligand - binding domain of BC6ENTG , and the BC6OTHER of BC6OTHER is required for the interaction of BC6OTHER and BC6OTHER proteins.	False
Furthermore, we demonstrated that BC6OTHER binds to both the BC6ENTC - terminal domain and the ligand - binding domain of BC6OTHER , and the BC6ENTG of BC6OTHER is required for the interaction of BC6OTHER and BC6OTHER proteins.	False
Furthermore, we demonstrated that BC6OTHER binds to both the BC6ENTC - terminal domain and the ligand - binding domain of BC6OTHER , and the BC6OTHER of BC6ENTG is required for the interaction of BC6OTHER and BC6OTHER proteins.	False
Furthermore, we demonstrated that BC6OTHER binds to both the BC6ENTC - terminal domain and the ligand - binding domain of BC6OTHER , and the BC6OTHER of BC6OTHER is required for the interaction of BC6ENTG and BC6OTHER proteins.	False
Furthermore, we demonstrated that BC6OTHER binds to both the BC6ENTC - terminal domain and the ligand - binding domain of BC6OTHER , and the BC6OTHER of BC6OTHER is required for the interaction of BC6OTHER and BC6ENTG proteins.	False
BC6ENTG perturbs the BC6ENTC - induced interaction between the BC6OTHER terminus and BC6OTHER terminus of BC6OTHER .	False
BC6OTHER perturbs the BC6ENTC - induced interaction between the BC6OTHER terminus and BC6OTHER terminus of BC6ENTG .	False
BC6ENTG perturbs the BC6OTHER - induced interaction between the BC6ENTC terminus and BC6OTHER terminus of BC6OTHER .	False
BC6OTHER perturbs the BC6OTHER - induced interaction between the BC6ENTC terminus and BC6OTHER terminus of BC6ENTG .	False
BC6ENTG perturbs the BC6OTHER - induced interaction between the BC6OTHER terminus and BC6ENTC terminus of BC6OTHER .	False
BC6OTHER perturbs the BC6OTHER - induced interaction between the BC6OTHER terminus and BC6ENTC terminus of BC6ENTG .	False
Here, we provide evidence that BC6ENTG physically interacts with BC6OTHER and functions as an BC6OTHER corespressor in both an BC6ENTC - dependent and BC6OTHER - independent manner.	False
Here, we provide evidence that BC6OTHER physically interacts with BC6ENTG and functions as an BC6OTHER corespressor in both an BC6ENTC - dependent and BC6OTHER - independent manner.	False
Here, we provide evidence that BC6OTHER physically interacts with BC6OTHER and functions as an BC6ENTG corespressor in both an BC6ENTC - dependent and BC6OTHER - independent manner.	False
Here, we provide evidence that BC6ENTG physically interacts with BC6OTHER and functions as an BC6OTHER corespressor in both an BC6OTHER - dependent and BC6ENTC - independent manner.	False
Here, we provide evidence that BC6OTHER physically interacts with BC6ENTG and functions as an BC6OTHER corespressor in both an BC6OTHER - dependent and BC6ENTC - independent manner.	False
Here, we provide evidence that BC6OTHER physically interacts with BC6OTHER and functions as an BC6ENTG corespressor in both an BC6OTHER - dependent and BC6ENTC - independent manner.	False
 Endogenous BC6ENTG ( BC6OTHER in human and BC6OTHER in mouse) and BC6OTHER colocalize in both human PCa cells in vitro and PCa tissues of mouse and human in vivo. Overexpression of BC6OTHER in PCa cells significantly attenuates the activities of BC6ENTC response region ( BC6OTHER ) - BC6OTHER .	False
 Endogenous BC6OTHER ( BC6ENTG in human and BC6OTHER in mouse) and BC6OTHER colocalize in both human PCa cells in vitro and PCa tissues of mouse and human in vivo. Overexpression of BC6OTHER in PCa cells significantly attenuates the activities of BC6ENTC response region ( BC6OTHER ) - BC6OTHER .	False
 Endogenous BC6OTHER ( BC6OTHER in human and BC6ENTG in mouse) and BC6OTHER colocalize in both human PCa cells in vitro and PCa tissues of mouse and human in vivo. Overexpression of BC6OTHER in PCa cells significantly attenuates the activities of BC6ENTC response region ( BC6OTHER ) - BC6OTHER .	False
 Endogenous BC6OTHER ( BC6OTHER in human and BC6OTHER in mouse) and BC6ENTG colocalize in both human PCa cells in vitro and PCa tissues of mouse and human in vivo. Overexpression of BC6OTHER in PCa cells significantly attenuates the activities of BC6ENTC response region ( BC6OTHER ) - BC6OTHER .	False
 Endogenous BC6OTHER ( BC6OTHER in human and BC6OTHER in mouse) and BC6OTHER colocalize in both human PCa cells in vitro and PCa tissues of mouse and human in vivo. Overexpression of BC6ENTG in PCa cells significantly attenuates the activities of BC6ENTC response region ( BC6OTHER ) - BC6OTHER .	False
 Endogenous BC6OTHER ( BC6OTHER in human and BC6OTHER in mouse) and BC6OTHER colocalize in both human PCa cells in vitro and PCa tissues of mouse and human in vivo. Overexpression of BC6OTHER in PCa cells significantly attenuates the activities of BC6ENTC response region ( BC6ENTG ) - BC6OTHER .	False
 Endogenous BC6OTHER ( BC6OTHER in human and BC6OTHER in mouse) and BC6OTHER colocalize in both human PCa cells in vitro and PCa tissues of mouse and human in vivo. Overexpression of BC6OTHER in PCa cells significantly attenuates the activities of BC6ENTC response region ( BC6OTHER ) - BC6ENTG .	False
BC6ENTC treatment (4 X 40 mg / day) increased the density of BC6ENTG by 25% after 2 days; concomitantly PRA and heart rate were reduced.	CPR:3
BC6OTHER density, however, declined slowly being still significantly increased after 3 days, although BC6ENTC was not detectable in plasma after 24 h. The affinity of BC6OTHER to BC6ENTG was not changed during or after treatment.	False
BC6ENTG density, however, declined slowly being still significantly increased after 3 days, although BC6ENTC was not detectable in plasma after 24 h. The affinity of BC6OTHER to BC6OTHER was not changed during or after treatment.	False
BC6OTHER density, however, declined slowly being still significantly increased after 3 days, although BC6OTHER was not detectable in plasma after 24 h. The affinity of BC6ENTC to BC6ENTG was not changed during or after treatment.	False
BC6ENTG density, however, declined slowly being still significantly increased after 3 days, although BC6OTHER was not detectable in plasma after 24 h. The affinity of BC6ENTC to BC6OTHER was not changed during or after treatment.	False
BC6ENTC treatment (2 X 5 mg / day) caused a 30% decrease of BC6ENTG density and PRA after 2 days; both parameters remained reduced during treatment.	CPR:4
BC6ENTC treatment (4 X 100 mg / day) led to a rapid fall in PRA, but did not significantly affect BC6ENTG density.	False
To study the mechanism underlying this phenomenon, the effects of the nonselective BC6ENTG antagonists BC6ENTC [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6OTHER density - - assessed by BC6OTHER ( BC6OTHER ) binding - - and plasma BC6OTHER activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years.	CPR:6
To study the mechanism underlying this phenomenon, the effects of the nonselective BC6OTHER antagonists BC6ENTC [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6ENTG density - - assessed by BC6OTHER ( BC6OTHER ) binding - - and plasma BC6OTHER activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years.	False
To study the mechanism underlying this phenomenon, the effects of the nonselective BC6OTHER antagonists BC6ENTC [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6OTHER density - - assessed by BC6OTHER ( BC6OTHER ) binding - - and plasma BC6ENTG activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years.	False
To study the mechanism underlying this phenomenon, the effects of the nonselective BC6ENTG antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6ENTC (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6OTHER density - - assessed by BC6OTHER ( BC6OTHER ) binding - - and plasma BC6OTHER activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years.	CPR:6
To study the mechanism underlying this phenomenon, the effects of the nonselective BC6OTHER antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6ENTC (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6ENTG density - - assessed by BC6OTHER ( BC6OTHER ) binding - - and plasma BC6OTHER activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years.	False
To study the mechanism underlying this phenomenon, the effects of the nonselective BC6OTHER antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6ENTC (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6OTHER density - - assessed by BC6OTHER ( BC6OTHER ) binding - - and plasma BC6ENTG activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years.	False
To study the mechanism underlying this phenomenon, the effects of the nonselective BC6ENTG antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6ENTC (strong ISA) on lymphocyte BC6OTHER density - - assessed by BC6OTHER ( BC6OTHER ) binding - - and plasma BC6OTHER activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years.	CPR:6
To study the mechanism underlying this phenomenon, the effects of the nonselective BC6OTHER antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6ENTC (strong ISA) on lymphocyte BC6ENTG density - - assessed by BC6OTHER ( BC6OTHER ) binding - - and plasma BC6OTHER activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years.	False
To study the mechanism underlying this phenomenon, the effects of the nonselective BC6OTHER antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6ENTC (strong ISA) on lymphocyte BC6OTHER density - - assessed by BC6OTHER ( BC6OTHER ) binding - - and plasma BC6ENTG activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years.	False
To study the mechanism underlying this phenomenon, the effects of the nonselective BC6ENTG antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6OTHER density - - assessed by BC6ENTC ( BC6OTHER ) binding - - and plasma BC6OTHER activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years.	False
To study the mechanism underlying this phenomenon, the effects of the nonselective BC6OTHER antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6ENTG density - - assessed by BC6ENTC ( BC6OTHER ) binding - - and plasma BC6OTHER activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years.	False
To study the mechanism underlying this phenomenon, the effects of the nonselective BC6OTHER antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6OTHER density - - assessed by BC6ENTC ( BC6OTHER ) binding - - and plasma BC6ENTG activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years.	False
To study the mechanism underlying this phenomenon, the effects of the nonselective BC6ENTG antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6OTHER density - - assessed by BC6OTHER ( BC6ENTC ) binding - - and plasma BC6OTHER activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years.	False
To study the mechanism underlying this phenomenon, the effects of the nonselective BC6OTHER antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6ENTG density - - assessed by BC6OTHER ( BC6ENTC ) binding - - and plasma BC6OTHER activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years.	False
To study the mechanism underlying this phenomenon, the effects of the nonselective BC6OTHER antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6OTHER density - - assessed by BC6OTHER ( BC6ENTC ) binding - - and plasma BC6ENTG activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years.	False
All three analogues bound to the myometrial BC6ENTC V1 receptor, albeit with much lower affinities than to the BC6ENTG .	False
All three analogues bound to the myometrial BC6ENTG , albeit with much lower affinities than to the BC6ENTC receptor.	False
Only BC6ENTC bound to the renal BC6ENTG though the binding affinity was very low (61.3 + / - 14.6 nM).	False
Both BC6ENTC , BC6OTHER CHEM and BC6OTHER metabolite II displayed binding affinities to the myometrial BC6ENTG of a similar magnitude as BC6OTHER .	False
Both BC6ENTC , BC6OTHER CHEM and BC6OTHER metabolite II displayed binding affinities to the myometrial BC6OTHER of a similar magnitude as BC6ENTG .	False
Both BC6OTHER , BC6ENTC CHEM and BC6OTHER metabolite II displayed binding affinities to the myometrial BC6ENTG of a similar magnitude as BC6OTHER .	False
Both BC6OTHER , BC6ENTC CHEM and BC6OTHER metabolite II displayed binding affinities to the myometrial BC6OTHER of a similar magnitude as BC6ENTG .	False
Both BC6OTHER , BC6OTHER CHEM and BC6ENTC metabolite II displayed binding affinities to the myometrial BC6ENTG of a similar magnitude as BC6OTHER .	False
Both BC6OTHER , BC6OTHER CHEM and BC6ENTC metabolite II displayed binding affinities to the myometrial BC6OTHER of a similar magnitude as BC6ENTG .	False
Both BC6OTHER , BC6OTHER CHEM and BC6OTHER metabolite II displayed binding affinities to the myometrial BC6ENTC receptor of a similar magnitude as BC6ENTG .	False
Both BC6OTHER , BC6OTHER CHEM and BC6OTHER metabolite II displayed binding affinities to the myometrial BC6ENTG of a similar magnitude as BC6ENTC .	False
BC6ENTC was found to have agonistic properties on isolated myometrial strips and it was found to exert this effect through generation of BC6OTHER , as is the case for BC6ENTG .	False
BC6OTHER was found to have agonistic properties on isolated myometrial strips and it was found to exert this effect through generation of BC6ENTC , as is the case for BC6ENTG .	False
However, maximal contractile effect of BC6ENTC was approximately 50% lower than that of BC6ENTG (2.70 + / - 0.12 g compared to 5.22 + / - 0.26 g) and EC50 was approximately ten times higher (48.0 + / - 8.20 nM compared to 5.62 + / - 1.22 nM).	False
Metabolites of the analogue CHEM ( BC6ENTC ) following incubation with a rat kidney homogenate were isolated and their pharmacodynamic properties investigated.	False
 BC6ENTG binding and uterotonic activity of BC6ENTC and its metabolites following enzymatic degradation.	False
All three compounds displayed antagonistic properties against BC6ENTG in vitro, with BC6ENTC being the strongest inhibitor (pA2 = 8.21) and BC6OTHER metabolite II (pA2 = 8.01) being stronger than BC6OTHER CHEM (pA2 = 7.81).	CPR:4
All three compounds displayed antagonistic properties against BC6ENTG in vitro, with BC6OTHER being the strongest inhibitor (pA2 = 8.21) and BC6ENTC metabolite II (pA2 = 8.01) being stronger than BC6OTHER CHEM (pA2 = 7.81).	CPR:4
All three compounds displayed antagonistic properties against BC6ENTG in vitro, with BC6OTHER being the strongest inhibitor (pA2 = 8.21) and BC6OTHER metabolite II (pA2 = 8.01) being stronger than BC6ENTC CHEM (pA2 = 7.81).	CPR:4
These results indicate that BC6ENTC is a partial agonist / antagonist to the BC6ENTG while the two metabolites BC6OTHER CHEM and BC6OTHER metabolite II are pure antagonists.	CPR:6
These results indicate that BC6OTHER is a partial agonist / antagonist to the BC6ENTG while the two metabolites BC6ENTC CHEM and BC6OTHER metabolite II are pure antagonists.	CPR:6
These results indicate that BC6OTHER is a partial agonist / antagonist to the BC6ENTG while the two metabolites BC6OTHER CHEM and BC6ENTC metabolite II are pure antagonists.	CPR:6
It was saturable, with between 1 and 2 mol of BC6ENTC bound to 1 mol of BC6ENTG .	False
The site at which BC6ENTC bound to BC6ENTG appears to be similar to that at which certain antipsychotic agents bind, since several of them, including BC6OTHER , BC6OTHER and BC6OTHER , prevented the binding of BC6OTHER to BC6OTHER .	False
The site at which BC6ENTC bound to BC6OTHER appears to be similar to that at which certain antipsychotic agents bind, since several of them, including BC6OTHER , BC6OTHER and BC6OTHER , prevented the binding of BC6OTHER to BC6ENTG .	False
To determine the factors that influence the interaction between BC6ENTC and BC6OTHER , the binding of BC6OTHER to BC6ENTG was determined by equilibrium dialysis under a variety of experimental conditions.	False
To determine the factors that influence the interaction between BC6ENTC and BC6ENTG , the binding of BC6OTHER to BC6OTHER was determined by equilibrium dialysis under a variety of experimental conditions.	False
The site at which BC6OTHER bound to BC6ENTG appears to be similar to that at which certain antipsychotic agents bind, since several of them, including BC6ENTC , BC6OTHER and BC6OTHER , prevented the binding of BC6OTHER to BC6OTHER .	False
The site at which BC6OTHER bound to BC6OTHER appears to be similar to that at which certain antipsychotic agents bind, since several of them, including BC6ENTC , BC6OTHER and BC6OTHER , prevented the binding of BC6OTHER to BC6ENTG .	False
The site at which BC6OTHER bound to BC6ENTG appears to be similar to that at which certain antipsychotic agents bind, since several of them, including BC6OTHER , BC6ENTC and BC6OTHER , prevented the binding of BC6OTHER to BC6OTHER .	False
The site at which BC6OTHER bound to BC6OTHER appears to be similar to that at which certain antipsychotic agents bind, since several of them, including BC6OTHER , BC6ENTC and BC6OTHER , prevented the binding of BC6OTHER to BC6ENTG .	False
The site at which BC6OTHER bound to BC6ENTG appears to be similar to that at which certain antipsychotic agents bind, since several of them, including BC6OTHER , BC6OTHER and BC6ENTC , prevented the binding of BC6OTHER to BC6OTHER .	False
The site at which BC6OTHER bound to BC6OTHER appears to be similar to that at which certain antipsychotic agents bind, since several of them, including BC6OTHER , BC6OTHER and BC6ENTC , prevented the binding of BC6OTHER to BC6ENTG .	False
The site at which BC6OTHER bound to BC6ENTG appears to be similar to that at which certain antipsychotic agents bind, since several of them, including BC6OTHER , BC6OTHER and BC6OTHER , prevented the binding of BC6ENTC to BC6OTHER .	False
The site at which BC6OTHER bound to BC6OTHER appears to be similar to that at which certain antipsychotic agents bind, since several of them, including BC6OTHER , BC6OTHER and BC6OTHER , prevented the binding of BC6ENTC to BC6ENTG .	False
However, in contrast to the reversible binding of most BC6ENTC to BC6ENTG , BC6OTHER bound to BC6OTHER irreversibly.	False
However, in contrast to the reversible binding of most BC6ENTC to BC6OTHER , BC6OTHER bound to BC6ENTG irreversibly.	False
However, in contrast to the reversible binding of most BC6OTHER to BC6ENTG , BC6ENTC bound to BC6OTHER irreversibly.	False
However, in contrast to the reversible binding of most BC6OTHER to BC6OTHER , BC6ENTC bound to BC6ENTG irreversibly.	False
The binding of BC6ENTC to BC6ENTG was fairly selective in that other BC6OTHER agents such as BC6OTHER , BC6OTHER and BC6OTHER failed to bind to BC6OTHER when examined under the same experimental conditions.	False
The binding of BC6ENTC to BC6OTHER was fairly selective in that other BC6ENTG agents such as BC6OTHER , BC6OTHER and BC6OTHER failed to bind to BC6OTHER when examined under the same experimental conditions.	False
The binding of BC6ENTC to BC6OTHER was fairly selective in that other BC6OTHER agents such as BC6OTHER , BC6OTHER and BC6OTHER failed to bind to BC6ENTG when examined under the same experimental conditions.	False
Characteristics of the binding of BC6ENTC to BC6ENTG .	False
To determine the factors that influence the interaction between BC6OTHER and BC6OTHER , the binding of BC6ENTC to BC6ENTG was determined by equilibrium dialysis under a variety of experimental conditions.	False
To determine the factors that influence the interaction between BC6OTHER and BC6ENTG , the binding of BC6ENTC to BC6OTHER was determined by equilibrium dialysis under a variety of experimental conditions.	False
The binding of BC6OTHER to BC6ENTG was fairly selective in that other BC6OTHER agents such as BC6ENTC , BC6OTHER and BC6OTHER failed to bind to BC6OTHER when examined under the same experimental conditions.	False
The binding of BC6OTHER to BC6OTHER was fairly selective in that other BC6ENTG agents such as BC6ENTC , BC6OTHER and BC6OTHER failed to bind to BC6OTHER when examined under the same experimental conditions.	False
The binding of BC6OTHER to BC6OTHER was fairly selective in that other BC6OTHER agents such as BC6ENTC , BC6OTHER and BC6OTHER failed to bind to BC6ENTG when examined under the same experimental conditions.	False
The binding of BC6OTHER to BC6ENTG was fairly selective in that other BC6OTHER agents such as BC6OTHER , BC6ENTC and BC6OTHER failed to bind to BC6OTHER when examined under the same experimental conditions.	False
The binding of BC6OTHER to BC6OTHER was fairly selective in that other BC6ENTG agents such as BC6OTHER , BC6ENTC and BC6OTHER failed to bind to BC6OTHER when examined under the same experimental conditions.	False
The binding of BC6OTHER to BC6OTHER was fairly selective in that other BC6OTHER agents such as BC6OTHER , BC6ENTC and BC6OTHER failed to bind to BC6ENTG when examined under the same experimental conditions.	False
The binding of BC6OTHER to BC6ENTG was fairly selective in that other BC6OTHER agents such as BC6OTHER , BC6OTHER and BC6ENTC failed to bind to BC6OTHER when examined under the same experimental conditions.	False
The binding of BC6OTHER to BC6OTHER was fairly selective in that other BC6ENTG agents such as BC6OTHER , BC6OTHER and BC6ENTC failed to bind to BC6OTHER when examined under the same experimental conditions.	False
The binding of BC6OTHER to BC6OTHER was fairly selective in that other BC6OTHER agents such as BC6OTHER , BC6OTHER and BC6ENTC failed to bind to BC6ENTG when examined under the same experimental conditions.	False
In addition, BC6ENTC showed little or no BC6OTHER - dependent binding to the BC6ENTG , BC6OTHER or BC6OTHER .	False
In addition, BC6ENTC showed little or no BC6OTHER - dependent binding to the BC6OTHER , BC6ENTG or BC6OTHER .	False
In addition, BC6ENTC showed little or no BC6OTHER - dependent binding to the BC6OTHER , BC6OTHER or BC6ENTG .	False
In addition, BC6OTHER showed little or no BC6ENTC - dependent binding to the BC6ENTG , BC6OTHER or BC6OTHER .	False
In addition, BC6OTHER showed little or no BC6ENTC - dependent binding to the BC6OTHER , BC6ENTG or BC6OTHER .	False
In addition, BC6OTHER showed little or no BC6ENTC - dependent binding to the BC6OTHER , BC6OTHER or BC6ENTG .	False
The irreversible complex between BC6ENTC and BC6ENTG may be useful for inhibiting certain BC6OTHER - dependent reactions and for studying the various biological functions of BC6OTHER .	False
The irreversible complex between BC6ENTC and BC6OTHER may be useful for inhibiting certain BC6ENTG - dependent reactions and for studying the various biological functions of BC6OTHER .	CPR:4
The irreversible complex between BC6ENTC and BC6OTHER may be useful for inhibiting certain BC6OTHER - dependent reactions and for studying the various biological functions of BC6ENTG .	False
This interaction was found to be similar in some respects to the interaction between BC6ENTC and BC6ENTG .	False
Inhibition of BC6ENTG - primed eosinophil chemotaxis by BC6ENTC .	CPR:4
CONCLUSIONS: The chemotactic responses toward BC6ENTG were inhibited by BC6ENTC at higher concentrations than were required in the priming studies (IC50 approximately 10 to 100 nmol / L).	CPR:4
These BC6ENTG have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6ENTC , ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) / BC6OTHER , but not toward BC6OTHER ( BC6OTHER ).	False
These BC6OTHER have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6ENTC , ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) / BC6OTHER , but not toward BC6OTHER ( BC6OTHER ).	False
These BC6OTHER have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6ENTC , ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) / BC6OTHER , but not toward BC6OTHER ( BC6OTHER ).	False
These BC6OTHER have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6ENTC , ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) / BC6ENTG , but not toward BC6OTHER ( BC6OTHER ).	False
These BC6OTHER have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6ENTC , ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) / BC6OTHER , but not toward BC6ENTG ( BC6OTHER ).	False
These BC6OTHER have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6ENTC , ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) / BC6OTHER , but not toward BC6OTHER ( BC6ENTG ).	False
These BC6ENTG have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6OTHER , ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) / BC6OTHER , but not toward BC6OTHER ( BC6OTHER ).	False
These BC6OTHER have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6OTHER , ( BC6ENTC ) and BC6ENTG ( BC6OTHER ) / BC6OTHER , but not toward BC6OTHER ( BC6OTHER ).	False
These BC6OTHER have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6OTHER , ( BC6ENTC ) and BC6OTHER ( BC6ENTG ) / BC6OTHER , but not toward BC6OTHER ( BC6OTHER ).	False
These BC6OTHER have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6OTHER , ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) / BC6ENTG , but not toward BC6OTHER ( BC6OTHER ).	False
These BC6OTHER have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6OTHER , ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) / BC6OTHER , but not toward BC6ENTG ( BC6OTHER ).	False
These BC6OTHER have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6OTHER , ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) / BC6OTHER , but not toward BC6OTHER ( BC6ENTG ).	False
Here the effect of BC6ENTC on the chemotactic response of eosinophils from allergic asthmatic individuals and from normal donors preincubated with BC6ENTG or BC6OTHER toward CHEM, BC6OTHER / BC6OTHER was evaluated.	False
Here the effect of BC6ENTC on the chemotactic response of eosinophils from allergic asthmatic individuals and from normal donors preincubated with BC6OTHER or BC6ENTG toward CHEM, BC6OTHER / BC6OTHER was evaluated.	False
Here the effect of BC6ENTC on the chemotactic response of eosinophils from allergic asthmatic individuals and from normal donors preincubated with BC6OTHER or BC6OTHER toward CHEM, BC6ENTG / BC6OTHER was evaluated.	False
Here the effect of BC6ENTC on the chemotactic response of eosinophils from allergic asthmatic individuals and from normal donors preincubated with BC6OTHER or BC6OTHER toward CHEM, BC6OTHER / BC6ENTG was evaluated.	False
RESULTS: BC6ENTC inhibited the chemotactic response toward BC6OTHER and BC6OTHER / BC6OTHER of BC6OTHER primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol / L), whereas these responses of BC6ENTG primed eosinophils was completely inhibited (IC50 approximately 1 nmol / L).	CPR:4
RESULTS: BC6ENTC inhibited the chemotactic response toward BC6OTHER and BC6ENTG / BC6OTHER of BC6OTHER primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol / L), whereas these responses of BC6OTHER primed eosinophils was completely inhibited (IC50 approximately 1 nmol / L).	CPR:4
RESULTS: BC6ENTC inhibited the chemotactic response toward BC6OTHER and BC6OTHER / BC6ENTG of BC6OTHER primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol / L), whereas these responses of BC6OTHER primed eosinophils was completely inhibited (IC50 approximately 1 nmol / L).	CPR:4
RESULTS: BC6ENTC inhibited the chemotactic response toward BC6OTHER and BC6OTHER / BC6OTHER of BC6ENTG primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol / L), whereas these responses of BC6OTHER primed eosinophils was completely inhibited (IC50 approximately 1 nmol / L).	CPR:4
RESULTS: BC6OTHER inhibited the chemotactic response toward BC6ENTC and BC6OTHER / BC6OTHER of BC6OTHER primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol / L), whereas these responses of BC6ENTG primed eosinophils was completely inhibited (IC50 approximately 1 nmol / L).	False
RESULTS: BC6OTHER inhibited the chemotactic response toward BC6ENTC and BC6ENTG / BC6OTHER of BC6OTHER primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol / L), whereas these responses of BC6OTHER primed eosinophils was completely inhibited (IC50 approximately 1 nmol / L).	False
RESULTS: BC6OTHER inhibited the chemotactic response toward BC6ENTC and BC6OTHER / BC6ENTG of BC6OTHER primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol / L), whereas these responses of BC6OTHER primed eosinophils was completely inhibited (IC50 approximately 1 nmol / L).	False
RESULTS: BC6OTHER inhibited the chemotactic response toward BC6ENTC and BC6OTHER / BC6OTHER of BC6ENTG primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol / L), whereas these responses of BC6OTHER primed eosinophils was completely inhibited (IC50 approximately 1 nmol / L).	False
The following was demonstrated in the rat and confirmed in man: interaction of BC6ENTC with the BC6ENTG , antiandrogen activity against BC6OTHER (in particular against the early transient rise induced by BC6OTHER analogs) and adrenal BC6OTHER .	False
The following was demonstrated in the rat and confirmed in man: interaction of BC6ENTC with the prostatic BC6OTHER receptor, antiandrogen activity against BC6OTHER (in particular against the early transient rise induced by BC6ENTG analogs) and adrenal BC6OTHER .	False
The following was demonstrated in the rat and confirmed in man: interaction of BC6OTHER with the prostatic BC6ENTC receptor, antiandrogen activity against BC6OTHER (in particular against the early transient rise induced by BC6ENTG analogs) and adrenal BC6OTHER .	False
The following was demonstrated in the rat and confirmed in man: interaction of BC6OTHER with the BC6ENTG , antiandrogen activity against BC6ENTC (in particular against the early transient rise induced by BC6OTHER analogs) and adrenal BC6OTHER .	False
The following was demonstrated in the rat and confirmed in man: interaction of BC6OTHER with the prostatic BC6OTHER receptor, antiandrogen activity against BC6ENTC (in particular against the early transient rise induced by BC6ENTG analogs) and adrenal BC6OTHER .	False
The following was demonstrated in the rat and confirmed in man: interaction of BC6OTHER with the BC6ENTG , antiandrogen activity against BC6OTHER (in particular against the early transient rise induced by BC6OTHER analogs) and adrenal BC6ENTC .	False
The following was demonstrated in the rat and confirmed in man: interaction of BC6OTHER with the prostatic BC6OTHER receptor, antiandrogen activity against BC6OTHER (in particular against the early transient rise induced by BC6ENTG analogs) and adrenal BC6ENTC .	False
This mechanism occurs at therapeutic concentrations of BC6ENTC and is dissociated from BC6ENTG inhibition (the mechanism of bronchodilation) or the blockade of BC6OTHER , which are partially responsible for its side effects.	False
This mechanism occurs at therapeutic concentrations of BC6ENTC and is dissociated from BC6OTHER inhibition (the mechanism of bronchodilation) or the blockade of BC6ENTG , which are partially responsible for its side effects.	False
This mechanism occurs at therapeutic concentrations of BC6OTHER and is dissociated from BC6ENTG inhibition (the mechanism of bronchodilation) or the blockade of BC6ENTC receptors, which are partially responsible for its side effects.	False
A molecular mechanism of action of BC6ENTC : Induction of BC6ENTG activity to decrease inflammatory gene expression.	CPR:3
Thus we have shown that low - dose BC6ENTC exerts an anti - asthma effect through increasing activation of BC6ENTG which is subsequently recruited by BC6OTHER to suppress inflammatory genes.	CPR:3
Thus we have shown that low - dose BC6OTHER exerts an anti - asthma effect through increasing activation of BC6ENTG which is subsequently recruited by BC6ENTC to suppress inflammatory genes.	False
BC6ENTC act, at least in part, by recruitment of BC6ENTG ( BC6OTHER ) to the site of active inflammatory gene transcription.	False
BC6ENTC act, at least in part, by recruitment of BC6OTHER ( BC6ENTG ) to the site of active inflammatory gene transcription.	False
We show both in vitro and in vivo that low - dose BC6ENTC enhances BC6ENTG activity in epithelial cells and macrophages.	CPR:3
This increased BC6ENTG activity is then available for BC6ENTC recruitment and predicts a cooperative interaction between BC6OTHER and BC6OTHER .	False
This increased BC6ENTG activity is then available for BC6OTHER recruitment and predicts a cooperative interaction between BC6ENTC and BC6OTHER .	False
This increased BC6ENTG activity is then available for BC6OTHER recruitment and predicts a cooperative interaction between BC6OTHER and BC6ENTC .	False
BC6ENTC (0.1 to 10 microM) induced a BC6OTHER current and hyperpolarized CHO cells expressing BC6ENTG cells but not in wild - type cells.	False
BC6OTHER (0.1 to 10 microM) induced a BC6ENTC current and hyperpolarized CHO cells expressing BC6ENTG cells but not in wild - type cells.	False
BC6ENTC - induced currents in CHO - BC6ENTG cells were inhibited by 60.6 + / - 11% (n = 4) by the BC6OTHER blocker, BC6OTHER (10 microM), and 82.7 + / - 5.4% (n = 4) by BC6OTHER (10 mM).	False
BC6ENTC - induced currents in CHO - BC6OTHER cells were inhibited by 60.6 + / - 11% (n = 4) by the BC6ENTG blocker, BC6OTHER (10 microM), and 82.7 + / - 5.4% (n = 4) by BC6OTHER (10 mM).	False
BC6OTHER - induced currents in CHO - BC6ENTG cells were inhibited by 60.6 + / - 11% (n = 4) by the BC6OTHER blocker, BC6ENTC (10 microM), and 82.7 + / - 5.4% (n = 4) by BC6OTHER (10 mM).	False
BC6OTHER - induced currents in CHO - BC6OTHER cells were inhibited by 60.6 + / - 11% (n = 4) by the BC6ENTG blocker, BC6ENTC (10 microM), and 82.7 + / - 5.4% (n = 4) by BC6OTHER (10 mM).	False
BC6OTHER - induced currents in CHO - BC6ENTG cells were inhibited by 60.6 + / - 11% (n = 4) by the BC6OTHER blocker, BC6OTHER (10 microM), and 82.7 + / - 5.4% (n = 4) by BC6ENTC (10 mM).	False
BC6OTHER - induced currents in CHO - BC6OTHER cells were inhibited by 60.6 + / - 11% (n = 4) by the BC6ENTG blocker, BC6OTHER (10 microM), and 82.7 + / - 5.4% (n = 4) by BC6ENTC (10 mM).	False
The mechanism by which BC6ENTC enhanced BC6ENTG currents involved large, drug - induced, leftward shifts in the voltage dependence of channel activation ( - 33.1 + / - 2.6 mV, n = 4, by 10 microM BC6OTHER ).	False
 BC6ENTC , a novel anti - convulsant, enhances activation of BC6ENTG BC6OTHER .	False
 BC6ENTC , a novel anti - convulsant, enhances activation of BC6OTHER BC6ENTG .	CPR:3
 BC6OTHER , a novel anti - convulsant, enhances activation of BC6ENTG BC6ENTC channels.	False
The mechanism by which BC6OTHER enhanced BC6ENTG currents involved large, drug - induced, leftward shifts in the voltage dependence of channel activation ( - 33.1 + / - 2.6 mV, n = 4, by 10 microM BC6ENTC ).	False
Our findings identify BC6ENTG channels as a molecular target for BC6ENTC and suggest that activation of BC6OTHER channels may be responsible for at least some of the anticonvulsant activity of this agent.	False
Our findings identify BC6OTHER channels as a molecular target for BC6ENTC and suggest that activation of BC6ENTG channels may be responsible for at least some of the anticonvulsant activity of this agent.	False
In the present study, we sought to determine whether CHEM could enhance current through M - like currents in PC12 cells and BC6ENTG BC6ENTC channels expressed in Chinese hamster ovary cells (CHO - BC6OTHER ).	False
In the present study, we sought to determine whether CHEM could enhance current through M - like currents in PC12 cells and BC6OTHER BC6ENTC channels expressed in Chinese hamster ovary cells (CHO - BC6ENTG ).	False
It is physiologically generated by BC6ENTC - γ - lyase, BC6ENTG , and BC6OTHER sulfurtransferase.	False
It is physiologically generated by BC6ENTC - γ - lyase, BC6OTHER - β - synthase, and BC6ENTG .	False
It is physiologically generated by BC6ENTG , BC6ENTC - β - synthase, and BC6OTHER sulfurtransferase.	False
It is physiologically generated by BC6OTHER - γ - lyase, BC6ENTC - β - synthase, and BC6ENTG .	False
It is physiologically generated by BC6ENTG , BC6OTHER - β - synthase, and BC6ENTC sulfurtransferase.	False
It is physiologically generated by BC6OTHER - γ - lyase, BC6ENTG , and BC6ENTC sulfurtransferase.	False
Substantial evidence shows that BC6ENTC is involved in aging by inhibiting free - radical reactions, activating BC6ENTG , and probably interacting with the age - related gene BC6OTHER .	CPR:3
Substantial evidence shows that BC6ENTC is involved in aging by inhibiting free - radical reactions, activating BC6OTHER , and probably interacting with the age - related gene BC6ENTG .	False
In this study we explore the mechanisms by which a double mutation ( BC6ENTG / BC6OTHER ) in BC6OTHER ( BC6OTHER ) associated with dilated cardiomyopathy reduces the BC6ENTC - activated maximal tension of cardiac muscle.	False
In this study we explore the mechanisms by which a double mutation ( BC6OTHER / BC6ENTG ) in BC6OTHER ( BC6OTHER ) associated with dilated cardiomyopathy reduces the BC6ENTC - activated maximal tension of cardiac muscle.	False
In this study we explore the mechanisms by which a double mutation ( BC6OTHER / BC6OTHER ) in BC6ENTG ( BC6OTHER ) associated with dilated cardiomyopathy reduces the BC6ENTC - activated maximal tension of cardiac muscle.	False
In this study we explore the mechanisms by which a double mutation ( BC6OTHER / BC6OTHER ) in BC6OTHER ( BC6ENTG ) associated with dilated cardiomyopathy reduces the BC6ENTC - activated maximal tension of cardiac muscle.	False
 Studying the single mutants (i.e. BC6ENTG or BC6OTHER ) indicates that BC6OTHER , but not BC6OTHER , causes a reduction in the CHEM affinity of BC6OTHER in BC6OTHER complex, BC6OTHER ( BC6OTHER ), and the BC6ENTC sensitivity of contraction and BC6OTHER in cardiac muscle preparations.	False
 Studying the single mutants (i.e. BC6OTHER or BC6ENTG ) indicates that BC6OTHER , but not BC6OTHER , causes a reduction in the CHEM affinity of BC6OTHER in BC6OTHER complex, BC6OTHER ( BC6OTHER ), and the BC6ENTC sensitivity of contraction and BC6OTHER in cardiac muscle preparations.	False
 Studying the single mutants (i.e. BC6OTHER or BC6OTHER ) indicates that BC6ENTG , but not BC6OTHER , causes a reduction in the CHEM affinity of BC6OTHER in BC6OTHER complex, BC6OTHER ( BC6OTHER ), and the BC6ENTC sensitivity of contraction and BC6OTHER in cardiac muscle preparations.	False
 Studying the single mutants (i.e. BC6OTHER or BC6OTHER ) indicates that BC6OTHER , but not BC6ENTG , causes a reduction in the CHEM affinity of BC6OTHER in BC6OTHER complex, BC6OTHER ( BC6OTHER ), and the BC6ENTC sensitivity of contraction and BC6OTHER in cardiac muscle preparations.	False
 Studying the single mutants (i.e. BC6OTHER or BC6OTHER ) indicates that BC6OTHER , but not BC6OTHER , causes a reduction in the CHEM affinity of BC6ENTG in BC6OTHER complex, BC6OTHER ( BC6OTHER ), and the BC6ENTC sensitivity of contraction and BC6OTHER in cardiac muscle preparations.	False
 Studying the single mutants (i.e. BC6OTHER or BC6OTHER ) indicates that BC6OTHER , but not BC6OTHER , causes a reduction in the CHEM affinity of BC6OTHER in BC6ENTG complex, BC6OTHER ( BC6OTHER ), and the BC6ENTC sensitivity of contraction and BC6OTHER in cardiac muscle preparations.	False
 Studying the single mutants (i.e. BC6OTHER or BC6OTHER ) indicates that BC6OTHER , but not BC6OTHER , causes a reduction in the CHEM affinity of BC6OTHER in BC6OTHER complex, BC6ENTG ( BC6OTHER ), and the BC6ENTC sensitivity of contraction and BC6OTHER in cardiac muscle preparations.	False
 Studying the single mutants (i.e. BC6OTHER or BC6OTHER ) indicates that BC6OTHER , but not BC6OTHER , causes a reduction in the CHEM affinity of BC6OTHER in BC6OTHER complex, BC6OTHER ( BC6ENTG ), and the BC6ENTC sensitivity of contraction and BC6OTHER in cardiac muscle preparations.	False
 Studying the single mutants (i.e. BC6OTHER or BC6OTHER ) indicates that BC6OTHER , but not BC6OTHER , causes a reduction in the CHEM affinity of BC6OTHER in BC6OTHER complex, BC6OTHER ( BC6OTHER ), and the BC6ENTC sensitivity of contraction and BC6ENTG in cardiac muscle preparations.	False
Like conventional BC6ENTG inhibitors, BC6ENTC causes extracellular volume reduction and vasodilatation; moreover, it increases levels of BC6OTHER and BC6OTHER .	CPR:4
Like conventional BC6OTHER inhibitors, BC6ENTC causes extracellular volume reduction and vasodilatation; moreover, it increases levels of BC6ENTG and BC6OTHER .	CPR:3
Like conventional BC6OTHER inhibitors, BC6ENTC causes extracellular volume reduction and vasodilatation; moreover, it increases levels of BC6OTHER and BC6ENTG .	CPR:3
Like conventional BC6ENTG inhibitors, BC6OTHER causes extracellular volume reduction and vasodilatation; moreover, it increases levels of BC6OTHER and BC6ENTC .	False
Like conventional BC6OTHER inhibitors, BC6OTHER causes extracellular volume reduction and vasodilatation; moreover, it increases levels of BC6ENTG and BC6ENTC .	False
The preferred initial agents for the treatment of high blood pressure are low - dose BC6ENTC diuretics, beta blockers, BC6OTHER antagonists, and BC6ENTG ( BC6OTHER ) inhibitors.	False
The preferred initial agents for the treatment of high blood pressure are low - dose BC6ENTC diuretics, beta blockers, BC6OTHER antagonists, and BC6OTHER - converting enzyme ( BC6ENTG ) inhibitors.	False
Advances in antihypertensive combination therapy: benefits of low - dose BC6OTHER diuretics in conjunction with BC6ENTC , a BC6ENTG inhibitor.	CPR:4
Advances in antihypertensive combination therapy: benefits of low - dose BC6ENTC diuretics in conjunction with BC6OTHER , a BC6ENTG inhibitor.	False
The preferred initial agents for the treatment of high blood pressure are low - dose BC6OTHER diuretics, beta blockers, BC6ENTC antagonists, and BC6ENTG ( BC6OTHER ) inhibitors.	False
The preferred initial agents for the treatment of high blood pressure are low - dose BC6OTHER diuretics, beta blockers, BC6ENTC antagonists, and BC6OTHER - converting enzyme ( BC6ENTG ) inhibitors.	False
The preferred initial agents for the treatment of high blood pressure are low - dose BC6OTHER diuretics, beta blockers, BC6OTHER antagonists, and BC6ENTC - converting enzyme ( BC6ENTG ) inhibitors.	False
BC6ENTC , the prototypical BC6ENTG inhibitor, inhibits not only BC6OTHER but also BC6OTHER .	CPR:4
BC6ENTC , the prototypical BC6OTHER inhibitor, inhibits not only BC6ENTG but also BC6OTHER .	CPR:4
BC6ENTC , the prototypical BC6OTHER inhibitor, inhibits not only BC6OTHER but also BC6ENTG .	CPR:4
BC6ENTC forms a ring around the internal cavity in BC6ENTG through aromatic stacking interactions between the drug and BC6OTHER as well as between the drug molecules themselves.	False
BC6ENTC forms a ring around the internal cavity in BC6OTHER through aromatic stacking interactions between the drug and BC6ENTG as well as between the drug molecules themselves.	False
Mammalian BC6ENTC dehydrogenase ( BC6ENTG ) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of BC6OTHER to BC6OTHER using BC6OTHER as coenzyme.	False
BC6ENTG ( BC6OTHER ) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of BC6ENTC to BC6OTHER using BC6OTHER as coenzyme.	CPR:9
Mammalian BC6OTHER dehydrogenase ( BC6ENTG ) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of BC6ENTC to BC6OTHER using BC6OTHER as coenzyme.	CPR:9
BC6ENTG ( BC6OTHER ) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of BC6OTHER to BC6ENTC using BC6OTHER as coenzyme.	CPR:9
Mammalian BC6OTHER dehydrogenase ( BC6ENTG ) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of BC6OTHER to BC6ENTC using BC6OTHER as coenzyme.	CPR:9
BC6ENTG ( BC6OTHER ) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of BC6OTHER to BC6OTHER using BC6ENTC as coenzyme.	False
Mammalian BC6OTHER dehydrogenase ( BC6ENTG ) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of BC6OTHER to BC6OTHER using BC6ENTC as coenzyme.	False
The recently discovered hyperinsulinism / hyperammonemia disorder showed that the loss of allosteric inhibition of BC6ENTG by BC6ENTC causes excessive secretion of BC6OTHER .	False
The recently discovered hyperinsulinism / hyperammonemia disorder showed that the loss of allosteric inhibition of BC6OTHER by BC6ENTC causes excessive secretion of BC6ENTG .	CPR:3
Subsequent studies demonstrated that wild - type and hyperinsulinemia / hyperammonemia forms of BC6ENTG are inhibited by the green tea CHEM, BC6ENTC and BC6OTHER .	CPR:4
Subsequent studies demonstrated that wild - type and hyperinsulinemia / hyperammonemia forms of BC6ENTG are inhibited by the green tea CHEM, BC6OTHER and BC6ENTC .	CPR:4
The observed inhibition on BC6ENTG , BC6OTHER , and BC6OTHER mRNA was blocked by the selective BC6OTHER antagonist BC6ENTC (10( - 6) M) and by BC6OTHER (10( - 6) M), a nonselective antagonist.	CPR:3
The observed inhibition on BC6OTHER , BC6ENTG , and BC6OTHER mRNA was blocked by the selective BC6OTHER antagonist BC6ENTC (10( - 6) M) and by BC6OTHER (10( - 6) M), a nonselective antagonist.	CPR:3
The observed inhibition on BC6OTHER , BC6OTHER , and BC6ENTG mRNA was blocked by the selective BC6OTHER antagonist BC6ENTC (10( - 6) M) and by BC6OTHER (10( - 6) M), a nonselective antagonist.	CPR:3
The observed inhibition on BC6OTHER , BC6OTHER , and BC6OTHER mRNA was blocked by the selective BC6ENTG antagonist BC6ENTC (10( - 6) M) and by BC6OTHER (10( - 6) M), a nonselective antagonist.	CPR:6
The observed inhibition on BC6ENTG , BC6OTHER , and BC6OTHER mRNA was blocked by the selective BC6OTHER antagonist BC6OTHER (10( - 6) M) and by BC6ENTC (10( - 6) M), a nonselective antagonist.	CPR:3
The observed inhibition on BC6OTHER , BC6ENTG , and BC6OTHER mRNA was blocked by the selective BC6OTHER antagonist BC6OTHER (10( - 6) M) and by BC6ENTC (10( - 6) M), a nonselective antagonist.	CPR:3
The observed inhibition on BC6OTHER , BC6OTHER , and BC6ENTG mRNA was blocked by the selective BC6OTHER antagonist BC6OTHER (10( - 6) M) and by BC6ENTC (10( - 6) M), a nonselective antagonist.	CPR:3
The observed inhibition on BC6OTHER , BC6OTHER , and BC6OTHER mRNA was blocked by the selective BC6ENTG antagonist BC6OTHER (10( - 6) M) and by BC6ENTC (10( - 6) M), a nonselective antagonist.	CPR:6
The selective BC6ENTG antagonist BC6ENTC (0.3 x 10( - 6) M) did not have any effect.	CPR:6
Secretion of BC6ENTG protein in the presence of increasing concentrations of BC6ENTC followed a similar pattern as observed for BC6OTHER mRNA.	CPR:3
Secretion of BC6OTHER protein in the presence of increasing concentrations of BC6ENTC followed a similar pattern as observed for BC6ENTG mRNA.	CPR:3
In addition, the BC6ENTG - mediated inhibition of BC6OTHER , BC6OTHER , and BC6OTHER mRNA accumulation and BC6OTHER protein secretion were related to the accumulation of intracellular BC6ENTC ( BC6OTHER ) levels.	False
In addition, the BC6OTHER - mediated inhibition of BC6ENTG , BC6OTHER , and BC6OTHER mRNA accumulation and BC6OTHER protein secretion were related to the accumulation of intracellular BC6ENTC ( BC6OTHER ) levels.	False
In addition, the BC6OTHER - mediated inhibition of BC6OTHER , BC6ENTG , and BC6OTHER mRNA accumulation and BC6OTHER protein secretion were related to the accumulation of intracellular BC6ENTC ( BC6OTHER ) levels.	False
In addition, the BC6OTHER - mediated inhibition of BC6OTHER , BC6OTHER , and BC6ENTG mRNA accumulation and BC6OTHER protein secretion were related to the accumulation of intracellular BC6ENTC ( BC6OTHER ) levels.	False
In addition, the BC6OTHER - mediated inhibition of BC6OTHER , BC6OTHER , and BC6OTHER mRNA accumulation and BC6ENTG protein secretion were related to the accumulation of intracellular BC6ENTC ( BC6OTHER ) levels.	False
In addition, the BC6ENTG - mediated inhibition of BC6OTHER , BC6OTHER , and BC6OTHER mRNA accumulation and BC6OTHER protein secretion were related to the accumulation of intracellular BC6OTHER ( BC6ENTC ) levels.	False
In addition, the BC6OTHER - mediated inhibition of BC6ENTG , BC6OTHER , and BC6OTHER mRNA accumulation and BC6OTHER protein secretion were related to the accumulation of intracellular BC6OTHER ( BC6ENTC ) levels.	False
In addition, the BC6OTHER - mediated inhibition of BC6OTHER , BC6ENTG , and BC6OTHER mRNA accumulation and BC6OTHER protein secretion were related to the accumulation of intracellular BC6OTHER ( BC6ENTC ) levels.	False
In addition, the BC6OTHER - mediated inhibition of BC6OTHER , BC6OTHER , and BC6ENTG mRNA accumulation and BC6OTHER protein secretion were related to the accumulation of intracellular BC6OTHER ( BC6ENTC ) levels.	False
In addition, the BC6OTHER - mediated inhibition of BC6OTHER , BC6OTHER , and BC6OTHER mRNA accumulation and BC6ENTG protein secretion were related to the accumulation of intracellular BC6OTHER ( BC6ENTC ) levels.	False
Although BC6ENTG mRNA was detectable in BC6OTHER - activated T lymphocytes, we could not demonstrate a functional activity in the regulation of BC6OTHER expression: the BC6OTHER agonist BC6ENTC had no effect on the accumulation of the studied BC6OTHER mRNAs, and did not significantly affect cellular BC6OTHER levels.	False
Although BC6OTHER mRNA was detectable in BC6ENTG - activated T lymphocytes, we could not demonstrate a functional activity in the regulation of BC6OTHER expression: the BC6OTHER agonist BC6ENTC had no effect on the accumulation of the studied BC6OTHER mRNAs, and did not significantly affect cellular BC6OTHER levels.	False
Although BC6OTHER mRNA was detectable in BC6OTHER - activated T lymphocytes, we could not demonstrate a functional activity in the regulation of BC6ENTG expression: the BC6OTHER agonist BC6ENTC had no effect on the accumulation of the studied BC6OTHER mRNAs, and did not significantly affect cellular BC6OTHER levels.	False
Although BC6OTHER mRNA was detectable in BC6OTHER - activated T lymphocytes, we could not demonstrate a functional activity in the regulation of BC6OTHER expression: the BC6ENTG agonist BC6ENTC had no effect on the accumulation of the studied BC6OTHER mRNAs, and did not significantly affect cellular BC6OTHER levels.	CPR:5
Although BC6OTHER mRNA was detectable in BC6OTHER - activated T lymphocytes, we could not demonstrate a functional activity in the regulation of BC6OTHER expression: the BC6OTHER agonist BC6ENTC had no effect on the accumulation of the studied BC6ENTG mRNAs, and did not significantly affect cellular BC6OTHER levels.	False
Although BC6ENTG mRNA was detectable in BC6OTHER - activated T lymphocytes, we could not demonstrate a functional activity in the regulation of BC6OTHER expression: the BC6OTHER agonist BC6OTHER had no effect on the accumulation of the studied BC6OTHER mRNAs, and did not significantly affect cellular BC6ENTC levels.	False
Although BC6OTHER mRNA was detectable in BC6ENTG - activated T lymphocytes, we could not demonstrate a functional activity in the regulation of BC6OTHER expression: the BC6OTHER agonist BC6OTHER had no effect on the accumulation of the studied BC6OTHER mRNAs, and did not significantly affect cellular BC6ENTC levels.	False
Although BC6OTHER mRNA was detectable in BC6OTHER - activated T lymphocytes, we could not demonstrate a functional activity in the regulation of BC6ENTG expression: the BC6OTHER agonist BC6OTHER had no effect on the accumulation of the studied BC6OTHER mRNAs, and did not significantly affect cellular BC6ENTC levels.	False
Although BC6OTHER mRNA was detectable in BC6OTHER - activated T lymphocytes, we could not demonstrate a functional activity in the regulation of BC6OTHER expression: the BC6ENTG agonist BC6OTHER had no effect on the accumulation of the studied BC6OTHER mRNAs, and did not significantly affect cellular BC6ENTC levels.	False
Although BC6OTHER mRNA was detectable in BC6OTHER - activated T lymphocytes, we could not demonstrate a functional activity in the regulation of BC6OTHER expression: the BC6OTHER agonist BC6OTHER had no effect on the accumulation of the studied BC6ENTG mRNAs, and did not significantly affect cellular BC6ENTC levels.	False
BC6ENTG ( BC6OTHER ) - induced BC6OTHER , BC6OTHER , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6ENTC and by the selective BC6OTHER agonist BC6OTHER .	False
BC6OTHER ( BC6ENTG ) - induced BC6OTHER , BC6OTHER , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6ENTC and by the selective BC6OTHER agonist BC6OTHER .	False
BC6OTHER ( BC6OTHER ) - induced BC6ENTG , BC6OTHER , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6ENTC and by the selective BC6OTHER agonist BC6OTHER .	CPR:4
BC6OTHER ( BC6OTHER ) - induced BC6OTHER , BC6ENTG , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6ENTC and by the selective BC6OTHER agonist BC6OTHER .	CPR:4
BC6OTHER ( BC6OTHER ) - induced BC6OTHER , BC6OTHER , and BC6ENTG mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6ENTC and by the selective BC6OTHER agonist BC6OTHER .	CPR:4
BC6OTHER ( BC6OTHER ) - induced BC6OTHER , BC6OTHER , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6ENTG agonist BC6ENTC and by the selective BC6OTHER agonist BC6OTHER .	CPR:5
BC6OTHER ( BC6OTHER ) - induced BC6OTHER , BC6OTHER , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6ENTC and by the selective BC6ENTG agonist BC6OTHER .	False
BC6ENTG ( BC6OTHER ) - induced BC6OTHER , BC6OTHER , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6OTHER and by the selective BC6OTHER agonist BC6ENTC .	False
BC6OTHER ( BC6ENTG ) - induced BC6OTHER , BC6OTHER , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6OTHER and by the selective BC6OTHER agonist BC6ENTC .	False
BC6OTHER ( BC6OTHER ) - induced BC6ENTG , BC6OTHER , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6OTHER and by the selective BC6OTHER agonist BC6ENTC .	CPR:4
BC6OTHER ( BC6OTHER ) - induced BC6OTHER , BC6ENTG , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6OTHER and by the selective BC6OTHER agonist BC6ENTC .	CPR:4
BC6OTHER ( BC6OTHER ) - induced BC6OTHER , BC6OTHER , and BC6ENTG mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6OTHER and by the selective BC6OTHER agonist BC6ENTC .	CPR:4
BC6OTHER ( BC6OTHER ) - induced BC6OTHER , BC6OTHER , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6ENTG agonist BC6OTHER and by the selective BC6OTHER agonist BC6ENTC .	False
BC6OTHER ( BC6OTHER ) - induced BC6OTHER , BC6OTHER , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6OTHER and by the selective BC6ENTG agonist BC6ENTC .	CPR:5
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6ENTC [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG agonist - BC6ENTC [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	CPR:5
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6ENTC [ BC6OTHER ], a selective BC6ENTG antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6ENTC [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6ENTG antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6ENTC ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG agonist - BC6OTHER [ BC6ENTC ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	CPR:5
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6ENTC ], a selective BC6ENTG antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6ENTC ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6ENTG antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6ENTC [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6ENTC [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG antagonist - BC6ENTC [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	CPR:6
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6ENTC [ BC6OTHER ] - BC6OTHER ] or a selective BC6ENTG antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6ENTC ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6ENTC ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG antagonist - BC6OTHER [ BC6ENTC ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	CPR:6
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6ENTC ] - BC6OTHER ] or a selective BC6ENTG antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6ENTC ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6ENTC ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG antagonist - BC6OTHER [ BC6OTHER ] - BC6ENTC ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	CPR:6
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6ENTC ] or a selective BC6ENTG antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6ENTC ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6ENTC ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6ENTC ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6ENTG antagonist - BC6ENTC ( BC6OTHER ).	CPR:6
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6ENTC ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6ENTC ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6ENTC ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6ENTG antagonist - BC6OTHER ( BC6ENTC ).	CPR:6
The number of BC6ENTC - diaphorase positive elements in the SON and the PVN was modulated by both BC6ENTG but, depending on the nucleus, BC6OTHER and BC6OTHER ligands induced different effects.	False
The number of BC6ENTC - diaphorase positive elements in the SON and the PVN was modulated by both BC6OTHER but, depending on the nucleus, BC6ENTG and BC6OTHER ligands induced different effects.	False
The number of BC6ENTC - diaphorase positive elements in the SON and the PVN was modulated by both BC6OTHER but, depending on the nucleus, BC6OTHER and BC6ENTG ligands induced different effects.	False
Role of BC6ENTG on the modulation of BC6ENTC - diaphorase - positive cell number in supraoptic and paraventricular nuclei of ovariectomised female rats.	False
Modulation of the BC6OTHER producing system (demonstrated via the BC6ENTG histochemical reaction) by BC6ENTC has been established in several structures of the rat brain.	False
Role of BC6ENTC receptors on the modulation of BC6ENTG - positive cell number in supraoptic and paraventricular nuclei of ovariectomised female rats.	False
These results suggest that the regulation of nitrergic system by BC6ENTG may play a role in the control of BC6ENTC - dependent physiological mechanisms regulated by the SON and the PVN.	False
Modulation of the BC6ENTC producing system (demonstrated via the BC6ENTG histochemical reaction) by BC6OTHER has been established in several structures of the rat brain.	CPR:9
The present study aimed to explore the possible regulation of BC6ENTC - diaphorase activity by BC6OTHER in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of BC6ENTG ( BC6OTHER and BC6OTHER ) in this regulation.	False
The present study aimed to explore the possible regulation of BC6ENTC - diaphorase activity by BC6OTHER in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of BC6OTHER receptors ( BC6ENTG and BC6OTHER ) in this regulation.	False
The present study aimed to explore the possible regulation of BC6ENTC - diaphorase activity by BC6OTHER in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of BC6OTHER receptors ( BC6OTHER and BC6ENTG ) in this regulation.	False
The present study aimed to explore the possible regulation of BC6ENTG activity by BC6ENTC in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of BC6OTHER receptors ( BC6OTHER and BC6OTHER ) in this regulation.	False
The present study aimed to explore the possible regulation of BC6OTHER - diaphorase activity by BC6ENTC in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of BC6ENTG ( BC6OTHER and BC6OTHER ) in this regulation.	False
The present study aimed to explore the possible regulation of BC6OTHER - diaphorase activity by BC6ENTC in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of BC6OTHER receptors ( BC6ENTG and BC6OTHER ) in this regulation.	False
The present study aimed to explore the possible regulation of BC6OTHER - diaphorase activity by BC6ENTC in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of BC6OTHER receptors ( BC6OTHER and BC6ENTG ) in this regulation.	False
The present study aimed to explore the possible regulation of BC6ENTG activity by BC6OTHER in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of BC6ENTC receptors ( BC6OTHER and BC6OTHER ) in this regulation.	False
The present study aimed to explore the possible regulation of BC6OTHER - diaphorase activity by BC6OTHER in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of BC6ENTC receptors ( BC6ENTG and BC6OTHER ) in this regulation.	False
The present study aimed to explore the possible regulation of BC6OTHER - diaphorase activity by BC6OTHER in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of BC6ENTC receptors ( BC6OTHER and BC6ENTG ) in this regulation.	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6ENTC , a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6ENTC , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6ENTC , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6ENTC , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6ENTG antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6ENTG agonist - BC6ENTC [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	CPR:5
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6ENTC [ BC6OTHER ], a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6ENTC [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6ENTC [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6ENTG antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6ENTG agonist - BC6OTHER [ BC6ENTC ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	CPR:5
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6ENTC ], a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6ENTC ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ).	False
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6ENTC ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6ENTG antagonist - BC6OTHER ( BC6OTHER ).	False
Both microtubule and BC6OTHER are required for BC6ENTG - induced BC6ENTC uptake.	False
Both microtubule and BC6ENTG are required for BC6OTHER - induced BC6ENTC uptake.	False
Disruption of microtubule prevented BC6ENTG - induced BC6OTHER remodeling and distal BC6OTHER signal transduction, with reduction in surface BC6ENTC transporter isoform 4 ( BC6OTHER ) and BC6OTHER uptake.	False
Disruption of microtubule prevented BC6OTHER - induced BC6ENTG remodeling and distal BC6OTHER signal transduction, with reduction in surface BC6ENTC transporter isoform 4 ( BC6OTHER ) and BC6OTHER uptake.	False
Disruption of microtubule prevented BC6OTHER - induced BC6OTHER remodeling and distal BC6ENTG signal transduction, with reduction in surface BC6ENTC transporter isoform 4 ( BC6OTHER ) and BC6OTHER uptake.	False
Disruption of microtubule prevented BC6OTHER - induced BC6OTHER remodeling and distal BC6OTHER signal transduction, with reduction in surface BC6ENTC transporter isoform 4 ( BC6ENTG ) and BC6OTHER uptake.	False
Disruption of microtubule prevented BC6ENTG - induced BC6OTHER remodeling and distal BC6OTHER signal transduction, with reduction in surface BC6OTHER transporter isoform 4 ( BC6OTHER ) and BC6ENTC uptake.	False
Disruption of microtubule prevented BC6OTHER - induced BC6ENTG remodeling and distal BC6OTHER signal transduction, with reduction in surface BC6OTHER transporter isoform 4 ( BC6OTHER ) and BC6ENTC uptake.	False
Disruption of microtubule prevented BC6OTHER - induced BC6OTHER remodeling and distal BC6ENTG signal transduction, with reduction in surface BC6OTHER transporter isoform 4 ( BC6OTHER ) and BC6ENTC uptake.	False
Disruption of microtubule prevented BC6OTHER - induced BC6OTHER remodeling and distal BC6OTHER signal transduction, with reduction in surface BC6ENTG ( BC6OTHER ) and BC6ENTC uptake.	CPR:9
Disruption of microtubule prevented BC6OTHER - induced BC6OTHER remodeling and distal BC6OTHER signal transduction, with reduction in surface BC6OTHER transporter isoform 4 ( BC6ENTG ) and BC6ENTC uptake.	CPR:9
Though microtubule mediated BC6ENTG remodeling through BC6OTHER , reorganization of microtubule depended on BC6ENTC phosphorylation of BC6OTHER , the mechanism is different from BC6OTHER - induced BC6OTHER remodeling, which relied on the activity of BC6OTHER and BC6OTHER .	False
Though microtubule mediated BC6OTHER remodeling through BC6ENTG , reorganization of microtubule depended on BC6ENTC phosphorylation of BC6OTHER , the mechanism is different from BC6OTHER - induced BC6OTHER remodeling, which relied on the activity of BC6OTHER and BC6OTHER .	False
Though microtubule mediated BC6OTHER remodeling through BC6OTHER , reorganization of microtubule depended on BC6ENTC phosphorylation of BC6ENTG , the mechanism is different from BC6OTHER - induced BC6OTHER remodeling, which relied on the activity of BC6OTHER and BC6OTHER .	False
Though microtubule mediated BC6OTHER remodeling through BC6OTHER , reorganization of microtubule depended on BC6ENTC phosphorylation of BC6OTHER , the mechanism is different from BC6ENTG - induced BC6OTHER remodeling, which relied on the activity of BC6OTHER and BC6OTHER .	False
Though microtubule mediated BC6OTHER remodeling through BC6OTHER , reorganization of microtubule depended on BC6ENTC phosphorylation of BC6OTHER , the mechanism is different from BC6OTHER - induced BC6ENTG remodeling, which relied on the activity of BC6OTHER and BC6OTHER .	False
Though microtubule mediated BC6OTHER remodeling through BC6OTHER , reorganization of microtubule depended on BC6ENTC phosphorylation of BC6OTHER , the mechanism is different from BC6OTHER - induced BC6OTHER remodeling, which relied on the activity of BC6ENTG and BC6OTHER .	False
Though microtubule mediated BC6OTHER remodeling through BC6OTHER , reorganization of microtubule depended on BC6ENTC phosphorylation of BC6OTHER , the mechanism is different from BC6OTHER - induced BC6OTHER remodeling, which relied on the activity of BC6OTHER and BC6ENTG .	False
Interestingly, BC6ENTG expression positively correlated with urine BC6OTHER BC6ENTC ratio (ACR), BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6OTHER clearance ratio (Ccr) and BC6OTHER protein.	CPR:3
Interestingly, BC6OTHER expression positively correlated with urine BC6ENTG BC6ENTC ratio (ACR), BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6OTHER clearance ratio (Ccr) and BC6OTHER protein.	False
Interestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6ENTC ratio (ACR), BC6ENTG , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6OTHER clearance ratio (Ccr) and BC6OTHER protein.	False
Interestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6ENTC ratio (ACR), BC6OTHER , BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6OTHER clearance ratio (Ccr) and BC6OTHER protein.	False
Interestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6ENTC ratio (ACR), BC6OTHER , BC6OTHER ( BC6ENTG ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6OTHER clearance ratio (Ccr) and BC6OTHER protein.	False
Interestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6ENTC ratio (ACR), BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ); while negatively correlated with BC6OTHER clearance ratio (Ccr) and BC6OTHER protein.	False
Interestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6ENTC ratio (ACR), BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG ); while negatively correlated with BC6OTHER clearance ratio (Ccr) and BC6OTHER protein.	False
Interestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6ENTC ratio (ACR), BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6OTHER clearance ratio (Ccr) and BC6ENTG protein.	False
Interestingly, BC6ENTG expression positively correlated with urine BC6OTHER BC6OTHER ratio (ACR), BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6ENTC clearance ratio (Ccr) and BC6OTHER protein.	CPR:4
Interestingly, BC6OTHER expression positively correlated with urine BC6ENTG BC6OTHER ratio (ACR), BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6ENTC clearance ratio (Ccr) and BC6OTHER protein.	False
Interestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6OTHER ratio (ACR), BC6ENTG , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6ENTC clearance ratio (Ccr) and BC6OTHER protein.	False
Interestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6OTHER ratio (ACR), BC6OTHER , BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6ENTC clearance ratio (Ccr) and BC6OTHER protein.	False
Interestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6OTHER ratio (ACR), BC6OTHER , BC6OTHER ( BC6ENTG ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6ENTC clearance ratio (Ccr) and BC6OTHER protein.	False
Interestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6OTHER ratio (ACR), BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ); while negatively correlated with BC6ENTC clearance ratio (Ccr) and BC6OTHER protein.	False
Interestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6OTHER ratio (ACR), BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG ); while negatively correlated with BC6ENTC clearance ratio (Ccr) and BC6OTHER protein.	False
Interestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6OTHER ratio (ACR), BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6ENTC clearance ratio (Ccr) and BC6ENTG protein.	False
BC6ENTC did not affect BC6ENTG responses.	False
These experiments show that in striatonigral projections, BC6ENTG inhibits the action of BC6OTHER in a BC6ENTC dependent manner blocking their modulatory effects on BC6OTHER release.	False
These experiments show that in striatonigral projections, BC6OTHER inhibits the action of BC6ENTG in a BC6ENTC dependent manner blocking their modulatory effects on BC6OTHER release.	False
These experiments show that in striatonigral projections, BC6ENTG inhibits the action of BC6OTHER in a BC6OTHER dependent manner blocking their modulatory effects on BC6ENTC release.	False
These experiments show that in striatonigral projections, BC6OTHER inhibits the action of BC6ENTG in a BC6OTHER dependent manner blocking their modulatory effects on BC6ENTC release.	False
In this study we examined whether the presynaptic effects of BC6ENTG stimulation in the substantia nigra reticulata (SNr) are modulated by BC6ENTC activation of BC6OTHER .	False
In this study we examined whether the presynaptic effects of BC6OTHER stimulation in the substantia nigra reticulata (SNr) are modulated by BC6ENTC activation of BC6ENTG .	False
In SNr synaptosomes two procedures that increase cytoplasmic BC6ENTC , BC6OTHER and BC6OTHER - depolarization, blocked the additional stimulation of BC6OTHER accumulation produced by coactivating BC6ENTG .	False
In SNr synaptosomes two procedures that increase cytoplasmic BC6OTHER , BC6ENTC and BC6OTHER - depolarization, blocked the additional stimulation of BC6OTHER accumulation produced by coactivating BC6ENTG .	False
In SNr synaptosomes two procedures that increase cytoplasmic BC6OTHER , BC6OTHER and BC6ENTC - depolarization, blocked the additional stimulation of BC6OTHER accumulation produced by coactivating BC6ENTG .	False
Immunoblot studies showed that BC6OTHER - depolarization increased BC6OTHER phosphorylation in a BC6ENTC sensitive manner and promoted BC6ENTG binding to BC6OTHER .	False
Immunoblot studies showed that BC6OTHER - depolarization increased BC6OTHER phosphorylation in a BC6ENTC sensitive manner and promoted BC6OTHER binding to BC6ENTG .	False
Immunoblot studies showed that BC6OTHER - depolarization increased BC6ENTG phosphorylation in a BC6ENTC sensitive manner and promoted BC6OTHER binding to BC6OTHER .	False
In SNr synaptosomes two procedures that increase cytoplasmic BC6OTHER , BC6OTHER and BC6OTHER - depolarization, blocked the additional stimulation of BC6ENTC accumulation produced by coactivating BC6ENTG .	False
The selective BC6ENTG inhibitor BC6ENTC reversed the blockade produced by BC6OTHER and BC6OTHER - depolarization.	CPR:4
The selective BC6ENTG inhibitor BC6OTHER reversed the blockade produced by BC6ENTC and BC6OTHER - depolarization.	CPR:4
The selective BC6ENTG inhibitor BC6OTHER reversed the blockade produced by BC6OTHER and BC6ENTC - depolarization.	False
Immunoblot studies showed that BC6ENTC - depolarization increased BC6OTHER phosphorylation in a BC6OTHER sensitive manner and promoted BC6ENTG binding to BC6OTHER .	False
Immunoblot studies showed that BC6ENTC - depolarization increased BC6OTHER phosphorylation in a BC6OTHER sensitive manner and promoted BC6OTHER binding to BC6ENTG .	False
Immunoblot studies showed that BC6ENTC - depolarization increased BC6ENTG phosphorylation in a BC6OTHER sensitive manner and promoted BC6OTHER binding to BC6OTHER .	False
In BC6ENTC - depolarized tissues, BC6ENTG potentiated BC6OTHER - induced stimulation of BC6OTHER release only when BC6OTHER was blocked with BC6OTHER .	False
In BC6ENTC - depolarized tissues, BC6OTHER potentiated BC6ENTG - induced stimulation of BC6OTHER release only when BC6OTHER was blocked with BC6OTHER .	False
In BC6ENTC - depolarized tissues, BC6OTHER potentiated BC6OTHER - induced stimulation of BC6OTHER release only when BC6ENTG was blocked with BC6OTHER .	False
Presynaptic BC6ENTG modulates BC6OTHER activation in striatonigral terminals of the rat brain in a BC6ENTC dependent manner.	False
Presynaptic BC6OTHER modulates BC6ENTG activation in striatonigral terminals of the rat brain in a BC6ENTC dependent manner.	False
Presynaptic BC6ENTG modulates BC6ENTC D3 receptor activation in striatonigral terminals of the rat brain in a BC6OTHER dependent manner.	False
In BC6OTHER - depolarized tissues, BC6ENTG potentiated BC6OTHER - induced stimulation of BC6ENTC release only when BC6OTHER was blocked with BC6OTHER .	False
In BC6OTHER - depolarized tissues, BC6OTHER potentiated BC6ENTG - induced stimulation of BC6ENTC release only when BC6OTHER was blocked with BC6OTHER .	False
In BC6OTHER - depolarized tissues, BC6OTHER potentiated BC6OTHER - induced stimulation of BC6ENTC release only when BC6ENTG was blocked with BC6OTHER .	False
In BC6OTHER - depolarized tissues, BC6ENTG potentiated BC6OTHER - induced stimulation of BC6OTHER release only when BC6OTHER was blocked with BC6ENTC .	False
In BC6OTHER - depolarized tissues, BC6OTHER potentiated BC6ENTG - induced stimulation of BC6OTHER release only when BC6OTHER was blocked with BC6ENTC .	False
In BC6OTHER - depolarized tissues, BC6OTHER potentiated BC6OTHER - induced stimulation of BC6OTHER release only when BC6ENTG was blocked with BC6ENTC .	CPR:4
In the presence of this inhibitor, the selective BC6ENTG agonist BC6ENTC reduced the ED50 for the BC6OTHER agonist BC6OTHER from 56 to 4 nM.	CPR:5
In the presence of this inhibitor, the selective BC6OTHER agonist BC6ENTC reduced the ED50 for the BC6ENTG agonist BC6OTHER from 56 to 4 nM.	False
In the presence of this inhibitor, the selective BC6ENTG agonist BC6OTHER reduced the ED50 for the BC6OTHER agonist BC6ENTC from 56 to 4 nM.	False
In the presence of this inhibitor, the selective BC6OTHER agonist BC6OTHER reduced the ED50 for the BC6ENTG agonist BC6ENTC from 56 to 4 nM.	CPR:5
All the compounds were evaluated for their anti - tumor activity against MCF - 7, A549 and B16 - F10 tumor cell lines as well as BC6ENTG ( BC6OTHER ) - derived BC6ENTC ( BC6OTHER ) inhibitory activity of murine macrophage RAW 264.7 cell line.	CPR:9
All the compounds were evaluated for their anti - tumor activity against MCF - 7, A549 and B16 - F10 tumor cell lines as well as BC6OTHER ( BC6ENTG ) - derived BC6ENTC ( BC6OTHER ) inhibitory activity of murine macrophage RAW 264.7 cell line.	CPR:9
All the compounds were evaluated for their anti - tumor activity against MCF - 7, A549 and B16 - F10 tumor cell lines as well as BC6ENTG ( BC6OTHER ) - derived BC6OTHER ( BC6ENTC ) inhibitory activity of murine macrophage RAW 264.7 cell line.	CPR:9
All the compounds were evaluated for their anti - tumor activity against MCF - 7, A549 and B16 - F10 tumor cell lines as well as BC6OTHER ( BC6ENTG ) - derived BC6OTHER ( BC6ENTC ) inhibitory activity of murine macrophage RAW 264.7 cell line.	CPR:9
Recent evidence suggests that processes other than BC6ENTC binding, such as phosphorylation of BC6ENTG ( BC6OTHER ) also controls contraction of vertebrate striated muscle (Cooke, R. (2011) Biophys.	False
Recent evidence suggests that processes other than BC6ENTC binding, such as phosphorylation of BC6OTHER ( BC6ENTG ) also controls contraction of vertebrate striated muscle (Cooke, R. (2011) Biophys.	False
We find that: (i) relaxed cross - bridges, but not active ones, are statistically better ordered in muscle where the BC6ENTG is dephosporylated compared with BC6OTHER ; (ii) relaxed phosphorylated and dephosphorylated cross - bridges rotate equally slowly; and (iii) active phosphorylated cross - bridges rotate considerably faster than dephosphorylated ones during isometric contraction but the duty cycle remained the same, suggesting that both phosphorylated and dephosphorylated muscles develop the same isometric tension at full BC6ENTC saturation.	False
We find that: (i) relaxed cross - bridges, but not active ones, are statistically better ordered in muscle where the BC6OTHER is dephosporylated compared with BC6ENTG ; (ii) relaxed phosphorylated and dephosphorylated cross - bridges rotate equally slowly; and (iii) active phosphorylated cross - bridges rotate considerably faster than dephosphorylated ones during isometric contraction but the duty cycle remained the same, suggesting that both phosphorylated and dephosphorylated muscles develop the same isometric tension at full BC6ENTC saturation.	False
Electron paramagnetic resonance (EPR) studies using BC6ENTC analog spin label probes showed that BC6OTHER heads are highly ordered in the relaxed fibers and have very low BC6ENTG activity.	False
Electron paramagnetic resonance (EPR) studies using BC6ENTC analog spin label probes showed that BC6ENTG heads are highly ordered in the relaxed fibers and have very low BC6OTHER activity.	False
Accumulated evidence in humans and animals shows that both BC6ENTC and H. pylori upregulate the expression of BC6ENTG both at mRNA and protein levels at the ulcer margin, but failed to influence significantly that of BC6OTHER .	CPR:3
Accumulated evidence in humans and animals shows that both BC6ENTC and H. pylori upregulate the expression of BC6OTHER both at mRNA and protein levels at the ulcer margin, but failed to influence significantly that of BC6ENTG .	False
It was, therefore, proposed that H. pylori may in fact, antagonize, BC6ENTC - induced delay of ulcer healing due to suppression of acid secretion by the enhancement in BC6OTHER possibly derived from BC6OTHER expression and activity and to the overexpression of growth factors such as BC6ENTG and BC6OTHER .	CPR:3
It was, therefore, proposed that H. pylori may in fact, antagonize, BC6ENTC - induced delay of ulcer healing due to suppression of acid secretion by the enhancement in BC6OTHER possibly derived from BC6OTHER expression and activity and to the overexpression of growth factors such as BC6OTHER and BC6ENTG .	CPR:3
It was, therefore, proposed that H. pylori may in fact, antagonize, BC6ENTC - induced delay of ulcer healing due to suppression of acid secretion by the enhancement in BC6OTHER possibly derived from BC6ENTG expression and activity and to the overexpression of growth factors such as BC6OTHER and BC6OTHER .	CPR:3
It was, therefore, proposed that H. pylori may in fact, antagonize, BC6OTHER - induced delay of ulcer healing due to suppression of acid secretion by the enhancement in BC6ENTC possibly derived from BC6OTHER expression and activity and to the overexpression of growth factors such as BC6ENTG and BC6OTHER .	False
It was, therefore, proposed that H. pylori may in fact, antagonize, BC6OTHER - induced delay of ulcer healing due to suppression of acid secretion by the enhancement in BC6ENTC possibly derived from BC6OTHER expression and activity and to the overexpression of growth factors such as BC6OTHER and BC6ENTG .	False
It was, therefore, proposed that H. pylori may in fact, antagonize, BC6OTHER - induced delay of ulcer healing due to suppression of acid secretion by the enhancement in BC6ENTC possibly derived from BC6ENTG expression and activity and to the overexpression of growth factors such as BC6OTHER and BC6OTHER .	CPR:9
Molecular docking studies were performed with BC6ENTG ( BC6OTHER : PDB 1E78), showing binding pattern with BC6ENTC residues BC6OTHER 218, BC6OTHER 222 and BC6OTHER 444, identifies the ligand - BC6OTHER interaction for the transportation affinity of the ligand at the specific site of the target.	False
Molecular docking studies were performed with BC6OTHER ( BC6ENTG : PDB 1E78), showing binding pattern with BC6ENTC residues BC6OTHER 218, BC6OTHER 222 and BC6OTHER 444, identifies the ligand - BC6OTHER interaction for the transportation affinity of the ligand at the specific site of the target.	False
Molecular docking studies were performed with BC6OTHER ( BC6OTHER : PDB 1E78), showing binding pattern with BC6ENTC residues BC6OTHER 218, BC6OTHER 222 and BC6OTHER 444, identifies the ligand - BC6ENTG interaction for the transportation affinity of the ligand at the specific site of the target.	False
Molecular docking studies were performed with BC6ENTG ( BC6OTHER : PDB 1E78), showing binding pattern with BC6OTHER residues BC6ENTC 218, BC6OTHER 222 and BC6OTHER 444, identifies the ligand - BC6OTHER interaction for the transportation affinity of the ligand at the specific site of the target.	False
Molecular docking studies were performed with BC6OTHER ( BC6ENTG : PDB 1E78), showing binding pattern with BC6OTHER residues BC6ENTC 218, BC6OTHER 222 and BC6OTHER 444, identifies the ligand - BC6OTHER interaction for the transportation affinity of the ligand at the specific site of the target.	False
Molecular docking studies were performed with BC6OTHER ( BC6OTHER : PDB 1E78), showing binding pattern with BC6OTHER residues BC6ENTC 218, BC6OTHER 222 and BC6OTHER 444, identifies the ligand - BC6ENTG interaction for the transportation affinity of the ligand at the specific site of the target.	False
Molecular docking studies were performed with BC6ENTG ( BC6OTHER : PDB 1E78), showing binding pattern with BC6OTHER residues BC6OTHER 218, BC6ENTC 222 and BC6OTHER 444, identifies the ligand - BC6OTHER interaction for the transportation affinity of the ligand at the specific site of the target.	False
Molecular docking studies were performed with BC6OTHER ( BC6ENTG : PDB 1E78), showing binding pattern with BC6OTHER residues BC6OTHER 218, BC6ENTC 222 and BC6OTHER 444, identifies the ligand - BC6OTHER interaction for the transportation affinity of the ligand at the specific site of the target.	False
Molecular docking studies were performed with BC6OTHER ( BC6OTHER : PDB 1E78), showing binding pattern with BC6OTHER residues BC6OTHER 218, BC6ENTC 222 and BC6OTHER 444, identifies the ligand - BC6ENTG interaction for the transportation affinity of the ligand at the specific site of the target.	False
Molecular docking studies were performed with BC6ENTG ( BC6OTHER : PDB 1E78), showing binding pattern with BC6OTHER residues BC6OTHER 218, BC6OTHER 222 and BC6ENTC 444, identifies the ligand - BC6OTHER interaction for the transportation affinity of the ligand at the specific site of the target.	False
Molecular docking studies were performed with BC6OTHER ( BC6ENTG : PDB 1E78), showing binding pattern with BC6OTHER residues BC6OTHER 218, BC6OTHER 222 and BC6ENTC 444, identifies the ligand - BC6OTHER interaction for the transportation affinity of the ligand at the specific site of the target.	False
Molecular docking studies were performed with BC6OTHER ( BC6OTHER : PDB 1E78), showing binding pattern with BC6OTHER residues BC6OTHER 218, BC6OTHER 222 and BC6ENTC 444, identifies the ligand - BC6ENTG interaction for the transportation affinity of the ligand at the specific site of the target.	False
Agents which have recently been shown to block BC6ENTG translation by regulating CHEM levels are the BC6ENTC , BC6OTHER ( BC6OTHER ), the antidiabetic BC6OTHER , and the antifungal agent, BC6OTHER .	CPR:4
Agents which have recently been shown to block BC6ENTG translation by regulating CHEM levels are the BC6OTHER , BC6ENTC ( BC6OTHER ), the antidiabetic BC6OTHER , and the antifungal agent, BC6OTHER .	CPR:4
A low toxicity maintenance regime, using BC6ENTC and readily available drugs, for mantle cell lymphoma and other malignancies with excess BC6ENTG levels.	False
Agents which have recently been shown to block BC6ENTG translation by regulating CHEM levels are the BC6OTHER , BC6OTHER ( BC6ENTC ), the antidiabetic BC6OTHER , and the antifungal agent, BC6OTHER .	CPR:4
Agents which have recently been shown to block BC6ENTG translation by regulating CHEM levels are the BC6OTHER , BC6OTHER ( BC6OTHER ), the antidiabetic BC6ENTC , and the antifungal agent, BC6OTHER .	CPR:4
Agents which have recently been shown to block BC6ENTG translation by regulating CHEM levels are the BC6OTHER , BC6OTHER ( BC6OTHER ), the antidiabetic BC6OTHER , and the antifungal agent, BC6ENTC .	CPR:4
Two types of agent which have been shown to inhibit angiogenesis are the teratogen, BC6ENTC , and the selective inhibitors of BC6ENTG ( BC6OTHER ).	False
Two types of agent which have been shown to inhibit angiogenesis are the teratogen, BC6ENTC , and the selective inhibitors of BC6OTHER ( BC6ENTG ).	False
BACKGROUND AND AIMS: BC6ENTG ( BC6OTHER ) is an important enzyme for DNA synthesis and the target for BC6ENTC ( BC6OTHER ).	False
BACKGROUND AND AIMS: BC6OTHER synthase ( BC6ENTG ) is an important enzyme for DNA synthesis and the target for BC6ENTC ( BC6OTHER ).	False
BACKGROUND AND AIMS: BC6ENTG ( BC6OTHER ) is an important enzyme for DNA synthesis and the target for BC6OTHER ( BC6ENTC ).	False
BACKGROUND AND AIMS: BC6OTHER synthase ( BC6ENTG ) is an important enzyme for DNA synthesis and the target for BC6OTHER ( BC6ENTC ).	False
BACKGROUND AND AIMS: BC6ENTC synthase ( BC6ENTG ) is an important enzyme for DNA synthesis and the target for BC6OTHER ( BC6OTHER ).	False
BC6ENTC , a BC6OTHER ( BC6OTHER )ylated peptide - based erythropoiesis - stimulating agent, stimulates the BC6ENTG dimer that governs erythropoiesis.	CPR:3
BC6OTHER , a BC6ENTC ( BC6OTHER )ylated peptide - based erythropoiesis - stimulating agent, stimulates the BC6ENTG dimer that governs erythropoiesis.	CPR:3
BC6OTHER , a BC6OTHER ( BC6ENTC )ylated peptide - based erythropoiesis - stimulating agent, stimulates the BC6ENTG dimer that governs erythropoiesis.	CPR:3
Genetic polymorphism and activities of BC6ENTG BC6OTHER dehydrogenases: implications for BC6ENTC metabolism and cytotoxicity.	False
Genetic polymorphism and activities of BC6ENTG BC6ENTC dehydrogenases: implications for BC6OTHER metabolism and cytotoxicity.	False
BC6ENTC dehydrogenase ( BC6ENTG ) and BC6OTHER dehydrogenase ( BC6OTHER ) exhibit genetic polymorphism and tissue specificity.	False
BC6ENTC dehydrogenase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) exhibit genetic polymorphism and tissue specificity.	False
BC6ENTC dehydrogenase ( BC6OTHER ) and BC6OTHER dehydrogenase ( BC6ENTG ) exhibit genetic polymorphism and tissue specificity.	False
These findings indicate that human pulmonary BC6ENTC - metabolizing activities differ significantly with respect to genetic polymorphism at both the BC6ENTG and the BC6OTHER loci.	CPR:9
These findings indicate that human pulmonary BC6ENTC - metabolizing activities differ significantly with respect to genetic polymorphism at both the BC6OTHER and the BC6ENTG loci.	CPR:9
The results suggest that individuals with high Vmax BC6ENTG and deficient in low - Km mitochondrial BC6OTHER , accounting for approximately 45% of the Chinese population, may end up with BC6ENTC accumulation during BC6OTHER consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.	CPR:9
The results suggest that individuals with high Vmax BC6OTHER and deficient in low - Km mitochondrial BC6ENTG , accounting for approximately 45% of the Chinese population, may end up with BC6ENTC accumulation during BC6OTHER consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.	CPR:9
The results suggest that individuals with high Vmax BC6ENTG and deficient in low - Km mitochondrial BC6OTHER , accounting for approximately 45% of the Chinese population, may end up with BC6OTHER accumulation during BC6ENTC consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.	CPR:9
The results suggest that individuals with high Vmax BC6OTHER and deficient in low - Km mitochondrial BC6ENTG , accounting for approximately 45% of the Chinese population, may end up with BC6OTHER accumulation during BC6ENTC consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.	CPR:9
BC6ENTG ( BC6OTHER ) and BC6ENTC dehydrogenase ( BC6OTHER ) exhibit genetic polymorphism and tissue specificity.	False
BC6OTHER dehydrogenase ( BC6ENTG ) and BC6ENTC dehydrogenase ( BC6OTHER ) exhibit genetic polymorphism and tissue specificity.	False
BC6OTHER dehydrogenase ( BC6OTHER ) and BC6ENTC dehydrogenase ( BC6ENTG ) exhibit genetic polymorphism and tissue specificity.	False
The identity of the lung BC6ENTG was further demonstrated by their characteristic pH - activity profiles for BC6ENTC oxidation, Km values for CHEM and BC6OTHER , and inhibition by BC6OTHER or BC6OTHER .	CPR:9
The identity of the lung BC6ENTG was further demonstrated by their characteristic pH - activity profiles for BC6OTHER oxidation, Km values for CHEM and BC6ENTC , and inhibition by BC6OTHER or BC6OTHER .	CPR:9
The identity of the lung BC6ENTG was further demonstrated by their characteristic pH - activity profiles for BC6OTHER oxidation, Km values for CHEM and BC6OTHER , and inhibition by BC6ENTC or BC6OTHER .	CPR:4
The identity of the lung BC6ENTG was further demonstrated by their characteristic pH - activity profiles for BC6OTHER oxidation, Km values for CHEM and BC6OTHER , and inhibition by BC6OTHER or BC6ENTC .	CPR:4
Loss of any of the enzymes needed to make either BC6OTHER or BC6OTHER (which also - prevent the production of BC6OTHER ) is lethal, but male mice lacking BC6ENTC synthase ( BC6ENTG ) due to a deletion of part of the X chromosome are viable on the B6C3H background.	False
Use of (Gyro) Gy and BC6ENTG transgenic mice to study functions of BC6ENTC .	False
An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement BC6ENTC and this can be accomplished by breeding with CAG - BC6ENTG mice that express BC6OTHER from a ubiquitous promoter.	CPR:9
An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement BC6ENTC and this can be accomplished by breeding with CAG - BC6OTHER mice that express BC6ENTG from a ubiquitous promoter.	CPR:9
Loss of any of the enzymes needed to make either BC6ENTC or BC6OTHER (which also - prevent the production of BC6OTHER ) is lethal, but male mice lacking BC6ENTG ( BC6OTHER ) due to a deletion of part of the X chromosome are viable on the B6C3H background.	False
Loss of any of the enzymes needed to make either BC6ENTC or BC6OTHER (which also - prevent the production of BC6OTHER ) is lethal, but male mice lacking BC6OTHER ( BC6ENTG ) due to a deletion of part of the X chromosome are viable on the B6C3H background.	False
Loss of any of the enzymes needed to make either BC6OTHER or BC6ENTC (which also - prevent the production of BC6OTHER ) is lethal, but male mice lacking BC6ENTG ( BC6OTHER ) due to a deletion of part of the X chromosome are viable on the B6C3H background.	False
Loss of any of the enzymes needed to make either BC6OTHER or BC6ENTC (which also - prevent the production of BC6OTHER ) is lethal, but male mice lacking BC6OTHER ( BC6ENTG ) due to a deletion of part of the X chromosome are viable on the B6C3H background.	False
Loss of any of the enzymes needed to make either BC6OTHER or BC6OTHER (which also - prevent the production of BC6ENTC ) is lethal, but male mice lacking BC6ENTG ( BC6OTHER ) due to a deletion of part of the X chromosome are viable on the B6C3H background.	False
Loss of any of the enzymes needed to make either BC6OTHER or BC6OTHER (which also - prevent the production of BC6ENTC ) is lethal, but male mice lacking BC6OTHER ( BC6ENTG ) due to a deletion of part of the X chromosome are viable on the B6C3H background.	False
Here, we report that BC6ENTG is necessary for expression of the vesicular BC6ENTC / BC6OTHER - antiport.	False
Here, we report that BC6ENTG is necessary for expression of the vesicular BC6OTHER / BC6ENTC - antiport.	False
The results were congruent and highly significant: BC6ENTC / BC6OTHER - antiport activity is detectable only in acidic organelles expressing functional BC6ENTG .	False
In contrast, BC6ENTG - deficient cells - and cells where transgenically encoded BC6OTHER was acutely photo - inactivated - were devoid of any BC6ENTC / BC6OTHER - antiport activity.	False
In contrast, BC6OTHER - deficient cells - and cells where transgenically encoded BC6ENTG was acutely photo - inactivated - were devoid of any BC6ENTC / BC6OTHER - antiport activity.	False
The results were congruent and highly significant: BC6OTHER / BC6ENTC - antiport activity is detectable only in acidic organelles expressing functional BC6ENTG .	False
 BC6ENTG is required for vesicular BC6ENTC / BC6OTHER - antiport activity.	False
 BC6ENTG is required for vesicular BC6OTHER / BC6ENTC - antiport activity.	False
In contrast, BC6ENTG - deficient cells - and cells where transgenically encoded BC6OTHER was acutely photo - inactivated - were devoid of any BC6OTHER / BC6ENTC - antiport activity.	False
In contrast, BC6OTHER - deficient cells - and cells where transgenically encoded BC6ENTG was acutely photo - inactivated - were devoid of any BC6OTHER / BC6ENTC - antiport activity.	False
Therefore, in addition to its previously described functions, BC6ENTG is involved in a rapid vesicular BC6ENTC sequestration through a BC6OTHER / BC6OTHER antiport.	False
Therefore, in addition to its previously described functions, BC6ENTG is involved in a rapid vesicular BC6OTHER sequestration through a BC6ENTC / BC6OTHER antiport.	False
Therefore, in addition to its previously described functions, BC6ENTG is involved in a rapid vesicular BC6OTHER sequestration through a BC6OTHER / BC6ENTC antiport.	False
BC6ENTG , a vesicular protein interacting with membranes upon low - affinity BC6ENTC - binding, plays a major role in excitation - release coupling, by synchronizing BC6OTHER entry with fast neurotransmitter release.	False
BC6ENTG , a vesicular protein interacting with membranes upon low - affinity BC6OTHER - binding, plays a major role in excitation - release coupling, by synchronizing BC6ENTC entry with fast neurotransmitter release.	False
BC6ENTC uptake in PC12 cells, which express the BC6ENTG endogenously, was 20 - to 28 - fold lower than in transduced cells.	CPR:9
In vivo, A431 BC6ENTG tumors demonstrated a 33 - fold higher BC6ENTC uptake than parental tumors.	CPR:9
BACKGROUND: The BC6ENTC transporter ( BC6ENTG ) is a high - affinity transporter for BC6OTHER .	False
 CONCLUSIONS: Transduction of tumor cells with BC6ENTG cDNA causes highly specific uptake and significant retention of BC6ENTC analogs in vitro and in vivo. These characteristics make the BC6OTHER suitable as a reporter gene for non - invasive monitoring of gene transfer.	False
 CONCLUSIONS: Transduction of tumor cells with BC6OTHER cDNA causes highly specific uptake and significant retention of BC6ENTC analogs in vitro and in vivo. These characteristics make the BC6ENTG suitable as a reporter gene for non - invasive monitoring of gene transfer.	False
The specificity of tracer uptake was determined by adding the BC6ENTG inhibitor BC6ENTC .	CPR:4
Parental and A431 BC6ENTG cells were xenotransplanted into nude mice and tumor uptake of BC6ENTC in vivo was determined after tracer administration.	False
BACKGROUND: The BC6ENTG ( BC6OTHER ) is a high - affinity transporter for BC6ENTC .	False
BACKGROUND: The BC6OTHER transporter ( BC6ENTG ) is a high - affinity transporter for BC6ENTC .	False
Furthermore, the BC6OTHER inhibitor BC6ENTC inhibited BC6OTHER - induced BC6OTHER expression, cell migration and invasion, as well as the activation of BC6OTHER / BC6OTHER , suggesting that BC6ENTG / BC6OTHER activation occur downstream of BC6OTHER activation.	CPR:4
Furthermore, the BC6OTHER inhibitor BC6ENTC inhibited BC6OTHER - induced BC6OTHER expression, cell migration and invasion, as well as the activation of BC6OTHER / BC6OTHER , suggesting that BC6OTHER / BC6ENTG activation occur downstream of BC6OTHER activation.	CPR:4
Furthermore, the BC6OTHER inhibitor BC6ENTC inhibited BC6OTHER - induced BC6OTHER expression, cell migration and invasion, as well as the activation of BC6OTHER / BC6OTHER , suggesting that BC6OTHER / BC6OTHER activation occur downstream of BC6ENTG activation.	CPR:4
Furthermore, the BC6ENTG inhibitor BC6ENTC inhibited BC6OTHER - induced BC6OTHER expression, cell migration and invasion, as well as the activation of BC6OTHER / BC6OTHER , suggesting that BC6OTHER / BC6OTHER activation occur downstream of BC6OTHER activation.	CPR:4
Furthermore, the BC6OTHER inhibitor BC6ENTC inhibited BC6ENTG - induced BC6OTHER expression, cell migration and invasion, as well as the activation of BC6OTHER / BC6OTHER , suggesting that BC6OTHER / BC6OTHER activation occur downstream of BC6OTHER activation.	CPR:4
Furthermore, the BC6OTHER inhibitor BC6ENTC inhibited BC6OTHER - induced BC6ENTG expression, cell migration and invasion, as well as the activation of BC6OTHER / BC6OTHER , suggesting that BC6OTHER / BC6OTHER activation occur downstream of BC6OTHER activation.	CPR:4
Furthermore, the BC6OTHER inhibitor BC6ENTC inhibited BC6OTHER - induced BC6OTHER expression, cell migration and invasion, as well as the activation of BC6ENTG / BC6OTHER , suggesting that BC6OTHER / BC6OTHER activation occur downstream of BC6OTHER activation.	CPR:4
Furthermore, the BC6OTHER inhibitor BC6ENTC inhibited BC6OTHER - induced BC6OTHER expression, cell migration and invasion, as well as the activation of BC6OTHER / BC6ENTG , suggesting that BC6OTHER / BC6OTHER activation occur downstream of BC6OTHER activation.	CPR:4
Inhibition of BC6ENTG / BC6OTHER activation with BC6ENTC blocks migration and invasion of CHEM - MB - 231 cells.	CPR:4
Inhibition of BC6OTHER / BC6ENTG activation with BC6ENTC blocks migration and invasion of CHEM - MB - 231 cells.	CPR:4
These findings suggest that BC6ENTC inhibited the BC6ENTG - induced invasion and migration of CHEM - MB - 231 cells via BC6OTHER - dependent BC6OTHER / BC6OTHER signaling, leading to the down - regulation of BC6OTHER expression.	CPR:4
These findings suggest that BC6ENTC inhibited the BC6OTHER - induced invasion and migration of CHEM - MB - 231 cells via BC6ENTG - dependent BC6OTHER / BC6OTHER signaling, leading to the down - regulation of BC6OTHER expression.	CPR:4
These findings suggest that BC6ENTC inhibited the BC6OTHER - induced invasion and migration of CHEM - MB - 231 cells via BC6OTHER - dependent BC6ENTG / BC6OTHER signaling, leading to the down - regulation of BC6OTHER expression.	CPR:4
These findings suggest that BC6ENTC inhibited the BC6OTHER - induced invasion and migration of CHEM - MB - 231 cells via BC6OTHER - dependent BC6OTHER / BC6ENTG signaling, leading to the down - regulation of BC6OTHER expression.	CPR:4
These findings suggest that BC6ENTC inhibited the BC6OTHER - induced invasion and migration of CHEM - MB - 231 cells via BC6OTHER - dependent BC6OTHER / BC6OTHER signaling, leading to the down - regulation of BC6ENTG expression.	CPR:4
We use BC6ENTG as a metastatic inducer of CHEM - MB - 231 cells to investigate the effect of BC6ENTC on cell migration and invasion.	False
BC6ENTC suppressed BC6ENTG - mediated protein levels of BC6OTHER and BC6OTHER , and reduced BC6OTHER expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.	CPR:4
BC6ENTC suppressed BC6OTHER - mediated protein levels of BC6ENTG and BC6OTHER , and reduced BC6OTHER expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.	CPR:4
BC6ENTC suppressed BC6OTHER - mediated protein levels of BC6OTHER and BC6ENTG , and reduced BC6OTHER expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.	CPR:4
BC6ENTC suppressed BC6OTHER - mediated protein levels of BC6OTHER and BC6OTHER , and reduced BC6ENTG expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.	CPR:4
BC6ENTC abrogated BC6ENTG - induced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6OTHER 3 - kinase ( BC6OTHER ) / BC6OTHER .	CPR:4
BC6ENTC abrogated BC6OTHER - induced phosphorylation of BC6ENTG ( BC6OTHER ) and BC6OTHER 3 - kinase ( BC6OTHER ) / BC6OTHER .	CPR:4
BC6ENTC abrogated BC6OTHER - induced phosphorylation of BC6OTHER ( BC6ENTG ) and BC6OTHER 3 - kinase ( BC6OTHER ) / BC6OTHER .	CPR:4
BC6ENTC abrogated BC6OTHER - induced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) / BC6OTHER .	CPR:4
BC6ENTC abrogated BC6OTHER - induced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6OTHER 3 - kinase ( BC6ENTG ) / BC6OTHER .	CPR:4
BC6ENTC abrogated BC6OTHER - induced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6OTHER 3 - kinase ( BC6OTHER ) / BC6ENTG .	CPR:4
BC6OTHER abrogated BC6ENTG - induced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6ENTC 3 - kinase ( BC6OTHER ) / BC6OTHER .	False
BC6OTHER abrogated BC6OTHER - induced phosphorylation of BC6ENTG ( BC6OTHER ) and BC6ENTC 3 - kinase ( BC6OTHER ) / BC6OTHER .	False
BC6OTHER abrogated BC6OTHER - induced phosphorylation of BC6OTHER ( BC6ENTG ) and BC6ENTC 3 - kinase ( BC6OTHER ) / BC6OTHER .	False
BC6OTHER abrogated BC6OTHER - induced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6ENTC 3 - kinase ( BC6ENTG ) / BC6OTHER .	False
BC6OTHER abrogated BC6OTHER - induced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6ENTC 3 - kinase ( BC6OTHER ) / BC6ENTG .	False
The specific BC6ENTG inhibitor, BC6ENTC , blocked significantly BC6OTHER - induced cell migration and invasion.	CPR:4
The specific BC6OTHER inhibitor, BC6ENTC , blocked significantly BC6ENTG - induced cell migration and invasion.	CPR:4
In conclusion, BC6OTHER is a potent BC6ENTC D2, D3 and BC6ENTG antagonist, and a novel anti - emetic agent with a broad - spectrum of anti - emetic activity.	False
The anti - emetic and pharmacological profile of BC6OTHER ( BC6OTHER ), a novel and potent BC6ENTC D2, D3 and BC6ENTG ligand, was investigated in the present study.	False
The anti - emetic and pharmacological profile of BC6OTHER ( BC6OTHER ), a novel and potent BC6ENTG and CHEM receptors ligand, was investigated in the present study.	False
In guinea - pig isolated colon, BC6ENTC produced a rightward shift of the concentration - response curves of BC6OTHER , a BC6ENTG agonist (pA2 value of 7.04).	CPR:6
In guinea - pig isolated colon, BC6OTHER produced a rightward shift of the concentration - response curves of BC6ENTC , a BC6ENTG agonist (pA2 value of 7.04).	CPR:5
The anti - emetic and pharmacological profile of BC6ENTC ( BC6OTHER ), a novel and potent BC6ENTG and BC6OTHER ligand, was investigated in the present study.	False
The anti - emetic and pharmacological profile of BC6ENTC ( BC6OTHER ), a novel and potent BC6OTHER and BC6ENTG ligand, was investigated in the present study.	False
The anti - emetic and pharmacological profile of BC6OTHER ( BC6ENTC ), a novel and potent BC6ENTG and BC6OTHER ligand, was investigated in the present study.	False
The anti - emetic and pharmacological profile of BC6OTHER ( BC6ENTC ), a novel and potent BC6OTHER and BC6ENTG ligand, was investigated in the present study.	False
Other BC6ENTG antagonists also produced such a shift in the following antagonistic - potency order: BC6ENTC > BC6OTHER = BC6OTHER >> BC6OTHER .	CPR:6
Other BC6ENTG antagonists also produced such a shift in the following antagonistic - potency order: BC6OTHER > BC6ENTC = BC6OTHER >> BC6OTHER .	CPR:6
Other BC6ENTG antagonists also produced such a shift in the following antagonistic - potency order: BC6OTHER > BC6OTHER = BC6ENTC >> BC6OTHER .	CPR:6
Other BC6ENTG antagonists also produced such a shift in the following antagonistic - potency order: BC6OTHER > BC6OTHER = BC6OTHER >> BC6ENTC .	CPR:6
In mice, BC6ENTC (1.0 - 3.0 mg kg( - 1) s.c.) potently inhibited hypothermia induced by the BC6ENTG agonist; BC6OTHER ( BC6OTHER ) (0.3 mg kg( - 1) s.c.).	CPR:4
In mice, BC6OTHER (1.0 - 3.0 mg kg( - 1) s.c.) potently inhibited hypothermia induced by the BC6ENTG agonist; BC6ENTC ( BC6OTHER ) (0.3 mg kg( - 1) s.c.).	CPR:5
In mice, BC6OTHER (1.0 - 3.0 mg kg( - 1) s.c.) potently inhibited hypothermia induced by the BC6ENTG agonist; BC6OTHER ( BC6ENTC ) (0.3 mg kg( - 1) s.c.).	CPR:5
BC6ENTC and BC6OTHER , which have affinity for BC6ENTG , also inhibited BC6OTHER - induced hypothermia.	False
BC6OTHER and BC6ENTC , which have affinity for BC6ENTG , also inhibited BC6OTHER - induced hypothermia.	False
BC6OTHER and BC6OTHER , which have affinity for BC6ENTG , also inhibited BC6ENTC - induced hypothermia.	False
The broad - spectrum anti - emetic activity of BC6ENTC , a novel BC6ENTG and BC6OTHER antagonist.	False
The broad - spectrum anti - emetic activity of BC6ENTC , a novel BC6OTHER and BC6ENTG antagonist.	CPR:6
The broad - spectrum anti - emetic activity of BC6OTHER , a novel BC6ENTC D2, D3 and BC6ENTG antagonist.	False
In conclusion, BC6ENTC is a potent BC6ENTG and BC6OTHER antagonist, and a novel anti - emetic agent with a broad - spectrum of anti - emetic activity.	False
In conclusion, BC6ENTC is a potent BC6OTHER and BC6ENTG antagonist, and a novel anti - emetic agent with a broad - spectrum of anti - emetic activity.	CPR:6
Evaluation of BC6ENTG ligands at the human BC6OTHER H4 receptor: identification of BC6ENTC as the first potent and selective BC6OTHER agonist.	False
Evaluation of BC6OTHER ligands at the human BC6OTHER H4 receptor: identification of BC6ENTC as the first potent and selective BC6ENTG agonist.	CPR:5
Evaluation of BC6OTHER ligands at the BC6ENTG : identification of BC6ENTC as the first potent and selective BC6OTHER agonist.	False
Evaluation of BC6ENTC H1 - , CHEM- , and H3 - receptor ligands at the human BC6OTHER H4 receptor: identification of BC6OTHER as the first potent and selective BC6ENTG agonist.	False
Evaluation of BC6ENTC H1 - , CHEM- , and H3 - receptor ligands at the BC6ENTG : identification of BC6OTHER as the first potent and selective BC6OTHER agonist.	False
Evaluation of BC6ENTG ligands at the human BC6ENTC H4 receptor: identification of BC6OTHER as the first potent and selective BC6OTHER agonist.	False
Evaluation of BC6OTHER ligands at the human BC6ENTC H4 receptor: identification of BC6OTHER as the first potent and selective BC6ENTG agonist.	False
Moreover, BC6ENTC potently activated the BC6ENTG (CHEM = 7.4 + / - 0.1; alpha = 1), and this response was competitively antagonized by the selective BC6OTHER antagonist BC6OTHER [ BC6OTHER ] (pA(2) = 7.8).	CPR:3
Moreover, BC6ENTC potently activated the BC6OTHER (CHEM = 7.4 + / - 0.1; alpha = 1), and this response was competitively antagonized by the selective BC6ENTG antagonist BC6OTHER [ BC6OTHER ] (pA(2) = 7.8).	False
Moreover, BC6OTHER potently activated the BC6ENTG (CHEM = 7.4 + / - 0.1; alpha = 1), and this response was competitively antagonized by the selective BC6OTHER antagonist BC6ENTC [ BC6OTHER ] (pA(2) = 7.8).	False
Moreover, BC6OTHER potently activated the BC6OTHER (CHEM = 7.4 + / - 0.1; alpha = 1), and this response was competitively antagonized by the selective BC6ENTG antagonist BC6ENTC [ BC6OTHER ] (pA(2) = 7.8).	CPR:6
Moreover, BC6OTHER potently activated the BC6ENTG (CHEM = 7.4 + / - 0.1; alpha = 1), and this response was competitively antagonized by the selective BC6OTHER antagonist BC6OTHER [ BC6ENTC ] (pA(2) = 7.8).	False
Moreover, BC6OTHER potently activated the BC6OTHER (CHEM = 7.4 + / - 0.1; alpha = 1), and this response was competitively antagonized by the selective BC6ENTG antagonist BC6OTHER [ BC6ENTC ] (pA(2) = 7.8).	CPR:6
The identification of BC6ENTC as a potent BC6ENTG agonist is of major importance for future studies to unravel the physiological roles of the BC6OTHER .	CPR:5
The identification of BC6ENTC as a potent BC6OTHER agonist is of major importance for future studies to unravel the physiological roles of the BC6ENTG .	False
The BC6ENTC CHEM receptor ( BC6ENTG ) is involved in the chemotaxis of leukocytes and mast cells to sites of inflammation and is suggested to be a potential drug target for asthma and allergy.	False
Almost all of the tested BC6ENTG and BC6OTHER antagonists, including several important therapeutics, displaced less than 30% of specific BC6ENTC binding to the BC6OTHER at concentrations up to 10 microM.	False
Almost all of the tested BC6OTHER and BC6ENTG antagonists, including several important therapeutics, displaced less than 30% of specific BC6ENTC binding to the BC6OTHER at concentrations up to 10 microM.	False
Almost all of the tested BC6OTHER and BC6OTHER antagonists, including several important therapeutics, displaced less than 30% of specific BC6ENTC binding to the BC6ENTG at concentrations up to 10 microM.	False
Most of the tested BC6ENTG agonists and BC6ENTC - based BC6OTHER ligands show micromolar - to - nanomolar range BC6OTHER affinity, and these ligands exert different intrinsic BC6OTHER activities, ranging from full agonists to inverse agonists.	False
Most of the tested BC6OTHER agonists and BC6ENTC - based BC6ENTG ligands show micromolar - to - nanomolar range BC6OTHER affinity, and these ligands exert different intrinsic BC6OTHER activities, ranging from full agonists to inverse agonists.	False
Most of the tested BC6OTHER agonists and BC6ENTC - based BC6OTHER ligands show micromolar - to - nanomolar range BC6ENTG affinity, and these ligands exert different intrinsic BC6OTHER activities, ranging from full agonists to inverse agonists.	False
Most of the tested BC6OTHER agonists and BC6ENTC - based BC6OTHER ligands show micromolar - to - nanomolar range BC6OTHER affinity, and these ligands exert different intrinsic BC6ENTG activities, ranging from full agonists to inverse agonists.	CPR:5
Interestingly, we identified BC6ENTC as a high - affinity BC6ENTG ligand (K(i) = 50 nM) that has a >100 - fold selectivity for the BC6OTHER over the other BC6OTHER receptor subtypes.	False
Interestingly, we identified BC6ENTC as a high - affinity BC6OTHER ligand (K(i) = 50 nM) that has a >100 - fold selectivity for the BC6ENTG over the other BC6OTHER receptor subtypes.	False
Interestingly, we identified BC6ENTC as a high - affinity BC6OTHER ligand (K(i) = 50 nM) that has a >100 - fold selectivity for the BC6OTHER over the other BC6ENTG subtypes.	False
Interestingly, we identified BC6OTHER as a high - affinity BC6ENTG ligand (K(i) = 50 nM) that has a >100 - fold selectivity for the BC6OTHER over the other BC6ENTC receptor subtypes.	False
Interestingly, we identified BC6OTHER as a high - affinity BC6OTHER ligand (K(i) = 50 nM) that has a >100 - fold selectivity for the BC6ENTG over the other BC6ENTC receptor subtypes.	False
BC6ENTC reductase deficiency impairs BC6OTHER synthesis, defects in cytosolic reduction of BC6OTHER (CblC / D) impair the synthesis of both BC6OTHER - and BC6OTHER and deficiencies of BC6ENTG (CblE / G) are associated with defective BC6OTHER synthesis.	False
BC6ENTG deficiency impairs BC6ENTC synthesis, defects in cytosolic reduction of BC6OTHER (CblC / D) impair the synthesis of both BC6OTHER - and BC6OTHER and deficiencies of BC6OTHER synthase (CblE / G) are associated with defective BC6OTHER synthesis.	CPR:9
BC6OTHER reductase deficiency impairs BC6ENTC synthesis, defects in cytosolic reduction of BC6OTHER (CblC / D) impair the synthesis of both BC6OTHER - and BC6OTHER and deficiencies of BC6ENTG (CblE / G) are associated with defective BC6OTHER synthesis.	False
BC6ENTG deficiency impairs BC6OTHER synthesis, defects in cytosolic reduction of BC6ENTC (CblC / D) impair the synthesis of both BC6OTHER - and BC6OTHER and deficiencies of BC6OTHER synthase (CblE / G) are associated with defective BC6OTHER synthesis.	False
BC6OTHER reductase deficiency impairs BC6OTHER synthesis, defects in cytosolic reduction of BC6ENTC (CblC / D) impair the synthesis of both BC6OTHER - and BC6OTHER and deficiencies of BC6ENTG (CblE / G) are associated with defective BC6OTHER synthesis.	False
BC6ENTG deficiency impairs BC6OTHER synthesis, defects in cytosolic reduction of BC6OTHER (CblC / D) impair the synthesis of both BC6ENTC - and BC6OTHER and deficiencies of BC6OTHER synthase (CblE / G) are associated with defective BC6OTHER synthesis.	False
BC6OTHER reductase deficiency impairs BC6OTHER synthesis, defects in cytosolic reduction of BC6OTHER (CblC / D) impair the synthesis of both BC6ENTC - and BC6OTHER and deficiencies of BC6ENTG (CblE / G) are associated with defective BC6OTHER synthesis.	False
BC6ENTG deficiency impairs BC6OTHER synthesis, defects in cytosolic reduction of BC6OTHER (CblC / D) impair the synthesis of both BC6OTHER - and BC6ENTC and deficiencies of BC6OTHER synthase (CblE / G) are associated with defective BC6OTHER synthesis.	False
BC6OTHER reductase deficiency impairs BC6OTHER synthesis, defects in cytosolic reduction of BC6OTHER (CblC / D) impair the synthesis of both BC6OTHER - and BC6ENTC and deficiencies of BC6ENTG (CblE / G) are associated with defective BC6OTHER synthesis.	False
BC6ENTG deficiency impairs BC6OTHER synthesis, defects in cytosolic reduction of BC6OTHER (CblC / D) impair the synthesis of both BC6OTHER - and BC6OTHER and deficiencies of BC6ENTC synthase (CblE / G) are associated with defective BC6OTHER synthesis.	False
BC6ENTG deficiency impairs BC6OTHER synthesis, defects in cytosolic reduction of BC6OTHER (CblC / D) impair the synthesis of both BC6OTHER - and BC6OTHER and deficiencies of BC6OTHER synthase (CblE / G) are associated with defective BC6ENTC synthesis.	False
BC6OTHER reductase deficiency impairs BC6OTHER synthesis, defects in cytosolic reduction of BC6OTHER (CblC / D) impair the synthesis of both BC6OTHER - and BC6OTHER and deficiencies of BC6ENTG (CblE / G) are associated with defective BC6ENTC synthesis.	CPR:9
Effect of BC6OTHER and BC6ENTC on BC6ENTG expression in Jurkat T cells.	False
The compounds BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) belong to inhibitors of BC6ENTG , whose low activity correlates with increase in transcription of various genes.	CPR:4
The compounds BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) belong to inhibitors of BC6ENTG , whose low activity correlates with increase in transcription of various genes.	CPR:4
The compounds BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) belong to inhibitors of BC6ENTG , whose low activity correlates with increase in transcription of various genes.	CPR:4
The compounds BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) belong to inhibitors of BC6ENTG , whose low activity correlates with increase in transcription of various genes.	CPR:4
Using the reverse - transcription and real - time quantitative PCR (RQ - PCR) analysis, we indicated that BC6ENTC and BC6OTHER did not profoundly affect on BC6ENTG transcription in Jurkat T leukemia cells clone E6 - 1.	False
Using the reverse - transcription and real - time quantitative PCR (RQ - PCR) analysis, we indicated that BC6OTHER and BC6ENTC did not profoundly affect on BC6ENTG transcription in Jurkat T leukemia cells clone E6 - 1.	False
However, the flowcytometric analysis revealed that BC6ENTC and BC6OTHER decreased intracellular contents of BC6ENTG in these cells in dose dependent manner.	CPR:4
However, the flowcytometric analysis revealed that BC6OTHER and BC6ENTC decreased intracellular contents of BC6ENTG in these cells in dose dependent manner.	CPR:4
Effect of BC6ENTC and BC6OTHER on BC6ENTG expression in Jurkat T cells.	False
Furthermore, h[ BC6ENTC ] - BC6OTHER reduced chemotherapy - induced apoptosis, decreased activation of BC6OTHER , and inhibited poly( BC6OTHER ) polymerase cleavage in heterologous cells transfected with the BC6ENTG .	False
Furthermore, h[ BC6ENTC ] - BC6ENTG reduced chemotherapy - induced apoptosis, decreased activation of BC6OTHER , and inhibited poly( BC6OTHER ) polymerase cleavage in heterologous cells transfected with the BC6OTHER .	False
Furthermore, h[ BC6ENTC ] - BC6OTHER reduced chemotherapy - induced apoptosis, decreased activation of BC6ENTG , and inhibited poly( BC6OTHER ) polymerase cleavage in heterologous cells transfected with the BC6OTHER .	False
Furthermore, h[ BC6ENTC ] - BC6OTHER reduced chemotherapy - induced apoptosis, decreased activation of BC6OTHER , and inhibited BC6ENTG cleavage in heterologous cells transfected with the BC6OTHER .	CPR:4
Furthermore, h[ BC6OTHER ] - BC6OTHER reduced chemotherapy - induced apoptosis, decreased activation of BC6OTHER , and inhibited poly( BC6ENTC ) polymerase cleavage in heterologous cells transfected with the BC6ENTG .	False
Furthermore, h[ BC6OTHER ] - BC6ENTG reduced chemotherapy - induced apoptosis, decreased activation of BC6OTHER , and inhibited poly( BC6ENTC ) polymerase cleavage in heterologous cells transfected with the BC6OTHER .	False
Furthermore, h[ BC6OTHER ] - BC6OTHER reduced chemotherapy - induced apoptosis, decreased activation of BC6ENTG , and inhibited poly( BC6ENTC ) polymerase cleavage in heterologous cells transfected with the BC6OTHER .	False
We report here that a human degradation - resistant BC6ENTG analogue, h[ BC6ENTC ] - BC6OTHER significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of BC6OTHER inhibitor BC6OTHER or the antimetabolite BC6OTHER .	False
We report here that a human degradation - resistant BC6OTHER analogue, h[ BC6ENTC ] - BC6ENTG significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of BC6OTHER inhibitor BC6OTHER or the antimetabolite BC6OTHER .	False
We report here that a human degradation - resistant BC6OTHER analogue, h[ BC6ENTC ] - BC6OTHER significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of BC6ENTG inhibitor BC6OTHER or the antimetabolite BC6OTHER .	False
We report here that a human degradation - resistant BC6ENTG analogue, h[ BC6OTHER ] - BC6OTHER significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of BC6OTHER inhibitor BC6ENTC or the antimetabolite BC6OTHER .	False
We report here that a human degradation - resistant BC6OTHER analogue, h[ BC6OTHER ] - BC6ENTG significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of BC6OTHER inhibitor BC6ENTC or the antimetabolite BC6OTHER .	False
We report here that a human degradation - resistant BC6OTHER analogue, h[ BC6OTHER ] - BC6OTHER significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of BC6ENTG inhibitor BC6ENTC or the antimetabolite BC6OTHER .	CPR:4
We report here that a human degradation - resistant BC6ENTG analogue, h[ BC6OTHER ] - BC6OTHER significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of BC6OTHER inhibitor BC6OTHER or the antimetabolite BC6ENTC .	False
We report here that a human degradation - resistant BC6OTHER analogue, h[ BC6OTHER ] - BC6ENTG significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of BC6OTHER inhibitor BC6OTHER or the antimetabolite BC6ENTC .	False
We report here that a human degradation - resistant BC6OTHER analogue, h[ BC6OTHER ] - BC6OTHER significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of BC6ENTG inhibitor BC6OTHER or the antimetabolite BC6ENTC .	False
h[ BC6ENTC ] - BC6ENTG significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor - bearing mice treated with cyclical CHEM.	False
Our optimized BC6ENTC production assay to measure BC6ENTG activity correlated closely with the direct measure of the rate of asymmetric BC6OTHER consumption.	CPR:9
Our optimized BC6OTHER production assay to measure BC6ENTG activity correlated closely with the direct measure of the rate of asymmetric BC6ENTC consumption.	CPR:9
Using this assay, we found that both BC6ENTC and BC6OTHER inhibit renal cortical BC6ENTG activity in vitro.	CPR:4
Using this assay, we found that both BC6OTHER and BC6ENTC inhibit renal cortical BC6ENTG activity in vitro.	CPR:4
BC6ENTG ( BC6OTHER ) metabolizes asymmetric BC6OTHER to generate BC6ENTC and is present in large quantities in the kidney.	CPR:9
BC6OTHER dimethylaminohydrolase ( BC6ENTG ) metabolizes asymmetric BC6OTHER to generate BC6ENTC and is present in large quantities in the kidney.	CPR:9
BC6ENTC dimethylaminohydrolase ( BC6ENTG ) metabolizes asymmetric BC6OTHER to generate BC6OTHER and is present in large quantities in the kidney.	False
We present a new study that optimizes the Prescott - Jones colorimetric assay to measure BC6ENTG - dependent BC6ENTC generation in kidney homogenates.	CPR:9
We found that the removal of BC6ENTC with BC6ENTG is necessary since BC6OTHER also produces a positive reaction.	CPR:9
We found that the removal of BC6OTHER with BC6ENTG is necessary since BC6ENTC also produces a positive reaction.	False
Deproteinization with BC6ENTC was found to be optimal and that BC6ENTG inhibitors were not necessary.	False
BC6ENTG or BC6ENTC synthase isoenzymes were not found to influence BC6OTHER production.	False
BC6ENTG ( BC6OTHER ) metabolizes asymmetric BC6ENTC to generate BC6OTHER and is present in large quantities in the kidney.	CPR:9
BC6OTHER dimethylaminohydrolase ( BC6ENTG ) metabolizes asymmetric BC6ENTC to generate BC6OTHER and is present in large quantities in the kidney.	CPR:9
BC6ENTG or BC6OTHER synthase isoenzymes were not found to influence BC6ENTC production.	False
BC6OTHER or BC6ENTG isoenzymes were not found to influence BC6ENTC production.	False
 BC6ENTC enhances the depolarizing afterpotential of immunohistochemically identified BC6OTHER neurons in the rat supraoptic nucleus via BC6ENTG activation.	CPR:3
 BC6OTHER enhances the depolarizing afterpotential of immunohistochemically identified BC6ENTC neurons in the rat supraoptic nucleus via BC6ENTG activation.	False
The enhancement of the depolarizing afterpotential by BC6ENTC was mimicked by the BC6ENTG agonist BC6OTHER and was reduced or blocked by the BC6OTHER antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6OTHER H2 - receptor antagonist, BC6OTHER .	False
The enhancement of the depolarizing afterpotential by BC6ENTC was mimicked by the BC6OTHER H1 - receptor agonist BC6OTHER and was reduced or blocked by the BC6ENTG antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6OTHER H2 - receptor antagonist, BC6OTHER .	False
The enhancement of the depolarizing afterpotential by BC6ENTC was mimicked by the BC6OTHER H1 - receptor agonist BC6OTHER and was reduced or blocked by the BC6OTHER antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6ENTG antagonist, BC6OTHER .	False
The enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6ENTC H1 - receptor agonist BC6OTHER and was reduced or blocked by the BC6ENTG antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6OTHER H2 - receptor antagonist, BC6OTHER .	False
The enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6ENTC H1 - receptor agonist BC6OTHER and was reduced or blocked by the BC6OTHER antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6ENTG antagonist, BC6OTHER .	False
The enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6ENTG agonist BC6ENTC and was reduced or blocked by the BC6OTHER antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6OTHER H2 - receptor antagonist, BC6OTHER .	CPR:5
The enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6OTHER H1 - receptor agonist BC6ENTC and was reduced or blocked by the BC6ENTG antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6OTHER H2 - receptor antagonist, BC6OTHER .	False
The enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6OTHER H1 - receptor agonist BC6ENTC and was reduced or blocked by the BC6OTHER antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6ENTG antagonist, BC6OTHER .	False
The enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6ENTG agonist BC6OTHER and was reduced or blocked by the BC6OTHER antagonist BC6ENTC , but was not blocked or reduced in the presence of the BC6OTHER H2 - receptor antagonist, BC6OTHER .	False
The enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6OTHER H1 - receptor agonist BC6OTHER and was reduced or blocked by the BC6ENTG antagonist BC6ENTC , but was not blocked or reduced in the presence of the BC6OTHER H2 - receptor antagonist, BC6OTHER .	CPR:6
The enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6OTHER H1 - receptor agonist BC6OTHER and was reduced or blocked by the BC6OTHER antagonist BC6ENTC , but was not blocked or reduced in the presence of the BC6ENTG antagonist, BC6OTHER .	False
The enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6ENTG agonist BC6OTHER and was reduced or blocked by the BC6OTHER antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6ENTC H2 - receptor antagonist, BC6OTHER .	False
The enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6OTHER H1 - receptor agonist BC6OTHER and was reduced or blocked by the BC6ENTG antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6ENTC H2 - receptor antagonist, BC6OTHER .	False
The enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6ENTG agonist BC6OTHER and was reduced or blocked by the BC6OTHER antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6OTHER H2 - receptor antagonist, BC6ENTC .	False
The enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6OTHER H1 - receptor agonist BC6OTHER and was reduced or blocked by the BC6ENTG antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6OTHER H2 - receptor antagonist, BC6ENTC .	False
The enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6OTHER H1 - receptor agonist BC6OTHER and was reduced or blocked by the BC6OTHER antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6ENTG antagonist, BC6ENTC .	CPR:6
In summary, these results show that the excitatory effect of BC6ENTC on immunohistochemically identified BC6OTHER neurons in the supraoptic nucleus is due in part to the BC6ENTG - mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential.	CPR:3
In summary, these results show that the excitatory effect of BC6OTHER on immunohistochemically identified BC6ENTC neurons in the supraoptic nucleus is due in part to the BC6ENTG - mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential.	False
Transcripts of BC6ENTG genes were more highly expressed in most tissues examined in vivo (except blood, head kidney and spleen), whereas those of the BC6OTHER genes were more responsive to BC6ENTC exposure in vitro, especially to the organic form.	False
Transcripts of BC6OTHER genes were more highly expressed in most tissues examined in vivo (except blood, head kidney and spleen), whereas those of the BC6ENTG genes were more responsive to BC6ENTC exposure in vitro, especially to the organic form.	False
Interestingly, BC6ENTG was the most sensitive to BC6ENTC availability in non stressful conditions, whereas BC6OTHER and BC6OTHER were highly induced by exposure to BC6OTHER levels that had some toxic effects on the cells.	False
Interestingly, BC6OTHER was the most sensitive to BC6ENTC availability in non stressful conditions, whereas BC6ENTG and BC6OTHER were highly induced by exposure to BC6OTHER levels that had some toxic effects on the cells.	False
Interestingly, BC6OTHER was the most sensitive to BC6ENTC availability in non stressful conditions, whereas BC6OTHER and BC6ENTG were highly induced by exposure to BC6OTHER levels that had some toxic effects on the cells.	False
Interestingly, BC6ENTG was the most sensitive to BC6OTHER availability in non stressful conditions, whereas BC6OTHER and BC6OTHER were highly induced by exposure to BC6ENTC levels that had some toxic effects on the cells.	False
Interestingly, BC6OTHER was the most sensitive to BC6OTHER availability in non stressful conditions, whereas BC6ENTG and BC6OTHER were highly induced by exposure to BC6ENTC levels that had some toxic effects on the cells.	CPR:3
Interestingly, BC6OTHER was the most sensitive to BC6OTHER availability in non stressful conditions, whereas BC6OTHER and BC6ENTG were highly induced by exposure to BC6ENTC levels that had some toxic effects on the cells.	CPR:3
Our results lead us to conclude that trout BC6ENTG transcripts expression level may represent a sensitive biomarker for BC6ENTC intake, helping to evaluate if BC6OTHER concentration and chemical speciation impact on cell homeostasis.	False
Our results lead us to conclude that trout BC6ENTG transcripts expression level may represent a sensitive biomarker for BC6OTHER intake, helping to evaluate if BC6ENTC concentration and chemical speciation impact on cell homeostasis.	False
BC6ENTC peroxidase ( BC6ENTG ) is the largest and the most studied BC6OTHER family.	False
BC6ENTC peroxidase ( BC6OTHER ) is the largest and the most studied BC6ENTG family.	False
Cytosolic BC6ENTC peroxidase ( BC6ENTG , BC6OTHER ) and phospholipid BC6OTHER BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	False
Cytosolic BC6ENTC peroxidase ( BC6OTHER , BC6ENTG ) and phospholipid BC6OTHER BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	False
Cytosolic BC6ENTC peroxidase ( BC6OTHER , BC6OTHER ) and BC6ENTG BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	False
Cytosolic BC6ENTC peroxidase ( BC6OTHER , BC6OTHER ) and phospholipid BC6OTHER BC6OTHER peroxidase ( BC6ENTG , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	False
Cytosolic BC6ENTC peroxidase ( BC6OTHER , BC6OTHER ) and phospholipid BC6OTHER BC6OTHER peroxidase ( BC6OTHER , BC6ENTG ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	False
BC6ENTG ( BC6OTHER , BC6OTHER ) and phospholipid BC6ENTC BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	False
Cytosolic BC6OTHER peroxidase ( BC6ENTG , BC6OTHER ) and phospholipid BC6ENTC BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	False
Cytosolic BC6OTHER peroxidase ( BC6OTHER , BC6ENTG ) and phospholipid BC6ENTC BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	False
Cytosolic BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) and phospholipid BC6ENTC BC6OTHER peroxidase ( BC6ENTG , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	False
Cytosolic BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) and phospholipid BC6ENTC BC6OTHER peroxidase ( BC6OTHER , BC6ENTG ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	False
BC6ENTG ( BC6OTHER , BC6OTHER ) and phospholipid BC6OTHER BC6ENTC peroxidase ( BC6OTHER , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	False
Cytosolic BC6OTHER peroxidase ( BC6ENTG , BC6OTHER ) and phospholipid BC6OTHER BC6ENTC peroxidase ( BC6OTHER , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	False
Cytosolic BC6OTHER peroxidase ( BC6OTHER , BC6ENTG ) and phospholipid BC6OTHER BC6ENTC peroxidase ( BC6OTHER , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	False
Cytosolic BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) and BC6ENTG BC6ENTC peroxidase ( BC6OTHER , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	False
Cytosolic BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) and phospholipid BC6OTHER BC6ENTC peroxidase ( BC6ENTG , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	False
Cytosolic BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) and phospholipid BC6OTHER BC6ENTC peroxidase ( BC6OTHER , BC6ENTG ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	False
Characterization of BC6ENTG and CHEM - BC6OTHER BC6OTHER peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro BC6ENTC exposure.	False
Characterization of cytosolic BC6OTHER peroxidase and BC6ENTG BC6OTHER peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro BC6ENTC exposure.	False
Characterization of cytosolic BC6ENTC peroxidase and BC6ENTG BC6OTHER peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro BC6OTHER exposure.	False
Characterization of BC6ENTG and CHEM - BC6ENTC BC6OTHER peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro BC6OTHER exposure.	False
Characterization of BC6ENTG and CHEM - BC6OTHER BC6ENTC peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro BC6OTHER exposure.	False
Characterization of cytosolic BC6OTHER peroxidase and BC6ENTG BC6ENTC peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro BC6OTHER exposure.	False
BC6ENTG , a phase II enzyme, was inhibited by both BC6OTHER and BC6OTHER but no such inhibition was noted in BC6OTHER - treated animals pre - exposed to BC6ENTC .	False
BC6ENTG , a phase II enzyme, was inhibited by both BC6ENTC and BC6OTHER but no such inhibition was noted in BC6OTHER - treated animals pre - exposed to BC6OTHER .	CPR:4
BC6ENTG , a phase II enzyme, was inhibited by both BC6OTHER and BC6ENTC but no such inhibition was noted in BC6OTHER - treated animals pre - exposed to BC6OTHER .	CPR:4
BC6ENTG , a phase II enzyme, was inhibited by both BC6OTHER and BC6OTHER but no such inhibition was noted in BC6ENTC - treated animals pre - exposed to BC6OTHER .	False
Upon BC6ENTC pre - exposure, brain BC6ENTG increased, while BC6OTHER ( BC6OTHER ) decreased.	CPR:3
Upon BC6ENTC pre - exposure, brain BC6OTHER increased, while BC6ENTG ( BC6OTHER ) decreased.	CPR:4
Upon BC6ENTC pre - exposure, brain BC6OTHER increased, while BC6OTHER ( BC6ENTG ) decreased.	CPR:4
The toxic effects of BC6ENTG significantly attenuated with BC6ENTC pre - exposure.	CPR:4
Next, BC6OTHER significantly decreased the levels of BC6ENTC - ERK2 and BC6ENTG in BC6OTHER or BC6OTHER siRNA - transfected cells concomitantly with a marked reduction on cell invasion and migration.	False
Next, BC6OTHER significantly decreased the levels of BC6ENTC - ERK2 and BC6OTHER in BC6ENTG or BC6OTHER siRNA - transfected cells concomitantly with a marked reduction on cell invasion and migration.	False
Next, BC6OTHER significantly decreased the levels of BC6ENTC - ERK2 and BC6OTHER in BC6OTHER or BC6ENTG siRNA - transfected cells concomitantly with a marked reduction on cell invasion and migration.	False
Next, BC6OTHER significantly decreased the levels of BC6ENTG and BC6ENTC - Akt in BC6OTHER or BC6OTHER siRNA - transfected cells concomitantly with a marked reduction on cell invasion and migration.	False
Next, BC6OTHER significantly decreased the levels of BC6OTHER and BC6ENTC - Akt in BC6ENTG or BC6OTHER siRNA - transfected cells concomitantly with a marked reduction on cell invasion and migration.	False
Next, BC6OTHER significantly decreased the levels of BC6OTHER and BC6ENTC - Akt in BC6OTHER or BC6ENTG siRNA - transfected cells concomitantly with a marked reduction on cell invasion and migration.	False
 BC6ENTC attenuates metastasis via both BC6ENTG and BC6OTHER / BC6OTHER pathways in BC6OTHER - treated liver cancer HepG2 cells.	CPR:4
 BC6ENTC attenuates metastasis via both BC6OTHER and BC6ENTG / BC6OTHER pathways in BC6OTHER - treated liver cancer HepG2 cells.	CPR:4
 BC6ENTC attenuates metastasis via both BC6OTHER and BC6OTHER / BC6ENTG pathways in BC6OTHER - treated liver cancer HepG2 cells.	CPR:4
 BC6ENTC attenuates metastasis via both BC6OTHER and BC6OTHER / BC6OTHER pathways in BC6ENTG - treated liver cancer HepG2 cells.	False
In conclusion, BC6ENTC attenuates BC6ENTG - induced HepG2 cells metastasis involving both BC6OTHER and BC6OTHER / BC6OTHER pathways and are potentially useful as anti - metastatic agents for the treatment of hepatoma.	CPR:4
In conclusion, BC6ENTC attenuates BC6OTHER - induced HepG2 cells metastasis involving both BC6ENTG and BC6OTHER / BC6OTHER pathways and are potentially useful as anti - metastatic agents for the treatment of hepatoma.	CPR:4
In conclusion, BC6ENTC attenuates BC6OTHER - induced HepG2 cells metastasis involving both BC6OTHER and BC6ENTG / BC6OTHER pathways and are potentially useful as anti - metastatic agents for the treatment of hepatoma.	CPR:4
In conclusion, BC6ENTC attenuates BC6OTHER - induced HepG2 cells metastasis involving both BC6OTHER and BC6OTHER / BC6ENTG pathways and are potentially useful as anti - metastatic agents for the treatment of hepatoma.	CPR:4
We use BC6ENTG as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER on BC6OTHER / BC6OTHER - mediated tumor invasion and metastasis.	False
We use BC6OTHER as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER on BC6ENTG / BC6OTHER - mediated tumor invasion and metastasis.	False
We use BC6OTHER as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER on BC6OTHER / BC6ENTG - mediated tumor invasion and metastasis.	False
We use BC6ENTG as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER on BC6OTHER / BC6OTHER - mediated tumor invasion and metastasis.	False
We use BC6OTHER as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER on BC6ENTG / BC6OTHER - mediated tumor invasion and metastasis.	False
We use BC6OTHER as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER on BC6OTHER / BC6ENTG - mediated tumor invasion and metastasis.	False
We use BC6ENTG as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER on BC6OTHER / BC6OTHER - mediated tumor invasion and metastasis.	False
We use BC6OTHER as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER on BC6ENTG / BC6OTHER - mediated tumor invasion and metastasis.	False
We use BC6OTHER as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER on BC6OTHER / BC6ENTG - mediated tumor invasion and metastasis.	False
We use BC6ENTG as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC on BC6OTHER / BC6OTHER - mediated tumor invasion and metastasis.	False
We use BC6OTHER as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC on BC6ENTG / BC6OTHER - mediated tumor invasion and metastasis.	False
We use BC6OTHER as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC on BC6OTHER / BC6ENTG - mediated tumor invasion and metastasis.	False
Among them, BC6ENTC markedly inhibited BC6ENTG - induced the abilities of the adhesion, invasion, and migration by cell - matrix adhesion assay and transwell - chamber invasion / migration assay under non - cytotoxic concentrations.	CPR:4
Data also showed BC6ENTC inhibited BC6ENTG - induced cell scattering and cytoskeleton changed such as filopodia and lamellipodia.	CPR:4
Furthermore, BC6ENTC could inhibit BC6ENTG - induced the membrane localization of phosphorylated BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER and BC6OTHER .	CPR:4
Furthermore, BC6ENTC could inhibit BC6OTHER - induced the membrane localization of phosphorylated BC6ENTG , BC6OTHER , and BC6OTHER , but not BC6OTHER and BC6OTHER .	CPR:4
Furthermore, BC6ENTC could inhibit BC6OTHER - induced the membrane localization of phosphorylated BC6OTHER , BC6ENTG , and BC6OTHER , but not BC6OTHER and BC6OTHER .	CPR:4
Furthermore, BC6ENTC could inhibit BC6OTHER - induced the membrane localization of phosphorylated BC6OTHER , BC6OTHER , and BC6ENTG , but not BC6OTHER and BC6OTHER .	CPR:4
Furthermore, BC6ENTC could inhibit BC6OTHER - induced the membrane localization of phosphorylated BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6ENTG and BC6OTHER .	False
Furthermore, BC6ENTC could inhibit BC6OTHER - induced the membrane localization of phosphorylated BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER and BC6ENTG .	False
Next, BC6ENTC significantly decreased the levels of BC6ENTG and BC6OTHER in BC6OTHER or BC6OTHER siRNA - transfected cells concomitantly with a marked reduction on cell invasion and migration.	CPR:4
Next, BC6ENTC significantly decreased the levels of BC6OTHER and BC6ENTG in BC6OTHER or BC6OTHER siRNA - transfected cells concomitantly with a marked reduction on cell invasion and migration.	CPR:4
Next, BC6ENTC significantly decreased the levels of BC6OTHER and BC6OTHER in BC6ENTG or BC6OTHER siRNA - transfected cells concomitantly with a marked reduction on cell invasion and migration.	CPR:4
Next, BC6ENTC significantly decreased the levels of BC6OTHER and BC6OTHER in BC6OTHER or BC6ENTG siRNA - transfected cells concomitantly with a marked reduction on cell invasion and migration.	CPR:4
BC6OTHER and BC6OTHER metabolized through BC6ENTG have the highest potency for drug - drug interaction with potent BC6OTHER inhibitors such as BC6OTHER - or BC6OTHER - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6OTHER or BC6ENTC , and therefore their coadministration is contraindicated.	False
BC6OTHER and BC6OTHER metabolized through BC6OTHER have the highest potency for drug - drug interaction with potent BC6ENTG inhibitors such as BC6OTHER - or BC6OTHER - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6OTHER or BC6ENTC , and therefore their coadministration is contraindicated.	CPR:4
BC6ENTC is also a BC6ENTG substrate, but less potent drug - drug interactions have been reported with BC6OTHER inhibitors.	CPR:9
BC6ENTC is also a BC6OTHER substrate, but less potent drug - drug interactions have been reported with BC6ENTG inhibitors.	False
All HIV PIs except BC6ENTC are coadministered with a low dose of BC6OTHER , a potent BC6ENTG inhibitor to improve their pharmacokinetic properties.	False
Drug - drug interactions are dependent on CHEM' pharmacokinetic profile: BC6ENTC , BC6OTHER and BC6OTHER are metabolized through BC6ENTG , while the metabolism of the other CHEM is independent of this BC6OTHER .	CPR:9
Drug - drug interactions are dependent on CHEM' pharmacokinetic profile: BC6ENTC , BC6OTHER and BC6OTHER are metabolized through BC6OTHER , while the metabolism of the other CHEM is independent of this BC6ENTG .	False
Drug - drug interactions are dependent on CHEM' pharmacokinetic profile: BC6OTHER , BC6ENTC and BC6OTHER are metabolized through BC6ENTG , while the metabolism of the other CHEM is independent of this BC6OTHER .	CPR:9
Drug - drug interactions are dependent on CHEM' pharmacokinetic profile: BC6OTHER , BC6ENTC and BC6OTHER are metabolized through BC6OTHER , while the metabolism of the other CHEM is independent of this BC6ENTG .	False
Drug - drug interactions are dependent on CHEM' pharmacokinetic profile: BC6OTHER , BC6OTHER and BC6ENTC are metabolized through BC6ENTG , while the metabolism of the other CHEM is independent of this BC6OTHER .	CPR:9
Drug - drug interactions are dependent on CHEM' pharmacokinetic profile: BC6OTHER , BC6OTHER and BC6ENTC are metabolized through BC6OTHER , while the metabolism of the other CHEM is independent of this BC6ENTG .	False
Drug - drug interactions between BC6ENTC reductase inhibitors (CHEM) and antiviral BC6ENTG inhibitors.	False
All HIV PIs except BC6OTHER are coadministered with a low dose of BC6ENTC , a potent BC6ENTG inhibitor to improve their pharmacokinetic properties.	CPR:4
The HCV - PIs BC6ENTC and BC6OTHER are both, to different extents, inhibitors of BC6ENTG .	CPR:4
The HCV - PIs BC6OTHER and BC6ENTC are both, to different extents, inhibitors of BC6ENTG .	CPR:4
BC6ENTC and BC6OTHER metabolized through BC6ENTG have the highest potency for drug - drug interaction with potent BC6OTHER inhibitors such as BC6OTHER - or BC6OTHER - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6OTHER or BC6OTHER , and therefore their coadministration is contraindicated.	CPR:9
BC6ENTC and BC6OTHER metabolized through BC6OTHER have the highest potency for drug - drug interaction with potent BC6ENTG inhibitors such as BC6OTHER - or BC6OTHER - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6OTHER or BC6OTHER , and therefore their coadministration is contraindicated.	False
BC6OTHER and BC6ENTC metabolized through BC6ENTG have the highest potency for drug - drug interaction with potent BC6OTHER inhibitors such as BC6OTHER - or BC6OTHER - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6OTHER or BC6OTHER , and therefore their coadministration is contraindicated.	CPR:9
BC6OTHER and BC6ENTC metabolized through BC6OTHER have the highest potency for drug - drug interaction with potent BC6ENTG inhibitors such as BC6OTHER - or BC6OTHER - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6OTHER or BC6OTHER , and therefore their coadministration is contraindicated.	False
BC6OTHER and BC6OTHER metabolized through BC6ENTG have the highest potency for drug - drug interaction with potent BC6OTHER inhibitors such as BC6ENTC - or BC6OTHER - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6OTHER or BC6OTHER , and therefore their coadministration is contraindicated.	False
BC6OTHER and BC6OTHER metabolized through BC6OTHER have the highest potency for drug - drug interaction with potent BC6ENTG inhibitors such as BC6ENTC - or BC6OTHER - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6OTHER or BC6OTHER , and therefore their coadministration is contraindicated.	CPR:4
BC6OTHER and BC6OTHER metabolized through BC6ENTG have the highest potency for drug - drug interaction with potent BC6OTHER inhibitors such as BC6OTHER - or BC6ENTC - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6OTHER or BC6OTHER , and therefore their coadministration is contraindicated.	False
BC6OTHER and BC6OTHER metabolized through BC6OTHER have the highest potency for drug - drug interaction with potent BC6ENTG inhibitors such as BC6OTHER - or BC6ENTC - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6OTHER or BC6OTHER , and therefore their coadministration is contraindicated.	CPR:4
BC6OTHER and BC6OTHER metabolized through BC6ENTG have the highest potency for drug - drug interaction with potent BC6OTHER inhibitors such as BC6OTHER - or BC6OTHER - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6ENTC or BC6OTHER , and therefore their coadministration is contraindicated.	False
BC6OTHER and BC6OTHER metabolized through BC6OTHER have the highest potency for drug - drug interaction with potent BC6ENTG inhibitors such as BC6OTHER - or BC6OTHER - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6ENTC or BC6OTHER , and therefore their coadministration is contraindicated.	CPR:4
From these results, it is proposed that BC6ENTG activity determines BC6ENTC concentrations by regulating BC6OTHER availability.	False
From these results, it is proposed that BC6ENTG activity determines BC6OTHER concentrations by regulating BC6ENTC availability.	CPR:9
An BC6ENTG antagonist, BC6ENTC augments BC6OTHER uptake and BC6OTHER protein expression in 3T3 - L1 adipocytes.	CPR:6
An BC6OTHER AT1 receptor antagonist, BC6ENTC augments BC6OTHER uptake and BC6ENTG protein expression in 3T3 - L1 adipocytes.	CPR:3
An BC6ENTG antagonist, BC6OTHER augments BC6ENTC uptake and BC6OTHER protein expression in 3T3 - L1 adipocytes.	False
An BC6OTHER AT1 receptor antagonist, BC6OTHER augments BC6ENTC uptake and BC6ENTG protein expression in 3T3 - L1 adipocytes.	CPR:9
We thus examined the effect of BC6ENTC on BC6ENTG action using 3T3 - L1 adipocytes.	False
Treatment of both differentiating adipocytes and fully differentiated adipocytes with BC6ENTC caused a dose - dependent increase in mRNA levels for BC6ENTG target genes such as BC6OTHER and BC6OTHER .	CPR:3
Treatment of both differentiating adipocytes and fully differentiated adipocytes with BC6ENTC caused a dose - dependent increase in mRNA levels for BC6OTHER target genes such as BC6ENTG and BC6OTHER .	CPR:3
Treatment of both differentiating adipocytes and fully differentiated adipocytes with BC6ENTC caused a dose - dependent increase in mRNA levels for BC6OTHER target genes such as BC6OTHER and BC6ENTG .	CPR:3
Evidence has accumulated that some of the BC6ENTC AT1 receptor antagonists have BC6ENTG - sensitizing property.	False
By contrast, BC6ENTC attenuated BC6ENTG mRNA level in differentiated adipocytes.	CPR:3
Of note, we demonstrated for the first time that BC6ENTC augmented BC6ENTG protein expression and BC6OTHER uptake both in basal and BC6OTHER - stimulated state of adipocytes, which may contribute, at least partly, to its BC6OTHER - sensitizing ability.	CPR:3
Of note, we demonstrated for the first time that BC6ENTC augmented BC6OTHER protein expression and BC6OTHER uptake both in basal and BC6ENTG - stimulated state of adipocytes, which may contribute, at least partly, to its BC6OTHER - sensitizing ability.	False
Of note, we demonstrated for the first time that BC6ENTC augmented BC6OTHER protein expression and BC6OTHER uptake both in basal and BC6OTHER - stimulated state of adipocytes, which may contribute, at least partly, to its BC6ENTG - sensitizing ability.	False
Of note, we demonstrated for the first time that BC6OTHER augmented BC6ENTG protein expression and BC6ENTC uptake both in basal and BC6OTHER - stimulated state of adipocytes, which may contribute, at least partly, to its BC6OTHER - sensitizing ability.	CPR:9
Of note, we demonstrated for the first time that BC6OTHER augmented BC6OTHER protein expression and BC6ENTC uptake both in basal and BC6ENTG - stimulated state of adipocytes, which may contribute, at least partly, to its BC6OTHER - sensitizing ability.	False
Of note, we demonstrated for the first time that BC6OTHER augmented BC6OTHER protein expression and BC6ENTC uptake both in basal and BC6OTHER - stimulated state of adipocytes, which may contribute, at least partly, to its BC6ENTG - sensitizing ability.	False
An BC6ENTC AT1 receptor antagonist, BC6OTHER augments BC6OTHER uptake and BC6ENTG protein expression in 3T3 - L1 adipocytes.	False
BC6ENTC ( BC6OTHER ) is a small - molecule inhibitor that has been shown to target members of multiple classes of BC6ENTG that are known to be involved in tumor cell proliferation and tumor angiogenesis.	CPR:4
BC6OTHER ( BC6ENTC ) is a small - molecule inhibitor that has been shown to target members of multiple classes of BC6ENTG that are known to be involved in tumor cell proliferation and tumor angiogenesis.	CPR:4
 BC6ENTC : recent update on activity as a single agent and in combination with BC6ENTG in patients with advanced - stage renal cell carcinoma.	False
The involvement of BC6ENTG in the absorption of BC6ENTC was clearly shown by coperfusion of BC6OTHER with the BC6OTHER inhibitor BC6OTHER .	CPR:9
The involvement of BC6OTHER in the absorption of BC6ENTC was clearly shown by coperfusion of BC6OTHER with the BC6ENTG inhibitor BC6OTHER .	False
The involvement of BC6ENTG in the absorption of BC6OTHER was clearly shown by coperfusion of BC6ENTC with the BC6OTHER inhibitor BC6OTHER .	False
The involvement of BC6OTHER in the absorption of BC6OTHER was clearly shown by coperfusion of BC6ENTC with the BC6ENTG inhibitor BC6OTHER .	False
The involvement of BC6ENTG in the absorption of BC6OTHER was clearly shown by coperfusion of BC6OTHER with the BC6OTHER inhibitor BC6ENTC .	False
The involvement of BC6OTHER in the absorption of BC6OTHER was clearly shown by coperfusion of BC6OTHER with the BC6ENTG inhibitor BC6ENTC .	CPR:4
Involvement of BC6ENTG mediated metabolism in the absorption of BC6ENTC could not be demonstrated in this rat model.	CPR:9
Upon studying the drug - drug interaction of BC6ENTC with BC6OTHER , data were indicative for an inhibitory effect of BC6OTHER on BC6ENTG as the main mechanism for the increased transport of BC6OTHER across the small intestine.	False
Upon studying the drug - drug interaction of BC6OTHER with BC6ENTC , data were indicative for an inhibitory effect of BC6OTHER on BC6ENTG as the main mechanism for the increased transport of BC6OTHER across the small intestine.	False
Upon studying the drug - drug interaction of BC6OTHER with BC6OTHER , data were indicative for an inhibitory effect of BC6ENTC on BC6ENTG as the main mechanism for the increased transport of BC6OTHER across the small intestine.	CPR:4
Upon studying the drug - drug interaction of BC6OTHER with BC6OTHER , data were indicative for an inhibitory effect of BC6OTHER on BC6ENTG as the main mechanism for the increased transport of BC6ENTC across the small intestine.	CPR:9
To evaluate to what extent the regional differences in expression of BC6ENTG and BC6OTHER affect the absorption of a dual substrate, we investigated the transport of BC6ENTC across different small intestinal segments (duodenum, proximal jejunum and ileum).	CPR:9
To evaluate to what extent the regional differences in expression of BC6OTHER and BC6ENTG affect the absorption of a dual substrate, we investigated the transport of BC6ENTC across different small intestinal segments (duodenum, proximal jejunum and ileum).	CPR:9
Indirect systemic and direct oral factor Xa and direct oral BC6ENTG inhibitors with improved pharmacologic profiles compared with heparins and BC6ENTC antagonists are currently in clinical development.	False
This overview focuses on the indirect CHEM dependent BC6ENTC derivatives of BC6OTHER and on the most advanced oral direct inhibitors to BC6ENTG ( BC6OTHER and BC6OTHER ) and IIa ( BC6OTHER ).	False
This overview focuses on the indirect CHEM dependent BC6OTHER derivatives of BC6ENTC and on the most advanced oral direct inhibitors to BC6ENTG ( BC6OTHER and BC6OTHER ) and IIa ( BC6OTHER ).	False
This overview focuses on the indirect CHEM dependent BC6OTHER derivatives of BC6OTHER and on the most advanced oral direct inhibitors to BC6ENTG ( BC6ENTC and BC6OTHER ) and IIa ( BC6OTHER ).	CPR:4
This overview focuses on the indirect CHEM dependent BC6OTHER derivatives of BC6OTHER and on the most advanced oral direct inhibitors to BC6ENTG ( BC6OTHER and BC6ENTC ) and IIa ( BC6OTHER ).	CPR:4
This overview focuses on the indirect CHEM dependent BC6OTHER derivatives of BC6OTHER and on the most advanced oral direct inhibitors to BC6ENTG ( BC6OTHER and BC6OTHER ) and IIa ( BC6ENTC ).	False
This agent acts synergistically with many BC6ENTC , such as BC6OTHER , BC6OTHER , and the like, and with BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER to inhibit gram - negative bacilli, probably on the basis of binding to different proteins needed for the production of the BC6ENTG of the bacterial cell wall.	CPR:3
This agent acts synergistically with many BC6OTHER , such as BC6ENTC , BC6OTHER , and the like, and with BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER to inhibit gram - negative bacilli, probably on the basis of binding to different proteins needed for the production of the BC6ENTG of the bacterial cell wall.	CPR:3
This agent acts synergistically with many BC6OTHER , such as BC6OTHER , BC6ENTC , and the like, and with BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER to inhibit gram - negative bacilli, probably on the basis of binding to different proteins needed for the production of the BC6ENTG of the bacterial cell wall.	CPR:3
This agent acts synergistically with many BC6OTHER , such as BC6OTHER , BC6OTHER , and the like, and with BC6ENTC , BC6OTHER , BC6OTHER , or BC6OTHER to inhibit gram - negative bacilli, probably on the basis of binding to different proteins needed for the production of the BC6ENTG of the bacterial cell wall.	CPR:3
This agent acts synergistically with many BC6OTHER , such as BC6OTHER , BC6OTHER , and the like, and with BC6OTHER , BC6ENTC , BC6OTHER , or BC6OTHER to inhibit gram - negative bacilli, probably on the basis of binding to different proteins needed for the production of the BC6ENTG of the bacterial cell wall.	CPR:3
This agent acts synergistically with many BC6OTHER , such as BC6OTHER , BC6OTHER , and the like, and with BC6OTHER , BC6OTHER , BC6ENTC , or BC6OTHER to inhibit gram - negative bacilli, probably on the basis of binding to different proteins needed for the production of the BC6ENTG of the bacterial cell wall.	CPR:3
This agent acts synergistically with many BC6OTHER , such as BC6OTHER , BC6OTHER , and the like, and with BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTC to inhibit gram - negative bacilli, probably on the basis of binding to different proteins needed for the production of the BC6ENTG of the bacterial cell wall.	CPR:3
Binding of BC6OTHER to BC6OTHER produces lysis, binding to BC6ENTC - binding protein 2 produces round cells, and binding to BC6ENTG produces long filaments.	False
Binding of BC6OTHER to BC6ENTG produces lysis, binding to BC6ENTC - binding protein 2 produces round cells, and binding to BC6OTHER produces long filaments.	False
Selection of mutants has shown that there are three essential proteins: BC6ENTC - binding protein 1, which is divided into BC6ENTG , a BC6OTHER , and BC6OTHER , which acts as a replacement for BC6OTHER .	False
Selection of mutants has shown that there are three essential proteins: BC6ENTC - binding protein 1, which is divided into BC6OTHER , a BC6ENTG , and BC6OTHER , which acts as a replacement for BC6OTHER .	False
Selection of mutants has shown that there are three essential proteins: BC6ENTC - binding protein 1, which is divided into BC6OTHER , a BC6OTHER , and BC6ENTG , which acts as a replacement for BC6OTHER .	False
Selection of mutants has shown that there are three essential proteins: BC6ENTC - binding protein 1, which is divided into BC6OTHER , a BC6OTHER , and BC6OTHER , which acts as a replacement for BC6ENTG .	False
Selection of mutants has shown that there are three essential proteins: BC6ENTG , which is divided into BC6ENTC - binding protein 1Bs, a BC6OTHER , and BC6OTHER , which acts as a replacement for BC6OTHER .	False
Selection of mutants has shown that there are three essential proteins: BC6OTHER , which is divided into BC6ENTC - binding protein 1Bs, a BC6ENTG , and BC6OTHER , which acts as a replacement for BC6OTHER .	False
Selection of mutants has shown that there are three essential proteins: BC6OTHER , which is divided into BC6ENTC - binding protein 1Bs, a BC6OTHER , and BC6ENTG , which acts as a replacement for BC6OTHER .	False
Selection of mutants has shown that there are three essential proteins: BC6OTHER , which is divided into BC6ENTC - binding protein 1Bs, a BC6OTHER , and BC6OTHER , which acts as a replacement for BC6ENTG .	False
Selection of mutants has shown that there are three essential proteins: BC6ENTG , which is divided into BC6OTHER , a BC6OTHER , and BC6ENTC - binding protein 1A, which acts as a replacement for BC6OTHER .	False
Selection of mutants has shown that there are three essential proteins: BC6OTHER , which is divided into BC6ENTG , a BC6OTHER , and BC6ENTC - binding protein 1A, which acts as a replacement for BC6OTHER .	False
Selection of mutants has shown that there are three essential proteins: BC6OTHER , which is divided into BC6OTHER , a BC6ENTG , and BC6ENTC - binding protein 1A, which acts as a replacement for BC6OTHER .	False
Selection of mutants has shown that there are three essential proteins: BC6OTHER , which is divided into BC6OTHER , a BC6OTHER , and BC6ENTC - binding protein 1A, which acts as a replacement for BC6ENTG .	False
Selection of mutants has shown that there are three essential proteins: BC6ENTG , which is divided into BC6OTHER , a BC6OTHER , and BC6OTHER , which acts as a replacement for BC6ENTC - binding protein 1Bs.	False
Selection of mutants has shown that there are three essential proteins: BC6OTHER , which is divided into BC6ENTG , a BC6OTHER , and BC6OTHER , which acts as a replacement for BC6ENTC - binding protein 1Bs.	False
Selection of mutants has shown that there are three essential proteins: BC6OTHER , which is divided into BC6OTHER , a BC6ENTG , and BC6OTHER , which acts as a replacement for BC6ENTC - binding protein 1Bs.	False
Selection of mutants has shown that there are three essential proteins: BC6OTHER , which is divided into BC6OTHER , a BC6OTHER , and BC6ENTG , which acts as a replacement for BC6ENTC - binding protein 1Bs.	False
BC6ENTC - binding protein 2 is a BC6ENTG - elongation initiating enzyme and BC6OTHER is a septal BC6OTHER - synthesizing enzyme.	False
BC6ENTC - binding protein 2 is a BC6OTHER - elongation initiating enzyme and BC6ENTG is a septal BC6OTHER - synthesizing enzyme.	False
BC6ENTC - binding protein 2 is a BC6OTHER - elongation initiating enzyme and BC6OTHER is a septal BC6ENTG - synthesizing enzyme.	False
Binding of BC6OTHER to BC6OTHER produces lysis, binding to BC6ENTG produces round cells, and binding to BC6ENTC - binding protein 3 produces long filaments.	False
Binding of BC6OTHER to BC6ENTG produces lysis, binding to BC6OTHER produces round cells, and binding to BC6ENTC - binding protein 3 produces long filaments.	False
BC6ENTG is a BC6OTHER - elongation initiating enzyme and BC6ENTC - binding protein 3 is a septal BC6OTHER - synthesizing enzyme.	False
BC6OTHER is a BC6ENTG - elongation initiating enzyme and BC6ENTC - binding protein 3 is a septal BC6OTHER - synthesizing enzyme.	False
BC6OTHER is a BC6OTHER - elongation initiating enzyme and BC6ENTC - binding protein 3 is a septal BC6ENTG - synthesizing enzyme.	False
Binding of BC6ENTC to BC6OTHER produces lysis, binding to BC6ENTG produces round cells, and binding to BC6OTHER produces long filaments.	False
Binding of BC6ENTC to BC6OTHER produces lysis, binding to BC6OTHER produces round cells, and binding to BC6ENTG produces long filaments.	False
Binding of BC6ENTC to BC6ENTG produces lysis, binding to BC6OTHER produces round cells, and binding to BC6OTHER produces long filaments.	False
Binding of BC6OTHER to BC6ENTC - binding protein 1Bs produces lysis, binding to BC6ENTG produces round cells, and binding to BC6OTHER produces long filaments.	False
Binding of BC6OTHER to BC6ENTC - binding protein 1Bs produces lysis, binding to BC6OTHER produces round cells, and binding to BC6ENTG produces long filaments.	False
 BC6ENTG and role of BC6ENTC in causing bacterial cell death.	False
BC6ENTC is a BC6OTHER derivative that binds specifically to BC6ENTG .	False
BC6OTHER is a BC6ENTC derivative that binds specifically to BC6ENTG .	False
The compound is more BC6ENTG stable than BC6ENTC and has no major delay in entry into the periplasmic space as do some BC6OTHER .	False
The compound is more BC6ENTG stable than BC6OTHER and has no major delay in entry into the periplasmic space as do some BC6ENTC .	False
After 18 h incubation with 0.5 μM BC6ENTC and subsequent red light irradiation (3.6 J / cm(2)), a high number of cells die by apoptosis, as evaluated by morphological alterations, immunofluorescent relocalization of BC6ENTG from cytosol to mitochondria, and TUNEL assay.	False
New modes of therapy have recently been introduced, and data on the BC6ENTG ( BC6OTHER ) - specific inhibitors BC6ENTC and BC6OTHER suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.	CPR:4
New modes of therapy have recently been introduced, and data on the BC6OTHER ( BC6ENTG ) - specific inhibitors BC6ENTC and BC6OTHER suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.	CPR:4
New modes of therapy have recently been introduced, and data on the BC6ENTG ( BC6OTHER ) - specific inhibitors BC6OTHER and BC6ENTC suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.	CPR:4
New modes of therapy have recently been introduced, and data on the BC6OTHER ( BC6ENTG ) - specific inhibitors BC6OTHER and BC6ENTC suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.	CPR:4
Evidence for a role of BC6OTHER and BC6OTHER in the control of BC6OTHER intake in animals suggests that BC6ENTG ( BC6OTHER ) inhibitors, which increase the synaptic availability of BC6ENTC and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence.	False
Evidence for a role of BC6OTHER and BC6OTHER in the control of BC6OTHER intake in animals suggests that BC6OTHER oxidase ( BC6ENTG ) inhibitors, which increase the synaptic availability of BC6ENTC and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence.	False
Evidence for a role of BC6OTHER and BC6OTHER in the control of BC6OTHER intake in animals suggests that BC6ENTG ( BC6OTHER ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6ENTC by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence.	False
Evidence for a role of BC6OTHER and BC6OTHER in the control of BC6OTHER intake in animals suggests that BC6OTHER oxidase ( BC6ENTG ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6ENTC by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence.	False
Evidence for a role of BC6ENTC and BC6OTHER in the control of BC6OTHER intake in animals suggests that BC6ENTG ( BC6OTHER ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence.	False
Evidence for a role of BC6ENTC and BC6OTHER in the control of BC6OTHER intake in animals suggests that BC6OTHER oxidase ( BC6ENTG ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence.	False
Evidence for a role of BC6OTHER and BC6OTHER in the control of BC6OTHER intake in animals suggests that BC6ENTG ( BC6OTHER ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6ENTC dependence.	False
Evidence for a role of BC6OTHER and BC6OTHER in the control of BC6OTHER intake in animals suggests that BC6OTHER oxidase ( BC6ENTG ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6ENTC dependence.	False
Evidence for a role of BC6OTHER and BC6ENTC in the control of BC6OTHER intake in animals suggests that BC6ENTG ( BC6OTHER ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence.	False
Evidence for a role of BC6OTHER and BC6ENTC in the control of BC6OTHER intake in animals suggests that BC6OTHER oxidase ( BC6ENTG ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence.	False
The aim of the present study was, therefore, to evaluate several BC6ENTG inhibitors for their capacity to affect BC6ENTC self - administration in rats trained to self - administer BC6OTHER (10% v / v) orally in a free - choice two - lever operant task.	False
The aim of the present study was, therefore, to evaluate several BC6ENTG inhibitors for their capacity to affect BC6OTHER self - administration in rats trained to self - administer BC6ENTC (10% v / v) orally in a free - choice two - lever operant task.	False
The nonselective and irreversible BC6ENTG inhibitors, BC6ENTC (3 - 10 mg / kg), BC6OTHER (1 - 3 mg / kg), and BC6OTHER (30 mg / kg), decreased rates of responding maintained by BC6OTHER reinforcement.	CPR:4
The nonselective and irreversible BC6ENTG inhibitors, BC6OTHER (3 - 10 mg / kg), BC6ENTC (1 - 3 mg / kg), and BC6OTHER (30 mg / kg), decreased rates of responding maintained by BC6OTHER reinforcement.	CPR:4
The nonselective and irreversible BC6ENTG inhibitors, BC6OTHER (3 - 10 mg / kg), BC6OTHER (1 - 3 mg / kg), and BC6ENTC (30 mg / kg), decreased rates of responding maintained by BC6OTHER reinforcement.	CPR:4
The irreversible BC6ENTG inhibitors, BC6ENTC (30 mg / kg) and BC6OTHER (3 - 10 mg / kg) also decreased responding maintained by BC6OTHER reinforcement; these results are consistent with previous findings that both drugs decreased BC6OTHER intake in mice.	CPR:4
Evidence for a role of BC6OTHER and BC6OTHER in the control of BC6ENTC intake in animals suggests that BC6ENTG ( BC6OTHER ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence.	False
Evidence for a role of BC6OTHER and BC6OTHER in the control of BC6ENTC intake in animals suggests that BC6OTHER oxidase ( BC6ENTG ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence.	False
The nonselective and irreversible BC6ENTG inhibitors, BC6OTHER (3 - 10 mg / kg), BC6OTHER (1 - 3 mg / kg), and BC6OTHER (30 mg / kg), decreased rates of responding maintained by BC6ENTC reinforcement.	False
The reversible BC6ENTG inhibitor, BC6ENTC (0.3 - 3 mg / kg), and the irreversible BC6OTHER inhibitor, BC6OTHER (10 - 30 mg / kg), also reduced BC6OTHER self - administration.	CPR:4
The reversible BC6OTHER inhibitor, BC6ENTC (0.3 - 3 mg / kg), and the irreversible BC6ENTG inhibitor, BC6OTHER (10 - 30 mg / kg), also reduced BC6OTHER self - administration.	False
The reversible BC6ENTG inhibitor, BC6OTHER (0.3 - 3 mg / kg), and the irreversible BC6OTHER inhibitor, BC6ENTC (10 - 30 mg / kg), also reduced BC6OTHER self - administration.	False
The reversible BC6OTHER inhibitor, BC6OTHER (0.3 - 3 mg / kg), and the irreversible BC6ENTG inhibitor, BC6ENTC (10 - 30 mg / kg), also reduced BC6OTHER self - administration.	CPR:4
The reversible BC6ENTG inhibitor, BC6OTHER (0.3 - 3 mg / kg), and the irreversible BC6OTHER inhibitor, BC6OTHER (10 - 30 mg / kg), also reduced BC6ENTC self - administration.	False
The reversible BC6OTHER inhibitor, BC6OTHER (0.3 - 3 mg / kg), and the irreversible BC6ENTG inhibitor, BC6OTHER (10 - 30 mg / kg), also reduced BC6ENTC self - administration.	False
Reduction of oral BC6ENTC self - administration in rats by BC6ENTG inhibitors.	False
The irreversible BC6ENTG inhibitors, BC6OTHER (30 mg / kg) and BC6ENTC (3 - 10 mg / kg) also decreased responding maintained by BC6OTHER reinforcement; these results are consistent with previous findings that both drugs decreased BC6OTHER intake in mice.	CPR:4
Evidence for a role of BC6OTHER and BC6OTHER in the control of BC6OTHER intake in animals suggests that BC6ENTC oxidase ( BC6ENTG ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence.	False
The irreversible BC6ENTG inhibitors, BC6OTHER (30 mg / kg) and BC6OTHER (3 - 10 mg / kg) also decreased responding maintained by BC6ENTC reinforcement; these results are consistent with previous findings that both drugs decreased BC6OTHER intake in mice.	False
The irreversible BC6ENTG inhibitors, BC6OTHER (30 mg / kg) and BC6OTHER (3 - 10 mg / kg) also decreased responding maintained by BC6OTHER reinforcement; these results are consistent with previous findings that both drugs decreased BC6ENTC intake in mice.	False
In conclusion, the present results showing that several BC6ENTG inhibitors decreased BC6ENTC self - administration in rats are consistent with previous findings that synaptic levels of BC6OTHER and BC6OTHER play a critical role in the control of BC6OTHER self - administration.	False
In conclusion, the present results showing that several BC6ENTG inhibitors decreased BC6OTHER self - administration in rats are consistent with previous findings that synaptic levels of BC6ENTC and BC6OTHER play a critical role in the control of BC6OTHER self - administration.	False
In conclusion, the present results showing that several BC6ENTG inhibitors decreased BC6OTHER self - administration in rats are consistent with previous findings that synaptic levels of BC6OTHER and BC6ENTC play a critical role in the control of BC6OTHER self - administration.	False
In conclusion, the present results showing that several BC6ENTG inhibitors decreased BC6OTHER self - administration in rats are consistent with previous findings that synaptic levels of BC6OTHER and BC6OTHER play a critical role in the control of BC6ENTC self - administration.	False
Delivery of CHEM transdermally (EMSAM((R))) bypasses hepatic first pass metabolism, thereby avoiding significant inhibition of gastrointestinal and hepatic BC6ENTG activity (ie, reduced risk of BC6ENTC - provoked events) while still providing sufficient levels of BC6OTHER in the brain to produce an antidepressant effect.	False
Delivery of CHEM transdermally (EMSAM((R))) bypasses hepatic first pass metabolism, thereby avoiding significant inhibition of gastrointestinal and hepatic BC6ENTG activity (ie, reduced risk of BC6OTHER - provoked events) while still providing sufficient levels of BC6ENTC in the brain to produce an antidepressant effect.	False
Non - selective inhibition of BC6ENTC oxidase ( BC6ENTG ) enzymes (ie, isoforms A and B) in the brain are associated with clinically significant antidepressant effects.	False
"Currently, the use of orally administered BC6ENTG inhibitor antidepressants (eg, BC6ENTC , BC6OTHER ) is limited by the risk of BC6OTHER - provoked events (eg, acute hypertension and headache, also known as the ""cheese reaction"") when combined with dietary BC6OTHER ."	CPR:4
"Currently, the use of orally administered BC6ENTG inhibitor antidepressants (eg, BC6OTHER , BC6ENTC ) is limited by the risk of BC6OTHER - provoked events (eg, acute hypertension and headache, also known as the ""cheese reaction"") when combined with dietary BC6OTHER ."	CPR:4
"Currently, the use of orally administered BC6ENTG inhibitor antidepressants (eg, BC6OTHER , BC6OTHER ) is limited by the risk of BC6ENTC - provoked events (eg, acute hypertension and headache, also known as the ""cheese reaction"") when combined with dietary BC6OTHER ."	False
"Currently, the use of orally administered BC6ENTG inhibitor antidepressants (eg, BC6OTHER , BC6OTHER ) is limited by the risk of BC6OTHER - provoked events (eg, acute hypertension and headache, also known as the ""cheese reaction"") when combined with dietary BC6ENTC ."	False
BC6ENTC [(+) - 1] is one of the most potent members of a class of chiral drug substances used to regulate the synthesis and release of BC6OTHER by the BC6ENTG , and as such, is an important biomarker for pharmaceutical companies conducting research in this field.	False
BC6OTHER [(+) - 1] is one of the most potent members of a class of chiral drug substances used to regulate the synthesis and release of BC6ENTC by the BC6ENTG , and as such, is an important biomarker for pharmaceutical companies conducting research in this field.	False
An investigation of the absolute configuration of the potent BC6ENTG antagonist BC6ENTC using vibrational circular dichroism.	CPR:6
A review of the structural and functional features of BC6ENTC , an BC6ENTG blocker.	CPR:4
The marked antihypertensive efficacy of BC6ENTC may result from a unique pharmacological interaction of the drug with the BC6ENTG receptor, resulting in a potent, long - lasting, dose - dependent blockade of BC6OTHER .	False
The marked antihypertensive efficacy of BC6ENTC may result from a unique pharmacological interaction of the drug with the BC6OTHER receptor, resulting in a potent, long - lasting, dose - dependent blockade of BC6ENTG .	CPR:4
The marked antihypertensive efficacy of BC6OTHER may result from a unique pharmacological interaction of the drug with the BC6ENTG receptor, resulting in a potent, long - lasting, dose - dependent blockade of BC6ENTC .	False
Effective inhibition of BC6ENTC is provided by the latest class of antihypertensive medications, the BC6ENTG receptor blockers (ARBs).	False
The BC6OTHER ( BC6ENTC ) type 1 (AT1) receptor - mediated effects of BC6ENTG play a key role in the pathophysiology of hypertension.	False
The BC6ENTC ( BC6OTHER ) type 1 (AT1) receptor - mediated effects of BC6ENTG play a key role in the pathophysiology of hypertension.	False
The BC6ENTG - mediated effects of BC6ENTC play a key role in the pathophysiology of hypertension.	False
In these tissues, BC6ENTC , BC6OTHER (a non - selective BC6ENTG antagonist), and BC6OTHER (an BC6OTHER antagonist) competitively antagonized contraction in a concentration - dependent manner.	CPR:6
In these tissues, BC6ENTC , BC6OTHER (a non - selective BC6OTHER antagonist), and BC6OTHER (an BC6ENTG antagonist) competitively antagonized contraction in a concentration - dependent manner.	False
In these tissues, BC6OTHER , BC6ENTC (a non - selective BC6ENTG antagonist), and BC6OTHER (an BC6OTHER antagonist) competitively antagonized contraction in a concentration - dependent manner.	CPR:6
In these tissues, BC6OTHER , BC6ENTC (a non - selective BC6OTHER antagonist), and BC6OTHER (an BC6ENTG antagonist) competitively antagonized contraction in a concentration - dependent manner.	False
In these tissues, BC6OTHER , BC6OTHER (a non - selective BC6ENTG antagonist), and BC6ENTC (an BC6OTHER antagonist) competitively antagonized contraction in a concentration - dependent manner.	False
In these tissues, BC6OTHER , BC6OTHER (a non - selective BC6OTHER antagonist), and BC6ENTC (an BC6ENTG antagonist) competitively antagonized contraction in a concentration - dependent manner.	CPR:6
We examined the effect of BC6OTHER (3 - inverted question mark BC6ENTC BC6OTHER inverted question mark - BC6OTHER ), a new BC6ENTG antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.	CPR:6
We examined the effect of BC6OTHER (3 - inverted question mark BC6OTHER BC6ENTC inverted question mark - BC6OTHER ), a new BC6ENTG antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.	CPR:6
 BC6ENTC showed higher selectivity for canine prostate both in vitro and in vivo. In prostate, an important role of the BC6ENTG is suggested in the smooth muscle contraction mediated by BC6OTHER .	False
 BC6ENTC showed higher selectivity for canine prostate both in vitro and in vivo. In prostate, an important role of the BC6OTHER is suggested in the smooth muscle contraction mediated by BC6ENTG .	False
BC6ENTC is expected to be an effective BC6ENTG antagonist for the treatment of urinary outlet obstruction by benign prostatic hypertrophy with a minimum effect on the cardiovascular system.	CPR:6
We examined the effect of BC6OTHER (3 - inverted question mark BC6OTHER BC6OTHER inverted question mark - BC6ENTC ), a new BC6ENTG antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.	CPR:6
We examined the effect of BC6ENTC (3 - inverted question mark BC6OTHER BC6OTHER inverted question mark - BC6OTHER ), a new BC6ENTG antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.	CPR:6
BC6ENTG ( BC6OTHER ) is an BC6OTHER belonging to the BC6ENTC - binding cassette transporter superfamily expressed in several organs.	False
BC6OTHER ( BC6ENTG ) is an BC6OTHER belonging to the BC6ENTC - binding cassette transporter superfamily expressed in several organs.	False
BC6OTHER ( BC6OTHER ) is an BC6ENTG belonging to the BC6ENTC - binding cassette transporter superfamily expressed in several organs.	False
In conclusion, in this cellular model, BC6ENTC effectively protects against PQ toxicity by inducing BC6ENTG and through the interaction with the BC6OTHER transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.	CPR:3
In conclusion, in this cellular model, BC6ENTC effectively protects against PQ toxicity by inducing BC6OTHER and through the interaction with the BC6ENTG , suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.	False
In conclusion, in this cellular model, BC6OTHER effectively protects against PQ toxicity by inducing BC6ENTG and through the interaction with the BC6ENTC transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.	False
The herbicide BC6ENTC (PQ) is a BC6ENTG substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote.	CPR:9
The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether BC6ENTC ( BC6OTHER ), a known BC6ENTG inducer, could efficiently protect Caco - 2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real - life intoxication scenario.	CPR:3
The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether BC6OTHER ( BC6ENTC ), a known BC6ENTG inducer, could efficiently protect Caco - 2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real - life intoxication scenario.	CPR:3
Activity - dependent cleavage of brain BC6ENTC decarboxylase 65 by BC6ENTG .	False
Previously, we reported that BC6OTHER decarboxylase isoform 65 ( BC6OTHER ) could be cleaved in vitro to release a stable truncated form which lacks BC6ENTC 1 - 69 from the BC6OTHER - terminus, BC6ENTG .	False
Previously, we reported that BC6ENTG ( BC6OTHER ) could be cleaved in vitro to release a stable truncated form which lacks BC6ENTC 1 - 69 from the BC6OTHER - terminus, BC6OTHER .	False
Previously, we reported that BC6OTHER decarboxylase isoform 65 ( BC6ENTG ) could be cleaved in vitro to release a stable truncated form which lacks BC6ENTC 1 - 69 from the BC6OTHER - terminus, BC6OTHER .	False
Previously, we reported that BC6OTHER decarboxylase isoform 65 ( BC6OTHER ) could be cleaved in vitro to release a stable truncated form which lacks BC6OTHER 1 - 69 from the BC6ENTC - terminus, BC6ENTG .	False
Previously, we reported that BC6ENTG ( BC6OTHER ) could be cleaved in vitro to release a stable truncated form which lacks BC6OTHER 1 - 69 from the BC6ENTC - terminus, BC6OTHER .	False
Previously, we reported that BC6OTHER decarboxylase isoform 65 ( BC6ENTG ) could be cleaved in vitro to release a stable truncated form which lacks BC6OTHER 1 - 69 from the BC6ENTC - terminus, BC6OTHER .	False
Previously, we reported that BC6ENTC decarboxylase isoform 65 ( BC6OTHER ) could be cleaved in vitro to release a stable truncated form which lacks BC6OTHER 1 - 69 from the BC6OTHER - terminus, BC6ENTG .	False
Previously, we reported that BC6ENTC decarboxylase isoform 65 ( BC6ENTG ) could be cleaved in vitro to release a stable truncated form which lacks BC6OTHER 1 - 69 from the BC6OTHER - terminus, BC6OTHER .	False
BC6ENTC - chelating reagents such as BC6OTHER and BC6OTHER prevented the cleavage of BC6ENTG .	False
BC6OTHER - chelating reagents such as BC6ENTC and BC6OTHER prevented the cleavage of BC6ENTG .	False
BC6OTHER - chelating reagents such as BC6OTHER and BC6ENTC prevented the cleavage of BC6ENTG .	False
In addition, our data suggested that BC6OTHER , a BC6ENTC - dependent BC6OTHER protease, is activated upon neuronal stimulation and could be responsible for the conversion of full - length BC6OTHER to truncated BC6ENTG in the brain.	False
In addition, our data suggested that BC6ENTG , a BC6ENTC - dependent BC6OTHER protease, is activated upon neuronal stimulation and could be responsible for the conversion of full - length BC6OTHER to truncated BC6OTHER in the brain.	False
In addition, our data suggested that BC6OTHER , a BC6ENTC - dependent BC6OTHER protease, is activated upon neuronal stimulation and could be responsible for the conversion of full - length BC6ENTG to truncated BC6OTHER in the brain.	False
In addition, our data suggested that BC6OTHER , a BC6OTHER - dependent BC6ENTC protease, is activated upon neuronal stimulation and could be responsible for the conversion of full - length BC6OTHER to truncated BC6ENTG in the brain.	False
In addition, our data suggested that BC6ENTG , a BC6OTHER - dependent BC6ENTC protease, is activated upon neuronal stimulation and could be responsible for the conversion of full - length BC6OTHER to truncated BC6OTHER in the brain.	False
In addition, our data suggested that BC6OTHER , a BC6OTHER - dependent BC6ENTC protease, is activated upon neuronal stimulation and could be responsible for the conversion of full - length BC6ENTG to truncated BC6OTHER in the brain.	False
BC6OTHER has greater selectivity for BC6ENTG than BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6OTHER has greater selectivity for BC6ENTG than BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER .	False
BC6ENTC is a selective BC6ENTG inhibitor which has little or no effect on the BC6OTHER isoenzyme at doses up to 1000 mg / day.	CPR:4
BC6ENTC is a selective BC6OTHER inhibitor which has little or no effect on the BC6ENTG isoenzyme at doses up to 1000 mg / day.	False
BC6OTHER has greater selectivity for BC6ENTG than BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER .	False
BC6OTHER has greater selectivity for BC6ENTG than BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC .	False
BC6ENTC has greater selectivity for BC6ENTG than BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	CPR:4
 The pharmacokinetics parameters were determined by using noncompartmental analyses, including the AUC(0 - t) in plasma (1695.22, 1326.45 and 636.98mg*h / L), the AUC(0 - t) in brain (1812.35, 2125.17 and 1145.83ng*h / g) as well as the T1 / 2 in plasma (0.66, 0.82, 0.97h) and brain (0.96, 1.1, 0.99h) for BC6ENTC , BC6OTHER and BC6OTHER , respectively, suggesting that the three BC6OTHER could easily pass through the BBB in vivo. In the in vitro model we observed high permeability of BC6OTHER and BC6OTHER with the BC6ENTG - mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of BC6OTHER with 0.82.	False
 The pharmacokinetics parameters were determined by using noncompartmental analyses, including the AUC(0 - t) in plasma (1695.22, 1326.45 and 636.98mg*h / L), the AUC(0 - t) in brain (1812.35, 2125.17 and 1145.83ng*h / g) as well as the T1 / 2 in plasma (0.66, 0.82, 0.97h) and brain (0.96, 1.1, 0.99h) for BC6OTHER , BC6ENTC and BC6OTHER , respectively, suggesting that the three BC6OTHER could easily pass through the BBB in vivo. In the in vitro model we observed high permeability of BC6OTHER and BC6OTHER with the BC6ENTG - mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of BC6OTHER with 0.82.	False
 The pharmacokinetics parameters were determined by using noncompartmental analyses, including the AUC(0 - t) in plasma (1695.22, 1326.45 and 636.98mg*h / L), the AUC(0 - t) in brain (1812.35, 2125.17 and 1145.83ng*h / g) as well as the T1 / 2 in plasma (0.66, 0.82, 0.97h) and brain (0.96, 1.1, 0.99h) for BC6OTHER , BC6OTHER and BC6ENTC , respectively, suggesting that the three BC6OTHER could easily pass through the BBB in vivo. In the in vitro model we observed high permeability of BC6OTHER and BC6OTHER with the BC6ENTG - mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of BC6OTHER with 0.82.	False
 The pharmacokinetics parameters were determined by using noncompartmental analyses, including the AUC(0 - t) in plasma (1695.22, 1326.45 and 636.98mg*h / L), the AUC(0 - t) in brain (1812.35, 2125.17 and 1145.83ng*h / g) as well as the T1 / 2 in plasma (0.66, 0.82, 0.97h) and brain (0.96, 1.1, 0.99h) for BC6OTHER , BC6OTHER and BC6OTHER , respectively, suggesting that the three BC6ENTC could easily pass through the BBB in vivo. In the in vitro model we observed high permeability of BC6OTHER and BC6OTHER with the BC6ENTG - mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of BC6OTHER with 0.82.	False
 The pharmacokinetics parameters were determined by using noncompartmental analyses, including the AUC(0 - t) in plasma (1695.22, 1326.45 and 636.98mg*h / L), the AUC(0 - t) in brain (1812.35, 2125.17 and 1145.83ng*h / g) as well as the T1 / 2 in plasma (0.66, 0.82, 0.97h) and brain (0.96, 1.1, 0.99h) for BC6OTHER , BC6OTHER and BC6OTHER , respectively, suggesting that the three BC6OTHER could easily pass through the BBB in vivo. In the in vitro model we observed high permeability of BC6ENTC and BC6OTHER with the BC6ENTG - mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of BC6OTHER with 0.82.	CPR:9
 The pharmacokinetics parameters were determined by using noncompartmental analyses, including the AUC(0 - t) in plasma (1695.22, 1326.45 and 636.98mg*h / L), the AUC(0 - t) in brain (1812.35, 2125.17 and 1145.83ng*h / g) as well as the T1 / 2 in plasma (0.66, 0.82, 0.97h) and brain (0.96, 1.1, 0.99h) for BC6OTHER , BC6OTHER and BC6OTHER , respectively, suggesting that the three BC6OTHER could easily pass through the BBB in vivo. In the in vitro model we observed high permeability of BC6OTHER and BC6ENTC with the BC6ENTG - mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of BC6OTHER with 0.82.	CPR:9
 The pharmacokinetics parameters were determined by using noncompartmental analyses, including the AUC(0 - t) in plasma (1695.22, 1326.45 and 636.98mg*h / L), the AUC(0 - t) in brain (1812.35, 2125.17 and 1145.83ng*h / g) as well as the T1 / 2 in plasma (0.66, 0.82, 0.97h) and brain (0.96, 1.1, 0.99h) for BC6OTHER , BC6OTHER and BC6OTHER , respectively, suggesting that the three BC6OTHER could easily pass through the BBB in vivo. In the in vitro model we observed high permeability of BC6OTHER and BC6OTHER with the BC6ENTG - mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of BC6ENTC with 0.82.	CPR:9
BC6ENTC decreased expression of pro - inflammatory BC6ENTG , such as BC6OTHER , BC6OTHER BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC decreased expression of pro - inflammatory BC6OTHER , such as BC6ENTG , BC6OTHER BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC decreased expression of pro - inflammatory BC6OTHER , such as BC6OTHER , BC6ENTG BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC decreased expression of pro - inflammatory BC6OTHER , such as BC6OTHER , BC6OTHER BC6ENTG , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC decreased expression of pro - inflammatory BC6OTHER , such as BC6OTHER , BC6OTHER BC6OTHER , BC6ENTG , and BC6OTHER .	CPR:4
BC6ENTC decreased expression of pro - inflammatory BC6OTHER , such as BC6OTHER , BC6OTHER BC6OTHER , BC6OTHER , and BC6ENTG .	CPR:4
The inhibitory effect of BC6ENTC on theses pro - inflammatory BC6ENTG was related with BC6OTHER BC6OTHER , and BC6OTHER BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
The inhibitory effect of BC6ENTC on theses pro - inflammatory BC6OTHER was related with BC6ENTG BC6OTHER , and BC6OTHER BC6OTHER , BC6OTHER , and BC6OTHER .	False
The inhibitory effect of BC6ENTC on theses pro - inflammatory BC6OTHER was related with BC6OTHER BC6ENTG , and BC6OTHER BC6OTHER , BC6OTHER , and BC6OTHER .	False
The inhibitory effect of BC6ENTC on theses pro - inflammatory BC6OTHER was related with BC6OTHER BC6OTHER , and BC6ENTG BC6OTHER , BC6OTHER , and BC6OTHER .	False
The inhibitory effect of BC6ENTC on theses pro - inflammatory BC6OTHER was related with BC6OTHER BC6OTHER , and BC6OTHER BC6ENTG , BC6OTHER , and BC6OTHER .	False
The inhibitory effect of BC6ENTC on theses pro - inflammatory BC6OTHER was related with BC6OTHER BC6OTHER , and BC6OTHER BC6OTHER , BC6ENTG , and BC6OTHER .	False
The inhibitory effect of BC6ENTC on theses pro - inflammatory BC6OTHER was related with BC6OTHER BC6OTHER , and BC6OTHER BC6OTHER , BC6OTHER , and BC6ENTG .	False
The inhibitory effect of BC6OTHER on theses pro - inflammatory BC6ENTG was related with BC6OTHER BC6ENTC - terminal kinases, and BC6OTHER BC6OTHER , BC6OTHER , and BC6OTHER .	False
The inhibitory effect of BC6OTHER on theses pro - inflammatory BC6OTHER was related with BC6ENTG BC6ENTC - terminal kinases, and BC6OTHER BC6OTHER , BC6OTHER , and BC6OTHER .	False
The inhibitory effect of BC6OTHER on theses pro - inflammatory BC6OTHER was related with BC6OTHER BC6ENTC - terminal kinases, and BC6ENTG BC6OTHER , BC6OTHER , and BC6OTHER .	False
The inhibitory effect of BC6OTHER on theses pro - inflammatory BC6OTHER was related with BC6OTHER BC6ENTC - terminal kinases, and BC6OTHER BC6ENTG , BC6OTHER , and BC6OTHER .	False
The inhibitory effect of BC6OTHER on theses pro - inflammatory BC6OTHER was related with BC6OTHER BC6ENTC - terminal kinases, and BC6OTHER BC6OTHER , BC6ENTG , and BC6OTHER .	False
The inhibitory effect of BC6OTHER on theses pro - inflammatory BC6OTHER was related with BC6OTHER BC6ENTC - terminal kinases, and BC6OTHER BC6OTHER , BC6OTHER , and BC6ENTG .	False
Furthermore, BC6ENTC attenuated BC6ENTG - mediated passive cutaneous anaphylaxis and the expression of BC6OTHER at the inflamed tissue.	CPR:4
Furthermore, BC6ENTC attenuated BC6OTHER - mediated passive cutaneous anaphylaxis and the expression of BC6ENTG at the inflamed tissue.	CPR:4
Furthermore, BC6OTHER attenuated BC6ENTG - mediated passive cutaneous anaphylaxis and the expression of BC6ENTC receptor 1 at the inflamed tissue.	False
Our results showed that BC6ENTC down - regulates mast cell - derived allergic inflammatory reactions by blocking BC6OTHER release and expression of pro - inflammatory BC6ENTG .	CPR:4
Our results showed that BC6OTHER down - regulates mast cell - derived allergic inflammatory reactions by blocking BC6ENTC release and expression of pro - inflammatory BC6ENTG .	False
The short lifetime of BC6ENTC makes this detection very challenging in measuring BC6ENTG responses.	False
It has been known for decades that BC6ENTC ( BC6OTHER ) leads to BC6OTHER accumulation on BC6ENTG activation by inhibiting BC6OTHER , the final enzyme of the BC6OTHER metabolic cascade.	CPR:3
It has been known for decades that BC6ENTC ( BC6OTHER ) leads to BC6OTHER accumulation on BC6OTHER activation by inhibiting BC6ENTG , the final enzyme of the BC6OTHER metabolic cascade.	CPR:4
It has been known for decades that BC6OTHER ( BC6ENTC ) leads to BC6OTHER accumulation on BC6ENTG activation by inhibiting BC6OTHER , the final enzyme of the BC6OTHER metabolic cascade.	CPR:3
It has been known for decades that BC6OTHER ( BC6ENTC ) leads to BC6OTHER accumulation on BC6OTHER activation by inhibiting BC6ENTG , the final enzyme of the BC6OTHER metabolic cascade.	CPR:4
It has been known for decades that BC6OTHER ( BC6OTHER ) leads to BC6ENTC accumulation on BC6ENTG activation by inhibiting BC6OTHER , the final enzyme of the BC6OTHER metabolic cascade.	False
It has been known for decades that BC6OTHER ( BC6OTHER ) leads to BC6ENTC accumulation on BC6OTHER activation by inhibiting BC6ENTG , the final enzyme of the BC6OTHER metabolic cascade.	CPR:9
It has been known for decades that BC6OTHER ( BC6OTHER ) leads to BC6OTHER accumulation on BC6ENTG activation by inhibiting BC6OTHER , the final enzyme of the BC6ENTC metabolic cascade.	False
It has been known for decades that BC6OTHER ( BC6OTHER ) leads to BC6OTHER accumulation on BC6OTHER activation by inhibiting BC6ENTG , the final enzyme of the BC6ENTC metabolic cascade.	CPR:9
We show here that BC6ENTC can be used as a surrogate of BC6OTHER to monitor BC6ENTG activation.	False
We show here that BC6OTHER can be used as a surrogate of BC6ENTC to monitor BC6ENTG activation.	False
It has the advantage over the traditional BC6ENTC assay of allowing the measurement of inverse agonist activity as well as the analysis of BC6ENTG activity in any nontransfected primary cultures.	False
 BC6ENTC as a surrogate of BC6OTHER to monitor BC6ENTG activation.	False
 BC6OTHER as a surrogate of BC6ENTC to monitor BC6ENTG activation.	False
BC6ENTG ( BC6OTHER ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6ENTC triggered by BC6OTHER ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays.	False
BC6OTHER ( BC6OTHER ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6ENTC triggered by BC6OTHER ( BC6OTHER ), a BC6ENTG hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays.	False
BC6OTHER ( BC6ENTG ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6ENTC triggered by BC6OTHER ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays.	False
BC6OTHER ( BC6OTHER ) - coupled BC6ENTG ( BC6OTHER ) activities traditionally are assessed by measuring BC6ENTC triggered by BC6OTHER ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays.	False
BC6OTHER ( BC6OTHER ) - coupled BC6OTHER ( BC6ENTG ) activities traditionally are assessed by measuring BC6ENTC triggered by BC6OTHER ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays.	False
BC6ENTG ( BC6OTHER ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6ENTC ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays.	False
BC6OTHER ( BC6OTHER ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6ENTC ( BC6OTHER ), a BC6ENTG hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays.	CPR:9
BC6OTHER ( BC6ENTG ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6ENTC ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays.	False
BC6OTHER ( BC6OTHER ) - coupled BC6ENTG ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6ENTC ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays.	False
BC6OTHER ( BC6OTHER ) - coupled BC6OTHER ( BC6ENTG ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6ENTC ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays.	False
BC6ENTG ( BC6OTHER ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6OTHER ( BC6ENTC ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays.	False
BC6OTHER ( BC6OTHER ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6OTHER ( BC6ENTC ), a BC6ENTG hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays.	CPR:9
BC6OTHER ( BC6ENTG ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6OTHER ( BC6ENTC ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays.	False
BC6OTHER ( BC6OTHER ) - coupled BC6ENTG ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6OTHER ( BC6ENTC ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays.	False
BC6OTHER ( BC6OTHER ) - coupled BC6OTHER ( BC6ENTG ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6OTHER ( BC6ENTC ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays.	False
BC6ENTG ( BC6OTHER ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6OTHER ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6ENTC using cumbersome radioactive assays.	False
BC6OTHER ( BC6OTHER ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6OTHER ( BC6OTHER ), a BC6ENTG hydrolysis product, or by measuring the production of BC6ENTC using cumbersome radioactive assays.	CPR:9
BC6OTHER ( BC6ENTG ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6OTHER ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6ENTC using cumbersome radioactive assays.	False
BC6OTHER ( BC6OTHER ) - coupled BC6ENTG ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6OTHER ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6ENTC using cumbersome radioactive assays.	False
BC6OTHER ( BC6OTHER ) - coupled BC6OTHER ( BC6ENTG ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6OTHER ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6ENTC using cumbersome radioactive assays.	False
BC6ENTG , BC6ENTC - BC6OTHER - transferase and BC6OTHER activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6OTHER and BC6OTHER immunoreactivity.	False
BC6OTHER , BC6ENTC - BC6OTHER - transferase and BC6ENTG activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6OTHER and BC6OTHER immunoreactivity.	False
BC6ENTG , CHEM - BC6ENTC - transferase and BC6OTHER activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6OTHER and BC6OTHER immunoreactivity.	False
BC6OTHER , CHEM - BC6ENTC - transferase and BC6ENTG activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6OTHER and BC6OTHER immunoreactivity.	False
BC6ENTG , CHEM - BC6OTHER - transferase and BC6ENTC oxidase activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6OTHER and BC6OTHER immunoreactivity.	False
BC6OTHER , BC6ENTG and BC6ENTC oxidase activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6OTHER and BC6OTHER immunoreactivity.	False
BC6ENTG , CHEM - BC6OTHER - transferase and BC6OTHER activities were not altered by BC6ENTC treatment or withdrawal, as well as protein BC6OTHER and BC6OTHER immunoreactivity.	False
BC6OTHER , BC6ENTG and BC6OTHER activities were not altered by BC6ENTC treatment or withdrawal, as well as protein BC6OTHER and BC6OTHER immunoreactivity.	False
BC6OTHER , CHEM - BC6OTHER - transferase and BC6ENTG activities were not altered by BC6ENTC treatment or withdrawal, as well as protein BC6OTHER and BC6OTHER immunoreactivity.	False
BC6ENTG , CHEM - BC6OTHER - transferase and BC6OTHER activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6ENTC and BC6OTHER immunoreactivity.	False
BC6OTHER , BC6ENTG and BC6OTHER activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6ENTC and BC6OTHER immunoreactivity.	False
BC6OTHER , CHEM - BC6OTHER - transferase and BC6ENTG activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6ENTC and BC6OTHER immunoreactivity.	False
BC6ENTG , CHEM - BC6OTHER - transferase and BC6OTHER activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6OTHER and BC6ENTC immunoreactivity.	False
BC6OTHER , BC6ENTG and BC6OTHER activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6OTHER and BC6ENTC immunoreactivity.	False
BC6OTHER , CHEM - BC6OTHER - transferase and BC6ENTG activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6OTHER and BC6ENTC immunoreactivity.	False
Immunoprecipitation of BC6ENTG followed by analysis of BC6ENTC revealed increased levels of nitrated BC6OTHER , suggesting the mechanism underlying the BC6OTHER withdrawal - induced decrease in enzyme activity.	False
Immunoprecipitation of BC6OTHER followed by analysis of BC6ENTC revealed increased levels of nitrated BC6ENTG , suggesting the mechanism underlying the BC6OTHER withdrawal - induced decrease in enzyme activity.	False
Immunoprecipitation of BC6ENTG followed by analysis of BC6OTHER revealed increased levels of nitrated BC6OTHER , suggesting the mechanism underlying the BC6ENTC withdrawal - induced decrease in enzyme activity.	False
Immunoprecipitation of BC6OTHER followed by analysis of BC6OTHER revealed increased levels of nitrated BC6ENTG , suggesting the mechanism underlying the BC6ENTC withdrawal - induced decrease in enzyme activity.	False
Altogether, our results indicate the BC6ENTC withdrawal elicits oxidative / nitrosative damage in the rat cerebral cortex, and that changes in BC6ENTG activity and mitochondrial BC6OTHER dismutase activities may underlie such harmful effects.	False
Altogether, our results indicate the BC6ENTC withdrawal elicits oxidative / nitrosative damage in the rat cerebral cortex, and that changes in BC6OTHER activity and BC6ENTG activities may underlie such harmful effects.	False
Altogether, our results indicate the BC6OTHER withdrawal elicits oxidative / nitrosative damage in the rat cerebral cortex, and that changes in BC6ENTC oxidase activity and BC6ENTG activities may underlie such harmful effects.	False
Altogether, our results indicate the BC6OTHER withdrawal elicits oxidative / nitrosative damage in the rat cerebral cortex, and that changes in BC6ENTG activity and mitochondrial BC6ENTC dismutase activities may underlie such harmful effects.	False
CHEM are inhibitors of the enzyme BC6ENTG , the rate - limiting step in BC6ENTC biosynthesis.	CPR:9
We found that BC6ENTC withdrawal decreased levels of BC6OTHER and BC6ENTG activity, whereas increased BC6OTHER oxidase activity and immunoreactivity for the protein nitration marker BC6OTHER in the cerebral cortex.	False
We found that BC6ENTC withdrawal decreased levels of BC6OTHER and mitochondrial BC6OTHER dismutase activity, whereas increased BC6ENTG activity and immunoreactivity for the protein nitration marker BC6OTHER in the cerebral cortex.	False
We found that BC6OTHER withdrawal decreased levels of BC6ENTC and BC6ENTG activity, whereas increased BC6OTHER oxidase activity and immunoreactivity for the protein nitration marker BC6OTHER in the cerebral cortex.	False
We found that BC6OTHER withdrawal decreased levels of BC6ENTC and mitochondrial BC6OTHER dismutase activity, whereas increased BC6ENTG activity and immunoreactivity for the protein nitration marker BC6OTHER in the cerebral cortex.	False
We found that BC6OTHER withdrawal decreased levels of BC6OTHER and mitochondrial BC6ENTC dismutase activity, whereas increased BC6ENTG activity and immunoreactivity for the protein nitration marker BC6OTHER in the cerebral cortex.	False
We found that BC6OTHER withdrawal decreased levels of BC6OTHER and BC6ENTG activity, whereas increased BC6ENTC oxidase activity and immunoreactivity for the protein nitration marker BC6OTHER in the cerebral cortex.	False
We found that BC6OTHER withdrawal decreased levels of BC6OTHER and BC6ENTG activity, whereas increased BC6OTHER oxidase activity and immunoreactivity for the protein nitration marker BC6ENTC in the cerebral cortex.	False
We found that BC6OTHER withdrawal decreased levels of BC6OTHER and mitochondrial BC6OTHER dismutase activity, whereas increased BC6ENTG activity and immunoreactivity for the protein nitration marker BC6ENTC in the cerebral cortex.	CPR:3
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6ENTC on BC6ENTG ( BC6OTHER ) and the effect of one compound ( BC6OTHER ) on neuronal BC6OTHER channels ( BC6OTHER ) heterologously expressed in human embryonic kidney cell line 293.	False
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6ENTC on voltage - operated human skeletal muscle BC6OTHER channels ( BC6ENTG ) and the effect of one compound ( BC6OTHER ) on neuronal BC6OTHER channels ( BC6OTHER ) heterologously expressed in human embryonic kidney cell line 293.	False
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6ENTC on voltage - operated human skeletal muscle BC6OTHER channels ( BC6OTHER ) and the effect of one compound ( BC6OTHER ) on BC6ENTG ( BC6OTHER ) heterologously expressed in human embryonic kidney cell line 293.	False
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6ENTC on voltage - operated human skeletal muscle BC6OTHER channels ( BC6OTHER ) and the effect of one compound ( BC6OTHER ) on neuronal BC6OTHER channels ( BC6ENTG ) heterologously expressed in human embryonic kidney cell line 293.	False
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6OTHER on voltage - operated human skeletal muscle BC6ENTC channels ( BC6ENTG ) and the effect of one compound ( BC6OTHER ) on neuronal BC6OTHER channels ( BC6OTHER ) heterologously expressed in human embryonic kidney cell line 293.	False
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6OTHER on voltage - operated human skeletal muscle BC6ENTC channels ( BC6OTHER ) and the effect of one compound ( BC6OTHER ) on BC6ENTG ( BC6OTHER ) heterologously expressed in human embryonic kidney cell line 293.	False
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6OTHER on voltage - operated human skeletal muscle BC6ENTC channels ( BC6OTHER ) and the effect of one compound ( BC6OTHER ) on neuronal BC6OTHER channels ( BC6ENTG ) heterologously expressed in human embryonic kidney cell line 293.	False
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6OTHER on BC6ENTG ( BC6OTHER ) and the effect of one compound ( BC6ENTC ) on neuronal BC6OTHER channels ( BC6OTHER ) heterologously expressed in human embryonic kidney cell line 293.	False
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6OTHER on voltage - operated human skeletal muscle BC6OTHER channels ( BC6ENTG ) and the effect of one compound ( BC6ENTC ) on neuronal BC6OTHER channels ( BC6OTHER ) heterologously expressed in human embryonic kidney cell line 293.	False
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6OTHER on voltage - operated human skeletal muscle BC6OTHER channels ( BC6OTHER ) and the effect of one compound ( BC6ENTC ) on BC6ENTG ( BC6OTHER ) heterologously expressed in human embryonic kidney cell line 293.	False
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6OTHER on voltage - operated human skeletal muscle BC6OTHER channels ( BC6OTHER ) and the effect of one compound ( BC6ENTC ) on neuronal BC6OTHER channels ( BC6ENTG ) heterologously expressed in human embryonic kidney cell line 293.	False
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6OTHER on BC6ENTG ( BC6OTHER ) and the effect of one compound ( BC6OTHER ) on neuronal BC6ENTC channels ( BC6OTHER ) heterologously expressed in human embryonic kidney cell line 293.	False
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6OTHER on voltage - operated human skeletal muscle BC6OTHER channels ( BC6ENTG ) and the effect of one compound ( BC6OTHER ) on neuronal BC6ENTC channels ( BC6OTHER ) heterologously expressed in human embryonic kidney cell line 293.	False
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6OTHER on voltage - operated human skeletal muscle BC6OTHER channels ( BC6OTHER ) and the effect of one compound ( BC6OTHER ) on neuronal BC6ENTC channels ( BC6ENTG ) heterologously expressed in human embryonic kidney cell line 293.	False
The IC(50) for block of resting channels at - 150 mV was 2.3, 3.9 and 11.3 microM in BC6ENTG , respectively, and 29.2 microM for BC6ENTC in BC6OTHER .	False
The IC(50) for block of resting channels at - 150 mV was 2.3, 3.9 and 11.3 microM in BC6OTHER , respectively, and 29.2 microM for BC6ENTC in BC6ENTG .	CPR:4
Estimated affinities for the fast - inactivated channel state were 81 nM, 312 nM and 227 nM for BC6ENTC , BC6OTHER and BC6OTHER in BC6ENTG , and 450 nM for BC6OTHER in BC6OTHER .	CPR:4
Estimated affinities for the fast - inactivated channel state were 81 nM, 312 nM and 227 nM for BC6ENTC , BC6OTHER and BC6OTHER in BC6OTHER , and 450 nM for BC6OTHER in BC6ENTG .	False
High - affinity blockade of BC6ENTG by BC6ENTC analogues.	CPR:4
Estimated affinities for the fast - inactivated channel state were 81 nM, 312 nM and 227 nM for BC6OTHER , BC6ENTC and BC6OTHER in BC6ENTG , and 450 nM for BC6OTHER in BC6OTHER .	CPR:4
Estimated affinities for the fast - inactivated channel state were 81 nM, 312 nM and 227 nM for BC6OTHER , BC6ENTC and BC6OTHER in BC6OTHER , and 450 nM for BC6OTHER in BC6ENTG .	False
Estimated affinities for the fast - inactivated channel state were 81 nM, 312 nM and 227 nM for BC6OTHER , BC6OTHER and BC6ENTC in BC6ENTG , and 450 nM for BC6OTHER in BC6OTHER .	CPR:4
Estimated affinities for the fast - inactivated channel state were 81 nM, 312 nM and 227 nM for BC6OTHER , BC6OTHER and BC6ENTC in BC6OTHER , and 450 nM for BC6OTHER in BC6ENTG .	False
Estimated affinities for the fast - inactivated channel state were 81 nM, 312 nM and 227 nM for BC6OTHER , BC6OTHER and BC6OTHER in BC6ENTG , and 450 nM for BC6ENTC in BC6OTHER .	False
Estimated affinities for the fast - inactivated channel state were 81 nM, 312 nM and 227 nM for BC6OTHER , BC6OTHER and BC6OTHER in BC6OTHER , and 450 nM for BC6ENTC in BC6ENTG .	CPR:4
CONCLUSIONS AND IMPLICATIONS: BC6ENTC analogues constitute a novel class of BC6ENTG - blocking drugs possessing almost 100 - fold higher potency compared with the local anaesthetic and anti - arrhythmic drug BC6OTHER .	CPR:4
CONCLUSIONS AND IMPLICATIONS: BC6OTHER analogues constitute a novel class of BC6ENTG - blocking drugs possessing almost 100 - fold higher potency compared with the local anaesthetic and anti - arrhythmic drug BC6ENTC .	False
Both BC6ENTC treatments, induced a significant decrease (p<0.01) in uterine BC6ENTG ( BC6OTHER ) content, had no effect on uterine BC6OTHER ( BC6OTHER ) protein expression and caused marked nuclear localization of BC6OTHER , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals.	CPR:4
Both BC6ENTC treatments, induced a significant decrease (p<0.01) in uterine BC6OTHER ( BC6ENTG ) content, had no effect on uterine BC6OTHER ( BC6OTHER ) protein expression and caused marked nuclear localization of BC6OTHER , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals.	CPR:4
Both BC6ENTC treatments, induced a significant decrease (p<0.01) in uterine BC6OTHER ( BC6OTHER ) content, had no effect on uterine BC6ENTG ( BC6OTHER ) protein expression and caused marked nuclear localization of BC6OTHER , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals.	False
Both BC6ENTC treatments, induced a significant decrease (p<0.01) in uterine BC6OTHER ( BC6OTHER ) content, had no effect on uterine BC6OTHER ( BC6ENTG ) protein expression and caused marked nuclear localization of BC6OTHER , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals.	False
Both BC6ENTC treatments, induced a significant decrease (p<0.01) in uterine BC6OTHER ( BC6OTHER ) content, had no effect on uterine BC6OTHER ( BC6OTHER ) protein expression and caused marked nuclear localization of BC6ENTG , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals.	False
Both BC6OTHER treatments, induced a significant decrease (p<0.01) in uterine BC6ENTC receptor alpha ( BC6ENTG ) content, had no effect on uterine BC6OTHER ( BC6OTHER ) protein expression and caused marked nuclear localization of BC6OTHER , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals.	False
Both BC6OTHER treatments, induced a significant decrease (p<0.01) in uterine BC6ENTC receptor alpha ( BC6OTHER ) content, had no effect on uterine BC6ENTG ( BC6OTHER ) protein expression and caused marked nuclear localization of BC6OTHER , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals.	False
Both BC6OTHER treatments, induced a significant decrease (p<0.01) in uterine BC6ENTC receptor alpha ( BC6OTHER ) content, had no effect on uterine BC6OTHER ( BC6ENTG ) protein expression and caused marked nuclear localization of BC6OTHER , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals.	False
Both BC6OTHER treatments, induced a significant decrease (p<0.01) in uterine BC6ENTC receptor alpha ( BC6OTHER ) content, had no effect on uterine BC6OTHER ( BC6OTHER ) protein expression and caused marked nuclear localization of BC6ENTG , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals.	False
Both BC6OTHER treatments, induced a significant decrease (p<0.01) in uterine BC6ENTG ( BC6OTHER ) content, had no effect on uterine BC6ENTC receptor ( BC6OTHER ) protein expression and caused marked nuclear localization of BC6OTHER , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals.	False
Both BC6OTHER treatments, induced a significant decrease (p<0.01) in uterine BC6OTHER ( BC6ENTG ) content, had no effect on uterine BC6ENTC receptor ( BC6OTHER ) protein expression and caused marked nuclear localization of BC6OTHER , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals.	False
Both BC6OTHER treatments, induced a significant decrease (p<0.01) in uterine BC6OTHER ( BC6OTHER ) content, had no effect on uterine BC6ENTC receptor ( BC6ENTG ) protein expression and caused marked nuclear localization of BC6OTHER , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals.	False
Both BC6OTHER treatments, induced a significant decrease (p<0.01) in uterine BC6OTHER ( BC6OTHER ) content, had no effect on uterine BC6ENTC receptor ( BC6OTHER ) protein expression and caused marked nuclear localization of BC6ENTG , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals.	False
Furthermore, we detected that BC6ENTC treatment induced BC6ENTG ( BC6OTHER ) CHEM 9 phosphorylation, which correlates with BC6OTHER nuclear localization.	CPR:3
Furthermore, we detected that BC6ENTC treatment induced BC6OTHER ( BC6ENTG ) CHEM 9 phosphorylation, which correlates with BC6OTHER nuclear localization.	CPR:3
Furthermore, we detected that BC6ENTC treatment induced BC6OTHER ( BC6OTHER ) CHEM 9 phosphorylation, which correlates with BC6ENTG nuclear localization.	False
Agonistic activity of BC6ENTC on activation of BC6ENTG / BC6OTHER pathway in the rat uterus during the estrous cycle.	CPR:5
Agonistic activity of BC6ENTC on activation of BC6OTHER / BC6ENTG pathway in the rat uterus during the estrous cycle.	CPR:3
We observed that the administration of BC6ENTC at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of BC6ENTG phosphorylation at BC6OTHER 473 as compared to vehicle - treated animals, whereas BC6OTHER treatment at 00:00h on estrus day had no effect on these parameters.	CPR:4
We observed that the administration of BC6OTHER at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of BC6ENTG phosphorylation at BC6ENTC 473 as compared to vehicle - treated animals, whereas BC6OTHER treatment at 00:00h on estrus day had no effect on these parameters.	False
We observed that the administration of BC6OTHER at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of BC6ENTG phosphorylation at BC6OTHER 473 as compared to vehicle - treated animals, whereas BC6ENTC treatment at 00:00h on estrus day had no effect on these parameters.	False
The overall results indicate that BC6ENTC may exert agonistic and antagonistic effects on uterine cell proliferation through differential activation of the BC6ENTG pathway depending on the administration period during the estrous cycle, and indicates that the mechanism of cell proliferation during the physiological conditions of the estrous cycle, is under a different and more complex regulation than in the ovariectomized +E2 animal model.	CPR:3
We examined the ability of BC6ENTC ( BC6OTHER ) to block uterine cell proliferation via BC6OTHER / BC6ENTG pathway in the uterus of the rat during the estrous cycle.	False
We examined the ability of BC6ENTC ( BC6OTHER ) to block uterine cell proliferation via BC6ENTG / BC6OTHER pathway in the uterus of the rat during the estrous cycle.	False
We examined the ability of BC6OTHER ( BC6ENTC ) to block uterine cell proliferation via BC6OTHER / BC6ENTG pathway in the uterus of the rat during the estrous cycle.	False
We examined the ability of BC6OTHER ( BC6ENTC ) to block uterine cell proliferation via BC6ENTG / BC6OTHER pathway in the uterus of the rat during the estrous cycle.	False
Pretreatment with a combination of BC6ENTC ( BC6OTHER , a selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6ENTG .	False
Pretreatment with a combination of BC6ENTC ( BC6OTHER , a selective BC6ENTG antagonist) and BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6OTHER .	CPR:6
Pretreatment with a combination of BC6ENTC ( BC6OTHER , a selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER , a selective BC6ENTG antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6OTHER .	False
Pretreatment with a combination of BC6OTHER ( BC6ENTC , a selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6ENTG .	False
Pretreatment with a combination of BC6OTHER ( BC6ENTC , a selective BC6ENTG antagonist) and BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6OTHER .	CPR:6
Pretreatment with a combination of BC6OTHER ( BC6ENTC , a selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER , a selective BC6ENTG antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6OTHER .	False
Pretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) and BC6ENTC ( BC6OTHER , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6ENTG .	False
Pretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6ENTG antagonist) and BC6ENTC ( BC6OTHER , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6OTHER .	False
Pretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) and BC6ENTC ( BC6OTHER , a selective BC6ENTG antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6OTHER .	CPR:6
Pretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) and BC6OTHER ( BC6ENTC , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6ENTG .	False
Pretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6ENTG antagonist) and BC6OTHER ( BC6ENTC , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6OTHER .	False
Pretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) and BC6OTHER ( BC6ENTC , a selective BC6ENTG antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6OTHER .	CPR:6
Pretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6ENTC ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6ENTG .	False
Pretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6ENTG antagonist) and BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6ENTC ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6OTHER .	False
Pretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER , a selective BC6ENTG antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6ENTC ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6OTHER .	False
Pretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6ENTC was unaffected by the blockade of BC6ENTG .	False
Pretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6ENTG antagonist) and BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6ENTC was unaffected by the blockade of BC6OTHER .	False
Pretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER , a selective BC6ENTG antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6ENTC was unaffected by the blockade of BC6OTHER .	False
In the presence of BC6ENTC and BC6OTHER (0.1 microM for each), the concentration - response curves for BC6OTHER and BC6OTHER were shifted to the right by a nonselective BC6ENTG antagonist, BC6OTHER (3 and 10 microM).	False
In the presence of BC6OTHER and BC6ENTC (0.1 microM for each), the concentration - response curves for BC6OTHER and BC6OTHER were shifted to the right by a nonselective BC6ENTG antagonist, BC6OTHER (3 and 10 microM).	False
In the presence of BC6OTHER and BC6OTHER (0.1 microM for each), the concentration - response curves for BC6ENTC and BC6OTHER were shifted to the right by a nonselective BC6ENTG antagonist, BC6OTHER (3 and 10 microM).	False
In the presence of BC6OTHER and BC6OTHER (0.1 microM for each), the concentration - response curves for BC6OTHER and BC6ENTC were shifted to the right by a nonselective BC6ENTG antagonist, BC6OTHER (3 and 10 microM).	False
In the presence of BC6OTHER and BC6OTHER (0.1 microM for each), the concentration - response curves for BC6OTHER and BC6OTHER were shifted to the right by a nonselective BC6ENTG antagonist, BC6ENTC (3 and 10 microM).	False
BC6ENTC and a nonconventional BC6ENTG agonist, BC6OTHER ( BC6OTHER ), induced concentration - dependent relaxation of BC6OTHER (0.3 microM) preconstricted spiral preparations.	False
BC6OTHER and a nonconventional BC6ENTG agonist, BC6ENTC ( BC6OTHER ), induced concentration - dependent relaxation of BC6OTHER (0.3 microM) preconstricted spiral preparations.	CPR:5
BC6OTHER and a nonconventional BC6ENTG agonist, BC6OTHER ( BC6ENTC ), induced concentration - dependent relaxation of BC6OTHER (0.3 microM) preconstricted spiral preparations.	CPR:5
BC6OTHER and a nonconventional BC6ENTG agonist, BC6OTHER ( BC6OTHER ), induced concentration - dependent relaxation of BC6ENTC (0.3 microM) preconstricted spiral preparations.	False
Agents that specifically target BC6OTHER , such as BC6ENTC , as well as new molecules that function both upstream and downstream of BC6ENTG , are being actively investigated.	False
Agents that specifically target BC6ENTG , such as BC6ENTC , as well as new molecules that function both upstream and downstream of BC6OTHER , are being actively investigated.	False
These observations show substrate - and enzyme - specific BC6ENTG inhibition by BC6OTHER and support the possibility that a certain BC6OTHER (s) may be the molecular target for BC6ENTC action.	False
These observations show substrate - and enzyme - specific BC6OTHER inhibition by BC6OTHER and support the possibility that a certain BC6ENTG (s) may be the molecular target for BC6ENTC action.	False
Here we report that BC6ENTC is a potent inhibitor of the BC6ENTG ( BC6OTHER ).	CPR:4
Here we report that BC6ENTC is a potent inhibitor of the protein - BC6OTHER - phosphatase - meg1 ( BC6ENTG ).	CPR:4
Here we report that BC6OTHER is a potent inhibitor of the protein - BC6ENTC - phosphatase - meg1 ( BC6ENTG ).	False
Two substrates were employed in this study: CHEM BC6ENTC and the CHEM peptide BC6ENTG - pY527.	False
With either substrate, BC6ENTC was a slow binding inhibitor of BC6ENTG .	CPR:4
Among the other BC6ENTC studied, BC6OTHER was more potent and selective for BC6ENTG .	CPR:4
Among the other BC6OTHER studied, BC6ENTC was more potent and selective for BC6ENTG .	CPR:4
The hydrolysis of CHEM BC6ENTC by BC6ENTG and BC6OTHER was sensitive to BC6OTHER , with IC50 values of less than 1 microM; BC6OTHER , however, under the same conditions, was inhibited by only 50% with 141 microM BC6OTHER .	CPR:9
The hydrolysis of CHEM BC6ENTC by BC6OTHER and BC6ENTG was sensitive to BC6OTHER , with IC50 values of less than 1 microM; BC6OTHER , however, under the same conditions, was inhibited by only 50% with 141 microM BC6OTHER .	CPR:9
The hydrolysis of CHEM BC6ENTC by BC6OTHER and BC6OTHER was sensitive to BC6OTHER , with IC50 values of less than 1 microM; BC6ENTG , however, under the same conditions, was inhibited by only 50% with 141 microM BC6OTHER .	False
The hydrolysis of CHEM BC6OTHER by BC6ENTG and BC6OTHER was sensitive to BC6ENTC , with IC50 values of less than 1 microM; BC6OTHER , however, under the same conditions, was inhibited by only 50% with 141 microM BC6OTHER .	False
The hydrolysis of CHEM BC6OTHER by BC6OTHER and BC6ENTG was sensitive to BC6ENTC , with IC50 values of less than 1 microM; BC6OTHER , however, under the same conditions, was inhibited by only 50% with 141 microM BC6OTHER .	False
The hydrolysis of CHEM BC6OTHER by BC6OTHER and BC6OTHER was sensitive to BC6ENTC , with IC50 values of less than 1 microM; BC6ENTG , however, under the same conditions, was inhibited by only 50% with 141 microM BC6OTHER .	False
The hydrolysis of CHEM BC6OTHER by BC6ENTG and BC6OTHER was sensitive to BC6OTHER , with IC50 values of less than 1 microM; BC6OTHER , however, under the same conditions, was inhibited by only 50% with 141 microM BC6ENTC .	False
The hydrolysis of CHEM BC6OTHER by BC6OTHER and BC6ENTG was sensitive to BC6OTHER , with IC50 values of less than 1 microM; BC6OTHER , however, under the same conditions, was inhibited by only 50% with 141 microM BC6ENTC .	False
The hydrolysis of CHEM BC6OTHER by BC6OTHER and BC6OTHER was sensitive to BC6OTHER , with IC50 values of less than 1 microM; BC6ENTG , however, under the same conditions, was inhibited by only 50% with 141 microM BC6ENTC .	CPR:4
Similarly, with the BC6ENTG - pY527 substrate, BC6ENTC inhibition was also BC6OTHER dependent.	False
Similarly, with the BC6OTHER - pY527 substrate, BC6ENTC inhibition was also BC6ENTG dependent.	False
BC6ENTC inhibited BC6ENTG with an IC50 value of 23 microM, BC6OTHER with an IC50 value of 2 microM, and did not inhibit BC6OTHER at concentrations up to 1 mM.	CPR:4
BC6ENTC inhibited BC6OTHER with an IC50 value of 23 microM, BC6ENTG with an IC50 value of 2 microM, and did not inhibit BC6OTHER at concentrations up to 1 mM.	CPR:4
BC6ENTC inhibited BC6OTHER with an IC50 value of 23 microM, BC6OTHER with an IC50 value of 2 microM, and did not inhibit BC6ENTG at concentrations up to 1 mM.	False
 BC6ENTC inhibition of BC6ENTG .	CPR:4
The BC6ENTC inhibition of these three BC6ENTG and two substrates is consistent with the formation of a ternary complex comprised of enzyme, substrate, and inhibitor.	CPR:4
BC6ENTG inhibition by BC6ENTC or BC6OTHER was diminished by the CHEM BC6OTHER , or by the reducing agent BC6OTHER , suggesting that a metal ion and the oxidation of a BC6OTHER residue are required for full inhibition.	CPR:4
BC6ENTG inhibition by BC6OTHER or BC6ENTC was diminished by the CHEM BC6OTHER , or by the reducing agent BC6OTHER , suggesting that a metal ion and the oxidation of a BC6OTHER residue are required for full inhibition.	CPR:4
BC6ENTG inhibition by BC6OTHER or BC6OTHER was diminished by the CHEM BC6ENTC , or by the reducing agent BC6OTHER , suggesting that a metal ion and the oxidation of a BC6OTHER residue are required for full inhibition.	False
BC6ENTG inhibition by BC6OTHER or BC6OTHER was diminished by the CHEM BC6OTHER , or by the reducing agent BC6ENTC , suggesting that a metal ion and the oxidation of a BC6OTHER residue are required for full inhibition.	False
BC6ENTG inhibition by BC6OTHER or BC6OTHER was diminished by the CHEM BC6OTHER , or by the reducing agent BC6OTHER , suggesting that a metal ion and the oxidation of a BC6ENTC residue are required for full inhibition.	False
These observations show substrate - and enzyme - specific BC6ENTG inhibition by BC6ENTC and support the possibility that a certain BC6OTHER (s) may be the molecular target for BC6OTHER action.	CPR:4
These observations show substrate - and enzyme - specific BC6OTHER inhibition by BC6ENTC and support the possibility that a certain BC6ENTG (s) may be the molecular target for BC6OTHER action.	False
These findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6OTHER , to BC6ENTG and not to high affinity central BC6OTHER receptors, and that BC6OTHER limit SRF by slowing recovery of BC6ENTC channels from inactivation.	False
These findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6OTHER , to voltage - dependent BC6OTHER channels and not to high affinity central BC6ENTG , and that BC6OTHER limit SRF by slowing recovery of BC6ENTC channels from inactivation.	False
Limitation of SRF was produced by the anticonvulsant BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6ENTG ( BC6OTHER ) at high nanomolar concentrations and by a BC6OTHER weak partial agonist ( BC6OTHER ) at micromolar concentrations.	False
Limitation of SRF was produced by the anticonvulsant BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6OTHER ( BC6OTHER ) at high nanomolar concentrations and by a BC6ENTG weak partial agonist ( BC6OTHER ) at micromolar concentrations.	False
Limitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6ENTG ( BC6OTHER ) at high nanomolar concentrations and by a BC6OTHER weak partial agonist ( BC6OTHER ) at micromolar concentrations.	False
Limitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6OTHER ( BC6OTHER ) at high nanomolar concentrations and by a BC6ENTG weak partial agonist ( BC6OTHER ) at micromolar concentrations.	False
Limitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6ENTG ( BC6OTHER ) at high nanomolar concentrations and by a BC6OTHER weak partial agonist ( BC6OTHER ) at micromolar concentrations.	False
Limitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6OTHER ( BC6OTHER ) at high nanomolar concentrations and by a BC6ENTG weak partial agonist ( BC6OTHER ) at micromolar concentrations.	False
Limitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6ENTG ( BC6OTHER ) at high nanomolar concentrations and by a BC6OTHER weak partial agonist ( BC6OTHER ) at micromolar concentrations.	False
Limitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6OTHER ( BC6OTHER ) at high nanomolar concentrations and by a BC6ENTG weak partial agonist ( BC6OTHER ) at micromolar concentrations.	False
Limitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6ENTG ( BC6OTHER ) at high nanomolar concentrations and by a BC6OTHER weak partial agonist ( BC6OTHER ) at micromolar concentrations.	False
Limitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6OTHER ( BC6OTHER ) at high nanomolar concentrations and by a BC6ENTG weak partial agonist ( BC6OTHER ) at micromolar concentrations.	False
Limitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6ENTC which does not bind to high affinity BC6ENTG ( BC6OTHER ) at high nanomolar concentrations and by a BC6OTHER weak partial agonist ( BC6OTHER ) at micromolar concentrations.	False
Limitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6ENTC which does not bind to high affinity BC6OTHER ( BC6OTHER ) at high nanomolar concentrations and by a BC6ENTG weak partial agonist ( BC6OTHER ) at micromolar concentrations.	False
Limitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6ENTC receptors ( BC6OTHER ) at high nanomolar concentrations and by a BC6ENTG weak partial agonist ( BC6OTHER ) at micromolar concentrations.	False
Limitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6ENTG ( BC6ENTC ) at high nanomolar concentrations and by a BC6OTHER weak partial agonist ( BC6OTHER ) at micromolar concentrations.	False
Limitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6OTHER ( BC6ENTC ) at high nanomolar concentrations and by a BC6ENTG weak partial agonist ( BC6OTHER ) at micromolar concentrations.	False
Limitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6ENTG ( BC6OTHER ) at high nanomolar concentrations and by a BC6ENTC receptor weak partial agonist ( BC6OTHER ) at micromolar concentrations.	False
Limitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6ENTG ( BC6OTHER ) at high nanomolar concentrations and by a BC6OTHER weak partial agonist ( BC6ENTC ) at micromolar concentrations.	False
Limitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6OTHER ( BC6OTHER ) at high nanomolar concentrations and by a BC6ENTG weak partial agonist ( BC6ENTC ) at micromolar concentrations.	CPR:5
The limitation of SRF by BC6ENTC was not prevented by inverse or partial agonists at the BC6ENTG , including BC6OTHER and the BC6OTHER .	False
The limitation of SRF by BC6OTHER was not prevented by inverse or partial agonists at the BC6ENTG , including BC6ENTC and the BC6OTHER .	CPR:5
The limitation of SRF by BC6OTHER was not prevented by inverse or partial agonists at the BC6ENTG , including BC6OTHER and the BC6ENTC .	CPR:5
These findings suggest that limitation of SRF was produced by binding of BC6ENTC , but not BC6OTHER , to BC6ENTG and not to high affinity central BC6OTHER receptors, and that BC6OTHER limit SRF by slowing recovery of BC6OTHER from inactivation.	False
These findings suggest that limitation of SRF was produced by binding of BC6ENTC , but not BC6OTHER , to voltage - dependent BC6OTHER channels and not to high affinity central BC6ENTG , and that BC6OTHER limit SRF by slowing recovery of BC6OTHER from inactivation.	False
These findings suggest that limitation of SRF was produced by binding of BC6ENTC , but not BC6OTHER , to voltage - dependent BC6OTHER channels and not to high affinity central BC6OTHER receptors, and that BC6OTHER limit SRF by slowing recovery of BC6ENTG from inactivation.	False
These findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6ENTC , to BC6ENTG and not to high affinity central BC6OTHER receptors, and that BC6OTHER limit SRF by slowing recovery of BC6OTHER from inactivation.	False
These findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6ENTC , to voltage - dependent BC6OTHER channels and not to high affinity central BC6ENTG , and that BC6OTHER limit SRF by slowing recovery of BC6OTHER from inactivation.	False
These findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6ENTC , to voltage - dependent BC6OTHER channels and not to high affinity central BC6OTHER receptors, and that BC6OTHER limit SRF by slowing recovery of BC6ENTG from inactivation.	False
These findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6OTHER , to voltage - dependent BC6ENTC channels and not to high affinity central BC6ENTG , and that BC6OTHER limit SRF by slowing recovery of BC6OTHER from inactivation.	False
These findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6OTHER , to voltage - dependent BC6ENTC channels and not to high affinity central BC6OTHER receptors, and that BC6OTHER limit SRF by slowing recovery of BC6ENTG from inactivation.	False
These findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6OTHER , to BC6ENTG and not to high affinity central BC6ENTC receptors, and that BC6OTHER limit SRF by slowing recovery of BC6OTHER from inactivation.	False
These findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6OTHER , to voltage - dependent BC6OTHER channels and not to high affinity central BC6ENTC receptors, and that BC6OTHER limit SRF by slowing recovery of BC6ENTG from inactivation.	False
These findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6OTHER , to BC6ENTG and not to high affinity central BC6OTHER receptors, and that BC6ENTC limit SRF by slowing recovery of BC6OTHER from inactivation.	False
These findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6OTHER , to voltage - dependent BC6OTHER channels and not to high affinity central BC6ENTG , and that BC6ENTC limit SRF by slowing recovery of BC6OTHER from inactivation.	False
These findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6OTHER , to voltage - dependent BC6OTHER channels and not to high affinity central BC6OTHER receptors, and that BC6ENTC limit SRF by slowing recovery of BC6ENTG from inactivation.	CPR:3
Changes in gene expression associated with loss of function of the BC6ENTG BC6ENTC dehydrogenase in mouse embryonic fibroblasts.	False
Among 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6ENTC biosynthesis, 7 are involved in BC6OTHER synthesis, 3 ( BC6ENTG , BC6OTHER , and BC6OTHER ) encode BC6OTHER - regulatory proteins, and 2 ( BC6OTHER and BC6OTHER ) are lipid transporters.	False
Among 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6ENTC biosynthesis, 7 are involved in BC6OTHER synthesis, 3 ( BC6OTHER , BC6ENTG , and BC6OTHER ) encode BC6OTHER - regulatory proteins, and 2 ( BC6OTHER and BC6OTHER ) are lipid transporters.	False
Among 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6ENTC biosynthesis, 7 are involved in BC6OTHER synthesis, 3 ( BC6OTHER , BC6OTHER , and BC6ENTG ) encode BC6OTHER - regulatory proteins, and 2 ( BC6OTHER and BC6OTHER ) are lipid transporters.	False
Among 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6ENTC biosynthesis, 7 are involved in BC6OTHER synthesis, 3 ( BC6OTHER , BC6OTHER , and BC6OTHER ) encode BC6OTHER - regulatory proteins, and 2 ( BC6ENTG and BC6OTHER ) are lipid transporters.	False
Among 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6ENTC biosynthesis, 7 are involved in BC6OTHER synthesis, 3 ( BC6OTHER , BC6OTHER , and BC6OTHER ) encode BC6OTHER - regulatory proteins, and 2 ( BC6OTHER and BC6ENTG ) are lipid transporters.	False
Among 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6OTHER biosynthesis, 7 are involved in BC6ENTC synthesis, 3 ( BC6ENTG , BC6OTHER , and BC6OTHER ) encode BC6OTHER - regulatory proteins, and 2 ( BC6OTHER and BC6OTHER ) are lipid transporters.	False
Among 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6OTHER biosynthesis, 7 are involved in BC6ENTC synthesis, 3 ( BC6OTHER , BC6ENTG , and BC6OTHER ) encode BC6OTHER - regulatory proteins, and 2 ( BC6OTHER and BC6OTHER ) are lipid transporters.	False
Among 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6OTHER biosynthesis, 7 are involved in BC6ENTC synthesis, 3 ( BC6OTHER , BC6OTHER , and BC6ENTG ) encode BC6OTHER - regulatory proteins, and 2 ( BC6OTHER and BC6OTHER ) are lipid transporters.	False
Among 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6OTHER biosynthesis, 7 are involved in BC6ENTC synthesis, 3 ( BC6OTHER , BC6OTHER , and BC6OTHER ) encode BC6OTHER - regulatory proteins, and 2 ( BC6ENTG and BC6OTHER ) are lipid transporters.	False
Among 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6OTHER biosynthesis, 7 are involved in BC6ENTC synthesis, 3 ( BC6OTHER , BC6OTHER , and BC6OTHER ) encode BC6OTHER - regulatory proteins, and 2 ( BC6OTHER and BC6ENTG ) are lipid transporters.	False
Among 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6OTHER biosynthesis, 7 are involved in BC6OTHER synthesis, 3 ( BC6ENTG , BC6OTHER , and BC6OTHER ) encode BC6ENTC - regulatory proteins, and 2 ( BC6OTHER and BC6OTHER ) are lipid transporters.	False
Among 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6OTHER biosynthesis, 7 are involved in BC6OTHER synthesis, 3 ( BC6OTHER , BC6ENTG , and BC6OTHER ) encode BC6ENTC - regulatory proteins, and 2 ( BC6OTHER and BC6OTHER ) are lipid transporters.	False
Among 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6OTHER biosynthesis, 7 are involved in BC6OTHER synthesis, 3 ( BC6OTHER , BC6OTHER , and BC6ENTG ) encode BC6ENTC - regulatory proteins, and 2 ( BC6OTHER and BC6OTHER ) are lipid transporters.	False
Among 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6OTHER biosynthesis, 7 are involved in BC6OTHER synthesis, 3 ( BC6OTHER , BC6OTHER , and BC6OTHER ) encode BC6ENTC - regulatory proteins, and 2 ( BC6ENTG and BC6OTHER ) are lipid transporters.	False
Among 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6OTHER biosynthesis, 7 are involved in BC6OTHER synthesis, 3 ( BC6OTHER , BC6OTHER , and BC6OTHER ) encode BC6ENTC - regulatory proteins, and 2 ( BC6OTHER and BC6ENTG ) are lipid transporters.	False
One of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X - linked gene BC6ENTC BC6OTHER dehydrogenase - like ( BC6ENTG ) encoding a BC6OTHER dehydrogenase.	False
One of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X - linked gene BC6ENTC BC6OTHER dehydrogenase - like ( BC6OTHER ) encoding a BC6ENTG .	False
One of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X - linked gene BC6OTHER BC6ENTC dehydrogenase - like ( BC6ENTG ) encoding a BC6OTHER dehydrogenase.	False
One of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X - linked gene BC6OTHER BC6ENTC dehydrogenase - like ( BC6OTHER ) encoding a BC6ENTG .	False
One of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X - linked gene BC6ENTG ( BC6OTHER ) encoding a BC6ENTC dehydrogenase.	False
One of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X - linked gene BC6OTHER BC6OTHER dehydrogenase - like ( BC6ENTG ) encoding a BC6ENTC dehydrogenase.	False
Inhibition of the BC6ENTG - depalmitoylating enzyme BC6ENTC protein thioesterases APT1 and - 2 is a new approach to modulating the BC6OTHER cycle.	False
Inhibition of the BC6OTHER - depalmitoylating enzyme BC6ENTC protein thioesterases APT1 and - 2 is a new approach to modulating the BC6ENTG cycle.	False
Here we present BC6ENTC and BC6OTHER derivatives as a new class of potent and nontoxic BC6ENTG inhibitors.	CPR:4
Here we present BC6OTHER and BC6ENTC derivatives as a new class of potent and nontoxic BC6ENTG inhibitors.	CPR:4
 BC6ENTC - based inhibitors of BC6ENTG .	CPR:4
Oral BC6ENTC (as a representative of the BC6OTHER family) inhibited diabetes - induced increase in BC6ENTG DNA - binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina.	CPR:4
Oral BC6OTHER (as a representative of the BC6ENTC family) inhibited diabetes - induced increase in BC6ENTG DNA - binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina.	CPR:4
All three BC6ENTC inhibited the diabetes - induced translocation of BC6ENTG (a subunit of BC6OTHER ) into nuclei of CHEM vascular endothelial cells of the isolated CHEM vasculature, as well as of BC6OTHER and BC6OTHER into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole - CHEM sections.	CPR:4
All three BC6ENTC inhibited the diabetes - induced translocation of BC6OTHER (a subunit of BC6ENTG ) into nuclei of CHEM vascular endothelial cells of the isolated CHEM vasculature, as well as of BC6OTHER and BC6OTHER into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole - CHEM sections.	CPR:4
All three BC6ENTC inhibited the diabetes - induced translocation of BC6OTHER (a subunit of BC6OTHER ) into nuclei of CHEM vascular endothelial cells of the isolated CHEM vasculature, as well as of BC6ENTG and BC6OTHER into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole - CHEM sections.	CPR:4
All three BC6ENTC inhibited the diabetes - induced translocation of BC6OTHER (a subunit of BC6OTHER ) into nuclei of CHEM vascular endothelial cells of the isolated CHEM vasculature, as well as of BC6OTHER and BC6ENTG into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole - CHEM sections.	CPR:4
BC6ENTC (also as a representative of the BC6OTHER ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6ENTG , including vascular cell adhesion molecule, BC6OTHER , inducible BC6OTHER synthase, and BC6OTHER in whole - CHEM lysate.	CPR:4
BC6ENTC (also as a representative of the BC6OTHER ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6OTHER , including vascular cell adhesion molecule, BC6ENTG , inducible BC6OTHER synthase, and BC6OTHER in whole - CHEM lysate.	CPR:4
BC6ENTC (also as a representative of the BC6OTHER ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6OTHER , including vascular cell adhesion molecule, BC6OTHER , BC6ENTG , and BC6OTHER in whole - CHEM lysate.	CPR:4
BC6ENTC (also as a representative of the BC6OTHER ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6OTHER , including vascular cell adhesion molecule, BC6OTHER , inducible BC6OTHER synthase, and BC6ENTG in whole - CHEM lysate.	CPR:4
BC6OTHER (also as a representative of the BC6ENTC ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6ENTG , including vascular cell adhesion molecule, BC6OTHER , inducible BC6OTHER synthase, and BC6OTHER in whole - CHEM lysate.	CPR:4
BC6OTHER (also as a representative of the BC6ENTC ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6OTHER , including vascular cell adhesion molecule, BC6ENTG , inducible BC6OTHER synthase, and BC6OTHER in whole - CHEM lysate.	False
BC6OTHER (also as a representative of the BC6ENTC ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6OTHER , including vascular cell adhesion molecule, BC6OTHER , BC6ENTG , and BC6OTHER in whole - CHEM lysate.	False
BC6OTHER (also as a representative of the BC6ENTC ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6OTHER , including vascular cell adhesion molecule, BC6OTHER , inducible BC6OTHER synthase, and BC6ENTG in whole - CHEM lysate.	False
BC6OTHER (also as a representative of the BC6OTHER ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6ENTG , including vascular cell adhesion molecule, BC6OTHER , inducible BC6ENTC synthase, and BC6OTHER in whole - CHEM lysate.	False
BC6OTHER (also as a representative of the BC6OTHER ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6OTHER , including vascular cell adhesion molecule, BC6ENTG , inducible BC6ENTC synthase, and BC6OTHER in whole - CHEM lysate.	False
BC6OTHER (also as a representative of the BC6OTHER ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6OTHER , including vascular cell adhesion molecule, BC6OTHER , inducible BC6ENTC synthase, and BC6ENTG in whole - CHEM lysate.	False
BC6ENTC , in doses administrated in our experiments, inhibited BC6ENTG B and perhaps other transcription factors in the retina, were well tolerated, and offered new tools to investigate and inhibit the development of diabetic retinopathy.	CPR:4
Additionally, more specific mechanisms exist where xenobiotics act as ligands, including the BC6ENTC receptor, BC6ENTG and the BC6OTHER family of transcription factors.	False
Additionally, more specific mechanisms exist where xenobiotics act as ligands, including the BC6ENTC receptor, BC6OTHER and the BC6ENTG family of transcription factors.	False
We expressed cardiac or BC6ENTG subunits in combination with beta2a and alpha2 / delta subunits in human embryonic kidney cells, and used 2 mM BC6ENTC as the permeant ion.	False
Isoform - specific inhibition of BC6ENTG by BC6ENTC is independent of isoform - specific gating properties.	CPR:4
BC6ENTC ( BC6OTHER ) block BC6ENTG more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state.	CPR:4
We thus conclude that the more potent BC6ENTC inhibition of smooth muscle versus BC6ENTG is not attributable to differences in channel inactivation or activation.	CPR:4
BC6ENTC (a BC6OTHER antagonist) blocks the BC6ENTG more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels.	CPR:4
Intrinsic, gating - independent BC6ENTG binding affinity differences must be invoked to explain the isoform - specific sensitivity of the BC6ENTC block.	False
BC6OTHER (a BC6ENTC antagonist) blocks the BC6ENTG more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels.	CPR:4
BC6OTHER ( BC6ENTC ) block BC6ENTG more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state.	CPR:4
Design, Synthesis and Biological Evaluation of BC6OTHER Derivatives as BC6ENTG Ligands with Potential for Treatment of BC6ENTC Abuse.	False
Design, Synthesis and Biological Evaluation of BC6ENTC Derivatives as BC6ENTG Ligands with Potential for Treatment of BC6OTHER Abuse.	False
Collectively, these initial findings suggest that design and systematic modification of BC6OTHER such as 3 may lead to development of novel CHEM ligands with dual BC6OTHER antagonist / BC6ENTG agonist activity with potential for use as treatments of BC6ENTC abuse.	False
Collectively, these initial findings suggest that design and systematic modification of BC6OTHER such as 3 may lead to development of novel CHEM ligands with dual BC6ENTG antagonist / BC6OTHER agonist activity with potential for use as treatments of BC6ENTC abuse.	False
Attenuation of increased endocannabinoid signaling with a BC6ENTG neutral antagonist might offer a new therapeutic direction for treatment of BC6ENTC abuse.	False
We have recently reported that a CHEM - hydroxylated metabolite of the synthetic BC6ENTC CHEM BC6OTHER (3) exhibits neutral antagonist activity at BC6ENTG and thus may serve as a promising lead for the development of novel BC6OTHER abuse therapies.	CPR:6
We have recently reported that a CHEM - hydroxylated metabolite of the synthetic BC6OTHER CHEM BC6ENTC (3) exhibits neutral antagonist activity at BC6ENTG and thus may serve as a promising lead for the development of novel BC6OTHER abuse therapies.	CPR:6
We have recently reported that a CHEM - hydroxylated metabolite of the synthetic BC6OTHER CHEM BC6OTHER (3) exhibits neutral antagonist activity at BC6ENTG and thus may serve as a promising lead for the development of novel BC6ENTC abuse therapies.	False
In the current study, we show that systematic modification of an BC6ENTC scaffold identifies two new compounds with dual BC6ENTG antagonist / BC6OTHER agonist activity.	CPR:6
In the current study, we show that systematic modification of an BC6ENTC scaffold identifies two new compounds with dual BC6OTHER antagonist / BC6ENTG agonist activity.	CPR:5
Similar to the BC6ENTG antagonist / inverse agonist CHEM, analogues 27 and 30 decrease oral BC6ENTC self - administration, without affecting total fluid intake and block the development of BC6OTHER - conditioned place preference.	False
Similar to the BC6ENTG antagonist / inverse agonist CHEM, analogues 27 and 30 decrease oral BC6OTHER self - administration, without affecting total fluid intake and block the development of BC6ENTC - conditioned place preference.	False
Collectively, these initial findings suggest that design and systematic modification of BC6ENTC such as 3 may lead to development of novel CHEM ligands with dual BC6OTHER antagonist / BC6ENTG agonist activity with potential for use as treatments of BC6OTHER abuse.	CPR:5
Collectively, these initial findings suggest that design and systematic modification of BC6ENTC such as 3 may lead to development of novel CHEM ligands with dual BC6ENTG antagonist / BC6OTHER agonist activity with potential for use as treatments of BC6OTHER abuse.	CPR:6
In rat plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTG was degraded into BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6ENTG , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6OTHER , BC6ENTG and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6OTHER , BC6OTHER and BC6ENTG plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTG , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTG and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTG metabolites not found in human plasma.	False
In rat plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6ENTC , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTC , BC6ENTG and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTC , BC6OTHER and BC6ENTG plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER plus BC6ENTG , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTG and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTG metabolites not found in human plasma.	False
In rat plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6ENTC and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6ENTC and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTC and BC6ENTG plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER plus BC6ENTG , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER plus BC6OTHER , BC6ENTG and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTG metabolites not found in human plasma.	False
In rat plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6ENTC plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6ENTC plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6ENTC plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC plus BC6ENTG , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC plus BC6OTHER , BC6ENTG and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC plus BC6OTHER , BC6OTHER and BC6ENTG metabolites not found in human plasma.	False
In rat plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTC , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTC , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTC , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER plus BC6ENTC , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER plus BC6ENTC , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG plus BC6ENTC , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTC , BC6ENTG and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTC , BC6OTHER and BC6ENTG metabolites not found in human plasma.	False
In rat plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTC and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTC and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTC and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTC and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER plus BC6OTHER , BC6ENTC and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG plus BC6OTHER , BC6ENTC and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTG , BC6ENTC and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTC and BC6ENTG metabolites not found in human plasma.	False
In rat plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTC metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTC metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTC metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTC metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTC metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG plus BC6OTHER , BC6OTHER and BC6ENTC metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTG , BC6OTHER and BC6ENTC metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTG and BC6ENTC metabolites not found in human plasma.	False
BC6ENTC and BC6OTHER reduced the production of BC6ENTG and BC6OTHER with more effect being observed with BC6OTHER .	CPR:4
BC6ENTC and BC6OTHER reduced the production of BC6OTHER and BC6ENTG with more effect being observed with BC6OTHER .	CPR:4
BC6OTHER and BC6ENTC reduced the production of BC6ENTG and BC6OTHER with more effect being observed with BC6OTHER .	CPR:4
BC6OTHER and BC6ENTC reduced the production of BC6OTHER and BC6ENTG with more effect being observed with BC6OTHER .	CPR:4
BC6OTHER and BC6OTHER reduced the production of BC6ENTC and BC6ENTG with more effect being observed with BC6OTHER .	False
BC6OTHER and BC6OTHER reduced the production of BC6ENTG and BC6ENTC with more effect being observed with BC6OTHER .	False
BC6OTHER and BC6OTHER reduced the production of BC6ENTG and BC6OTHER with more effect being observed with BC6ENTC .	CPR:4
BC6OTHER and BC6OTHER reduced the production of BC6OTHER and BC6ENTG with more effect being observed with BC6ENTC .	CPR:4
BC6ENTC and BC6OTHER increased the production of both BC6ENTG and BC6OTHER but not that of BC6OTHER and BC6OTHER .	CPR:3
BC6ENTC and BC6OTHER increased the production of both BC6OTHER and BC6ENTG but not that of BC6OTHER and BC6OTHER .	CPR:3
BC6ENTC and BC6OTHER increased the production of both BC6OTHER and BC6OTHER but not that of BC6ENTG and BC6OTHER .	False
BC6ENTC and BC6OTHER increased the production of both BC6OTHER and BC6OTHER but not that of BC6OTHER and BC6ENTG .	False
BC6OTHER and BC6ENTC increased the production of both BC6ENTG and BC6OTHER but not that of BC6OTHER and BC6OTHER .	CPR:3
BC6OTHER and BC6ENTC increased the production of both BC6OTHER and BC6ENTG but not that of BC6OTHER and BC6OTHER .	CPR:3
BC6OTHER and BC6ENTC increased the production of both BC6OTHER and BC6OTHER but not that of BC6ENTG and BC6OTHER .	False
BC6OTHER and BC6ENTC increased the production of both BC6OTHER and BC6OTHER but not that of BC6OTHER and BC6ENTG .	False
BC6OTHER and BC6OTHER increased the production of both BC6ENTC and BC6ENTG but not that of BC6OTHER and BC6OTHER .	False
BC6OTHER and BC6OTHER increased the production of both BC6ENTC and BC6OTHER but not that of BC6ENTG and BC6OTHER .	False
BC6OTHER and BC6OTHER increased the production of both BC6ENTC and BC6OTHER but not that of BC6OTHER and BC6ENTG .	False
BC6OTHER and BC6OTHER increased the production of both BC6ENTG and BC6ENTC but not that of BC6OTHER and BC6OTHER .	False
BC6OTHER and BC6OTHER increased the production of both BC6OTHER and BC6ENTC but not that of BC6ENTG and BC6OTHER .	False
BC6OTHER and BC6OTHER increased the production of both BC6OTHER and BC6ENTC but not that of BC6OTHER and BC6ENTG .	False
BC6OTHER and BC6OTHER increased the production of both BC6ENTG and BC6OTHER but not that of BC6ENTC and BC6OTHER .	False
BC6OTHER and BC6OTHER increased the production of both BC6OTHER and BC6ENTG but not that of BC6ENTC and BC6OTHER .	False
BC6OTHER and BC6OTHER increased the production of both BC6OTHER and BC6OTHER but not that of BC6ENTC and BC6ENTG .	False
BC6OTHER and BC6OTHER increased the production of both BC6ENTG and BC6OTHER but not that of BC6OTHER and BC6ENTC .	False
BC6OTHER and BC6OTHER increased the production of both BC6OTHER and BC6ENTG but not that of BC6OTHER and BC6ENTC .	False
BC6OTHER and BC6OTHER increased the production of both BC6OTHER and BC6OTHER but not that of BC6ENTG and BC6ENTC .	False
This study shows that the potency of BC6ENTC in comparison with BC6OTHER is more than 100 - fold lower in human, but less than 10 - fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of BC6ENTG / BC6OTHER inhibition in relation to effects in humans.	CPR:4
This study shows that the potency of BC6ENTC in comparison with BC6OTHER is more than 100 - fold lower in human, but less than 10 - fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of BC6OTHER / BC6ENTG inhibition in relation to effects in humans.	CPR:4
This study shows that the potency of BC6OTHER in comparison with BC6ENTC is more than 100 - fold lower in human, but less than 10 - fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of BC6ENTG / BC6OTHER inhibition in relation to effects in humans.	False
This study shows that the potency of BC6OTHER in comparison with BC6ENTC is more than 100 - fold lower in human, but less than 10 - fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of BC6OTHER / BC6ENTG inhibition in relation to effects in humans.	CPR:4
In addition the production of BC6ENTG was enhanced in the presence of these inhibitors with a greater accumulation being observed with BC6ENTC .	CPR:3
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6ENTC ( BC6ENTG ) BC6OTHER in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial.	False
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6ENTC (79 / 81 BC6OTHER ) BC6ENTG in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial.	False
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6ENTC (79 / 81 BC6OTHER ) BC6OTHER in the presence of two new dual BC6ENTG / BC6OTHER inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial.	False
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6ENTC (79 / 81 BC6OTHER ) BC6OTHER in the presence of two new dual BC6OTHER / BC6ENTG inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial.	False
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6ENTG (79 / 81 BC6ENTC ) BC6OTHER in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial.	False
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6ENTC ) BC6ENTG in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial.	False
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6ENTC ) BC6OTHER in the presence of two new dual BC6ENTG / BC6OTHER inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial.	False
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6ENTC ) BC6OTHER in the presence of two new dual BC6OTHER / BC6ENTG inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial.	False
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6ENTG (79 / 81 BC6OTHER ) BC6ENTC in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial.	False
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER ( BC6ENTG ) BC6ENTC in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial.	False
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6OTHER ) BC6ENTC in the presence of two new dual BC6ENTG / BC6OTHER inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial.	False
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6OTHER ) BC6ENTC in the presence of two new dual BC6OTHER / BC6ENTG inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial.	False
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6ENTG (79 / 81 BC6OTHER ) BC6OTHER in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6ENTC and BC6OTHER ) currently under clinical trial.	False
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER ( BC6ENTG ) BC6OTHER in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6ENTC and BC6OTHER ) currently under clinical trial.	False
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6OTHER ) BC6ENTG in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6ENTC and BC6OTHER ) currently under clinical trial.	False
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6OTHER ) BC6OTHER in the presence of two new dual BC6ENTG / BC6OTHER inhibitors ( BC6ENTC and BC6OTHER ) currently under clinical trial.	CPR:4
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6OTHER ) BC6OTHER in the presence of two new dual BC6OTHER / BC6ENTG inhibitors ( BC6ENTC and BC6OTHER ) currently under clinical trial.	CPR:4
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6ENTG (79 / 81 BC6OTHER ) BC6OTHER in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6OTHER and BC6ENTC ) currently under clinical trial.	False
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER ( BC6ENTG ) BC6OTHER in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6OTHER and BC6ENTC ) currently under clinical trial.	False
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6OTHER ) BC6ENTG in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6OTHER and BC6ENTC ) currently under clinical trial.	False
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6OTHER ) BC6OTHER in the presence of two new dual BC6ENTG / BC6OTHER inhibitors ( BC6OTHER and BC6ENTC ) currently under clinical trial.	CPR:4
In this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6OTHER ) BC6OTHER in the presence of two new dual BC6OTHER / BC6ENTG inhibitors ( BC6OTHER and BC6ENTC ) currently under clinical trial.	CPR:4
In human plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
In human plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER .	False
In human plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER .	False
In human plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER .	False
In human plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG .	False
Several studies have suggested that the accumulation of BC6ENTC , or that of one its metabolites BK1 - 8, is involved in the occurrence of side effects such as AE associated with the use of various BC6ENTG i.	False
In human plasma the BC6ENTG half - life values in the absence or in the presence of BC6ENTC (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG .	False
In human plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6ENTC (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6ENTC (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6ENTC (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6ENTC (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6ENTC (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6ENTC (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG .	False
In human plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTC was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG .	False
In human plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTG was degraded into BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6ENTG , BC6OTHER and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6OTHER , BC6ENTG and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6OTHER , BC6OTHER and BC6ENTG .	False
In human plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6ENTC , BC6OTHER and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTC , BC6ENTG and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTC , BC6OTHER and BC6ENTG .	False
In human plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6ENTC and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6ENTC and BC6OTHER .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTC and BC6ENTG .	False
In human plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6ENTC .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6ENTC .	False
In human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6ENTC .	False
Unlike BC6ENTC , BC6OTHER abolished the production of BC6ENTG and BC6OTHER , suggesting a better BC6OTHER inhibition effect over BC6OTHER as no BC6OTHER activity was found.	False
Unlike BC6ENTC , BC6OTHER abolished the production of BC6OTHER and BC6ENTG , suggesting a better BC6OTHER inhibition effect over BC6OTHER as no BC6OTHER activity was found.	False
Unlike BC6ENTC , BC6OTHER abolished the production of BC6OTHER and BC6OTHER , suggesting a better BC6ENTG inhibition effect over BC6OTHER as no BC6OTHER activity was found.	False
Unlike BC6ENTC , BC6OTHER abolished the production of BC6OTHER and BC6OTHER , suggesting a better BC6OTHER inhibition effect over BC6OTHER as no BC6ENTG activity was found.	False
Unlike BC6OTHER , BC6ENTC abolished the production of BC6ENTG and BC6OTHER , suggesting a better BC6OTHER inhibition effect over BC6OTHER as no BC6OTHER activity was found.	CPR:4
Unlike BC6OTHER , BC6ENTC abolished the production of BC6OTHER and BC6ENTG , suggesting a better BC6OTHER inhibition effect over BC6OTHER as no BC6OTHER activity was found.	CPR:4
Unlike BC6OTHER , BC6ENTC abolished the production of BC6OTHER and BC6OTHER , suggesting a better BC6ENTG inhibition effect over BC6OTHER as no BC6OTHER activity was found.	CPR:4
Unlike BC6OTHER , BC6ENTC abolished the production of BC6OTHER and BC6OTHER , suggesting a better BC6OTHER inhibition effect over BC6OTHER as no BC6ENTG activity was found.	False
Unlike BC6OTHER , BC6OTHER abolished the production of BC6ENTC and BC6ENTG , suggesting a better BC6OTHER inhibition effect over BC6OTHER as no BC6OTHER activity was found.	False
Unlike BC6OTHER , BC6OTHER abolished the production of BC6ENTC and BC6OTHER , suggesting a better BC6ENTG inhibition effect over BC6OTHER as no BC6OTHER activity was found.	False
Unlike BC6OTHER , BC6OTHER abolished the production of BC6ENTC and BC6OTHER , suggesting a better BC6OTHER inhibition effect over BC6OTHER as no BC6ENTG activity was found.	False
Unlike BC6OTHER , BC6OTHER abolished the production of BC6ENTG and BC6ENTC , suggesting a better BC6OTHER inhibition effect over BC6OTHER as no BC6OTHER activity was found.	False
Unlike BC6OTHER , BC6OTHER abolished the production of BC6OTHER and BC6ENTC , suggesting a better BC6ENTG inhibition effect over BC6OTHER as no BC6OTHER activity was found.	False
Unlike BC6OTHER , BC6OTHER abolished the production of BC6OTHER and BC6ENTC , suggesting a better BC6OTHER inhibition effect over BC6OTHER as no BC6ENTG activity was found.	False
Unlike BC6OTHER , BC6OTHER abolished the production of BC6ENTG and BC6OTHER , suggesting a better BC6OTHER inhibition effect over BC6ENTC as no BC6OTHER activity was found.	False
Unlike BC6OTHER , BC6OTHER abolished the production of BC6OTHER and BC6ENTG , suggesting a better BC6OTHER inhibition effect over BC6ENTC as no BC6OTHER activity was found.	False
Unlike BC6OTHER , BC6OTHER abolished the production of BC6OTHER and BC6OTHER , suggesting a better BC6ENTG inhibition effect over BC6ENTC as no BC6OTHER activity was found.	CPR:4
Unlike BC6OTHER , BC6OTHER abolished the production of BC6OTHER and BC6OTHER , suggesting a better BC6OTHER inhibition effect over BC6ENTC as no BC6ENTG activity was found.	False
Investigation of BC6ENTG metabolism in human and rat plasma in the presence of the dual BC6OTHER / BC6OTHER inhibitors BC6ENTC and BC6OTHER .	False
Investigation of BC6OTHER metabolism in human and rat plasma in the presence of the dual BC6ENTG / BC6OTHER inhibitors BC6ENTC and BC6OTHER .	CPR:4
Investigation of BC6OTHER metabolism in human and rat plasma in the presence of the dual BC6OTHER / BC6ENTG inhibitors BC6ENTC and BC6OTHER .	CPR:4
The production of BC6ENTG was reduced with BC6ENTC while no significant change was observed with BC6OTHER after 4 h of incubation.	CPR:4
Investigation of BC6ENTG metabolism in human and rat plasma in the presence of the dual BC6OTHER / BC6OTHER inhibitors BC6OTHER and BC6ENTC .	False
Investigation of BC6OTHER metabolism in human and rat plasma in the presence of the dual BC6ENTG / BC6OTHER inhibitors BC6OTHER and BC6ENTC .	CPR:4
Investigation of BC6OTHER metabolism in human and rat plasma in the presence of the dual BC6OTHER / BC6ENTG inhibitors BC6OTHER and BC6ENTC .	CPR:4
Investigation of BC6ENTC metabolism in human and rat plasma in the presence of the dual BC6ENTG / BC6OTHER inhibitors BC6OTHER and BC6OTHER .	False
Investigation of BC6ENTC metabolism in human and rat plasma in the presence of the dual BC6OTHER / BC6ENTG inhibitors BC6OTHER and BC6OTHER .	False
The production of BC6ENTG was reduced with BC6OTHER while no significant change was observed with BC6ENTC after 4 h of incubation.	False
In rat plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTG , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTG and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTG metabolites not found in human plasma.	False
In rat plasma the BC6ENTG half - life values in the absence or in the presence of BC6ENTC (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTG , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTG and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTG metabolites not found in human plasma.	False
In rat plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6ENTC (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6ENTC (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6ENTC (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6ENTC (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6ENTC (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6ENTC (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6ENTC (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTG , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6ENTC (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTG and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6ENTC (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTG metabolites not found in human plasma.	False
In rat plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTC was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTG , BC6OTHER and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTG and BC6OTHER metabolites not found in human plasma.	False
In rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTG metabolites not found in human plasma.	False
Clonal T cells defined as a predominance of a single BC6ENTG gene usage, in one case verified by BC6OTHER CDR3 fragment analysis and BC6ENTC sequencing, emerged within the CD52 - / CD8+ cell population during CHEM therapy in 2 CLL patients, both achieving a long - lasting remission.	False
Clonal T cells defined as a predominance of a single BC6OTHER gene usage, in one case verified by BC6ENTG CDR3 fragment analysis and BC6ENTC sequencing, emerged within the CD52 - / CD8+ cell population during CHEM therapy in 2 CLL patients, both achieving a long - lasting remission.	False
In addition, our exploration further revealed that the suppressive action of BC6ENTC on inflammation was mediated via inhibiting BC6OTHER ( BC6ENTG ) activation.	CPR:4
In addition, our exploration further revealed that the suppressive action of BC6ENTC on inflammation was mediated via inhibiting BC6ENTG ( BC6OTHER ) activation.	CPR:4
 BC6ENTC inhibits LPS plus BC6ENTG - induced inflammatory response in astrocytes primary cultures.	CPR:4
Collectively, these results suggest that BC6ENTC can exert inhibitory effects on the inflammatory reaction in astrocytes and that inactivation of BC6ENTG could be the major determinant for its anti - inflammatory mechanism.	CPR:4
To further investigate the protective effect and underlying mechanism of BC6ENTC , astrocytes were pretreated with low (0.1mM) and high dose (0.5mM) BC6OTHER for 1h prior to LPS plus BC6ENTG stimulation.	False
To further investigate the protective effect and underlying mechanism of BC6OTHER , astrocytes were pretreated with low (0.1mM) and high dose (0.5mM) BC6ENTC for 1h prior to LPS plus BC6ENTG stimulation.	False
Biochemical analyses showed that BC6ENTC and ROS production and BC6ENTG activity were significantly reduced by BC6OTHER .	False
Biochemical analyses showed that BC6OTHER and ROS production and BC6ENTG activity were significantly reduced by BC6ENTC .	CPR:4
Data at transcriptional level also demonstrated that BC6ENTC potently attenuated gene expressions involved in inflammation, such as BC6ENTG , BC6OTHER and BC6OTHER .	CPR:4
Data at transcriptional level also demonstrated that BC6ENTC potently attenuated gene expressions involved in inflammation, such as BC6OTHER , BC6ENTG and BC6OTHER .	CPR:4
Data at transcriptional level also demonstrated that BC6ENTC potently attenuated gene expressions involved in inflammation, such as BC6OTHER , BC6OTHER and BC6ENTG .	CPR:4
Consistent with the results of a computer analysis, the binding of BC6ENTG to BC6OTHER ( BC6ENTC ) was significantly decreased to 38% that of the wild type.	False
However, a BC6ENTC - BC6OTHER - transferase pull - down assay showed reduced binding of BC6ENTG with BC6OTHER in the absence of BC6OTHER and impaired release in the presence of BC6OTHER .	False
However, a BC6ENTC - BC6OTHER - transferase pull - down assay showed reduced binding of BC6OTHER with BC6ENTG in the absence of BC6OTHER and impaired release in the presence of BC6OTHER .	False
However, a BC6OTHER - BC6ENTC - transferase pull - down assay showed reduced binding of BC6ENTG with BC6OTHER in the absence of BC6OTHER and impaired release in the presence of BC6OTHER .	False
However, a BC6OTHER - BC6ENTC - transferase pull - down assay showed reduced binding of BC6OTHER with BC6ENTG in the absence of BC6OTHER and impaired release in the presence of BC6OTHER .	False
However, a BC6OTHER - BC6OTHER - transferase pull - down assay showed reduced binding of BC6ENTG with BC6OTHER in the absence of BC6ENTC and impaired release in the presence of BC6OTHER .	False
However, a BC6OTHER - BC6OTHER - transferase pull - down assay showed reduced binding of BC6OTHER with BC6ENTG in the absence of BC6ENTC and impaired release in the presence of BC6OTHER .	False
However, a BC6OTHER - BC6OTHER - transferase pull - down assay showed reduced binding of BC6ENTG with BC6OTHER in the absence of BC6OTHER and impaired release in the presence of BC6ENTC .	False
However, a BC6OTHER - BC6OTHER - transferase pull - down assay showed reduced binding of BC6OTHER with BC6ENTG in the absence of BC6OTHER and impaired release in the presence of BC6ENTC .	False
Our findings suggest that BC6ENTG causes reduced association with and impaired release of BC6OTHER , resulting in RTH predominantly at the pituitary level, and that slightly elevated serum BC6OTHER level with high dose of BC6ENTC might be optimum for normal growth.	False
Our findings suggest that BC6OTHER causes reduced association with and impaired release of BC6ENTG , resulting in RTH predominantly at the pituitary level, and that slightly elevated serum BC6OTHER level with high dose of BC6ENTC might be optimum for normal growth.	False
Our findings suggest that BC6OTHER causes reduced association with and impaired release of BC6OTHER , resulting in RTH predominantly at the pituitary level, and that slightly elevated serum BC6ENTG level with high dose of BC6ENTC might be optimum for normal growth.	CPR:3
As the RTH mutant, BC6ENTG , was new, the optimum dose of BC6ENTC was unclear.	False
SUMMARY: The patient was a newborn female having severe hypothyroidism with a free BC6ENTC level of 0.36 ng / dL and a serum BC6ENTG level of 177 microU / mL.	False
Supplementation with BC6ENTC at a dose of >350 microg / day did not normalize the serum BC6ENTG level; however, the patient showed normal growth and intelligence at 14 years of age.	False
Consistent with the results of a computer analysis, the binding of BC6ENTG to BC6ENTC ( BC6OTHER ) was significantly decreased to 38% that of the wild type.	False
BC6ENTC dehydrogenase 5 ( BC6ENTG ) is a member of the mammalian BC6OTHER dehydrogenase family of yet undefined functions.	False
BC6ENTC dehydrogenase 5 ( BC6OTHER ) is a member of the BC6ENTG family of yet undefined functions.	False
A rat BC6ENTC dehydrogenase structure of similar type has been isolated at the cDNA level using BC6ENTG as a screening probe, where the rat cDNA structure displayed several atypical properties.	False
BC6OTHER ( BC6ENTG ) is a member of the mammalian BC6ENTC dehydrogenase family of yet undefined functions.	False
BC6ENTG ( BC6OTHER ) is a member of the mammalian BC6ENTC dehydrogenase family of yet undefined functions.	False
However, no soluble BC6ENTG protein could be heterologously expressed in Escherichia coli cells with expression systems successfully used for other BC6OTHER , including fused to BC6ENTC - BC6OTHER - transferase.	False
However, no soluble BC6OTHER protein could be heterologously expressed in Escherichia coli cells with expression systems successfully used for other BC6ENTG , including fused to BC6ENTC - BC6OTHER - transferase.	False
However, no soluble BC6ENTG protein could be heterologously expressed in Escherichia coli cells with expression systems successfully used for other BC6OTHER , including fused to BC6OTHER - BC6ENTC - transferase.	False
However, no soluble BC6OTHER protein could be heterologously expressed in Escherichia coli cells with expression systems successfully used for other BC6ENTG , including fused to BC6OTHER - BC6ENTC - transferase.	False
Analysis of mammalian BC6ENTC dehydrogenase 5 ( BC6ENTG ): characterisation of BC6OTHER with comparisons to the corresponding human variant.	False
Analysis of mammalian BC6ENTC dehydrogenase 5 ( BC6OTHER ): characterisation of BC6ENTG with comparisons to the corresponding human variant.	False
A streamlined and high - yielding synthesis of BC6ENTC (1), a potent BC6ENTG antagonist, is described.	CPR:6
Practical asymmetric synthesis of BC6ENTC , a potent human BC6ENTG antagonist, via a stereoselective CHEM - catalyzed trans acetalization reaction.	CPR:6
Furthermore, BC6ENTG inhibition in astrocytes is associated with the rapid onset of intracellular BC6ENTC oscillations.	False
Surprisingly, this rapid BC6ENTC influx is blocked by the BC6ENTG antagonist, BC6OTHER .	False
Surprisingly, this rapid BC6ENTC influx is blocked by the CHEM - type BC6OTHER channel antagonist, BC6ENTG .	False
Surprisingly, this rapid BC6OTHER influx is blocked by the BC6ENTC - type BC6OTHER channel antagonist, BC6ENTG .	False
Surprisingly, this rapid BC6OTHER influx is blocked by the CHEM - type BC6ENTC channel antagonist, BC6ENTG .	False
While the function of BC6ENTC - type BC6OTHER channels within astrocytes is controversial, these BC6ENTG have been linked to BC6OTHER - dependent vesicular gliotransmitter release.	False
While the function of CHEM - type BC6ENTC channels within astrocytes is controversial, these BC6ENTG have been linked to BC6OTHER - dependent vesicular gliotransmitter release.	False
While the function of BC6ENTG within astrocytes is controversial, these voltage - gated BC6ENTC channels have been linked to BC6OTHER - dependent vesicular gliotransmitter release.	False
While the function of BC6ENTG within astrocytes is controversial, these voltage - gated BC6OTHER channels have been linked to BC6ENTC - dependent vesicular gliotransmitter release.	False
While the function of CHEM - type BC6OTHER channels within astrocytes is controversial, these BC6ENTG have been linked to BC6ENTC - dependent vesicular gliotransmitter release.	False
When extracellular BC6ENTC and BC6OTHER levels are measured following BC6ENTG inhibition within our enriched astrocyte cultures, no alterations in BC6OTHER levels are observed, whereas BC6OTHER levels in the extracellular environment significantly increase.	False
When extracellular BC6OTHER and BC6ENTC levels are measured following BC6ENTG inhibition within our enriched astrocyte cultures, no alterations in BC6OTHER levels are observed, whereas BC6OTHER levels in the extracellular environment significantly increase.	False
When extracellular BC6OTHER and BC6OTHER levels are measured following BC6ENTG inhibition within our enriched astrocyte cultures, no alterations in BC6ENTC levels are observed, whereas BC6OTHER levels in the extracellular environment significantly increase.	False
Loss of BC6ENTG Activity in Cortical Astrocytes Decreases BC6OTHER Uptake and Induces Neurotoxic Release of BC6ENTC .	False
Loss of BC6ENTG Activity in Cortical Astrocytes Decreases BC6ENTC Uptake and Induces Neurotoxic Release of BC6OTHER .	False
When extracellular BC6OTHER and BC6OTHER levels are measured following BC6ENTG inhibition within our enriched astrocyte cultures, no alterations in BC6OTHER levels are observed, whereas BC6ENTC levels in the extracellular environment significantly increase.	False
Extracellular BC6ENTC accumulation associated with BC6ENTG inhibition contributes both to BC6OTHER oscillations within astrocytes and ultimately cortical neuron toxicity.	False
Extracellular BC6OTHER accumulation associated with BC6ENTG inhibition contributes both to BC6ENTC oscillations within astrocytes and ultimately cortical neuron toxicity.	False
Thus, a loss of BC6ENTG signaling within astrocytes dysregulates BC6ENTC uptake and supports BC6OTHER release, two processes that would compromise neuronal survival following ischemic / excitotoxic insults.	False
Thus, a loss of BC6ENTG signaling within astrocytes dysregulates BC6OTHER uptake and supports BC6ENTC release, two processes that would compromise neuronal survival following ischemic / excitotoxic insults.	False
The extent of BC6ENTC / calmodulin - dependent protein kinase II ( BC6ENTG ) inactivation in the brain following ischemia correlates with the extent of damage.	False
We have previously shown that a loss of BC6ENTG activity in neurons is detrimental to neuronal viability by inducing excitotoxic BC6ENTC release.	False
In the current study, we extend these findings to show that the ability of astrocytes to buffer extracellular BC6ENTC is reduced when BC6ENTG is inhibited.	CPR:9
In conclusion, the BC6ENTG antagonist properties of BC6ENTC increase BC6OTHER and BC6OTHER levels both alone and in association with CHEM.	CPR:6
In conclusion, the BC6ENTG antagonist properties of BC6OTHER increase BC6ENTC and BC6OTHER levels both alone and in association with CHEM.	False
In conclusion, the BC6ENTG antagonist properties of BC6OTHER increase BC6OTHER and BC6ENTC levels both alone and in association with CHEM.	False
However, in contrast to the selective BC6ENTG antagonist, BC6ENTC , the BC6OTHER agonist actions of BC6OTHER suppress BC6OTHER levels alone and underlie its inability to augment the influence of BC6OTHER upon BC6OTHER levels.	CPR:6
However, in contrast to the selective BC6OTHER antagonist, BC6ENTC , the BC6ENTG agonist actions of BC6OTHER suppress BC6OTHER levels alone and underlie its inability to augment the influence of BC6OTHER upon BC6OTHER levels.	False
However, in contrast to the selective BC6ENTG antagonist, BC6OTHER , the BC6ENTC (1A) agonist actions of BC6OTHER suppress BC6OTHER levels alone and underlie its inability to augment the influence of BC6OTHER upon BC6OTHER levels.	False
However, in contrast to the selective BC6ENTG antagonist, BC6OTHER , the BC6OTHER agonist actions of BC6ENTC suppress BC6OTHER levels alone and underlie its inability to augment the influence of BC6OTHER upon BC6OTHER levels.	False
However, in contrast to the selective BC6OTHER antagonist, BC6OTHER , the BC6ENTG agonist actions of BC6ENTC suppress BC6OTHER levels alone and underlie its inability to augment the influence of BC6OTHER upon BC6OTHER levels.	CPR:5
However, in contrast to the selective BC6ENTG antagonist, BC6OTHER , the BC6OTHER agonist actions of BC6OTHER suppress BC6ENTC levels alone and underlie its inability to augment the influence of BC6OTHER upon BC6OTHER levels.	False
However, in contrast to the selective BC6OTHER antagonist, BC6OTHER , the BC6ENTG agonist actions of BC6OTHER suppress BC6ENTC levels alone and underlie its inability to augment the influence of BC6OTHER upon BC6OTHER levels.	False
However, in contrast to the selective BC6ENTG antagonist, BC6OTHER , the BC6OTHER agonist actions of BC6OTHER suppress BC6OTHER levels alone and underlie its inability to augment the influence of BC6ENTC upon BC6OTHER levels.	False
However, in contrast to the selective BC6OTHER antagonist, BC6OTHER , the BC6ENTG agonist actions of BC6OTHER suppress BC6OTHER levels alone and underlie its inability to augment the influence of BC6ENTC upon BC6OTHER levels.	False
However, in contrast to the selective BC6ENTG antagonist, BC6OTHER , the BC6OTHER agonist actions of BC6OTHER suppress BC6OTHER levels alone and underlie its inability to augment the influence of BC6OTHER upon BC6ENTC levels.	False
However, in contrast to the selective BC6OTHER antagonist, BC6OTHER , the BC6ENTG agonist actions of BC6OTHER suppress BC6OTHER levels alone and underlie its inability to augment the influence of BC6OTHER upon BC6ENTC levels.	False
BC6ENTC displays marked affinity at BC6ENTG , significant affinity for BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER and weak affinity for BC6OTHER .	False
BC6ENTC displays marked affinity at BC6OTHER , significant affinity for BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER and weak affinity for BC6OTHER .	False
BC6ENTC displays marked affinity at BC6OTHER , significant affinity for BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER and weak affinity for BC6OTHER .	False
BC6ENTC displays marked affinity at BC6OTHER , significant affinity for BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER and weak affinity for BC6OTHER .	False
BC6ENTC displays marked affinity at BC6OTHER , significant affinity for BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG and weak affinity for BC6OTHER .	False
BC6ENTC displays marked affinity at BC6OTHER , significant affinity for BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER and weak affinity for BC6ENTG .	False
In [ BC6ENTC ]GTPgammaS binding protocols, BC6OTHER exerts antagonist actions at BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER sites, yet partial agonist actions at BC6OTHER sites.	False
In [ BC6ENTC ]GTPgammaS binding protocols, BC6OTHER exerts antagonist actions at BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER sites, yet partial agonist actions at BC6OTHER sites.	False
In [ BC6ENTC ]GTPgammaS binding protocols, BC6OTHER exerts antagonist actions at BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER sites, yet partial agonist actions at BC6OTHER sites.	False
In [ BC6ENTC ]GTPgammaS binding protocols, BC6OTHER exerts antagonist actions at BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG sites, yet partial agonist actions at BC6OTHER sites.	False
In [ BC6ENTC ]GTPgammaS binding protocols, BC6OTHER exerts antagonist actions at BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER sites, yet partial agonist actions at BC6ENTG sites.	False
In [ BC6OTHER ]GTPgammaS binding protocols, BC6ENTC exerts antagonist actions at BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER sites, yet partial agonist actions at BC6OTHER sites.	CPR:6
In [ BC6OTHER ]GTPgammaS binding protocols, BC6ENTC exerts antagonist actions at BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER sites, yet partial agonist actions at BC6OTHER sites.	CPR:6
In [ BC6OTHER ]GTPgammaS binding protocols, BC6ENTC exerts antagonist actions at BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER sites, yet partial agonist actions at BC6OTHER sites.	CPR:6
In [ BC6OTHER ]GTPgammaS binding protocols, BC6ENTC exerts antagonist actions at BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG sites, yet partial agonist actions at BC6OTHER sites.	CPR:6
In [ BC6OTHER ]GTPgammaS binding protocols, BC6ENTC exerts antagonist actions at BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER sites, yet partial agonist actions at BC6ENTG sites.	CPR:5
Herein, we evaluate the interaction of the BC6OTHER , BC6ENTC , as compared to BC6OTHER , at multiple BC6ENTG and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely - moving rats.	False
Herein, we evaluate the interaction of the BC6ENTG , BC6ENTC , as compared to BC6OTHER , at multiple BC6OTHER and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely - moving rats.	CPR:6
In vivo, agonist actions of BC6ENTC at BC6ENTG sites are revealed by BC6OTHER - reversible induction of hypothermia in the rat.	CPR:5
In vivo, agonist actions of BC6OTHER at BC6ENTG sites are revealed by BC6ENTC - reversible induction of hypothermia in the rat.	CPR:6
In guinea pigs, antagonist actions of BC6ENTC at BC6ENTG receptors are revealed by blockade of hypothermia evoked by the BC6OTHER agonist, BC6OTHER .	CPR:6
In guinea pigs, antagonist actions of BC6ENTC at BC6OTHER receptors are revealed by blockade of hypothermia evoked by the BC6ENTG agonist, BC6OTHER .	False
In guinea pigs, antagonist actions of BC6OTHER at BC6ENTC (1B) receptors are revealed by blockade of hypothermia evoked by the BC6ENTG agonist, BC6OTHER .	False
In guinea pigs, antagonist actions of BC6OTHER at BC6ENTG receptors are revealed by blockade of hypothermia evoked by the BC6ENTC (1B) agonist, BC6OTHER .	False
In guinea pigs, antagonist actions of BC6OTHER at BC6ENTG receptors are revealed by blockade of hypothermia evoked by the BC6OTHER agonist, BC6ENTC .	False
In guinea pigs, antagonist actions of BC6OTHER at BC6OTHER receptors are revealed by blockade of hypothermia evoked by the BC6ENTG agonist, BC6ENTC .	CPR:5
Herein, we evaluate the interaction of the BC6OTHER , BC6OTHER , as compared to BC6ENTC , at multiple BC6ENTG and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely - moving rats.	False
Herein, we evaluate the interaction of the BC6ENTG , BC6OTHER , as compared to BC6ENTC , at multiple BC6OTHER and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely - moving rats.	CPR:6
In distinction to BC6ENTC , BC6OTHER shows only modest partial agonist actions at BC6ENTG sites versus marked antagonist actions at BC6OTHER .	CPR:5
In distinction to BC6ENTC , BC6OTHER shows only modest partial agonist actions at BC6OTHER sites versus marked antagonist actions at BC6ENTG .	CPR:6
In distinction to BC6OTHER , BC6ENTC shows only modest partial agonist actions at BC6ENTG sites versus marked antagonist actions at BC6OTHER .	CPR:5
In distinction to BC6OTHER , BC6ENTC shows only modest partial agonist actions at BC6OTHER sites versus marked antagonist actions at BC6ENTG .	CPR:6
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6ENTG , BC6ENTC ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6OTHER .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6ENTC BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6ENTC ( BC6OTHER )(1A), BC6ENTG , BC6OTHER and BC6OTHER .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6ENTC ( BC6OTHER )(1A), BC6OTHER , BC6ENTG and BC6OTHER .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6ENTC ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6ENTG .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6ENTG BC6OTHER , BC6ENTC ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6OTHER .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6ENTG , BC6OTHER (CHEM), BC6OTHER , BC6OTHER and BC6OTHER .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER (CHEM), BC6ENTG , BC6OTHER and BC6OTHER .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER (CHEM), BC6OTHER , BC6ENTG and BC6OTHER .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER (CHEM), BC6OTHER , BC6OTHER and BC6ENTG .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6ENTG BC6OTHER , BC6OTHER (CHEM), BC6OTHER , BC6OTHER and BC6OTHER .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER )(1A), BC6ENTC (1B), BC6OTHER and BC6OTHER .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER BC6ENTG , BC6ENTC (1B), BC6OTHER and BC6OTHER .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6ENTC (1B), BC6ENTG and BC6OTHER .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6ENTC (1B), BC6OTHER and BC6ENTG .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6ENTC (1B), BC6OTHER and BC6OTHER .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6ENTC (1D) and BC6OTHER .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER BC6ENTG , BC6OTHER , BC6ENTC (1D) and BC6OTHER .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6ENTG , BC6ENTC (1D) and BC6OTHER .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6ENTC (1D) and BC6ENTG .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6ENTC (1D) and BC6OTHER .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6ENTC D(2) and D(3) receptors.	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER BC6ENTG , BC6OTHER , BC6OTHER and BC6ENTC D(2) and D(3) receptors.	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6ENTG , BC6OTHER and BC6ENTC D(2) and D(3) receptors.	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6ENTG and BC6ENTC D(2) and D(3) receptors.	False
Agonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6ENTC D(2) and D(3) receptors.	False
Agonist and antagonist actions of BC6ENTC as compared to BC6OTHER at BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6OTHER .	CPR:6
Agonist and antagonist actions of BC6ENTC as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER .	CPR:6
Agonist and antagonist actions of BC6ENTC as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6ENTG , BC6OTHER and BC6OTHER .	CPR:6
Agonist and antagonist actions of BC6ENTC as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6ENTG and BC6OTHER .	CPR:6
Agonist and antagonist actions of BC6ENTC as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6ENTG .	False
Agonist and antagonist actions of BC6ENTC as compared to BC6OTHER at BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6OTHER .	CPR:6
Agonist and antagonist actions of BC6OTHER as compared to BC6ENTC at BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6OTHER .	CPR:6
Agonist and antagonist actions of BC6OTHER as compared to BC6ENTC at BC6OTHER BC6OTHER , BC6OTHER BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6ENTC at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6ENTG , BC6OTHER and BC6OTHER .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6ENTC at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6ENTG and BC6OTHER .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6ENTC at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6ENTG .	False
Agonist and antagonist actions of BC6OTHER as compared to BC6ENTC at BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6OTHER .	CPR:6
In conclusion, these findings indicate that BC6ENTC is a new potent antagonist radioligand which recognizes with high affinity both BC6ENTG and BC6OTHER and represents thus an excellent tool to study BC6OTHER in the rat brain.	CPR:6
In conclusion, these findings indicate that BC6ENTC is a new potent antagonist radioligand which recognizes with high affinity both BC6OTHER and BC6ENTG and represents thus an excellent tool to study BC6OTHER in the rat brain.	CPR:6
In conclusion, these findings indicate that BC6ENTC is a new potent antagonist radioligand which recognizes with high affinity both BC6OTHER and BC6OTHER and represents thus an excellent tool to study BC6ENTG in the rat brain.	False
In conclusion, these findings indicate that BC6OTHER is a new potent antagonist radioligand which recognizes with high affinity both BC6ENTC NT1 and BC6ENTG and represents thus an excellent tool to study BC6OTHER in the rat brain.	False
In conclusion, these findings indicate that BC6OTHER is a new potent antagonist radioligand which recognizes with high affinity both BC6ENTC NT1 and BC6OTHER and represents thus an excellent tool to study BC6ENTG in the rat brain.	False
The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of BC6ENTG , BC6ENTC ( BC6OTHER ), in the rat brain.	CPR:6
In conclusion, these findings indicate that BC6OTHER is a new potent antagonist radioligand which recognizes with high affinity both BC6ENTG and BC6OTHER and represents thus an excellent tool to study BC6ENTC receptors in the rat brain.	False
In conclusion, these findings indicate that BC6OTHER is a new potent antagonist radioligand which recognizes with high affinity both BC6OTHER and BC6ENTG and represents thus an excellent tool to study BC6ENTC receptors in the rat brain.	False
The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of BC6ENTG , BC6OTHER ( BC6ENTC ), in the rat brain.	CPR:6
BC6ENTC binding was inhibited by BC6OTHER , the related nonpeptide receptor antagonist, BC6OTHER ( BC6OTHER ) and BC6ENTG .	False
BC6OTHER binding was inhibited by BC6ENTC , the related nonpeptide receptor antagonist, BC6OTHER ( BC6OTHER ) and BC6ENTG .	False
Saturation and competition studies in the presence or absence of the BC6ENTC H1 receptor antagonist, BC6OTHER , revealed that BC6OTHER bound with similar affinities to both the BC6OTHER - insensitive BC6ENTG (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6OTHER (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	False
Saturation and competition studies in the presence or absence of the BC6ENTC H1 receptor antagonist, BC6OTHER , revealed that BC6OTHER bound with similar affinities to both the BC6OTHER - insensitive BC6OTHER NT1 receptors (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6ENTG (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	False
BC6OTHER binding was inhibited by BC6OTHER , the related nonpeptide receptor antagonist, BC6ENTC ( BC6OTHER ) and BC6ENTG .	False
BC6OTHER binding was inhibited by BC6OTHER , the related nonpeptide receptor antagonist, BC6OTHER ( BC6ENTC ) and BC6ENTG .	False
Characterization of binding sites of a new BC6ENTG antagonist, BC6ENTC , in the rat brain.	CPR:6
Saturation and competition studies in the presence or absence of the BC6ENTG antagonist, BC6ENTC , revealed that BC6OTHER bound with similar affinities to both the BC6OTHER - insensitive BC6OTHER NT1 receptors (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6OTHER (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	CPR:6
Saturation and competition studies in the presence or absence of the BC6OTHER antagonist, BC6ENTC , revealed that BC6OTHER bound with similar affinities to both the BC6OTHER - insensitive BC6ENTG (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6OTHER (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	False
Saturation and competition studies in the presence or absence of the BC6OTHER antagonist, BC6ENTC , revealed that BC6OTHER bound with similar affinities to both the BC6OTHER - insensitive BC6OTHER NT1 receptors (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6ENTG (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	False
Saturation and competition studies in the presence or absence of the BC6ENTG antagonist, BC6OTHER , revealed that BC6ENTC bound with similar affinities to both the BC6OTHER - insensitive BC6OTHER NT1 receptors (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6OTHER (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	False
Saturation and competition studies in the presence or absence of the BC6OTHER antagonist, BC6OTHER , revealed that BC6ENTC bound with similar affinities to both the BC6OTHER - insensitive BC6ENTG (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6OTHER (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	False
Saturation and competition studies in the presence or absence of the BC6OTHER antagonist, BC6OTHER , revealed that BC6ENTC bound with similar affinities to both the BC6OTHER - insensitive BC6OTHER NT1 receptors (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6ENTG (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	False
Saturation and competition studies in the presence or absence of the BC6ENTG antagonist, BC6OTHER , revealed that BC6OTHER bound with similar affinities to both the BC6ENTC - insensitive BC6OTHER NT1 receptors (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6OTHER (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	False
Saturation and competition studies in the presence or absence of the BC6OTHER antagonist, BC6OTHER , revealed that BC6OTHER bound with similar affinities to both the BC6ENTC - insensitive BC6ENTG (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6OTHER (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	False
Saturation and competition studies in the presence or absence of the BC6OTHER antagonist, BC6OTHER , revealed that BC6OTHER bound with similar affinities to both the BC6ENTC - insensitive BC6OTHER NT1 receptors (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6ENTG (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	False
Saturation and competition studies in the presence or absence of the BC6ENTG antagonist, BC6OTHER , revealed that BC6OTHER bound with similar affinities to both the BC6OTHER - insensitive BC6ENTC NT1 receptors (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6OTHER (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	False
Saturation and competition studies in the presence or absence of the BC6OTHER antagonist, BC6OTHER , revealed that BC6OTHER bound with similar affinities to both the BC6OTHER - insensitive BC6ENTC NT1 receptors (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6ENTG (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	False
Saturation and competition studies in the presence or absence of the BC6ENTG antagonist, BC6OTHER , revealed that BC6OTHER bound with similar affinities to both the BC6OTHER - insensitive BC6OTHER NT1 receptors (20% of the total binding population) and the recently cloned BC6ENTC - sensitive BC6OTHER (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	False
Saturation and competition studies in the presence or absence of the BC6OTHER antagonist, BC6OTHER , revealed that BC6OTHER bound with similar affinities to both the BC6OTHER - insensitive BC6ENTG (20% of the total binding population) and the recently cloned BC6ENTC - sensitive BC6OTHER (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	False
Saturation and competition studies in the presence or absence of the BC6OTHER antagonist, BC6OTHER , revealed that BC6OTHER bound with similar affinities to both the BC6OTHER - insensitive BC6OTHER NT1 receptors (20% of the total binding population) and the recently cloned BC6ENTC - sensitive BC6ENTG (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	False
BC6ENTC caused a significant concentration - dependent increase in limb abnormalities, which was correlated with its BC6ENTG inhibitory effect.	CPR:4
The signaling of both BC6ENTG and BC6OTHER , key regulators of chondrogenesis, was downregulated by BC6ENTC .	CPR:4
The signaling of both BC6OTHER and BC6ENTG , key regulators of chondrogenesis, was downregulated by BC6ENTC .	CPR:4
In contrast, BC6ENTC had little effect on limb morphology and no significant effect on BC6ENTG activity or the expression of marker genes.	False
Disturbances in these signaling pathways are likely to be a consequence of BC6ENTG inhibition because BC6ENTC did not affect their expressions.	False
 BC6ENTC ( BC6OTHER ), the BC6OTHER derivative of BC6OTHER , does not inhibit BC6ENTG activity and is a weak teratogen in vivo. The detailed mechanism of action of BC6OTHER as a teratogen is not known.	False
 BC6OTHER ( BC6ENTC ), the BC6OTHER derivative of BC6OTHER , does not inhibit BC6ENTG activity and is a weak teratogen in vivo. The detailed mechanism of action of BC6OTHER as a teratogen is not known.	False
 BC6OTHER ( BC6OTHER ), the BC6ENTC derivative of BC6OTHER , does not inhibit BC6ENTG activity and is a weak teratogen in vivo. The detailed mechanism of action of BC6OTHER as a teratogen is not known.	False
 BC6OTHER ( BC6OTHER ), the BC6OTHER derivative of BC6ENTC , does not inhibit BC6ENTG activity and is a weak teratogen in vivo. The detailed mechanism of action of BC6OTHER as a teratogen is not known.	False
In utero exposure to BC6ENTC ( BC6OTHER ), a BC6ENTG ( BC6OTHER ) inhibitor, causes neural tube, heart, and limb defects.	CPR:4
In utero exposure to BC6ENTC ( BC6OTHER ), a BC6OTHER ( BC6ENTG ) inhibitor, causes neural tube, heart, and limb defects.	CPR:4
 BC6OTHER ( BC6OTHER ), the BC6OTHER derivative of BC6OTHER , does not inhibit BC6ENTG activity and is a weak teratogen in vivo. The detailed mechanism of action of BC6ENTC as a teratogen is not known.	False
In utero exposure to BC6OTHER ( BC6ENTC ), a BC6ENTG ( BC6OTHER ) inhibitor, causes neural tube, heart, and limb defects.	CPR:4
In utero exposure to BC6OTHER ( BC6ENTC ), a BC6OTHER ( BC6ENTG ) inhibitor, causes neural tube, heart, and limb defects.	CPR:4
Mechanistically, BC6ENTG is recruited to DSBs via the BC6ENTC - terminal BC6OTHER - SQ / TQ domain of BC6OTHER , and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of BC6OTHER .	False
Mechanistically, BC6OTHER is recruited to DSBs via the BC6ENTC - terminal BC6OTHER - SQ / TQ domain of BC6ENTG , and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of BC6OTHER .	False
Mechanistically, BC6OTHER is recruited to DSBs via the BC6ENTC - terminal BC6OTHER - SQ / TQ domain of BC6OTHER , and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of BC6ENTG .	False
Mechanistically, BC6ENTG is recruited to DSBs via the BC6OTHER - terminal BC6ENTC - SQ / TQ domain of BC6OTHER , and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of BC6OTHER .	False
Mechanistically, BC6OTHER is recruited to DSBs via the BC6OTHER - terminal BC6ENTC - SQ / TQ domain of BC6ENTG , and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of BC6OTHER .	False
Mechanistically, BC6OTHER is recruited to DSBs via the BC6OTHER - terminal BC6ENTC - SQ / TQ domain of BC6OTHER , and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of BC6ENTG .	False
BC6ENTG ( BC6OTHER ) in the liver catalyzes most of the BC6ENTC transamination in mammalian tissues (E. V. Rowsell, K. Snell, J.	CPR:9
BC6OTHER : BC6OTHER aminotransferase ( BC6ENTG ) in the liver catalyzes most of the BC6ENTC transamination in mammalian tissues (E. V. Rowsell, K. Snell, J.	CPR:9
The effects of BC6ENTC deficiency on hepatic BC6ENTG isoenzymes, designated BC6OTHER and BC6OTHER , respectively, were examined with male rats; BC6OTHER is located both in the peroxisomes and in the mitochondria, and BC6OTHER only in the mitochondria.	False
The effects of BC6ENTC deficiency on hepatic BC6OTHER isoenzymes, designated BC6ENTG and BC6OTHER , respectively, were examined with male rats; BC6OTHER is located both in the peroxisomes and in the mitochondria, and BC6OTHER only in the mitochondria.	False
The effects of BC6ENTC deficiency on hepatic BC6OTHER isoenzymes, designated BC6OTHER and BC6ENTG , respectively, were examined with male rats; BC6OTHER is located both in the peroxisomes and in the mitochondria, and BC6OTHER only in the mitochondria.	False
The effects of BC6ENTC deficiency on hepatic BC6OTHER isoenzymes, designated BC6OTHER and BC6OTHER , respectively, were examined with male rats; BC6ENTG is located both in the peroxisomes and in the mitochondria, and BC6OTHER only in the mitochondria.	False
The effects of BC6ENTC deficiency on hepatic BC6OTHER isoenzymes, designated BC6OTHER and BC6OTHER , respectively, were examined with male rats; BC6OTHER is located both in the peroxisomes and in the mitochondria, and BC6ENTG only in the mitochondria.	False
The holo activity of combined peroxisomal and mitochondrial BC6ENTG with a low Km for BC6ENTC rapidly decreased after a lag time of about 2 days during feeding of the BC6OTHER - deficient diet (by 50% in 5 days, by 86% in 14 days).	CPR:9
The holo activity of combined peroxisomal and mitochondrial BC6ENTG with a low Km for BC6OTHER rapidly decreased after a lag time of about 2 days during feeding of the BC6ENTC - deficient diet (by 50% in 5 days, by 86% in 14 days).	False
The holo activity of BC6OTHER with a high Km for BC6ENTC decreased more slowly than BC6ENTG (by 33% in 14 days, by 60% in 28 days).	CPR:9
The holo activity of BC6ENTG with a high Km for BC6ENTC decreased more slowly than BC6OTHER (by 33% in 14 days, by 60% in 28 days).	CPR:9
The effect of BC6ENTC deficiency on BC6ENTG isoenzymes in rat liver.	False
Urinary excretion of BC6ENTC began to increase in 8 - 9 days, when BC6ENTG remained intact but most of BC6OTHER is depleted.	False
Urinary excretion of BC6ENTC began to increase in 8 - 9 days, when BC6OTHER remained intact but most of BC6ENTG is depleted.	False
When the defect in the BC6ENTC transamination in vivo in BC6OTHER deficiency is considered, these findings suggest that it is due to the deficiency of BC6ENTG .	False
When the defect in the BC6OTHER transamination in vivo in BC6ENTC deficiency is considered, these findings suggest that it is due to the deficiency of BC6ENTG .	False
The importance of peroxisomal BC6ENTG is discussed, since peroxisomes have been described to be probably the major site of BC6ENTC formation.	False
BC6ENTC : BC6OTHER aminotransferase ( BC6ENTG ) in the liver catalyzes most of the BC6OTHER transamination in mammalian tissues (E. V. Rowsell, K. Snell, J.	False
BC6OTHER : BC6ENTC aminotransferase ( BC6ENTG ) in the liver catalyzes most of the BC6OTHER transamination in mammalian tissues (E. V. Rowsell, K. Snell, J.	False
BC6ENTC eliminated all Leydig cells in the control testis on day 4 post - BC6OTHER , as judged by undetectable serum BC6OTHER level and no BC6ENTG positive ( BC6OTHER (pos)) cells in the interstitium.	False
BC6ENTC eliminated all Leydig cells in the control testis on day 4 post - BC6OTHER , as judged by undetectable serum BC6OTHER level and no BC6OTHER positive ( BC6ENTG (pos)) cells in the interstitium.	False
BC6OTHER eliminated all Leydig cells in the control testis on day 4 post - BC6ENTC , as judged by undetectable serum BC6OTHER level and no BC6ENTG positive ( BC6OTHER (pos)) cells in the interstitium.	False
BC6OTHER eliminated all Leydig cells in the control testis on day 4 post - BC6ENTC , as judged by undetectable serum BC6OTHER level and no BC6OTHER positive ( BC6ENTG (pos)) cells in the interstitium.	False
BC6OTHER eliminated all Leydig cells in the control testis on day 4 post - BC6OTHER , as judged by undetectable serum BC6ENTC level and no BC6ENTG positive ( BC6OTHER (pos)) cells in the interstitium.	False
BC6OTHER eliminated all Leydig cells in the control testis on day 4 post - BC6OTHER , as judged by undetectable serum BC6ENTC level and no BC6OTHER positive ( BC6ENTG (pos)) cells in the interstitium.	False
BC6OTHER eliminated all Leydig cells in the control testis on day 4 post - BC6OTHER , as judged by undetectable serum BC6OTHER level and no BC6ENTC dehydrogenase positive ( BC6ENTG (pos)) cells in the interstitium.	False
However, in BC6ENTC - treated groups, there were detectable serum BC6OTHER concentrations and some oval - shaped BC6ENTG (pos) cells in the interstitium.	False
However, in BC6OTHER - treated groups, there were detectable serum BC6ENTC concentrations and some oval - shaped BC6ENTG (pos) cells in the interstitium.	False
These BC6OTHER (pos) cells were not stained by the antibody against BC6ENTC dehydrogenase 1 ( BC6ENTG 1), a marker for Leydig cells at a more advanced stage.	False
These BC6ENTG (pos) cells were not stained by the antibody against BC6ENTC dehydrogenase 1 ( BC6OTHER 1), a marker for Leydig cells at a more advanced stage.	False
However, there were detectable concentrations of BC6ENTG , BC6OTHER and BC6OTHER mRNAs but undetectable concentrations of BC6OTHER , BC6OTHER and BC6OTHER in the BC6ENTC - treated testes, indicating that these BC6OTHER (pos) cells were newly formed progenitor Leydig cells.	False
However, there were detectable concentrations of BC6OTHER , BC6ENTG and BC6OTHER mRNAs but undetectable concentrations of BC6OTHER , BC6OTHER and BC6OTHER in the BC6ENTC - treated testes, indicating that these BC6OTHER (pos) cells were newly formed progenitor Leydig cells.	False
However, there were detectable concentrations of BC6OTHER , BC6OTHER and BC6ENTG mRNAs but undetectable concentrations of BC6OTHER , BC6OTHER and BC6OTHER in the BC6ENTC - treated testes, indicating that these BC6OTHER (pos) cells were newly formed progenitor Leydig cells.	False
However, there were detectable concentrations of BC6OTHER , BC6OTHER and BC6OTHER mRNAs but undetectable concentrations of BC6ENTG , BC6OTHER and BC6OTHER in the BC6ENTC - treated testes, indicating that these BC6OTHER (pos) cells were newly formed progenitor Leydig cells.	False
However, there were detectable concentrations of BC6OTHER , BC6OTHER and BC6OTHER mRNAs but undetectable concentrations of BC6OTHER , BC6ENTG and BC6OTHER in the BC6ENTC - treated testes, indicating that these BC6OTHER (pos) cells were newly formed progenitor Leydig cells.	False
However, there were detectable concentrations of BC6OTHER , BC6OTHER and BC6OTHER mRNAs but undetectable concentrations of BC6OTHER , BC6OTHER and BC6ENTG in the BC6ENTC - treated testes, indicating that these BC6OTHER (pos) cells were newly formed progenitor Leydig cells.	False
However, there were detectable concentrations of BC6OTHER , BC6OTHER and BC6OTHER mRNAs but undetectable concentrations of BC6OTHER , BC6OTHER and BC6OTHER in the BC6ENTC - treated testes, indicating that these BC6ENTG (pos) cells were newly formed progenitor Leydig cells.	False
The mRNA level for BC6ENTG ( BC6OTHER , biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post - BC6ENTC , but not in the BC6OTHER treated testes, suggesting that these BC6OTHER positive stem cells were differentiated into progenitor Leydig cells in the BC6OTHER - treated testes.	CPR:3
The mRNA level for BC6OTHER ( BC6ENTG , biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post - BC6ENTC , but not in the BC6OTHER treated testes, suggesting that these BC6OTHER positive stem cells were differentiated into progenitor Leydig cells in the BC6OTHER - treated testes.	CPR:3
The mRNA level for BC6OTHER ( BC6OTHER , biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post - BC6ENTC , but not in the BC6OTHER treated testes, suggesting that these BC6ENTG positive stem cells were differentiated into progenitor Leydig cells in the BC6OTHER - treated testes.	False
The mRNA level for BC6ENTG ( BC6OTHER , biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post - BC6OTHER , but not in the BC6ENTC treated testes, suggesting that these BC6OTHER positive stem cells were differentiated into progenitor Leydig cells in the BC6OTHER - treated testes.	False
The mRNA level for BC6OTHER ( BC6ENTG , biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post - BC6OTHER , but not in the BC6ENTC treated testes, suggesting that these BC6OTHER positive stem cells were differentiated into progenitor Leydig cells in the BC6OTHER - treated testes.	False
The mRNA level for BC6OTHER ( BC6OTHER , biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post - BC6OTHER , but not in the BC6ENTC treated testes, suggesting that these BC6ENTG positive stem cells were differentiated into progenitor Leydig cells in the BC6OTHER - treated testes.	False
The mRNA level for BC6ENTG ( BC6OTHER , biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post - BC6OTHER , but not in the BC6OTHER treated testes, suggesting that these BC6OTHER positive stem cells were differentiated into progenitor Leydig cells in the BC6ENTC - treated testes.	False
The mRNA level for BC6OTHER ( BC6ENTG , biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post - BC6OTHER , but not in the BC6OTHER treated testes, suggesting that these BC6OTHER positive stem cells were differentiated into progenitor Leydig cells in the BC6ENTC - treated testes.	False
The mRNA level for BC6OTHER ( BC6OTHER , biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post - BC6OTHER , but not in the BC6OTHER treated testes, suggesting that these BC6ENTG positive stem cells were differentiated into progenitor Leydig cells in the BC6ENTC - treated testes.	False
In this small library of novel bioactive macrocyclic BC6ENTC derivatives, designed to evaluate structure - activity relationships essential in overcoming multidrug resistance (MDR), some correlations between MDR reversal and molecular weight, accessible solvent areas, and BC6OTHER / water partition coefficient were identified that can contribute to the development of new selective BC6ENTG reversal agents.	False
In this small library of novel bioactive macrocyclic BC6OTHER derivatives, designed to evaluate structure - activity relationships essential in overcoming multidrug resistance (MDR), some correlations between MDR reversal and molecular weight, accessible solvent areas, and BC6ENTC / water partition coefficient were identified that can contribute to the development of new selective BC6ENTG reversal agents.	False
BC6ENTC - independent BC6OTHER [ BC6ENTG ; BC6OTHER D - isomerase, BC6OTHER ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system.	False
BC6ENTC - independent BC6OTHER [ BC6OTHER D - isomerase; BC6ENTG , BC6OTHER ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system.	False
BC6ENTC - independent BC6OTHER [ BC6OTHER D - isomerase; BC6OTHER D - isomerase, BC6ENTG ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system.	False
BC6ENTC - independent BC6ENTG [ BC6OTHER D - isomerase; BC6OTHER D - isomerase, BC6OTHER ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system.	False
BC6OTHER - independent BC6OTHER [ BC6ENTG ; BC6OTHER D - isomerase, BC6OTHER ] is an enzyme responsible for biosynthesis of BC6ENTC in the central nervous system.	CPR:9
BC6OTHER - independent BC6OTHER [ BC6OTHER D - isomerase; BC6ENTG , BC6OTHER ] is an enzyme responsible for biosynthesis of BC6ENTC in the central nervous system.	CPR:9
BC6OTHER - independent BC6OTHER [ BC6OTHER D - isomerase; BC6OTHER D - isomerase, BC6ENTG ] is an enzyme responsible for biosynthesis of BC6ENTC in the central nervous system.	CPR:9
BC6OTHER - independent BC6ENTG [ BC6OTHER D - isomerase; BC6OTHER D - isomerase, BC6OTHER ] is an enzyme responsible for biosynthesis of BC6ENTC in the central nervous system.	CPR:9
BC6OTHER - independent BC6ENTC synthase [ BC6ENTG ; BC6OTHER D - isomerase, BC6OTHER ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system.	False
BC6OTHER - independent BC6ENTC synthase [ BC6OTHER D - isomerase; BC6ENTG , BC6OTHER ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system.	False
BC6OTHER - independent BC6ENTC synthase [ BC6OTHER D - isomerase; BC6OTHER D - isomerase, BC6ENTG ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system.	False
BC6OTHER - independent BC6OTHER [ BC6ENTC D - isomerase; BC6ENTG , BC6OTHER ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system.	False
BC6OTHER - independent BC6OTHER [ BC6ENTC D - isomerase; BC6OTHER D - isomerase, BC6ENTG ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system.	False
BC6OTHER - independent BC6ENTG [ BC6ENTC D - isomerase; BC6OTHER D - isomerase, BC6OTHER ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system.	False
BC6OTHER - independent BC6OTHER [ BC6ENTG ; BC6ENTC D - isomerase, BC6OTHER ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system.	False
BC6OTHER - independent BC6OTHER [ BC6OTHER D - isomerase; BC6ENTC D - isomerase, BC6ENTG ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system.	False
BC6OTHER - independent BC6ENTG [ BC6OTHER D - isomerase; BC6ENTC D - isomerase, BC6OTHER ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system.	False
Following BC6OTHER treatment, BC6ENTG was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6OTHER by 6 - 16 h. Interestingly, there was a loss in the binding of BC6OTHER to BC6OTHER during BC6ENTC - induced germ cell loss, suggesting that a loss of BC6OTHER - BC6OTHER interactions might have facilitated junction restructuring.	False
Following BC6OTHER treatment, BC6OTHER was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6ENTG by 6 - 16 h. Interestingly, there was a loss in the binding of BC6OTHER to BC6OTHER during BC6ENTC - induced germ cell loss, suggesting that a loss of BC6OTHER - BC6OTHER interactions might have facilitated junction restructuring.	False
Following BC6OTHER treatment, BC6OTHER was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6OTHER by 6 - 16 h. Interestingly, there was a loss in the binding of BC6ENTG to BC6OTHER during BC6ENTC - induced germ cell loss, suggesting that a loss of BC6OTHER - BC6OTHER interactions might have facilitated junction restructuring.	False
Following BC6OTHER treatment, BC6OTHER was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6OTHER by 6 - 16 h. Interestingly, there was a loss in the binding of BC6OTHER to BC6ENTG during BC6ENTC - induced germ cell loss, suggesting that a loss of BC6OTHER - BC6OTHER interactions might have facilitated junction restructuring.	CPR:4
Following BC6OTHER treatment, BC6OTHER was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6OTHER by 6 - 16 h. Interestingly, there was a loss in the binding of BC6OTHER to BC6OTHER during BC6ENTC - induced germ cell loss, suggesting that a loss of BC6ENTG - BC6OTHER interactions might have facilitated junction restructuring.	False
Following BC6OTHER treatment, BC6OTHER was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6OTHER by 6 - 16 h. Interestingly, there was a loss in the binding of BC6OTHER to BC6OTHER during BC6ENTC - induced germ cell loss, suggesting that a loss of BC6OTHER - BC6ENTG interactions might have facilitated junction restructuring.	False
Interestingly, BC6ENTG was found to associate with BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM - rich BC6ENTC kinase 2, BC6OTHER , and BC6OTHER .	False
Interestingly, BC6OTHER was found to associate with BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , CHEM - rich BC6ENTC kinase 2, BC6OTHER , and BC6OTHER .	False
Interestingly, BC6OTHER was found to associate with BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , CHEM - rich BC6ENTC kinase 2, BC6OTHER , and BC6OTHER .	False
Interestingly, BC6OTHER was found to associate with BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , CHEM - rich BC6ENTC kinase 2, BC6OTHER , and BC6OTHER .	False
Interestingly, BC6OTHER was found to associate with BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , CHEM - rich BC6ENTC kinase 2, BC6OTHER , and BC6OTHER .	False
Interestingly, BC6OTHER was found to associate with BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM - rich BC6ENTC kinase 2, BC6ENTG , and BC6OTHER .	False
Interestingly, BC6OTHER was found to associate with BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM - rich BC6ENTC kinase 2, BC6OTHER , and BC6ENTG .	False
Following BC6ENTC treatment, BC6ENTG was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6OTHER by 6 - 16 h. Interestingly, there was a loss in the binding of BC6OTHER to BC6OTHER during BC6OTHER - induced germ cell loss, suggesting that a loss of BC6OTHER - BC6OTHER interactions might have facilitated junction restructuring.	CPR:3
Following BC6ENTC treatment, BC6OTHER was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6ENTG by 6 - 16 h. Interestingly, there was a loss in the binding of BC6OTHER to BC6OTHER during BC6OTHER - induced germ cell loss, suggesting that a loss of BC6OTHER - BC6OTHER interactions might have facilitated junction restructuring.	False
Following BC6ENTC treatment, BC6OTHER was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6OTHER by 6 - 16 h. Interestingly, there was a loss in the binding of BC6ENTG to BC6OTHER during BC6OTHER - induced germ cell loss, suggesting that a loss of BC6OTHER - BC6OTHER interactions might have facilitated junction restructuring.	False
Following BC6ENTC treatment, BC6OTHER was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6OTHER by 6 - 16 h. Interestingly, there was a loss in the binding of BC6OTHER to BC6ENTG during BC6OTHER - induced germ cell loss, suggesting that a loss of BC6OTHER - BC6OTHER interactions might have facilitated junction restructuring.	False
Following BC6ENTC treatment, BC6OTHER was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6OTHER by 6 - 16 h. Interestingly, there was a loss in the binding of BC6OTHER to BC6OTHER during BC6OTHER - induced germ cell loss, suggesting that a loss of BC6ENTG - BC6OTHER interactions might have facilitated junction restructuring.	False
Following BC6ENTC treatment, BC6OTHER was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6OTHER by 6 - 16 h. Interestingly, there was a loss in the binding of BC6OTHER to BC6OTHER during BC6OTHER - induced germ cell loss, suggesting that a loss of BC6OTHER - BC6ENTG interactions might have facilitated junction restructuring.	False
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6ENTC and its metabolite BC6OTHER ( BC6OTHER ), erythrocyte BC6ENTG activity, CSF BC6OTHER activity, and plasma and CSF BC6OTHER ( BC6OTHER ) activity.	False
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6ENTC and its metabolite BC6OTHER ( BC6OTHER ), erythrocyte BC6OTHER activity, CSF BC6ENTG activity, and plasma and CSF BC6OTHER ( BC6OTHER ) activity.	False
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6ENTC and its metabolite BC6OTHER ( BC6OTHER ), erythrocyte BC6OTHER activity, CSF BC6OTHER activity, and plasma and CSF BC6ENTG ( BC6OTHER ) activity.	False
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6ENTC and its metabolite BC6OTHER ( BC6OTHER ), erythrocyte BC6OTHER activity, CSF BC6OTHER activity, and plasma and CSF BC6OTHER ( BC6ENTG ) activity.	False
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6OTHER and its metabolite BC6ENTC ( BC6OTHER ), erythrocyte BC6ENTG activity, CSF BC6OTHER activity, and plasma and CSF BC6OTHER ( BC6OTHER ) activity.	False
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6OTHER and its metabolite BC6ENTC ( BC6OTHER ), erythrocyte BC6OTHER activity, CSF BC6ENTG activity, and plasma and CSF BC6OTHER ( BC6OTHER ) activity.	False
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6OTHER and its metabolite BC6ENTC ( BC6OTHER ), erythrocyte BC6OTHER activity, CSF BC6OTHER activity, and plasma and CSF BC6ENTG ( BC6OTHER ) activity.	False
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6OTHER and its metabolite BC6ENTC ( BC6OTHER ), erythrocyte BC6OTHER activity, CSF BC6OTHER activity, and plasma and CSF BC6OTHER ( BC6ENTG ) activity.	False
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6OTHER and its metabolite BC6OTHER ( BC6ENTC ), erythrocyte BC6ENTG activity, CSF BC6OTHER activity, and plasma and CSF BC6OTHER ( BC6OTHER ) activity.	False
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6OTHER and its metabolite BC6OTHER ( BC6ENTC ), erythrocyte BC6OTHER activity, CSF BC6ENTG activity, and plasma and CSF BC6OTHER ( BC6OTHER ) activity.	False
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6OTHER and its metabolite BC6OTHER ( BC6ENTC ), erythrocyte BC6OTHER activity, CSF BC6OTHER activity, and plasma and CSF BC6ENTG ( BC6OTHER ) activity.	False
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6OTHER and its metabolite BC6OTHER ( BC6ENTC ), erythrocyte BC6OTHER activity, CSF BC6OTHER activity, and plasma and CSF BC6OTHER ( BC6ENTG ) activity.	False
Preferential cerebrospinal fluid BC6ENTG inhibition by BC6ENTC in humans.	CPR:4
Inhibition of BC6ENTG in the CSF after BC6ENTC administration was significantly greater than after placebo for up to 8.4 hours after the dose and was maximal (40%) at 2.4 hours.	CPR:4
Plasma BC6ENTG activity was significantly lower after BC6ENTC than after placebo, but this was not clinically relevant.	CPR:4
This study sought to examine the feasibility of prolonged assessment of BC6OTHER ( BC6OTHER ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that BC6ENTC ( BC6OTHER ; BC6OTHER , Novartis Pharma AG, Basel, Switzerland) selectively inhibits BC6ENTG in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.	False
This study sought to examine the feasibility of prolonged assessment of BC6ENTG ( BC6OTHER ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that BC6ENTC ( BC6OTHER ; BC6OTHER , Novartis Pharma AG, Basel, Switzerland) selectively inhibits BC6OTHER in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.	False
This study sought to examine the feasibility of prolonged assessment of BC6OTHER ( BC6ENTG ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that BC6ENTC ( BC6OTHER ; BC6OTHER , Novartis Pharma AG, Basel, Switzerland) selectively inhibits BC6OTHER in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.	False
BC6ENTG activity in CSF was significantly lower after BC6ENTC than after placebo for up to 3.6 hours after dosing, but this difference was not sustained.	CPR:4
This study sought to examine the feasibility of prolonged assessment of BC6OTHER ( BC6OTHER ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that BC6OTHER ( BC6ENTC ; BC6OTHER , Novartis Pharma AG, Basel, Switzerland) selectively inhibits BC6ENTG in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.	False
This study sought to examine the feasibility of prolonged assessment of BC6ENTG ( BC6OTHER ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that BC6OTHER ( BC6ENTC ; BC6OTHER , Novartis Pharma AG, Basel, Switzerland) selectively inhibits BC6OTHER in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.	False
This study sought to examine the feasibility of prolonged assessment of BC6OTHER ( BC6ENTG ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that BC6OTHER ( BC6ENTC ; BC6OTHER , Novartis Pharma AG, Basel, Switzerland) selectively inhibits BC6OTHER in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.	False
This study sought to examine the feasibility of prolonged assessment of BC6OTHER ( BC6OTHER ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that BC6OTHER ( BC6OTHER ; BC6ENTC , Novartis Pharma AG, Basel, Switzerland) selectively inhibits BC6ENTG in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.	False
This study sought to examine the feasibility of prolonged assessment of BC6ENTG ( BC6OTHER ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that BC6OTHER ( BC6OTHER ; BC6ENTC , Novartis Pharma AG, Basel, Switzerland) selectively inhibits BC6OTHER in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.	False
This study sought to examine the feasibility of prolonged assessment of BC6OTHER ( BC6ENTG ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that BC6OTHER ( BC6OTHER ; BC6ENTC , Novartis Pharma AG, Basel, Switzerland) selectively inhibits BC6OTHER in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.	False
This study confirms the feasibility of using continuous measurement of BC6ENTG activity in CSF over prolonged periods, that BC6ENTC markedly inhibits CSF BC6OTHER after a single oral dose of 3 mg, and that the inhibition of central BC6OTHER is substantially greater than that of peripheral BC6OTHER or BC6OTHER .	False
This study confirms the feasibility of using continuous measurement of BC6OTHER activity in CSF over prolonged periods, that BC6ENTC markedly inhibits CSF BC6ENTG after a single oral dose of 3 mg, and that the inhibition of central BC6OTHER is substantially greater than that of peripheral BC6OTHER or BC6OTHER .	CPR:4
This study confirms the feasibility of using continuous measurement of BC6OTHER activity in CSF over prolonged periods, that BC6ENTC markedly inhibits CSF BC6OTHER after a single oral dose of 3 mg, and that the inhibition of central BC6ENTG is substantially greater than that of peripheral BC6OTHER or BC6OTHER .	CPR:4
This study confirms the feasibility of using continuous measurement of BC6OTHER activity in CSF over prolonged periods, that BC6ENTC markedly inhibits CSF BC6OTHER after a single oral dose of 3 mg, and that the inhibition of central BC6OTHER is substantially greater than that of peripheral BC6ENTG or BC6OTHER .	CPR:4
This study confirms the feasibility of using continuous measurement of BC6OTHER activity in CSF over prolonged periods, that BC6ENTC markedly inhibits CSF BC6OTHER after a single oral dose of 3 mg, and that the inhibition of central BC6OTHER is substantially greater than that of peripheral BC6OTHER or BC6ENTG .	CPR:4
BC6ENTC decreased the peak amplitude of hippocampal area CA1 BC6ENTG - mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 + / - 0.8 microM) with no apparent effect on response kinetics.	CPR:4
BC6ENTC prolonged the decay time constant of BC6ENTG - mediated e.p.s.cs (EC50 35.7 + / - 6.5 microM) with less pronounced effects in slowing e.p.s.c.	CPR:4
BC6ENTC (330 microM) shifted the concentration - response curve for the effects of BC6OTHER on BC6ENTG - mediated e.p.s.c.	False
BC6OTHER (330 microM) shifted the concentration - response curve for the effects of BC6ENTC on BC6ENTG - mediated e.p.s.c.	False
Likewise, BC6ENTC (30 - 100 microM)) shifted the concentration - response curve for the effects of BC6OTHER on BC6ENTG - mediated e.p.s.c.	False
Likewise, BC6OTHER (30 - 100 microM)) shifted the concentration - response curve for the effects of BC6ENTC on BC6ENTG - mediated e.p.s.c.	False
In conclusion, BC6ENTC and the BC6OTHER seem to bind to different sites on BC6ENTG but exert strong allosteric interactions with one another and with other domains such as the agonist recognition site.	False
In conclusion, BC6OTHER and the BC6ENTC seem to bind to different sites on BC6ENTG but exert strong allosteric interactions with one another and with other domains such as the agonist recognition site.	False
The interactions of BC6ENTC and BC6OTHER on BC6ENTG - mediated e.p.s.cs in area CA1 of hippocampal slices provide evidence that the decay time constant of these synaptic events are not governed by desensitization.	False
The interactions of BC6OTHER and BC6ENTC on BC6ENTG - mediated e.p.s.cs in area CA1 of hippocampal slices provide evidence that the decay time constant of these synaptic events are not governed by desensitization.	False
Interactions of BC6ENTC and BC6OTHER at BC6ENTG : patch clamp recordings in cultured neurones and area CA1 in hippocampal slices.	False
Interactions of BC6OTHER and BC6ENTC at BC6ENTG : patch clamp recordings in cultured neurones and area CA1 in hippocampal slices.	False
 BC6ENTC : a novel anti - Parkinsonian BC6ENTG inhibitor with neuroprotective activity.	CPR:4
BC6ENTC ( BC6OTHER ) is a novel, highly potent irreversible BC6ENTG inhibitor, anti - Parkinsonian drug.	CPR:4
BC6OTHER ( BC6ENTC ) is a novel, highly potent irreversible BC6ENTG inhibitor, anti - Parkinsonian drug.	CPR:4
Its S - isomer, BC6ENTC is thousand times less potent as an BC6ENTG inhibitor.	CPR:4
However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of BC6ENTC does not depend on inhibition of BC6ENTG , but rather is associated with the BC6OTHER moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating BC6OTHER family proteins.	CPR:4
However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of BC6ENTC does not depend on inhibition of BC6OTHER , but rather is associated with the BC6OTHER moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating BC6ENTG family proteins.	False
However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of BC6OTHER does not depend on inhibition of BC6ENTG , but rather is associated with the BC6ENTC moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating BC6OTHER family proteins.	False
However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of BC6OTHER does not depend on inhibition of BC6OTHER , but rather is associated with the BC6ENTC moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating BC6ENTG family proteins.	CPR:3
The most potent compound 5 ( BC6ENTC ) has demonstrated to inhibit BC6ENTG activity, downregulate phosphorylation of BC6OTHER , increase the expression of cleaved BC6OTHER , inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values.	CPR:4
The most potent compound 5 ( BC6ENTC ) has demonstrated to inhibit BC6OTHER activity, downregulate phosphorylation of BC6ENTG , increase the expression of cleaved BC6OTHER , inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values.	CPR:4
The most potent compound 5 ( BC6ENTC ) has demonstrated to inhibit BC6OTHER activity, downregulate phosphorylation of BC6OTHER , increase the expression of cleaved BC6ENTG , inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values.	CPR:3
Furthermore, compound 5 significantly suppressed BC6ENTC receptor ( BC6ENTG ) - negative breast cancer CHEM - MB - 231 xenograft tumor growth in vivo (p.o.	False
Fragment - based drug design and identification of BC6ENTC , a novel orally bioavailable BC6ENTG inhibitor for cancer therapy.	CPR:4
Urinary BC6OTHER , fasting plasma BC6ENTC (FPG), fasting serum BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER , and other chemistry laboratory parameters of T2DM participants and controls were measured.	False
Urinary BC6OTHER , fasting plasma BC6ENTC (FPG), fasting serum BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG , and other chemistry laboratory parameters of T2DM participants and controls were measured.	False
Urinary BC6ENTG , fasting plasma BC6ENTC (FPG), fasting serum BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER , and other chemistry laboratory parameters of T2DM participants and controls were measured.	False
Urinary BC6OTHER , fasting plasma BC6ENTC (FPG), fasting serum BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER , and other chemistry laboratory parameters of T2DM participants and controls were measured.	False
Urinary BC6OTHER , fasting plasma BC6ENTC (FPG), fasting serum BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER , and other chemistry laboratory parameters of T2DM participants and controls were measured.	False
Urinary BC6OTHER , fasting plasma BC6ENTC (FPG), fasting serum BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER , and other chemistry laboratory parameters of T2DM participants and controls were measured.	False
Although genetic polymorphisms in the endothelial BC6ENTC synthase ( BC6ENTG ) gene may impair endogenous BC6OTHER formation, there is little information about how BC6OTHER polymorphisms and haplotypes affect the responses to BC6OTHER .	False
Although genetic polymorphisms in the endothelial BC6ENTC synthase ( BC6OTHER ) gene may impair endogenous BC6OTHER formation, there is little information about how BC6ENTG polymorphisms and haplotypes affect the responses to BC6OTHER .	False
Our findings show evidence that BC6ENTG polymorphisms affect the responses of PED and clinical ED patients to BC6ENTC .	False
Although genetic polymorphisms in the endothelial BC6OTHER synthase ( BC6ENTG ) gene may impair endogenous BC6ENTC formation, there is little information about how BC6OTHER polymorphisms and haplotypes affect the responses to BC6OTHER .	CPR:9
Although genetic polymorphisms in the endothelial BC6OTHER synthase ( BC6OTHER ) gene may impair endogenous BC6ENTC formation, there is little information about how BC6ENTG polymorphisms and haplotypes affect the responses to BC6OTHER .	False
Although genetic polymorphisms in the BC6ENTG ( BC6OTHER ) gene may impair endogenous BC6ENTC formation, there is little information about how BC6OTHER polymorphisms and haplotypes affect the responses to BC6OTHER .	CPR:9
Although genetic polymorphisms in the endothelial BC6OTHER synthase ( BC6ENTG ) gene may impair endogenous BC6OTHER formation, there is little information about how BC6OTHER polymorphisms and haplotypes affect the responses to BC6ENTC .	False
Although genetic polymorphisms in the endothelial BC6OTHER synthase ( BC6OTHER ) gene may impair endogenous BC6OTHER formation, there is little information about how BC6ENTG polymorphisms and haplotypes affect the responses to BC6ENTC .	False
Although genetic polymorphisms in the BC6ENTG ( BC6OTHER ) gene may impair endogenous BC6OTHER formation, there is little information about how BC6OTHER polymorphisms and haplotypes affect the responses to BC6ENTC .	False
 BC6ENTG genotypes and haplotypes modify the responses to BC6ENTC in patients with erectile dysfunction.	False
 Variation in their effectiveness as positive reinforcers was not a function of differences in effectiveness as BC6ENTC uptake blockers, but may be related to relative potency over the concentrations that are achieved in vivo. Effects at BC6ENTG may limit the reinforcing effects of local anesthetics.	False
OBJECTIVES: The hypothesis of the present study was that differences among BC6ENTC transporter ( BC6ENTG ) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as BC6OTHER uptake inhibitors.	False
OBJECTIVES: The hypothesis of the present study was that differences among BC6ENTG ( BC6OTHER ) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as BC6ENTC uptake inhibitors.	CPR:9
OBJECTIVES: The hypothesis of the present study was that differences among BC6OTHER ( BC6ENTG ) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as BC6ENTC uptake inhibitors.	CPR:9
Accordingly, self - administration of a group of local anesthetics that are BC6ENTG ligands was compared to their effects as BC6ENTC uptake blockers in vitro in brain tissue.	CPR:9
As possible long - term effects of honey after its withdrawal, statistically significant reductions in midarm circumference (P=.000), triceps skin fold thickness (P=.006), SSFT (P=.003), FSG (P=.005), 2 - h postprandial serum BC6ENTC (P=.000), TG (P=.003), and BC6OTHER (P=.043), and significant increases in BC6ENTG (P=.002) and BC6OTHER (P=.003) were observed.	False
As possible long - term effects of honey after its withdrawal, statistically significant reductions in midarm circumference (P=.000), triceps skin fold thickness (P=.006), SSFT (P=.003), FSG (P=.005), 2 - h postprandial serum BC6ENTC (P=.000), TG (P=.003), and BC6OTHER (P=.043), and significant increases in BC6OTHER (P=.002) and BC6ENTG (P=.003) were observed.	False
As possible long - term effects of honey after its withdrawal, statistically significant reductions in midarm circumference (P=.000), triceps skin fold thickness (P=.006), SSFT (P=.003), FSG (P=.005), 2 - h postprandial serum BC6ENTC (P=.000), TG (P=.003), and BC6ENTG (P=.043), and significant increases in BC6OTHER (P=.002) and BC6OTHER (P=.003) were observed.	False
The main outcome measures were serum BC6ENTC , lipids, and BC6ENTG , and anthropometric measurements.	False
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6ENTC (FSG; P=.001), total BC6OTHER (P=.0001), serum BC6OTHER (TG; P=.0001), and BC6ENTG (P=.0009), and significant increases in BC6OTHER ( BC6OTHER ; P=.0004) and 2 - h BC6OTHER ( BC6OTHER ; P=.002).	False
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6ENTC (FSG; P=.001), total BC6OTHER (P=.0001), serum BC6OTHER (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6ENTG ( BC6OTHER ; P=.0004) and 2 - h BC6OTHER ( BC6OTHER ; P=.002).	False
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6ENTC (FSG; P=.001), total BC6OTHER (P=.0001), serum BC6OTHER (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6OTHER ( BC6ENTG ; P=.0004) and 2 - h BC6OTHER ( BC6OTHER ; P=.002).	False
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6ENTC (FSG; P=.001), total BC6OTHER (P=.0001), serum BC6OTHER (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6OTHER ( BC6OTHER ; P=.0004) and 2 - h BC6ENTG ( BC6OTHER ; P=.002).	False
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6ENTC (FSG; P=.001), total BC6OTHER (P=.0001), serum BC6OTHER (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6OTHER ( BC6OTHER ; P=.0004) and 2 - h BC6OTHER ( BC6ENTG ; P=.002).	False
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6OTHER (FSG; P=.001), total BC6ENTC (P=.0001), serum BC6OTHER (TG; P=.0001), and BC6ENTG (P=.0009), and significant increases in BC6OTHER ( BC6OTHER ; P=.0004) and 2 - h BC6OTHER ( BC6OTHER ; P=.002).	False
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6OTHER (FSG; P=.001), total BC6ENTC (P=.0001), serum BC6OTHER (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6ENTG ( BC6OTHER ; P=.0004) and 2 - h BC6OTHER ( BC6OTHER ; P=.002).	False
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6OTHER (FSG; P=.001), total BC6ENTC (P=.0001), serum BC6OTHER (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6OTHER ( BC6ENTG ; P=.0004) and 2 - h BC6OTHER ( BC6OTHER ; P=.002).	False
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6OTHER (FSG; P=.001), total BC6ENTC (P=.0001), serum BC6OTHER (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6OTHER ( BC6OTHER ; P=.0004) and 2 - h BC6ENTG ( BC6OTHER ; P=.002).	False
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6OTHER (FSG; P=.001), total BC6ENTC (P=.0001), serum BC6OTHER (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6OTHER ( BC6OTHER ; P=.0004) and 2 - h BC6OTHER ( BC6ENTG ; P=.002).	False
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6OTHER (FSG; P=.001), total BC6OTHER (P=.0001), serum BC6ENTC (TG; P=.0001), and BC6ENTG (P=.0009), and significant increases in BC6OTHER ( BC6OTHER ; P=.0004) and 2 - h BC6OTHER ( BC6OTHER ; P=.002).	False
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6OTHER (FSG; P=.001), total BC6OTHER (P=.0001), serum BC6ENTC (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6ENTG ( BC6OTHER ; P=.0004) and 2 - h BC6OTHER ( BC6OTHER ; P=.002).	False
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6OTHER (FSG; P=.001), total BC6OTHER (P=.0001), serum BC6ENTC (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6OTHER ( BC6ENTG ; P=.0004) and 2 - h BC6OTHER ( BC6OTHER ; P=.002).	False
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6OTHER (FSG; P=.001), total BC6OTHER (P=.0001), serum BC6ENTC (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6OTHER ( BC6OTHER ; P=.0004) and 2 - h BC6ENTG ( BC6OTHER ; P=.002).	False
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6OTHER (FSG; P=.001), total BC6OTHER (P=.0001), serum BC6ENTC (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6OTHER ( BC6OTHER ; P=.0004) and 2 - h BC6OTHER ( BC6ENTG ; P=.002).	False
In cultures from severely obese subjects, BC6ENTC induced a decrease of BC6ENTG antigen secretion from newly differentiated omental adipocytes by 49 + / - 8% (p < 0.01) and from subcutaneous adipocytes by 30 + / - 7% (p < 0.05).	CPR:4
Exposure of freshly isolated subcutaneous and omental adipocytes in suspension culture to BC6ENTC induced a similar reduction of BC6ENTG concentration in the culture medium (by 35 + / - 11%, p < 0.05, and 33 + / - 8%, p < 0.05 compared with control, respectively).	CPR:4
CONCLUSION / INTERPRETATION: This study provides evidence that BC6ENTC reduces BC6ENTG production in human adipocytes, probably at the transcriptional level.	CPR:4
In this study, we investigated the effect of BC6ENTC , a ligand of the BC6ENTG BC6OTHER , on BC6OTHER expression and secretion in human adipocytes.	False
In this study, we investigated the effect of BC6ENTC , a ligand of the BC6OTHER BC6ENTG , on BC6OTHER expression and secretion in human adipocytes.	False
In this study, we investigated the effect of BC6ENTC , a ligand of the BC6OTHER BC6OTHER , on BC6ENTG expression and secretion in human adipocytes.	False
RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal - weight females to 1 microgram / ml BC6ENTC for 72 h caused a reduction of both BC6ENTG secretion (by 29 + / - 5%; p < 0.01) and BC6OTHER mRNA expression (by 26 + / - 3%; p < 0.05).	CPR:4
RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal - weight females to 1 microgram / ml BC6ENTC for 72 h caused a reduction of both BC6OTHER secretion (by 29 + / - 5%; p < 0.01) and BC6ENTG mRNA expression (by 26 + / - 3%; p < 0.05).	CPR:4
 BC6ENTC reduces BC6ENTG expression and secretion in cultured human adipocytes.	CPR:4
BC6ENTC were also effective in inhibiting BC6ENTG - stimulated BC6OTHER production, with EC50 values for BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER of 8 + / - 2, 47 + / - 2, 28 + / - 2, 2 + / - 1, and 8 + / - 1 nM, respectively.	CPR:4
BC6OTHER were also effective in inhibiting BC6ENTG - stimulated BC6ENTC production, with EC50 values for BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER of 8 + / - 2, 47 + / - 2, 28 + / - 2, 2 + / - 1, and 8 + / - 1 nM, respectively.	CPR:9
BC6OTHER inhibition of radioligand binding to the D2 BC6ENTC receptor and BC6OTHER inhibition of BC6ENTG ( BC6OTHER ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated.	False
BC6OTHER inhibition of radioligand binding to the D2 BC6ENTC receptor and BC6OTHER inhibition of BC6OTHER ( BC6ENTG ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated.	False
BC6OTHER inhibition of radioligand binding to the D2 BC6ENTC receptor and BC6OTHER inhibition of BC6OTHER ( BC6OTHER ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a BC6ENTG , were evaluated.	False
BC6OTHER were also effective in inhibiting BC6ENTG - stimulated BC6OTHER production, with EC50 values for BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER of 8 + / - 2, 47 + / - 2, 28 + / - 2, 2 + / - 1, and 8 + / - 1 nM, respectively.	CPR:4
BC6OTHER were also effective in inhibiting BC6ENTG - stimulated BC6OTHER production, with EC50 values for BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER of 8 + / - 2, 47 + / - 2, 28 + / - 2, 2 + / - 1, and 8 + / - 1 nM, respectively.	CPR:4
BC6OTHER were also effective in inhibiting BC6ENTG - stimulated BC6OTHER production, with EC50 values for BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER of 8 + / - 2, 47 + / - 2, 28 + / - 2, 2 + / - 1, and 8 + / - 1 nM, respectively.	CPR:4
BC6OTHER were also effective in inhibiting BC6ENTG - stimulated BC6OTHER production, with EC50 values for BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER of 8 + / - 2, 47 + / - 2, 28 + / - 2, 2 + / - 1, and 8 + / - 1 nM, respectively.	CPR:4
BC6OTHER were also effective in inhibiting BC6ENTG - stimulated BC6OTHER production, with EC50 values for BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC of 8 + / - 2, 47 + / - 2, 28 + / - 2, 2 + / - 1, and 8 + / - 1 nM, respectively.	CPR:4
Inhibition of BC6ENTC production by BC6OTHER was blocked by the BC6ENTG antagonist, BC6OTHER (IC50, 300 + / - 150 nM).	False
Inhibition of BC6OTHER production by BC6ENTC was blocked by the BC6ENTG antagonist, BC6OTHER (IC50, 300 + / - 150 nM).	False
BC6ENTC inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6OTHER inhibition of BC6ENTG ( BC6OTHER ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated.	False
BC6ENTC inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6OTHER inhibition of BC6OTHER ( BC6ENTG ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated.	False
BC6ENTC inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6OTHER inhibition of BC6OTHER ( BC6OTHER ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a BC6ENTG , were evaluated.	False
BC6ENTC inhibition of radioligand binding to the BC6ENTG and BC6OTHER inhibition of BC6OTHER ( BC6OTHER ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated.	False
BC6OTHER inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6ENTC inhibition of BC6ENTG ( BC6OTHER ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated.	CPR:4
BC6OTHER inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6ENTC inhibition of BC6OTHER ( BC6ENTG ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated.	CPR:4
BC6OTHER inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6ENTC inhibition of BC6OTHER ( BC6OTHER ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a BC6ENTG , were evaluated.	False
BC6OTHER inhibition of radioligand binding to the BC6ENTG and BC6ENTC inhibition of BC6OTHER ( BC6OTHER ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated.	False
Inhibition of BC6OTHER production by BC6OTHER was blocked by the BC6ENTG antagonist, BC6ENTC (IC50, 300 + / - 150 nM).	CPR:6
Our results indicate that ergot compounds, especially BC6ENTC , bind to BC6ENTG and elicit second messenger responses similar to that of BC6OTHER .	False
Our results indicate that ergot compounds, especially BC6OTHER , bind to BC6ENTG and elicit second messenger responses similar to that of BC6ENTC .	False
 BC6ENTC binding and activation of BC6ENTG in GH4ZR7 cells.	CPR:3
These findings suggest that some of the deleterious effects of consumption of endophyte - infected tall fescue, which contains several BC6ENTC including BC6OTHER , may be due to BC6ENTG activation.	CPR:3
These findings suggest that some of the deleterious effects of consumption of endophyte - infected tall fescue, which contains several BC6OTHER including BC6ENTC , may be due to BC6ENTG activation.	CPR:3
BC6OTHER inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6OTHER inhibition of BC6ENTG ( BC6OTHER ) - stimulated BC6ENTC production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated.	CPR:9
BC6OTHER inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6OTHER inhibition of BC6OTHER ( BC6ENTG ) - stimulated BC6ENTC production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated.	CPR:9
BC6OTHER inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6OTHER inhibition of BC6OTHER ( BC6OTHER ) - stimulated BC6ENTC production in GH4ZR7 cells, stably transfected with a BC6ENTG , were evaluated.	False
BC6OTHER inhibition of radioligand binding to the BC6ENTG and BC6OTHER inhibition of BC6OTHER ( BC6OTHER ) - stimulated BC6ENTC production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated.	False
BC6OTHER inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6OTHER inhibition of BC6ENTG ( BC6OTHER ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6ENTC receptor, were evaluated.	False
BC6OTHER inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6OTHER inhibition of BC6OTHER ( BC6ENTG ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6ENTC receptor, were evaluated.	False
BC6OTHER inhibition of radioligand binding to the BC6ENTG and BC6OTHER inhibition of BC6OTHER ( BC6OTHER ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6ENTC receptor, were evaluated.	False
BC6ENTC inhibition of the binding of the BC6ENTG - specific radioligand, BC6OTHER , exhibited a KI (inhibition constant) of 6.9 + / - 2.6 nM, whereas BC6OTHER was much less potent (370 + / - 160 nM).	False
BC6OTHER inhibition of the binding of the BC6ENTG - specific radioligand, BC6ENTC , exhibited a KI (inhibition constant) of 6.9 + / - 2.6 nM, whereas BC6OTHER was much less potent (370 + / - 160 nM).	False
BC6OTHER inhibition of the binding of the BC6ENTG - specific radioligand, BC6OTHER , exhibited a KI (inhibition constant) of 6.9 + / - 2.6 nM, whereas BC6ENTC was much less potent (370 + / - 160 nM).	False
In our previous study, we identified the BC6ENTC receptor alpha ( BC6ENTG ) as a relevant enhancer of BC6OTHER - induced signal transduction leading to transactivation of BC6OTHER ( BC6OTHER ).	False
In our previous study, we identified the BC6ENTC receptor alpha ( BC6OTHER ) as a relevant enhancer of BC6ENTG - induced signal transduction leading to transactivation of BC6OTHER ( BC6OTHER ).	False
In our previous study, we identified the BC6ENTC receptor alpha ( BC6OTHER ) as a relevant enhancer of BC6OTHER - induced signal transduction leading to transactivation of BC6ENTG ( BC6OTHER ).	False
In our previous study, we identified the BC6ENTC receptor alpha ( BC6OTHER ) as a relevant enhancer of BC6OTHER - induced signal transduction leading to transactivation of BC6OTHER ( BC6ENTG ).	False
BC6ENTC , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER inhibitors and BC6OTHER are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs.	False
BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG inhibitors and BC6OTHER are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs.	False
BC6OTHER , BC6ENTC , BC6ENTG , BC6OTHER , BC6OTHER inhibitors and BC6OTHER are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs.	False
BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6ENTG inhibitors and BC6OTHER are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs.	False
BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC , BC6OTHER inhibitors and BC6OTHER are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs.	False
BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6ENTG inhibitors and BC6OTHER are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs.	False
BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC inhibitors and BC6OTHER are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs.	False
BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER inhibitors and BC6ENTC are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs.	False
BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG inhibitors and BC6ENTC are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs.	False
Effects of BC6OTHER were compared to those of the BC6OTHER reuptake inhibitor, BC6OTHER (10 mg / kg / day), and the partial BC6ENTG agonist, BC6ENTC (10 mg / kg / day), two compounds which have demonstrated clinical efficacy against PTSD.	CPR:5
RATIONALE: The selective BC6ENTG antagonist BC6ENTC has been previously shown to attenuate the long - term cognitive deficit produced by traumatic stress exposure.	CPR:6
The BC6ENTG antagonist BC6OTHER prevents stress - induced cognitive deficit associated with hippocampal dysfunction: Comparison with BC6ENTC and BC6OTHER .	False
The BC6ENTG antagonist BC6OTHER prevents stress - induced cognitive deficit associated with hippocampal dysfunction: Comparison with BC6OTHER and BC6ENTC .	False
The BC6ENTG antagonist BC6ENTC prevents stress - induced cognitive deficit associated with hippocampal dysfunction: Comparison with BC6OTHER and BC6OTHER .	CPR:6
CONCLUSIONS: These findings confirm that the BC6ENTG antagonist BC6ENTC is able to attenuate the behavioral effects of traumatic stress exposure and indicate that these effects are associated with a normalization of hippocampal neuronal excitability impaired by stress.	CPR:6
Effects of BC6ENTC were compared to those of the BC6OTHER reuptake inhibitor, BC6OTHER (10 mg / kg / day), and the partial BC6ENTG agonist, BC6OTHER (10 mg / kg / day), two compounds which have demonstrated clinical efficacy against PTSD.	False
Effects of BC6OTHER were compared to those of the BC6ENTC reuptake inhibitor, BC6OTHER (10 mg / kg / day), and the partial BC6ENTG agonist, BC6OTHER (10 mg / kg / day), two compounds which have demonstrated clinical efficacy against PTSD.	False
Effects of BC6OTHER were compared to those of the BC6OTHER reuptake inhibitor, BC6ENTC (10 mg / kg / day), and the partial BC6ENTG agonist, BC6OTHER (10 mg / kg / day), two compounds which have demonstrated clinical efficacy against PTSD.	False
The BC6ENTG - blocking action of BC6OTHER per se does not appear to be involved in the rapid pressor response to BC6ENTC .	False
BC6OTHER (0.03 - 3 mg / kg) produced dose - dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the BC6ENTG antagonist, BC6ENTC .	CPR:6
BC6ENTC (0.03 - 3 mg / kg) produced dose - dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the BC6ENTG antagonist, BC6OTHER .	False
BC6ENTC uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response.	False
BC6OTHER uptake inhibitors structurally analogous to BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response.	False
BC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response.	False
BC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response.	False
BC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response.	False
BC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response.	False
BC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response.	False
BC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response.	False
BC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response.	False
BC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response.	CPR:4
BC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response.	CPR:4
BC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response.	CPR:4
BC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response.	CPR:4
BC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response.	CPR:4
BC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ) either did not produce a rapid pressor response or produced only a small pressor response.	CPR:4
At nonconvulsant doses, the BC6ENTG blockers BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER produced a small pressor response or no increase in BP.	CPR:4
At nonconvulsant doses, the BC6ENTG blockers BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER produced a small pressor response or no increase in BP.	CPR:4
At nonconvulsant doses, the BC6ENTG blockers BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER produced a small pressor response or no increase in BP.	CPR:4
At nonconvulsant doses, the BC6ENTG blockers BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER produced a small pressor response or no increase in BP.	CPR:4
At nonconvulsant doses, the BC6ENTG blockers BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER produced a small pressor response or no increase in BP.	CPR:4
At nonconvulsant doses, the BC6ENTG blockers BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER produced a small pressor response or no increase in BP.	CPR:4
At nonconvulsant doses, the BC6ENTG blockers BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC produced a small pressor response or no increase in BP.	CPR:4
 BC6ENTC transporter and BC6ENTG mechanisms in the rapid pressor response to BC6OTHER .	False
 BC6ENTG and BC6ENTC channel mechanisms in the rapid pressor response to BC6OTHER .	False
 BC6ENTG and BC6OTHER mechanisms in the rapid pressor response to BC6ENTC .	False
 BC6OTHER and BC6ENTG mechanisms in the rapid pressor response to BC6ENTC .	False
The present data suggest that the inhibition of BC6ENTG BC6ENTC transporter functions, either alone or in combination, does not mediate the rapid pressor response to BC6OTHER .	False
The present data suggest that the inhibition of BC6ENTG BC6OTHER transporter functions, either alone or in combination, does not mediate the rapid pressor response to BC6ENTC .	False
The BC6ENTG - blocking action of BC6ENTC per se does not appear to be involved in the rapid pressor response to BC6OTHER .	CPR:4
Full - length cDNAs of BC6OTHER ( BC6OTHER ) were cloned by screening a human placental cDNA library, which encode a 243 CHEM protein, identical to human BC6ENTC pyrophosphokinase ( BC6ENTG ) as confirmed by protein sequence analysis.	False
Full - length cDNAs of BC6ENTG ( BC6OTHER ) were cloned by screening a human placental cDNA library, which encode a 243 CHEM protein, identical to human BC6ENTC pyrophosphokinase ( BC6OTHER ) as confirmed by protein sequence analysis.	False
Full - length cDNAs of BC6OTHER ( BC6ENTG ) were cloned by screening a human placental cDNA library, which encode a 243 CHEM protein, identical to human BC6ENTC pyrophosphokinase ( BC6OTHER ) as confirmed by protein sequence analysis.	False
As BC6ENTC metabolism deficiencies have been seen in placental infarcts previously, these indicate that BC6ENTG / BC6OTHER may have a role in placental diseases.	CPR:9
As BC6ENTC metabolism deficiencies have been seen in placental infarcts previously, these indicate that BC6OTHER / BC6ENTG may have a role in placental diseases.	CPR:9
Cloning, sequencing, structural and molecular biological characterization of BC6OTHER ( BC6OTHER ) / human BC6ENTC pyrophosphokinase ( BC6ENTG ).	False
Cloning, sequencing, structural and molecular biological characterization of BC6ENTG ( BC6OTHER ) / human BC6ENTC pyrophosphokinase ( BC6OTHER ).	False
Cloning, sequencing, structural and molecular biological characterization of BC6OTHER ( BC6ENTG ) / human BC6ENTC pyrophosphokinase ( BC6OTHER ).	False
The BC6ENTC secretory response is mediated via a non - BC6ENTG pathway, and the driving force for BC6OTHER secretion is enhanced by the effect of BC6OTHER activation to also inhibit epithelial BC6OTHER transport.	CPR:9
The BC6ENTC secretory response is mediated via a non - BC6OTHER pathway, and the driving force for BC6OTHER secretion is enhanced by the effect of BC6ENTG activation to also inhibit epithelial BC6OTHER transport.	False
The BC6OTHER secretory response is mediated via a non - BC6ENTG pathway, and the driving force for BC6ENTC secretion is enhanced by the effect of BC6OTHER activation to also inhibit epithelial BC6OTHER transport.	False
The BC6OTHER secretory response is mediated via a non - BC6OTHER pathway, and the driving force for BC6ENTC secretion is enhanced by the effect of BC6ENTG activation to also inhibit epithelial BC6OTHER transport.	False
The BC6OTHER secretory response is mediated via a non - BC6ENTG pathway, and the driving force for BC6OTHER secretion is enhanced by the effect of BC6OTHER activation to also inhibit epithelial BC6ENTC transport.	False
The BC6OTHER secretory response is mediated via a non - BC6OTHER pathway, and the driving force for BC6OTHER secretion is enhanced by the effect of BC6ENTG activation to also inhibit epithelial BC6ENTC transport.	False
BC6ENTC is metabolically more stable and better tolerated, and may enhance mucociliary clearance for a longer period of time than previously investigated BC6ENTG agonists.	CPR:5
Safety and tolerability of BC6ENTC inhalation solution, a novel BC6ENTG agonist: results of a phase 1 / phase 2 multicenter study in mild to moderate cystic fibrosis.	CPR:5
BC6ENTC ( BC6OTHER ) is a selective BC6ENTG agonist that stimulates ciliary beat frequency and BC6OTHER secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.	CPR:5
BC6OTHER ( BC6OTHER ) is a selective BC6ENTG agonist that stimulates ciliary beat frequency and BC6ENTC secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.	False
BC6OTHER ( BC6ENTC ) is a selective BC6ENTG agonist that stimulates ciliary beat frequency and BC6OTHER secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.	CPR:5
Three lines of evidence suggest that BC6ENTG inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6ENTC ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6ENTG functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6ENTC ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6ENTG into cells did not reverse the effects of BC6ENTC ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6ENTC ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6ENTG over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6ENTC ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6ENTG , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6ENTC ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6ENTG , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6ENTC ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6ENTG , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6ENTC ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6ENTG .	False
Three lines of evidence suggest that BC6ENTG inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6ENTC - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6ENTG functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6ENTC - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6ENTG into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6ENTC - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6ENTG over native levels into individual gerbil fibroma cells; using BC6ENTC - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6ENTC - labeled BC6ENTG , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6ENTC - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6ENTG , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6ENTC - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6ENTG , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6ENTC - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6ENTG .	False
Three lines of evidence suggest that BC6ENTG inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6ENTC induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6ENTG functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6ENTC induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6ENTG into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6ENTC induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6ENTG over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6ENTC induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6ENTG , we saw that the BC6ENTC induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6ENTC induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6ENTG , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6ENTC induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6ENTG , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6ENTC induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6ENTG .	False
Three lines of evidence suggest that BC6ENTG inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6ENTC - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6ENTG functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6ENTC - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6ENTG into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6ENTC - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6ENTG over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6ENTC - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6ENTG , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6ENTC - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6ENTG , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6ENTC - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6ENTG , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6ENTC - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6ENTC - labeled BC6ENTG .	False
We have found that certain BC6ENTC [e.g., BC6OTHER ( BC6OTHER )] and BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6ENTG , and BC6OTHER ( BC6OTHER ) in fibroblasts.	False
We have found that certain BC6ENTC [e.g., BC6OTHER ( BC6OTHER )] and BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6OTHER , and BC6ENTG ( BC6OTHER ) in fibroblasts.	False
We have found that certain BC6ENTC [e.g., BC6OTHER ( BC6OTHER )] and BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6OTHER , and BC6OTHER ( BC6ENTG ) in fibroblasts.	False
The extent of BC6ENTG loss is less than for BC6OTHER , and the BC6OTHER do not reappear at the surface when BC6ENTC is removed.	False
The extent of BC6OTHER loss is less than for BC6ENTG , and the BC6OTHER do not reappear at the surface when BC6ENTC is removed.	False
The extent of BC6OTHER loss is less than for BC6OTHER , and the BC6ENTG do not reappear at the surface when BC6ENTC is removed.	False
We have found that certain BC6OTHER [e.g., BC6ENTC ( BC6OTHER )] and BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6ENTG , and BC6OTHER ( BC6OTHER ) in fibroblasts.	False
We have found that certain BC6OTHER [e.g., BC6ENTC ( BC6OTHER )] and BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6OTHER , and BC6ENTG ( BC6OTHER ) in fibroblasts.	False
We have found that certain BC6OTHER [e.g., BC6ENTC ( BC6OTHER )] and BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6OTHER , and BC6OTHER ( BC6ENTG ) in fibroblasts.	False
BC6ENTC did not induce a loss of cell surface BC6ENTG , a membrane protein which is excluded from coated pits and which is not internalized, indicating that the effect of BC6OTHER was specific for membrane receptors and not a result of bulk depletion of plasma membrane.	False
BC6OTHER did not induce a loss of cell surface BC6ENTG , a membrane protein which is excluded from coated pits and which is not internalized, indicating that the effect of BC6ENTC was specific for membrane receptors and not a result of bulk depletion of plasma membrane.	False
Loss of BC6OTHER and BC6ENTG surface binding induced by BC6OTHER and BC6ENTC .	False
Loss of BC6ENTG and BC6OTHER surface binding induced by BC6OTHER and BC6ENTC .	False
We have found that certain BC6OTHER [e.g., BC6OTHER ( BC6ENTC )] and BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6ENTG , and BC6OTHER ( BC6OTHER ) in fibroblasts.	False
We have found that certain BC6OTHER [e.g., BC6OTHER ( BC6ENTC )] and BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6OTHER , and BC6ENTG ( BC6OTHER ) in fibroblasts.	False
We have found that certain BC6OTHER [e.g., BC6OTHER ( BC6ENTC )] and BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6OTHER , and BC6OTHER ( BC6ENTG ) in fibroblasts.	False
Loss of BC6OTHER and BC6ENTG surface binding induced by BC6ENTC and BC6OTHER .	False
Loss of BC6ENTG and BC6OTHER surface binding induced by BC6ENTC and BC6OTHER .	False
We have found that certain BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] and BC6ENTC [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6ENTG , and BC6OTHER ( BC6OTHER ) in fibroblasts.	False
We have found that certain BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] and BC6ENTC [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6OTHER , and BC6ENTG ( BC6OTHER ) in fibroblasts.	False
We have found that certain BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] and BC6ENTC [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6OTHER , and BC6OTHER ( BC6ENTG ) in fibroblasts.	False
Since both BC6ENTC and BC6OTHER are potent inhibitors of BC6ENTG , we investigated the possibility that inhibition of BC6OTHER was responsible for the loss of receptors.	CPR:4
Since both BC6ENTC and BC6OTHER are potent inhibitors of BC6OTHER , we investigated the possibility that inhibition of BC6ENTG was responsible for the loss of receptors.	False
Since both BC6OTHER and BC6ENTC are potent inhibitors of BC6ENTG , we investigated the possibility that inhibition of BC6OTHER was responsible for the loss of receptors.	CPR:4
Since both BC6OTHER and BC6ENTC are potent inhibitors of BC6OTHER , we investigated the possibility that inhibition of BC6ENTG was responsible for the loss of receptors.	False
We have found that certain BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] and BC6OTHER [e.g., BC6ENTC ( BC6OTHER )] induce a loss of cell - surface receptors for BC6ENTG , and BC6OTHER ( BC6OTHER ) in fibroblasts.	False
We have found that certain BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] and BC6OTHER [e.g., BC6ENTC ( BC6OTHER )] induce a loss of cell - surface receptors for BC6OTHER , and BC6ENTG ( BC6OTHER ) in fibroblasts.	False
We have found that certain BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] and BC6OTHER [e.g., BC6ENTC ( BC6OTHER )] induce a loss of cell - surface receptors for BC6OTHER , and BC6OTHER ( BC6ENTG ) in fibroblasts.	False
We have found that certain BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] and BC6OTHER [e.g., BC6OTHER ( BC6ENTC )] induce a loss of cell - surface receptors for BC6ENTG , and BC6OTHER ( BC6OTHER ) in fibroblasts.	False
We have found that certain BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] and BC6OTHER [e.g., BC6OTHER ( BC6ENTC )] induce a loss of cell - surface receptors for BC6OTHER , and BC6ENTG ( BC6OTHER ) in fibroblasts.	False
We have found that certain BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] and BC6OTHER [e.g., BC6OTHER ( BC6ENTC )] induce a loss of cell - surface receptors for BC6OTHER , and BC6OTHER ( BC6ENTG ) in fibroblasts.	False
Three lines of evidence suggest that BC6ENTG inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6ENTC , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6ENTC , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6ENTG functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	CPR:4
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6ENTC , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6ENTG into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6ENTC , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6ENTG over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6ENTC , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6ENTG , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6ENTC , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6ENTG , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6ENTC , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6ENTG , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6ENTC , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6ENTG .	False
Three lines of evidence suggest that BC6ENTG inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6ENTC that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6ENTC that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6ENTG functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	CPR:4
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6ENTC that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6ENTG into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6ENTC that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6ENTG over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6ENTC that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6ENTG , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6ENTC that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6ENTG , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6ENTC that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6ENTG , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6ENTC that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6ENTG .	False
Three lines of evidence suggest that BC6ENTG inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6ENTC at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6ENTC at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6ENTG functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	CPR:4
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6ENTC at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6ENTG into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6ENTC at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6ENTG over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6ENTC at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6ENTG , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6ENTC at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6ENTG , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6ENTC at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6ENTG , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER .	False
Three lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6ENTC at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6ENTG .	False
Wild - type enzymes and variants of BC6ENTG ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6ENTC ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6ENTG and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6ENTC ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6ENTG ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6ENTC ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6ENTC ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6ENTG , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6ENTC ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTG , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6ENTC ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6ENTG ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6ENTC ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6ENTG ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6ENTC , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6ENTG and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6ENTC , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6ENTG ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6ENTC , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6ENTC , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6ENTG , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6ENTC , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTG , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6ENTC , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6ENTG ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6ENTC , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6ENTG ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6ENTC ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6ENTG and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6ENTC ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6ENTG ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6ENTC ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6ENTC ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6ENTG , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6ENTC ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTG , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6ENTC ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6ENTG ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6ENTC ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6ENTG ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6ENTC ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6ENTG and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6ENTC ) as substrates.	False
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6ENTG ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6ENTC ) as substrates.	False
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6ENTC ) as substrates.	False
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6ENTG , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6ENTC ) as substrates.	False
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTG , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6ENTC ) as substrates.	False
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6ENTG ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6ENTC ) as substrates.	False
All three BC6ENTG proteins showed similar K(m) and V(max) for BC6ENTC and BC6OTHER deamination, except for BC6OTHER 70Thr, which had a 2.5 - fold lower K(m) and 6 - fold lower V(max) for BC6OTHER deamination.	CPR:9
All three BC6OTHER proteins showed similar K(m) and V(max) for BC6ENTC and BC6OTHER deamination, except for BC6ENTG 70Thr, which had a 2.5 - fold lower K(m) and 6 - fold lower V(max) for BC6OTHER deamination.	False
All three BC6ENTG proteins showed similar K(m) and V(max) for BC6OTHER and BC6ENTC deamination, except for BC6OTHER 70Thr, which had a 2.5 - fold lower K(m) and 6 - fold lower V(max) for BC6OTHER deamination.	CPR:9
All three BC6OTHER proteins showed similar K(m) and V(max) for BC6OTHER and BC6ENTC deamination, except for BC6ENTG 70Thr, which had a 2.5 - fold lower K(m) and 6 - fold lower V(max) for BC6OTHER deamination.	False
BC6OTHER ( BC6OTHER , BC6OTHER ) is metabolized by BC6ENTC deaminase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	False
BC6OTHER ( BC6OTHER , BC6OTHER ) is metabolized by BC6ENTC deaminase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	False
BC6OTHER ( BC6OTHER , BC6OTHER ) is metabolized by BC6ENTC deaminase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	False
All three BC6ENTG proteins showed similar K(m) and V(max) for BC6OTHER and BC6OTHER deamination, except for BC6OTHER 70Thr, which had a 2.5 - fold lower K(m) and 6 - fold lower V(max) for BC6ENTC deamination.	False
All three BC6OTHER proteins showed similar K(m) and V(max) for BC6OTHER and BC6OTHER deamination, except for BC6ENTG 70Thr, which had a 2.5 - fold lower K(m) and 6 - fold lower V(max) for BC6ENTC deamination.	CPR:9
All four BC6ENTG proteins yielded comparable metabolic activity for BC6ENTC and BC6OTHER monophosphorylation, except for BC6OTHER 24Val, which demonstrated an approximately 2 - fold increase (P < 0.05) in the intrinsic clearance of BC6OTHER monophosphorylation due to a 40% decrease in K(m) (P < 0.05).	CPR:9
All four BC6OTHER proteins yielded comparable metabolic activity for BC6ENTC and BC6OTHER monophosphorylation, except for BC6ENTG 24Val, which demonstrated an approximately 2 - fold increase (P < 0.05) in the intrinsic clearance of BC6OTHER monophosphorylation due to a 40% decrease in K(m) (P < 0.05).	False
All four BC6ENTG proteins yielded comparable metabolic activity for BC6OTHER and BC6ENTC monophosphorylation, except for BC6OTHER 24Val, which demonstrated an approximately 2 - fold increase (P < 0.05) in the intrinsic clearance of BC6OTHER monophosphorylation due to a 40% decrease in K(m) (P < 0.05).	CPR:9
All four BC6OTHER proteins yielded comparable metabolic activity for BC6OTHER and BC6ENTC monophosphorylation, except for BC6ENTG 24Val, which demonstrated an approximately 2 - fold increase (P < 0.05) in the intrinsic clearance of BC6OTHER monophosphorylation due to a 40% decrease in K(m) (P < 0.05).	False
BC6ENTC ( BC6OTHER , BC6OTHER ) is metabolized by BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	CPR:9
BC6ENTC ( BC6OTHER , BC6OTHER ) is metabolized by BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	CPR:9
BC6ENTC ( BC6OTHER , BC6OTHER ) is metabolized by BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	CPR:9
BC6ENTC ( BC6OTHER , BC6OTHER ) is metabolized by BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	CPR:9
BC6OTHER ( BC6OTHER , BC6OTHER ) is metabolized by BC6OTHER ( BC6OTHER ) and BC6ENTC kinase ( BC6ENTG ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	False
BC6OTHER ( BC6OTHER , BC6OTHER ) is metabolized by BC6ENTG ( BC6OTHER ) and BC6ENTC kinase ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	False
BC6OTHER ( BC6OTHER , BC6OTHER ) is metabolized by BC6OTHER ( BC6ENTG ) and BC6ENTC kinase ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	False
All four BC6ENTG proteins yielded comparable metabolic activity for BC6OTHER and BC6OTHER monophosphorylation, except for BC6OTHER 24Val, which demonstrated an approximately 2 - fold increase (P < 0.05) in the intrinsic clearance of BC6ENTC monophosphorylation due to a 40% decrease in K(m) (P < 0.05).	False
All four BC6OTHER proteins yielded comparable metabolic activity for BC6OTHER and BC6OTHER monophosphorylation, except for BC6ENTG 24Val, which demonstrated an approximately 2 - fold increase (P < 0.05) in the intrinsic clearance of BC6ENTC monophosphorylation due to a 40% decrease in K(m) (P < 0.05).	CPR:9
Pharmacogenomics of BC6OTHER metabolism: functional analysis of genetic variants in BC6ENTG and BC6ENTC kinase.	False
Pharmacogenomics of BC6ENTC metabolism: functional analysis of genetic variants in BC6OTHER and BC6ENTG .	False
Pharmacogenomics of BC6ENTC metabolism: functional analysis of genetic variants in BC6ENTG and BC6OTHER .	False
Pharmacogenomics of BC6OTHER metabolism: functional analysis of genetic variants in BC6ENTC deaminase and BC6ENTG .	False
BC6ENTG did not significantly contribute to BC6ENTC monophosphorylation.	False
In conclusion, the BC6ENTG substitution does not significantly modulate BC6OTHER activity toward BC6ENTC , and therefore would not contribute to interindividual variability in response to BC6OTHER .	CPR:9
In conclusion, the BC6OTHER substitution does not significantly modulate BC6ENTG activity toward BC6ENTC , and therefore would not contribute to interindividual variability in response to BC6OTHER .	CPR:9
In conclusion, the BC6ENTG substitution does not significantly modulate BC6OTHER activity toward BC6OTHER , and therefore would not contribute to interindividual variability in response to BC6ENTC .	False
In conclusion, the BC6OTHER substitution does not significantly modulate BC6ENTG activity toward BC6OTHER , and therefore would not contribute to interindividual variability in response to BC6ENTC .	False
BC6OTHER ( BC6ENTC , BC6OTHER ) is metabolized by BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	CPR:9
BC6OTHER ( BC6ENTC , BC6OTHER ) is metabolized by BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	CPR:9
BC6OTHER ( BC6ENTC , BC6OTHER ) is metabolized by BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	CPR:9
BC6OTHER ( BC6ENTC , BC6OTHER ) is metabolized by BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	CPR:9
The higher in vitro catalytic efficiency of BC6ENTG 24Val toward BC6ENTC monophosphorylation may be relevant to BC6OTHER clinical response.	CPR:9
The higher in vitro catalytic efficiency of BC6ENTG 24Val toward BC6OTHER monophosphorylation may be relevant to BC6ENTC clinical response.	CPR:9
BC6OTHER ( BC6OTHER , BC6ENTC ) is metabolized by BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	CPR:9
BC6OTHER ( BC6OTHER , BC6ENTC ) is metabolized by BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	CPR:9
BC6OTHER ( BC6OTHER , BC6ENTC ) is metabolized by BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	CPR:9
BC6OTHER ( BC6OTHER , BC6ENTC ) is metabolized by BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	CPR:9
Wild - type enzymes and variants of BC6ENTG ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6ENTC ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6ENTG and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6ENTC ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6ENTG ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6ENTC ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6ENTC ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6ENTG , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6ENTC ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTG , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6ENTC ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
Wild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6ENTG ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6ENTC ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates.	CPR:9
We propose that volatile anesthetics inhibit BC6ENTC - ATPase by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for BC6ENTG , BC6OTHER , and BC6OTHER kinase (Schoenborn, B. P., and CHEM, R. M. (1967) Adv.	False
We propose that volatile anesthetics inhibit BC6ENTC - ATPase by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for BC6OTHER , BC6ENTG , and BC6OTHER kinase (Schoenborn, B. P., and CHEM, R. M. (1967) Adv.	False
We propose that volatile anesthetics inhibit BC6ENTC - ATPase by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for BC6OTHER , BC6OTHER , and BC6ENTG (Schoenborn, B. P., and CHEM, R. M. (1967) Adv.	False
We propose that volatile anesthetics inhibit BC6ENTG by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for BC6OTHER , BC6OTHER , and BC6ENTC kinase (Schoenborn, B. P., and CHEM, R. M. (1967) Adv.	False
We propose that volatile anesthetics inhibit BC6OTHER - ATPase by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for BC6ENTG , BC6OTHER , and BC6ENTC kinase (Schoenborn, B. P., and CHEM, R. M. (1967) Adv.	False
We propose that volatile anesthetics inhibit BC6OTHER - ATPase by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for BC6OTHER , BC6ENTG , and BC6ENTC kinase (Schoenborn, B. P., and CHEM, R. M. (1967) Adv.	False
We have investigated the mechanism of the inhibitory action of several anesthetics on the purified erythrocyte BC6ENTG by employing fluorescence spectroscopy measurements that report changes in the environment of intrinsic BC6ENTC and of an extrinsic probe attached in the active site of the enzyme.	False
BC6ENTG - facilitated BC6OTHER efflux and lipid parameters did not differ between BC6OTHER - producing and non - BC6ENTC - producing women.	False
CONCLUSION: In postmenopausal women, isolated BC6ENTC treatment does not affect BC6ENTG - dependent BC6OTHER efflux potential from macrophages but increases circulating BC6OTHER level, which could provide beneficial vascular effects.	False
CONCLUSION: In postmenopausal women, isolated BC6ENTC treatment does not affect BC6OTHER - dependent BC6OTHER efflux potential from macrophages but increases circulating BC6ENTG level, which could provide beneficial vascular effects.	CPR:3
CONCLUSION: In postmenopausal women, isolated BC6OTHER treatment does not affect BC6ENTG - dependent BC6ENTC efflux potential from macrophages but increases circulating BC6OTHER level, which could provide beneficial vascular effects.	CPR:9
CONCLUSION: In postmenopausal women, isolated BC6OTHER treatment does not affect BC6OTHER - dependent BC6ENTC efflux potential from macrophages but increases circulating BC6ENTG level, which could provide beneficial vascular effects.	False
We studied in a clinical trial whether isolated BC6OTHER treatment in postmenopausal women could affect reverse BC6ENTC transport as evaluated by BC6ENTG - ( BC6OTHER ), dependent BC6OTHER efflux from macrophages.	False
We studied in a clinical trial whether isolated BC6OTHER treatment in postmenopausal women could affect reverse BC6ENTC transport as evaluated by BC6OTHER - ( BC6ENTG ), dependent BC6OTHER efflux from macrophages.	False
We studied in a clinical trial whether isolated BC6OTHER treatment in postmenopausal women could affect reverse BC6OTHER transport as evaluated by BC6ENTC - binding cassette A1 - ( BC6ENTG ), dependent BC6OTHER efflux from macrophages.	False
We studied in a clinical trial whether isolated BC6OTHER treatment in postmenopausal women could affect reverse BC6OTHER transport as evaluated by BC6ENTG - ( BC6OTHER ), dependent BC6ENTC efflux from macrophages.	CPR:9
We studied in a clinical trial whether isolated BC6OTHER treatment in postmenopausal women could affect reverse BC6OTHER transport as evaluated by BC6OTHER - ( BC6ENTG ), dependent BC6ENTC efflux from macrophages.	CPR:9
BC6ENTC - labeled J774 macrophage cells, with and without BC6OTHER up - regulation, were incubated with the samples, and BC6OTHER - dependent BC6OTHER efflux and serum lipid and BC6ENTG levels were assessed.	False
BC6ENTC - labeled J774 macrophage cells, with and without BC6ENTG up - regulation, were incubated with the samples, and BC6OTHER - dependent BC6OTHER efflux and serum lipid and BC6OTHER levels were assessed.	False
BC6ENTC - labeled J774 macrophage cells, with and without BC6OTHER up - regulation, were incubated with the samples, and BC6ENTG - dependent BC6OTHER efflux and serum lipid and BC6OTHER levels were assessed.	False
BC6OTHER - labeled J774 macrophage cells, with and without BC6OTHER up - regulation, were incubated with the samples, and BC6OTHER - dependent BC6ENTC efflux and serum lipid and BC6ENTG levels were assessed.	False
BC6OTHER - labeled J774 macrophage cells, with and without BC6ENTG up - regulation, were incubated with the samples, and BC6OTHER - dependent BC6ENTC efflux and serum lipid and BC6OTHER levels were assessed.	False
BC6OTHER - labeled J774 macrophage cells, with and without BC6OTHER up - regulation, were incubated with the samples, and BC6ENTG - dependent BC6ENTC efflux and serum lipid and BC6OTHER levels were assessed.	CPR:9
Effect of isolated BC6ENTC supplementation on BC6ENTG - dependent BC6OTHER efflux potential in postmenopausal women.	False
Effect of isolated BC6OTHER supplementation on BC6ENTG - dependent BC6ENTC efflux potential in postmenopausal women.	False
Thus, BC6ENTC supplementation did not affect BC6ENTG - dependent BC6OTHER efflux to serum.	False
Thus, BC6OTHER supplementation did not affect BC6ENTG - dependent BC6ENTC efflux to serum.	CPR:9
However, as a novel finding, BC6ENTC treatment increased a subclass of BC6ENTG , the BC6OTHER levels by 18% without affecting any other serum lipid concentrations.	CPR:3
However, as a novel finding, BC6ENTC treatment increased a subclass of BC6OTHER , the BC6ENTG levels by 18% without affecting any other serum lipid concentrations.	CPR:3
We studied in a clinical trial whether isolated BC6ENTC treatment in postmenopausal women could affect reverse BC6OTHER transport as evaluated by BC6ENTG - ( BC6OTHER ), dependent BC6OTHER efflux from macrophages.	False
We studied in a clinical trial whether isolated BC6ENTC treatment in postmenopausal women could affect reverse BC6OTHER transport as evaluated by BC6OTHER - ( BC6ENTG ), dependent BC6OTHER efflux from macrophages.	False
BC6ENTG - facilitated BC6ENTC efflux and lipid parameters did not differ between BC6OTHER - producing and non - BC6OTHER - producing women.	CPR:9
BC6ENTG - facilitated BC6OTHER efflux and lipid parameters did not differ between BC6ENTC - producing and non - BC6OTHER - producing women.	False
This study evaluates the production of inflammatory biomarkers ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6ENTC absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6ENTC absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6ENTC absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ) and the influence of gene expression transporters and enzymes related to BC6ENTC absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6ENTC absorption and metabolism ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6ENTC absorption and metabolism ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6ENTC absorption and metabolism ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6ENTC absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6ENTG , BC6OTHER , BC6ENTC , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6ENTG , BC6ENTC , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6ENTC , BC6ENTG ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6ENTC ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6ENTC ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6ENTC ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6ENTC ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6ENTC ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ) produced by BC6ENTC ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ) produced by BC6ENTC ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ) produced by BC6ENTC ( BC6OTHER / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6ENTC / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6ENTC / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6ENTC / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6ENTC / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6ENTC / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6ENTC / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ) produced by BC6OTHER ( BC6ENTC / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ) produced by BC6OTHER ( BC6ENTC / BC6OTHER ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6ENTC ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6ENTC ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6ENTC ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6ENTC ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6ENTC ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6ENTC ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6ENTC ) in Caco - 2 cells.	False
This study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ) produced by BC6OTHER ( BC6OTHER / BC6ENTC ) in Caco - 2 cells.	False
In non - pre - treated cells, only BC6ENTG were down - regulated by BC6ENTC , showing a greater influence upon BC6OTHER expression.	CPR:4
In non - pre - treated cells, only BC6OTHER were down - regulated by BC6ENTC , showing a greater influence upon BC6ENTG expression.	False
Cell - pre - incubation with BC6ENTC induced changes in BC6ENTG expression levels after BC6OTHER - incubation; however, the energetic metabolism inhibition reduced BC6OTHER expression only in BC6OTHER - incubated cells.	False
Cell - pre - incubation with BC6ENTC induced changes in BC6OTHER expression levels after BC6OTHER - incubation; however, the energetic metabolism inhibition reduced BC6ENTG expression only in BC6OTHER - incubated cells.	False
Cell - pre - incubation with BC6ENTG induced changes in BC6OTHER expression levels after BC6OTHER - incubation; however, the energetic metabolism inhibition reduced BC6OTHER expression only in BC6ENTC - incubated cells.	False
Cell - pre - incubation with BC6OTHER induced changes in BC6ENTG expression levels after BC6OTHER - incubation; however, the energetic metabolism inhibition reduced BC6OTHER expression only in BC6ENTC - incubated cells.	False
Cell - pre - incubation with BC6OTHER induced changes in BC6OTHER expression levels after BC6OTHER - incubation; however, the energetic metabolism inhibition reduced BC6ENTG expression only in BC6ENTC - incubated cells.	CPR:4
Cell - pre - incubation with BC6ENTG induced changes in BC6OTHER expression levels after BC6ENTC - incubation; however, the energetic metabolism inhibition reduced BC6OTHER expression only in BC6OTHER - incubated cells.	False
Cell - pre - incubation with BC6OTHER induced changes in BC6ENTG expression levels after BC6ENTC - incubation; however, the energetic metabolism inhibition reduced BC6OTHER expression only in BC6OTHER - incubated cells.	False
Cell - pre - incubation with BC6OTHER induced changes in BC6OTHER expression levels after BC6ENTC - incubation; however, the energetic metabolism inhibition reduced BC6ENTG expression only in BC6OTHER - incubated cells.	False
Relative expression of c BC6ENTG and inflammation markers through the induction of BC6ENTC - mediated stress in Caco - 2 cells.	False
In non - pre - treated cells, BC6ENTG was up - regulated by both BC6ENTC .	CPR:3
These results suggest that internalization and excretion of BC6ENTC is probably influenced by [ BC6OTHER ]i, which also could mediate BC6ENTG activity in POPs metabolism.	False
These results suggest that internalization and excretion of BC6OTHER is probably influenced by [ BC6ENTC ]i, which also could mediate BC6ENTG activity in POPs metabolism.	False
The predicted structure of BC6ENTG showed three BC6OTHER , a BC6OTHER and a BC6ENTC protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6ENTG , a BC6OTHER and a BC6ENTC protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6ENTG and a BC6ENTC protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6ENTC protease domain, from its BC6OTHER - terminus, although BC6ENTG has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6ENTC protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6ENTG , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6ENTC protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6ENTG , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6ENTC protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6ENTG , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6ENTC protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6ENTG , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6ENTC protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6ENTG , and a BC6OTHER protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6ENTC protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6ENTG , from its BC6OTHER - terminus.	False
The predicted structure of BC6ENTG showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6ENTC - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6ENTG , a BC6OTHER and a BC6OTHER protease domain, from its BC6ENTC - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6ENTG and a BC6OTHER protease domain, from its BC6ENTC - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6ENTG , from its BC6ENTC - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6ENTC - terminus, although BC6ENTG has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6ENTC - terminus, although BC6OTHER has a BC6ENTG , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6ENTC - terminus, although BC6OTHER has a BC6OTHER , an BC6ENTG , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6ENTC - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6ENTG , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6ENTC - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6ENTG , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6ENTC - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6ENTG , and a BC6OTHER protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6ENTC - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6ENTG , from its BC6OTHER - terminus.	False
The predicted structure of BC6ENTG showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6ENTC protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6ENTG , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6ENTC protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6ENTG and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6ENTC protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6ENTG , from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6ENTC protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6ENTG has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6ENTC protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6ENTG , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6ENTC protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6ENTG , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6ENTC protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6ENTG , an BC6OTHER , a BC6OTHER , and a BC6ENTC protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6ENTG , a BC6OTHER , and a BC6ENTC protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6ENTG , and a BC6ENTC protease domain, from its BC6OTHER - terminus.	False
The predicted structure of BC6ENTG showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6ENTC - terminus.	False
The predicted structure of BC6OTHER showed three BC6ENTG , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6ENTC - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6ENTG and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6ENTC - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6ENTG , from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6ENTC - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6ENTG has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6ENTC - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6ENTG , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6ENTC - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6ENTG , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6ENTC - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6ENTG , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6ENTC - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6ENTG , a BC6OTHER , and a BC6OTHER protease domain, from its BC6ENTC - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6ENTG , and a BC6OTHER protease domain, from its BC6ENTC - terminus.	False
The predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6ENTG , from its BC6ENTC - terminus.	False
Thus, BC6ENTG was a heterodimer composed of 50 - kDa and 17 - kDa subunits, bridged by a BC6ENTC linkage.	False
Both subunits had novel BC6ENTC sequences, indicating that BC6ENTG was a novel hyaluronan - binding protein in human plasma.	False
The BC6ENTC sequence deduced from the BC6OTHER sequence of the cloned BC6ENTG cDNA exhibited significant homology to that of BC6OTHER ( BC6OTHER ).	False
The BC6ENTC sequence deduced from the BC6OTHER sequence of the cloned BC6OTHER cDNA exhibited significant homology to that of BC6ENTG ( BC6OTHER ).	False
The BC6ENTC sequence deduced from the BC6OTHER sequence of the cloned BC6OTHER cDNA exhibited significant homology to that of BC6OTHER ( BC6ENTG ).	False
The BC6OTHER sequence deduced from the BC6ENTC sequence of the cloned BC6ENTG cDNA exhibited significant homology to that of BC6OTHER ( BC6OTHER ).	False
The BC6OTHER sequence deduced from the BC6ENTC sequence of the cloned BC6OTHER cDNA exhibited significant homology to that of BC6ENTG ( BC6OTHER ).	False
The BC6OTHER sequence deduced from the BC6ENTC sequence of the cloned BC6OTHER cDNA exhibited significant homology to that of BC6OTHER ( BC6ENTG ).	False
Purification and characterization of a novel BC6ENTG ( BC6OTHER ) from human plasma: it has three EGF, a kringle and a BC6ENTC protease domain, similar to hepatocyte growth factor activator.	False
Purification and characterization of a novel BC6OTHER ( BC6ENTG ) from human plasma: it has three EGF, a kringle and a BC6ENTC protease domain, similar to hepatocyte growth factor activator.	False
However, plasma pro - BC6ENTG and BC6ENTC concentrations were closely correlated (P < .0001; r = 0.73).	False
Moreover, the active permethylated BC6ENTC aglycon derivatives examined exhibit BC6ENTG VRE antimicrobial activity at levels that approach (typically within 2 - fold) their activity against sensitive bacteria.	False
Consistent with an adult - onset isolated GHD model, mutant animals are hypoglycemic and display increased BC6ENTG sensitivity and BC6ENTC clearance.	False
Oxidation with BC6OTHER was similarly assessed, and adhesion of BC6ENTG and BC6OTHER from BC6ENTC buffered saline was then assayed by QCM and imaged by AFM.	False
Oxidation with BC6OTHER was similarly assessed, and adhesion of BC6OTHER and BC6ENTG from BC6ENTC buffered saline was then assayed by QCM and imaged by AFM.	False
BC6ENTC - functionalized sensors adsorbed multilayers of aggregated BC6ENTG , whereas BC6OTHER and BC6OTHER - terminated monolayers are consistent with small protein aggregates.	False
Selective oxidation of BC6OTHER self - assembled BC6OTHER monolayers to BC6ENTC is shown to transform the adhesion of model proteins BC6ENTG and BC6OTHER upon them.	False
Selective oxidation of BC6OTHER self - assembled BC6OTHER monolayers to BC6ENTC is shown to transform the adhesion of model proteins BC6OTHER and BC6ENTG upon them.	False
BC6OTHER - functionalized sensors adsorbed multilayers of aggregated BC6ENTG , whereas BC6ENTC and BC6OTHER - terminated monolayers are consistent with small protein aggregates.	False
BC6OTHER - functionalized sensors adsorbed multilayers of aggregated BC6ENTG , whereas BC6OTHER and BC6ENTC - terminated monolayers are consistent with small protein aggregates.	False
Selective oxidation of BC6ENTC self - assembled BC6OTHER monolayers to BC6OTHER is shown to transform the adhesion of model proteins BC6ENTG and BC6OTHER upon them.	False
Selective oxidation of BC6ENTC self - assembled BC6OTHER monolayers to BC6OTHER is shown to transform the adhesion of model proteins BC6OTHER and BC6ENTG upon them.	False
Selective oxidation of BC6OTHER self - assembled BC6ENTC monolayers to BC6OTHER is shown to transform the adhesion of model proteins BC6ENTG and BC6OTHER upon them.	False
Selective oxidation of BC6OTHER self - assembled BC6ENTC monolayers to BC6OTHER is shown to transform the adhesion of model proteins BC6OTHER and BC6ENTG upon them.	False
Oxidation with BC6ENTC was similarly assessed, and adhesion of BC6ENTG and BC6OTHER from BC6OTHER buffered saline was then assayed by QCM and imaged by AFM.	False
Oxidation with BC6ENTC was similarly assessed, and adhesion of BC6OTHER and BC6ENTG from BC6OTHER buffered saline was then assayed by QCM and imaged by AFM.	False
The key difference in structure of BC6ENTG and BC6OTHER is replacement of BC6ENTC with BC6OTHER at position 560.	False
The key difference in structure of BC6OTHER and BC6ENTG is replacement of BC6ENTC with BC6OTHER at position 560.	False
The key difference in structure of BC6ENTG and BC6OTHER is replacement of BC6OTHER with BC6ENTC at position 560.	False
The key difference in structure of BC6OTHER and BC6ENTG is replacement of BC6OTHER with BC6ENTC at position 560.	False
A series of compounds based on a BC6ENTC scaffold that are potent and selective inhibitors of BC6ENTG ( BC6OTHER ) activity are described.	CPR:4
A series of compounds based on a BC6ENTC scaffold that are potent and selective inhibitors of BC6OTHER ( BC6ENTG ) activity are described.	CPR:4
Discovery of BC6ENTC based BC6ENTG inhibitors.	CPR:4
After pretreatment with single BC6ENTC , cells were stimulated with pro - inflammatory BC6OTHER ( BC6ENTG , BC6OTHER , BC6OTHER ).	False
After pretreatment with single BC6ENTC , cells were stimulated with pro - inflammatory BC6OTHER ( BC6OTHER , BC6ENTG , BC6OTHER ).	False
After pretreatment with single BC6ENTC , cells were stimulated with pro - inflammatory BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTG ).	False
After pretreatment with single BC6ENTC , cells were stimulated with pro - inflammatory BC6ENTG ( BC6OTHER , BC6OTHER , BC6OTHER ).	False
We show that BC6ENTG and BC6OTHER do not reveal activity towards the checked CHEM, but that BC6OTHER reduces CHEM to BC6ENTC , and is thus also involved in CHEM metabolism.	False
We show that BC6OTHER and BC6ENTG do not reveal activity towards the checked CHEM, but that BC6OTHER reduces CHEM to BC6ENTC , and is thus also involved in CHEM metabolism.	False
We show that BC6OTHER and BC6OTHER do not reveal activity towards the checked CHEM, but that BC6ENTG reduces CHEM to BC6ENTC , and is thus also involved in CHEM metabolism.	CPR:9
Three BC6ENTC dehydrogenases ( BC6OTHER ) were tested for CHEM converting abilities: BC6ENTG and BC6OTHER .	False
Three BC6ENTC dehydrogenases ( BC6OTHER ) were tested for CHEM converting abilities: BC6OTHER and BC6ENTG .	False
Three BC6ENTC dehydrogenases ( BC6ENTG ) were tested for CHEM converting abilities: BC6OTHER and BC6OTHER .	False
 BC6ENTG , a BC6ENTC dehydrogenase causing Leber's congenital amaurosis, is also involved in CHEM metabolism.	False
BC6OTHER administration enhanced BC6ENTC ( BC6OTHER ) activity, BC6ENTG ( BC6OTHER ) expression and BC6OTHER / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice.	False
BC6OTHER administration enhanced BC6ENTC ( BC6OTHER ) activity, BC6OTHER ( BC6ENTG ) expression and BC6OTHER / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice.	False
BC6OTHER administration enhanced BC6ENTC ( BC6OTHER ) activity, BC6OTHER ( BC6OTHER ) expression and BC6ENTG / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice.	False
BC6OTHER administration enhanced BC6ENTC ( BC6OTHER ) activity, BC6OTHER ( BC6OTHER ) expression and BC6OTHER / BC6ENTG pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice.	False
BC6OTHER administration enhanced BC6OTHER ( BC6ENTC ) activity, BC6ENTG ( BC6OTHER ) expression and BC6OTHER / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice.	False
BC6OTHER administration enhanced BC6OTHER ( BC6ENTC ) activity, BC6OTHER ( BC6ENTG ) expression and BC6OTHER / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice.	False
BC6OTHER administration enhanced BC6OTHER ( BC6ENTC ) activity, BC6OTHER ( BC6OTHER ) expression and BC6ENTG / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice.	False
BC6OTHER administration enhanced BC6OTHER ( BC6ENTC ) activity, BC6OTHER ( BC6OTHER ) expression and BC6OTHER / BC6ENTG pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice.	False
BC6OTHER administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6ENTG ( BC6OTHER ) expression and BC6OTHER / BC6OTHER pathway activation, which might ameliorate BC6ENTC injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice.	False
BC6OTHER administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6OTHER ( BC6ENTG ) expression and BC6OTHER / BC6OTHER pathway activation, which might ameliorate BC6ENTC injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice.	False
BC6OTHER administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6OTHER ( BC6OTHER ) expression and BC6ENTG / BC6OTHER pathway activation, which might ameliorate BC6ENTC injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice.	False
BC6OTHER administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6OTHER ( BC6OTHER ) expression and BC6OTHER / BC6ENTG pathway activation, which might ameliorate BC6ENTC injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice.	False
BC6OTHER administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6ENTG ( BC6OTHER ) expression and BC6OTHER / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6ENTC species (ROS) formation in mice.	False
BC6OTHER administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6OTHER ( BC6ENTG ) expression and BC6OTHER / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6ENTC species (ROS) formation in mice.	False
BC6OTHER administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6OTHER ( BC6OTHER ) expression and BC6ENTG / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6ENTC species (ROS) formation in mice.	False
BC6OTHER administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6OTHER ( BC6OTHER ) expression and BC6OTHER / BC6ENTG pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6ENTC species (ROS) formation in mice.	False
In addition to the effect on ROS, BC6ENTC ameliorated BC6OTHER - reduced BC6ENTG ( BC6OTHER ) expression.	False
In addition to the effect on ROS, BC6ENTC ameliorated BC6OTHER - reduced BC6OTHER ( BC6ENTG ) expression.	CPR:4
In addition to the effect on ROS, BC6OTHER ameliorated BC6ENTC - reduced BC6ENTG ( BC6OTHER ) expression.	CPR:4
In addition to the effect on ROS, BC6OTHER ameliorated BC6ENTC - reduced BC6OTHER ( BC6ENTG ) expression.	CPR:4
Taken together, our data demonstrate that BC6ENTC attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6ENTG expression, BC6OTHER / BC6OTHER pathway and BC6OTHER activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6OTHER expression.	False
Taken together, our data demonstrate that BC6ENTC attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6ENTG / BC6OTHER pathway and BC6OTHER activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6OTHER expression.	False
Taken together, our data demonstrate that BC6ENTC attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6OTHER / BC6ENTG pathway and BC6OTHER activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6OTHER expression.	False
Taken together, our data demonstrate that BC6ENTC attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6OTHER / BC6OTHER pathway and BC6OTHER activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6ENTG expression.	CPR:4
Taken together, our data demonstrate that BC6OTHER attenuates BC6ENTC - induced dopaminergic neuronal degeneration via modulating BC6ENTG expression, BC6OTHER / BC6OTHER pathway and BC6OTHER activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6OTHER expression.	False
Taken together, our data demonstrate that BC6OTHER attenuates BC6ENTC - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6ENTG / BC6OTHER pathway and BC6OTHER activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6OTHER expression.	False
Taken together, our data demonstrate that BC6OTHER attenuates BC6ENTC - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6OTHER / BC6ENTG pathway and BC6OTHER activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6OTHER expression.	False
Taken together, our data demonstrate that BC6OTHER attenuates BC6ENTC - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6OTHER / BC6OTHER pathway and BC6OTHER activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6ENTG expression.	False
Taken together, our data demonstrate that BC6OTHER attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6ENTG expression, BC6OTHER / BC6OTHER pathway and BC6ENTC activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6OTHER expression.	False
Taken together, our data demonstrate that BC6OTHER attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6ENTG / BC6OTHER pathway and BC6ENTC activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6OTHER expression.	False
Taken together, our data demonstrate that BC6OTHER attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6OTHER / BC6ENTG pathway and BC6ENTC activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6OTHER expression.	False
Taken together, our data demonstrate that BC6OTHER attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6OTHER / BC6OTHER pathway and BC6ENTC activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6ENTG expression.	False
Taken together, our data demonstrate that BC6OTHER attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6ENTG expression, BC6OTHER / BC6OTHER pathway and BC6OTHER activation, which subsequently ameliorate BC6ENTC - induced ROS formation and decrease of BC6OTHER expression.	False
Taken together, our data demonstrate that BC6OTHER attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6ENTG / BC6OTHER pathway and BC6OTHER activation, which subsequently ameliorate BC6ENTC - induced ROS formation and decrease of BC6OTHER expression.	False
Taken together, our data demonstrate that BC6OTHER attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6OTHER / BC6ENTG pathway and BC6OTHER activation, which subsequently ameliorate BC6ENTC - induced ROS formation and decrease of BC6OTHER expression.	False
Taken together, our data demonstrate that BC6OTHER attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6OTHER / BC6OTHER pathway and BC6OTHER activation, which subsequently ameliorate BC6ENTC - induced ROS formation and decrease of BC6ENTG expression.	CPR:4
BC6ENTC administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6ENTG ( BC6OTHER ) expression and BC6OTHER / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice.	CPR:3
BC6ENTC administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6OTHER ( BC6ENTG ) expression and BC6OTHER / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice.	CPR:3
BC6ENTC administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6OTHER ( BC6OTHER ) expression and BC6ENTG / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice.	CPR:3
BC6ENTC administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6OTHER ( BC6OTHER ) expression and BC6OTHER / BC6ENTG pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice.	CPR:3
We have identified BC6ENTC deaminase, an enzyme involved in BC6OTHER metabolism whose deficiency is associated with severe combined immunodeficiency, as a BC6ENTG binding protein that is not able to bind to BC6OTHER .	False
We have identified BC6ENTC deaminase, an enzyme involved in BC6OTHER metabolism whose deficiency is associated with severe combined immunodeficiency, as a BC6OTHER binding protein that is not able to bind to BC6ENTG .	False
We have identified BC6ENTG , an enzyme involved in BC6ENTC metabolism whose deficiency is associated with severe combined immunodeficiency, as a BC6OTHER binding protein that is not able to bind to BC6OTHER .	CPR:9
We have identified BC6OTHER deaminase, an enzyme involved in BC6ENTC metabolism whose deficiency is associated with severe combined immunodeficiency, as a BC6ENTG binding protein that is not able to bind to BC6OTHER .	False
We have identified BC6OTHER deaminase, an enzyme involved in BC6ENTC metabolism whose deficiency is associated with severe combined immunodeficiency, as a BC6OTHER binding protein that is not able to bind to BC6ENTG .	False
 BC6ENTC deaminase is a specific partner for the BC6ENTG isoform BC6OTHER .	False
 BC6ENTC deaminase is a specific partner for the BC6OTHER isoform BC6ENTG .	False
injection of a subthreshold dose of BC6ENTC , a use - dependent BC6ENTG antagonist, reduces cortical electroencephalogram delta power and transiently inhibits spontaneous seizure activity in ADNFLE mutant mice.	CPR:6
Among all the BC6OTHER tested, the combination of a CHEM group and a negatively charged BC6ENTC attached to the BC6OTHER atom, BC6OTHER - BC6ENTG , conferred the greatest protection to the active site of aged or nonaged BC6OTHER conjugates of BC6OTHER .	False
Among all the BC6OTHER tested, the combination of a CHEM group and a negatively charged BC6ENTC attached to the BC6OTHER atom, BC6OTHER - BC6OTHER , conferred the greatest protection to the active site of aged or nonaged BC6OTHER conjugates of BC6ENTG .	False
Among all the BC6OTHER tested, the combination of a CHEM group and a negatively charged BC6OTHER attached to the BC6ENTC atom, BC6OTHER - BC6ENTG , conferred the greatest protection to the active site of aged or nonaged BC6OTHER conjugates of BC6OTHER .	False
Among all the BC6OTHER tested, the combination of a CHEM group and a negatively charged BC6OTHER attached to the BC6ENTC atom, BC6OTHER - BC6OTHER , conferred the greatest protection to the active site of aged or nonaged BC6OTHER conjugates of BC6ENTG .	False
Among all the BC6OTHER tested, the combination of a CHEM group and a negatively charged BC6OTHER attached to the BC6OTHER atom, BC6ENTC - BC6ENTG , conferred the greatest protection to the active site of aged or nonaged BC6OTHER conjugates of BC6OTHER .	False
Among all the BC6OTHER tested, the combination of a CHEM group and a negatively charged BC6OTHER attached to the BC6OTHER atom, BC6ENTC - BC6OTHER , conferred the greatest protection to the active site of aged or nonaged BC6OTHER conjugates of BC6ENTG .	False
Among all the BC6OTHER tested, the combination of a CHEM group and a negatively charged BC6OTHER attached to the BC6OTHER atom, BC6OTHER - BC6ENTG , conferred the greatest protection to the active site of aged or nonaged BC6ENTC conjugates of BC6OTHER .	False
Among all the BC6OTHER tested, the combination of a CHEM group and a negatively charged BC6OTHER attached to the BC6OTHER atom, BC6OTHER - BC6OTHER , conferred the greatest protection to the active site of aged or nonaged BC6ENTC conjugates of BC6ENTG .	False
Monoclonal antibody 25B1 generated against BC6ENTC inhibited fetal BC6OTHER has been extensively characterized with respect to its BC6ENTG properties.	False
Monoclonal antibody 25B1 generated against BC6ENTC inhibited fetal BC6ENTG has been extensively characterized with respect to its BC6OTHER properties.	CPR:4
Monoclonal antibody 25B1 appears to be directed against a conformational epitope located in close proximity to the catalytic center of the enzyme and was found to be most suitable for studying the stabilization of the active site of BC6ENTG against denaturation by heat or BC6ENTC following phosphorylation by CHEM BC6OTHER compounds.	CPR:4
Monoclonal antibody 25B1 appears to be directed against a conformational epitope located in close proximity to the catalytic center of the enzyme and was found to be most suitable for studying the stabilization of the active site of BC6OTHER against denaturation by heat or BC6ENTC following phosphorylation by CHEM BC6ENTG compounds.	False
Among all the BC6ENTC tested, the combination of a CHEM group and a negatively charged BC6OTHER attached to the BC6OTHER atom, BC6OTHER - BC6ENTG , conferred the greatest protection to the active site of aged or nonaged BC6OTHER conjugates of BC6OTHER .	False
Among all the BC6ENTC tested, the combination of a CHEM group and a negatively charged BC6OTHER attached to the BC6OTHER atom, BC6OTHER - BC6OTHER , conferred the greatest protection to the active site of aged or nonaged BC6OTHER conjugates of BC6ENTG .	False
Here, we demonstrate that BC6ENTG ( BC6OTHER ) modulates the action of BC6OTHER - mediated signalling by interacting with BC6ENTC kinase Jak2 ( BC6OTHER ) in a BC6OTHER - dependent manner.	False
Here, we demonstrate that BC6OTHER ( BC6ENTG ) modulates the action of BC6OTHER - mediated signalling by interacting with BC6ENTC kinase Jak2 ( BC6OTHER ) in a BC6OTHER - dependent manner.	False
Here, we demonstrate that BC6OTHER ( BC6OTHER ) modulates the action of BC6ENTG - mediated signalling by interacting with BC6ENTC kinase Jak2 ( BC6OTHER ) in a BC6OTHER - dependent manner.	False
Here, we demonstrate that BC6OTHER ( BC6OTHER ) modulates the action of BC6OTHER - mediated signalling by interacting with BC6ENTC kinase Jak2 ( BC6ENTG ) in a BC6OTHER - dependent manner.	False
Here, we demonstrate that BC6OTHER ( BC6OTHER ) modulates the action of BC6OTHER - mediated signalling by interacting with BC6ENTC kinase Jak2 ( BC6OTHER ) in a BC6ENTG - dependent manner.	False
Interestingly, BC6ENTG physically linked BC6OTHER and protein BC6ENTC phosphatase - 1B ( BC6OTHER ) by binding to both using different domains, and this process was implicated in the modulation of BC6OTHER signalling through BC6OTHER .	False
Interestingly, BC6OTHER physically linked BC6ENTG and protein BC6ENTC phosphatase - 1B ( BC6OTHER ) by binding to both using different domains, and this process was implicated in the modulation of BC6OTHER signalling through BC6OTHER .	False
Interestingly, BC6OTHER physically linked BC6OTHER and protein BC6ENTC phosphatase - 1B ( BC6ENTG ) by binding to both using different domains, and this process was implicated in the modulation of BC6OTHER signalling through BC6OTHER .	False
Interestingly, BC6OTHER physically linked BC6OTHER and protein BC6ENTC phosphatase - 1B ( BC6OTHER ) by binding to both using different domains, and this process was implicated in the modulation of BC6ENTG signalling through BC6OTHER .	False
Interestingly, BC6OTHER physically linked BC6OTHER and protein BC6ENTC phosphatase - 1B ( BC6OTHER ) by binding to both using different domains, and this process was implicated in the modulation of BC6OTHER signalling through BC6ENTG .	False
 BC6ENTG negatively regulates BC6OTHER signalling by forming a ternary complex with BC6OTHER and protein BC6ENTC phosphatase - 1B.	False
 BC6OTHER negatively regulates BC6OTHER signalling by forming a ternary complex with BC6ENTG and protein BC6ENTC phosphatase - 1B.	False
 BC6OTHER negatively regulates BC6ENTG signalling by forming a ternary complex with BC6OTHER and protein BC6ENTC phosphatase - 1B.	False
In contrast, BC6OTHER - like nonselective NSAIDs such as BC6OTHER and BC6ENTC inhibit not only the enzymatic action of the highly inducible, proinflammatory BC6ENTG but the constitutively expressed, cytoprotective BC6OTHER as well.	CPR:4
In contrast, BC6OTHER - like nonselective NSAIDs such as BC6OTHER and BC6ENTC inhibit not only the enzymatic action of the highly inducible, proinflammatory BC6OTHER but the constitutively expressed, cytoprotective BC6ENTG as well.	CPR:4
Selective BC6OTHER inhibitors, such as BC6ENTC , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6ENTG but not BC6OTHER .	CPR:4
Selective BC6OTHER inhibitors, such as BC6ENTC , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6OTHER but not BC6ENTG .	False
Selective BC6ENTG inhibitors, such as BC6ENTC , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6OTHER but not BC6OTHER .	CPR:4
Selective BC6OTHER inhibitors, such as BC6OTHER , BC6ENTC ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6ENTG but not BC6OTHER .	CPR:4
Selective BC6OTHER inhibitors, such as BC6OTHER , BC6ENTC ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6OTHER but not BC6ENTG .	False
Selective BC6ENTG inhibitors, such as BC6OTHER , BC6ENTC ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6OTHER but not BC6OTHER .	CPR:4
Selective BC6OTHER inhibitors, such as BC6OTHER , BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6ENTG but not BC6OTHER .	CPR:4
Selective BC6OTHER inhibitors, such as BC6OTHER , BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6OTHER but not BC6ENTG .	False
Selective BC6ENTG inhibitors, such as BC6OTHER , BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6OTHER but not BC6OTHER .	CPR:4
Selective BC6OTHER inhibitors, such as BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTC ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6ENTG but not BC6OTHER .	CPR:4
Selective BC6OTHER inhibitors, such as BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTC ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6OTHER but not BC6ENTG .	False
Selective BC6ENTG inhibitors, such as BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTC ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6OTHER but not BC6OTHER .	CPR:4
Selective BC6OTHER inhibitors, such as BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTC ), are NSAIDs that have been modified chemically to preferentially inhibit BC6ENTG but not BC6OTHER .	CPR:4
Selective BC6OTHER inhibitors, such as BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTC ), are NSAIDs that have been modified chemically to preferentially inhibit BC6OTHER but not BC6ENTG .	False
Selective BC6ENTG inhibitors, such as BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTC ), are NSAIDs that have been modified chemically to preferentially inhibit BC6OTHER but not BC6OTHER .	CPR:4
For instance, BC6ENTC inhibits the growth of cultured colon cancer cells (HCA - 7 and Moser - S) that express BC6ENTG but has no effect on HCT - 116 tumor cells that do not express BC6OTHER .	CPR:4
For instance, BC6ENTC inhibits the growth of cultured colon cancer cells (HCA - 7 and Moser - S) that express BC6OTHER but has no effect on HCT - 116 tumor cells that do not express BC6ENTG .	False
BC6ENTC induces apoptosis in BC6ENTG expressing LNCaP prostate cancer cells and, surprisingly, in colon cancer S / KS cells that does not express BC6OTHER .	False
BC6ENTC induces apoptosis in BC6OTHER expressing LNCaP prostate cancer cells and, surprisingly, in colon cancer S / KS cells that does not express BC6ENTG .	False
This effect may due to induction of apoptosis through uncoupling of oxidative phosphorylation and down - regulation of BC6ENTG , as has been demonstrated for some nonselective NSAIDs, for instance, BC6ENTC .	CPR:4
BC6ENTG produces BC6ENTC that inhibit apoptosis and stimulate angiogenesis and invasiveness.	CPR:9
Selective BC6ENTG inhibitors reduce BC6ENTC synthesis, restore apoptosis, and inhibit cancer cell proliferation.	False
In contrast, BC6ENTC - like nonselective NSAIDs such as BC6OTHER and BC6OTHER inhibit not only the enzymatic action of the highly inducible, proinflammatory BC6ENTG but the constitutively expressed, cytoprotective BC6OTHER as well.	CPR:4
In contrast, BC6ENTC - like nonselective NSAIDs such as BC6OTHER and BC6OTHER inhibit not only the enzymatic action of the highly inducible, proinflammatory BC6OTHER but the constitutively expressed, cytoprotective BC6ENTG as well.	CPR:4
In contrast, BC6OTHER - like nonselective NSAIDs such as BC6ENTC and BC6OTHER inhibit not only the enzymatic action of the highly inducible, proinflammatory BC6ENTG but the constitutively expressed, cytoprotective BC6OTHER as well.	CPR:4
In contrast, BC6OTHER - like nonselective NSAIDs such as BC6ENTC and BC6OTHER inhibit not only the enzymatic action of the highly inducible, proinflammatory BC6OTHER but the constitutively expressed, cytoprotective BC6ENTG as well.	CPR:4
The large - conductance, BC6ENTG blocker, iberiotoxin, attenuated BC6ENTC actions.	False
Effects of glutamatergic input would be, thus, expected not only to be excitation via stimulation of ionotropic BC6ENTC receptors and BC6ENTG , but also inhibition via actions at BC6OTHER and BC6OTHER on these neurons.	False
Effects of glutamatergic input would be, thus, expected not only to be excitation via stimulation of ionotropic BC6ENTC receptors and BC6OTHER , but also inhibition via actions at BC6ENTG and BC6OTHER on these neurons.	False
Effects of glutamatergic input would be, thus, expected not only to be excitation via stimulation of ionotropic BC6ENTC receptors and BC6OTHER , but also inhibition via actions at BC6OTHER and BC6ENTG on these neurons.	False
Both outward currents were significantly reduced by the BC6ENTG antagonist BC6ENTC and the BC6OTHER - induced current was blocked by the specific BC6OTHER antagonist BC6OTHER .	CPR:6
Both outward currents were significantly reduced by the BC6OTHER antagonist BC6ENTC and the BC6OTHER - induced current was blocked by the specific BC6ENTG antagonist BC6OTHER .	False
Therefore, electrophysiological responses and changes in levels of intracellular BC6ENTC in mouse cholinergic LDT neurons following application of specific BC6ENTG agonists and antagonists were examined.	False
Unexpectedly, both the BC6ENTG specific agonist, BC6ENTC , and the BC6OTHER ( BC6OTHER ) agonist, BC6OTHER (LY), induced a BC6OTHER - insensitive outward current / hyperpolarization.	CPR:5
Unexpectedly, both the BC6OTHER specific agonist, BC6ENTC , and the BC6ENTG ( BC6OTHER ) agonist, BC6OTHER (LY), induced a BC6OTHER - insensitive outward current / hyperpolarization.	False
Unexpectedly, both the BC6OTHER specific agonist, BC6ENTC , and the BC6OTHER ( BC6ENTG ) agonist, BC6OTHER (LY), induced a BC6OTHER - insensitive outward current / hyperpolarization.	False
Unexpectedly, both the BC6ENTG specific agonist, BC6OTHER , and the BC6OTHER ( BC6OTHER ) agonist, BC6ENTC (LY), induced a BC6OTHER - insensitive outward current / hyperpolarization.	False
Unexpectedly, both the BC6OTHER specific agonist, BC6OTHER , and the BC6ENTG ( BC6OTHER ) agonist, BC6ENTC (LY), induced a BC6OTHER - insensitive outward current / hyperpolarization.	CPR:5
Unexpectedly, both the BC6OTHER specific agonist, BC6OTHER , and the BC6OTHER ( BC6ENTG ) agonist, BC6ENTC (LY), induced a BC6OTHER - insensitive outward current / hyperpolarization.	False
Unexpectedly, both the BC6ENTG specific agonist, BC6OTHER , and the BC6OTHER ( BC6OTHER ) agonist, BC6OTHER (LY), induced a BC6ENTC - insensitive outward current / hyperpolarization.	False
Unexpectedly, both the BC6OTHER specific agonist, BC6OTHER , and the BC6ENTG ( BC6OTHER ) agonist, BC6OTHER (LY), induced a BC6ENTC - insensitive outward current / hyperpolarization.	False
Unexpectedly, both the BC6OTHER specific agonist, BC6OTHER , and the BC6OTHER ( BC6ENTG ) agonist, BC6OTHER (LY), induced a BC6ENTC - insensitive outward current / hyperpolarization.	False
Both outward currents were significantly reduced by the BC6ENTG antagonist BC6OTHER and the BC6ENTC - induced current was blocked by the specific BC6OTHER antagonist BC6OTHER .	False
Both outward currents were significantly reduced by the BC6OTHER antagonist BC6OTHER and the BC6ENTC - induced current was blocked by the specific BC6ENTG antagonist BC6OTHER .	False
Both outward currents were significantly reduced by the BC6ENTG antagonist BC6OTHER and the BC6OTHER - induced current was blocked by the specific BC6OTHER antagonist BC6ENTC .	False
Both outward currents were significantly reduced by the BC6OTHER antagonist BC6OTHER and the BC6OTHER - induced current was blocked by the specific BC6ENTG antagonist BC6ENTC .	CPR:6
In Experiment 2, BC6ENTC induced a significant decrease (p<0.05) in BC6ENTG number and binding affinity at both 0.5 and 4 hours compared with controls.	CPR:4
BC6ENTC and BC6OTHER did not alter BC6ENTG number or binding affinity significantly at each time point studied compared with controls.	False
BC6OTHER and BC6ENTC did not alter BC6ENTG number or binding affinity significantly at each time point studied compared with controls.	False
In conclusion, BC6ENTC may inhibit the uterine response to BC6ENTG by decreasing BC6OTHER numbers and BC6OTHER binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6OTHER .	CPR:4
In conclusion, BC6ENTC may inhibit the uterine response to BC6OTHER by decreasing BC6ENTG numbers and BC6OTHER binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6OTHER .	CPR:4
In conclusion, BC6ENTC may inhibit the uterine response to BC6OTHER by decreasing BC6OTHER numbers and BC6ENTG binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6OTHER .	False
In conclusion, BC6ENTC may inhibit the uterine response to BC6OTHER by decreasing BC6OTHER numbers and BC6OTHER binding affinity, which might explain the prolonged BC6ENTG antagonist activity of BC6OTHER .	False
In conclusion, BC6OTHER may inhibit the uterine response to BC6ENTC by decreasing BC6ENTG numbers and BC6OTHER binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6OTHER .	False
In conclusion, BC6OTHER may inhibit the uterine response to BC6ENTC by decreasing BC6OTHER numbers and BC6ENTG binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6OTHER .	False
In conclusion, BC6OTHER may inhibit the uterine response to BC6ENTC by decreasing BC6OTHER numbers and BC6OTHER binding affinity, which might explain the prolonged BC6ENTG antagonist activity of BC6OTHER .	False
In conclusion, BC6OTHER may inhibit the uterine response to BC6ENTG by decreasing BC6ENTC receptor numbers and BC6OTHER binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6OTHER .	False
In conclusion, BC6OTHER may inhibit the uterine response to BC6OTHER by decreasing BC6ENTC receptor numbers and BC6ENTG binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6OTHER .	False
In conclusion, BC6OTHER may inhibit the uterine response to BC6OTHER by decreasing BC6ENTC receptor numbers and BC6OTHER binding affinity, which might explain the prolonged BC6ENTG antagonist activity of BC6OTHER .	False
BC6ENTC antagonist (OTA), BC6OTHER , was developed by our group and shown to inhibit either spontaneous or BC6ENTG - induced uterine contractions in primates.	False
In conclusion, BC6OTHER may inhibit the uterine response to BC6ENTG by decreasing BC6OTHER numbers and BC6ENTC binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6OTHER .	False
In conclusion, BC6OTHER may inhibit the uterine response to BC6OTHER by decreasing BC6ENTG numbers and BC6ENTC binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6OTHER .	False
In conclusion, BC6OTHER may inhibit the uterine response to BC6OTHER by decreasing BC6OTHER numbers and BC6ENTC binding affinity, which might explain the prolonged BC6ENTG antagonist activity of BC6OTHER .	False
In conclusion, BC6OTHER may inhibit the uterine response to BC6ENTG by decreasing BC6OTHER numbers and BC6OTHER binding affinity, which might explain the prolonged BC6ENTC antagonist activity of BC6OTHER .	False
In conclusion, BC6OTHER may inhibit the uterine response to BC6OTHER by decreasing BC6ENTG numbers and BC6OTHER binding affinity, which might explain the prolonged BC6ENTC antagonist activity of BC6OTHER .	False
In conclusion, BC6OTHER may inhibit the uterine response to BC6OTHER by decreasing BC6OTHER numbers and BC6ENTG binding affinity, which might explain the prolonged BC6ENTC antagonist activity of BC6OTHER .	False
The purpose of the present study was to confirm the duration of BC6ENTC to block BC6ENTG - induced uterine contractions in estrous rats.	CPR:4
In conclusion, BC6OTHER may inhibit the uterine response to BC6ENTG by decreasing BC6OTHER numbers and BC6OTHER binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6ENTC .	False
In conclusion, BC6OTHER may inhibit the uterine response to BC6OTHER by decreasing BC6ENTG numbers and BC6OTHER binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6ENTC .	False
In conclusion, BC6OTHER may inhibit the uterine response to BC6OTHER by decreasing BC6OTHER numbers and BC6ENTG binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6ENTC .	False
In conclusion, BC6OTHER may inhibit the uterine response to BC6OTHER by decreasing BC6OTHER numbers and BC6OTHER binding affinity, which might explain the prolonged BC6ENTG antagonist activity of BC6ENTC .	CPR:6
BC6ENTG antagonist (OTA), BC6ENTC , was developed by our group and shown to inhibit either spontaneous or BC6OTHER - induced uterine contractions in primates.	CPR:6
BC6OTHER antagonist (OTA), BC6ENTC , was developed by our group and shown to inhibit either spontaneous or BC6ENTG - induced uterine contractions in primates.	CPR:4
BC6ENTG antagonist (OTA), BC6OTHER , was developed by our group and shown to inhibit either spontaneous or BC6ENTC - induced uterine contractions in primates.	False
In Experiment 1, BC6ENTC , BC6OTHER and BC6OTHER inhibited the integrated uterine response to BC6ENTG at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05).	CPR:4
In Experiment 1, BC6OTHER , BC6ENTC and BC6OTHER inhibited the integrated uterine response to BC6ENTG at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05).	CPR:4
In Experiment 1, BC6OTHER , BC6OTHER and BC6ENTC inhibited the integrated uterine response to BC6ENTG at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05).	CPR:4
At a mechanistic level both extracts down - regulated BC6ENTG activation, which is associated with BC6ENTC - induced BC6OTHER resistance.	False
At a mechanistic level both extracts down - regulated BC6OTHER activation, which is associated with BC6ENTC - induced BC6ENTG resistance.	False
Protein levels of the BC6ENTC transporter ( BC6ENTG ) involved in BC6OTHER transport via these two pathways were also increased.	False
Protein levels of the BC6ENTG ( BC6OTHER ) involved in BC6ENTC transport via these two pathways were also increased.	CPR:9
Protein levels of the BC6OTHER ( BC6ENTG ) involved in BC6ENTC transport via these two pathways were also increased.	CPR:9
This in vitro study therefore confirms that rooibos can ameliorate BC6ENTC - induced BC6ENTG resistance in C2C12 skeletal muscle cells.	False
Increased levels of BC6ENTC ( BC6OTHER ), specifically BC6OTHER such as BC6OTHER are associated with BC6ENTG resistance of muscle, fat and liver.	False
Rooibos (Aspalathus linearis) and its unique BC6ENTC , BC6OTHER , shown to reduce hyperglycemia in diabetic rats, could play a role in preventing or ameliorating the development of BC6ENTG resistance.	False
Increased levels of BC6OTHER ( BC6ENTC ), specifically BC6OTHER such as BC6OTHER are associated with BC6ENTG resistance of muscle, fat and liver.	False
Rooibos (Aspalathus linearis) and its unique BC6OTHER , BC6ENTC , shown to reduce hyperglycemia in diabetic rats, could play a role in preventing or ameliorating the development of BC6ENTG resistance.	False
Increased levels of BC6OTHER ( BC6OTHER ), specifically BC6ENTC such as BC6OTHER are associated with BC6ENTG resistance of muscle, fat and liver.	False
Increased levels of BC6OTHER ( BC6OTHER ), specifically BC6OTHER such as BC6ENTC are associated with BC6ENTG resistance of muscle, fat and liver.	False
Amelioration of BC6ENTC - induced BC6ENTG resistance in C2C12 muscle cells by rooibos (Aspalathus linearis).	False
In the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6ENTC , was abolished by the BC6ENTG antagonist, BC6OTHER , the potent BC6OTHER antagonist, BC6OTHER and the preferential BC6OTHER antagonist, BC6OTHER .	False
In the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6ENTC , was abolished by the BC6OTHER antagonist, BC6OTHER , the potent BC6ENTG antagonist, BC6OTHER and the preferential BC6OTHER antagonist, BC6OTHER .	False
In the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6ENTC , was abolished by the BC6OTHER antagonist, BC6OTHER , the potent BC6OTHER antagonist, BC6OTHER and the preferential BC6ENTG antagonist, BC6OTHER .	False
In the hot - plate test in mice, the antinociceptive action of the BC6ENTG agonist, BC6ENTC , was abolished by the BC6OTHER antagonist, BC6OTHER , the potent BC6OTHER antagonist, BC6OTHER and the preferential BC6OTHER antagonist, BC6OTHER .	CPR:5
In the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6OTHER , was abolished by the BC6ENTG antagonist, BC6ENTC , the potent BC6OTHER antagonist, BC6OTHER and the preferential BC6OTHER antagonist, BC6OTHER .	CPR:6
In the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6OTHER , was abolished by the BC6OTHER antagonist, BC6ENTC , the potent BC6ENTG antagonist, BC6OTHER and the preferential BC6OTHER antagonist, BC6OTHER .	False
In the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6OTHER , was abolished by the BC6OTHER antagonist, BC6ENTC , the potent BC6OTHER antagonist, BC6OTHER and the preferential BC6ENTG antagonist, BC6OTHER .	False
In the hot - plate test in mice, the antinociceptive action of the BC6ENTG agonist, BC6OTHER , was abolished by the BC6OTHER antagonist, BC6ENTC , the potent BC6OTHER antagonist, BC6OTHER and the preferential BC6OTHER antagonist, BC6OTHER .	False
In the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6OTHER , was abolished by the BC6ENTG antagonist, BC6OTHER , the potent BC6OTHER antagonist, BC6ENTC and the preferential BC6OTHER antagonist, BC6OTHER .	False
In the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6OTHER , was abolished by the BC6OTHER antagonist, BC6OTHER , the potent BC6ENTG antagonist, BC6ENTC and the preferential BC6OTHER antagonist, BC6OTHER .	CPR:6
In the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6OTHER , was abolished by the BC6OTHER antagonist, BC6OTHER , the potent BC6OTHER antagonist, BC6ENTC and the preferential BC6ENTG antagonist, BC6OTHER .	False
In the hot - plate test in mice, the antinociceptive action of the BC6ENTG agonist, BC6OTHER , was abolished by the BC6OTHER antagonist, BC6OTHER , the potent BC6OTHER antagonist, BC6ENTC and the preferential BC6OTHER antagonist, BC6OTHER .	False
In the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6OTHER , was abolished by the BC6ENTG antagonist, BC6OTHER , the potent BC6OTHER antagonist, BC6OTHER and the preferential BC6OTHER antagonist, BC6ENTC .	False
In the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6OTHER , was abolished by the BC6OTHER antagonist, BC6OTHER , the potent BC6ENTG antagonist, BC6OTHER and the preferential BC6OTHER antagonist, BC6ENTC .	False
In the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6OTHER , was abolished by the BC6OTHER antagonist, BC6OTHER , the potent BC6OTHER antagonist, BC6OTHER and the preferential BC6ENTG antagonist, BC6ENTC .	CPR:6
In the hot - plate test in mice, the antinociceptive action of the BC6ENTG agonist, BC6OTHER , was abolished by the BC6OTHER antagonist, BC6OTHER , the potent BC6OTHER antagonist, BC6OTHER and the preferential BC6OTHER antagonist, BC6ENTC .	False
In contrast, the preferential BC6ENTG ligands ('antagonists'), BC6ENTC , BC6OTHER and BC6OTHER were inactive.	False
In contrast, the preferential BC6ENTG ligands ('antagonists'), BC6OTHER , BC6ENTC and BC6OTHER were inactive.	False
In contrast, the preferential BC6ENTG ligands ('antagonists'), BC6OTHER , BC6OTHER and BC6ENTC were inactive.	False
The preferential BC6ENTG partial agonist, BC6ENTC , partially inhibited BC6OTHER - induced antinociception.	CPR:5
The preferential BC6ENTG partial agonist, BC6OTHER , partially inhibited BC6ENTC - induced antinociception.	CPR:5
EA (15mg / kgb.w., p.o.×14days) treatment modulated enhanced BC6ENTC level, lipid peroxidation, BC6ENTG activity, BC6OTHER production and protein BC6OTHER formation in lungs of rats exposed to toxic anticancer drugs.	False
EA (15mg / kgb.w., p.o.×14days) treatment modulated enhanced BC6OTHER level, lipid peroxidation, BC6ENTG activity, BC6ENTC production and protein BC6OTHER formation in lungs of rats exposed to toxic anticancer drugs.	False
EA (15mg / kgb.w., p.o.×14days) treatment modulated enhanced BC6OTHER level, lipid peroxidation, BC6ENTG activity, BC6OTHER production and protein BC6ENTC formation in lungs of rats exposed to toxic anticancer drugs.	False
As discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6ENTG and BC6OTHER activities.	CPR:4
As discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6OTHER and BC6ENTG activities.	CPR:4
As discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6ENTG and BC6OTHER activities.	CPR:4
As discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6OTHER and BC6ENTG activities.	CPR:4
As discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6ENTG and BC6OTHER activities.	CPR:4
As discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6OTHER and BC6ENTG activities.	CPR:4
As discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6ENTC in breast cancer by blocking BC6ENTG and BC6OTHER activities.	CPR:9
As discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6ENTC in breast cancer by blocking BC6OTHER and BC6ENTG activities.	CPR:9
As discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6ENTG and BC6ENTC - dehydrogenase type 1 activities.	False
In conclusion, treatment with anti - aromatases combined with anti - BC6ENTG or BC6ENTC - dehydrogenase type 1 could provide new therapeutic possibilities in the treatment of patients with hormone - dependent breast cancer.	False
These include BC6ENTG , BC6OTHER , BC6ENTC - dehydrogenases, BC6OTHER , BC6OTHER and BC6OTHER .	False
These include BC6OTHER , BC6ENTG , BC6ENTC - dehydrogenases, BC6OTHER , BC6OTHER and BC6OTHER .	False
These include BC6OTHER , BC6OTHER , BC6ENTC - dehydrogenases, BC6ENTG , BC6OTHER and BC6OTHER .	False
These include BC6OTHER , BC6OTHER , BC6ENTC - dehydrogenases, BC6OTHER , BC6ENTG and BC6OTHER .	False
These include BC6OTHER , BC6OTHER , BC6ENTC - dehydrogenases, BC6OTHER , BC6OTHER and BC6ENTG .	False
As discussed in this review, various BC6ENTC including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6ENTG and BC6OTHER activities.	CPR:4
As discussed in this review, various BC6ENTC including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6OTHER and BC6ENTG activities.	CPR:4
As discussed in this review, various BC6OTHER including BC6ENTC and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6ENTG and BC6OTHER activities.	CPR:4
As discussed in this review, various BC6OTHER including BC6ENTC and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6OTHER and BC6ENTG activities.	CPR:4
As discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6ENTG and BC6OTHER activities.	CPR:4
As discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6OTHER and BC6ENTG activities.	CPR:4
However, BC6OTHER at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of BC6ENTC , indicating the BC6ENTG and not an BC6OTHER as their primary site of action.	CPR:9
However, BC6OTHER at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of BC6ENTC , indicating the BC6OTHER and not an BC6ENTG as their primary site of action.	False
No trans - stimulation of BC6ENTC outflow was observed by the BC6ENTG and BC6OTHER substrate CHEM at 100 microM.	False
No trans - stimulation of BC6ENTC outflow was observed by the BC6OTHER and BC6ENTG substrate CHEM at 100 microM.	False
Our observations indicate an BC6ENTG - mediated transmembrane transport of BC6ENTC .	CPR:9
Amongst the three BC6ENTG expressed in the SCG, BC6OTHER best fits the profile of substrates and antagonists that cause trans - stimulation and trans - inhibition, respectively, of BC6ENTC release.	CPR:9
Amongst the three BC6OTHER expressed in the SCG, BC6ENTG best fits the profile of substrates and antagonists that cause trans - stimulation and trans - inhibition, respectively, of BC6ENTC release.	CPR:9
Reuptake of extracellular BC6ENTC ( BC6OTHER ) into superior cervical ganglion (SCG) neurones is mediated by means of the BC6ENTG ( BC6OTHER , uptake 1).	CPR:9
Reuptake of extracellular BC6ENTC ( BC6OTHER ) into superior cervical ganglion (SCG) neurones is mediated by means of the BC6OTHER transporter ( BC6ENTG , uptake 1).	CPR:9
Reuptake of extracellular BC6OTHER ( BC6ENTC ) into superior cervical ganglion (SCG) neurones is mediated by means of the BC6ENTG ( BC6OTHER , uptake 1).	CPR:9
Reuptake of extracellular BC6OTHER ( BC6ENTC ) into superior cervical ganglion (SCG) neurones is mediated by means of the BC6OTHER transporter ( BC6ENTG , uptake 1).	CPR:9
Making use of the BC6ENTG as a powerful, neurone - specific transporter system, we loaded BC6ENTC ( BC6OTHER ) into cultured rat SCG neurones.	False
Two observations suggest that a depletion of storage vesicles by CHEM accounts for the latter phenomenon: first, the primary radioactive product isolated from supernatants of cultures loaded with BC6ENTC was the metabolite BC6OTHER ; and second, inhibition of BC6ENTG significantly reduced the radioactive outflow in response to CHEM.	False
Making use of the BC6ENTG as a powerful, neurone - specific transporter system, we loaded BC6OTHER ( BC6ENTC ) into cultured rat SCG neurones.	False
The ensuing radioactive outflow from these cultures was enhanced by BC6ENTC and BC6OTHER , but reduced (in the presence of BC6OTHER ) by the BC6ENTG inhibitors CHEM, BC6OTHER and BC6OTHER .	False
The ensuing radioactive outflow from these cultures was enhanced by BC6OTHER and BC6ENTC , but reduced (in the presence of BC6OTHER ) by the BC6ENTG inhibitors CHEM, BC6OTHER and BC6OTHER .	False
The ensuing radioactive outflow from these cultures was enhanced by BC6OTHER and BC6OTHER , but reduced (in the presence of BC6ENTC ) by the BC6ENTG inhibitors CHEM, BC6OTHER and BC6OTHER .	False
The ensuing radioactive outflow from these cultures was enhanced by BC6OTHER and BC6OTHER , but reduced (in the presence of BC6OTHER ) by the BC6ENTG inhibitors CHEM, BC6ENTC and BC6OTHER .	CPR:4
The ensuing radioactive outflow from these cultures was enhanced by BC6OTHER and BC6OTHER , but reduced (in the presence of BC6OTHER ) by the BC6ENTG inhibitors CHEM, BC6OTHER and BC6ENTC .	CPR:4
Two observations suggest that a depletion of storage vesicles by CHEM accounts for the latter phenomenon: first, the primary radioactive product isolated from supernatants of cultures loaded with BC6OTHER was the metabolite BC6ENTC ; and second, inhibition of BC6ENTG significantly reduced the radioactive outflow in response to CHEM.	False
Reuptake of extracellular BC6OTHER ( BC6OTHER ) into superior cervical ganglion (SCG) neurones is mediated by means of the BC6ENTC transporter ( BC6ENTG , uptake 1).	False
The outflow of BC6ENTC was significantly enhanced by BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER as potential substrates for BC6ENTG - related BC6OTHER .	CPR:9
The outflow of BC6ENTC was significantly enhanced by BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER as potential substrates for BC6OTHER - related BC6ENTG .	CPR:9
The outflow of BC6OTHER was significantly enhanced by BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER as potential substrates for BC6ENTG - related BC6OTHER .	CPR:9
The outflow of BC6OTHER was significantly enhanced by BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER as potential substrates for BC6OTHER - related BC6ENTG .	CPR:9
The outflow of BC6OTHER was significantly enhanced by BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER as potential substrates for BC6ENTG - related BC6OTHER .	CPR:9
The outflow of BC6OTHER was significantly enhanced by BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER as potential substrates for BC6OTHER - related BC6ENTG .	CPR:9
The outflow of BC6OTHER was significantly enhanced by BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER as potential substrates for BC6ENTG - related BC6OTHER .	CPR:9
The outflow of BC6OTHER was significantly enhanced by BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER as potential substrates for BC6OTHER - related BC6ENTG .	CPR:9
The outflow of BC6OTHER was significantly enhanced by BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC as potential substrates for BC6ENTG - related BC6OTHER .	CPR:9
The outflow of BC6OTHER was significantly enhanced by BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC as potential substrates for BC6OTHER - related BC6ENTG .	CPR:9
However, BC6ENTC at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of BC6OTHER , indicating the BC6ENTG and not an BC6OTHER as their primary site of action.	False
However, BC6ENTC at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of BC6OTHER , indicating the BC6OTHER and not an BC6ENTG as their primary site of action.	False
Counterregulatory responses and BC6OTHER / BC6OTHER concentrations in the VMH were assessed during a hyperinsulinemic - hypoglycemic BC6ENTC clamp study in chronically catheterized awake male Sprague - Dawley rats that received an acute VMH microinjection of BC6ENTG - Fc, chronic VMH knockdown, or overexpression of BC6OTHER using an adenoassociated viral construct.	False
Counterregulatory responses and BC6OTHER / BC6OTHER concentrations in the VMH were assessed during a hyperinsulinemic - hypoglycemic BC6ENTC clamp study in chronically catheterized awake male Sprague - Dawley rats that received an acute VMH microinjection of BC6OTHER - Fc, chronic VMH knockdown, or overexpression of BC6ENTG using an adenoassociated viral construct.	False
 BC6ENTG - BC6OTHER interactions within the ventromedial hypothalamus influence counterregulatory hormone release and local BC6ENTC / BC6OTHER balance during hypoglycemia.	False
 BC6OTHER - BC6ENTG interactions within the ventromedial hypothalamus influence counterregulatory hormone release and local BC6ENTC / BC6OTHER balance during hypoglycemia.	False
 BC6ENTG - BC6OTHER interactions within the ventromedial hypothalamus influence counterregulatory hormone release and local BC6OTHER / BC6ENTC balance during hypoglycemia.	False
 BC6OTHER - BC6ENTG interactions within the ventromedial hypothalamus influence counterregulatory hormone release and local BC6OTHER / BC6ENTC balance during hypoglycemia.	False
Overexpression of VMH BC6OTHER transiently increased local BC6ENTC concentrations, whereas BC6ENTG knockdown produced profound suppression of VMH interstitial fluid BC6OTHER concentrations in the basal state and during hypoglycemia.	False
Overexpression of VMH BC6ENTG transiently increased local BC6ENTC concentrations, whereas BC6OTHER knockdown produced profound suppression of VMH interstitial fluid BC6OTHER concentrations in the basal state and during hypoglycemia.	False
Overexpression of VMH BC6OTHER transiently increased local BC6OTHER concentrations, whereas BC6ENTG knockdown produced profound suppression of VMH interstitial fluid BC6ENTC concentrations in the basal state and during hypoglycemia.	False
Overexpression of VMH BC6ENTG transiently increased local BC6OTHER concentrations, whereas BC6OTHER knockdown produced profound suppression of VMH interstitial fluid BC6ENTC concentrations in the basal state and during hypoglycemia.	False
Changes in BC6ENTG / BC6OTHER interactions within the VMH, a key brain BC6ENTC - sensing region, act in concert with islets to restore BC6OTHER homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in BC6OTHER / BC6OTHER cycling.	False
Changes in BC6OTHER / BC6ENTG interactions within the VMH, a key brain BC6ENTC - sensing region, act in concert with islets to restore BC6OTHER homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in BC6OTHER / BC6OTHER cycling.	False
Changes in BC6ENTG / BC6OTHER interactions within the VMH, a key brain BC6OTHER - sensing region, act in concert with islets to restore BC6ENTC homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in BC6OTHER / BC6OTHER cycling.	False
Changes in BC6OTHER / BC6ENTG interactions within the VMH, a key brain BC6OTHER - sensing region, act in concert with islets to restore BC6ENTC homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in BC6OTHER / BC6OTHER cycling.	False
Changes in BC6ENTG / BC6OTHER interactions within the VMH, a key brain BC6OTHER - sensing region, act in concert with islets to restore BC6OTHER homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in BC6ENTC / BC6OTHER cycling.	False
Changes in BC6OTHER / BC6ENTG interactions within the VMH, a key brain BC6OTHER - sensing region, act in concert with islets to restore BC6OTHER homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in BC6ENTC / BC6OTHER cycling.	False
Changes in BC6ENTG / BC6OTHER interactions within the VMH, a key brain BC6OTHER - sensing region, act in concert with islets to restore BC6OTHER homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in BC6OTHER / BC6ENTC cycling.	False
Changes in BC6OTHER / BC6ENTG interactions within the VMH, a key brain BC6OTHER - sensing region, act in concert with islets to restore BC6OTHER homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in BC6OTHER / BC6ENTC cycling.	False
Given the similarities between islet and ventromedial hypothalamus (VMH) BC6ENTC sensing, we tested the hypothesis that the BC6ENTG / BC6OTHER system might function within the VMH during hypoglycemia to stimulate counterregulatory hormone release as well.	False
Given the similarities between islet and ventromedial hypothalamus (VMH) BC6ENTC sensing, we tested the hypothesis that the BC6OTHER / BC6ENTG system might function within the VMH during hypoglycemia to stimulate counterregulatory hormone release as well.	False
Counterregulatory responses and BC6ENTC / BC6OTHER concentrations in the VMH were assessed during a hyperinsulinemic - hypoglycemic BC6OTHER clamp study in chronically catheterized awake male Sprague - Dawley rats that received an acute VMH microinjection of BC6ENTG - Fc, chronic VMH knockdown, or overexpression of BC6OTHER using an adenoassociated viral construct.	False
Counterregulatory responses and BC6ENTC / BC6OTHER concentrations in the VMH were assessed during a hyperinsulinemic - hypoglycemic BC6OTHER clamp study in chronically catheterized awake male Sprague - Dawley rats that received an acute VMH microinjection of BC6OTHER - Fc, chronic VMH knockdown, or overexpression of BC6ENTG using an adenoassociated viral construct.	False
Counterregulatory responses and BC6OTHER / BC6ENTC concentrations in the VMH were assessed during a hyperinsulinemic - hypoglycemic BC6OTHER clamp study in chronically catheterized awake male Sprague - Dawley rats that received an acute VMH microinjection of BC6ENTG - Fc, chronic VMH knockdown, or overexpression of BC6OTHER using an adenoassociated viral construct.	False
Counterregulatory responses and BC6OTHER / BC6ENTC concentrations in the VMH were assessed during a hyperinsulinemic - hypoglycemic BC6OTHER clamp study in chronically catheterized awake male Sprague - Dawley rats that received an acute VMH microinjection of BC6OTHER - Fc, chronic VMH knockdown, or overexpression of BC6ENTG using an adenoassociated viral construct.	False
Inhibition of cardiac voltage - gated BC6ENTC channels ( BC6ENTG ) is antiarrhythmic and cardioprotective.	False
Late INa induced by the BC6ENTG long QT mutant BC6OTHER was reduced by BC6ENTC and BC6OTHER .	CPR:4
Late INa induced by the BC6OTHER long QT mutant BC6ENTG was reduced by BC6ENTC and BC6OTHER .	CPR:4
Late INa induced by the BC6ENTG long QT mutant BC6OTHER was reduced by BC6OTHER and BC6ENTC .	CPR:4
Late INa induced by the BC6OTHER long QT mutant BC6ENTG was reduced by BC6OTHER and BC6ENTC .	CPR:4
In contrast, the BC6ENTC catabolising enzymes BC6ENTG and BC6OTHER which are known to be BC6OTHER - responsive were not expressed at all in the developing eye.	CPR:9
In contrast, the BC6ENTC catabolising enzymes BC6OTHER and BC6ENTG which are known to be BC6OTHER - responsive were not expressed at all in the developing eye.	CPR:9
In contrast, the BC6OTHER catabolising enzymes BC6ENTG and BC6OTHER which are known to be BC6ENTC - responsive were not expressed at all in the developing eye.	False
In contrast, the BC6OTHER catabolising enzymes BC6OTHER and BC6ENTG which are known to be BC6ENTC - responsive were not expressed at all in the developing eye.	False
Using a photo incorporable analogue of the general anesthetic, BC6OTHER , we identified two transmembrane BC6ENTC that were affinity labelled in purified BC6ENTG .	False
Homology protein structural modelling positions these two residues, alphaM1 - 11' and betaM3 - 4', close to each other in a single type of intersubunit BC6ENTC binding pocket at the BC6ENTG .	False
PURPOSE: The purpose of this review is to summarize current knowledge of detailed biochemical evidence for the role of BC6ENTC type A receptors ( BC6ENTG ) in the mechanisms of general anesthesia.	False
PRINCIPAL FINDINGS: With the knowledge that all general anesthetics positively modulate BC6ENTG - mediated inhibitory transmission, site - directed mutagenesis comparing sequences of BC6OTHER subunits of varying sensitivity led to identification of BC6ENTC residues in the transmembrane domain that are critical for the drug actions in vitro.	False
PRINCIPAL FINDINGS: With the knowledge that all general anesthetics positively modulate BC6OTHER - mediated inhibitory transmission, site - directed mutagenesis comparing sequences of BC6ENTG subunits of varying sensitivity led to identification of BC6ENTC residues in the transmembrane domain that are critical for the drug actions in vitro.	False
Using a photo incorporable analogue of the general anesthetic, BC6ENTC , we identified two transmembrane BC6OTHER that were affinity labelled in purified BC6ENTG .	False
The BC6OTHER / BC6OTHER pathway and the energy sensor BC6ENTC - activated protein kinase ( BC6ENTG ) are attractive therapeutic targets as a part of preventive management of disease.	False
The BC6ENTG / BC6OTHER pathway and the energy sensor BC6ENTC - activated protein kinase ( BC6OTHER ) are attractive therapeutic targets as a part of preventive management of disease.	False
The BC6OTHER / BC6ENTG pathway and the energy sensor BC6ENTC - activated protein kinase ( BC6OTHER ) are attractive therapeutic targets as a part of preventive management of disease.	False
Several effects of BC6ENTC are useful in this scenario, including a reduction in the activities of BC6ENTG and modulation of cellular metabolism through BC6OTHER inhibitors, BC6OTHER activators, calorie - restriction mimetics or epigenetic regulators.	CPR:4
Several effects of BC6ENTC are useful in this scenario, including a reduction in the activities of BC6OTHER and modulation of cellular metabolism through BC6ENTG inhibitors, BC6OTHER activators, calorie - restriction mimetics or epigenetic regulators.	CPR:4
Several effects of BC6ENTC are useful in this scenario, including a reduction in the activities of BC6OTHER and modulation of cellular metabolism through BC6OTHER inhibitors, BC6ENTG activators, calorie - restriction mimetics or epigenetic regulators.	CPR:3
Multifunctional targets of dietary BC6ENTC in disease: a case for the BC6ENTG network and energy metabolism.	False
In conclusion, our results demonstrate that Jurkat T cells express BC6ENTC receptors functionally active in controlling cell growth and adhesion to BC6ENTG .	False
Stimulation of BC6ENTC receptors modulates Jurkat T cell growth and adhesion to BC6ENTG .	False
RT - PCR and immunofluorescence / confocal microscopy analysis showed that Jurkat T cells express the BC6ENTG and BC6OTHER subunits of the BC6ENTC receptors.	False
RT - PCR and immunofluorescence / confocal microscopy analysis showed that Jurkat T cells express the BC6OTHER and BC6ENTG subunits of the BC6ENTC receptors.	False
Exposure of Jurkat cells to either BC6ENTC [ BC6OTHER ] or BC6OTHER ( BC6OTHER ), two selective BC6ENTG antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6OTHER .	CPR:6
Exposure of Jurkat cells to either BC6ENTC [ BC6OTHER ] or BC6OTHER ( BC6OTHER ), two selective BC6OTHER receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6ENTG .	False
Exposure of Jurkat cells to either BC6OTHER [ BC6ENTC ] or BC6OTHER ( BC6OTHER ), two selective BC6ENTG antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6OTHER .	CPR:6
Exposure of Jurkat cells to either BC6OTHER [ BC6ENTC ] or BC6OTHER ( BC6OTHER ), two selective BC6OTHER receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6ENTG .	False
Exposure of Jurkat cells to either BC6OTHER [ BC6OTHER ] or BC6ENTC ( BC6OTHER ), two selective BC6ENTG antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6OTHER .	CPR:6
Exposure of Jurkat cells to either BC6OTHER [ BC6OTHER ] or BC6ENTC ( BC6OTHER ), two selective BC6OTHER receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6ENTG .	False
Exposure of Jurkat cells to either BC6OTHER [ BC6OTHER ] or BC6OTHER ( BC6ENTC ), two selective BC6ENTG antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6OTHER .	CPR:6
Exposure of Jurkat cells to either BC6OTHER [ BC6OTHER ] or BC6OTHER ( BC6ENTC ), two selective BC6OTHER receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6ENTG .	False
Exposure of Jurkat cells to either BC6OTHER [ BC6OTHER ] or BC6OTHER ( BC6OTHER ), two selective BC6ENTC receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6ENTG .	False
Exposure of Jurkat cells to either BC6OTHER [ BC6OTHER ] or BC6OTHER ( BC6OTHER ), two selective BC6ENTG antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6ENTC (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6OTHER .	False
Exposure of Jurkat cells to either BC6OTHER [ BC6OTHER ] or BC6OTHER ( BC6OTHER ), two selective BC6OTHER receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6ENTC (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6ENTG .	False
Exposure of Jurkat cells to either BC6OTHER [ BC6OTHER ] or BC6OTHER ( BC6OTHER ), two selective BC6ENTG antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6ENTC (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6OTHER .	False
Exposure of Jurkat cells to either BC6OTHER [ BC6OTHER ] or BC6OTHER ( BC6OTHER ), two selective BC6OTHER receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6ENTC (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6ENTG .	False
These results reveal, for the first time, the differential distribution of BC6ENTG in fast - and slow - twitch muscles, which might support the crucial role of BC6ENTC - dependent signaling in controlling the synapse - specific expression of BC6OTHER in fast - twitch muscles.	False
These results reveal, for the first time, the differential distribution of BC6OTHER in fast - and slow - twitch muscles, which might support the crucial role of BC6ENTC - dependent signaling in controlling the synapse - specific expression of BC6ENTG in fast - twitch muscles.	False
BC6ENTG is expressed at the neuromuscular junction (NMJ) in fast - twitch muscle, and this expression depends on trophic factors supplied by motor neurons signaling via a BC6ENTC - dependent pathway in muscle.	False
To further elucidate the molecular basis of BC6ENTG synaptic expression, here we investigated the expression and localization of BC6ENTC - responsive element binding protein ( BC6OTHER ) at the synaptic and extra - synaptic regions of fast - and slow - twitch muscles from adult rats.	False
To further elucidate the molecular basis of BC6OTHER synaptic expression, here we investigated the expression and localization of BC6ENTC - responsive element binding protein ( BC6ENTG ) at the synaptic and extra - synaptic regions of fast - and slow - twitch muscles from adult rats.	False
Expression of BC6ENTC - responsive element binding proteins ( BC6OTHER ) in fast - and slow - twitch muscles: A signaling pathway to account for the synaptic expression of BC6ENTG ( BC6OTHER ) of BC6OTHER at the rat neuromuscular junction.	False
Expression of BC6ENTC - responsive element binding proteins ( BC6OTHER ) in fast - and slow - twitch muscles: A signaling pathway to account for the synaptic expression of BC6OTHER ( BC6ENTG ) of BC6OTHER at the rat neuromuscular junction.	False
Expression of BC6ENTC - responsive element binding proteins ( BC6OTHER ) in fast - and slow - twitch muscles: A signaling pathway to account for the synaptic expression of BC6OTHER ( BC6OTHER ) of BC6ENTG at the rat neuromuscular junction.	False
Expression of BC6ENTC - responsive element binding proteins ( BC6ENTG ) in fast - and slow - twitch muscles: A signaling pathway to account for the synaptic expression of BC6OTHER ( BC6OTHER ) of BC6OTHER at the rat neuromuscular junction.	False
In contrast, BC6ENTG exerts glucoregulatory actions via slowing of gastric emptying and BC6ENTC - dependent inhibition of BC6OTHER secretion.	False
In contrast, BC6OTHER exerts glucoregulatory actions via slowing of gastric emptying and BC6ENTC - dependent inhibition of BC6ENTG secretion.	False
This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the BC6ENTG peptides BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the BC6OTHER peptides BC6ENTC - dependent insulinotropic polypeptide ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the BC6OTHER peptides BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the BC6OTHER peptides BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
BC6ENTG activation leads to BC6ENTC - dependent BC6OTHER secretion, induction of beta - cell proliferation, and enhanced resistance to apoptosis.	False
BC6OTHER activation leads to BC6ENTC - dependent BC6ENTG secretion, induction of beta - cell proliferation, and enhanced resistance to apoptosis.	CPR:3
BC6ENTC , an BC6OTHER that reversibly inhibits BC6ENTG and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option.	CPR:4
BC6OTHER , an BC6ENTC that reversibly inhibits BC6ENTG and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option.	CPR:4
Therefore, we examined whether the BC6ENTG - I BC6ENTC improves memory and executive functioning and affect electroencephalography (EEG) in healthy young adults.	CPR:4
The effects of the BC6ENTG inhibitor BC6ENTC on cognitive performance in healthy adults: a behavioral - electroencephalography study.	CPR:4
In early pregnancy, there were no significant differences in BC6ENTG sensitivity ( BC6OTHER sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for BC6OTHER resistance [HOMA - IR]) and BC6OTHER secretion (a ratio of the total area - under - the - BC6OTHER - curve to the total area - under - the - BC6ENTC - curve [AUCins / glu] and insulinogenic index [IGI]) between the NGT and late - onset GDM groups.	False
In early pregnancy, there were no significant differences in BC6OTHER sensitivity ( BC6ENTG sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for BC6OTHER resistance [HOMA - IR]) and BC6OTHER secretion (a ratio of the total area - under - the - BC6OTHER - curve to the total area - under - the - BC6ENTC - curve [AUCins / glu] and insulinogenic index [IGI]) between the NGT and late - onset GDM groups.	False
In early pregnancy, there were no significant differences in BC6OTHER sensitivity ( BC6OTHER sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for BC6ENTG resistance [HOMA - IR]) and BC6OTHER secretion (a ratio of the total area - under - the - BC6OTHER - curve to the total area - under - the - BC6ENTC - curve [AUCins / glu] and insulinogenic index [IGI]) between the NGT and late - onset GDM groups.	False
In early pregnancy, there were no significant differences in BC6OTHER sensitivity ( BC6OTHER sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for BC6OTHER resistance [HOMA - IR]) and BC6ENTG secretion (a ratio of the total area - under - the - BC6OTHER - curve to the total area - under - the - BC6ENTC - curve [AUCins / glu] and insulinogenic index [IGI]) between the NGT and late - onset GDM groups.	False
In early pregnancy, there were no significant differences in BC6OTHER sensitivity ( BC6OTHER sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for BC6OTHER resistance [HOMA - IR]) and BC6OTHER secretion (a ratio of the total area - under - the - BC6ENTG - curve to the total area - under - the - BC6ENTC - curve [AUCins / glu] and insulinogenic index [IGI]) between the NGT and late - onset GDM groups.	False
Other groups received either an infusion of the selective BC6ENTG antagonist ( BC6ENTC ; 10 nmol; intra - mPFC) or vehicle, 10 min prior to BC6OTHER preceding LFS600, or prior to a supra - threshold LTD protocol (900 pulses, 1 Hz; LFS900).	CPR:6
Other groups received either an infusion of the selective BC6ENTG antagonist ( BC6OTHER ; 10 nmol; intra - mPFC) or vehicle, 10 min prior to BC6ENTC preceding LFS600, or prior to a supra - threshold LTD protocol (900 pulses, 1 Hz; LFS900).	False
Our results show that BC6ENTC converts a transient cortical depression induced by LFS600 into a robust LTD, stable for at least 4 h. When applied after LFS600, BC6OTHER does not change either mPFC basal neurotransmission or late LTD. Our data also indicate that BC6ENTG pre - activation is essential to the muscarinic enhancement of mPFC synaptic depression, since BC6OTHER microinjection into the mPFC blocked the conversion of transient depression into long - lasting LTD produced by BC6OTHER .	False
Our results show that BC6OTHER converts a transient cortical depression induced by LFS600 into a robust LTD, stable for at least 4 h. When applied after LFS600, BC6ENTC does not change either mPFC basal neurotransmission or late LTD. Our data also indicate that BC6ENTG pre - activation is essential to the muscarinic enhancement of mPFC synaptic depression, since BC6OTHER microinjection into the mPFC blocked the conversion of transient depression into long - lasting LTD produced by BC6OTHER .	False
Our results show that BC6OTHER converts a transient cortical depression induced by LFS600 into a robust LTD, stable for at least 4 h. When applied after LFS600, BC6OTHER does not change either mPFC basal neurotransmission or late LTD. Our data also indicate that BC6ENTG pre - activation is essential to the muscarinic enhancement of mPFC synaptic depression, since BC6ENTC microinjection into the mPFC blocked the conversion of transient depression into long - lasting LTD produced by BC6OTHER .	CPR:4
Our results show that BC6OTHER converts a transient cortical depression induced by LFS600 into a robust LTD, stable for at least 4 h. When applied after LFS600, BC6OTHER does not change either mPFC basal neurotransmission or late LTD. Our data also indicate that BC6ENTG pre - activation is essential to the muscarinic enhancement of mPFC synaptic depression, since BC6OTHER microinjection into the mPFC blocked the conversion of transient depression into long - lasting LTD produced by BC6ENTC .	False
Electrical stimulation, BC6OTHER , and BC6ENTG each increased fluorescent BC6ENTC ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6OTHER and by BC6OTHER blockade ( BC6OTHER ).	False
Electrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6ENTC ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6ENTG and by BC6OTHER blockade ( BC6OTHER ).	False
Electrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6ENTC ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6OTHER and by BC6ENTG blockade ( BC6OTHER ).	False
Electrical stimulation, BC6OTHER , and BC6ENTG each increased fluorescent BC6OTHER ( BC6ENTC ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6OTHER and by BC6OTHER blockade ( BC6OTHER ).	False
Electrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6OTHER ( BC6ENTC ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6ENTG and by BC6OTHER blockade ( BC6OTHER ).	False
Electrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6OTHER ( BC6ENTC ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6OTHER and by BC6ENTG blockade ( BC6OTHER ).	False
Electrical stimulation, BC6OTHER , and BC6ENTG each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6ENTC - dependent BC6OTHER uptake were inhibited by BC6OTHER and by BC6OTHER blockade ( BC6OTHER ).	False
Electrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6ENTC - dependent BC6OTHER uptake were inhibited by BC6ENTG and by BC6OTHER blockade ( BC6OTHER ).	False
Electrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6ENTC - dependent BC6OTHER uptake were inhibited by BC6OTHER and by BC6ENTG blockade ( BC6OTHER ).	False
Electrical stimulation, BC6OTHER , and BC6ENTG each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6ENTC uptake were inhibited by BC6OTHER and by BC6OTHER blockade ( BC6OTHER ).	False
Electrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6ENTC uptake were inhibited by BC6ENTG and by BC6OTHER blockade ( BC6OTHER ).	False
Electrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6ENTC uptake were inhibited by BC6OTHER and by BC6ENTG blockade ( BC6OTHER ).	False
Electrical stimulation, BC6OTHER , and BC6ENTG each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6ENTC phosphatase and by BC6OTHER blockade ( BC6OTHER ).	False
Electrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6ENTC phosphatase and by BC6ENTG blockade ( BC6OTHER ).	False
Electrical stimulation, BC6OTHER , and BC6ENTG each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6OTHER and by BC6OTHER blockade ( BC6ENTC ).	False
Electrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6ENTG and by BC6OTHER blockade ( BC6ENTC ).	CPR:4
Electrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6OTHER and by BC6ENTG blockade ( BC6ENTC ).	CPR:4
Electrical stimulation transiently elevated extracellular BC6ENTC and caused BC6ENTG phosphorylation that was additive to BC6OTHER and inhibited by BC6OTHER .	False
Electrical stimulation transiently elevated extracellular BC6ENTC and caused BC6OTHER phosphorylation that was additive to BC6ENTG and inhibited by BC6OTHER .	False
Electrical stimulation transiently elevated extracellular BC6OTHER and caused BC6ENTG phosphorylation that was additive to BC6OTHER and inhibited by BC6ENTC .	CPR:4
Electrical stimulation transiently elevated extracellular BC6OTHER and caused BC6OTHER phosphorylation that was additive to BC6ENTG and inhibited by BC6ENTC .	False
Exogenous BC6ENTC transiently activated BC6ENTG and, inhibiting BC6OTHER ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6OTHER - dependent BC6OTHER uptake and BC6OTHER phosphorylation.	CPR:3
Exogenous BC6ENTC transiently activated BC6OTHER and, inhibiting BC6ENTG ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6OTHER - dependent BC6OTHER uptake and BC6OTHER phosphorylation.	False
Exogenous BC6ENTC transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6ENTG ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6OTHER - dependent BC6OTHER uptake and BC6OTHER phosphorylation.	False
Exogenous BC6ENTC transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6OTHER ) or BC6ENTG as well as dominant - negative BC6OTHER mutant, reduced BC6OTHER - dependent BC6OTHER uptake and BC6OTHER phosphorylation.	False
Exogenous BC6ENTC transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6ENTG mutant, reduced BC6OTHER - dependent BC6OTHER uptake and BC6OTHER phosphorylation.	False
Exogenous BC6ENTC transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6OTHER - dependent BC6OTHER uptake and BC6ENTG phosphorylation.	False
Exogenous BC6OTHER transiently activated BC6ENTG and, inhibiting BC6OTHER ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6ENTC - dependent BC6OTHER uptake and BC6OTHER phosphorylation.	False
Exogenous BC6OTHER transiently activated BC6OTHER and, inhibiting BC6ENTG ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6ENTC - dependent BC6OTHER uptake and BC6OTHER phosphorylation.	False
Exogenous BC6OTHER transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6ENTG ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6ENTC - dependent BC6OTHER uptake and BC6OTHER phosphorylation.	False
Exogenous BC6OTHER transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6OTHER ) or BC6ENTG as well as dominant - negative BC6OTHER mutant, reduced BC6ENTC - dependent BC6OTHER uptake and BC6OTHER phosphorylation.	False
Exogenous BC6OTHER transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6ENTG mutant, reduced BC6ENTC - dependent BC6OTHER uptake and BC6OTHER phosphorylation.	False
Exogenous BC6OTHER transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6ENTC - dependent BC6OTHER uptake and BC6ENTG phosphorylation.	False
BC6OTHER - dependent BC6OTHER uptake was also inhibited by the BC6OTHER subunit - interacting peptide βark - ct and by the BC6ENTG ( BC6OTHER ) inhibitor BC6ENTC .	CPR:4
BC6OTHER - dependent BC6OTHER uptake was also inhibited by the BC6OTHER subunit - interacting peptide βark - ct and by the BC6OTHER ( BC6ENTG ) inhibitor BC6ENTC .	CPR:4
BC6OTHER - dependent BC6OTHER uptake was also inhibited by the BC6ENTG subunit - interacting peptide βark - ct and by the BC6OTHER ( BC6OTHER ) inhibitor BC6ENTC .	False
Exogenous BC6OTHER transiently activated BC6ENTG and, inhibiting BC6OTHER ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6OTHER - dependent BC6ENTC uptake and BC6OTHER phosphorylation.	False
Exogenous BC6OTHER transiently activated BC6OTHER and, inhibiting BC6ENTG ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6OTHER - dependent BC6ENTC uptake and BC6OTHER phosphorylation.	False
Exogenous BC6OTHER transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6ENTG ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6OTHER - dependent BC6ENTC uptake and BC6OTHER phosphorylation.	False
Exogenous BC6OTHER transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6OTHER ) or BC6ENTG as well as dominant - negative BC6OTHER mutant, reduced BC6OTHER - dependent BC6ENTC uptake and BC6OTHER phosphorylation.	False
Exogenous BC6OTHER transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6ENTG mutant, reduced BC6OTHER - dependent BC6ENTC uptake and BC6OTHER phosphorylation.	False
Exogenous BC6OTHER transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6OTHER - dependent BC6ENTC uptake and BC6ENTG phosphorylation.	False
BC6ENTC - dependent BC6OTHER uptake was also inhibited by the BC6OTHER subunit - interacting peptide βark - ct and by the BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER .	False
BC6ENTC - dependent BC6OTHER uptake was also inhibited by the BC6OTHER subunit - interacting peptide βark - ct and by the BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER .	False
BC6ENTC - dependent BC6OTHER uptake was also inhibited by the BC6ENTG subunit - interacting peptide βark - ct and by the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
BC6OTHER - dependent BC6ENTC uptake was also inhibited by the BC6OTHER subunit - interacting peptide βark - ct and by the BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER .	False
BC6OTHER - dependent BC6ENTC uptake was also inhibited by the BC6OTHER subunit - interacting peptide βark - ct and by the BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER .	False
BC6OTHER - dependent BC6ENTC uptake was also inhibited by the BC6ENTG subunit - interacting peptide βark - ct and by the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
Electrical Stimuli Release BC6ENTC to Increase BC6ENTG Translocation and BC6OTHER Uptake via BC6OTHER - BC6OTHER - BC6OTHER in Skeletal Muscle Cells.	False
Electrical Stimuli Release BC6ENTC to Increase BC6OTHER Translocation and BC6OTHER Uptake via BC6ENTG - BC6OTHER - BC6OTHER in Skeletal Muscle Cells.	False
Electrical Stimuli Release BC6ENTC to Increase BC6OTHER Translocation and BC6OTHER Uptake via BC6OTHER - BC6ENTG - BC6OTHER in Skeletal Muscle Cells.	False
Electrical Stimuli Release BC6ENTC to Increase BC6OTHER Translocation and BC6OTHER Uptake via BC6OTHER - BC6OTHER - BC6ENTG in Skeletal Muscle Cells.	False
Electrical Stimuli Release BC6OTHER to Increase BC6ENTG Translocation and BC6ENTC Uptake via BC6OTHER - BC6OTHER - BC6OTHER in Skeletal Muscle Cells.	CPR:9
Electrical Stimuli Release BC6OTHER to Increase BC6OTHER Translocation and BC6ENTC Uptake via BC6ENTG - BC6OTHER - BC6OTHER in Skeletal Muscle Cells.	False
Electrical Stimuli Release BC6OTHER to Increase BC6OTHER Translocation and BC6ENTC Uptake via BC6OTHER - BC6ENTG - BC6OTHER in Skeletal Muscle Cells.	False
Electrical Stimuli Release BC6OTHER to Increase BC6OTHER Translocation and BC6ENTC Uptake via BC6OTHER - BC6OTHER - BC6ENTG in Skeletal Muscle Cells.	False
BC6ENTC caused translocation of BC6ENTG myc - eGFP to the cell surface, mechanistically mediated by increased exocytosis involving BC6OTHER / BC6OTHER reduced by dominant - negative BC6OTHER or BC6OTHER BC6OTHER - dead mutants, and potentiated by BC6OTHER .	False
BC6ENTC caused translocation of BC6OTHER myc - eGFP to the cell surface, mechanistically mediated by increased exocytosis involving BC6ENTG / BC6OTHER reduced by dominant - negative BC6OTHER or BC6OTHER BC6OTHER - dead mutants, and potentiated by BC6OTHER .	False
BC6ENTC caused translocation of BC6OTHER myc - eGFP to the cell surface, mechanistically mediated by increased exocytosis involving BC6OTHER / BC6ENTG reduced by dominant - negative BC6OTHER or BC6OTHER BC6OTHER - dead mutants, and potentiated by BC6OTHER .	False
BC6ENTC caused translocation of BC6OTHER myc - eGFP to the cell surface, mechanistically mediated by increased exocytosis involving BC6OTHER / BC6OTHER reduced by dominant - negative BC6ENTG or BC6OTHER BC6OTHER - dead mutants, and potentiated by BC6OTHER .	False
BC6ENTC caused translocation of BC6OTHER myc - eGFP to the cell surface, mechanistically mediated by increased exocytosis involving BC6OTHER / BC6OTHER reduced by dominant - negative BC6OTHER or BC6ENTG BC6OTHER - dead mutants, and potentiated by BC6OTHER .	False
BC6ENTC caused translocation of BC6OTHER myc - eGFP to the cell surface, mechanistically mediated by increased exocytosis involving BC6OTHER / BC6OTHER reduced by dominant - negative BC6OTHER or BC6OTHER BC6ENTG - dead mutants, and potentiated by BC6OTHER .	False
BC6ENTC caused translocation of BC6OTHER myc - eGFP to the cell surface, mechanistically mediated by increased exocytosis involving BC6OTHER / BC6OTHER reduced by dominant - negative BC6OTHER or BC6OTHER BC6OTHER - dead mutants, and potentiated by BC6ENTG .	False
BC6ENTC stimulated BC6OTHER uptake in normal and BC6ENTG - resistant adult muscle fibers, resembling the reported effect of exercise.	False
BC6OTHER stimulated BC6ENTC uptake in normal and BC6ENTG - resistant adult muscle fibers, resembling the reported effect of exercise.	False
BC6ENTC is released from skeletal muscle by contractile activity and can autocrinely signal through BC6ENTG , and we hypothesized it may influence BC6OTHER uptake.	False
Hence, the BC6ENTC - induced pathway may be tapped to bypass BC6ENTG resistance.	False
Skeletal muscle BC6ENTC uptake in response to exercise is preserved in BC6ENTG - resistant conditions, but the signals involved are debated.	False
BC6OTHER is released from skeletal muscle by contractile activity and can autocrinely signal through BC6ENTG , and we hypothesized it may influence BC6ENTC uptake.	False
Electrical stimulation, BC6ENTC , and BC6ENTG each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6OTHER and by BC6OTHER blockade ( BC6OTHER ).	False
Electrical stimulation, BC6ENTC , and BC6OTHER each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6ENTG and by BC6OTHER blockade ( BC6OTHER ).	False
Electrical stimulation, BC6ENTC , and BC6OTHER each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6OTHER and by BC6ENTG blockade ( BC6OTHER ).	False
In conclusion, this study provides the first evidence implicating that BC6ENTC inhibits BC6ENTG - induced ROS accumulation and myofibroblast differentiation via enhanced BC6OTHER - BC6OTHER signaling.	CPR:4
In conclusion, this study provides the first evidence implicating that BC6ENTC inhibits BC6OTHER - induced ROS accumulation and myofibroblast differentiation via enhanced BC6ENTG - BC6OTHER signaling.	CPR:3
In conclusion, this study provides the first evidence implicating that BC6ENTC inhibits BC6OTHER - induced ROS accumulation and myofibroblast differentiation via enhanced BC6OTHER - BC6ENTG signaling.	CPR:3
 BC6OTHER ( BC6ENTC ) has been shown to prevent fibrosis in vitro and in vivo. The present study aimed at investigating the role of reactive BC6OTHER species (ROS) scavenging by BC6OTHER on BC6ENTG ( BC6OTHER - induced myofibroblast differentiation of corneal fibroblasts in vitro.	False
 BC6OTHER ( BC6ENTC ) has been shown to prevent fibrosis in vitro and in vivo. The present study aimed at investigating the role of reactive BC6OTHER species (ROS) scavenging by BC6OTHER on BC6OTHER ( BC6ENTG - induced myofibroblast differentiation of corneal fibroblasts in vitro.	False
 BC6OTHER ( BC6OTHER ) has been shown to prevent fibrosis in vitro and in vivo. The present study aimed at investigating the role of reactive BC6OTHER species (ROS) scavenging by BC6ENTC on BC6ENTG ( BC6OTHER - induced myofibroblast differentiation of corneal fibroblasts in vitro.	False
 BC6OTHER ( BC6OTHER ) has been shown to prevent fibrosis in vitro and in vivo. The present study aimed at investigating the role of reactive BC6OTHER species (ROS) scavenging by BC6ENTC on BC6OTHER ( BC6ENTG - induced myofibroblast differentiation of corneal fibroblasts in vitro.	False
Human immortalized corneal fibroblasts were treated with BC6ENTG in the presence of BC6ENTC , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6ENTC , the BC6ENTG inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6ENTC , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6ENTG - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6ENTC , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6ENTG ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6ENTC , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6ENTG - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6ENTC , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6ENTG ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6ENTG in the presence of BC6OTHER , the BC6ENTC oxidase inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6ENTC oxidase inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6ENTG - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6ENTC oxidase inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6ENTG ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6ENTC oxidase inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6ENTG - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6ENTC oxidase inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6ENTG ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6ENTG in the presence of BC6OTHER , the BC6OTHER inhibitor BC6ENTC ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6ENTG inhibitor BC6ENTC ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	CPR:4
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6ENTC ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6ENTG - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6ENTC ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6ENTG ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6ENTC ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6ENTG - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6ENTC ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6ENTG ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6ENTG in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6ENTC ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6ENTG inhibitor BC6OTHER ( BC6ENTC ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	CPR:4
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6ENTC ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6ENTG - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6ENTC ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6ENTG ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6ENTC ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6ENTG - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6ENTC ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6ENTG ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6ENTG in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6ENTC ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6ENTG inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6ENTC ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6ENTC ( BC6OTHER ), the BC6ENTG - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6ENTC ( BC6OTHER ), the BC6OTHER - BC6ENTG ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6ENTC ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6ENTG - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6ENTC ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6ENTG ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6ENTG in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6ENTC ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6ENTG inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6ENTC ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6ENTC ), the BC6ENTG - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6ENTC ), the BC6OTHER - BC6ENTG ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6ENTC ), the BC6OTHER - BC6OTHER ( BC6ENTG - BC6OTHER ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6ENTC ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6ENTG ) activator BC6OTHER , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6ENTG in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6ENTC , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6ENTG inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6ENTC , or small interfering RNA.	False
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6ENTG - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6ENTC , or small interfering RNA.	CPR:3
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6ENTG ( BC6OTHER - BC6OTHER ) activator BC6ENTC , or small interfering RNA.	CPR:3
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6ENTG - BC6OTHER ) activator BC6ENTC , or small interfering RNA.	CPR:3
Human immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6ENTG ) activator BC6ENTC , or small interfering RNA.	CPR:3
 BC6ENTC ( BC6OTHER ) has been shown to prevent fibrosis in vitro and in vivo. The present study aimed at investigating the role of reactive BC6OTHER species (ROS) scavenging by BC6OTHER on BC6ENTG ( BC6OTHER - induced myofibroblast differentiation of corneal fibroblasts in vitro.	False
 BC6ENTC ( BC6OTHER ) has been shown to prevent fibrosis in vitro and in vivo. The present study aimed at investigating the role of reactive BC6OTHER species (ROS) scavenging by BC6OTHER on BC6OTHER ( BC6ENTG - induced myofibroblast differentiation of corneal fibroblasts in vitro.	False
ROS, BC6ENTC , intracellular BC6OTHER ( BC6OTHER ) level, cellular total antioxidant capacity, and the activation of BC6ENTG - BC6OTHER signaling were determined with various assays.	False
ROS, BC6ENTC , intracellular BC6OTHER ( BC6OTHER ) level, cellular total antioxidant capacity, and the activation of BC6OTHER - BC6ENTG signaling were determined with various assays.	False
ROS, BC6OTHER , intracellular BC6ENTC ( BC6OTHER ) level, cellular total antioxidant capacity, and the activation of BC6ENTG - BC6OTHER signaling were determined with various assays.	False
ROS, BC6OTHER , intracellular BC6ENTC ( BC6OTHER ) level, cellular total antioxidant capacity, and the activation of BC6OTHER - BC6ENTG signaling were determined with various assays.	False
ROS, BC6OTHER , intracellular BC6OTHER ( BC6ENTC ) level, cellular total antioxidant capacity, and the activation of BC6ENTG - BC6OTHER signaling were determined with various assays.	False
ROS, BC6OTHER , intracellular BC6OTHER ( BC6ENTC ) level, cellular total antioxidant capacity, and the activation of BC6OTHER - BC6ENTG signaling were determined with various assays.	False
Treatment with BC6ENTC and the BC6ENTG - BC6OTHER activator resulted in increased inhibition of the BC6OTHER - induced myofibroblast differentiation as compared with treatment with BC6OTHER or BC6OTHER .	False
Treatment with BC6ENTC and the BC6OTHER - BC6ENTG activator resulted in increased inhibition of the BC6OTHER - induced myofibroblast differentiation as compared with treatment with BC6OTHER or BC6OTHER .	False
Treatment with BC6ENTC and the BC6OTHER - BC6OTHER activator resulted in increased inhibition of the BC6ENTG - induced myofibroblast differentiation as compared with treatment with BC6OTHER or BC6OTHER .	CPR:4
 BC6ENTC inhibits BC6OTHER - induced reactive BC6OTHER species accumulation and myofibroblast differentiation via enhanced BC6ENTG - BC6OTHER signaling.	CPR:3
 BC6ENTC inhibits BC6OTHER - induced reactive BC6OTHER species accumulation and myofibroblast differentiation via enhanced BC6OTHER - BC6ENTG signaling.	CPR:3
 BC6ENTC inhibits BC6ENTG - induced reactive BC6OTHER species accumulation and myofibroblast differentiation via enhanced BC6OTHER - BC6OTHER signaling.	CPR:4
 BC6OTHER inhibits BC6OTHER - induced reactive BC6ENTC species accumulation and myofibroblast differentiation via enhanced BC6ENTG - BC6OTHER signaling.	False
 BC6OTHER inhibits BC6OTHER - induced reactive BC6ENTC species accumulation and myofibroblast differentiation via enhanced BC6OTHER - BC6ENTG signaling.	False
 BC6OTHER inhibits BC6ENTG - induced reactive BC6ENTC species accumulation and myofibroblast differentiation via enhanced BC6OTHER - BC6OTHER signaling.	False
Treatment with BC6OTHER and the BC6ENTG - BC6OTHER activator resulted in increased inhibition of the BC6OTHER - induced myofibroblast differentiation as compared with treatment with BC6ENTC or BC6OTHER .	False
Treatment with BC6OTHER and the BC6OTHER - BC6ENTG activator resulted in increased inhibition of the BC6OTHER - induced myofibroblast differentiation as compared with treatment with BC6ENTC or BC6OTHER .	False
Treatment with BC6OTHER and the BC6OTHER - BC6OTHER activator resulted in increased inhibition of the BC6ENTG - induced myofibroblast differentiation as compared with treatment with BC6ENTC or BC6OTHER .	False
Treatment with BC6OTHER and the BC6ENTG - BC6OTHER activator resulted in increased inhibition of the BC6OTHER - induced myofibroblast differentiation as compared with treatment with BC6OTHER or BC6ENTC .	False
Treatment with BC6OTHER and the BC6OTHER - BC6ENTG activator resulted in increased inhibition of the BC6OTHER - induced myofibroblast differentiation as compared with treatment with BC6OTHER or BC6ENTC .	False
Treatment with BC6OTHER and the BC6OTHER - BC6OTHER activator resulted in increased inhibition of the BC6ENTG - induced myofibroblast differentiation as compared with treatment with BC6OTHER or BC6ENTC .	False
Furthermore, BC6ENTC also decreased cellular ROS and BC6OTHER accumulation induced by BC6ENTG , whereas it elevated intracellular BC6OTHER level and cellular total antioxidant capacity.	CPR:4
Furthermore, BC6OTHER also decreased cellular ROS and BC6ENTC accumulation induced by BC6ENTG , whereas it elevated intracellular BC6OTHER level and cellular total antioxidant capacity.	False
Furthermore, BC6OTHER also decreased cellular ROS and BC6OTHER accumulation induced by BC6ENTG , whereas it elevated intracellular BC6ENTC level and cellular total antioxidant capacity.	False
In addition, BC6ENTC induced BC6ENTG nuclear translocation and up - regulated the expression of BC6OTHER - BC6OTHER downstream antioxidant genes, whereas BC6OTHER knockdown by RNA interference blocked the inhibition of BC6OTHER on myofibroblast differentiation.	False
In addition, BC6ENTC induced BC6OTHER nuclear translocation and up - regulated the expression of BC6ENTG - BC6OTHER downstream antioxidant genes, whereas BC6OTHER knockdown by RNA interference blocked the inhibition of BC6OTHER on myofibroblast differentiation.	CPR:3
In addition, BC6ENTC induced BC6OTHER nuclear translocation and up - regulated the expression of BC6OTHER - BC6ENTG downstream antioxidant genes, whereas BC6OTHER knockdown by RNA interference blocked the inhibition of BC6OTHER on myofibroblast differentiation.	CPR:3
In addition, BC6ENTC induced BC6OTHER nuclear translocation and up - regulated the expression of BC6OTHER - BC6OTHER downstream antioxidant genes, whereas BC6ENTG knockdown by RNA interference blocked the inhibition of BC6OTHER on myofibroblast differentiation.	False
 BC6OTHER ( BC6OTHER ) has been shown to prevent fibrosis in vitro and in vivo. The present study aimed at investigating the role of reactive BC6ENTC species (ROS) scavenging by BC6OTHER on BC6ENTG ( BC6OTHER - induced myofibroblast differentiation of corneal fibroblasts in vitro.	False
 BC6OTHER ( BC6OTHER ) has been shown to prevent fibrosis in vitro and in vivo. The present study aimed at investigating the role of reactive BC6ENTC species (ROS) scavenging by BC6OTHER on BC6OTHER ( BC6ENTG - induced myofibroblast differentiation of corneal fibroblasts in vitro.	False
In addition, BC6OTHER induced BC6ENTG nuclear translocation and up - regulated the expression of BC6OTHER - BC6OTHER downstream antioxidant genes, whereas BC6OTHER knockdown by RNA interference blocked the inhibition of BC6ENTC on myofibroblast differentiation.	False
In addition, BC6OTHER induced BC6OTHER nuclear translocation and up - regulated the expression of BC6ENTG - BC6OTHER downstream antioxidant genes, whereas BC6OTHER knockdown by RNA interference blocked the inhibition of BC6ENTC on myofibroblast differentiation.	False
In addition, BC6OTHER induced BC6OTHER nuclear translocation and up - regulated the expression of BC6OTHER - BC6ENTG downstream antioxidant genes, whereas BC6OTHER knockdown by RNA interference blocked the inhibition of BC6ENTC on myofibroblast differentiation.	False
In addition, BC6OTHER induced BC6OTHER nuclear translocation and up - regulated the expression of BC6OTHER - BC6OTHER downstream antioxidant genes, whereas BC6ENTG knockdown by RNA interference blocked the inhibition of BC6ENTC on myofibroblast differentiation.	False
This approach is validated by the clinical efficacy and safety of BC6ENTC , the pioneering drug for selective BC6ENTG inhibitor therapy for ED.	CPR:4
BC6ENTC exhibits inhibitory potency against BC6OTHER and a 10 - fold lower dose - related inhibitory potency against rod outer segment BC6OTHER , the predominant BC6ENTG in the phototransduction cascade in rods.	CPR:4
BC6ENTC exhibits inhibitory potency against BC6ENTG and a 10 - fold lower dose - related inhibitory potency against rod outer segment BC6OTHER , the predominant BC6OTHER in the phototransduction cascade in rods.	CPR:4
BC6ENTC exhibits inhibitory potency against BC6OTHER and a 10 - fold lower dose - related inhibitory potency against rod outer segment BC6ENTG , the predominant BC6OTHER in the phototransduction cascade in rods.	CPR:4
As free BC6ENTC plasma concentrations approach concentrations sufficient to inhibit CHEM BC6ENTG , usually at higher therapeutic doses, transient, reversible visual adverse events can occur, albeit infrequently.	CPR:4
Published literature on the BC6ENTC - BC6OTHER ( BC6OTHER ) pathway for penile erection and on BC6ENTG inhibition using CHEM as the model for pharmacologic BC6OTHER inhibition are assessed.	False
Published literature on the BC6ENTC - BC6OTHER ( BC6OTHER ) pathway for penile erection and on BC6OTHER inhibition using CHEM as the model for pharmacologic BC6ENTG inhibition are assessed.	False
Selective inhibition of BC6ENTG is a rational therapeutic approach in ED, as proved by the clinical success of BC6ENTC .	CPR:4
Published literature on the BC6OTHER - BC6ENTC ( BC6OTHER ) pathway for penile erection and on BC6ENTG inhibition using CHEM as the model for pharmacologic BC6OTHER inhibition are assessed.	False
Published literature on the BC6OTHER - BC6ENTC ( BC6OTHER ) pathway for penile erection and on BC6OTHER inhibition using CHEM as the model for pharmacologic BC6ENTG inhibition are assessed.	False
Published literature on the BC6OTHER - BC6OTHER ( BC6ENTC ) pathway for penile erection and on BC6ENTG inhibition using CHEM as the model for pharmacologic BC6OTHER inhibition are assessed.	False
Published literature on the BC6OTHER - BC6OTHER ( BC6ENTC ) pathway for penile erection and on BC6OTHER inhibition using CHEM as the model for pharmacologic BC6ENTG inhibition are assessed.	False
BC6ENTG is the predominant BC6OTHER in the corpus cavernosum, and BC6ENTC is its primary substrate.	CPR:9
BC6OTHER is the predominant BC6ENTG in the corpus cavernosum, and BC6ENTC is its primary substrate.	CPR:9
Therefore, in men with ED, elevation of BC6ENTC in corpus cavernosal tissue via selective inhibition of BC6OTHER - specific BC6ENTG is a means of improving erectile function at minimal risk of adverse events.	False
Therefore, in men with ED, elevation of BC6OTHER in corpus cavernosal tissue via selective inhibition of BC6ENTC - specific BC6ENTG is a means of improving erectile function at minimal risk of adverse events.	CPR:4
Here we show that BC6OTHER increases proliferation and differentiation and opposes BC6ENTC - induced apoptosis in human osteoblastic MG - 63 cells containing two BC6ENTG ( BC6OTHER ) isoforms.	False
Here we show that BC6OTHER increases proliferation and differentiation and opposes BC6ENTC - induced apoptosis in human osteoblastic MG - 63 cells containing two BC6OTHER ( BC6ENTG ) isoforms.	False
Here we show that BC6OTHER increases proliferation and differentiation and opposes BC6OTHER - induced apoptosis in human osteoblastic MG - 63 cells containing two BC6ENTC receptor ( BC6ENTG ) isoforms.	False
BC6ENTC promotes proliferation by altering cell cycle distribution whereas BC6OTHER - mediated survival may be associated with up - regulation of BC6ENTG expression.	False
BC6OTHER promotes proliferation by altering cell cycle distribution whereas BC6ENTC - mediated survival may be associated with up - regulation of BC6ENTG expression.	CPR:3
Treatment with the BC6ENTG antagonist BC6ENTC abolishes the above actions of BC6OTHER on osteoblast - derived cells.	CPR:6
Treatment with the BC6ENTG antagonist BC6OTHER abolishes the above actions of BC6ENTC on osteoblast - derived cells.	False
 BC6ENTC stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG - 63 cells via BC6ENTG - dependent BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER activation.	False
 BC6ENTC stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG - 63 cells via BC6OTHER - dependent BC6ENTG / BC6OTHER and BC6OTHER / BC6OTHER activation.	CPR:3
 BC6ENTC stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG - 63 cells via BC6OTHER - dependent BC6OTHER / BC6ENTG and BC6OTHER / BC6OTHER activation.	CPR:3
 BC6ENTC stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG - 63 cells via BC6OTHER - dependent BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER activation.	CPR:3
 BC6ENTC stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG - 63 cells via BC6OTHER - dependent BC6OTHER / BC6OTHER and BC6OTHER / BC6ENTG activation.	CPR:3
Using small interfering double - stranded RNA technology, we further demonstrate that the effects of BC6ENTC on proliferation, differentiation and survival are mediated by both BC6ENTG and BC6OTHER .	False
Using small interfering double - stranded RNA technology, we further demonstrate that the effects of BC6ENTC on proliferation, differentiation and survival are mediated by both BC6OTHER and BC6ENTG .	False
Moreover, we also demonstrate that BC6ENTC functions at least partially through activation of BC6ENTG / BC6OTHER and BC6OTHER / BC6OTHER signaling.	CPR:3
Moreover, we also demonstrate that BC6ENTC functions at least partially through activation of BC6OTHER / BC6ENTG and BC6OTHER / BC6OTHER signaling.	CPR:3
Moreover, we also demonstrate that BC6ENTC functions at least partially through activation of BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER signaling.	CPR:3
Moreover, we also demonstrate that BC6ENTC functions at least partially through activation of BC6OTHER / BC6OTHER and BC6OTHER / BC6ENTG signaling.	CPR:3
Here we show that BC6ENTC increases proliferation and differentiation and opposes BC6OTHER - induced apoptosis in human osteoblastic MG - 63 cells containing two BC6ENTG ( BC6OTHER ) isoforms.	False
Here we show that BC6ENTC increases proliferation and differentiation and opposes BC6OTHER - induced apoptosis in human osteoblastic MG - 63 cells containing two BC6OTHER ( BC6ENTG ) isoforms.	False
Furthermore, BC6ENTG - stimulated T - I cell proliferation and the expression of BC6OTHER BC6OTHER , BC6OTHER and BC6OTHER were also blocked by BC6ENTC .	CPR:4
Furthermore, BC6OTHER - stimulated T - I cell proliferation and the expression of BC6ENTG BC6OTHER , BC6OTHER and BC6OTHER were also blocked by BC6ENTC .	CPR:4
Furthermore, BC6OTHER - stimulated T - I cell proliferation and the expression of BC6OTHER BC6ENTG , BC6OTHER and BC6OTHER were also blocked by BC6ENTC .	CPR:4
Furthermore, BC6OTHER - stimulated T - I cell proliferation and the expression of BC6OTHER BC6OTHER , BC6ENTG and BC6OTHER were also blocked by BC6ENTC .	CPR:4
Furthermore, BC6OTHER - stimulated T - I cell proliferation and the expression of BC6OTHER BC6OTHER , BC6OTHER and BC6ENTG were also blocked by BC6ENTC .	CPR:4
Pharmacological inhibition of BC6ENTG with BC6ENTC abrogated the BC6OTHER - induced phosphorylation of BC6OTHER , BC6OTHER and its downstream effector, BC6OTHER .	CPR:4
Pharmacological inhibition of BC6OTHER with BC6ENTC abrogated the BC6ENTG - induced phosphorylation of BC6OTHER , BC6OTHER and its downstream effector, BC6OTHER .	CPR:4
Pharmacological inhibition of BC6OTHER with BC6ENTC abrogated the BC6OTHER - induced phosphorylation of BC6ENTG , BC6OTHER and its downstream effector, BC6OTHER .	CPR:4
Pharmacological inhibition of BC6OTHER with BC6ENTC abrogated the BC6OTHER - induced phosphorylation of BC6OTHER , BC6ENTG and its downstream effector, BC6OTHER .	CPR:4
Pharmacological inhibition of BC6OTHER with BC6ENTC abrogated the BC6OTHER - induced phosphorylation of BC6OTHER , BC6OTHER and its downstream effector, BC6ENTG .	CPR:4
The present study examined the effect of BC6OTHER - mediated activation of the mammalian target of BC6ENTC complex 1 ( BC6ENTG ) signaling network on the proliferation of primary culture of theca - interstitial (T - I) cells.	False
The present study examined the effect of BC6ENTG - mediated activation of the mammalian target of BC6ENTC complex 1 ( BC6OTHER ) signaling network on the proliferation of primary culture of theca - interstitial (T - I) cells.	False
The drug had a potent cytotoxic effect on RIN cells expressing BC6ENTG , but had no effect on cells lacking BC6OTHER expression, as indicated by histological analysis and measurement of the blood BC6ENTC levels of treated animals.	CPR:9
The drug had a potent cytotoxic effect on RIN cells expressing BC6OTHER , but had no effect on cells lacking BC6ENTG expression, as indicated by histological analysis and measurement of the blood BC6ENTC levels of treated animals.	False
The preferential cytotoxic effect of BC6ENTC on BC6OTHER - expressing cell lines was confirmed by in vitro analysis of BC6OTHER - expressing and untransfected RIN cells, as well as BC6ENTG - and BC6OTHER - overexpressing AtT - 20ins cells.	False
The preferential cytotoxic effect of BC6ENTC on BC6OTHER - expressing cell lines was confirmed by in vitro analysis of BC6OTHER - expressing and untransfected RIN cells, as well as BC6OTHER - and BC6ENTG - overexpressing AtT - 20ins cells.	False
The preferential cytotoxic effect of BC6ENTC on BC6ENTG - expressing cell lines was confirmed by in vitro analysis of BC6OTHER - expressing and untransfected RIN cells, as well as BC6OTHER - and BC6OTHER - overexpressing AtT - 20ins cells.	False
The preferential cytotoxic effect of BC6ENTC on BC6OTHER - expressing cell lines was confirmed by in vitro analysis of BC6ENTG - expressing and untransfected RIN cells, as well as BC6OTHER - and BC6OTHER - overexpressing AtT - 20ins cells.	False
Consistent with these data, only BC6ENTG - expressing RIN or AtT - 20ins cells transported BC6ENTC efficiently.	CPR:9
We conclude that expression of BC6ENTG is required for efficient killing of neuroendocrine cells by BC6ENTC , and this effect is related to specific recognition of the drug as a transported substrate by BC6OTHER but not BC6OTHER .	CPR:9
We conclude that expression of BC6OTHER is required for efficient killing of neuroendocrine cells by BC6ENTC , and this effect is related to specific recognition of the drug as a transported substrate by BC6ENTG but not BC6OTHER .	CPR:9
We conclude that expression of BC6OTHER is required for efficient killing of neuroendocrine cells by BC6ENTC , and this effect is related to specific recognition of the drug as a transported substrate by BC6OTHER but not BC6ENTG .	False
In the current study, we have used insulinoma (RIN) and AtT - 20ins cell lines engineered for overexpression of BC6ENTG or BC6OTHER to investigate the role of BC6ENTC transporter isoforms in mediating BC6OTHER cytotoxicity.	False
In the current study, we have used insulinoma (RIN) and AtT - 20ins cell lines engineered for overexpression of BC6OTHER or BC6ENTG to investigate the role of BC6ENTC transporter isoforms in mediating BC6OTHER cytotoxicity.	False
In the current study, we have used insulinoma (RIN) and AtT - 20ins cell lines engineered for overexpression of BC6ENTG or BC6OTHER to investigate the role of BC6OTHER transporter isoforms in mediating BC6ENTC cytotoxicity.	False
In the current study, we have used insulinoma (RIN) and AtT - 20ins cell lines engineered for overexpression of BC6OTHER or BC6ENTG to investigate the role of BC6OTHER transporter isoforms in mediating BC6ENTC cytotoxicity.	False
In the current study, we have used insulinoma (RIN) and AtT - 20ins cell lines engineered for overexpression of BC6OTHER or BC6OTHER to investigate the role of BC6ENTG isoforms in mediating BC6ENTC cytotoxicity.	False
The in vivo effects of BC6ENTC were evaluated by implantation of RIN cells expressing or lacking BC6ENTG into athymic nude rats.	False
Both BC6ENTC , but BC6OTHER to a lesser extent compared with BC6OTHER , selectively and dose - dependently reduced the percentage of BC6ENTG - expressing Th cells in a BC6OTHER - dependent fashion, whereas the expression of the cell surface marker BC6OTHER was unaltered on activated T cells.	CPR:4
Both BC6ENTC , but BC6OTHER to a lesser extent compared with BC6OTHER , selectively and dose - dependently reduced the percentage of BC6OTHER - expressing Th cells in a BC6ENTG - dependent fashion, whereas the expression of the cell surface marker BC6OTHER was unaltered on activated T cells.	False
Both BC6ENTC , but BC6OTHER to a lesser extent compared with BC6OTHER , selectively and dose - dependently reduced the percentage of BC6OTHER - expressing Th cells in a BC6OTHER - dependent fashion, whereas the expression of the cell surface marker BC6ENTG was unaltered on activated T cells.	False
Both BC6OTHER , but BC6ENTC to a lesser extent compared with BC6OTHER , selectively and dose - dependently reduced the percentage of BC6ENTG - expressing Th cells in a BC6OTHER - dependent fashion, whereas the expression of the cell surface marker BC6OTHER was unaltered on activated T cells.	CPR:4
Both BC6OTHER , but BC6ENTC to a lesser extent compared with BC6OTHER , selectively and dose - dependently reduced the percentage of BC6OTHER - expressing Th cells in a BC6ENTG - dependent fashion, whereas the expression of the cell surface marker BC6OTHER was unaltered on activated T cells.	False
Both BC6OTHER , but BC6ENTC to a lesser extent compared with BC6OTHER , selectively and dose - dependently reduced the percentage of BC6OTHER - expressing Th cells in a BC6OTHER - dependent fashion, whereas the expression of the cell surface marker BC6ENTG was unaltered on activated T cells.	False
Both BC6OTHER , but BC6OTHER to a lesser extent compared with BC6ENTC , selectively and dose - dependently reduced the percentage of BC6ENTG - expressing Th cells in a BC6OTHER - dependent fashion, whereas the expression of the cell surface marker BC6OTHER was unaltered on activated T cells.	CPR:4
Both BC6OTHER , but BC6OTHER to a lesser extent compared with BC6ENTC , selectively and dose - dependently reduced the percentage of BC6OTHER - expressing Th cells in a BC6ENTG - dependent fashion, whereas the expression of the cell surface marker BC6OTHER was unaltered on activated T cells.	False
Both BC6OTHER , but BC6OTHER to a lesser extent compared with BC6ENTC , selectively and dose - dependently reduced the percentage of BC6OTHER - expressing Th cells in a BC6OTHER - dependent fashion, whereas the expression of the cell surface marker BC6ENTG was unaltered on activated T cells.	False
In monocytes, both BC6ENTC and BC6OTHER increased BC6ENTG without affecting BC6OTHER and BC6OTHER .	CPR:3
In monocytes, both BC6ENTC and BC6OTHER increased BC6OTHER without affecting BC6ENTG and BC6OTHER .	False
In monocytes, both BC6ENTC and BC6OTHER increased BC6OTHER without affecting BC6OTHER and BC6ENTG .	False
In monocytes, both BC6OTHER and BC6ENTC increased BC6ENTG without affecting BC6OTHER and BC6OTHER .	CPR:3
In monocytes, both BC6OTHER and BC6ENTC increased BC6OTHER without affecting BC6ENTG and BC6OTHER .	False
In monocytes, both BC6OTHER and BC6ENTC increased BC6OTHER without affecting BC6OTHER and BC6ENTG .	False
Single nucleotide polymorphisms (SNPs) in the BC6ENTC - BC6OTHER - methyltransferase ( BC6ENTG ) gene have been related to cognitive function.	False
Single nucleotide polymorphisms (SNPs) in the CHEM - BC6ENTC - methyltransferase ( BC6ENTG ) gene have been related to cognitive function.	False
Adenovirus - delivered BC6ENTG treatment for BC6ENTC - induced acute lung injury.	False
The lung injury induced by BC6ENTC was markedly reduced after the injection of Ad / BC6ENTG .	False
The increase of BC6ENTG and BC6OTHER and decrease of BC6OTHER in the serum and bronchoalveolar lavage fluid of BC6ENTC - exposed animals were abolished by the administration of Ad / BC6OTHER .	False
The increase of BC6OTHER and BC6ENTG and decrease of BC6OTHER in the serum and bronchoalveolar lavage fluid of BC6ENTC - exposed animals were abolished by the administration of Ad / BC6OTHER .	False
The increase of BC6OTHER and BC6OTHER and decrease of BC6ENTG in the serum and bronchoalveolar lavage fluid of BC6ENTC - exposed animals were abolished by the administration of Ad / BC6OTHER .	False
The increase of BC6OTHER and BC6OTHER and decrease of BC6OTHER in the serum and bronchoalveolar lavage fluid of BC6ENTC - exposed animals were abolished by the administration of Ad / BC6ENTG .	False
Discussion and conclusions: BC6ENTG has the beneficial effects on BC6ENTC - induced lung injury.	False
The adenovirus - delivered BC6ENTG may have the potential as a novel approach for the treatment of the acute lung injury caused by BC6ENTC gas inhalation in humans.	False
Objective: In this study, the histopathological changes of the lungs after exposure to BC6ENTC and the effect of BC6ENTG treatment were examined.	False
Isolation and characterization of labeled peptides from BC6ENTC - modified BC6ENTG indicated that peptides encompassing residues 38 - 75, 107 - 126, and 127 - 148 contained BC6OTHER label.	False
Isolation and characterization of labeled peptides from BC6OTHER - modified BC6ENTG indicated that peptides encompassing residues 38 - 75, 107 - 126, and 127 - 148 contained BC6ENTC label.	False
Drug - protein interactions: isolation and characterization of covalent adducts of BC6ENTC and BC6ENTG .	False
BC6ENTC , an alpha - adrenergic antagonist containing a BC6OTHER group, labels BC6ENTG in the presence of BC6OTHER .	False
BC6OTHER , an alpha - adrenergic antagonist containing a BC6OTHER group, labels BC6ENTG in the presence of BC6ENTC .	False
Adducts of BC6ENTG and BC6ENTC were separated by high - performance liquid chromatography into four major fractions: two containing 0.6 and 1.2 mol of drug per mol of protein and two different fractions each containing 2.0 mol / mol.	False
Each adduct had a reduced ability to activate BC6ENTC phosphodiesterase and BC6ENTG , and the BC6OTHER binding capacities of the BC6OTHER - BC6OTHER adducts were diminished to the extent of BC6OTHER incorporation into each adduct.	False
Each adduct had a reduced ability to activate BC6ENTC phosphodiesterase and BC6OTHER , and the BC6OTHER binding capacities of the BC6OTHER - BC6ENTG adducts were diminished to the extent of BC6OTHER incorporation into each adduct.	False
Each adduct had a reduced ability to activate BC6ENTG and BC6OTHER , and the BC6ENTC binding capacities of the BC6OTHER - BC6OTHER adducts were diminished to the extent of BC6OTHER incorporation into each adduct.	False
Each adduct had a reduced ability to activate BC6OTHER phosphodiesterase and BC6ENTG , and the BC6ENTC binding capacities of the BC6OTHER - BC6OTHER adducts were diminished to the extent of BC6OTHER incorporation into each adduct.	False
Each adduct had a reduced ability to activate BC6OTHER phosphodiesterase and BC6OTHER , and the BC6ENTC binding capacities of the BC6OTHER - BC6ENTG adducts were diminished to the extent of BC6OTHER incorporation into each adduct.	False
BC6OTHER , an alpha - adrenergic antagonist containing a BC6ENTC group, labels BC6ENTG in the presence of BC6OTHER .	False
Each adduct had a reduced ability to activate BC6ENTG and BC6OTHER , and the BC6OTHER binding capacities of the BC6ENTC - BC6OTHER adducts were diminished to the extent of BC6OTHER incorporation into each adduct.	False
Each adduct had a reduced ability to activate BC6OTHER phosphodiesterase and BC6ENTG , and the BC6OTHER binding capacities of the BC6ENTC - BC6OTHER adducts were diminished to the extent of BC6OTHER incorporation into each adduct.	False
Each adduct had a reduced ability to activate BC6OTHER phosphodiesterase and BC6OTHER , and the BC6OTHER binding capacities of the BC6ENTC - BC6ENTG adducts were diminished to the extent of BC6OTHER incorporation into each adduct.	False
Each adduct had a reduced ability to activate BC6ENTG and BC6OTHER , and the BC6OTHER binding capacities of the BC6OTHER - BC6OTHER adducts were diminished to the extent of BC6ENTC incorporation into each adduct.	False
Each adduct had a reduced ability to activate BC6OTHER phosphodiesterase and BC6ENTG , and the BC6OTHER binding capacities of the BC6OTHER - BC6OTHER adducts were diminished to the extent of BC6ENTC incorporation into each adduct.	False
Each adduct had a reduced ability to activate BC6OTHER phosphodiesterase and BC6OTHER , and the BC6OTHER binding capacities of the BC6OTHER - BC6ENTG adducts were diminished to the extent of BC6ENTC incorporation into each adduct.	False
Novel highly affine BC6ENTG ligands with additional inhibitory effects on the main BC6OTHER metabolizing enzyme in the brain, BC6ENTC - methyltransferase, chemically show structural elements of the BC6OTHER inhibitor BC6OTHER .	False
Novel highly affine BC6OTHER H3 receptor ligands with additional inhibitory effects on the main BC6OTHER metabolizing enzyme in the brain, BC6ENTC - methyltransferase, chemically show structural elements of the BC6ENTG inhibitor BC6OTHER .	False
Novel highly affine BC6ENTC H3 receptor ligands with additional inhibitory effects on the main BC6OTHER metabolizing enzyme in the brain, BC6ENTG , chemically show structural elements of the BC6OTHER inhibitor BC6OTHER .	False
Novel highly affine BC6ENTC H3 receptor ligands with additional inhibitory effects on the main BC6OTHER metabolizing enzyme in the brain, BC6OTHER - methyltransferase, chemically show structural elements of the BC6ENTG inhibitor BC6OTHER .	False
Novel highly affine BC6OTHER H3 receptor ligands with additional inhibitory effects on the main BC6OTHER metabolizing enzyme in the brain, BC6ENTG , chemically show structural elements of the BC6OTHER inhibitor BC6ENTC .	False
Novel highly affine BC6ENTG ligands with additional inhibitory effects on the main BC6OTHER metabolizing enzyme in the brain, BC6OTHER - methyltransferase, chemically show structural elements of the BC6OTHER inhibitor BC6ENTC .	False
Novel highly affine BC6OTHER H3 receptor ligands with additional inhibitory effects on the main BC6OTHER metabolizing enzyme in the brain, BC6OTHER - methyltransferase, chemically show structural elements of the BC6ENTG inhibitor BC6ENTC .	CPR:4
BC6ENTG antagonism, inhibition of metabolisation of neuronal BC6ENTC as well as inhibition of hydrolysis of BC6OTHER are each one believed to improve reduced cognitive functions, which is useful for symptomatic treatment of Alzheimer's disease.	False
BC6ENTG antagonism, inhibition of metabolisation of neuronal BC6OTHER as well as inhibition of hydrolysis of BC6ENTC are each one believed to improve reduced cognitive functions, which is useful for symptomatic treatment of Alzheimer's disease.	False
Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of BC6ENTG and of BC6OTHER which is another catalytic enzyme hydrolysing BC6ENTC .	CPR:9
Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of BC6OTHER and of BC6ENTG which is another catalytic enzyme hydrolysing BC6ENTC .	CPR:9
Some compounds with (sub)nanomolar activities on the BC6ENTC - related targets are also active in the nanomolar concentration range on both BC6ENTG targets being 5 - to 40 - times more potent than BC6OTHER .	False
Some compounds with (sub)nanomolar activities on the BC6OTHER - related targets are also active in the nanomolar concentration range on both BC6ENTG targets being 5 - to 40 - times more potent than BC6ENTC .	False
Novel highly affine BC6OTHER H3 receptor ligands with additional inhibitory effects on the main BC6ENTC metabolizing enzyme in the brain, BC6ENTG , chemically show structural elements of the BC6OTHER inhibitor BC6OTHER .	CPR:9
Novel highly affine BC6ENTG ligands with additional inhibitory effects on the main BC6ENTC metabolizing enzyme in the brain, BC6OTHER - methyltransferase, chemically show structural elements of the BC6OTHER inhibitor BC6OTHER .	False
Novel highly affine BC6OTHER H3 receptor ligands with additional inhibitory effects on the main BC6ENTC metabolizing enzyme in the brain, BC6OTHER - methyltransferase, chemically show structural elements of the BC6ENTG inhibitor BC6OTHER .	False
Consistent with this, we found that knockdown of BC6OTHER inhibits, whereas ectopic expression of BC6OTHER enhances, BC6ENTC - induced degradation of BC6ENTG protein.	CPR:4
Consistent with this, we found that knockdown of BC6ENTG inhibits, whereas ectopic expression of BC6OTHER enhances, BC6ENTC - induced degradation of BC6OTHER protein.	False
Consistent with this, we found that knockdown of BC6OTHER inhibits, whereas ectopic expression of BC6ENTG enhances, BC6ENTC - induced degradation of BC6OTHER protein.	False
Importantly, we found that knockdown of BC6ENTG sensitizes, whereas ectopic expression of BC6OTHER inhibits, growth suppression induced by BC6ENTC .	False
Importantly, we found that knockdown of BC6OTHER sensitizes, whereas ectopic expression of BC6ENTG inhibits, growth suppression induced by BC6ENTC .	False
Together, these data suggest that BC6ENTC degrades BC6ENTG protein at least in part via BC6OTHER - dependent proteolysis and that inhibition of BC6OTHER expression facilitates tumor cells to BC6OTHER - induced death.	CPR:4
Together, these data suggest that BC6ENTC degrades BC6OTHER protein at least in part via BC6ENTG - dependent proteolysis and that inhibition of BC6OTHER expression facilitates tumor cells to BC6OTHER - induced death.	False
Together, these data suggest that BC6ENTC degrades BC6OTHER protein at least in part via BC6OTHER - dependent proteolysis and that inhibition of BC6ENTG expression facilitates tumor cells to BC6OTHER - induced death.	CPR:4
Together, these data suggest that BC6OTHER degrades BC6ENTG protein at least in part via BC6OTHER - dependent proteolysis and that inhibition of BC6OTHER expression facilitates tumor cells to BC6ENTC - induced death.	False
Together, these data suggest that BC6OTHER degrades BC6OTHER protein at least in part via BC6ENTG - dependent proteolysis and that inhibition of BC6OTHER expression facilitates tumor cells to BC6ENTC - induced death.	False
Together, these data suggest that BC6OTHER degrades BC6OTHER protein at least in part via BC6OTHER - dependent proteolysis and that inhibition of BC6ENTG expression facilitates tumor cells to BC6ENTC - induced death.	False
Here we found that BC6ENTC , a frontline agent for acute promyelocytic leukemia, inhibits BC6ENTG but not BC6OTHER expression in time - and dose - dependent manners.	CPR:4
Here we found that BC6ENTC , a frontline agent for acute promyelocytic leukemia, inhibits BC6OTHER but not BC6ENTG expression in time - and dose - dependent manners.	False
In addition, we found that BC6ENTC decreases the stability of BC6ENTG protein via a BC6OTHER - dependent pathway but has little effect on the level of BC6OTHER transcript.	CPR:4
In addition, we found that BC6ENTC decreases the stability of BC6OTHER protein via a BC6ENTG - dependent pathway but has little effect on the level of BC6OTHER transcript.	False
In addition, we found that BC6ENTC decreases the stability of BC6OTHER protein via a BC6OTHER - dependent pathway but has little effect on the level of BC6ENTG transcript.	False
Furthermore, we found that BC6ENTC activates the BC6ENTG and consequently induces BC6OTHER expression.	CPR:3
Furthermore, we found that BC6ENTC activates the BC6OTHER and consequently induces BC6ENTG expression.	CPR:3
 BC6ENTC suppresses cell survival via BC6ENTG - mediated proteasomal degradation of BC6OTHER protein.	False
 BC6ENTC suppresses cell survival via BC6OTHER - mediated proteasomal degradation of BC6ENTG protein.	False
In the current study dietary relevant mixtures of BC6ENTC and their metabolites, BC6OTHER and their metabolites, BC6OTHER , and a mixture containing all of them, were examined for effects on adipogenesis in 3T3 - L1 adipocytes, as well as tested for their BC6ENTG activating abilities.	False
In the current study dietary relevant mixtures of BC6OTHER and their metabolites, BC6ENTC and their metabolites, BC6OTHER , and a mixture containing all of them, were examined for effects on adipogenesis in 3T3 - L1 adipocytes, as well as tested for their BC6ENTG activating abilities.	False
In the current study dietary relevant mixtures of BC6OTHER and their metabolites, BC6OTHER and their metabolites, BC6ENTC , and a mixture containing all of them, were examined for effects on adipogenesis in 3T3 - L1 adipocytes, as well as tested for their BC6ENTG activating abilities.	False
Furthermore, a mixture of BC6ENTC parent compounds, and a mixture of BC6OTHER metabolites were found to have BC6ENTG activating abilities.	CPR:3
Furthermore, a mixture of BC6OTHER parent compounds, and a mixture of BC6ENTC metabolites were found to have BC6ENTG activating abilities.	CPR:3
The repeated exposures of CHEM, compared to single administration of CHEM, increased oral bioavailability and affected the pharmacokinetics of BC6ENTC and BC6OTHER , by inhibiting BC6ENTG .	False
The repeated exposures of CHEM, compared to single administration of CHEM, increased oral bioavailability and affected the pharmacokinetics of BC6OTHER and BC6ENTC , by inhibiting BC6ENTG .	False
The objective of this article is to examine the effects of single and repeated administrations of CHEM on pharmacokinetics of a BC6ENTG substrate, BC6ENTC , and its major metabolite, BC6OTHER , in rats.	CPR:9
The objective of this article is to examine the effects of single and repeated administrations of CHEM on pharmacokinetics of a BC6ENTG substrate, BC6OTHER , and its major metabolite, BC6ENTC , in rats.	CPR:9
The specific activity of only BC6ENTC aminotransferase ( BC6ENTG ), the rate - limiting enzyme in the conversion of BC6OTHER to BC6OTHER , increased in 2 weeks of hypertrophy.	False
The specific activity of only BC6ENTG ( BC6OTHER ), the rate - limiting enzyme in the conversion of BC6ENTC to BC6OTHER , increased in 2 weeks of hypertrophy.	CPR:9
The specific activity of only BC6OTHER ( BC6ENTG ), the rate - limiting enzyme in the conversion of BC6ENTC to BC6OTHER , increased in 2 weeks of hypertrophy.	CPR:9
The specific activity of only BC6ENTG ( BC6OTHER ), the rate - limiting enzyme in the conversion of BC6OTHER to BC6ENTC , increased in 2 weeks of hypertrophy.	CPR:9
The specific activity of only BC6OTHER ( BC6ENTG ), the rate - limiting enzyme in the conversion of BC6OTHER to BC6ENTC , increased in 2 weeks of hypertrophy.	CPR:9
The present study investigates enzyme activities of the CHEM cycle, BC6ENTG and BC6ENTC - BC6OTHER inter - conversion in the hypertrophied kidney after unilateral nephrectomy in mice.	False
The present study investigates enzyme activities of the CHEM cycle, BC6ENTG and BC6OTHER - BC6ENTC inter - conversion in the hypertrophied kidney after unilateral nephrectomy in mice.	False
Anabolic effects of BC6ENTC on skeletal muscle are mediated by BC6ENTG activation.	CPR:3
These results indicate that the anabolic effects of BC6ENTC are dependent on interaction with the BC6ENTG .	False
These effects were not mimicked by oral administration of the BC6ENTG agonist BC6ENTC even at high dose (52 mg / kg diet), and the effects of BC6OTHER were not inhibited by addition of BC6OTHER (200 mg / kg diet).	CPR:5
These effects were not mimicked by oral administration of the BC6ENTG agonist BC6OTHER even at high dose (52 mg / kg diet), and the effects of BC6ENTC were not inhibited by addition of BC6OTHER (200 mg / kg diet).	CPR:5
These effects were not mimicked by oral administration of the BC6ENTG agonist BC6OTHER even at high dose (52 mg / kg diet), and the effects of BC6OTHER were not inhibited by addition of BC6ENTC (200 mg / kg diet).	False
The potent anabolic effects of the BC6OTHER agonist BC6ENTC on skeletal muscle have been reported to be independent of actions on BC6ENTG .	False
The potent anabolic effects of the BC6ENTG agonist BC6ENTC on skeletal muscle have been reported to be independent of actions on BC6OTHER .	CPR:5
Posttranslational modification of the BC6ENTG ( BC6OTHER ) by BC6OTHER ( BC6ENTC ) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity.	False
Posttranslational modification of the BC6OTHER ( BC6ENTG ) by BC6OTHER ( BC6ENTC ) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity.	False
As shown in a cell culture model, BC6OTHER - BC6OTHER was kept in the late trans - Golgi apparatus of lung epithelial cells and stimulation by BC6ENTG or lipopolysaccharide induced BC6OTHER - mediated BC6OTHER shedding, resulting in the secretion of soluble BC6ENTC - NCAM.	False
As shown in a cell culture model, BC6OTHER - BC6OTHER was kept in the late trans - Golgi apparatus of lung epithelial cells and stimulation by BC6OTHER or lipopolysaccharide induced BC6ENTG - mediated BC6OTHER shedding, resulting in the secretion of soluble BC6ENTC - NCAM.	False
As shown in a cell culture model, BC6OTHER - BC6OTHER was kept in the late trans - Golgi apparatus of lung epithelial cells and stimulation by BC6OTHER or lipopolysaccharide induced BC6OTHER - mediated BC6ENTG shedding, resulting in the secretion of soluble BC6ENTC - NCAM.	False
As shown in a cell culture model, BC6OTHER - BC6ENTG was kept in the late trans - Golgi apparatus of lung epithelial cells and stimulation by BC6OTHER or lipopolysaccharide induced BC6OTHER - mediated BC6OTHER shedding, resulting in the secretion of soluble BC6ENTC - NCAM.	False
"Interestingly, BC6ENTC chains of secreted BC6ENTG neutralized the cytotoxic activity of extracellular BC6OTHER as well as DNA / BC6OTHER - network - containing ""neutrophil extracellular traps"", which are formed during invasion of microorganisms."	False
"Interestingly, BC6ENTC chains of secreted BC6OTHER neutralized the cytotoxic activity of extracellular BC6ENTG as well as DNA / BC6OTHER - network - containing ""neutrophil extracellular traps"", which are formed during invasion of microorganisms."	False
"Interestingly, BC6ENTC chains of secreted BC6OTHER neutralized the cytotoxic activity of extracellular BC6OTHER as well as DNA / BC6ENTG - network - containing ""neutrophil extracellular traps"", which are formed during invasion of microorganisms."	False
Here, we describe a novel function of BC6ENTG ( BC6ENTC - NCAM) in innate immunity of the lung.	False
In mature lung tissue of healthy donors, BC6ENTC was exclusively attached to the transmembrane isoform BC6ENTG and located to intracellular compartments of epithelial cells.	False
In patients with chronic obstructive pulmonary disease, however, increased BC6ENTC levels and processing of the BC6ENTG carrier were observed.	False
Processing of BC6ENTG was reproduced in a mouse model by BC6ENTC administration leading to an activation of the inflammasome and secretion of BC6OTHER .	False
Processing of BC6OTHER was reproduced in a mouse model by BC6ENTC administration leading to an activation of the inflammasome and secretion of BC6ENTG .	CPR:3
Posttranslational modification of the BC6ENTG ( BC6OTHER ) by BC6ENTC ( BC6OTHER ) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity.	False
Posttranslational modification of the BC6OTHER ( BC6ENTG ) by BC6ENTC ( BC6OTHER ) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity.	False
As shown in a cell culture model, BC6ENTC - BC6OTHER was kept in the late trans - Golgi apparatus of lung epithelial cells and stimulation by BC6ENTG or lipopolysaccharide induced BC6OTHER - mediated BC6OTHER shedding, resulting in the secretion of soluble BC6OTHER - NCAM.	False
As shown in a cell culture model, BC6ENTC - BC6OTHER was kept in the late trans - Golgi apparatus of lung epithelial cells and stimulation by BC6OTHER or lipopolysaccharide induced BC6ENTG - mediated BC6OTHER shedding, resulting in the secretion of soluble BC6OTHER - NCAM.	False
As shown in a cell culture model, BC6ENTC - BC6OTHER was kept in the late trans - Golgi apparatus of lung epithelial cells and stimulation by BC6OTHER or lipopolysaccharide induced BC6OTHER - mediated BC6ENTG shedding, resulting in the secretion of soluble BC6OTHER - NCAM.	False
As shown in a cell culture model, BC6ENTC - BC6OTHER was kept in the late trans - Golgi apparatus of lung epithelial cells and stimulation by BC6OTHER or lipopolysaccharide induced BC6OTHER - mediated BC6OTHER shedding, resulting in the secretion of soluble BC6ENTG .	False
As shown in a cell culture model, BC6ENTC - BC6ENTG was kept in the late trans - Golgi apparatus of lung epithelial cells and stimulation by BC6OTHER or lipopolysaccharide induced BC6OTHER - mediated BC6OTHER shedding, resulting in the secretion of soluble BC6OTHER - NCAM.	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6ENTC (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6ENTG numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6ENTC (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6ENTG that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6ENTC (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6ENTG of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6ENTC (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6ENTG was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6ENTC (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6ENTG numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6ENTC (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6ENTG that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6ENTC (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6ENTG of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6ENTC (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6ENTG was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6ENTC (169), BC6OTHER (236), and BC6OTHER (240) ( BC6ENTG numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6ENTC (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6ENTG that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6ENTC (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6ENTG of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6ENTC (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6ENTG was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6ENTC (236), and BC6OTHER (240) ( BC6ENTG numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6ENTC (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6ENTG that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6ENTC (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6ENTG of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6ENTC (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6ENTG was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6ENTC (240) ( BC6ENTG numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6ENTC (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6ENTG that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6ENTC (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6ENTG of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6ENTC (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6ENTG was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6ENTG numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6ENTC - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6ENTG that can effectively bind heparin only if the acidic BC6ENTC - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6ENTC - terminal CHEM domain of the BC6ENTG was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6ENTG numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6ENTC .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6ENTG that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6ENTC .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6ENTG of the BC6OTHER was neutralized by physiological levels of BC6ENTC .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6ENTG was neutralized by physiological levels of BC6ENTC .	False
Binding of a full - length heparin chain to this site of BC6ENTG in the presence of BC6ENTC makes a significant contribution to acceleration of the BC6OTHER inhibition by BC6OTHER through a ternary complex bridging or template mechanism.	False
Binding of a full - length heparin chain to this site of BC6OTHER in the presence of BC6ENTC makes a significant contribution to acceleration of the BC6ENTG inhibition by BC6OTHER through a ternary complex bridging or template mechanism.	False
Binding of a full - length heparin chain to this site of BC6OTHER in the presence of BC6ENTC makes a significant contribution to acceleration of the BC6OTHER inhibition by BC6ENTG through a ternary complex bridging or template mechanism.	False
Recent studies have indicated that the basic residues BC6ENTC (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6ENTG numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6ENTC (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6ENTG that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6ENTC (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6ENTG of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6ENTC (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6ENTG was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6ENTC (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6ENTG numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6ENTC (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6ENTG that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6ENTC (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6ENTG of the BC6OTHER was neutralized by physiological levels of BC6OTHER .	False
Recent studies have indicated that the basic residues BC6OTHER (93), BC6ENTC (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6ENTG was neutralized by physiological levels of BC6OTHER .	False
Moreover, certain basic residues of this site, particularly BC6ENTC (165) and BC6OTHER (169), play a key role in BC6ENTG and / or BC6OTHER recognition by BC6OTHER in the prothrombinase complex.	False
Moreover, certain basic residues of this site, particularly BC6ENTC (165) and BC6OTHER (169), play a key role in BC6OTHER and / or BC6ENTG recognition by BC6OTHER in the prothrombinase complex.	False
Moreover, certain basic residues of this site, particularly BC6ENTC (165) and BC6OTHER (169), play a key role in BC6OTHER and / or BC6OTHER recognition by BC6ENTG in the prothrombinase complex.	False
Moreover, certain basic residues of this site, particularly BC6OTHER (165) and BC6ENTC (169), play a key role in BC6ENTG and / or BC6OTHER recognition by BC6OTHER in the prothrombinase complex.	False
Moreover, certain basic residues of this site, particularly BC6OTHER (165) and BC6ENTC (169), play a key role in BC6OTHER and / or BC6ENTG recognition by BC6OTHER in the prothrombinase complex.	False
Moreover, certain basic residues of this site, particularly BC6OTHER (165) and BC6ENTC (169), play a key role in BC6OTHER and / or BC6OTHER recognition by BC6ENTG in the prothrombinase complex.	False
Out of the three putative sites (i.e., BC6OTHER 70 - BC6OTHER 78, BC6OTHER 82 - BC6OTHER 96, and BC6ENTC 113 - BC6OTHER 122) available on OPG for BC6ENTG binding, BC6OTHER 113 - BC6OTHER 122 was used as a template for peptide synthesis.	False
Out of the three putative sites (i.e., BC6OTHER 70 - BC6OTHER 78, BC6OTHER 82 - BC6OTHER 96, and BC6OTHER 113 - BC6ENTC 122) available on OPG for BC6ENTG binding, BC6OTHER 113 - BC6OTHER 122 was used as a template for peptide synthesis.	False
Out of the three putative sites (i.e., BC6OTHER 70 - BC6OTHER 78, BC6OTHER 82 - BC6OTHER 96, and BC6OTHER 113 - BC6OTHER 122) available on OPG for BC6ENTG binding, BC6ENTC 113 - BC6OTHER 122 was used as a template for peptide synthesis.	False
Out of the three putative sites (i.e., BC6OTHER 70 - BC6OTHER 78, BC6OTHER 82 - BC6OTHER 96, and BC6OTHER 113 - BC6OTHER 122) available on OPG for BC6ENTG binding, BC6OTHER 113 - BC6ENTC 122 was used as a template for peptide synthesis.	False
The peptide BC6ENTC (YLEIEFSLKHR), obtained by direct substitution of BC6OTHER with a BC6OTHER residue in the template sequence, significantly (p<0.05) inhibited BC6ENTG - BC6OTHER binding, and BC6OTHER induced BC6OTHER activity and formation of multinucleated osteoclasts without any cytotoxicity.	False
The peptide BC6ENTC (YLEIEFSLKHR), obtained by direct substitution of BC6OTHER with a BC6OTHER residue in the template sequence, significantly (p<0.05) inhibited BC6OTHER - BC6ENTG binding, and BC6OTHER induced BC6OTHER activity and formation of multinucleated osteoclasts without any cytotoxicity.	False
The peptide BC6ENTC (YLEIEFSLKHR), obtained by direct substitution of BC6OTHER with a BC6OTHER residue in the template sequence, significantly (p<0.05) inhibited BC6OTHER - BC6OTHER binding, and BC6ENTG induced BC6OTHER activity and formation of multinucleated osteoclasts without any cytotoxicity.	CPR:4
The peptide BC6ENTC (YLEIEFSLKHR), obtained by direct substitution of BC6OTHER with a BC6OTHER residue in the template sequence, significantly (p<0.05) inhibited BC6OTHER - BC6OTHER binding, and BC6OTHER induced BC6ENTG activity and formation of multinucleated osteoclasts without any cytotoxicity.	CPR:4
The peptide BC6OTHER (YLEIEFSLKHR), obtained by direct substitution of BC6ENTC with a BC6OTHER residue in the template sequence, significantly (p<0.05) inhibited BC6ENTG - BC6OTHER binding, and BC6OTHER induced BC6OTHER activity and formation of multinucleated osteoclasts without any cytotoxicity.	False
The peptide BC6OTHER (YLEIEFSLKHR), obtained by direct substitution of BC6ENTC with a BC6OTHER residue in the template sequence, significantly (p<0.05) inhibited BC6OTHER - BC6ENTG binding, and BC6OTHER induced BC6OTHER activity and formation of multinucleated osteoclasts without any cytotoxicity.	False
The peptide BC6OTHER (YLEIEFSLKHR), obtained by direct substitution of BC6ENTC with a BC6OTHER residue in the template sequence, significantly (p<0.05) inhibited BC6OTHER - BC6OTHER binding, and BC6ENTG induced BC6OTHER activity and formation of multinucleated osteoclasts without any cytotoxicity.	CPR:4
The peptide BC6OTHER (YLEIEFSLKHR), obtained by direct substitution of BC6ENTC with a BC6OTHER residue in the template sequence, significantly (p<0.05) inhibited BC6OTHER - BC6OTHER binding, and BC6OTHER induced BC6ENTG activity and formation of multinucleated osteoclasts without any cytotoxicity.	CPR:4
The peptide BC6OTHER (YLEIEFSLKHR), obtained by direct substitution of BC6OTHER with a BC6ENTC residue in the template sequence, significantly (p<0.05) inhibited BC6ENTG - BC6OTHER binding, and BC6OTHER induced BC6OTHER activity and formation of multinucleated osteoclasts without any cytotoxicity.	False
The peptide BC6OTHER (YLEIEFSLKHR), obtained by direct substitution of BC6OTHER with a BC6ENTC residue in the template sequence, significantly (p<0.05) inhibited BC6OTHER - BC6ENTG binding, and BC6OTHER induced BC6OTHER activity and formation of multinucleated osteoclasts without any cytotoxicity.	False
The peptide BC6OTHER (YLEIEFSLKHR), obtained by direct substitution of BC6OTHER with a BC6ENTC residue in the template sequence, significantly (p<0.05) inhibited BC6OTHER - BC6OTHER binding, and BC6ENTG induced BC6OTHER activity and formation of multinucleated osteoclasts without any cytotoxicity.	CPR:4
The peptide BC6OTHER (YLEIEFSLKHR), obtained by direct substitution of BC6OTHER with a BC6ENTC residue in the template sequence, significantly (p<0.05) inhibited BC6OTHER - BC6OTHER binding, and BC6OTHER induced BC6ENTG activity and formation of multinucleated osteoclasts without any cytotoxicity.	CPR:4
Results confirmed that BC6ENTC peptide inhibited pro - inflammatory BC6ENTG in the sera and hind paw tissues of AIA rats through its suppressive effect on BC6OTHER induced nuclear translocation of BC6OTHER .	CPR:4
Results confirmed that BC6ENTC peptide inhibited pro - inflammatory BC6OTHER in the sera and hind paw tissues of AIA rats through its suppressive effect on BC6ENTG induced nuclear translocation of BC6OTHER .	CPR:4
Results confirmed that BC6ENTC peptide inhibited pro - inflammatory BC6OTHER in the sera and hind paw tissues of AIA rats through its suppressive effect on BC6OTHER induced nuclear translocation of BC6ENTG .	CPR:4
Out of the three putative sites (i.e., BC6ENTC 70 - BC6OTHER 78, BC6OTHER 82 - BC6OTHER 96, and BC6OTHER 113 - BC6OTHER 122) available on OPG for BC6ENTG binding, BC6OTHER 113 - BC6OTHER 122 was used as a template for peptide synthesis.	False
Out of the three putative sites (i.e., BC6OTHER 70 - BC6ENTC 78, BC6OTHER 82 - BC6OTHER 96, and BC6OTHER 113 - BC6OTHER 122) available on OPG for BC6ENTG binding, BC6OTHER 113 - BC6OTHER 122 was used as a template for peptide synthesis.	False
Out of the three putative sites (i.e., BC6OTHER 70 - BC6OTHER 78, BC6ENTC 82 - BC6OTHER 96, and BC6OTHER 113 - BC6OTHER 122) available on OPG for BC6ENTG binding, BC6OTHER 113 - BC6OTHER 122 was used as a template for peptide synthesis.	False
Out of the three putative sites (i.e., BC6OTHER 70 - BC6OTHER 78, BC6OTHER 82 - BC6ENTC 96, and BC6OTHER 113 - BC6OTHER 122) available on OPG for BC6ENTG binding, BC6OTHER 113 - BC6OTHER 122 was used as a template for peptide synthesis.	False
We conclude that BC6ENTC binds at two sites in the recombinant BC6ENTG .	False
To verify the hypothesis that the non - conventional partial agonist BC6OTHER binds at two BC6OTHER sites, BC6ENTG , expressed in CHO cells, were labelled with BC6ENTC .	False
To verify the hypothesis that the non - conventional partial agonist BC6OTHER binds at two BC6ENTG sites, BC6OTHER , expressed in CHO cells, were labelled with BC6ENTC .	False
BC6ENTC dissociated from the BC6ENTG with a fast component (k(off)=0.45 min( - 1)), consistent with the L - site, and a slow component (k(off)=0.017 - 0.033 min( - 1)), consistent with the CHEM - site.	False
To verify the hypothesis that the non - conventional partial agonist BC6ENTC binds at two BC6OTHER sites, BC6ENTG , expressed in CHO cells, were labelled with BC6OTHER .	CPR:5
To verify the hypothesis that the non - conventional partial agonist BC6ENTC binds at two BC6ENTG sites, BC6OTHER , expressed in CHO cells, were labelled with BC6OTHER .	CPR:5
Binding of BC6ENTC at two sites in recombinant BC6ENTG and interaction with beta - blockers.	False
METHODS: Activation and repolarization characteristics of the explanted heart of a patient with a loss - of - function mutation in BC6ENTG ( BC6OTHER ) and dilated cardiomyopathy were determined after induction of right - sided ST - segment elevation by BC6ENTC .	False
METHODS: Activation and repolarization characteristics of the explanted heart of a patient with a loss - of - function mutation in BC6OTHER ( BC6ENTG ) and dilated cardiomyopathy were determined after induction of right - sided ST - segment elevation by BC6ENTC .	False
A series of BC6OTHER analogs were designed and the interaction between BC6ENTC and BC6ENTG studied by the docking method to improve the biological activity and reduce the gastrointestinal side effects of BC6OTHER .	False
A series of BC6ENTC analogs were designed and the interaction between BC6OTHER and BC6ENTG studied by the docking method to improve the biological activity and reduce the gastrointestinal side effects of BC6OTHER .	False
A series of BC6OTHER analogs were designed and the interaction between BC6OTHER and BC6ENTG studied by the docking method to improve the biological activity and reduce the gastrointestinal side effects of BC6ENTC .	False
The nonsteroidal anti - inflammatory drugs BC6ENTC and BC6OTHER were modified in an attempt to alter the kinetics of inhibitor binding by BC6ENTG .	False
The nonsteroidal anti - inflammatory drugs BC6OTHER and BC6ENTC were modified in an attempt to alter the kinetics of inhibitor binding by BC6ENTG .	False
Manipulation of kinetic profiles in BC6ENTC BC6ENTG inhibitors.	CPR:4
Our results suggest that only negatively charged BC6ENTC derivatives have a BC6ENTG - dependent microtubule inhibitory effect.	False
The negatively charged BC6ENTC has been found previously to be a BC6ENTG ( BC6OTHER ) - dependent microtubule inhibitor [Wallin M, Deinum J and CHEM, FEBS Lett 179: 289 - 293, 1985].	False
The negatively charged BC6ENTC has been found previously to be a BC6OTHER ( BC6ENTG ) - dependent microtubule inhibitor [Wallin M, Deinum J and CHEM, FEBS Lett 179: 289 - 293, 1985].	False
In the present study the binding of BC6ENTC to BC6ENTG and BC6OTHER was investigated.	False
In the present study the binding of BC6ENTC to BC6OTHER and BC6ENTG was investigated.	False
Both these BC6ENTG were found to have two to three binding sites for BC6ENTC which is compatible with the reported number of basic BC6OTHER repeats of these BC6OTHER , considered to be the ultimate BC6OTHER binding domains.	False
Both these BC6OTHER were found to have two to three binding sites for BC6ENTC which is compatible with the reported number of basic BC6OTHER repeats of these BC6ENTG , considered to be the ultimate BC6OTHER binding domains.	False
Both these BC6OTHER were found to have two to three binding sites for BC6ENTC which is compatible with the reported number of basic BC6OTHER repeats of these BC6OTHER , considered to be the ultimate BC6ENTG binding domains.	False
Both these BC6ENTG were found to have two to three binding sites for BC6OTHER which is compatible with the reported number of basic BC6ENTC repeats of these BC6OTHER , considered to be the ultimate BC6OTHER binding domains.	False
Both these BC6OTHER were found to have two to three binding sites for BC6OTHER which is compatible with the reported number of basic BC6ENTC repeats of these BC6ENTG , considered to be the ultimate BC6OTHER binding domains.	False
Both these BC6OTHER were found to have two to three binding sites for BC6OTHER which is compatible with the reported number of basic BC6ENTC repeats of these BC6OTHER , considered to be the ultimate BC6ENTG binding domains.	False
The Kd for the binding of BC6ENTC to BC6ENTG was estimated to be 20 microM at 4 degrees, and for the binding of tau, 200 microM.	False
Two new negatively charged BC6ENTC derivatives, BC6OTHER and BC6OTHER , were found to be similar BC6ENTG - dependent microtubule inhibitors.	False
Two new negatively charged BC6OTHER derivatives, BC6ENTC and BC6OTHER , were found to be similar BC6ENTG - dependent microtubule inhibitors.	False
Two new negatively charged BC6OTHER derivatives, BC6OTHER and BC6ENTC , were found to be similar BC6ENTG - dependent microtubule inhibitors.	False
A positively charged derivative, BC6ENTC , did not inhibit microtubule assembly or alter the composition of the coassembled BC6ENTG .	False
The uncharged BC6ENTC bound to both BC6ENTG and BC6OTHER , but no effects were seen on microtubule assembly, the composition of coassembled BC6OTHER or the microtubule morphology.	False
The uncharged BC6ENTC bound to both BC6OTHER and BC6ENTG , but no effects were seen on microtubule assembly, the composition of coassembled BC6OTHER or the microtubule morphology.	False
The uncharged BC6ENTC bound to both BC6OTHER and BC6OTHER , but no effects were seen on microtubule assembly, the composition of coassembled BC6ENTG or the microtubule morphology.	False
Importantly, treatment with BC6ENTC did not increase lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of BC6ENTG signaling that do not target BC6OTHER .	CPR:4
Importantly, treatment with BC6ENTC did not increase lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of BC6OTHER signaling that do not target BC6ENTG .	False
Collectively, these data suggest that BC6ENTC is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated BC6ENTG and BC6OTHER signaling.	CPR:4
Collectively, these data suggest that BC6ENTC is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated BC6OTHER and BC6ENTG signaling.	CPR:4
BC6ENTC ( BC6OTHER ) is a small - molecule BC6ENTG inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6ENTG and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6ENTG ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6ENTG ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other BC6ENTG that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG .	CPR:4
BC6OTHER ( BC6ENTC ) is a small - molecule BC6ENTG inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTC ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6ENTG and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTC ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6ENTG ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTC ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6ENTG ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTC ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other BC6ENTG that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTC ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTC ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTC ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTC ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG .	CPR:4
BC6OTHER ( BC6OTHER ) is a small - molecule BC6ENTG inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6ENTC kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6ENTG and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6ENTC kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6ENTG ( BC6OTHER ), as well as a number of other receptor BC6ENTC kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6ENTG ), as well as a number of other receptor BC6ENTC kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6ENTC kinases that have also been implicated in tumor pathobiology, including BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6ENTC kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6ENTC kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER .	False
BC6OTHER ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6ENTC kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG .	False
Treatment with BC6ENTC inhibited BC6ENTG and BC6OTHER phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro.	CPR:4
Treatment with BC6ENTC inhibited BC6OTHER and BC6ENTG phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro.	CPR:4
 BC6ENTC ( BC6OTHER ), a novel BC6ENTG and BC6OTHER inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.	CPR:4
 BC6ENTC ( BC6OTHER ), a novel BC6OTHER and BC6ENTG inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.	CPR:4
 BC6OTHER ( BC6ENTC ), a novel BC6ENTG and BC6OTHER inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.	CPR:4
 BC6OTHER ( BC6ENTC ), a novel BC6OTHER and BC6ENTG inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.	CPR:4
These agents include newer BC6ENTG - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6OTHER cotransporter 2 inhibitors, free BC6ENTC receptor agonists, BC6OTHER inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade.	False
These agents include newer BC6OTHER - based therapies and BC6ENTG agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6OTHER cotransporter 2 inhibitors, free BC6ENTC receptor agonists, BC6OTHER inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade.	False
These agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6ENTG inhibitors, free BC6ENTC receptor agonists, BC6OTHER inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade.	False
These agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6OTHER cotransporter 2 inhibitors, free BC6ENTC receptor agonists, BC6ENTG inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade.	False
These agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6OTHER cotransporter 2 inhibitors, free BC6ENTC receptor agonists, BC6OTHER inhibitors, BC6ENTG activators, and several others that may enter clinical use over the next decade.	False
These agents include newer BC6ENTG - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6OTHER cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6ENTC dehydrogenase type 1 inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade.	False
These agents include newer BC6OTHER - based therapies and BC6ENTG agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6OTHER cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6ENTC dehydrogenase type 1 inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade.	False
These agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6ENTG inhibitors, free BC6OTHER receptor agonists, BC6ENTC dehydrogenase type 1 inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade.	False
These agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6OTHER cotransporter 2 inhibitors, BC6ENTG agonists, BC6ENTC dehydrogenase type 1 inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade.	False
These agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6OTHER cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6ENTC dehydrogenase type 1 inhibitors, BC6ENTG activators, and several others that may enter clinical use over the next decade.	False
These agents include newer BC6ENTG - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6ENTC - coupled BC6OTHER cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6OTHER inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade.	False
These agents include newer BC6OTHER - based therapies and BC6ENTG agonists, as well as new therapeutic classes such as BC6ENTC - coupled BC6OTHER cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6OTHER inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade.	False
These agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6ENTC - coupled BC6OTHER cotransporter 2 inhibitors, BC6ENTG agonists, BC6OTHER inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade.	False
These agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6ENTC - coupled BC6OTHER cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6ENTG inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade.	False
These agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6ENTC - coupled BC6OTHER cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6OTHER inhibitors, BC6ENTG activators, and several others that may enter clinical use over the next decade.	False
These agents include newer BC6ENTG - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6ENTC cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6OTHER inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade.	False
These agents include newer BC6OTHER - based therapies and BC6ENTG agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6ENTC cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6OTHER inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade.	False
These agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6ENTC cotransporter 2 inhibitors, BC6ENTG agonists, BC6OTHER inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade.	False
These agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6ENTC cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6ENTG inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade.	False
These agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6ENTC cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6OTHER inhibitors, BC6ENTG activators, and several others that may enter clinical use over the next decade.	False
This trial investigated the possibility of pharmacokinetic interactions between the BC6ENTG antagonist BC6ENTC and the BC6OTHER diuretic BC6OTHER in healthy subjects.	CPR:6
This trial investigated the possibility of pharmacokinetic interactions between the BC6ENTG antagonist BC6OTHER and the BC6ENTC diuretic BC6OTHER in healthy subjects.	False
This trial investigated the possibility of pharmacokinetic interactions between the BC6ENTG antagonist BC6OTHER and the BC6OTHER diuretic BC6ENTC in healthy subjects.	False
When using double staining with BC6ENTC for mineralized matrix and BC6OTHER for cartilaginous matrix, we observed previously that mineralization was totally absent at embryonic day 15.5 throughout the body in BC6ENTG ( - / - ) mice, but was found in areas undergoing intramembranous ossification such as skull and clavicles in BC6OTHER - Cre; BC6OTHER (flox / flox) mice.	False
When using double staining with BC6ENTC for mineralized matrix and BC6OTHER for cartilaginous matrix, we observed previously that mineralization was totally absent at embryonic day 15.5 throughout the body in BC6OTHER ( - / - ) mice, but was found in areas undergoing intramembranous ossification such as skull and clavicles in BC6ENTG - Cre; BC6OTHER (flox / flox) mice.	False
When using double staining with BC6ENTC for mineralized matrix and BC6OTHER for cartilaginous matrix, we observed previously that mineralization was totally absent at embryonic day 15.5 throughout the body in BC6OTHER ( - / - ) mice, but was found in areas undergoing intramembranous ossification such as skull and clavicles in BC6OTHER - Cre; BC6ENTG (flox / flox) mice.	False
When using double staining with BC6OTHER for mineralized matrix and BC6ENTC for cartilaginous matrix, we observed previously that mineralization was totally absent at embryonic day 15.5 throughout the body in BC6ENTG ( - / - ) mice, but was found in areas undergoing intramembranous ossification such as skull and clavicles in BC6OTHER - Cre; BC6OTHER (flox / flox) mice.	False
When using double staining with BC6OTHER for mineralized matrix and BC6ENTC for cartilaginous matrix, we observed previously that mineralization was totally absent at embryonic day 15.5 throughout the body in BC6OTHER ( - / - ) mice, but was found in areas undergoing intramembranous ossification such as skull and clavicles in BC6ENTG - Cre; BC6OTHER (flox / flox) mice.	False
When using double staining with BC6OTHER for mineralized matrix and BC6ENTC for cartilaginous matrix, we observed previously that mineralization was totally absent at embryonic day 15.5 throughout the body in BC6OTHER ( - / - ) mice, but was found in areas undergoing intramembranous ossification such as skull and clavicles in BC6OTHER - Cre; BC6ENTG (flox / flox) mice.	False
Our findings indicate that serum BC6ENTC levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6ENTG level <10 pg / ml (or poor plasma BC6OTHER response to BC6OTHER ) and (2) serum BC6OTHER ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6OTHER levels, urine free BC6OTHER levels, adrenal scintigraphy, and clinical manifestation.	False
Our findings indicate that serum BC6ENTC levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6OTHER level <10 pg / ml (or poor plasma BC6ENTG response to BC6OTHER ) and (2) serum BC6OTHER ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6OTHER levels, urine free BC6OTHER levels, adrenal scintigraphy, and clinical manifestation.	False
Our findings indicate that serum BC6ENTC levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6OTHER level <10 pg / ml (or poor plasma BC6OTHER response to BC6ENTG ) and (2) serum BC6OTHER ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6OTHER levels, urine free BC6OTHER levels, adrenal scintigraphy, and clinical manifestation.	False
Our findings indicate that serum BC6OTHER levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6ENTG level <10 pg / ml (or poor plasma BC6OTHER response to BC6OTHER ) and (2) serum BC6ENTC ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6OTHER levels, urine free BC6OTHER levels, adrenal scintigraphy, and clinical manifestation.	False
Our findings indicate that serum BC6OTHER levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6OTHER level <10 pg / ml (or poor plasma BC6ENTG response to BC6OTHER ) and (2) serum BC6ENTC ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6OTHER levels, urine free BC6OTHER levels, adrenal scintigraphy, and clinical manifestation.	False
Our findings indicate that serum BC6OTHER levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6OTHER level <10 pg / ml (or poor plasma BC6OTHER response to BC6ENTG ) and (2) serum BC6ENTC ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6OTHER levels, urine free BC6OTHER levels, adrenal scintigraphy, and clinical manifestation.	False
Our findings indicate that serum BC6OTHER levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6ENTG level <10 pg / ml (or poor plasma BC6OTHER response to BC6OTHER ) and (2) serum BC6OTHER ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6ENTC levels, urine free BC6OTHER levels, adrenal scintigraphy, and clinical manifestation.	False
Our findings indicate that serum BC6OTHER levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6OTHER level <10 pg / ml (or poor plasma BC6ENTG response to BC6OTHER ) and (2) serum BC6OTHER ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6ENTC levels, urine free BC6OTHER levels, adrenal scintigraphy, and clinical manifestation.	False
Our findings indicate that serum BC6OTHER levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6OTHER level <10 pg / ml (or poor plasma BC6OTHER response to BC6ENTG ) and (2) serum BC6OTHER ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6ENTC levels, urine free BC6OTHER levels, adrenal scintigraphy, and clinical manifestation.	False
Our findings indicate that serum BC6OTHER levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6ENTG level <10 pg / ml (or poor plasma BC6OTHER response to BC6OTHER ) and (2) serum BC6OTHER ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6OTHER levels, urine free BC6ENTC levels, adrenal scintigraphy, and clinical manifestation.	False
Our findings indicate that serum BC6OTHER levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6OTHER level <10 pg / ml (or poor plasma BC6ENTG response to BC6OTHER ) and (2) serum BC6OTHER ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6OTHER levels, urine free BC6ENTC levels, adrenal scintigraphy, and clinical manifestation.	False
Our findings indicate that serum BC6OTHER levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6OTHER level <10 pg / ml (or poor plasma BC6OTHER response to BC6ENTG ) and (2) serum BC6OTHER ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6OTHER levels, urine free BC6ENTC levels, adrenal scintigraphy, and clinical manifestation.	False
BC6ENTC were designed and synthesized as potent BC6OTHER - BC6ENTG inhibitors.	CPR:4
BC6ENTC were designed and synthesized as potent BC6ENTG - BC6OTHER inhibitors.	CPR:4
An X - ray crystal structure of optimized compound 9b bound in the active site of BC6ENTG showed that the CHEM scaffold provides 5 BC6ENTC bonding interactions in addition to projecting groups for interactions within the S1, S2 and S3 pockets.	False
Design and synthesis of BC6ENTC as potent BC6ENTG - BC6OTHER inhibitors.	CPR:4
Design and synthesis of BC6ENTC as potent BC6OTHER - BC6ENTG inhibitors.	CPR:4
When the cloned BC6ENTG was transfected into COS 1 cells, BC6OTHER stimulated intracellular BC6ENTC accumulation with an EC50 of 0.1 nM, whereas BC6OTHER was >250 - fold less potent (EC50 27.6 nM).	False
When the cloned BC6OTHER was transfected into COS 1 cells, BC6ENTG stimulated intracellular BC6ENTC accumulation with an EC50 of 0.1 nM, whereas BC6OTHER was >250 - fold less potent (EC50 27.6 nM).	False
When the cloned BC6OTHER was transfected into COS 1 cells, BC6OTHER stimulated intracellular BC6ENTC accumulation with an EC50 of 0.1 nM, whereas BC6ENTG was >250 - fold less potent (EC50 27.6 nM).	False
Stimulation of the transfected BC6ENTG by salmon calcitonin also resulted in BC6ENTC hydrolysis with an EC50 of 2.5 nM.	False
Native BC6ENTG stimulates BC6OTHER secretion in a BC6ENTC - dependent manner, as well as suppressing BC6OTHER production and slowing gastric emptying.	False
Native BC6OTHER stimulates BC6ENTG secretion in a BC6ENTC - dependent manner, as well as suppressing BC6OTHER production and slowing gastric emptying.	False
Native BC6OTHER stimulates BC6OTHER secretion in a BC6ENTC - dependent manner, as well as suppressing BC6ENTG production and slowing gastric emptying.	False
BC6ENTC , an antirheumatic gold compound, is an inhibitor of BC6OTHER enzymes, such as BC6OTHER and BC6ENTG .	CPR:4
BC6ENTC , an antirheumatic gold compound, is an inhibitor of BC6ENTG , such as BC6OTHER and BC6OTHER peroxidase.	CPR:4
BC6ENTC , an antirheumatic gold compound, is an inhibitor of BC6OTHER enzymes, such as BC6ENTG and BC6OTHER peroxidase.	CPR:4
BC6OTHER , an antirheumatic gold compound, is an inhibitor of BC6ENTG , such as BC6OTHER and BC6ENTC peroxidase.	False
BC6OTHER , an antirheumatic gold compound, is an inhibitor of BC6OTHER enzymes, such as BC6ENTG and BC6ENTC peroxidase.	False
The activity of BC6ENTG and BC6ENTC peroxidase was determined in liver and heart tissues in an attempt to correlate enzymatic activity with heart recovery after ischaemia - reperfusion.	False
BC6OTHER , an antirheumatic gold compound, is an inhibitor of BC6ENTC enzymes, such as BC6OTHER and BC6ENTG .	False
BC6OTHER , an antirheumatic gold compound, is an inhibitor of BC6ENTC enzymes, such as BC6ENTG and BC6OTHER peroxidase.	False
There was significantly less BC6ENTG activity in rat liver extracts, whereas the level of BC6ENTC activity remained unchanged, demonstrating that the dose of BC6OTHER used was able to selectively inhibit one of these enzyme systems.	False
There was significantly less BC6ENTG activity in rat liver extracts, whereas the level of BC6OTHER activity remained unchanged, demonstrating that the dose of BC6ENTC used was able to selectively inhibit one of these enzyme systems.	CPR:4
To map supercoiling, we used BC6ENTC as a DNA structure probe to show that the human genome is organized into BC6ENTG .	False
Moreover, BC6ENTC could also down - regulate the expression and activity of BC6ENTG ( BC6OTHER ).	CPR:4
Moreover, BC6ENTC could also down - regulate the expression and activity of BC6OTHER ( BC6ENTG ).	CPR:4
It undergoes extensive biotransformation, which is affected by poor metabolism by BC6ENTG in a small percentage of the population; these patients have greater exposure to and slower elimination of BC6ENTC than extensive metabolizers.	CPR:9
BC6ENTG inhibitors, such as BC6ENTC , are associated with changes in BC6OTHER pharmacokinetics similar to those observed among poor BC6OTHER metabolizers.	CPR:4
BC6OTHER inhibitors, such as BC6ENTC , are associated with changes in BC6OTHER pharmacokinetics similar to those observed among poor BC6ENTG metabolizers.	False
BC6ENTG inhibitors, such as BC6OTHER , are associated with changes in BC6ENTC pharmacokinetics similar to those observed among poor BC6OTHER metabolizers.	False
BC6OTHER inhibitors, such as BC6OTHER , are associated with changes in BC6ENTC pharmacokinetics similar to those observed among poor BC6ENTG metabolizers.	CPR:9
BC6ENTC appeared better tolerated among extensive BC6ENTG metabolizers than among poor metabolizers.	CPR:9
BC6ENTC has a high affinity and selectivity for BC6ENTG , but little or no affinity for various BC6OTHER .	False
BC6ENTC has a high affinity and selectivity for BC6OTHER transporters, but little or no affinity for various BC6ENTG .	False
BC6OTHER has a high affinity and selectivity for BC6ENTC transporters, but little or no affinity for various BC6ENTG .	False
BC6ENTC is a moderate inhibitor of BC6ENTG ( BC6OTHER ) with KI values of 19, 16 and 4.5 µM, respectively.	False
BC6OTHER is a moderate inhibitor of BC6ENTG ( BC6ENTC ) with KI values of 19, 16 and 4.5 µM, respectively.	False
BC6ENTC is both a substrate and inhibitor (IC50 = 1.9 µM) of BC6ENTG .	CPR:9
BC6ENTC is highly bound to plasma proteins and has minimal interaction with BC6ENTG .	False
BC6ENTC is not a potent reversible inhibitor of BC6ENTG ( BC6OTHER ).	False
BC6OTHER is not a potent reversible inhibitor of BC6ENTG ( BC6ENTC ).	False
It has a particular selectivity profile for the known nuclear BC6ENTC receptors with low affinity for BC6ENTG and no transactivating potential for BC6OTHER .	False
It has a particular selectivity profile for the known nuclear BC6ENTC receptors with low affinity for BC6OTHER and no transactivating potential for BC6ENTG .	False
Furthermore, BC6ENTC does not bind to members of the cellular BC6ENTG family.	False
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6ENTC metabolite, BC6OTHER ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6ENTG ( BC6OTHER ) isoenzymes, BC6OTHER and BC6OTHER or; (d) a combination of these factors.	False
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6ENTC metabolite, BC6OTHER ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6OTHER ( BC6ENTG ) isoenzymes, BC6OTHER and BC6OTHER or; (d) a combination of these factors.	False
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6ENTC metabolite, BC6OTHER ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6OTHER ( BC6OTHER ) isoenzymes, BC6ENTG and BC6OTHER or; (d) a combination of these factors.	False
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6ENTC metabolite, BC6OTHER ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6OTHER ( BC6OTHER ) isoenzymes, BC6OTHER and BC6ENTG or; (d) a combination of these factors.	False
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6ENTC ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6ENTG ( BC6OTHER ) isoenzymes, BC6OTHER and BC6OTHER or; (d) a combination of these factors.	False
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6ENTC ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6OTHER ( BC6ENTG ) isoenzymes, BC6OTHER and BC6OTHER or; (d) a combination of these factors.	False
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6ENTC ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6OTHER ( BC6OTHER ) isoenzymes, BC6ENTG and BC6OTHER or; (d) a combination of these factors.	False
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6ENTC ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6OTHER ( BC6OTHER ) isoenzymes, BC6OTHER and BC6ENTG or; (d) a combination of these factors.	False
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6OTHER ; (b) a greater degree of binding of BC6ENTC to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6ENTG ( BC6OTHER ) isoenzymes, BC6OTHER and BC6OTHER or; (d) a combination of these factors.	False
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6OTHER ; (b) a greater degree of binding of BC6ENTC to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6OTHER ( BC6ENTG ) isoenzymes, BC6OTHER and BC6OTHER or; (d) a combination of these factors.	False
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6OTHER ; (b) a greater degree of binding of BC6ENTC to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6OTHER ( BC6OTHER ) isoenzymes, BC6ENTG and BC6OTHER or; (d) a combination of these factors.	False
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6OTHER ; (b) a greater degree of binding of BC6ENTC to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6OTHER ( BC6OTHER ) isoenzymes, BC6OTHER and BC6ENTG or; (d) a combination of these factors.	False
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6OTHER ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6ENTC of the BC6ENTG ( BC6OTHER ) isoenzymes, BC6OTHER and BC6OTHER or; (d) a combination of these factors.	False
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6OTHER ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6ENTC of the BC6OTHER ( BC6ENTG ) isoenzymes, BC6OTHER and BC6OTHER or; (d) a combination of these factors.	False
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6OTHER ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6ENTC of the BC6OTHER ( BC6OTHER ) isoenzymes, BC6ENTG and BC6OTHER or; (d) a combination of these factors.	False
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6OTHER ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6ENTC of the BC6OTHER ( BC6OTHER ) isoenzymes, BC6OTHER and BC6ENTG or; (d) a combination of these factors.	False
The higher concentrations in calves were insufficient to inhibit significantly exudate BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTG concentrations and exudate leucocyte numbers, serum BC6OTHER ( BC6OTHER ), and BC6OTHER - induced skin swelling.	False
The higher concentrations in calves were insufficient to inhibit significantly exudate BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER concentrations and exudate leucocyte numbers, serum BC6OTHER ( BC6OTHER ), and BC6ENTG - induced skin swelling.	False
The higher concentrations in calves were insufficient to inhibit significantly exudate BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ) and BC6ENTG concentrations and exudate leucocyte numbers, serum BC6OTHER ( BC6OTHER ), and BC6OTHER - induced skin swelling.	False
The higher concentrations in calves were insufficient to inhibit significantly exudate BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ) and BC6OTHER concentrations and exudate leucocyte numbers, serum BC6OTHER ( BC6OTHER ), and BC6ENTG - induced skin swelling.	False
The higher concentrations in calves were insufficient to inhibit significantly exudate BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and BC6ENTG concentrations and exudate leucocyte numbers, serum BC6OTHER ( BC6OTHER ), and BC6OTHER - induced skin swelling.	False
The higher concentrations in calves were insufficient to inhibit significantly exudate BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and BC6OTHER concentrations and exudate leucocyte numbers, serum BC6OTHER ( BC6OTHER ), and BC6ENTG - induced skin swelling.	False
The higher concentrations in calves were insufficient to inhibit significantly exudate BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and BC6ENTG concentrations and exudate leucocyte numbers, serum BC6OTHER ( BC6OTHER ), and BC6OTHER - induced skin swelling.	False
The higher concentrations in calves were insufficient to inhibit significantly exudate BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and BC6OTHER concentrations and exudate leucocyte numbers, serum BC6OTHER ( BC6OTHER ), and BC6ENTG - induced skin swelling.	False
The higher concentrations in calves were insufficient to inhibit significantly exudate BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTG concentrations and exudate leucocyte numbers, serum BC6ENTC ( BC6OTHER ), and BC6OTHER - induced skin swelling.	False
The higher concentrations in calves were insufficient to inhibit significantly exudate BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER concentrations and exudate leucocyte numbers, serum BC6ENTC ( BC6OTHER ), and BC6ENTG - induced skin swelling.	False
The higher concentrations in calves were insufficient to inhibit significantly exudate BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTG concentrations and exudate leucocyte numbers, serum BC6OTHER ( BC6ENTC ), and BC6OTHER - induced skin swelling.	False
The higher concentrations in calves were insufficient to inhibit significantly exudate BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER concentrations and exudate leucocyte numbers, serum BC6OTHER ( BC6ENTC ), and BC6ENTG - induced skin swelling.	False
These results suggest that both BC6ENTG ) increase the BC6OTHER sensitivity of contractile elements, and that the BC6ENTC sensitization produced by BC6OTHER is mediated through BC6OTHER and BC6OTHER , and plays an important role in contraction of smooth muscle of rabbit thoracic aorta.	False
These results suggest that both BC6OTHER ) increase the BC6OTHER sensitivity of contractile elements, and that the BC6ENTC sensitization produced by BC6ENTG is mediated through BC6OTHER and BC6OTHER , and plays an important role in contraction of smooth muscle of rabbit thoracic aorta.	False
These results suggest that both BC6OTHER ) increase the BC6OTHER sensitivity of contractile elements, and that the BC6ENTC sensitization produced by BC6OTHER is mediated through BC6ENTG and BC6OTHER , and plays an important role in contraction of smooth muscle of rabbit thoracic aorta.	False
These results suggest that both BC6OTHER ) increase the BC6OTHER sensitivity of contractile elements, and that the BC6ENTC sensitization produced by BC6OTHER is mediated through BC6OTHER and BC6ENTG , and plays an important role in contraction of smooth muscle of rabbit thoracic aorta.	False
In beta - CHEM - skinned strips of BC6ENTC - pretreated smooth muscle, the enhancement of BC6OTHER contraction produced by BC6OTHER was significantly decreased, whereas the amplitude was the same as that produced by BC6OTHER or BC6OTHER ; this enhancement was inhibited by the selective BC6ENTG antagonist BC6OTHER (100 nM).	False
In beta - CHEM - skinned strips of BC6OTHER - pretreated smooth muscle, the enhancement of BC6ENTC contraction produced by BC6OTHER was significantly decreased, whereas the amplitude was the same as that produced by BC6OTHER or BC6OTHER ; this enhancement was inhibited by the selective BC6ENTG antagonist BC6OTHER (100 nM).	False
In beta - CHEM - skinned strips of BC6OTHER - pretreated smooth muscle, the enhancement of BC6OTHER contraction produced by BC6ENTC was significantly decreased, whereas the amplitude was the same as that produced by BC6OTHER or BC6OTHER ; this enhancement was inhibited by the selective BC6ENTG antagonist BC6OTHER (100 nM).	False
In beta - CHEM - skinned strips of BC6OTHER - pretreated smooth muscle, the enhancement of BC6OTHER contraction produced by BC6OTHER was significantly decreased, whereas the amplitude was the same as that produced by BC6ENTC or BC6OTHER ; this enhancement was inhibited by the selective BC6ENTG antagonist BC6OTHER (100 nM).	False
In beta - CHEM - skinned strips of BC6OTHER - pretreated smooth muscle, the enhancement of BC6OTHER contraction produced by BC6OTHER was significantly decreased, whereas the amplitude was the same as that produced by BC6OTHER or BC6ENTC ; this enhancement was inhibited by the selective BC6ENTG antagonist BC6OTHER (100 nM).	False
In beta - CHEM - skinned strips of BC6OTHER - pretreated smooth muscle, the enhancement of BC6OTHER contraction produced by BC6OTHER was significantly decreased, whereas the amplitude was the same as that produced by BC6OTHER or BC6OTHER ; this enhancement was inhibited by the selective BC6ENTG antagonist BC6ENTC (100 nM).	CPR:6
 BC6ENTG subtypes mediating the regulation and modulation of BC6ENTC sensitization in rabbit thoracic aorta.	False
Furthermore, the phosphorylation of BC6ENTG produced by BC6ENTC was greater than that produced by BC6OTHER .	CPR:3
Furthermore, the phosphorylation of BC6ENTG produced by BC6OTHER was greater than that produced by BC6ENTC .	CPR:3
These results suggest that both BC6ENTG ) increase the BC6ENTC sensitivity of contractile elements, and that the BC6OTHER sensitization produced by BC6OTHER is mediated through BC6OTHER and BC6OTHER , and plays an important role in contraction of smooth muscle of rabbit thoracic aorta.	False
These results suggest that both BC6OTHER ) increase the BC6ENTC sensitivity of contractile elements, and that the BC6OTHER sensitization produced by BC6ENTG is mediated through BC6OTHER and BC6OTHER , and plays an important role in contraction of smooth muscle of rabbit thoracic aorta.	False
These results suggest that both BC6OTHER ) increase the BC6ENTC sensitivity of contractile elements, and that the BC6OTHER sensitization produced by BC6OTHER is mediated through BC6ENTG and BC6OTHER , and plays an important role in contraction of smooth muscle of rabbit thoracic aorta.	False
These results suggest that both BC6OTHER ) increase the BC6ENTC sensitivity of contractile elements, and that the BC6OTHER sensitization produced by BC6OTHER is mediated through BC6OTHER and BC6ENTG , and plays an important role in contraction of smooth muscle of rabbit thoracic aorta.	False
Immunoreactivity for a second putative BC6ENTC transporter, BC6ENTG , was present in the apical region of cells with almost the same distribution as BC6OTHER .	False
Immunoreactivity for a second putative BC6ENTC transporter, BC6OTHER , was present in the apical region of cells with almost the same distribution as BC6ENTG .	False
Recent studies have identified a family of putative BC6ENTC transporters; mRNA for two members of this family, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), is expressed in the kidney.	False
Recent studies have identified a family of putative BC6ENTC transporters; mRNA for two members of this family, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ), is expressed in the kidney.	False
Recent studies have identified a family of putative BC6ENTC transporters; mRNA for two members of this family, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), is expressed in the kidney.	False
Recent studies have identified a family of putative BC6ENTC transporters; mRNA for two members of this family, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ), is expressed in the kidney.	False
These findings suggest that BC6ENTG and BC6OTHER may play important and cell - specific roles in BC6ENTC transport and signaling in these regions of the kidney.	CPR:9
These findings suggest that BC6OTHER and BC6ENTG may play important and cell - specific roles in BC6ENTC transport and signaling in these regions of the kidney.	CPR:9
Colocalization of BC6OTHER with BC6OTHER , the BC6ENTC - sensitive transporter, and the BC6OTHER BC6OTHER and BC6OTHER demonstrated BC6ENTG immunoreactivity in all CNT cells and all CCD and ICT principal cells.	False
Colocalization of BC6ENTG with BC6OTHER , the BC6ENTC - sensitive transporter, and the BC6OTHER BC6OTHER and BC6OTHER demonstrated BC6OTHER immunoreactivity in all CNT cells and all CCD and ICT principal cells.	False
Colocalization of BC6OTHER with BC6ENTG , the BC6ENTC - sensitive transporter, and the BC6OTHER BC6OTHER and BC6OTHER demonstrated BC6OTHER immunoreactivity in all CNT cells and all CCD and ICT principal cells.	False
Colocalization of BC6OTHER with BC6OTHER , the BC6ENTC - sensitive transporter, and the BC6ENTG BC6OTHER and BC6OTHER demonstrated BC6OTHER immunoreactivity in all CNT cells and all CCD and ICT principal cells.	False
Colocalization of BC6OTHER with BC6OTHER , the BC6ENTC - sensitive transporter, and the BC6OTHER BC6ENTG and BC6OTHER demonstrated BC6OTHER immunoreactivity in all CNT cells and all CCD and ICT principal cells.	False
Colocalization of BC6OTHER with BC6OTHER , the BC6ENTC - sensitive transporter, and the BC6OTHER BC6OTHER and BC6ENTG demonstrated BC6OTHER immunoreactivity in all CNT cells and all CCD and ICT principal cells.	False
Localization of the BC6ENTC transporter proteins BC6ENTG and BC6OTHER in mouse kidney.	False
Localization of the BC6ENTC transporter proteins BC6OTHER and BC6ENTG in mouse kidney.	False
These cells express high levels of BC6ENTC A(2A) receptors, which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the BC6ENTG BC6OTHER .	False
These cells express high levels of BC6ENTC A(2A) receptors, which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the BC6OTHER - and BC6OTHER - regulated 32 - kDa phosphoprotein BC6ENTG .	False
These cells express high levels of BC6ENTG , which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the BC6ENTC - and BC6OTHER - regulated 32 - kDa phosphoprotein BC6OTHER .	False
These cells express high levels of BC6OTHER A(2A) receptors, which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the BC6ENTC - and BC6OTHER - regulated 32 - kDa phosphoprotein BC6ENTG .	False
These cells express high levels of BC6ENTG , which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the BC6OTHER - and BC6ENTC - regulated 32 - kDa phosphoprotein BC6OTHER .	False
These cells express high levels of BC6OTHER A(2A) receptors, which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the BC6OTHER - and BC6ENTC - regulated 32 - kDa phosphoprotein BC6ENTG .	False
Effect of BC6ENTC on serum BC6ENTG levels.	False
The mean body weight at baseline (52.59 kg) did not differ significantly from that at 1 week after treatment (52.84 kg; P > .05), but the mean BC6ENTG level after 1 week of treatment with BC6ENTC (3.14 ng / mL) was 14.2% higher than that at baseline (2.75 ng / mL; P < .05).	CPR:3
This increase may suggest that both BC6ENTG and BC6ENTC may affect appetite via similar receptors and that BC6OTHER does not impair leptin activity through these receptors.	False
This increase may suggest that both BC6ENTG and BC6OTHER may affect appetite via similar receptors and that BC6ENTC does not impair leptin activity through these receptors.	False
BC6ENTG is a 167 BC6ENTC protein encoded by the obesity gene that is synthesized in adipose tissue and interacts with receptors in the hypothalamus linked to the regulation of appetite and metabolism.	False
BC6ENTC is a BC6OTHER BC6OTHER that increases appetite through its antiserotonergic effect on BC6ENTG receptors in the brain.	False
BC6OTHER is a BC6ENTC BC6OTHER that increases appetite through its antiserotonergic effect on BC6ENTG receptors in the brain.	False
BC6OTHER is a BC6OTHER BC6ENTC that increases appetite through its antiserotonergic effect on BC6ENTG receptors in the brain.	False
Although both BC6ENTG and BC6ENTC are effective in controlling appetite, their interaction has not been addressed in clinical studies.	False
The aim of present study was to identify BC6ENTG ( BC6OTHER ) isoforms which can catalyze the BC6OTHER - demethylation of BC6OTHER to BC6ENTC , and to find out whether that alternative pathway of BC6OTHER synthesis may take place in the brain.	False
The aim of present study was to identify BC6OTHER ( BC6ENTG ) isoforms which can catalyze the BC6OTHER - demethylation of BC6OTHER to BC6ENTC , and to find out whether that alternative pathway of BC6OTHER synthesis may take place in the brain.	False
The aim of present study was to identify BC6ENTG ( BC6OTHER ) isoforms which can catalyze the BC6OTHER - demethylation of BC6OTHER to BC6OTHER , and to find out whether that alternative pathway of BC6ENTC synthesis may take place in the brain.	False
The aim of present study was to identify BC6OTHER ( BC6ENTG ) isoforms which can catalyze the BC6OTHER - demethylation of BC6OTHER to BC6OTHER , and to find out whether that alternative pathway of BC6ENTC synthesis may take place in the brain.	False
Of the BC6ENTG isoforms studied, BC6OTHER isoforms were the most efficient in catalyzing the BC6ENTC - demethylation of BC6OTHER to BC6OTHER , but they were less effective than the BC6OTHER .	False
Of the BC6OTHER isoforms studied, BC6ENTG isoforms were the most efficient in catalyzing the BC6ENTC - demethylation of BC6OTHER to BC6OTHER , but they were less effective than the BC6OTHER .	CPR:9
Of the BC6OTHER isoforms studied, BC6OTHER isoforms were the most efficient in catalyzing the BC6ENTC - demethylation of BC6OTHER to BC6OTHER , but they were less effective than the BC6ENTG .	CPR:9
Of the BC6ENTG isoforms studied, BC6OTHER isoforms were the most efficient in catalyzing the BC6OTHER - demethylation of BC6ENTC to BC6OTHER , but they were less effective than the BC6OTHER .	False
Of the BC6OTHER isoforms studied, BC6ENTG isoforms were the most efficient in catalyzing the BC6OTHER - demethylation of BC6ENTC to BC6OTHER , but they were less effective than the BC6OTHER .	CPR:9
Of the BC6OTHER isoforms studied, BC6OTHER isoforms were the most efficient in catalyzing the BC6OTHER - demethylation of BC6ENTC to BC6OTHER , but they were less effective than the BC6ENTG .	CPR:9
Of the BC6ENTG isoforms studied, BC6OTHER isoforms were the most efficient in catalyzing the BC6OTHER - demethylation of BC6OTHER to BC6ENTC , but they were less effective than the BC6OTHER .	False
Of the BC6OTHER isoforms studied, BC6ENTG isoforms were the most efficient in catalyzing the BC6OTHER - demethylation of BC6OTHER to BC6ENTC , but they were less effective than the BC6OTHER .	CPR:9
Of the BC6OTHER isoforms studied, BC6OTHER isoforms were the most efficient in catalyzing the BC6OTHER - demethylation of BC6OTHER to BC6ENTC , but they were less effective than the BC6ENTG .	CPR:9
The catalytic competence of BC6ENTG in the synthesis of BC6ENTC from BC6OTHER in the brain: an in vitro study.	CPR:9
The catalytic competence of BC6ENTG in the synthesis of BC6OTHER from BC6ENTC in the brain: an in vitro study.	CPR:9
The reaction was inhibited by the specific BC6ENTG inhibitors BC6ENTC and BC6OTHER .	CPR:4
The reaction was inhibited by the specific BC6ENTG inhibitors BC6OTHER and BC6ENTC .	CPR:4
Human liver microsomes of the wild - type BC6ENTG metabolized BC6ENTC to BC6OTHER more effectively than did the defective BC6OTHER *4*4 ones.	CPR:9
Human liver microsomes of the wild - type BC6OTHER metabolized BC6ENTC to BC6OTHER more effectively than did the defective BC6ENTG *4*4 ones.	CPR:9
Human liver microsomes of the wild - type BC6ENTG metabolized BC6OTHER to BC6ENTC more effectively than did the defective BC6OTHER *4*4 ones.	CPR:9
Human liver microsomes of the wild - type BC6OTHER metabolized BC6OTHER to BC6ENTC more effectively than did the defective BC6ENTG *4*4 ones.	CPR:9
The obtained results indicate that BC6ENTG isoforms catalyze the formation of BC6ENTC from BC6OTHER , and that the deficit or genetic defect of BC6OTHER may affect BC6OTHER metabolism in the brain.	CPR:9
The obtained results indicate that BC6OTHER isoforms catalyze the formation of BC6ENTC from BC6OTHER , and that the deficit or genetic defect of BC6ENTG may affect BC6OTHER metabolism in the brain.	False
The obtained results indicate that BC6ENTG isoforms catalyze the formation of BC6OTHER from BC6ENTC , and that the deficit or genetic defect of BC6OTHER may affect BC6OTHER metabolism in the brain.	CPR:9
The obtained results indicate that BC6OTHER isoforms catalyze the formation of BC6OTHER from BC6ENTC , and that the deficit or genetic defect of BC6ENTG may affect BC6OTHER metabolism in the brain.	False
The obtained results indicate that BC6ENTG isoforms catalyze the formation of BC6OTHER from BC6OTHER , and that the deficit or genetic defect of BC6OTHER may affect BC6ENTC metabolism in the brain.	False
The obtained results indicate that BC6OTHER isoforms catalyze the formation of BC6OTHER from BC6OTHER , and that the deficit or genetic defect of BC6ENTG may affect BC6ENTC metabolism in the brain.	CPR:9
The aim of present study was to identify BC6ENTG ( BC6OTHER ) isoforms which can catalyze the BC6ENTC - demethylation of BC6OTHER to BC6OTHER , and to find out whether that alternative pathway of BC6OTHER synthesis may take place in the brain.	False
The aim of present study was to identify BC6OTHER ( BC6ENTG ) isoforms which can catalyze the BC6ENTC - demethylation of BC6OTHER to BC6OTHER , and to find out whether that alternative pathway of BC6OTHER synthesis may take place in the brain.	False
The aim of present study was to identify BC6ENTG ( BC6OTHER ) isoforms which can catalyze the BC6OTHER - demethylation of BC6ENTC to BC6OTHER , and to find out whether that alternative pathway of BC6OTHER synthesis may take place in the brain.	False
The aim of present study was to identify BC6OTHER ( BC6ENTG ) isoforms which can catalyze the BC6OTHER - demethylation of BC6ENTC to BC6OTHER , and to find out whether that alternative pathway of BC6OTHER synthesis may take place in the brain.	False
Triple pharmacological blockade of the BC6ENTG - BC6OTHER - BC6ENTC system in nondiabetic CKD: an open - label crossover randomized controlled trial.	False
Triple pharmacological blockade of the BC6OTHER - BC6ENTG - BC6ENTC system in nondiabetic CKD: an open - label crossover randomized controlled trial.	False
We evaluated the hypothesis that the addition of an BC6ENTC receptor antagonist to an BC6ENTG ( BC6OTHER ) inhibitor and BC6OTHER type 1 (AT - 1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an BC6OTHER inhibitor and ARB (double RAAS blockade).	False
We evaluated the hypothesis that the addition of an BC6ENTC receptor antagonist to an BC6OTHER ( BC6ENTG ) inhibitor and BC6OTHER type 1 (AT - 1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an BC6OTHER inhibitor and ARB (double RAAS blockade).	False
We evaluated the hypothesis that the addition of an BC6ENTC receptor antagonist to an BC6OTHER ( BC6OTHER ) inhibitor and BC6ENTG blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an BC6OTHER inhibitor and ARB (double RAAS blockade).	False
We evaluated the hypothesis that the addition of an BC6ENTC receptor antagonist to an BC6OTHER ( BC6OTHER ) inhibitor and BC6OTHER type 1 (AT - 1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an BC6ENTG inhibitor and ARB (double RAAS blockade).	False
CONCLUSIONS: Administration of an BC6ENTC receptor antagonist in addition to double RAAS blockade with an BC6ENTG inhibitor and ARB may slow the progression of chronic kidney disease.	False
We evaluated the hypothesis that the addition of an BC6ENTG antagonist to an BC6OTHER ( BC6OTHER ) inhibitor and BC6ENTC type 1 (AT - 1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an BC6OTHER inhibitor and ARB (double RAAS blockade).	False
We evaluated the hypothesis that the addition of an BC6OTHER receptor antagonist to an BC6ENTG ( BC6OTHER ) inhibitor and BC6ENTC type 1 (AT - 1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an BC6OTHER inhibitor and ARB (double RAAS blockade).	False
We evaluated the hypothesis that the addition of an BC6OTHER receptor antagonist to an BC6OTHER ( BC6ENTG ) inhibitor and BC6ENTC type 1 (AT - 1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an BC6OTHER inhibitor and ARB (double RAAS blockade).	False
We evaluated the hypothesis that the addition of an BC6OTHER receptor antagonist to an BC6OTHER ( BC6OTHER ) inhibitor and BC6ENTC type 1 (AT - 1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an BC6ENTG inhibitor and ARB (double RAAS blockade).	False
BACKGROUND: Agents inhibiting the BC6ENTG - BC6OTHER - BC6ENTC (RAAS) system have an important role in slowing the progression of chronic kidney disease.	False
BACKGROUND: Agents inhibiting the BC6OTHER - BC6ENTG - BC6ENTC (RAAS) system have an important role in slowing the progression of chronic kidney disease.	False
INTERVENTIONS: In the 8 - week run - in period, all participants received the BC6ENTG inhibitor BC6ENTC (5 mg), the ARB BC6OTHER n (80 mg), and the diuretic BC6OTHER (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130 / 80 mm CHEM.	CPR:4
INTERVENTIONS: In the 8 - week run - in period, all participants received the BC6ENTG inhibitor BC6OTHER (5 mg), the ARB BC6ENTC n (80 mg), and the diuretic BC6OTHER (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130 / 80 mm CHEM.	False
INTERVENTIONS: In the 8 - week run - in period, all participants received the BC6ENTG inhibitor BC6OTHER (5 mg), the ARB BC6OTHER n (80 mg), and the diuretic BC6ENTC (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130 / 80 mm CHEM.	False
Disruption of the BC6ENTG also affected growth in a BC6OTHER - defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent BC6ENTC ( BC6OTHER ).	False
Disruption of the BC6OTHER also affected growth in a BC6ENTG - defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent BC6ENTC ( BC6OTHER ).	False
Disruption of the BC6ENTG also affected growth in a BC6OTHER - defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent BC6OTHER ( BC6ENTC ).	False
Disruption of the BC6OTHER also affected growth in a BC6ENTG - defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent BC6OTHER ( BC6ENTC ).	False
Promoter replacements conferring constitutive expression of BC6ENTG revealed that the transcriptional induction in response to BC6ENTC is required to maintain induced levels of BC6OTHER .	False
Promoter replacements conferring constitutive expression of BC6OTHER revealed that the transcriptional induction in response to BC6ENTC is required to maintain induced levels of BC6ENTG .	False
Its pathogenesis is complex, and involves a state of 'lipotoxicity' in which BC6ENTG resistance, with increased BC6ENTC release from adipose tissue to the liver, play a key role in the onset of a 'lipotoxic liver disease' and its progression to NASH.	False
BC6ENTC synthase ( BC6ENTG ), the key metabolic multi - enzyme that is responsible for the terminal catalytic step in the de novo CHEM biosynthesis, plays an active role in the development, maintenance, and enhancement of the malignant phenotype in a subset of breast carcinomas.	False
SK - Br3 cells cultured in the presence of BC6ENTG ( BC6OTHER ) inhibitors BC6ENTC and BC6OTHER ( BC6OTHER ) demonstrated a 2 - to 3 - fold increase in BC6OTHER activity when compared with control cells growing in drug - free culture conditions.	CPR:4
SK - Br3 cells cultured in the presence of BC6OTHER ( BC6ENTG ) inhibitors BC6ENTC and BC6OTHER ( BC6OTHER ) demonstrated a 2 - to 3 - fold increase in BC6OTHER activity when compared with control cells growing in drug - free culture conditions.	CPR:4
SK - Br3 cells cultured in the presence of BC6OTHER ( BC6OTHER ) inhibitors BC6ENTC and BC6OTHER ( BC6OTHER ) demonstrated a 2 - to 3 - fold increase in BC6ENTG activity when compared with control cells growing in drug - free culture conditions.	CPR:3
SK - Br3 cells cultured in the presence of BC6ENTG ( BC6OTHER ) inhibitors BC6OTHER and BC6ENTC ( BC6OTHER ) demonstrated a 2 - to 3 - fold increase in BC6OTHER activity when compared with control cells growing in drug - free culture conditions.	CPR:4
SK - Br3 cells cultured in the presence of BC6OTHER ( BC6ENTG ) inhibitors BC6OTHER and BC6ENTC ( BC6OTHER ) demonstrated a 2 - to 3 - fold increase in BC6OTHER activity when compared with control cells growing in drug - free culture conditions.	CPR:4
SK - Br3 cells cultured in the presence of BC6OTHER ( BC6OTHER ) inhibitors BC6OTHER and BC6ENTC ( BC6OTHER ) demonstrated a 2 - to 3 - fold increase in BC6ENTG activity when compared with control cells growing in drug - free culture conditions.	CPR:3
SK - Br3 cells cultured in the presence of BC6ENTG ( BC6OTHER ) inhibitors BC6OTHER and BC6OTHER ( BC6ENTC ) demonstrated a 2 - to 3 - fold increase in BC6OTHER activity when compared with control cells growing in drug - free culture conditions.	CPR:4
SK - Br3 cells cultured in the presence of BC6OTHER ( BC6ENTG ) inhibitors BC6OTHER and BC6OTHER ( BC6ENTC ) demonstrated a 2 - to 3 - fold increase in BC6OTHER activity when compared with control cells growing in drug - free culture conditions.	CPR:4
SK - Br3 cells cultured in the presence of BC6OTHER ( BC6OTHER ) inhibitors BC6OTHER and BC6OTHER ( BC6ENTC ) demonstrated a 2 - to 3 - fold increase in BC6ENTG activity when compared with control cells growing in drug - free culture conditions.	CPR:3
We failed to observe any significant activation of BC6ENTG following exposure to the anti - metabolite BC6ENTC , the alkylating drug BC6OTHER , or the microtubule interfering - agents BC6OTHER and BC6OTHER .	False
We failed to observe any significant activation of BC6ENTG following exposure to the anti - metabolite BC6OTHER , the alkylating drug BC6ENTC , or the microtubule interfering - agents BC6OTHER and BC6OTHER .	False
We failed to observe any significant activation of BC6ENTG following exposure to the anti - metabolite BC6OTHER , the alkylating drug BC6OTHER , or the microtubule interfering - agents BC6ENTC and BC6OTHER .	False
We failed to observe any significant activation of BC6ENTG following exposure to the anti - metabolite BC6OTHER , the alkylating drug BC6OTHER , or the microtubule interfering - agents BC6OTHER and BC6ENTC .	False
 BC6ENTG ( BC6OTHER ) inhibitors up - regulate BC6ENTC synthase gene expression in SK - Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving BC6OTHER , BC6OTHER / BC6OTHER and BC6OTHER genes.	False
 BC6OTHER ( BC6OTHER ) inhibitors up - regulate BC6ENTC synthase gene expression in SK - Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving BC6ENTG , BC6OTHER / BC6OTHER and BC6OTHER genes.	False
 BC6OTHER ( BC6OTHER ) inhibitors up - regulate BC6ENTC synthase gene expression in SK - Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving BC6OTHER , BC6ENTG / BC6OTHER and BC6OTHER genes.	False
 BC6OTHER ( BC6OTHER ) inhibitors up - regulate BC6ENTC synthase gene expression in SK - Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving BC6OTHER , BC6OTHER / BC6ENTG and BC6OTHER genes.	False
 BC6OTHER ( BC6OTHER ) inhibitors up - regulate BC6ENTC synthase gene expression in SK - Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving BC6OTHER , BC6OTHER / BC6OTHER and BC6ENTG genes.	False
 BC6OTHER ( BC6ENTG ) inhibitors up - regulate BC6ENTC synthase gene expression in SK - Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving BC6OTHER , BC6OTHER / BC6OTHER and BC6OTHER genes.	False
In vitro experiments assessed the inhibition of BC6ENTG and BC6OTHER enzymes by BC6OTHER , and a clinical drug interaction study investigated the effect of BC6ENTC (300 mg CHEM) on the pharmacokinetic profile of BC6OTHER (40 mg single dose) and BC6OTHER (10 mg single dose).	False
In vitro experiments assessed the inhibition of BC6OTHER and BC6ENTG enzymes by BC6OTHER , and a clinical drug interaction study investigated the effect of BC6ENTC (300 mg CHEM) on the pharmacokinetic profile of BC6OTHER (40 mg single dose) and BC6OTHER (10 mg single dose).	False
In vitro experiments assessed the inhibition of BC6ENTG and BC6OTHER enzymes by BC6OTHER , and a clinical drug interaction study investigated the effect of BC6OTHER (300 mg CHEM) on the pharmacokinetic profile of BC6ENTC (40 mg single dose) and BC6OTHER (10 mg single dose).	False
In vitro experiments assessed the inhibition of BC6OTHER and BC6ENTG enzymes by BC6OTHER , and a clinical drug interaction study investigated the effect of BC6OTHER (300 mg CHEM) on the pharmacokinetic profile of BC6ENTC (40 mg single dose) and BC6OTHER (10 mg single dose).	False
In vitro experiments assessed the inhibition of BC6ENTG and BC6OTHER enzymes by BC6OTHER , and a clinical drug interaction study investigated the effect of BC6OTHER (300 mg CHEM) on the pharmacokinetic profile of BC6OTHER (40 mg single dose) and BC6ENTC (10 mg single dose).	False
In vitro experiments assessed the inhibition of BC6OTHER and BC6ENTG enzymes by BC6OTHER , and a clinical drug interaction study investigated the effect of BC6OTHER (300 mg CHEM) on the pharmacokinetic profile of BC6OTHER (40 mg single dose) and BC6ENTC (10 mg single dose).	False
In vitro, BC6ENTC demonstrated little / weak inhibition (IC50 values >30 μM) towards BC6ENTG ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER , BC6OTHER , or BC6OTHER .	CPR:4
In vitro, BC6ENTC demonstrated little / weak inhibition (IC50 values >30 μM) towards BC6OTHER ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER , BC6OTHER , or BC6OTHER .	CPR:4
In vitro, BC6ENTC demonstrated little / weak inhibition (IC50 values >30 μM) towards BC6OTHER ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER , BC6OTHER , or BC6OTHER .	CPR:4
In vitro, BC6ENTC demonstrated little / weak inhibition (IC50 values >30 μM) towards BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ), BC6OTHER , BC6OTHER , or BC6OTHER .	CPR:4
In vitro, BC6ENTC demonstrated little / weak inhibition (IC50 values >30 μM) towards BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ), BC6OTHER , BC6OTHER , or BC6OTHER .	CPR:4
In vitro, BC6ENTC demonstrated little / weak inhibition (IC50 values >30 μM) towards BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ), BC6OTHER , BC6OTHER , or BC6OTHER .	CPR:4
In vitro, BC6ENTC demonstrated little / weak inhibition (IC50 values >30 μM) towards BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ), BC6ENTG , BC6OTHER , or BC6OTHER .	CPR:4
In vitro, BC6ENTC demonstrated little / weak inhibition (IC50 values >30 μM) towards BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER , BC6ENTG , or BC6OTHER .	CPR:4
In vitro, BC6ENTC demonstrated little / weak inhibition (IC50 values >30 μM) towards BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER , BC6OTHER , or BC6ENTG .	CPR:4
This work investigated the drug interaction potential of BC6ENTC , a novel BC6OTHER agonist, with the BC6ENTG inhibitors BC6OTHER and BC6OTHER .	False
This work investigated the drug interaction potential of BC6ENTC , a novel BC6ENTG agonist, with the BC6OTHER inhibitors BC6OTHER and BC6OTHER .	CPR:5
However, BC6ENTC inhibited BC6ENTG and BC6OTHER , which are transporters involved in CHEM disposition.	CPR:4
However, BC6ENTC inhibited BC6OTHER and BC6ENTG , which are transporters involved in CHEM disposition.	CPR:4
In the clinical study, small increases in the AUC(0 - inf) of BC6ENTC [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and BC6OTHER [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co - administered with BC6OTHER , which is consistent with an inhibitory effect on intestinal BC6OTHER and BC6ENTG .	False
In the clinical study, small increases in the AUC(0 - inf) of BC6ENTC [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and BC6OTHER [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co - administered with BC6OTHER , which is consistent with an inhibitory effect on intestinal BC6ENTG and BC6OTHER .	False
In the clinical study, small increases in the AUC(0 - inf) of BC6OTHER [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and BC6ENTC [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co - administered with BC6OTHER , which is consistent with an inhibitory effect on intestinal BC6OTHER and BC6ENTG .	False
In the clinical study, small increases in the AUC(0 - inf) of BC6OTHER [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and BC6ENTC [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co - administered with BC6OTHER , which is consistent with an inhibitory effect on intestinal BC6ENTG and BC6OTHER .	False
In the clinical study, small increases in the AUC(0 - inf) of BC6OTHER [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and BC6OTHER [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co - administered with BC6ENTC , which is consistent with an inhibitory effect on intestinal BC6OTHER and BC6ENTG .	CPR:4
In the clinical study, small increases in the AUC(0 - inf) of BC6OTHER [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and BC6OTHER [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co - administered with BC6ENTC , which is consistent with an inhibitory effect on intestinal BC6ENTG and BC6OTHER .	CPR:4
Evaluation of drug interactions of BC6ENTC (a BC6ENTG agonist) with CHEM: from in vitro data to clinical study design.	CPR:5
In contrast, BC6ENTC did not inhibit BC6ENTG based on the lack of changes in BC6OTHER acid exposure [mean AUC(0 - inf) ratio (90% CI) of 1.05 (0.91, 1.21)].	False
In contrast, BC6OTHER did not inhibit BC6ENTG based on the lack of changes in BC6ENTC acid exposure [mean AUC(0 - inf) ratio (90% CI) of 1.05 (0.91, 1.21)].	False
This work investigated the drug interaction potential of BC6OTHER , a novel BC6OTHER agonist, with the BC6ENTG inhibitors BC6ENTC and BC6OTHER .	CPR:4
This work investigated the drug interaction potential of BC6OTHER , a novel BC6ENTG agonist, with the BC6OTHER inhibitors BC6ENTC and BC6OTHER .	False
This study provides a mechanistic understanding of the in vivo inhibition of BC6ENTG and enzymes by BC6ENTC .	CPR:4
This work investigated the drug interaction potential of BC6OTHER , a novel BC6OTHER agonist, with the BC6ENTG inhibitors BC6OTHER and BC6ENTC .	CPR:4
This work investigated the drug interaction potential of BC6OTHER , a novel BC6ENTG agonist, with the BC6OTHER inhibitors BC6OTHER and BC6ENTC .	False
In vitro experiments assessed the inhibition of BC6ENTG and BC6OTHER enzymes by BC6ENTC , and a clinical drug interaction study investigated the effect of BC6OTHER (300 mg CHEM) on the pharmacokinetic profile of BC6OTHER (40 mg single dose) and BC6OTHER (10 mg single dose).	CPR:4
In vitro experiments assessed the inhibition of BC6OTHER and BC6ENTG enzymes by BC6ENTC , and a clinical drug interaction study investigated the effect of BC6OTHER (300 mg CHEM) on the pharmacokinetic profile of BC6OTHER (40 mg single dose) and BC6OTHER (10 mg single dose).	CPR:4
In particular, triple negative breast cancers (TNBCs), which do not express the genes for BC6ENTC / BC6ENTG ( BC6OTHER / BC6OTHER ) and BC6OTHER ( BC6OTHER ), have been associated with poor prognosis and metastasis.	False
In particular, triple negative breast cancers (TNBCs), which do not express the genes for BC6ENTC / BC6OTHER ( BC6ENTG / BC6OTHER ) and BC6OTHER ( BC6OTHER ), have been associated with poor prognosis and metastasis.	False
In particular, triple negative breast cancers (TNBCs), which do not express the genes for BC6ENTC / BC6OTHER ( BC6OTHER / BC6ENTG ) and BC6OTHER ( BC6OTHER ), have been associated with poor prognosis and metastasis.	False
In particular, triple negative breast cancers (TNBCs), which do not express the genes for BC6ENTC / BC6OTHER ( BC6OTHER / BC6OTHER ) and BC6ENTG ( BC6OTHER ), have been associated with poor prognosis and metastasis.	False
In particular, triple negative breast cancers (TNBCs), which do not express the genes for BC6ENTC / BC6OTHER ( BC6OTHER / BC6OTHER ) and BC6OTHER ( BC6ENTG ), have been associated with poor prognosis and metastasis.	False
In particular, triple negative breast cancers (TNBCs), which do not express the genes for BC6ENTG / BC6ENTC receptors ( BC6OTHER / BC6OTHER ) and BC6OTHER ( BC6OTHER ), have been associated with poor prognosis and metastasis.	False
In particular, triple negative breast cancers (TNBCs), which do not express the genes for BC6OTHER / BC6ENTC receptors ( BC6ENTG / BC6OTHER ) and BC6OTHER ( BC6OTHER ), have been associated with poor prognosis and metastasis.	False
In particular, triple negative breast cancers (TNBCs), which do not express the genes for BC6OTHER / BC6ENTC receptors ( BC6OTHER / BC6ENTG ) and BC6OTHER ( BC6OTHER ), have been associated with poor prognosis and metastasis.	False
In particular, triple negative breast cancers (TNBCs), which do not express the genes for BC6OTHER / BC6ENTC receptors ( BC6OTHER / BC6OTHER ) and BC6ENTG ( BC6OTHER ), have been associated with poor prognosis and metastasis.	False
In particular, triple negative breast cancers (TNBCs), which do not express the genes for BC6OTHER / BC6ENTC receptors ( BC6OTHER / BC6OTHER ) and BC6OTHER ( BC6ENTG ), have been associated with poor prognosis and metastasis.	False
BC6ENTC and BC6OTHER induced apoptosis by BC6ENTG downregulation.	CPR:4
BC6OTHER and BC6ENTC induced apoptosis by BC6ENTG downregulation.	CPR:4
Importantly, BC6ENTC and BC6OTHER exerted more potent inhibitory effects on the proliferation, BC6ENTG expression and invasive phenotype of CHEM - MB - 231 than BC6OTHER .	CPR:4
Importantly, BC6OTHER and BC6ENTC exerted more potent inhibitory effects on the proliferation, BC6ENTG expression and invasive phenotype of CHEM - MB - 231 than BC6OTHER .	CPR:4
Importantly, BC6OTHER and BC6OTHER exerted more potent inhibitory effects on the proliferation, BC6ENTG expression and invasive phenotype of CHEM - MB - 231 than BC6ENTC .	False
Both inhibitors, moreover, blunted the BC6ENTG secretory responses to beta - adrenergic agonist - generated second messenger, BC6OTHER as well as BC6OTHER cyclase activator, BC6ENTC .	CPR:4
Both inhibitors, moreover, blunted the BC6OTHER secretory responses to beta - adrenergic agonist - generated second messenger, BC6OTHER as well as BC6ENTG activator, BC6ENTC .	CPR:3
The BC6OTHER secretory responses to BC6ENTC , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6OTHER BC6OTHER responsible for ligand - independent BC6ENTG autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER .	False
The BC6OTHER secretory responses to BC6ENTC , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6OTHER BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6ENTG inhibitor, BC6OTHER .	False
The BC6ENTG secretory responses to BC6ENTC , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6OTHER BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER .	False
The BC6OTHER secretory responses to BC6ENTC , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6ENTG BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER .	False
The BC6OTHER secretory responses to BC6ENTC , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6OTHER BC6ENTG responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER .	False
The BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6ENTC , a selective inhibitor of BC6OTHER BC6OTHER responsible for ligand - independent BC6ENTG autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER .	CPR:3
The BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6ENTC , a selective inhibitor of BC6OTHER BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6ENTG inhibitor, BC6OTHER .	False
The BC6ENTG secretory responses to BC6OTHER , furthermore, were inhibited by BC6ENTC , a selective inhibitor of BC6OTHER BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER .	CPR:4
The BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6ENTC , a selective inhibitor of BC6ENTG BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER .	CPR:4
The BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6ENTC , a selective inhibitor of BC6OTHER BC6ENTG responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER .	CPR:4
The BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6ENTC kinase BC6OTHER responsible for ligand - independent BC6ENTG autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER .	False
The BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6ENTC kinase BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6ENTG inhibitor, BC6OTHER .	False
The BC6ENTG secretory responses to BC6OTHER , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6ENTC kinase BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER .	False
The BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6ENTC kinase BC6ENTG responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER .	False
The BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6OTHER BC6OTHER responsible for ligand - independent BC6ENTG autophosphorylation, but not by BC6OTHER inhibitor, BC6ENTC .	False
The BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6OTHER BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6ENTG inhibitor, BC6ENTC .	CPR:4
The BC6ENTG secretory responses to BC6OTHER , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6OTHER BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6ENTC .	False
The BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6ENTG BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6ENTC .	False
The BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6OTHER BC6ENTG responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6ENTC .	False
The inhibition of BC6ENTG , moreover, did not cause attenuation in BC6OTHER secretion in response to BC6ENTC and BC6OTHER .	CPR:4
The inhibition of BC6OTHER , moreover, did not cause attenuation in BC6ENTG secretion in response to BC6ENTC and BC6OTHER .	False
The inhibition of BC6ENTG , moreover, did not cause attenuation in BC6OTHER secretion in response to BC6OTHER and BC6ENTC .	CPR:4
The inhibition of BC6OTHER , moreover, did not cause attenuation in BC6ENTG secretion in response to BC6OTHER and BC6ENTC .	False
In many systems, the integration of converging regulatory signals that relay on BC6OTHER ( BC6ENTG ) activation into functional cellular pathways requires the involvement of receptor BC6ENTC kinase.	False
In many systems, the integration of converging regulatory signals that relay on BC6ENTG ( BC6OTHER ) activation into functional cellular pathways requires the involvement of receptor BC6ENTC kinase.	False
Using BC6ENTC - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6ENTG secretion was inhibited by BC6OTHER BC6OTHER inhibitor, BC6OTHER , as well as BC6OTHER , a specific inhibitor of BC6OTHER .	False
Using BC6ENTC - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6OTHER secretion was inhibited by BC6ENTG BC6OTHER inhibitor, BC6OTHER , as well as BC6OTHER , a specific inhibitor of BC6OTHER .	False
Using BC6ENTC - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6OTHER secretion was inhibited by BC6OTHER BC6ENTG inhibitor, BC6OTHER , as well as BC6OTHER , a specific inhibitor of BC6OTHER .	False
Using BC6ENTC - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6OTHER secretion was inhibited by BC6OTHER BC6OTHER inhibitor, BC6OTHER , as well as BC6OTHER , a specific inhibitor of BC6ENTG .	False
Using BC6OTHER - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6ENTG secretion was inhibited by BC6OTHER BC6OTHER inhibitor, BC6ENTC , as well as BC6OTHER , a specific inhibitor of BC6OTHER .	CPR:4
Using BC6OTHER - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6OTHER secretion was inhibited by BC6ENTG BC6OTHER inhibitor, BC6ENTC , as well as BC6OTHER , a specific inhibitor of BC6OTHER .	CPR:4
Using BC6OTHER - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6OTHER secretion was inhibited by BC6OTHER BC6ENTG inhibitor, BC6ENTC , as well as BC6OTHER , a specific inhibitor of BC6OTHER .	CPR:4
Using BC6OTHER - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6OTHER secretion was inhibited by BC6OTHER BC6OTHER inhibitor, BC6ENTC , as well as BC6OTHER , a specific inhibitor of BC6ENTG .	False
Using BC6OTHER - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6ENTG secretion was inhibited by BC6OTHER BC6OTHER inhibitor, BC6OTHER , as well as BC6ENTC , a specific inhibitor of BC6OTHER .	CPR:4
Using BC6OTHER - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6OTHER secretion was inhibited by BC6ENTG BC6OTHER inhibitor, BC6OTHER , as well as BC6ENTC , a specific inhibitor of BC6OTHER .	False
Using BC6OTHER - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6OTHER secretion was inhibited by BC6OTHER BC6ENTG inhibitor, BC6OTHER , as well as BC6ENTC , a specific inhibitor of BC6OTHER .	False
Using BC6OTHER - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6OTHER secretion was inhibited by BC6OTHER BC6OTHER inhibitor, BC6OTHER , as well as BC6ENTC , a specific inhibitor of BC6ENTG .	CPR:4
Both inhibitors, moreover, blunted the BC6ENTG secretory responses to beta - adrenergic agonist - generated second messenger, BC6ENTC as well as BC6OTHER cyclase activator, BC6OTHER .	False
Both inhibitors, moreover, blunted the BC6OTHER secretory responses to beta - adrenergic agonist - generated second messenger, BC6ENTC as well as BC6ENTG activator, BC6OTHER .	CPR:9
Both inhibitors, moreover, blunted the BC6ENTG secretory responses to beta - adrenergic agonist - generated second messenger, BC6OTHER as well as BC6ENTC cyclase activator, BC6OTHER .	False
BC6ENTG catalyse the last step in BC6ENTC biosynthesis, the formation of BC6OTHER from BC6OTHER , a reaction dependent on BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	CPR:9
BC6ENTG catalyse the last step in BC6OTHER biosynthesis, the formation of BC6ENTC from BC6OTHER , a reaction dependent on BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	CPR:9
BC6ENTG catalyse the last step in BC6OTHER biosynthesis, the formation of BC6OTHER from BC6ENTC , a reaction dependent on BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	CPR:9
BC6ENTG catalyse the last step in BC6OTHER biosynthesis, the formation of BC6OTHER from BC6OTHER , a reaction dependent on BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6ENTG catalyse the last step in BC6OTHER biosynthesis, the formation of BC6OTHER from BC6OTHER , a reaction dependent on BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER .	False
BC6ENTG catalyse the last step in BC6OTHER biosynthesis, the formation of BC6OTHER from BC6OTHER , a reaction dependent on BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER .	False
BC6ENTG catalyse the last step in BC6OTHER biosynthesis, the formation of BC6OTHER from BC6OTHER , a reaction dependent on BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC .	False
BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ), an BC6ENTG antagonist, is approved in many countries worldwide for the treatment of hypertension.	CPR:6
BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER ), an BC6ENTG antagonist, is approved in many countries worldwide for the treatment of hypertension.	CPR:6
BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER ), an BC6ENTG antagonist, is approved in many countries worldwide for the treatment of hypertension.	CPR:6
BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ), an BC6ENTG antagonist, is approved in many countries worldwide for the treatment of hypertension.	CPR:6
BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC ), an BC6ENTG antagonist, is approved in many countries worldwide for the treatment of hypertension.	CPR:6
BC6ENTC (30 mg / kg) or BC6OTHER treatment (30 mg / kg) did not reduce the levels of BC6ENTG or BC6OTHER immunostaining.	False
BC6ENTC (30 mg / kg) or BC6OTHER treatment (30 mg / kg) did not reduce the levels of BC6OTHER or BC6ENTG immunostaining.	False
BC6ENTC , a selective BC6ENTG , and its active metabolite BC6OTHER may inhibit apoptosis and inflammation after cerebral ischemia.	False
BC6OTHER (30 mg / kg) or BC6ENTC treatment (30 mg / kg) did not reduce the levels of BC6ENTG or BC6OTHER immunostaining.	False
BC6OTHER (30 mg / kg) or BC6ENTC treatment (30 mg / kg) did not reduce the levels of BC6OTHER or BC6ENTG immunostaining.	False
BC6ENTC (30 mg / kg) also significantly decreased the protein levels of BC6ENTG but not BC6OTHER or BC6OTHER in the cortex ipsilateral to the middle cerebral artery occlusion.	CPR:4
BC6ENTC (30 mg / kg) also significantly decreased the protein levels of BC6OTHER but not BC6ENTG or BC6OTHER in the cortex ipsilateral to the middle cerebral artery occlusion.	False
BC6ENTC (30 mg / kg) also significantly decreased the protein levels of BC6OTHER but not BC6OTHER or BC6ENTG in the cortex ipsilateral to the middle cerebral artery occlusion.	False
BC6OTHER , a selective BC6ENTG , and its active metabolite BC6ENTC may inhibit apoptosis and inflammation after cerebral ischemia.	False
The improved survival rates for obese mice chronically treated with BC6ENTC suggest that chronic BC6ENTG inhibition potentially results in additional quality - adjusted life - years for individuals with type 2 diabetes, which is the primary goal of any diabetes therapy.	CPR:4
METHODS: After 1 month of HFD alone, the mice were given the BC6ENTG inhibitor BC6ENTC for a further 11 months.	CPR:4
Enhanced beta cell function and anti - inflammatory effect after chronic treatment with the BC6ENTG inhibitor BC6ENTC in an advanced - aged diet - induced obesity mouse model.	CPR:4
Replacement of the BC6OTHER groups of BC6OTHER with BC6ENTC or larger BC6OTHER groups yields BC6OTHER with selectivity for BC6ENTG , particularly when combined with an BC6OTHER moiety.	False
Replacement of the BC6OTHER groups of BC6OTHER with BC6OTHER or larger BC6ENTC groups yields BC6OTHER with selectivity for BC6ENTG , particularly when combined with an BC6OTHER moiety.	False
Replacement of the BC6OTHER groups of BC6OTHER with BC6OTHER or larger BC6OTHER groups yields BC6ENTC with selectivity for BC6ENTG , particularly when combined with an BC6OTHER moiety.	False
Replacement of the BC6OTHER groups of BC6OTHER with BC6OTHER or larger BC6OTHER groups yields BC6OTHER with selectivity for BC6ENTG , particularly when combined with an BC6ENTC moiety.	False
BC6OTHER modulates a variety of physiological functions through interaction with BC6ENTG , where agonists mediate inhibition and stimulation, respectively, of BC6ENTC cyclase.	False
BC6ENTC modulates a variety of physiological functions through interaction with A1 and A2 BC6OTHER receptors, where agonists mediate inhibition and stimulation, respectively, of BC6ENTG .	False
BC6ENTC modulates a variety of physiological functions through interaction with BC6ENTG , where agonists mediate inhibition and stimulation, respectively, of BC6OTHER .	False
Certain analogs of BC6ENTC in which the BC6OTHER group at the 1 - or 7 - position is replaced with a CHEM or BC6OTHER group display selectivity for BC6ENTG .	False
Certain analogs of BC6OTHER in which the BC6ENTC group at the 1 - or 7 - position is replaced with a CHEM or BC6OTHER group display selectivity for BC6ENTG .	False
Certain analogs of BC6OTHER in which the BC6OTHER group at the 1 - or 7 - position is replaced with a CHEM or BC6ENTC group display selectivity for BC6ENTG .	False
The profile of a series of BC6ENTC analogs or of BC6OTHER antagonists can be used to define the nature of BC6ENTG .	False
The profile of a series of BC6OTHER analogs or of BC6ENTC antagonists can be used to define the nature of BC6ENTG .	False
BC6ENTC analogs in particular the BC6OTHER - substituted compounds are more potent at BC6ENTG than at BC6OTHER .	False
BC6ENTC analogs in particular the BC6OTHER - substituted compounds are more potent at BC6OTHER than at BC6ENTG .	False
BC6OTHER analogs in particular the BC6ENTC - substituted compounds are more potent at BC6ENTG than at BC6OTHER .	False
BC6OTHER analogs in particular the BC6ENTC - substituted compounds are more potent at BC6OTHER than at BC6ENTG .	False
Certain of the BC6ENTC conjugates are highly selective for BC6ENTG .	False
The subregion of the BC6ENTC receptor that interacts with the BC6OTHER - substituent is different for BC6ENTG , particularly with respect to BC6OTHER interactions, bulk tolerance and stereoselectivity.	False
The subregion of the BC6ENTG that interacts with the BC6ENTC - substituent is different for BC6OTHER , particularly with respect to BC6OTHER interactions, bulk tolerance and stereoselectivity.	False
The subregion of the BC6OTHER that interacts with the BC6ENTC - substituent is different for BC6ENTG , particularly with respect to BC6OTHER interactions, bulk tolerance and stereoselectivity.	False
The subregion of the BC6ENTG that interacts with the BC6OTHER - substituent is different for BC6OTHER , particularly with respect to BC6ENTC interactions, bulk tolerance and stereoselectivity.	False
The subregion of the BC6OTHER that interacts with the BC6OTHER - substituent is different for BC6ENTG , particularly with respect to BC6ENTC interactions, bulk tolerance and stereoselectivity.	False
BC6OTHER modulates a variety of physiological functions through interaction with A1 and A2 BC6ENTC receptors, where agonists mediate inhibition and stimulation, respectively, of BC6ENTG .	False
BC6ENTC are classical antagonists for BC6ENTG for many of their pharmacological actions may be due to blockade of BC6OTHER receptors.	CPR:6
BC6ENTC are classical antagonists for BC6OTHER receptors for many of their pharmacological actions may be due to blockade of BC6ENTG .	CPR:4
BC6OTHER are classical antagonists for BC6ENTC receptors for many of their pharmacological actions may be due to blockade of BC6ENTG .	False
BC6OTHER are classical antagonists for BC6ENTG for many of their pharmacological actions may be due to blockade of BC6ENTC receptors.	False
BC6ENTC and BC6OTHER are virtually non - selective for BC6ENTG .	False
BC6OTHER and BC6ENTC are virtually non - selective for BC6ENTG .	False
Replacement of the BC6ENTC groups of BC6OTHER with BC6OTHER or larger BC6OTHER groups yields BC6OTHER with selectivity for BC6ENTG , particularly when combined with an BC6OTHER moiety.	False
Replacement of the BC6OTHER groups of BC6ENTC with BC6OTHER or larger BC6OTHER groups yields BC6OTHER with selectivity for BC6ENTG , particularly when combined with an BC6OTHER moiety.	False
BC6ENTG antagonism with BC6ENTC reduced responses to BC6OTHER in controls but not during inflammation.	CPR:6
BC6ENTG antagonism with BC6OTHER reduced responses to BC6ENTC in controls but not during inflammation.	False
Responses to the mast cell degranulator 48 / 80 mimicked those to BC6ENTC in inflamed tissue but not in controls, and more BC6OTHER - containing mast cells were seen close to BC6ENTG - containing fibres in inflamed serosa.	False
Responses to the mast cell degranulator 48 / 80 mimicked those to BC6OTHER in inflamed tissue but not in controls, and more BC6ENTC - containing mast cells were seen close to BC6ENTG - containing fibres in inflamed serosa.	False
BC6ENTC affected mainly the BC6OTHER transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total BC6ENTG protein content or the BC6OTHER mRNA level.	False
BC6ENTC affected mainly the BC6OTHER transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total BC6OTHER protein content or the BC6ENTG mRNA level.	False
BC6ENTC affected mainly the BC6ENTG transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total BC6OTHER protein content or the BC6OTHER mRNA level.	False
Effect of long - term BC6ENTC treatment on the BC6ENTG in Caco - 2 cells.	False
These results suggest that the effect of BC6ENTC on the expression of BC6ENTG is post - translational and has shown itself to be independent of BC6OTHER and BC6OTHER activity.	False
These results suggest that the effect of BC6ENTC on the expression of BC6OTHER is post - translational and has shown itself to be independent of BC6ENTG and BC6OTHER activity.	False
These results suggest that the effect of BC6ENTC on the expression of BC6OTHER is post - translational and has shown itself to be independent of BC6OTHER and BC6ENTG activity.	False
The chronic effect of SSRIs on the activity of the BC6ENTC transporter ( BC6ENTG ) has been less studied and the results have been contradictory.	False
The aim of this study was to determine the specific effect of long - term BC6ENTC treatment on BC6ENTG ( BC6OTHER ) in vitro, by using the human enterocyte - like cell line Caco - 2.	False
The aim of this study was to determine the specific effect of long - term BC6ENTC treatment on human BC6OTHER transporter ( BC6ENTG ) in vitro, by using the human enterocyte - like cell line Caco - 2.	False
The aim of this study was to determine the specific effect of long - term BC6OTHER treatment on human BC6ENTC transporter ( BC6ENTG ) in vitro, by using the human enterocyte - like cell line Caco - 2.	False
The cytosolic BC6ENTG is expressed primarily in liver and adipose tissue, and uses BC6ENTC as a key building block in BC6OTHER biosynthesis.	False
The cytosolic BC6ENTG is expressed primarily in liver and adipose tissue, and uses BC6OTHER as a key building block in BC6ENTC biosynthesis.	CPR:9
The mitochondrial BC6ENTG is primarily expressed in heart and skeletal muscle, where it is involved in the regulation of BC6ENTC oxidation.	CPR:9
Discovery of BC6ENTG inhibitors: comparison of a fluorescence intensity - based BC6ENTC assay and a fluorescence polarization - based BC6OTHER Assay for high - throughput screening.	False
Discovery of BC6ENTG inhibitors: comparison of a fluorescence intensity - based BC6OTHER assay and a fluorescence polarization - based BC6ENTC Assay for high - throughput screening.	False
BC6ENTC carboxylase ( BC6ENTG ) enzymes exist as two isoforms, BC6OTHER and BC6OTHER , which play critical roles in BC6OTHER biosynthesis and oxidation.	False
BC6ENTC carboxylase ( BC6OTHER ) enzymes exist as two isoforms, BC6ENTG and BC6OTHER , which play critical roles in BC6OTHER biosynthesis and oxidation.	False
BC6ENTC carboxylase ( BC6OTHER ) enzymes exist as two isoforms, BC6OTHER and BC6ENTG , which play critical roles in BC6OTHER biosynthesis and oxidation.	False
BC6ENTG ( BC6OTHER ) enzymes exist as two isoforms, BC6OTHER and BC6OTHER , which play critical roles in BC6ENTC biosynthesis and oxidation.	CPR:9
BC6OTHER carboxylase ( BC6ENTG ) enzymes exist as two isoforms, BC6OTHER and BC6OTHER , which play critical roles in BC6ENTC biosynthesis and oxidation.	CPR:9
BC6OTHER carboxylase ( BC6OTHER ) enzymes exist as two isoforms, BC6ENTG and BC6OTHER , which play critical roles in BC6ENTC biosynthesis and oxidation.	CPR:9
BC6OTHER carboxylase ( BC6OTHER ) enzymes exist as two isoforms, BC6OTHER and BC6ENTG , which play critical roles in BC6ENTC biosynthesis and oxidation.	CPR:9
BC6ENTG inhibitors were identified by these high - throughput screening methods and were confirmed in a radiometric high performance liquid chromatography assay of BC6ENTC production.	False
From these results we conclude that 1) BC6ENTC levels in circulating platelets reflect ongoing signaling through BC6ENTG , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6ENTC levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6ENTG , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6ENTC levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6ENTG , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6ENTC levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6ENTG ; 2) platelet BC6OTHER BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6ENTC levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6ENTG ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6ENTC levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6OTHER ( BC6ENTG ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6ENTC levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6ENTG family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6ENTC levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6ENTG .	False
From these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6ENTG , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6ENTC BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6ENTG , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6ENTC BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6ENTG , but not BC6OTHER ; 2) platelet BC6ENTC BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6ENTG ; 2) platelet BC6ENTC BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6ENTC BC6ENTG ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6ENTC BC6OTHER ) and BC6OTHER ( BC6ENTG ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6ENTC BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6ENTG family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6ENTC BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6ENTG .	False
From these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6ENTG , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6ENTC ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6ENTG , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6ENTC ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6ENTG , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6ENTC ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6ENTG ; 2) platelet BC6OTHER BC6OTHER ) and BC6ENTC ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6ENTG ) and BC6ENTC ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6ENTC ( BC6ENTG ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6ENTC ( BC6OTHER ) receptors display strong preferences among BC6ENTG family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER .	False
From these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6ENTC ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6ENTG .	False
Platelet agonists such as BC6ENTC and CHEM suppress BC6OTHER - stimulated BC6OTHER formation by activating receptors coupled to BC6ENTG family members, four of which are present in platelets.	False
Finally, the failure of BC6ENTC and BC6OTHER to inhibit basal, as opposed to BC6OTHER - stimulated, BC6OTHER formation highlights the need during platelet activation for BC6ENTG signaling pathways that involve effectors other than BC6OTHER .	False
Finally, the failure of BC6ENTC and BC6OTHER to inhibit basal, as opposed to BC6OTHER - stimulated, BC6OTHER formation highlights the need during platelet activation for BC6OTHER signaling pathways that involve effectors other than BC6ENTG .	False
Finally, the failure of BC6OTHER and BC6ENTC to inhibit basal, as opposed to BC6OTHER - stimulated, BC6OTHER formation highlights the need during platelet activation for BC6ENTG signaling pathways that involve effectors other than BC6OTHER .	False
Finally, the failure of BC6OTHER and BC6ENTC to inhibit basal, as opposed to BC6OTHER - stimulated, BC6OTHER formation highlights the need during platelet activation for BC6OTHER signaling pathways that involve effectors other than BC6ENTG .	False
Finally, the failure of BC6OTHER and BC6OTHER to inhibit basal, as opposed to BC6ENTC - stimulated, BC6OTHER formation highlights the need during platelet activation for BC6ENTG signaling pathways that involve effectors other than BC6OTHER .	False
Finally, the failure of BC6OTHER and BC6OTHER to inhibit basal, as opposed to BC6ENTC - stimulated, BC6OTHER formation highlights the need during platelet activation for BC6OTHER signaling pathways that involve effectors other than BC6ENTG .	False
Finally, the failure of BC6OTHER and BC6OTHER to inhibit basal, as opposed to BC6OTHER - stimulated, BC6ENTC formation highlights the need during platelet activation for BC6ENTG signaling pathways that involve effectors other than BC6OTHER .	False
Finally, the failure of BC6OTHER and BC6OTHER to inhibit basal, as opposed to BC6OTHER - stimulated, BC6ENTC formation highlights the need during platelet activation for BC6OTHER signaling pathways that involve effectors other than BC6ENTG .	False
Finally, the failure of BC6OTHER and BC6OTHER to inhibit basal, as opposed to BC6OTHER - stimulated, BC6OTHER formation highlights the need during platelet activation for BC6ENTG signaling pathways that involve effectors other than BC6ENTC cyclase.	False
Platelet agonists such as BC6OTHER and CHEM suppress BC6ENTC - stimulated BC6OTHER formation by activating receptors coupled to BC6ENTG family members, four of which are present in platelets.	False
Platelet agonists such as BC6OTHER and CHEM suppress BC6OTHER - stimulated BC6ENTC formation by activating receptors coupled to BC6ENTG family members, four of which are present in platelets.	False
To address questions about the specificity of receptor: BC6ENTG coupling, the regulation of BC6ENTC formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6OTHER , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6OTHER , BC6OTHER .	False
To address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6ENTC formation in vivo and the contribution of BC6ENTG - mediated pathways that do not involve BC6OTHER , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6OTHER , BC6OTHER .	False
To address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6ENTC formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6ENTG , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6OTHER , BC6OTHER .	False
To address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6ENTC formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6OTHER , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6ENTG family members and compared the results with platelets from mice that lacked the BC6OTHER , BC6OTHER .	False
To address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6ENTC formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6OTHER , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6ENTG , BC6OTHER .	False
To address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6ENTC formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6OTHER , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6OTHER , BC6ENTG .	False
To address questions about the specificity of receptor: BC6ENTG coupling, the regulation of BC6OTHER formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6ENTC cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6OTHER , BC6OTHER .	False
To address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6OTHER formation in vivo and the contribution of BC6ENTG - mediated pathways that do not involve BC6ENTC cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6OTHER , BC6OTHER .	False
To address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6OTHER formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6ENTC cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6ENTG family members and compared the results with platelets from mice that lacked the BC6OTHER , BC6OTHER .	False
To address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6OTHER formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6ENTC cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6ENTG , BC6OTHER .	False
To address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6OTHER formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6ENTC cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6OTHER , BC6ENTG .	False
To address questions about the specificity of receptor: BC6ENTG coupling, the regulation of BC6OTHER formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6OTHER , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6ENTC receptor, BC6OTHER .	False
To address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6OTHER formation in vivo and the contribution of BC6ENTG - mediated pathways that do not involve BC6OTHER , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6ENTC receptor, BC6OTHER .	False
To address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6OTHER formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6ENTG , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6ENTC receptor, BC6OTHER .	False
To address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6OTHER formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6OTHER , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6ENTG family members and compared the results with platelets from mice that lacked the BC6ENTC receptor, BC6OTHER .	False
To address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6OTHER formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6OTHER , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6ENTC receptor, BC6ENTG .	False
As reported previously, loss of BC6ENTG or BC6OTHER inhibited aggregation in response to BC6ENTC and BC6OTHER , respectively, producing defects that could not be reversed by adding an BC6OTHER inhibitor.	False
As reported previously, loss of BC6OTHER or BC6ENTG inhibited aggregation in response to BC6ENTC and BC6OTHER , respectively, producing defects that could not be reversed by adding an BC6OTHER inhibitor.	False
As reported previously, loss of BC6OTHER or BC6OTHER inhibited aggregation in response to BC6ENTC and BC6OTHER , respectively, producing defects that could not be reversed by adding an BC6ENTG inhibitor.	False
As reported previously, loss of BC6ENTG or BC6OTHER inhibited aggregation in response to BC6OTHER and BC6ENTC , respectively, producing defects that could not be reversed by adding an BC6OTHER inhibitor.	False
As reported previously, loss of BC6OTHER or BC6ENTG inhibited aggregation in response to BC6OTHER and BC6ENTC , respectively, producing defects that could not be reversed by adding an BC6OTHER inhibitor.	False
As reported previously, loss of BC6OTHER or BC6OTHER inhibited aggregation in response to BC6OTHER and BC6ENTC , respectively, producing defects that could not be reversed by adding an BC6ENTG inhibitor.	False
As reported previously, loss of BC6ENTG or BC6OTHER inhibited aggregation in response to BC6OTHER and BC6OTHER , respectively, producing defects that could not be reversed by adding an BC6ENTC cyclase inhibitor.	False
As reported previously, loss of BC6OTHER or BC6ENTG inhibited aggregation in response to BC6OTHER and BC6OTHER , respectively, producing defects that could not be reversed by adding an BC6ENTC cyclase inhibitor.	False
Loss of either BC6ENTG or BC6OTHER impaired the ability of BC6ENTC and BC6OTHER to inhibit BC6OTHER - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not.	False
Loss of either BC6OTHER or BC6ENTG impaired the ability of BC6ENTC and BC6OTHER to inhibit BC6OTHER - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not.	False
Loss of either BC6OTHER or BC6OTHER impaired the ability of BC6ENTC and BC6OTHER to inhibit BC6OTHER - stimulated BC6ENTG activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not.	False
Loss of either BC6OTHER or BC6OTHER impaired the ability of BC6ENTC and BC6OTHER to inhibit BC6OTHER - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6ENTG did not.	False
Loss of either BC6ENTG or BC6OTHER impaired the ability of BC6OTHER and BC6ENTC to inhibit BC6OTHER - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not.	False
Loss of either BC6OTHER or BC6ENTG impaired the ability of BC6OTHER and BC6ENTC to inhibit BC6OTHER - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not.	False
Loss of either BC6OTHER or BC6OTHER impaired the ability of BC6OTHER and BC6ENTC to inhibit BC6OTHER - stimulated BC6ENTG activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not.	False
Loss of either BC6OTHER or BC6OTHER impaired the ability of BC6OTHER and BC6ENTC to inhibit BC6OTHER - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6ENTG did not.	False
Loss of either BC6ENTG or BC6OTHER impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6ENTC - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not.	False
Loss of either BC6OTHER or BC6ENTG impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6ENTC - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not.	False
Loss of either BC6OTHER or BC6OTHER impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6ENTC - stimulated BC6ENTG activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not.	False
Loss of either BC6OTHER or BC6OTHER impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6ENTC - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6ENTG did not.	False
Loss of either BC6ENTG or BC6OTHER impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6OTHER - stimulated BC6ENTC cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not.	False
Loss of either BC6OTHER or BC6ENTG impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6OTHER - stimulated BC6ENTC cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not.	False
Loss of either BC6OTHER or BC6OTHER impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6OTHER - stimulated BC6ENTC cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6ENTG did not.	False
Loss of either BC6ENTG or BC6OTHER impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6OTHER - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6ENTC levels, whereas loss of BC6OTHER did not.	False
Loss of either BC6OTHER or BC6ENTG impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6OTHER - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6ENTC levels, whereas loss of BC6OTHER did not.	False
Loss of either BC6OTHER or BC6OTHER impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6OTHER - stimulated BC6ENTG activity and caused a 40% - 50% rise in basal BC6ENTC levels, whereas loss of BC6OTHER did not.	False
Loss of either BC6OTHER or BC6OTHER impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6OTHER - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6ENTC levels, whereas loss of BC6ENTG did not.	False
Conversely, deletion of BC6ENTG abolished responses to BC6ENTC and caused BC6OTHER levels to fall by 30%, effects that did not translate into enhanced responsiveness to agonists ex vivo.	False
Conversely, deletion of BC6ENTG abolished responses to BC6OTHER and caused BC6ENTC levels to fall by 30%, effects that did not translate into enhanced responsiveness to agonists ex vivo.	False
BC6OTHER trapped in membranes was displaceable by the structurally unrelated BC6ENTG inhibitor, BC6OTHER , in a concentration - dependent manner, implying interaction of retained BC6ENTC with the BC6OTHER .	False
BC6OTHER trapped in membranes was displaceable by the structurally unrelated BC6OTHER inhibitor, BC6OTHER , in a concentration - dependent manner, implying interaction of retained BC6ENTC with the BC6ENTG .	False
The present study examined the potential membrane retention of BC6OTHER ( BC6ENTC ) following exposures of 293 - BC6ENTG cells to BC6OTHER , and its effect on BC6OTHER uptake.	False
The results demonstrate that BC6ENTC and BC6OTHER are persistently retained in cell membranes, at least partly in association with the BC6ENTG .	False
The results demonstrate that BC6OTHER and BC6ENTC are persistently retained in cell membranes, at least partly in association with the BC6ENTG .	False
The retention and slow diffusion of BC6ENTC and BC6OTHER from membranes may contribute to their pharmacological and modulatory action on BC6ENTG .	False
The retention and slow diffusion of BC6OTHER and BC6ENTC from membranes may contribute to their pharmacological and modulatory action on BC6ENTG .	False
The persistent membrane retention of BC6ENTC causes lasting inhibition of BC6ENTG function.	CPR:4
The present study examined the potential membrane retention of BC6OTHER ( BC6OTHER ) following exposures of 293 - BC6ENTG cells to BC6ENTC , and its effect on BC6OTHER uptake.	False
The present study examined the potential membrane retention of BC6OTHER ( BC6OTHER ) following exposures of 293 - BC6ENTG cells to BC6OTHER , and its effect on BC6ENTC uptake.	False
BC6ENTC trapped in membranes was displaceable by the structurally unrelated BC6ENTG inhibitor, BC6OTHER , in a concentration - dependent manner, implying interaction of retained BC6OTHER with the BC6OTHER .	False
BC6ENTC trapped in membranes was displaceable by the structurally unrelated BC6OTHER inhibitor, BC6OTHER , in a concentration - dependent manner, implying interaction of retained BC6OTHER with the BC6ENTG .	False
BC6OTHER trapped in membranes was displaceable by the structurally unrelated BC6ENTG inhibitor, BC6ENTC , in a concentration - dependent manner, implying interaction of retained BC6OTHER with the BC6OTHER .	CPR:4
BC6OTHER trapped in membranes was displaceable by the structurally unrelated BC6OTHER inhibitor, BC6ENTC , in a concentration - dependent manner, implying interaction of retained BC6OTHER with the BC6ENTG .	False
The present study examined the potential membrane retention of BC6ENTC ( BC6OTHER ) following exposures of 293 - BC6ENTG cells to BC6OTHER , and its effect on BC6OTHER uptake.	False
In order to address one aspect of the feasibility of performing time - resolved studies on BC6ENTG , a data set has been collected using the Laue technique on a trigonal crystal of BC6OTHER soaked with the reversible inhibitor BC6ENTC , using a total X - ray exposure time of 24 ms. Electron - density maps obtained from the Laue data, which are of surprisingly good quality compared with similar maps from monochromatic data, show essentially the same features.	False
In order to address one aspect of the feasibility of performing time - resolved studies on BC6OTHER , a data set has been collected using the Laue technique on a trigonal crystal of BC6ENTG soaked with the reversible inhibitor BC6ENTC , using a total X - ray exposure time of 24 ms. Electron - density maps obtained from the Laue data, which are of surprisingly good quality compared with similar maps from monochromatic data, show essentially the same features.	CPR:4
The enzyme ( BC6OTHER ) has a very high catalytic activity for the BC6ENTC hydration reaction, being similar kinetically to the human (h) isoform BC6ENTG , although it is devoid of the BC6OTHER 64 proton shuttle.	CPR:9
The enzyme ( BC6ENTG ) has a very high catalytic activity for the BC6ENTC hydration reaction, being similar kinetically to the human (h) isoform BC6OTHER , although it is devoid of the BC6OTHER 64 proton shuttle.	CPR:9
The enzyme ( BC6OTHER ) has a very high catalytic activity for the BC6OTHER hydration reaction, being similar kinetically to the human (h) isoform BC6ENTG , although it is devoid of the BC6ENTC 64 proton shuttle.	False
The enzyme ( BC6ENTG ) has a very high catalytic activity for the BC6OTHER hydration reaction, being similar kinetically to the human (h) isoform BC6OTHER , although it is devoid of the BC6ENTC 64 proton shuttle.	False
A large number of BC6ENTC and some BC6OTHER were investigated as BC6ENTG inhibitors.	CPR:4
A large number of BC6OTHER and some BC6ENTC were investigated as BC6ENTG inhibitors.	CPR:4
Cloning, Characterization, and BC6ENTC and BC6OTHER Inhibition Studies of an BC6ENTG from Trypanosoma cruzi, the Causative Agent of Chagas Disease.	CPR:4
Cloning, Characterization, and BC6OTHER and BC6ENTC Inhibition Studies of an BC6ENTG from Trypanosoma cruzi, the Causative Agent of Chagas Disease.	CPR:4
Effect of BC6ENTC on BC6ENTG production in endotoxic shock.	False
Abrupt removal of BC6ENTC or BC6OTHER from the culture medium prior to LPS stimulation, however, caused significantly augmented BC6ENTG production.	CPR:3
Abrupt removal of BC6OTHER or BC6ENTC from the culture medium prior to LPS stimulation, however, caused significantly augmented BC6ENTG production.	CPR:3
Therefore, BC6ENTC and other BC6ENTG inhibitors may also enhance sensitivity to LPS during a period of time following discontinuation of therapy.	False
 We now demonstrate that BC6ENTC , a noncatechol inotrope, strongly inhibits lipopolysaccharide (LPS) - induced BC6ENTG production at concentrations readily achieved in vivo. This inhibition is apparent in murine macrophages, in macrophage cell lines, in vivo, and in cell lines containing a reporter gene construct that substitutes the CHEM transferase (CAT) coding sequence for the BC6OTHER coding sequence and introns.	CPR:4
 We now demonstrate that BC6ENTC , a noncatechol inotrope, strongly inhibits lipopolysaccharide (LPS) - induced BC6OTHER production at concentrations readily achieved in vivo. This inhibition is apparent in murine macrophages, in macrophage cell lines, in vivo, and in cell lines containing a reporter gene construct that substitutes the CHEM transferase (CAT) coding sequence for the BC6ENTG coding sequence and introns.	False
Combined application of BC6ENTC and BC6OTHER caused additive inhibition of BC6ENTG biosynthesis in vitro.	CPR:4
Combined application of BC6OTHER and BC6ENTC caused additive inhibition of BC6ENTG biosynthesis in vitro.	CPR:4
To identify selective compounds for nonadrenergic I1 - BC6ENTC receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at BC6ENTG (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic I1 - BC6ENTC receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6ENTG ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic I1 - BC6ENTC receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6ENTG , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic I1 - BC6ENTC receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6ENTG and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic I1 - BC6ENTC receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6ENTG stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic I1 - BC6ENTC receptors ( BC6ENTG ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
BC6ENTC , an endogenous neurotransmitter candidate for the BC6ENTG , was identified as the most selective agent for a subcomponent of platelet BC6OTHER .	False
BC6ENTC , an endogenous neurotransmitter candidate for the I1 - BC6OTHER receptor, was identified as the most selective agent for a subcomponent of platelet BC6ENTG .	False
BC6OTHER , an endogenous neurotransmitter candidate for the I1 - BC6ENTC receptor, was identified as the most selective agent for a subcomponent of platelet BC6ENTG .	False
The affinity of BC6ENTC at the high affinity component of platelet BC6ENTG was 1400 - fold selective over BC6OTHER , 5000 - fold selective over BC6OTHER and 800 - fold selective over BC6OTHER .	False
The affinity of BC6ENTC at the high affinity component of platelet BC6OTHER was 1400 - fold selective over BC6ENTG , 5000 - fold selective over BC6OTHER and 800 - fold selective over BC6OTHER .	False
The affinity of BC6ENTC at the high affinity component of platelet BC6OTHER was 1400 - fold selective over BC6OTHER , 5000 - fold selective over BC6ENTG and 800 - fold selective over BC6OTHER .	False
The affinity of BC6ENTC at the high affinity component of platelet BC6OTHER was 1400 - fold selective over BC6OTHER , 5000 - fold selective over BC6OTHER and 800 - fold selective over BC6ENTG .	False
BC6ENTC and BC6OTHER also displayed selectivities for a high affinity component of the platelet BC6ENTG over BC6OTHER .	False
BC6ENTC and BC6OTHER also displayed selectivities for a high affinity component of the platelet BC6OTHER over BC6ENTG .	False
BC6OTHER and BC6ENTC also displayed selectivities for a high affinity component of the platelet BC6ENTG over BC6OTHER .	False
BC6OTHER and BC6ENTC also displayed selectivities for a high affinity component of the platelet BC6OTHER over BC6ENTG .	False
Comparison of ligand binding affinities at human I1 - BC6ENTC binding sites and the high affinity state of BC6ENTG subtypes.	False
BC6ENTC was the most selective compound for the high affinity state of the BC6ENTG , displaying 7 - , 23 - and 9 - fold higher affinity than BC6OTHER , BC6OTHER and platelet I1 - BC6OTHER binding sites, respectively.	False
BC6ENTC was the most selective compound for the high affinity state of the BC6OTHER , displaying 7 - , 23 - and 9 - fold higher affinity than BC6ENTG , BC6OTHER and platelet I1 - BC6OTHER binding sites, respectively.	False
BC6ENTC was the most selective compound for the high affinity state of the BC6OTHER , displaying 7 - , 23 - and 9 - fold higher affinity than BC6OTHER , BC6ENTG and platelet I1 - BC6OTHER binding sites, respectively.	False
BC6ENTC was the most selective compound for the high affinity state of the BC6OTHER , displaying 7 - , 23 - and 9 - fold higher affinity than BC6OTHER , BC6OTHER and platelet BC6ENTG , respectively.	False
To identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6ENTC binding have been compared at BC6ENTG (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6ENTC binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6ENTG ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6ENTC binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6ENTG , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6ENTC binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6ENTG and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6ENTC binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6ENTG stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic BC6ENTG ( BC6OTHER ), the affinities of 22 ligands for BC6ENTC binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6ENTG ), the affinities of 22 ligands for BC6ENTC binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
BC6OTHER was the most selective compound for the high affinity state of the BC6ENTG , displaying 7 - , 23 - and 9 - fold higher affinity than BC6OTHER , BC6OTHER and platelet I1 - BC6ENTC binding sites, respectively.	False
BC6OTHER was the most selective compound for the high affinity state of the BC6OTHER , displaying 7 - , 23 - and 9 - fold higher affinity than BC6ENTG , BC6OTHER and platelet I1 - BC6ENTC binding sites, respectively.	False
BC6OTHER was the most selective compound for the high affinity state of the BC6OTHER , displaying 7 - , 23 - and 9 - fold higher affinity than BC6OTHER , BC6ENTG and platelet I1 - BC6ENTC binding sites, respectively.	False
BC6ENTC displayed, respectively, 18 - and 31 - fold selectivity for the high affinity state of the BC6ENTG as compared to BC6OTHER - or BC6OTHER , and was > 100,000 - fold selective over platelet I1 - BC6OTHER sites.	False
BC6ENTC displayed, respectively, 18 - and 31 - fold selectivity for the high affinity state of the BC6OTHER as compared to BC6ENTG - or BC6OTHER , and was > 100,000 - fold selective over platelet I1 - BC6OTHER sites.	False
BC6ENTC displayed, respectively, 18 - and 31 - fold selectivity for the high affinity state of the BC6OTHER as compared to BC6OTHER - or BC6ENTG , and was > 100,000 - fold selective over platelet I1 - BC6OTHER sites.	False
BC6ENTC displayed, respectively, 18 - and 31 - fold selectivity for the high affinity state of the BC6OTHER as compared to BC6OTHER - or BC6OTHER , and was > 100,000 - fold selective over platelet BC6ENTG .	False
BC6OTHER displayed, respectively, 18 - and 31 - fold selectivity for the high affinity state of the BC6ENTG as compared to BC6OTHER - or BC6OTHER , and was > 100,000 - fold selective over platelet I1 - BC6ENTC sites.	False
BC6OTHER displayed, respectively, 18 - and 31 - fold selectivity for the high affinity state of the BC6OTHER as compared to BC6ENTG - or BC6OTHER , and was > 100,000 - fold selective over platelet I1 - BC6ENTC sites.	False
BC6OTHER displayed, respectively, 18 - and 31 - fold selectivity for the high affinity state of the BC6OTHER as compared to BC6OTHER - or BC6ENTG , and was > 100,000 - fold selective over platelet I1 - BC6ENTC sites.	False
Thus, BC6ENTG and the platelet I1 - BC6ENTC binding site can be clearly discriminated based on their affinities for certain compounds.	False
To identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6ENTC binding sites (analyzed under BC6OTHER mask of BC6ENTG ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6ENTC binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6ENTG , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6ENTC binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6ENTG and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6ENTC binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6ENTG stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic BC6ENTG ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6ENTC binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6ENTG ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6ENTC binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at BC6ENTG (analyzed under BC6ENTC mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6ENTC mask of BC6ENTG ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6ENTC mask of BC6OTHER ) and at BC6ENTG , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6ENTC mask of BC6OTHER ) and at BC6OTHER , BC6ENTG and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6ENTC mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6ENTG stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic BC6ENTG ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6ENTC mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
To identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6ENTG ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6ENTC mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells.	False
BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6ENTG , BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6ENTG , BC6OTHER - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6ENTG - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6ENTG , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6OTHER , BC6ENTG , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER , and BC6ENTG represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6ENTG , BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6ENTG , BC6OTHER - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6ENTG - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6ENTG , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6OTHER , BC6ENTG , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER , and BC6ENTG represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6ENTG , BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6ENTG , BC6OTHER - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6ENTG - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6ENTG , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6OTHER , BC6ENTG , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER , and BC6ENTG represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6ENTG , BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6ENTG , BC6OTHER - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6ENTG - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6ENTG , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6OTHER , BC6ENTG , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER , and BC6ENTG represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	CPR:4
The reported mechanism of BC6ENTC resistance in GISTs involves missense mutation in the BC6ENTG of BC6OTHER including BC6OTHER , BC6OTHER , and BC6OTHER .	False
The reported mechanism of BC6ENTC resistance in GISTs involves missense mutation in the BC6OTHER of BC6ENTG including BC6OTHER , BC6OTHER , and BC6OTHER .	False
The reported mechanism of BC6ENTC resistance in GISTs involves missense mutation in the BC6OTHER of BC6OTHER including BC6ENTG , BC6OTHER , and BC6OTHER .	False
The reported mechanism of BC6ENTC resistance in GISTs involves missense mutation in the BC6OTHER of BC6OTHER including BC6OTHER , BC6ENTG , and BC6OTHER .	False
The reported mechanism of BC6ENTC resistance in GISTs involves missense mutation in the BC6OTHER of BC6OTHER including BC6OTHER , BC6OTHER , and BC6ENTG .	False
Fibroblast cultures from the patient exhibited severe reduction of the CHEM - sensitive BC6ENTC - - >UQ oxidoreductase activity of BC6ENTG , which was insensitive to BC6OTHER stimulation.	False
Fibroblast cultures from the patient exhibited severe reduction of the CHEM - sensitive BC6ENTG activity of BC6OTHER , which was insensitive to BC6ENTC stimulation.	False
Fibroblast cultures from the patient exhibited severe reduction of the CHEM - sensitive BC6OTHER - - >UQ oxidoreductase activity of BC6ENTG , which was insensitive to BC6ENTC stimulation.	False
Blocking BC6OTHER signaling with the BC6OTHER / BC6OTHER kinase inhibitor (KI) BC6ENTC decreased the postradiation survival of irradiated BC6ENTG - transformed cells and normal cells but had no effect on the survival of unirradiated cells.	CPR:4
Blocking BC6ENTG signaling with the BC6OTHER / BC6OTHER kinase inhibitor (KI) BC6ENTC decreased the postradiation survival of irradiated BC6OTHER - transformed cells and normal cells but had no effect on the survival of unirradiated cells.	CPR:4
Blocking BC6OTHER signaling with the BC6ENTG / BC6OTHER kinase inhibitor (KI) BC6ENTC decreased the postradiation survival of irradiated BC6OTHER - transformed cells and normal cells but had no effect on the survival of unirradiated cells.	CPR:4
Blocking BC6OTHER signaling with the BC6OTHER / BC6ENTG kinase inhibitor (KI) BC6ENTC decreased the postradiation survival of irradiated BC6OTHER - transformed cells and normal cells but had no effect on the survival of unirradiated cells.	CPR:4
BC6ENTG - CM and BC6OTHER also increase BC6OTHER activity downstream of the BC6OTHER and increase postradiation survival, both of which are abrogated by BC6ENTC .	False
BC6OTHER - CM and BC6ENTG also increase BC6OTHER activity downstream of the BC6OTHER and increase postradiation survival, both of which are abrogated by BC6ENTC .	False
BC6OTHER - CM and BC6OTHER also increase BC6ENTG activity downstream of the BC6OTHER and increase postradiation survival, both of which are abrogated by BC6ENTC .	CPR:4
BC6OTHER - CM and BC6OTHER also increase BC6OTHER activity downstream of the BC6ENTG and increase postradiation survival, both of which are abrogated by BC6ENTC .	CPR:4
Thus, BC6ENTG utilizes autocrine signaling through BC6OTHER to increase radioresistance, and the BC6OTHER KI BC6ENTC acts as a radiosensitizer.	CPR:4
Thus, BC6OTHER utilizes autocrine signaling through BC6ENTG to increase radioresistance, and the BC6OTHER KI BC6ENTC acts as a radiosensitizer.	False
Thus, BC6OTHER utilizes autocrine signaling through BC6OTHER to increase radioresistance, and the BC6ENTG KI BC6ENTC acts as a radiosensitizer.	CPR:4
The observation that BC6ENTG - transformed cells can be sensitized to killing by ionizing radiation with BC6ENTC demonstrates that BC6OTHER KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on BC6OTHER - driven autocrine signaling through BC6OTHER .	CPR:4
The observation that BC6OTHER - transformed cells can be sensitized to killing by ionizing radiation with BC6ENTC demonstrates that BC6ENTG KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on BC6OTHER - driven autocrine signaling through BC6OTHER .	CPR:4
The observation that BC6OTHER - transformed cells can be sensitized to killing by ionizing radiation with BC6ENTC demonstrates that BC6OTHER KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on BC6ENTG - driven autocrine signaling through BC6OTHER .	False
The observation that BC6OTHER - transformed cells can be sensitized to killing by ionizing radiation with BC6ENTC demonstrates that BC6OTHER KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on BC6OTHER - driven autocrine signaling through BC6ENTG .	False
Although not all of the signaling pathways for radioresistance are well defined, it is now clear that BC6ENTG - dependent signaling pathways involved in radioresistance include those mediated by BC6ENTC 3' - kinase ( BC6OTHER ) and BC6OTHER .	False
Although not all of the signaling pathways for radioresistance are well defined, it is now clear that BC6OTHER - dependent signaling pathways involved in radioresistance include those mediated by BC6ENTC 3' - kinase ( BC6ENTG ) and BC6OTHER .	False
Although not all of the signaling pathways for radioresistance are well defined, it is now clear that BC6OTHER - dependent signaling pathways involved in radioresistance include those mediated by BC6ENTC 3' - kinase ( BC6OTHER ) and BC6ENTG .	False
However at IC80, BC6OTHER (+134.4%) and BC6OTHER (+29.7%) had greater BC6ENTG selectivity than at IC50, and BC6OTHER ( - 41.2%) and BC6ENTC ( - 12.9%) had lower BC6OTHER selectivity than at IC50.	False
However at IC80, BC6OTHER (+134.4%) and BC6OTHER (+29.7%) had greater BC6OTHER selectivity than at IC50, and BC6OTHER ( - 41.2%) and BC6ENTC ( - 12.9%) had lower BC6ENTG selectivity than at IC50.	CPR:4
We report on the inhibitory activity of the NSAIDs BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , on blood BC6ENTG in the horse using in vitro enzyme - linked assays.	CPR:4
We report on the inhibitory activity of the NSAIDs BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , on blood BC6ENTG in the horse using in vitro enzyme - linked assays.	CPR:4
We report on the inhibitory activity of the NSAIDs BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC , on blood BC6ENTG in the horse using in vitro enzyme - linked assays.	CPR:4
 BC6ENTG and BC6OTHER inhibition in horse blood by BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER : an in vitro analysis.	CPR:4
 BC6OTHER and BC6ENTG inhibition in horse blood by BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER : an in vitro analysis.	CPR:4
 BC6ENTG and BC6OTHER inhibition in horse blood by BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER : an in vitro analysis.	CPR:4
 BC6OTHER and BC6ENTG inhibition in horse blood by BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER : an in vitro analysis.	CPR:4
 BC6ENTG and BC6OTHER inhibition in horse blood by BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER : an in vitro analysis.	CPR:4
 BC6OTHER and BC6ENTG inhibition in horse blood by BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER : an in vitro analysis.	CPR:4
 BC6ENTG and BC6OTHER inhibition in horse blood by BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC : an in vitro analysis.	CPR:4
 BC6OTHER and BC6ENTG inhibition in horse blood by BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC : an in vitro analysis.	CPR:4
As expected, comparison of IC50 indicated that BC6ENTC and BC6OTHER are more selective inhibitors of BC6ENTG than BC6OTHER and BC6OTHER ; BC6OTHER was the most advantageous for horses of four NSAIDs examined.	CPR:4
As expected, comparison of IC50 indicated that BC6OTHER and BC6ENTC are more selective inhibitors of BC6ENTG than BC6OTHER and BC6OTHER ; BC6OTHER was the most advantageous for horses of four NSAIDs examined.	CPR:4
As expected, comparison of IC50 indicated that BC6OTHER and BC6OTHER are more selective inhibitors of BC6ENTG than BC6ENTC and BC6OTHER ; BC6OTHER was the most advantageous for horses of four NSAIDs examined.	CPR:4
As expected, comparison of IC50 indicated that BC6OTHER and BC6OTHER are more selective inhibitors of BC6ENTG than BC6OTHER and BC6ENTC ; BC6OTHER was the most advantageous for horses of four NSAIDs examined.	CPR:4
As expected, comparison of IC50 indicated that BC6OTHER and BC6OTHER are more selective inhibitors of BC6ENTG than BC6OTHER and BC6OTHER ; BC6ENTC was the most advantageous for horses of four NSAIDs examined.	False
However at IC80, BC6ENTC (+134.4%) and BC6OTHER (+29.7%) had greater BC6ENTG selectivity than at IC50, and BC6OTHER ( - 41.2%) and BC6OTHER ( - 12.9%) had lower BC6OTHER selectivity than at IC50.	CPR:4
However at IC80, BC6ENTC (+134.4%) and BC6OTHER (+29.7%) had greater BC6OTHER selectivity than at IC50, and BC6OTHER ( - 41.2%) and BC6OTHER ( - 12.9%) had lower BC6ENTG selectivity than at IC50.	False
However at IC80, BC6OTHER (+134.4%) and BC6ENTC (+29.7%) had greater BC6ENTG selectivity than at IC50, and BC6OTHER ( - 41.2%) and BC6OTHER ( - 12.9%) had lower BC6OTHER selectivity than at IC50.	CPR:4
However at IC80, BC6OTHER (+134.4%) and BC6ENTC (+29.7%) had greater BC6OTHER selectivity than at IC50, and BC6OTHER ( - 41.2%) and BC6OTHER ( - 12.9%) had lower BC6ENTG selectivity than at IC50.	False
However at IC80, BC6OTHER (+134.4%) and BC6OTHER (+29.7%) had greater BC6ENTG selectivity than at IC50, and BC6ENTC ( - 41.2%) and BC6OTHER ( - 12.9%) had lower BC6OTHER selectivity than at IC50.	False
However at IC80, BC6OTHER (+134.4%) and BC6OTHER (+29.7%) had greater BC6OTHER selectivity than at IC50, and BC6ENTC ( - 41.2%) and BC6OTHER ( - 12.9%) had lower BC6ENTG selectivity than at IC50.	CPR:4
We report on the inhibitory activity of the NSAIDs BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , on blood BC6ENTG in the horse using in vitro enzyme - linked assays.	CPR:4
In addition, SCPP11 (at 50mg / kg) could also increased in thymus indexes as well as BC6ENTG and BC6OTHER levels in serum in vivo and significantly enhance the phagocytosis activity and the productions of BC6ENTC of RAW264.7 in vitro.	False
In addition, SCPP11 (at 50mg / kg) could also increased in thymus indexes as well as BC6OTHER and BC6ENTG levels in serum in vivo and significantly enhance the phagocytosis activity and the productions of BC6ENTC of RAW264.7 in vitro.	False
BC6ENTC (intravenous, 1 mg / kg), whose serotonergic actions include BC6ENTG and BC6OTHER antagonism, typically raised BC6OTHER levels (four of five cells) and always blocked inhibition by BC6OTHER (n = 3).	CPR:6
BC6ENTC (intravenous, 1 mg / kg), whose serotonergic actions include BC6OTHER and BC6ENTG antagonism, typically raised BC6OTHER levels (four of five cells) and always blocked inhibition by BC6OTHER (n = 3).	CPR:6
BC6OTHER (intravenous, 1 mg / kg), whose serotonergic actions include BC6ENTG and BC6OTHER antagonism, typically raised BC6ENTC levels (four of five cells) and always blocked inhibition by BC6OTHER (n = 3).	False
BC6OTHER (intravenous, 1 mg / kg), whose serotonergic actions include BC6OTHER and BC6ENTG antagonism, typically raised BC6ENTC levels (four of five cells) and always blocked inhibition by BC6OTHER (n = 3).	False
BC6OTHER (intravenous, 1 mg / kg), whose serotonergic actions include BC6ENTG and BC6OTHER antagonism, typically raised BC6OTHER levels (four of five cells) and always blocked inhibition by BC6ENTC (n = 3).	False
BC6OTHER (intravenous, 1 mg / kg), whose serotonergic actions include BC6OTHER and BC6ENTG antagonism, typically raised BC6OTHER levels (four of five cells) and always blocked inhibition by BC6ENTC (n = 3).	False
The released BC6ENTC could contribute to the inhibition of off(M) cells and excitation of on(M) cells by noxious stimulation, since inhibitory BC6ENTG receptors and excitatory BC6OTHER receptors, respectively, have previously been shown to dominate their serotonergic responses.	False
The released BC6ENTC could contribute to the inhibition of off(M) cells and excitation of on(M) cells by noxious stimulation, since inhibitory BC6OTHER receptors and excitatory BC6ENTG receptors, respectively, have previously been shown to dominate their serotonergic responses.	False
Iontophoresis of BC6ENTC , whose serotonergic actions include antagonism and partial agonism at BC6ENTG receptors, also increased BC6OTHER and decreased firing (n=4).	CPR:6
Iontophoresis of BC6OTHER , whose serotonergic actions include antagonism and partial agonism at BC6ENTG receptors, also increased BC6ENTC and decreased firing (n=4).	False
OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized BC6OTHER (a selective, long - acting BC6ENTG agonist that is the BC6ENTC ) and BC6OTHER versus placebo in patients with chronic obstructive pulmonary disease (COPD).	CPR:5
OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized BC6OTHER (a selective, long - acting BC6ENTG agonist that is the BC6OTHER ) and BC6ENTC versus placebo in patients with chronic obstructive pulmonary disease (COPD).	False
OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized BC6ENTC (a selective, long - acting BC6ENTG agonist that is the BC6OTHER ) and BC6OTHER versus placebo in patients with chronic obstructive pulmonary disease (COPD).	CPR:5
We characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6ENTG ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6OTHER production.	False
We characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6ENTG ) with regard to secretion of BC6OTHER , BC6OTHER , BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6OTHER production.	False
We characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6ENTG , BC6OTHER , BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6OTHER production.	False
We characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6ENTG , BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6OTHER production.	False
We characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6ENTC - dependent insulinotropic polypeptide ( BC6ENTG ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6OTHER production.	False
We characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ), BC6ENTG ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6OTHER production.	False
We characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6ENTG ) as well as BC6OTHER sensitivity and endogenous BC6OTHER production.	False
We characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6ENTG sensitivity and endogenous BC6OTHER production.	False
We characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6ENTG ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6OTHER - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6ENTC production.	False
We characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6ENTG ) with regard to secretion of BC6OTHER , BC6OTHER , BC6OTHER - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6ENTC production.	False
We characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6ENTG , BC6OTHER , BC6OTHER - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6ENTC production.	False
We characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6ENTG , BC6OTHER - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6ENTC production.	False
We characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6ENTC production.	False
We characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6OTHER - dependent insulinotropic polypeptide ( BC6ENTG ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6ENTC production.	False
We characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6OTHER - dependent insulinotropic polypeptide ( BC6OTHER ), BC6ENTG ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6ENTC production.	False
We characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6OTHER - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6ENTG ) as well as BC6OTHER sensitivity and endogenous BC6ENTC production.	False
We characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6OTHER - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6ENTG sensitivity and endogenous BC6ENTC production.	False
We found no significant differences in endogenous BC6ENTC production, hepatic BC6ENTG sensitivity or fasting concentrations of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER between the groups.	False
We found no significant differences in endogenous BC6ENTC production, hepatic BC6OTHER sensitivity or fasting concentrations of BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER between the groups.	False
We found no significant differences in endogenous BC6ENTC production, hepatic BC6OTHER sensitivity or fasting concentrations of BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER between the groups.	False
We found no significant differences in endogenous BC6ENTC production, hepatic BC6OTHER sensitivity or fasting concentrations of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG between the groups.	False
We found no significant differences in endogenous BC6OTHER production, hepatic BC6ENTG sensitivity or fasting concentrations of BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER between the groups.	False
We found no significant differences in endogenous BC6OTHER production, hepatic BC6OTHER sensitivity or fasting concentrations of BC6ENTC , BC6ENTG , BC6OTHER and BC6OTHER between the groups.	False
We found no significant differences in endogenous BC6OTHER production, hepatic BC6OTHER sensitivity or fasting concentrations of BC6ENTC , BC6OTHER , BC6ENTG and BC6OTHER between the groups.	False
We found no significant differences in endogenous BC6OTHER production, hepatic BC6OTHER sensitivity or fasting concentrations of BC6ENTC , BC6OTHER , BC6OTHER and BC6ENTG between the groups.	False
Furthermore, co - injection of encapsulated BC6ENTG - ligands with BC6ENTC particles carrying BC6OTHER HIV - 1 antigen allowed a 100 fold increase in antibody responses in comparison to Alum.	False
Furthermore, co - injection of encapsulated BC6OTHER - ligands with BC6ENTC particles carrying BC6ENTG HIV - 1 antigen allowed a 100 fold increase in antibody responses in comparison to Alum.	False
These results suggest that encapsulation of BC6ENTG ligands into BC6ENTC - NPs could be an effective way to improve vaccine efficiency.	False
As activation of intracytoplasmic BC6ENTG is able to induce proinflammatory molecules, the added value of encapsulation of BC6OTHER and BC6OTHER receptor ligands into BC6ENTC ( BC6OTHER ) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated.	False
As activation of intracytoplasmic BC6OTHER is able to induce proinflammatory molecules, the added value of encapsulation of BC6ENTG and BC6OTHER receptor ligands into BC6ENTC ( BC6OTHER ) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated.	False
As activation of intracytoplasmic BC6OTHER is able to induce proinflammatory molecules, the added value of encapsulation of BC6OTHER and BC6ENTG receptor ligands into BC6ENTC ( BC6OTHER ) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated.	False
As activation of intracytoplasmic BC6ENTG is able to induce proinflammatory molecules, the added value of encapsulation of BC6OTHER and BC6OTHER receptor ligands into BC6OTHER ( BC6ENTC ) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated.	False
As activation of intracytoplasmic BC6OTHER is able to induce proinflammatory molecules, the added value of encapsulation of BC6ENTG and BC6OTHER receptor ligands into BC6OTHER ( BC6ENTC ) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated.	False
As activation of intracytoplasmic BC6OTHER is able to induce proinflammatory molecules, the added value of encapsulation of BC6OTHER and BC6ENTG receptor ligands into BC6OTHER ( BC6ENTC ) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated.	False
BC6ENTG ligands encapsulated into BC6ENTC NPs were efficiently taken up by DCs and subsequently induced a strong up - regulation of maturation markers and the enhancement of proinflammatory BC6OTHER secretion by DCs.	False
BC6OTHER ligands encapsulated into BC6ENTC NPs were efficiently taken up by DCs and subsequently induced a strong up - regulation of maturation markers and the enhancement of proinflammatory BC6ENTG secretion by DCs.	False
Encapsulation of BC6ENTG and BC6OTHER receptor ligands into BC6ENTC nanoparticles potentiates their immune properties.	False
Encapsulation of BC6OTHER and BC6ENTG receptor ligands into BC6ENTC nanoparticles potentiates their immune properties.	False
The current study examined the bioactivation potential of BC6ENTG inverse agonists, BC6OTHER (1) and BC6ENTC (2), containing a fused BC6OTHER motif in the core structure.	CPR:5
The current study examined the bioactivation potential of BC6ENTG inverse agonists, BC6OTHER (1) and BC6OTHER (2), containing a fused BC6ENTC motif in the core structure.	CPR:5
The current study examined the bioactivation potential of BC6ENTG inverse agonists, BC6ENTC (1) and BC6OTHER (2), containing a fused BC6OTHER motif in the core structure.	CPR:5
Reactive Metabolite Trapping Studies on BC6ENTC - based Inverse Agonists of the BC6ENTG .	CPR:5
Measurement of Transport Activities of BC6ENTC in BC6ENTG and BC6OTHER Using LC - MS / MS.	CPR:9
Measurement of Transport Activities of BC6ENTC in BC6OTHER and BC6ENTG Using LC - MS / MS.	CPR:9
Measurement of Transport Activities of BC6OTHER in BC6ENTC Export Pump and BC6ENTG Using LC - MS / MS.	False
The analytical method was applied to measurements of transport activities in membrane vesicles obtained from BC6ENTG - , and human BC6ENTC export pump - expressing Sf9 cells for conjugated BC6OTHER .	False
The analytical method was applied to measurements of transport activities in membrane vesicles obtained from BC6ENTG - , and human BC6OTHER export pump - expressing Sf9 cells for conjugated BC6ENTC .	False
The analytical method was applied to measurements of transport activities in membrane vesicles obtained from BC6OTHER - , and BC6ENTG - expressing Sf9 cells for conjugated BC6ENTC .	CPR:9
The present study demonstrated that BC6ENTG vesicles accepted conjugated BC6ENTC along with common BC6OTHER such as BC6OTHER and BC6OTHER .	CPR:9
The present study demonstrated that BC6ENTG vesicles accepted conjugated BC6OTHER along with common BC6ENTC such as BC6OTHER and BC6OTHER .	CPR:9
The present study demonstrated that BC6ENTG vesicles accepted conjugated BC6OTHER along with common BC6OTHER such as BC6ENTC and BC6OTHER .	CPR:9
The present study demonstrated that BC6ENTG vesicles accepted conjugated BC6OTHER along with common BC6OTHER such as BC6OTHER and BC6ENTC .	CPR:9
Here, we show that the BC6ENTG is the brain binding site of BC6ENTC ( BC6OTHER ), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy.	False
Furthermore, there is a high degree of correlation between binding affinities of a series of BC6OTHER derivatives to BC6ENTG in fibroblasts and to the BC6ENTC - binding site in brain.	False
Here, we show that the BC6ENTG is the brain binding site of BC6OTHER ( BC6ENTC ), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy.	False
The BC6ENTG is the binding site for the antiepileptic drug BC6ENTC .	False
These experimental results suggest that BC6ENTG is the binding site of BC6ENTC in the brain and that BC6OTHER acts by modulating the function of BC6OTHER , supporting previous indications that BC6OTHER possesses a mechanism of action distinct from that of other antiepileptic drugs.	False
These experimental results suggest that BC6OTHER is the binding site of BC6ENTC in the brain and that BC6OTHER acts by modulating the function of BC6ENTG , supporting previous indications that BC6OTHER possesses a mechanism of action distinct from that of other antiepileptic drugs.	False
These experimental results suggest that BC6ENTG is the binding site of BC6OTHER in the brain and that BC6ENTC acts by modulating the function of BC6OTHER , supporting previous indications that BC6OTHER possesses a mechanism of action distinct from that of other antiepileptic drugs.	False
These experimental results suggest that BC6OTHER is the binding site of BC6OTHER in the brain and that BC6ENTC acts by modulating the function of BC6ENTG , supporting previous indications that BC6OTHER possesses a mechanism of action distinct from that of other antiepileptic drugs.	False
These experimental results suggest that BC6ENTG is the binding site of BC6OTHER in the brain and that BC6OTHER acts by modulating the function of BC6OTHER , supporting previous indications that BC6ENTC possesses a mechanism of action distinct from that of other antiepileptic drugs.	False
These experimental results suggest that BC6OTHER is the binding site of BC6OTHER in the brain and that BC6OTHER acts by modulating the function of BC6ENTG , supporting previous indications that BC6ENTC possesses a mechanism of action distinct from that of other antiepileptic drugs.	False
Brain membranes and purified synaptic vesicles from mice lacking BC6ENTG do not bind a tritiated BC6ENTC derivative, indicating that BC6OTHER is necessary for BC6OTHER binding.	False
Brain membranes and purified synaptic vesicles from mice lacking BC6OTHER do not bind a tritiated BC6ENTC derivative, indicating that BC6ENTG is necessary for BC6OTHER binding.	False
Brain membranes and purified synaptic vesicles from mice lacking BC6ENTG do not bind a tritiated BC6OTHER derivative, indicating that BC6OTHER is necessary for BC6ENTC binding.	False
Brain membranes and purified synaptic vesicles from mice lacking BC6OTHER do not bind a tritiated BC6OTHER derivative, indicating that BC6ENTG is necessary for BC6ENTC binding.	False
BC6ENTC and related compounds bind to BC6ENTG expressed in fibroblasts, indicating that BC6OTHER is sufficient for BC6OTHER binding.	False
BC6ENTC and related compounds bind to BC6OTHER expressed in fibroblasts, indicating that BC6ENTG is sufficient for BC6OTHER binding.	False
BC6OTHER and related compounds bind to BC6ENTG expressed in fibroblasts, indicating that BC6OTHER is sufficient for BC6ENTC binding.	False
BC6OTHER and related compounds bind to BC6OTHER expressed in fibroblasts, indicating that BC6ENTG is sufficient for BC6ENTC binding.	False
Furthermore, there is a high degree of correlation between binding affinities of a series of BC6ENTC derivatives to BC6ENTG in fibroblasts and to the BC6OTHER - binding site in brain.	False
BC6ENTG has mostly been studied in the context of the leukemic BC6OTHER - BC6OTHER fusion protein, which lacks the BC6ENTC - terminal PHD fingers of BC6OTHER .	False
BC6OTHER has mostly been studied in the context of the leukemic BC6ENTG - BC6OTHER fusion protein, which lacks the BC6ENTC - terminal PHD fingers of BC6OTHER .	False
BC6OTHER has mostly been studied in the context of the leukemic BC6OTHER - BC6ENTG fusion protein, which lacks the BC6ENTC - terminal PHD fingers of BC6OTHER .	False
BC6OTHER has mostly been studied in the context of the leukemic BC6OTHER - BC6OTHER fusion protein, which lacks the BC6ENTC - terminal PHD fingers of BC6ENTG .	False
In this study, we used genetic and biochemical approaches to examine the BC6ENTG region of the Caenorhabditis elegans ortholog of BC6OTHER , BC6ENTC finger protein 1 ( BC6OTHER ).	False
In this study, we used genetic and biochemical approaches to examine the BC6OTHER region of the Caenorhabditis elegans ortholog of BC6ENTG , BC6ENTC finger protein 1 ( BC6OTHER ).	False
In this study, we used genetic and biochemical approaches to examine the BC6OTHER region of the Caenorhabditis elegans ortholog of BC6OTHER , BC6ENTC finger protein 1 ( BC6ENTG ).	False
We demonstrate that the BC6ENTG region is essential for viability and that the first BC6OTHER contributes to the preferred binding of BC6OTHER to BC6ENTC 4 - methylated histone H3 tails.	False
We demonstrate that the BC6OTHER region is essential for viability and that the first BC6ENTG contributes to the preferred binding of BC6OTHER to BC6ENTC 4 - methylated histone H3 tails.	False
We demonstrate that the BC6OTHER region is essential for viability and that the first BC6OTHER contributes to the preferred binding of BC6ENTG to BC6ENTC 4 - methylated histone H3 tails.	False
We have previously demonstrated that phosphorylation of BC6ENTG ( BC6OTHER ) at 194 BC6ENTC through c - jun BC6OTHER - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6OTHER .	False
We have previously demonstrated that phosphorylation of BC6OTHER ( BC6ENTG ) at 194 BC6ENTC through c - jun BC6OTHER - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6OTHER .	False
We have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6ENTC through BC6ENTG ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6OTHER .	False
We have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6ENTC through c - jun BC6OTHER - terminal kinase ( BC6ENTG ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6OTHER .	False
We have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6ENTC through c - jun BC6OTHER - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6ENTG phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6OTHER .	False
We have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6ENTC through c - jun BC6OTHER - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6ENTG / BC6OTHER plays an important role in cell growth suppression by BC6OTHER .	False
We have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6ENTC through c - jun BC6OTHER - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6ENTG plays an important role in cell growth suppression by BC6OTHER .	False
We have previously demonstrated that phosphorylation of BC6ENTG ( BC6OTHER ) at 194 BC6OTHER through c - jun BC6ENTC - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6OTHER .	False
We have previously demonstrated that phosphorylation of BC6OTHER ( BC6ENTG ) at 194 BC6OTHER through c - jun BC6ENTC - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6OTHER .	False
We have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6OTHER through c - jun BC6ENTC - terminal kinase ( BC6ENTG ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6OTHER .	False
We have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6OTHER through c - jun BC6ENTC - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6ENTG phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6OTHER .	False
We have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6OTHER through c - jun BC6ENTC - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6ENTG / BC6OTHER plays an important role in cell growth suppression by BC6OTHER .	False
We have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6OTHER through c - jun BC6ENTC - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6ENTG plays an important role in cell growth suppression by BC6OTHER .	False
We have previously demonstrated that phosphorylation of BC6ENTG ( BC6OTHER ) at 194 BC6OTHER through c - jun BC6OTHER - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6ENTC .	CPR:3
We have previously demonstrated that phosphorylation of BC6OTHER ( BC6ENTG ) at 194 BC6OTHER through c - jun BC6OTHER - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6ENTC .	CPR:3
We have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6OTHER through BC6ENTG ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6ENTC .	CPR:3
We have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6OTHER through c - jun BC6OTHER - terminal kinase ( BC6ENTG ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6ENTC .	CPR:3
We have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6OTHER through c - jun BC6OTHER - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6ENTG phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6ENTC .	False
We have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6OTHER through c - jun BC6OTHER - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6ENTG / BC6OTHER plays an important role in cell growth suppression by BC6ENTC .	CPR:3
We have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6OTHER through c - jun BC6OTHER - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6ENTG plays an important role in cell growth suppression by BC6ENTC .	CPR:3
In this study, the clinicopathological association of BC6ENTG ( BC6OTHER ) with BC6ENTC , BC6OTHER , c - erbB - 2 receptors, BC6OTHER expressions and BC6OTHER / BC6OTHER ( BC6OTHER / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens.	False
In this study, the clinicopathological association of BC6OTHER ( BC6ENTG ) with BC6ENTC , BC6OTHER , c - erbB - 2 receptors, BC6OTHER expressions and BC6OTHER / BC6OTHER ( BC6OTHER / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens.	False
In this study, the clinicopathological association of BC6OTHER ( BC6OTHER ) with BC6ENTC , BC6OTHER , c - erbB - 2 receptors, BC6ENTG expressions and BC6OTHER / BC6OTHER ( BC6OTHER / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens.	False
In this study, the clinicopathological association of BC6OTHER ( BC6OTHER ) with BC6ENTC , BC6OTHER , c - erbB - 2 receptors, BC6OTHER expressions and BC6ENTG / BC6OTHER ( BC6OTHER / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens.	False
In this study, the clinicopathological association of BC6OTHER ( BC6OTHER ) with BC6ENTC , BC6OTHER , c - erbB - 2 receptors, BC6OTHER expressions and BC6OTHER / BC6ENTG ( BC6OTHER / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens.	False
In this study, the clinicopathological association of BC6OTHER ( BC6OTHER ) with BC6ENTC , BC6OTHER , c - erbB - 2 receptors, BC6OTHER expressions and BC6OTHER / BC6OTHER ( BC6ENTG / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens.	False
In this study, the clinicopathological association of BC6OTHER ( BC6OTHER ) with BC6ENTC , BC6OTHER , c - erbB - 2 receptors, BC6OTHER expressions and BC6OTHER / BC6OTHER ( BC6OTHER / BC6ENTG ) was analyzed immunohistochemically using 107 human breast cancer specimens.	False
In this study, the clinicopathological association of BC6ENTG ( BC6OTHER ) with BC6OTHER , BC6ENTC , c - erbB - 2 receptors, BC6OTHER expressions and BC6OTHER / BC6OTHER ( BC6OTHER / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens.	False
In this study, the clinicopathological association of BC6OTHER ( BC6ENTG ) with BC6OTHER , BC6ENTC , c - erbB - 2 receptors, BC6OTHER expressions and BC6OTHER / BC6OTHER ( BC6OTHER / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens.	False
In this study, the clinicopathological association of BC6OTHER ( BC6OTHER ) with BC6OTHER , BC6ENTC , c - erbB - 2 receptors, BC6ENTG expressions and BC6OTHER / BC6OTHER ( BC6OTHER / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens.	False
In this study, the clinicopathological association of BC6OTHER ( BC6OTHER ) with BC6OTHER , BC6ENTC , c - erbB - 2 receptors, BC6OTHER expressions and BC6ENTG / BC6OTHER ( BC6OTHER / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens.	False
In this study, the clinicopathological association of BC6OTHER ( BC6OTHER ) with BC6OTHER , BC6ENTC , c - erbB - 2 receptors, BC6OTHER expressions and BC6OTHER / BC6ENTG ( BC6OTHER / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens.	False
In this study, the clinicopathological association of BC6OTHER ( BC6OTHER ) with BC6OTHER , BC6ENTC , c - erbB - 2 receptors, BC6OTHER expressions and BC6OTHER / BC6OTHER ( BC6ENTG / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens.	False
In this study, the clinicopathological association of BC6OTHER ( BC6OTHER ) with BC6OTHER , BC6ENTC , c - erbB - 2 receptors, BC6OTHER expressions and BC6OTHER / BC6OTHER ( BC6OTHER / BC6ENTG ) was analyzed immunohistochemically using 107 human breast cancer specimens.	False
Also, reactive astrogliosis takes part of the early responses to the insult with BC6ENTC , evidenced by upregulated BC6ENTG in Western blot, PCR and immunofluorescence analysis.	CPR:3
Six days after BC6ENTC injection we found persistent astrogliosis, increased BC6OTHER (PI) positive cells in BC6OTHER positive population evidenced by flow cytometry and reduced immunofluorescence for BC6ENTG , suggesting that the in vivo exposure to BC6OTHER progressed to neuronal death.	False
Six days after BC6ENTC injection we found persistent astrogliosis, increased BC6OTHER (PI) positive cells in BC6ENTG positive population evidenced by flow cytometry and reduced immunofluorescence for BC6OTHER , suggesting that the in vivo exposure to BC6OTHER progressed to neuronal death.	False
Six days after BC6OTHER injection we found persistent astrogliosis, increased BC6ENTC (PI) positive cells in BC6OTHER positive population evidenced by flow cytometry and reduced immunofluorescence for BC6ENTG , suggesting that the in vivo exposure to BC6OTHER progressed to neuronal death.	False
Six days after BC6OTHER injection we found persistent astrogliosis, increased BC6ENTC (PI) positive cells in BC6ENTG positive population evidenced by flow cytometry and reduced immunofluorescence for BC6OTHER , suggesting that the in vivo exposure to BC6OTHER progressed to neuronal death.	False
Six days after BC6OTHER injection we found persistent astrogliosis, increased BC6OTHER (PI) positive cells in BC6OTHER positive population evidenced by flow cytometry and reduced immunofluorescence for BC6ENTG , suggesting that the in vivo exposure to BC6ENTC progressed to neuronal death.	CPR:4
Six days after BC6OTHER injection we found persistent astrogliosis, increased BC6OTHER (PI) positive cells in BC6ENTG positive population evidenced by flow cytometry and reduced immunofluorescence for BC6OTHER , suggesting that the in vivo exposure to BC6ENTC progressed to neuronal death.	False
Neurodegeneration was related with decreased BC6ENTC uptake and decreased BC6ENTG immunoreactivity, however BC6OTHER ( BC6OTHER 9) was not altered in BC6OTHER injected rat.	False
Neurodegeneration was related with decreased BC6ENTC uptake and decreased BC6OTHER immunoreactivity, however BC6ENTG ( BC6OTHER 9) was not altered in BC6OTHER injected rat.	False
Neurodegeneration was related with decreased BC6OTHER uptake and decreased BC6ENTG immunoreactivity, however BC6OTHER ( BC6ENTC 9) was not altered in BC6OTHER injected rat.	False
Neurodegeneration was related with decreased BC6OTHER uptake and decreased BC6OTHER immunoreactivity, however BC6ENTG ( BC6ENTC 9) was not altered in BC6OTHER injected rat.	False
Neurodegeneration was related with decreased BC6OTHER uptake and decreased BC6ENTG immunoreactivity, however BC6OTHER ( BC6OTHER 9) was not altered in BC6ENTC injected rat.	CPR:4
Neurodegeneration was related with decreased BC6OTHER uptake and decreased BC6OTHER immunoreactivity, however BC6ENTG ( BC6OTHER 9) was not altered in BC6ENTC injected rat.	False
Therefore, the present results show that the earlier cerebellar responses to BC6ENTC include disruption of cytoskeletal homeostasis that could be related with BC6ENTG and BC6OTHER activation and reactive astrogliosis.	CPR:3
Therefore, the present results show that the earlier cerebellar responses to BC6ENTC include disruption of cytoskeletal homeostasis that could be related with BC6OTHER and BC6ENTG activation and reactive astrogliosis.	CPR:3
The later events of the neurodegenerative process are characterized by persistent astrogliosis and activation of apoptotic neuronal death through BC6ENTG mediated mechanisms, which could be related with BC6ENTC excitotoxicity.	False
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6ENTG - BC6OTHER - and BC6OTHER ) and neuron ( BC6OTHER : BC6OTHER , BC6OTHER and BC6OTHER ); increased BC6OTHER ( BC6OTHER ) ( BC6OTHER and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities.	False
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6ENTG - and BC6OTHER ) and neuron ( BC6OTHER : BC6OTHER , BC6OTHER and BC6OTHER ); increased BC6OTHER ( BC6OTHER ) ( BC6OTHER and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities.	False
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6OTHER - and BC6ENTG ) and neuron ( BC6OTHER : BC6OTHER , BC6OTHER and BC6OTHER ); increased BC6OTHER ( BC6OTHER ) ( BC6OTHER and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities.	False
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6OTHER - and BC6OTHER ) and neuron ( BC6ENTG : BC6OTHER , BC6OTHER and BC6OTHER ); increased BC6OTHER ( BC6OTHER ) ( BC6OTHER and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities.	False
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6OTHER - and BC6OTHER ) and neuron ( BC6OTHER : BC6ENTG , BC6OTHER and BC6OTHER ); increased BC6OTHER ( BC6OTHER ) ( BC6OTHER and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities.	False
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6OTHER - and BC6OTHER ) and neuron ( BC6OTHER : BC6OTHER , BC6ENTG and BC6OTHER ); increased BC6OTHER ( BC6OTHER ) ( BC6OTHER and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities.	False
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6OTHER - and BC6OTHER ) and neuron ( BC6OTHER : BC6OTHER , BC6OTHER and BC6ENTG ); increased BC6OTHER ( BC6OTHER ) ( BC6OTHER and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities.	False
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6OTHER - and BC6OTHER ) and neuron ( BC6OTHER : BC6OTHER , BC6OTHER and BC6OTHER ); increased BC6ENTG ( BC6OTHER ) ( BC6OTHER and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities.	False
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6OTHER - and BC6OTHER ) and neuron ( BC6OTHER : BC6OTHER , BC6OTHER and BC6OTHER ); increased BC6OTHER ( BC6ENTG ) ( BC6OTHER and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities.	False
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6OTHER - and BC6OTHER ) and neuron ( BC6OTHER : BC6OTHER , BC6OTHER and BC6OTHER ); increased BC6OTHER ( BC6OTHER ) ( BC6ENTG and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities.	False
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6OTHER - and BC6OTHER ) and neuron ( BC6OTHER : BC6OTHER , BC6OTHER and BC6OTHER ); increased BC6OTHER ( BC6OTHER ) ( BC6OTHER and BC6ENTG ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities.	False
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6OTHER - and BC6OTHER ) and neuron ( BC6OTHER : BC6OTHER , BC6OTHER and BC6OTHER ); increased BC6OTHER ( BC6OTHER ) ( BC6OTHER and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6ENTG ) activities.	False
In conclusion, these results show that BC6ENTC and BC6OTHER interact with BC6ENTG - mediated substrate transport to different extents.	False
In conclusion, these results show that BC6OTHER and BC6ENTC interact with BC6ENTG - mediated substrate transport to different extents.	False
Inhibition of BC6ENTG can explain the previously observed effects of BC6ENTC and BC6OTHER on hepatic organic anion elimination.	CPR:4
Inhibition of BC6ENTG can explain the previously observed effects of BC6OTHER and BC6ENTC on hepatic organic anion elimination.	CPR:4
Therefore, we investigated the effects of BC6ENTC and BC6OTHER on the BC6ENTG of human liver and determined whether BC6OTHER is a substrate of 1 or several of these carriers.	False
Therefore, we investigated the effects of BC6OTHER and BC6ENTC on the BC6ENTG of human liver and determined whether BC6OTHER is a substrate of 1 or several of these carriers.	False
Therefore, we investigated the effects of BC6OTHER and BC6OTHER on the BC6ENTG of human liver and determined whether BC6ENTC is a substrate of 1 or several of these carriers.	False
In complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6ENTG ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	CPR:4
In complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6ENTG ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	CPR:4
In complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6OTHER ) ( BC6ENTG ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	CPR:4
In complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6ENTG ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	CPR:4
In complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6ENTG ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	CPR:4
In complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6ENTG ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	CPR:4
In complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6ENTG ( BC6OTHER ) ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	CPR:4
In complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6ENTG ) ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	CPR:4
In complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6ENTG ), and BC6OTHER ( BC6OTHER ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	CPR:4
In complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	CPR:4
In complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), and BC6OTHER ( BC6ENTG ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	CPR:4
In complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) ( BC6ENTG ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	CPR:4
BC6ENTC (10 micromol / L) inhibited BC6ENTG - mediated BC6OTHER uptake by 50%, whereas inhibition of BC6OTHER - , BC6OTHER - , and BC6OTHER - mediated BC6OTHER transport was below 15%.	CPR:4
BC6ENTC (10 micromol / L) inhibited BC6OTHER - mediated BC6OTHER uptake by 50%, whereas inhibition of BC6ENTG - , BC6OTHER - , and BC6OTHER - mediated BC6OTHER transport was below 15%.	CPR:4
BC6ENTC (10 micromol / L) inhibited BC6OTHER - mediated BC6OTHER uptake by 50%, whereas inhibition of BC6OTHER - , BC6ENTG - , and BC6OTHER - mediated BC6OTHER transport was below 15%.	CPR:4
BC6ENTC (10 micromol / L) inhibited BC6OTHER - mediated BC6OTHER uptake by 50%, whereas inhibition of BC6OTHER - , BC6OTHER - , and BC6ENTG - mediated BC6OTHER transport was below 15%.	CPR:4
BC6OTHER (10 micromol / L) inhibited BC6ENTG - mediated BC6ENTC uptake by 50%, whereas inhibition of BC6OTHER - , BC6OTHER - , and BC6OTHER - mediated BC6OTHER transport was below 15%.	CPR:9
BC6OTHER (10 micromol / L) inhibited BC6OTHER - mediated BC6ENTC uptake by 50%, whereas inhibition of BC6ENTG - , BC6OTHER - , and BC6OTHER - mediated BC6OTHER transport was below 15%.	False
BC6OTHER (10 micromol / L) inhibited BC6OTHER - mediated BC6ENTC uptake by 50%, whereas inhibition of BC6OTHER - , BC6ENTG - , and BC6OTHER - mediated BC6OTHER transport was below 15%.	False
BC6OTHER (10 micromol / L) inhibited BC6OTHER - mediated BC6ENTC uptake by 50%, whereas inhibition of BC6OTHER - , BC6OTHER - , and BC6ENTG - mediated BC6OTHER transport was below 15%.	False
In rats, BC6ENTC and BC6OTHER were shown to interfere with hepatic organic anion uptake by inhibition of the BC6ENTG BC6OTHER and BC6OTHER .	CPR:4
In rats, BC6ENTC and BC6OTHER were shown to interfere with hepatic organic anion uptake by inhibition of the BC6OTHER BC6ENTG and BC6OTHER .	CPR:4
In rats, BC6ENTC and BC6OTHER were shown to interfere with hepatic organic anion uptake by inhibition of the BC6OTHER BC6OTHER and BC6ENTG .	CPR:4
BC6OTHER (10 micromol / L) inhibited BC6ENTG - mediated BC6OTHER uptake by 50%, whereas inhibition of BC6OTHER - , BC6OTHER - , and BC6OTHER - mediated BC6ENTC transport was below 15%.	False
BC6OTHER (10 micromol / L) inhibited BC6OTHER - mediated BC6OTHER uptake by 50%, whereas inhibition of BC6ENTG - , BC6OTHER - , and BC6OTHER - mediated BC6ENTC transport was below 15%.	CPR:9
BC6OTHER (10 micromol / L) inhibited BC6OTHER - mediated BC6OTHER uptake by 50%, whereas inhibition of BC6OTHER - , BC6ENTG - , and BC6OTHER - mediated BC6ENTC transport was below 15%.	CPR:9
BC6OTHER (10 micromol / L) inhibited BC6OTHER - mediated BC6OTHER uptake by 50%, whereas inhibition of BC6OTHER - , BC6OTHER - , and BC6ENTG - mediated BC6ENTC transport was below 15%.	CPR:9
100 micromol / L BC6ENTC inhibited BC6ENTG - and BC6OTHER - , BC6OTHER - and BC6OTHER - mediated BC6OTHER uptake by 66%, 96%, 25%, and 49%, respectively.	CPR:4
100 micromol / L BC6ENTC inhibited BC6OTHER - and BC6ENTG - , BC6OTHER - and BC6OTHER - mediated BC6OTHER uptake by 66%, 96%, 25%, and 49%, respectively.	CPR:4
100 micromol / L BC6ENTC inhibited BC6OTHER - and BC6OTHER - , BC6ENTG - and BC6OTHER - mediated BC6OTHER uptake by 66%, 96%, 25%, and 49%, respectively.	CPR:4
100 micromol / L BC6ENTC inhibited BC6OTHER - and BC6OTHER - , BC6OTHER - and BC6ENTG - mediated BC6OTHER uptake by 66%, 96%, 25%, and 49%, respectively.	CPR:4
In rats, BC6OTHER and BC6ENTC were shown to interfere with hepatic organic anion uptake by inhibition of the BC6ENTG BC6OTHER and BC6OTHER .	CPR:4
In rats, BC6OTHER and BC6ENTC were shown to interfere with hepatic organic anion uptake by inhibition of the BC6OTHER BC6ENTG and BC6OTHER .	CPR:4
In rats, BC6OTHER and BC6ENTC were shown to interfere with hepatic organic anion uptake by inhibition of the BC6OTHER BC6OTHER and BC6ENTG .	CPR:4
100 micromol / L BC6OTHER inhibited BC6ENTG - and BC6OTHER - , BC6OTHER - and BC6OTHER - mediated BC6ENTC uptake by 66%, 96%, 25%, and 49%, respectively.	CPR:9
100 micromol / L BC6OTHER inhibited BC6OTHER - and BC6ENTG - , BC6OTHER - and BC6OTHER - mediated BC6ENTC uptake by 66%, 96%, 25%, and 49%, respectively.	CPR:9
100 micromol / L BC6OTHER inhibited BC6OTHER - and BC6OTHER - , BC6ENTG - and BC6OTHER - mediated BC6ENTC uptake by 66%, 96%, 25%, and 49%, respectively.	CPR:9
100 micromol / L BC6OTHER inhibited BC6OTHER - and BC6OTHER - , BC6OTHER - and BC6ENTG - mediated BC6ENTC uptake by 66%, 96%, 25%, and 49%, respectively.	CPR:9
Direct transport of BC6ENTC could be shown for BC6ENTG (apparent K(m) value 13 micromol / L) and BC6OTHER (2.3 micromol / L).	CPR:9
Direct transport of BC6ENTC could be shown for BC6OTHER (apparent K(m) value 13 micromol / L) and BC6ENTG (2.3 micromol / L).	CPR:9
The data also showed significant decrease in the levels of serum BC6ENTC , BC6ENTG and BC6OTHER and significant increase in the level of serum BC6OTHER in BC6OTHER - intoxicated rats.	False
The data also showed significant decrease in the levels of serum BC6ENTC , BC6OTHER and BC6ENTG and significant increase in the level of serum BC6OTHER in BC6OTHER - intoxicated rats.	False
The data also showed significant decrease in the levels of serum BC6ENTC , BC6OTHER and BC6OTHER and significant increase in the level of serum BC6ENTG in BC6OTHER - intoxicated rats.	False
The data also showed significant decrease in the levels of serum BC6OTHER , BC6ENTG and BC6OTHER and significant increase in the level of serum BC6OTHER in BC6ENTC - intoxicated rats.	False
The data also showed significant decrease in the levels of serum BC6OTHER , BC6OTHER and BC6ENTG and significant increase in the level of serum BC6OTHER in BC6ENTC - intoxicated rats.	False
The data also showed significant decrease in the levels of serum BC6OTHER , BC6OTHER and BC6OTHER and significant increase in the level of serum BC6ENTG in BC6ENTC - intoxicated rats.	False
BC6OTHER ( BC6OTHER , 1) and BC6ENTC ( BC6OTHER , 2) were synthesized and evaluated for binding to the BC6ENTG BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6OTHER , respectively) using transfected cells.	False
BC6OTHER ( BC6OTHER , 1) and BC6ENTC ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6ENTG , BC6OTHER , and BC6OTHER , respectively) using transfected cells.	False
BC6OTHER ( BC6OTHER , 1) and BC6ENTC ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6ENTG , and BC6OTHER , respectively) using transfected cells.	False
BC6OTHER ( BC6OTHER , 1) and BC6ENTC ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6ENTG , respectively) using transfected cells.	False
Chase studies with BC6ENTC and BC6OTHER demonstrated that this uptake is the result of preferential binding to the BC6ENTG .	False
Chase studies with BC6OTHER and BC6ENTC demonstrated that this uptake is the result of preferential binding to the BC6ENTG .	False
Synthesis, radiosynthesis, and biological evaluation of BC6ENTC : candidate radioligands for in vivo imaging of the BC6ENTG with positron emission tomography.	False
BC6ENTC ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the BC6ENTG BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6OTHER , respectively) using transfected cells.	False
BC6ENTC ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6ENTG , BC6OTHER , and BC6OTHER , respectively) using transfected cells.	False
BC6ENTC ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6ENTG , and BC6OTHER , respectively) using transfected cells.	False
BC6ENTC ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6ENTG , respectively) using transfected cells.	False
BC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6ENTC , 2) were synthesized and evaluated for binding to the BC6ENTG BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6OTHER , respectively) using transfected cells.	False
BC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6ENTC , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6ENTG , BC6OTHER , and BC6OTHER , respectively) using transfected cells.	False
BC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6ENTC , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6ENTG , and BC6OTHER , respectively) using transfected cells.	False
BC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6ENTC , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6ENTG , respectively) using transfected cells.	False
BC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6ENTC , BC6OTHER , and BC6OTHER transporters ( BC6ENTG , BC6OTHER , and BC6OTHER , respectively) using transfected cells.	False
BC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6ENTC , BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6ENTG , and BC6OTHER , respectively) using transfected cells.	False
BC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6ENTC , BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6ENTG , respectively) using transfected cells.	False
BC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the BC6ENTG BC6ENTC , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6OTHER , respectively) using transfected cells.	False
BC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6ENTC , and BC6OTHER transporters ( BC6ENTG , BC6OTHER , and BC6OTHER , respectively) using transfected cells.	False
BC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6ENTC , and BC6OTHER transporters ( BC6OTHER , BC6ENTG , and BC6OTHER , respectively) using transfected cells.	False
BC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6ENTC , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6ENTG , respectively) using transfected cells.	False
BC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the BC6ENTG BC6OTHER , and BC6ENTC transporters ( BC6OTHER , BC6OTHER , and BC6OTHER , respectively) using transfected cells.	False
BC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6ENTC transporters ( BC6ENTG , BC6OTHER , and BC6OTHER , respectively) using transfected cells.	False
BC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6ENTC transporters ( BC6OTHER , BC6ENTG , and BC6OTHER , respectively) using transfected cells.	False
BC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6ENTC transporters ( BC6OTHER , BC6OTHER , and BC6ENTG , respectively) using transfected cells.	False
Compound 2 has a significantly higher affinity for the BC6ENTG than 1, and this may be a result of the different size and electronegativity of the BC6ENTC atoms.	False
MicroPET imaging in nonhuman primates with [ BC6ENTC ]1 and [ BC6OTHER ]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the BC6ENTG - rich brain regions and peak uptake being achieved in about 55 min postinjection.	CPR:9
BC6OTHER ( BC6ENTC , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the BC6ENTG BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6OTHER , respectively) using transfected cells.	False
BC6OTHER ( BC6ENTC , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6ENTG , BC6OTHER , and BC6OTHER , respectively) using transfected cells.	False
BC6OTHER ( BC6ENTC , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6ENTG , and BC6OTHER , respectively) using transfected cells.	False
BC6OTHER ( BC6ENTC , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6ENTG , respectively) using transfected cells.	False
MicroPET imaging in nonhuman primates with [ BC6OTHER ]1 and [ BC6ENTC ]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the BC6ENTG - rich brain regions and peak uptake being achieved in about 55 min postinjection.	CPR:9
In nonsmokers, BC6ENTG and BC6ENTC were negatively correlated with BC6OTHER and correlated with BC6OTHER ( BC6OTHER ), and BC6OTHER was negatively correlated with BC6OTHER .	False
In nonsmokers, BC6OTHER and BC6ENTC were negatively correlated with BC6ENTG and correlated with BC6OTHER ( BC6OTHER ), and BC6OTHER was negatively correlated with BC6OTHER .	False
In nonsmokers, BC6ENTG and BC6OTHER were negatively correlated with BC6OTHER and correlated with BC6ENTC ( BC6OTHER ), and BC6OTHER was negatively correlated with BC6OTHER .	False
In nonsmokers, BC6OTHER and BC6OTHER were negatively correlated with BC6ENTG and correlated with BC6ENTC ( BC6OTHER ), and BC6OTHER was negatively correlated with BC6OTHER .	False
In nonsmokers, BC6ENTG and BC6OTHER were negatively correlated with BC6OTHER and correlated with BC6OTHER ( BC6ENTC ), and BC6OTHER was negatively correlated with BC6OTHER .	False
In nonsmokers, BC6OTHER and BC6OTHER were negatively correlated with BC6ENTG and correlated with BC6OTHER ( BC6ENTC ), and BC6OTHER was negatively correlated with BC6OTHER .	False
In nonsmokers, BC6ENTG and BC6OTHER were negatively correlated with BC6OTHER and correlated with BC6OTHER ( BC6OTHER ), and BC6ENTC was negatively correlated with BC6OTHER .	False
In nonsmokers, BC6OTHER and BC6OTHER were negatively correlated with BC6ENTG and correlated with BC6OTHER ( BC6OTHER ), and BC6ENTC was negatively correlated with BC6OTHER .	False
In nonsmokers, BC6ENTG and BC6OTHER were negatively correlated with BC6OTHER and correlated with BC6OTHER ( BC6OTHER ), and BC6OTHER was negatively correlated with BC6ENTC .	False
In nonsmokers, BC6OTHER and BC6OTHER were negatively correlated with BC6ENTG and correlated with BC6OTHER ( BC6OTHER ), and BC6OTHER was negatively correlated with BC6ENTC .	False
BC6ENTG was negatively correlated with BC6ENTC in all the sprayers, but was correlated with BC6OTHER in smokers and with BC6OTHER in nonsmokers.	False
BC6OTHER was negatively correlated with BC6ENTC in all the sprayers, but was correlated with BC6ENTG in smokers and with BC6OTHER in nonsmokers.	False
BC6ENTG was negatively correlated with BC6OTHER in all the sprayers, but was correlated with BC6OTHER in smokers and with BC6ENTC in nonsmokers.	False
BC6OTHER was negatively correlated with BC6OTHER in all the sprayers, but was correlated with BC6ENTG in smokers and with BC6ENTC in nonsmokers.	False
In smokers, BC6OTHER was negatively correlated with BC6OTHER , BC6OTHER was negatively correlated with BC6ENTC and BC6OTHER and BC6ENTG were negatively correlated with BC6OTHER .	False
In smokers, BC6ENTG was negatively correlated with BC6OTHER , BC6OTHER was negatively correlated with BC6ENTC and BC6OTHER and BC6OTHER were negatively correlated with BC6OTHER .	False
In smokers, BC6OTHER was negatively correlated with BC6ENTG , BC6OTHER was negatively correlated with BC6ENTC and BC6OTHER and BC6OTHER were negatively correlated with BC6OTHER .	False
In smokers, BC6OTHER was negatively correlated with BC6OTHER , BC6ENTG was negatively correlated with BC6ENTC and BC6OTHER and BC6OTHER were negatively correlated with BC6OTHER .	False
In smokers, BC6OTHER was negatively correlated with BC6OTHER , BC6OTHER was negatively correlated with BC6OTHER and BC6ENTC and BC6ENTG were negatively correlated with BC6OTHER .	False
In smokers, BC6ENTG was negatively correlated with BC6OTHER , BC6OTHER was negatively correlated with BC6OTHER and BC6ENTC and BC6OTHER were negatively correlated with BC6OTHER .	False
In smokers, BC6OTHER was negatively correlated with BC6ENTG , BC6OTHER was negatively correlated with BC6OTHER and BC6ENTC and BC6OTHER were negatively correlated with BC6OTHER .	False
In smokers, BC6OTHER was negatively correlated with BC6OTHER , BC6ENTG was negatively correlated with BC6OTHER and BC6ENTC and BC6OTHER were negatively correlated with BC6OTHER .	False
In smokers, BC6OTHER was negatively correlated with BC6OTHER , BC6OTHER was negatively correlated with BC6OTHER and BC6OTHER and BC6ENTG were negatively correlated with BC6ENTC .	False
In smokers, BC6ENTG was negatively correlated with BC6OTHER , BC6OTHER was negatively correlated with BC6OTHER and BC6OTHER and BC6OTHER were negatively correlated with BC6ENTC .	False
In smokers, BC6OTHER was negatively correlated with BC6ENTG , BC6OTHER was negatively correlated with BC6OTHER and BC6OTHER and BC6OTHER were negatively correlated with BC6ENTC .	False
In smokers, BC6OTHER was negatively correlated with BC6OTHER , BC6ENTG was negatively correlated with BC6OTHER and BC6OTHER and BC6OTHER were negatively correlated with BC6ENTC .	False
BC6ENTC was negatively correlated with BC6ENTG , BC6OTHER and BC6OTHER .	False
BC6ENTC was negatively correlated with BC6OTHER , BC6ENTG and BC6OTHER .	False
BC6OTHER was negatively correlated with BC6ENTG , BC6OTHER and BC6ENTC .	False
BC6OTHER was negatively correlated with BC6OTHER , BC6ENTG and BC6ENTC .	False
Results revealed that BC6ENTC , BC6ENTG ( BC6OTHER ) and BC6OTHER peroxidase ( BC6OTHER ) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers.	False
Results revealed that BC6ENTC , BC6OTHER ( BC6ENTG ) and BC6OTHER peroxidase ( BC6OTHER ) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers.	False
Results revealed that BC6ENTC , BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers.	False
Results revealed that BC6ENTC , BC6OTHER ( BC6OTHER ) and BC6OTHER peroxidase ( BC6ENTG ) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers.	False
Results revealed that BC6OTHER , BC6ENTG ( BC6OTHER ) and BC6ENTC peroxidase ( BC6OTHER ) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers.	False
Results revealed that BC6OTHER , BC6OTHER ( BC6ENTG ) and BC6ENTC peroxidase ( BC6OTHER ) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers.	False
Results revealed that BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC peroxidase ( BC6ENTG ) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers.	False
BC6ENTC and BC6ENTG were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) enzyme and BC6OTHER ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure.	False
BC6ENTC and BC6OTHER were correlated with smoking index and BC6ENTG ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) enzyme and BC6OTHER ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure.	False
BC6ENTC and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6ENTG ), BC6OTHER dismutase ( BC6OTHER ) enzyme and BC6OTHER ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure.	False
BC6ENTC and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) enzyme and BC6OTHER ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure.	False
BC6ENTC and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6ENTG ) enzyme and BC6OTHER ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure.	False
BC6OTHER and BC6ENTG were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6ENTC dismutase ( BC6OTHER ) enzyme and BC6OTHER ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure.	False
BC6OTHER and BC6OTHER were correlated with smoking index and BC6ENTG ( BC6OTHER ), BC6ENTC dismutase ( BC6OTHER ) enzyme and BC6OTHER ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure.	False
BC6OTHER and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6ENTG ), BC6ENTC dismutase ( BC6OTHER ) enzyme and BC6OTHER ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure.	False
BC6OTHER and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6ENTC dismutase ( BC6ENTG ) enzyme and BC6OTHER ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure.	False
BC6OTHER and BC6ENTG were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) enzyme and BC6ENTC ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure.	False
BC6OTHER and BC6OTHER were correlated with smoking index and BC6ENTG ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) enzyme and BC6ENTC ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure.	False
BC6OTHER and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6ENTG ), BC6OTHER dismutase ( BC6OTHER ) enzyme and BC6ENTC ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure.	False
BC6OTHER and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) enzyme and BC6ENTC ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure.	False
BC6OTHER and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6ENTG ) enzyme and BC6ENTC ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure.	False
BC6OTHER and BC6ENTG were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) enzyme and BC6OTHER ( BC6ENTC ) were inversely correlated with duration of pesticides' exposure.	False
BC6OTHER and BC6OTHER were correlated with smoking index and BC6ENTG ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) enzyme and BC6OTHER ( BC6ENTC ) were inversely correlated with duration of pesticides' exposure.	False
BC6OTHER and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6ENTG ), BC6OTHER dismutase ( BC6OTHER ) enzyme and BC6OTHER ( BC6ENTC ) were inversely correlated with duration of pesticides' exposure.	False
BC6OTHER and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) enzyme and BC6OTHER ( BC6ENTC ) were inversely correlated with duration of pesticides' exposure.	False
BC6OTHER and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6ENTG ) enzyme and BC6OTHER ( BC6ENTC ) were inversely correlated with duration of pesticides' exposure.	False
Given the treatment with three doses of BC6ENTC (15 approximately 45 mg / kg) markedly attenuated inhibition of vasodilator responses to BC6OTHER , and eliminated the increased level of BC6OTHER , the decreased level of BC6OTHER , activity of BC6ENTG and BC6OTHER in serum by single intragastric gavaged BC6OTHER .	CPR:3
Given the treatment with three doses of BC6ENTC (15 approximately 45 mg / kg) markedly attenuated inhibition of vasodilator responses to BC6OTHER , and eliminated the increased level of BC6OTHER , the decreased level of BC6OTHER , activity of BC6OTHER and BC6ENTG in serum by single intragastric gavaged BC6OTHER .	CPR:3
To examine the role of BC6OTHER ( - BC6OTHER ) group in improvement of endothelial dysfunction with BC6OTHER ( BC6ENTG ) inhibitors in experimental high dose of BC6ENTC dieted rats.	False
To examine the role of BC6OTHER ( - BC6OTHER ) group in improvement of endothelial dysfunction with BC6ENTG ( BC6OTHER ) inhibitors in experimental high dose of BC6ENTC dieted rats.	False
Given the treatment with three doses of BC6OTHER (15 approximately 45 mg / kg) markedly attenuated inhibition of vasodilator responses to BC6ENTC , and eliminated the increased level of BC6OTHER , the decreased level of BC6OTHER , activity of BC6ENTG and BC6OTHER in serum by single intragastric gavaged BC6OTHER .	False
Given the treatment with three doses of BC6OTHER (15 approximately 45 mg / kg) markedly attenuated inhibition of vasodilator responses to BC6ENTC , and eliminated the increased level of BC6OTHER , the decreased level of BC6OTHER , activity of BC6OTHER and BC6ENTG in serum by single intragastric gavaged BC6OTHER .	False
Given the treatment with three doses of BC6OTHER (15 approximately 45 mg / kg) markedly attenuated inhibition of vasodilator responses to BC6OTHER , and eliminated the increased level of BC6ENTC , the decreased level of BC6OTHER , activity of BC6ENTG and BC6OTHER in serum by single intragastric gavaged BC6OTHER .	False
Given the treatment with three doses of BC6OTHER (15 approximately 45 mg / kg) markedly attenuated inhibition of vasodilator responses to BC6OTHER , and eliminated the increased level of BC6ENTC , the decreased level of BC6OTHER , activity of BC6OTHER and BC6ENTG in serum by single intragastric gavaged BC6OTHER .	False
Given the treatment with three doses of BC6OTHER (15 approximately 45 mg / kg) markedly attenuated inhibition of vasodilator responses to BC6OTHER , and eliminated the increased level of BC6OTHER , the decreased level of BC6ENTC , activity of BC6ENTG and BC6OTHER in serum by single intragastric gavaged BC6OTHER .	False
Given the treatment with three doses of BC6OTHER (15 approximately 45 mg / kg) markedly attenuated inhibition of vasodilator responses to BC6OTHER , and eliminated the increased level of BC6OTHER , the decreased level of BC6ENTC , activity of BC6OTHER and BC6ENTG in serum by single intragastric gavaged BC6OTHER .	False
Given the treatment with three doses of BC6OTHER (15 approximately 45 mg / kg) markedly attenuated inhibition of vasodilator responses to BC6OTHER , and eliminated the increased level of BC6OTHER , the decreased level of BC6OTHER , activity of BC6ENTG and BC6OTHER in serum by single intragastric gavaged BC6ENTC .	False
Given the treatment with three doses of BC6OTHER (15 approximately 45 mg / kg) markedly attenuated inhibition of vasodilator responses to BC6OTHER , and eliminated the increased level of BC6OTHER , the decreased level of BC6OTHER , activity of BC6OTHER and BC6ENTG in serum by single intragastric gavaged BC6ENTC .	False
However, there were some significant differences among BC6ENTC (30 mg / kg or 45 mg / kg), BC6OTHER (20 mg / kg), and BC6OTHER particular in the activity of BC6ENTG and BC6OTHER .	False
However, there were some significant differences among BC6ENTC (30 mg / kg or 45 mg / kg), BC6OTHER (20 mg / kg), and BC6OTHER particular in the activity of BC6OTHER and BC6ENTG .	False
However, there were some significant differences among BC6OTHER (30 mg / kg or 45 mg / kg), BC6ENTC (20 mg / kg), and BC6OTHER particular in the activity of BC6ENTG and BC6OTHER .	False
However, there were some significant differences among BC6OTHER (30 mg / kg or 45 mg / kg), BC6ENTC (20 mg / kg), and BC6OTHER particular in the activity of BC6OTHER and BC6ENTG .	False
However, there were some significant differences among BC6OTHER (30 mg / kg or 45 mg / kg), BC6OTHER (20 mg / kg), and BC6ENTC particular in the activity of BC6ENTG and BC6OTHER .	False
However, there were some significant differences among BC6OTHER (30 mg / kg or 45 mg / kg), BC6OTHER (20 mg / kg), and BC6ENTC particular in the activity of BC6OTHER and BC6ENTG .	False
These results suggested that BC6ENTC can protect the vascular endothelium against the damages induced by BC6OTHER in rats, and the beneficial effects of BC6OTHER may be related to attenuating the decrease in BC6ENTG activity and BC6OTHER levels.	False
BC6ENTG ( BC6OTHER ) and BC6OTHER activity, BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed.	False
BC6OTHER ( BC6ENTG ) and BC6OTHER activity, BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed.	False
BC6OTHER ( BC6OTHER ) and BC6ENTG activity, BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed.	False
BC6OTHER ( BC6OTHER ) and BC6OTHER activity, BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) in serum were analyzed.	False
BC6OTHER ( BC6OTHER ) and BC6OTHER activity, BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6ENTG ) in serum were analyzed.	False
These results suggested that BC6OTHER can protect the vascular endothelium against the damages induced by BC6ENTC in rats, and the beneficial effects of BC6OTHER may be related to attenuating the decrease in BC6ENTG activity and BC6OTHER levels.	CPR:4
These results suggested that BC6OTHER can protect the vascular endothelium against the damages induced by BC6OTHER in rats, and the beneficial effects of BC6ENTC may be related to attenuating the decrease in BC6ENTG activity and BC6OTHER levels.	CPR:3
We compared the effects of BC6ENTC (an BC6ENTG inhibitor with - BC6OTHER group), BC6OTHER (an BC6OTHER - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats.	CPR:4
We compared the effects of BC6ENTC (an BC6OTHER inhibitor with - BC6OTHER group), BC6OTHER (an BC6ENTG - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats.	False
We compared the effects of BC6ENTC (an BC6OTHER inhibitor with - BC6OTHER group), BC6OTHER (an BC6OTHER - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6ENTG inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats.	False
These results suggested that BC6OTHER can protect the vascular endothelium against the damages induced by BC6OTHER in rats, and the beneficial effects of BC6OTHER may be related to attenuating the decrease in BC6ENTG activity and BC6ENTC levels.	False
To examine the role of BC6ENTC ( - BC6OTHER ) group in improvement of endothelial dysfunction with BC6OTHER ( BC6ENTG ) inhibitors in experimental high dose of BC6OTHER dieted rats.	False
To examine the role of BC6ENTC ( - BC6OTHER ) group in improvement of endothelial dysfunction with BC6ENTG ( BC6OTHER ) inhibitors in experimental high dose of BC6OTHER dieted rats.	False
We compared the effects of BC6OTHER (an BC6ENTG inhibitor with - BC6ENTC group), BC6OTHER (an BC6OTHER - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats.	CPR:4
We compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6ENTC group), BC6OTHER (an BC6ENTG - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats.	False
We compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6ENTC group), BC6OTHER (an BC6OTHER - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6ENTG inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats.	False
We compared the effects of BC6OTHER (an BC6ENTG inhibitor with - BC6OTHER group), BC6ENTC (an BC6OTHER - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats.	False
We compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6OTHER group), BC6ENTC (an BC6ENTG - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats.	CPR:4
We compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6OTHER group), BC6ENTC (an BC6OTHER - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6ENTG inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats.	False
We compared the effects of BC6OTHER (an BC6ENTG inhibitor with - BC6OTHER group), BC6OTHER (an BC6OTHER - inhibitor without - BC6ENTC group), BC6OTHER (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats.	False
We compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6OTHER group), BC6OTHER (an BC6ENTG - inhibitor without - BC6ENTC group), BC6OTHER (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats.	False
We compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6OTHER group), BC6OTHER (an BC6OTHER - inhibitor without - BC6ENTC group), BC6OTHER (only - BC6OTHER group not BC6ENTG inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats.	False
We compared the effects of BC6OTHER (an BC6ENTG inhibitor with - BC6OTHER group), BC6OTHER (an BC6OTHER - inhibitor without - BC6OTHER group), BC6ENTC (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats.	False
We compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6OTHER group), BC6OTHER (an BC6ENTG - inhibitor without - BC6OTHER group), BC6ENTC (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats.	False
We compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6OTHER group), BC6OTHER (an BC6OTHER - inhibitor without - BC6OTHER group), BC6ENTC (only - BC6OTHER group not BC6ENTG inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats.	False
BC6ENTG ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed.	False
BC6OTHER ( BC6ENTG ) and BC6OTHER activity, BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed.	False
BC6OTHER ( BC6OTHER ) and BC6ENTG activity, BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed.	False
BC6OTHER ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) in serum were analyzed.	False
BC6OTHER ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6ENTG ) in serum were analyzed.	False
We compared the effects of BC6OTHER (an BC6ENTG inhibitor with - BC6OTHER group), BC6OTHER (an BC6OTHER - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6ENTC group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats.	False
We compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6OTHER group), BC6OTHER (an BC6ENTG - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6ENTC group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats.	False
We compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6OTHER group), BC6OTHER (an BC6OTHER - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6ENTC group not BC6ENTG inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats.	False
To examine the role of BC6OTHER ( - BC6ENTC ) group in improvement of endothelial dysfunction with BC6OTHER ( BC6ENTG ) inhibitors in experimental high dose of BC6OTHER dieted rats.	False
To examine the role of BC6OTHER ( - BC6ENTC ) group in improvement of endothelial dysfunction with BC6ENTG ( BC6OTHER ) inhibitors in experimental high dose of BC6OTHER dieted rats.	False
We compared the effects of BC6OTHER (an BC6ENTG inhibitor with - BC6OTHER group), BC6OTHER (an BC6OTHER - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6ENTC - induced hyperhomocysteinemia (HHcy) in rats.	False
We compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6OTHER group), BC6OTHER (an BC6ENTG - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6ENTC - induced hyperhomocysteinemia (HHcy) in rats.	False
We compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6OTHER group), BC6OTHER (an BC6OTHER - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6ENTG inhibitor) on endothelial dysfunction injured by BC6ENTC - induced hyperhomocysteinemia (HHcy) in rats.	False
BC6ENTG ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed.	False
BC6OTHER ( BC6ENTG ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed.	False
BC6OTHER ( BC6OTHER ) and BC6ENTG activity, BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed.	False
BC6OTHER ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), BC6ENTG ( BC6OTHER ) in serum were analyzed.	False
BC6OTHER ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), BC6OTHER dismutase ( BC6ENTG ) in serum were analyzed.	False
To examine the role of BC6OTHER ( - BC6OTHER ) group in improvement of endothelial dysfunction with BC6ENTC - converting enzyme ( BC6ENTG ) inhibitors in experimental high dose of BC6OTHER dieted rats.	False
Comparison of BC6ENTC and BC6OTHER to study the role of the BC6OTHER - group in improvement of endothelial dysfunction with BC6ENTG inhibitors in high dieted BC6OTHER mice.	CPR:4
Comparison of BC6OTHER and BC6OTHER to study the role of the BC6OTHER - group in improvement of endothelial dysfunction with BC6ENTG inhibitors in high dieted BC6ENTC mice.	False
Comparison of BC6OTHER and BC6ENTC to study the role of the BC6OTHER - group in improvement of endothelial dysfunction with BC6ENTG inhibitors in high dieted BC6OTHER mice.	CPR:4
Comparison of BC6OTHER and BC6OTHER to study the role of the BC6ENTC - group in improvement of endothelial dysfunction with BC6ENTG inhibitors in high dieted BC6OTHER mice.	CPR:4
BC6ENTG ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed.	False
BC6OTHER ( BC6ENTG ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed.	False
BC6OTHER ( BC6OTHER ) and BC6ENTG activity, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed.	False
BC6OTHER ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), BC6ENTG ( BC6OTHER ) in serum were analyzed.	False
BC6OTHER ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), BC6OTHER dismutase ( BC6ENTG ) in serum were analyzed.	False
BC6ENTG ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC dismutase ( BC6OTHER ) in serum were analyzed.	False
BC6OTHER ( BC6ENTG ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC dismutase ( BC6OTHER ) in serum were analyzed.	False
BC6OTHER ( BC6OTHER ) and BC6ENTG activity, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC dismutase ( BC6OTHER ) in serum were analyzed.	False
BC6OTHER ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC dismutase ( BC6ENTG ) in serum were analyzed.	False
It was found that a single intragastric gavage by BC6ENTC resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6OTHER and decreased the activity of BC6ENTG and BC6OTHER , similarly decreased the level of BC6OTHER in the serum; but had no effects on endothelium - independent relaxation and BC6OTHER - converting enzyme activity compared with the control group.	CPR:4
It was found that a single intragastric gavage by BC6ENTC resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6OTHER and decreased the activity of BC6OTHER and BC6ENTG , similarly decreased the level of BC6OTHER in the serum; but had no effects on endothelium - independent relaxation and BC6OTHER - converting enzyme activity compared with the control group.	CPR:4
It was found that a single intragastric gavage by BC6ENTC resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6OTHER and decreased the activity of BC6OTHER and BC6OTHER , similarly decreased the level of BC6OTHER in the serum; but had no effects on endothelium - independent relaxation and BC6ENTG activity compared with the control group.	False
It was found that a single intragastric gavage by BC6OTHER resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6ENTC and decreased the activity of BC6ENTG and BC6OTHER , similarly decreased the level of BC6OTHER in the serum; but had no effects on endothelium - independent relaxation and BC6OTHER - converting enzyme activity compared with the control group.	False
It was found that a single intragastric gavage by BC6OTHER resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6ENTC and decreased the activity of BC6OTHER and BC6ENTG , similarly decreased the level of BC6OTHER in the serum; but had no effects on endothelium - independent relaxation and BC6OTHER - converting enzyme activity compared with the control group.	False
It was found that a single intragastric gavage by BC6OTHER resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6ENTC and decreased the activity of BC6OTHER and BC6OTHER , similarly decreased the level of BC6OTHER in the serum; but had no effects on endothelium - independent relaxation and BC6ENTG activity compared with the control group.	False
It was found that a single intragastric gavage by BC6OTHER resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6OTHER and decreased the activity of BC6ENTG and BC6OTHER , similarly decreased the level of BC6ENTC in the serum; but had no effects on endothelium - independent relaxation and BC6OTHER - converting enzyme activity compared with the control group.	False
It was found that a single intragastric gavage by BC6OTHER resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6OTHER and decreased the activity of BC6OTHER and BC6ENTG , similarly decreased the level of BC6ENTC in the serum; but had no effects on endothelium - independent relaxation and BC6OTHER - converting enzyme activity compared with the control group.	False
It was found that a single intragastric gavage by BC6OTHER resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6OTHER and decreased the activity of BC6OTHER and BC6OTHER , similarly decreased the level of BC6ENTC in the serum; but had no effects on endothelium - independent relaxation and BC6ENTG activity compared with the control group.	False
It was found that a single intragastric gavage by BC6OTHER resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6OTHER and decreased the activity of BC6ENTG and BC6OTHER , similarly decreased the level of BC6OTHER in the serum; but had no effects on endothelium - independent relaxation and BC6ENTC - converting enzyme activity compared with the control group.	False
It was found that a single intragastric gavage by BC6OTHER resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6OTHER and decreased the activity of BC6OTHER and BC6ENTG , similarly decreased the level of BC6OTHER in the serum; but had no effects on endothelium - independent relaxation and BC6ENTC - converting enzyme activity compared with the control group.	False
Here, we explored the role of inducible BC6ENTC synthase ( BC6ENTG ) in the BC6OTHER - nitrosation of proteins involved in the early steps of the BC6OTHER - signaling pathway and BC6OTHER resistance in the skeletal muscle of aged mice.	False
Here, we explored the role of inducible BC6ENTC synthase ( BC6OTHER ) in the BC6OTHER - nitrosation of proteins involved in the early steps of the BC6ENTG - signaling pathway and BC6OTHER resistance in the skeletal muscle of aged mice.	False
Here, we explored the role of inducible BC6ENTC synthase ( BC6OTHER ) in the BC6OTHER - nitrosation of proteins involved in the early steps of the BC6OTHER - signaling pathway and BC6ENTG resistance in the skeletal muscle of aged mice.	False
Here, we explored the role of BC6ENTG ( BC6OTHER ) in the BC6ENTC - nitrosation of proteins involved in the early steps of the BC6OTHER - signaling pathway and BC6OTHER resistance in the skeletal muscle of aged mice.	False
Here, we explored the role of inducible BC6OTHER synthase ( BC6ENTG ) in the BC6ENTC - nitrosation of proteins involved in the early steps of the BC6OTHER - signaling pathway and BC6OTHER resistance in the skeletal muscle of aged mice.	False
Here, we explored the role of inducible BC6OTHER synthase ( BC6OTHER ) in the BC6ENTC - nitrosation of proteins involved in the early steps of the BC6ENTG - signaling pathway and BC6OTHER resistance in the skeletal muscle of aged mice.	False
Here, we explored the role of inducible BC6OTHER synthase ( BC6OTHER ) in the BC6ENTC - nitrosation of proteins involved in the early steps of the BC6OTHER - signaling pathway and BC6ENTG resistance in the skeletal muscle of aged mice.	False
Aging increased BC6ENTG expression and BC6ENTC - nitrosation of major proteins involved in BC6OTHER signaling, thereby reducing BC6OTHER sensitivity in skeletal muscle.	False
Aging increased BC6OTHER expression and BC6ENTC - nitrosation of major proteins involved in BC6ENTG signaling, thereby reducing BC6OTHER sensitivity in skeletal muscle.	False
Aging increased BC6OTHER expression and BC6ENTC - nitrosation of major proteins involved in BC6OTHER signaling, thereby reducing BC6ENTG sensitivity in skeletal muscle.	False
Conversely, aged BC6ENTG - null mice were protected from BC6ENTC - nitrosation - induced BC6OTHER resistance.	False
Conversely, aged BC6OTHER - null mice were protected from BC6ENTC - nitrosation - induced BC6ENTG resistance.	False
Moreover, pharmacological treatment with an BC6ENTG inhibitor and acute exercise reduced BC6OTHER - induced BC6ENTC - nitrosation and increased BC6OTHER sensitivity in the muscle of aged animals.	False
Moreover, pharmacological treatment with an BC6OTHER inhibitor and acute exercise reduced BC6ENTG - induced BC6ENTC - nitrosation and increased BC6OTHER sensitivity in the muscle of aged animals.	False
Moreover, pharmacological treatment with an BC6OTHER inhibitor and acute exercise reduced BC6OTHER - induced BC6ENTC - nitrosation and increased BC6ENTG sensitivity in the muscle of aged animals.	False
These findings indicate that the BC6ENTG resistance observed in aged mice is mainly mediated through the BC6ENTC - nitrosation of the BC6OTHER - signaling pathway.	False
These findings indicate that the BC6OTHER resistance observed in aged mice is mainly mediated through the BC6ENTC - nitrosation of the BC6ENTG - signaling pathway.	False
Targeted disruption of inducible BC6ENTC synthase protects against aging, BC6OTHER - nitrosation, and BC6ENTG resistance in muscle of male mice.	False
Targeted disruption of BC6ENTG protects against aging, BC6ENTC - nitrosation, and BC6OTHER resistance in muscle of male mice.	False
Targeted disruption of inducible BC6OTHER synthase protects against aging, BC6ENTC - nitrosation, and BC6ENTG resistance in muscle of male mice.	False
The purpose of this review is to summarize current knowledge about BC6ENTC - dependent activation by BC6OTHER of genes involved in reverse BC6OTHER transport, and what these defects of cell BC6OTHER homeostasis can teach us about the critical pathways of BC6OTHER generation for expression of BC6ENTG - dependent genes.	False
The purpose of this review is to summarize current knowledge about BC6ENTC - dependent activation by BC6ENTG of genes involved in reverse BC6OTHER transport, and what these defects of cell BC6OTHER homeostasis can teach us about the critical pathways of BC6OTHER generation for expression of BC6OTHER - dependent genes.	CPR:3
The purpose of this review is to summarize current knowledge about BC6OTHER - dependent activation by BC6OTHER of genes involved in reverse BC6ENTC transport, and what these defects of cell BC6OTHER homeostasis can teach us about the critical pathways of BC6OTHER generation for expression of BC6ENTG - dependent genes.	False
The purpose of this review is to summarize current knowledge about BC6OTHER - dependent activation by BC6ENTG of genes involved in reverse BC6ENTC transport, and what these defects of cell BC6OTHER homeostasis can teach us about the critical pathways of BC6OTHER generation for expression of BC6OTHER - dependent genes.	False
The purpose of this review is to summarize current knowledge about BC6OTHER - dependent activation by BC6OTHER of genes involved in reverse BC6OTHER transport, and what these defects of cell BC6ENTC homeostasis can teach us about the critical pathways of BC6OTHER generation for expression of BC6ENTG - dependent genes.	False
The purpose of this review is to summarize current knowledge about BC6OTHER - dependent activation by BC6ENTG of genes involved in reverse BC6OTHER transport, and what these defects of cell BC6ENTC homeostasis can teach us about the critical pathways of BC6OTHER generation for expression of BC6OTHER - dependent genes.	False
The purpose of this review is to summarize current knowledge about BC6OTHER - dependent activation by BC6OTHER of genes involved in reverse BC6OTHER transport, and what these defects of cell BC6OTHER homeostasis can teach us about the critical pathways of BC6ENTC generation for expression of BC6ENTG - dependent genes.	False
The purpose of this review is to summarize current knowledge about BC6OTHER - dependent activation by BC6ENTG of genes involved in reverse BC6OTHER transport, and what these defects of cell BC6OTHER homeostasis can teach us about the critical pathways of BC6ENTC generation for expression of BC6OTHER - dependent genes.	False
 BC6ENTC generation and BC6ENTG - dependent reverse BC6OTHER transport: not all roads lead to Rome.	False
 BC6OTHER generation and BC6ENTG - dependent reverse BC6ENTC transport: not all roads lead to Rome.	False
Cell BC6OTHER metabolism is a tightly regulated process, dependent in part on activation of BC6OTHER ( BC6ENTG ) to increase expression of genes mediating removal of excess BC6ENTC from cells in the reverse BC6OTHER transport pathway.	False
Cell BC6OTHER metabolism is a tightly regulated process, dependent in part on activation of BC6ENTG ( BC6OTHER ) to increase expression of genes mediating removal of excess BC6ENTC from cells in the reverse BC6OTHER transport pathway.	False
Cell BC6OTHER metabolism is a tightly regulated process, dependent in part on activation of BC6OTHER ( BC6ENTG ) to increase expression of genes mediating removal of excess BC6OTHER from cells in the reverse BC6ENTC transport pathway.	False
Cell BC6OTHER metabolism is a tightly regulated process, dependent in part on activation of BC6ENTG ( BC6OTHER ) to increase expression of genes mediating removal of excess BC6OTHER from cells in the reverse BC6ENTC transport pathway.	False
BC6ENTG are thought to be activated predominantly by BC6ENTC generated enzymatically from BC6OTHER in different cell organelles.	CPR:3
BC6ENTG are thought to be activated predominantly by BC6OTHER generated enzymatically from BC6ENTC in different cell organelles.	False
Defects resulting in slowed release of BC6ENTC from late endosomes and lysosomes or reduction in BC6ENTG activity lead to specific blocks in BC6OTHER production and impaired BC6OTHER - dependent gene activation.	False
Defects resulting in slowed release of BC6ENTC from late endosomes and lysosomes or reduction in BC6OTHER - 27 - hydroxylase activity lead to specific blocks in BC6OTHER production and impaired BC6ENTG - dependent gene activation.	False
Defects resulting in slowed release of BC6OTHER from late endosomes and lysosomes or reduction in BC6ENTC - 27 - hydroxylase activity lead to specific blocks in BC6OTHER production and impaired BC6ENTG - dependent gene activation.	False
Cell BC6ENTC metabolism is a tightly regulated process, dependent in part on activation of BC6OTHER ( BC6ENTG ) to increase expression of genes mediating removal of excess BC6OTHER from cells in the reverse BC6OTHER transport pathway.	False
Cell BC6ENTC metabolism is a tightly regulated process, dependent in part on activation of BC6ENTG ( BC6OTHER ) to increase expression of genes mediating removal of excess BC6OTHER from cells in the reverse BC6OTHER transport pathway.	False
Defects resulting in slowed release of BC6OTHER from late endosomes and lysosomes or reduction in BC6ENTG activity lead to specific blocks in BC6ENTC production and impaired BC6OTHER - dependent gene activation.	CPR:9
Defects resulting in slowed release of BC6OTHER from late endosomes and lysosomes or reduction in BC6OTHER - 27 - hydroxylase activity lead to specific blocks in BC6ENTC production and impaired BC6ENTG - dependent gene activation.	False
A series of substituted BC6ENTC were synthesized and evaluated for their ability to inhibit hypoxia - induced BC6ENTG transcriptional activity using a cell - based reporter assay in HeLa cells expressing the BC6OTHER - dependent firefly luciferase reporter construct ( BC6OTHER - Luc) and constitutively expressing CMV - driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the BC6OTHER assay.	False
A series of substituted BC6ENTC were synthesized and evaluated for their ability to inhibit hypoxia - induced BC6OTHER transcriptional activity using a cell - based reporter assay in HeLa cells expressing the BC6ENTG - dependent firefly luciferase reporter construct ( BC6OTHER - Luc) and constitutively expressing CMV - driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the BC6OTHER assay.	False
A series of substituted BC6ENTC were synthesized and evaluated for their ability to inhibit hypoxia - induced BC6OTHER transcriptional activity using a cell - based reporter assay in HeLa cells expressing the BC6OTHER - dependent firefly luciferase reporter construct ( BC6ENTG - Luc) and constitutively expressing CMV - driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the BC6OTHER assay.	False
A series of substituted BC6OTHER were synthesized and evaluated for their ability to inhibit hypoxia - induced BC6ENTG transcriptional activity using a cell - based reporter assay in HeLa cells expressing the BC6OTHER - dependent firefly luciferase reporter construct ( BC6OTHER - Luc) and constitutively expressing CMV - driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the BC6ENTC assay.	False
A series of substituted BC6OTHER were synthesized and evaluated for their ability to inhibit hypoxia - induced BC6OTHER transcriptional activity using a cell - based reporter assay in HeLa cells expressing the BC6ENTG - dependent firefly luciferase reporter construct ( BC6OTHER - Luc) and constitutively expressing CMV - driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the BC6ENTC assay.	False
A series of substituted BC6OTHER were synthesized and evaluated for their ability to inhibit hypoxia - induced BC6OTHER transcriptional activity using a cell - based reporter assay in HeLa cells expressing the BC6OTHER - dependent firefly luciferase reporter construct ( BC6ENTG - Luc) and constitutively expressing CMV - driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the BC6ENTC assay.	False
The porcine heart BC6ENTC dehydrogenase ( BC6ENTG ) refolding assay revealed that compound 1l inhibited BC6OTHER chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of BC6OTHER (IC(50): 10.9 ± 0.63 μM).	False
The porcine heart BC6ENTC dehydrogenase ( BC6OTHER ) refolding assay revealed that compound 1l inhibited BC6ENTG chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of BC6OTHER (IC(50): 10.9 ± 0.63 μM).	False
The BC6ENTG ( BC6OTHER ) refolding assay revealed that compound 1l inhibited BC6OTHER chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of BC6ENTC (IC(50): 10.9 ± 0.63 μM).	False
The porcine heart BC6OTHER dehydrogenase ( BC6ENTG ) refolding assay revealed that compound 1l inhibited BC6OTHER chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of BC6ENTC (IC(50): 10.9 ± 0.63 μM).	False
The porcine heart BC6OTHER dehydrogenase ( BC6OTHER ) refolding assay revealed that compound 1l inhibited BC6ENTG chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of BC6ENTC (IC(50): 10.9 ± 0.63 μM).	CPR:4
Development of BC6OTHER inhibitors: effect of BC6ENTC substituents on BC6ENTG transcriptional activity under hypoxia.	False
Development of BC6ENTG inhibitors: effect of BC6ENTC substituents on BC6OTHER transcriptional activity under hypoxia.	False
These BC6ENTC , but not CHEM, showed a certain level of inhibition of human - cDNA - expressed BC6ENTG .	CPR:4
In a comparison of GLT and grapefruit juice, GLT showed weaker inhibition of BC6ENTG activities and of BC6ENTC 1' - hydroxylation than grapefruit juice.	False
Therefore, we studied whether GLT had potential for inhibition or induction of BC6ENTG ( BC6OTHER ) and an influence on the action of BC6ENTC .	False
Therefore, we studied whether GLT had potential for inhibition or induction of BC6OTHER ( BC6ENTG ) and an influence on the action of BC6ENTC .	False
The recent identification of BC6ENTC permeability of the lysosomal BC6ENTG BC6OTHER ( BC6OTHER ), and the evidence of abnormal BC6OTHER levels in cells deficient in BC6OTHER , suggested a role for BC6OTHER in BC6OTHER transport.	False
The recent identification of BC6ENTC permeability of the lysosomal BC6OTHER BC6ENTG ( BC6OTHER ), and the evidence of abnormal BC6OTHER levels in cells deficient in BC6OTHER , suggested a role for BC6OTHER in BC6OTHER transport.	CPR:9
The recent identification of BC6ENTC permeability of the lysosomal BC6OTHER BC6OTHER ( BC6ENTG ), and the evidence of abnormal BC6OTHER levels in cells deficient in BC6OTHER , suggested a role for BC6OTHER in BC6OTHER transport.	CPR:9
The recent identification of BC6ENTC permeability of the lysosomal BC6OTHER BC6OTHER ( BC6OTHER ), and the evidence of abnormal BC6OTHER levels in cells deficient in BC6ENTG , suggested a role for BC6OTHER in BC6OTHER transport.	False
The recent identification of BC6ENTC permeability of the lysosomal BC6OTHER BC6OTHER ( BC6OTHER ), and the evidence of abnormal BC6OTHER levels in cells deficient in BC6OTHER , suggested a role for BC6ENTG in BC6OTHER transport.	False
The recent identification of BC6OTHER permeability of the lysosomal BC6ENTG BC6OTHER ( BC6OTHER ), and the evidence of abnormal BC6ENTC levels in cells deficient in BC6OTHER , suggested a role for BC6OTHER in BC6OTHER transport.	False
The recent identification of BC6OTHER permeability of the lysosomal BC6OTHER BC6ENTG ( BC6OTHER ), and the evidence of abnormal BC6ENTC levels in cells deficient in BC6OTHER , suggested a role for BC6OTHER in BC6OTHER transport.	False
The recent identification of BC6OTHER permeability of the lysosomal BC6OTHER BC6OTHER ( BC6ENTG ), and the evidence of abnormal BC6ENTC levels in cells deficient in BC6OTHER , suggested a role for BC6OTHER in BC6OTHER transport.	False
The recent identification of BC6OTHER permeability of the lysosomal BC6OTHER BC6OTHER ( BC6OTHER ), and the evidence of abnormal BC6ENTC levels in cells deficient in BC6ENTG , suggested a role for BC6OTHER in BC6OTHER transport.	False
The recent identification of BC6OTHER permeability of the lysosomal BC6OTHER BC6OTHER ( BC6OTHER ), and the evidence of abnormal BC6ENTC levels in cells deficient in BC6OTHER , suggested a role for BC6ENTG in BC6OTHER transport.	False
The recent identification of BC6OTHER permeability of the lysosomal BC6ENTG BC6OTHER ( BC6OTHER ), and the evidence of abnormal BC6OTHER levels in cells deficient in BC6OTHER , suggested a role for BC6OTHER in BC6ENTC transport.	False
The recent identification of BC6OTHER permeability of the lysosomal BC6OTHER BC6ENTG ( BC6OTHER ), and the evidence of abnormal BC6OTHER levels in cells deficient in BC6OTHER , suggested a role for BC6OTHER in BC6ENTC transport.	False
The recent identification of BC6OTHER permeability of the lysosomal BC6OTHER BC6OTHER ( BC6ENTG ), and the evidence of abnormal BC6OTHER levels in cells deficient in BC6OTHER , suggested a role for BC6OTHER in BC6ENTC transport.	False
The recent identification of BC6OTHER permeability of the lysosomal BC6OTHER BC6OTHER ( BC6OTHER ), and the evidence of abnormal BC6OTHER levels in cells deficient in BC6ENTG , suggested a role for BC6OTHER in BC6ENTC transport.	False
The recent identification of BC6OTHER permeability of the lysosomal BC6OTHER BC6OTHER ( BC6OTHER ), and the evidence of abnormal BC6OTHER levels in cells deficient in BC6OTHER , suggested a role for BC6ENTG in BC6ENTC transport.	CPR:9
In agreement with the previously published data, an acute siRNA (small interfering RNA) - driven BC6ENTG KD (knockdown) leads to the build - up of large cytoplasmic vesicles positive for LysoTracker™ and BC6ENTC staining, when cells are exposed to high concentrations of BC6OTHER .	False
In agreement with the previously published data, an acute siRNA (small interfering RNA) - driven BC6ENTG KD (knockdown) leads to the build - up of large cytoplasmic vesicles positive for LysoTracker™ and BC6OTHER staining, when cells are exposed to high concentrations of BC6ENTC .	False
We now show that lysosomal enlargement and BC6ENTC build - up in BC6OTHER - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6OTHER BC6OTHER ( BC6ENTG ) or the BC6OTHER transporter CHEM.	False
We now show that lysosomal enlargement and BC6ENTC build - up in BC6OTHER - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6OTHER BC6OTHER ( BC6OTHER ) or the BC6ENTG .	False
We now show that lysosomal enlargement and BC6ENTC build - up in BC6ENTG - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6OTHER BC6OTHER ( BC6OTHER ) or the BC6OTHER transporter CHEM.	False
We now show that lysosomal enlargement and BC6ENTC build - up in BC6OTHER - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6ENTG BC6OTHER ( BC6OTHER ) or the BC6OTHER transporter CHEM.	False
We now show that lysosomal enlargement and BC6ENTC build - up in BC6OTHER - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6OTHER BC6ENTG ( BC6OTHER ) or the BC6OTHER transporter CHEM.	False
We now show that lysosomal enlargement and BC6OTHER build - up in BC6OTHER - KD cells exposed to BC6ENTC are ameliorated by KD of the BC6OTHER BC6OTHER ( BC6ENTG ) or the BC6OTHER transporter CHEM.	False
We now show that lysosomal enlargement and BC6OTHER build - up in BC6OTHER - KD cells exposed to BC6ENTC are ameliorated by KD of the BC6OTHER BC6OTHER ( BC6OTHER ) or the BC6ENTG .	False
We now show that lysosomal enlargement and BC6OTHER build - up in BC6ENTG - KD cells exposed to BC6ENTC are ameliorated by KD of the BC6OTHER BC6OTHER ( BC6OTHER ) or the BC6OTHER transporter CHEM.	False
We now show that lysosomal enlargement and BC6OTHER build - up in BC6OTHER - KD cells exposed to BC6ENTC are ameliorated by KD of the BC6ENTG BC6OTHER ( BC6OTHER ) or the BC6OTHER transporter CHEM.	False
We now show that lysosomal enlargement and BC6OTHER build - up in BC6OTHER - KD cells exposed to BC6ENTC are ameliorated by KD of the BC6OTHER BC6ENTG ( BC6OTHER ) or the BC6OTHER transporter CHEM.	False
We now show that lysosomal enlargement and BC6OTHER build - up in BC6OTHER - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6ENTC - sensitive transcription factor BC6OTHER ( BC6ENTG ) or the BC6OTHER transporter CHEM.	False
We now show that lysosomal enlargement and BC6OTHER build - up in BC6OTHER - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6ENTC - sensitive transcription factor BC6OTHER ( BC6OTHER ) or the BC6ENTG .	False
We now show that lysosomal enlargement and BC6OTHER build - up in BC6ENTG - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6ENTC - sensitive transcription factor BC6OTHER ( BC6OTHER ) or the BC6OTHER transporter CHEM.	False
We now show that lysosomal enlargement and BC6OTHER build - up in BC6OTHER - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6ENTC - sensitive transcription factor BC6ENTG ( BC6OTHER ) or the BC6OTHER transporter CHEM.	False
 BC6ENTC - dependent lysosomal enlargement in BC6OTHER - deficient cells involves BC6OTHER transcription factor and BC6ENTG ( BC6OTHER ) transporter.	False
 BC6ENTC - dependent lysosomal enlargement in BC6OTHER - deficient cells involves BC6OTHER transcription factor and BC6OTHER ( BC6ENTG ) transporter.	False
 BC6ENTC - dependent lysosomal enlargement in BC6ENTG - deficient cells involves BC6OTHER transcription factor and BC6OTHER ( BC6OTHER ) transporter.	False
 BC6ENTC - dependent lysosomal enlargement in BC6OTHER - deficient cells involves BC6ENTG transcription factor and BC6OTHER ( BC6OTHER ) transporter.	False
We now show that lysosomal enlargement and BC6OTHER build - up in BC6OTHER - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6OTHER BC6OTHER ( BC6ENTG ) or the BC6ENTC transporter CHEM.	False
We now show that lysosomal enlargement and BC6OTHER build - up in BC6ENTG - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6OTHER BC6OTHER ( BC6OTHER ) or the BC6ENTC transporter CHEM.	False
We now show that lysosomal enlargement and BC6OTHER build - up in BC6OTHER - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6ENTG BC6OTHER ( BC6OTHER ) or the BC6ENTC transporter CHEM.	False
We now show that lysosomal enlargement and BC6OTHER build - up in BC6OTHER - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6OTHER BC6ENTG ( BC6OTHER ) or the BC6ENTC transporter CHEM.	False
BC6ENTG KD is associated with a build - up of cytoplasmic BC6ENTC and with enhanced transcriptional response of mRNA for BC6OTHER ( BC6OTHER ).	False
BC6OTHER KD is associated with a build - up of cytoplasmic BC6ENTC and with enhanced transcriptional response of mRNA for BC6ENTG ( BC6OTHER ).	False
BC6OTHER KD is associated with a build - up of cytoplasmic BC6ENTC and with enhanced transcriptional response of mRNA for BC6OTHER ( BC6ENTG ).	False
Cellular BC6ENTC is controlled by BC6ENTG and by BC6OTHER transporters.	CPR:9
Cellular BC6ENTC is controlled by BC6OTHER - chelating proteins and by BC6ENTG .	CPR:9
BC6ENTG KD did not suppress lysosomal secretion, but it did delay BC6ENTC leak from the lysosomes into the cytoplasm.	False
These results underscore a role for BC6ENTG in BC6ENTC metabolism.	CPR:9
Furthermore, they suggest that BC6ENTG works in concert with BC6OTHER to regulate BC6ENTC translocation between the cytoplasm and lysosomes.	CPR:9
Furthermore, they suggest that BC6OTHER works in concert with BC6ENTG to regulate BC6ENTC translocation between the cytoplasm and lysosomes.	CPR:9
Cellular BC6OTHER is controlled by BC6ENTC - chelating proteins and by BC6ENTG .	False
Cellular BC6OTHER is controlled by BC6ENTG and by BC6ENTC transporters.	False
Airway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The BC6ENTC and BC6OTHER (HE) staining, Th1 / Th2 and Th17 BC6ENTG were evaluated by enzyme - linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the BC6OTHER ( BC6OTHER ) was evaluated by western blotting.	False
Airway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The BC6ENTC and BC6OTHER (HE) staining, Th1 / Th2 and Th17 BC6OTHER were evaluated by enzyme - linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the BC6ENTG ( BC6OTHER ) was evaluated by western blotting.	False
Airway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The BC6ENTC and BC6OTHER (HE) staining, Th1 / Th2 and Th17 BC6OTHER were evaluated by enzyme - linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the BC6OTHER ( BC6ENTG ) was evaluated by western blotting.	False
Airway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The BC6OTHER and BC6ENTC (HE) staining, Th1 / Th2 and Th17 BC6ENTG were evaluated by enzyme - linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the BC6OTHER ( BC6OTHER ) was evaluated by western blotting.	False
Airway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The BC6OTHER and BC6ENTC (HE) staining, Th1 / Th2 and Th17 BC6OTHER were evaluated by enzyme - linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the BC6ENTG ( BC6OTHER ) was evaluated by western blotting.	False
Airway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The BC6OTHER and BC6ENTC (HE) staining, Th1 / Th2 and Th17 BC6OTHER were evaluated by enzyme - linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the BC6OTHER ( BC6ENTG ) was evaluated by western blotting.	False
Immunoregulatory effects of BC6ENTC exerts anti - asthmatic effects via modulation of Th1 / Th2 BC6ENTG and enhancement of CD4(+)CD25(+)Foxp3(+) regulatory T cells in BC6OTHER - sensitized mice.	False
Immunoregulatory effects of BC6ENTC exerts anti - asthmatic effects via modulation of Th1 / Th2 BC6OTHER and enhancement of CD4(+)CD25(+)Foxp3(+) regulatory T cells in BC6ENTG - sensitized mice.	False
Of these, the BC6ENTG inhibitor BC6ENTC and BC6OTHER inhibitor BC6OTHER have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe.	CPR:4
Of these, the BC6OTHER inhibitor BC6ENTC and BC6ENTG inhibitor BC6OTHER have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe.	False
Of these, the BC6ENTG inhibitor BC6OTHER and BC6OTHER inhibitor BC6ENTC have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe.	False
Of these, the BC6OTHER inhibitor BC6OTHER and BC6ENTG inhibitor BC6ENTC have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe.	CPR:4
In addition, the BC6ENTG inhibitor BC6ENTC is in late - stage clinical development.	CPR:4
However, alterations of BC6ENTC and BC6OTHER pharmacokinetics upon interactions with inhibitors and inducers of BC6ENTG or BC6OTHER may complicate the use of these compounds in daily practice, whereas BC6OTHER elimination largely depends on renal function.	False
However, alterations of BC6ENTC and BC6OTHER pharmacokinetics upon interactions with inhibitors and inducers of BC6OTHER or BC6ENTG may complicate the use of these compounds in daily practice, whereas BC6OTHER elimination largely depends on renal function.	False
However, alterations of BC6OTHER and BC6ENTC pharmacokinetics upon interactions with inhibitors and inducers of BC6ENTG or BC6OTHER may complicate the use of these compounds in daily practice, whereas BC6OTHER elimination largely depends on renal function.	False
However, alterations of BC6OTHER and BC6ENTC pharmacokinetics upon interactions with inhibitors and inducers of BC6OTHER or BC6ENTG may complicate the use of these compounds in daily practice, whereas BC6OTHER elimination largely depends on renal function.	False
However, alterations of BC6OTHER and BC6OTHER pharmacokinetics upon interactions with inhibitors and inducers of BC6ENTG or BC6OTHER may complicate the use of these compounds in daily practice, whereas BC6ENTC elimination largely depends on renal function.	False
However, alterations of BC6OTHER and BC6OTHER pharmacokinetics upon interactions with inhibitors and inducers of BC6OTHER or BC6ENTG may complicate the use of these compounds in daily practice, whereas BC6ENTC elimination largely depends on renal function.	False
Compared to control BC6ENTG , ABLP BC6OTHER showed a 40% decrease of BC6ENTC and an 11 - fold increased BC6OTHER concentration.	False
Compared to control BC6OTHER , ABLP BC6ENTG showed a 40% decrease of BC6ENTC and an 11 - fold increased BC6OTHER concentration.	False
Compared to control BC6ENTG , ABLP BC6OTHER showed a 40% decrease of BC6OTHER and an 11 - fold increased BC6ENTC concentration.	False
Compared to control BC6OTHER , ABLP BC6ENTG showed a 40% decrease of BC6OTHER and an 11 - fold increased BC6ENTC concentration.	False
The test procedure was verified with respect to intestinal BC6ENTC hydrolysis by demonstrating a linear relationship between BC6OTHER / BC6OTHER excretion and log jejunal mucosal BC6ENTG activity by in vitro assay (R2 = 0.95) in a further group of subjects.	CPR:9
The test procedure was verified with respect to intestinal BC6OTHER hydrolysis by demonstrating a linear relationship between BC6ENTC / BC6OTHER excretion and log jejunal mucosal BC6ENTG activity by in vitro assay (R2 = 0.95) in a further group of subjects.	CPR:9
The test procedure was verified with respect to intestinal BC6OTHER hydrolysis by demonstrating a linear relationship between BC6OTHER / BC6ENTC excretion and log jejunal mucosal BC6ENTG activity by in vitro assay (R2 = 0.95) in a further group of subjects.	CPR:9
Differential BC6ENTC / BC6OTHER / BC6OTHER absorption provides a non - invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal BC6ENTG deficiency.	CPR:9
Differential BC6OTHER / BC6ENTC / BC6OTHER absorption provides a non - invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal BC6ENTG deficiency.	CPR:9
Differential BC6OTHER / BC6OTHER / BC6ENTC absorption provides a non - invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal BC6ENTG deficiency.	CPR:9
In addition, during acute exposure tests performed at the end of the chronic exposure, biofilms chronically exposed to 75 and 150μgL( - 1) BC6ENTC showed a higher BC6ENTG activity than controls.	CPR:3
Chronic exposure to BC6ENTC provoked then structural changes but also functional changes in the capacity of biofilm BC6ENTG activity to respond to a sudden increase in concentration, suggesting a selection of species with higher antioxidant capacity.	False
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in BC6ENTC peroxidase ( BC6ENTG ) activity during the exponential growth and a more important role of BC6OTHER ( BC6OTHER ) and BC6OTHER reductase ( BC6OTHER ) activities during the slow growth phase.	False
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in BC6ENTC peroxidase ( BC6OTHER ) activity during the exponential growth and a more important role of BC6ENTG ( BC6OTHER ) and BC6OTHER reductase ( BC6OTHER ) activities during the slow growth phase.	False
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in BC6ENTC peroxidase ( BC6OTHER ) activity during the exponential growth and a more important role of BC6OTHER ( BC6ENTG ) and BC6OTHER reductase ( BC6OTHER ) activities during the slow growth phase.	False
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in BC6ENTC peroxidase ( BC6OTHER ) activity during the exponential growth and a more important role of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities during the slow growth phase.	False
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in BC6ENTC peroxidase ( BC6OTHER ) activity during the exponential growth and a more important role of BC6OTHER ( BC6OTHER ) and BC6OTHER reductase ( BC6ENTG ) activities during the slow growth phase.	False
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in BC6ENTG ( BC6OTHER ) activity during the exponential growth and a more important role of BC6OTHER ( BC6OTHER ) and BC6ENTC reductase ( BC6OTHER ) activities during the slow growth phase.	False
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in BC6OTHER peroxidase ( BC6ENTG ) activity during the exponential growth and a more important role of BC6OTHER ( BC6OTHER ) and BC6ENTC reductase ( BC6OTHER ) activities during the slow growth phase.	False
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in BC6OTHER peroxidase ( BC6OTHER ) activity during the exponential growth and a more important role of BC6ENTG ( BC6OTHER ) and BC6ENTC reductase ( BC6OTHER ) activities during the slow growth phase.	False
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in BC6OTHER peroxidase ( BC6OTHER ) activity during the exponential growth and a more important role of BC6OTHER ( BC6ENTG ) and BC6ENTC reductase ( BC6OTHER ) activities during the slow growth phase.	False
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in BC6OTHER peroxidase ( BC6OTHER ) activity during the exponential growth and a more important role of BC6OTHER ( BC6OTHER ) and BC6ENTC reductase ( BC6ENTG ) activities during the slow growth phase.	False
The main molecular target of BC6ENTC antifungals is the BC6ENTG protein BC6OTHER / BC6OTHER .	False
The main molecular target of BC6ENTC antifungals is the BC6OTHER protein BC6ENTG / BC6OTHER .	False
The main molecular target of BC6ENTC antifungals is the BC6OTHER protein BC6OTHER / BC6ENTG .	False
The BC6ENTC , of which BC6OTHER is the sole representative in human therapy, affect two targets in the CHEM pathway: BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The BC6ENTC , of which BC6OTHER is the sole representative in human therapy, affect two targets in the CHEM pathway: BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
The BC6ENTC , of which BC6OTHER is the sole representative in human therapy, affect two targets in the CHEM pathway: BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
The BC6ENTC , of which BC6OTHER is the sole representative in human therapy, affect two targets in the CHEM pathway: BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
The BC6OTHER , of which BC6ENTC is the sole representative in human therapy, affect two targets in the CHEM pathway: BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The BC6OTHER , of which BC6ENTC is the sole representative in human therapy, affect two targets in the CHEM pathway: BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
The BC6OTHER , of which BC6ENTC is the sole representative in human therapy, affect two targets in the CHEM pathway: BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
The BC6OTHER , of which BC6ENTC is the sole representative in human therapy, affect two targets in the CHEM pathway: BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
The BC6ENTC group are protein synthesis inhibitors that work by blocking the function of BC6ENTG .	CPR:4
Our results suggest that modification of multiple BC6ENTC residues by electrophilic compounds can generate both activation and desensitization of the BC6ENTG channel.	False
Electrophilic chemicals activate both insect and vertebrate BC6ENTG via covalent modification of BC6ENTC residues in the BC6OTHER - terminal region.	False
Electrophilic chemicals activate both insect and vertebrate BC6ENTG via covalent modification of BC6OTHER residues in the BC6ENTC - terminal region.	False
Although naturally occurring electrophilic plant compounds, such as mustard oil and BC6ENTC , are BC6ENTG agonists, it is unknown whether arthropod - produced electrophiles activate BC6OTHER .	CPR:5
Although naturally occurring electrophilic plant compounds, such as mustard oil and BC6ENTC , are BC6OTHER agonists, it is unknown whether arthropod - produced electrophiles activate BC6ENTG .	False
We characterized the effects of the electrophilic arthropod defensive compound BC6ENTC ( BC6OTHER ) on the BC6ENTG channel.	False
We characterized the effects of the electrophilic arthropod defensive compound BC6OTHER ( BC6ENTC ) on the BC6ENTG channel.	False
We used whole - cell recordings of human embryonic kidney cells heterologously expressing either wild - type BC6ENTG or BC6OTHER with three BC6ENTC - substituted BC6OTHER crucial for electrophile activation ( BC6OTHER , BC6OTHER , BC6OTHER ).	False
We used whole - cell recordings of human embryonic kidney cells heterologously expressing either wild - type BC6OTHER or BC6ENTG with three BC6ENTC - substituted BC6OTHER crucial for electrophile activation ( BC6OTHER , BC6OTHER , BC6OTHER ).	False
We used whole - cell recordings of human embryonic kidney cells heterologously expressing either wild - type BC6OTHER or BC6OTHER with three BC6ENTC - substituted BC6OTHER crucial for electrophile activation ( BC6ENTG , BC6OTHER , BC6OTHER ).	False
We used whole - cell recordings of human embryonic kidney cells heterologously expressing either wild - type BC6OTHER or BC6OTHER with three BC6ENTC - substituted BC6OTHER crucial for electrophile activation ( BC6OTHER , BC6ENTG , BC6OTHER ).	False
We used whole - cell recordings of human embryonic kidney cells heterologously expressing either wild - type BC6OTHER or BC6OTHER with three BC6ENTC - substituted BC6OTHER crucial for electrophile activation ( BC6OTHER , BC6OTHER , BC6ENTG ).	False
We used whole - cell recordings of human embryonic kidney cells heterologously expressing either wild - type BC6ENTG or BC6OTHER with three BC6OTHER - substituted BC6ENTC crucial for electrophile activation ( BC6OTHER , BC6OTHER , BC6OTHER ).	False
We used whole - cell recordings of human embryonic kidney cells heterologously expressing either wild - type BC6OTHER or BC6ENTG with three BC6OTHER - substituted BC6ENTC crucial for electrophile activation ( BC6OTHER , BC6OTHER , BC6OTHER ).	False
We used whole - cell recordings of human embryonic kidney cells heterologously expressing either wild - type BC6OTHER or BC6OTHER with three BC6OTHER - substituted BC6ENTC crucial for electrophile activation ( BC6ENTG , BC6OTHER , BC6OTHER ).	False
We used whole - cell recordings of human embryonic kidney cells heterologously expressing either wild - type BC6OTHER or BC6OTHER with three BC6OTHER - substituted BC6ENTC crucial for electrophile activation ( BC6OTHER , BC6ENTG , BC6OTHER ).	False
We used whole - cell recordings of human embryonic kidney cells heterologously expressing either wild - type BC6OTHER or BC6OTHER with three BC6OTHER - substituted BC6ENTC crucial for electrophile activation ( BC6OTHER , BC6OTHER , BC6ENTG ).	False
We found that BC6ENTC activates BC6ENTG starting at 10 nM and peaking at 300 nM; higher concentrations caused rapid activation followed by a fast decline.	CPR:3
 BC6ENTC Reveals a BC6OTHER - Dependent Desensitization Mechanism of BC6ENTG .	False
 BC6OTHER Reveals a BC6ENTC - Dependent Desensitization Mechanism of BC6ENTG .	False
The current reduction we found at higher BC6ENTC concentrations was a CHEM - dependent desensitization of BC6ENTG , and did not require prior activation.	False
Interestingly, following BC6ENTC desensitization, wild - type BC6ENTG had dramatically reduced response to the nonelectrophile agonist BC6OTHER , whereas the triple BC6OTHER mutant BC6OTHER retained its full response.	False
Interestingly, following BC6ENTC desensitization, wild - type BC6OTHER had dramatically reduced response to the nonelectrophile agonist BC6OTHER , whereas the triple BC6OTHER mutant BC6ENTG retained its full response.	False
Interestingly, following BC6OTHER desensitization, wild - type BC6ENTG had dramatically reduced response to the nonelectrophile agonist BC6ENTC , whereas the triple BC6OTHER mutant BC6OTHER retained its full response.	CPR:5
Interestingly, following BC6OTHER desensitization, wild - type BC6OTHER had dramatically reduced response to the nonelectrophile agonist BC6ENTC , whereas the triple BC6OTHER mutant BC6ENTG retained its full response.	CPR:5
Interestingly, following BC6OTHER desensitization, wild - type BC6ENTG had dramatically reduced response to the nonelectrophile agonist BC6OTHER , whereas the triple BC6ENTC mutant BC6OTHER retained its full response.	False
Interestingly, following BC6OTHER desensitization, wild - type BC6OTHER had dramatically reduced response to the nonelectrophile agonist BC6OTHER , whereas the triple BC6ENTC mutant BC6ENTG retained its full response.	False
for 15 days or along with a BC6ENTG agonist BC6ENTC ( BC6OTHER ; 30 μg / 100 g BW, oral) and were found to improve in the BC6OTHER co - treated condition.	CPR:5
for 15 days or along with a BC6ENTG agonist BC6OTHER ( BC6ENTC ; 30 μg / 100 g BW, oral) and were found to improve in the BC6OTHER co - treated condition.	CPR:5
for 15 days or along with a BC6ENTG agonist BC6OTHER ( BC6OTHER ; 30 μg / 100 g BW, oral) and were found to improve in the BC6ENTC co - treated condition.	False
Hyperthyroidism - induced oxidative stress, reduction in BC6ENTG activity, and myocardial BC6ENTC concentration were also significantly checked by BC6OTHER .	False
Hyperthyroidism - induced oxidative stress, reduction in BC6ENTG activity, and myocardial BC6OTHER concentration were also significantly checked by BC6ENTC .	False
Overexpression of BC6ENTG ( BC6OTHER ) is also caused by the mammalian target of BC6ENTC ( BC6OTHER ), a key component of signaling pathways inside the cell, involved in cell proliferation.	False
Overexpression of BC6OTHER ( BC6ENTG ) is also caused by the mammalian target of BC6ENTC ( BC6OTHER ), a key component of signaling pathways inside the cell, involved in cell proliferation.	False
Overexpression of BC6OTHER ( BC6OTHER ) is also caused by the mammalian target of BC6ENTC ( BC6ENTG ), a key component of signaling pathways inside the cell, involved in cell proliferation.	False
 BC6ENTC , BC6OTHER and BC6ENTG inhibitors in renal cancer.	False
 BC6OTHER , BC6ENTC and BC6ENTG inhibitors in renal cancer.	False
BC6ENTC and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ), while BC6OTHER is an BC6OTHER inhibitor.	False
BC6ENTC and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6ENTG , BC6OTHER ) and BC6OTHER ( BC6OTHER ), while BC6OTHER is an BC6OTHER inhibitor.	CPR:4
BC6ENTC and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6ENTG ) and BC6OTHER ( BC6OTHER ), while BC6OTHER is an BC6OTHER inhibitor.	CPR:4
BC6ENTC and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER ), while BC6OTHER is an BC6OTHER inhibitor.	CPR:4
BC6ENTC and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTG ), while BC6OTHER is an BC6OTHER inhibitor.	CPR:4
BC6ENTC and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ), while BC6OTHER is an BC6ENTG inhibitor.	False
BC6OTHER and BC6ENTC are synthetic, orally active agents shown to directly inhibit BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ), while BC6OTHER is an BC6OTHER inhibitor.	False
BC6OTHER and BC6ENTC are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6ENTG , BC6OTHER ) and BC6OTHER ( BC6OTHER ), while BC6OTHER is an BC6OTHER inhibitor.	CPR:4
BC6OTHER and BC6ENTC are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6ENTG ) and BC6OTHER ( BC6OTHER ), while BC6OTHER is an BC6OTHER inhibitor.	CPR:4
BC6OTHER and BC6ENTC are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER ), while BC6OTHER is an BC6OTHER inhibitor.	CPR:4
BC6OTHER and BC6ENTC are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTG ), while BC6OTHER is an BC6OTHER inhibitor.	CPR:4
BC6OTHER and BC6ENTC are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ), while BC6OTHER is an BC6ENTG inhibitor.	False
BC6OTHER and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ), while BC6ENTC is an BC6OTHER inhibitor.	False
BC6OTHER and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6ENTG , BC6OTHER ) and BC6OTHER ( BC6OTHER ), while BC6ENTC is an BC6OTHER inhibitor.	False
BC6OTHER and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6ENTG ) and BC6OTHER ( BC6OTHER ), while BC6ENTC is an BC6OTHER inhibitor.	False
BC6OTHER and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER ), while BC6ENTC is an BC6OTHER inhibitor.	False
BC6OTHER and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTG ), while BC6ENTC is an BC6OTHER inhibitor.	False
BC6OTHER and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ), while BC6ENTC is an BC6ENTG inhibitor.	CPR:4
BC6ENTG is unusual due to its 11 - BC6ENTC bulge.	False
The simulations indicate that the long bulge is a stalk - specific eight - BC6ENTC insertion into consensual BC6ENTG only subtly modifying its structural dynamics.	False
Still, even bsc0χOL3 is unable to fully stabilize an essential BC6ENTC - edge BC6OTHER - bond between the bulge and non - canonical stem of the BC6ENTG .	False
Still, even bsc0χOL3 is unable to fully stabilize an essential BC6OTHER - edge BC6ENTC - bond between the bulge and non - canonical stem of the BC6ENTG .	False
The available X - ray structures contain only BC6ENTG BC6OTHER which in addition differ in orientation (anti vs syn) of the BC6ENTC .	False
The available X - ray structures contain only BC6OTHER BC6ENTG which in addition differ in orientation (anti vs syn) of the BC6ENTC .	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6ENTG [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6ENTG [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6ENTG [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6ENTG [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6ENTG [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6ENTG [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6ENTG [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6ENTG [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6ENTG [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6ENTG [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTG [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6ENTG [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6ENTG [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6ENTG [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTG [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6ENTG [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6ENTG [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6ENTG [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6ENTG [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6ENTG [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6ENTG [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6ENTG [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6ENTG [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6ENTG [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6ENTG [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6ENTG [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6ENTG [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6ENTG [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6ENTG [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6ENTG [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6ENTG [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTG [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6ENTG [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTG ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6ENTG [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6ENTG [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6ENTG [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6ENTG [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6ENTG [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6ENTG [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6ENTG [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6ENTG [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6ENTG [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6ENTG [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6ENTG [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6ENTG [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTG [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6ENTG [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6ENTG [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6ENTG [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6ENTG [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTG ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6ENTG [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]).	False
In comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6ENTG [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]).	False
These results are consistent with the interpretation that both BC6OTHER and BC6OTHER inhibit BC6OTHER formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of BC6ENTC in the BC6ENTG reaction.	CPR:9
Similar concentrations also inhibited the formation of BC6ENTC ( BC6OTHER ) by BC6ENTG , a detergent - solubilized cell free particulate enzyme from RBL cells which is capable of coupling BC6OTHER to BC6OTHER .	CPR:9
Similar concentrations also inhibited the formation of BC6OTHER ( BC6ENTC ) by BC6ENTG , a detergent - solubilized cell free particulate enzyme from RBL cells which is capable of coupling BC6OTHER to BC6OTHER .	CPR:9
Similar concentrations also inhibited the formation of BC6OTHER ( BC6OTHER ) by BC6ENTG , a detergent - solubilized cell free particulate enzyme from RBL cells which is capable of coupling BC6ENTC to BC6OTHER .	CPR:9
Similar concentrations also inhibited the formation of BC6OTHER ( BC6OTHER ) by BC6ENTG , a detergent - solubilized cell free particulate enzyme from RBL cells which is capable of coupling BC6OTHER to BC6ENTC .	False
The EC50 for inhibition of the BC6ENTG of RBL cells was directly proportional to the BC6ENTC concentration in the incubations, ranging from 1.5 mM at 10 microM BC6OTHER to over 40 mM at 500 microM BC6OTHER .	CPR:9
The EC50 for inhibition of the BC6ENTG of RBL cells was directly proportional to the BC6OTHER concentration in the incubations, ranging from 1.5 mM at 10 microM BC6ENTC to over 40 mM at 500 microM BC6OTHER .	False
The EC50 for inhibition of the BC6ENTG of RBL cells was directly proportional to the BC6OTHER concentration in the incubations, ranging from 1.5 mM at 10 microM BC6OTHER to over 40 mM at 500 microM BC6ENTC .	False
Kinetic analysis revealed that the inhibition of the BC6ENTG reaction by BC6ENTC was competitive with respect to BC6OTHER .	CPR:4
Kinetic analysis revealed that the inhibition of the BC6ENTG reaction by BC6OTHER was competitive with respect to BC6ENTC .	False
In contrast to BC6ENTC , BC6OTHER ( BC6OTHER ; BC6OTHER ), which inhibits the formation of BC6OTHER in RBL cells at the BC6ENTG step (EC50 5 microM), did not inhibit the BC6OTHER synthetase of these cells.	CPR:4
In contrast to BC6ENTC , BC6OTHER ( BC6OTHER ; BC6OTHER ), which inhibits the formation of BC6OTHER in RBL cells at the BC6OTHER step (EC50 5 microM), did not inhibit the BC6ENTG of these cells.	CPR:4
In contrast to BC6OTHER , BC6ENTC ( BC6OTHER ; BC6OTHER ), which inhibits the formation of BC6OTHER in RBL cells at the BC6ENTG step (EC50 5 microM), did not inhibit the BC6OTHER synthetase of these cells.	CPR:4
In contrast to BC6OTHER , BC6ENTC ( BC6OTHER ; BC6OTHER ), which inhibits the formation of BC6OTHER in RBL cells at the BC6OTHER step (EC50 5 microM), did not inhibit the BC6ENTG of these cells.	False
In contrast to BC6OTHER , BC6OTHER ( BC6ENTC ; BC6OTHER ), which inhibits the formation of BC6OTHER in RBL cells at the BC6ENTG step (EC50 5 microM), did not inhibit the BC6OTHER synthetase of these cells.	CPR:4
In contrast to BC6OTHER , BC6OTHER ( BC6ENTC ; BC6OTHER ), which inhibits the formation of BC6OTHER in RBL cells at the BC6OTHER step (EC50 5 microM), did not inhibit the BC6ENTG of these cells.	False
In contrast to BC6OTHER , BC6OTHER ( BC6OTHER ; BC6ENTC ), which inhibits the formation of BC6OTHER in RBL cells at the BC6ENTG step (EC50 5 microM), did not inhibit the BC6OTHER synthetase of these cells.	CPR:4
In contrast to BC6OTHER , BC6OTHER ( BC6OTHER ; BC6ENTC ), which inhibits the formation of BC6OTHER in RBL cells at the BC6OTHER step (EC50 5 microM), did not inhibit the BC6ENTG of these cells.	False
In contrast to BC6OTHER , BC6OTHER ( BC6OTHER ; BC6OTHER ), which inhibits the formation of BC6ENTC in RBL cells at the BC6ENTG step (EC50 5 microM), did not inhibit the BC6OTHER synthetase of these cells.	CPR:9
In contrast to BC6OTHER , BC6OTHER ( BC6OTHER ; BC6OTHER ), which inhibits the formation of BC6ENTC in RBL cells at the BC6OTHER step (EC50 5 microM), did not inhibit the BC6ENTG of these cells.	False
Inhibition of the BC6OTHER of rat basophil leukemia cells by BC6OTHER , and synergism between BC6ENTC and BC6OTHER , a BC6ENTG inhibitor.	CPR:4
Inhibition of the BC6ENTG of rat basophil leukemia cells by BC6OTHER , and synergism between BC6ENTC and BC6OTHER , a BC6OTHER inhibitor.	False
Inhibition of the BC6OTHER of rat basophil leukemia cells by BC6OTHER , and synergism between BC6OTHER and BC6ENTC , a BC6ENTG inhibitor.	CPR:4
Inhibition of the BC6ENTG of rat basophil leukemia cells by BC6OTHER , and synergism between BC6OTHER and BC6ENTC , a BC6OTHER inhibitor.	False
Inhibition of the BC6ENTC synthetase of rat basophil leukemia cells by BC6OTHER , and synergism between BC6OTHER and BC6OTHER , a BC6ENTG inhibitor.	False
Inhibition of the BC6OTHER of rat basophil leukemia cells by BC6ENTC , and synergism between BC6OTHER and BC6OTHER , a BC6ENTG inhibitor.	False
Inhibition of the BC6ENTG of rat basophil leukemia cells by BC6ENTC , and synergism between BC6OTHER and BC6OTHER , a BC6OTHER inhibitor.	CPR:4
In contrast to BC6OTHER , BC6OTHER ( BC6OTHER ; BC6OTHER ), which inhibits the formation of BC6OTHER in RBL cells at the BC6ENTG step (EC50 5 microM), did not inhibit the BC6ENTC synthetase of these cells.	False
These results are consistent with the interpretation that both BC6ENTC and BC6OTHER inhibit BC6OTHER formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of BC6OTHER in the BC6ENTG reaction.	False
These results are consistent with the interpretation that both BC6OTHER and BC6ENTC inhibit BC6OTHER formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of BC6OTHER in the BC6ENTG reaction.	False
These results are consistent with the interpretation that both BC6OTHER and BC6OTHER inhibit BC6ENTC formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of BC6OTHER in the BC6ENTG reaction.	False
Here we show that BC6ENTG and BC6OTHER cooperatively repress BC6ENTC receptor - dependent activity of BC6OTHER - class endogenous retroviruses (ERVs) in liver.	False
Here we show that BC6OTHER and BC6ENTG cooperatively repress BC6ENTC receptor - dependent activity of BC6OTHER - class endogenous retroviruses (ERVs) in liver.	False
Here we show that BC6OTHER and BC6OTHER cooperatively repress BC6ENTC receptor - dependent activity of BC6ENTG - class endogenous retroviruses (ERVs) in liver.	False
Similar to the BC6ENTG , BC6OTHER is activated only by the naturally occurring BC6ENTC isomer of PS and not the BC6OTHER stereoisomer.	CPR:3
Similar to the plasma membrane BC6OTHER transporter, BC6ENTG is activated only by the naturally occurring BC6ENTC isomer of PS and not the BC6OTHER stereoisomer.	CPR:3
Similar to the BC6ENTG , BC6OTHER is activated only by the naturally occurring BC6OTHER isomer of PS and not the BC6ENTC stereoisomer.	False
Similar to the plasma membrane BC6OTHER transporter, BC6ENTG is activated only by the naturally occurring BC6OTHER isomer of PS and not the BC6ENTC stereoisomer.	False
Most modifications of the BC6ENTC headgroup structure decrease recognition by the plasma membrane BC6ENTG .	False
Activation of BC6ENTG is also reduced by these modifications; BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , which are not transported by the plasma membrane flippase, do not activate BC6OTHER .	CPR:4
Activation of BC6OTHER is also reduced by these modifications; BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , which are not transported by the plasma membrane flippase, do not activate BC6ENTG .	False
Activation of BC6ENTG is also reduced by these modifications; BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , which are not transported by the plasma membrane flippase, do not activate BC6OTHER .	CPR:4
Activation of BC6OTHER is also reduced by these modifications; BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , which are not transported by the plasma membrane flippase, do not activate BC6ENTG .	False
Activation of BC6ENTG is also reduced by these modifications; BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , which are not transported by the plasma membrane flippase, do not activate BC6OTHER .	CPR:4
Activation of BC6OTHER is also reduced by these modifications; BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , which are not transported by the plasma membrane flippase, do not activate BC6ENTG .	False
Activation of BC6ENTG is also reduced by these modifications; BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , which are not transported by the plasma membrane flippase, do not activate BC6OTHER .	CPR:4
Activation of BC6OTHER is also reduced by these modifications; BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , which are not transported by the plasma membrane flippase, do not activate BC6ENTG .	False
Weakly translocated lipids ( BC6ENTC , BC6OTHER , and BC6OTHER ) are also weak BC6ENTG activators.	CPR:3
The purified BC6ENTG is inactive in detergent micelles or in micelles containing BC6ENTC , BC6OTHER , or BC6OTHER , is minimally activated by BC6OTHER or BC6OTHER ( BC6OTHER ), and is maximally activated by BC6OTHER .	False
Weakly translocated lipids ( BC6OTHER , BC6ENTC , and BC6OTHER ) are also weak BC6ENTG activators.	CPR:3
Weakly translocated lipids ( BC6OTHER , BC6OTHER , and BC6ENTC ) are also weak BC6ENTG activators.	CPR:3
However, BC6ENTC , which is transported by the plasma membrane BC6ENTG at a rate equivalent to BC6OTHER , is incapable of activating BC6OTHER activity.	CPR:9
However, BC6ENTC , which is transported by the plasma membrane BC6OTHER at a rate equivalent to BC6OTHER , is incapable of activating BC6ENTG activity.	False
However, BC6OTHER , which is transported by the plasma membrane BC6ENTG at a rate equivalent to BC6ENTC , is incapable of activating BC6OTHER activity.	False
However, BC6OTHER , which is transported by the plasma membrane BC6OTHER at a rate equivalent to BC6ENTC , is incapable of activating BC6ENTG activity.	False
"This aminophospholipid "" BC6ENTG "" selectively transports BC6ENTC to the cytosolic leaflet of the bilayer and is sensitive to BC6OTHER , BC6OTHER , and modification by BC6OTHER reagents."	CPR:9
These results indicate that the BC6ENTG activity of the secretory granule BC6OTHER is activated by phospholipids binding to a specific site whose properties ( BC6ENTC selectivity, dependence upon BC6OTHER but not BC6OTHER , stereochemistry, and CHEM sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane BC6OTHER .	CPR:3
These results indicate that the BC6OTHER activity of the secretory granule BC6ENTG is activated by phospholipids binding to a specific site whose properties ( BC6ENTC selectivity, dependence upon BC6OTHER but not BC6OTHER , stereochemistry, and CHEM sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane BC6OTHER .	CPR:3
These results indicate that the BC6OTHER activity of the secretory granule BC6OTHER is activated by phospholipids binding to a specific site whose properties ( BC6ENTC selectivity, dependence upon BC6OTHER but not BC6OTHER , stereochemistry, and CHEM sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane BC6ENTG .	False
These results indicate that the BC6ENTG activity of the secretory granule BC6OTHER is activated by phospholipids binding to a specific site whose properties ( BC6OTHER selectivity, dependence upon BC6ENTC but not BC6OTHER , stereochemistry, and CHEM sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane BC6OTHER .	False
These results indicate that the BC6OTHER activity of the secretory granule BC6ENTG is activated by phospholipids binding to a specific site whose properties ( BC6OTHER selectivity, dependence upon BC6ENTC but not BC6OTHER , stereochemistry, and CHEM sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane BC6OTHER .	False
These results indicate that the BC6OTHER activity of the secretory granule BC6OTHER is activated by phospholipids binding to a specific site whose properties ( BC6OTHER selectivity, dependence upon BC6ENTC but not BC6OTHER , stereochemistry, and CHEM sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane BC6ENTG .	False
These results indicate that the BC6ENTG activity of the secretory granule BC6OTHER is activated by phospholipids binding to a specific site whose properties ( BC6OTHER selectivity, dependence upon BC6OTHER but not BC6ENTC , stereochemistry, and CHEM sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane BC6OTHER .	False
These results indicate that the BC6OTHER activity of the secretory granule BC6ENTG is activated by phospholipids binding to a specific site whose properties ( BC6OTHER selectivity, dependence upon BC6OTHER but not BC6ENTC , stereochemistry, and CHEM sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane BC6OTHER .	False
These results indicate that the BC6OTHER activity of the secretory granule BC6OTHER is activated by phospholipids binding to a specific site whose properties ( BC6OTHER selectivity, dependence upon BC6OTHER but not BC6ENTC , stereochemistry, and CHEM sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane BC6ENTG .	False
"This aminophospholipid "" BC6ENTG "" selectively transports BC6OTHER to the cytosolic leaflet of the bilayer and is sensitive to BC6ENTC , BC6OTHER , and modification by BC6OTHER reagents."	False
"This aminophospholipid "" BC6ENTG "" selectively transports BC6OTHER to the cytosolic leaflet of the bilayer and is sensitive to BC6OTHER , BC6ENTC , and modification by BC6OTHER reagents."	False
The purified BC6ENTG is inactive in detergent micelles or in micelles containing BC6OTHER , BC6ENTC , or BC6OTHER , is minimally activated by BC6OTHER or BC6OTHER ( BC6OTHER ), and is maximally activated by BC6OTHER .	False
"This aminophospholipid "" BC6ENTG "" selectively transports BC6OTHER to the cytosolic leaflet of the bilayer and is sensitive to BC6OTHER , BC6OTHER , and modification by BC6ENTC reagents."	False
A candidate BC6ENTC flippase ATP8A1 ( BC6ENTG ), originally isolated from bovine secretory vesicles, is a member of this subfamily based on sequence homology to the founding member of the subfamily, the BC6OTHER , which has been linked to ribosomal assembly, the formation of Golgi - coated vesicles, and the maintenance of PS asymmetry.	False
A candidate BC6ENTC flippase ATP8A1 ( BC6OTHER ), originally isolated from bovine secretory vesicles, is a member of this subfamily based on sequence homology to the founding member of the subfamily, the BC6ENTG , which has been linked to ribosomal assembly, the formation of Golgi - coated vesicles, and the maintenance of PS asymmetry.	False
To determine if BC6ENTG has biochemical characteristics consistent with a BC6ENTC flippase, a murine homologue of this enzyme was expressed in insect cells and purified.	False
The purified BC6ENTG is inactive in detergent micelles or in micelles containing BC6OTHER , BC6OTHER , or BC6ENTC , is minimally activated by BC6OTHER or BC6OTHER ( BC6OTHER ), and is maximally activated by BC6OTHER .	False
The purified BC6ENTG is inactive in detergent micelles or in micelles containing BC6OTHER , BC6OTHER , or BC6OTHER , is minimally activated by BC6ENTC or BC6OTHER ( BC6OTHER ), and is maximally activated by BC6OTHER .	CPR:3
The purified BC6ENTG is inactive in detergent micelles or in micelles containing BC6OTHER , BC6OTHER , or BC6OTHER , is minimally activated by BC6OTHER or BC6ENTC ( BC6OTHER ), and is maximally activated by BC6OTHER .	CPR:3
The purified BC6ENTG is inactive in detergent micelles or in micelles containing BC6OTHER , BC6OTHER , or BC6OTHER , is minimally activated by BC6OTHER or BC6OTHER ( BC6ENTC ), and is maximally activated by BC6OTHER .	CPR:3
The purified BC6ENTG is inactive in detergent micelles or in micelles containing BC6OTHER , BC6OTHER , or BC6OTHER , is minimally activated by BC6OTHER or BC6OTHER ( BC6OTHER ), and is maximally activated by BC6ENTC .	CPR:3
Similar to the plasma membrane BC6ENTC transporter, BC6ENTG is activated only by the naturally occurring BC6OTHER isomer of PS and not the BC6OTHER stereoisomer.	False
In another experiment, topical application of CFB, CFE or BC6ENTC prior to UVB irradiation (200mJ / cm(2)) on BALB / c mice, inhibited the UVB - elevated protein levels of BC6ENTG , BC6OTHER , and BC6OTHER .	CPR:4
In another experiment, topical application of CFB, CFE or BC6ENTC prior to UVB irradiation (200mJ / cm(2)) on BALB / c mice, inhibited the UVB - elevated protein levels of BC6OTHER , BC6ENTG , and BC6OTHER .	CPR:4
In another experiment, topical application of CFB, CFE or BC6ENTC prior to UVB irradiation (200mJ / cm(2)) on BALB / c mice, inhibited the UVB - elevated protein levels of BC6OTHER , BC6OTHER , and BC6ENTG .	CPR:4
In HaCaT cells, BC6ENTC and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6ENTG ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6ENTC and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6ENTG ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6ENTC and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6ENTC and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6ENTG ), and BC6OTHER ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6ENTC and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6ENTC and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6ENTG ).	CPR:4
In HaCaT cells, BC6OTHER and BC6ENTC fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6ENTG ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6OTHER and BC6ENTC fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6ENTG ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6OTHER and BC6ENTC fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6OTHER and BC6ENTC fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6ENTG ), and BC6OTHER ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6OTHER and BC6ENTC fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6OTHER and BC6ENTC fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6ENTG ).	CPR:4
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6ENTC C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6ENTG ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6ENTC C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6ENTG ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6ENTC C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6ENTC C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6ENTG ), and BC6OTHER ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6ENTC C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6ENTC C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6ENTG ).	CPR:4
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6ENTC ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6ENTG ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6ENTC ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6ENTG ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6ENTC ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6ENTC ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6ENTG ), and BC6OTHER ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6ENTC ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6ENTC ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6ENTG ).	CPR:4
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6ENTC ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6ENTG ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6ENTC ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6ENTG ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6ENTC ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6ENTC ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6ENTG ), and BC6OTHER ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6ENTC ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ).	CPR:4
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6ENTC ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6ENTG ).	CPR:4
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6ENTG ( BC6OTHER ), inducible BC6ENTC synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ).	False
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6ENTG ), inducible BC6ENTC synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ).	False
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6ENTC synthase ( BC6ENTG ), and BC6OTHER ( BC6OTHER ).	False
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6ENTC synthase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ).	False
In HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6ENTC synthase ( BC6OTHER ), and BC6OTHER ( BC6ENTG ).	False
Beta 2 - but not BC6ENTG are involved in BC6ENTC enhancement of aggressive behavior in long - term isolated mice.	False
Taken together with our previous finding that the BC6ENTC - induced enhancement of aggressive behavior can be blocked by BC6OTHER , an BC6ENTG antagonist, the present results indicate that not only alpha 2 - but also BC6OTHER stimulation plays important roles in modulation of aggressive behavior in long - term isolated mice.	False
Taken together with our previous finding that the BC6ENTC - induced enhancement of aggressive behavior can be blocked by BC6OTHER , an BC6OTHER antagonist, the present results indicate that not only alpha 2 - but also BC6ENTG stimulation plays important roles in modulation of aggressive behavior in long - term isolated mice.	False
Taken together with our previous finding that the BC6OTHER - induced enhancement of aggressive behavior can be blocked by BC6ENTC , an BC6ENTG antagonist, the present results indicate that not only alpha 2 - but also BC6OTHER stimulation plays important roles in modulation of aggressive behavior in long - term isolated mice.	CPR:6
Taken together with our previous finding that the BC6OTHER - induced enhancement of aggressive behavior can be blocked by BC6ENTC , an BC6OTHER antagonist, the present results indicate that not only alpha 2 - but also BC6ENTG stimulation plays important roles in modulation of aggressive behavior in long - term isolated mice.	False
Intraperitoneal administration of BC6ENTC (2.5 - 10 mg / kg), a nonselective BC6ENTG antagonist, dose dependently attenuated the BC6OTHER - induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses.	CPR:6
Intraperitoneal administration of BC6OTHER (2.5 - 10 mg / kg), a nonselective BC6ENTG antagonist, dose dependently attenuated the BC6ENTC - induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses.	False
The effects of several BC6ENTG antagonists on the BC6ENTC - induced increase in aggressive behavior in long - term isolated mice were examined.	False
BC6ENTC (1.25 - 5 mg / kg, IP), a selective BC6ENTG antagonist, also blocked the CHEM - induced enhancement of aggressive behavior in a dose - dependent manner, whereas BC6OTHER (5 - 20 mg / kg, IP), a selective BC6OTHER antagonist, did not affect it.	CPR:6
BC6ENTC (1.25 - 5 mg / kg, IP), a selective BC6OTHER antagonist, also blocked the CHEM - induced enhancement of aggressive behavior in a dose - dependent manner, whereas BC6OTHER (5 - 20 mg / kg, IP), a selective BC6ENTG antagonist, did not affect it.	False
BC6OTHER (1.25 - 5 mg / kg, IP), a selective BC6ENTG antagonist, also blocked the CHEM - induced enhancement of aggressive behavior in a dose - dependent manner, whereas BC6ENTC (5 - 20 mg / kg, IP), a selective BC6OTHER antagonist, did not affect it.	False
BC6OTHER (1.25 - 5 mg / kg, IP), a selective BC6OTHER antagonist, also blocked the CHEM - induced enhancement of aggressive behavior in a dose - dependent manner, whereas BC6ENTC (5 - 20 mg / kg, IP), a selective BC6ENTG antagonist, did not affect it.	CPR:6
Moreover, BC6ENTC (0.1 - 0.5 mg / kg, IP), a lipophilic BC6ENTG agonist, significantly increased the duration of basal aggressive behavior.	CPR:5
BC6OTHER and BC6ENTC possessed similar affinity for BC6ENTG .	False
Cooperative effects for BC6ENTG differ between BC6ENTC and its metabolites.	False
We hypothesized that BC6ENTC metabolites have lower affinity than BC6OTHER toward BC6ENTG and limited ability to induce cooperative effects during metabolism.	False
We hypothesized that BC6OTHER metabolites have lower affinity than BC6ENTC toward BC6ENTG and limited ability to induce cooperative effects during metabolism.	False
To test the hypothesis, we determined the potency and mechanism of inhibition for BC6ENTC and its metabolites toward oxidation of BC6OTHER using BC6ENTG Supersomes® and human liver microsomes.	False
To test the hypothesis, we determined the potency and mechanism of inhibition for BC6OTHER and its metabolites toward oxidation of BC6ENTC using BC6ENTG Supersomes® and human liver microsomes.	False
BC6ENTC and BC6OTHER possessed similar affinity for BC6ENTG .	False
While BC6OTHER in hypoxia translocates to the nucleus where it transcribes the target genes including BC6OTHER ( BC6OTHER ) mRNA, BC6OTHER is degraded under normoxia, which involves its BC6ENTC hydroxylation and subsequent binding to the BC6ENTG - BC6OTHER - BC6OTHER ( BC6OTHER ) complex.	False
While BC6OTHER in hypoxia translocates to the nucleus where it transcribes the target genes including BC6OTHER ( BC6OTHER ) mRNA, BC6OTHER is degraded under normoxia, which involves its BC6ENTC hydroxylation and subsequent binding to the BC6OTHER - BC6ENTG - BC6OTHER ( BC6OTHER ) complex.	False
While BC6OTHER in hypoxia translocates to the nucleus where it transcribes the target genes including BC6OTHER ( BC6OTHER ) mRNA, BC6OTHER is degraded under normoxia, which involves its BC6ENTC hydroxylation and subsequent binding to the BC6OTHER - BC6OTHER - BC6ENTG ( BC6OTHER ) complex.	False
While BC6OTHER in hypoxia translocates to the nucleus where it transcribes the target genes including BC6OTHER ( BC6OTHER ) mRNA, BC6OTHER is degraded under normoxia, which involves its BC6ENTC hydroxylation and subsequent binding to the BC6OTHER - BC6OTHER - BC6OTHER ( BC6ENTG ) complex.	False
While BC6ENTG in hypoxia translocates to the nucleus where it transcribes the target genes including BC6OTHER ( BC6OTHER ) mRNA, BC6OTHER is degraded under normoxia, which involves its BC6ENTC hydroxylation and subsequent binding to the BC6OTHER - BC6OTHER - BC6OTHER ( BC6OTHER ) complex.	False
While BC6OTHER in hypoxia translocates to the nucleus where it transcribes the target genes including BC6ENTG ( BC6OTHER ) mRNA, BC6OTHER is degraded under normoxia, which involves its BC6ENTC hydroxylation and subsequent binding to the BC6OTHER - BC6OTHER - BC6OTHER ( BC6OTHER ) complex.	False
While BC6OTHER in hypoxia translocates to the nucleus where it transcribes the target genes including BC6OTHER ( BC6ENTG ) mRNA, BC6OTHER is degraded under normoxia, which involves its BC6ENTC hydroxylation and subsequent binding to the BC6OTHER - BC6OTHER - BC6OTHER ( BC6OTHER ) complex.	False
While BC6OTHER in hypoxia translocates to the nucleus where it transcribes the target genes including BC6OTHER ( BC6OTHER ) mRNA, BC6ENTG is degraded under normoxia, which involves its BC6ENTC hydroxylation and subsequent binding to the BC6OTHER - BC6OTHER - BC6OTHER ( BC6OTHER ) complex.	False
The BC6ENTG agonist CHEM's ability to reduce aggressive behavior in humans and its interaction with the well - known aggression - enhancing drug BC6ENTC were examined.	False
RATIONALE: The BC6ENTC 1(B / D) ( BC6ENTG ) receptor has shown potential as a target for decreasing aggression.	False
A series of studies is reviewed that assesses the relationship between BC6ENTG released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective BC6OTHER inhibitor ( BC6ENTC ) in comparison to a dual BC6OTHER / BC6OTHER inhibitor ( BC6OTHER ).	False
A series of studies is reviewed that assesses the relationship between BC6OTHER released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective BC6ENTG inhibitor ( BC6ENTC ) in comparison to a dual BC6OTHER / BC6OTHER inhibitor ( BC6OTHER ).	CPR:4
A series of studies is reviewed that assesses the relationship between BC6OTHER released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective BC6OTHER inhibitor ( BC6ENTC ) in comparison to a dual BC6ENTG / BC6OTHER inhibitor ( BC6OTHER ).	False
A series of studies is reviewed that assesses the relationship between BC6OTHER released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective BC6OTHER inhibitor ( BC6ENTC ) in comparison to a dual BC6OTHER / BC6ENTG inhibitor ( BC6OTHER ).	False
A series of studies is reviewed that assesses the relationship between BC6ENTG released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective BC6OTHER inhibitor ( BC6OTHER ) in comparison to a dual BC6OTHER / BC6OTHER inhibitor ( BC6ENTC ).	False
A series of studies is reviewed that assesses the relationship between BC6OTHER released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective BC6ENTG inhibitor ( BC6OTHER ) in comparison to a dual BC6OTHER / BC6OTHER inhibitor ( BC6ENTC ).	False
A series of studies is reviewed that assesses the relationship between BC6OTHER released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective BC6OTHER inhibitor ( BC6OTHER ) in comparison to a dual BC6ENTG / BC6OTHER inhibitor ( BC6ENTC ).	CPR:4
A series of studies is reviewed that assesses the relationship between BC6OTHER released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective BC6OTHER inhibitor ( BC6OTHER ) in comparison to a dual BC6OTHER / BC6ENTG inhibitor ( BC6ENTC ).	CPR:4
Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of BC6ENTC ( BC6OTHER ; a product of both BC6ENTG and BC6OTHER ) and BC6OTHER (as a biomarker for BC6OTHER activity) with parallel assessments of pain.	CPR:9
Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of BC6ENTC ( BC6OTHER ; a product of both BC6OTHER and BC6ENTG ) and BC6OTHER (as a biomarker for BC6OTHER activity) with parallel assessments of pain.	CPR:9
Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of BC6ENTC ( BC6OTHER ; a product of both BC6OTHER and BC6OTHER ) and BC6OTHER (as a biomarker for BC6ENTG activity) with parallel assessments of pain.	False
Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of BC6OTHER ( BC6ENTC ; a product of both BC6ENTG and BC6OTHER ) and BC6OTHER (as a biomarker for BC6OTHER activity) with parallel assessments of pain.	CPR:9
Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of BC6OTHER ( BC6ENTC ; a product of both BC6OTHER and BC6ENTG ) and BC6OTHER (as a biomarker for BC6OTHER activity) with parallel assessments of pain.	CPR:9
Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of BC6OTHER ( BC6ENTC ; a product of both BC6OTHER and BC6OTHER ) and BC6OTHER (as a biomarker for BC6ENTG activity) with parallel assessments of pain.	False
Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of BC6OTHER ( BC6OTHER ; a product of both BC6ENTG and BC6OTHER ) and BC6ENTC (as a biomarker for BC6OTHER activity) with parallel assessments of pain.	False
Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of BC6OTHER ( BC6OTHER ; a product of both BC6OTHER and BC6ENTG ) and BC6ENTC (as a biomarker for BC6OTHER activity) with parallel assessments of pain.	False
Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of BC6OTHER ( BC6OTHER ; a product of both BC6OTHER and BC6OTHER ) and BC6ENTC (as a biomarker for BC6ENTG activity) with parallel assessments of pain.	False
The time course of BC6ENTC production was consistent with early release due to BC6ENTG activity followed by increased production 2 - 3 hours after surgery, consistent with BC6OTHER expression.	CPR:9
The time course of BC6ENTC production was consistent with early release due to BC6OTHER activity followed by increased production 2 - 3 hours after surgery, consistent with BC6ENTG expression.	CPR:9
BC6ENTC selectively suppressed BC6OTHER but not BC6OTHER at time points consistent with BC6ENTG activity, while producing analgesia.	CPR:4
BC6OTHER selectively suppressed BC6ENTC but not BC6OTHER at time points consistent with BC6ENTG activity, while producing analgesia.	CPR:9
BC6OTHER selectively suppressed BC6OTHER but not BC6ENTC at time points consistent with BC6ENTG activity, while producing analgesia.	False
These studies demonstrate the ability to assess the time course and selective effects of BC6ENTG inhibitors in vivo and suggest that suppression of BC6OTHER mediated BC6ENTC is temporally related to NSAID analgesia.	False
These studies demonstrate the ability to assess the time course and selective effects of BC6OTHER inhibitors in vivo and suggest that suppression of BC6ENTG mediated BC6ENTC is temporally related to NSAID analgesia.	CPR:9
It appears likely that the BC6ENTG blocked by BC6ENTC obviated the pulmonary vasodilator effect of BC6OTHER therapy.	CPR:4
It appears likely that the BC6ENTG blocked by BC6OTHER obviated the pulmonary vasodilator effect of BC6ENTC therapy.	False
Here, we identified BC6ENTG ( BC6OTHER ) as a BC6ENTC - binding protein.	False
Here, we identified BC6OTHER ( BC6ENTG ) as a BC6ENTC - binding protein.	False
BC6ENTC initiates its teratogenic effects by binding to BC6ENTG and inhibiting the associated BC6OTHER activity.	False
BC6ENTC initiates its teratogenic effects by binding to BC6OTHER and inhibiting the associated BC6ENTG activity.	CPR:4
At each menstruation a bolus injection of 10 pmol / kg of BC6ENTG was administered before and during infusion of either 300 microg / min of BC6ENTC or placebo.	False
Ischemia markers in plasma and pain recorded by a visual analog scale were measured before and after each BC6ENTG injection as well as before and after the start of either BC6ENTC or placebo infusion.	False
Intrauterine pressure, ischemia markers, and experienced pain during administration of a BC6ENTG antagonist in spontaneous and BC6ENTC - induced dysmenorrhea.	False
Intrauterine pressure, ischemia markers, and experienced pain during administration of a BC6ENTC V1a receptor antagonist in spontaneous and BC6ENTG - induced dysmenorrhea.	False
In subjects with dysmenorrhea the increase in pain following the administration of BC6ENTG was significantly lower during BC6ENTC than during placebo infusion.	CPR:4
CONCLUSIONS: BC6ENTC reduces BC6ENTG - induced intrauterine pressure in both healthy volunteers and dysmenorrheics, and reported pain in subjects with dysmenorrhea.	CPR:4
The dysmenorrhea pain evoked by BC6ENTC correlated poorly with area under the curve, which may suggest that the effect is mediated by more than one BC6ENTG .	False
Exposure to BC6ENTC (a BC6ENTG antagonist), but not BC6OTHER (a BC6OTHER antagonist), precluded both the CHEM - induced elevation in BC6OTHER - sensitive I(sc) and the induced changes in BC6OTHER mRNA.	CPR:6
Exposure to BC6ENTC (a BC6OTHER antagonist), but not BC6OTHER (a BC6ENTG antagonist), precluded both the CHEM - induced elevation in BC6OTHER - sensitive I(sc) and the induced changes in BC6OTHER mRNA.	False
Exposure to BC6ENTC (a BC6OTHER antagonist), but not BC6OTHER (a BC6OTHER antagonist), precluded both the CHEM - induced elevation in BC6OTHER - sensitive I(sc) and the induced changes in BC6ENTG mRNA.	False
Exposure to BC6OTHER (a BC6ENTG antagonist), but not BC6ENTC (a BC6OTHER antagonist), precluded both the CHEM - induced elevation in BC6OTHER - sensitive I(sc) and the induced changes in BC6OTHER mRNA.	False
Exposure to BC6OTHER (a BC6OTHER antagonist), but not BC6ENTC (a BC6ENTG antagonist), precluded both the CHEM - induced elevation in BC6OTHER - sensitive I(sc) and the induced changes in BC6OTHER mRNA.	CPR:6
Exposure to BC6OTHER (a BC6OTHER antagonist), but not BC6ENTC (a BC6OTHER antagonist), precluded both the CHEM - induced elevation in BC6OTHER - sensitive I(sc) and the induced changes in BC6ENTG mRNA.	False
Exposure to BC6OTHER (a BC6ENTG antagonist), but not BC6OTHER (a BC6OTHER antagonist), precluded both the CHEM - induced elevation in BC6ENTC - sensitive I(sc) and the induced changes in BC6OTHER mRNA.	False
Exposure to BC6OTHER (a BC6OTHER antagonist), but not BC6OTHER (a BC6ENTG antagonist), precluded both the CHEM - induced elevation in BC6ENTC - sensitive I(sc) and the induced changes in BC6OTHER mRNA.	False
Exposure to BC6OTHER (a BC6OTHER antagonist), but not BC6OTHER (a BC6OTHER antagonist), precluded both the CHEM - induced elevation in BC6ENTC - sensitive I(sc) and the induced changes in BC6ENTG mRNA.	False
We conclude that BC6ENTC movement across mammary epithelia is modulated by CHEM via a BC6ENTG - mediated mechanism that regulates the expression of the BC6OTHER .	False
We conclude that BC6ENTC movement across mammary epithelia is modulated by CHEM via a BC6OTHER - mediated mechanism that regulates the expression of the BC6ENTG .	False
BC6ENTG expression and activity could account for the low BC6ENTC concentration that is typical of milk.	False
We hypothesized that CHEM exposure modulates epithelial BC6ENTC channel ( BC6ENTG ) expression and / or activity in bovine mammary epithelial cells.	False
METHOD: Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two BC6ENTG region polymorphisms ( BC6OTHER and - 141C Ins / Del) and were randomly assigned to receive 16 weeks of treatment with either BC6ENTC or BC6OTHER .	False
METHOD: Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two BC6OTHER region polymorphisms ( BC6ENTG and - 141C Ins / Del) and were randomly assigned to receive 16 weeks of treatment with either BC6ENTC or BC6OTHER .	False
METHOD: Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two BC6ENTG region polymorphisms ( BC6OTHER and - 141C Ins / Del) and were randomly assigned to receive 16 weeks of treatment with either BC6OTHER or BC6ENTC .	False
METHOD: Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two BC6OTHER region polymorphisms ( BC6ENTG and - 141C Ins / Del) and were randomly assigned to receive 16 weeks of treatment with either BC6OTHER or BC6ENTC .	False
BC6ENTC , a potent inhibitor of BC6ENTG , at high concentration (500 microm ) caused only a 72% decrease in the utilization of BC6OTHER .	CPR:4
BC6OTHER , a potent inhibitor of BC6ENTG , at high concentration (500 microm ) caused only a 72% decrease in the utilization of BC6ENTC .	False
The BC6ENTG / BC6OTHER interaction occurred on the BC6ENTC and BC6OTHER termini of BC6OTHER ; a single internal deletion from BC6OTHER 455 to 466 (Δ455 - 466) was found to significantly reduce BC6OTHER protein stability.	False
The BC6OTHER / BC6ENTG interaction occurred on the BC6ENTC and BC6OTHER termini of BC6OTHER ; a single internal deletion from BC6OTHER 455 to 466 (Δ455 - 466) was found to significantly reduce BC6OTHER protein stability.	False
The BC6OTHER / BC6OTHER interaction occurred on the BC6ENTC and BC6OTHER termini of BC6ENTG ; a single internal deletion from BC6OTHER 455 to 466 (Δ455 - 466) was found to significantly reduce BC6OTHER protein stability.	False
The BC6OTHER / BC6OTHER interaction occurred on the BC6ENTC and BC6OTHER termini of BC6OTHER ; a single internal deletion from BC6OTHER 455 to 466 (Δ455 - 466) was found to significantly reduce BC6ENTG protein stability.	False
The BC6ENTG / BC6OTHER interaction occurred on the BC6OTHER and BC6ENTC termini of BC6OTHER ; a single internal deletion from BC6OTHER 455 to 466 (Δ455 - 466) was found to significantly reduce BC6OTHER protein stability.	False
The BC6OTHER / BC6ENTG interaction occurred on the BC6OTHER and BC6ENTC termini of BC6OTHER ; a single internal deletion from BC6OTHER 455 to 466 (Δ455 - 466) was found to significantly reduce BC6OTHER protein stability.	False
The BC6OTHER / BC6OTHER interaction occurred on the BC6OTHER and BC6ENTC termini of BC6ENTG ; a single internal deletion from BC6OTHER 455 to 466 (Δ455 - 466) was found to significantly reduce BC6OTHER protein stability.	False
The BC6OTHER / BC6OTHER interaction occurred on the BC6OTHER and BC6ENTC termini of BC6OTHER ; a single internal deletion from BC6OTHER 455 to 466 (Δ455 - 466) was found to significantly reduce BC6ENTG protein stability.	False
The BC6ENTG / BC6OTHER interaction occurred on the BC6OTHER and BC6OTHER termini of BC6OTHER ; a single internal deletion from BC6ENTC 455 to 466 (Δ455 - 466) was found to significantly reduce BC6OTHER protein stability.	False
The BC6OTHER / BC6ENTG interaction occurred on the BC6OTHER and BC6OTHER termini of BC6OTHER ; a single internal deletion from BC6ENTC 455 to 466 (Δ455 - 466) was found to significantly reduce BC6OTHER protein stability.	False
The BC6OTHER / BC6OTHER interaction occurred on the BC6OTHER and BC6OTHER termini of BC6ENTG ; a single internal deletion from BC6ENTC 455 to 466 (Δ455 - 466) was found to significantly reduce BC6OTHER protein stability.	False
The BC6OTHER / BC6OTHER interaction occurred on the BC6OTHER and BC6OTHER termini of BC6OTHER ; a single internal deletion from BC6ENTC 455 to 466 (Δ455 - 466) was found to significantly reduce BC6ENTG protein stability.	False
Cerebral BC6ENTC H1 receptor ( BC6ENTG ) binding was measured in 10 patients with major depression and in 10 normal age - matched subjects using PET and BC6OTHER .	False
Cerebral BC6ENTG ( BC6OTHER ) binding was measured in 10 patients with major depression and in 10 normal age - matched subjects using PET and BC6ENTC .	False
Cerebral BC6OTHER H1 receptor ( BC6ENTG ) binding was measured in 10 patients with major depression and in 10 normal age - matched subjects using PET and BC6ENTC .	False
BC6ENTC also attenuated the hypolocomotion induced by the BC6ENTG agonist BC6OTHER and BC6OTHER precursor BC6OTHER , whereas BC6OTHER (and BC6OTHER ) worsened it.	False
BC6OTHER also attenuated the hypolocomotion induced by the BC6ENTG agonist BC6ENTC and BC6OTHER precursor BC6OTHER , whereas BC6OTHER (and BC6OTHER ) worsened it.	False
BC6OTHER also attenuated the hypolocomotion induced by the BC6ENTG agonist BC6OTHER and BC6ENTC precursor BC6OTHER , whereas BC6OTHER (and BC6OTHER ) worsened it.	False
BC6OTHER also attenuated the hypolocomotion induced by the BC6ENTG agonist BC6OTHER and BC6OTHER precursor BC6ENTC , whereas BC6OTHER (and BC6OTHER ) worsened it.	False
BC6OTHER also attenuated the hypolocomotion induced by the BC6ENTG agonist BC6OTHER and BC6OTHER precursor BC6OTHER , whereas BC6ENTC (and BC6OTHER ) worsened it.	False
BC6OTHER also attenuated the hypolocomotion induced by the BC6ENTG agonist BC6OTHER and BC6OTHER precursor BC6OTHER , whereas BC6OTHER (and BC6ENTC ) worsened it.	False
A combined pharmacological and genetic approach was undertaken to investigate the contribution of endogenous BC6ENTC to the motor actions of BC6ENTG ( BC6OTHER ) ligands.	False
A combined pharmacological and genetic approach was undertaken to investigate the contribution of endogenous BC6ENTC to the motor actions of BC6OTHER ( BC6ENTG ) ligands.	False
Motor facilitation induced by BC6ENTG and BC6OTHER antagonists was lost in BC6OTHER ( - / - ) and BC6OTHER ( - / - ) mice whereas motor inhibition induced by BC6OTHER antagonists (and BC6ENTC ) was lost in BC6OTHER ( - / - ) but preserved in BC6OTHER ( - / - ) mice.	False
Motor facilitation induced by BC6OTHER and BC6ENTG antagonists was lost in BC6OTHER ( - / - ) and BC6OTHER ( - / - ) mice whereas motor inhibition induced by BC6OTHER antagonists (and BC6ENTC ) was lost in BC6OTHER ( - / - ) but preserved in BC6OTHER ( - / - ) mice.	False
Motor facilitation induced by BC6OTHER and BC6OTHER antagonists was lost in BC6ENTG ( - / - ) and BC6OTHER ( - / - ) mice whereas motor inhibition induced by BC6OTHER antagonists (and BC6ENTC ) was lost in BC6OTHER ( - / - ) but preserved in BC6OTHER ( - / - ) mice.	False
Motor facilitation induced by BC6OTHER and BC6OTHER antagonists was lost in BC6OTHER ( - / - ) and BC6ENTG ( - / - ) mice whereas motor inhibition induced by BC6OTHER antagonists (and BC6ENTC ) was lost in BC6OTHER ( - / - ) but preserved in BC6OTHER ( - / - ) mice.	False
Motor facilitation induced by BC6OTHER and BC6OTHER antagonists was lost in BC6OTHER ( - / - ) and BC6OTHER ( - / - ) mice whereas motor inhibition induced by BC6ENTG antagonists (and BC6ENTC ) was lost in BC6OTHER ( - / - ) but preserved in BC6OTHER ( - / - ) mice.	False
Motor facilitation induced by BC6OTHER and BC6OTHER antagonists was lost in BC6OTHER ( - / - ) and BC6OTHER ( - / - ) mice whereas motor inhibition induced by BC6OTHER antagonists (and BC6ENTC ) was lost in BC6ENTG ( - / - ) but preserved in BC6OTHER ( - / - ) mice.	False
Motor facilitation induced by BC6OTHER and BC6OTHER antagonists was lost in BC6OTHER ( - / - ) and BC6OTHER ( - / - ) mice whereas motor inhibition induced by BC6OTHER antagonists (and BC6ENTC ) was lost in BC6OTHER ( - / - ) but preserved in BC6ENTG ( - / - ) mice.	False
We demonstrate that motor actions of BC6ENTG ligands rely on the modulation of endogenous BC6ENTC .	False
The involvement of the various BC6ENTG subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6ENTC ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6ENTG and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6ENTC ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6ENTG antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6ENTC ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6ENTG / BC6OTHER ( BC6ENTC ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	CPR:6
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6ENTG ( BC6ENTC ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	CPR:6
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6ENTC ), BC6ENTG / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6ENTC ), BC6OTHER / BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6ENTC ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6ENTC ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6ENTG knockout mice.	False
The involvement of the various BC6ENTG subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6ENTG and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6ENTG antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6ENTG / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6ENTG ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6ENTG / BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	CPR:6
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6ENTG ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	CPR:6
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6ENTG ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6ENTG knockout mice.	False
The involvement of the various BC6ENTG subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6ENTG and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6ENTG antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6ENTG / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6ENTG ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6ENTG / BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	CPR:6
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6ENTG ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	CPR:6
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6ENTG ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6ENTG knockout mice.	False
The involvement of the various BC6ENTG subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6ENTG and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6ENTG antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6ENTG / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6ENTG ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6ENTG / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC ) receptor antagonists, and by using BC6OTHER knockout mice.	False
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6ENTC ) receptor antagonists, and by using BC6OTHER knockout mice.	CPR:6
The involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC ) receptor antagonists, and by using BC6ENTG knockout mice.	False
Based on our previously published work on BC6ENTG antagonists, we have synthesized a series of BC6ENTC that inhibit the BC6OTHER / BC6OTHER interaction.	False
Based on our previously published work on BC6OTHER antagonists, we have synthesized a series of BC6ENTC that inhibit the BC6ENTG / BC6OTHER interaction.	CPR:4
Based on our previously published work on BC6OTHER antagonists, we have synthesized a series of BC6ENTC that inhibit the BC6OTHER / BC6ENTG interaction.	CPR:4
These data demonstrate that BC6ENTC are a unique class of BC6ENTG inhibitors with high potency.	CPR:4
 BC6ENTC : a unique class of BC6ENTG inhibitors.	CPR:4
Biological evaluation revealed that most tested compounds were potent BC6ENTG ( BC6OTHER ) inhibitors, among them, the BC6ENTC derivative 11h displayed the most potent BC6OTHER inhibitory activity with an IC50 value of 0.247 μM.	False
Biological evaluation revealed that most tested compounds were potent BC6OTHER ( BC6ENTG ) inhibitors, among them, the BC6ENTC derivative 11h displayed the most potent BC6OTHER inhibitory activity with an IC50 value of 0.247 μM.	False
Biological evaluation revealed that most tested compounds were potent BC6OTHER ( BC6OTHER ) inhibitors, among them, the BC6ENTC derivative 11h displayed the most potent BC6ENTG inhibitory activity with an IC50 value of 0.247 μM.	CPR:4
Design, Synthesis, Biological Evaluation, and Docking Studies of BC6OTHER Derivatives with a BC6ENTC Moiety as Potent BC6ENTG Inhibitors.	CPR:4
Design, Synthesis, Biological Evaluation, and Docking Studies of BC6ENTC Derivatives with a BC6OTHER Moiety as Potent BC6ENTG Inhibitors.	CPR:4
Administration of low, but not high, doses of oral BC6ENTC in DSS - treated mice resulted in a significant decrease in disease severity, histologic damage scores, as well as colonic level of BC6ENTG .	CPR:3
Treatment with BC6ENTC or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6ENTG at BC6OTHER 10, phosphorylation of BC6OTHER at BC6OTHER 15, expression of BC6OTHER , and decreased expression of BC6OTHER .	CPR:3
Treatment with BC6ENTC or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6OTHER 10, phosphorylation of BC6ENTG at BC6OTHER 15, expression of BC6OTHER , and decreased expression of BC6OTHER .	CPR:3
Treatment with BC6ENTC or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6OTHER 10, phosphorylation of BC6OTHER at BC6OTHER 15, expression of BC6ENTG , and decreased expression of BC6OTHER .	CPR:3
Treatment with BC6ENTC or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6OTHER 10, phosphorylation of BC6OTHER at BC6OTHER 15, expression of BC6OTHER , and decreased expression of BC6ENTG .	CPR:4
Treatment with BC6OTHER or BC6ENTC resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6ENTG at BC6OTHER 10, phosphorylation of BC6OTHER at BC6OTHER 15, expression of BC6OTHER , and decreased expression of BC6OTHER .	CPR:3
Treatment with BC6OTHER or BC6ENTC resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6OTHER 10, phosphorylation of BC6ENTG at BC6OTHER 15, expression of BC6OTHER , and decreased expression of BC6OTHER .	CPR:3
Treatment with BC6OTHER or BC6ENTC resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6OTHER 10, phosphorylation of BC6OTHER at BC6OTHER 15, expression of BC6ENTG , and decreased expression of BC6OTHER .	CPR:3
Treatment with BC6OTHER or BC6ENTC resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6OTHER 10, phosphorylation of BC6OTHER at BC6OTHER 15, expression of BC6OTHER , and decreased expression of BC6ENTG .	CPR:4
Treatment with BC6OTHER or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6ENTG at BC6ENTC 10, phosphorylation of BC6OTHER at BC6OTHER 15, expression of BC6OTHER , and decreased expression of BC6OTHER .	False
Treatment with BC6OTHER or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6ENTC 10, phosphorylation of BC6ENTG at BC6OTHER 15, expression of BC6OTHER , and decreased expression of BC6OTHER .	False
Treatment with BC6OTHER or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6ENTC 10, phosphorylation of BC6OTHER at BC6OTHER 15, expression of BC6ENTG , and decreased expression of BC6OTHER .	False
Treatment with BC6OTHER or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6ENTC 10, phosphorylation of BC6OTHER at BC6OTHER 15, expression of BC6OTHER , and decreased expression of BC6ENTG .	False
Treatment with BC6OTHER or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6ENTG at BC6OTHER 10, phosphorylation of BC6OTHER at BC6ENTC 15, expression of BC6OTHER , and decreased expression of BC6OTHER .	False
Treatment with BC6OTHER or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6OTHER 10, phosphorylation of BC6ENTG at BC6ENTC 15, expression of BC6OTHER , and decreased expression of BC6OTHER .	False
Treatment with BC6OTHER or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6OTHER 10, phosphorylation of BC6OTHER at BC6ENTC 15, expression of BC6ENTG , and decreased expression of BC6OTHER .	False
Treatment with BC6OTHER or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6OTHER 10, phosphorylation of BC6OTHER at BC6ENTC 15, expression of BC6OTHER , and decreased expression of BC6ENTG .	False
Inhibition of Th1 / Th17 responses via suppression of BC6ENTG and BC6OTHER activation contributes to the amelioration of murine experimental colitis by a natural BC6OTHER CHEM BC6ENTC .	CPR:4
Inhibition of Th1 / Th17 responses via suppression of BC6OTHER and BC6ENTG activation contributes to the amelioration of murine experimental colitis by a natural BC6OTHER CHEM BC6ENTC .	CPR:4
Moreover, BC6ENTC treatment inhibited the phosphorylations of BC6ENTG and BC6OTHER in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively.	CPR:4
Moreover, BC6ENTC treatment inhibited the phosphorylations of BC6OTHER and BC6ENTG in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively.	CPR:4
Further study showed that BC6ENTC dose - dependently inhibited the proliferation and activation of T lymphocytes, and suppressed pro - inflammatory BC6ENTG levels of activated T cells.	CPR:4
Inhibition of Th1 / Th17 responses via suppression of BC6ENTG and BC6OTHER activation contributes to the amelioration of murine experimental colitis by a natural BC6ENTC CHEM BC6OTHER .	CPR:4
Inhibition of Th1 / Th17 responses via suppression of BC6OTHER and BC6ENTG activation contributes to the amelioration of murine experimental colitis by a natural BC6ENTC CHEM BC6OTHER .	CPR:4
BC6ENTG overexpression in mice significantly increases plasma BC6OTHER levels while silencing BC6OTHER decreases BC6ENTC levels.	False
BC6OTHER overexpression in mice significantly increases plasma BC6OTHER levels while silencing BC6ENTG decreases BC6ENTC levels.	CPR:9
In mice, this reduction in BC6ENTG expression is due primarily to downregulation by BC6ENTC .	CPR:4
BC6ENTG expression is induced by dietary BC6ENTC by a mechanism that involves the BC6OTHER ( BC6OTHER ), a BC6OTHER - activated nuclear receptor.	CPR:3
BC6OTHER expression is induced by dietary BC6ENTC by a mechanism that involves the BC6ENTG ( BC6OTHER ), a BC6OTHER - activated nuclear receptor.	False
BC6OTHER expression is induced by dietary BC6ENTC by a mechanism that involves the BC6OTHER ( BC6ENTG ), a BC6OTHER - activated nuclear receptor.	False
BC6ENTG expression is induced by dietary BC6OTHER by a mechanism that involves the BC6OTHER ( BC6OTHER ), a BC6ENTC - activated nuclear receptor.	False
BC6OTHER expression is induced by dietary BC6OTHER by a mechanism that involves the BC6ENTG ( BC6OTHER ), a BC6ENTC - activated nuclear receptor.	CPR:3
BC6OTHER expression is induced by dietary BC6OTHER by a mechanism that involves the BC6OTHER ( BC6ENTG ), a BC6ENTC - activated nuclear receptor.	CPR:3
Analysis of natural genetic variation among inbred strains of mice indicates that BC6ENTG and BC6ENTC are significantly correlated, and BC6OTHER levels explain 11% of the variation in atherosclerosis.	CPR:9
Analysis of natural genetic variation among inbred strains of mice indicates that BC6ENTG and BC6OTHER are significantly correlated, and BC6ENTC levels explain 11% of the variation in atherosclerosis.	False
We demonstrate that two BC6ENTC mono - oxygenase family members, BC6ENTG and BC6OTHER , oxidize BC6OTHER ( BC6OTHER ), derived from gut flora metabolism of BC6OTHER , to BC6OTHER .	False
We demonstrate that two BC6ENTC mono - oxygenase family members, BC6OTHER and BC6ENTG , oxidize BC6OTHER ( BC6OTHER ), derived from gut flora metabolism of BC6OTHER , to BC6OTHER .	False
We demonstrate that two BC6ENTG family members, BC6OTHER and BC6OTHER , oxidize BC6ENTC ( BC6OTHER ), derived from gut flora metabolism of BC6OTHER , to BC6OTHER .	CPR:9
We demonstrate that two BC6OTHER mono - oxygenase family members, BC6ENTG and BC6OTHER , oxidize BC6ENTC ( BC6OTHER ), derived from gut flora metabolism of BC6OTHER , to BC6OTHER .	CPR:9
We demonstrate that two BC6OTHER mono - oxygenase family members, BC6OTHER and BC6ENTG , oxidize BC6ENTC ( BC6OTHER ), derived from gut flora metabolism of BC6OTHER , to BC6OTHER .	CPR:9
We demonstrate that two BC6ENTG family members, BC6OTHER and BC6OTHER , oxidize BC6OTHER ( BC6ENTC ), derived from gut flora metabolism of BC6OTHER , to BC6OTHER .	CPR:9
We demonstrate that two BC6OTHER mono - oxygenase family members, BC6ENTG and BC6OTHER , oxidize BC6OTHER ( BC6ENTC ), derived from gut flora metabolism of BC6OTHER , to BC6OTHER .	CPR:9
We demonstrate that two BC6OTHER mono - oxygenase family members, BC6OTHER and BC6ENTG , oxidize BC6OTHER ( BC6ENTC ), derived from gut flora metabolism of BC6OTHER , to BC6OTHER .	CPR:9
We demonstrate that two BC6ENTG family members, BC6OTHER and BC6OTHER , oxidize BC6OTHER ( BC6OTHER ), derived from gut flora metabolism of BC6ENTC , to BC6OTHER .	CPR:9
We demonstrate that two BC6OTHER mono - oxygenase family members, BC6ENTG and BC6OTHER , oxidize BC6OTHER ( BC6OTHER ), derived from gut flora metabolism of BC6ENTC , to BC6OTHER .	CPR:9
We demonstrate that two BC6OTHER mono - oxygenase family members, BC6OTHER and BC6ENTG , oxidize BC6OTHER ( BC6OTHER ), derived from gut flora metabolism of BC6ENTC , to BC6OTHER .	CPR:9
We demonstrate that two BC6ENTG family members, BC6OTHER and BC6OTHER , oxidize BC6OTHER ( BC6OTHER ), derived from gut flora metabolism of BC6OTHER , to BC6ENTC .	CPR:9
We demonstrate that two BC6OTHER mono - oxygenase family members, BC6ENTG and BC6OTHER , oxidize BC6OTHER ( BC6OTHER ), derived from gut flora metabolism of BC6OTHER , to BC6ENTC .	CPR:9
We demonstrate that two BC6OTHER mono - oxygenase family members, BC6OTHER and BC6ENTG , oxidize BC6OTHER ( BC6OTHER ), derived from gut flora metabolism of BC6OTHER , to BC6ENTC .	CPR:9
BC6ENTG overexpression in mice significantly increases plasma BC6ENTC levels while silencing BC6OTHER decreases BC6OTHER levels.	CPR:9
BC6OTHER overexpression in mice significantly increases plasma BC6ENTC levels while silencing BC6ENTG decreases BC6OTHER levels.	False
BG also showed a protective effect in the presence of a BC6ENTG inhibitor ( BC6ENTC , BC6OTHER ), demonstrating that BG does not act through an anti - mutagenic mechanism of action involving BC6OTHER .	CPR:4
BG also showed a protective effect in the presence of a BC6OTHER inhibitor ( BC6ENTC , BC6OTHER ), demonstrating that BG does not act through an anti - mutagenic mechanism of action involving BC6ENTG .	False
BG also showed a protective effect in the presence of a BC6ENTG inhibitor ( BC6OTHER , BC6ENTC ), demonstrating that BG does not act through an anti - mutagenic mechanism of action involving BC6OTHER .	CPR:4
BG also showed a protective effect in the presence of a BC6OTHER inhibitor ( BC6OTHER , BC6ENTC ), demonstrating that BG does not act through an anti - mutagenic mechanism of action involving BC6ENTG .	False
BC6ENTC + BC6OTHER were more effective than placebo+ BC6OTHER in reducing body weight and BMI, glycemic control, HOMA - IR, BC6ENTG and BC6OTHER resistance measurements.	False
BC6ENTC + BC6OTHER were more effective than placebo+ BC6OTHER in reducing body weight and BMI, glycemic control, HOMA - IR, BC6OTHER and BC6ENTG resistance measurements.	False
BC6OTHER + BC6ENTC were more effective than placebo+ BC6OTHER in reducing body weight and BMI, glycemic control, HOMA - IR, BC6ENTG and BC6OTHER resistance measurements.	False
BC6OTHER + BC6ENTC were more effective than placebo+ BC6OTHER in reducing body weight and BMI, glycemic control, HOMA - IR, BC6OTHER and BC6ENTG resistance measurements.	False
BC6OTHER + BC6OTHER were more effective than placebo+ BC6ENTC in reducing body weight and BMI, glycemic control, HOMA - IR, BC6ENTG and BC6OTHER resistance measurements.	False
BC6OTHER + BC6OTHER were more effective than placebo+ BC6ENTC in reducing body weight and BMI, glycemic control, HOMA - IR, BC6OTHER and BC6ENTG resistance measurements.	False
Evaluation of the positive effects on BC6ENTG - resistance and β - cell measurements of BC6OTHER in addition to BC6ENTC in type 2 diabetic patients.	False
Evaluation of the positive effects on BC6ENTG - resistance and β - cell measurements of BC6ENTC in addition to BC6OTHER in type 2 diabetic patients.	False
We also recorded a significant correlation between M value increase and the decrease of BC6ENTG , BC6OTHER , and BC6OTHER obtained with BC6ENTC + BC6OTHER .	False
We also recorded a significant correlation between M value increase and the decrease of BC6OTHER , BC6ENTG , and BC6OTHER obtained with BC6ENTC + BC6OTHER .	False
We also recorded a significant correlation between M value increase and the decrease of BC6OTHER , BC6OTHER , and BC6ENTG obtained with BC6ENTC + BC6OTHER .	False
We also recorded a significant correlation between M value increase and the decrease of BC6ENTG , BC6OTHER , and BC6OTHER obtained with BC6OTHER + BC6ENTC .	False
We also recorded a significant correlation between M value increase and the decrease of BC6OTHER , BC6ENTG , and BC6OTHER obtained with BC6OTHER + BC6ENTC .	False
We also recorded a significant correlation between M value increase and the decrease of BC6OTHER , BC6OTHER , and BC6ENTG obtained with BC6OTHER + BC6ENTC .	False
BC6ENTC , in addition to BC6OTHER , proved to be effective in improving β - cell function and in reducing BC6ENTG resistance measurements.	False
BC6OTHER , in addition to BC6ENTC , proved to be effective in improving β - cell function and in reducing BC6ENTG resistance measurements.	False
We examined BC6ENTC , BC6OTHER and BC6OTHER serum concentrations and polymorphism of the BC6ENTG BC6OTHER gene in Turkish children with neural tube defects.	False
We examined BC6ENTC , BC6OTHER and BC6OTHER serum concentrations and polymorphism of the BC6OTHER BC6ENTG gene in Turkish children with neural tube defects.	False
We examined BC6OTHER , BC6ENTC and BC6OTHER serum concentrations and polymorphism of the BC6ENTG BC6OTHER gene in Turkish children with neural tube defects.	False
We examined BC6OTHER , BC6ENTC and BC6OTHER serum concentrations and polymorphism of the BC6OTHER BC6ENTG gene in Turkish children with neural tube defects.	False
We examined BC6OTHER , BC6OTHER and BC6ENTC serum concentrations and polymorphism of the BC6ENTG BC6OTHER gene in Turkish children with neural tube defects.	False
We examined BC6OTHER , BC6OTHER and BC6ENTC serum concentrations and polymorphism of the BC6OTHER BC6ENTG gene in Turkish children with neural tube defects.	False
The levels of BC6ENTC , BC6OTHER and BC6OTHER serum concentrations in NTDs were evaluated and compared, along with information concerning alleles of the BC6ENTG gene.	False
The levels of BC6OTHER , BC6ENTC and BC6OTHER serum concentrations in NTDs were evaluated and compared, along with information concerning alleles of the BC6ENTG gene.	False
The levels of BC6OTHER , BC6OTHER and BC6ENTC serum concentrations in NTDs were evaluated and compared, along with information concerning alleles of the BC6ENTG gene.	False
Association between neural tube defects (NTDs) and BC6OTHER polymorphism of the BC6ENTC reductase ( BC6ENTG ) gene was suspected, because the BC6OTHER gene codes for a key enzyme in BC6OTHER metabolism.	False
Association between neural tube defects (NTDs) and BC6OTHER polymorphism of the BC6ENTC reductase ( BC6OTHER ) gene was suspected, because the BC6ENTG gene codes for a key enzyme in BC6OTHER metabolism.	False
Association between neural tube defects (NTDs) and BC6ENTG polymorphism of the BC6ENTC reductase ( BC6OTHER ) gene was suspected, because the BC6OTHER gene codes for a key enzyme in BC6OTHER metabolism.	False
 BC6ENTG polymorphism of the BC6OTHER gene does not affect BC6OTHER , BC6OTHER , and BC6ENTC serum levels in Turkish children with neural tube defects.	False
 BC6OTHER polymorphism of the BC6ENTG gene does not affect BC6OTHER , BC6OTHER , and BC6ENTC serum levels in Turkish children with neural tube defects.	False
 BC6ENTG polymorphism of the BC6ENTC reductase gene does not affect BC6OTHER , BC6OTHER , and BC6OTHER serum levels in Turkish children with neural tube defects.	False
 BC6ENTG polymorphism of the BC6OTHER gene does not affect BC6ENTC , BC6OTHER , and BC6OTHER serum levels in Turkish children with neural tube defects.	False
 BC6OTHER polymorphism of the BC6ENTG gene does not affect BC6ENTC , BC6OTHER , and BC6OTHER serum levels in Turkish children with neural tube defects.	False
 BC6ENTG polymorphism of the BC6OTHER gene does not affect BC6OTHER , BC6ENTC , and BC6OTHER serum levels in Turkish children with neural tube defects.	False
 BC6OTHER polymorphism of the BC6ENTG gene does not affect BC6OTHER , BC6ENTC , and BC6OTHER serum levels in Turkish children with neural tube defects.	False
We concluded that BC6ENTG BC6OTHER gene polymorphism does not affect BC6ENTC , BC6OTHER and BC6OTHER metabolism in Turkish children with NTDs.	False
We concluded that BC6OTHER BC6ENTG gene polymorphism does not affect BC6ENTC , BC6OTHER and BC6OTHER metabolism in Turkish children with NTDs.	False
We concluded that BC6ENTG BC6OTHER gene polymorphism does not affect BC6OTHER , BC6ENTC and BC6OTHER metabolism in Turkish children with NTDs.	False
We concluded that BC6OTHER BC6ENTG gene polymorphism does not affect BC6OTHER , BC6ENTC and BC6OTHER metabolism in Turkish children with NTDs.	False
We concluded that BC6ENTG BC6OTHER gene polymorphism does not affect BC6OTHER , BC6OTHER and BC6ENTC metabolism in Turkish children with NTDs.	False
We concluded that BC6OTHER BC6ENTG gene polymorphism does not affect BC6OTHER , BC6OTHER and BC6ENTC metabolism in Turkish children with NTDs.	False
Association between neural tube defects (NTDs) and BC6OTHER polymorphism of the BC6OTHER ( BC6ENTG ) gene was suspected, because the BC6OTHER gene codes for a key enzyme in BC6ENTC metabolism.	False
Association between neural tube defects (NTDs) and BC6OTHER polymorphism of the BC6OTHER ( BC6OTHER ) gene was suspected, because the BC6ENTG gene codes for a key enzyme in BC6ENTC metabolism.	False
Association between neural tube defects (NTDs) and BC6ENTG polymorphism of the BC6OTHER ( BC6OTHER ) gene was suspected, because the BC6OTHER gene codes for a key enzyme in BC6ENTC metabolism.	False
Association between neural tube defects (NTDs) and BC6OTHER polymorphism of the BC6ENTG ( BC6OTHER ) gene was suspected, because the BC6OTHER gene codes for a key enzyme in BC6ENTC metabolism.	False
BC6ENTC induced G2 / M phase cell cycle arrest and modulated the levels of BC6ENTG and BC6OTHER in Hec1A cells.	False
BC6ENTC induced G2 / M phase cell cycle arrest and modulated the levels of BC6OTHER and BC6ENTG in Hec1A cells.	False
Knockdown of BC6ENTG using specific siRNAs partially abrogated BC6ENTC - induced cell growth inhibition.	False
Additional mechanistic studies revealed that BC6ENTC treatment resulted in an increase in phosphorylation of BC6ENTG and BC6OTHER - BC6OTHER .	CPR:3
Additional mechanistic studies revealed that BC6ENTC treatment resulted in an increase in phosphorylation of BC6OTHER and BC6ENTG - BC6OTHER .	CPR:3
Additional mechanistic studies revealed that BC6ENTC treatment resulted in an increase in phosphorylation of BC6OTHER and BC6OTHER - BC6ENTG .	False
 BC6ENTC , isolated from dietary mugwort (Artemisia princeps), induces G2 / M cell cycle arrest by inactivating BC6ENTG - BC6OTHER via BC6OTHER - BC6OTHER activation.	CPR:4
 BC6ENTC , isolated from dietary mugwort (Artemisia princeps), induces G2 / M cell cycle arrest by inactivating BC6OTHER - BC6ENTG via BC6OTHER - BC6OTHER activation.	CPR:4
 BC6ENTC , isolated from dietary mugwort (Artemisia princeps), induces G2 / M cell cycle arrest by inactivating BC6OTHER - BC6OTHER via BC6ENTG - BC6OTHER activation.	CPR:3
 BC6ENTC , isolated from dietary mugwort (Artemisia princeps), induces G2 / M cell cycle arrest by inactivating BC6OTHER - BC6OTHER via BC6OTHER - BC6ENTG activation.	False
CHEM, an BC6ENTG inhibitor, reversed BC6ENTC - induced cell growth inhibition, in part.	False
Moreover, BC6ENTC treatment resulted in phosphorylation of BC6ENTG , and pretreatment with the BC6OTHER inhibitor, BC6OTHER , attenuated cell growth inhibition by BC6OTHER .	False
Moreover, BC6ENTC treatment resulted in phosphorylation of BC6OTHER , and pretreatment with the BC6ENTG inhibitor, BC6OTHER , attenuated cell growth inhibition by BC6OTHER .	False
Moreover, BC6OTHER treatment resulted in phosphorylation of BC6ENTG , and pretreatment with the BC6OTHER inhibitor, BC6ENTC , attenuated cell growth inhibition by BC6OTHER .	False
Moreover, BC6OTHER treatment resulted in phosphorylation of BC6OTHER , and pretreatment with the BC6ENTG inhibitor, BC6ENTC , attenuated cell growth inhibition by BC6OTHER .	CPR:4
Moreover, BC6OTHER treatment resulted in phosphorylation of BC6ENTG , and pretreatment with the BC6OTHER inhibitor, BC6OTHER , attenuated cell growth inhibition by BC6ENTC .	False
Moreover, BC6OTHER treatment resulted in phosphorylation of BC6OTHER , and pretreatment with the BC6ENTG inhibitor, BC6OTHER , attenuated cell growth inhibition by BC6ENTC .	False
These data suggest that BC6ENTC , isolated from Japanese mugwort, modulates the BC6ENTG / BC6OTHER / BC6OTHER pathway, leading to inactivation of the BC6OTHER - BC6OTHER complex, followed by G2 / M cell cycle arrest in endometrial cancer cells.	False
These data suggest that BC6ENTC , isolated from Japanese mugwort, modulates the BC6OTHER / BC6ENTG / BC6OTHER pathway, leading to inactivation of the BC6OTHER - BC6OTHER complex, followed by G2 / M cell cycle arrest in endometrial cancer cells.	False
These data suggest that BC6ENTC , isolated from Japanese mugwort, modulates the BC6OTHER / BC6OTHER / BC6ENTG pathway, leading to inactivation of the BC6OTHER - BC6OTHER complex, followed by G2 / M cell cycle arrest in endometrial cancer cells.	False
These data suggest that BC6ENTC , isolated from Japanese mugwort, modulates the BC6OTHER / BC6OTHER / BC6OTHER pathway, leading to inactivation of the BC6ENTG - BC6OTHER complex, followed by G2 / M cell cycle arrest in endometrial cancer cells.	CPR:4
These data suggest that BC6ENTC , isolated from Japanese mugwort, modulates the BC6OTHER / BC6OTHER / BC6OTHER pathway, leading to inactivation of the BC6OTHER - BC6ENTG complex, followed by G2 / M cell cycle arrest in endometrial cancer cells.	CPR:4
To explore the functional properties of the two alleles, a full - length cDNA encoding the beta subunit, a key functional component of the BC6ENTC receptor, was isolated from Caenorhabditis elegans ( BC6ENTG , corresponding to the BC6OTHER ) and coexpressed in Xenopus oocytes with the BC6OTHER alleles.	False
To explore the functional properties of the two alleles, a full - length cDNA encoding the beta subunit, a key functional component of the BC6ENTC receptor, was isolated from Caenorhabditis elegans ( BC6OTHER , corresponding to the BC6ENTG ) and coexpressed in Xenopus oocytes with the BC6OTHER alleles.	False
To explore the functional properties of the two alleles, a full - length cDNA encoding the beta subunit, a key functional component of the BC6ENTC receptor, was isolated from Caenorhabditis elegans ( BC6OTHER , corresponding to the BC6OTHER ) and coexpressed in Xenopus oocytes with the BC6ENTG alleles.	False
Two alleles of the BC6ENTG gene, which encodes a putative BC6ENTC receptor alpha / gamma subunit, were isolated from Haemonchus contortus.	False
When BC6ENTG was coexpressed with either the BC6OTHER allele or the BC6OTHER allele in Xenopus oocytes, BC6ENTC ( BC6OTHER ) - responsive channels with different sensitivity to the agonist were formed.	False
When BC6OTHER was coexpressed with either the BC6ENTG allele or the BC6OTHER allele in Xenopus oocytes, BC6ENTC ( BC6OTHER ) - responsive channels with different sensitivity to the agonist were formed.	False
When BC6OTHER was coexpressed with either the BC6OTHER allele or the BC6ENTG allele in Xenopus oocytes, BC6ENTC ( BC6OTHER ) - responsive channels with different sensitivity to the agonist were formed.	False
When BC6ENTG was coexpressed with either the BC6OTHER allele or the BC6OTHER allele in Xenopus oocytes, CHEM ( BC6ENTC ) - responsive channels with different sensitivity to the agonist were formed.	False
When BC6OTHER was coexpressed with either the BC6ENTG allele or the BC6OTHER allele in Xenopus oocytes, CHEM ( BC6ENTC ) - responsive channels with different sensitivity to the agonist were formed.	False
When BC6OTHER was coexpressed with either the BC6OTHER allele or the BC6ENTG allele in Xenopus oocytes, CHEM ( BC6ENTC ) - responsive channels with different sensitivity to the agonist were formed.	False
Study of the nematode putative BC6ENTG subunits: evidence for modulation by BC6ENTC .	False
However, when coapplied with 10 micro m BC6ENTC , BC6OTHER potentiated the BC6OTHER - evoked current of the BC6ENTG / BC6OTHER receptor, but attenuated the BC6OTHER response of the BC6OTHER / BC6OTHER receptor.	False
However, when coapplied with 10 micro m BC6ENTC , BC6OTHER potentiated the BC6OTHER - evoked current of the BC6OTHER / BC6ENTG receptor, but attenuated the BC6OTHER response of the BC6OTHER / BC6OTHER receptor.	False
However, when coapplied with 10 micro m BC6ENTC , BC6OTHER potentiated the BC6OTHER - evoked current of the BC6OTHER / BC6OTHER receptor, but attenuated the BC6OTHER response of the BC6ENTG / BC6OTHER receptor.	False
However, when coapplied with 10 micro m BC6ENTC , BC6OTHER potentiated the BC6OTHER - evoked current of the BC6OTHER / BC6OTHER receptor, but attenuated the BC6OTHER response of the BC6OTHER / BC6ENTG receptor.	False
However, when coapplied with 10 micro m BC6OTHER , BC6ENTC potentiated the BC6OTHER - evoked current of the BC6ENTG / BC6OTHER receptor, but attenuated the BC6OTHER response of the BC6OTHER / BC6OTHER receptor.	CPR:3
However, when coapplied with 10 micro m BC6OTHER , BC6ENTC potentiated the BC6OTHER - evoked current of the BC6OTHER / BC6ENTG receptor, but attenuated the BC6OTHER response of the BC6OTHER / BC6OTHER receptor.	CPR:3
However, when coapplied with 10 micro m BC6OTHER , BC6ENTC potentiated the BC6OTHER - evoked current of the BC6OTHER / BC6OTHER receptor, but attenuated the BC6OTHER response of the BC6ENTG / BC6OTHER receptor.	CPR:4
However, when coapplied with 10 micro m BC6OTHER , BC6ENTC potentiated the BC6OTHER - evoked current of the BC6OTHER / BC6OTHER receptor, but attenuated the BC6OTHER response of the BC6OTHER / BC6ENTG receptor.	CPR:4
However, when coapplied with 10 micro m BC6OTHER , BC6OTHER potentiated the BC6ENTC - evoked current of the BC6ENTG / BC6OTHER receptor, but attenuated the BC6OTHER response of the BC6OTHER / BC6OTHER receptor.	False
However, when coapplied with 10 micro m BC6OTHER , BC6OTHER potentiated the BC6ENTC - evoked current of the BC6OTHER / BC6ENTG receptor, but attenuated the BC6OTHER response of the BC6OTHER / BC6OTHER receptor.	False
However, when coapplied with 10 micro m BC6OTHER , BC6OTHER potentiated the BC6ENTC - evoked current of the BC6OTHER / BC6OTHER receptor, but attenuated the BC6OTHER response of the BC6ENTG / BC6OTHER receptor.	False
However, when coapplied with 10 micro m BC6OTHER , BC6OTHER potentiated the BC6ENTC - evoked current of the BC6OTHER / BC6OTHER receptor, but attenuated the BC6OTHER response of the BC6OTHER / BC6ENTG receptor.	False
However, when coapplied with 10 micro m BC6OTHER , BC6OTHER potentiated the BC6OTHER - evoked current of the BC6ENTG / BC6OTHER receptor, but attenuated the BC6ENTC response of the BC6OTHER / BC6OTHER receptor.	False
However, when coapplied with 10 micro m BC6OTHER , BC6OTHER potentiated the BC6OTHER - evoked current of the BC6OTHER / BC6ENTG receptor, but attenuated the BC6ENTC response of the BC6OTHER / BC6OTHER receptor.	False
However, when coapplied with 10 micro m BC6OTHER , BC6OTHER potentiated the BC6OTHER - evoked current of the BC6OTHER / BC6OTHER receptor, but attenuated the BC6ENTC response of the BC6ENTG / BC6OTHER receptor.	False
However, when coapplied with 10 micro m BC6OTHER , BC6OTHER potentiated the BC6OTHER - evoked current of the BC6OTHER / BC6OTHER receptor, but attenuated the BC6ENTC response of the BC6OTHER / BC6ENTG receptor.	False
We demonstrated that the coexpressed BC6ENTG and BC6OTHER receptors are BC6ENTC - responsive, and provide evidence for the possible involvement of BC6OTHER receptors in the mechanism of BC6OTHER resistance.	False
We demonstrated that the coexpressed BC6OTHER and BC6ENTG receptors are BC6ENTC - responsive, and provide evidence for the possible involvement of BC6OTHER receptors in the mechanism of BC6OTHER resistance.	False
We demonstrated that the coexpressed BC6OTHER and BC6OTHER receptors are BC6ENTC - responsive, and provide evidence for the possible involvement of BC6ENTG in the mechanism of BC6OTHER resistance.	False
We demonstrated that the coexpressed BC6ENTG and BC6OTHER receptors are BC6OTHER - responsive, and provide evidence for the possible involvement of BC6ENTC receptors in the mechanism of BC6OTHER resistance.	False
We demonstrated that the coexpressed BC6OTHER and BC6ENTG receptors are BC6OTHER - responsive, and provide evidence for the possible involvement of BC6ENTC receptors in the mechanism of BC6OTHER resistance.	False
We demonstrated that the coexpressed BC6ENTG and BC6OTHER receptors are BC6OTHER - responsive, and provide evidence for the possible involvement of BC6OTHER receptors in the mechanism of BC6ENTC resistance.	False
We demonstrated that the coexpressed BC6OTHER and BC6ENTG receptors are BC6OTHER - responsive, and provide evidence for the possible involvement of BC6OTHER receptors in the mechanism of BC6ENTC resistance.	False
We demonstrated that the coexpressed BC6OTHER and BC6OTHER receptors are BC6OTHER - responsive, and provide evidence for the possible involvement of BC6ENTG in the mechanism of BC6ENTC resistance.	False
These two alleles were shown previously to be associated with BC6ENTC susceptibility ( BC6ENTG ) and resistance ( BC6OTHER ), respectively.	False
These two alleles were shown previously to be associated with BC6ENTC susceptibility ( BC6OTHER ) and resistance ( BC6ENTG ), respectively.	False
BC6ENTC exhibited the predicted binding mode and demonstrated high inhibitory activity for BC6ENTG in enzyme - and cell - based assays.	CPR:4
BC6ENTG ( BC6OTHER ) catalyzes the oxidation of BC6OTHER including BC6ENTC , a coagonist of the BC6OTHER receptor.	CPR:9
BC6OTHER oxidase ( BC6OTHER ) catalyzes the oxidation of BC6OTHER including BC6ENTC , a coagonist of the BC6ENTG .	CPR:5
BC6OTHER oxidase ( BC6ENTG ) catalyzes the oxidation of BC6OTHER including BC6ENTC , a coagonist of the BC6OTHER receptor.	CPR:9
 BC6ENTC Derivatives as Novel BC6ENTG Inhibitors.	CPR:4
BC6ENTC oxidase ( BC6OTHER ) catalyzes the oxidation of BC6OTHER including BC6OTHER , a coagonist of the BC6ENTG .	False
BC6ENTC oxidase ( BC6ENTG ) catalyzes the oxidation of BC6OTHER including BC6OTHER , a coagonist of the BC6OTHER receptor.	False
BC6ENTG ( BC6OTHER ) catalyzes the oxidation of BC6OTHER including BC6OTHER , a coagonist of the BC6ENTC receptor.	False
BC6OTHER oxidase ( BC6ENTG ) catalyzes the oxidation of BC6OTHER including BC6OTHER , a coagonist of the BC6ENTC receptor.	False
We identified a series of BC6ENTC derivatives as novel BC6ENTG inhibitors with high potency and substantial cell permeability using fragment - based drug design.	CPR:4
BC6ENTG ( BC6OTHER ) catalyzes the oxidation of BC6ENTC including BC6OTHER , a coagonist of the BC6OTHER receptor.	CPR:9
BC6OTHER oxidase ( BC6OTHER ) catalyzes the oxidation of BC6ENTC including BC6OTHER , a coagonist of the BC6ENTG .	False
BC6OTHER oxidase ( BC6ENTG ) catalyzes the oxidation of BC6ENTC including BC6OTHER , a coagonist of the BC6OTHER receptor.	CPR:9
 Oral BC6ENTC ( BC6OTHER (®)), a selective BC6OTHER BC6ENTG receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight - related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes).	CPR:5
 Oral BC6OTHER ( BC6ENTC (®)), a selective BC6OTHER BC6ENTG receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight - related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes).	CPR:5
 Oral BC6OTHER ( BC6OTHER (®)), a selective BC6ENTC BC6ENTG receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight - related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes).	False
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of BC6ENTC synthase ( BC6ENTG ; BC6OTHER - BC6OTHER : BC6OTHER glucosyltransferase).	False
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of BC6ENTC synthase ( BC6OTHER ; BC6ENTG BC6OTHER glucosyltransferase).	False
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of BC6OTHER ( BC6ENTG ; BC6ENTC - BC6OTHER : BC6OTHER glucosyltransferase).	False
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of BC6ENTG ( BC6OTHER ; BC6ENTC - BC6OTHER : BC6OTHER glucosyltransferase).	False
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of BC6OTHER ( BC6ENTG ; BC6OTHER - BC6ENTC : BC6OTHER glucosyltransferase).	False
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of BC6ENTG ( BC6OTHER ; BC6OTHER - BC6ENTC : BC6OTHER glucosyltransferase).	False
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of BC6OTHER ( BC6ENTG ; BC6OTHER - BC6OTHER : BC6ENTC glucosyltransferase).	False
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of BC6OTHER ( BC6OTHER ; BC6ENTG BC6ENTC glucosyltransferase).	False
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of BC6ENTG ( BC6OTHER ; BC6OTHER - BC6OTHER : BC6ENTC glucosyltransferase).	False
Consequently, mice with inducible forebrain neuron - specific deletion of the BC6ENTC - BC6OTHER : BC6OTHER glucosyltransferase gene ( BC6ENTG ) display obesity, hypothermia, and lower sympathetic activity.	False
Consequently, mice with inducible forebrain neuron - specific deletion of the BC6OTHER - BC6ENTC : BC6OTHER glucosyltransferase gene ( BC6ENTG ) display obesity, hypothermia, and lower sympathetic activity.	False
Consequently, mice with inducible forebrain neuron - specific deletion of the BC6ENTG BC6ENTC glucosyltransferase gene ( BC6OTHER ) display obesity, hypothermia, and lower sympathetic activity.	False
Consequently, mice with inducible forebrain neuron - specific deletion of the BC6OTHER - BC6OTHER : BC6ENTC glucosyltransferase gene ( BC6ENTG ) display obesity, hypothermia, and lower sympathetic activity.	False
BC6ENTC , an effective compound derived from foxtail - like sophora herb and seed, has been reported that it can alleviate non - alcoholic steatohepatitis (NASH) in rats and affect BC6ENTG synthesis.	False
Moreover, compared with the model group, BC6ENTC could significantly increase BC6OTHER (>5.82 - fold), BC6OTHER (>1.29 - fold) and BC6ENTG (>3.27 - fold) protein expressions, and reduce BC6OTHER (<0.30 - fold) and BC6OTHER (<0.20 - fold) protein expression.	CPR:3
Moreover, compared with the model group, BC6ENTC could significantly increase BC6OTHER (>5.82 - fold), BC6OTHER (>1.29 - fold) and BC6OTHER (>3.27 - fold) protein expressions, and reduce BC6ENTG (<0.30 - fold) and BC6OTHER (<0.20 - fold) protein expression.	CPR:4
Moreover, compared with the model group, BC6ENTC could significantly increase BC6OTHER (>5.82 - fold), BC6OTHER (>1.29 - fold) and BC6OTHER (>3.27 - fold) protein expressions, and reduce BC6OTHER (<0.30 - fold) and BC6ENTG (<0.20 - fold) protein expression.	CPR:4
Moreover, compared with the model group, BC6ENTC could significantly increase BC6ENTG (>5.82 - fold), BC6OTHER (>1.29 - fold) and BC6OTHER (>3.27 - fold) protein expressions, and reduce BC6OTHER (<0.30 - fold) and BC6OTHER (<0.20 - fold) protein expression.	CPR:3
Moreover, compared with the model group, BC6ENTC could significantly increase BC6OTHER (>5.82 - fold), BC6ENTG (>1.29 - fold) and BC6OTHER (>3.27 - fold) protein expressions, and reduce BC6OTHER (<0.30 - fold) and BC6OTHER (<0.20 - fold) protein expression.	CPR:3
We concluded that BC6ENTC could alleviate hepatocyte steatosis and the potential mechanism might be the activated signaling pathway of BC6ENTG .	CPR:3
While BC6ENTC treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of BC6ENTG expression (<0.57 - fold) and increase of BC6OTHER expression (>1.48 - fold).	CPR:4
While BC6ENTC treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of BC6OTHER expression (<0.57 - fold) and increase of BC6ENTG expression (>1.48 - fold).	CPR:3
 BC6ENTC alleviates hepatocyte steatosis through activating BC6ENTG signaling pathway.	CPR:3
Taken together, the levels of plasma four FAs with shorter BC6OTHER chains were higher in pregnant BC6ENTG mice than in other genotypes, and BC6OTHER exposure decreased these specific FA concentrations only in BC6OTHER mice, similarly to BC6ENTC levels.	False
Taken together, the levels of plasma four FAs with shorter BC6OTHER chains were higher in pregnant BC6OTHER mice than in other genotypes, and BC6OTHER exposure decreased these specific FA concentrations only in BC6ENTG mice, similarly to BC6ENTC levels.	False
To identify the BC6OTHER (FA) species involved and to understand the underlying mechanisms, pregnant Sv / 129 wild - type ( BC6ENTG ), BC6OTHER - null ( BC6OTHER - null) and BC6OTHER ( BC6OTHER ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% BC6ENTC .	False
To identify the BC6OTHER (FA) species involved and to understand the underlying mechanisms, pregnant Sv / 129 wild - type ( BC6OTHER ), BC6ENTG - null ( BC6OTHER - null) and BC6OTHER ( BC6OTHER ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% BC6ENTC .	False
To identify the BC6OTHER (FA) species involved and to understand the underlying mechanisms, pregnant Sv / 129 wild - type ( BC6OTHER ), BC6OTHER - null ( BC6ENTG - null) and BC6OTHER ( BC6OTHER ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% BC6ENTC .	False
To identify the BC6OTHER (FA) species involved and to understand the underlying mechanisms, pregnant Sv / 129 wild - type ( BC6OTHER ), BC6OTHER - null ( BC6OTHER - null) and BC6ENTG ( BC6OTHER ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% BC6ENTC .	False
To identify the BC6OTHER (FA) species involved and to understand the underlying mechanisms, pregnant Sv / 129 wild - type ( BC6OTHER ), BC6OTHER - null ( BC6OTHER - null) and BC6OTHER ( BC6ENTG ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% BC6ENTC .	False
The plasma levels of BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER were higher in the pregnant control BC6ENTG mice than in BC6OTHER - null and BC6OTHER mice.	False
The plasma levels of BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER were higher in the pregnant control BC6OTHER mice than in BC6ENTG - null and BC6OTHER mice.	False
The plasma levels of BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER were higher in the pregnant control BC6OTHER mice than in BC6OTHER - null and BC6ENTG mice.	False
The plasma levels of BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER were higher in the pregnant control BC6ENTG mice than in BC6OTHER - null and BC6OTHER mice.	False
The plasma levels of BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER were higher in the pregnant control BC6OTHER mice than in BC6ENTG - null and BC6OTHER mice.	False
The plasma levels of BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER were higher in the pregnant control BC6OTHER mice than in BC6OTHER - null and BC6ENTG mice.	False
The plasma levels of BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER were higher in the pregnant control BC6ENTG mice than in BC6OTHER - null and BC6OTHER mice.	False
The plasma levels of BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER were higher in the pregnant control BC6OTHER mice than in BC6ENTG - null and BC6OTHER mice.	False
The plasma levels of BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER were higher in the pregnant control BC6OTHER mice than in BC6OTHER - null and BC6ENTG mice.	False
The plasma levels of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC were higher in the pregnant control BC6ENTG mice than in BC6OTHER - null and BC6OTHER mice.	False
The plasma levels of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC were higher in the pregnant control BC6OTHER mice than in BC6ENTG - null and BC6OTHER mice.	False
The plasma levels of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC were higher in the pregnant control BC6OTHER mice than in BC6OTHER - null and BC6ENTG mice.	False
BC6ENTC exposure significantly decreased the levels of these four FAs only in pregnant BC6ENTG mice.	False
To identify the BC6ENTC (FA) species involved and to understand the underlying mechanisms, pregnant Sv / 129 wild - type ( BC6ENTG ), BC6OTHER - null ( BC6OTHER - null) and BC6OTHER ( BC6OTHER ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% BC6OTHER .	False
To identify the BC6ENTC (FA) species involved and to understand the underlying mechanisms, pregnant Sv / 129 wild - type ( BC6OTHER ), BC6ENTG - null ( BC6OTHER - null) and BC6OTHER ( BC6OTHER ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% BC6OTHER .	False
To identify the BC6ENTC (FA) species involved and to understand the underlying mechanisms, pregnant Sv / 129 wild - type ( BC6OTHER ), BC6OTHER - null ( BC6ENTG - null) and BC6OTHER ( BC6OTHER ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% BC6OTHER .	False
To identify the BC6ENTC (FA) species involved and to understand the underlying mechanisms, pregnant Sv / 129 wild - type ( BC6OTHER ), BC6OTHER - null ( BC6OTHER - null) and BC6ENTG ( BC6OTHER ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% BC6OTHER .	False
To identify the BC6ENTC (FA) species involved and to understand the underlying mechanisms, pregnant Sv / 129 wild - type ( BC6OTHER ), BC6OTHER - null ( BC6OTHER - null) and BC6OTHER ( BC6ENTG ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% BC6OTHER .	False
However, BC6ENTC exposure did not clearly influence BC6ENTG nor BC6OTHER expressions in the liver of all maternal mice.	False
However, BC6ENTC exposure did not clearly influence BC6OTHER nor BC6ENTG expressions in the liver of all maternal mice.	False
Taken together, the levels of plasma four FAs with shorter BC6ENTC chains were higher in pregnant BC6ENTG mice than in other genotypes, and BC6OTHER exposure decreased these specific FA concentrations only in BC6OTHER mice, similarly to BC6OTHER levels.	False
Taken together, the levels of plasma four FAs with shorter BC6ENTC chains were higher in pregnant BC6OTHER mice than in other genotypes, and BC6OTHER exposure decreased these specific FA concentrations only in BC6ENTG mice, similarly to BC6OTHER levels.	False
Taken together, the levels of plasma four FAs with shorter BC6OTHER chains were higher in pregnant BC6ENTG mice than in other genotypes, and BC6ENTC exposure decreased these specific FA concentrations only in BC6OTHER mice, similarly to BC6OTHER levels.	False
Taken together, the levels of plasma four FAs with shorter BC6OTHER chains were higher in pregnant BC6OTHER mice than in other genotypes, and BC6ENTC exposure decreased these specific FA concentrations only in BC6ENTG mice, similarly to BC6OTHER levels.	False
With exposure to BC6ENTC , a selective BC6ENTG inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective BC6OTHER inhibitors in breast cancer prophylaxis.	CPR:4
With exposure to BC6ENTC , a selective BC6OTHER inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective BC6ENTG inhibitors in breast cancer prophylaxis.	CPR:4
METHODS: We conducted a case - control study to measure the association between selective BC6ENTG inhibitors, particularly BC6ENTC , BC6OTHER , BC6OTHER and non - specific NSAID subgroups, and breast cancer risk.	CPR:4
METHODS: We conducted a case - control study to measure the association between selective BC6ENTG inhibitors, particularly BC6OTHER , BC6ENTC , BC6OTHER and non - specific NSAID subgroups, and breast cancer risk.	CPR:4
METHODS: We conducted a case - control study to measure the association between selective BC6ENTG inhibitors, particularly BC6OTHER , BC6OTHER , BC6ENTC and non - specific NSAID subgroups, and breast cancer risk.	CPR:4
BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non - BC6ENTC anti - inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of BC6ENTG ( BC6OTHER ).	CPR:4
BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non - BC6ENTC anti - inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of BC6OTHER ( BC6ENTG ).	CPR:4
Systemic administration of BC6ENTC recapitulates many of its effects when administered centrally, raising the questions of whether and to what extent circulating BC6ENTG contributes to energy regulation.	False
The neuropeptide BC6ENTG has emerged as an important BC6ENTC in the regulation of energy balance.	False
Systemic administration of BC6ENTG recapitulates many of its effects when administered centrally, raising the questions of whether and to what extent circulating BC6ENTC contributes to energy regulation.	False
A comparison of BC6OTHER with BC6ENTC across the whole BC6ENTG panel revealed overlapping, but distinct, inhibition profiles.	CPR:4
BC6ENTC did not inhibit BC6ENTG or BC6OTHER , but prominently targeted the apoptosis - linked BC6OTHER .	False
BC6ENTC did not inhibit BC6OTHER or BC6ENTG , but prominently targeted the apoptosis - linked BC6OTHER .	False
BC6ENTC did not inhibit BC6OTHER or BC6OTHER , but prominently targeted the apoptosis - linked BC6ENTG .	False
Global target profile of the BC6ENTG inhibitor BC6ENTC in primary chronic myeloid leukemia cells.	CPR:4
Although in vivo BC6ENTC is inactive against BC6ENTG BC6OTHER , we found this clinically important mutant to be enzymatically inhibited in the mid - nanomolar range.	False
Although in vivo BC6ENTC is inactive against BC6OTHER BC6ENTG , we found this clinically important mutant to be enzymatically inhibited in the mid - nanomolar range.	False
Finally, BC6ENTC is the first BC6ENTG inhibitor shown to target BC6OTHER , recently implicated in myeloid leukemia cell proliferation.	CPR:4
Finally, BC6ENTC is the first BC6OTHER inhibitor shown to target BC6ENTG , recently implicated in myeloid leukemia cell proliferation.	CPR:4
Here, we characterized the target profile of the dual BC6ENTG / BC6OTHER inhibitor BC6ENTC employing a two - tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro BC6OTHER assays against a large recombinant BC6OTHER panel.	CPR:4
Here, we characterized the target profile of the dual BC6OTHER / BC6ENTG inhibitor BC6ENTC employing a two - tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro BC6OTHER assays against a large recombinant BC6OTHER panel.	CPR:4
Here, we characterized the target profile of the dual BC6OTHER / BC6OTHER inhibitor BC6ENTC employing a two - tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro BC6ENTG assays against a large recombinant BC6OTHER panel.	False
Here, we characterized the target profile of the dual BC6OTHER / BC6OTHER inhibitor BC6ENTC employing a two - tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro BC6OTHER assays against a large recombinant BC6ENTG panel.	False
The combined strategy resulted in a global survey of BC6ENTC targets comprised of over 45 novel BC6ENTG BC6OTHER kinases.	False
The combined strategy resulted in a global survey of BC6OTHER targets comprised of over 45 novel BC6ENTG BC6ENTC kinases.	False
A comparison of BC6ENTC with BC6OTHER across the whole BC6ENTG panel revealed overlapping, but distinct, inhibition profiles.	CPR:4
These findings indicate that MBE and its BC6ENTC suppress the light - induced photoreceptor cell death by inhibiting ROS production, suggesting that the inhibition of BC6ENTG may be involved in the underlying mechanism.	CPR:4
Maqui berry (Aristotelia chilensis) and the constituent BC6ENTC inhibit BC6ENTG cell death induced by visible light.	CPR:3
BC6ENTC - evoked currents were completely and reversibly blocked by the competitive BC6ENTG antagonist BC6OTHER (IC50 = 1.7 microM), indicating expression of BC6OTHER but not BC6OTHER .	False
BC6ENTC - evoked currents were completely and reversibly blocked by the competitive BC6OTHER antagonist BC6OTHER (IC50 = 1.7 microM), indicating expression of BC6ENTG but not BC6OTHER .	False
BC6ENTC - evoked currents were completely and reversibly blocked by the competitive BC6OTHER antagonist BC6OTHER (IC50 = 1.7 microM), indicating expression of BC6OTHER but not BC6ENTG .	False
BC6OTHER - evoked currents were completely and reversibly blocked by the competitive BC6ENTG antagonist BC6ENTC (IC50 = 1.7 microM), indicating expression of BC6OTHER but not BC6OTHER .	CPR:6
BC6OTHER - evoked currents were completely and reversibly blocked by the competitive BC6OTHER antagonist BC6ENTC (IC50 = 1.7 microM), indicating expression of BC6ENTG but not BC6OTHER .	False
BC6OTHER - evoked currents were completely and reversibly blocked by the competitive BC6OTHER antagonist BC6ENTC (IC50 = 1.7 microM), indicating expression of BC6OTHER but not BC6ENTG .	False
Their affinity for BC6ENTC was moderate (EC50 = 30 microM), and the Hill coefficient was 1.3, corresponding to two BC6ENTG .	False
Furthermore, BC6ENTC receptors of horizontal cells were modulated by extracellular application of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , thus showing typical pharmacological properties of CNS BC6ENTG .	False
Furthermore, BC6ENTG of horizontal cells were modulated by extracellular application of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , thus showing typical pharmacological properties of CNS BC6OTHER .	False
Furthermore, BC6OTHER receptors of horizontal cells were modulated by extracellular application of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , thus showing typical pharmacological properties of CNS BC6ENTG .	False
Furthermore, BC6ENTG of horizontal cells were modulated by extracellular application of BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , thus showing typical pharmacological properties of CNS BC6OTHER .	False
Furthermore, BC6OTHER receptors of horizontal cells were modulated by extracellular application of BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , thus showing typical pharmacological properties of CNS BC6ENTG .	False
Furthermore, BC6ENTG of horizontal cells were modulated by extracellular application of BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , thus showing typical pharmacological properties of CNS BC6OTHER .	False
Furthermore, BC6OTHER receptors of horizontal cells were modulated by extracellular application of BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , thus showing typical pharmacological properties of CNS BC6ENTG .	False
Furthermore, BC6ENTG of horizontal cells were modulated by extracellular application of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , thus showing typical pharmacological properties of CNS BC6OTHER .	False
Furthermore, BC6OTHER receptors of horizontal cells were modulated by extracellular application of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , thus showing typical pharmacological properties of CNS BC6ENTG .	False
Furthermore, BC6ENTG of horizontal cells were modulated by extracellular application of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , thus showing typical pharmacological properties of CNS BC6OTHER .	False
Furthermore, BC6OTHER receptors of horizontal cells were modulated by extracellular application of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , thus showing typical pharmacological properties of CNS BC6ENTG .	False
In terms of the mechanisms, we found that BC6ENTC BC6OTHER hydrolase ( BC6ENTG ) which degrades BC6OTHER , was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age - dependent differences.	False
In terms of the mechanisms, we found that CHEM BC6ENTC hydrolase ( BC6ENTG ) which degrades BC6OTHER , was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age - dependent differences.	False
In terms of the mechanisms, we found that CHEM BC6OTHER hydrolase ( BC6ENTG ) which degrades BC6ENTC , was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age - dependent differences.	CPR:9
In terms of the mechanisms, we found that BC6ENTG ( BC6OTHER ) which degrades BC6ENTC , was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age - dependent differences.	CPR:9
However, enzymes contributing to oxidative metabolism of BC6ENTC , namely BC6ENTG and BC6OTHER , were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of BC6OTHER .	CPR:9
However, enzymes contributing to oxidative metabolism of BC6ENTC , namely BC6OTHER and BC6ENTG , were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of BC6OTHER .	CPR:9
However, enzymes contributing to oxidative metabolism of BC6OTHER , namely BC6ENTG and BC6OTHER , were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of BC6ENTC .	CPR:9
However, enzymes contributing to oxidative metabolism of BC6OTHER , namely BC6OTHER and BC6ENTG , were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of BC6ENTC .	CPR:9
BC6OTHER activation induces numerous proinflammatory gene products including BC6ENTG , BC6OTHER ( BC6OTHER ), and inducible BC6ENTC synthase ( BC6OTHER ).	False
BC6OTHER activation induces numerous proinflammatory gene products including BC6OTHER , BC6ENTG ( BC6OTHER ), and inducible BC6ENTC synthase ( BC6OTHER ).	False
BC6OTHER activation induces numerous proinflammatory gene products including BC6OTHER , BC6OTHER ( BC6ENTG ), and inducible BC6ENTC synthase ( BC6OTHER ).	False
BC6OTHER activation induces numerous proinflammatory gene products including BC6OTHER , BC6OTHER ( BC6OTHER ), and inducible BC6ENTC synthase ( BC6ENTG ).	False
BC6ENTG activation induces numerous proinflammatory gene products including BC6OTHER , BC6OTHER ( BC6OTHER ), and inducible BC6ENTC synthase ( BC6OTHER ).	False
Here, we report biochemical evidence that BC6ENTC alone induces BC6ENTG activation, resulting in the induced expression of BC6OTHER and BC6OTHER .	CPR:3
Here, we report biochemical evidence that BC6ENTC alone induces BC6OTHER activation, resulting in the induced expression of BC6ENTG and BC6OTHER .	CPR:3
Here, we report biochemical evidence that BC6ENTC alone induces BC6OTHER activation, resulting in the induced expression of BC6OTHER and BC6ENTG .	CPR:3
 BC6ENTC induces the expression of BC6ENTG and inducible BC6OTHER synthase.	CPR:3
 BC6ENTC induces the expression of BC6OTHER and BC6ENTG .	CPR:3
 BC6OTHER induces the expression of BC6ENTG and inducible BC6ENTC synthase.	False
Sedation and BC6ENTG antagonism: studies in man with the enantiomers of BC6OTHER and BC6ENTC .	CPR:6
Sedation and BC6ENTG antagonism: studies in man with the enantiomers of BC6ENTC and BC6OTHER .	CPR:6
Herein, the derangement of the BC6ENTC / BC6ENTG pathway and its impact on transformation - linked changes of mitochondrial functions is investigated.	False
Exogenous stimulation of BC6ENTG activity, achieved by BC6ENTC treatment, protected BC6OTHER - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6OTHER activity, intracellular BC6OTHER ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels.	CPR:3
Exogenous stimulation of BC6OTHER activity, achieved by BC6ENTC treatment, protected BC6ENTG - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6OTHER activity, intracellular BC6OTHER ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels.	False
Exogenous stimulation of BC6OTHER activity, achieved by BC6ENTC treatment, protected BC6OTHER - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6ENTG activity, intracellular BC6OTHER ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels.	CPR:3
Exogenous stimulation of BC6ENTG activity, achieved by BC6OTHER treatment, protected BC6OTHER - transformed cells from apoptosis induced by BC6ENTC deprivation, enhanced BC6OTHER activity, intracellular BC6OTHER ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels.	False
Exogenous stimulation of BC6OTHER activity, achieved by BC6OTHER treatment, protected BC6ENTG - transformed cells from apoptosis induced by BC6ENTC deprivation, enhanced BC6OTHER activity, intracellular BC6OTHER ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels.	CPR:4
Exogenous stimulation of BC6OTHER activity, achieved by BC6OTHER treatment, protected BC6OTHER - transformed cells from apoptosis induced by BC6ENTC deprivation, enhanced BC6ENTG activity, intracellular BC6OTHER ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels.	False
Oncogenic BC6ENTG expression is associated with derangement of the BC6ENTC / BC6OTHER pathway and BC6OTHER - reversible alterations of mitochondrial dynamics and respiration.	False
Oncogenic BC6OTHER expression is associated with derangement of the BC6ENTC / BC6ENTG pathway and BC6OTHER - reversible alterations of mitochondrial dynamics and respiration.	False
Oncogenic BC6ENTG expression is associated with derangement of the BC6OTHER / BC6OTHER pathway and BC6ENTC - reversible alterations of mitochondrial dynamics and respiration.	False
Oncogenic BC6OTHER expression is associated with derangement of the BC6OTHER / BC6ENTG pathway and BC6ENTC - reversible alterations of mitochondrial dynamics and respiration.	False
Exogenous stimulation of BC6ENTG activity, achieved by BC6OTHER treatment, protected BC6OTHER - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6OTHER activity, intracellular BC6ENTC ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels.	False
Exogenous stimulation of BC6OTHER activity, achieved by BC6OTHER treatment, protected BC6ENTG - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6OTHER activity, intracellular BC6ENTC ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels.	False
Exogenous stimulation of BC6OTHER activity, achieved by BC6OTHER treatment, protected BC6OTHER - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6ENTG activity, intracellular BC6ENTC ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels.	False
Exogenous stimulation of BC6ENTG activity, achieved by BC6OTHER treatment, protected BC6OTHER - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6OTHER activity, intracellular BC6OTHER ( BC6ENTC ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels.	False
Exogenous stimulation of BC6OTHER activity, achieved by BC6OTHER treatment, protected BC6ENTG - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6OTHER activity, intracellular BC6OTHER ( BC6ENTC ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels.	False
Exogenous stimulation of BC6OTHER activity, achieved by BC6OTHER treatment, protected BC6OTHER - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6ENTG activity, intracellular BC6OTHER ( BC6ENTC ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels.	False
Exogenous stimulation of BC6ENTG activity, achieved by BC6OTHER treatment, protected BC6OTHER - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6OTHER activity, intracellular BC6OTHER ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6ENTC species (ROS) levels.	False
Exogenous stimulation of BC6OTHER activity, achieved by BC6OTHER treatment, protected BC6ENTG - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6OTHER activity, intracellular BC6OTHER ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6ENTC species (ROS) levels.	False
Exogenous stimulation of BC6OTHER activity, achieved by BC6OTHER treatment, protected BC6OTHER - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6ENTG activity, intracellular BC6OTHER ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6ENTC species (ROS) levels.	False
These findings support the notion that BC6ENTC shortage - induced apoptosis, specific of BC6ENTG - transformed cells, is associated to a derangement of BC6OTHER signaling that leads to BC6OTHER decrease, reduction of BC6OTHER formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs.	False
These findings support the notion that BC6ENTC shortage - induced apoptosis, specific of BC6OTHER - transformed cells, is associated to a derangement of BC6ENTG signaling that leads to BC6OTHER decrease, reduction of BC6OTHER formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs.	False
These findings support the notion that BC6ENTC shortage - induced apoptosis, specific of BC6OTHER - transformed cells, is associated to a derangement of BC6OTHER signaling that leads to BC6ENTG decrease, reduction of BC6OTHER formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs.	False
These findings support the notion that BC6OTHER shortage - induced apoptosis, specific of BC6ENTG - transformed cells, is associated to a derangement of BC6OTHER signaling that leads to BC6OTHER decrease, reduction of BC6ENTC formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs.	False
These findings support the notion that BC6OTHER shortage - induced apoptosis, specific of BC6OTHER - transformed cells, is associated to a derangement of BC6ENTG signaling that leads to BC6OTHER decrease, reduction of BC6ENTC formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs.	False
These findings support the notion that BC6OTHER shortage - induced apoptosis, specific of BC6OTHER - transformed cells, is associated to a derangement of BC6OTHER signaling that leads to BC6ENTG decrease, reduction of BC6ENTC formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs.	False
In previous papers, it has been shown that BC6ENTG transformed mouse cells are much more sensitive as compared with normal cells to BC6ENTC withdrawal (undergoing apoptosis) and present a high glycolytic rate and a strong reduction of BC6OTHER .	False
In previous papers, it has been shown that BC6OTHER transformed mouse cells are much more sensitive as compared with normal cells to BC6ENTC withdrawal (undergoing apoptosis) and present a high glycolytic rate and a strong reduction of BC6ENTG .	False
Recent observations suggest that transformed cells have a derangement in the BC6ENTC / BC6ENTG ( BC6OTHER / BC6OTHER ) pathway, which is known to regulate several mitochondrial functions.	False
Recent observations suggest that transformed cells have a derangement in the BC6ENTC / BC6OTHER - dependent protein kinase ( BC6OTHER / BC6ENTG ) pathway, which is known to regulate several mitochondrial functions.	False
Recent observations suggest that transformed cells have a derangement in the BC6OTHER / BC6ENTC - dependent protein kinase ( BC6OTHER / BC6ENTG ) pathway, which is known to regulate several mitochondrial functions.	False
Recent observations suggest that transformed cells have a derangement in the BC6OTHER / BC6ENTG ( BC6ENTC / BC6OTHER ) pathway, which is known to regulate several mitochondrial functions.	False
Recent observations suggest that transformed cells have a derangement in the BC6OTHER / BC6OTHER - dependent protein kinase ( BC6ENTC / BC6ENTG ) pathway, which is known to regulate several mitochondrial functions.	False
Incubation with BC6ENTC (0.2 - 1 mM) activated BC6OTHER in both human islets and MIN6 beta - cells in parallel with an inhibition of BC6ENTG secretion, whereas leptin (10 - 100 nM) was without effect in MIN6 cells.	CPR:4
Incubation with BC6ENTC (0.2 - 1 mM) activated BC6ENTG in both human islets and MIN6 beta - cells in parallel with an inhibition of BC6OTHER secretion, whereas leptin (10 - 100 nM) was without effect in MIN6 cells.	CPR:3
 BC6ENTC , but not leptin, regulates BC6OTHER in pancreatic islets: impact on BC6OTHER - stimulated BC6ENTG secretion.	False
 BC6ENTC , but not leptin, regulates BC6ENTG in pancreatic islets: impact on BC6OTHER - stimulated BC6OTHER secretion.	False
 BC6OTHER , but not leptin, regulates BC6ENTC - activated protein kinase in pancreatic islets: impact on BC6OTHER - stimulated BC6ENTG secretion.	False
 BC6OTHER , but not leptin, regulates BC6OTHER in pancreatic islets: impact on BC6ENTC - stimulated BC6ENTG secretion.	CPR:3
 BC6OTHER , but not leptin, regulates BC6ENTG in pancreatic islets: impact on BC6ENTC - stimulated BC6OTHER secretion.	False
BC6ENTC , a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of BC6ENTG ( BC6OTHER ).	CPR:3
BC6ENTC , a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of BC6OTHER - activated protein kinase ( BC6ENTG ).	CPR:3
These studies demonstrate that BC6ENTG activity is subject to regulation by both BC6ENTC and BC6OTHER in pancreatic islets and clonal beta - cells.	False
These studies demonstrate that BC6ENTG activity is subject to regulation by both BC6OTHER and BC6ENTC in pancreatic islets and clonal beta - cells.	False
The inhibitory effects of BC6ENTC on BC6ENTG secretion may therefore need to be considered with respect to the use of this drug for the treatment of type 2 diabetes.	CPR:4
BC6OTHER , a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of BC6ENTC - activated protein kinase ( BC6ENTG ).	False
Whether BC6ENTC or the satiety factor leptin, which also stimulates BC6ENTG in muscle, regulates this enzyme in pancreatic islets is unknown.	CPR:3
Here, we explore whether 1) BC6ENTC , BC6OTHER , or leptin regulates BC6ENTG activity in isolated islets from rodent and human and 2) whether changes in BC6OTHER activity modulate BC6OTHER secretion from human islets.	False
Here, we explore whether 1) BC6ENTC , BC6OTHER , or leptin regulates BC6OTHER activity in isolated islets from rodent and human and 2) whether changes in BC6ENTG activity modulate BC6OTHER secretion from human islets.	False
Here, we explore whether 1) BC6ENTC , BC6OTHER , or leptin regulates BC6OTHER activity in isolated islets from rodent and human and 2) whether changes in BC6OTHER activity modulate BC6ENTG secretion from human islets.	False
Here, we explore whether 1) BC6OTHER , BC6ENTC , or leptin regulates BC6ENTG activity in isolated islets from rodent and human and 2) whether changes in BC6OTHER activity modulate BC6OTHER secretion from human islets.	False
Here, we explore whether 1) BC6OTHER , BC6ENTC , or leptin regulates BC6OTHER activity in isolated islets from rodent and human and 2) whether changes in BC6ENTG activity modulate BC6OTHER secretion from human islets.	False
Here, we explore whether 1) BC6OTHER , BC6ENTC , or leptin regulates BC6OTHER activity in isolated islets from rodent and human and 2) whether changes in BC6OTHER activity modulate BC6ENTG secretion from human islets.	False
Increases in BC6ENTC concentration from 0 to 3 and from 3 to 17 mM inhibited BC6ENTG activity in primary islets from mouse, rat, and human, confirming previous findings in insulinoma cells.	CPR:4
"These data support the hypothesis that mutations of BC6ENTG may provide the ""activated BC6ENTC kinase signal"" that is thought to be important for leukemogenesis."	False
As expected, mutations of BC6ENTC kinase genes ( BC6OTHER , BC6OTHER , and BC6ENTG ) were common in de novo AML, with a cumulative frequency of 30%.	False
As expected, mutations of BC6ENTC kinase genes ( BC6ENTG , BC6OTHER , and BC6OTHER ) were common in de novo AML, with a cumulative frequency of 30%.	False
As expected, mutations of BC6ENTC kinase genes ( BC6OTHER , BC6ENTG , and BC6OTHER ) were common in de novo AML, with a cumulative frequency of 30%.	False
This anti - proliferative effect was abolished by elevating [ BC6ENTC ]i. BC6OTHER overexpression induced VSMC proliferation, and potentiated BC6OTHER - induced proliferation, by inducing BC6OTHER phosphorylation, BC6OTHER and BC6ENTG .	False
This anti - proliferative effect was abolished by elevating [ BC6ENTC ]i. BC6ENTG overexpression induced VSMC proliferation, and potentiated BC6OTHER - induced proliferation, by inducing BC6OTHER phosphorylation, BC6OTHER and BC6OTHER .	False
This anti - proliferative effect was abolished by elevating [ BC6ENTC ]i. BC6OTHER overexpression induced VSMC proliferation, and potentiated BC6ENTG - induced proliferation, by inducing BC6OTHER phosphorylation, BC6OTHER and BC6OTHER .	False
This anti - proliferative effect was abolished by elevating [ BC6ENTC ]i. BC6OTHER overexpression induced VSMC proliferation, and potentiated BC6OTHER - induced proliferation, by inducing BC6ENTG phosphorylation, BC6OTHER and BC6OTHER .	False
This anti - proliferative effect was abolished by elevating [ BC6ENTC ]i. BC6OTHER overexpression induced VSMC proliferation, and potentiated BC6OTHER - induced proliferation, by inducing BC6OTHER phosphorylation, BC6ENTG and BC6OTHER .	False
The BC6ENTG BC6OTHER Channel KCa3.1 Regulates Vascular Smooth Muscle Cell Proliferation via Controlling BC6ENTC - dependent Signaling.	CPR:9
The BC6ENTG BC6ENTC Channel KCa3.1 Regulates Vascular Smooth Muscle Cell Proliferation via Controlling BC6OTHER - dependent Signaling.	False
Pharmacological stimulation of BC6ENTG unexpectedly suppressed proliferation by inhibiting the rise in [ BC6ENTC ]i and abolishing the expression and activity of BC6OTHER and BC6OTHER .	False
Pharmacological stimulation of BC6OTHER unexpectedly suppressed proliferation by inhibiting the rise in [ BC6ENTC ]i and abolishing the expression and activity of BC6ENTG and BC6OTHER .	False
Pharmacological stimulation of BC6OTHER unexpectedly suppressed proliferation by inhibiting the rise in [ BC6ENTC ]i and abolishing the expression and activity of BC6OTHER and BC6ENTG .	False
In conclusion, BC6ENTG plays an important role in VSMC proliferation via controlling BC6ENTC - dependent signaling pathways and its modulation may therefore constitute a new therapeutic target for cell proliferative diseases such as atherosclerosis.	False
The BC6ENTG BC6ENTC channel KCa3.1 contributes to a variety of cell activation processes in pathologies such as inflammation, carcinogenesis and vascular remodeling.	False
BC6ENTG ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6ENTC concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6ENTG ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6ENTC concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6ENTC concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6ENTG blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6ENTC concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of BC6ENTG ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6ENTC concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6ENTG ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6ENTC concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6ENTG and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6ENTC concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6ENTG ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6ENTC concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6ENTG ).	False
BC6ENTG ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6ENTC ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6ENTG ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6ENTC ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6ENTC ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6ENTG blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6ENTC ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of BC6ENTG ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6ENTC ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6ENTG ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6ENTC ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6ENTG and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6ENTC ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6ENTG ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6ENTC ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6ENTG ).	False
BC6ENTG ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6ENTC ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6ENTG ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6ENTC ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6ENTC ]i. BC6ENTG blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6ENTC ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of BC6ENTG ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6ENTC ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6ENTG ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6ENTC ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6ENTG and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6ENTC ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6ENTG ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6ENTC ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6ENTG ).	False
BC6ENTG ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6ENTC ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6ENTG ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6ENTC ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6ENTG blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6ENTC ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6ENTC ]i and attenuating the expression of BC6ENTG ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6ENTC ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6ENTG ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6ENTC ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6ENTG and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6ENTC ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6ENTG ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6ENTC ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6ENTG ).	False
BC6ENTG ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6ENTC response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6ENTG ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6ENTC response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6ENTG blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6ENTC response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6ENTC response element binding protein ( BC6ENTG ), BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6ENTC response element binding protein ( BC6OTHER ), BC6ENTG and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6ENTC response element binding protein ( BC6OTHER ), BC6OTHER and BC6ENTG ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6ENTC response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6ENTG ).	False
 BC6ENTG binding of BC6OTHER in vivo: increased receptor number with low - dose BC6ENTC .	False
 BC6ENTG binding of BC6ENTC in vivo: increased receptor number with low - dose BC6OTHER .	False
The apparent affinity of BC6ENTG for BC6ENTC in mice receiving BC6OTHER (0.05 mg / kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of BC6OTHER increased receptor number.	False
The apparent affinity of BC6ENTG for BC6OTHER in mice receiving BC6ENTC (0.05 mg / kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of BC6OTHER increased receptor number.	False
The apparent affinity of BC6ENTG for BC6OTHER in mice receiving BC6OTHER (0.05 mg / kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of BC6ENTC increased receptor number.	CPR:3
These results suggest that BC6ENTG compensates for the loss of functional BC6OTHER in cells derived from BC6OTHER knockout mice and mediates the majority of high affinity BC6ENTC transport.	CPR:9
These results suggest that BC6OTHER compensates for the loss of functional BC6ENTG in cells derived from BC6OTHER knockout mice and mediates the majority of high affinity BC6ENTC transport.	False
These results suggest that BC6OTHER compensates for the loss of functional BC6OTHER in cells derived from BC6ENTG knockout mice and mediates the majority of high affinity BC6ENTC transport.	False
The majority of BC6ENTC transport is mediated by BC6ENTG , although several other carriers have been kinetically defined.	CPR:9
BC6ENTG cationic BC6ENTC transport is mediated by proteins encoded by a family of genes, BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:9
BC6OTHER cationic BC6ENTC transport is mediated by proteins encoded by a family of genes, BC6ENTG , BC6OTHER , and BC6OTHER .	CPR:9
BC6OTHER cationic BC6ENTC transport is mediated by proteins encoded by a family of genes, BC6OTHER , BC6ENTG , and BC6OTHER .	CPR:9
BC6OTHER cationic BC6ENTC transport is mediated by proteins encoded by a family of genes, BC6OTHER , BC6OTHER , and BC6ENTG .	CPR:9
High affinity BC6ENTC transport was investigated in embryonic fibroblast cells derived from BC6ENTG knockout mice that lack functional BC6OTHER .	False
High affinity BC6ENTC transport was investigated in embryonic fibroblast cells derived from BC6OTHER knockout mice that lack functional BC6ENTG .	False
However, the apparent affinity for BC6ENTC transport was 2.4 times lower in BC6ENTG ( - / - ) cells when compared with wild type cells, a property characteristic of BC6OTHER - mediated transport.	False
However, the apparent affinity for BC6ENTC transport was 2.4 times lower in BC6OTHER ( - / - ) cells when compared with wild type cells, a property characteristic of BC6ENTG - mediated transport.	CPR:9
Increased BC6ENTG - mediated cationic BC6ENTC transport functionally compensates in BC6OTHER knockout cell lines.	CPR:9
Increased BC6OTHER - mediated cationic BC6ENTC transport functionally compensates in BC6ENTG knockout cell lines.	False
The BC6ENTG subunit contains several functional domains: the BC6ENTC - terminal heptad repeat (NHR) domains fold a triple stranded coiled - coil forming a meta - stable prefusion intermediate.	False
With a BC6ENTC modification at BC6OTHER - terminal, the inhibitor containing BC6ENTG mutation represented higher anti - viral activity than C34 - BC6OTHER combination without mutation.	False
With a BC6OTHER modification at BC6ENTC - terminal, the inhibitor containing BC6ENTG mutation represented higher anti - viral activity than C34 - BC6OTHER combination without mutation.	False
With a BC6OTHER modification at BC6OTHER - terminal, the inhibitor containing BC6ENTG mutation represented higher anti - viral activity than C34 - BC6ENTC combination without mutation.	False
In Drosophila, BC6ENTG is a multifunctional synthetase encoded by a unique gene and composed of three domains: the BC6ENTC - and BC6OTHER - terminal domains catalyze the aminoacylation of BC6OTHER and CHEM tRNA species, respectively, and the central domain is made of 75 BC6OTHER repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J.	False
In Drosophila, BC6ENTG is a multifunctional synthetase encoded by a unique gene and composed of three domains: the BC6OTHER - and BC6ENTC - terminal domains catalyze the aminoacylation of BC6OTHER and CHEM tRNA species, respectively, and the central domain is made of 75 BC6OTHER repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J.	False
In Drosophila, BC6ENTG is a multifunctional synthetase encoded by a unique gene and composed of three domains: the BC6OTHER - and BC6OTHER - terminal domains catalyze the aminoacylation of BC6ENTC and CHEM tRNA species, respectively, and the central domain is made of 75 BC6OTHER repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J.	False
In Drosophila, BC6ENTG is a multifunctional synthetase encoded by a unique gene and composed of three domains: the BC6OTHER - and BC6OTHER - terminal domains catalyze the aminoacylation of BC6OTHER and CHEM tRNA species, respectively, and the central domain is made of 75 BC6ENTC repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J.	False
Evolution of the BC6ENTC - tRNA synthetase family and the organization of the Drosophila BC6ENTG gene.	False
Evolution of the BC6ENTG family and the organization of the Drosophila BC6ENTC - CHEM - tRNA synthetase gene.	False
Among the measured compounds, BC6ENTC and BC6OTHER (two BC6OTHER ), as well as BC6OTHER (a BC6OTHER ), exhibit BC6ENTG agonistic activity at concentrations comparable with those reached under pharmacological treatment.	CPR:5
Among the measured compounds, BC6OTHER and BC6ENTC (two BC6OTHER ), as well as BC6OTHER (a BC6OTHER ), exhibit BC6ENTG agonistic activity at concentrations comparable with those reached under pharmacological treatment.	CPR:5
Among the measured compounds, BC6OTHER and BC6OTHER (two BC6ENTC ), as well as BC6OTHER (a BC6OTHER ), exhibit BC6ENTG agonistic activity at concentrations comparable with those reached under pharmacological treatment.	CPR:5
Among the measured compounds, BC6OTHER and BC6OTHER (two BC6OTHER ), as well as BC6ENTC (a BC6OTHER ), exhibit BC6ENTG agonistic activity at concentrations comparable with those reached under pharmacological treatment.	CPR:5
Among the measured compounds, BC6OTHER and BC6OTHER (two BC6OTHER ), as well as BC6OTHER (a BC6ENTC ), exhibit BC6ENTG agonistic activity at concentrations comparable with those reached under pharmacological treatment.	CPR:5
Most drugs currently employed in the treatment of type 2 diabetes either target the BC6ENTC receptor stimulating BC6ENTG release ( BC6OTHER , BC6OTHER ), or target the BC6OTHER ( BC6OTHER ) improving BC6OTHER resistance ( BC6OTHER ).	False
Most drugs currently employed in the treatment of type 2 diabetes either target the BC6ENTC receptor stimulating BC6OTHER release ( BC6OTHER , BC6OTHER ), or target the BC6ENTG ( BC6OTHER ) improving BC6OTHER resistance ( BC6OTHER ).	False
Most drugs currently employed in the treatment of type 2 diabetes either target the BC6ENTC receptor stimulating BC6OTHER release ( BC6OTHER , BC6OTHER ), or target the BC6OTHER ( BC6ENTG ) improving BC6OTHER resistance ( BC6OTHER ).	False
Most drugs currently employed in the treatment of type 2 diabetes either target the BC6ENTC receptor stimulating BC6OTHER release ( BC6OTHER , BC6OTHER ), or target the BC6OTHER ( BC6OTHER ) improving BC6ENTG resistance ( BC6OTHER ).	False
The most active of these compounds, BC6ENTC , is shown to be as potent as BC6OTHER at inducing BC6ENTG target gene expression.	CPR:3
The most active of these compounds, BC6OTHER , is shown to be as potent as BC6ENTC at inducing BC6ENTG target gene expression.	CPR:3
This dual mode of action of BC6ENTC and BC6OTHER may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the BC6ENTG and BC6OTHER .	False
This dual mode of action of BC6ENTC and BC6OTHER may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the BC6OTHER and BC6ENTG .	False
This dual mode of action of BC6OTHER and BC6ENTC may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the BC6ENTG and BC6OTHER .	False
This dual mode of action of BC6OTHER and BC6ENTC may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the BC6OTHER and BC6ENTG .	False
This dual mode of action of BC6OTHER and BC6OTHER may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the BC6ENTC receptor and BC6ENTG .	False
 BC6ENTC and BC6OTHER exhibit BC6ENTG activity: a combined virtual screening and biological assay approach.	False
 BC6OTHER and BC6ENTC exhibit BC6ENTG activity: a combined virtual screening and biological assay approach.	False
BC6ENTC , BC6OTHER , and other BC6OTHER may be promising leads in the development of new BC6ENTG agonists.	CPR:5
BC6OTHER , BC6ENTC , and other BC6OTHER may be promising leads in the development of new BC6ENTG agonists.	CPR:5
BC6OTHER , BC6OTHER , and other BC6ENTC may be promising leads in the development of new BC6ENTG agonists.	CPR:5
Most drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6ENTG release ( BC6ENTC , BC6OTHER ), or target the BC6OTHER ( BC6OTHER ) improving BC6OTHER resistance ( BC6OTHER ).	CPR:3
Most drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6OTHER release ( BC6ENTC , BC6OTHER ), or target the BC6ENTG ( BC6OTHER ) improving BC6OTHER resistance ( BC6OTHER ).	False
Most drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6OTHER release ( BC6ENTC , BC6OTHER ), or target the BC6OTHER ( BC6ENTG ) improving BC6OTHER resistance ( BC6OTHER ).	False
Most drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6OTHER release ( BC6ENTC , BC6OTHER ), or target the BC6OTHER ( BC6OTHER ) improving BC6ENTG resistance ( BC6OTHER ).	False
Most drugs currently employed in the treatment of type 2 diabetes either target the BC6ENTG stimulating BC6OTHER release ( BC6ENTC , BC6OTHER ), or target the BC6OTHER ( BC6OTHER ) improving BC6OTHER resistance ( BC6OTHER ).	False
Most drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6ENTG release ( BC6OTHER , BC6ENTC ), or target the BC6OTHER ( BC6OTHER ) improving BC6OTHER resistance ( BC6OTHER ).	CPR:3
Most drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6OTHER release ( BC6OTHER , BC6ENTC ), or target the BC6ENTG ( BC6OTHER ) improving BC6OTHER resistance ( BC6OTHER ).	False
Most drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6OTHER release ( BC6OTHER , BC6ENTC ), or target the BC6OTHER ( BC6ENTG ) improving BC6OTHER resistance ( BC6OTHER ).	False
Most drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6OTHER release ( BC6OTHER , BC6ENTC ), or target the BC6OTHER ( BC6OTHER ) improving BC6ENTG resistance ( BC6OTHER ).	False
Most drugs currently employed in the treatment of type 2 diabetes either target the BC6ENTG stimulating BC6OTHER release ( BC6OTHER , BC6ENTC ), or target the BC6OTHER ( BC6OTHER ) improving BC6OTHER resistance ( BC6OTHER ).	False
Most drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6ENTG release ( BC6OTHER , BC6OTHER ), or target the BC6OTHER ( BC6OTHER ) improving BC6OTHER resistance ( BC6ENTC ).	False
Most drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6OTHER release ( BC6OTHER , BC6OTHER ), or target the BC6ENTG ( BC6OTHER ) improving BC6OTHER resistance ( BC6ENTC ).	False
Most drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6OTHER release ( BC6OTHER , BC6OTHER ), or target the BC6OTHER ( BC6ENTG ) improving BC6OTHER resistance ( BC6ENTC ).	False
Most drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6OTHER release ( BC6OTHER , BC6OTHER ), or target the BC6OTHER ( BC6OTHER ) improving BC6ENTG resistance ( BC6ENTC ).	False
Most drugs currently employed in the treatment of type 2 diabetes either target the BC6ENTG stimulating BC6OTHER release ( BC6OTHER , BC6OTHER ), or target the BC6OTHER ( BC6OTHER ) improving BC6OTHER resistance ( BC6ENTC ).	False
Our work shows that BC6ENTC and BC6OTHER additionally bind to BC6ENTG and exhibit BC6OTHER agonistic activity.	False
Our work shows that BC6ENTC and BC6OTHER additionally bind to BC6OTHER and exhibit BC6ENTG agonistic activity.	CPR:5
Our work shows that BC6OTHER and BC6ENTC additionally bind to BC6ENTG and exhibit BC6OTHER agonistic activity.	False
Our work shows that BC6OTHER and BC6ENTC additionally bind to BC6OTHER and exhibit BC6ENTG agonistic activity.	CPR:5
In the presence of BC6ENTG , BC6ENTC suppressed the expression of BC6OTHER and BC6OTHER as well as the production of BC6OTHER , BC6OTHER and BC6OTHER in PBMC, contributing to the anti - inflammatory effect of BC6OTHER .	False
In the presence of BC6OTHER , BC6ENTC suppressed the expression of BC6ENTG and BC6OTHER as well as the production of BC6OTHER , BC6OTHER and BC6OTHER in PBMC, contributing to the anti - inflammatory effect of BC6OTHER .	CPR:4
In the presence of BC6OTHER , BC6ENTC suppressed the expression of BC6OTHER and BC6ENTG as well as the production of BC6OTHER , BC6OTHER and BC6OTHER in PBMC, contributing to the anti - inflammatory effect of BC6OTHER .	CPR:4
In the presence of BC6OTHER , BC6ENTC suppressed the expression of BC6OTHER and BC6OTHER as well as the production of BC6ENTG , BC6OTHER and BC6OTHER in PBMC, contributing to the anti - inflammatory effect of BC6OTHER .	CPR:3
In the presence of BC6OTHER , BC6ENTC suppressed the expression of BC6OTHER and BC6OTHER as well as the production of BC6OTHER , BC6ENTG and BC6OTHER in PBMC, contributing to the anti - inflammatory effect of BC6OTHER .	CPR:3
In the presence of BC6OTHER , BC6ENTC suppressed the expression of BC6OTHER and BC6OTHER as well as the production of BC6OTHER , BC6OTHER and BC6ENTG in PBMC, contributing to the anti - inflammatory effect of BC6OTHER .	CPR:3
In the presence of BC6ENTG , BC6OTHER suppressed the expression of BC6OTHER and BC6OTHER as well as the production of BC6OTHER , BC6OTHER and BC6OTHER in PBMC, contributing to the anti - inflammatory effect of BC6ENTC .	False
In the presence of BC6OTHER , BC6OTHER suppressed the expression of BC6ENTG and BC6OTHER as well as the production of BC6OTHER , BC6OTHER and BC6OTHER in PBMC, contributing to the anti - inflammatory effect of BC6ENTC .	False
In the presence of BC6OTHER , BC6OTHER suppressed the expression of BC6OTHER and BC6ENTG as well as the production of BC6OTHER , BC6OTHER and BC6OTHER in PBMC, contributing to the anti - inflammatory effect of BC6ENTC .	False
In the presence of BC6OTHER , BC6OTHER suppressed the expression of BC6OTHER and BC6OTHER as well as the production of BC6ENTG , BC6OTHER and BC6OTHER in PBMC, contributing to the anti - inflammatory effect of BC6ENTC .	False
In the presence of BC6OTHER , BC6OTHER suppressed the expression of BC6OTHER and BC6OTHER as well as the production of BC6OTHER , BC6ENTG and BC6OTHER in PBMC, contributing to the anti - inflammatory effect of BC6ENTC .	False
In the presence of BC6OTHER , BC6OTHER suppressed the expression of BC6OTHER and BC6OTHER as well as the production of BC6OTHER , BC6OTHER and BC6ENTG in PBMC, contributing to the anti - inflammatory effect of BC6ENTC .	False
The effects of BC6ENTC were abolished by the addition of the product of the BC6OTHER , BC6OTHER , indicating the involvement of BC6ENTG in the action of BC6OTHER .	False
The effects of BC6ENTC were abolished by the addition of the product of the BC6ENTG , BC6OTHER , indicating the involvement of BC6OTHER reductase in the action of BC6OTHER .	False
The effects of BC6OTHER were abolished by the addition of the product of the BC6ENTC reductase, BC6OTHER , indicating the involvement of BC6ENTG in the action of BC6OTHER .	False
 BC6ENTC induces BC6ENTG production in human peripheral blood mononuclear cells.	CPR:3
The effects of BC6OTHER were abolished by the addition of the product of the BC6OTHER , BC6ENTC , indicating the involvement of BC6ENTG in the action of BC6OTHER .	False
The effects of BC6OTHER were abolished by the addition of the product of the BC6ENTG , BC6ENTC , indicating the involvement of BC6OTHER reductase in the action of BC6OTHER .	CPR:9
The effects of BC6OTHER were abolished by the addition of the product of the BC6ENTG , BC6OTHER , indicating the involvement of BC6ENTC reductase in the action of BC6OTHER .	False
The effects of BC6OTHER were abolished by the addition of the product of the BC6OTHER , BC6OTHER , indicating the involvement of BC6ENTG in the action of BC6ENTC .	False
The effects of BC6OTHER were abolished by the addition of the product of the BC6ENTG , BC6OTHER , indicating the involvement of BC6OTHER reductase in the action of BC6ENTC .	False
The effects of CHEM on immune response depend on the inhibition of BC6OTHER ( BC6ENTC ) reductase and BC6ENTG , which is a ligand of BC6OTHER .	False
The effects of CHEM on immune response depend on the inhibition of BC6OTHER ( BC6ENTC ) reductase and BC6OTHER , which is a ligand of BC6ENTG .	False
BC6ENTC , an BC6ENTG inhibitor with mild inhibition of BC6OTHER , induced the production of BC6OTHER , BC6OTHER and BC6OTHER in human peripheral blood mononuclear cells (PBMC).	CPR:4
BC6ENTC , an BC6OTHER reductase inhibitor with mild inhibition of BC6ENTG , induced the production of BC6OTHER , BC6OTHER and BC6OTHER in human peripheral blood mononuclear cells (PBMC).	CPR:4
BC6ENTC , an BC6OTHER reductase inhibitor with mild inhibition of BC6OTHER , induced the production of BC6ENTG , BC6OTHER and BC6OTHER in human peripheral blood mononuclear cells (PBMC).	CPR:3
BC6ENTC , an BC6OTHER reductase inhibitor with mild inhibition of BC6OTHER , induced the production of BC6OTHER , BC6ENTG and BC6OTHER in human peripheral blood mononuclear cells (PBMC).	CPR:3
BC6ENTC , an BC6OTHER reductase inhibitor with mild inhibition of BC6OTHER , induced the production of BC6OTHER , BC6OTHER and BC6ENTG in human peripheral blood mononuclear cells (PBMC).	CPR:3
BC6OTHER , an BC6ENTC reductase inhibitor with mild inhibition of BC6ENTG , induced the production of BC6OTHER , BC6OTHER and BC6OTHER in human peripheral blood mononuclear cells (PBMC).	False
BC6OTHER , an BC6ENTC reductase inhibitor with mild inhibition of BC6OTHER , induced the production of BC6ENTG , BC6OTHER and BC6OTHER in human peripheral blood mononuclear cells (PBMC).	False
BC6OTHER , an BC6ENTC reductase inhibitor with mild inhibition of BC6OTHER , induced the production of BC6OTHER , BC6ENTG and BC6OTHER in human peripheral blood mononuclear cells (PBMC).	False
BC6OTHER , an BC6ENTC reductase inhibitor with mild inhibition of BC6OTHER , induced the production of BC6OTHER , BC6OTHER and BC6ENTG in human peripheral blood mononuclear cells (PBMC).	False
The BC6ENTG production is located upstream of the BC6OTHER cascade activated by BC6ENTC .	CPR:3
The BC6OTHER production is located upstream of the BC6ENTG cascade activated by BC6ENTC .	CPR:3
Moreover, BC6ENTC concentration - dependently inhibited the expression of BC6ENTG and induced the expression of BC6OTHER on monocytes.	CPR:4
Moreover, BC6ENTC concentration - dependently inhibited the expression of BC6OTHER and induced the expression of BC6ENTG on monocytes.	CPR:3
The effects of CHEM on immune response depend on the inhibition of BC6ENTC ( BC6OTHER ) reductase and BC6ENTG , which is a ligand of BC6OTHER .	False
The effects of CHEM on immune response depend on the inhibition of BC6ENTC ( BC6OTHER ) reductase and BC6OTHER , which is a ligand of BC6ENTG .	False
BC6ENTC - activated protein kinase ( BC6ENTG ) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of BC6OTHER uptake into skeletal muscle and the inhibition of liver gluconeogenesis.	False
BC6ENTG ( BC6OTHER ) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of BC6ENTC uptake into skeletal muscle and the inhibition of liver gluconeogenesis.	CPR:9
BC6OTHER ( BC6ENTG ) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of BC6ENTC uptake into skeletal muscle and the inhibition of liver gluconeogenesis.	CPR:9
We recently reported that BC6ENTG is activated by BC6ENTC in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic BC6OTHER production.	CPR:3
We recently reported that BC6ENTG is activated by BC6OTHER in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic BC6ENTC production.	False
In the present study, we evaluated whether therapeutic doses of BC6ENTC increase BC6ENTG activity in vivo in subjects with type 2 diabetes.	CPR:3
BC6ENTC treatment for 10 weeks significantly increased BC6ENTG activity in the skeletal muscle, and this was associated with increased phosphorylation of BC6OTHER on CHEM172 and decreased BC6OTHER activity.	CPR:3
BC6ENTC treatment for 10 weeks significantly increased BC6OTHER activity in the skeletal muscle, and this was associated with increased phosphorylation of BC6ENTG on CHEM172 and decreased BC6OTHER activity.	CPR:3
BC6ENTC treatment for 10 weeks significantly increased BC6OTHER activity in the skeletal muscle, and this was associated with increased phosphorylation of BC6OTHER on CHEM172 and decreased BC6ENTG activity.	CPR:4
BC6OTHER treatment for 10 weeks significantly increased BC6ENTG activity in the skeletal muscle, and this was associated with increased phosphorylation of BC6OTHER on CHEM172 and decreased BC6ENTC carboxylase - 2 activity.	False
BC6OTHER treatment for 10 weeks significantly increased BC6OTHER activity in the skeletal muscle, and this was associated with increased phosphorylation of BC6ENTG on CHEM172 and decreased BC6ENTC carboxylase - 2 activity.	False
 BC6ENTC increases BC6ENTG activity in skeletal muscle of subjects with type 2 diabetes.	CPR:3
The increase in BC6ENTG activity was likely due to a change in muscle energy status because BC6ENTC and BC6OTHER concentrations were lower after BC6OTHER treatment.	False
The increase in BC6ENTG activity was likely due to a change in muscle energy status because BC6OTHER and BC6ENTC concentrations were lower after BC6OTHER treatment.	False
The increase in BC6ENTG activity was likely due to a change in muscle energy status because BC6OTHER and BC6OTHER concentrations were lower after BC6ENTC treatment.	CPR:3
BC6ENTC - induced increases in BC6ENTG activity were associated with higher rates of BC6OTHER disposal and muscle glycogen concentrations.	CPR:3
BC6OTHER - induced increases in BC6ENTG activity were associated with higher rates of BC6ENTC disposal and muscle glycogen concentrations.	False
Analysis of the patient family showed that heterozygotes for this BC6ENTG gene mutation, in spite of a 69% lower BC6OTHER enzymatic activity than that of healthy subjects, had no detectable BC6ENTC concentrations in both serum and urine.	False
Analysis of the patient family showed that heterozygotes for this BC6OTHER gene mutation, in spite of a 69% lower BC6ENTG enzymatic activity than that of healthy subjects, had no detectable BC6ENTC concentrations in both serum and urine.	False
Results of renal biopsy prompted us to undertake a biochemical and molecular biological evaluation of the patient for suspected BC6ENTC phosphoribosyltransferase ( BC6ENTG ) deficiency.	False
In vivo, CHEM inhibited tumor growth in mice bearing tumor with endogenous BC6ENTG (BxPC - 3: control, mean = 1.6 x 10(9) photons / s, versus CHEM, mean = 4.4 x 10(8) photons / s, difference = 1.2 x 10(9) photons / s; 95% CI = 6.2 x 10(8) to 1.6 x 10(9) photons / s; P<.001, n = 5; MPanc - 96: control, mean = 1.1 x 10(10) photons / s, versus CHEM, mean = 4.8 x 10(9) photons / s, difference = 6.2 x 10(9) photons / s; 95% CI = 1.9 x 10(9) to 1.0 x 10(10) photons / s; P = .009, n = 5) and increased the effectiveness of BC6ENTC (BxPC - 3: BC6OTHER , mean = 9.2 x 10(8) photons / s, versus combination, mean = 1.8 x 10(8) photons / s, difference = 7.4 x 10(8) photons / s; 95% CI = 4.5 x 10(8) to 1.0 x 10(9) photons / s; P<.001; MPanc - 96: BC6OTHER , mean = 4.1 x 10(9) photons / s, versus combination, mean = 2.0 x 10(9) photons / s, difference = 2.1 x 10(9) photons / s; 95% CI = 4.4 x 10(8) to 3.8 x 10(9) photons / s; P<.001).	False
In vivo, CHEM inhibited tumor growth in mice bearing tumor with endogenous BC6ENTG (BxPC - 3: control, mean = 1.6 x 10(9) photons / s, versus CHEM, mean = 4.4 x 10(8) photons / s, difference = 1.2 x 10(9) photons / s; 95% CI = 6.2 x 10(8) to 1.6 x 10(9) photons / s; P<.001, n = 5; MPanc - 96: control, mean = 1.1 x 10(10) photons / s, versus CHEM, mean = 4.8 x 10(9) photons / s, difference = 6.2 x 10(9) photons / s; 95% CI = 1.9 x 10(9) to 1.0 x 10(10) photons / s; P = .009, n = 5) and increased the effectiveness of BC6OTHER (BxPC - 3: BC6ENTC , mean = 9.2 x 10(8) photons / s, versus combination, mean = 1.8 x 10(8) photons / s, difference = 7.4 x 10(8) photons / s; 95% CI = 4.5 x 10(8) to 1.0 x 10(9) photons / s; P<.001; MPanc - 96: BC6OTHER , mean = 4.1 x 10(9) photons / s, versus combination, mean = 2.0 x 10(9) photons / s, difference = 2.1 x 10(9) photons / s; 95% CI = 4.4 x 10(8) to 3.8 x 10(9) photons / s; P<.001).	False
In vivo, CHEM inhibited tumor growth in mice bearing tumor with endogenous BC6ENTG (BxPC - 3: control, mean = 1.6 x 10(9) photons / s, versus CHEM, mean = 4.4 x 10(8) photons / s, difference = 1.2 x 10(9) photons / s; 95% CI = 6.2 x 10(8) to 1.6 x 10(9) photons / s; P<.001, n = 5; MPanc - 96: control, mean = 1.1 x 10(10) photons / s, versus CHEM, mean = 4.8 x 10(9) photons / s, difference = 6.2 x 10(9) photons / s; 95% CI = 1.9 x 10(9) to 1.0 x 10(10) photons / s; P = .009, n = 5) and increased the effectiveness of BC6OTHER (BxPC - 3: BC6OTHER , mean = 9.2 x 10(8) photons / s, versus combination, mean = 1.8 x 10(8) photons / s, difference = 7.4 x 10(8) photons / s; 95% CI = 4.5 x 10(8) to 1.0 x 10(9) photons / s; P<.001; MPanc - 96: BC6ENTC , mean = 4.1 x 10(9) photons / s, versus combination, mean = 2.0 x 10(9) photons / s, difference = 2.1 x 10(9) photons / s; 95% CI = 4.4 x 10(8) to 3.8 x 10(9) photons / s; P<.001).	False
CONCLUSION: CHEM binds BC6ENTG , prevents activation of RAGE, inhibits tumor growth, and increases the effectiveness of BC6ENTC in experimental models.	False
PURPOSE: Cellular BC6OTHER - binding protein ( BC6ENTG ), transcribed from the BC6OTHER gene, is a BC6OTHER with 316 BC6ENTC found in the BC6OTHER pigment epithelium (RPE) and in BC6OTHER Muller cells.	False
PURPOSE: Cellular BC6OTHER - binding protein ( BC6OTHER ), transcribed from the BC6ENTG gene, is a BC6OTHER with 316 BC6ENTC found in the BC6OTHER pigment epithelium (RPE) and in BC6OTHER Muller cells.	False
PURPOSE: BC6ENTG ( BC6OTHER ), transcribed from the BC6OTHER gene, is a BC6OTHER with 316 BC6ENTC found in the BC6OTHER pigment epithelium (RPE) and in BC6OTHER Muller cells.	False
PURPOSE: Cellular BC6OTHER - binding protein ( BC6OTHER ), transcribed from the BC6OTHER gene, is a BC6ENTG with 316 BC6ENTC found in the BC6OTHER pigment epithelium (RPE) and in BC6OTHER Muller cells.	False
PURPOSE: Cellular BC6OTHER - binding protein ( BC6ENTG ), transcribed from the BC6OTHER gene, is a BC6OTHER with 316 BC6OTHER found in the BC6ENTC pigment epithelium (RPE) and in BC6OTHER Muller cells.	False
PURPOSE: Cellular BC6OTHER - binding protein ( BC6OTHER ), transcribed from the BC6ENTG gene, is a BC6OTHER with 316 BC6OTHER found in the BC6ENTC pigment epithelium (RPE) and in BC6OTHER Muller cells.	False
PURPOSE: BC6ENTG ( BC6OTHER ), transcribed from the BC6OTHER gene, is a BC6OTHER with 316 BC6OTHER found in the BC6ENTC pigment epithelium (RPE) and in BC6OTHER Muller cells.	False
PURPOSE: Cellular BC6OTHER - binding protein ( BC6OTHER ), transcribed from the BC6OTHER gene, is a BC6ENTG with 316 BC6OTHER found in the BC6ENTC pigment epithelium (RPE) and in BC6OTHER Muller cells.	False
PURPOSE: Cellular BC6ENTC - binding protein ( BC6ENTG ), transcribed from the BC6OTHER gene, is a BC6OTHER with 316 BC6OTHER found in the BC6OTHER pigment epithelium (RPE) and in BC6OTHER Muller cells.	False
PURPOSE: Cellular BC6ENTC - binding protein ( BC6OTHER ), transcribed from the BC6ENTG gene, is a BC6OTHER with 316 BC6OTHER found in the BC6OTHER pigment epithelium (RPE) and in BC6OTHER Muller cells.	False
PURPOSE: Cellular BC6ENTC - binding protein ( BC6OTHER ), transcribed from the BC6OTHER gene, is a BC6ENTG with 316 BC6OTHER found in the BC6OTHER pigment epithelium (RPE) and in BC6OTHER Muller cells.	False
PURPOSE: Cellular BC6OTHER - binding protein ( BC6ENTG ), transcribed from the BC6OTHER gene, is a BC6OTHER with 316 BC6OTHER found in the BC6OTHER pigment epithelium (RPE) and in BC6ENTC Muller cells.	False
PURPOSE: Cellular BC6OTHER - binding protein ( BC6OTHER ), transcribed from the BC6ENTG gene, is a BC6OTHER with 316 BC6OTHER found in the BC6OTHER pigment epithelium (RPE) and in BC6ENTC Muller cells.	False
PURPOSE: BC6ENTG ( BC6OTHER ), transcribed from the BC6OTHER gene, is a BC6OTHER with 316 BC6OTHER found in the BC6OTHER pigment epithelium (RPE) and in BC6ENTC Muller cells.	False
PURPOSE: Cellular BC6OTHER - binding protein ( BC6OTHER ), transcribed from the BC6OTHER gene, is a BC6ENTG with 316 BC6OTHER found in the BC6OTHER pigment epithelium (RPE) and in BC6ENTC Muller cells.	False
It is thought to play a critical role in the visual cycle by functioning as an acceptor of BC6ENTC from the BC6ENTG reaction.	CPR:9
Here, we report that a specific 29 - BC6ENTC peptide derived from the intracellular domain fragment of BC6OTHER interacts with and potentiates binding of BC6ENTG to BC6OTHER - expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced BC6OTHER and BC6OTHER signaling.	False
Here, we report that a specific 29 - BC6ENTC peptide derived from the intracellular domain fragment of BC6OTHER interacts with and potentiates binding of BC6OTHER to BC6ENTG - expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced BC6OTHER and BC6OTHER signaling.	False
Here, we report that a specific 29 - BC6ENTC peptide derived from the intracellular domain fragment of BC6OTHER interacts with and potentiates binding of BC6OTHER to BC6OTHER - expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced BC6ENTG and BC6OTHER signaling.	False
Here, we report that a specific 29 - BC6ENTC peptide derived from the intracellular domain fragment of BC6OTHER interacts with and potentiates binding of BC6OTHER to BC6OTHER - expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced BC6OTHER and BC6ENTG signaling.	False
Here, we report that a specific 29 - BC6ENTC peptide derived from the intracellular domain fragment of BC6ENTG interacts with and potentiates binding of BC6OTHER to BC6OTHER - expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced BC6OTHER and BC6OTHER signaling.	False
An endogenous intracellular domain fragment of BC6ENTG ( BC6OTHER ) containing these 29 BC6ENTC is produced by regulated proteolysis of the full - length receptor.	False
An endogenous intracellular domain fragment of BC6OTHER ( BC6ENTG ) containing these 29 BC6ENTC is produced by regulated proteolysis of the full - length receptor.	False
The mitogenic effect of BC6ENTC on bone cells was inhibited by antiandrogens ( BC6OTHER and BC6OTHER ) which compete for binding to the BC6ENTG .	False
The mitogenic effect of BC6OTHER on bone cells was inhibited by antiandrogens ( BC6ENTC and BC6OTHER ) which compete for binding to the BC6ENTG .	False
The mitogenic effect of BC6OTHER on bone cells was inhibited by antiandrogens ( BC6OTHER and BC6ENTC ) which compete for binding to the BC6ENTG .	False
In addition to effects on cell proliferation, BC6ENTC increased the percentage of BC6ENTG ( BC6OTHER ) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens.	CPR:3
In addition to effects on cell proliferation, BC6ENTC increased the percentage of BC6OTHER ( BC6ENTG ) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens.	CPR:3
We conclude that BC6ENTC can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the BC6ENTG BC6OTHER , presumably by an BC6OTHER receptor mediated mechanism.	CPR:3
We conclude that BC6ENTC can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the BC6OTHER BC6ENTG , presumably by an BC6OTHER receptor mediated mechanism.	CPR:3
We conclude that BC6ENTC can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the BC6OTHER BC6OTHER , presumably by an BC6ENTG mediated mechanism.	False
We conclude that BC6OTHER can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the BC6ENTG BC6OTHER , presumably by an BC6ENTC receptor mediated mechanism.	False
We conclude that BC6OTHER can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the BC6OTHER BC6ENTG , presumably by an BC6ENTC receptor mediated mechanism.	False
 BC6ENTG Deficiency Impairs Secretory Vesicle Biogenesis and Leads to Growth Retardation and Decreased BC6ENTC Tolerance.	False
From these results, it was suggested that the contraction induced by BC6OTHER in the rat coronary artery in the presence of BC6OTHER and BC6OTHER is endothelium dependent, and involves reactive BC6OTHER species and endothelial BC6ENTG metabolites of BC6ENTC .	False
BC6ENTC radical scavengers, BC6ENTG and BC6OTHER , significantly attenuated the contraction.	False
BC6ENTC radical scavengers, BC6OTHER and BC6ENTG , significantly attenuated the contraction.	False
BC6ENTG ( BC6OTHER ) inhibitors ( BC6ENTC , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction.	CPR:4
BC6OTHER ( BC6ENTG ) inhibitors ( BC6ENTC , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction.	CPR:4
BC6OTHER ( BC6OTHER ) inhibitors ( BC6ENTC , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6ENTG ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction.	False
BC6OTHER ( BC6OTHER ) inhibitors ( BC6ENTC , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6ENTG ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction.	False
BC6ENTG ( BC6OTHER ) inhibitors ( BC6OTHER , BC6ENTC and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction.	CPR:4
BC6OTHER ( BC6ENTG ) inhibitors ( BC6OTHER , BC6ENTC and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction.	CPR:4
BC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER , BC6ENTC and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6ENTG ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction.	False
BC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER , BC6ENTC and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6ENTG ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction.	False
BC6ENTG ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6ENTC ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction.	CPR:4
BC6OTHER ( BC6ENTG ) inhibitors ( BC6OTHER , BC6OTHER and BC6ENTC ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction.	CPR:4
BC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6ENTC ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6ENTG ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction.	False
BC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6ENTC ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6ENTG ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction.	False
BC6ENTG ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6ENTC - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction.	False
BC6OTHER ( BC6ENTG ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6ENTC - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction.	False
BC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6ENTC - induced contraction in a concentration - dependent manner, and BC6ENTG ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction.	False
BC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6ENTC - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6ENTG ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction.	False
BC6ENTG ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6ENTC and BC6OTHER ) slightly attenuated the contraction.	False
BC6OTHER ( BC6ENTG ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6ENTC and BC6OTHER ) slightly attenuated the contraction.	False
BC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6ENTG ( BC6OTHER ) inhibitors at high concentrations ( BC6ENTC and BC6OTHER ) slightly attenuated the contraction.	CPR:4
BC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6ENTG ) inhibitors at high concentrations ( BC6ENTC and BC6OTHER ) slightly attenuated the contraction.	CPR:4
BC6ENTG ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6ENTC ) slightly attenuated the contraction.	False
BC6OTHER ( BC6ENTG ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6ENTC ) slightly attenuated the contraction.	False
BC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6ENTG ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6ENTC ) slightly attenuated the contraction.	CPR:4
BC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6ENTG ) inhibitors at high concentrations ( BC6OTHER and BC6ENTC ) slightly attenuated the contraction.	CPR:4
A BC6ENTG inhibitor ( BC6ENTC ) attenuated the contraction to a small extent only at high concentrations.	CPR:4
A BC6ENTG antagonist ( BC6ENTC ) attenuated the contraction in a concentration - dependent manner.	CPR:6
 BC6ENTC - induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive BC6OTHER species and BC6ENTG metabolites.	False
 BC6OTHER - induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive BC6ENTC species and BC6ENTG metabolites.	False
A BC6ENTG antagonist ( BC6ENTC ) attenuated the contraction in part and an BC6OTHER antagonist ( BC6OTHER ) nearly abolished the contraction.	CPR:6
A BC6OTHER antagonist ( BC6ENTC ) attenuated the contraction in part and an BC6ENTG antagonist ( BC6OTHER ) nearly abolished the contraction.	False
A BC6ENTG antagonist ( BC6OTHER ) attenuated the contraction in part and an BC6OTHER antagonist ( BC6ENTC ) nearly abolished the contraction.	False
A BC6OTHER antagonist ( BC6OTHER ) attenuated the contraction in part and an BC6ENTG antagonist ( BC6ENTC ) nearly abolished the contraction.	CPR:6
From these results, it was suggested that the contraction induced by BC6ENTC in the rat coronary artery in the presence of BC6OTHER and BC6OTHER is endothelium dependent, and involves reactive BC6OTHER species and endothelial BC6ENTG metabolites of BC6OTHER .	False
From these results, it was suggested that the contraction induced by BC6OTHER in the rat coronary artery in the presence of BC6ENTC and BC6OTHER is endothelium dependent, and involves reactive BC6OTHER species and endothelial BC6ENTG metabolites of BC6OTHER .	False
From these results, it was suggested that the contraction induced by BC6OTHER in the rat coronary artery in the presence of BC6OTHER and BC6ENTC is endothelium dependent, and involves reactive BC6OTHER species and endothelial BC6ENTG metabolites of BC6OTHER .	False
From these results, it was suggested that the contraction induced by BC6OTHER in the rat coronary artery in the presence of BC6OTHER and BC6OTHER is endothelium dependent, and involves reactive BC6ENTC species and endothelial BC6ENTG metabolites of BC6OTHER .	False
The effects of repeated administration of the BC6OTHER antidepressant drug, BC6OTHER ( BC6ENTC ), on behaviour (locomotor activity and rearing) and the number and affinity of brain BC6ENTG and BC6OTHER receptor binding sites were examined in olfactory bulbectomized (OB) and sham - operated control rats.	False
The effects of repeated administration of the BC6OTHER antidepressant drug, BC6OTHER ( BC6ENTC ), on behaviour (locomotor activity and rearing) and the number and affinity of brain BC6OTHER and BC6ENTG receptor binding sites were examined in olfactory bulbectomized (OB) and sham - operated control rats.	False
After 7 days of BC6ENTC administration the number of BC6ENTG was lower in frontal and occipital cortex and hippocampus.	CPR:4
 BC6ENTC administration in the olfactory bulbectomized rat: changes in brain BC6OTHER and BC6ENTG binding sites and their relationship to behaviour.	False
 BC6ENTC administration in the olfactory bulbectomized rat: changes in brain BC6ENTG and BC6OTHER binding sites and their relationship to behaviour.	False
Administration of BC6ENTC for 14 or 21 days did not further reduce the number of BC6ENTG .	False
The BC6ENTC induced reduction in BC6ENTG did not differ in OB and sham - operated control rats.	CPR:4
BC6ENTC administration for up to 21 days produced a progressive reduction in the number of BC6ENTG receptors in frontal cortex, without significant alterations in occipital cortex.	CPR:4
The time course of the reduction in the number of BC6ENTG receptors was similar to that of the BC6ENTC - induced behavioural changes whereas that for the reduction in BC6OTHER was clearly different.	CPR:4
The time course of the reduction in the number of BC6OTHER receptors was similar to that of the BC6ENTC - induced behavioural changes whereas that for the reduction in BC6ENTG was clearly different.	CPR:4
The present results suggest that the action of BC6ENTC in this animal model is unlikely to be directly related to a reduction in BC6ENTG but may be related to a reduction in frontal cortical BC6OTHER receptors.	CPR:4
The present results suggest that the action of BC6ENTC in this animal model is unlikely to be directly related to a reduction in BC6OTHER but may be related to a reduction in frontal cortical BC6ENTG receptors.	CPR:4
The effects of repeated administration of the BC6ENTC antidepressant drug, BC6OTHER ( BC6OTHER ), on behaviour (locomotor activity and rearing) and the number and affinity of brain BC6ENTG and BC6OTHER receptor binding sites were examined in olfactory bulbectomized (OB) and sham - operated control rats.	False
The effects of repeated administration of the BC6ENTC antidepressant drug, BC6OTHER ( BC6OTHER ), on behaviour (locomotor activity and rearing) and the number and affinity of brain BC6OTHER and BC6ENTG receptor binding sites were examined in olfactory bulbectomized (OB) and sham - operated control rats.	False
The effects of repeated administration of the BC6OTHER antidepressant drug, BC6ENTC ( BC6OTHER ), on behaviour (locomotor activity and rearing) and the number and affinity of brain BC6ENTG and BC6OTHER receptor binding sites were examined in olfactory bulbectomized (OB) and sham - operated control rats.	False
The effects of repeated administration of the BC6OTHER antidepressant drug, BC6ENTC ( BC6OTHER ), on behaviour (locomotor activity and rearing) and the number and affinity of brain BC6OTHER and BC6ENTG receptor binding sites were examined in olfactory bulbectomized (OB) and sham - operated control rats.	False
BC6ENTG release was higher ( approximately 1.6 - fold) in 25 mM (high) compared with 5 mM (normal) BC6ENTC .	CPR:3
BC6ENTG increases BC6ENTC transport (half maximal effect approximately 1.6 ng / ml) in normal BC6OTHER , but did not alter high BC6OTHER - increased BC6OTHER transport.	False
BC6ENTG increases BC6OTHER transport (half maximal effect approximately 1.6 ng / ml) in normal BC6ENTC , but did not alter high BC6OTHER - increased BC6OTHER transport.	False
BC6ENTG increases BC6OTHER transport (half maximal effect approximately 1.6 ng / ml) in normal BC6OTHER , but did not alter high BC6ENTC - increased BC6OTHER transport.	False
BC6ENTG increases BC6OTHER transport (half maximal effect approximately 1.6 ng / ml) in normal BC6OTHER , but did not alter high BC6OTHER - increased BC6ENTC transport.	False
BC6ENTG and high BC6ENTC increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation.	False
BC6OTHER and high BC6ENTC increased BC6ENTG mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation.	CPR:3
BC6OTHER and high BC6ENTC increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6OTHER synthesis) and BC6ENTG ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation.	False
BC6OTHER and high BC6ENTC increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6ENTG ) protein abundance, but did not alter BC6OTHER phosphorylation.	False
BC6OTHER and high BC6ENTC increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6ENTG phosphorylation.	False
BC6ENTG and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6ENTC formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation.	False
BC6OTHER and high BC6OTHER increased BC6ENTG mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6ENTC formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation.	False
BC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6ENTC formation from BC6OTHER (index of BC6OTHER synthesis) and BC6ENTG ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation.	False
BC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6ENTC formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6ENTG ) protein abundance, but did not alter BC6OTHER phosphorylation.	False
BC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6ENTC formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6ENTG phosphorylation.	False
BC6ENTG and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6ENTC (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation.	False
BC6OTHER and high BC6OTHER increased BC6ENTG mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6ENTC (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation.	False
BC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6ENTC (index of BC6OTHER synthesis) and BC6ENTG ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation.	False
BC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6ENTC (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6ENTG ) protein abundance, but did not alter BC6OTHER phosphorylation.	False
BC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6ENTC (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6ENTG phosphorylation.	False
BC6ENTG and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6ENTC synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation.	False
BC6OTHER and high BC6OTHER increased BC6ENTG mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6ENTC synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation.	False
BC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6ENTC synthesis) and BC6ENTG ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation.	CPR:9
BC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6ENTC synthesis) and endothelial BC6OTHER synthase ( BC6ENTG ) protein abundance, but did not alter BC6OTHER phosphorylation.	CPR:9
BC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6ENTC synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6ENTG phosphorylation.	False
BC6ENTG and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6ENTC synthase ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation.	False
BC6OTHER and high BC6OTHER increased BC6ENTG mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6ENTC synthase ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation.	False
BC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6ENTC synthase ( BC6ENTG ) protein abundance, but did not alter BC6OTHER phosphorylation.	False
BC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6ENTC synthase ( BC6OTHER ) protein abundance, but did not alter BC6ENTG phosphorylation.	False
BC6ENTG and high BC6ENTC increased BC6OTHER ( BC6OTHER ) and BC6OTHER phosphorylation, an effect blocked by BC6OTHER ( BC6OTHER inhibitor).	False
BC6OTHER and high BC6ENTC increased BC6ENTG ( BC6OTHER ) and BC6OTHER phosphorylation, an effect blocked by BC6OTHER ( BC6OTHER inhibitor).	False
BC6OTHER and high BC6ENTC increased BC6OTHER ( BC6ENTG ) and BC6OTHER phosphorylation, an effect blocked by BC6OTHER ( BC6OTHER inhibitor).	False
BC6OTHER and high BC6ENTC increased BC6OTHER ( BC6OTHER ) and BC6ENTG phosphorylation, an effect blocked by BC6OTHER ( BC6OTHER inhibitor).	CPR:3
BC6OTHER and high BC6ENTC increased BC6OTHER ( BC6OTHER ) and BC6OTHER phosphorylation, an effect blocked by BC6OTHER ( BC6ENTG inhibitor).	False
 BC6ENTC stimulation of BC6OTHER transport and BC6OTHER synthesis results from activation of BC6ENTG and BC6OTHER requiring functional BC6OTHER in human umbilical vein endothelium.	False
 BC6ENTC stimulation of BC6OTHER transport and BC6OTHER synthesis results from activation of BC6OTHER and BC6ENTG requiring functional BC6OTHER in human umbilical vein endothelium.	CPR:3
 BC6ENTC stimulation of BC6OTHER transport and BC6OTHER synthesis results from activation of BC6OTHER and BC6OTHER requiring functional BC6ENTG in human umbilical vein endothelium.	False
 BC6OTHER stimulation of BC6ENTC transport and BC6OTHER synthesis results from activation of BC6ENTG and BC6OTHER requiring functional BC6OTHER in human umbilical vein endothelium.	False
 BC6OTHER stimulation of BC6ENTC transport and BC6OTHER synthesis results from activation of BC6OTHER and BC6ENTG requiring functional BC6OTHER in human umbilical vein endothelium.	False
 BC6OTHER stimulation of BC6ENTC transport and BC6OTHER synthesis results from activation of BC6OTHER and BC6OTHER requiring functional BC6ENTG in human umbilical vein endothelium.	False
 BC6OTHER stimulation of BC6OTHER transport and BC6ENTC synthesis results from activation of BC6ENTG and BC6OTHER requiring functional BC6OTHER in human umbilical vein endothelium.	False
 BC6OTHER stimulation of BC6OTHER transport and BC6ENTC synthesis results from activation of BC6OTHER and BC6ENTG requiring functional BC6OTHER in human umbilical vein endothelium.	False
 BC6OTHER stimulation of BC6OTHER transport and BC6ENTC synthesis results from activation of BC6OTHER and BC6OTHER requiring functional BC6ENTG in human umbilical vein endothelium.	False
BC6ENTG and high BC6OTHER increased BC6OTHER ( BC6OTHER ) and BC6OTHER phosphorylation, an effect blocked by BC6ENTC ( BC6OTHER inhibitor).	False
BC6OTHER and high BC6OTHER increased BC6ENTG ( BC6OTHER ) and BC6OTHER phosphorylation, an effect blocked by BC6ENTC ( BC6OTHER inhibitor).	False
BC6OTHER and high BC6OTHER increased BC6OTHER ( BC6ENTG ) and BC6OTHER phosphorylation, an effect blocked by BC6ENTC ( BC6OTHER inhibitor).	False
BC6OTHER and high BC6OTHER increased BC6OTHER ( BC6OTHER ) and BC6ENTG phosphorylation, an effect blocked by BC6ENTC ( BC6OTHER inhibitor).	CPR:4
BC6OTHER and high BC6OTHER increased BC6OTHER ( BC6OTHER ) and BC6OTHER phosphorylation, an effect blocked by BC6ENTC ( BC6ENTG inhibitor).	False
However, BC6ENTG and high BC6ENTC were ineffective in cells expressing a truncated, negative dominant BC6OTHER .	False
However, BC6OTHER and high BC6ENTC were ineffective in cells expressing a truncated, negative dominant BC6ENTG .	False
High BC6ENTC increases BC6OTHER transport and BC6ENTG expression following BC6OTHER activation by BC6OTHER involving BC6OTHER ( BC6OTHER ) and BC6OTHER in HUVEC.	CPR:3
High BC6ENTC increases BC6OTHER transport and BC6OTHER expression following BC6ENTG activation by BC6OTHER involving BC6OTHER ( BC6OTHER ) and BC6OTHER in HUVEC.	CPR:3
High BC6ENTC increases BC6OTHER transport and BC6OTHER expression following BC6OTHER activation by BC6ENTG involving BC6OTHER ( BC6OTHER ) and BC6OTHER in HUVEC.	False
High BC6ENTC increases BC6OTHER transport and BC6OTHER expression following BC6OTHER activation by BC6OTHER involving BC6ENTG ( BC6OTHER ) and BC6OTHER in HUVEC.	False
High BC6ENTC increases BC6OTHER transport and BC6OTHER expression following BC6OTHER activation by BC6OTHER involving BC6OTHER ( BC6ENTG ) and BC6OTHER in HUVEC.	False
High BC6ENTC increases BC6OTHER transport and BC6OTHER expression following BC6OTHER activation by BC6OTHER involving BC6OTHER ( BC6OTHER ) and BC6ENTG in HUVEC.	CPR:3
High BC6OTHER increases BC6ENTC transport and BC6ENTG expression following BC6OTHER activation by BC6OTHER involving BC6OTHER ( BC6OTHER ) and BC6OTHER in HUVEC.	False
High BC6OTHER increases BC6ENTC transport and BC6OTHER expression following BC6ENTG activation by BC6OTHER involving BC6OTHER ( BC6OTHER ) and BC6OTHER in HUVEC.	False
High BC6OTHER increases BC6ENTC transport and BC6OTHER expression following BC6OTHER activation by BC6ENTG involving BC6OTHER ( BC6OTHER ) and BC6OTHER in HUVEC.	False
High BC6OTHER increases BC6ENTC transport and BC6OTHER expression following BC6OTHER activation by BC6OTHER involving BC6ENTG ( BC6OTHER ) and BC6OTHER in HUVEC.	False
High BC6OTHER increases BC6ENTC transport and BC6OTHER expression following BC6OTHER activation by BC6OTHER involving BC6OTHER ( BC6ENTG ) and BC6OTHER in HUVEC.	False
High BC6OTHER increases BC6ENTC transport and BC6OTHER expression following BC6OTHER activation by BC6OTHER involving BC6OTHER ( BC6OTHER ) and BC6ENTG in HUVEC.	False
Elevated extracellular BC6ENTC increases BC6ENTG ( BC6OTHER ) release from human umbilical vein endothelium (HUVEC).	CPR:3
Elevated extracellular BC6ENTC increases BC6OTHER ( BC6ENTG ) release from human umbilical vein endothelium (HUVEC).	CPR:3
We studied whether BC6ENTC - stimulation of BC6OTHER transport and BC6OTHER synthesis involves BC6ENTG in primary cultures of HUVEC.	False
We studied whether BC6OTHER - stimulation of BC6ENTC transport and BC6OTHER synthesis involves BC6ENTG in primary cultures of HUVEC.	False
We studied whether BC6OTHER - stimulation of BC6OTHER transport and BC6ENTC synthesis involves BC6ENTG in primary cultures of HUVEC.	False
RESULTS: BC6OTHER inhibited constitutive and / or ligand - induced BC6ENTG or BC6OTHER BC6ENTC phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.	False
RESULTS: BC6OTHER inhibited constitutive and / or ligand - induced BC6OTHER or BC6ENTG BC6ENTC phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.	False
Effects of the BC6ENTG / BC6OTHER BC6OTHER inhibitor BC6ENTC on BC6OTHER - and BC6OTHER - overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.	CPR:4
Effects of the BC6OTHER / BC6ENTG BC6OTHER inhibitor BC6ENTC on BC6OTHER - and BC6OTHER - overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.	CPR:4
Effects of the BC6OTHER / BC6OTHER BC6ENTG inhibitor BC6ENTC on BC6OTHER - and BC6OTHER - overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.	CPR:4
Effects of the BC6OTHER / BC6OTHER BC6OTHER inhibitor BC6ENTC on BC6ENTG - and BC6OTHER - overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.	False
Effects of the BC6OTHER / BC6OTHER BC6OTHER inhibitor BC6ENTC on BC6OTHER - and BC6ENTG - overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.	False
BC6ENTC radiosensitized BC6ENTG - overexpressing cell lines, but BC6OTHER - overexpressing cells were unable to form colonies after brief exposure to BC6OTHER even in the absence of radiation, and thus could not be evaluated for radiosensitization.	False
BC6ENTC radiosensitized BC6OTHER - overexpressing cell lines, but BC6ENTG - overexpressing cells were unable to form colonies after brief exposure to BC6OTHER even in the absence of radiation, and thus could not be evaluated for radiosensitization.	False
BC6OTHER radiosensitized BC6ENTG - overexpressing cell lines, but BC6OTHER - overexpressing cells were unable to form colonies after brief exposure to BC6ENTC even in the absence of radiation, and thus could not be evaluated for radiosensitization.	False
BC6OTHER radiosensitized BC6OTHER - overexpressing cell lines, but BC6ENTG - overexpressing cells were unable to form colonies after brief exposure to BC6ENTC even in the absence of radiation, and thus could not be evaluated for radiosensitization.	False
Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of BC6ENTC to inhibit downstream BC6ENTG and BC6OTHER activation, despite inhibition of BC6OTHER phosphorylation.	False
Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of BC6ENTC to inhibit downstream BC6OTHER and BC6ENTG activation, despite inhibition of BC6OTHER phosphorylation.	False
Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of BC6ENTC to inhibit downstream BC6OTHER and BC6OTHER activation, despite inhibition of BC6ENTG phosphorylation.	CPR:4
CONCLUSION: BC6ENTC potently inhibits receptor phosphorylation in either BC6ENTG - or BC6OTHER - overexpressing cell lines and has both antiproliferative and radiosensitizing effects.	CPR:4
CONCLUSION: BC6ENTC potently inhibits receptor phosphorylation in either BC6OTHER - or BC6ENTG - overexpressing cell lines and has both antiproliferative and radiosensitizing effects.	CPR:4
Resistance to BC6ENTC was not due to a lack of receptor inhibition, but rather with a lack of inhibition of BC6ENTG and BC6OTHER , suggesting that measurement of inhibition of crucial signaling pathways may better predict response than inhibition of receptor phosphorylation.	False
Resistance to BC6ENTC was not due to a lack of receptor inhibition, but rather with a lack of inhibition of BC6OTHER and BC6ENTG , suggesting that measurement of inhibition of crucial signaling pathways may better predict response than inhibition of receptor phosphorylation.	False
To gauge the potential clinical utility of targeting both BC6ENTG and BC6OTHER to control growth and radiosensitize human breast cancers, we examined the effect of a dual BC6OTHER / BC6OTHER inhibitor, BC6ENTC , on the proliferation and radiation response of either BC6OTHER - or BC6OTHER - overexpressing human breast cancer cell lines.	False
To gauge the potential clinical utility of targeting both BC6OTHER and BC6ENTG to control growth and radiosensitize human breast cancers, we examined the effect of a dual BC6OTHER / BC6OTHER inhibitor, BC6ENTC , on the proliferation and radiation response of either BC6OTHER - or BC6OTHER - overexpressing human breast cancer cell lines.	False
To gauge the potential clinical utility of targeting both BC6OTHER and BC6OTHER to control growth and radiosensitize human breast cancers, we examined the effect of a dual BC6ENTG / BC6OTHER inhibitor, BC6ENTC , on the proliferation and radiation response of either BC6OTHER - or BC6OTHER - overexpressing human breast cancer cell lines.	CPR:4
To gauge the potential clinical utility of targeting both BC6OTHER and BC6OTHER to control growth and radiosensitize human breast cancers, we examined the effect of a dual BC6OTHER / BC6ENTG inhibitor, BC6ENTC , on the proliferation and radiation response of either BC6OTHER - or BC6OTHER - overexpressing human breast cancer cell lines.	CPR:4
To gauge the potential clinical utility of targeting both BC6OTHER and BC6OTHER to control growth and radiosensitize human breast cancers, we examined the effect of a dual BC6OTHER / BC6OTHER inhibitor, BC6ENTC , on the proliferation and radiation response of either BC6ENTG - or BC6OTHER - overexpressing human breast cancer cell lines.	False
To gauge the potential clinical utility of targeting both BC6OTHER and BC6OTHER to control growth and radiosensitize human breast cancers, we examined the effect of a dual BC6OTHER / BC6OTHER inhibitor, BC6ENTC , on the proliferation and radiation response of either BC6OTHER - or BC6ENTG - overexpressing human breast cancer cell lines.	False
METHODS AND MATERIALS: Primary human breast cancer cell lines that endogenously overexpress BC6ENTG or BC6OTHER and luminal mammary epithelial H16N2 cells stably transfected with BC6OTHER were evaluated for the effect of BC6ENTC on inhibition of ligand - induced or BC6OTHER phosphorylation, proliferation, radiosensitization, and inhibition of downstream signaling.	False
METHODS AND MATERIALS: Primary human breast cancer cell lines that endogenously overexpress BC6OTHER or BC6ENTG and luminal mammary epithelial H16N2 cells stably transfected with BC6OTHER were evaluated for the effect of BC6ENTC on inhibition of ligand - induced or BC6OTHER phosphorylation, proliferation, radiosensitization, and inhibition of downstream signaling.	False
METHODS AND MATERIALS: Primary human breast cancer cell lines that endogenously overexpress BC6OTHER or BC6OTHER and luminal mammary epithelial H16N2 cells stably transfected with BC6ENTG were evaluated for the effect of BC6ENTC on inhibition of ligand - induced or BC6OTHER phosphorylation, proliferation, radiosensitization, and inhibition of downstream signaling.	False
METHODS AND MATERIALS: Primary human breast cancer cell lines that endogenously overexpress BC6OTHER or BC6OTHER and luminal mammary epithelial H16N2 cells stably transfected with BC6OTHER were evaluated for the effect of BC6ENTC on inhibition of ligand - induced or BC6ENTG phosphorylation, proliferation, radiosensitization, and inhibition of downstream signaling.	False
RESULTS: BC6ENTC inhibited constitutive and / or ligand - induced BC6ENTG or BC6OTHER BC6OTHER phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.	CPR:4
RESULTS: BC6ENTC inhibited constitutive and / or ligand - induced BC6OTHER or BC6ENTG BC6OTHER phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.	CPR:4
BC6ENTG levels were negatively correlated with variables of vagal control, reaching significance for rMSSD and log(10)HF, but not for pvRSA, during the last four phases of the hyperglycaemic clamp (hyperglycaemic second phase, BC6OTHER first and second phases, and BC6ENTC ).	False
BC6OTHER levels were negatively correlated with variables of vagal control, reaching significance for rMSSD and log(10)HF, but not for pvRSA, during the last four phases of the hyperglycaemic clamp (hyperglycaemic second phase, BC6ENTG first and second phases, and BC6ENTC ).	False
Administration of the beta cell secretagogues BC6ENTG and BC6ENTC led to a significant increase in HR, but this was not paired with a significant reduction in HRV measures.	False
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6ENTG (achieved by administering BC6OTHER plus BC6ENTC , BC6OTHER only, BC6OTHER and BC6OTHER , and BC6OTHER and BC6OTHER combined with BC6OTHER ).	CPR:3
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6ENTG plus BC6ENTC , BC6OTHER only, BC6OTHER and BC6OTHER , and BC6OTHER and BC6OTHER combined with BC6OTHER ).	False
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6OTHER plus BC6ENTC , BC6OTHER only, BC6OTHER and BC6ENTG , and BC6OTHER and BC6OTHER combined with BC6OTHER ).	False
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6OTHER plus BC6ENTC , BC6OTHER only, BC6OTHER and BC6OTHER , and BC6OTHER and BC6ENTG combined with BC6OTHER ).	False
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6ENTG (achieved by administering BC6OTHER plus BC6OTHER , BC6ENTC only, BC6OTHER and BC6OTHER , and BC6OTHER and BC6OTHER combined with BC6OTHER ).	CPR:3
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6ENTG plus BC6OTHER , BC6ENTC only, BC6OTHER and BC6OTHER , and BC6OTHER and BC6OTHER combined with BC6OTHER ).	False
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6OTHER plus BC6OTHER , BC6ENTC only, BC6OTHER and BC6ENTG , and BC6OTHER and BC6OTHER combined with BC6OTHER ).	False
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6OTHER plus BC6OTHER , BC6ENTC only, BC6OTHER and BC6OTHER , and BC6OTHER and BC6ENTG combined with BC6OTHER ).	False
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6ENTG (achieved by administering BC6OTHER plus BC6OTHER , BC6OTHER only, BC6ENTC and BC6OTHER , and BC6OTHER and BC6OTHER combined with BC6OTHER ).	CPR:3
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6ENTG plus BC6OTHER , BC6OTHER only, BC6ENTC and BC6OTHER , and BC6OTHER and BC6OTHER combined with BC6OTHER ).	False
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6OTHER plus BC6OTHER , BC6OTHER only, BC6ENTC and BC6ENTG , and BC6OTHER and BC6OTHER combined with BC6OTHER ).	False
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6OTHER plus BC6OTHER , BC6OTHER only, BC6ENTC and BC6OTHER , and BC6OTHER and BC6ENTG combined with BC6OTHER ).	False
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6ENTG (achieved by administering BC6OTHER plus BC6OTHER , BC6OTHER only, BC6OTHER and BC6OTHER , and BC6ENTC and BC6OTHER combined with BC6OTHER ).	CPR:3
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6ENTG plus BC6OTHER , BC6OTHER only, BC6OTHER and BC6OTHER , and BC6ENTC and BC6OTHER combined with BC6OTHER ).	False
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6OTHER plus BC6OTHER , BC6OTHER only, BC6OTHER and BC6ENTG , and BC6ENTC and BC6OTHER combined with BC6OTHER ).	False
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6OTHER plus BC6OTHER , BC6OTHER only, BC6OTHER and BC6OTHER , and BC6ENTC and BC6ENTG combined with BC6OTHER ).	False
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6ENTG (achieved by administering BC6OTHER plus BC6OTHER , BC6OTHER only, BC6OTHER and BC6OTHER , and BC6OTHER and BC6OTHER combined with BC6ENTC ).	CPR:3
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6ENTG plus BC6OTHER , BC6OTHER only, BC6OTHER and BC6OTHER , and BC6OTHER and BC6OTHER combined with BC6ENTC ).	False
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6OTHER plus BC6OTHER , BC6OTHER only, BC6OTHER and BC6ENTG , and BC6OTHER and BC6OTHER combined with BC6ENTC ).	False
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6OTHER plus BC6OTHER , BC6OTHER only, BC6OTHER and BC6OTHER , and BC6OTHER and BC6ENTG combined with BC6ENTC ).	False
Conjugates bearing the anticancer agents BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), or BC6OTHER and the BC6ENTG targeting peptide WDLAWMFRLPVG were synthesized and characterized.	False
Conjugates bearing the anticancer agents BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), or BC6OTHER and the BC6ENTG targeting peptide WDLAWMFRLPVG were synthesized and characterized.	False
Conjugates bearing the anticancer agents BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), or BC6OTHER and the BC6ENTG targeting peptide WDLAWMFRLPVG were synthesized and characterized.	False
Conjugates bearing the anticancer agents BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), or BC6OTHER and the BC6ENTG targeting peptide WDLAWMFRLPVG were synthesized and characterized.	False
Conjugates bearing the anticancer agents BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), or BC6ENTC and the BC6ENTG targeting peptide WDLAWMFRLPVG were synthesized and characterized.	False
BC6ENTG targeted BC6ENTC and BC6OTHER conjugates demonstrated active binding comparable to native targeting peptide.	False
BC6ENTG targeted BC6OTHER and BC6ENTC conjugates demonstrated active binding comparable to native targeting peptide.	False
Synergistic enhancement of cancer therapy using a combination of BC6ENTG targeted BC6ENTC copolymer - drug conjugates and gold nanorod induced hyperthermia.	False
BC6ENTG targeted BC6ENTC conjugates exhibited high potency against DU145 cells with an IC50 of 2.4nM.	False
BC6ENTG targeted BC6ENTC and BC6OTHER conjugates demonstrated synergistic effects in combination with hyperthermia with combination index values of 0.65 and 0.45 respectively.	False
BC6ENTG targeted BC6OTHER and BC6ENTC conjugates demonstrated synergistic effects in combination with hyperthermia with combination index values of 0.65 and 0.45 respectively.	False
Based on these results, BC6ENTG targeted BC6ENTC conjugates were selected for in vivo evaluation.	False
In DU145 tumor bearing mice, a single treatment of tumor hyperthermia, induced via gold nanorod mediated plasmonic photothermal therapy, and intravenous administration of BC6ENTG targeted BC6ENTC copolymer - BC6OTHER at 10mg / kg resulted in maintained tumor regression for a period of 30days.	False
In DU145 tumor bearing mice, a single treatment of tumor hyperthermia, induced via gold nanorod mediated plasmonic photothermal therapy, and intravenous administration of BC6ENTG targeted BC6OTHER copolymer - BC6ENTC at 10mg / kg resulted in maintained tumor regression for a period of 30days.	False
In this study, tumor hyperthermia was utilized as a means to increase the active delivery of BC6ENTG ( BC6OTHER ) targeted BC6ENTC ( BC6OTHER ) copolymer - drug conjugates.	False
In this study, tumor hyperthermia was utilized as a means to increase the active delivery of BC6OTHER ( BC6ENTG ) targeted BC6ENTC ( BC6OTHER ) copolymer - drug conjugates.	False
In this study, tumor hyperthermia was utilized as a means to increase the active delivery of BC6ENTG ( BC6OTHER ) targeted BC6OTHER ( BC6ENTC ) copolymer - drug conjugates.	False
In this study, tumor hyperthermia was utilized as a means to increase the active delivery of BC6OTHER ( BC6ENTG ) targeted BC6OTHER ( BC6ENTC ) copolymer - drug conjugates.	False
Following hyperthermia, induced expression of cell surface BC6ENTG ( BC6OTHER ) BC6ENTC regulated protein 78kDa ( BC6OTHER ) was utilized for targeted drug therapy.	False
Following hyperthermia, induced expression of cell surface BC6OTHER ( BC6ENTG ) BC6ENTC regulated protein 78kDa ( BC6OTHER ) was utilized for targeted drug therapy.	False
Following hyperthermia, induced expression of cell surface BC6OTHER ( BC6OTHER ) BC6ENTC regulated protein 78kDa ( BC6ENTG ) was utilized for targeted drug therapy.	False
The carcinogenic relevance of BC6ENTG - BC6OTHER locus ncRNA induction was further supported by in vivo genetic dependence on constitutive BC6ENTC receptor and BC6OTHER pathways.	False
The carcinogenic relevance of BC6OTHER - BC6ENTG locus ncRNA induction was further supported by in vivo genetic dependence on constitutive BC6ENTC receptor and BC6OTHER pathways.	False
The carcinogenic relevance of BC6OTHER - BC6OTHER locus ncRNA induction was further supported by in vivo genetic dependence on constitutive BC6ENTC receptor and BC6ENTG pathways.	False
 Here, we have investigated the temporal sequence of molecular and pathological perturbations at early stages of BC6ENTC (PB) mediated liver tumor promotion in vivo. Molecular profiling (mRNA, microRNA [miRNA], DNA methylation, and proteins) of mouse liver during 13 weeks of PB treatment revealed progressive increases in hepatic expression of long noncoding RNAs and miRNAs originating from the BC6ENTG - BC6OTHER imprinted gene cluster, a locus that has recently been associated with stem cell pluripotency in mice and various neoplasms in humans.	False
 Here, we have investigated the temporal sequence of molecular and pathological perturbations at early stages of BC6ENTC (PB) mediated liver tumor promotion in vivo. Molecular profiling (mRNA, microRNA [miRNA], DNA methylation, and proteins) of mouse liver during 13 weeks of PB treatment revealed progressive increases in hepatic expression of long noncoding RNAs and miRNAs originating from the BC6OTHER - BC6ENTG imprinted gene cluster, a locus that has recently been associated with stem cell pluripotency in mice and various neoplasms in humans.	False
PB induction of the BC6ENTG - BC6OTHER cluster noncoding RNA (ncRNA) Meg3 was localized to BC6ENTC synthetase - positive hypertrophic perivenous hepatocytes, suggesting a role for BC6OTHER signaling in the dysregulation of BC6OTHER - BC6OTHER ncRNAs.	False
PB induction of the BC6OTHER - BC6ENTG cluster noncoding RNA (ncRNA) Meg3 was localized to BC6ENTC synthetase - positive hypertrophic perivenous hepatocytes, suggesting a role for BC6OTHER signaling in the dysregulation of BC6OTHER - BC6OTHER ncRNAs.	False
PB induction of the BC6OTHER - BC6OTHER cluster noncoding RNA (ncRNA) Meg3 was localized to BC6ENTC synthetase - positive hypertrophic perivenous hepatocytes, suggesting a role for BC6ENTG signaling in the dysregulation of BC6OTHER - BC6OTHER ncRNAs.	False
PB induction of the BC6OTHER - BC6OTHER cluster noncoding RNA (ncRNA) Meg3 was localized to BC6ENTC synthetase - positive hypertrophic perivenous hepatocytes, suggesting a role for BC6OTHER signaling in the dysregulation of BC6ENTG - BC6OTHER ncRNAs.	False
PB induction of the BC6OTHER - BC6OTHER cluster noncoding RNA (ncRNA) Meg3 was localized to BC6ENTC synthetase - positive hypertrophic perivenous hepatocytes, suggesting a role for BC6OTHER signaling in the dysregulation of BC6OTHER - BC6ENTG ncRNAs.	False
The noted conformational changes where the BC6OTHER position is closer to the BC6OTHER position of BC6OTHER provided the first experimental data for understanding the molecular mechanism of the catalytic function of BC6ENTG in the isomerization of BC6OTHER to BC6ENTC .	False
The binding of BC6ENTC to the BC6ENTG protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6OTHER , BC6OTHER , and BC6OTHER of BC6OTHER were observed upon BC6OTHER binding to the engineered BC6OTHER in a concentration - dependent manner.	False
The binding of BC6ENTC to the BC6OTHER protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6OTHER , BC6OTHER , and BC6OTHER of BC6OTHER were observed upon BC6OTHER binding to the engineered BC6ENTG in a concentration - dependent manner.	False
The binding of BC6OTHER to the BC6ENTG protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6ENTC , BC6OTHER , and BC6OTHER of BC6OTHER were observed upon BC6OTHER binding to the engineered BC6OTHER in a concentration - dependent manner.	False
The binding of BC6OTHER to the BC6OTHER protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6ENTC , BC6OTHER , and BC6OTHER of BC6OTHER were observed upon BC6OTHER binding to the engineered BC6ENTG in a concentration - dependent manner.	False
The binding of BC6OTHER to the BC6ENTG protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6OTHER , BC6ENTC , and BC6OTHER of BC6OTHER were observed upon BC6OTHER binding to the engineered BC6OTHER in a concentration - dependent manner.	False
The binding of BC6OTHER to the BC6OTHER protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6OTHER , BC6ENTC , and BC6OTHER of BC6OTHER were observed upon BC6OTHER binding to the engineered BC6ENTG in a concentration - dependent manner.	False
The binding of BC6OTHER to the BC6ENTG protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6OTHER , BC6OTHER , and BC6ENTC of BC6OTHER were observed upon BC6OTHER binding to the engineered BC6OTHER in a concentration - dependent manner.	False
The binding of BC6OTHER to the BC6OTHER protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6OTHER , BC6OTHER , and BC6ENTC of BC6OTHER were observed upon BC6OTHER binding to the engineered BC6ENTG in a concentration - dependent manner.	False
The binding of BC6OTHER to the BC6ENTG protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6OTHER , BC6OTHER , and BC6OTHER of BC6ENTC were observed upon BC6OTHER binding to the engineered BC6OTHER in a concentration - dependent manner.	False
The binding of BC6OTHER to the BC6OTHER protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6OTHER , BC6OTHER , and BC6OTHER of BC6ENTC were observed upon BC6OTHER binding to the engineered BC6ENTG in a concentration - dependent manner.	False
The binding of BC6OTHER to the BC6ENTG protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6OTHER , BC6OTHER , and BC6OTHER of BC6OTHER were observed upon BC6ENTC binding to the engineered BC6OTHER in a concentration - dependent manner.	False
The binding of BC6OTHER to the BC6OTHER protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6OTHER , BC6OTHER , and BC6OTHER of BC6OTHER were observed upon BC6ENTC binding to the engineered BC6ENTG in a concentration - dependent manner.	False
The detailed conformational change and 3D structure of the BC6ENTG - bound BC6ENTC were further demonstrated by 2D BC6OTHER NMR experiments using the transferred NOE technique.	False
The detailed conformational change and 3D structure of the BC6ENTG - bound BC6OTHER were further demonstrated by 2D BC6ENTC NMR experiments using the transferred NOE technique.	False
The distances between the protons BC6ENTC and BC6OTHER , BC6OTHER and BC6OTHER , and BC6OTHER and BC6OTHER are shorter following their binding to the BC6ENTG in solution - down to within 5 A.	False
High - resolution NMR spectroscopy was used to determine the docking of a substrate ( BC6OTHER ) mimic ( BC6ENTC ) to the engineered BC6ENTG ( BC6OTHER ) in solution.	False
High - resolution NMR spectroscopy was used to determine the docking of a substrate ( BC6OTHER ) mimic ( BC6ENTC ) to the engineered BC6OTHER ( BC6OTHER ) synthase ( BC6ENTG ) in solution.	False
The distances between the protons BC6OTHER and BC6ENTC , BC6OTHER and BC6OTHER , and BC6OTHER and BC6OTHER are shorter following their binding to the BC6ENTG in solution - down to within 5 A.	False
The distances between the protons BC6OTHER and BC6OTHER , BC6ENTC and BC6OTHER , and BC6OTHER and BC6OTHER are shorter following their binding to the BC6ENTG in solution - down to within 5 A.	False
The distances between the protons BC6OTHER and BC6OTHER , BC6OTHER and BC6ENTC , and BC6OTHER and BC6OTHER are shorter following their binding to the BC6ENTG in solution - down to within 5 A.	False
The distances between the protons BC6OTHER and BC6OTHER , BC6OTHER and BC6OTHER , and BC6ENTC and BC6OTHER are shorter following their binding to the BC6ENTG in solution - down to within 5 A.	False
The distances between the protons BC6OTHER and BC6OTHER , BC6OTHER and BC6OTHER , and BC6OTHER and BC6ENTC are shorter following their binding to the BC6ENTG in solution - down to within 5 A.	False
High - resolution NMR spectroscopy was used to determine the docking of a substrate ( BC6ENTC ) mimic ( BC6OTHER ) to the engineered BC6ENTG ( BC6OTHER ) in solution.	False
High - resolution NMR spectroscopy was used to determine the docking of a substrate ( BC6ENTC ) mimic ( BC6OTHER ) to the engineered BC6OTHER ( BC6OTHER ) synthase ( BC6ENTG ) in solution.	False
The bound conformation of BC6ENTC fits the crystal structure of the BC6ENTG substrate binding pocket considerably better than that of the unbound BC6OTHER .	False
Characterization of the substrate mimic bound to engineered BC6ENTG in solution using high - resolution NMR spectroscopy and mutagenesis: implication of the molecular mechanism in biosynthesis of BC6ENTC .	False
The bound conformation of BC6OTHER fits the crystal structure of the BC6ENTG substrate binding pocket considerably better than that of the unbound BC6ENTC .	False
High - resolution NMR spectroscopy was used to determine the docking of a substrate ( BC6OTHER ) mimic ( BC6OTHER ) to the engineered BC6ENTC ( BC6OTHER ) synthase ( BC6ENTG ) in solution.	False
For example, CHEM282 could be one of the most important residues and is suspected to play a role in the determination of specific catalytic function, which has been established by the docking studies using the NMR structure of the BC6ENTG - bound form of BC6ENTC and the BC6OTHER crystal structure.	False
For example, CHEM282 could be one of the most important residues and is suspected to play a role in the determination of specific catalytic function, which has been established by the docking studies using the NMR structure of the BC6OTHER - bound form of BC6ENTC and the BC6ENTG crystal structure.	False
High - resolution NMR spectroscopy was used to determine the docking of a substrate ( BC6OTHER ) mimic ( BC6OTHER ) to the engineered BC6OTHER ( BC6ENTC ) synthase ( BC6ENTG ) in solution.	False
The noted conformational changes where the BC6ENTC position is closer to the BC6OTHER position of BC6OTHER provided the first experimental data for understanding the molecular mechanism of the catalytic function of BC6ENTG in the isomerization of BC6OTHER to BC6OTHER .	False
The noted conformational changes where the BC6OTHER position is closer to the BC6ENTC position of BC6OTHER provided the first experimental data for understanding the molecular mechanism of the catalytic function of BC6ENTG in the isomerization of BC6OTHER to BC6OTHER .	False
The noted conformational changes where the BC6OTHER position is closer to the BC6OTHER position of BC6ENTC provided the first experimental data for understanding the molecular mechanism of the catalytic function of BC6ENTG in the isomerization of BC6OTHER to BC6OTHER .	False
The noted conformational changes where the BC6OTHER position is closer to the BC6OTHER position of BC6OTHER provided the first experimental data for understanding the molecular mechanism of the catalytic function of BC6ENTG in the isomerization of BC6ENTC to BC6OTHER .	False
X - linked hypophosphatemia (XLH / HYP) - with renal BC6OTHER wasting, hypophosphatemia, osteomalacia, and tooth abscesses - is caused by mutations in the BC6ENTC - metallopeptidase BC6ENTG gene ( BC6OTHER - regulating gene with homologies to BC6OTHER on the X chromosome).	False
X - linked hypophosphatemia (XLH / HYP) - with renal BC6OTHER wasting, hypophosphatemia, osteomalacia, and tooth abscesses - is caused by mutations in the BC6ENTC - metallopeptidase BC6OTHER gene ( BC6OTHER - regulating gene with homologies to BC6ENTG on the X chromosome).	False
X - linked hypophosphatemia (XLH / HYP) - with renal BC6OTHER wasting, hypophosphatemia, osteomalacia, and tooth abscesses - is caused by mutations in the BC6ENTG BC6OTHER gene ( BC6ENTC - regulating gene with homologies to BC6OTHER on the X chromosome).	False
X - linked hypophosphatemia (XLH / HYP) - with renal BC6OTHER wasting, hypophosphatemia, osteomalacia, and tooth abscesses - is caused by mutations in the BC6OTHER - metallopeptidase BC6ENTG gene ( BC6ENTC - regulating gene with homologies to BC6OTHER on the X chromosome).	False
X - linked hypophosphatemia (XLH / HYP) - with renal BC6OTHER wasting, hypophosphatemia, osteomalacia, and tooth abscesses - is caused by mutations in the BC6OTHER - metallopeptidase BC6OTHER gene ( BC6ENTC - regulating gene with homologies to BC6ENTG on the X chromosome).	False
X - linked hypophosphatemia (XLH / HYP) - with renal BC6ENTC wasting, hypophosphatemia, osteomalacia, and tooth abscesses - is caused by mutations in the BC6ENTG BC6OTHER gene ( BC6OTHER - regulating gene with homologies to BC6OTHER on the X chromosome).	False
X - linked hypophosphatemia (XLH / HYP) - with renal BC6ENTC wasting, hypophosphatemia, osteomalacia, and tooth abscesses - is caused by mutations in the BC6OTHER - metallopeptidase BC6ENTG gene ( BC6OTHER - regulating gene with homologies to BC6OTHER on the X chromosome).	False
X - linked hypophosphatemia (XLH / HYP) - with renal BC6ENTC wasting, hypophosphatemia, osteomalacia, and tooth abscesses - is caused by mutations in the BC6OTHER - metallopeptidase BC6OTHER gene ( BC6OTHER - regulating gene with homologies to BC6ENTG on the X chromosome).	False
Inactivating mutations in BC6ENTG lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6ENTC - and BC6OTHER - rich motif ( BC6OTHER ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6OTHER family (small, integrin - binding ligand BC6OTHER - linked glycoproteins).	False
Inactivating mutations in BC6OTHER lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6ENTC - and BC6OTHER - rich motif ( BC6ENTG ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6OTHER family (small, integrin - binding ligand BC6OTHER - linked glycoproteins).	False
Inactivating mutations in BC6OTHER lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6ENTC - and BC6OTHER - rich motif ( BC6OTHER ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6ENTG family (small, integrin - binding ligand BC6OTHER - linked glycoproteins).	False
Inactivating mutations in BC6OTHER lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6ENTC - and BC6OTHER - rich motif ( BC6OTHER ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6OTHER family ( BC6ENTG ).	False
Inactivating mutations in BC6ENTG lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6OTHER - and BC6ENTC - rich motif ( BC6OTHER ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6OTHER family (small, integrin - binding ligand BC6OTHER - linked glycoproteins).	False
Inactivating mutations in BC6OTHER lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, BC6ENTG BC6ENTC - rich motif ( BC6OTHER ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6OTHER family (small, integrin - binding ligand BC6OTHER - linked glycoproteins).	False
Inactivating mutations in BC6OTHER lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6OTHER - and BC6ENTC - rich motif ( BC6ENTG ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6OTHER family (small, integrin - binding ligand BC6OTHER - linked glycoproteins).	False
Inactivating mutations in BC6OTHER lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6OTHER - and BC6ENTC - rich motif ( BC6OTHER ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6ENTG family (small, integrin - binding ligand BC6OTHER - linked glycoproteins).	False
Inactivating mutations in BC6OTHER lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6OTHER - and BC6ENTC - rich motif ( BC6OTHER ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6OTHER family ( BC6ENTG ).	False
Inactivating mutations in BC6ENTG lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6OTHER - and BC6OTHER - rich motif ( BC6OTHER ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6OTHER family (small, integrin - binding ligand BC6ENTC - linked glycoproteins).	False
Inactivating mutations in BC6OTHER lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, BC6ENTG BC6OTHER - rich motif ( BC6OTHER ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6OTHER family (small, integrin - binding ligand BC6ENTC - linked glycoproteins).	False
Inactivating mutations in BC6OTHER lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6OTHER - and BC6OTHER - rich motif ( BC6ENTG ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6OTHER family (small, integrin - binding ligand BC6ENTC - linked glycoproteins).	False
Inactivating mutations in BC6OTHER lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6OTHER - and BC6OTHER - rich motif ( BC6OTHER ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6ENTG family (small, integrin - binding ligand BC6ENTC - linked glycoproteins).	False
The net accumulation of BC6OTHER ( BC6ENTC ) and the BC6OTHER - DNA adduct levels were reduced in BC6ENTG KD and BC6OTHER KD cells.	False
The net accumulation of BC6OTHER ( BC6ENTC ) and the BC6OTHER - DNA adduct levels were reduced in BC6OTHER KD and BC6ENTG KD cells.	False
The net accumulation of BC6OTHER ( BC6OTHER ) and the BC6ENTC - DNA adduct levels were reduced in BC6ENTG KD and BC6OTHER KD cells.	False
The net accumulation of BC6OTHER ( BC6OTHER ) and the BC6ENTC - DNA adduct levels were reduced in BC6OTHER KD and BC6ENTG KD cells.	False
The endogenous mRNA levels of BC6ENTC influx transporter BC6OTHER were found to be significantly reduced in the knockdown cells, and exogenous expression of BC6ENTG restored their sensitivity to CHEM.	False
The endogenous mRNA levels of BC6ENTC influx transporter BC6ENTG were found to be significantly reduced in the knockdown cells, and exogenous expression of BC6OTHER restored their sensitivity to CHEM.	False
 BC6ENTG and BC6OTHER regulate sensitivity to BC6OTHER by controlling expression of the CHEM and BC6ENTC influx transporter BC6OTHER .	False
 BC6OTHER and BC6OTHER regulate sensitivity to BC6OTHER by controlling expression of the CHEM and BC6ENTC influx transporter BC6ENTG .	False
 BC6OTHER and BC6ENTG regulate sensitivity to BC6OTHER by controlling expression of the CHEM and BC6ENTC influx transporter BC6OTHER .	False
 BC6ENTG and BC6OTHER regulate sensitivity to BC6ENTC by controlling expression of the CHEM and BC6OTHER influx transporter BC6OTHER .	False
 BC6OTHER and BC6OTHER regulate sensitivity to BC6ENTC by controlling expression of the CHEM and BC6OTHER influx transporter BC6ENTG .	False
 BC6OTHER and BC6ENTG regulate sensitivity to BC6ENTC by controlling expression of the CHEM and BC6OTHER influx transporter BC6OTHER .	False
 BC6OTHER and BC6OTHER regulate sensitivity to BC6ENTC by controlling expression of the BC6ENTG BC6OTHER .	False
 BC6ENTG and BC6OTHER regulate sensitivity to BC6OTHER by controlling expression of the BC6ENTC and BC6OTHER influx transporter BC6OTHER .	False
 BC6OTHER and BC6OTHER regulate sensitivity to BC6OTHER by controlling expression of the BC6ENTC and BC6OTHER influx transporter BC6ENTG .	False
 BC6OTHER and BC6ENTG regulate sensitivity to BC6OTHER by controlling expression of the BC6ENTC and BC6OTHER influx transporter BC6OTHER .	False
Baseline BC6ENTC ( BC6OTHER ) level, BC6OTHER uptake, and BC6OTHER cytotoxicity were also reduced in BC6ENTG KD and BC6OTHER KD cells.	False
Baseline BC6ENTC ( BC6OTHER ) level, BC6OTHER uptake, and BC6OTHER cytotoxicity were also reduced in BC6OTHER KD and BC6ENTG KD cells.	False
Baseline BC6OTHER ( BC6ENTC ) level, BC6OTHER uptake, and BC6OTHER cytotoxicity were also reduced in BC6ENTG KD and BC6OTHER KD cells.	False
Baseline BC6OTHER ( BC6ENTC ) level, BC6OTHER uptake, and BC6OTHER cytotoxicity were also reduced in BC6OTHER KD and BC6ENTG KD cells.	False
Baseline BC6OTHER ( BC6OTHER ) level, BC6ENTC uptake, and BC6OTHER cytotoxicity were also reduced in BC6ENTG KD and BC6OTHER KD cells.	False
Baseline BC6OTHER ( BC6OTHER ) level, BC6ENTC uptake, and BC6OTHER cytotoxicity were also reduced in BC6OTHER KD and BC6ENTG KD cells.	False
Baseline BC6OTHER ( BC6OTHER ) level, BC6OTHER uptake, and BC6ENTC cytotoxicity were also reduced in BC6ENTG KD and BC6OTHER KD cells.	False
Baseline BC6OTHER ( BC6OTHER ) level, BC6OTHER uptake, and BC6ENTC cytotoxicity were also reduced in BC6OTHER KD and BC6ENTG KD cells.	False
BC6ENTC - dependent BC6ENTG activity was also markedly reduced in both types of BC6OTHER knockdown cells when incubated with the substrate BC6OTHER .	False
BC6ENTC - dependent BC6OTHER activity was also markedly reduced in both types of BC6ENTG knockdown cells when incubated with the substrate BC6OTHER .	False
BC6OTHER - dependent BC6ENTG activity was also markedly reduced in both types of BC6OTHER knockdown cells when incubated with the substrate BC6ENTC .	CPR:9
BC6OTHER - dependent BC6OTHER activity was also markedly reduced in both types of BC6ENTG knockdown cells when incubated with the substrate BC6ENTC .	False
These results indicate that BC6ENTG and BC6OTHER affect sensitivity of the ovarian cancer cells to the cytotoxic effect of CHEM by regulating expression of the BC6ENTC transporter BC6OTHER .	False
These results indicate that BC6OTHER and BC6ENTG affect sensitivity of the ovarian cancer cells to the cytotoxic effect of CHEM by regulating expression of the BC6ENTC transporter BC6OTHER .	False
These results indicate that BC6OTHER and BC6OTHER affect sensitivity of the ovarian cancer cells to the cytotoxic effect of CHEM by regulating expression of the BC6ENTC transporter BC6ENTG .	False
We found that knockdown of the expression of either BC6ENTG or BC6OTHER produced marked changes in the phenotype of ovarian cancer cells, including an increase in resistance to BC6ENTC (CHEM).	False
We found that knockdown of the expression of either BC6OTHER or BC6ENTG produced marked changes in the phenotype of ovarian cancer cells, including an increase in resistance to BC6ENTC (CHEM).	False
The net accumulation of BC6ENTC ( BC6OTHER ) and the BC6OTHER - DNA adduct levels were reduced in BC6ENTG KD and BC6OTHER KD cells.	False
The net accumulation of BC6ENTC ( BC6OTHER ) and the BC6OTHER - DNA adduct levels were reduced in BC6OTHER KD and BC6ENTG KD cells.	False
Gitelman's variant of Bartter's syndrome, inherited hypokalemic alkalosis, is caused by mutation in the BC6ENTC - sensitive BC6OTHER co - transporter ( BC6ENTG ).	False
Gitelman's variant of Bartter's syndrome, inherited hypokalemic alkalosis, is caused by mutation in the CHEM - sensitive BC6ENTC co - transporter ( BC6ENTG ).	False
Different forms of therapy, BC6ENTC and BC6OTHER substitution, BC6OTHER and BC6OTHER failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized BC6ENTG levels in the three patients with short stature.	False
Different forms of therapy, BC6OTHER and BC6ENTC substitution, BC6OTHER and BC6OTHER failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized BC6ENTG levels in the three patients with short stature.	False
Different forms of therapy, BC6OTHER and BC6OTHER substitution, BC6ENTC and BC6OTHER failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized BC6ENTG levels in the three patients with short stature.	False
Different forms of therapy, BC6OTHER and BC6OTHER substitution, BC6OTHER and BC6ENTC failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized BC6ENTG levels in the three patients with short stature.	False
We show that the binding of BC6OTHER photoaffinity label to authentic BC6ENTG is competed with both BC6OTHER and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of BC6OTHER from human monocytes, suggesting that BC6OTHER may be involved in the immunomodulatory activity of BC6ENTC .	False
We show that the binding of BC6OTHER photoaffinity label to authentic BC6OTHER is competed with both BC6OTHER and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of BC6ENTG from human monocytes, suggesting that BC6OTHER may be involved in the immunomodulatory activity of BC6ENTC .	False
We show that the binding of BC6OTHER photoaffinity label to authentic BC6OTHER is competed with both BC6OTHER and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of BC6OTHER from human monocytes, suggesting that BC6ENTG may be involved in the immunomodulatory activity of BC6ENTC .	False
The immunomodulatory activity of BC6ENTC has been ascribed to the selective inhibition of BC6ENTG from monocytes.	CPR:4
We show that the binding of BC6ENTC photoaffinity label to authentic BC6ENTG is competed with both BC6OTHER and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of BC6OTHER from human monocytes, suggesting that BC6OTHER may be involved in the immunomodulatory activity of BC6OTHER .	False
We show that the binding of BC6ENTC photoaffinity label to authentic BC6OTHER is competed with both BC6OTHER and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of BC6ENTG from human monocytes, suggesting that BC6OTHER may be involved in the immunomodulatory activity of BC6OTHER .	False
We show that the binding of BC6ENTC photoaffinity label to authentic BC6OTHER is competed with both BC6OTHER and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of BC6OTHER from human monocytes, suggesting that BC6ENTG may be involved in the immunomodulatory activity of BC6OTHER .	False
We show that the binding of BC6OTHER photoaffinity label to authentic BC6ENTG is competed with both BC6ENTC and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of BC6OTHER from human monocytes, suggesting that BC6OTHER may be involved in the immunomodulatory activity of BC6OTHER .	False
We show that the binding of BC6OTHER photoaffinity label to authentic BC6OTHER is competed with both BC6ENTC and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of BC6ENTG from human monocytes, suggesting that BC6OTHER may be involved in the immunomodulatory activity of BC6OTHER .	CPR:4
We show that the binding of BC6OTHER photoaffinity label to authentic BC6OTHER is competed with both BC6ENTC and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of BC6OTHER from human monocytes, suggesting that BC6ENTG may be involved in the immunomodulatory activity of BC6OTHER .	False
Binding of BC6ENTC to BC6ENTG may be involved in its inhibition of BC6OTHER production.	False
Binding of BC6ENTC to BC6OTHER may be involved in its inhibition of BC6ENTG production.	CPR:4
The role of extranuclear signaling actions of BC6ENTG in mediating BC6ENTC regulation of gene expression and the cell cycle.	False
BC6OTHER induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6ENTC response element was unaffected by mutations that interfere with BC6ENTG activation of BC6OTHER .	False
BC6OTHER induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6ENTC response element was unaffected by mutations that interfere with BC6OTHER activation of BC6ENTG .	False
BC6OTHER induction of the BC6ENTG gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6ENTC response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	False
BC6OTHER induction of the BC6OTHER gene, which lacks a BC6ENTG , was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6ENTC response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	False
BC6OTHER induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6ENTG activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6ENTC response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	False
BC6OTHER induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6ENTG / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6ENTC response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	False
BC6OTHER induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6ENTG pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6ENTC response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	False
BC6OTHER induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6ENTG ( BC6OTHER ) gene that contains a functional BC6ENTC response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	False
BC6OTHER induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6ENTG ) gene that contains a functional BC6ENTC response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	False
BC6ENTC induction of cell cycle progression was also abrogated in cells expressing BC6ENTG , and no effect of BC6OTHER on BC6OTHER expression and cell cycle was observed in the presence of BC6OTHER .	False
BC6ENTC induction of cell cycle progression was also abrogated in cells expressing BC6OTHER , and no effect of BC6OTHER on BC6ENTG expression and cell cycle was observed in the presence of BC6OTHER .	False
BC6ENTC induction of cell cycle progression was also abrogated in cells expressing BC6OTHER , and no effect of BC6OTHER on BC6OTHER expression and cell cycle was observed in the presence of BC6ENTG .	False
BC6OTHER induction of cell cycle progression was also abrogated in cells expressing BC6ENTG , and no effect of BC6ENTC on BC6OTHER expression and cell cycle was observed in the presence of BC6OTHER .	False
BC6OTHER induction of cell cycle progression was also abrogated in cells expressing BC6OTHER , and no effect of BC6ENTC on BC6ENTG expression and cell cycle was observed in the presence of BC6OTHER .	False
BC6OTHER induction of cell cycle progression was also abrogated in cells expressing BC6OTHER , and no effect of BC6ENTC on BC6OTHER expression and cell cycle was observed in the presence of BC6ENTG .	False
These results highlight the importance of BC6ENTG activation of the BC6OTHER / BC6OTHER signaling pathway for BC6ENTC - induced transcription of select target genes and cell cycle progression.	CPR:3
These results highlight the importance of BC6OTHER activation of the BC6ENTG / BC6OTHER signaling pathway for BC6ENTC - induced transcription of select target genes and cell cycle progression.	CPR:3
These results highlight the importance of BC6OTHER activation of the BC6OTHER / BC6ENTG signaling pathway for BC6ENTC - induced transcription of select target genes and cell cycle progression.	CPR:3
BC6ENTC activation of BC6ENTG / BC6OTHER occurred outside the nucleus with the BC6OTHER that was distributed between the cytoplasm and nucleus, but not with BC6OTHER that was predominantly nuclear.	CPR:3
BC6ENTC activation of BC6OTHER / BC6ENTG occurred outside the nucleus with the BC6OTHER that was distributed between the cytoplasm and nucleus, but not with BC6OTHER that was predominantly nuclear.	CPR:3
BC6ENTC activation of BC6OTHER / BC6OTHER occurred outside the nucleus with the BC6ENTG that was distributed between the cytoplasm and nucleus, but not with BC6OTHER that was predominantly nuclear.	False
BC6ENTC activation of BC6OTHER / BC6OTHER occurred outside the nucleus with the BC6OTHER that was distributed between the cytoplasm and nucleus, but not with BC6ENTG that was predominantly nuclear.	False
Human BC6ENTC receptor ( BC6OTHER ) contains a motif that interacts with the BC6OTHER of BC6OTHER and mediates rapid activation of BC6ENTG and downstream BC6OTHER ( BC6OTHER ) without relying on the transcriptional activity of the receptor.	False
Human BC6ENTC receptor ( BC6OTHER ) contains a motif that interacts with the BC6OTHER of BC6OTHER and mediates rapid activation of BC6OTHER and downstream BC6ENTG ( BC6OTHER ) without relying on the transcriptional activity of the receptor.	False
Human BC6ENTC receptor ( BC6OTHER ) contains a motif that interacts with the BC6OTHER of BC6OTHER and mediates rapid activation of BC6OTHER and downstream BC6OTHER ( BC6ENTG ) without relying on the transcriptional activity of the receptor.	False
Human BC6ENTC receptor ( BC6ENTG ) contains a motif that interacts with the BC6OTHER of BC6OTHER and mediates rapid activation of BC6OTHER and downstream BC6OTHER ( BC6OTHER ) without relying on the transcriptional activity of the receptor.	False
Human BC6ENTC receptor ( BC6OTHER ) contains a motif that interacts with the BC6ENTG of BC6OTHER and mediates rapid activation of BC6OTHER and downstream BC6OTHER ( BC6OTHER ) without relying on the transcriptional activity of the receptor.	False
Human BC6ENTC receptor ( BC6OTHER ) contains a motif that interacts with the BC6OTHER of BC6ENTG and mediates rapid activation of BC6OTHER and downstream BC6OTHER ( BC6OTHER ) without relying on the transcriptional activity of the receptor.	False
Breast cancer cells stably expressing wild - type BC6ENTG or BC6OTHER with disrupting point mutations in the BC6OTHER ( BC6OTHER ) that do not affect the transcriptional activity of BC6OTHER , were compared for effects of BC6ENTC on endogenous target gene expression and cell proliferation.	False
Breast cancer cells stably expressing wild - type BC6OTHER or BC6ENTG with disrupting point mutations in the BC6OTHER ( BC6OTHER ) that do not affect the transcriptional activity of BC6OTHER , were compared for effects of BC6ENTC on endogenous target gene expression and cell proliferation.	False
Breast cancer cells stably expressing wild - type BC6OTHER or BC6OTHER with disrupting point mutations in the BC6ENTG ( BC6OTHER ) that do not affect the transcriptional activity of BC6OTHER , were compared for effects of BC6ENTC on endogenous target gene expression and cell proliferation.	False
Breast cancer cells stably expressing wild - type BC6OTHER or BC6OTHER with disrupting point mutations in the BC6OTHER ( BC6ENTG ) that do not affect the transcriptional activity of BC6OTHER , were compared for effects of BC6ENTC on endogenous target gene expression and cell proliferation.	False
Breast cancer cells stably expressing wild - type BC6OTHER or BC6OTHER with disrupting point mutations in the BC6OTHER ( BC6OTHER ) that do not affect the transcriptional activity of BC6ENTG , were compared for effects of BC6ENTC on endogenous target gene expression and cell proliferation.	False
BC6ENTC induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6ENTG was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	False
BC6ENTC induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6ENTG activation of BC6OTHER .	False
BC6ENTC induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6ENTG .	False
BC6ENTC induction of the BC6ENTG gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	False
BC6ENTC induction of the BC6OTHER gene, which lacks a BC6ENTG , was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	False
BC6ENTC induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6ENTG activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	CPR:3
BC6ENTC induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6ENTG / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	CPR:3
BC6ENTC induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6ENTG pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	CPR:3
BC6ENTC induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6ENTG ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	False
BC6ENTC induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6ENTG ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	False
BC6OTHER induction of the BC6OTHER gene, which lacks a BC6ENTC response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6ENTG was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	False
BC6OTHER induction of the BC6OTHER gene, which lacks a BC6ENTC response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6ENTG activation of BC6OTHER .	False
BC6OTHER induction of the BC6OTHER gene, which lacks a BC6ENTC response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6ENTG .	False
BC6OTHER induction of the BC6ENTG gene, which lacks a BC6ENTC response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	False
BC6OTHER induction of the BC6OTHER gene, which lacks a BC6ENTC response element, was dependent on BC6ENTG activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	False
BC6OTHER induction of the BC6OTHER gene, which lacks a BC6ENTC response element, was dependent on BC6OTHER activation of the BC6ENTG / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	False
BC6OTHER induction of the BC6OTHER gene, which lacks a BC6ENTC response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6ENTG pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	False
BC6OTHER induction of the BC6OTHER gene, which lacks a BC6ENTC response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6ENTG ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	False
BC6OTHER induction of the BC6OTHER gene, which lacks a BC6ENTC response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6ENTG ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER .	False
The subtypes of BC6ENTG mediating contractions to exogenous BC6ENTC ( BC6OTHER ) in rat aorta have been examined in both biochemical and functional studies.	False
The affinity of the same antagonists for the BC6ENTG was evaluated by utilizing membranes from rat hippocampus pretreated with BC6ENTC , and rat liver, respectively.	False
The subtypes of BC6ENTG mediating contractions to exogenous BC6OTHER ( BC6ENTC ) in rat aorta have been examined in both biochemical and functional studies.	False
Mediation of BC6ENTC - induced contractions of rat aorta by the BC6ENTG subtype.	False
BC6ENTC and BC6OTHER were confirmed as selective for the BC6ENTG , whereas BC6OTHER was alpha 1B - selective.	False
BC6OTHER and BC6ENTC were confirmed as selective for the BC6ENTG , whereas BC6OTHER was alpha 1B - selective.	False
BC6OTHER and BC6OTHER were confirmed as selective for the BC6ENTG , whereas BC6ENTC was alpha 1B - selective.	False
Incubation of rat aortic membranes with the irreversible BC6ENTG antagonist, BC6ENTC ( BC6OTHER : 10 microM) did not change the KD of BC6OTHER binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).	CPR:6
Incubation of rat aortic membranes with the irreversible BC6ENTG antagonist, BC6OTHER ( BC6ENTC : 10 microM) did not change the KD of BC6OTHER binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).	CPR:6
Incubation of rat aortic membranes with the irreversible BC6ENTG antagonist, BC6OTHER ( BC6OTHER : 10 microM) did not change the KD of BC6ENTC binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).	False
The BC6ENTC action of BC6OTHER are mediated by the BC6OTHER BC6OTHER BC6ENTG and BC6OTHER .	False
The BC6ENTC action of BC6OTHER are mediated by the BC6OTHER BC6OTHER BC6OTHER and BC6ENTG .	False
The BC6ENTC action of BC6OTHER are mediated by the BC6ENTG BC6OTHER BC6OTHER and BC6OTHER .	False
The BC6ENTC action of BC6OTHER are mediated by the BC6OTHER BC6ENTG BC6OTHER and BC6OTHER .	False
The BC6OTHER action of BC6ENTC are mediated by the BC6OTHER BC6OTHER BC6ENTG and BC6OTHER .	False
The BC6OTHER action of BC6ENTC are mediated by the BC6OTHER BC6OTHER BC6OTHER and BC6ENTG .	False
The BC6OTHER action of BC6ENTC are mediated by the BC6ENTG BC6OTHER BC6OTHER and BC6OTHER .	False
The BC6OTHER action of BC6ENTC are mediated by the BC6OTHER BC6ENTG BC6OTHER and BC6OTHER .	False
The BC6OTHER action of BC6OTHER are mediated by the BC6OTHER BC6ENTC receptors BC6ENTG and BC6OTHER .	False
The BC6OTHER action of BC6OTHER are mediated by the BC6OTHER BC6ENTC receptors BC6OTHER and BC6ENTG .	False
The BC6OTHER action of BC6OTHER are mediated by the BC6ENTG BC6ENTC receptors BC6OTHER and BC6OTHER .	False
Down - regulation of BC6ENTG ( BC6OTHER ) expression, an BC6OTHER - target gene, by BC6ENTC and BC6OTHER was accompanied by the blockade of the mutated BC6OTHER .	CPR:4
Down - regulation of BC6OTHER ( BC6ENTG ) expression, an BC6OTHER - target gene, by BC6ENTC and BC6OTHER was accompanied by the blockade of the mutated BC6OTHER .	CPR:4
Down - regulation of BC6OTHER ( BC6OTHER ) expression, an BC6ENTG - target gene, by BC6ENTC and BC6OTHER was accompanied by the blockade of the mutated BC6OTHER .	CPR:4
Down - regulation of BC6OTHER ( BC6OTHER ) expression, an BC6OTHER - target gene, by BC6ENTC and BC6OTHER was accompanied by the blockade of the mutated BC6ENTG .	CPR:4
Down - regulation of BC6ENTG ( BC6OTHER ) expression, an BC6OTHER - target gene, by BC6OTHER and BC6ENTC was accompanied by the blockade of the mutated BC6OTHER .	CPR:4
Down - regulation of BC6OTHER ( BC6ENTG ) expression, an BC6OTHER - target gene, by BC6OTHER and BC6ENTC was accompanied by the blockade of the mutated BC6OTHER .	CPR:4
Down - regulation of BC6OTHER ( BC6OTHER ) expression, an BC6ENTG - target gene, by BC6OTHER and BC6ENTC was accompanied by the blockade of the mutated BC6OTHER .	CPR:4
Down - regulation of BC6OTHER ( BC6OTHER ) expression, an BC6OTHER - target gene, by BC6OTHER and BC6ENTC was accompanied by the blockade of the mutated BC6ENTG .	CPR:4
Down - regulation of BC6ENTG ( BC6OTHER ) expression, an BC6OTHER - target gene, by BC6OTHER and BC6OTHER was accompanied by the blockade of the mutated BC6ENTC receptor.	False
Down - regulation of BC6OTHER ( BC6ENTG ) expression, an BC6OTHER - target gene, by BC6OTHER and BC6OTHER was accompanied by the blockade of the mutated BC6ENTC receptor.	False
Down - regulation of BC6OTHER ( BC6OTHER ) expression, an BC6ENTG - target gene, by BC6OTHER and BC6OTHER was accompanied by the blockade of the mutated BC6ENTC receptor.	False
Exposure of LNCaP cells to BC6ENTC for 24 hr caused transcriptional inhibition of BC6ENTG in a concentration - dependent manner.	CPR:4
The levels of BC6ENTG mRNA decreased 56 and 90% when LNCaP cells were treated with 5 and 10 microM of BC6ENTC , respectively (IC50 = 10.97 + / - 1.68 microM).	CPR:4
Binding of BC6ENTC to m - BC6ENTG in LNCaP cells resulted in a concentration - dependent stimulation of BC6OTHER expression, suggesting that BC6OTHER acted as an agonist of the m - BC6OTHER .	False
Binding of BC6ENTC to m - BC6OTHER in LNCaP cells resulted in a concentration - dependent stimulation of BC6ENTG expression, suggesting that BC6OTHER acted as an agonist of the m - BC6OTHER .	CPR:3
Binding of BC6ENTC to m - BC6OTHER in LNCaP cells resulted in a concentration - dependent stimulation of BC6OTHER expression, suggesting that BC6OTHER acted as an agonist of the m - BC6ENTG .	False
Binding of BC6OTHER to m - BC6ENTG in LNCaP cells resulted in a concentration - dependent stimulation of BC6OTHER expression, suggesting that BC6ENTC acted as an agonist of the m - BC6OTHER .	False
Binding of BC6OTHER to m - BC6OTHER in LNCaP cells resulted in a concentration - dependent stimulation of BC6ENTG expression, suggesting that BC6ENTC acted as an agonist of the m - BC6OTHER .	False
Binding of BC6OTHER to m - BC6OTHER in LNCaP cells resulted in a concentration - dependent stimulation of BC6OTHER expression, suggesting that BC6ENTC acted as an agonist of the m - BC6ENTG .	CPR:5
Our data indicate that BC6ENTC metabolites perform as BC6OTHER antagonists of BC6ENTG , an additional mechanism involved in the therapeutic effect of BC6OTHER in patients with prostate cancer.	CPR:6
Our data indicate that BC6OTHER metabolites perform as BC6ENTC antagonists of BC6ENTG , an additional mechanism involved in the therapeutic effect of BC6OTHER in patients with prostate cancer.	CPR:6
Our data indicate that BC6OTHER metabolites perform as BC6OTHER antagonists of BC6ENTG , an additional mechanism involved in the therapeutic effect of BC6ENTC in patients with prostate cancer.	False
Analogous to the antiandrogens, BC6ENTC and BC6OTHER , binding of BC6OTHER metabolites to the BC6ENTG was observed.	False
We investigated, by displacement of BC6ENTC in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6ENTC in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6ENTC in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6ENTC in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6ENTC , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6ENTC , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6ENTC , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6ENTC , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6ENTC and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6ENTC and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6ENTC and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6ENTC and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6ENTC , BC6OTHER , and BC6OTHER , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6ENTC , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6ENTC , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6ENTC , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
Analogous to the antiandrogens, BC6OTHER and BC6ENTC , binding of BC6OTHER metabolites to the BC6ENTG was observed.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6ENTC , and BC6OTHER , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6ENTC , and BC6OTHER , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6ENTC , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6ENTC , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6ENTC , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6ENTC , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6ENTC , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6ENTC , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTC receptor (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTC receptor (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTC receptor (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTC receptor in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6ENTC receptor in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
We investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTC receptor in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells.	False
 BC6ENTC antagonistic effect of BC6OTHER ( BC6OTHER ) metabolites on wild - type and mutated BC6ENTG .	CPR:6
 BC6OTHER antagonistic effect of BC6ENTC ( BC6OTHER ) metabolites on wild - type and mutated BC6ENTG .	CPR:6
 BC6OTHER antagonistic effect of BC6OTHER ( BC6ENTC ) metabolites on wild - type and mutated BC6ENTG .	CPR:6
Analogous to the antiandrogens, BC6OTHER and BC6OTHER , binding of BC6ENTC metabolites to the BC6ENTG was observed.	False
Even though its inability to shift between the trivalent and a divalent oxidation state precludes that BC6ENTC behaves as an BC6OTHER analogue in every respect, it strongly interferes with cellular acquisition of CHEM from blood by competitive interaction with BC6ENTG and BC6OTHER - mediated endocytosis.	False
Even though its inability to shift between the trivalent and a divalent oxidation state precludes that BC6ENTC behaves as an BC6OTHER analogue in every respect, it strongly interferes with cellular acquisition of CHEM from blood by competitive interaction with BC6OTHER and BC6ENTG - mediated endocytosis.	False
Even though its inability to shift between the trivalent and a divalent oxidation state precludes that BC6OTHER behaves as an BC6ENTC analogue in every respect, it strongly interferes with cellular acquisition of CHEM from blood by competitive interaction with BC6ENTG and BC6OTHER - mediated endocytosis.	False
Even though its inability to shift between the trivalent and a divalent oxidation state precludes that BC6OTHER behaves as an BC6ENTC analogue in every respect, it strongly interferes with cellular acquisition of CHEM from blood by competitive interaction with BC6OTHER and BC6ENTG - mediated endocytosis.	False
Furthermore, BC6ENTC also seems to affect intracellular availability of BC6OTHER already taken up via this pathway, probably due to its inhibitory activity on BC6ENTG .	CPR:4
Furthermore, BC6OTHER also seems to affect intracellular availability of BC6ENTC already taken up via this pathway, probably due to its inhibitory activity on BC6ENTG .	False
Apart from the consequences of BC6ENTC deprivation, BC6OTHER exerts cytotoxic effects by direct interaction with the BC6OTHER - dependent enzyme BC6ENTG , resulting in reduced CHEM pools and inhibition of DNA synthesis.	False
Both the abundance of BC6ENTG and upregulation of BC6ENTC reductase render tumors susceptible to BC6OTHER - induced cytotoxicity.	False
Apart from the consequences of BC6OTHER deprivation, BC6ENTC exerts cytotoxic effects by direct interaction with the BC6OTHER - dependent enzyme BC6ENTG , resulting in reduced CHEM pools and inhibition of DNA synthesis.	False
Apart from the consequences of BC6OTHER deprivation, BC6OTHER exerts cytotoxic effects by direct interaction with the BC6ENTC - dependent enzyme BC6ENTG , resulting in reduced CHEM pools and inhibition of DNA synthesis.	False
Both the abundance of BC6ENTG and upregulation of BC6OTHER render tumors susceptible to BC6ENTC - induced cytotoxicity.	False
Both the abundance of BC6OTHER and upregulation of BC6ENTG render tumors susceptible to BC6ENTC - induced cytotoxicity.	False
However, some experimental findings raise the question whether these effects resulting from the BC6ENTC - mimicking properties of BC6OTHER are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting BC6ENTG polymerization.	CPR:4
However, some experimental findings raise the question whether these effects resulting from the BC6OTHER - mimicking properties of BC6ENTC are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting BC6ENTG polymerization.	CPR:4
In the current study, we crossed BC6ENTG .fLUC mice into the BC6OTHER knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6ENTC and BC6OTHER .	False
In the current study, we crossed BC6OTHER .fLUC mice into the BC6ENTG knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6ENTC and BC6OTHER .	False
In the current study, we crossed BC6OTHER .fLUC mice into the BC6OTHER knockout ( BC6ENTG ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6ENTC and BC6OTHER .	False
In the current study, we crossed BC6OTHER .fLUC mice into the BC6OTHER knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6ENTG ligand, and two therapeutically relevant BC6OTHER , BC6ENTC and BC6OTHER .	False
In the current study, we crossed BC6ENTG .fLUC mice into the BC6OTHER knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6ENTC .	False
In the current study, we crossed BC6OTHER .fLUC mice into the BC6ENTG knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6ENTC .	False
In the current study, we crossed BC6OTHER .fLUC mice into the BC6OTHER knockout ( BC6ENTG ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6ENTC .	False
In the current study, we crossed BC6OTHER .fLUC mice into the BC6OTHER knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6ENTG ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6ENTC .	False
All three agents induced BC6OTHER .fLUC expression (bioluminescence), but only BC6ENTC and BC6OTHER appeared to act primarily via BC6ENTG .	False
All three agents induced BC6ENTG .fLUC expression (bioluminescence), but only BC6ENTC and BC6OTHER appeared to act primarily via BC6OTHER .	False
All three agents induced BC6OTHER .fLUC expression (bioluminescence), but only BC6OTHER and BC6ENTC appeared to act primarily via BC6ENTG .	False
All three agents induced BC6ENTG .fLUC expression (bioluminescence), but only BC6OTHER and BC6ENTC appeared to act primarily via BC6OTHER .	False
BC6ENTC , a BC6ENTG ligand, modestly induced BC6OTHER .fLUC in BC6OTHER (+ / +) and BC6OTHER ( - / - ) strains, consistent with BC6OTHER 's minor role in BC6OTHER regulation.	False
BC6ENTC , a BC6OTHER ligand, modestly induced BC6ENTG .fLUC in BC6OTHER (+ / +) and BC6OTHER ( - / - ) strains, consistent with BC6OTHER 's minor role in BC6OTHER regulation.	CPR:3
BC6ENTC , a BC6OTHER ligand, modestly induced BC6OTHER .fLUC in BC6ENTG (+ / +) and BC6OTHER ( - / - ) strains, consistent with BC6OTHER 's minor role in BC6OTHER regulation.	False
BC6ENTC , a BC6OTHER ligand, modestly induced BC6OTHER .fLUC in BC6OTHER (+ / +) and BC6ENTG ( - / - ) strains, consistent with BC6OTHER 's minor role in BC6OTHER regulation.	False
BC6ENTC , a BC6OTHER ligand, modestly induced BC6OTHER .fLUC in BC6OTHER (+ / +) and BC6OTHER ( - / - ) strains, consistent with BC6ENTG 's minor role in BC6OTHER regulation.	False
BC6ENTC , a BC6OTHER ligand, modestly induced BC6OTHER .fLUC in BC6OTHER (+ / +) and BC6OTHER ( - / - ) strains, consistent with BC6OTHER 's minor role in BC6ENTG regulation.	False
In the current study, we crossed BC6ENTG .fLUC mice into the BC6OTHER knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6ENTC ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6OTHER .	False
In the current study, we crossed BC6OTHER .fLUC mice into the BC6ENTG knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6ENTC ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6OTHER .	False
In the current study, we crossed BC6OTHER .fLUC mice into the BC6OTHER knockout ( BC6ENTG ( - / - )) genetic background and injected mice with BC6ENTC ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6OTHER .	False
In the current study, we crossed BC6OTHER .fLUC mice into the BC6OTHER knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6ENTC ( BC6OTHER ), a strong BC6ENTG ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6OTHER .	False
In the current study, we crossed BC6ENTG .fLUC mice into the BC6OTHER knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6ENTC ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6OTHER .	False
In the current study, we crossed BC6OTHER .fLUC mice into the BC6ENTG knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6ENTC ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6OTHER .	False
In the current study, we crossed BC6OTHER .fLUC mice into the BC6OTHER knockout ( BC6ENTG ( - / - )) genetic background and injected mice with BC6OTHER ( BC6ENTC ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6OTHER .	False
In the current study, we crossed BC6OTHER .fLUC mice into the BC6OTHER knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6ENTC ), a strong BC6ENTG ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6OTHER .	False
In the current study, we crossed BC6ENTG .fLUC mice into the BC6OTHER knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6ENTC , BC6OTHER and BC6OTHER .	False
In the current study, we crossed BC6OTHER .fLUC mice into the BC6ENTG knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6ENTC , BC6OTHER and BC6OTHER .	False
In the current study, we crossed BC6OTHER .fLUC mice into the BC6OTHER knockout ( BC6ENTG ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6ENTC , BC6OTHER and BC6OTHER .	False
In the current study, we crossed BC6OTHER .fLUC mice into the BC6OTHER knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6ENTG ligand, and two therapeutically relevant BC6ENTC , BC6OTHER and BC6OTHER .	False
We determined whether an BC6ENTC - converting enzyme ( BC6ENTG ) inhibitor, BC6OTHER , inhibits BC6OTHER activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6OTHER - BC6OTHER complex.	False
We determined whether an BC6ENTC - converting enzyme ( BC6OTHER ) inhibitor, BC6OTHER , inhibits BC6ENTG activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6OTHER - BC6OTHER complex.	False
We determined whether an BC6ENTC - converting enzyme ( BC6OTHER ) inhibitor, BC6OTHER , inhibits BC6OTHER activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6ENTG - BC6OTHER complex.	False
We determined whether an BC6ENTG ( BC6OTHER ) inhibitor, BC6ENTC , inhibits BC6OTHER activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6OTHER - BC6OTHER complex.	CPR:4
We determined whether an BC6OTHER - converting enzyme ( BC6ENTG ) inhibitor, BC6ENTC , inhibits BC6OTHER activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6OTHER - BC6OTHER complex.	CPR:4
We determined whether an BC6OTHER - converting enzyme ( BC6OTHER ) inhibitor, BC6ENTC , inhibits BC6ENTG activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6OTHER - BC6OTHER complex.	False
We determined whether an BC6OTHER - converting enzyme ( BC6OTHER ) inhibitor, BC6ENTC , inhibits BC6OTHER activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6ENTG - BC6OTHER complex.	False
We determined whether an BC6ENTG ( BC6OTHER ) inhibitor, BC6OTHER , inhibits BC6OTHER activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6OTHER - BC6ENTC complex.	False
We determined whether an BC6OTHER - converting enzyme ( BC6ENTG ) inhibitor, BC6OTHER , inhibits BC6OTHER activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6OTHER - BC6ENTC complex.	False
We determined whether an BC6OTHER - converting enzyme ( BC6OTHER ) inhibitor, BC6OTHER , inhibits BC6ENTG activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6OTHER - BC6ENTC complex.	False
We determined whether an BC6OTHER - converting enzyme ( BC6OTHER ) inhibitor, BC6OTHER , inhibits BC6OTHER activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6ENTG - BC6ENTC complex.	False
METHODS: The inhibitory effect of BC6ENTC on BC6ENTG activity was measured in peritoneal effluents from 17 patients on CAPD.	CPR:4
Molecular models of the BC6ENTG - BC6ENTC complex were simulated by 1000 iterations of random docking and energy minimization.	False
RESULTS: BC6ENTC directly inhibited BC6ENTG activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol / l), and that BC6OTHER binding to the BC6OTHER active site could be formed in each complex model without molecular distortion.	CPR:4
RESULTS: BC6ENTC directly inhibited BC6OTHER activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol / l), and that BC6OTHER binding to the BC6ENTG active site could be formed in each complex model without molecular distortion.	False
RESULTS: BC6OTHER directly inhibited BC6ENTG activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol / l), and that BC6ENTC binding to the BC6OTHER active site could be formed in each complex model without molecular distortion.	False
RESULTS: BC6OTHER directly inhibited BC6OTHER activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol / l), and that BC6ENTC binding to the BC6ENTG active site could be formed in each complex model without molecular distortion.	False
CONCLUSION: BC6OTHER inhibitors, such as BC6ENTC , may be applied as important compounds for BC6ENTG inhibition in inflammation caused by CAPD.	CPR:4
CONCLUSION: BC6ENTG inhibitors, such as BC6ENTC , may be applied as important compounds for BC6OTHER inhibition in inflammation caused by CAPD.	CPR:4
 BC6ENTC directly inhibits BC6ENTG activity in continuous ambulatory peritoneal dialysis therapy.	CPR:4
Both, BC6ENTG overexpression and BC6OTHER knockdown led to a strong reduction of endogenous reactive - BC6ENTC species (ROS), DNA damage and senescence.	False
Both, BC6OTHER overexpression and BC6ENTG knockdown led to a strong reduction of endogenous reactive - BC6ENTC species (ROS), DNA damage and senescence.	False
Importantly, pharmacological inhibition of BC6ENTG in human melanoma cells also reconstituted senescence in the majority of cell lines, and BC6OTHER knockdown reduced tumorigenic effects such as proliferation, BC6ENTC resistance and soft agar growth.	False
Importantly, pharmacological inhibition of BC6OTHER in human melanoma cells also reconstituted senescence in the majority of cell lines, and BC6ENTG knockdown reduced tumorigenic effects such as proliferation, BC6ENTC resistance and soft agar growth.	False
We observed that BC6ENTG drives the evasion of reactive - BC6ENTC stress - induced melanocyte senescence, caused by activated receptor BC6OTHER kinase signaling.	False
We observed that BC6OTHER drives the evasion of reactive - BC6ENTC stress - induced melanocyte senescence, caused by activated BC6ENTG signaling.	False
We observed that BC6ENTG drives the evasion of reactive - BC6OTHER stress - induced melanocyte senescence, caused by activated receptor BC6ENTC kinase signaling.	False
The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral BC6ENTC kinase inhibitor targeting BC6ENTG / BC6OTHER as well as the BC6OTHER ( BC6OTHER ), BC6OTHER .	False
The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral BC6ENTC kinase inhibitor targeting BC6OTHER / BC6ENTG as well as the BC6OTHER ( BC6OTHER ), BC6OTHER .	False
The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral BC6ENTC kinase inhibitor targeting BC6OTHER / BC6OTHER as well as the BC6ENTG ( BC6OTHER ), BC6OTHER .	False
The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral BC6ENTC kinase inhibitor targeting BC6OTHER / BC6OTHER as well as the BC6OTHER ( BC6ENTG ), BC6OTHER .	False
The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral BC6OTHER kinase inhibitor targeting BC6ENTG / BC6OTHER as well as the BC6OTHER ( BC6OTHER ), BC6ENTC .	CPR:4
The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral BC6OTHER kinase inhibitor targeting BC6OTHER / BC6ENTG as well as the BC6OTHER ( BC6OTHER ), BC6ENTC .	CPR:4
The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral BC6OTHER kinase inhibitor targeting BC6OTHER / BC6OTHER as well as the BC6ENTG ( BC6OTHER ), BC6ENTC .	CPR:4
The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral BC6OTHER kinase inhibitor targeting BC6OTHER / BC6OTHER as well as the BC6OTHER ( BC6ENTG ), BC6ENTC .	CPR:4
A humanized antibody to BC6ENTG / BC6OTHER , trastuzumab, is now FDA approved for the treatment of early stage, BC6OTHER / BC6OTHER overexpressing breast cancer sequenced with chemotherapy including BC6ENTC , BC6OTHER , and BC6OTHER .	False
A humanized antibody to BC6OTHER / BC6ENTG , trastuzumab, is now FDA approved for the treatment of early stage, BC6OTHER / BC6OTHER overexpressing breast cancer sequenced with chemotherapy including BC6ENTC , BC6OTHER , and BC6OTHER .	False
A humanized antibody to BC6OTHER / BC6OTHER , trastuzumab, is now FDA approved for the treatment of early stage, BC6ENTG / BC6OTHER overexpressing breast cancer sequenced with chemotherapy including BC6ENTC , BC6OTHER , and BC6OTHER .	False
A humanized antibody to BC6OTHER / BC6OTHER , trastuzumab, is now FDA approved for the treatment of early stage, BC6OTHER / BC6ENTG overexpressing breast cancer sequenced with chemotherapy including BC6ENTC , BC6OTHER , and BC6OTHER .	False
A humanized antibody to BC6ENTG / BC6OTHER , trastuzumab, is now FDA approved for the treatment of early stage, BC6OTHER / BC6OTHER overexpressing breast cancer sequenced with chemotherapy including BC6OTHER , BC6ENTC , and BC6OTHER .	False
A humanized antibody to BC6OTHER / BC6ENTG , trastuzumab, is now FDA approved for the treatment of early stage, BC6OTHER / BC6OTHER overexpressing breast cancer sequenced with chemotherapy including BC6OTHER , BC6ENTC , and BC6OTHER .	False
A humanized antibody to BC6OTHER / BC6OTHER , trastuzumab, is now FDA approved for the treatment of early stage, BC6ENTG / BC6OTHER overexpressing breast cancer sequenced with chemotherapy including BC6OTHER , BC6ENTC , and BC6OTHER .	False
A humanized antibody to BC6OTHER / BC6OTHER , trastuzumab, is now FDA approved for the treatment of early stage, BC6OTHER / BC6ENTG overexpressing breast cancer sequenced with chemotherapy including BC6OTHER , BC6ENTC , and BC6OTHER .	False
A humanized antibody to BC6ENTG / BC6OTHER , trastuzumab, is now FDA approved for the treatment of early stage, BC6OTHER / BC6OTHER overexpressing breast cancer sequenced with chemotherapy including BC6OTHER , BC6OTHER , and BC6ENTC .	False
A humanized antibody to BC6OTHER / BC6ENTG , trastuzumab, is now FDA approved for the treatment of early stage, BC6OTHER / BC6OTHER overexpressing breast cancer sequenced with chemotherapy including BC6OTHER , BC6OTHER , and BC6ENTC .	False
A humanized antibody to BC6OTHER / BC6OTHER , trastuzumab, is now FDA approved for the treatment of early stage, BC6ENTG / BC6OTHER overexpressing breast cancer sequenced with chemotherapy including BC6OTHER , BC6OTHER , and BC6ENTC .	False
A humanized antibody to BC6OTHER / BC6OTHER , trastuzumab, is now FDA approved for the treatment of early stage, BC6OTHER / BC6ENTG overexpressing breast cancer sequenced with chemotherapy including BC6OTHER , BC6OTHER , and BC6ENTC .	False
These compounds resulted from our efforts to merge the pharmacophores of selective BC6OTHER inhibitor BC6ENTC with a mimic of the BC6OTHER ( BC6OTHER ) sequence of BC6ENTG to obtain designed multiple ligands with potential antithrombotic activity.	False
These compounds resulted from our efforts to merge the pharmacophores of selective BC6ENTG inhibitor BC6ENTC with a mimic of the BC6OTHER ( BC6OTHER ) sequence of BC6OTHER to obtain designed multiple ligands with potential antithrombotic activity.	CPR:4
These compounds resulted from our efforts to merge the pharmacophores of selective BC6OTHER inhibitor BC6ENTC with a mimic of the BC6ENTG ( BC6OTHER ) sequence of BC6OTHER to obtain designed multiple ligands with potential antithrombotic activity.	False
These compounds resulted from our efforts to merge the pharmacophores of selective BC6OTHER inhibitor BC6ENTC with a mimic of the BC6OTHER ( BC6ENTG ) sequence of BC6OTHER to obtain designed multiple ligands with potential antithrombotic activity.	False
These compounds resulted from our efforts to merge the pharmacophores of selective BC6OTHER inhibitor BC6OTHER with a mimic of the BC6ENTC ( BC6OTHER ) sequence of BC6ENTG to obtain designed multiple ligands with potential antithrombotic activity.	False
These compounds resulted from our efforts to merge the pharmacophores of selective BC6ENTG inhibitor BC6OTHER with a mimic of the BC6ENTC ( BC6OTHER ) sequence of BC6OTHER to obtain designed multiple ligands with potential antithrombotic activity.	False
These compounds resulted from our efforts to merge the pharmacophores of selective BC6OTHER inhibitor BC6OTHER with a mimic of the BC6ENTC ( BC6ENTG ) sequence of BC6OTHER to obtain designed multiple ligands with potential antithrombotic activity.	False
Resulting from this study, a structurally novel class of submicromolar fibrinogen BC6ENTG binding inhibitor bearing BC6ENTC moiety is also described.	CPR:4
Moreover, BC6ENTC resulted in activation of astrocytes, up - regulation of BC6ENTG in cortex and down - regulation of BC6OTHER in hippocampus and cortex.	CPR:3
Moreover, BC6ENTC resulted in activation of astrocytes, up - regulation of BC6OTHER in cortex and down - regulation of BC6ENTG in hippocampus and cortex.	CPR:4
Interestingly, BC6ENTC increased proteins' levels of BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and the BC6OTHER BC6OTHER , and decreased BC6OTHER levels.	CPR:3
Interestingly, BC6ENTC increased proteins' levels of BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and the BC6OTHER BC6OTHER , and decreased BC6OTHER levels.	False
Interestingly, BC6ENTC increased proteins' levels of BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and the BC6OTHER BC6OTHER , and decreased BC6OTHER levels.	CPR:3
Interestingly, BC6ENTC increased proteins' levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and the BC6OTHER BC6OTHER , and decreased BC6OTHER levels.	CPR:3
Interestingly, BC6ENTC increased proteins' levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and the BC6ENTG BC6OTHER , and decreased BC6OTHER levels.	CPR:3
Interestingly, BC6ENTC increased proteins' levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and the BC6OTHER BC6ENTG , and decreased BC6OTHER levels.	CPR:3
Interestingly, BC6ENTC increased proteins' levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and the BC6OTHER BC6OTHER , and decreased BC6ENTG levels.	CPR:4
The activity of BC6ENTG was down - regulated while the level of BC6ENTC was up - regulated in rat brain.	False
Various high - BC6ENTC - type glycan modifications of BC6OTHER reductase ( BC6OTHER ) were achieved by ligand - based approach using glycan - BC6OTHER ( BC6OTHER ) conjugates as tight binding glycan bearing ligands for BC6ENTG .	False
Various high - BC6ENTC - type glycan modifications of BC6ENTG ( BC6OTHER ) were achieved by ligand - based approach using glycan - BC6OTHER ( BC6OTHER ) conjugates as tight binding glycan bearing ligands for BC6OTHER .	False
Various high - BC6ENTC - type glycan modifications of BC6OTHER reductase ( BC6ENTG ) were achieved by ligand - based approach using glycan - BC6OTHER ( BC6OTHER ) conjugates as tight binding glycan bearing ligands for BC6OTHER .	False
Various high - BC6OTHER - type glycan modifications of BC6OTHER reductase ( BC6OTHER ) were achieved by ligand - based approach using glycan - BC6ENTC ( BC6OTHER ) conjugates as tight binding glycan bearing ligands for BC6ENTG .	False
Various high - BC6OTHER - type glycan modifications of BC6ENTG ( BC6OTHER ) were achieved by ligand - based approach using glycan - BC6ENTC ( BC6OTHER ) conjugates as tight binding glycan bearing ligands for BC6OTHER .	False
Various high - BC6OTHER - type glycan modifications of BC6OTHER reductase ( BC6ENTG ) were achieved by ligand - based approach using glycan - BC6ENTC ( BC6OTHER ) conjugates as tight binding glycan bearing ligands for BC6OTHER .	False
Various high - BC6OTHER - type glycan modifications of BC6OTHER reductase ( BC6OTHER ) were achieved by ligand - based approach using glycan - BC6OTHER ( BC6ENTC ) conjugates as tight binding glycan bearing ligands for BC6ENTG .	False
Various high - BC6OTHER - type glycan modifications of BC6ENTG ( BC6OTHER ) were achieved by ligand - based approach using glycan - BC6OTHER ( BC6ENTC ) conjugates as tight binding glycan bearing ligands for BC6OTHER .	False
Various high - BC6OTHER - type glycan modifications of BC6OTHER reductase ( BC6ENTG ) were achieved by ligand - based approach using glycan - BC6OTHER ( BC6ENTC ) conjugates as tight binding glycan bearing ligands for BC6OTHER .	False
The resulting glycan - BC6ENTC conjugates and the corresponding artificial glycoproteins could be useful as CHEM - and glycoprotein - probes to perform quantitative analysis of BC6ENTG such as BC6OTHER , BC6OTHER or BC6OTHER .	False
The resulting glycan - BC6ENTC conjugates and the corresponding artificial glycoproteins could be useful as CHEM - and glycoprotein - probes to perform quantitative analysis of BC6OTHER such as BC6ENTG , BC6OTHER or BC6OTHER .	False
The resulting glycan - BC6ENTC conjugates and the corresponding artificial glycoproteins could be useful as CHEM - and glycoprotein - probes to perform quantitative analysis of BC6OTHER such as BC6OTHER , BC6ENTG or BC6OTHER .	False
The resulting glycan - BC6ENTC conjugates and the corresponding artificial glycoproteins could be useful as CHEM - and glycoprotein - probes to perform quantitative analysis of BC6OTHER such as BC6OTHER , BC6OTHER or BC6ENTG .	False
Various high - BC6OTHER - type glycan modifications of BC6ENTC reductase ( BC6OTHER ) were achieved by ligand - based approach using glycan - BC6OTHER ( BC6OTHER ) conjugates as tight binding glycan bearing ligands for BC6ENTG .	False
Various high - BC6OTHER - type glycan modifications of BC6ENTC reductase ( BC6ENTG ) were achieved by ligand - based approach using glycan - BC6OTHER ( BC6OTHER ) conjugates as tight binding glycan bearing ligands for BC6OTHER .	False
High - BC6ENTC - type glycan modifications of BC6ENTG using glycan - BC6OTHER conjugates.	False
High - BC6OTHER - type glycan modifications of BC6ENTG using glycan - BC6ENTC conjugates.	False
Because these speeds are significantly faster than the responses to antagonists, these data indicate that BC6ENTC and BC6OTHER are allosteric ligands and actively induce a conformation of the BC6ENTG with a reduced affinity for its agonists.	False
Because these speeds are significantly faster than the responses to antagonists, these data indicate that BC6OTHER and BC6ENTC are allosteric ligands and actively induce a conformation of the BC6ENTG with a reduced affinity for its agonists.	False
Cyan fluorescent protein was fused to the BC6ENTC terminus of the BC6ENTG , and a specific binding sequence for the small fluorescent compound BC6OTHER arsenical hairpin binder, FlAsH, was inserted into the third intracellular loop; the latter site was labeled in intact cells by incubation with FlAsH.	False
Cyan fluorescent protein was fused to the BC6OTHER terminus of the BC6ENTG , and a specific binding sequence for the small fluorescent compound BC6ENTC arsenical hairpin binder, FlAsH, was inserted into the third intracellular loop; the latter site was labeled in intact cells by incubation with FlAsH.	False
Our studies demonstrate that BC6OTHER , BC6OTHER and another immunomodulatory drug, BC6ENTC , bound endogenous BC6ENTG and recombinant BC6OTHER - BC6OTHER ( BC6OTHER ) complexes.	False
Our studies demonstrate that BC6OTHER , BC6OTHER and another immunomodulatory drug, BC6ENTC , bound endogenous BC6OTHER and recombinant BC6ENTG - BC6OTHER ( BC6OTHER ) complexes.	False
Our studies demonstrate that BC6OTHER , BC6OTHER and another immunomodulatory drug, BC6ENTC , bound endogenous BC6OTHER and recombinant BC6OTHER - BC6ENTG ( BC6OTHER ) complexes.	False
Our studies demonstrate that BC6OTHER , BC6OTHER and another immunomodulatory drug, BC6ENTC , bound endogenous BC6OTHER and recombinant BC6OTHER - BC6OTHER ( BC6ENTG ) complexes.	False
BC6ENTG mediated antiproliferative activities of BC6ENTC and BC6OTHER in myeloma cells, as well as BC6OTHER - and BC6OTHER - induced BC6OTHER production in T cells.	False
BC6OTHER mediated antiproliferative activities of BC6ENTC and BC6OTHER in myeloma cells, as well as BC6OTHER - and BC6OTHER - induced BC6ENTG production in T cells.	False
BC6ENTG mediated antiproliferative activities of BC6OTHER and BC6ENTC in myeloma cells, as well as BC6OTHER - and BC6OTHER - induced BC6OTHER production in T cells.	False
BC6OTHER mediated antiproliferative activities of BC6OTHER and BC6ENTC in myeloma cells, as well as BC6OTHER - and BC6OTHER - induced BC6ENTG production in T cells.	False
BC6ENTG mediated antiproliferative activities of BC6OTHER and BC6OTHER in myeloma cells, as well as BC6ENTC - and BC6OTHER - induced BC6OTHER production in T cells.	False
BC6OTHER mediated antiproliferative activities of BC6OTHER and BC6OTHER in myeloma cells, as well as BC6ENTC - and BC6OTHER - induced BC6ENTG production in T cells.	CPR:3
BC6ENTG mediated antiproliferative activities of BC6OTHER and BC6OTHER in myeloma cells, as well as BC6OTHER - and BC6ENTC - induced BC6OTHER production in T cells.	False
BC6OTHER mediated antiproliferative activities of BC6OTHER and BC6OTHER in myeloma cells, as well as BC6OTHER - and BC6ENTC - induced BC6ENTG production in T cells.	CPR:3
BC6ENTC and BC6OTHER inhibited autoubiquitination of BC6ENTG in HEK293T cells expressing BC6OTHER - binding competent wild - type BC6OTHER , but not BC6OTHER - binding defective BC6OTHER (YW / AA).	CPR:4
BC6ENTC and BC6OTHER inhibited autoubiquitination of BC6OTHER in HEK293T cells expressing BC6OTHER - binding competent wild - type BC6ENTG , but not BC6OTHER - binding defective BC6OTHER (YW / AA).	CPR:4
BC6ENTC and BC6OTHER inhibited autoubiquitination of BC6OTHER in HEK293T cells expressing BC6OTHER - binding competent wild - type BC6OTHER , but not BC6OTHER - binding defective BC6ENTG (YW / AA).	False
BC6OTHER and BC6ENTC inhibited autoubiquitination of BC6ENTG in HEK293T cells expressing BC6OTHER - binding competent wild - type BC6OTHER , but not BC6OTHER - binding defective BC6OTHER (YW / AA).	CPR:4
BC6OTHER and BC6ENTC inhibited autoubiquitination of BC6OTHER in HEK293T cells expressing BC6OTHER - binding competent wild - type BC6ENTG , but not BC6OTHER - binding defective BC6OTHER (YW / AA).	CPR:4
BC6OTHER and BC6ENTC inhibited autoubiquitination of BC6OTHER in HEK293T cells expressing BC6OTHER - binding competent wild - type BC6OTHER , but not BC6OTHER - binding defective BC6ENTG (YW / AA).	False
BC6OTHER and BC6OTHER inhibited autoubiquitination of BC6ENTG in HEK293T cells expressing BC6ENTC - binding competent wild - type BC6OTHER , but not BC6OTHER - binding defective BC6OTHER (YW / AA).	False
BC6OTHER and BC6OTHER inhibited autoubiquitination of BC6OTHER in HEK293T cells expressing BC6ENTC - binding competent wild - type BC6ENTG , but not BC6OTHER - binding defective BC6OTHER (YW / AA).	False
BC6OTHER and BC6OTHER inhibited autoubiquitination of BC6OTHER in HEK293T cells expressing BC6ENTC - binding competent wild - type BC6OTHER , but not BC6OTHER - binding defective BC6ENTG (YW / AA).	False
BC6OTHER and BC6OTHER inhibited autoubiquitination of BC6ENTG in HEK293T cells expressing BC6OTHER - binding competent wild - type BC6OTHER , but not BC6ENTC - binding defective BC6OTHER (YW / AA).	False
BC6OTHER and BC6OTHER inhibited autoubiquitination of BC6OTHER in HEK293T cells expressing BC6OTHER - binding competent wild - type BC6ENTG , but not BC6ENTC - binding defective BC6OTHER (YW / AA).	False
BC6OTHER and BC6OTHER inhibited autoubiquitination of BC6OTHER in HEK293T cells expressing BC6OTHER - binding competent wild - type BC6OTHER , but not BC6ENTC - binding defective BC6ENTG (YW / AA).	False
Overexpression of BC6OTHER wild - type protein, but not BC6OTHER (YW / AA) mutant protein, in KMS12 myeloma cells, amplified BC6ENTC - mediated reductions in BC6OTHER and BC6OTHER expression and increases in BC6OTHER ( BC6ENTG ) expression.	CPR:3
Overexpression of BC6ENTG wild - type protein, but not BC6OTHER (YW / AA) mutant protein, in KMS12 myeloma cells, amplified BC6ENTC - mediated reductions in BC6OTHER and BC6OTHER expression and increases in BC6OTHER ( BC6OTHER ) expression.	False
Overexpression of BC6OTHER wild - type protein, but not BC6ENTG (YW / AA) mutant protein, in KMS12 myeloma cells, amplified BC6ENTC - mediated reductions in BC6OTHER and BC6OTHER expression and increases in BC6OTHER ( BC6OTHER ) expression.	False
Overexpression of BC6OTHER wild - type protein, but not BC6OTHER (YW / AA) mutant protein, in KMS12 myeloma cells, amplified BC6ENTC - mediated reductions in BC6ENTG and BC6OTHER expression and increases in BC6OTHER ( BC6OTHER ) expression.	CPR:4
Overexpression of BC6OTHER wild - type protein, but not BC6OTHER (YW / AA) mutant protein, in KMS12 myeloma cells, amplified BC6ENTC - mediated reductions in BC6OTHER and BC6ENTG expression and increases in BC6OTHER ( BC6OTHER ) expression.	CPR:4
Overexpression of BC6OTHER wild - type protein, but not BC6OTHER (YW / AA) mutant protein, in KMS12 myeloma cells, amplified BC6ENTC - mediated reductions in BC6OTHER and BC6OTHER expression and increases in BC6ENTG ( BC6OTHER ) expression.	CPR:3
 BC6ENTG is a direct protein target for immunomodulatory and antiproliferative activities of BC6OTHER and BC6ENTC .	False
 BC6ENTG is a direct protein target for immunomodulatory and antiproliferative activities of BC6ENTC and BC6OTHER .	False
Long - term selection for BC6ENTC resistance in H929 myeloma cell lines was accompanied by a reduction in BC6ENTG , while in DF15R myeloma cells resistant to both BC6OTHER and BC6OTHER , BC6OTHER protein was undetectable.	CPR:4
Long - term selection for BC6ENTC resistance in H929 myeloma cell lines was accompanied by a reduction in BC6OTHER , while in DF15R myeloma cells resistant to both BC6OTHER and BC6OTHER , BC6ENTG protein was undetectable.	False
Long - term selection for BC6OTHER resistance in H929 myeloma cell lines was accompanied by a reduction in BC6ENTG , while in DF15R myeloma cells resistant to both BC6ENTC and BC6OTHER , BC6OTHER protein was undetectable.	False
Long - term selection for BC6OTHER resistance in H929 myeloma cell lines was accompanied by a reduction in BC6OTHER , while in DF15R myeloma cells resistant to both BC6ENTC and BC6OTHER , BC6ENTG protein was undetectable.	False
Long - term selection for BC6OTHER resistance in H929 myeloma cell lines was accompanied by a reduction in BC6ENTG , while in DF15R myeloma cells resistant to both BC6OTHER and BC6ENTC , BC6OTHER protein was undetectable.	False
Long - term selection for BC6OTHER resistance in H929 myeloma cell lines was accompanied by a reduction in BC6OTHER , while in DF15R myeloma cells resistant to both BC6OTHER and BC6ENTC , BC6ENTG protein was undetectable.	False
Our biophysical, biochemical and gene silencing studies show that BC6ENTG is a proximate, therapeutically important molecular target of BC6ENTC and BC6OTHER .	False
Our biophysical, biochemical and gene silencing studies show that BC6ENTG is a proximate, therapeutically important molecular target of BC6OTHER and BC6ENTC .	False
The ubiquitously expressed E3 ligase protein BC6ENTG ( BC6OTHER ) has been identified as the primary teratogenic target of BC6ENTC .	False
The ubiquitously expressed E3 ligase protein BC6OTHER ( BC6ENTG ) has been identified as the primary teratogenic target of BC6ENTC .	False
Our studies demonstrate that BC6ENTC , BC6OTHER and another immunomodulatory drug, BC6OTHER , bound endogenous BC6ENTG and recombinant BC6OTHER - BC6OTHER ( BC6OTHER ) complexes.	False
Our studies demonstrate that BC6ENTC , BC6OTHER and another immunomodulatory drug, BC6OTHER , bound endogenous BC6OTHER and recombinant BC6ENTG - BC6OTHER ( BC6OTHER ) complexes.	False
Our studies demonstrate that BC6ENTC , BC6OTHER and another immunomodulatory drug, BC6OTHER , bound endogenous BC6OTHER and recombinant BC6OTHER - BC6ENTG ( BC6OTHER ) complexes.	False
Our studies demonstrate that BC6ENTC , BC6OTHER and another immunomodulatory drug, BC6OTHER , bound endogenous BC6OTHER and recombinant BC6OTHER - BC6OTHER ( BC6ENTG ) complexes.	False
Our studies demonstrate that BC6OTHER , BC6ENTC and another immunomodulatory drug, BC6OTHER , bound endogenous BC6ENTG and recombinant BC6OTHER - BC6OTHER ( BC6OTHER ) complexes.	False
Our studies demonstrate that BC6OTHER , BC6ENTC and another immunomodulatory drug, BC6OTHER , bound endogenous BC6OTHER and recombinant BC6ENTG - BC6OTHER ( BC6OTHER ) complexes.	False
Our studies demonstrate that BC6OTHER , BC6ENTC and another immunomodulatory drug, BC6OTHER , bound endogenous BC6OTHER and recombinant BC6OTHER - BC6ENTG ( BC6OTHER ) complexes.	False
Our studies demonstrate that BC6OTHER , BC6ENTC and another immunomodulatory drug, BC6OTHER , bound endogenous BC6OTHER and recombinant BC6OTHER - BC6OTHER ( BC6ENTG ) complexes.	False
This mutation is the first described in exon 9 and impairs the last 27 BC6ENTC of the BC6ENTG .	False
RESULTS: BC6ENTC unmasked the inhibitory effect of BC6ENTG stimulation with BC6OTHER and significantly attenuated the stimulated release of BC6OTHER and subsequent BC6OTHER .	False
RESULTS: BC6OTHER unmasked the inhibitory effect of BC6ENTG stimulation with BC6ENTC and significantly attenuated the stimulated release of BC6OTHER and subsequent BC6OTHER .	CPR:3
RESULTS: BC6OTHER unmasked the inhibitory effect of BC6ENTG stimulation with BC6OTHER and significantly attenuated the stimulated release of BC6ENTC and subsequent BC6OTHER .	False
RESULTS: BC6OTHER unmasked the inhibitory effect of BC6ENTG stimulation with BC6OTHER and significantly attenuated the stimulated release of BC6OTHER and subsequent BC6ENTC .	False
Inhibition corresponded to increased BC6ENTC production caused by BC6OTHER alone or BC6OTHER plus BC6OTHER and blocked proportionately the phosphorylation and activation of BC6ENTG in CHEM / B - activated eosinophils.	False
Inhibition corresponded to increased BC6OTHER production caused by BC6ENTC alone or BC6OTHER plus BC6OTHER and blocked proportionately the phosphorylation and activation of BC6ENTG in CHEM / B - activated eosinophils.	False
Inhibition corresponded to increased BC6OTHER production caused by BC6OTHER alone or BC6ENTC plus BC6OTHER and blocked proportionately the phosphorylation and activation of BC6ENTG in CHEM / B - activated eosinophils.	CPR:4
Inhibition corresponded to increased BC6OTHER production caused by BC6OTHER alone or BC6OTHER plus BC6ENTC and blocked proportionately the phosphorylation and activation of BC6ENTG in CHEM / B - activated eosinophils.	CPR:4
CONCLUSIONS: Inhibition of BC6ENTC by BC6OTHER unmasks BC6ENTG blockade of BC6OTHER synthesis caused by CHEM / B.	False
CONCLUSIONS: Inhibition of BC6ENTG by BC6ENTC unmasks BC6OTHER blockade of BC6OTHER synthesis caused by CHEM / B.	CPR:4
CONCLUSIONS: Inhibition of BC6OTHER by BC6ENTC unmasks BC6ENTG blockade of BC6OTHER synthesis caused by CHEM / B.	False
OBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6ENTC concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6ENTC concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6ENTC concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
CONCLUSIONS: Inhibition of BC6ENTG by BC6OTHER unmasks BC6OTHER blockade of BC6ENTC synthesis caused by CHEM / B.	False
CONCLUSIONS: Inhibition of BC6OTHER by BC6OTHER unmasks BC6ENTG blockade of BC6ENTC synthesis caused by CHEM / B.	False
We postulated that selective blockade of BC6ENTC in eosinophils would unmask the inhibitory effect of BC6ENTG stimulation and that this inhibition would result from decreased phosphor - ylation of BC6OTHER ( BC6OTHER ).	False
We postulated that selective blockade of BC6ENTC in eosinophils would unmask the inhibitory effect of BC6OTHER stimulation and that this inhibition would result from decreased phosphor - ylation of BC6ENTG ( BC6OTHER ).	False
We postulated that selective blockade of BC6ENTC in eosinophils would unmask the inhibitory effect of BC6OTHER stimulation and that this inhibition would result from decreased phosphor - ylation of BC6OTHER ( BC6ENTG ).	False
OBJECTIVE: To determine (a) whether BC6ENTC inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6ENTC inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6ENTC blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	CPR:4
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6ENTC blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6ENTC blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6ENTC and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6ENTC and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6ENTC and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6ENTC plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6ENTC plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6ENTC plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6ENTC (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6ENTC (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6ENTC (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTC inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTC inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER .	False
Blockade of BC6OTHER synthesis caused by additive inhibition of BC6ENTG phosphorylation: Effect of BC6OTHER and BC6ENTC inhibition in human eosinophils.	False
Blockade of BC6ENTC synthesis caused by additive inhibition of BC6OTHER phosphorylation: Effect of BC6OTHER and BC6ENTG inhibition in human eosinophils.	False
Blockade of BC6ENTC synthesis caused by additive inhibition of BC6ENTG phosphorylation: Effect of BC6OTHER and BC6OTHER inhibition in human eosinophils.	CPR:9
Blockade of BC6OTHER synthesis caused by additive inhibition of BC6OTHER phosphorylation: Effect of BC6ENTC and BC6ENTG inhibition in human eosinophils.	False
Blockade of BC6OTHER synthesis caused by additive inhibition of BC6ENTG phosphorylation: Effect of BC6ENTC and BC6OTHER inhibition in human eosinophils.	False
OBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6ENTC synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6ENTC synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6ENTC synthesis is regulated by BC6OTHER .	False
OBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6ENTC .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6ENTC .	False
OBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6ENTC .	False
Release of BC6ENTC and BC6OTHER , intracellular BC6OTHER concentration, and phosphorylation and activation of BC6ENTG were determined.	False
Release of BC6OTHER and BC6ENTC , intracellular BC6OTHER concentration, and phosphorylation and activation of BC6ENTG were determined.	False
Release of BC6OTHER and BC6OTHER , intracellular BC6ENTC concentration, and phosphorylation and activation of BC6ENTG were determined.	False
BC6ENTC is an BC6ENTG antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH).	CPR:6
BC6ENTG mediates the vasoconstrictor effect of BC6OTHER on vascular smooth muscle, whereas BC6OTHER is expressed primarily on vascular endothelial cells where it induces BC6ENTC synthesis and acts to clear BC6OTHER from the circulation.	False
BC6OTHER mediates the vasoconstrictor effect of BC6ENTG on vascular smooth muscle, whereas BC6OTHER is expressed primarily on vascular endothelial cells where it induces BC6ENTC synthesis and acts to clear BC6OTHER from the circulation.	False
BC6OTHER mediates the vasoconstrictor effect of BC6OTHER on vascular smooth muscle, whereas BC6ENTG is expressed primarily on vascular endothelial cells where it induces BC6ENTC synthesis and acts to clear BC6OTHER from the circulation.	False
BC6OTHER mediates the vasoconstrictor effect of BC6OTHER on vascular smooth muscle, whereas BC6OTHER is expressed primarily on vascular endothelial cells where it induces BC6ENTC synthesis and acts to clear BC6ENTG from the circulation.	False
BC6ENTC is the first BC6ENTG selective ERA approved for use in the US.	CPR:6
Enhancement of radiosensitivity by BC6ENTG inhibitor, BC6ENTC and BC6OTHER , in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction.	CPR:4
Enhancement of radiosensitivity by BC6ENTG inhibitor, BC6OTHER and BC6ENTC , in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction.	CPR:4
Similar to BC6ENTC and BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ) are BC6ENTG inhibitors.	CPR:4
Similar to BC6OTHER and BC6ENTC , BC6OTHER and BC6OTHER ( BC6OTHER ) are BC6ENTG inhibitors.	CPR:4
Similar to BC6OTHER and BC6OTHER , BC6ENTC and BC6OTHER ( BC6OTHER ) are BC6ENTG inhibitors.	CPR:4
Similar to BC6OTHER and BC6OTHER , BC6OTHER and BC6ENTC ( BC6OTHER ) are BC6ENTG inhibitors.	CPR:4
Similar to BC6OTHER and BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTC ) are BC6ENTG inhibitors.	CPR:4
To test this hypothesis, constructs were evaluated consisting of an BC6ENTG : human BC6ENTC binding protein 12 ( BC6OTHER ) attached to an BC6OTHER .	False
To test this hypothesis, constructs were evaluated consisting of an BC6OTHER : human BC6ENTC binding protein 12 ( BC6ENTG ) attached to an BC6OTHER .	False
To test this hypothesis, constructs were evaluated consisting of an BC6OTHER : human BC6ENTC binding protein 12 ( BC6OTHER ) attached to an BC6ENTG .	False
In thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6ENTG and the effect of BC6ENTC on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER expression) were analysed.	False
In thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6ENTC on growth, expression of marker of stem cells and thyroid differentiation ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER expression) were analysed.	False
In thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6ENTC on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER expression) were analysed.	False
In thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6ENTC on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER expression) were analysed.	False
In thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6ENTC on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG expression) were analysed.	False
In thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6ENTG and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC symporter expression) were analysed.	False
In thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC symporter expression) were analysed.	False
In thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC symporter expression) were analysed.	False
In thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC symporter expression) were analysed.	False
Thyroid stem and progenitor cells expressed BC6ENTC receptor alpha and beta with an 8 time higher expression level of BC6ENTG mRNA compared to differentiated thyrocytes.	False
Thyroid stem and progenitor cells expressed BC6ENTG with an 8 time higher expression level of BC6ENTC receptor alpha mRNA compared to differentiated thyrocytes.	False
In contrast, TSH - induced differentiation of progenitor cells, in particular the expression of the BC6ENTG , was significantly inhibited by BC6ENTC CHEM conclusion, BC6OTHER stimulated growth and simultaneously inhibited differentiation of thyroid nodules derived stem / progenitor cells.	CPR:4
In contrast, TSH - induced differentiation of progenitor cells, in particular the expression of the BC6ENTG , was significantly inhibited by BC6OTHER CHEM conclusion, BC6ENTC stimulated growth and simultaneously inhibited differentiation of thyroid nodules derived stem / progenitor cells.	False
In thyroid stem / progenitor cells derived from nodular goitres the ability of BC6ENTC to induce thyrosphere formation, the expression of BC6ENTG and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER expression) were analysed.	False
In thyroid stem / progenitor cells derived from nodular goitres the ability of BC6ENTC to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER expression) were analysed.	False
In thyroid stem / progenitor cells derived from nodular goitres the ability of BC6ENTC to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER expression) were analysed.	False
In thyroid stem / progenitor cells derived from nodular goitres the ability of BC6ENTC to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER expression) were analysed.	False
In thyroid stem / progenitor cells derived from nodular goitres the ability of BC6ENTC to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG expression) were analysed.	False
In thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6ENTC receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER expression) were analysed.	False
In thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6ENTC receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER expression) were analysed.	False
In thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6ENTC receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER expression) were analysed.	False
In thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6ENTC receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG expression) were analysed.	False
To assess the feasibility of targeting these high BC6ENTG levels for chemotherapy, BC6OTHER inhibitors BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were incubated (72 h) with NCI - H727 human lung carcinoid cells.	False
To assess the feasibility of targeting these high BC6OTHER levels for chemotherapy, BC6ENTG inhibitors BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were incubated (72 h) with NCI - H727 human lung carcinoid cells.	CPR:4
To assess the feasibility of targeting these high BC6ENTG levels for chemotherapy, BC6OTHER inhibitors BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were incubated (72 h) with NCI - H727 human lung carcinoid cells.	False
To assess the feasibility of targeting these high BC6OTHER levels for chemotherapy, BC6ENTG inhibitors BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were incubated (72 h) with NCI - H727 human lung carcinoid cells.	CPR:4
To assess the feasibility of targeting these high BC6ENTG levels for chemotherapy, BC6OTHER inhibitors BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were incubated (72 h) with NCI - H727 human lung carcinoid cells.	False
To assess the feasibility of targeting these high BC6OTHER levels for chemotherapy, BC6ENTG inhibitors BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were incubated (72 h) with NCI - H727 human lung carcinoid cells.	CPR:4
To assess the feasibility of targeting these high BC6ENTG levels for chemotherapy, BC6OTHER inhibitors BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER ) were incubated (72 h) with NCI - H727 human lung carcinoid cells.	False
To assess the feasibility of targeting these high BC6OTHER levels for chemotherapy, BC6ENTG inhibitors BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER ) were incubated (72 h) with NCI - H727 human lung carcinoid cells.	CPR:4
To assess the feasibility of targeting these high BC6ENTG levels for chemotherapy, BC6OTHER inhibitors BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC ( BC6OTHER ) were incubated (72 h) with NCI - H727 human lung carcinoid cells.	False
To assess the feasibility of targeting these high BC6OTHER levels for chemotherapy, BC6ENTG inhibitors BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC ( BC6OTHER ) were incubated (72 h) with NCI - H727 human lung carcinoid cells.	CPR:4
To assess the feasibility of targeting these high BC6ENTG levels for chemotherapy, BC6OTHER inhibitors BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTC ) were incubated (72 h) with NCI - H727 human lung carcinoid cells.	False
To assess the feasibility of targeting these high BC6OTHER levels for chemotherapy, BC6ENTG inhibitors BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTC ) were incubated (72 h) with NCI - H727 human lung carcinoid cells.	CPR:4
In studying kinetics of BC6ENTC hydroxylase and BC6ENTG ( BC6OTHER ) in human carcinoid hepatic metastases and adjacent normal liver (J.	False
In studying kinetics of BC6ENTC hydroxylase and BC6OTHER decarboxylase ( BC6ENTG ) in human carcinoid hepatic metastases and adjacent normal liver (J.	False
In studying kinetics of BC6ENTG and BC6ENTC decarboxylase ( BC6OTHER ) in human carcinoid hepatic metastases and adjacent normal liver (J.	False
In studying kinetics of BC6OTHER hydroxylase and BC6ENTC decarboxylase ( BC6ENTG ) in human carcinoid hepatic metastases and adjacent normal liver (J.	False
For lung tumor lines (carcinoid, two SCLC, and one large cell lung carcinoma), BC6ENTG activity was correlated with the potency of BC6ENTC - induced cytotoxicity.	False
However, carcinoid cell death was not solely attributable to complete inhibition of either BC6ENTG activity or the BC6ENTC synthetic pathway.	False
Wattakaka volubilis BC6ENTC mixture (WVSM) and BC6OTHER (1 - 50μM) significantly inhibited the BC6ENTG and BC6OTHER enzymes resulting in low levels of CHEM and CHEM in LPS - induced RAW 264.7 macrophage cells.	CPR:4
Wattakaka volubilis BC6ENTC mixture (WVSM) and BC6OTHER (1 - 50μM) significantly inhibited the BC6OTHER and BC6ENTG enzymes resulting in low levels of CHEM and CHEM in LPS - induced RAW 264.7 macrophage cells.	CPR:4
Wattakaka volubilis BC6OTHER mixture (WVSM) and BC6ENTC (1 - 50μM) significantly inhibited the BC6ENTG and BC6OTHER enzymes resulting in low levels of CHEM and CHEM in LPS - induced RAW 264.7 macrophage cells.	CPR:4
Wattakaka volubilis BC6OTHER mixture (WVSM) and BC6ENTC (1 - 50μM) significantly inhibited the BC6OTHER and BC6ENTG enzymes resulting in low levels of CHEM and CHEM in LPS - induced RAW 264.7 macrophage cells.	CPR:4
BC6OTHER and BC6ENTC (an activator of BC6ENTG ) increased inhibition of BC6OTHER and BC6OTHER , as well as autophagy in CRC cells.	CPR:3
BC6OTHER and BC6ENTC (an activator of BC6OTHER ) increased inhibition of BC6ENTG and BC6OTHER , as well as autophagy in CRC cells.	CPR:4
BC6OTHER and BC6ENTC (an activator of BC6OTHER ) increased inhibition of BC6OTHER and BC6ENTG , as well as autophagy in CRC cells.	CPR:4
BC6OTHER and BC6OTHER (an activator of BC6ENTG ) increased inhibition of BC6ENTC and BC6OTHER , as well as autophagy in CRC cells.	False
BC6OTHER and BC6OTHER (an activator of BC6OTHER ) increased inhibition of BC6ENTC and BC6ENTG , as well as autophagy in CRC cells.	False
Rectal mucosal samples from patients given BC6ENTC had reduced phosphorylation of BC6ENTG and BC6OTHER .	CPR:4
Rectal mucosal samples from patients given BC6ENTC had reduced phosphorylation of BC6OTHER and BC6ENTG .	CPR:4
CONCLUSIONS: BC6ENTC is an inhibitor of BC6ENTG and an activator of BC6OTHER , targeting regulators of intracellular energy homeostasis and metabolism.	CPR:4
CONCLUSIONS: BC6ENTC is an inhibitor of BC6OTHER and an activator of BC6ENTG , targeting regulators of intracellular energy homeostasis and metabolism.	CPR:3
CONCLUSIONS: BC6OTHER is an inhibitor of BC6ENTC and an activator of BC6ENTG , targeting regulators of intracellular energy homeostasis and metabolism.	False
Cancer cells have defects in signaling via the mechanistic target of BC6ENTC ( BC6ENTG ), which regulates proliferation.	False
Cancer cells have defects in signaling via the BC6ENTG ( BC6ENTC ), which regulates proliferation.	False
We investigated whether BC6ENTC affects BC6ENTG ( BC6OTHER ) and BC6OTHER signaling in CRC cells.	False
We investigated whether BC6ENTC affects BC6OTHER ( BC6ENTG ) and BC6OTHER signaling in CRC cells.	False
We investigated whether BC6ENTC affects BC6OTHER ( BC6OTHER ) and BC6ENTG signaling in CRC cells.	False
We investigated whether BC6OTHER affects BC6ENTC - activated protein kinase ( BC6ENTG ) and BC6OTHER signaling in CRC cells.	False
We investigated whether BC6OTHER affects BC6ENTC - activated protein kinase ( BC6OTHER ) and BC6ENTG signaling in CRC cells.	False
RESULTS: BC6OTHER reduced BC6OTHER signaling in CRC cells by inhibiting the BC6ENTC effectors BC6ENTG and BC6OTHER .	False
RESULTS: BC6OTHER reduced BC6OTHER signaling in CRC cells by inhibiting the BC6ENTC effectors BC6OTHER and BC6ENTG .	False
RESULTS: BC6OTHER reduced BC6ENTG signaling in CRC cells by inhibiting the BC6ENTC effectors BC6OTHER and BC6OTHER .	False
We investigated whether BC6OTHER affects BC6ENTG ( BC6OTHER ) and BC6ENTC signaling in CRC cells.	False
We investigated whether BC6OTHER affects BC6OTHER ( BC6ENTG ) and BC6ENTC signaling in CRC cells.	False
METHODS: The effects of BC6ENTC on BC6ENTG signaling, the BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were examined in CRC cells by immunoblotting.	False
METHODS: The effects of BC6ENTC on BC6OTHER signaling, the BC6ENTG , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were examined in CRC cells by immunoblotting.	False
METHODS: The effects of BC6ENTC on BC6OTHER signaling, the BC6OTHER , BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were examined in CRC cells by immunoblotting.	False
METHODS: The effects of BC6ENTC on BC6OTHER signaling, the BC6OTHER , BC6OTHER ( BC6ENTG ), and BC6OTHER ( BC6OTHER ) were examined in CRC cells by immunoblotting.	False
METHODS: The effects of BC6ENTC on BC6OTHER signaling, the BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) were examined in CRC cells by immunoblotting.	False
METHODS: The effects of BC6ENTC on BC6OTHER signaling, the BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG ) were examined in CRC cells by immunoblotting.	False
METHODS: The effects of BC6OTHER on BC6ENTC signaling, the BC6ENTG , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were examined in CRC cells by immunoblotting.	False
METHODS: The effects of BC6OTHER on BC6ENTC signaling, the BC6OTHER , BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were examined in CRC cells by immunoblotting.	False
METHODS: The effects of BC6OTHER on BC6ENTC signaling, the BC6OTHER , BC6OTHER ( BC6ENTG ), and BC6OTHER ( BC6OTHER ) were examined in CRC cells by immunoblotting.	False
METHODS: The effects of BC6OTHER on BC6ENTC signaling, the BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) were examined in CRC cells by immunoblotting.	False
METHODS: The effects of BC6OTHER on BC6ENTC signaling, the BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG ) were examined in CRC cells by immunoblotting.	False
Phosphorylation of BC6ENTG was measured; the effects of loss of BC6OTHER on the BC6ENTC - induced effects of BC6OTHER were determined using small interfering RNA (siRNA) in CRC cells and in BC6OTHER - / - ) mouse embryonic fibroblasts.	False
Phosphorylation of BC6OTHER was measured; the effects of loss of BC6ENTG on the BC6ENTC - induced effects of BC6OTHER were determined using small interfering RNA (siRNA) in CRC cells and in BC6OTHER - / - ) mouse embryonic fibroblasts.	False
Phosphorylation of BC6OTHER was measured; the effects of loss of BC6OTHER on the BC6ENTC - induced effects of BC6ENTG were determined using small interfering RNA (siRNA) in CRC cells and in BC6OTHER - / - ) mouse embryonic fibroblasts.	False
Phosphorylation of BC6OTHER was measured; the effects of loss of BC6OTHER on the BC6ENTC - induced effects of BC6OTHER were determined using small interfering RNA (siRNA) in CRC cells and in BC6ENTG - / - ) mouse embryonic fibroblasts.	False
Phosphorylation of BC6ENTG was measured; the effects of loss of BC6OTHER on the BC6OTHER - induced effects of BC6ENTC were determined using small interfering RNA (siRNA) in CRC cells and in BC6OTHER - / - ) mouse embryonic fibroblasts.	False
Phosphorylation of BC6OTHER was measured; the effects of loss of BC6ENTG on the BC6OTHER - induced effects of BC6ENTC were determined using small interfering RNA (siRNA) in CRC cells and in BC6OTHER - / - ) mouse embryonic fibroblasts.	False
Phosphorylation of BC6OTHER was measured; the effects of loss of BC6OTHER on the BC6OTHER - induced effects of BC6ENTC were determined using small interfering RNA (siRNA) in CRC cells and in BC6ENTG - / - ) mouse embryonic fibroblasts.	False
RESULTS: BC6ENTC reduced BC6OTHER signaling in CRC cells by inhibiting the BC6ENTG effectors BC6OTHER and BC6OTHER .	CPR:4
RESULTS: BC6ENTC reduced BC6OTHER signaling in CRC cells by inhibiting the BC6OTHER effectors BC6ENTG and BC6OTHER .	CPR:4
RESULTS: BC6ENTC reduced BC6OTHER signaling in CRC cells by inhibiting the BC6OTHER effectors BC6OTHER and BC6ENTG .	CPR:4
RESULTS: BC6ENTC reduced BC6ENTG signaling in CRC cells by inhibiting the BC6OTHER effectors BC6OTHER and BC6OTHER .	CPR:4
RESULTS: BC6OTHER reduced BC6ENTC signaling in CRC cells by inhibiting the BC6ENTG effectors BC6OTHER and BC6OTHER .	False
RESULTS: BC6OTHER reduced BC6ENTC signaling in CRC cells by inhibiting the BC6OTHER effectors BC6ENTG and BC6OTHER .	False
RESULTS: BC6OTHER reduced BC6ENTC signaling in CRC cells by inhibiting the BC6OTHER effectors BC6OTHER and BC6ENTG .	False
 BC6ENTC inhibits BC6ENTG signaling, activates BC6OTHER , and induces autophagy in colorectal cancer cells.	CPR:4
 BC6ENTC inhibits BC6OTHER signaling, activates BC6ENTG , and induces autophagy in colorectal cancer cells.	CPR:3
 BC6OTHER inhibits BC6ENTC signaling, activates BC6ENTG , and induces autophagy in colorectal cancer cells.	False
BC6ENTC changed nucleotide ratios and activated BC6ENTG in CRC cells.	CPR:3
 BC6OTHER inhibits BC6ENTG signaling, activates BC6ENTC - activated protein kinase, and induces autophagy in colorectal cancer cells.	False
BC6ENTC was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6ENTG , indicating BC6OTHER - dependent and BC6OTHER - independent mechanisms of BC6OTHER - induced inhibition of BC6OTHER .	False
BC6ENTC was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6ENTG - dependent and BC6OTHER - independent mechanisms of BC6OTHER - induced inhibition of BC6OTHER .	False
BC6ENTC was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6OTHER - dependent and BC6ENTG - independent mechanisms of BC6OTHER - induced inhibition of BC6OTHER .	False
BC6ENTC was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6OTHER - dependent and BC6OTHER - independent mechanisms of BC6OTHER - induced inhibition of BC6ENTG .	False
BC6ENTG was still inhibited by BC6ENTC in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6OTHER - dependent and BC6OTHER - independent mechanisms of BC6OTHER - induced inhibition of BC6OTHER .	CPR:4
BC6OTHER was still inhibited by BC6ENTC in CRC cells after siRNA knockdown of BC6ENTG , indicating BC6OTHER - dependent and BC6OTHER - independent mechanisms of BC6OTHER - induced inhibition of BC6OTHER .	False
BC6OTHER was still inhibited by BC6ENTC in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6ENTG - dependent and BC6OTHER - independent mechanisms of BC6OTHER - induced inhibition of BC6OTHER .	False
BC6OTHER was still inhibited by BC6ENTC in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6OTHER - dependent and BC6ENTG - independent mechanisms of BC6OTHER - induced inhibition of BC6OTHER .	False
BC6OTHER was still inhibited by BC6ENTC in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6OTHER - dependent and BC6OTHER - independent mechanisms of BC6OTHER - induced inhibition of BC6ENTG .	False
BC6ENTG was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6OTHER - dependent and BC6OTHER - independent mechanisms of BC6ENTC - induced inhibition of BC6OTHER .	False
BC6OTHER was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6ENTG , indicating BC6OTHER - dependent and BC6OTHER - independent mechanisms of BC6ENTC - induced inhibition of BC6OTHER .	False
BC6OTHER was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6ENTG - dependent and BC6OTHER - independent mechanisms of BC6ENTC - induced inhibition of BC6OTHER .	False
BC6OTHER was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6OTHER - dependent and BC6ENTG - independent mechanisms of BC6ENTC - induced inhibition of BC6OTHER .	False
BC6OTHER was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6OTHER - dependent and BC6OTHER - independent mechanisms of BC6ENTC - induced inhibition of BC6ENTG .	CPR:4
BC6ENTG was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6OTHER - dependent and BC6OTHER - independent mechanisms of BC6OTHER - induced inhibition of BC6ENTC .	False
BC6OTHER was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6ENTG , indicating BC6OTHER - dependent and BC6OTHER - independent mechanisms of BC6OTHER - induced inhibition of BC6ENTC .	False
BC6OTHER was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6ENTG - dependent and BC6OTHER - independent mechanisms of BC6OTHER - induced inhibition of BC6ENTC .	False
BC6OTHER was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6OTHER - dependent and BC6ENTG - independent mechanisms of BC6OTHER - induced inhibition of BC6ENTC .	False
BC6ENTC induced autophagy, a feature of BC6ENTG inhibition.	CPR:4
BC6ENTC and BC6OTHER (an activator of BC6ENTG ) increased inhibition of BC6OTHER and BC6OTHER , as well as autophagy in CRC cells.	CPR:3
BC6ENTC and BC6OTHER (an activator of BC6OTHER ) increased inhibition of BC6ENTG and BC6OTHER , as well as autophagy in CRC cells.	CPR:4
BC6ENTC and BC6OTHER (an activator of BC6OTHER ) increased inhibition of BC6OTHER and BC6ENTG , as well as autophagy in CRC cells.	CPR:4
The editing of BC6ENTG is also completely lost in albino mutants and BC6ENTC - treated seedlings.	False
In addition, the expression of nucleus - encoded BC6ENTG dependent transcripts is specifically induced by BC6ENTC , and the splicing of BC6OTHER transcripts is significantly reduced in the albino mutants and inhibitor - treated seedlings.	False
In addition, the expression of nucleus - encoded BC6OTHER dependent transcripts is specifically induced by BC6ENTC , and the splicing of BC6ENTG transcripts is significantly reduced in the albino mutants and inhibitor - treated seedlings.	False
By contrast, the editing of some sites is completely lost or significantly reduced in other non - green tissues; for instance, the editing of BC6ENTG , BC6OTHER , and BC6OTHER is completely lost in roots and in BC6ENTC - treated seedlings.	False
By contrast, the editing of some sites is completely lost or significantly reduced in other non - green tissues; for instance, the editing of BC6OTHER , BC6ENTG , and BC6OTHER is completely lost in roots and in BC6ENTC - treated seedlings.	False
By contrast, the editing of some sites is completely lost or significantly reduced in other non - green tissues; for instance, the editing of BC6OTHER , BC6OTHER , and BC6ENTG is completely lost in roots and in BC6ENTC - treated seedlings.	False
Rats intoxicated with BC6OTHER for 30 days, significantly increased tissue BC6OTHER ( BC6OTHER ) levels and significantly decreased enzymatic antioxidants BC6ENTC dismutase, BC6ENTG and BC6OTHER in the frontal cortex tissue.	False
Rats intoxicated with BC6OTHER for 30 days, significantly increased tissue BC6OTHER ( BC6OTHER ) levels and significantly decreased enzymatic antioxidants BC6ENTC dismutase, BC6OTHER peroxidase and BC6ENTG in the frontal cortex tissue.	False
Rats intoxicated with BC6ENTC for 30 days, significantly increased tissue BC6OTHER ( BC6OTHER ) levels and significantly decreased enzymatic antioxidants BC6ENTG , BC6OTHER peroxidase and BC6OTHER in the frontal cortex tissue.	CPR:4
Rats intoxicated with BC6ENTC for 30 days, significantly increased tissue BC6OTHER ( BC6OTHER ) levels and significantly decreased enzymatic antioxidants BC6OTHER , BC6ENTG and BC6OTHER in the frontal cortex tissue.	CPR:4
Rats intoxicated with BC6ENTC for 30 days, significantly increased tissue BC6OTHER ( BC6OTHER ) levels and significantly decreased enzymatic antioxidants BC6OTHER , BC6OTHER peroxidase and BC6ENTG in the frontal cortex tissue.	CPR:4
Rats intoxicated with BC6OTHER for 30 days, significantly increased tissue BC6ENTC ( BC6OTHER ) levels and significantly decreased enzymatic antioxidants BC6ENTG , BC6OTHER peroxidase and BC6OTHER in the frontal cortex tissue.	False
Rats intoxicated with BC6OTHER for 30 days, significantly increased tissue BC6ENTC ( BC6OTHER ) levels and significantly decreased enzymatic antioxidants BC6OTHER , BC6ENTG and BC6OTHER in the frontal cortex tissue.	False
Rats intoxicated with BC6OTHER for 30 days, significantly increased tissue BC6ENTC ( BC6OTHER ) levels and significantly decreased enzymatic antioxidants BC6OTHER , BC6OTHER peroxidase and BC6ENTG in the frontal cortex tissue.	False
Rats intoxicated with BC6OTHER for 30 days, significantly increased tissue BC6OTHER ( BC6ENTC ) levels and significantly decreased enzymatic antioxidants BC6ENTG , BC6OTHER peroxidase and BC6OTHER in the frontal cortex tissue.	False
Rats intoxicated with BC6OTHER for 30 days, significantly increased tissue BC6OTHER ( BC6ENTC ) levels and significantly decreased enzymatic antioxidants BC6OTHER , BC6ENTG and BC6OTHER in the frontal cortex tissue.	False
Rats intoxicated with BC6OTHER for 30 days, significantly increased tissue BC6OTHER ( BC6ENTC ) levels and significantly decreased enzymatic antioxidants BC6OTHER , BC6OTHER peroxidase and BC6ENTG in the frontal cortex tissue.	False
Rats intoxicated with BC6OTHER for 30 days, significantly increased tissue BC6OTHER ( BC6OTHER ) levels and significantly decreased enzymatic antioxidants BC6ENTG , BC6ENTC peroxidase and BC6OTHER in the frontal cortex tissue.	False
Rats intoxicated with BC6OTHER for 30 days, significantly increased tissue BC6OTHER ( BC6OTHER ) levels and significantly decreased enzymatic antioxidants BC6OTHER , BC6ENTC peroxidase and BC6ENTG in the frontal cortex tissue.	False
The BC6ENTG immunopositivity was increased in degenerating neurons of the BC6ENTC group.	CPR:3
However, the precise mechanism by which BC6OTHER counteracts BC6ENTG - mediated BC6ENTC hepatotoxicity through BC6OTHER system is still remained unclear.	False
However, the precise mechanism by which BC6OTHER counteracts BC6OTHER - mediated BC6ENTC hepatotoxicity through BC6ENTG system is still remained unclear.	False
Our data showed that chronic BC6ENTC over - activated BC6ENTG but suppressed BC6OTHER with concurrent hepatic oxidative damage, which was partially normalized by BC6OTHER (100mg / kg.bw.).	CPR:3
Our data showed that chronic BC6ENTC over - activated BC6OTHER but suppressed BC6ENTG with concurrent hepatic oxidative damage, which was partially normalized by BC6OTHER (100mg / kg.bw.).	CPR:4
Naturally occuring BC6OTHER protects hepatocytes from BC6ENTC - induced oxidative stress, and BC6OTHER ( BC6ENTG ) induction and BC6OTHER ( BC6OTHER ) metabolite may be implicated in the beneficial effect.	False
Naturally occuring BC6OTHER protects hepatocytes from BC6ENTC - induced oxidative stress, and BC6ENTG ( BC6OTHER ) induction and BC6OTHER ( BC6OTHER ) metabolite may be implicated in the beneficial effect.	False
Our data showed that chronic BC6OTHER over - activated BC6ENTG but suppressed BC6OTHER with concurrent hepatic oxidative damage, which was partially normalized by BC6ENTC (100mg / kg.bw.).	False
Our data showed that chronic BC6OTHER over - activated BC6OTHER but suppressed BC6ENTG with concurrent hepatic oxidative damage, which was partially normalized by BC6ENTC (100mg / kg.bw.).	False
BC6ENTC (100μM) induced BC6ENTG and depleted CHEM pool when incubated to human hepatocytes.	CPR:3
BC6ENTC - stimulated (100mM) BC6ENTG upregulation was suppressed by BC6OTHER but further enhanced by BC6OTHER inhibition with resultant BC6OTHER accumulation.	CPR:3
BC6ENTC - stimulated (100mM) BC6OTHER upregulation was suppressed by BC6OTHER but further enhanced by BC6ENTG inhibition with resultant BC6OTHER accumulation.	CPR:4
BC6OTHER - stimulated (100mM) BC6ENTG upregulation was suppressed by BC6ENTC but further enhanced by BC6OTHER inhibition with resultant BC6OTHER accumulation.	CPR:4
BC6OTHER - stimulated (100mM) BC6OTHER upregulation was suppressed by BC6ENTC but further enhanced by BC6ENTG inhibition with resultant BC6OTHER accumulation.	False
BC6OTHER - stimulated (100mM) BC6ENTG upregulation was suppressed by BC6OTHER but further enhanced by BC6OTHER inhibition with resultant BC6ENTC accumulation.	False
BC6OTHER - stimulated (100mM) BC6OTHER upregulation was suppressed by BC6OTHER but further enhanced by BC6ENTG inhibition with resultant BC6ENTC accumulation.	CPR:9
BC6ENTC scavenging blocked the suppression of BC6OTHER only on BC6ENTG activity.	CPR:4
BC6OTHER donor dose - dependently inactivated BC6OTHER of BC6ENTC - incubated microsome, which was mimicked by BC6ENTG substrate but abolished by BC6OTHER scavenger.	False
BC6OTHER donor dose - dependently inactivated BC6ENTG of BC6ENTC - incubated microsome, which was mimicked by BC6OTHER substrate but abolished by BC6OTHER scavenger.	CPR:3
BC6OTHER scavenging blocked the suppression of BC6ENTC only on BC6ENTG activity.	False
Naturally occuring BC6OTHER protects hepatocytes from BC6OTHER - induced oxidative stress, and BC6ENTC oxygenase - 1 ( BC6ENTG ) induction and BC6OTHER ( BC6OTHER ) metabolite may be implicated in the beneficial effect.	False
BC6ENTC donor dose - dependently inactivated BC6OTHER of BC6OTHER - incubated microsome, which was mimicked by BC6ENTG substrate but abolished by BC6OTHER scavenger.	False
BC6ENTC donor dose - dependently inactivated BC6ENTG of BC6OTHER - incubated microsome, which was mimicked by BC6OTHER substrate but abolished by BC6OTHER scavenger.	CPR:4
 BC6ENTC suppressed BC6ENTG - dependent BC6OTHER hepatotoxicity via depleting CHEM pool and releasing BC6OTHER .	CPR:4
 BC6OTHER suppressed BC6ENTG - dependent BC6ENTC hepatotoxicity via depleting CHEM pool and releasing BC6OTHER .	False
 BC6OTHER suppressed BC6ENTG - dependent BC6OTHER hepatotoxicity via depleting CHEM pool and releasing BC6ENTC .	False
BC6OTHER donor dose - dependently inactivated BC6OTHER of BC6OTHER - incubated microsome, which was mimicked by BC6ENTG substrate but abolished by BC6ENTC scavenger.	False
BC6OTHER donor dose - dependently inactivated BC6ENTG of BC6OTHER - incubated microsome, which was mimicked by BC6OTHER substrate but abolished by BC6ENTC scavenger.	CPR:4
Thus, BC6ENTG - mediated BC6ENTC hepatotoxicity was alleviated by BC6OTHER through BC6OTHER induction.	False
Thus, BC6OTHER - mediated BC6ENTC hepatotoxicity was alleviated by BC6OTHER through BC6ENTG induction.	False
Thus, BC6ENTG - mediated BC6OTHER hepatotoxicity was alleviated by BC6ENTC through BC6OTHER induction.	False
Thus, BC6OTHER - mediated BC6OTHER hepatotoxicity was alleviated by BC6ENTC through BC6ENTG induction.	CPR:3
Depleted CHEM pool and BC6ENTC releasing limited protein synthesis and inhibited enzymatic activity of BC6ENTG , respectively.	CPR:4
Naturally occuring BC6OTHER protects hepatocytes from BC6OTHER - induced oxidative stress, and BC6OTHER ( BC6ENTG ) induction and BC6ENTC ( BC6OTHER ) metabolite may be implicated in the beneficial effect.	False
Naturally occuring BC6OTHER protects hepatocytes from BC6OTHER - induced oxidative stress, and BC6ENTG ( BC6OTHER ) induction and BC6ENTC ( BC6OTHER ) metabolite may be implicated in the beneficial effect.	False
Naturally occuring BC6OTHER protects hepatocytes from BC6OTHER - induced oxidative stress, and BC6OTHER ( BC6ENTG ) induction and BC6OTHER ( BC6ENTC ) metabolite may be implicated in the beneficial effect.	False
Naturally occuring BC6OTHER protects hepatocytes from BC6OTHER - induced oxidative stress, and BC6ENTG ( BC6OTHER ) induction and BC6OTHER ( BC6ENTC ) metabolite may be implicated in the beneficial effect.	False
Naturally occuring BC6ENTC protects hepatocytes from BC6OTHER - induced oxidative stress, and BC6OTHER ( BC6ENTG ) induction and BC6OTHER ( BC6OTHER ) metabolite may be implicated in the beneficial effect.	False
Naturally occuring BC6ENTC protects hepatocytes from BC6OTHER - induced oxidative stress, and BC6ENTG ( BC6OTHER ) induction and BC6OTHER ( BC6OTHER ) metabolite may be implicated in the beneficial effect.	False
However, the precise mechanism by which BC6ENTC counteracts BC6ENTG - mediated BC6OTHER hepatotoxicity through BC6OTHER system is still remained unclear.	CPR:4
However, the precise mechanism by which BC6ENTC counteracts BC6OTHER - mediated BC6OTHER hepatotoxicity through BC6ENTG system is still remained unclear.	False
 BC6ENTG - receptor antagonism in hypertension: what has been learned with BC6ENTC ?	False
BC6ENTC is a long - acting BC6OTHER antagonist acting specifically at the level of the Type 1 - receptor subtype ( BC6ENTG - receptor).	False
BC6ENTC is a long - acting BC6ENTG antagonist acting specifically at the level of the Type 1 - receptor subtype ( BC6OTHER - receptor).	CPR:6
BC6OTHER is a long - acting BC6ENTC antagonist acting specifically at the level of the Type 1 - receptor subtype ( BC6ENTG - receptor).	False
BC6ENTC may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this BC6ENTG - blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro - inflammatory effects of BC6OTHER .	CPR:4
BC6ENTC may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this BC6OTHER - blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro - inflammatory effects of BC6ENTG .	CPR:4
BC6OTHER may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this BC6ENTG - blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro - inflammatory effects of BC6ENTC .	False
The antidepressant BC6ENTC has been shown to decrease synaptic membrane concentrations of the BC6OTHER re - uptake transporter ( BC6ENTG ) in vivo and in vitro, on both an acute and a chronic basis.	CPR:4
The antidepressant BC6ENTC has been shown to decrease synaptic membrane concentrations of the BC6ENTG ( BC6OTHER ) in vivo and in vitro, on both an acute and a chronic basis.	CPR:4
In this study, we treated SK - N - SHSY5Y cells with 100 nM BC6ENTC for 24 or 72 h, and measured BC6OTHER binding (as an estimate of BC6ENTG ) and BC6OTHER mRNA by quantitative reverse transcription polymerase chain reaction.	False
In this study, we treated SK - N - SHSY5Y cells with 100 nM BC6ENTC for 24 or 72 h, and measured BC6OTHER binding (as an estimate of BC6OTHER ) and BC6ENTG mRNA by quantitative reverse transcription polymerase chain reaction.	False
In this study, we treated SK - N - SHSY5Y cells with 100 nM BC6OTHER for 24 or 72 h, and measured BC6ENTC binding (as an estimate of BC6ENTG ) and BC6OTHER mRNA by quantitative reverse transcription polymerase chain reaction.	False
In this study, we treated SK - N - SHSY5Y cells with 100 nM BC6OTHER for 24 or 72 h, and measured BC6ENTC binding (as an estimate of BC6OTHER ) and BC6ENTG mRNA by quantitative reverse transcription polymerase chain reaction.	False
We conclude that decreased BC6ENTG synthesis may contribute to the chronic, but not acute, effect of BC6ENTC to downregulate the BC6OTHER .	False
We conclude that decreased BC6OTHER synthesis may contribute to the chronic, but not acute, effect of BC6ENTC to downregulate the BC6ENTG .	CPR:4
The antidepressant BC6OTHER has been shown to decrease synaptic membrane concentrations of the BC6ENTC re - uptake transporter ( BC6ENTG ) in vivo and in vitro, on both an acute and a chronic basis.	False
 BC6ENTC treatment decreases BC6OTHER binding and BC6ENTG mRNA in SK - N - SHSY5Y cells.	CPR:4
 BC6OTHER treatment decreases BC6ENTC binding and BC6ENTG mRNA in SK - N - SHSY5Y cells.	False
This study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6ENTC diphosphohydrolase), BC6ENTG , BC6OTHER and BC6OTHER deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
This study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6ENTC diphosphohydrolase), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6ENTG and BC6OTHER deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
This study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6ENTC diphosphohydrolase), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6OTHER and BC6ENTG ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
This study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6ENTC diphosphohydrolase), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6OTHER and BC6OTHER deaminase ( BC6ENTG ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
This study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6ENTG ( BC6ENTC diphosphohydrolase), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6OTHER and BC6OTHER deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
In lymphocytes, the BC6OTHER and BC6ENTG activities were increased in all groups treated with BC6ENTC when compared to control (P<0.05).	CPR:3
In lymphocytes, the BC6ENTG and BC6OTHER activities were increased in all groups treated with BC6ENTC when compared to control (P<0.05).	CPR:3
This study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6OTHER ), Ecto - NPP ( BC6ENTC pyrophosphatase / phosphodiesterase), BC6ENTG and BC6OTHER deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
This study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6OTHER ), Ecto - NPP ( BC6ENTC pyrophosphatase / phosphodiesterase), BC6OTHER and BC6ENTG ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
This study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6OTHER ), Ecto - NPP ( BC6ENTC pyrophosphatase / phosphodiesterase), BC6OTHER and BC6OTHER deaminase ( BC6ENTG ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
This study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6ENTG ( BC6OTHER ), Ecto - NPP ( BC6ENTC pyrophosphatase / phosphodiesterase), BC6OTHER and BC6OTHER deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
This study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6ENTG ), Ecto - NPP ( BC6ENTC pyrophosphatase / phosphodiesterase), BC6OTHER and BC6OTHER deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
This study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6OTHER ), BC6ENTG , BC6OTHER and BC6ENTC deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
This study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6OTHER ), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6ENTG and BC6ENTC deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
This study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6OTHER ), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6OTHER and BC6ENTC deaminase ( BC6ENTG ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
This study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6ENTG ( BC6OTHER ), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6OTHER and BC6ENTC deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
This study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6ENTG ), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6OTHER and BC6ENTC deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
This study evaluated the effects of BC6ENTC on ectonucleotidase activities such as BC6OTHER ( BC6OTHER ), BC6ENTG , BC6OTHER and BC6OTHER deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
This study evaluated the effects of BC6ENTC on ectonucleotidase activities such as BC6OTHER ( BC6OTHER ), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6ENTG and BC6OTHER deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
This study evaluated the effects of BC6ENTC on ectonucleotidase activities such as BC6OTHER ( BC6OTHER ), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6OTHER and BC6ENTG ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
This study evaluated the effects of BC6ENTC on ectonucleotidase activities such as BC6OTHER ( BC6OTHER ), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6OTHER and BC6OTHER deaminase ( BC6ENTG ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
This study evaluated the effects of BC6ENTC on ectonucleotidase activities such as BC6ENTG ( BC6OTHER ), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6OTHER and BC6OTHER deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
This study evaluated the effects of BC6ENTC on ectonucleotidase activities such as BC6OTHER ( BC6ENTG ), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6OTHER and BC6OTHER deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	False
Efficacies and potencies of these ligands were determined relative to the endogenous ligand BC6ENTG and the common mu agonist, BC6ENTC .	False
Additionally, the role of BC6ENTG ( BC6OTHER ; BC6OTHER ) and BC6OTHER ( BC6OTHER ; BC6OTHER ) in BC6ENTC disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats.	False
Additionally, the role of BC6OTHER ( BC6ENTG ; BC6OTHER ) and BC6OTHER ( BC6OTHER ; BC6OTHER ) in BC6ENTC disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats.	False
Additionally, the role of BC6OTHER ( BC6OTHER ; BC6ENTG ) and BC6OTHER ( BC6OTHER ; BC6OTHER ) in BC6ENTC disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats.	False
Additionally, the role of BC6OTHER ( BC6OTHER ; BC6OTHER ) and BC6ENTG ( BC6OTHER ; BC6OTHER ) in BC6ENTC disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats.	False
Additionally, the role of BC6OTHER ( BC6OTHER ; BC6OTHER ) and BC6OTHER ( BC6ENTG ; BC6OTHER ) in BC6ENTC disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats.	False
Additionally, the role of BC6OTHER ( BC6OTHER ; BC6OTHER ) and BC6OTHER ( BC6OTHER ; BC6ENTG ) in BC6ENTC disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats.	False
The fecal elimination, IC, and systemic clearance of BC6ENTC were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with BC6OTHER , a dual BC6ENTG and BC6OTHER inhibitor).	False
The fecal elimination, IC, and systemic clearance of BC6ENTC were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with BC6OTHER , a dual BC6OTHER and BC6ENTG inhibitor).	False
Investigating the enteroenteric recirculation of BC6ENTC , a BC6ENTG inhibitor: administration of activated CHEM to bile duct - cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.	CPR:4
The fecal elimination, IC, and systemic clearance of BC6OTHER were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with BC6ENTC , a dual BC6ENTG and BC6OTHER inhibitor).	CPR:4
The fecal elimination, IC, and systemic clearance of BC6OTHER were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with BC6ENTC , a dual BC6OTHER and BC6ENTG inhibitor).	CPR:4
 BC6ENTG appeared to play a more important role for absorption and intestinal and renal elimination of BC6ENTC than BC6OTHER in transporter - KO rats after oral and i.v. dosing, which led to a higher level of active renal excretion in rat than other species.	CPR:9
 BC6OTHER appeared to play a more important role for absorption and intestinal and renal elimination of BC6ENTC than BC6ENTG in transporter - KO rats after oral and i.v. dosing, which led to a higher level of active renal excretion in rat than other species.	CPR:9
The BC6ENTC - lowering drug CHEM inhibits BC6ENTG signaling by binding to an allosteric site on BC6OTHER ( BC6OTHER chain), which leads to immunomodulation.	False
The BC6ENTC - lowering drug CHEM inhibits BC6OTHER signaling by binding to an allosteric site on BC6ENTG ( BC6OTHER chain), which leads to immunomodulation.	False
The BC6ENTC - lowering drug CHEM inhibits BC6OTHER signaling by binding to an allosteric site on BC6OTHER ( BC6ENTG chain), which leads to immunomodulation.	False
Lymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6ENTC ); BC6ENTG ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6OTHER and BC6OTHER , respectively).	CPR:9
Lymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6ENTC ); BC6OTHER acetyltransferase ( BC6ENTG ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6OTHER and BC6OTHER , respectively).	CPR:9
Lymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6ENTC ); BC6OTHER acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both BC6ENTG ( BC6OTHER and BC6OTHER , respectively).	False
Lymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6ENTC ); BC6OTHER acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6ENTG and BC6OTHER , respectively).	False
Lymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6ENTC ); BC6OTHER acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6OTHER and BC6ENTG , respectively).	False
Lymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6OTHER ); BC6ENTC acetyltransferase ( BC6ENTG ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6OTHER and BC6OTHER , respectively).	False
Lymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6OTHER ); BC6ENTC acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both BC6ENTG ( BC6OTHER and BC6OTHER , respectively).	False
Lymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6OTHER ); BC6ENTC acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6ENTG and BC6OTHER , respectively).	False
Lymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6OTHER ); BC6ENTC acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6OTHER and BC6ENTG , respectively).	False
We found that BC6ENTC abolishes anti - BC6ENTG mAb - induced increases in lymphocytic cholinergic activity in a manner independent of its BC6OTHER - lowering activity.	CPR:4
We found that BC6OTHER abolishes anti - BC6ENTG mAb - induced increases in lymphocytic cholinergic activity in a manner independent of its BC6ENTC - lowering activity.	False
Collectively then, these results indicate that BC6ENTG contributes to the regulation of lymphocytic cholinergic activity via BC6OTHER - mediated pathways and suggest that BC6ENTC exerts its immunosuppressive effects in part via modification of lymphocytic cholinergic activity.	False
Collectively then, these results indicate that BC6OTHER contributes to the regulation of lymphocytic cholinergic activity via BC6ENTG - mediated pathways and suggest that BC6ENTC exerts its immunosuppressive effects in part via modification of lymphocytic cholinergic activity.	False
Lymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6ENTC receptors ( BC6OTHER and BC6OTHER , respectively).	False
Lymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6OTHER ); BC6OTHER acetyltransferase ( BC6ENTG ), its synthesizing enzyme; and both muscarinic and nicotinic BC6ENTC receptors ( BC6OTHER and BC6OTHER , respectively).	False
Lymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6OTHER ); BC6OTHER acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6ENTC receptors ( BC6ENTG and BC6OTHER , respectively).	False
Lymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6OTHER ); BC6OTHER acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6ENTC receptors ( BC6OTHER and BC6ENTG , respectively).	False
Stimulation of lymphocytes with BC6ENTG , which activates T cells via the BC6OTHER / BC6OTHER complex, enhances the synthesis and release of BC6ENTC and up - regulates expression of BC6OTHER and BC6OTHER mRNAs.	False
Stimulation of lymphocytes with BC6OTHER , which activates T cells via the BC6ENTG / BC6OTHER complex, enhances the synthesis and release of BC6ENTC and up - regulates expression of BC6OTHER and BC6OTHER mRNAs.	False
Stimulation of lymphocytes with BC6OTHER , which activates T cells via the BC6OTHER / BC6ENTG complex, enhances the synthesis and release of BC6ENTC and up - regulates expression of BC6OTHER and BC6OTHER mRNAs.	False
Stimulation of lymphocytes with BC6OTHER , which activates T cells via the BC6OTHER / BC6OTHER complex, enhances the synthesis and release of BC6ENTC and up - regulates expression of BC6ENTG and BC6OTHER mRNAs.	False
Stimulation of lymphocytes with BC6OTHER , which activates T cells via the BC6OTHER / BC6OTHER complex, enhances the synthesis and release of BC6ENTC and up - regulates expression of BC6OTHER and BC6ENTG mRNAs.	False
In addition, activation of BC6ENTG and increases in intracellular BC6ENTC also enhance cholinergic activity in T cells, and BC6OTHER ( BC6OTHER ; BC6OTHER / BC6OTHER ) is an important mediator of leukocyte migration and T cell activation.	False
In addition, activation of BC6OTHER and increases in intracellular BC6ENTC also enhance cholinergic activity in T cells, and BC6ENTG ( BC6OTHER ; BC6OTHER / BC6OTHER ) is an important mediator of leukocyte migration and T cell activation.	CPR:3
In addition, activation of BC6OTHER and increases in intracellular BC6ENTC also enhance cholinergic activity in T cells, and BC6OTHER ( BC6ENTG ; BC6OTHER / BC6OTHER ) is an important mediator of leukocyte migration and T cell activation.	CPR:3
In addition, activation of BC6OTHER and increases in intracellular BC6ENTC also enhance cholinergic activity in T cells, and BC6OTHER ( BC6OTHER ; BC6ENTG / BC6OTHER ) is an important mediator of leukocyte migration and T cell activation.	CPR:3
In addition, activation of BC6OTHER and increases in intracellular BC6ENTC also enhance cholinergic activity in T cells, and BC6OTHER ( BC6OTHER ; BC6OTHER / BC6ENTG ) is an important mediator of leukocyte migration and T cell activation.	CPR:3
Lymphocytes possess the essential components of a cholinergic system, including BC6ENTC ( BC6OTHER ); BC6ENTG ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6OTHER and BC6OTHER , respectively).	CPR:9
Lymphocytes possess the essential components of a cholinergic system, including BC6ENTC ( BC6OTHER ); BC6OTHER acetyltransferase ( BC6ENTG ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6OTHER and BC6OTHER , respectively).	CPR:9
Lymphocytes possess the essential components of a cholinergic system, including BC6ENTC ( BC6OTHER ); BC6OTHER acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both BC6ENTG ( BC6OTHER and BC6OTHER , respectively).	False
Lymphocytes possess the essential components of a cholinergic system, including BC6ENTC ( BC6OTHER ); BC6OTHER acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6ENTG and BC6OTHER , respectively).	False
Lymphocytes possess the essential components of a cholinergic system, including BC6ENTC ( BC6OTHER ); BC6OTHER acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6OTHER and BC6ENTG , respectively).	False
Anti - BC6ENTG monoclonal antibody (mAb) as well as antithymocyte BC6OTHER containing antibodies against BC6OTHER , BC6OTHER and BC6OTHER all increase BC6OTHER activity, BC6ENTC synthesis and release, and expression of BC6OTHER and BC6OTHER mRNAs in T cells.	False
Anti - BC6OTHER monoclonal antibody (mAb) as well as antithymocyte BC6ENTG containing antibodies against BC6OTHER , BC6OTHER and BC6OTHER all increase BC6OTHER activity, BC6ENTC synthesis and release, and expression of BC6OTHER and BC6OTHER mRNAs in T cells.	False
Anti - BC6OTHER monoclonal antibody (mAb) as well as antithymocyte BC6OTHER containing antibodies against BC6ENTG , BC6OTHER and BC6OTHER all increase BC6OTHER activity, BC6ENTC synthesis and release, and expression of BC6OTHER and BC6OTHER mRNAs in T cells.	False
Anti - BC6OTHER monoclonal antibody (mAb) as well as antithymocyte BC6OTHER containing antibodies against BC6OTHER , BC6ENTG and BC6OTHER all increase BC6OTHER activity, BC6ENTC synthesis and release, and expression of BC6OTHER and BC6OTHER mRNAs in T cells.	False
Anti - BC6OTHER monoclonal antibody (mAb) as well as antithymocyte BC6OTHER containing antibodies against BC6OTHER , BC6OTHER and BC6ENTG all increase BC6OTHER activity, BC6ENTC synthesis and release, and expression of BC6OTHER and BC6OTHER mRNAs in T cells.	False
Anti - BC6OTHER monoclonal antibody (mAb) as well as antithymocyte BC6OTHER containing antibodies against BC6OTHER , BC6OTHER and BC6OTHER all increase BC6ENTG activity, BC6ENTC synthesis and release, and expression of BC6OTHER and BC6OTHER mRNAs in T cells.	False
Anti - BC6OTHER monoclonal antibody (mAb) as well as antithymocyte BC6OTHER containing antibodies against BC6OTHER , BC6OTHER and BC6OTHER all increase BC6OTHER activity, BC6ENTC synthesis and release, and expression of BC6ENTG and BC6OTHER mRNAs in T cells.	False
Anti - BC6OTHER monoclonal antibody (mAb) as well as antithymocyte BC6OTHER containing antibodies against BC6OTHER , BC6OTHER and BC6OTHER all increase BC6OTHER activity, BC6ENTC synthesis and release, and expression of BC6OTHER and BC6ENTG mRNAs in T cells.	False
Quantitative analysis of the interaction of BC6ENTG with chemicals and BC6ENTC receptor coactivator 1 using surface plasmon resonance biosensor systems: a case study of the Baikal seal (Pusa sibirica) and the mouse.	False
BC6OTHER and BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER showed compound - specific but similar affinities for both BC6ENTG .	False
BC6OTHER and BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER showed compound - specific but similar affinities for both BC6ENTG .	False
BC6OTHER and BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER showed compound - specific but similar affinities for both BC6ENTG .	False
BC6OTHER and BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER showed compound - specific but similar affinities for both BC6ENTG .	False
BC6OTHER and BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC showed compound - specific but similar affinities for both BC6ENTG .	False
The constitutive BC6ENTC receptor ( BC6ENTG ) not only displays a high basal transcriptional activity but also acts as a ligand - dependent transcriptional factor.	False
The objectives of this study are to establish a high - throughput tool to screen BC6ENTG ligands and to clarify how BC6OTHER proteins from the Baikal seal ( BC6OTHER ) and the mouse ( BC6OTHER ) interact with chemicals and BC6ENTC receptor coactivator 1 ( BC6OTHER ).	False
The objectives of this study are to establish a high - throughput tool to screen BC6OTHER ligands and to clarify how BC6ENTG proteins from the Baikal seal ( BC6OTHER ) and the mouse ( BC6OTHER ) interact with chemicals and BC6ENTC receptor coactivator 1 ( BC6OTHER ).	False
The objectives of this study are to establish a high - throughput tool to screen BC6OTHER ligands and to clarify how BC6OTHER proteins from the Baikal seal ( BC6ENTG ) and the mouse ( BC6OTHER ) interact with chemicals and BC6ENTC receptor coactivator 1 ( BC6OTHER ).	False
The objectives of this study are to establish a high - throughput tool to screen BC6OTHER ligands and to clarify how BC6OTHER proteins from the Baikal seal ( BC6OTHER ) and the mouse ( BC6ENTG ) interact with chemicals and BC6ENTC receptor coactivator 1 ( BC6OTHER ).	False
The objectives of this study are to establish a high - throughput tool to screen BC6OTHER ligands and to clarify how BC6OTHER proteins from the Baikal seal ( BC6OTHER ) and the mouse ( BC6OTHER ) interact with chemicals and BC6ENTC receptor coactivator 1 ( BC6ENTG ).	False
BC6ENTC and BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER showed compound - specific but similar affinities for both BC6ENTG .	False
Quantitative analysis of the interaction of constitutive BC6ENTC receptor with chemicals and BC6ENTG using surface plasmon resonance biosensor systems: a case study of the Baikal seal (Pusa sibirica) and the mouse.	False
Thus, BC6ENTG antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as BC6ENTC .	CPR:6
It is currently not known how much this BC6ENTG antagonism of BC6ENTC contributes to the therapeutic or adverse side effects of BC6OTHER .	CPR:6
It is currently not known how much this BC6ENTG antagonism of BC6OTHER contributes to the therapeutic or adverse side effects of BC6ENTC .	False
The current studies with Sprague - Dawley rats were conducted to determine the participation of BC6ENTG subtype in sensorimotor plasticity and memory function affected by BC6ENTC using tests of prepulse inhibition (PPI) and radial - arm maze choice accuracy.	False
In the current project, we found that the selective BC6ENTG antagonist BC6ENTC also reversed the BC6OTHER - induced impairment in PPI of tactile startle with an auditory prepulse.	CPR:6
In the current project, we found that the selective BC6ENTG antagonist BC6OTHER also reversed the BC6ENTC - induced impairment in PPI of tactile startle with an auditory prepulse.	CPR:3
 BC6ENTG involvement in prepulse inhibition and memory function: relevance for the antipsychotic actions of BC6ENTC .	False
BC6ENTG blockade is one of the more prominent actions of the multi - receptor acting antipsychotic BC6ENTC .	CPR:4
In summary, the therapeutic effect of BC6ENTC in reversing PPI impairment was mimicked by the BC6ENTG antagonist BC6OTHER , while BC6OTHER had a mixed effect on cognition.	CPR:4
In summary, the therapeutic effect of BC6OTHER in reversing PPI impairment was mimicked by the BC6ENTG antagonist BC6ENTC , while BC6OTHER had a mixed effect on cognition.	CPR:6
In summary, the therapeutic effect of BC6OTHER in reversing PPI impairment was mimicked by the BC6ENTG antagonist BC6OTHER , while BC6ENTC had a mixed effect on cognition.	CPR:6
UNLABELLED: BC6ENTC is a BC6ENTG antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.	CPR:6
Evidence has been obtained in man for interaction with BC6ENTG in the brain; and in the peripheral circulation BC6ENTC does not, as do other beta blockers, increase peripheral vascular resistance, but reduces it.	False
It is suggested that all the additional actions of BC6ENTC can be attributed to a partial agonist action on BC6ENTG .	CPR:5
 BC6ENTC : a BC6ENTG antagonist with unique additional actions.	CPR:6
Inhibition of the BC6OTHER pathway was responsible for this effect since the BC6ENTC inhibited BC6OTHER - induced BC6ENTG activation, activation of BC6OTHER ( BC6OTHER ) and suppressed inhibitor of BC6OTHER ( BC6OTHER ) phosphorylation and degradation, an inhibitor of BC6OTHER .	CPR:4
Inhibition of the BC6OTHER pathway was responsible for this effect since the BC6ENTC inhibited BC6OTHER - induced BC6OTHER activation, activation of BC6ENTG ( BC6OTHER ) and suppressed inhibitor of BC6OTHER ( BC6OTHER ) phosphorylation and degradation, an inhibitor of BC6OTHER .	CPR:4
Inhibition of the BC6OTHER pathway was responsible for this effect since the BC6ENTC inhibited BC6OTHER - induced BC6OTHER activation, activation of BC6OTHER ( BC6ENTG ) and suppressed inhibitor of BC6OTHER ( BC6OTHER ) phosphorylation and degradation, an inhibitor of BC6OTHER .	CPR:4
Inhibition of the BC6OTHER pathway was responsible for this effect since the BC6ENTC inhibited BC6OTHER - induced BC6OTHER activation, activation of BC6OTHER ( BC6OTHER ) and suppressed inhibitor of BC6ENTG ( BC6OTHER ) phosphorylation and degradation, an inhibitor of BC6OTHER .	CPR:4
Inhibition of the BC6OTHER pathway was responsible for this effect since the BC6ENTC inhibited BC6OTHER - induced BC6OTHER activation, activation of BC6OTHER ( BC6OTHER ) and suppressed inhibitor of BC6OTHER ( BC6ENTG ) phosphorylation and degradation, an inhibitor of BC6OTHER .	CPR:4
Inhibition of the BC6OTHER pathway was responsible for this effect since the BC6ENTC inhibited BC6OTHER - induced BC6OTHER activation, activation of BC6OTHER ( BC6OTHER ) and suppressed inhibitor of BC6OTHER ( BC6OTHER ) phosphorylation and degradation, an inhibitor of BC6ENTG .	CPR:4
Inhibition of the BC6ENTG pathway was responsible for this effect since the BC6ENTC inhibited BC6OTHER - induced BC6OTHER activation, activation of BC6OTHER ( BC6OTHER ) and suppressed inhibitor of BC6OTHER ( BC6OTHER ) phosphorylation and degradation, an inhibitor of BC6OTHER .	False
Inhibition of the BC6OTHER pathway was responsible for this effect since the BC6ENTC inhibited BC6ENTG - induced BC6OTHER activation, activation of BC6OTHER ( BC6OTHER ) and suppressed inhibitor of BC6OTHER ( BC6OTHER ) phosphorylation and degradation, an inhibitor of BC6OTHER .	CPR:4
CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that BC6ENTC significantly suppressed osteoclastogenesis induced by BC6ENTG and tumour cells via the BC6OTHER signalling pathway.	CPR:4
CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that BC6ENTC significantly suppressed osteoclastogenesis induced by BC6OTHER and tumour cells via the BC6ENTG signalling pathway.	CPR:4
To search for an inhibitor of cancer - induced bone loss, we investigated the effect of BC6ENTC , a semi - synthetic BC6OTHER derived from the plant Gloriosa CHEM and clinically used as a muscle relaxant, on osteoclastogenesis induced by BC6ENTG ( BC6OTHER ) and tumour cells.	False
To search for an inhibitor of cancer - induced bone loss, we investigated the effect of BC6ENTC , a semi - synthetic BC6OTHER derived from the plant Gloriosa CHEM and clinically used as a muscle relaxant, on osteoclastogenesis induced by BC6OTHER ( BC6ENTG ) and tumour cells.	False
To search for an inhibitor of cancer - induced bone loss, we investigated the effect of BC6OTHER , a semi - synthetic BC6ENTC derived from the plant Gloriosa CHEM and clinically used as a muscle relaxant, on osteoclastogenesis induced by BC6ENTG ( BC6OTHER ) and tumour cells.	False
To search for an inhibitor of cancer - induced bone loss, we investigated the effect of BC6OTHER , a semi - synthetic BC6ENTC derived from the plant Gloriosa CHEM and clinically used as a muscle relaxant, on osteoclastogenesis induced by BC6OTHER ( BC6ENTG ) and tumour cells.	False
EXPERIMENTAL APPROACH: We used RAW 264.7 (murine macrophage) cells, a well - established system for osteoclastogenesis, and evaluated the effect of BC6ENTC on BC6ENTG - induced BC6OTHER signalling and osteoclastogenesis as well as on osteoclastogenesis induced by tumour cells.	False
EXPERIMENTAL APPROACH: We used RAW 264.7 (murine macrophage) cells, a well - established system for osteoclastogenesis, and evaluated the effect of BC6ENTC on BC6OTHER - induced BC6ENTG signalling and osteoclastogenesis as well as on osteoclastogenesis induced by tumour cells.	False
KEY RESULTS: BC6ENTC suppressed osteoclastogenesis induced by BC6ENTG , and by breast cancer and multiple myeloma cells.	False
 BC6ENTC suppresses osteoclastogenesis induced by BC6ENTG and cancer cells through inhibition of inflammatory pathways: a new use for an old drug.	False
Our findings that BC6OTHER / BC6ENTC target both BC6ENTG and BC6OTHER may have implications for understanding the impact of nitrosylation on cellular redox homeostasis.	False
Our findings that BC6OTHER / BC6ENTC target both BC6OTHER and BC6ENTG may have implications for understanding the impact of nitrosylation on cellular redox homeostasis.	False
In this study we investigated how BC6ENTC / BC6OTHER may affect the redox cycle of BC6ENTG ( BC6OTHER ), a representative of the 2 - BC6OTHER Prxs, a group of BC6OTHER ( BC6OTHER ) - dependent BC6OTHER .	False
In this study we investigated how BC6ENTC / BC6OTHER may affect the redox cycle of BC6OTHER ( BC6ENTG ), a representative of the 2 - BC6OTHER Prxs, a group of BC6OTHER ( BC6OTHER ) - dependent BC6OTHER .	False
In this study we investigated how BC6ENTC / BC6OTHER may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the BC6ENTG , a group of BC6OTHER ( BC6OTHER ) - dependent BC6OTHER .	False
In this study we investigated how BC6ENTC / BC6OTHER may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the 2 - BC6OTHER Prxs, a group of BC6ENTG ( BC6OTHER ) - dependent BC6OTHER .	False
In this study we investigated how BC6ENTC / BC6OTHER may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the 2 - BC6OTHER Prxs, a group of BC6OTHER ( BC6ENTG ) - dependent BC6OTHER .	False
In this study we investigated how BC6ENTC / BC6OTHER may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the 2 - BC6OTHER Prxs, a group of BC6OTHER ( BC6OTHER ) - dependent BC6ENTG .	False
In this study we investigated how BC6OTHER / BC6ENTC may affect the redox cycle of BC6ENTG ( BC6OTHER ), a representative of the 2 - BC6OTHER Prxs, a group of BC6OTHER ( BC6OTHER ) - dependent BC6OTHER .	False
In this study we investigated how BC6OTHER / BC6ENTC may affect the redox cycle of BC6OTHER ( BC6ENTG ), a representative of the 2 - BC6OTHER Prxs, a group of BC6OTHER ( BC6OTHER ) - dependent BC6OTHER .	False
In this study we investigated how BC6OTHER / BC6ENTC may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the BC6ENTG , a group of BC6OTHER ( BC6OTHER ) - dependent BC6OTHER .	False
In this study we investigated how BC6OTHER / BC6ENTC may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the 2 - BC6OTHER Prxs, a group of BC6ENTG ( BC6OTHER ) - dependent BC6OTHER .	False
In this study we investigated how BC6OTHER / BC6ENTC may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the 2 - BC6OTHER Prxs, a group of BC6OTHER ( BC6ENTG ) - dependent BC6OTHER .	False
In this study we investigated how BC6OTHER / BC6ENTC may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the 2 - BC6OTHER Prxs, a group of BC6OTHER ( BC6OTHER ) - dependent BC6ENTG .	False
In this study we investigated how BC6OTHER / BC6OTHER may affect the redox cycle of BC6ENTG ( BC6OTHER ), a representative of the 2 - BC6ENTC Prxs, a group of BC6OTHER ( BC6OTHER ) - dependent BC6OTHER .	False
In this study we investigated how BC6OTHER / BC6OTHER may affect the redox cycle of BC6OTHER ( BC6ENTG ), a representative of the 2 - BC6ENTC Prxs, a group of BC6OTHER ( BC6OTHER ) - dependent BC6OTHER .	False
In this study we investigated how BC6OTHER / BC6OTHER may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the 2 - BC6ENTC Prxs, a group of BC6ENTG ( BC6OTHER ) - dependent BC6OTHER .	False
In this study we investigated how BC6OTHER / BC6OTHER may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the 2 - BC6ENTC Prxs, a group of BC6OTHER ( BC6ENTG ) - dependent BC6OTHER .	False
In this study we investigated how BC6OTHER / BC6OTHER may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the 2 - BC6ENTC Prxs, a group of BC6OTHER ( BC6OTHER ) - dependent BC6ENTG .	False
We found that, both in a cell - free system and in cells, BC6ENTC / BC6OTHER donors such as BC6OTHER and BC6OTHER readily induced the BC6OTHER - nitrosylation of BC6ENTG , causing structural and functional alterations.	False
We found that, both in a cell - free system and in cells, BC6OTHER / BC6ENTC donors such as BC6OTHER and BC6OTHER readily induced the BC6OTHER - nitrosylation of BC6ENTG , causing structural and functional alterations.	False
We found that, both in a cell - free system and in cells, BC6OTHER / BC6OTHER donors such as BC6ENTC and BC6OTHER readily induced the BC6OTHER - nitrosylation of BC6ENTG , causing structural and functional alterations.	False
We found that, both in a cell - free system and in cells, BC6OTHER / BC6OTHER donors such as BC6OTHER and BC6ENTC readily induced the BC6OTHER - nitrosylation of BC6ENTG , causing structural and functional alterations.	False
We found that, both in a cell - free system and in cells, BC6OTHER / BC6OTHER donors such as BC6OTHER and BC6OTHER readily induced the BC6ENTC - nitrosylation of BC6ENTG , causing structural and functional alterations.	False
In particular, nitrosylation promoted BC6ENTC formation involving the pair of catalytic BC6OTHER ( BC6OTHER - 52 and BC6OTHER - 173) and disrupted the oligomeric structure of BC6ENTG , leading to loss of BC6OTHER activity.	False
In particular, nitrosylation promoted BC6ENTC formation involving the pair of catalytic BC6OTHER ( BC6OTHER - 52 and BC6OTHER - 173) and disrupted the oligomeric structure of BC6OTHER , leading to loss of BC6ENTG activity.	False
In particular, nitrosylation promoted BC6OTHER formation involving the pair of catalytic BC6ENTC ( BC6OTHER - 52 and BC6OTHER - 173) and disrupted the oligomeric structure of BC6ENTG , leading to loss of BC6OTHER activity.	False
In particular, nitrosylation promoted BC6OTHER formation involving the pair of catalytic BC6ENTC ( BC6OTHER - 52 and BC6OTHER - 173) and disrupted the oligomeric structure of BC6OTHER , leading to loss of BC6ENTG activity.	False
In particular, nitrosylation promoted BC6OTHER formation involving the pair of catalytic BC6OTHER ( BC6ENTC - 52 and BC6OTHER - 173) and disrupted the oligomeric structure of BC6ENTG , leading to loss of BC6OTHER activity.	False
In particular, nitrosylation promoted BC6OTHER formation involving the pair of catalytic BC6OTHER ( BC6ENTC - 52 and BC6OTHER - 173) and disrupted the oligomeric structure of BC6OTHER , leading to loss of BC6ENTG activity.	False
In particular, nitrosylation promoted BC6OTHER formation involving the pair of catalytic BC6OTHER ( BC6OTHER - 52 and BC6ENTC - 173) and disrupted the oligomeric structure of BC6ENTG , leading to loss of BC6OTHER activity.	False
In particular, nitrosylation promoted BC6OTHER formation involving the pair of catalytic BC6OTHER ( BC6OTHER - 52 and BC6ENTC - 173) and disrupted the oligomeric structure of BC6OTHER , leading to loss of BC6ENTG activity.	False
A highly potent inhibition of the BC6ENTG catalytic reaction by BC6ENTC / BC6OTHER was seen in assays employing the coupled BC6OTHER - BC6OTHER system.	CPR:4
A highly potent inhibition of the BC6OTHER catalytic reaction by BC6ENTC / BC6OTHER was seen in assays employing the coupled BC6ENTG - BC6OTHER system.	False
A highly potent inhibition of the BC6OTHER catalytic reaction by BC6ENTC / BC6OTHER was seen in assays employing the coupled BC6OTHER - BC6ENTG system.	False
A highly potent inhibition of the BC6ENTG catalytic reaction by BC6OTHER / BC6ENTC was seen in assays employing the coupled BC6OTHER - BC6OTHER system.	CPR:4
A highly potent inhibition of the BC6OTHER catalytic reaction by BC6OTHER / BC6ENTC was seen in assays employing the coupled BC6ENTG - BC6OTHER system.	False
A highly potent inhibition of the BC6OTHER catalytic reaction by BC6OTHER / BC6ENTC was seen in assays employing the coupled BC6OTHER - BC6ENTG system.	False
In this setting, BC6ENTC (10 μm) effectively blocked the BC6ENTG - mediated regeneration of BC6OTHER .	CPR:4
In this setting, BC6ENTC (10 μm) effectively blocked the BC6OTHER - mediated regeneration of BC6ENTG .	CPR:4
This effect appeared to be due to both competition between BC6ENTC and BC6ENTG for the BC6OTHER system and direct modulation by BC6OTHER of BC6OTHER activity.	False
This effect appeared to be due to both competition between BC6ENTC and BC6OTHER for the BC6ENTG system and direct modulation by BC6OTHER of BC6OTHER activity.	False
This effect appeared to be due to both competition between BC6ENTC and BC6OTHER for the BC6OTHER system and direct modulation by BC6OTHER of BC6ENTG activity.	False
This effect appeared to be due to both competition between BC6OTHER and BC6ENTG for the BC6OTHER system and direct modulation by BC6ENTC of BC6OTHER activity.	False
This effect appeared to be due to both competition between BC6OTHER and BC6OTHER for the BC6ENTG system and direct modulation by BC6ENTC of BC6OTHER activity.	False
This effect appeared to be due to both competition between BC6OTHER and BC6OTHER for the BC6OTHER system and direct modulation by BC6ENTC of BC6ENTG activity.	False
Our findings that BC6ENTC / BC6OTHER target both BC6ENTG and BC6OTHER may have implications for understanding the impact of nitrosylation on cellular redox homeostasis.	False
Our findings that BC6ENTC / BC6OTHER target both BC6OTHER and BC6ENTG may have implications for understanding the impact of nitrosylation on cellular redox homeostasis.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTC ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTC ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTC ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTC ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTC ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) specific for BC6ENTG kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) specific for BC6ENTG kinase.	CPR:4
The following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
The following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
The following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
The following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
BC6ENTC kinases ( BC6ENTG ) are attractive targets for cancer therapy, as quite often their abnormal signaling has been linked with tumor development and growth.	False
The following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
The following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
The following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
The following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
The following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
The following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
The following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6ENTC ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
The following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6ENTC ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
The following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6ENTC , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
The following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6ENTC ), and BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6ENTC ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6ENTC ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6ENTC ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6ENTC ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6ENTC ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase.	False
The following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6ENTC ( BC6OTHER , BC6OTHER ).	CPR:4
The following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6ENTC , BC6OTHER ).	CPR:4
The following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6ENTC ).	CPR:4
During the last few years, thorough analysis of the mechanism underlying BC6ENTC kinase's activity led to novel cancer therapy using BC6ENTG blockers.	False
The most successful example of BC6ENTG blockers is BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ), the inhibitor of BC6OTHER / BC6OTHER oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia.	CPR:4
The most successful example of BC6OTHER blockers is BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ), the inhibitor of BC6ENTG / BC6OTHER oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia.	CPR:4
The most successful example of BC6OTHER blockers is BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ), the inhibitor of BC6OTHER / BC6ENTG oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia.	CPR:4
The most successful example of BC6ENTG blockers is BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ), the inhibitor of BC6OTHER / BC6OTHER oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia.	CPR:4
The most successful example of BC6OTHER blockers is BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ), the inhibitor of BC6ENTG / BC6OTHER oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia.	CPR:4
The most successful example of BC6OTHER blockers is BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ), the inhibitor of BC6OTHER / BC6ENTG oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia.	CPR:4
The most successful example of BC6ENTG blockers is BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ), the inhibitor of BC6OTHER / BC6OTHER oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia.	CPR:4
The most successful example of BC6OTHER blockers is BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ), the inhibitor of BC6ENTG / BC6OTHER oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia.	CPR:4
The most successful example of BC6OTHER blockers is BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ), the inhibitor of BC6OTHER / BC6ENTG oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia.	CPR:4
The most successful example of BC6ENTG blockers is BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ), the inhibitor of BC6OTHER / BC6OTHER oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia.	CPR:4
The most successful example of BC6OTHER blockers is BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ), the inhibitor of BC6ENTG / BC6OTHER oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia.	CPR:4
The most successful example of BC6OTHER blockers is BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ), the inhibitor of BC6OTHER / BC6ENTG oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6ENTC ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6ENTC ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6ENTC ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6ENTC ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6ENTC ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTC ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTC ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	False
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTC ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTC ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase.	CPR:4
Others kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTC ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase.	False
Extracellular BC6OTHER (protein bound and free) and intracellular BC6OTHER (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6OTHER ( BC6ENTC ) bound to BC6ENTG ( BC6OTHER , BC6OTHER ).	False
Extracellular BC6OTHER (protein bound and free) and intracellular BC6OTHER (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6OTHER ( BC6ENTC ) bound to BC6OTHER ( BC6ENTG , BC6OTHER ).	False
Extracellular BC6OTHER (protein bound and free) and intracellular BC6OTHER (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6OTHER ( BC6ENTC ) bound to BC6OTHER ( BC6OTHER , BC6ENTG ).	False
Intracellular protein - bound BC6ENTC fractionated with BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activity.	False
Intracellular protein - bound BC6ENTC fractionated with BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activity.	False
Intracellular protein - bound BC6ENTC fractionated with BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activity.	False
Intracellular protein - bound BC6ENTC fractionated with BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activity.	False
Intracellular protein - bound BC6OTHER fractionated with BC6ENTC synthase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activity.	False
Intracellular protein - bound BC6OTHER fractionated with BC6ENTC synthase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activity.	False
Intracellular protein - bound BC6OTHER fractionated with BC6ENTC synthase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activity.	False
Intracellular protein - bound BC6OTHER fractionated with BC6ENTG ( BC6OTHER ) and BC6ENTC mutase ( BC6OTHER ) activity.	False
Intracellular protein - bound BC6OTHER fractionated with BC6OTHER ( BC6ENTG ) and BC6ENTC mutase ( BC6OTHER ) activity.	False
Intracellular protein - bound BC6OTHER fractionated with BC6OTHER ( BC6OTHER ) and BC6ENTC mutase ( BC6ENTG ) activity.	False
Cells propagated in medium containing BC6ENTC and BC6OTHER showed a substantial increase in BC6ENTG activity which paralleled the increase in the intracellular concentration of BC6OTHER and the BC6OTHER bound to the enzyme.	CPR:3
Cells propagated in medium containing BC6OTHER and BC6ENTC showed a substantial increase in BC6ENTG activity which paralleled the increase in the intracellular concentration of BC6OTHER and the BC6OTHER bound to the enzyme.	CPR:3
Cells propagated in medium containing BC6OTHER and BC6OTHER showed a substantial increase in BC6ENTG activity which paralleled the increase in the intracellular concentration of BC6ENTC and the BC6OTHER bound to the enzyme.	False
Cells propagated in medium containing BC6OTHER and BC6OTHER showed a substantial increase in BC6ENTG activity which paralleled the increase in the intracellular concentration of BC6OTHER and the BC6ENTC bound to the enzyme.	False
Extracellular BC6ENTC (protein bound and free) and intracellular BC6OTHER (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6OTHER ( BC6OTHER ) bound to BC6ENTG ( BC6OTHER , BC6OTHER ).	False
Extracellular BC6ENTC (protein bound and free) and intracellular BC6OTHER (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6OTHER ( BC6OTHER ) bound to BC6OTHER ( BC6ENTG , BC6OTHER ).	False
Extracellular BC6ENTC (protein bound and free) and intracellular BC6OTHER (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6OTHER ( BC6OTHER ) bound to BC6OTHER ( BC6OTHER , BC6ENTG ).	False
Extracellular BC6OTHER (protein bound and free) and intracellular BC6ENTC (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6OTHER ( BC6OTHER ) bound to BC6ENTG ( BC6OTHER , BC6OTHER ).	False
Extracellular BC6OTHER (protein bound and free) and intracellular BC6ENTC (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6OTHER ( BC6OTHER ) bound to BC6OTHER ( BC6ENTG , BC6OTHER ).	False
Extracellular BC6OTHER (protein bound and free) and intracellular BC6ENTC (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6OTHER ( BC6OTHER ) bound to BC6OTHER ( BC6OTHER , BC6ENTG ).	False
Extracellular BC6OTHER (protein bound and free) and intracellular BC6OTHER (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6ENTC ( BC6OTHER ) bound to BC6ENTG ( BC6OTHER , BC6OTHER ).	False
Extracellular BC6OTHER (protein bound and free) and intracellular BC6OTHER (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6ENTC ( BC6OTHER ) bound to BC6OTHER ( BC6ENTG , BC6OTHER ).	False
Extracellular BC6OTHER (protein bound and free) and intracellular BC6OTHER (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6ENTC ( BC6OTHER ) bound to BC6OTHER ( BC6OTHER , BC6ENTG ).	False
BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6ENTC (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6ENTC (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6ENTC (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6ENTC (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6ENTC ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6ENTC ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6ENTC ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6ENTC ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTC reductase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTC reductase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTC reductase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6ENTC peroxidase ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6ENTC peroxidase ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTC peroxidase ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6ENTC - Px) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6ENTC - Px) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6ENTC - Px) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6ENTC ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6ENTC ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6ENTC ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6ENTC ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6ENTC ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6ENTC ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6ENTC ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6ENTC ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6ENTC ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6ENTC ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6ENTC ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6ENTC ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6ENTC ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6ENTC ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6ENTC ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6ENTC ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured.	False
BC6ENTC and total - BC6OTHER content, BC6OTHER / BC6OTHER ratio, BC6ENTG activity significantly decreased in cerebral cortex of rats, coupling with the increase of BC6OTHER level.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6ENTC modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6ENTC modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6ENTC modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6ENTC modified proteins in homogenates of cerebral cortex were measured.	False
BC6OTHER and total - BC6ENTC content, BC6OTHER / BC6OTHER ratio, BC6ENTG activity significantly decreased in cerebral cortex of rats, coupling with the increase of BC6OTHER level.	False
BC6OTHER and total - BC6OTHER content, BC6ENTC / BC6OTHER ratio, BC6ENTG activity significantly decreased in cerebral cortex of rats, coupling with the increase of BC6OTHER level.	False
BC6OTHER and total - BC6OTHER content, BC6OTHER / BC6ENTC ratio, BC6ENTG activity significantly decreased in cerebral cortex of rats, coupling with the increase of BC6OTHER level.	False
BC6OTHER and total - BC6OTHER content, BC6OTHER / BC6OTHER ratio, BC6ENTG activity significantly decreased in cerebral cortex of rats, coupling with the increase of BC6ENTC level.	False
Nevertheless, BC6ENTG is involved in the expression of genes that control BC6ENTC and lipid metabolism and is an important target for drugs against type 2 diabetes, dyslipidemia, atherosclerosis, and cardiovascular disease.	False
Full agonists to the BC6ENTG , such as BC6ENTC , have been associated with a series of undesired side effects, such as weight gain, fluid retention, cardiac hypertrophy, and hepatotoxicity.	CPR:5
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6ENTG - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6ENTG ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6ENTG - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6ENTG ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6ENTG - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6ENTG ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of BC6ENTG ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6ENTG , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6ENTG ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6ENTG - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6ENTG ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6ENTG agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTG modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6ENTG - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6ENTG ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6ENTG - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6ENTG ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6ENTG - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6ENTG ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of BC6ENTG ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6ENTG , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6ENTG ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6ENTG - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6ENTG ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6ENTG agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTG modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6ENTG - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6ENTG ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6ENTG - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6ENTG ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6ENTG - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6ENTG ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of BC6ENTG ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6ENTG , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6ENTG ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6ENTG - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6ENTG ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6ENTG agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTG modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6ENTG - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6ENTG ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6ENTG - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6ENTG ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6ENTG - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6ENTG ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6ENTG , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6ENTG ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6ENTG - BC6OTHER ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6ENTG ) or BC6OTHER agonist in PPC.	False
Results from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6ENTG agonist in PPC.	False
"The recently discovered BC6ENTC enzyme "" BC6ENTG "" ( BC6OTHER ) catalyses together with its BC6OTHER BC6OTHER and BC6OTHER the reduction of BC6OTHER - hydroxylated prodrugs."	False
"The recently discovered BC6ENTC enzyme ""mitochondrial BC6OTHER Reducing Component"" ( BC6ENTG ) catalyses together with its BC6OTHER BC6OTHER and BC6OTHER the reduction of BC6OTHER - hydroxylated prodrugs."	False
"The recently discovered BC6ENTC enzyme ""mitochondrial BC6OTHER Reducing Component"" ( BC6OTHER ) catalyses together with its BC6ENTG BC6OTHER and BC6OTHER the reduction of BC6OTHER - hydroxylated prodrugs."	False
"The recently discovered BC6ENTC enzyme ""mitochondrial BC6OTHER Reducing Component"" ( BC6OTHER ) catalyses together with its BC6OTHER BC6ENTG and BC6OTHER the reduction of BC6OTHER - hydroxylated prodrugs."	False
"The recently discovered BC6ENTC enzyme ""mitochondrial BC6OTHER Reducing Component"" ( BC6OTHER ) catalyses together with its BC6OTHER BC6OTHER and BC6ENTG the reduction of BC6OTHER - hydroxylated prodrugs."	False
"The recently discovered BC6OTHER enzyme ""mitochondrial BC6ENTC Reducing Component"" ( BC6ENTG ) catalyses together with its BC6OTHER BC6OTHER and BC6OTHER the reduction of BC6OTHER - hydroxylated prodrugs."	False
"The recently discovered BC6OTHER enzyme ""mitochondrial BC6ENTC Reducing Component"" ( BC6OTHER ) catalyses together with its BC6ENTG BC6OTHER and BC6OTHER the reduction of BC6OTHER - hydroxylated prodrugs."	False
"The recently discovered BC6OTHER enzyme ""mitochondrial BC6ENTC Reducing Component"" ( BC6OTHER ) catalyses together with its BC6OTHER BC6ENTG and BC6OTHER the reduction of BC6OTHER - hydroxylated prodrugs."	False
"The recently discovered BC6OTHER enzyme ""mitochondrial BC6ENTC Reducing Component"" ( BC6OTHER ) catalyses together with its BC6OTHER BC6OTHER and BC6ENTG the reduction of BC6OTHER - hydroxylated prodrugs."	False
"The recently discovered BC6OTHER enzyme "" BC6ENTG "" ( BC6OTHER ) catalyses together with its BC6OTHER BC6OTHER and BC6ENTC cytochrome b(5) reductase the reduction of BC6OTHER - hydroxylated prodrugs."	False
"The recently discovered BC6OTHER enzyme ""mitochondrial BC6OTHER Reducing Component"" ( BC6ENTG ) catalyses together with its BC6OTHER BC6OTHER and BC6ENTC cytochrome b(5) reductase the reduction of BC6OTHER - hydroxylated prodrugs."	False
"The recently discovered BC6OTHER enzyme ""mitochondrial BC6OTHER Reducing Component"" ( BC6OTHER ) catalyses together with its BC6ENTG BC6OTHER and BC6ENTC cytochrome b(5) reductase the reduction of BC6OTHER - hydroxylated prodrugs."	False
"The recently discovered BC6OTHER enzyme ""mitochondrial BC6OTHER Reducing Component"" ( BC6OTHER ) catalyses together with its BC6OTHER BC6ENTG and BC6ENTC cytochrome b(5) reductase the reduction of BC6OTHER - hydroxylated prodrugs."	False
"The recently discovered BC6OTHER enzyme "" BC6ENTG "" ( BC6OTHER ) catalyses together with its BC6OTHER BC6OTHER and BC6OTHER the reduction of BC6ENTC - hydroxylated prodrugs."	False
"The recently discovered BC6OTHER enzyme ""mitochondrial BC6OTHER Reducing Component"" ( BC6ENTG ) catalyses together with its BC6OTHER BC6OTHER and BC6OTHER the reduction of BC6ENTC - hydroxylated prodrugs."	False
"The recently discovered BC6OTHER enzyme ""mitochondrial BC6OTHER Reducing Component"" ( BC6OTHER ) catalyses together with its BC6ENTG BC6OTHER and BC6OTHER the reduction of BC6ENTC - hydroxylated prodrugs."	False
"The recently discovered BC6OTHER enzyme ""mitochondrial BC6OTHER Reducing Component"" ( BC6OTHER ) catalyses together with its BC6OTHER BC6ENTG and BC6OTHER the reduction of BC6ENTC - hydroxylated prodrugs."	False
"The recently discovered BC6OTHER enzyme ""mitochondrial BC6OTHER Reducing Component"" ( BC6OTHER ) catalyses together with its BC6OTHER BC6OTHER and BC6ENTG the reduction of BC6ENTC - hydroxylated prodrugs."	False
In vitro biotransformation assays with porcine subcellular fractions and the reconstituted human enzymes demonstrate an BC6ENTG - dependent BC6ENTC - reduction of BC6OTHER .	False
Activation of the anti - cancer agent BC6ENTC by the BC6ENTG enzyme system.	False
In vitro biotransformation assays with porcine subcellular fractions and the reconstituted human enzymes demonstrate an BC6ENTG - dependent BC6OTHER - reduction of BC6ENTC .	False
BC6ENTC ( BC6OTHER ®) is a new small molecule BC6ENTG inhibitor.	CPR:4
BC6OTHER ( BC6ENTC ®) is a new small molecule BC6ENTG inhibitor.	CPR:4
The effect of BC6ENTC level on this end - point was modulated by the BC6ENTG genotype (P for interaction = 0.02), with TT cells grown at low BC6OTHER concentration apparently resistant to the induction of radiation - induced bridges.	False
The effect of BC6OTHER level on this end - point was modulated by the BC6ENTG genotype (P for interaction = 0.02), with TT cells grown at low BC6ENTC concentration apparently resistant to the induction of radiation - induced bridges.	False
The BC6ENTG polymorphism of the BC6ENTC reductase ( BC6OTHER ) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on BC6OTHER status.	False
The BC6OTHER polymorphism of the BC6ENTC reductase ( BC6ENTG ) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on BC6OTHER status.	False
The BC6ENTG polymorphism of the BC6OTHER ( BC6OTHER ) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on BC6ENTC status.	False
The BC6OTHER polymorphism of the BC6ENTG ( BC6OTHER ) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on BC6ENTC status.	False
The BC6OTHER polymorphism of the BC6OTHER ( BC6ENTG ) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on BC6ENTC status.	False
In this work the effect of BC6ENTC deficiency on genome stability and radiosensitivity has been investigated in cultured lymphocytes of 12 subjects with different BC6ENTG genotype (four for each genotype).	False
Effects of BC6ENTC deficiency and BC6ENTG BC6OTHER polymorphism on spontaneous and radiation - induced micronuclei in human lymphocytes.	False
Effects of BC6ENTC deficiency and BC6OTHER BC6ENTG polymorphism on spontaneous and radiation - induced micronuclei in human lymphocytes.	False
The results obtained indicate that BC6ENTC deficiency induces to a comparable extent chromosome loss and breakage, irrespective of the BC6ENTG genotype.	False
Also nucleoplasmic bridges and buds were significantly increased under low BC6ENTC supply; the increase in bridges was mainly observed in TT cells, highlighting a significant effect of the BC6ENTG genotype (P = 0.006) on this biomarker.	False
BC6ENTC concentration significantly affected radiation - induced micronuclei (P < 0.001): the increased incidence of radiation - induced micronuclei with low BC6OTHER was mainly accounted for by carriers of the variant BC6ENTG allele (both homozygotes and heterozygotes), but the overall effect of genotype did not attain statistical significance.	False
BC6OTHER concentration significantly affected radiation - induced micronuclei (P < 0.001): the increased incidence of radiation - induced micronuclei with low BC6ENTC was mainly accounted for by carriers of the variant BC6ENTG allele (both homozygotes and heterozygotes), but the overall effect of genotype did not attain statistical significance.	False
A cDNA clone similar to human BC6ENTC dehydratase ( BC6ENTG ) is deposited in the GenBank / EMBL databases, but its structural and functional bases remain unknown.	False
The purified protein showed BC6ENTC and BC6OTHER dehydratase activity, demonstrating to be an isoform of BC6ENTG .	False
The purified protein showed BC6OTHER and BC6ENTC dehydratase activity, demonstrating to be an isoform of BC6ENTG .	False
Removal of CHEM128 from the hepatic BC6ENTG consisting of 328 residues, which is missing in the corresponding position of the isoform consisting of 329 residues, significantly changed the Michaelis constants and Kd value for BC6ENTC , whereas addition of a BC6OTHER residue to the isoform was without effect.	False
Removal of CHEM128 from the hepatic BC6ENTG consisting of 328 residues, which is missing in the corresponding position of the isoform consisting of 329 residues, significantly changed the Michaelis constants and Kd value for BC6OTHER , whereas addition of a BC6ENTC residue to the isoform was without effect.	False
 BC6OTHER and nonsteroidal anti - inflammatory drugs induce conformational changes in the human BC6ENTC synthase - 2 ( BC6ENTG ).	False
By using the technique of site - directed spin labeling combined with EPR spectroscopy, we have observed that binding of BC6ENTC and nonsteroidal anti - inflammatory drugs induces conformational changes in the BC6ENTG ( BC6OTHER ).	False
By using the technique of site - directed spin labeling combined with EPR spectroscopy, we have observed that binding of BC6ENTC and nonsteroidal anti - inflammatory drugs induces conformational changes in the human BC6OTHER synthase enzyme ( BC6ENTG ).	False
Proteolysis protection assays had previously provided circumstantial evidence that binding of CHEM and non - BC6ENTC anti - inflammatory drugs alters the conformation of BC6ENTG , but the present experiments are the first to directly measure such changes.	False
The finding that BC6ENTC can also induce a conformational change in BC6ENTG was unexpected, and the magnitude of changes suggests this structural flexibility may be integral to the BC6OTHER catalytic mechanism.	False
The finding that BC6ENTC can also induce a conformational change in BC6OTHER was unexpected, and the magnitude of changes suggests this structural flexibility may be integral to the BC6ENTG catalytic mechanism.	False
By using the technique of site - directed spin labeling combined with EPR spectroscopy, we have observed that binding of BC6OTHER and nonsteroidal anti - inflammatory drugs induces conformational changes in the human BC6ENTC synthase enzyme ( BC6ENTG ).	False
Line shape broadening resulting from spin - spin coupling of BC6ENTC pairs introduced into the membrane - binding helices of BC6ENTG was used to calculate the inter - helical distances and changes in these distances that occur in response to binding various ligands.	False
However, inter - helical distances calculated and determined by EPR for BC6ENTG complexed with BC6ENTC , BC6OTHER , and BC6OTHER were in close agreement with those obtained from the cognate crystal structures.	False
However, inter - helical distances calculated and determined by EPR for BC6ENTG complexed with BC6OTHER , BC6ENTC , and BC6OTHER were in close agreement with those obtained from the cognate crystal structures.	False
However, inter - helical distances calculated and determined by EPR for BC6ENTG complexed with BC6OTHER , BC6OTHER , and BC6ENTC were in close agreement with those obtained from the cognate crystal structures.	False
 BC6ENTC and nonsteroidal anti - inflammatory drugs induce conformational changes in the human BC6OTHER synthase - 2 ( BC6ENTG ).	False
 BC6ENTC and nonsteroidal anti - inflammatory drugs induce conformational changes in the BC6ENTG ( BC6OTHER ).	False
We found that BC6ENTC NPs were highly cytotoxic to hepatocytes (LC(50) BC6ENTG : 2.5 μg / cm(2)) and affected hepatocyte homeostasis by reducing BC6OTHER release.	False
We found that BC6ENTC NPs were highly cytotoxic to hepatocytes (LC(50) BC6OTHER dehydrogenase: 2.5 μg / cm(2)) and affected hepatocyte homeostasis by reducing BC6ENTG release.	CPR:4
We found that BC6OTHER NPs were highly cytotoxic to hepatocytes (LC(50) BC6ENTC dehydrogenase: 2.5 μg / cm(2)) and affected hepatocyte homeostasis by reducing BC6ENTG release.	False
We observed similar effects of BC6ENTC NPs on inflammatory mediator expression in vitro and in vivo with increase of BC6ENTG ( BC6OTHER ) / BC6OTHER , BC6OTHER , and BC6OTHER expression in both models and increased BC6OTHER protein release in vitro.	CPR:3
We observed similar effects of BC6ENTC NPs on inflammatory mediator expression in vitro and in vivo with increase of BC6OTHER ( BC6ENTG ) / BC6OTHER , BC6OTHER , and BC6OTHER expression in both models and increased BC6OTHER protein release in vitro.	CPR:3
We observed similar effects of BC6ENTC NPs on inflammatory mediator expression in vitro and in vivo with increase of BC6OTHER ( BC6OTHER ) / BC6ENTG , BC6OTHER , and BC6OTHER expression in both models and increased BC6OTHER protein release in vitro.	CPR:3
We observed similar effects of BC6ENTC NPs on inflammatory mediator expression in vitro and in vivo with increase of BC6OTHER ( BC6OTHER ) / BC6OTHER , BC6ENTG , and BC6OTHER expression in both models and increased BC6OTHER protein release in vitro.	CPR:3
We observed similar effects of BC6ENTC NPs on inflammatory mediator expression in vitro and in vivo with increase of BC6OTHER ( BC6OTHER ) / BC6OTHER , BC6OTHER , and BC6ENTG expression in both models and increased BC6OTHER protein release in vitro.	CPR:3
We observed similar effects of BC6ENTC NPs on inflammatory mediator expression in vitro and in vivo with increase of BC6OTHER ( BC6OTHER ) / BC6OTHER , BC6OTHER , and BC6OTHER expression in both models and increased BC6ENTG protein release in vitro.	CPR:3
Treatment with BC6OTHER ( BC6OTHER ), an inhibitor of transmethylation - suppressive BC6ENTC ( BC6OTHER ) hydrolase ( BC6ENTG ), enhanced the level of BC6OTHER and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose - dependent manner.	False
Treatment with BC6OTHER ( BC6OTHER ), an inhibitor of transmethylation - suppressive CHEM ( BC6ENTC ) hydrolase ( BC6ENTG ), enhanced the level of BC6OTHER and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose - dependent manner.	False
Treatment with BC6OTHER ( BC6OTHER ), an inhibitor of transmethylation - suppressive BC6ENTG ( BC6OTHER ), enhanced the level of BC6ENTC and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose - dependent manner.	CPR:9
Treatment with BC6OTHER ( BC6OTHER ), an inhibitor of transmethylation - suppressive CHEM ( BC6OTHER ) hydrolase ( BC6ENTG ), enhanced the level of BC6ENTC and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose - dependent manner.	CPR:9
Through immunoblotting analysis, it was found that BC6ENTC was capable of indirectly diminishing the phosphorylation of oncogenic BC6ENTG and its BC6OTHER activity.	CPR:4
Through immunoblotting analysis, it was found that BC6ENTC was capable of indirectly diminishing the phosphorylation of oncogenic BC6OTHER and its BC6ENTG activity.	CPR:4
Involvement of BC6ENTG and the BC6OTHER cytoskeleton in the antitumorigenic action of BC6ENTC .	False
Involvement of BC6OTHER and the BC6ENTG cytoskeleton in the antitumorigenic action of BC6ENTC .	False
Interestingly, BC6ENTC disrupted BC6ENTG cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of BC6OTHER and BC6OTHER / BC6OTHER , which is linked to various tumorigenic responses.	CPR:4
Interestingly, BC6ENTC disrupted BC6OTHER cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of BC6ENTG and BC6OTHER / BC6OTHER , which is linked to various tumorigenic responses.	CPR:4
Interestingly, BC6ENTC disrupted BC6OTHER cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of BC6OTHER and BC6ENTG / BC6OTHER , which is linked to various tumorigenic responses.	CPR:4
Interestingly, BC6ENTC disrupted BC6OTHER cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of BC6OTHER and BC6OTHER / BC6ENTG , which is linked to various tumorigenic responses.	CPR:4
In agreement with these data, the exogenous treatment of BC6ENTC or inhibition of BC6ENTG by specific siRNA or another type of inhibitor, BC6OTHER ( BC6OTHER ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6OTHER .	False
In agreement with these data, the exogenous treatment of BC6ENTC or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6OTHER ( BC6OTHER ), similarly resulted in antitumorigenic responses, suppressive activity on BC6ENTG , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6OTHER .	CPR:4
In agreement with these data, the exogenous treatment of BC6ENTC or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6OTHER ( BC6OTHER ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6ENTG cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6OTHER .	False
In agreement with these data, the exogenous treatment of BC6ENTC or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6OTHER ( BC6OTHER ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6ENTG and BC6OTHER .	False
In agreement with these data, the exogenous treatment of BC6ENTC or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6OTHER ( BC6OTHER ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6ENTG .	False
In agreement with these data, the exogenous treatment of BC6OTHER or inhibition of BC6ENTG by specific siRNA or another type of inhibitor, BC6ENTC ( BC6OTHER ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6OTHER .	CPR:4
In agreement with these data, the exogenous treatment of BC6OTHER or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6ENTC ( BC6OTHER ), similarly resulted in antitumorigenic responses, suppressive activity on BC6ENTG , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6OTHER .	False
In agreement with these data, the exogenous treatment of BC6OTHER or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6ENTC ( BC6OTHER ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6ENTG cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6OTHER .	False
In agreement with these data, the exogenous treatment of BC6OTHER or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6ENTC ( BC6OTHER ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6ENTG and BC6OTHER .	False
In agreement with these data, the exogenous treatment of BC6OTHER or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6ENTC ( BC6OTHER ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6ENTG .	False
In agreement with these data, the exogenous treatment of BC6OTHER or inhibition of BC6ENTG by specific siRNA or another type of inhibitor, BC6OTHER ( BC6ENTC ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6OTHER .	CPR:4
In agreement with these data, the exogenous treatment of BC6OTHER or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6OTHER ( BC6ENTC ), similarly resulted in antitumorigenic responses, suppressive activity on BC6ENTG , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6OTHER .	False
In agreement with these data, the exogenous treatment of BC6OTHER or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6OTHER ( BC6ENTC ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6ENTG cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6OTHER .	False
In agreement with these data, the exogenous treatment of BC6OTHER or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6OTHER ( BC6ENTC ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6ENTG and BC6OTHER .	False
In agreement with these data, the exogenous treatment of BC6OTHER or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6OTHER ( BC6ENTC ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6ENTG .	False
Taken together, these results suggest that BC6ENTC / BC6ENTG - mediated transmethylation could be linked to the tumorigenic processes through cross - regulation between the BC6OTHER cytoskeleton and BC6OTHER BC6OTHER activity.	False
Taken together, these results suggest that BC6ENTC / BC6OTHER - mediated transmethylation could be linked to the tumorigenic processes through cross - regulation between the BC6ENTG cytoskeleton and BC6OTHER BC6OTHER activity.	False
Taken together, these results suggest that BC6ENTC / BC6OTHER - mediated transmethylation could be linked to the tumorigenic processes through cross - regulation between the BC6OTHER cytoskeleton and BC6ENTG BC6OTHER activity.	False
Taken together, these results suggest that BC6ENTC / BC6OTHER - mediated transmethylation could be linked to the tumorigenic processes through cross - regulation between the BC6OTHER cytoskeleton and BC6OTHER BC6ENTG activity.	False
Treatment with BC6ENTC ( BC6OTHER ), an inhibitor of transmethylation - suppressive BC6ENTG ( BC6OTHER ), enhanced the level of BC6OTHER and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose - dependent manner.	CPR:4
Treatment with BC6ENTC ( BC6OTHER ), an inhibitor of transmethylation - suppressive CHEM ( BC6OTHER ) hydrolase ( BC6ENTG ), enhanced the level of BC6OTHER and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose - dependent manner.	CPR:4
Treatment with BC6OTHER ( BC6ENTC ), an inhibitor of transmethylation - suppressive BC6ENTG ( BC6OTHER ), enhanced the level of BC6OTHER and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose - dependent manner.	CPR:4
Treatment with BC6OTHER ( BC6ENTC ), an inhibitor of transmethylation - suppressive CHEM ( BC6OTHER ) hydrolase ( BC6ENTG ), enhanced the level of BC6OTHER and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose - dependent manner.	CPR:4
BC6ENTG - regulated expression of these enzymes leads to an increase in the intracellular generation of BC6OTHER ( BC6OTHER ) from BC6ENTC .	False
BC6ENTC regulates gene expression via the activation of the BC6ENTG in human DCs, and BC6OTHER acutely regulates BC6OTHER expression.	CPR:3
BC6ENTC regulates gene expression via the activation of the BC6OTHER in human DCs, and BC6ENTG acutely regulates BC6OTHER expression.	CPR:3
BC6ENTC regulates gene expression via the activation of the BC6OTHER in human DCs, and BC6OTHER acutely regulates BC6ENTG expression.	CPR:3
BC6OTHER regulates gene expression via the activation of the BC6ENTC receptor (RAR)alpha in human DCs, and BC6ENTG acutely regulates BC6OTHER expression.	False
BC6OTHER regulates gene expression via the activation of the BC6ENTC receptor (RAR)alpha in human DCs, and BC6OTHER acutely regulates BC6ENTG expression.	False
The BC6ENTC - induced elevated expression of BC6ENTG is coupled to enhanced iNKT cell activation.	CPR:3
 BC6ENTG controls BC6OTHER expression by turning on BC6ENTC synthesis in developing human dendritic cells.	False
 BC6OTHER controls BC6ENTG expression by turning on BC6ENTC synthesis in developing human dendritic cells.	False
Furthermore, in vivo relevant lipids such as oxidized low - density lipoprotein can also elicit BC6ENTC signaling leading to BC6ENTG up - regulation.	CPR:3
These data show that regulation of BC6ENTC metabolism and signaling is part of the BC6ENTG - controlled transcriptional events in DCs.	False
Here we demonstrate that BC6ENTG , turns on BC6ENTC synthesis by inducing the expression of BC6OTHER and BC6OTHER metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6OTHER dehydrogenase type 2 ( BC6OTHER ).	False
Here we demonstrate that BC6OTHER , turns on BC6ENTC synthesis by inducing the expression of BC6OTHER and BC6OTHER metabolizing enzymes such as BC6ENTG and BC6OTHER dehydrogenase type 2 ( BC6OTHER ).	CPR:9
Here we demonstrate that BC6OTHER , turns on BC6ENTC synthesis by inducing the expression of BC6OTHER and BC6OTHER metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6ENTG ( BC6OTHER ).	CPR:9
Here we demonstrate that BC6OTHER , turns on BC6ENTC synthesis by inducing the expression of BC6OTHER and BC6OTHER metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6OTHER dehydrogenase type 2 ( BC6ENTG ).	CPR:9
Here we demonstrate that BC6ENTG , turns on BC6OTHER synthesis by inducing the expression of BC6ENTC and BC6OTHER metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6OTHER dehydrogenase type 2 ( BC6OTHER ).	False
Here we demonstrate that BC6OTHER , turns on BC6OTHER synthesis by inducing the expression of BC6ENTC and BC6OTHER metabolizing enzymes such as BC6ENTG and BC6OTHER dehydrogenase type 2 ( BC6OTHER ).	CPR:9
Here we demonstrate that BC6OTHER , turns on BC6OTHER synthesis by inducing the expression of BC6ENTC and BC6OTHER metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6ENTG ( BC6OTHER ).	CPR:9
Here we demonstrate that BC6OTHER , turns on BC6OTHER synthesis by inducing the expression of BC6ENTC and BC6OTHER metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6OTHER dehydrogenase type 2 ( BC6ENTG ).	CPR:9
Here we demonstrate that BC6ENTG , turns on BC6OTHER synthesis by inducing the expression of BC6OTHER and BC6ENTC metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6OTHER dehydrogenase type 2 ( BC6OTHER ).	False
Here we demonstrate that BC6OTHER , turns on BC6OTHER synthesis by inducing the expression of BC6OTHER and BC6ENTC metabolizing enzymes such as BC6ENTG and BC6OTHER dehydrogenase type 2 ( BC6OTHER ).	CPR:9
Here we demonstrate that BC6OTHER , turns on BC6OTHER synthesis by inducing the expression of BC6OTHER and BC6ENTC metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6ENTG ( BC6OTHER ).	CPR:9
Here we demonstrate that BC6OTHER , turns on BC6OTHER synthesis by inducing the expression of BC6OTHER and BC6ENTC metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6OTHER dehydrogenase type 2 ( BC6ENTG ).	CPR:9
Here we demonstrate that BC6ENTG , turns on BC6OTHER synthesis by inducing the expression of BC6OTHER and BC6OTHER metabolizing enzymes such as BC6ENTC dehydrogenase 10 and BC6OTHER dehydrogenase type 2 ( BC6OTHER ).	False
Here we demonstrate that BC6OTHER , turns on BC6OTHER synthesis by inducing the expression of BC6OTHER and BC6OTHER metabolizing enzymes such as BC6ENTC dehydrogenase 10 and BC6ENTG ( BC6OTHER ).	False
Here we demonstrate that BC6OTHER , turns on BC6OTHER synthesis by inducing the expression of BC6OTHER and BC6OTHER metabolizing enzymes such as BC6ENTC dehydrogenase 10 and BC6OTHER dehydrogenase type 2 ( BC6ENTG ).	False
Here we demonstrate that BC6ENTG , turns on BC6OTHER synthesis by inducing the expression of BC6OTHER and BC6OTHER metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6ENTC dehydrogenase type 2 ( BC6OTHER ).	False
Here we demonstrate that BC6OTHER , turns on BC6OTHER synthesis by inducing the expression of BC6OTHER and BC6OTHER metabolizing enzymes such as BC6ENTG and BC6ENTC dehydrogenase type 2 ( BC6OTHER ).	False
Here we demonstrate that BC6OTHER , turns on BC6OTHER synthesis by inducing the expression of BC6OTHER and BC6OTHER metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6ENTC dehydrogenase type 2 ( BC6ENTG ).	False
BC6ENTG - regulated expression of these enzymes leads to an increase in the intracellular generation of BC6ENTC ( BC6OTHER ) from BC6OTHER .	False
BC6ENTG - regulated expression of these enzymes leads to an increase in the intracellular generation of BC6OTHER ( BC6ENTC ) from BC6OTHER .	False
Previously, we and others have shown that mutations in the BC6ENTG gene encoding an BC6ENTC - binding cassette (ABC) transporter underlie the skin disease HI.	False
Moreover, GTC - treated groups showed lower levels of total BC6ENTC and BC6ENTG BC6OTHER , whereas the level of BC6OTHER BC6OTHER increased.	False
Moreover, GTC - treated groups showed lower levels of total BC6ENTC and BC6OTHER BC6OTHER , whereas the level of BC6ENTG BC6OTHER increased.	False
Moreover, GTC - treated groups showed lower levels of total BC6OTHER and BC6ENTG BC6ENTC , whereas the level of BC6OTHER BC6OTHER increased.	False
Moreover, GTC - treated groups showed lower levels of total BC6OTHER and BC6OTHER BC6ENTC , whereas the level of BC6ENTG BC6OTHER increased.	False
Moreover, GTC - treated groups showed lower levels of total BC6OTHER and BC6ENTG BC6OTHER , whereas the level of BC6OTHER BC6ENTC increased.	False
Moreover, GTC - treated groups showed lower levels of total BC6OTHER and BC6OTHER BC6OTHER , whereas the level of BC6ENTG BC6ENTC increased.	False
Green tea BC6ENTC leads to global improvement among Alzheimer's disease - related phenotypes in BC6OTHER / BC6OTHER - BC6ENTG Tg mice.	False
Green tea BC6ENTC leads to global improvement among Alzheimer's disease - related phenotypes in BC6ENTG / BC6OTHER - BC6OTHER Tg mice.	False
Green tea BC6ENTC leads to global improvement among Alzheimer's disease - related phenotypes in BC6OTHER / BC6ENTG - BC6OTHER Tg mice.	False
All GCs including the antagonistic compound BC6ENTC efficiently reduced BC6ENTG - mediated transactivation to comparable extents, suggesting that ligand - induced nuclear localization of the BC6OTHER is sufficient for transrepression.	CPR:4
All GCs including the antagonistic compound BC6ENTC efficiently reduced BC6OTHER - mediated transactivation to comparable extents, suggesting that ligand - induced nuclear localization of the BC6ENTG is sufficient for transrepression.	False
Our findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic BC6ENTC receptor ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on bronchodilatory response to anticholinergic agents in patients with COPD.	False
Our findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic BC6ENTC receptor ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on bronchodilatory response to anticholinergic agents in patients with COPD.	False
Our findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic BC6ENTC receptor ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on bronchodilatory response to anticholinergic agents in patients with COPD.	False
Our findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic BC6ENTC receptor ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on bronchodilatory response to anticholinergic agents in patients with COPD.	False
Our findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic BC6ENTC receptor ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) on bronchodilatory response to anticholinergic agents in patients with COPD.	False
Our findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic BC6ENTC receptor ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) on bronchodilatory response to anticholinergic agents in patients with COPD.	False
Our findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic BC6ENTC receptor ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) on bronchodilatory response to anticholinergic agents in patients with COPD.	False
BC6ENTC ( BC6OTHER [ BC6OTHER ]) might be an effective therapy in this case, since BC6OTHER targets both BC6ENTG and BC6OTHER oncoproteins.	False
BC6ENTC ( BC6OTHER [ BC6OTHER ]) might be an effective therapy in this case, since BC6OTHER targets both BC6OTHER and BC6ENTG oncoproteins.	False
BC6OTHER ( BC6ENTC [ BC6OTHER ]) might be an effective therapy in this case, since BC6OTHER targets both BC6ENTG and BC6OTHER oncoproteins.	False
BC6OTHER ( BC6ENTC [ BC6OTHER ]) might be an effective therapy in this case, since BC6OTHER targets both BC6OTHER and BC6ENTG oncoproteins.	False
BC6OTHER ( BC6OTHER [ BC6ENTC ]) might be an effective therapy in this case, since BC6OTHER targets both BC6ENTG and BC6OTHER oncoproteins.	False
BC6OTHER ( BC6OTHER [ BC6ENTC ]) might be an effective therapy in this case, since BC6OTHER targets both BC6OTHER and BC6ENTG oncoproteins.	False
BC6OTHER ( BC6OTHER [ BC6OTHER ]) might be an effective therapy in this case, since BC6ENTC targets both BC6ENTG and BC6OTHER oncoproteins.	False
BC6OTHER ( BC6OTHER [ BC6OTHER ]) might be an effective therapy in this case, since BC6ENTC targets both BC6OTHER and BC6ENTG oncoproteins.	False
A series of BC6ENTG inhibitors have been identified based upon a BC6ENTC scaffold using structure - based drug design methods.	CPR:4
Synthesis of derivatives of BC6ENTC and their inhibitory activities against BC6OTHER ( BC6ENTG ).	CPR:4
Synthesis of derivatives of BC6ENTC and their inhibitory activities against BC6ENTG ( BC6OTHER ).	CPR:4
As BC6OTHER undergoes BC6ENTC - dependent co - oxygenation catalyzed by BC6ENTG , we propose that it is an oxygenated derivative of BC6OTHER , rather than the parent compound, which is responsible for the inactivation of BC6OTHER and BC6OTHER .	False
As BC6OTHER undergoes BC6ENTC - dependent co - oxygenation catalyzed by BC6OTHER , we propose that it is an oxygenated derivative of BC6OTHER , rather than the parent compound, which is responsible for the inactivation of BC6ENTG and BC6OTHER .	False
As BC6OTHER undergoes BC6ENTC - dependent co - oxygenation catalyzed by BC6OTHER , we propose that it is an oxygenated derivative of BC6OTHER , rather than the parent compound, which is responsible for the inactivation of BC6OTHER and BC6ENTG .	False
As BC6OTHER undergoes BC6OTHER - dependent co - oxygenation catalyzed by BC6ENTG , we propose that it is an oxygenated derivative of BC6ENTC , rather than the parent compound, which is responsible for the inactivation of BC6OTHER and BC6OTHER .	False
As BC6OTHER undergoes BC6OTHER - dependent co - oxygenation catalyzed by BC6OTHER , we propose that it is an oxygenated derivative of BC6ENTC , rather than the parent compound, which is responsible for the inactivation of BC6ENTG and BC6OTHER .	False
As BC6OTHER undergoes BC6OTHER - dependent co - oxygenation catalyzed by BC6OTHER , we propose that it is an oxygenated derivative of BC6ENTC , rather than the parent compound, which is responsible for the inactivation of BC6OTHER and BC6ENTG .	False
As BC6OTHER undergoes BC6OTHER - dependent co - oxygenation catalyzed by BC6ENTG , we propose that it is an oxygenated derivative of BC6OTHER , rather than the parent compound, which is responsible for the inactivation of BC6OTHER and BC6ENTC synthase.	False
As BC6OTHER undergoes BC6OTHER - dependent co - oxygenation catalyzed by BC6OTHER , we propose that it is an oxygenated derivative of BC6OTHER , rather than the parent compound, which is responsible for the inactivation of BC6ENTG and BC6ENTC synthase.	False
BC6OTHER ( BC6ENTC ), a nonsteroidal anti - inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of BC6ENTG ( BC6OTHER ).	False
BC6OTHER ( BC6ENTC ), a nonsteroidal anti - inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of BC6OTHER synthase ( BC6ENTG ).	False
Most reducing cofactors for the peroxidase protect BC6ENTG and BC6ENTC synthase from inactivation by BC6OTHER .	False
Most reducing cofactors for the peroxidase protect BC6ENTG and BC6OTHER from inactivation by BC6ENTC .	CPR:4
Most reducing cofactors for the peroxidase protect BC6OTHER and BC6ENTG from inactivation by BC6ENTC .	CPR:4
BC6ENTC ( BC6OTHER ), a nonsteroidal anti - inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of BC6ENTG ( BC6OTHER ).	False
BC6ENTC ( BC6OTHER ), a nonsteroidal anti - inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of BC6OTHER synthase ( BC6ENTG ).	False
Using ram seminal vesicle microsomes as a source of BC6ENTG and BC6ENTC synthase, we have examined the interaction of BC6OTHER and exogenous BC6OTHER .	False
Using ram seminal vesicle microsomes as a source of BC6ENTG and BC6OTHER , we have examined the interaction of BC6ENTC and exogenous BC6OTHER .	False
Using ram seminal vesicle microsomes as a source of BC6OTHER and BC6ENTG , we have examined the interaction of BC6ENTC and exogenous BC6OTHER .	False
Using ram seminal vesicle microsomes as a source of BC6ENTG and BC6OTHER , we have examined the interaction of BC6OTHER and exogenous BC6ENTC .	False
Using ram seminal vesicle microsomes as a source of BC6OTHER and BC6ENTG , we have examined the interaction of BC6OTHER and exogenous BC6ENTC .	False
Chromatographic analysis of the metabolism of BC6ENTC in this system revealed that BC6OTHER - dependent inactivation of BC6ENTG is markedly increased in the presence of 100 microM BC6OTHER .	CPR:9
Chromatographic analysis of the metabolism of BC6OTHER in this system revealed that BC6ENTC - dependent inactivation of BC6ENTG is markedly increased in the presence of 100 microM BC6OTHER .	False
Chromatographic analysis of the metabolism of BC6OTHER in this system revealed that BC6OTHER - dependent inactivation of BC6ENTG is markedly increased in the presence of 100 microM BC6ENTC .	CPR:4
BC6ENTG is even more sensitive to inactivation by the combined BC6OTHER and BC6OTHER treatment, with a corresponding half - maximal effect at BC6ENTC concentrations near 25 microM.	False
BC6ENTG is even more sensitive to inactivation by the combined BC6ENTC and BC6OTHER treatment, with a corresponding half - maximal effect at BC6OTHER concentrations near 25 microM.	False
BC6ENTG is even more sensitive to inactivation by the combined BC6OTHER and BC6ENTC treatment, with a corresponding half - maximal effect at BC6OTHER concentrations near 25 microM.	False
Inactivation of BC6ENTC synthase and BC6ENTG by BC6OTHER .	False
Inactivation of BC6ENTG and BC6ENTC synthase by BC6OTHER .	False
Inactivation of BC6ENTG and BC6OTHER by BC6ENTC .	CPR:4
Inactivation of BC6OTHER and BC6ENTG by BC6ENTC .	CPR:4
This BC6ENTC - and BC6OTHER - dependent inactivation is demonstrable whether BC6OTHER is generated in situ from BC6OTHER or is added exogenously, supporting a direct effect of the treatment on BC6ENTG .	False
This BC6OTHER - and BC6ENTC - dependent inactivation is demonstrable whether BC6OTHER is generated in situ from BC6OTHER or is added exogenously, supporting a direct effect of the treatment on BC6ENTG .	False
This BC6OTHER - and BC6OTHER - dependent inactivation is demonstrable whether BC6ENTC is generated in situ from BC6OTHER or is added exogenously, supporting a direct effect of the treatment on BC6ENTG .	False
This BC6OTHER - and BC6OTHER - dependent inactivation is demonstrable whether BC6OTHER is generated in situ from BC6ENTC or is added exogenously, supporting a direct effect of the treatment on BC6ENTG .	False
BC6OTHER ( BC6OTHER ), a nonsteroidal anti - inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of BC6ENTC synthase ( BC6ENTG ).	False
As BC6ENTC undergoes BC6OTHER - dependent co - oxygenation catalyzed by BC6ENTG , we propose that it is an oxygenated derivative of BC6OTHER , rather than the parent compound, which is responsible for the inactivation of BC6OTHER and BC6OTHER .	False
As BC6ENTC undergoes BC6OTHER - dependent co - oxygenation catalyzed by BC6OTHER , we propose that it is an oxygenated derivative of BC6OTHER , rather than the parent compound, which is responsible for the inactivation of BC6ENTG and BC6OTHER .	False
As BC6ENTC undergoes BC6OTHER - dependent co - oxygenation catalyzed by BC6OTHER , we propose that it is an oxygenated derivative of BC6OTHER , rather than the parent compound, which is responsible for the inactivation of BC6OTHER and BC6ENTG .	False
Administration of BC6OTHER increased BC6ENTC 240 / 244 phosphorylation in a subpopulation of BC6OTHER - ergic medium spiny neurons (MSNs), which express BC6ENTG ( BC6OTHER ).	False
Administration of BC6OTHER increased BC6ENTC 240 / 244 phosphorylation in a subpopulation of BC6OTHER - ergic medium spiny neurons (MSNs), which express BC6OTHER ( BC6ENTG ).	False
Administration of BC6OTHER increased BC6OTHER 240 / 244 phosphorylation in a subpopulation of BC6ENTC - ergic medium spiny neurons (MSNs), which express BC6ENTG ( BC6OTHER ).	False
Administration of BC6OTHER increased BC6OTHER 240 / 244 phosphorylation in a subpopulation of BC6ENTC - ergic medium spiny neurons (MSNs), which express BC6OTHER ( BC6ENTG ).	False
Administration of BC6OTHER increased BC6OTHER 240 / 244 phosphorylation in a subpopulation of BC6OTHER - ergic medium spiny neurons (MSNs), which express BC6ENTC D2 receptors ( BC6ENTG ).	False
This effect was prevented by BC6ENTC , an inhibitor of the BC6ENTG ( BC6OTHER ), or by BC6OTHER , a selective inhibitor of the BC6OTHER ( BC6OTHER ).	CPR:4
This effect was prevented by BC6ENTC , an inhibitor of the mammalian target of BC6OTHER complex 1 ( BC6ENTG ), or by BC6OTHER , a selective inhibitor of the BC6OTHER ( BC6OTHER ).	CPR:4
This effect was prevented by BC6ENTC , an inhibitor of the mammalian target of BC6OTHER complex 1 ( BC6OTHER ), or by BC6OTHER , a selective inhibitor of the BC6ENTG ( BC6OTHER ).	False
This effect was prevented by BC6ENTC , an inhibitor of the mammalian target of BC6OTHER complex 1 ( BC6OTHER ), or by BC6OTHER , a selective inhibitor of the BC6OTHER ( BC6ENTG ).	False
This effect was prevented by BC6OTHER , an inhibitor of the mammalian target of BC6ENTC complex 1 ( BC6ENTG ), or by BC6OTHER , a selective inhibitor of the BC6OTHER ( BC6OTHER ).	False
This effect was prevented by BC6OTHER , an inhibitor of the mammalian target of BC6ENTC complex 1 ( BC6OTHER ), or by BC6OTHER , a selective inhibitor of the BC6ENTG ( BC6OTHER ).	False
This effect was prevented by BC6OTHER , an inhibitor of the mammalian target of BC6ENTC complex 1 ( BC6OTHER ), or by BC6OTHER , a selective inhibitor of the BC6OTHER ( BC6ENTG ).	False
This effect was prevented by BC6OTHER , an inhibitor of the BC6ENTG ( BC6OTHER ), or by BC6ENTC , a selective inhibitor of the BC6OTHER ( BC6OTHER ).	False
This effect was prevented by BC6OTHER , an inhibitor of the mammalian target of BC6OTHER complex 1 ( BC6ENTG ), or by BC6ENTC , a selective inhibitor of the BC6OTHER ( BC6OTHER ).	False
This effect was prevented by BC6OTHER , an inhibitor of the mammalian target of BC6OTHER complex 1 ( BC6OTHER ), or by BC6ENTC , a selective inhibitor of the BC6ENTG ( BC6OTHER ).	CPR:4
This effect was prevented by BC6OTHER , an inhibitor of the mammalian target of BC6OTHER complex 1 ( BC6OTHER ), or by BC6ENTC , a selective inhibitor of the BC6OTHER ( BC6ENTG ).	CPR:4
We also found that the effect of BC6ENTC on BC6OTHER 240 / 244 phosphorylation was prevented by functional inactivation of BC6ENTG ( BC6OTHER ), an endogenous inhibitor of BC6OTHER ( BC6OTHER ).	False
We also found that the effect of BC6ENTC on BC6OTHER 240 / 244 phosphorylation was prevented by functional inactivation of CHEM - and BC6OTHER - regulated phosphoprotein of 32 kDa ( BC6ENTG ), an endogenous inhibitor of BC6OTHER ( BC6OTHER ).	False
We also found that the effect of BC6ENTC on BC6OTHER 240 / 244 phosphorylation was prevented by functional inactivation of CHEM - and BC6OTHER - regulated phosphoprotein of 32 kDa ( BC6OTHER ), an endogenous inhibitor of BC6ENTG ( BC6OTHER ).	False
We also found that the effect of BC6ENTC on BC6OTHER 240 / 244 phosphorylation was prevented by functional inactivation of CHEM - and BC6OTHER - regulated phosphoprotein of 32 kDa ( BC6OTHER ), an endogenous inhibitor of BC6OTHER ( BC6ENTG ).	False
We also found that the effect of BC6OTHER on BC6ENTC 240 / 244 phosphorylation was prevented by functional inactivation of BC6ENTG ( BC6OTHER ), an endogenous inhibitor of BC6OTHER ( BC6OTHER ).	False
We also found that the effect of BC6OTHER on BC6ENTC 240 / 244 phosphorylation was prevented by functional inactivation of CHEM - and BC6OTHER - regulated phosphoprotein of 32 kDa ( BC6ENTG ), an endogenous inhibitor of BC6OTHER ( BC6OTHER ).	False
We also found that the effect of BC6OTHER on BC6ENTC 240 / 244 phosphorylation was prevented by functional inactivation of CHEM - and BC6OTHER - regulated phosphoprotein of 32 kDa ( BC6OTHER ), an endogenous inhibitor of BC6ENTG ( BC6OTHER ).	False
We also found that the effect of BC6OTHER on BC6ENTC 240 / 244 phosphorylation was prevented by functional inactivation of CHEM - and BC6OTHER - regulated phosphoprotein of 32 kDa ( BC6OTHER ), an endogenous inhibitor of BC6OTHER ( BC6ENTG ).	False
We also found that the effect of BC6OTHER on BC6OTHER 240 / 244 phosphorylation was prevented by functional inactivation of BC6ENTC - and BC6OTHER - regulated phosphoprotein of 32 kDa ( BC6ENTG ), an endogenous inhibitor of BC6OTHER ( BC6OTHER ).	False
We also found that the effect of BC6OTHER on BC6OTHER 240 / 244 phosphorylation was prevented by functional inactivation of BC6ENTC - and BC6OTHER - regulated phosphoprotein of 32 kDa ( BC6OTHER ), an endogenous inhibitor of BC6ENTG ( BC6OTHER ).	False
We also found that the effect of BC6OTHER on BC6OTHER 240 / 244 phosphorylation was prevented by functional inactivation of BC6ENTC - and BC6OTHER - regulated phosphoprotein of 32 kDa ( BC6OTHER ), an endogenous inhibitor of BC6OTHER ( BC6ENTG ).	False
We also found that the effect of BC6OTHER on BC6OTHER 240 / 244 phosphorylation was prevented by functional inactivation of CHEM - and BC6ENTC - regulated phosphoprotein of 32 kDa ( BC6ENTG ), an endogenous inhibitor of BC6OTHER ( BC6OTHER ).	False
We also found that the effect of BC6OTHER on BC6OTHER 240 / 244 phosphorylation was prevented by functional inactivation of CHEM - and BC6ENTC - regulated phosphoprotein of 32 kDa ( BC6OTHER ), an endogenous inhibitor of BC6ENTG ( BC6OTHER ).	False
We also found that the effect of BC6OTHER on BC6OTHER 240 / 244 phosphorylation was prevented by functional inactivation of CHEM - and BC6ENTC - regulated phosphoprotein of 32 kDa ( BC6OTHER ), an endogenous inhibitor of BC6OTHER ( BC6ENTG ).	False
In line with this observation, incubation of striatal slices with BC6ENTC and BC6OTHER , two inhibitors of BC6ENTG , increased BC6OTHER 240 / 244 phosphorylation.	CPR:4
 BC6ENTC promotes BC6OTHER - dependent phosphorylation of BC6OTHER via CHEM - and BC6OTHER - regulated phosphoprotein of 32 kDa and inhibition of BC6ENTG .	CPR:4
 BC6ENTC promotes BC6ENTG - dependent phosphorylation of BC6OTHER via CHEM - and BC6OTHER - regulated phosphoprotein of 32 kDa and inhibition of BC6OTHER .	False
 BC6ENTC promotes BC6OTHER - dependent phosphorylation of BC6ENTG via CHEM - and BC6OTHER - regulated phosphoprotein of 32 kDa and inhibition of BC6OTHER .	CPR:3
 BC6ENTC promotes BC6OTHER - dependent phosphorylation of BC6OTHER via BC6ENTG and inhibition of BC6OTHER .	False
 BC6OTHER promotes BC6OTHER - dependent phosphorylation of BC6OTHER via BC6ENTC - and BC6OTHER - regulated phosphoprotein of 32 kDa and inhibition of BC6ENTG .	False
 BC6OTHER promotes BC6ENTG - dependent phosphorylation of BC6OTHER via BC6ENTC - and BC6OTHER - regulated phosphoprotein of 32 kDa and inhibition of BC6OTHER .	False
 BC6OTHER promotes BC6OTHER - dependent phosphorylation of BC6ENTG via BC6ENTC - and BC6OTHER - regulated phosphoprotein of 32 kDa and inhibition of BC6OTHER .	False
 BC6OTHER promotes BC6OTHER - dependent phosphorylation of BC6OTHER via CHEM - and BC6ENTC - regulated phosphoprotein of 32 kDa and inhibition of BC6ENTG .	False
 BC6OTHER promotes BC6ENTG - dependent phosphorylation of BC6OTHER via CHEM - and BC6ENTC - regulated phosphoprotein of 32 kDa and inhibition of BC6OTHER .	False
 BC6OTHER promotes BC6OTHER - dependent phosphorylation of BC6ENTG via CHEM - and BC6ENTC - regulated phosphoprotein of 32 kDa and inhibition of BC6OTHER .	False
In line with this observation, incubation of striatal slices with BC6OTHER and BC6ENTC , two inhibitors of BC6ENTG , increased BC6OTHER 240 / 244 phosphorylation.	CPR:4
In line with this observation, incubation of striatal slices with BC6OTHER and BC6OTHER , two inhibitors of BC6ENTG , increased BC6ENTC 240 / 244 phosphorylation.	False
These results show that BC6ENTC promotes BC6ENTG - and BC6OTHER - dependent phosphorylation of BC6OTHER at BC6OTHER 240 / 244, in a subpopulation of striatal MSNs expressing BC6OTHER .	False
These results show that BC6ENTC promotes BC6OTHER - and BC6ENTG - dependent phosphorylation of BC6OTHER at BC6OTHER 240 / 244, in a subpopulation of striatal MSNs expressing BC6OTHER .	False
These results show that BC6ENTC promotes BC6OTHER - and BC6OTHER - dependent phosphorylation of BC6ENTG at BC6OTHER 240 / 244, in a subpopulation of striatal MSNs expressing BC6OTHER .	CPR:3
These results show that BC6ENTC promotes BC6OTHER - and BC6OTHER - dependent phosphorylation of BC6OTHER at BC6OTHER 240 / 244, in a subpopulation of striatal MSNs expressing BC6ENTG .	False
These results show that BC6OTHER promotes BC6ENTG - and BC6OTHER - dependent phosphorylation of BC6OTHER at BC6ENTC 240 / 244, in a subpopulation of striatal MSNs expressing BC6OTHER .	False
These results show that BC6OTHER promotes BC6OTHER - and BC6ENTG - dependent phosphorylation of BC6OTHER at BC6ENTC 240 / 244, in a subpopulation of striatal MSNs expressing BC6OTHER .	False
These results show that BC6OTHER promotes BC6OTHER - and BC6OTHER - dependent phosphorylation of BC6ENTG at BC6ENTC 240 / 244, in a subpopulation of striatal MSNs expressing BC6OTHER .	False
These results show that BC6OTHER promotes BC6OTHER - and BC6OTHER - dependent phosphorylation of BC6OTHER at BC6ENTC 240 / 244, in a subpopulation of striatal MSNs expressing BC6ENTG .	False
They also indicate that this effect is exerted by suppressing dephosphorylation at BC6ENTC 240 / 244, through BC6ENTG - dependent activation of BC6OTHER and inhibition of BC6OTHER .	False
They also indicate that this effect is exerted by suppressing dephosphorylation at BC6ENTC 240 / 244, through BC6OTHER - dependent activation of BC6ENTG and inhibition of BC6OTHER .	False
They also indicate that this effect is exerted by suppressing dephosphorylation at BC6ENTC 240 / 244, through BC6OTHER - dependent activation of BC6OTHER and inhibition of BC6ENTG .	False
Here, we examined the effects produced by BC6ENTC , a typical antipsychotic drug, on the phosphorylation of BC6ENTG at BC6OTHER 240 / 244 in the striatum, a brain region involved in neurodegenerative and neuropsychiatric disorders.	False
Here, we examined the effects produced by BC6OTHER , a typical antipsychotic drug, on the phosphorylation of BC6ENTG at BC6ENTC 240 / 244 in the striatum, a brain region involved in neurodegenerative and neuropsychiatric disorders.	False
Administration of BC6ENTC increased BC6OTHER 240 / 244 phosphorylation in a subpopulation of BC6OTHER - ergic medium spiny neurons (MSNs), which express BC6ENTG ( BC6OTHER ).	False
Administration of BC6ENTC increased BC6OTHER 240 / 244 phosphorylation in a subpopulation of BC6OTHER - ergic medium spiny neurons (MSNs), which express BC6OTHER ( BC6ENTG ).	False
Sources of BC6OTHER include dietary proteins and endogenous synthesis by BC6ENTG and BC6ENTC lyase.	False
BC6ENTC is converted to BC6OTHER by BC6ENTG in the liver and BC6OTHER in the kidney.	CPR:9
BC6ENTC is converted to BC6OTHER by BC6OTHER in the liver and BC6ENTG in the kidney.	CPR:9
BC6OTHER is converted to BC6ENTC by BC6ENTG in the liver and BC6OTHER in the kidney.	CPR:9
BC6OTHER is converted to BC6ENTC by BC6OTHER in the liver and BC6ENTG in the kidney.	CPR:9
We hypothesized that preservation of plasma BC6ENTC in CRF may be, partly, due to downregulation / inhibition of BC6ENTG .	CPR:9
In addition, BC6ENTG activity was measured in the presence of different BC6ENTC concentrations to simulate azotemia in vitro.	False
METHODS: BC6ENTC synthetase, BC6ENTG protein abundance and activity were measured in the liver and kidneys of rats 6 weeks after 5 / 6 nephrectomy or sham operation.	False
Effect of chronic renal failure on BC6ENTG and BC6ENTC synthetase expression.	False
Sources of BC6ENTC include dietary proteins and endogenous synthesis by BC6ENTG and BC6OTHER .	CPR:9
Sources of BC6ENTC include dietary proteins and endogenous synthesis by BC6OTHER synthetase and BC6ENTG .	CPR:9
However, in vitro experiments simulating a uremic milieu revealed a marked concentration - dependent inhibition of BC6ENTG activity by BC6ENTC in the tissue lysates.	CPR:4
CONCLUSIONS: Although CRF does not change the abundance or intrinsic properties of BC6ENTG , the inherent rise in BC6ENTC concentration inhibits its enzymatic activity.	CPR:4
Sources of BC6OTHER include dietary proteins and endogenous synthesis by BC6ENTC synthetase and BC6ENTG .	False
BC6ENTC was used to test whether any potential effect was due to activation of BC6ENTG ( BC6OTHER ).	False
BC6ENTC was used to test whether any potential effect was due to activation of endothelial BC6OTHER synthase ( BC6ENTG ).	False
BC6OTHER was used to test whether any potential effect was due to activation of endothelial BC6ENTC synthase ( BC6ENTG ).	False
Our purpose was to test the impact of single and / or combined treatment with the BC6OTHER - receptor blocker BC6ENTC and the BC6ENTG inhibitor BC6OTHER on infarct size and neuroscore in transient cerebral ischemia in rats.	False
Our purpose was to test the impact of single and / or combined treatment with the BC6ENTG - receptor blocker BC6ENTC and the BC6OTHER reductase inhibitor BC6OTHER on infarct size and neuroscore in transient cerebral ischemia in rats.	CPR:4
Reduction of cerebral infarct size by the BC6ENTG - receptor blocker BC6OTHER , the BC6OTHER inhibitor BC6ENTC and their combination.	False
Reduction of cerebral infarct size by the BC6OTHER - receptor blocker BC6OTHER , the BC6ENTG inhibitor BC6ENTC and their combination.	CPR:4
Reduction of cerebral infarct size by the BC6ENTG - receptor blocker BC6ENTC , the BC6OTHER inhibitor BC6OTHER and their combination.	CPR:4
Reduction of cerebral infarct size by the BC6OTHER - receptor blocker BC6ENTC , the BC6ENTG inhibitor BC6OTHER and their combination.	False
Reduction of cerebral infarct size by the BC6ENTG - receptor blocker BC6OTHER , the BC6ENTC reductase inhibitor BC6OTHER and their combination.	False
Our purpose was to test the impact of single and / or combined treatment with the BC6ENTG - receptor blocker BC6OTHER and the BC6ENTC reductase inhibitor BC6OTHER on infarct size and neuroscore in transient cerebral ischemia in rats.	False
Our purpose was to test the impact of single and / or combined treatment with the BC6OTHER - receptor blocker BC6OTHER and the BC6ENTG inhibitor BC6ENTC on infarct size and neuroscore in transient cerebral ischemia in rats.	CPR:4
Our purpose was to test the impact of single and / or combined treatment with the BC6ENTG - receptor blocker BC6OTHER and the BC6OTHER reductase inhibitor BC6ENTC on infarct size and neuroscore in transient cerebral ischemia in rats.	False
Various biochemical processes including oligomerization, BC6ENTC BC6OTHER / CHEM binding, and BC6ENTG interaction play a role in regulating the ternary death complex.	False
Various biochemical processes including oligomerization, BC6OTHER BC6ENTC / CHEM binding, and BC6ENTG interaction play a role in regulating the ternary death complex.	False
The BC6ENTG is predicted to transfer either BC6OTHER or a CHEM ( BC6ENTC ) to the aglycone.	False
Targeted disruption of the gene encoding the BC6ENTC - glycosyltransferase, BC6ENTG , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety.	False
Targeted disruption of the gene encoding the BC6ENTC - glycosyltransferase, BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6ENTG confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety.	False
Targeted disruption of the gene encoding the BC6ENTC - glycosyltransferase, BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a BC6ENTG involved in the formation of the BC6OTHER - BC6OTHER moiety.	False
Targeted disruption of the gene encoding the BC6ENTG , BC6OTHER , abolished BC6ENTC production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety.	CPR:9
Targeted disruption of the gene encoding the BC6OTHER , BC6ENTG , abolished BC6ENTC production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety.	CPR:9
Targeted disruption of the gene encoding the BC6OTHER , BC6OTHER , abolished BC6ENTC production, and recombinant expression of BC6ENTG confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety.	False
Targeted disruption of the gene encoding the BC6OTHER , BC6OTHER , abolished BC6ENTC production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a BC6ENTG involved in the formation of the BC6OTHER - BC6OTHER moiety.	False
Targeted disruption of the gene encoding the BC6ENTG , BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a BC6ENTC BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety.	False
Targeted disruption of the gene encoding the BC6OTHER , BC6ENTG , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a BC6ENTC BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety.	False
Targeted disruption of the gene encoding the BC6OTHER , BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6ENTG confirms the activity of this enzyme as a BC6ENTC BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety.	False
Targeted disruption of the gene encoding the BC6ENTG , BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a CHEM BC6ENTC cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety.	False
Targeted disruption of the gene encoding the BC6OTHER , BC6ENTG , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a CHEM BC6ENTC cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety.	False
Targeted disruption of the gene encoding the BC6OTHER , BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6ENTG confirms the activity of this enzyme as a CHEM BC6ENTC cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety.	False
Targeted disruption of the gene encoding the BC6ENTG , BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6ENTC - BC6OTHER moiety.	False
Targeted disruption of the gene encoding the BC6OTHER , BC6ENTG , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6ENTC - BC6OTHER moiety.	False
Targeted disruption of the gene encoding the BC6OTHER , BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6ENTG confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6ENTC - BC6OTHER moiety.	CPR:9
Targeted disruption of the gene encoding the BC6OTHER , BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a BC6ENTG involved in the formation of the BC6ENTC - BC6OTHER moiety.	CPR:9
Targeted disruption of the gene encoding the BC6ENTG , BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6ENTC moiety.	False
Targeted disruption of the gene encoding the BC6OTHER , BC6ENTG , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6ENTC moiety.	False
Targeted disruption of the gene encoding the BC6OTHER , BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6ENTG confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6ENTC moiety.	CPR:9
Targeted disruption of the gene encoding the BC6OTHER , BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a BC6ENTG involved in the formation of the BC6OTHER - BC6ENTC moiety.	CPR:9
This includes BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6ENTC core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6OTHER - methyltransferase, and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure.	CPR:9
This includes BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6ENTC core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6OTHER - methyltransferase, and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure.	CPR:9
This includes BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) required for the formation of the BC6ENTC core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6OTHER - methyltransferase, and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure.	CPR:9
This includes BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) required for the formation of the BC6ENTC core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6OTHER - methyltransferase, and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure.	CPR:9
This includes BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6ENTC core unit, as well as a suite of tailoring enzymes (e.g., four BC6ENTG , an BC6OTHER - methyltransferase, and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure.	CPR:9
This includes BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6ENTC core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6ENTG , and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure.	CPR:9
This includes BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6ENTC core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6OTHER - methyltransferase, and an BC6ENTG ) necessary for further modifications of the core structure.	CPR:9
This includes BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6ENTC - methyltransferase, and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure.	False
This includes BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6ENTC - methyltransferase, and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure.	False
This includes BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6ENTC - methyltransferase, and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure.	False
This includes BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6ENTC - methyltransferase, and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure.	False
This includes BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6ENTG , an BC6ENTC - methyltransferase, and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure.	False
This includes BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6ENTC - methyltransferase, and an BC6ENTG ) necessary for further modifications of the core structure.	False
This includes BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6OTHER - methyltransferase, and an BC6ENTC - glycosyltransferase) necessary for further modifications of the core structure.	False
This includes BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6OTHER - methyltransferase, and an BC6ENTC - glycosyltransferase) necessary for further modifications of the core structure.	False
This includes BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6OTHER - methyltransferase, and an BC6ENTC - glycosyltransferase) necessary for further modifications of the core structure.	False
This includes BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6OTHER - methyltransferase, and an BC6ENTC - glycosyltransferase) necessary for further modifications of the core structure.	False
This includes BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6ENTG , an BC6OTHER - methyltransferase, and an BC6ENTC - glycosyltransferase) necessary for further modifications of the core structure.	False
This includes BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6ENTG , and an BC6ENTC - glycosyltransferase) necessary for further modifications of the core structure.	False
The BC6ENTG is predicted to transfer either BC6ENTC or a CHEM ( BC6OTHER ) to the aglycone.	False
Down - regulation of BC6ENTG by BC6OTHER was blocked by BC6OTHER ( BC6ENTC ), a BC6OTHER inhibitor and by expression of BC6OTHER - BC6OTHER , a dominant negative form of BC6OTHER .	False
Down - regulation of BC6OTHER by BC6OTHER was blocked by BC6OTHER ( BC6ENTC ), a BC6ENTG inhibitor and by expression of BC6OTHER - BC6OTHER , a dominant negative form of BC6OTHER .	CPR:4
Down - regulation of BC6OTHER by BC6OTHER was blocked by BC6OTHER ( BC6ENTC ), a BC6OTHER inhibitor and by expression of BC6ENTG - BC6OTHER , a dominant negative form of BC6OTHER .	False
Down - regulation of BC6OTHER by BC6OTHER was blocked by BC6OTHER ( BC6ENTC ), a BC6OTHER inhibitor and by expression of BC6OTHER - BC6ENTG , a dominant negative form of BC6OTHER .	False
Down - regulation of BC6OTHER by BC6OTHER was blocked by BC6OTHER ( BC6ENTC ), a BC6OTHER inhibitor and by expression of BC6OTHER - BC6OTHER , a dominant negative form of BC6ENTG .	False
The BC6ENTG reduction was inhibited by BC6ENTC , an CHEM ( BC6OTHER ) receptor antagonist, but not by BC6OTHER ( BC6OTHER ), an BC6OTHER antagonist.	CPR:3
The BC6OTHER reduction was inhibited by BC6ENTC , an BC6ENTG antagonist, but not by BC6OTHER ( BC6OTHER ), an BC6OTHER antagonist.	CPR:6
The BC6OTHER reduction was inhibited by BC6ENTC , an CHEM ( BC6OTHER ) receptor antagonist, but not by BC6OTHER ( BC6OTHER ), an BC6ENTG antagonist.	False
The BC6ENTG reduction was inhibited by BC6OTHER , an BC6ENTC ( BC6OTHER ) receptor antagonist, but not by BC6OTHER ( BC6OTHER ), an BC6OTHER antagonist.	False
The BC6OTHER reduction was inhibited by BC6OTHER , an BC6ENTC ( BC6OTHER ) receptor antagonist, but not by BC6OTHER ( BC6OTHER ), an BC6ENTG antagonist.	False
The BC6ENTG reduction was inhibited by BC6OTHER , an CHEM ( BC6ENTC ) receptor antagonist, but not by BC6OTHER ( BC6OTHER ), an BC6OTHER antagonist.	False
The BC6OTHER reduction was inhibited by BC6OTHER , an CHEM ( BC6ENTC ) receptor antagonist, but not by BC6OTHER ( BC6OTHER ), an BC6ENTG antagonist.	False
The BC6ENTG reduction was inhibited by BC6OTHER , an CHEM ( BC6OTHER ) receptor antagonist, but not by BC6ENTC ( BC6OTHER ), an BC6OTHER antagonist.	False
The BC6OTHER reduction was inhibited by BC6OTHER , an BC6ENTG antagonist, but not by BC6ENTC ( BC6OTHER ), an BC6OTHER antagonist.	False
The BC6OTHER reduction was inhibited by BC6OTHER , an CHEM ( BC6OTHER ) receptor antagonist, but not by BC6ENTC ( BC6OTHER ), an BC6ENTG antagonist.	CPR:6
The BC6ENTG reduction was inhibited by BC6OTHER , an CHEM ( BC6OTHER ) receptor antagonist, but not by BC6OTHER ( BC6ENTC ), an BC6OTHER antagonist.	False
The BC6OTHER reduction was inhibited by BC6OTHER , an BC6ENTG antagonist, but not by BC6OTHER ( BC6ENTC ), an BC6OTHER antagonist.	False
The BC6OTHER reduction was inhibited by BC6OTHER , an CHEM ( BC6OTHER ) receptor antagonist, but not by BC6OTHER ( BC6ENTC ), an BC6ENTG antagonist.	CPR:6
The BC6ENTG reduction was inhibited by BC6OTHER , an CHEM ( BC6OTHER ) receptor antagonist, but not by BC6OTHER ( BC6OTHER ), an BC6ENTC receptor antagonist.	False
The BC6OTHER reduction was inhibited by BC6OTHER , an BC6ENTG antagonist, but not by BC6OTHER ( BC6OTHER ), an BC6ENTC receptor antagonist.	False
BC6ENTC and BC6OTHER ( BC6OTHER ), two BC6OTHER chelators, but not BC6OTHER , an BC6ENTG blocker, prevented BC6OTHER degradation.	False
BC6ENTC and BC6OTHER ( BC6OTHER ), two BC6OTHER chelators, but not BC6OTHER , an L - type BC6OTHER channel blocker, prevented BC6ENTG degradation.	CPR:3
BC6OTHER and BC6ENTC ( BC6OTHER ), two BC6OTHER chelators, but not BC6OTHER , an BC6ENTG blocker, prevented BC6OTHER degradation.	False
BC6OTHER and BC6ENTC ( BC6OTHER ), two BC6OTHER chelators, but not BC6OTHER , an L - type BC6OTHER channel blocker, prevented BC6ENTG degradation.	CPR:3
BC6OTHER and BC6OTHER ( BC6ENTC ), two BC6OTHER chelators, but not BC6OTHER , an BC6ENTG blocker, prevented BC6OTHER degradation.	False
BC6OTHER and BC6OTHER ( BC6ENTC ), two BC6OTHER chelators, but not BC6OTHER , an L - type BC6OTHER channel blocker, prevented BC6ENTG degradation.	CPR:3
Our results suggest that BC6ENTC induces BC6ENTG degradation by BC6OTHER through an BC6OTHER receptor - BC6OTHER pathway and that BC6OTHER degradation may play an important role in regulating BC6OTHER surface expression.	CPR:4
Our results suggest that BC6ENTC induces BC6OTHER degradation by BC6ENTG through an BC6OTHER receptor - BC6OTHER pathway and that BC6OTHER degradation may play an important role in regulating BC6OTHER surface expression.	False
Our results suggest that BC6ENTC induces BC6OTHER degradation by BC6OTHER through an BC6ENTG - BC6OTHER pathway and that BC6OTHER degradation may play an important role in regulating BC6OTHER surface expression.	False
Our results suggest that BC6ENTC induces BC6OTHER degradation by BC6OTHER through an BC6OTHER receptor - BC6OTHER pathway and that BC6ENTG degradation may play an important role in regulating BC6OTHER surface expression.	CPR:4
Our results suggest that BC6ENTC induces BC6OTHER degradation by BC6OTHER through an BC6OTHER receptor - BC6OTHER pathway and that BC6OTHER degradation may play an important role in regulating BC6ENTG surface expression.	False
BC6OTHER and BC6OTHER ( BC6OTHER ), two BC6ENTC chelators, but not BC6OTHER , an BC6ENTG blocker, prevented BC6OTHER degradation.	False
BC6OTHER and BC6OTHER ( BC6OTHER ), two BC6ENTC chelators, but not BC6OTHER , an L - type BC6OTHER channel blocker, prevented BC6ENTG degradation.	False
BC6OTHER and BC6OTHER ( BC6OTHER ), two BC6OTHER chelators, but not BC6ENTC , an BC6ENTG blocker, prevented BC6OTHER degradation.	CPR:4
BC6OTHER and BC6OTHER ( BC6OTHER ), two BC6OTHER chelators, but not BC6ENTC , an L - type BC6OTHER channel blocker, prevented BC6ENTG degradation.	False
BC6OTHER and BC6OTHER ( BC6OTHER ), two BC6OTHER chelators, but not BC6OTHER , an L - type BC6ENTC channel blocker, prevented BC6ENTG degradation.	False
Furthermore, BC6ENTC prevented BC6OTHER - stimulated reduction in surface amount of BC6ENTG , and knockdown of BC6OTHER by RNAi against BC6OTHER reduced surface BC6OTHER in neurons.	False
Furthermore, BC6ENTC prevented BC6OTHER - stimulated reduction in surface amount of BC6OTHER , and knockdown of BC6ENTG by RNAi against BC6OTHER reduced surface BC6OTHER in neurons.	False
Furthermore, BC6ENTC prevented BC6OTHER - stimulated reduction in surface amount of BC6OTHER , and knockdown of BC6OTHER by RNAi against BC6ENTG reduced surface BC6OTHER in neurons.	False
Furthermore, BC6ENTC prevented BC6OTHER - stimulated reduction in surface amount of BC6OTHER , and knockdown of BC6OTHER by RNAi against BC6OTHER reduced surface BC6ENTG in neurons.	False
Furthermore, BC6OTHER prevented BC6ENTC - stimulated reduction in surface amount of BC6ENTG , and knockdown of BC6OTHER by RNAi against BC6OTHER reduced surface BC6OTHER in neurons.	CPR:4
Furthermore, BC6OTHER prevented BC6ENTC - stimulated reduction in surface amount of BC6OTHER , and knockdown of BC6ENTG by RNAi against BC6OTHER reduced surface BC6OTHER in neurons.	False
Furthermore, BC6OTHER prevented BC6ENTC - stimulated reduction in surface amount of BC6OTHER , and knockdown of BC6OTHER by RNAi against BC6ENTG reduced surface BC6OTHER in neurons.	False
Furthermore, BC6OTHER prevented BC6ENTC - stimulated reduction in surface amount of BC6OTHER , and knockdown of BC6OTHER by RNAi against BC6OTHER reduced surface BC6ENTG in neurons.	False
 BC6ENTC stimulates BC6OTHER degradation by BC6OTHER - BC6OTHER system to regulate surface expression of BC6ENTG .	False
 BC6ENTC stimulates BC6ENTG degradation by BC6OTHER - BC6OTHER system to regulate surface expression of BC6OTHER .	CPR:4
 BC6ENTC stimulates BC6OTHER degradation by BC6ENTG - BC6OTHER system to regulate surface expression of BC6OTHER .	False
 BC6ENTC stimulates BC6OTHER degradation by BC6OTHER - BC6ENTG system to regulate surface expression of BC6OTHER .	False
 BC6OTHER stimulates BC6ENTC receptor interacting protein 1 degradation by BC6OTHER - BC6OTHER system to regulate surface expression of BC6ENTG .	False
 BC6OTHER stimulates BC6ENTC receptor interacting protein 1 degradation by BC6ENTG - BC6OTHER system to regulate surface expression of BC6OTHER .	False
 BC6OTHER stimulates BC6ENTC receptor interacting protein 1 degradation by BC6OTHER - BC6ENTG system to regulate surface expression of BC6OTHER .	False
The BC6ENTG ( BC6OTHER ) is a scaffolding protein in postsynaptic density (PSD), tethering BC6ENTC receptors to other signaling proteins.	False
The BC6OTHER receptor interacting protein 1 ( BC6ENTG ) is a scaffolding protein in postsynaptic density (PSD), tethering BC6ENTC receptors to other signaling proteins.	False
Our results suggest that BC6OTHER induces BC6ENTG degradation by BC6OTHER through an BC6ENTC receptor - BC6OTHER pathway and that BC6OTHER degradation may play an important role in regulating BC6OTHER surface expression.	False
Our results suggest that BC6OTHER induces BC6OTHER degradation by BC6ENTG through an BC6ENTC receptor - BC6OTHER pathway and that BC6OTHER degradation may play an important role in regulating BC6OTHER surface expression.	False
Our results suggest that BC6OTHER induces BC6OTHER degradation by BC6OTHER through an BC6ENTC receptor - BC6OTHER pathway and that BC6ENTG degradation may play an important role in regulating BC6OTHER surface expression.	False
Our results suggest that BC6OTHER induces BC6OTHER degradation by BC6OTHER through an BC6ENTC receptor - BC6OTHER pathway and that BC6OTHER degradation may play an important role in regulating BC6ENTG surface expression.	False
Our results suggest that BC6OTHER induces BC6ENTG degradation by BC6OTHER through an BC6OTHER receptor - BC6ENTC pathway and that BC6OTHER degradation may play an important role in regulating BC6OTHER surface expression.	False
Our results suggest that BC6OTHER induces BC6OTHER degradation by BC6ENTG through an BC6OTHER receptor - BC6ENTC pathway and that BC6OTHER degradation may play an important role in regulating BC6OTHER surface expression.	False
Our results suggest that BC6OTHER induces BC6OTHER degradation by BC6OTHER through an BC6ENTG - BC6ENTC pathway and that BC6OTHER degradation may play an important role in regulating BC6OTHER surface expression.	False
Our results suggest that BC6OTHER induces BC6OTHER degradation by BC6OTHER through an BC6OTHER receptor - BC6ENTC pathway and that BC6ENTG degradation may play an important role in regulating BC6OTHER surface expression.	False
Our results suggest that BC6OTHER induces BC6OTHER degradation by BC6OTHER through an BC6OTHER receptor - BC6ENTC pathway and that BC6OTHER degradation may play an important role in regulating BC6ENTG surface expression.	False
Here we report that BC6ENTC stimulation caused a rapid reduction in protein levels of BC6ENTG , but not that of BC6OTHER receptor BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ) in rat primary cortical neuron cultures.	CPR:4
Here we report that BC6ENTC stimulation caused a rapid reduction in protein levels of BC6OTHER , but not that of BC6OTHER receptor BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER ) in rat primary cortical neuron cultures.	False
Here we report that BC6ENTC stimulation caused a rapid reduction in protein levels of BC6OTHER , but not that of BC6OTHER receptor BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER ) in rat primary cortical neuron cultures.	False
Here we report that BC6ENTC stimulation caused a rapid reduction in protein levels of BC6OTHER , but not that of BC6OTHER receptor BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ) in rat primary cortical neuron cultures.	False
Here we report that BC6ENTC stimulation caused a rapid reduction in protein levels of BC6OTHER , but not that of BC6OTHER receptor BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG ) in rat primary cortical neuron cultures.	False
Here we report that BC6OTHER stimulation caused a rapid reduction in protein levels of BC6ENTG , but not that of BC6ENTC receptor BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ) in rat primary cortical neuron cultures.	False
Here we report that BC6OTHER stimulation caused a rapid reduction in protein levels of BC6OTHER , but not that of BC6ENTC receptor BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER ) in rat primary cortical neuron cultures.	False
Here we report that BC6OTHER stimulation caused a rapid reduction in protein levels of BC6OTHER , but not that of BC6ENTC receptor BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER ) in rat primary cortical neuron cultures.	False
Here we report that BC6OTHER stimulation caused a rapid reduction in protein levels of BC6OTHER , but not that of BC6ENTC receptor BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ) in rat primary cortical neuron cultures.	False
Here we report that BC6OTHER stimulation caused a rapid reduction in protein levels of BC6OTHER , but not that of BC6ENTC receptor BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG ) in rat primary cortical neuron cultures.	False
The BC6ENTC receptor interacting protein 1 ( BC6OTHER ) is a scaffolding protein in postsynaptic density (PSD), tethering BC6ENTG to other signaling proteins.	False
The BC6ENTC receptor interacting protein 1 ( BC6ENTG ) is a scaffolding protein in postsynaptic density (PSD), tethering BC6OTHER to other signaling proteins.	False
Down - regulation of BC6ENTG by BC6ENTC was blocked by BC6OTHER ( BC6OTHER ), a BC6OTHER inhibitor and by expression of BC6OTHER - BC6OTHER , a dominant negative form of BC6OTHER .	CPR:4
Down - regulation of BC6OTHER by BC6ENTC was blocked by BC6OTHER ( BC6OTHER ), a BC6ENTG inhibitor and by expression of BC6OTHER - BC6OTHER , a dominant negative form of BC6OTHER .	False
Down - regulation of BC6OTHER by BC6ENTC was blocked by BC6OTHER ( BC6OTHER ), a BC6OTHER inhibitor and by expression of BC6ENTG - BC6OTHER , a dominant negative form of BC6OTHER .	False
Down - regulation of BC6OTHER by BC6ENTC was blocked by BC6OTHER ( BC6OTHER ), a BC6OTHER inhibitor and by expression of BC6OTHER - BC6ENTG , a dominant negative form of BC6OTHER .	False
Down - regulation of BC6OTHER by BC6ENTC was blocked by BC6OTHER ( BC6OTHER ), a BC6OTHER inhibitor and by expression of BC6OTHER - BC6OTHER , a dominant negative form of BC6ENTG .	False
Down - regulation of BC6ENTG by BC6OTHER was blocked by BC6ENTC ( BC6OTHER ), a BC6OTHER inhibitor and by expression of BC6OTHER - BC6OTHER , a dominant negative form of BC6OTHER .	False
Down - regulation of BC6OTHER by BC6OTHER was blocked by BC6ENTC ( BC6OTHER ), a BC6ENTG inhibitor and by expression of BC6OTHER - BC6OTHER , a dominant negative form of BC6OTHER .	CPR:4
Down - regulation of BC6OTHER by BC6OTHER was blocked by BC6ENTC ( BC6OTHER ), a BC6OTHER inhibitor and by expression of BC6ENTG - BC6OTHER , a dominant negative form of BC6OTHER .	False
Down - regulation of BC6OTHER by BC6OTHER was blocked by BC6ENTC ( BC6OTHER ), a BC6OTHER inhibitor and by expression of BC6OTHER - BC6ENTG , a dominant negative form of BC6OTHER .	False
Down - regulation of BC6OTHER by BC6OTHER was blocked by BC6ENTC ( BC6OTHER ), a BC6OTHER inhibitor and by expression of BC6OTHER - BC6OTHER , a dominant negative form of BC6ENTG .	False
There was a positive correlation between BC6ENTG levels and fasting plasma BC6ENTC in hyperprolactinemic women.	False
Forty premenopausal women with prolactinoma or idiopathic hyperprolactinemia were compared to 41 age - matched healthy premenopausal women with regard to body weight, body mass index, waist and hip circumferences, waist to hip ratio, fasting plasma BC6ENTC , BC6ENTG levels, BC6OTHER resistance measured by homeostasis model assessment (HOMA) - BC6OTHER resistance index, beta cell function measured by HOMA - β index, BC6OTHER and BC6OTHER levels.	False
Forty premenopausal women with prolactinoma or idiopathic hyperprolactinemia were compared to 41 age - matched healthy premenopausal women with regard to body weight, body mass index, waist and hip circumferences, waist to hip ratio, fasting plasma BC6ENTC , BC6OTHER levels, BC6ENTG resistance measured by homeostasis model assessment (HOMA) - BC6OTHER resistance index, beta cell function measured by HOMA - β index, BC6OTHER and BC6OTHER levels.	False
Forty premenopausal women with prolactinoma or idiopathic hyperprolactinemia were compared to 41 age - matched healthy premenopausal women with regard to body weight, body mass index, waist and hip circumferences, waist to hip ratio, fasting plasma BC6ENTC , BC6OTHER levels, BC6OTHER resistance measured by homeostasis model assessment (HOMA) - BC6ENTG resistance index, beta cell function measured by HOMA - β index, BC6OTHER and BC6OTHER levels.	False
Forty premenopausal women with prolactinoma or idiopathic hyperprolactinemia were compared to 41 age - matched healthy premenopausal women with regard to body weight, body mass index, waist and hip circumferences, waist to hip ratio, fasting plasma BC6ENTC , BC6OTHER levels, BC6OTHER resistance measured by homeostasis model assessment (HOMA) - BC6OTHER resistance index, beta cell function measured by HOMA - β index, BC6ENTG and BC6OTHER levels.	False
Forty premenopausal women with prolactinoma or idiopathic hyperprolactinemia were compared to 41 age - matched healthy premenopausal women with regard to body weight, body mass index, waist and hip circumferences, waist to hip ratio, fasting plasma BC6ENTC , BC6OTHER levels, BC6OTHER resistance measured by homeostasis model assessment (HOMA) - BC6OTHER resistance index, beta cell function measured by HOMA - β index, BC6OTHER and BC6ENTG levels.	False
BC6ENTG and BC6OTHER may form metabolons with BC6OTHER and BC6OTHER , respectively, but no BC6ENTC enzyme is known to associate with BC6OTHER .	False
BC6OTHER and BC6ENTG may form metabolons with BC6OTHER and BC6OTHER , respectively, but no BC6ENTC enzyme is known to associate with BC6OTHER .	False
BC6OTHER and BC6OTHER may form metabolons with BC6ENTG and BC6OTHER , respectively, but no BC6ENTC enzyme is known to associate with BC6OTHER .	False
BC6OTHER and BC6OTHER may form metabolons with BC6OTHER and BC6ENTG , respectively, but no BC6ENTC enzyme is known to associate with BC6OTHER .	False
BC6OTHER and BC6OTHER may form metabolons with BC6OTHER and BC6OTHER , respectively, but no BC6ENTC enzyme is known to associate with BC6ENTG .	False
Nine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6ENTC BC6ENTG reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ).	False
Nine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6ENTC BC6OTHER reactions, including BC6ENTG ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ).	False
Nine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6ENTC BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6ENTG ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ).	False
Nine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6ENTC BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ).	False
Nine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6ENTC BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6ENTG ).	False
Most halogenated BC6ENTC are metabolized by BC6OTHER BC6ENTG to BC6OTHER , BC6OTHER , and an BC6OTHER (with BC6OTHER ) or an BC6OTHER (with BC6OTHER ) that may eliminate BC6OTHER to give a BC6OTHER , which reacts with BC6OTHER groups of BC6OTHER residues in proteins.	CPR:9
Most halogenated BC6OTHER are metabolized by BC6ENTC BC6ENTG to BC6OTHER , BC6OTHER , and an BC6OTHER (with BC6OTHER ) or an BC6OTHER (with BC6OTHER ) that may eliminate BC6OTHER to give a BC6OTHER , which reacts with BC6OTHER groups of BC6OTHER residues in proteins.	False
Most halogenated BC6OTHER are metabolized by BC6OTHER BC6ENTG to BC6ENTC , BC6OTHER , and an BC6OTHER (with BC6OTHER ) or an BC6OTHER (with BC6OTHER ) that may eliminate BC6OTHER to give a BC6OTHER , which reacts with BC6OTHER groups of BC6OTHER residues in proteins.	CPR:9
Most halogenated BC6OTHER are metabolized by BC6OTHER BC6ENTG to BC6OTHER , BC6ENTC , and an BC6OTHER (with BC6OTHER ) or an BC6OTHER (with BC6OTHER ) that may eliminate BC6OTHER to give a BC6OTHER , which reacts with BC6OTHER groups of BC6OTHER residues in proteins.	CPR:9
Most halogenated BC6OTHER are metabolized by BC6OTHER BC6ENTG to BC6OTHER , BC6OTHER , and an BC6ENTC (with BC6OTHER ) or an BC6OTHER (with BC6OTHER ) that may eliminate BC6OTHER to give a BC6OTHER , which reacts with BC6OTHER groups of BC6OTHER residues in proteins.	CPR:9
Most halogenated BC6OTHER are metabolized by BC6OTHER BC6ENTG to BC6OTHER , BC6OTHER , and an BC6OTHER (with BC6ENTC ) or an BC6OTHER (with BC6OTHER ) that may eliminate BC6OTHER to give a BC6OTHER , which reacts with BC6OTHER groups of BC6OTHER residues in proteins.	CPR:9
Most halogenated BC6OTHER are metabolized by BC6OTHER BC6ENTG to BC6OTHER , BC6OTHER , and an BC6OTHER (with BC6OTHER ) or an BC6ENTC (with BC6OTHER ) that may eliminate BC6OTHER to give a BC6OTHER , which reacts with BC6OTHER groups of BC6OTHER residues in proteins.	CPR:9
Most halogenated BC6OTHER are metabolized by BC6OTHER BC6ENTG to BC6OTHER , BC6OTHER , and an BC6OTHER (with BC6OTHER ) or an BC6OTHER (with BC6ENTC ) that may eliminate BC6OTHER to give a BC6OTHER , which reacts with BC6OTHER groups of BC6OTHER residues in proteins.	CPR:9
Most halogenated BC6OTHER are metabolized by BC6OTHER BC6ENTG to BC6OTHER , BC6OTHER , and an BC6OTHER (with BC6OTHER ) or an BC6OTHER (with BC6OTHER ) that may eliminate BC6ENTC to give a BC6OTHER , which reacts with BC6OTHER groups of BC6OTHER residues in proteins.	False
Nine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6ENTG reactions, including mitochondrial BC6ENTC aminotransferase ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ).	False
Nine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6ENTC aminotransferase ( BC6ENTG ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ).	False
Nine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6ENTC aminotransferase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ).	False
Nine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6ENTC aminotransferase ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6ENTG ).	False
Most halogenated BC6OTHER are metabolized by BC6OTHER BC6ENTG to BC6OTHER , BC6OTHER , and an BC6OTHER (with BC6OTHER ) or an BC6OTHER (with BC6OTHER ) that may eliminate BC6OTHER to give a BC6ENTC , which reacts with BC6OTHER groups of BC6OTHER residues in proteins.	False
Most halogenated BC6OTHER are metabolized by BC6OTHER BC6ENTG to BC6OTHER , BC6OTHER , and an BC6OTHER (with BC6OTHER ) or an BC6OTHER (with BC6OTHER ) that may eliminate BC6OTHER to give a BC6OTHER , which reacts with BC6ENTC groups of BC6OTHER residues in proteins.	False
Most halogenated BC6OTHER are metabolized by BC6OTHER BC6ENTG to BC6OTHER , BC6OTHER , and an BC6OTHER (with BC6OTHER ) or an BC6OTHER (with BC6OTHER ) that may eliminate BC6OTHER to give a BC6OTHER , which reacts with BC6OTHER groups of BC6ENTC residues in proteins.	False
Nine mammalian BC6ENTC ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6ENTG reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ).	False
Nine mammalian BC6ENTC ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including BC6ENTG ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ).	False
Nine mammalian BC6ENTC ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6ENTG ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ).	False
Nine mammalian BC6ENTC ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ).	False
Nine mammalian BC6ENTC ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6ENTG ).	False
Nine mammalian BC6OTHER ( BC6ENTC ) - containing enzymes catalyze BC6OTHER BC6ENTG reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ).	False
Nine mammalian BC6OTHER ( BC6ENTC ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including BC6ENTG ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ).	False
Nine mammalian BC6OTHER ( BC6ENTC ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6ENTG ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ).	False
Nine mammalian BC6OTHER ( BC6ENTC ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ).	False
Nine mammalian BC6OTHER ( BC6ENTC ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6ENTG ).	False
Nine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6ENTG reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and mitochondrial BC6ENTC aminotransferase ( BC6OTHER ).	False
Nine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including BC6ENTG ( BC6OTHER ), and mitochondrial BC6ENTC aminotransferase ( BC6OTHER ).	False
Nine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6ENTG ), and mitochondrial BC6ENTC aminotransferase ( BC6OTHER ).	False
Nine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and mitochondrial BC6ENTC aminotransferase ( BC6ENTG ).	False
Most of the BC6ENTC BC6ENTG are syncatalytically inactivated.	False
Interestingly, the BC6ENTC - and BC6OTHER dehydrogenase complexes ( BC6ENTG and BC6OTHER ), but not the BC6OTHER dehydrogenase complex ( BC6OTHER ), are susceptible to inactivation.	False
Interestingly, the BC6ENTC - and BC6OTHER dehydrogenase complexes ( BC6OTHER and BC6ENTG ), but not the BC6OTHER dehydrogenase complex ( BC6OTHER ), are susceptible to inactivation.	False
Interestingly, the BC6ENTC - and BC6OTHER dehydrogenase complexes ( BC6OTHER and BC6OTHER ), but not the BC6ENTG ( BC6OTHER ), are susceptible to inactivation.	False
Interestingly, the BC6ENTC - and BC6OTHER dehydrogenase complexes ( BC6OTHER and BC6OTHER ), but not the BC6OTHER dehydrogenase complex ( BC6ENTG ), are susceptible to inactivation.	False
Interestingly, the BC6OTHER - and BC6ENTC dehydrogenase complexes ( BC6ENTG and BC6OTHER ), but not the BC6OTHER dehydrogenase complex ( BC6OTHER ), are susceptible to inactivation.	False
Interestingly, the BC6OTHER - and BC6ENTC dehydrogenase complexes ( BC6OTHER and BC6ENTG ), but not the BC6OTHER dehydrogenase complex ( BC6OTHER ), are susceptible to inactivation.	False
Interestingly, the BC6OTHER - and BC6ENTC dehydrogenase complexes ( BC6OTHER and BC6OTHER ), but not the BC6ENTG ( BC6OTHER ), are susceptible to inactivation.	False
Interestingly, the BC6OTHER - and BC6ENTC dehydrogenase complexes ( BC6OTHER and BC6OTHER ), but not the BC6OTHER dehydrogenase complex ( BC6ENTG ), are susceptible to inactivation.	False
Interestingly, the BC6ENTG ( BC6OTHER and BC6OTHER ), but not the BC6ENTC dehydrogenase complex ( BC6OTHER ), are susceptible to inactivation.	False
Interestingly, the BC6OTHER - and BC6OTHER dehydrogenase complexes ( BC6ENTG and BC6OTHER ), but not the BC6ENTC dehydrogenase complex ( BC6OTHER ), are susceptible to inactivation.	False
Interestingly, the BC6OTHER - and BC6OTHER dehydrogenase complexes ( BC6OTHER and BC6ENTG ), but not the BC6ENTC dehydrogenase complex ( BC6OTHER ), are susceptible to inactivation.	False
Interestingly, the BC6OTHER - and BC6OTHER dehydrogenase complexes ( BC6OTHER and BC6OTHER ), but not the BC6ENTC dehydrogenase complex ( BC6ENTG ), are susceptible to inactivation.	False
This study shows ability of BC6OTHER to raise plasma BC6OTHER concentrations, mainly through BC6ENTG upregulation, and to decrease bile production through reduction in BC6OTHER - mediated BC6ENTC - independent bile flow.	False
This study shows ability of BC6OTHER to raise plasma BC6OTHER concentrations, mainly through BC6OTHER upregulation, and to decrease bile production through reduction in BC6ENTG - mediated BC6ENTC - independent bile flow.	False
Accordingly, the main BC6ENTC transporter on the hepatocyte canalicular membrane, BC6ENTG ( BC6OTHER ), was significantly decreased at the protein level.	False
Accordingly, the main BC6ENTC transporter on the hepatocyte canalicular membrane, BC6OTHER ( BC6ENTG ), was significantly decreased at the protein level.	False
While protein levels of the main hepatic BC6ENTC transporters were unchanged, the rate - limiting enzyme in the BC6OTHER synthesis, BC6ENTG , was significantly increased by BC6OTHER .	False
While protein levels of the main BC6ENTG were unchanged, the rate - limiting enzyme in the BC6ENTC synthesis, BC6OTHER , was significantly increased by BC6OTHER .	False
While protein levels of the main hepatic BC6OTHER transporters were unchanged, the rate - limiting enzyme in the BC6ENTC synthesis, BC6ENTG , was significantly increased by BC6OTHER .	False
While protein levels of the main BC6ENTG were unchanged, the rate - limiting enzyme in the BC6OTHER synthesis, BC6OTHER , was significantly increased by BC6ENTC .	False
While protein levels of the main hepatic BC6OTHER transporters were unchanged, the rate - limiting enzyme in the BC6OTHER synthesis, BC6ENTG , was significantly increased by BC6ENTC .	False
Cholestatic effect of BC6ENTC in rats is mediated via decreased expression of BC6ENTG .	False
In contrast, BC6ENTC markedly downregulated major BC6ENTG ( BC6OTHER and BC6OTHER ) and regulatory molecules ( BC6OTHER and BC6OTHER ) in the ileum.	CPR:4
In contrast, BC6ENTC markedly downregulated major BC6OTHER transporters ( BC6ENTG and BC6OTHER ) and regulatory molecules ( BC6OTHER and BC6OTHER ) in the ileum.	CPR:4
In contrast, BC6ENTC markedly downregulated major BC6OTHER transporters ( BC6OTHER and BC6ENTG ) and regulatory molecules ( BC6OTHER and BC6OTHER ) in the ileum.	CPR:4
In contrast, BC6ENTC markedly downregulated major BC6OTHER transporters ( BC6OTHER and BC6OTHER ) and regulatory molecules ( BC6ENTG and BC6OTHER ) in the ileum.	CPR:4
In contrast, BC6ENTC markedly downregulated major BC6OTHER transporters ( BC6OTHER and BC6OTHER ) and regulatory molecules ( BC6OTHER and BC6ENTG ) in the ileum.	CPR:4
In contrast, BC6OTHER markedly downregulated major BC6ENTC transporters ( BC6ENTG and BC6OTHER ) and regulatory molecules ( BC6OTHER and BC6OTHER ) in the ileum.	False
In contrast, BC6OTHER markedly downregulated major BC6ENTC transporters ( BC6OTHER and BC6ENTG ) and regulatory molecules ( BC6OTHER and BC6OTHER ) in the ileum.	False
In contrast, BC6OTHER markedly downregulated major BC6ENTC transporters ( BC6OTHER and BC6OTHER ) and regulatory molecules ( BC6ENTG and BC6OTHER ) in the ileum.	False
In contrast, BC6OTHER markedly downregulated major BC6ENTC transporters ( BC6OTHER and BC6OTHER ) and regulatory molecules ( BC6OTHER and BC6ENTG ) in the ileum.	False
This study shows ability of BC6ENTC to raise plasma BC6OTHER concentrations, mainly through BC6ENTG upregulation, and to decrease bile production through reduction in BC6OTHER - mediated BC6OTHER - independent bile flow.	CPR:3
This study shows ability of BC6ENTC to raise plasma BC6OTHER concentrations, mainly through BC6OTHER upregulation, and to decrease bile production through reduction in BC6ENTG - mediated BC6OTHER - independent bile flow.	False
This study shows ability of BC6OTHER to raise plasma BC6ENTC concentrations, mainly through BC6ENTG upregulation, and to decrease bile production through reduction in BC6OTHER - mediated BC6OTHER - independent bile flow.	False
This study shows ability of BC6OTHER to raise plasma BC6ENTC concentrations, mainly through BC6OTHER upregulation, and to decrease bile production through reduction in BC6ENTG - mediated BC6OTHER - independent bile flow.	False
Similarly, intraperitoneal administration of BC6ENTC (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6ENTC (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6ENTC (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6ENTC (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6ENTG , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6ENTG , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6ENTG , BC6ENTC , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6ENTC , BC6ENTG , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC dismutase, BC6ENTG , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC dismutase, BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC dismutase, BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , free BC6ENTC , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , free BC6ENTC , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , free BC6ENTC , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , free BC6ENTC , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , free BC6OTHER , protein BC6ENTC , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6ENTC , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6ENTC , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , free BC6OTHER , protein BC6ENTC , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , free BC6OTHER , protein BC6OTHER , BC6ENTC , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6ENTC , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6ENTC , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6ENTC , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6ENTC contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6ENTC contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6ENTC contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6ENTC contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6ENTC mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6ENTC mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6ENTC mediated oxidative stress induced mice.	False
Similarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6ENTC mediated oxidative stress induced mice.	False
In sum the results of the present study indicate that BC6OTHER - induced expression of BC6ENTG expression depends on a novel BC6ENTC response element.	False
BC6OTHER is known to induce expression of the BC6ENTG ( BC6OTHER ) gene which propels BC6OTHER - induced cell cycle arrest and differentiation of HL - 60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of BC6OTHER expression by BC6ENTC .	False
BC6OTHER is known to induce expression of the BC6OTHER ( BC6ENTG ) gene which propels BC6OTHER - induced cell cycle arrest and differentiation of HL - 60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of BC6OTHER expression by BC6ENTC .	False
BC6OTHER is known to induce expression of the BC6OTHER ( BC6OTHER ) gene which propels BC6OTHER - induced cell cycle arrest and differentiation of HL - 60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of BC6ENTG expression by BC6ENTC .	CPR:3
The BC6ENTC - treated HL - 60 cells used here expressed all BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) subtypes (as detected by Northern analysis) except BC6OTHER .	False
The BC6ENTC - treated HL - 60 cells used here expressed all BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) subtypes (as detected by Northern analysis) except BC6OTHER .	False
The BC6ENTC - treated HL - 60 cells used here expressed all BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) subtypes (as detected by Northern analysis) except BC6OTHER .	False
The BC6ENTC - treated HL - 60 cells used here expressed all BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) subtypes (as detected by Northern analysis) except BC6OTHER .	False
The BC6ENTC - treated HL - 60 cells used here expressed all BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) subtypes (as detected by Northern analysis) except BC6ENTG .	False
The BC6OTHER - treated HL - 60 cells used here expressed all BC6ENTC receptor ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) subtypes (as detected by Northern analysis) except BC6OTHER .	False
The BC6OTHER - treated HL - 60 cells used here expressed all BC6ENTC receptor ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) subtypes (as detected by Northern analysis) except BC6OTHER .	False
The BC6OTHER - treated HL - 60 cells used here expressed all BC6ENTC receptor ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) subtypes (as detected by Northern analysis) except BC6OTHER .	False
The BC6OTHER - treated HL - 60 cells used here expressed all BC6ENTC receptor ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) subtypes (as detected by Northern analysis) except BC6ENTG .	False
The BC6OTHER - treated HL - 60 cells used here expressed all BC6ENTG ( BC6OTHER ) and BC6ENTC X receptor ( BC6OTHER ) subtypes (as detected by Northern analysis) except BC6OTHER .	False
The BC6OTHER - treated HL - 60 cells used here expressed all BC6OTHER ( BC6ENTG ) and BC6ENTC X receptor ( BC6OTHER ) subtypes (as detected by Northern analysis) except BC6OTHER .	False
The BC6OTHER - treated HL - 60 cells used here expressed all BC6OTHER ( BC6OTHER ) and BC6ENTC X receptor ( BC6ENTG ) subtypes (as detected by Northern analysis) except BC6OTHER .	False
The BC6OTHER - treated HL - 60 cells used here expressed all BC6OTHER ( BC6OTHER ) and BC6ENTC X receptor ( BC6OTHER ) subtypes (as detected by Northern analysis) except BC6ENTG .	False
A 5' - flanking region capable of supporting BC6ENTC - induced BC6ENTG activation in HL - 60 cells was found to contain a 205 - bp sequence in the distal portion that was necessary for transcriptional activation by BC6OTHER .	CPR:3
A 5' - flanking region capable of supporting BC6OTHER - induced BC6ENTG activation in HL - 60 cells was found to contain a 205 - bp sequence in the distal portion that was necessary for transcriptional activation by BC6ENTC .	False
Within this sequence BC6OTHER footprinting revealed that BC6ENTC induced binding of a BC6OTHER to an element containing two BC6ENTG .	False
Within this sequence BC6ENTG footprinting revealed that BC6ENTC induced binding of a BC6OTHER to an element containing two BC6OTHER .	False
Within this sequence BC6OTHER footprinting revealed that BC6ENTC induced binding of a BC6ENTG to an element containing two BC6OTHER .	False
A novel BC6OTHER regulates BC6ENTC - induced BC6ENTG expression.	CPR:3
A novel BC6ENTG regulates BC6ENTC - induced BC6OTHER expression.	False
A novel BC6ENTC - responsive element regulates BC6OTHER - induced BC6ENTG expression.	False
BC6ENTC is known to induce expression of the BC6ENTG ( BC6OTHER ) gene which propels BC6OTHER - induced cell cycle arrest and differentiation of HL - 60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of BC6OTHER expression by BC6OTHER .	CPR:3
BC6ENTC is known to induce expression of the BC6OTHER ( BC6ENTG ) gene which propels BC6OTHER - induced cell cycle arrest and differentiation of HL - 60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of BC6OTHER expression by BC6OTHER .	CPR:3
BC6ENTC is known to induce expression of the BC6OTHER ( BC6OTHER ) gene which propels BC6OTHER - induced cell cycle arrest and differentiation of HL - 60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of BC6ENTG expression by BC6OTHER .	False
Both BC6ENTG were needed for binding the complex, and mutation of either BC6OTHER caused the loss of transcriptional activation by BC6ENTC .	False
Both BC6OTHER were needed for binding the complex, and mutation of either BC6ENTG caused the loss of transcriptional activation by BC6ENTC .	False
The ability of this cis - acting BC6ENTG to activate transcription in response to BC6ENTC also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6OTHER response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary.	False
The ability of this cis - acting BC6OTHER to activate transcription in response to BC6ENTC also depended on downstream sequences where an BC6ENTG ( BC6OTHER ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6OTHER response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary.	False
The ability of this cis - acting BC6OTHER to activate transcription in response to BC6ENTC also depended on downstream sequences where an BC6OTHER ( BC6ENTG ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6OTHER response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary.	False
The ability of this cis - acting BC6OTHER to activate transcription in response to BC6ENTC also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6ENTG ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6OTHER response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary.	CPR:4
The ability of this cis - acting BC6OTHER to activate transcription in response to BC6ENTC also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6OTHER ( BC6ENTG ) site between this element and the transcriptional start, as well as a BC6OTHER response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary.	False
The ability of this cis - acting BC6OTHER to activate transcription in response to BC6ENTC also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6ENTG ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary.	False
The ability of this cis - acting BC6OTHER to activate transcription in response to BC6ENTC also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6OTHER response element binding factor ( BC6ENTG ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary.	False
The ability of this cis - acting BC6OTHER to activate transcription in response to BC6ENTC also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6OTHER response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6ENTG gene, were necessary.	False
The ability of this cis - acting BC6ENTG to activate transcription in response to BC6OTHER also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6ENTC response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary.	False
The ability of this cis - acting BC6OTHER to activate transcription in response to BC6OTHER also depended on downstream sequences where an BC6ENTG ( BC6OTHER ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6ENTC response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary.	False
The ability of this cis - acting BC6OTHER to activate transcription in response to BC6OTHER also depended on downstream sequences where an BC6OTHER ( BC6ENTG ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6ENTC response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary.	False
The ability of this cis - acting BC6OTHER to activate transcription in response to BC6OTHER also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6ENTG ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6ENTC response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary.	False
The ability of this cis - acting BC6OTHER to activate transcription in response to BC6OTHER also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6OTHER ( BC6ENTG ) site between this element and the transcriptional start, as well as a BC6ENTC response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary.	False
The ability of this cis - acting BC6OTHER to activate transcription in response to BC6OTHER also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6ENTC response element binding factor ( BC6ENTG ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary.	False
The ability of this cis - acting BC6OTHER to activate transcription in response to BC6OTHER also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6ENTC response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6ENTG gene, were necessary.	False
A transcription factor - transcription factor binding array analysis of nuclear lysate from BC6ENTC - treated cells indicated several prominent BC6ENTG binding partners; among these, BC6OTHER , BC6OTHER , and BC6OTHER were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex.	False
A transcription factor - transcription factor binding array analysis of nuclear lysate from BC6ENTC - treated cells indicated several prominent BC6OTHER binding partners; among these, BC6ENTG , BC6OTHER , and BC6OTHER were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex.	False
A transcription factor - transcription factor binding array analysis of nuclear lysate from BC6ENTC - treated cells indicated several prominent BC6OTHER binding partners; among these, BC6OTHER , BC6ENTG , and BC6OTHER were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex.	False
A transcription factor - transcription factor binding array analysis of nuclear lysate from BC6ENTC - treated cells indicated several prominent BC6OTHER binding partners; among these, BC6OTHER , BC6OTHER , and BC6ENTG were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex.	False
In sum the results of the present study indicate that BC6ENTC - induced expression of BC6ENTG expression depends on a novel BC6OTHER .	CPR:3
In sum the results of the present study indicate that BC6ENTC - induced expression of BC6OTHER expression depends on a novel BC6ENTG .	False
BC6OTHER is known to induce expression of the BC6ENTG ( BC6OTHER ) gene which propels BC6ENTC - induced cell cycle arrest and differentiation of HL - 60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of BC6OTHER expression by BC6OTHER .	False
BC6OTHER is known to induce expression of the BC6OTHER ( BC6ENTG ) gene which propels BC6ENTC - induced cell cycle arrest and differentiation of HL - 60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of BC6OTHER expression by BC6OTHER .	False
BC6OTHER is known to induce expression of the BC6OTHER ( BC6OTHER ) gene which propels BC6ENTC - induced cell cycle arrest and differentiation of HL - 60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of BC6ENTG expression by BC6OTHER .	False
BC6ENTC ( BC6OTHER , BC6OTHER 's active form) failed to prevent E2 - induced proteolysis of BC6ENTG and migration, but rather triggered BC6OTHER cleavage coincident with augmented migration.	False
BC6ENTC ( BC6OTHER , BC6OTHER 's active form) failed to prevent E2 - induced proteolysis of BC6OTHER and migration, but rather triggered BC6ENTG cleavage coincident with augmented migration.	False
BC6OTHER ( BC6ENTC , BC6OTHER 's active form) failed to prevent E2 - induced proteolysis of BC6ENTG and migration, but rather triggered BC6OTHER cleavage coincident with augmented migration.	False
BC6OTHER ( BC6ENTC , BC6OTHER 's active form) failed to prevent E2 - induced proteolysis of BC6OTHER and migration, but rather triggered BC6ENTG cleavage coincident with augmented migration.	False
BC6OTHER ( BC6OTHER , BC6ENTC 's active form) failed to prevent E2 - induced proteolysis of BC6ENTG and migration, but rather triggered BC6OTHER cleavage coincident with augmented migration.	False
BC6OTHER ( BC6OTHER , BC6ENTC 's active form) failed to prevent E2 - induced proteolysis of BC6OTHER and migration, but rather triggered BC6ENTG cleavage coincident with augmented migration.	False
BC6ENTC - induced BC6OTHER truncation also occurred in SK - BR - 3 cells that express BC6OTHER and lack BC6OTHER , but not in CHEM - MB - 231 cells that express neither BC6ENTG nor BC6OTHER .	False
BC6ENTC - induced BC6OTHER truncation also occurred in SK - BR - 3 cells that express BC6OTHER and lack BC6OTHER , but not in CHEM - MB - 231 cells that express neither BC6OTHER nor BC6ENTG .	False
BC6ENTC - induced BC6ENTG truncation also occurred in SK - BR - 3 cells that express BC6OTHER and lack BC6OTHER , but not in CHEM - MB - 231 cells that express neither BC6OTHER nor BC6OTHER .	False
BC6ENTC - induced BC6OTHER truncation also occurred in SK - BR - 3 cells that express BC6ENTG and lack BC6OTHER , but not in CHEM - MB - 231 cells that express neither BC6OTHER nor BC6OTHER .	False
BC6ENTC - induced BC6OTHER truncation also occurred in SK - BR - 3 cells that express BC6OTHER and lack BC6ENTG , but not in CHEM - MB - 231 cells that express neither BC6OTHER nor BC6OTHER .	False
 BC6ENTC - stimulated processing of BC6OTHER is mediated via BC6OTHER ( BC6ENTG and accompanied by enhanced migration in MCF - 7 breast cancer cells.	False
 BC6ENTC - stimulated processing of BC6ENTG is mediated via BC6OTHER ( BC6OTHER and accompanied by enhanced migration in MCF - 7 breast cancer cells.	CPR:3
 BC6ENTC - stimulated processing of BC6OTHER is mediated via BC6ENTG ( BC6OTHER and accompanied by enhanced migration in MCF - 7 breast cancer cells.	False
Furthermore, BC6ENTC - stimulated cleavage of BC6ENTG and migration were tremendously attenuated by G15, a BC6OTHER antagonist, or siRNA against BC6OTHER .	False
Furthermore, BC6ENTC - stimulated cleavage of BC6OTHER and migration were tremendously attenuated by G15, a BC6ENTG antagonist, or siRNA against BC6OTHER .	False
Furthermore, BC6ENTC - stimulated cleavage of BC6OTHER and migration were tremendously attenuated by G15, a BC6OTHER antagonist, or siRNA against BC6ENTG .	False
BC6ENTC (E2) has been recently shown to induce BC6ENTG processing in breast cancer cells.	CPR:3
In addition, inhibitors for BC6ENTG or BC6OTHER remarkably suppressed BC6ENTC - induced truncation of BC6OTHER , suggesting involvement of BC6OTHER signaling.	False
In addition, inhibitors for BC6OTHER or BC6ENTG remarkably suppressed BC6ENTC - induced truncation of BC6OTHER , suggesting involvement of BC6OTHER signaling.	False
In addition, inhibitors for BC6OTHER or BC6OTHER remarkably suppressed BC6ENTC - induced truncation of BC6ENTG , suggesting involvement of BC6OTHER signaling.	False
In addition, inhibitors for BC6OTHER or BC6OTHER remarkably suppressed BC6ENTC - induced truncation of BC6OTHER , suggesting involvement of BC6ENTG signaling.	False
Collectively, our data indicate that BC6ENTC contributes to the production of proteolyzed BC6ENTG via BC6OTHER with augmented migration in MCF - 7 cells.	CPR:3
Collectively, our data indicate that BC6ENTC contributes to the production of proteolyzed BC6OTHER via BC6ENTG with augmented migration in MCF - 7 cells.	False
We therefore addressed possible effects of BC6ENTC on the generation of cleaved BC6ENTG and its signal mechanism(s) in BC6OTHER - responsive MCF - 7 breast cancer cells that express both BC6OTHER and BC6OTHER receptor α ( BC6OTHER ).	False
We therefore addressed possible effects of BC6ENTC on the generation of cleaved BC6OTHER and its signal mechanism(s) in BC6OTHER - responsive MCF - 7 breast cancer cells that express both BC6ENTG and BC6OTHER receptor α ( BC6OTHER ).	False
We therefore addressed possible effects of BC6ENTC on the generation of cleaved BC6OTHER and its signal mechanism(s) in BC6OTHER - responsive MCF - 7 breast cancer cells that express both BC6OTHER and BC6ENTG ( BC6OTHER ).	False
We therefore addressed possible effects of BC6ENTC on the generation of cleaved BC6OTHER and its signal mechanism(s) in BC6OTHER - responsive MCF - 7 breast cancer cells that express both BC6OTHER and BC6OTHER receptor α ( BC6ENTG ).	False
We therefore addressed possible effects of BC6OTHER on the generation of cleaved BC6ENTG and its signal mechanism(s) in BC6ENTC - responsive MCF - 7 breast cancer cells that express both BC6OTHER and BC6OTHER receptor α ( BC6OTHER ).	False
We therefore addressed possible effects of BC6OTHER on the generation of cleaved BC6OTHER and its signal mechanism(s) in BC6ENTC - responsive MCF - 7 breast cancer cells that express both BC6ENTG and BC6OTHER receptor α ( BC6OTHER ).	False
We therefore addressed possible effects of BC6OTHER on the generation of cleaved BC6OTHER and its signal mechanism(s) in BC6ENTC - responsive MCF - 7 breast cancer cells that express both BC6OTHER and BC6ENTG ( BC6OTHER ).	False
We therefore addressed possible effects of BC6OTHER on the generation of cleaved BC6OTHER and its signal mechanism(s) in BC6ENTC - responsive MCF - 7 breast cancer cells that express both BC6OTHER and BC6OTHER receptor α ( BC6ENTG ).	False
We therefore addressed possible effects of BC6OTHER on the generation of cleaved BC6ENTG and its signal mechanism(s) in BC6OTHER - responsive MCF - 7 breast cancer cells that express both BC6OTHER and BC6ENTC receptor α ( BC6OTHER ).	False
We therefore addressed possible effects of BC6OTHER on the generation of cleaved BC6OTHER and its signal mechanism(s) in BC6OTHER - responsive MCF - 7 breast cancer cells that express both BC6ENTG and BC6ENTC receptor α ( BC6OTHER ).	False
We therefore addressed possible effects of BC6OTHER on the generation of cleaved BC6OTHER and its signal mechanism(s) in BC6OTHER - responsive MCF - 7 breast cancer cells that express both BC6OTHER and BC6ENTC receptor α ( BC6ENTG ).	False
The BC6ENTG ( BC6OTHER ) activity and BC6OTHER ( BC6ENTC ) level in cell supernatant were detected by kits while the intracellular reactive BC6OTHER species (ROS) generation was determined by BC6OTHER ( BC6OTHER ) kit.	False
The BC6OTHER dismutase ( BC6ENTG ) activity and BC6OTHER ( BC6ENTC ) level in cell supernatant were detected by kits while the intracellular reactive BC6OTHER species (ROS) generation was determined by BC6OTHER ( BC6OTHER ) kit.	False
Protection of BC6ENTC against AGEs - induced endothelial dysfunction through inhibiting BC6OTHER / BC6ENTG pathway activation in human umbilical vein endothelial cells.	False
Protection of BC6ENTC against AGEs - induced endothelial dysfunction through inhibiting BC6ENTG / BC6OTHER pathway activation in human umbilical vein endothelial cells.	False
The BC6ENTG ( BC6OTHER ) activity and BC6OTHER ( BC6OTHER ) level in cell supernatant were detected by kits while the intracellular reactive BC6ENTC species (ROS) generation was determined by BC6OTHER ( BC6OTHER ) kit.	False
The BC6OTHER dismutase ( BC6ENTG ) activity and BC6OTHER ( BC6OTHER ) level in cell supernatant were detected by kits while the intracellular reactive BC6ENTC species (ROS) generation was determined by BC6OTHER ( BC6OTHER ) kit.	False
The BC6ENTG ( BC6OTHER ) activity and BC6OTHER ( BC6OTHER ) level in cell supernatant were detected by kits while the intracellular reactive BC6OTHER species (ROS) generation was determined by BC6ENTC ( BC6OTHER ) kit.	False
The BC6OTHER dismutase ( BC6ENTG ) activity and BC6OTHER ( BC6OTHER ) level in cell supernatant were detected by kits while the intracellular reactive BC6OTHER species (ROS) generation was determined by BC6ENTC ( BC6OTHER ) kit.	False
The BC6ENTG ( BC6OTHER ) activity and BC6OTHER ( BC6OTHER ) level in cell supernatant were detected by kits while the intracellular reactive BC6OTHER species (ROS) generation was determined by BC6OTHER ( BC6ENTC ) kit.	False
The BC6OTHER dismutase ( BC6ENTG ) activity and BC6OTHER ( BC6OTHER ) level in cell supernatant were detected by kits while the intracellular reactive BC6OTHER species (ROS) generation was determined by BC6OTHER ( BC6ENTC ) kit.	False
GA significantly increased antioxidant enzyme BC6ENTG activity and decreased CHEM degradation product BC6ENTC level in a dose - dependent manner.	False
The BC6ENTC dismutase ( BC6ENTG ) activity and BC6OTHER ( BC6OTHER ) level in cell supernatant were detected by kits while the intracellular reactive BC6OTHER species (ROS) generation was determined by BC6OTHER ( BC6OTHER ) kit.	False
The BC6ENTG ( BC6OTHER ) activity and BC6ENTC ( BC6OTHER ) level in cell supernatant were detected by kits while the intracellular reactive BC6OTHER species (ROS) generation was determined by BC6OTHER ( BC6OTHER ) kit.	False
The BC6OTHER dismutase ( BC6ENTG ) activity and BC6ENTC ( BC6OTHER ) level in cell supernatant were detected by kits while the intracellular reactive BC6OTHER species (ROS) generation was determined by BC6OTHER ( BC6OTHER ) kit.	False
BC6ENTC ( BC6OTHER , BC6OTHER ) is a relatively selective inhibitor of BC6ENTG ( BC6OTHER ), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.	CPR:4
BC6ENTC ( BC6OTHER , BC6OTHER ) is a relatively selective inhibitor of BC6OTHER ( BC6ENTG ), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.	CPR:4
BC6OTHER ( BC6ENTC , BC6OTHER ) is a relatively selective inhibitor of BC6ENTG ( BC6OTHER ), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.	CPR:4
BC6OTHER ( BC6ENTC , BC6OTHER ) is a relatively selective inhibitor of BC6OTHER ( BC6ENTG ), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.	CPR:4
BC6OTHER ( BC6OTHER , BC6ENTC ) is a relatively selective inhibitor of BC6ENTG ( BC6OTHER ), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.	CPR:4
BC6OTHER ( BC6OTHER , BC6ENTC ) is a relatively selective inhibitor of BC6OTHER ( BC6ENTG ), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.	CPR:4
Affinity chromatography investigations have shown that BC6ENTC also interacts with BC6ENTG .	False
BC6ENTG ( BC6OTHER ) catalyzes the phosphorylation of BC6ENTC , BC6OTHER , and BC6OTHER in the presence of BC6OTHER and BC6OTHER .	CPR:9
BC6OTHER ( BC6ENTG ) catalyzes the phosphorylation of BC6ENTC , BC6OTHER , and BC6OTHER in the presence of BC6OTHER and BC6OTHER .	CPR:9
BC6ENTG ( BC6OTHER ) catalyzes the phosphorylation of BC6OTHER , BC6ENTC , and BC6OTHER in the presence of BC6OTHER and BC6OTHER .	CPR:9
BC6OTHER ( BC6ENTG ) catalyzes the phosphorylation of BC6OTHER , BC6ENTC , and BC6OTHER in the presence of BC6OTHER and BC6OTHER .	CPR:9
To understand this interaction, we determined the crystal structure of BC6ENTG in complex with BC6ENTC , BC6OTHER , and BC6OTHER , the two latter derivatives being designed to bind to BC6OTHER but not to BC6OTHER .	False
To understand this interaction, we determined the crystal structure of BC6OTHER in complex with BC6ENTC , BC6OTHER , and BC6OTHER , the two latter derivatives being designed to bind to BC6ENTG but not to BC6OTHER .	False
To understand this interaction, we determined the crystal structure of BC6OTHER in complex with BC6ENTC , BC6OTHER , and BC6OTHER , the two latter derivatives being designed to bind to BC6OTHER but not to BC6ENTG .	False
To understand this interaction, we determined the crystal structure of BC6ENTG in complex with BC6OTHER , BC6ENTC , and BC6OTHER , the two latter derivatives being designed to bind to BC6OTHER but not to BC6OTHER .	False
To understand this interaction, we determined the crystal structure of BC6OTHER in complex with BC6OTHER , BC6ENTC , and BC6OTHER , the two latter derivatives being designed to bind to BC6ENTG but not to BC6OTHER .	False
To understand this interaction, we determined the crystal structure of BC6OTHER in complex with BC6OTHER , BC6ENTC , and BC6OTHER , the two latter derivatives being designed to bind to BC6OTHER but not to BC6ENTG .	False
To understand this interaction, we determined the crystal structure of BC6ENTG in complex with BC6OTHER , BC6OTHER , and BC6ENTC , the two latter derivatives being designed to bind to BC6OTHER but not to BC6OTHER .	False
To understand this interaction, we determined the crystal structure of BC6OTHER in complex with BC6OTHER , BC6OTHER , and BC6ENTC , the two latter derivatives being designed to bind to BC6ENTG but not to BC6OTHER .	False
To understand this interaction, we determined the crystal structure of BC6OTHER in complex with BC6OTHER , BC6OTHER , and BC6ENTC , the two latter derivatives being designed to bind to BC6OTHER but not to BC6ENTG .	False
BC6ENTC kinase ( BC6ENTG ) catalyzes the phosphorylation of BC6OTHER , BC6OTHER , and BC6OTHER in the presence of BC6OTHER and BC6OTHER .	False
BC6ENTG ( BC6OTHER ) catalyzes the phosphorylation of BC6OTHER , BC6OTHER , and BC6ENTC in the presence of BC6OTHER and BC6OTHER .	CPR:9
BC6OTHER ( BC6ENTG ) catalyzes the phosphorylation of BC6OTHER , BC6OTHER , and BC6ENTC in the presence of BC6OTHER and BC6OTHER .	CPR:9
Structural analysis revealed that these three BC6ENTC bind similarly in the BC6OTHER - binding site of BC6ENTG rather than in the anticipated BC6OTHER - binding site.	False
Structural analysis revealed that these three BC6OTHER bind similarly in the BC6ENTC - binding site of BC6ENTG rather than in the anticipated BC6OTHER - binding site.	False
Structural analysis revealed that these three BC6OTHER bind similarly in the BC6OTHER - binding site of BC6ENTG rather than in the anticipated BC6ENTC - binding site.	False
Crystal structure of BC6ENTG in complex with BC6ENTC and derivatives.	False
BC6ENTG ( BC6OTHER ) catalyzes the phosphorylation of BC6OTHER , BC6OTHER , and BC6OTHER in the presence of BC6ENTC and BC6OTHER .	False
BC6OTHER ( BC6ENTG ) catalyzes the phosphorylation of BC6OTHER , BC6OTHER , and BC6OTHER in the presence of BC6ENTC and BC6OTHER .	False
This work provides detailed structural information on the interactions between BC6ENTG and BC6ENTC and analogs.	False
BC6ENTG ( BC6OTHER ) catalyzes the phosphorylation of BC6OTHER , BC6OTHER , and BC6OTHER in the presence of BC6OTHER and BC6ENTC .	False
BC6OTHER ( BC6ENTG ) catalyzes the phosphorylation of BC6OTHER , BC6OTHER , and BC6OTHER in the presence of BC6OTHER and BC6ENTC .	False
It could also aid in the design of BC6ENTC derivatives displaying strict selectivity for either BC6ENTG or BC6OTHER .	False
It could also aid in the design of BC6ENTC derivatives displaying strict selectivity for either BC6OTHER or BC6ENTG .	False
Altered antioxidant levels were demonstrated by depletion of BC6ENTC ( BC6OTHER ), a decreased ratio of reduced BC6OTHER to BC6OTHER ( BC6OTHER / BC6OTHER ) and an increased BC6ENTG ( BC6OTHER ) activation.	False
Altered antioxidant levels were demonstrated by depletion of BC6ENTC ( BC6OTHER ), a decreased ratio of reduced BC6OTHER to BC6OTHER ( BC6OTHER / BC6OTHER ) and an increased BC6OTHER ( BC6ENTG ) activation.	False
Altered antioxidant levels were demonstrated by depletion of BC6OTHER ( BC6ENTC ), a decreased ratio of reduced BC6OTHER to BC6OTHER ( BC6OTHER / BC6OTHER ) and an increased BC6ENTG ( BC6OTHER ) activation.	False
Altered antioxidant levels were demonstrated by depletion of BC6OTHER ( BC6ENTC ), a decreased ratio of reduced BC6OTHER to BC6OTHER ( BC6OTHER / BC6OTHER ) and an increased BC6OTHER ( BC6ENTG ) activation.	False
Altered antioxidant levels were demonstrated by depletion of BC6OTHER ( BC6OTHER ), a decreased ratio of reduced BC6ENTC to BC6OTHER ( BC6OTHER / BC6OTHER ) and an increased BC6ENTG ( BC6OTHER ) activation.	False
Altered antioxidant levels were demonstrated by depletion of BC6OTHER ( BC6OTHER ), a decreased ratio of reduced BC6ENTC to BC6OTHER ( BC6OTHER / BC6OTHER ) and an increased BC6OTHER ( BC6ENTG ) activation.	False
Altered antioxidant levels were demonstrated by depletion of BC6OTHER ( BC6OTHER ), a decreased ratio of reduced BC6OTHER to BC6ENTC ( BC6OTHER / BC6OTHER ) and an increased BC6ENTG ( BC6OTHER ) activation.	False
Altered antioxidant levels were demonstrated by depletion of BC6OTHER ( BC6OTHER ), a decreased ratio of reduced BC6OTHER to BC6ENTC ( BC6OTHER / BC6OTHER ) and an increased BC6OTHER ( BC6ENTG ) activation.	False
Altered antioxidant levels were demonstrated by depletion of BC6OTHER ( BC6OTHER ), a decreased ratio of reduced BC6OTHER to BC6OTHER ( BC6ENTC / BC6OTHER ) and an increased BC6ENTG ( BC6OTHER ) activation.	False
Altered antioxidant levels were demonstrated by depletion of BC6OTHER ( BC6OTHER ), a decreased ratio of reduced BC6OTHER to BC6OTHER ( BC6ENTC / BC6OTHER ) and an increased BC6OTHER ( BC6ENTG ) activation.	False
Altered antioxidant levels were demonstrated by depletion of BC6OTHER ( BC6OTHER ), a decreased ratio of reduced BC6OTHER to BC6OTHER ( BC6OTHER / BC6ENTC ) and an increased BC6ENTG ( BC6OTHER ) activation.	False
Altered antioxidant levels were demonstrated by depletion of BC6OTHER ( BC6OTHER ), a decreased ratio of reduced BC6OTHER to BC6OTHER ( BC6OTHER / BC6ENTC ) and an increased BC6OTHER ( BC6ENTG ) activation.	False
Enzyme assays showed that BC6ENTC dismutase ( BC6ENTG ) activity was elevated whereas BC6OTHER ( BC6OTHER ) and CHEM - BC6OTHER - transferase ( BC6OTHER ) activities were depressed.	False
Enzyme assays showed that BC6ENTC dismutase ( BC6OTHER ) activity was elevated whereas BC6ENTG ( BC6OTHER ) and CHEM - BC6OTHER - transferase ( BC6OTHER ) activities were depressed.	False
Enzyme assays showed that BC6ENTC dismutase ( BC6OTHER ) activity was elevated whereas BC6OTHER ( BC6ENTG ) and CHEM - BC6OTHER - transferase ( BC6OTHER ) activities were depressed.	False
Enzyme assays showed that BC6ENTC dismutase ( BC6OTHER ) activity was elevated whereas BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities were depressed.	False
Enzyme assays showed that BC6ENTC dismutase ( BC6OTHER ) activity was elevated whereas BC6OTHER ( BC6OTHER ) and CHEM - BC6OTHER - transferase ( BC6ENTG ) activities were depressed.	False
Enzyme assays showed that BC6ENTG ( BC6OTHER ) activity was elevated whereas BC6OTHER ( BC6OTHER ) and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) activities were depressed.	False
Enzyme assays showed that BC6OTHER ( BC6ENTG ) activity was elevated whereas BC6OTHER ( BC6OTHER ) and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) activities were depressed.	False
Enzyme assays showed that BC6OTHER ( BC6OTHER ) activity was elevated whereas BC6ENTG ( BC6OTHER ) and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) activities were depressed.	False
Enzyme assays showed that BC6OTHER ( BC6OTHER ) activity was elevated whereas BC6OTHER ( BC6ENTG ) and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) activities were depressed.	False
Enzyme assays showed that BC6OTHER ( BC6OTHER ) activity was elevated whereas BC6OTHER ( BC6OTHER ) and BC6ENTC - BC6OTHER - transferase ( BC6ENTG ) activities were depressed.	False
Enzyme assays showed that BC6ENTG ( BC6OTHER ) activity was elevated whereas BC6OTHER ( BC6OTHER ) and CHEM - BC6ENTC - transferase ( BC6OTHER ) activities were depressed.	False
Enzyme assays showed that BC6OTHER ( BC6ENTG ) activity was elevated whereas BC6OTHER ( BC6OTHER ) and CHEM - BC6ENTC - transferase ( BC6OTHER ) activities were depressed.	False
Enzyme assays showed that BC6OTHER ( BC6OTHER ) activity was elevated whereas BC6ENTG ( BC6OTHER ) and CHEM - BC6ENTC - transferase ( BC6OTHER ) activities were depressed.	False
Enzyme assays showed that BC6OTHER ( BC6OTHER ) activity was elevated whereas BC6OTHER ( BC6ENTG ) and CHEM - BC6ENTC - transferase ( BC6OTHER ) activities were depressed.	False
Enzyme assays showed that BC6OTHER ( BC6OTHER ) activity was elevated whereas BC6OTHER ( BC6OTHER ) and CHEM - BC6ENTC - transferase ( BC6ENTG ) activities were depressed.	False
Further analyses revealed that BC6ENTC - QD exposure resulted in apoptosis, indicated by changes in levels of BC6ENTG activity, BC6OTHER ( BC6OTHER ) cleavage and BC6OTHER externalization.	False
Further analyses revealed that BC6ENTC - QD exposure resulted in apoptosis, indicated by changes in levels of BC6OTHER activity, BC6ENTG ( BC6OTHER ) cleavage and BC6OTHER externalization.	False
Further analyses revealed that BC6ENTC - QD exposure resulted in apoptosis, indicated by changes in levels of BC6OTHER activity, BC6OTHER ( BC6ENTG ) cleavage and BC6OTHER externalization.	False
Further analyses revealed that BC6OTHER - QD exposure resulted in apoptosis, indicated by changes in levels of BC6ENTG activity, BC6ENTC polymerase ( BC6OTHER ) cleavage and BC6OTHER externalization.	False
Further analyses revealed that BC6OTHER - QD exposure resulted in apoptosis, indicated by changes in levels of BC6OTHER activity, BC6ENTC polymerase ( BC6ENTG ) cleavage and BC6OTHER externalization.	False
Further analyses revealed that BC6OTHER - QD exposure resulted in apoptosis, indicated by changes in levels of BC6ENTG activity, BC6OTHER ( BC6OTHER ) cleavage and BC6ENTC externalization.	False
Further analyses revealed that BC6OTHER - QD exposure resulted in apoptosis, indicated by changes in levels of BC6OTHER activity, BC6ENTG ( BC6OTHER ) cleavage and BC6ENTC externalization.	False
Further analyses revealed that BC6OTHER - QD exposure resulted in apoptosis, indicated by changes in levels of BC6OTHER activity, BC6OTHER ( BC6ENTG ) cleavage and BC6ENTC externalization.	False
Extrinsic apoptotic pathway markers such as BC6ENTG levels and BC6OTHER activity increased as a result of BC6ENTC - QD exposure.	CPR:3
Extrinsic apoptotic pathway markers such as BC6OTHER levels and BC6ENTG activity increased as a result of BC6ENTC - QD exposure.	CPR:3
Further, BC6ENTG ( BC6OTHER ) such as c - Jun BC6ENTC - terminal kinases ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER were all activated.	False
Further, BC6OTHER ( BC6ENTG ) such as c - Jun BC6ENTC - terminal kinases ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER were all activated.	False
Further, BC6OTHER ( BC6OTHER ) such as c - Jun BC6ENTC - terminal kinases ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and BC6OTHER were all activated.	False
Further, BC6OTHER ( BC6OTHER ) such as c - Jun BC6ENTC - terminal kinases ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER were all activated.	False
Further, BC6OTHER ( BC6OTHER ) such as c - Jun BC6ENTC - terminal kinases ( BC6OTHER ), BC6OTHER ( BC6ENTG ), and BC6OTHER were all activated.	False
Further, BC6OTHER ( BC6OTHER ) such as c - Jun BC6ENTC - terminal kinases ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG were all activated.	False
Our findings reveal that BC6ENTC - QDs cause oxidative stress, interfere with antioxidant defenses and activate protein BC6ENTG , leading to apoptosis via both extrinsic and intrinsic pathways.	CPR:3
As the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6ENTC ) and a distinct shift in steady - state conformational population from one that favors the BC6ENTG - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6OTHER - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER .	False
As the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6ENTC ) and a distinct shift in steady - state conformational population from one that favors the BC6OTHER - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6ENTG - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER .	False
As the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6ENTG - BC6ENTC complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6OTHER - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER .	False
As the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6OTHER - BC6ENTC complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6ENTG - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER .	False
As the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6ENTG - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6ENTC ion to one that favors the BC6OTHER - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER .	False
As the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6OTHER - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6ENTC ion to one that favors the BC6ENTG - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER .	False
As the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6ENTG - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6OTHER - BC6ENTC complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER .	False
As the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6OTHER - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6ENTG - BC6ENTC complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER .	False
As the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6ENTG - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6OTHER - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6ENTC .	False
As the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6OTHER - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6ENTG - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6ENTC .	False
This shift in conformational population at higher BC6ENTC ion concentrations and to lower enzyme activity may be due to longer residence time of the BC6OTHER in the BC6ENTG pocket.	CPR:4
Physiologic levels of BC6OTHER ions decrease BC6ENTG activity in part by increasing BC6ENTC binding affinity to the enzyme.	False
This shift in conformational population at higher BC6OTHER ion concentrations and to lower enzyme activity may be due to longer residence time of the BC6ENTC in the BC6ENTG pocket.	False
The results from monitoring enzyme catalysis in the absence of BC6ENTC suggests that the BC6ENTG - BC6OTHER complex with the shorter fluorescence lifetime is the form initially produced, and the complex with the longer fluorescence lifetime is produced through isomerization.	False
The results from monitoring enzyme catalysis in the absence of BC6OTHER suggests that the BC6ENTG - BC6ENTC complex with the shorter fluorescence lifetime is the form initially produced, and the complex with the longer fluorescence lifetime is produced through isomerization.	False
BC6ENTC dehydrogenase 1 ( BC6ENTG ) catalyzes the oxidation of toxic BC6OTHER to BC6OTHER .	False
We used this technique to investigate the effects of BC6ENTC ions on the BC6ENTG - BC6OTHER binding characteristics and enzyme catalysis.	False
We used this technique to investigate the effects of BC6OTHER ions on the BC6ENTG - BC6ENTC binding characteristics and enzyme catalysis.	False
From the resolved free and bound BC6ENTC fluorescence signatures, the KD values for both BC6OTHER conformations in BC6ENTG ranged from about 24 μM to 1 μM for BC6OTHER ion concentrations of 0 - 6000 μM, respectively.	False
From the resolved free and bound BC6OTHER fluorescence signatures, the KD values for both BC6ENTC conformations in BC6ENTG ranged from about 24 μM to 1 μM for BC6OTHER ion concentrations of 0 - 6000 μM, respectively.	False
BC6ENTG ( BC6OTHER ) catalyzes the oxidation of toxic BC6ENTC to BC6OTHER .	CPR:9
BC6OTHER ( BC6ENTG ) catalyzes the oxidation of toxic BC6ENTC to BC6OTHER .	CPR:9
From the resolved free and bound BC6OTHER fluorescence signatures, the KD values for both BC6OTHER conformations in BC6ENTG ranged from about 24 μM to 1 μM for BC6ENTC ion concentrations of 0 - 6000 μM, respectively.	False
BC6ENTG ( BC6OTHER ) catalyzes the oxidation of toxic BC6OTHER to BC6ENTC .	CPR:9
BC6OTHER ( BC6ENTG ) catalyzes the oxidation of toxic BC6OTHER to BC6ENTC .	CPR:9
Fluorescence lifetime analysis and effect of BC6ENTC ions on binding of BC6OTHER to BC6ENTG .	False
Fluorescence lifetime analysis and effect of BC6OTHER ions on binding of BC6ENTC to BC6ENTG .	False
Physiologic levels of BC6ENTC ions decrease BC6ENTG activity in part by increasing BC6OTHER binding affinity to the enzyme.	CPR:4
As the BC6ENTC ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6ENTG - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6OTHER - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER .	CPR:4
As the BC6ENTC ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6OTHER - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6ENTG - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER .	False
As the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6ENTC ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6ENTG - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6OTHER - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER .	False
As the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6ENTC ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6OTHER - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6ENTG - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER .	False
Crystallographic analysis of the BC6ENTG with bound BC6ENTC inhibitors at 2.0 A resolution.	CPR:4
Crystallographic comparison with the structurally related BC6ENTG binary complex with the oxidized cofactor BC6ENTC revealed overlapping binding sites for the BC6OTHER and the cofactor, compatible with a competitive type of inhibition of the BC6OTHER versus CHEM.	False
Crystallographic comparison with the structurally related BC6ENTG binary complex with the oxidized cofactor BC6OTHER revealed overlapping binding sites for the BC6ENTC and the cofactor, compatible with a competitive type of inhibition of the BC6OTHER versus CHEM.	False
The BC6ENTG represent a superfamily of structurally and functionally closely related enzymes, one of those functions being reversible inhibition by BC6ENTC derivatives.	CPR:4
Crystallographic comparison with the structurally related BC6ENTG binary complex with the oxidized cofactor BC6OTHER revealed overlapping binding sites for the BC6OTHER and the cofactor, compatible with a competitive type of inhibition of the BC6ENTC versus CHEM.	CPR:4
Here we present the crystal structure of the dimeric catalytic domain (residues 117 - 424) of human BC6ENTC hydroxylase ( BC6ENTG ), cocrystallized with various potent and well - known BC6OTHER inhibitors and refined at a resolution of 2.0 A.	False
Here we present the crystal structure of the dimeric catalytic domain (residues 117 - 424) of BC6ENTG ( BC6OTHER ), cocrystallized with various potent and well - known BC6ENTC inhibitors and refined at a resolution of 2.0 A.	CPR:4
Here we present the crystal structure of the dimeric catalytic domain (residues 117 - 424) of human BC6OTHER hydroxylase ( BC6ENTG ), cocrystallized with various potent and well - known BC6ENTC inhibitors and refined at a resolution of 2.0 A.	CPR:4
With a fluorogenic peptide substrate for BC6ENTC proteases, a deficiency in BC6ENTG activity was found in the tumors.	False
To gain further insight into the functionality of the BC6ENTG pathway, cDNA microarrays were performed and the expression levels of a panel of 21 BC6OTHER - specific target genes were determined in BC6ENTC - induced tumors that overexpress the ligand.	False
To gain further insight into the functionality of the BC6OTHER pathway, cDNA microarrays were performed and the expression levels of a panel of 21 BC6ENTG - specific target genes were determined in BC6ENTC - induced tumors that overexpress the ligand.	False
To determine the expression and activation status of BC6ENTG in chemically induced tumors, 6 - wk - old A / J mice were injected intraperitoneally with either BC6ENTC ( BC6OTHER ) (10 mg / kg body weight, once a week for 6 wk) or CHEM solution, and colon tumors were isolated 24 wk following the last injection.	False
To determine the expression and activation status of BC6ENTG in chemically induced tumors, 6 - wk - old A / J mice were injected intraperitoneally with either BC6OTHER ( BC6ENTC ) (10 mg / kg body weight, once a week for 6 wk) or CHEM solution, and colon tumors were isolated 24 wk following the last injection.	False
Defective processing of the BC6ENTG in BC6ENTC - induced mouse colon tumors.	False
In a mouse tumor model, removal of only the BC6ENTC - terminal propeptide from full - length BC6ENTG was sufficient to enhance angiogenesis and tumor growth.	False
BC6ENTG is an angiogenic and lymphangiogenic glycoprotein that can be proteolytically processed generating various forms differing in subunit composition due to the presence or absence of BC6ENTC - and BC6OTHER - terminal propeptides.	False
BC6ENTG is an angiogenic and lymphangiogenic glycoprotein that can be proteolytically processed generating various forms differing in subunit composition due to the presence or absence of BC6OTHER - and BC6ENTC - terminal propeptides.	False
We report for the first time that BC6ENTG binds heparin, and that the BC6ENTC - terminal propeptide significantly enhances this interaction (removal of this propeptide from full - length BC6OTHER completely prevents heparin binding).	False
We report for the first time that BC6OTHER binds heparin, and that the BC6ENTC - terminal propeptide significantly enhances this interaction (removal of this propeptide from full - length BC6ENTG completely prevents heparin binding).	False
We also show that removal of either the BC6ENTC - or BC6OTHER - terminal propeptide is required for BC6ENTG to drive formation of BC6OTHER / BC6OTHER heterodimers which have recently been shown to positively regulate angiogenic sprouting.	False
We also show that removal of either the BC6ENTC - or BC6OTHER - terminal propeptide is required for BC6OTHER to drive formation of BC6ENTG / BC6OTHER heterodimers which have recently been shown to positively regulate angiogenic sprouting.	False
We also show that removal of either the BC6ENTC - or BC6OTHER - terminal propeptide is required for BC6OTHER to drive formation of BC6OTHER / BC6ENTG heterodimers which have recently been shown to positively regulate angiogenic sprouting.	False
We also show that removal of either the BC6OTHER - or BC6ENTC - terminal propeptide is required for BC6ENTG to drive formation of BC6OTHER / BC6OTHER heterodimers which have recently been shown to positively regulate angiogenic sprouting.	False
We also show that removal of either the BC6OTHER - or BC6ENTC - terminal propeptide is required for BC6OTHER to drive formation of BC6ENTG / BC6OTHER heterodimers which have recently been shown to positively regulate angiogenic sprouting.	False
We also show that removal of either the BC6OTHER - or BC6ENTC - terminal propeptide is required for BC6OTHER to drive formation of BC6OTHER / BC6ENTG heterodimers which have recently been shown to positively regulate angiogenic sprouting.	False
 BC6ENTC and BC6OTHER alleviate intermittent hypoxia induced abnormal BC6OTHER and BC6OTHER and low BC6OTHER by suppressing endoplasmic reticulum stress and activated BC6ENTG in rat testes.	CPR:4
 BC6ENTC and BC6OTHER alleviate intermittent hypoxia induced abnormal BC6ENTG and BC6OTHER and low BC6OTHER by suppressing endoplasmic reticulum stress and activated BC6OTHER in rat testes.	False
 BC6ENTC and BC6OTHER alleviate intermittent hypoxia induced abnormal BC6OTHER and BC6ENTG and low BC6OTHER by suppressing endoplasmic reticulum stress and activated BC6OTHER in rat testes.	False
 BC6OTHER and BC6ENTC alleviate intermittent hypoxia induced abnormal BC6OTHER and BC6OTHER and low BC6OTHER by suppressing endoplasmic reticulum stress and activated BC6ENTG in rat testes.	CPR:4
 BC6OTHER and BC6ENTC alleviate intermittent hypoxia induced abnormal BC6ENTG and BC6OTHER and low BC6OTHER by suppressing endoplasmic reticulum stress and activated BC6OTHER in rat testes.	False
 BC6OTHER and BC6ENTC alleviate intermittent hypoxia induced abnormal BC6OTHER and BC6ENTG and low BC6OTHER by suppressing endoplasmic reticulum stress and activated BC6OTHER in rat testes.	CPR:9
 BC6OTHER and BC6OTHER alleviate intermittent hypoxia induced abnormal BC6OTHER and BC6OTHER and low BC6ENTC by suppressing endoplasmic reticulum stress and activated BC6ENTG in rat testes.	False
 BC6OTHER and BC6OTHER alleviate intermittent hypoxia induced abnormal BC6ENTG and BC6OTHER and low BC6ENTC by suppressing endoplasmic reticulum stress and activated BC6OTHER in rat testes.	False
 BC6OTHER and BC6OTHER alleviate intermittent hypoxia induced abnormal BC6OTHER and BC6ENTG and low BC6ENTC by suppressing endoplasmic reticulum stress and activated BC6OTHER in rat testes.	False
We hypothesized that hypoxia induced testicular damage is mediated by an activated BC6OTHER oxidase ( BC6OTHER ), therefore, BC6ENTC ( BC6OTHER ) an inhibitor of BC6ENTG and BC6OTHER (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	CPR:4
We hypothesized that hypoxia induced testicular damage is mediated by an activated BC6ENTG ( BC6OTHER ), therefore, BC6ENTC ( BC6OTHER ) an inhibitor of BC6OTHER and BC6OTHER (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	False
We hypothesized that hypoxia induced testicular damage is mediated by an activated BC6OTHER oxidase ( BC6ENTG ), therefore, BC6ENTC ( BC6OTHER ) an inhibitor of BC6OTHER and BC6OTHER (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	False
We hypothesized that hypoxia induced testicular damage is mediated by an activated BC6OTHER oxidase ( BC6OTHER ), therefore, BC6OTHER ( BC6ENTC ) an inhibitor of BC6ENTG and BC6OTHER (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	CPR:4
We hypothesized that hypoxia induced testicular damage is mediated by an activated BC6ENTG ( BC6OTHER ), therefore, BC6OTHER ( BC6ENTC ) an inhibitor of BC6OTHER and BC6OTHER (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	False
We hypothesized that hypoxia induced testicular damage is mediated by an activated BC6OTHER oxidase ( BC6ENTG ), therefore, BC6OTHER ( BC6ENTC ) an inhibitor of BC6OTHER and BC6OTHER (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	False
We hypothesized that hypoxia induced testicular damage is mediated by an activated BC6OTHER oxidase ( BC6OTHER ), therefore, BC6OTHER ( BC6OTHER ) an inhibitor of BC6ENTG and BC6ENTC (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	False
We hypothesized that hypoxia induced testicular damage is mediated by an activated BC6ENTG ( BC6OTHER ), therefore, BC6OTHER ( BC6OTHER ) an inhibitor of BC6OTHER and BC6ENTC (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	False
We hypothesized that hypoxia induced testicular damage is mediated by an activated BC6OTHER oxidase ( BC6ENTG ), therefore, BC6OTHER ( BC6OTHER ) an inhibitor of BC6OTHER and BC6ENTC (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	False
We hypothesized that hypoxia induced testicular damage is mediated by an activated BC6OTHER oxidase ( BC6OTHER ), therefore, BC6OTHER ( BC6OTHER ) an inhibitor of BC6ENTG and BC6OTHER (RS), a BC6ENTC influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	False
We hypothesized that hypoxia induced testicular damage is mediated by an activated BC6ENTG ( BC6OTHER ), therefore, BC6OTHER ( BC6OTHER ) an inhibitor of BC6OTHER and BC6OTHER (RS), a BC6ENTC influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	False
We hypothesized that hypoxia induced testicular damage is mediated by an activated BC6OTHER oxidase ( BC6ENTG ), therefore, BC6OTHER ( BC6OTHER ) an inhibitor of BC6OTHER and BC6OTHER (RS), a BC6ENTC influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	False
Hypoxic rats displayed lower serum BC6ENTC and higher BC6ENTG and BC6OTHER .	False
Hypoxic rats displayed lower serum BC6ENTC and higher BC6OTHER and BC6ENTG .	False
We hypothesized that hypoxia induced testicular damage is mediated by an activated BC6ENTC oxidase ( BC6OTHER ), therefore, BC6OTHER ( BC6OTHER ) an inhibitor of BC6ENTG and BC6OTHER (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	False
We hypothesized that hypoxia induced testicular damage is mediated by an activated BC6ENTC oxidase ( BC6ENTG ), therefore, BC6OTHER ( BC6OTHER ) an inhibitor of BC6OTHER and BC6OTHER (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	False
BC6ENTC and RS at least partially normalize hypoxia caused male hypogonadism by suppressing ER stress, and BC6ENTG in testes.	CPR:4
Pharmacodynamic data suggest that BC6ENTC - BC6OTHER is rapidly bactericidal versus BC6ENTG - producing Gram - negative bacilli that are not inhibited by BC6OTHER alone.Clinical trials to date have reported that BC6OTHER - BC6OTHER is as effective as standard BC6OTHER therapy in complicated intra - abdominal infection and complicated urinary tract infection, including infection caused by BC6OTHER - resistant Gram - negative isolates.	CPR:4
Pharmacodynamic data suggest that BC6OTHER - BC6ENTC is rapidly bactericidal versus BC6ENTG - producing Gram - negative bacilli that are not inhibited by BC6OTHER alone.Clinical trials to date have reported that BC6OTHER - BC6OTHER is as effective as standard BC6OTHER therapy in complicated intra - abdominal infection and complicated urinary tract infection, including infection caused by BC6OTHER - resistant Gram - negative isolates.	CPR:4
BC6OTHER (formerly BC6ENTC , BC6OTHER ) is a synthetic non - BC6OTHER , BC6OTHER inhibitor that inhibits the activities of BC6ENTG and some BC6OTHER enzymes.	False
BC6OTHER (formerly BC6ENTC , BC6OTHER ) is a synthetic non - BC6OTHER , BC6OTHER inhibitor that inhibits the activities of BC6OTHER and some BC6ENTG enzymes.	CPR:4
BC6OTHER (formerly BC6ENTC , BC6OTHER ) is a synthetic non - BC6OTHER , BC6ENTG inhibitor that inhibits the activities of BC6OTHER and some BC6OTHER enzymes.	CPR:4
Pharmacodynamic data suggest that BC6OTHER - BC6OTHER is rapidly bactericidal versus BC6ENTG - producing Gram - negative bacilli that are not inhibited by BC6ENTC alone.Clinical trials to date have reported that BC6OTHER - BC6OTHER is as effective as standard BC6OTHER therapy in complicated intra - abdominal infection and complicated urinary tract infection, including infection caused by BC6OTHER - resistant Gram - negative isolates.	False
Pharmacodynamic data suggest that BC6OTHER - BC6OTHER is rapidly bactericidal versus BC6ENTG - producing Gram - negative bacilli that are not inhibited by BC6OTHER alone.Clinical trials to date have reported that BC6ENTC - BC6OTHER is as effective as standard BC6OTHER therapy in complicated intra - abdominal infection and complicated urinary tract infection, including infection caused by BC6OTHER - resistant Gram - negative isolates.	False
Pharmacodynamic data suggest that BC6OTHER - BC6OTHER is rapidly bactericidal versus BC6ENTG - producing Gram - negative bacilli that are not inhibited by BC6OTHER alone.Clinical trials to date have reported that BC6OTHER - BC6ENTC is as effective as standard BC6OTHER therapy in complicated intra - abdominal infection and complicated urinary tract infection, including infection caused by BC6OTHER - resistant Gram - negative isolates.	False
Pharmacodynamic data suggest that BC6OTHER - BC6OTHER is rapidly bactericidal versus BC6ENTG - producing Gram - negative bacilli that are not inhibited by BC6OTHER alone.Clinical trials to date have reported that BC6OTHER - BC6OTHER is as effective as standard BC6ENTC therapy in complicated intra - abdominal infection and complicated urinary tract infection, including infection caused by BC6OTHER - resistant Gram - negative isolates.	False
Pharmacodynamic data suggest that BC6OTHER - BC6OTHER is rapidly bactericidal versus BC6ENTG - producing Gram - negative bacilli that are not inhibited by BC6OTHER alone.Clinical trials to date have reported that BC6OTHER - BC6OTHER is as effective as standard BC6OTHER therapy in complicated intra - abdominal infection and complicated urinary tract infection, including infection caused by BC6ENTC - resistant Gram - negative isolates.	False
BC6ENTC (formerly BC6OTHER , BC6OTHER ) is a synthetic non - BC6OTHER , BC6OTHER inhibitor that inhibits the activities of BC6ENTG and some BC6OTHER enzymes.	False
BC6ENTC (formerly BC6OTHER , BC6OTHER ) is a synthetic non - BC6OTHER , BC6OTHER inhibitor that inhibits the activities of BC6OTHER and some BC6ENTG enzymes.	CPR:4
BC6ENTC (formerly BC6OTHER , BC6OTHER ) is a synthetic non - BC6OTHER , BC6ENTG inhibitor that inhibits the activities of BC6OTHER and some BC6OTHER enzymes.	CPR:4
BC6ENTC - BC6OTHER appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug - related treatment - emergent adverse events reported to date.In conclusion, BC6OTHER serves to broaden the spectrum of BC6OTHER versus BC6ENTG - producing Gram - negative bacilli.	False
BC6OTHER - BC6ENTC appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug - related treatment - emergent adverse events reported to date.In conclusion, BC6OTHER serves to broaden the spectrum of BC6OTHER versus BC6ENTG - producing Gram - negative bacilli.	False
BC6OTHER - BC6OTHER appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug - related treatment - emergent adverse events reported to date.In conclusion, BC6ENTC serves to broaden the spectrum of BC6OTHER versus BC6ENTG - producing Gram - negative bacilli.	CPR:4
BC6OTHER - BC6OTHER appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug - related treatment - emergent adverse events reported to date.In conclusion, BC6OTHER serves to broaden the spectrum of BC6ENTC versus BC6ENTG - producing Gram - negative bacilli.	CPR:4
BC6OTHER (formerly BC6OTHER , BC6ENTC ) is a synthetic non - BC6OTHER , BC6OTHER inhibitor that inhibits the activities of BC6ENTG and some BC6OTHER enzymes.	False
BC6OTHER (formerly BC6OTHER , BC6ENTC ) is a synthetic non - BC6OTHER , BC6OTHER inhibitor that inhibits the activities of BC6OTHER and some BC6ENTG enzymes.	CPR:4
BC6OTHER (formerly BC6OTHER , BC6ENTC ) is a synthetic non - BC6OTHER , BC6ENTG inhibitor that inhibits the activities of BC6OTHER and some BC6OTHER enzymes.	CPR:4
Potential future roles for BC6ENTC - BC6OTHER include the treatment of suspected or documented infections caused by resistant Gram - negative - bacilli producing BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and / or BC6OTHER .	False
Potential future roles for BC6ENTC - BC6OTHER include the treatment of suspected or documented infections caused by resistant Gram - negative - bacilli producing BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and / or BC6OTHER .	False
Potential future roles for BC6ENTC - BC6OTHER include the treatment of suspected or documented infections caused by resistant Gram - negative - bacilli producing BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and / or BC6OTHER .	False
Potential future roles for BC6ENTC - BC6OTHER include the treatment of suspected or documented infections caused by resistant Gram - negative - bacilli producing BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and / or BC6OTHER .	False
Potential future roles for BC6ENTC - BC6OTHER include the treatment of suspected or documented infections caused by resistant Gram - negative - bacilli producing BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and / or BC6ENTG .	False
Potential future roles for BC6OTHER - BC6ENTC include the treatment of suspected or documented infections caused by resistant Gram - negative - bacilli producing BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and / or BC6OTHER .	False
Potential future roles for BC6OTHER - BC6ENTC include the treatment of suspected or documented infections caused by resistant Gram - negative - bacilli producing BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and / or BC6OTHER .	False
Potential future roles for BC6OTHER - BC6ENTC include the treatment of suspected or documented infections caused by resistant Gram - negative - bacilli producing BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and / or BC6OTHER .	False
Potential future roles for BC6OTHER - BC6ENTC include the treatment of suspected or documented infections caused by resistant Gram - negative - bacilli producing BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and / or BC6OTHER .	False
Potential future roles for BC6OTHER - BC6ENTC include the treatment of suspected or documented infections caused by resistant Gram - negative - bacilli producing BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and / or BC6ENTG .	False
Although not a BC6ENTC , the chemical structure of BC6OTHER closely resembles portions of the BC6OTHER bicyclic ring system, and BC6OTHER has been shown to bond covalently to BC6ENTG .	False
Although not a BC6OTHER , the chemical structure of BC6ENTC closely resembles portions of the BC6OTHER bicyclic ring system, and BC6OTHER has been shown to bond covalently to BC6ENTG .	False
Although not a BC6OTHER , the chemical structure of BC6OTHER closely resembles portions of the BC6ENTC bicyclic ring system, and BC6OTHER has been shown to bond covalently to BC6ENTG .	False
Although not a BC6OTHER , the chemical structure of BC6OTHER closely resembles portions of the BC6OTHER bicyclic ring system, and BC6ENTC has been shown to bond covalently to BC6ENTG .	False
BC6OTHER (formerly BC6OTHER , BC6OTHER ) is a synthetic non - BC6ENTC , BC6OTHER inhibitor that inhibits the activities of BC6ENTG and some BC6OTHER enzymes.	False
BC6OTHER (formerly BC6OTHER , BC6OTHER ) is a synthetic non - BC6ENTC , BC6OTHER inhibitor that inhibits the activities of BC6OTHER and some BC6ENTG enzymes.	False
BC6OTHER (formerly BC6OTHER , BC6OTHER ) is a synthetic non - BC6ENTC , BC6ENTG inhibitor that inhibits the activities of BC6OTHER and some BC6OTHER enzymes.	False
The addition of BC6ENTC greatly (4 - 1024 - fold minimum inhibitory concentration [MIC] reduction) improves the activity of BC6OTHER versus most species of Enterobacteriaceae depending on the presence or absence of BC6ENTG enzyme(s).	CPR:4
The addition of BC6OTHER greatly (4 - 1024 - fold minimum inhibitory concentration [MIC] reduction) improves the activity of BC6ENTC versus most species of Enterobacteriaceae depending on the presence or absence of BC6ENTG enzyme(s).	CPR:4
 BC6ENTC - BC6OTHER : a novel BC6OTHER / BC6ENTG inhibitor combination.	CPR:4
 BC6OTHER - BC6ENTC : a novel BC6OTHER / BC6ENTG inhibitor combination.	CPR:4
 BC6OTHER - BC6OTHER : a novel BC6ENTC / BC6ENTG inhibitor combination.	False
The results showed that levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6ENTC / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6ENTC / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6ENTC / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6ENTC / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6ENTC / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6ENTC / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6ENTG BC6OTHER , very BC6OTHER BC6ENTC / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6ENTG BC6ENTC / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6ENTC / BC6ENTG BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6ENTC / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6ENTG was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6ENTC , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6ENTC , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6ENTC , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6ENTC , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6ENTC , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6ENTC , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6ENTG BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6ENTC , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6ENTG BC6OTHER / BC6OTHER BC6ENTC , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6ENTG BC6ENTC , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6ENTC , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6ENTG was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6ENTC species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6ENTC species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6ENTC species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6ENTC species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6ENTC species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6ENTC species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6ENTG BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6ENTC species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6ENTG BC6OTHER / BC6OTHER BC6OTHER , reactive BC6ENTC species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6ENTG BC6OTHER , reactive BC6ENTC species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6ENTC species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6ENTG was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6ENTC - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6ENTC - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6ENTC - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6ENTC - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6ENTC - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6ENTC - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6ENTG BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6ENTC - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6ENTG BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6ENTC - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6ENTG BC6OTHER , reactive BC6OTHER species (ROS), and BC6ENTC - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6ENTC - reactive substance (TBARS) in serum were down - regulated, while BC6ENTG was augmented by GS treatment.	False
The administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6ENTG ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6ENTG , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6ENTG , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6ENTG , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6ENTG BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG expressions.	False
The administration of GS significantly decreased BC6ENTG , BC6OTHER ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6ENTG ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6ENTG , inducible BC6ENTC synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6ENTG , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6OTHER , BC6ENTG , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6OTHER , BC6OTHER , BC6ENTG BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG expressions.	False
The administration of GS significantly decreased BC6ENTG , BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6ENTG ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6ENTG , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6ENTG , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6ENTG , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6ENTG BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER expressions.	False
The administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG expressions.	False
The results showed that levels of BC6ENTC , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6ENTC , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6ENTC , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6ENTG BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6ENTG BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6ENTG BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6ENTG was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , total BC6OTHER , non - esterified BC6OTHER , BC6ENTG BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6ENTG BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6ENTG BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6ENTG was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6ENTC , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6ENTC , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6ENTC , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , total BC6ENTC , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , total BC6ENTC , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , total BC6ENTC , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6ENTC , non - esterified BC6OTHER , BC6ENTG BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6ENTC , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6ENTG BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6ENTC , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6ENTG BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6ENTC , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6ENTG was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6ENTC , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6ENTC , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6ENTC , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6ENTC , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6ENTC , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , total BC6OTHER , non - esterified BC6ENTC , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6ENTC , BC6ENTG BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6ENTC , BC6OTHER BC6OTHER , very BC6ENTG BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6ENTC , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6ENTG BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6ENTC , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6ENTG was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6ENTC , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6ENTC , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6ENTC , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6ENTC , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6ENTC , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6ENTC , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6ENTG BC6ENTC , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6ENTC , very BC6ENTG BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6ENTC , very BC6OTHER BC6OTHER / BC6ENTG BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment.	False
The results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6ENTC , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6ENTG was augmented by GS treatment.	False
BC6OTHER ( BC6ENTG ) is currently the most suitable bioscavenger for the prophylaxis of highly toxic BC6ENTC (OP) nerve agents.	CPR:9
BC6ENTG ( BC6OTHER ) is currently the most suitable bioscavenger for the prophylaxis of highly toxic BC6ENTC (OP) nerve agents.	CPR:9
Studies have indicated that the three - dimensional structure and the domains of BC6ENTG ( BC6ENTC pocket, lip of the active center gorge, and the anionic substrate - binding domain) that are critical for the binding of substrate are also essential for the selectivity and binding of inhibitors including OPs.	False
 BC6ENTC residues at the CHEM - and C - termini are essential for the folding of active BC6ENTG polypeptide.	False
BC6OTHER [ BC6ENTC ] is a second - generation BC6OTHER pharmacophore that selectively and irreversibly inhibits brain BC6ENTG and is specifically designed for the treatment of Parkinson's disease (PD).	CPR:4
BC6OTHER [ BC6OTHER ] is a second - generation BC6ENTC pharmacophore that selectively and irreversibly inhibits brain BC6ENTG and is specifically designed for the treatment of Parkinson's disease (PD).	CPR:4
BACKGROUND: Inhibitors of BC6ENTC oxidase ( BC6ENTG ) with selectivity and specificity for BC6OTHER ( BC6OTHER ) prolong the duration of action of both endogenously and exogenously derived BC6OTHER .	False
BACKGROUND: Inhibitors of BC6ENTC oxidase ( BC6OTHER ) with selectivity and specificity for BC6ENTG ( BC6OTHER ) prolong the duration of action of both endogenously and exogenously derived BC6OTHER .	False
BACKGROUND: Inhibitors of BC6ENTC oxidase ( BC6OTHER ) with selectivity and specificity for BC6OTHER ( BC6ENTG ) prolong the duration of action of both endogenously and exogenously derived BC6OTHER .	False
In experimental models, BC6ENTC has been found to have neuroprotective properties that may be independent of BC6ENTG inhibition.	False
The search terms were BC6ENTG , neuroprotection, Parkinson disease, BC6ENTC , BC6OTHER , and BC6OTHER .	False
The search terms were BC6ENTG , neuroprotection, Parkinson disease, BC6OTHER , BC6ENTC , and BC6OTHER .	False
The search terms were BC6ENTG , neuroprotection, Parkinson disease, BC6OTHER , BC6OTHER , and BC6ENTC .	False
Comprehensive review of BC6ENTC , a second - generation BC6ENTG inhibitor, for the treatment of Parkinson's disease.	CPR:4
Based on the results from those studies, we concluded that BC6ENTC PO QD, at the therapeutic dosage range of 0.5 to 1 rag / d, is effective and well tolerated and completely, selectively, and specifically inhibited BC6ENTG .	CPR:4
BACKGROUND: Inhibitors of BC6ENTG ( BC6OTHER ) with selectivity and specificity for BC6OTHER ( BC6OTHER ) prolong the duration of action of both endogenously and exogenously derived BC6ENTC .	False
BACKGROUND: Inhibitors of BC6OTHER ( BC6ENTG ) with selectivity and specificity for BC6OTHER ( BC6OTHER ) prolong the duration of action of both endogenously and exogenously derived BC6ENTC .	False
BACKGROUND: Inhibitors of BC6OTHER ( BC6OTHER ) with selectivity and specificity for BC6ENTG ( BC6OTHER ) prolong the duration of action of both endogenously and exogenously derived BC6ENTC .	False
BACKGROUND: Inhibitors of BC6OTHER ( BC6OTHER ) with selectivity and specificity for BC6OTHER ( BC6ENTG ) prolong the duration of action of both endogenously and exogenously derived BC6ENTC .	False
BC6ENTC [ BC6OTHER ] is a second - generation BC6OTHER pharmacophore that selectively and irreversibly inhibits brain BC6ENTG and is specifically designed for the treatment of Parkinson's disease (PD).	CPR:4
T - Cells from BC6ENTG + Human Subjects Are Activated with BC6ENTC through Two Independent Pathways and Induce Cell Death by Multiple Mechanisms.	False
These data suggest that T - cells can be activated by BC6ENTC through a direct interaction with surface and intracellular BC6ENTG ( BC6OTHER ) molecules.	False
These data suggest that T - cells can be activated by BC6ENTC through a direct interaction with surface and intracellular BC6OTHER ( BC6ENTG ) molecules.	False
With the former, BC6ENTC seemingly participates in the BC6ENTG BC6OTHER binding interaction.	False
With the former, BC6ENTC seemingly participates in the BC6OTHER BC6ENTG binding interaction.	False
In contrast, the latter pathway likely involves BC6ENTG binding peptides displayed as a consequence of BC6ENTC exposure, but not BC6OTHER itself.	False
In contrast, the latter pathway likely involves BC6ENTG binding peptides displayed as a consequence of BC6OTHER exposure, but not BC6ENTC itself.	False
The objectives of this study were to characterize the functionality of drug - responsive CD8+ T - cell clones generated from BC6ENTG + drug - naive subjects and to explore the relationship between BC6ENTC accumulation in antigen presenting cells and the T - cell response.	False
Seventy - four CD8+ clones expressing different BC6ENTG were shown to proliferate and kill target cells via different mechanisms when exposed to BC6ENTC .	False
The mutant BC6OTHER ( BC6ENTG ) contained a total of 5 BC6ENTC substitutions that conferred an activating to inhibitory ratio of 25 (A / I ratio; BC6OTHER - R131: BC6OTHER ).	False
The mutant BC6OTHER ( BC6OTHER ) contained a total of 5 BC6ENTC substitutions that conferred an activating to inhibitory ratio of 25 (A / I ratio; BC6ENTG - R131: BC6OTHER ).	False
The mutant BC6OTHER ( BC6OTHER ) contained a total of 5 BC6ENTC substitutions that conferred an activating to inhibitory ratio of 25 (A / I ratio; BC6OTHER - R131: BC6ENTG ).	False
The mutant BC6ENTG ( BC6OTHER ) contained a total of 5 BC6ENTC substitutions that conferred an activating to inhibitory ratio of 25 (A / I ratio; BC6OTHER - R131: BC6OTHER ).	False
Single - strand conformational analysis and BC6ENTC sequencing of the entire coding region of the BC6ENTG gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 ( BC6OTHER ) and 14 ( BC6OTHER ), neither of which was associated with NIDDM in this population.	False
Single - strand conformational analysis and BC6ENTC sequencing of the entire coding region of the BC6OTHER gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 ( BC6ENTG ) and 14 ( BC6OTHER ), neither of which was associated with NIDDM in this population.	False
Single - strand conformational analysis and BC6ENTC sequencing of the entire coding region of the BC6OTHER gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 ( BC6OTHER ) and 14 ( BC6ENTG ), neither of which was associated with NIDDM in this population.	False
BC6ENTG is a BC6OTHER that initiates the sequential processing of BC6OTHER to BC6OTHER by cleaving the BC6OTHER molecule on the BC6ENTC - terminal side of the dibasic peptide, CHEM, joining the B - chain and BC6OTHER - peptide.	False
BC6OTHER is a BC6ENTG that initiates the sequential processing of BC6OTHER to BC6OTHER by cleaving the BC6OTHER molecule on the BC6ENTC - terminal side of the dibasic peptide, CHEM, joining the B - chain and BC6OTHER - peptide.	False
BC6OTHER is a BC6OTHER that initiates the sequential processing of BC6ENTG to BC6OTHER by cleaving the BC6OTHER molecule on the BC6ENTC - terminal side of the dibasic peptide, CHEM, joining the B - chain and BC6OTHER - peptide.	False
BC6OTHER is a BC6OTHER that initiates the sequential processing of BC6OTHER to BC6ENTG by cleaving the BC6OTHER molecule on the BC6ENTC - terminal side of the dibasic peptide, CHEM, joining the B - chain and BC6OTHER - peptide.	False
BC6OTHER is a BC6OTHER that initiates the sequential processing of BC6OTHER to BC6OTHER by cleaving the BC6ENTG molecule on the BC6ENTC - terminal side of the dibasic peptide, CHEM, joining the B - chain and BC6OTHER - peptide.	False
BC6ENTG is a BC6OTHER that initiates the sequential processing of BC6OTHER to BC6OTHER by cleaving the BC6OTHER molecule on the BC6OTHER - terminal side of the dibasic peptide, CHEM, joining the B - chain and BC6ENTC - peptide.	False
BC6OTHER is a BC6ENTG that initiates the sequential processing of BC6OTHER to BC6OTHER by cleaving the BC6OTHER molecule on the BC6OTHER - terminal side of the dibasic peptide, CHEM, joining the B - chain and BC6ENTC - peptide.	False
BC6OTHER is a BC6OTHER that initiates the sequential processing of BC6ENTG to BC6OTHER by cleaving the BC6OTHER molecule on the BC6OTHER - terminal side of the dibasic peptide, CHEM, joining the B - chain and BC6ENTC - peptide.	False
BC6OTHER is a BC6OTHER that initiates the sequential processing of BC6OTHER to BC6ENTG by cleaving the BC6OTHER molecule on the BC6OTHER - terminal side of the dibasic peptide, CHEM, joining the B - chain and BC6ENTC - peptide.	False
BC6OTHER is a BC6OTHER that initiates the sequential processing of BC6OTHER to BC6OTHER by cleaving the BC6ENTG molecule on the BC6OTHER - terminal side of the dibasic peptide, CHEM, joining the B - chain and BC6ENTC - peptide.	False
Expressions of BC6ENTG and BC6OTHER , but not BC6OTHER , are coordinately regulated by BC6ENTC , consistent with the important role of BC6OTHER in regulating BC6OTHER processing.	CPR:3
Expressions of BC6OTHER and BC6ENTG , but not BC6OTHER , are coordinately regulated by BC6ENTC , consistent with the important role of BC6OTHER in regulating BC6OTHER processing.	CPR:3
Expressions of BC6OTHER and BC6OTHER , but not BC6ENTG , are coordinately regulated by BC6ENTC , consistent with the important role of BC6OTHER in regulating BC6OTHER processing.	False
Expressions of BC6OTHER and BC6OTHER , but not BC6OTHER , are coordinately regulated by BC6ENTC , consistent with the important role of BC6ENTG in regulating BC6OTHER processing.	False
Expressions of BC6OTHER and BC6OTHER , but not BC6OTHER , are coordinately regulated by BC6ENTC , consistent with the important role of BC6OTHER in regulating BC6ENTG processing.	False
The residence time of a stoichiometric bioscavenger, BC6OTHER ( BC6ENTG ), in the plasma more closely matches that of VX than do the residence times of conventional therapy drugs ( BC6ENTC , anti - muscarinic, anticonvulsant).	False
The residence time of a stoichiometric bioscavenger, BC6ENTG ( BC6OTHER ), in the plasma more closely matches that of VX than do the residence times of conventional therapy drugs ( BC6ENTC , anti - muscarinic, anticonvulsant).	False
A combination of nerve agent therapy drugs ( BC6ENTC , anti - muscarinic, anticonvulsant) with BC6ENTG (i.m.)	False
BC6ENTG responded only to BC6ENTC .	False
These findings suggest that BC6OTHER specifically suppresses the barrel rotation evoked by BC6ENTC in a long - lasting manner possibly acting through BC6ENTG .	False
wt., IP) 3 days or 7 days prior to the injection of BC6ENTC significantly inhibited the response rate of barrel rotation induced by BC6OTHER , but not that induced by BC6ENTG (1 microgram / rat, ICV).	False
wt., IP) 3 days or 7 days prior to the injection of BC6OTHER significantly inhibited the response rate of barrel rotation induced by BC6ENTC , but not that induced by BC6ENTG (1 microgram / rat, ICV).	False
Intracerebroventricular administration of BC6ENTC (5 micrograms / rat), a BC6ENTG analogue, induced barrel rotation in rats.	False
The suppressive effect of BC6ENTC on barrel rotation could be partially countered by BC6OTHER , a selective peripheral BC6ENTG BC6OTHER antagonist.	CPR:4
The suppressive effect of BC6ENTC on barrel rotation could be partially countered by BC6OTHER , a selective peripheral BC6OTHER BC6ENTG antagonist.	CPR:4
The suppressive effect of BC6OTHER on barrel rotation could be partially countered by BC6ENTC , a selective peripheral BC6ENTG BC6OTHER antagonist.	CPR:6
The suppressive effect of BC6OTHER on barrel rotation could be partially countered by BC6ENTC , a selective peripheral BC6OTHER BC6ENTG antagonist.	CPR:6
These findings suggest that BC6ENTC specifically suppresses the barrel rotation evoked by BC6OTHER in a long - lasting manner possibly acting through BC6ENTG .	CPR:4
Double immunofluorescence studies with selective antibodies against BC6ENTG , BC6OTHER transporters (vesicular BC6ENTC transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6ENTG (vesicular BC6ENTC transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6ENTC transporters 1 and 2 ( BC6ENTG and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6ENTC transporters 1 and 2 ( BC6OTHER and BC6ENTG ), BC6OTHER ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6ENTC transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6ENTC transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6ENTG ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6ENTC transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTG itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6ENTC transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER itself, have shown that BC6ENTG in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6ENTG , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6ENTC decarboxylase - 67 ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6ENTG (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6ENTC decarboxylase - 67 ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters ( BC6ENTG ( BC6OTHER and BC6OTHER ), BC6ENTC decarboxylase - 67 ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6ENTG and BC6OTHER ), BC6ENTC decarboxylase - 67 ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6ENTG ), BC6ENTC decarboxylase - 67 ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6ENTC decarboxylase - 67 ( BC6ENTG ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6ENTC decarboxylase - 67 ( BC6OTHER ) and BC6ENTG itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6ENTC decarboxylase - 67 ( BC6OTHER ) and BC6OTHER itself, have shown that BC6ENTG in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6ENTG , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTC itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6ENTG (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTC itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters ( BC6ENTG ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTC itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6ENTG and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTC itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6ENTG ), BC6OTHER ( BC6OTHER ) and BC6ENTC itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6ENTC itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6ENTG ) and BC6ENTC itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTC itself, have shown that BC6ENTG in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
[ BC6OTHER ] ( BC6ENTC ), a selective BC6ENTG antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection.	CPR:6
As GABAergic synapses in the PVN impinge directly on oxytocinergic neurons or on excitatory glutamatergic synapses, which also impinge on oxytocinergic neurons, these results suggest that the blockade of BC6ENTG decreases BC6ENTC release in the PVN, increasing in turn glutamatergic neurotransmission to activate oxytocinergic neurons mediating penile erection.	False
The present findings confirm that PVN BC6ENTG , localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of BC6OTHER by BC6ENTC increases the density of these receptors in the PVN.	False
The present findings confirm that PVN BC6OTHER , localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of BC6ENTG by BC6ENTC increases the density of these receptors in the PVN.	CPR:4
[ BC6ENTC ] ( BC6OTHER ), a selective BC6ENTG antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection.	CPR:6
Double immunofluorescence studies with selective antibodies against BC6ENTG , BC6ENTC transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6ENTC transporters ( BC6ENTG ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6ENTC transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6ENTG and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6ENTC transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6ENTG ), BC6OTHER ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6ENTC transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6ENTC transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6ENTG ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6ENTC transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTG itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
Double immunofluorescence studies with selective antibodies against BC6OTHER , BC6ENTC transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER itself, have shown that BC6ENTG in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	False
These profiles suggest a mechanism of action for each agent, BC6ENTG agonism for BC6ENTC and alpha 1 antagonism for BC6OTHER and BC6OTHER .	CPR:5
These profiles suggest a mechanism of action for each agent, BC6ENTG agonism for BC6OTHER and alpha 1 antagonism for BC6ENTC and BC6OTHER .	False
These profiles suggest a mechanism of action for each agent, BC6ENTG agonism for BC6OTHER and alpha 1 antagonism for BC6OTHER and BC6ENTC .	False
The BC6ENTG agonist activity reported here clearly distinguishes BC6ENTC from currently available antipsychotic agents and suggests that this property may play a significant role in its pharmacologic actions.	CPR:5
While it is an antagonist at these latter receptors, BC6ENTC behaves as a BC6ENTG agonist in vitro in BC6OTHER measurements.	CPR:5
While it is an antagonist at these latter receptors, BC6ENTC behaves as a BC6OTHER agonist in vitro in BC6ENTG measurements.	False
While it is an antagonist at these latter receptors, BC6OTHER behaves as a BC6ENTG agonist in vitro in BC6ENTC cyclase measurements.	False
The goal of the present study was to examine the BC6ENTG properties of BC6ENTC in vivo using as a marker of central BC6OTHER activity the inhibition of firing of BC6OTHER - containing neurons in the dorsal raphe nucleus.	False
The goal of the present study was to examine the BC6OTHER properties of BC6ENTC in vivo using as a marker of central BC6ENTG activity the inhibition of firing of BC6OTHER - containing neurons in the dorsal raphe nucleus.	False
The goal of the present study was to examine the BC6ENTG properties of BC6OTHER in vivo using as a marker of central BC6OTHER activity the inhibition of firing of BC6ENTC - containing neurons in the dorsal raphe nucleus.	False
The goal of the present study was to examine the BC6OTHER properties of BC6OTHER in vivo using as a marker of central BC6ENTG activity the inhibition of firing of BC6ENTC - containing neurons in the dorsal raphe nucleus.	False
BC6ENTC is a novel antipsychotic agent which binds with high affinity to BC6OTHER (Ki = 3.4 nM), in addition to BC6ENTG , BC6OTHER , and BC6OTHER sites.	False
BC6ENTC is a novel antipsychotic agent which binds with high affinity to BC6OTHER (Ki = 3.4 nM), in addition to BC6OTHER , BC6ENTG , and BC6OTHER sites.	False
BC6ENTC is a novel antipsychotic agent which binds with high affinity to BC6OTHER (Ki = 3.4 nM), in addition to BC6OTHER , BC6OTHER , and BC6ENTG sites.	False
BC6ENTC is a novel antipsychotic agent which binds with high affinity to BC6ENTG (Ki = 3.4 nM), in addition to BC6OTHER , BC6OTHER , and BC6OTHER sites.	False
Pretreatment with the BC6ENTG antagonist BC6ENTC (10 micrograms / kg i.v.)	CPR:6
Comparison of the novel antipsychotic BC6ENTC with BC6OTHER and BC6OTHER : inhibition of dorsal raphe cell firing and the role of BC6ENTG activation.	False
Comparison of the novel antipsychotic BC6OTHER with BC6ENTC and BC6OTHER : inhibition of dorsal raphe cell firing and the role of BC6ENTG activation.	False
Comparison of the novel antipsychotic BC6OTHER with BC6OTHER and BC6ENTC : inhibition of dorsal raphe cell firing and the role of BC6ENTG activation.	False
Because all three agents also bind to BC6ENTG , antagonists of which inhibit BC6ENTC neuronal firing, this aspect of their pharmacology was assessed with BC6OTHER ( BC6OTHER ), a BC6OTHER re - uptake blocker previously shown to reverse the effects of alpha 1 antagonists on raphe unit activity.	False
Because all three agents also bind to BC6ENTG , antagonists of which inhibit BC6OTHER neuronal firing, this aspect of their pharmacology was assessed with BC6ENTC ( BC6OTHER ), a BC6OTHER re - uptake blocker previously shown to reverse the effects of alpha 1 antagonists on raphe unit activity.	False
Because all three agents also bind to BC6ENTG , antagonists of which inhibit BC6OTHER neuronal firing, this aspect of their pharmacology was assessed with BC6OTHER ( BC6ENTC ), a BC6OTHER re - uptake blocker previously shown to reverse the effects of alpha 1 antagonists on raphe unit activity.	False
Because all three agents also bind to BC6ENTG , antagonists of which inhibit BC6OTHER neuronal firing, this aspect of their pharmacology was assessed with BC6OTHER ( BC6OTHER ), a BC6ENTC re - uptake blocker previously shown to reverse the effects of alpha 1 antagonists on raphe unit activity.	False
Through demonstrating the selective inhibition of BC6ENTG - related T - lymphocyte responses by BC6ENTC , our results emphasize the substantial role of BC6OTHER - BC6OTHER complexes in T - cell activation.	CPR:4
Through demonstrating the selective inhibition of BC6OTHER - related T - lymphocyte responses by BC6ENTC , our results emphasize the substantial role of BC6ENTG - BC6OTHER complexes in T - cell activation.	False
Through demonstrating the selective inhibition of BC6OTHER - related T - lymphocyte responses by BC6ENTC , our results emphasize the substantial role of BC6OTHER - BC6ENTG complexes in T - cell activation.	False
Improper function of these proteins can be induced by selective disruption of their complexes with BC6ENTG using the BC6ENTC BC6OTHER .	CPR:4
Improper function of these proteins can be induced by selective disruption of their complexes with BC6ENTG using the BC6OTHER BC6ENTC .	CPR:4
In this study, we demonstrate that BC6ENTC treatment blocks BC6ENTG secretion, BC6OTHER expression, and proliferation of stimulated T - lymphocytes.	CPR:4
In this study, we demonstrate that BC6ENTC treatment blocks BC6OTHER secretion, BC6ENTG expression, and proliferation of stimulated T - lymphocytes.	CPR:4
Moreover, BC6ENTC decreases the amount and phosphorylation of BC6ENTG and BC6OTHER BC6OTHER and prevents activation of the BC6OTHER BC6OTHER .	CPR:4
Moreover, BC6ENTC decreases the amount and phosphorylation of BC6OTHER and BC6ENTG BC6OTHER and prevents activation of the BC6OTHER BC6OTHER .	CPR:4
Moreover, BC6ENTC decreases the amount and phosphorylation of BC6OTHER and BC6OTHER BC6ENTG and prevents activation of the BC6OTHER BC6OTHER .	CPR:4
Moreover, BC6ENTC decreases the amount and phosphorylation of BC6OTHER and BC6OTHER BC6OTHER and prevents activation of the BC6ENTG BC6OTHER .	CPR:4
Moreover, BC6ENTC decreases the amount and phosphorylation of BC6OTHER and BC6OTHER BC6OTHER and prevents activation of the BC6OTHER BC6ENTG .	CPR:4
BC6ENTC also disrupts the BC6ENTG - mediated activation of BC6OTHER ( BC6OTHER ).	CPR:4
BC6ENTC also disrupts the BC6OTHER - mediated activation of BC6ENTG ( BC6OTHER ).	CPR:4
BC6ENTC also disrupts the BC6OTHER - mediated activation of BC6OTHER ( BC6ENTG ).	CPR:4
Treatment with BC6ENTC , however, does not affect the activation of BC6OTHER , which is a plasma membrane enzyme coupled to the BC6ENTG after T - cell stimulation.	False
Treatment with BC6ENTC , however, does not affect the activation of BC6ENTG , which is a plasma membrane enzyme coupled to the BC6OTHER after T - cell stimulation.	False
The BC6ENTG - specific inhibitor BC6ENTC selectively disrupts BC6OTHER - mediated signaling events of T - lymphocyte activation.	CPR:4
The BC6OTHER - specific inhibitor BC6ENTC selectively disrupts BC6ENTG - mediated signaling events of T - lymphocyte activation.	CPR:4
The efficacy of the combination of BC6ENTC and BC6ENTG inhibitors for diabetic patients on hemodialysis (HD) has not been prospectively evaluated; therefore, we evaluated the efficacy and safety of BC6OTHER in these patients.	False
The efficacy of the combination of BC6OTHER and BC6ENTG inhibitors for diabetic patients on hemodialysis (HD) has not been prospectively evaluated; therefore, we evaluated the efficacy and safety of BC6ENTC in these patients.	False
The efficacy of the treatment was determined by monitoring plasma BC6ENTC , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) levels and using homeostasis model assessment of BC6ENTG resistance (HOMA - IR).	False
The efficacy of the treatment was determined by monitoring plasma BC6ENTC , BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) levels and using homeostasis model assessment of BC6OTHER resistance (HOMA - IR).	False
The efficacy of the treatment was determined by monitoring plasma BC6ENTC , BC6OTHER ( BC6ENTG ), and BC6OTHER ( BC6OTHER ) levels and using homeostasis model assessment of BC6OTHER resistance (HOMA - IR).	False
The efficacy of the treatment was determined by monitoring plasma BC6ENTC , BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) levels and using homeostasis model assessment of BC6OTHER resistance (HOMA - IR).	False
The efficacy of the treatment was determined by monitoring plasma BC6ENTC , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG ) levels and using homeostasis model assessment of BC6OTHER resistance (HOMA - IR).	False
OBJECTIVE: BC6ENTC , a rapid - and short - acting insulinotropic BC6ENTG ligand, exhibits hypoglycemic action unlike other BC6OTHER .	False
BC6ENTC reduced fasting plasma BC6OTHER and BC6ENTG levels after 4 weeks and BC6OTHER levels after 8 weeks.	CPR:4
BC6ENTC reduced fasting plasma BC6OTHER and BC6OTHER levels after 4 weeks and BC6ENTG levels after 8 weeks.	CPR:4
BC6OTHER reduced fasting plasma BC6ENTC and BC6ENTG levels after 4 weeks and BC6OTHER levels after 8 weeks.	False
BC6OTHER reduced fasting plasma BC6ENTC and BC6OTHER levels after 4 weeks and BC6ENTG levels after 8 weeks.	False
OBJECTIVE: BC6OTHER , a rapid - and short - acting insulinotropic BC6ENTG ligand, exhibits hypoglycemic action unlike other BC6ENTC .	False
BC6ENTC (a specific inhibitor of BC6OTHER BC6OTHER ) markedly suppressed the increased expression of BC6ENTG and BC6OTHER in BC6OTHER - induced NPDFs.	CPR:4
BC6ENTC (a specific inhibitor of BC6OTHER BC6OTHER ) markedly suppressed the increased expression of BC6OTHER and BC6ENTG in BC6OTHER - induced NPDFs.	CPR:4
BC6ENTC (a specific inhibitor of BC6OTHER BC6OTHER ) markedly suppressed the increased expression of BC6OTHER and BC6OTHER in BC6ENTG - induced NPDFs.	CPR:4
BC6ENTC (a specific inhibitor of BC6ENTG BC6OTHER ) markedly suppressed the increased expression of BC6OTHER and BC6OTHER in BC6OTHER - induced NPDFs.	CPR:4
BC6ENTC (a specific inhibitor of BC6OTHER BC6ENTG ) markedly suppressed the increased expression of BC6OTHER and BC6OTHER in BC6OTHER - induced NPDFs.	CPR:4
BC6ENTC exerts suppressive effects on phenotype changes and ECM production in NPDFs via BC6ENTG signaling pathway interference.	False
NPDFs were pre - treated with BC6ENTC prior to induction by BC6ENTG .	False
In BC6ENTG - induced NPDFs, BC6ENTC significantly inhibited the expression of BC6OTHER and BC6OTHER mRNA and reduced BC6OTHER and BC6OTHER protein levels.	CPR:4
In BC6OTHER - induced NPDFs, BC6ENTC significantly inhibited the expression of BC6ENTG and BC6OTHER mRNA and reduced BC6OTHER and BC6OTHER protein levels.	CPR:4
In BC6OTHER - induced NPDFs, BC6ENTC significantly inhibited the expression of BC6OTHER and BC6ENTG mRNA and reduced BC6OTHER and BC6OTHER protein levels.	CPR:4
In BC6OTHER - induced NPDFs, BC6ENTC significantly inhibited the expression of BC6OTHER and BC6OTHER mRNA and reduced BC6ENTG and BC6OTHER protein levels.	CPR:4
In BC6OTHER - induced NPDFs, BC6ENTC significantly inhibited the expression of BC6OTHER and BC6OTHER mRNA and reduced BC6OTHER and BC6ENTG protein levels.	CPR:4
BC6ENTC only suppressed the expression of BC6ENTG among the evaluated signaling molecules.	CPR:4
 BC6ENTC inhibits myofibroblast differentiation in nasal polyp - derived fibroblasts via the BC6ENTG pathway.	False
BC6ENTC has demonstrated efficacy against BC6ENTG - rearranged NSCLC, and has potential for broader application in select subsets of lung cancer.	False
BC6ENTC is an oral BC6ENTG inhibitor (TKI), which silences the protein product of the BC6OTHER fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing BC6OTHER .	CPR:4
BC6ENTC is an oral BC6OTHER kinase inhibitor (TKI), which silences the protein product of the BC6ENTG fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing BC6OTHER .	CPR:4
BC6ENTC is an oral BC6OTHER kinase inhibitor (TKI), which silences the protein product of the BC6OTHER fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing BC6ENTG .	False
BC6OTHER is an oral BC6ENTC kinase inhibitor (TKI), which silences the protein product of the BC6ENTG fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing BC6OTHER .	False
BC6OTHER is an oral BC6ENTC kinase inhibitor (TKI), which silences the protein product of the BC6OTHER fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing BC6ENTG .	False
Emerging data suggest that BC6ENTC may also have activity in other subsets of lung cancer, including tumors demonstrating amplification or mutation of the BC6ENTG oncogene, or translocation of the BC6OTHER oncogene.	False
Emerging data suggest that BC6ENTC may also have activity in other subsets of lung cancer, including tumors demonstrating amplification or mutation of the BC6OTHER oncogene, or translocation of the BC6ENTG oncogene.	False
BC6ENTC is an inhibitor of BC6ENTG which is able to block the absorption of 30% of ingested fat.	CPR:4
BC6ENTC receptor coactivator 1 ( BC6ENTG ), silencing mediator for CHEM and BC6OTHER receptors, and cell proliferation were evaluated by immunohistochemistry.	False
BC6ENTC receptor coactivator 1 ( BC6OTHER ), silencing mediator for BC6ENTG , and cell proliferation were evaluated by immunohistochemistry.	False
BC6ENTG ( BC6OTHER ), silencing mediator for BC6ENTC and BC6OTHER receptors, and cell proliferation were evaluated by immunohistochemistry.	False
BC6OTHER ( BC6ENTG ), silencing mediator for BC6ENTC and BC6OTHER receptors, and cell proliferation were evaluated by immunohistochemistry.	False
BC6ENTG ( BC6OTHER ), silencing mediator for CHEM and BC6ENTC receptors, and cell proliferation were evaluated by immunohistochemistry.	False
BC6OTHER ( BC6ENTG ), silencing mediator for CHEM and BC6ENTC receptors, and cell proliferation were evaluated by immunohistochemistry.	False
 BC6ENTC alters expression of endometrial BC6ENTG and their cofactors in new users of BC6OTHER .	False
 BC6OTHER alters expression of endometrial BC6ENTG and their cofactors in new users of BC6ENTC .	False
RESULT(S): The expression of endometrial BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER was increased significantly after 1 week of BC6ENTC , but the increase was no longer seen after 10 weeks.	CPR:3
RESULT(S): The expression of endometrial BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER was increased significantly after 1 week of BC6ENTC , but the increase was no longer seen after 10 weeks.	CPR:3
RESULT(S): The expression of endometrial BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER was increased significantly after 1 week of BC6ENTC , but the increase was no longer seen after 10 weeks.	CPR:3
RESULT(S): The expression of endometrial BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG was increased significantly after 1 week of BC6ENTC , but the increase was no longer seen after 10 weeks.	CPR:3
OBJECTIVE: To evaluate the effect of CHEM on the expression of endometrial BC6ENTG and their co - factors in depot BC6ENTC (CHEM) users.	False
CONCLUSION(S): Short - term exposure of BC6ENTC in new starters of CHEM increases the expression of endometrial BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER and promotes cell proliferation.	CPR:3
CONCLUSION(S): Short - term exposure of BC6ENTC in new starters of CHEM increases the expression of endometrial BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER and promotes cell proliferation.	CPR:3
CONCLUSION(S): Short - term exposure of BC6ENTC in new starters of CHEM increases the expression of endometrial BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER and promotes cell proliferation.	CPR:3
CONCLUSION(S): Short - term exposure of BC6ENTC in new starters of CHEM increases the expression of endometrial BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG and promotes cell proliferation.	CPR:3
MAIN OUTCOME MEASURE(S): The expression of BC6ENTC receptor subtypes alpha and beta ( BC6ENTG and BC6OTHER ), BC6OTHER receptors A and B ( BC6OTHER and BC6OTHER ), and BC6OTHER receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively.	False
MAIN OUTCOME MEASURE(S): The expression of BC6ENTC receptor subtypes alpha and beta ( BC6OTHER and BC6ENTG ), BC6OTHER receptors A and B ( BC6OTHER and BC6OTHER ), and BC6OTHER receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively.	False
MAIN OUTCOME MEASURE(S): The expression of BC6ENTC receptor subtypes alpha and beta ( BC6OTHER and BC6OTHER ), BC6ENTG ( BC6OTHER and BC6OTHER ), and BC6OTHER receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively.	False
MAIN OUTCOME MEASURE(S): The expression of BC6ENTC receptor subtypes alpha and beta ( BC6OTHER and BC6OTHER ), BC6OTHER receptors A and B ( BC6ENTG and BC6OTHER ), and BC6OTHER receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively.	False
MAIN OUTCOME MEASURE(S): The expression of BC6ENTC receptor subtypes alpha and beta ( BC6OTHER and BC6OTHER ), BC6OTHER receptors A and B ( BC6OTHER and BC6ENTG ), and BC6OTHER receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively.	False
MAIN OUTCOME MEASURE(S): The expression of BC6ENTC receptor subtypes alpha and beta ( BC6OTHER and BC6OTHER ), BC6OTHER receptors A and B ( BC6OTHER and BC6OTHER ), and BC6ENTG messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively.	False
MAIN OUTCOME MEASURE(S): The expression of BC6ENTG ( BC6OTHER and BC6OTHER ), BC6ENTC receptors A and B ( BC6OTHER and BC6OTHER ), and BC6OTHER receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively.	False
MAIN OUTCOME MEASURE(S): The expression of BC6OTHER receptor subtypes alpha and beta ( BC6ENTG and BC6OTHER ), BC6ENTC receptors A and B ( BC6OTHER and BC6OTHER ), and BC6OTHER receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively.	False
MAIN OUTCOME MEASURE(S): The expression of BC6OTHER receptor subtypes alpha and beta ( BC6OTHER and BC6ENTG ), BC6ENTC receptors A and B ( BC6OTHER and BC6OTHER ), and BC6OTHER receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively.	False
MAIN OUTCOME MEASURE(S): The expression of BC6OTHER receptor subtypes alpha and beta ( BC6OTHER and BC6OTHER ), BC6ENTC receptors A and B ( BC6ENTG and BC6OTHER ), and BC6OTHER receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively.	False
MAIN OUTCOME MEASURE(S): The expression of BC6OTHER receptor subtypes alpha and beta ( BC6OTHER and BC6OTHER ), BC6ENTC receptors A and B ( BC6OTHER and BC6ENTG ), and BC6OTHER receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively.	False
MAIN OUTCOME MEASURE(S): The expression of BC6OTHER receptor subtypes alpha and beta ( BC6OTHER and BC6OTHER ), BC6ENTC receptors A and B ( BC6OTHER and BC6OTHER ), and BC6ENTG messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively.	False
MAIN OUTCOME MEASURE(S): The expression of BC6ENTG ( BC6OTHER and BC6OTHER ), BC6OTHER receptors A and B ( BC6OTHER and BC6OTHER ), and BC6ENTC receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively.	False
MAIN OUTCOME MEASURE(S): The expression of BC6OTHER receptor subtypes alpha and beta ( BC6ENTG and BC6OTHER ), BC6OTHER receptors A and B ( BC6OTHER and BC6OTHER ), and BC6ENTC receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively.	False
MAIN OUTCOME MEASURE(S): The expression of BC6OTHER receptor subtypes alpha and beta ( BC6OTHER and BC6ENTG ), BC6OTHER receptors A and B ( BC6OTHER and BC6OTHER ), and BC6ENTC receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively.	False
MAIN OUTCOME MEASURE(S): The expression of BC6OTHER receptor subtypes alpha and beta ( BC6OTHER and BC6OTHER ), BC6ENTG ( BC6OTHER and BC6OTHER ), and BC6ENTC receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively.	False
MAIN OUTCOME MEASURE(S): The expression of BC6OTHER receptor subtypes alpha and beta ( BC6OTHER and BC6OTHER ), BC6OTHER receptors A and B ( BC6ENTG and BC6OTHER ), and BC6ENTC receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively.	False
MAIN OUTCOME MEASURE(S): The expression of BC6OTHER receptor subtypes alpha and beta ( BC6OTHER and BC6OTHER ), BC6OTHER receptors A and B ( BC6OTHER and BC6ENTG ), and BC6ENTC receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively.	False
These results are consistent with the premise that BC6ENTC synthetase inhibition is responsible for the antibacterial actions and support further studies on BC6ENTG as a new target for antibacterial agents.	False
These results are consistent with the premise that BC6ENTG inhibition is responsible for the antibacterial actions and support further studies on BC6ENTC synthetase as a new target for antibacterial agents.	False
BC6ENTC ( BC6OTHER ) is a first - in - class, potent, orally administered, covalent inhibitor of Bruton's BC6OTHER kinase ( BC6ENTG ) that inhibits BC6OTHER signalling downstream of BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER ) is a first - in - class, potent, orally administered, covalent inhibitor of Bruton's BC6OTHER kinase ( BC6OTHER ) that inhibits BC6ENTG signalling downstream of BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER ) is a first - in - class, potent, orally administered, covalent inhibitor of Bruton's BC6OTHER kinase ( BC6OTHER ) that inhibits BC6OTHER signalling downstream of BC6ENTG .	CPR:4
BC6ENTC ( BC6OTHER ) is a first - in - class, potent, orally administered, covalent inhibitor of BC6ENTG ( BC6OTHER ) that inhibits BC6OTHER signalling downstream of BC6OTHER .	CPR:4
BC6OTHER ( BC6OTHER ) is a first - in - class, potent, orally administered, covalent inhibitor of Bruton's BC6ENTC kinase ( BC6ENTG ) that inhibits BC6OTHER signalling downstream of BC6OTHER .	False
BC6OTHER ( BC6OTHER ) is a first - in - class, potent, orally administered, covalent inhibitor of Bruton's BC6ENTC kinase ( BC6OTHER ) that inhibits BC6ENTG signalling downstream of BC6OTHER .	False
BC6OTHER ( BC6OTHER ) is a first - in - class, potent, orally administered, covalent inhibitor of Bruton's BC6ENTC kinase ( BC6OTHER ) that inhibits BC6OTHER signalling downstream of BC6ENTG .	False
BC6OTHER ( BC6ENTC ) is a first - in - class, potent, orally administered, covalent inhibitor of Bruton's BC6OTHER kinase ( BC6ENTG ) that inhibits BC6OTHER signalling downstream of BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTC ) is a first - in - class, potent, orally administered, covalent inhibitor of Bruton's BC6OTHER kinase ( BC6OTHER ) that inhibits BC6ENTG signalling downstream of BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTC ) is a first - in - class, potent, orally administered, covalent inhibitor of Bruton's BC6OTHER kinase ( BC6OTHER ) that inhibits BC6OTHER signalling downstream of BC6ENTG .	False
BC6OTHER ( BC6ENTC ) is a first - in - class, potent, orally administered, covalent inhibitor of BC6ENTG ( BC6OTHER ) that inhibits BC6OTHER signalling downstream of BC6OTHER .	CPR:4
Given its efficacy and tolerability, once - daily, oral BC6ENTC is an emerging treatment option for patients with relapsed / refractory MCL or CLL and CLL patients with del 17p or BC6ENTG mutation.	False
Oral BC6ENTC is indicated for the treatment of patients with relapsed / refractory mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL) and for the treatment of patients with CLL and a chromosome 17 deletion (del 17p) or BC6ENTG mutation.	False
BC6ENTC are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6OTHER X receptor, BC6ENTG , and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism.	CPR:3
BC6ENTC are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6OTHER X receptor, constitutive BC6OTHER receptor, and BC6ENTG , and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism.	CPR:3
BC6ENTC are signaling molecules that activate BC6ENTG , such as BC6OTHER , BC6OTHER X receptor, constitutive BC6OTHER receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism.	CPR:3
BC6ENTC are signaling molecules that activate BC6OTHER , such as BC6ENTG , BC6OTHER X receptor, constitutive BC6OTHER receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism.	CPR:3
BC6ENTC are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6ENTG , constitutive BC6OTHER receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism.	CPR:3
BC6OTHER are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6OTHER X receptor, constitutive BC6ENTC receptor, and BC6ENTG , and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism.	False
BC6OTHER are signaling molecules that activate BC6ENTG , such as BC6OTHER , BC6OTHER X receptor, constitutive BC6ENTC receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism.	False
BC6OTHER are signaling molecules that activate BC6OTHER , such as BC6ENTG , BC6OTHER X receptor, constitutive BC6ENTC receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism.	False
BC6OTHER are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6ENTG , constitutive BC6ENTC receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism.	False
BC6OTHER are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6OTHER X receptor, BC6ENTG , and BC6ENTC receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism.	False
BC6OTHER are signaling molecules that activate BC6ENTG , such as BC6OTHER , BC6OTHER X receptor, constitutive BC6OTHER receptor, and BC6ENTC receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism.	False
BC6OTHER are signaling molecules that activate BC6OTHER , such as BC6ENTG , BC6OTHER X receptor, constitutive BC6OTHER receptor, and BC6ENTC receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism.	False
BC6OTHER are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6ENTG , constitutive BC6OTHER receptor, and BC6ENTC receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism.	False
BC6OTHER are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6OTHER X receptor, BC6ENTG , and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6ENTC , energy, and drug metabolism.	False
BC6OTHER are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6OTHER X receptor, constitutive BC6OTHER receptor, and BC6ENTG , and play a critical role in the regulation of lipid, BC6ENTC , energy, and drug metabolism.	False
BC6OTHER are signaling molecules that activate BC6ENTG , such as BC6OTHER , BC6OTHER X receptor, constitutive BC6OTHER receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6ENTC , energy, and drug metabolism.	False
BC6OTHER are signaling molecules that activate BC6OTHER , such as BC6ENTG , BC6OTHER X receptor, constitutive BC6OTHER receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6ENTC , energy, and drug metabolism.	False
BC6OTHER are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6ENTG , constitutive BC6OTHER receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6ENTC , energy, and drug metabolism.	False
These BC6ENTG regulate phase I oxidation, phase II conjugation, and phase III transport in BC6ENTC and drug metabolism in the digestive system.	False
BC6OTHER are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6ENTC X receptor, BC6ENTG , and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism.	False
BC6OTHER are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6ENTC X receptor, constitutive BC6OTHER receptor, and BC6ENTG , and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism.	False
BC6OTHER are signaling molecules that activate BC6ENTG , such as BC6OTHER , BC6ENTC X receptor, constitutive BC6OTHER receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism.	False
BC6OTHER are signaling molecules that activate BC6OTHER , such as BC6ENTG , BC6ENTC X receptor, constitutive BC6OTHER receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism.	False
 BC6ENTG in BC6ENTC metabolism.	False
The BC6OTHER (natural products) such as BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC carry the common molecular structure of BC6OTHER that possessed positive ionotropic effect and BC6ENTG blocking activity.	CPR:4
The BC6OTHER (natural products) such as BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER carry the common molecular structure of BC6ENTC that possessed positive ionotropic effect and BC6ENTG blocking activity.	CPR:4
The human BC6ENTC - a - go - go - related gene ( BC6ENTG ) is a BC6OTHER channel protein mainly expressed in the heart and the nervous systems and its blockade by non - cardiovascular acting drugs resulted in tachycardia and sudden death.	False
The human BC6ENTC - a - go - go - related gene ( BC6OTHER ) is a BC6ENTG protein mainly expressed in the heart and the nervous systems and its blockade by non - cardiovascular acting drugs resulted in tachycardia and sudden death.	False
The human BC6OTHER - a - go - go - related gene ( BC6ENTG ) is a BC6ENTC channel protein mainly expressed in the heart and the nervous systems and its blockade by non - cardiovascular acting drugs resulted in tachycardia and sudden death.	False
The BC6ENTG ( BC6OTHER ) is a BC6ENTC channel protein mainly expressed in the heart and the nervous systems and its blockade by non - cardiovascular acting drugs resulted in tachycardia and sudden death.	False
The BC6ENTC (natural products) such as BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER carry the common molecular structure of BC6OTHER that possessed positive ionotropic effect and BC6ENTG blocking activity.	CPR:4
The BC6OTHER (natural products) such as BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER carry the common molecular structure of BC6OTHER that possessed positive ionotropic effect and BC6ENTG blocking activity.	CPR:4
The BC6OTHER (natural products) such as BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER carry the common molecular structure of BC6OTHER that possessed positive ionotropic effect and BC6ENTG blocking activity.	CPR:4
The BC6OTHER (natural products) such as BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER carry the common molecular structure of BC6OTHER that possessed positive ionotropic effect and BC6ENTG blocking activity.	CPR:4
The CHEM ( BC6ENTC ) receptors of type 6 ( BC6OTHER ) are quite different from all other BC6ENTG , as they include a short third cytoplasmatic loop and a long BC6OTHER - terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	False
The CHEM ( BC6ENTC ) receptors of type 6 ( BC6ENTG ) are quite different from all other BC6OTHER receptors, as they include a short third cytoplasmatic loop and a long BC6OTHER - terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	False
The CHEM ( BC6OTHER ) receptors of type 6 ( BC6OTHER ) are quite different from all other BC6ENTG , as they include a short third cytoplasmatic loop and a long BC6ENTC - terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	False
The CHEM ( BC6OTHER ) receptors of type 6 ( BC6ENTG ) are quite different from all other BC6OTHER receptors, as they include a short third cytoplasmatic loop and a long BC6ENTC - terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	False
The BC6ENTG of type 6 ( BC6OTHER ) are quite different from all other BC6OTHER receptors, as they include a short third cytoplasmatic loop and a long BC6ENTC - terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	False
A lot of controversies still exist regarding their binding affinity, effects of BC6ENTG ligands on brain BC6ENTC , behavioral syndromes regulated by them, and brain distribution.	False
The BC6ENTC ( BC6OTHER ) receptors of type 6 ( BC6OTHER ) are quite different from all other BC6ENTG , as they include a short third cytoplasmatic loop and a long BC6OTHER - terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	False
The BC6ENTC ( BC6OTHER ) receptors of type 6 ( BC6ENTG ) are quite different from all other BC6OTHER receptors, as they include a short third cytoplasmatic loop and a long BC6OTHER - terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	False
The CHEM ( BC6OTHER ) receptors of type 6 ( BC6ENTG ) are quite different from all other BC6ENTC receptors, as they include a short third cytoplasmatic loop and a long BC6OTHER - terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	False
The BC6ENTG of type 6 ( BC6OTHER ) are quite different from all other BC6ENTC receptors, as they include a short third cytoplasmatic loop and a long BC6OTHER - terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	False
 BC6ENTC receptors of type 6 ( BC6ENTG ): from neuroscience to clinical pharmacology.	False
These findings are the first to show that long - term exposure to BC6ENTC during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, BC6ENTG ( BC6OTHER ) phosphorylation and BC6OTHER activity in the striatum.	CPR:3
These findings are the first to show that long - term exposure to BC6ENTC during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, BC6OTHER ( BC6ENTG ) phosphorylation and BC6OTHER activity in the striatum.	CPR:3
These findings are the first to show that long - term exposure to BC6ENTC during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, BC6OTHER ( BC6OTHER ) phosphorylation and BC6ENTG activity in the striatum.	CPR:3
BC6ENTC exposure (20 mg / kg) increased BC6ENTG ( BC6OTHER ) and BC6OTHER phosphorylation, but decreased BC6OTHER - CHEM - 34 phosphorylation.	CPR:3
BC6ENTC exposure (20 mg / kg) increased BC6OTHER ( BC6ENTG ) and BC6OTHER phosphorylation, but decreased BC6OTHER - CHEM - 34 phosphorylation.	CPR:3
BC6ENTC exposure (20 mg / kg) increased BC6OTHER ( BC6OTHER ) and BC6ENTG phosphorylation, but decreased BC6OTHER - CHEM - 34 phosphorylation.	CPR:3
BC6ENTC exposure (20 mg / kg) increased BC6OTHER ( BC6OTHER ) and BC6OTHER phosphorylation, but decreased BC6ENTG - CHEM - 34 phosphorylation.	CPR:4
BC6ENTC (10 and 20 mg / kg) increased BC6ENTG activity and BC6OTHER production (a biological marker of lipid peroxidation).	CPR:3
BC6OTHER (10 and 20 mg / kg) increased BC6ENTG activity and BC6ENTC production (a biological marker of lipid peroxidation).	False
Notably, the antioxidant BC6ENTC ™ reversed the BC6OTHER (20 mg / kg) - dependent augmentation in BC6ENTG ( BC6OTHER ) phosphorylation and reduced the BC6OTHER (20 mg / kg) - induced BC6OTHER activity and BC6OTHER production.	CPR:4
Notably, the antioxidant BC6ENTC ™ reversed the BC6OTHER (20 mg / kg) - dependent augmentation in BC6OTHER ( BC6ENTG ) phosphorylation and reduced the BC6OTHER (20 mg / kg) - induced BC6OTHER activity and BC6OTHER production.	CPR:4
Notably, the antioxidant BC6ENTC ™ reversed the BC6OTHER (20 mg / kg) - dependent augmentation in BC6OTHER ( BC6OTHER ) phosphorylation and reduced the BC6OTHER (20 mg / kg) - induced BC6ENTG activity and BC6OTHER production.	CPR:4
Notably, the antioxidant BC6OTHER ™ reversed the BC6ENTC (20 mg / kg) - dependent augmentation in BC6ENTG ( BC6OTHER ) phosphorylation and reduced the BC6OTHER (20 mg / kg) - induced BC6OTHER activity and BC6OTHER production.	CPR:3
Notably, the antioxidant BC6OTHER ™ reversed the BC6ENTC (20 mg / kg) - dependent augmentation in BC6OTHER ( BC6ENTG ) phosphorylation and reduced the BC6OTHER (20 mg / kg) - induced BC6OTHER activity and BC6OTHER production.	CPR:3
Notably, the antioxidant BC6OTHER ™ reversed the BC6ENTC (20 mg / kg) - dependent augmentation in BC6OTHER ( BC6OTHER ) phosphorylation and reduced the BC6OTHER (20 mg / kg) - induced BC6ENTG activity and BC6OTHER production.	False
Notably, the antioxidant BC6OTHER ™ reversed the BC6OTHER (20 mg / kg) - dependent augmentation in BC6ENTG ( BC6OTHER ) phosphorylation and reduced the BC6ENTC (20 mg / kg) - induced BC6OTHER activity and BC6OTHER production.	False
Notably, the antioxidant BC6OTHER ™ reversed the BC6OTHER (20 mg / kg) - dependent augmentation in BC6OTHER ( BC6ENTG ) phosphorylation and reduced the BC6ENTC (20 mg / kg) - induced BC6OTHER activity and BC6OTHER production.	False
Notably, the antioxidant BC6OTHER ™ reversed the BC6OTHER (20 mg / kg) - dependent augmentation in BC6OTHER ( BC6OTHER ) phosphorylation and reduced the BC6ENTC (20 mg / kg) - induced BC6ENTG activity and BC6OTHER production.	CPR:3
Notably, the antioxidant BC6OTHER ™ reversed the BC6OTHER (20 mg / kg) - dependent augmentation in BC6ENTG ( BC6OTHER ) phosphorylation and reduced the BC6OTHER (20 mg / kg) - induced BC6OTHER activity and BC6ENTC production.	False
Notably, the antioxidant BC6OTHER ™ reversed the BC6OTHER (20 mg / kg) - dependent augmentation in BC6OTHER ( BC6ENTG ) phosphorylation and reduced the BC6OTHER (20 mg / kg) - induced BC6OTHER activity and BC6ENTC production.	False
Notably, the antioxidant BC6OTHER ™ reversed the BC6OTHER (20 mg / kg) - dependent augmentation in BC6OTHER ( BC6OTHER ) phosphorylation and reduced the BC6OTHER (20 mg / kg) - induced BC6ENTG activity and BC6ENTC production.	False
This report reviews published and unpublished data that suggest that BC6OTHER acts as a selective partial agonist at the BC6ENTG and does not affect BC6ENTC receptors at therapeutic doses.	False
It has been claimed that partial agonism of the BC6ENTC D(2) and 5 - HT(1A) receptors and antagonism of the BC6ENTG receptor contribute to the clinical profile of BC6OTHER , a so - called BC6OTHER - and BC6OTHER stabiliser.	False
It has been claimed that partial agonism of the BC6ENTG and antagonism of the BC6OTHER receptor contribute to the clinical profile of BC6ENTC , a so - called BC6OTHER - and BC6OTHER stabiliser.	False
It has been claimed that partial agonism of the BC6OTHER D(2) and 5 - HT(1A) receptors and antagonism of the BC6ENTG receptor contribute to the clinical profile of BC6ENTC , a so - called BC6OTHER - and BC6OTHER stabiliser.	False
It has been claimed that partial agonism of the BC6ENTG and antagonism of the BC6OTHER receptor contribute to the clinical profile of BC6OTHER , a so - called BC6ENTC - and BC6OTHER stabiliser.	False
It has been claimed that partial agonism of the BC6OTHER D(2) and 5 - HT(1A) receptors and antagonism of the BC6ENTG receptor contribute to the clinical profile of BC6OTHER , a so - called BC6ENTC - and BC6OTHER stabiliser.	False
It has been claimed that partial agonism of the BC6ENTG and antagonism of the BC6OTHER receptor contribute to the clinical profile of BC6OTHER , a so - called BC6OTHER - and BC6ENTC stabiliser.	False
It has been claimed that partial agonism of the BC6OTHER D(2) and 5 - HT(1A) receptors and antagonism of the BC6ENTG receptor contribute to the clinical profile of BC6OTHER , a so - called BC6OTHER - and BC6ENTC stabiliser.	False
This report reviews published and unpublished data that suggest that BC6ENTC acts as a selective partial agonist at the BC6ENTG and does not affect BC6OTHER at therapeutic doses.	CPR:5
This report reviews published and unpublished data that suggest that BC6ENTC acts as a selective partial agonist at the BC6OTHER D(2) receptor and does not affect BC6ENTG at therapeutic doses.	False
This report reviews published and unpublished data that suggest that BC6OTHER acts as a selective partial agonist at the BC6ENTC D(2) receptor and does not affect BC6ENTG at therapeutic doses.	False
BC6OTHER was compared throughout the study to the pDC survival factors, BC6ENTG and BC6OTHER ; BC6ENTC more effectively matures pDC than either BC6OTHER or BC6OTHER alone.	False
BC6OTHER was compared throughout the study to the pDC survival factors, BC6OTHER and BC6ENTG ; BC6ENTC more effectively matures pDC than either BC6OTHER or BC6OTHER alone.	False
BC6OTHER was compared throughout the study to the pDC survival factors, BC6OTHER and BC6OTHER ; BC6ENTC more effectively matures pDC than either BC6ENTG or BC6OTHER alone.	False
BC6OTHER was compared throughout the study to the pDC survival factors, BC6OTHER and BC6OTHER ; BC6ENTC more effectively matures pDC than either BC6OTHER or BC6ENTG alone.	False
These results demonstrate that BC6ENTC molecules directly induce pDC maturation as determined by BC6ENTG induction, BC6OTHER and co - stimulatory marker expression and prolonging viability.	CPR:3
These results demonstrate that BC6ENTC molecules directly induce pDC maturation as determined by BC6OTHER induction, BC6ENTG and co - stimulatory marker expression and prolonging viability.	False
Plasmacytoid dendritic cells produce BC6ENTG and mature in response to the BC6OTHER agonists, BC6OTHER and BC6ENTC .	False
Plasmacytoid dendritic cells produce BC6OTHER and mature in response to the BC6ENTG agonists, BC6OTHER and BC6ENTC .	CPR:5
Plasmacytoid dendritic cells produce BC6ENTG and mature in response to the BC6OTHER agonists, BC6ENTC and BC6OTHER .	False
Plasmacytoid dendritic cells produce BC6OTHER and mature in response to the BC6ENTG agonists, BC6ENTC and BC6OTHER .	CPR:5
The immune response modifiers, BC6ENTC and BC6OTHER , are BC6ENTG agonists that induce BC6OTHER in numerous species, including humans.	CPR:5
The immune response modifiers, BC6ENTC and BC6OTHER , are BC6OTHER agonists that induce BC6ENTG in numerous species, including humans.	CPR:3
Here, we characterize the activation of human pDC with the BC6ENTG agonists BC6ENTC and BC6OTHER .	CPR:5
Here, we characterize the activation of human pDC with the BC6ENTG agonists BC6OTHER and BC6ENTC .	CPR:5
Results indicate that BC6ENTC and BC6OTHER induce BC6ENTG and BC6OTHER from purified pDC, and pDC are the principle BC6OTHER - producing cells in the blood.	CPR:3
Results indicate that BC6ENTC and BC6OTHER induce BC6OTHER and BC6ENTG from purified pDC, and pDC are the principle BC6OTHER - producing cells in the blood.	CPR:3
Results indicate that BC6ENTC and BC6OTHER induce BC6OTHER and BC6OTHER from purified pDC, and pDC are the principle BC6ENTG - producing cells in the blood.	False
Results indicate that BC6OTHER and BC6ENTC induce BC6ENTG and BC6OTHER from purified pDC, and pDC are the principle BC6OTHER - producing cells in the blood.	False
Results indicate that BC6OTHER and BC6ENTC induce BC6OTHER and BC6ENTG from purified pDC, and pDC are the principle BC6OTHER - producing cells in the blood.	False
Results indicate that BC6OTHER and BC6ENTC induce BC6OTHER and BC6OTHER from purified pDC, and pDC are the principle BC6ENTG - producing cells in the blood.	False
The immune response modifiers, BC6OTHER and BC6ENTC , are BC6ENTG agonists that induce BC6OTHER in numerous species, including humans.	CPR:5
The immune response modifiers, BC6OTHER and BC6ENTC , are BC6OTHER agonists that induce BC6ENTG in numerous species, including humans.	CPR:3
BC6ENTC - stimulated pDC also produce a number of other BC6ENTG including BC6OTHER and BC6OTHER .	CPR:3
BC6ENTC - stimulated pDC also produce a number of other BC6OTHER including BC6ENTG and BC6OTHER .	CPR:3
BC6ENTC - stimulated pDC also produce a number of other BC6OTHER including BC6OTHER and BC6ENTG .	CPR:3
BC6ENTC enhances co - stimulatory marker expression, BC6ENTG expression, and pDC viability.	CPR:3
BC6ENTC was compared throughout the study to the pDC survival factors, BC6ENTG and BC6OTHER ; BC6OTHER more effectively matures pDC than either BC6OTHER or BC6OTHER alone.	False
BC6ENTC was compared throughout the study to the pDC survival factors, BC6OTHER and BC6ENTG ; BC6OTHER more effectively matures pDC than either BC6OTHER or BC6OTHER alone.	False
BC6ENTC was compared throughout the study to the pDC survival factors, BC6OTHER and BC6OTHER ; BC6OTHER more effectively matures pDC than either BC6ENTG or BC6OTHER alone.	False
BC6ENTC was compared throughout the study to the pDC survival factors, BC6OTHER and BC6OTHER ; BC6OTHER more effectively matures pDC than either BC6OTHER or BC6ENTG alone.	False
In addition, other antioxidants like BC6ENTC dismutase ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6ENTG ( BC6OTHER ) mimetics and BC6OTHER synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
In addition, other antioxidants like BC6ENTC dismutase ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6ENTG ) mimetics and BC6OTHER synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
In addition, other antioxidants like BC6ENTC dismutase ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6OTHER ) mimetics and BC6ENTG ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
In addition, other antioxidants like BC6ENTC dismutase ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6OTHER ) mimetics and BC6OTHER synthase ( BC6ENTG ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
In addition, other antioxidants like BC6ENTC dismutase ( BC6ENTG ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6OTHER ) mimetics and BC6OTHER synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
In addition, other antioxidants like BC6ENTC dismutase ( BC6OTHER ) mimetics and BC6ENTG ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6OTHER ) mimetics and BC6OTHER synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
In addition, other antioxidants like BC6ENTC dismutase ( BC6OTHER ) mimetics and BC6OTHER ( BC6ENTG ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6OTHER ) mimetics and BC6OTHER synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
In addition, other antioxidants like BC6OTHER ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6ENTC peroxidase ( BC6ENTG ) mimetics and BC6OTHER synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
In addition, other antioxidants like BC6OTHER ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6ENTC peroxidase ( BC6OTHER ) mimetics and BC6ENTG ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
In addition, other antioxidants like BC6OTHER ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6ENTC peroxidase ( BC6OTHER ) mimetics and BC6OTHER synthase ( BC6ENTG ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
In addition, other antioxidants like BC6ENTG ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6ENTC peroxidase ( BC6OTHER ) mimetics and BC6OTHER synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
In addition, other antioxidants like BC6OTHER ( BC6ENTG ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6ENTC peroxidase ( BC6OTHER ) mimetics and BC6OTHER synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
In addition, other antioxidants like BC6OTHER ( BC6OTHER ) mimetics and BC6ENTG ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6ENTC peroxidase ( BC6OTHER ) mimetics and BC6OTHER synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
In addition, other antioxidants like BC6OTHER ( BC6OTHER ) mimetics and BC6OTHER ( BC6ENTG ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6ENTC peroxidase ( BC6OTHER ) mimetics and BC6OTHER synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
In addition, other antioxidants like BC6OTHER ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6ENTG ( BC6OTHER ) mimetics and BC6ENTC synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
In addition, other antioxidants like BC6OTHER ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6ENTG ) mimetics and BC6ENTC synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
In addition, other antioxidants like BC6OTHER ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6OTHER ) mimetics and BC6ENTC synthase ( BC6ENTG ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
In addition, other antioxidants like BC6ENTG ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6OTHER ) mimetics and BC6ENTC synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
In addition, other antioxidants like BC6OTHER ( BC6ENTG ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6OTHER ) mimetics and BC6ENTC synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
In addition, other antioxidants like BC6OTHER ( BC6OTHER ) mimetics and BC6ENTG ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6OTHER ) mimetics and BC6ENTC synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
In addition, other antioxidants like BC6OTHER ( BC6OTHER ) mimetics and BC6OTHER ( BC6ENTG ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6OTHER ) mimetics and BC6ENTC synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	False
 Recommended management may include use of BC6ENTG inhibitors (e.g. BC6ENTC ) and wound care on a case - by - case basis.	CPR:4
Identification of cDNAs encoding two human alpha class BC6ENTC transferases ( BC6OTHER and BC6OTHER ) and the heterologous expression of BC6ENTG .	False
Identification of cDNAs encoding two human alpha class BC6ENTC transferases ( BC6ENTG and BC6OTHER ) and the heterologous expression of BC6OTHER .	False
Identification of cDNAs encoding two human alpha class BC6ENTC transferases ( BC6OTHER and BC6ENTG ) and the heterologous expression of BC6OTHER .	False
In no other subject any activation of platelets by BC6OTHER inhibitors was observed and there were no statistically significant differences between BC6OTHER genotypes with respect to the effects of BC6ENTG inhibitors on basal or BC6ENTC - stimulated BC6OTHER expression.	False
In no other subject any activation of platelets by BC6OTHER inhibitors was observed and there were no statistically significant differences between BC6OTHER genotypes with respect to the effects of BC6OTHER inhibitors on basal or BC6ENTC - stimulated BC6ENTG expression.	CPR:3
In no other subject any activation of platelets by BC6ENTG inhibitors was observed and there were no statistically significant differences between BC6OTHER genotypes with respect to the effects of BC6OTHER inhibitors on basal or BC6ENTC - stimulated BC6OTHER expression.	False
In no other subject any activation of platelets by BC6OTHER inhibitors was observed and there were no statistically significant differences between BC6ENTG genotypes with respect to the effects of BC6OTHER inhibitors on basal or BC6ENTC - stimulated BC6OTHER expression.	False
The effects of CHEM (1 - 10 microg / ml), BC6ENTC (3 - 30 nM), or BC6OTHER (0.3 - 3 microg / ml) on basal and BC6OTHER (3 microM) - induced BC6ENTG externalization were measured in n=62 healthy blood donors and n=177 patients with stable coronary artery disease.	False
The effects of CHEM (1 - 10 microg / ml), BC6OTHER (3 - 30 nM), or BC6ENTC (0.3 - 3 microg / ml) on basal and BC6OTHER (3 microM) - induced BC6ENTG externalization were measured in n=62 healthy blood donors and n=177 patients with stable coronary artery disease.	False
The effects of CHEM (1 - 10 microg / ml), BC6OTHER (3 - 30 nM), or BC6OTHER (0.3 - 3 microg / ml) on basal and BC6ENTC (3 microM) - induced BC6ENTG externalization were measured in n=62 healthy blood donors and n=177 patients with stable coronary artery disease.	False
Although a significant platelet hyperreactivity was observed in the patients, the BC6ENTG genotype did not influence basal or BC6ENTC - induced BC6OTHER expression.	False
Although a significant platelet hyperreactivity was observed in the patients, the BC6OTHER genotype did not influence basal or BC6ENTC - induced BC6ENTG expression.	CPR:3
A moderate (twofold) stimulation of BC6ENTG expression by CHEM but not by BC6ENTC or BC6OTHER was observed in one patient.	False
A moderate (twofold) stimulation of BC6ENTG expression by CHEM but not by BC6OTHER or BC6ENTC was observed in one patient.	False
Herein, we report ischemic - reperfused myocardial infarction (MI) repair with siRNA against Src homology region 2 domain - containing BC6ENTC phosphatase - 1 ( BC6ENTG ), which is known as a key factor involved in regulating the progress of apoptosis in many cell types.	False
A low molecular weight BC6ENTC modified with BC6OTHER (CHEM) - based delivery strategy was suggested for the cardiac application of BC6ENTG siRNA to overcome the poor gene delivery efficiency to myocardium due to the highly charged structures of the compact cardiac muscles.	False
A low molecular weight BC6OTHER modified with BC6ENTC (CHEM) - based delivery strategy was suggested for the cardiac application of BC6ENTG siRNA to overcome the poor gene delivery efficiency to myocardium due to the highly charged structures of the compact cardiac muscles.	False
Anti - apoptotic cardioprotective effects of BC6ENTG gene silencing against ischemia - reperfusion injury: Use of BC6ENTC - modified low molecular weight BC6OTHER as a cardiac siRNA - carrier.	False
Anti - apoptotic cardioprotective effects of BC6ENTG gene silencing against ischemia - reperfusion injury: Use of BC6OTHER - modified low molecular weight BC6ENTC as a cardiac siRNA - carrier.	False
Additionally, these effects of BC6ENTC on γ - BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER / BC6OTHER ) were reduced by an BC6OTHER inhibitor.	CPR:3
Additionally, these effects of BC6ENTC on γ - BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER ( BC6OTHER / BC6OTHER ) were reduced by an BC6OTHER inhibitor.	CPR:3
Additionally, these effects of BC6ENTC on γ - BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER ( BC6OTHER / BC6OTHER ) were reduced by an BC6OTHER inhibitor.	CPR:3
Additionally, these effects of BC6ENTC on γ - BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG ( BC6OTHER / BC6OTHER ) were reduced by an BC6OTHER inhibitor.	CPR:3
Additionally, these effects of BC6ENTC on γ - BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6ENTG / BC6OTHER ) were reduced by an BC6OTHER inhibitor.	CPR:3
Additionally, these effects of BC6ENTC on γ - BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER / BC6ENTG ) were reduced by an BC6OTHER inhibitor.	CPR:3
Additionally, these effects of BC6ENTC on γ - BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER / BC6OTHER ) were reduced by an BC6ENTG inhibitor.	CPR:3
Additionally, these effects of BC6ENTC on γ - BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER / BC6OTHER ) were reduced by an BC6OTHER inhibitor.	CPR:3
Osteoblasts survive the BC6ENTC treatment by activation of BC6ENTG - mediated pathway.	CPR:3
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:5
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:5
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:6
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:6
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:6
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:6
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:6
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:6
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:6
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:6
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:6
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:6
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:6
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:6
Furthermore, we analyzed the BC6ENTG - mediated BC6ENTC cyclase activity in isolated membranes from these cell lines.	False
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:5
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:5
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:5
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:5
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:5
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:5
The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background.	CPR:5
In summary, activation of BC6ENTG and oxidative stress were observed after BC6OTHER / BC6OTHER cotreatment, and BC6OTHER inhibitors and a lipid - soluble free - radical scavenger attenuated BC6ENTC / BC6OTHER - induced cytotoxicity.	False
In summary, activation of BC6OTHER and oxidative stress were observed after BC6OTHER / BC6ENTG cotreatment, and BC6OTHER inhibitors and a lipid - soluble free - radical scavenger attenuated BC6ENTC / BC6OTHER - induced cytotoxicity.	False
In summary, activation of BC6OTHER and oxidative stress were observed after BC6OTHER / BC6OTHER cotreatment, and BC6ENTG inhibitors and a lipid - soluble free - radical scavenger attenuated BC6ENTC / BC6OTHER - induced cytotoxicity.	False
In summary, activation of BC6OTHER and oxidative stress were observed after BC6OTHER / BC6OTHER cotreatment, and BC6OTHER inhibitors and a lipid - soluble free - radical scavenger attenuated BC6ENTC / BC6ENTG - induced cytotoxicity.	False
We demonstrated previously that BC6ENTG ( BC6OTHER ) plays an important role in a rat model of BC6ENTC - induced hepatotoxicity under inflammatory stress.	False
We demonstrated previously that BC6OTHER ( BC6ENTG ) plays an important role in a rat model of BC6ENTC - induced hepatotoxicity under inflammatory stress.	False
In this study, we developed a model in vitro to study the roles of BC6ENTG activation and oxidative stress in BC6OTHER potentiation of BC6ENTC cytotoxicity.	False
In this study, we developed a model in vitro to study the roles of BC6OTHER activation and oxidative stress in BC6ENTG potentiation of BC6ENTC cytotoxicity.	False
BC6ENTC caused cell death in Hepa1c1c7 cells, and BC6ENTG cotreatment potentiated its toxicity.	False
Activation of BC6ENTG was observed in BC6ENTC / BC6OTHER - cotreated cells, and caspase inhibitors provided minor protection from cytotoxicity.	False
Activation of BC6OTHER was observed in BC6ENTC / BC6ENTG - cotreated cells, and caspase inhibitors provided minor protection from cytotoxicity.	False
Intracellular reactive BC6ENTC species (ROS) generation and lipid peroxidation were observed after treatment with BC6OTHER and were further elevated by BC6ENTG cotreatment.	False
Intracellular reactive BC6OTHER species (ROS) generation and lipid peroxidation were observed after treatment with BC6ENTC and were further elevated by BC6ENTG cotreatment.	False
Adding water - soluble antioxidants ( BC6ENTC , BC6OTHER , BC6OTHER , or BC6OTHER ) produced only minor attenuation of BC6OTHER / BC6ENTG - induced cytotoxicity and did not influence the effect of BC6OTHER alone.	False
Adding water - soluble antioxidants ( BC6OTHER , BC6ENTC , BC6OTHER , or BC6OTHER ) produced only minor attenuation of BC6OTHER / BC6ENTG - induced cytotoxicity and did not influence the effect of BC6OTHER alone.	False
Adding water - soluble antioxidants ( BC6OTHER , BC6OTHER , BC6ENTC , or BC6OTHER ) produced only minor attenuation of BC6OTHER / BC6ENTG - induced cytotoxicity and did not influence the effect of BC6OTHER alone.	False
Adding water - soluble antioxidants ( BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTC ) produced only minor attenuation of BC6OTHER / BC6ENTG - induced cytotoxicity and did not influence the effect of BC6OTHER alone.	False
Adding water - soluble antioxidants ( BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER ) produced only minor attenuation of BC6ENTC / BC6ENTG - induced cytotoxicity and did not influence the effect of BC6OTHER alone.	False
Adding water - soluble antioxidants ( BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER ) produced only minor attenuation of BC6OTHER / BC6ENTG - induced cytotoxicity and did not influence the effect of BC6ENTC alone.	False
 BC6ENTG potentiates the cytotoxicity of BC6ENTC in Hepa1c1c7 cells: roles of BC6OTHER activation and oxidative stress.	False
 BC6OTHER potentiates the cytotoxicity of BC6ENTC in Hepa1c1c7 cells: roles of BC6ENTG activation and oxidative stress.	False
On the other hand, BC6ENTC ( BC6OTHER ), which reduced lipid peroxidation and ROS generation, prevented BC6OTHER toxicity and caused pronounced reduction in cytotoxicity from BC6OTHER / BC6ENTG cotreatment.	False
On the other hand, BC6OTHER ( BC6ENTC ), which reduced lipid peroxidation and ROS generation, prevented BC6OTHER toxicity and caused pronounced reduction in cytotoxicity from BC6OTHER / BC6ENTG cotreatment.	False
On the other hand, BC6OTHER ( BC6OTHER ), which reduced lipid peroxidation and ROS generation, prevented BC6ENTC toxicity and caused pronounced reduction in cytotoxicity from BC6OTHER / BC6ENTG cotreatment.	False
On the other hand, BC6OTHER ( BC6OTHER ), which reduced lipid peroxidation and ROS generation, prevented BC6OTHER toxicity and caused pronounced reduction in cytotoxicity from BC6ENTC / BC6ENTG cotreatment.	False
BC6ENTC plus a BC6ENTG inhibitor completely abolished BC6OTHER / BC6OTHER - induced cytotoxicity.	CPR:4
BC6ENTC plus a BC6OTHER inhibitor completely abolished BC6OTHER / BC6ENTG - induced cytotoxicity.	False
BC6OTHER plus a BC6ENTG inhibitor completely abolished BC6ENTC / BC6OTHER - induced cytotoxicity.	False
BC6OTHER plus a BC6OTHER inhibitor completely abolished BC6ENTC / BC6ENTG - induced cytotoxicity.	False
In summary, activation of BC6ENTG and oxidative stress were observed after BC6ENTC / BC6OTHER cotreatment, and BC6OTHER inhibitors and a lipid - soluble free - radical scavenger attenuated BC6OTHER / BC6OTHER - induced cytotoxicity.	CPR:3
In summary, activation of BC6OTHER and oxidative stress were observed after BC6ENTC / BC6ENTG cotreatment, and BC6OTHER inhibitors and a lipid - soluble free - radical scavenger attenuated BC6OTHER / BC6OTHER - induced cytotoxicity.	False
In summary, activation of BC6OTHER and oxidative stress were observed after BC6ENTC / BC6OTHER cotreatment, and BC6ENTG inhibitors and a lipid - soluble free - radical scavenger attenuated BC6OTHER / BC6OTHER - induced cytotoxicity.	False
In summary, activation of BC6OTHER and oxidative stress were observed after BC6ENTC / BC6OTHER cotreatment, and BC6OTHER inhibitors and a lipid - soluble free - radical scavenger attenuated BC6OTHER / BC6ENTG - induced cytotoxicity.	False
In plasma membranes prepared from these isolated brown fat cells by BC6ENTC extraction there was a similar enrichment of activity of BC6ENTG and of the plasma membrane marker enzyme, BC6OTHER .	CPR:3
In plasma membranes prepared from these isolated brown fat cells by BC6ENTC extraction there was a similar enrichment of activity of BC6OTHER and of the plasma membrane marker enzyme, BC6ENTG .	False
 BC6ENTG activities in brown adipose tissue of the rat: identification of BC6OTHER - sensitive ( BC6ENTC - resistant) activity at the fat cell membrane.	False
 BC6ENTG activities in brown adipose tissue of the rat: identification of BC6ENTC - sensitive ( BC6OTHER - resistant) activity at the fat cell membrane.	False
Positive staining of mitochondria was achieved in the presence of the BC6ENTG substrate, BC6ENTC .	CPR:9
Staining around the edges of the brown fat cells was observed with the BC6ENTG substrates, BC6ENTC and BC6OTHER .	CPR:9
Staining around the edges of the brown fat cells was observed with the BC6ENTG substrates, BC6OTHER and BC6ENTC .	CPR:9
Staining was largely absent when substrate was omitted or after pretreatment with the irreversible BC6ENTG inhibitor, BC6ENTC and the slowly reversible inhibitor, BC6OTHER .	CPR:4
Staining was largely absent when substrate was omitted or after pretreatment with the irreversible BC6ENTG inhibitor, BC6OTHER and the slowly reversible inhibitor, BC6ENTC .	CPR:4
It was found that the specific activities of both BC6ENTC oxidase A ( BC6ENTG ) and of the BC6OTHER - sensitive BC6OTHER - resistant CHEM oxidase ( BC6OTHER ) were higher in isolated fat cells than in the original whole tissue.	False
It was found that the specific activities of both BC6ENTC oxidase A ( BC6OTHER ) and of the BC6ENTG ( BC6OTHER ) were higher in isolated fat cells than in the original whole tissue.	False
It was found that the specific activities of both BC6ENTC oxidase A ( BC6OTHER ) and of the BC6OTHER - sensitive BC6OTHER - resistant CHEM oxidase ( BC6ENTG ) were higher in isolated fat cells than in the original whole tissue.	False
It was found that the specific activities of both BC6ENTG ( BC6OTHER ) and of the BC6ENTC - sensitive BC6OTHER - resistant CHEM oxidase ( BC6OTHER ) were higher in isolated fat cells than in the original whole tissue.	False
It was found that the specific activities of both BC6OTHER oxidase A ( BC6ENTG ) and of the BC6ENTC - sensitive BC6OTHER - resistant CHEM oxidase ( BC6OTHER ) were higher in isolated fat cells than in the original whole tissue.	False
It was found that the specific activities of both BC6OTHER oxidase A ( BC6OTHER ) and of the BC6ENTC - sensitive BC6OTHER - resistant CHEM oxidase ( BC6ENTG ) were higher in isolated fat cells than in the original whole tissue.	False
It was found that the specific activities of both BC6ENTG ( BC6OTHER ) and of the BC6OTHER - sensitive BC6ENTC - resistant CHEM oxidase ( BC6OTHER ) were higher in isolated fat cells than in the original whole tissue.	False
It was found that the specific activities of both BC6OTHER oxidase A ( BC6ENTG ) and of the BC6OTHER - sensitive BC6ENTC - resistant CHEM oxidase ( BC6OTHER ) were higher in isolated fat cells than in the original whole tissue.	False
It was found that the specific activities of both BC6OTHER oxidase A ( BC6OTHER ) and of the BC6OTHER - sensitive BC6ENTC - resistant CHEM oxidase ( BC6ENTG ) were higher in isolated fat cells than in the original whole tissue.	False
Moreover, it was suggested that promotion of BC6ENTG mRNA expression in Th2 cells was partially involved due to an increase in level of BC6ENTC in splenic tissue and the breakdown of Th cell responses locally in the splenic tissue, which then affected the maintenance of Th2 cell functions in the microenvironment of tumor - bearing mice.	False
In addition, BC6ENTC levels in splenic tissue or serum and BC6OTHER mRNA expression (mRNA encoding BC6ENTG ) in CD4+ T cells were increased in these mice.	False
In addition, BC6ENTC levels in splenic tissue or serum and BC6ENTG mRNA expression (mRNA encoding BC6OTHER side - chain cleavage p450 enzyme) in CD4+ T cells were increased in these mice.	False
In addition, BC6OTHER levels in splenic tissue or serum and BC6ENTG mRNA expression (mRNA encoding BC6ENTC side - chain cleavage p450 enzyme) in CD4+ T cells were increased in these mice.	False
When the anti - CHEM drug BC6ENTC ( BC6ENTG inhibitor) was administered to B16F10 mice, BC6OTHER levels in splenic tissue or serum and BC6OTHER mRNA expression were decreased at 14 days after tumor inoculation.	CPR:4
When the anti - CHEM drug BC6ENTC ( BC6OTHER inhibitor) was administered to B16F10 mice, BC6OTHER levels in splenic tissue or serum and BC6ENTG mRNA expression were decreased at 14 days after tumor inoculation.	CPR:4
When the anti - CHEM drug BC6OTHER ( BC6ENTG inhibitor) was administered to B16F10 mice, BC6ENTC levels in splenic tissue or serum and BC6OTHER mRNA expression were decreased at 14 days after tumor inoculation.	False
When the anti - CHEM drug BC6OTHER ( BC6OTHER inhibitor) was administered to B16F10 mice, BC6ENTC levels in splenic tissue or serum and BC6ENTG mRNA expression were decreased at 14 days after tumor inoculation.	False
The structures of BC6ENTG complexed with BC6OTHER at the BC6OTHER - site and BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), or BC6OTHER ( BC6OTHER ) at the substrate - site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively.	False
The structures of BC6ENTG complexed with BC6OTHER at the BC6OTHER - site and BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), or BC6ENTC ( BC6OTHER ) at the substrate - site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively.	False
The structures of BC6ENTG complexed with BC6OTHER at the BC6OTHER - site and BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), or BC6OTHER ( BC6ENTC ) at the substrate - site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively.	False
BC6ENTG catalyzes the phosphorylation of BC6ENTC resulting in an BC6OTHER , and the phosphorylation of BC6OTHER giving rise to an BC6OTHER .	False
BC6ENTG catalyzes the phosphorylation of BC6OTHER resulting in an BC6ENTC , and the phosphorylation of BC6OTHER giving rise to an BC6OTHER .	False
BC6ENTG catalyzes the phosphorylation of BC6OTHER resulting in an BC6OTHER , and the phosphorylation of BC6ENTC giving rise to an BC6OTHER .	False
BC6ENTG catalyzes the phosphorylation of BC6OTHER resulting in an BC6OTHER , and the phosphorylation of BC6OTHER giving rise to an BC6ENTC .	False
BC6ENTC kinase from Herpes simplex virus type 1 ( BC6ENTG ) was crystallized in an BC6OTHER - terminally truncated but fully active form.	False
BC6ENTG from Herpes simplex virus type 1 ( BC6OTHER ) was crystallized in an BC6ENTC - terminally truncated but fully active form.	False
BC6OTHER from Herpes simplex virus type 1 ( BC6ENTG ) was crystallized in an BC6ENTC - terminally truncated but fully active form.	False
Cavity and water molecules reduce the substrate specificity to such an extent that BC6ENTG can BC6ENTC various substrate analogues useful in pharmaceutical applications.	False
BC6ENTC is structurally homologous to the well - known BC6ENTG but contains large additional peptide segments.	False
BC6ENTG is structurally homologous to the well - known BC6ENTC kinases but contains large additional peptide segments.	False
The structures of BC6ENTG complexed with BC6ENTC at the BC6OTHER - site and BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), or BC6OTHER ( BC6OTHER ) at the substrate - site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively.	False
The structures of BC6ENTG complexed with BC6OTHER at the BC6ENTC - site and BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), or BC6OTHER ( BC6OTHER ) at the substrate - site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively.	False
The structures of BC6ENTG complexed with BC6OTHER at the BC6OTHER - site and BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), or BC6OTHER ( BC6OTHER ) at the substrate - site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively.	False
The structures of BC6ENTG complexed with BC6OTHER at the BC6OTHER - site and BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), or BC6OTHER ( BC6OTHER ) at the substrate - site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively.	False
The structures of BC6ENTG complexed with BC6OTHER at the BC6OTHER - site and BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), or BC6OTHER ( BC6OTHER ) at the substrate - site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively.	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6ENTC synthase) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6ENTG ).	False
Global protein profiling revealed a number of targets of the BC6ENTG knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6ENTC synthase) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6ENTG , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6ENTC synthase) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6ENTG , BC6OTHER sulphurtransferase and BC6ENTC synthase) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6ENTG and BC6ENTC synthase) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6ENTC synthase) and detoxifying enzymes ( BC6ENTG and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes ( BC6ENTC BC6OTHER - transferase μ 2 and BC6ENTG ).	False
Global protein profiling revealed a number of targets of the BC6ENTG knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes ( BC6ENTC BC6OTHER - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6ENTG , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes ( BC6ENTC BC6OTHER - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6ENTG , BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes ( BC6ENTC BC6OTHER - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6ENTG and BC6OTHER ) and detoxifying enzymes ( BC6ENTC BC6OTHER - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6ENTG ) and detoxifying enzymes ( BC6ENTC BC6OTHER - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6ENTC - transferase μ 2 and BC6ENTG ).	False
Global protein profiling revealed a number of targets of the BC6ENTG knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6ENTC - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6ENTG , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6ENTC - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6ENTG , BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6ENTC - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6ENTG and BC6OTHER ) and detoxifying enzymes (CHEM BC6ENTC - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6ENTG ) and detoxifying enzymes (CHEM BC6ENTC - transferase μ 2 and BC6OTHER ).	False
At the metabolomic level, BC6ENTG silencing caused no overt changes, though there was some evidence for a subtle increase in intracellular BC6ENTC quantities.	False
BC6ENTG expression was suppressed by means of RNA interference technology, and the overall outcome of this treatment on the hepatocellular proteome and metabolome was investigated using tandem mass tag - based differential protein profiling and BC6ENTC NMR spectroscopy, respectively.	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6ENTC - regulated protein 75, BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6ENTG ).	False
Global protein profiling revealed a number of targets of the BC6ENTG knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6ENTC - regulated protein 75, BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6ENTG , BC6ENTC - regulated protein 75, BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6ENTC - regulated protein 75, BC6ENTG and BC6OTHER ) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6ENTC - regulated protein 75, BC6OTHER sulphurtransferase and BC6ENTG ) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6ENTC - regulated protein 75, BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes ( BC6ENTG and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6ENTC sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6ENTG ).	False
Global protein profiling revealed a number of targets of the BC6ENTG knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6ENTC sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6ENTG , BC6OTHER - regulated protein 75, BC6ENTC sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6ENTG , BC6ENTC sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6ENTC sulphurtransferase and BC6ENTG ) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ).	False
Global protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6ENTC sulphurtransferase and BC6OTHER ) and detoxifying enzymes ( BC6ENTG and BC6OTHER ).	False
BC6ENTC (0.06 mM) and BC6OTHER (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a BC6OTHER analogue and exogenous BC6ENTG or if (2) whole blood clots were formed in the presence of exogenous BC6OTHER and a BC6OTHER analogue.	CPR:4
BC6ENTC (0.06 mM) and BC6OTHER (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a BC6OTHER analogue and exogenous BC6OTHER or if (2) whole blood clots were formed in the presence of exogenous BC6ENTG and a BC6OTHER analogue.	CPR:4
BC6OTHER (0.06 mM) and BC6ENTC (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a BC6OTHER analogue and exogenous BC6ENTG or if (2) whole blood clots were formed in the presence of exogenous BC6OTHER and a BC6OTHER analogue.	CPR:4
BC6OTHER (0.06 mM) and BC6ENTC (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a BC6OTHER analogue and exogenous BC6OTHER or if (2) whole blood clots were formed in the presence of exogenous BC6ENTG and a BC6OTHER analogue.	CPR:4
BC6OTHER (0.06 mM) and BC6OTHER (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a BC6ENTC analogue and exogenous BC6ENTG or if (2) whole blood clots were formed in the presence of exogenous BC6OTHER and a BC6OTHER analogue.	False
BC6OTHER (0.06 mM) and BC6OTHER (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a BC6ENTC analogue and exogenous BC6OTHER or if (2) whole blood clots were formed in the presence of exogenous BC6ENTG and a BC6OTHER analogue.	False
BC6OTHER (0.06 mM) and BC6OTHER (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a BC6OTHER analogue and exogenous BC6ENTG or if (2) whole blood clots were formed in the presence of exogenous BC6OTHER and a BC6ENTC analogue.	False
BC6OTHER (0.06 mM) and BC6OTHER (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a BC6OTHER analogue and exogenous BC6OTHER or if (2) whole blood clots were formed in the presence of exogenous BC6ENTG and a BC6ENTC analogue.	False
Inhibitory effects of BC6ENTC analogues on BC6ENTG induced whole blood clot lysis.	CPR:4
The BC6OTHER analogues BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received BC6ENTG ( BC6OTHER ).	False
The BC6OTHER analogues BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received BC6OTHER ( BC6ENTG ).	False
However, their inhibitory effect was markedly reduced if clots were formed in the presence of BC6ENTG and then exposed to either of the BC6ENTC analogues.	CPR:4
The data suggest that BC6ENTC analogues, even at low concentrations, reduce the rate of BC6ENTG induced whole blood clot lysis by several mechanisms.	CPR:4
The BC6OTHER analogues BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received BC6ENTG ( BC6OTHER ).	False
The BC6OTHER analogues BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received BC6OTHER ( BC6ENTG ).	False
The BC6ENTC analogues BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received BC6ENTG ( BC6OTHER ).	False
The BC6ENTC analogues BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received BC6OTHER ( BC6ENTG ).	False
The BC6OTHER analogues BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received BC6ENTG ( BC6OTHER ).	False
The BC6OTHER analogues BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received BC6OTHER ( BC6ENTG ).	False
The present study utilized blood from normal volunteers and BC6ENTC - BC6ENTG in a dilute whole blood clot assay to determine the relative concentrations of BC6OTHER analogues required for inhibition of clot lysis induced by exogenous BC6OTHER .	False
The present study utilized blood from normal volunteers and BC6ENTC - BC6OTHER in a dilute whole blood clot assay to determine the relative concentrations of BC6OTHER analogues required for inhibition of clot lysis induced by exogenous BC6ENTG .	False
The BC6OTHER analogues BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received BC6ENTG ( BC6OTHER ).	False
The BC6OTHER analogues BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received BC6OTHER ( BC6ENTG ).	False
The present study utilized blood from normal volunteers and BC6OTHER - BC6ENTG in a dilute whole blood clot assay to determine the relative concentrations of BC6ENTC analogues required for inhibition of clot lysis induced by exogenous BC6OTHER .	False
The present study utilized blood from normal volunteers and BC6OTHER - BC6OTHER in a dilute whole blood clot assay to determine the relative concentrations of BC6ENTC analogues required for inhibition of clot lysis induced by exogenous BC6ENTG .	CPR:4
Molecular study did not reveal the same mutations in the cardiac BC6ENTC channel gene ( BC6ENTG ) as previously reported in Brugada syndrome.	False
BC6ENTC antagonists bind to BC6ENTG at an intracellular allosteric site denoted site II.	False
Synthesis and structure - activity relationships of BC6ENTC as allosteric BC6OTHER ( BC6ENTG ) antagonists.	False
Synthesis and structure - activity relationships of BC6ENTC as allosteric BC6ENTG ( BC6OTHER ) antagonists.	False
A series of BC6ENTC were synthesized and examined as BC6ENTG antagonists.	CPR:6
The vasopressor response to the BC6ENTG activator, BC6OTHER , which is mediated through the opening of voltage dependent BC6OTHER channels and the subsequent translocation of extracellular BC6ENTC , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6OTHER antagonist, consistent with our previous in vitro studies.	False
The vasopressor response to the BC6OTHER channel activator, BC6OTHER , which is mediated through the opening of BC6ENTG and the subsequent translocation of extracellular BC6ENTC , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6OTHER antagonist, consistent with our previous in vitro studies.	CPR:9
The vasopressor response to the BC6OTHER channel activator, BC6OTHER , which is mediated through the opening of voltage dependent BC6OTHER channels and the subsequent translocation of extracellular BC6ENTC , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6ENTG antagonist, consistent with our previous in vitro studies.	False
The vasopressor response to the BC6ENTG activator, BC6OTHER , which is mediated through the opening of voltage dependent BC6OTHER channels and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6ENTC (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6OTHER antagonist, consistent with our previous in vitro studies.	False
The vasopressor response to the BC6OTHER channel activator, BC6OTHER , which is mediated through the opening of BC6ENTG and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6ENTC (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6OTHER antagonist, consistent with our previous in vitro studies.	CPR:4
The vasopressor response to the BC6OTHER channel activator, BC6OTHER , which is mediated through the opening of voltage dependent BC6OTHER channels and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6ENTC (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6ENTG antagonist, consistent with our previous in vitro studies.	False
The vasopressor response to the BC6ENTG activator, BC6OTHER , which is mediated through the opening of voltage dependent BC6OTHER channels and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6ENTC is also a BC6OTHER antagonist, consistent with our previous in vitro studies.	False
The vasopressor response to the BC6OTHER channel activator, BC6OTHER , which is mediated through the opening of BC6ENTG and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6ENTC is also a BC6OTHER antagonist, consistent with our previous in vitro studies.	False
The vasopressor response to the BC6OTHER channel activator, BC6OTHER , which is mediated through the opening of voltage dependent BC6OTHER channels and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6ENTC is also a BC6ENTG antagonist, consistent with our previous in vitro studies.	CPR:6
The vasopressor response to the BC6ENTG activator, BC6OTHER , which is mediated through the opening of voltage dependent BC6OTHER channels and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6ENTC channel antagonist, consistent with our previous in vitro studies.	False
The vasopressor response to the BC6OTHER channel activator, BC6OTHER , which is mediated through the opening of BC6ENTG and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6ENTC channel antagonist, consistent with our previous in vitro studies.	False
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6ENTC was nearly abolished by combined pretreatment of the rats with high doses of the BC6ENTG antagonist, BC6OTHER (1 mg / kg, iv), and the nonselective BC6OTHER antagonist, BC6OTHER (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6OTHER may be accounted for by blockade of BC6OTHER .	False
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6ENTC was nearly abolished by combined pretreatment of the rats with high doses of the BC6OTHER antagonist, BC6OTHER (1 mg / kg, iv), and the nonselective BC6ENTG antagonist, BC6OTHER (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6OTHER may be accounted for by blockade of BC6OTHER .	False
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6ENTC was nearly abolished by combined pretreatment of the rats with high doses of the BC6OTHER antagonist, BC6OTHER (1 mg / kg, iv), and the nonselective BC6OTHER antagonist, BC6OTHER (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6OTHER may be accounted for by blockade of BC6ENTG .	False
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6OTHER was nearly abolished by combined pretreatment of the rats with high doses of the BC6ENTG antagonist, BC6ENTC (1 mg / kg, iv), and the nonselective BC6OTHER antagonist, BC6OTHER (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6OTHER may be accounted for by blockade of BC6OTHER .	CPR:6
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6OTHER was nearly abolished by combined pretreatment of the rats with high doses of the BC6OTHER antagonist, BC6ENTC (1 mg / kg, iv), and the nonselective BC6ENTG antagonist, BC6OTHER (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6OTHER may be accounted for by blockade of BC6OTHER .	False
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6OTHER was nearly abolished by combined pretreatment of the rats with high doses of the BC6OTHER antagonist, BC6ENTC (1 mg / kg, iv), and the nonselective BC6OTHER antagonist, BC6OTHER (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6OTHER may be accounted for by blockade of BC6ENTG .	False
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6OTHER was nearly abolished by combined pretreatment of the rats with high doses of the BC6ENTG antagonist, BC6OTHER (1 mg / kg, iv), and the nonselective BC6OTHER antagonist, BC6ENTC (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6OTHER may be accounted for by blockade of BC6OTHER .	False
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6OTHER was nearly abolished by combined pretreatment of the rats with high doses of the BC6OTHER antagonist, BC6OTHER (1 mg / kg, iv), and the nonselective BC6ENTG antagonist, BC6ENTC (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6OTHER may be accounted for by blockade of BC6OTHER .	CPR:6
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6OTHER was nearly abolished by combined pretreatment of the rats with high doses of the BC6OTHER antagonist, BC6OTHER (1 mg / kg, iv), and the nonselective BC6OTHER antagonist, BC6ENTC (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6OTHER may be accounted for by blockade of BC6ENTG .	False
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6OTHER was nearly abolished by combined pretreatment of the rats with high doses of the BC6ENTG antagonist, BC6OTHER (1 mg / kg, iv), and the nonselective BC6OTHER antagonist, BC6OTHER (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6ENTC may be accounted for by blockade of BC6OTHER .	False
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6OTHER was nearly abolished by combined pretreatment of the rats with high doses of the BC6OTHER antagonist, BC6OTHER (1 mg / kg, iv), and the nonselective BC6ENTG antagonist, BC6OTHER (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6ENTC may be accounted for by blockade of BC6OTHER .	False
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6OTHER was nearly abolished by combined pretreatment of the rats with high doses of the BC6OTHER antagonist, BC6OTHER (1 mg / kg, iv), and the nonselective BC6OTHER antagonist, BC6OTHER (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6ENTC may be accounted for by blockade of BC6ENTG .	False
We therefore conclude that BC6ENTC , at antihypertensive doses, is an antagonist of BC6ENTG , and also of BC6OTHER in vascular smooth muscle.	False
We therefore conclude that BC6ENTC , at antihypertensive doses, is an antagonist of BC6OTHER , and also of BC6ENTG in vascular smooth muscle.	CPR:6
Thus, BC6ENTC blocks both BC6ENTG at antihypertensive doses, with modest selectivity being observed for the BC6OTHER subtype.	False
Thus, BC6ENTC blocks both BC6OTHER at antihypertensive doses, with modest selectivity being observed for the BC6ENTG subtype.	CPR:4
We therefore conclude that BC6OTHER , at antihypertensive doses, is an antagonist of BC6ENTG , and also of BC6ENTC channels in vascular smooth muscle.	False
BC6ENTC (0.3 mg / kg, iv) produced a significant inhibition of the BC6ENTG mediated positive chronotropic response to BC6OTHER .	CPR:4
BC6OTHER (0.3 mg / kg, iv) produced a significant inhibition of the BC6ENTG mediated positive chronotropic response to BC6ENTC .	CPR:3
This same dose of BC6ENTC also inhibited, but to a lesser degree, the BC6OTHER mediated vasodepressor response to BC6OTHER in pithed rats whose blood pressure was elevated by a constant intravenous infusion of BC6ENTG .	False
This same dose of BC6ENTC also inhibited, but to a lesser degree, the BC6ENTG mediated vasodepressor response to BC6OTHER in pithed rats whose blood pressure was elevated by a constant intravenous infusion of BC6OTHER .	CPR:4
This same dose of BC6OTHER also inhibited, but to a lesser degree, the BC6OTHER mediated vasodepressor response to BC6ENTC in pithed rats whose blood pressure was elevated by a constant intravenous infusion of BC6ENTG .	False
This same dose of BC6OTHER also inhibited, but to a lesser degree, the BC6ENTG mediated vasodepressor response to BC6ENTC in pithed rats whose blood pressure was elevated by a constant intravenous infusion of BC6OTHER .	False
The mechanism(s) responsible for arterial vasodilation observed following acute administration of BC6ENTC , a novel vasodilator / BC6ENTG antagonist, has been investigated in rats.	CPR:6
BC6ENTC produced significant inhibition of the BC6ENTG mediated pressor response to BC6OTHER in the pithed rat, but had no effect on the BC6OTHER mediated pressor response to BC6OTHER , suggesting that BC6OTHER is also an BC6OTHER antagonist at antihypertensive doses.	CPR:4
BC6ENTC produced significant inhibition of the BC6OTHER mediated pressor response to BC6OTHER in the pithed rat, but had no effect on the BC6ENTG mediated pressor response to BC6OTHER , suggesting that BC6OTHER is also an BC6OTHER antagonist at antihypertensive doses.	False
BC6ENTC produced significant inhibition of the BC6OTHER mediated pressor response to BC6OTHER in the pithed rat, but had no effect on the BC6OTHER mediated pressor response to BC6OTHER , suggesting that BC6OTHER is also an BC6ENTG antagonist at antihypertensive doses.	False
BC6OTHER produced significant inhibition of the BC6ENTG mediated pressor response to BC6ENTC in the pithed rat, but had no effect on the BC6OTHER mediated pressor response to BC6OTHER , suggesting that BC6OTHER is also an BC6OTHER antagonist at antihypertensive doses.	False
BC6OTHER produced significant inhibition of the BC6OTHER mediated pressor response to BC6ENTC in the pithed rat, but had no effect on the BC6ENTG mediated pressor response to BC6OTHER , suggesting that BC6OTHER is also an BC6OTHER antagonist at antihypertensive doses.	False
BC6OTHER produced significant inhibition of the BC6OTHER mediated pressor response to BC6ENTC in the pithed rat, but had no effect on the BC6OTHER mediated pressor response to BC6OTHER , suggesting that BC6OTHER is also an BC6ENTG antagonist at antihypertensive doses.	False
BC6OTHER produced significant inhibition of the BC6ENTG mediated pressor response to BC6OTHER in the pithed rat, but had no effect on the BC6OTHER mediated pressor response to BC6ENTC , suggesting that BC6OTHER is also an BC6OTHER antagonist at antihypertensive doses.	False
BC6OTHER produced significant inhibition of the BC6OTHER mediated pressor response to BC6OTHER in the pithed rat, but had no effect on the BC6ENTG mediated pressor response to BC6ENTC , suggesting that BC6OTHER is also an BC6OTHER antagonist at antihypertensive doses.	False
BC6OTHER produced significant inhibition of the BC6OTHER mediated pressor response to BC6OTHER in the pithed rat, but had no effect on the BC6OTHER mediated pressor response to BC6ENTC , suggesting that BC6OTHER is also an BC6ENTG antagonist at antihypertensive doses.	False
BC6OTHER produced significant inhibition of the BC6ENTG mediated pressor response to BC6OTHER in the pithed rat, but had no effect on the BC6OTHER mediated pressor response to BC6OTHER , suggesting that BC6ENTC is also an BC6OTHER antagonist at antihypertensive doses.	False
BC6OTHER produced significant inhibition of the BC6OTHER mediated pressor response to BC6OTHER in the pithed rat, but had no effect on the BC6ENTG mediated pressor response to BC6OTHER , suggesting that BC6ENTC is also an BC6OTHER antagonist at antihypertensive doses.	False
BC6OTHER produced significant inhibition of the BC6OTHER mediated pressor response to BC6OTHER in the pithed rat, but had no effect on the BC6OTHER mediated pressor response to BC6OTHER , suggesting that BC6ENTC is also an BC6ENTG antagonist at antihypertensive doses.	CPR:6
BC6ENTC had no effect on the pressor response elicited by BC6ENTG , indicating a lack of nonspecific vasodilator activity.	False
The vasopressor response to the BC6ENTC channel activator, BC6OTHER , which is mediated through the opening of BC6ENTG and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6OTHER antagonist, consistent with our previous in vitro studies.	False
The vasopressor response to the BC6ENTC channel activator, BC6OTHER , which is mediated through the opening of voltage dependent BC6OTHER channels and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6ENTG antagonist, consistent with our previous in vitro studies.	False
The vasopressor response to the BC6ENTG activator, BC6ENTC , which is mediated through the opening of voltage dependent BC6OTHER channels and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6OTHER antagonist, consistent with our previous in vitro studies.	CPR:3
The vasopressor response to the BC6OTHER channel activator, BC6ENTC , which is mediated through the opening of BC6ENTG and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6OTHER antagonist, consistent with our previous in vitro studies.	CPR:3
The vasopressor response to the BC6OTHER channel activator, BC6ENTC , which is mediated through the opening of voltage dependent BC6OTHER channels and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6ENTG antagonist, consistent with our previous in vitro studies.	False
The vasopressor response to the BC6ENTG activator, BC6OTHER , which is mediated through the opening of voltage dependent BC6ENTC channels and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6OTHER antagonist, consistent with our previous in vitro studies.	False
The vasopressor response to the BC6OTHER channel activator, BC6OTHER , which is mediated through the opening of voltage dependent BC6ENTC channels and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6ENTG antagonist, consistent with our previous in vitro studies.	False
Intrahypothalamic administration of BC6ENTG (1 or 5 pmol / mouse) significantly and dose - dependently suppressed the development of postischemic BC6ENTC intolerance on day 1 and development of neuronal damage on day 3.	False
BC6ENTG (a BC6ENTC - sensing neuropeptide in the hypothalamus) and BC6OTHER ( BC6OTHER ; a member of the BC6OTHER family) play roles in many physiologic functions, including regulation of BC6OTHER metabolism.	False
BC6OTHER (a BC6ENTC - sensing neuropeptide in the hypothalamus) and BC6OTHER ( BC6ENTG ; a member of the BC6OTHER family) play roles in many physiologic functions, including regulation of BC6OTHER metabolism.	False
BC6OTHER (a BC6ENTC - sensing neuropeptide in the hypothalamus) and BC6OTHER ( BC6OTHER ; a member of the BC6ENTG family) play roles in many physiologic functions, including regulation of BC6OTHER metabolism.	False
BC6OTHER (a BC6ENTC - sensing neuropeptide in the hypothalamus) and BC6ENTG ( BC6OTHER ; a member of the BC6OTHER family) play roles in many physiologic functions, including regulation of BC6OTHER metabolism.	False
The MCAO - induced decrease in BC6ENTG levels in the liver and skeletal muscle on day 1 was recovered to control levels by BC6OTHER , and this effect of BC6OTHER was reversed by the administration of BC6ENTC as well as by hypothalamic BC6OTHER knockdown.	CPR:4
The MCAO - induced decrease in BC6OTHER levels in the liver and skeletal muscle on day 1 was recovered to control levels by BC6ENTG , and this effect of BC6OTHER was reversed by the administration of BC6ENTC as well as by hypothalamic BC6OTHER knockdown.	False
The MCAO - induced decrease in BC6OTHER levels in the liver and skeletal muscle on day 1 was recovered to control levels by BC6OTHER , and this effect of BC6ENTG was reversed by the administration of BC6ENTC as well as by hypothalamic BC6OTHER knockdown.	CPR:4
The MCAO - induced decrease in BC6OTHER levels in the liver and skeletal muscle on day 1 was recovered to control levels by BC6OTHER , and this effect of BC6OTHER was reversed by the administration of BC6ENTC as well as by hypothalamic BC6ENTG knockdown.	False
These results suggest that suppression of postischemic BC6ENTC intolerance by BC6ENTG assists in the prevention of cerebral ischemic neuronal damage.	False
BC6ENTG (a BC6OTHER - sensing neuropeptide in the hypothalamus) and BC6OTHER ( BC6OTHER ; a member of the BC6OTHER family) play roles in many physiologic functions, including regulation of BC6ENTC metabolism.	False
BC6OTHER (a BC6OTHER - sensing neuropeptide in the hypothalamus) and BC6OTHER ( BC6ENTG ; a member of the BC6OTHER family) play roles in many physiologic functions, including regulation of BC6ENTC metabolism.	False
BC6OTHER (a BC6OTHER - sensing neuropeptide in the hypothalamus) and BC6OTHER ( BC6OTHER ; a member of the BC6ENTG family) play roles in many physiologic functions, including regulation of BC6ENTC metabolism.	False
BC6OTHER (a BC6OTHER - sensing neuropeptide in the hypothalamus) and BC6ENTG ( BC6OTHER ; a member of the BC6OTHER family) play roles in many physiologic functions, including regulation of BC6ENTC metabolism.	False
Small interfering RNA directed BC6ENTG , BC6OTHER , and BC6ENTC [ BC6OTHER ; a specific BC6OTHER antagonist] were administered directly into the hypothalamus.	False
Small interfering RNA directed BC6OTHER , BC6ENTG , and BC6ENTC [ BC6OTHER ; a specific BC6OTHER antagonist] were administered directly into the hypothalamus.	False
Small interfering RNA directed BC6OTHER , BC6OTHER , and BC6ENTC [ BC6OTHER ; a specific BC6ENTG antagonist] were administered directly into the hypothalamus.	CPR:6
Small interfering RNA directed BC6ENTG , BC6OTHER , and BC6OTHER [ BC6ENTC ; a specific BC6OTHER antagonist] were administered directly into the hypothalamus.	False
Small interfering RNA directed BC6OTHER , BC6ENTG , and BC6OTHER [ BC6ENTC ; a specific BC6OTHER antagonist] were administered directly into the hypothalamus.	False
Small interfering RNA directed BC6OTHER , BC6OTHER , and BC6OTHER [ BC6ENTC ; a specific BC6ENTG antagonist] were administered directly into the hypothalamus.	CPR:6
 BC6ENTG suppresses postischemic BC6ENTC intolerance and neuronal damage through hypothalamic BC6OTHER .	False
 BC6OTHER suppresses postischemic BC6ENTC intolerance and neuronal damage through hypothalamic BC6ENTG .	False
The phosphorylation by BC6ENTG resulted in activation of BC6OTHER because a BC6OTHER mutant in which BC6OTHER - 776 and BC6OTHER - 779 were substituted with BC6ENTC to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6OTHER mutant.	False
The phosphorylation by BC6OTHER resulted in activation of BC6ENTG because a BC6OTHER mutant in which BC6OTHER - 776 and BC6OTHER - 779 were substituted with BC6ENTC to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6OTHER mutant.	False
The phosphorylation by BC6OTHER resulted in activation of BC6OTHER because a BC6ENTG mutant in which BC6OTHER - 776 and BC6OTHER - 779 were substituted with BC6ENTC to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6OTHER mutant.	False
The phosphorylation by BC6OTHER resulted in activation of BC6OTHER because a BC6OTHER mutant in which BC6OTHER - 776 and BC6OTHER - 779 were substituted with BC6ENTC to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6ENTG and an unphosphorylatable BC6OTHER mutant.	False
The phosphorylation by BC6OTHER resulted in activation of BC6OTHER because a BC6OTHER mutant in which BC6OTHER - 776 and BC6OTHER - 779 were substituted with BC6ENTC to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6ENTG mutant.	False
BC6OTHER ( BC6OTHER ) acts as an allosteric activator of BC6OTHER ( BC6OTHER ) and is converted to BC6ENTC by BC6ENTG ( BC6OTHER ).	CPR:9
BC6OTHER ( BC6OTHER ) acts as an allosteric activator of BC6OTHER ( BC6OTHER ) and is converted to BC6ENTC by BC6OTHER ( BC6ENTG ).	CPR:9
BC6OTHER ( BC6OTHER ) acts as an allosteric activator of BC6ENTG ( BC6OTHER ) and is converted to BC6ENTC by BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) acts as an allosteric activator of BC6OTHER ( BC6ENTG ) and is converted to BC6ENTC by BC6OTHER ( BC6OTHER ).	False
Phosphorylation and up - regulation of BC6ENTC kinase gamma via its interaction with BC6ENTG .	False
BC6ENTC ( BC6OTHER ) acts as an allosteric activator of BC6OTHER ( BC6OTHER ) and is converted to BC6OTHER by BC6ENTG ( BC6OTHER ).	CPR:9
BC6ENTC ( BC6OTHER ) acts as an allosteric activator of BC6OTHER ( BC6OTHER ) and is converted to BC6OTHER by BC6OTHER ( BC6ENTG ).	CPR:9
BC6ENTC ( BC6OTHER ) acts as an allosteric activator of BC6ENTG ( BC6OTHER ) and is converted to BC6OTHER by BC6OTHER ( BC6OTHER ).	False
BC6ENTC ( BC6OTHER ) acts as an allosteric activator of BC6OTHER ( BC6ENTG ) and is converted to BC6OTHER by BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6ENTC ) acts as an allosteric activator of BC6OTHER ( BC6OTHER ) and is converted to BC6OTHER by BC6ENTG ( BC6OTHER ).	CPR:9
BC6OTHER ( BC6ENTC ) acts as an allosteric activator of BC6OTHER ( BC6OTHER ) and is converted to BC6OTHER by BC6OTHER ( BC6ENTG ).	CPR:9
BC6OTHER ( BC6ENTC ) acts as an allosteric activator of BC6ENTG ( BC6OTHER ) and is converted to BC6OTHER by BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6ENTC ) acts as an allosteric activator of BC6OTHER ( BC6ENTG ) and is converted to BC6OTHER by BC6OTHER ( BC6OTHER ).	False
BC6ENTG directly associated with BC6OTHER through its accessory domain (AD), depending on BC6ENTC as well as BC6OTHER / BC6OTHER in vitro.	False
BC6OTHER directly associated with BC6ENTG through its accessory domain (AD), depending on BC6ENTC as well as BC6OTHER / BC6OTHER in vitro.	False
BC6ENTG directly associated with BC6OTHER through its accessory domain (AD), depending on BC6OTHER as well as BC6ENTC / BC6OTHER in vitro.	False
BC6OTHER directly associated with BC6ENTG through its accessory domain (AD), depending on BC6OTHER as well as BC6ENTC / BC6OTHER in vitro.	False
BC6ENTG directly associated with BC6OTHER through its accessory domain (AD), depending on BC6OTHER as well as BC6OTHER / BC6ENTC in vitro.	False
BC6OTHER directly associated with BC6ENTG through its accessory domain (AD), depending on BC6OTHER as well as BC6OTHER / BC6ENTC in vitro.	False
Mass spectrometric analysis and mutation studies revealed that BC6ENTG BC6ENTC - 776 and BC6OTHER - 779 in the AD of BC6OTHER .	False
Mass spectrometric analysis and mutation studies revealed that BC6OTHER BC6ENTC - 776 and BC6OTHER - 779 in the AD of BC6ENTG .	False
Mass spectrometric analysis and mutation studies revealed that BC6ENTG BC6OTHER - 776 and BC6ENTC - 779 in the AD of BC6OTHER .	False
Mass spectrometric analysis and mutation studies revealed that BC6OTHER BC6OTHER - 776 and BC6ENTC - 779 in the AD of BC6ENTG .	False
The phosphorylation by BC6ENTG resulted in activation of BC6OTHER because a BC6OTHER mutant in which BC6ENTC - 776 and BC6OTHER - 779 were substituted with BC6OTHER to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6OTHER mutant.	False
The phosphorylation by BC6OTHER resulted in activation of BC6ENTG because a BC6OTHER mutant in which BC6ENTC - 776 and BC6OTHER - 779 were substituted with BC6OTHER to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6OTHER mutant.	False
The phosphorylation by BC6OTHER resulted in activation of BC6OTHER because a BC6ENTG mutant in which BC6ENTC - 776 and BC6OTHER - 779 were substituted with BC6OTHER to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6OTHER mutant.	False
The phosphorylation by BC6OTHER resulted in activation of BC6OTHER because a BC6OTHER mutant in which BC6ENTC - 776 and BC6OTHER - 779 were substituted with BC6OTHER to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6ENTG and an unphosphorylatable BC6OTHER mutant.	False
The phosphorylation by BC6OTHER resulted in activation of BC6OTHER because a BC6OTHER mutant in which BC6ENTC - 776 and BC6OTHER - 779 were substituted with BC6OTHER to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6ENTG mutant.	False
The phosphorylation by BC6ENTG resulted in activation of BC6OTHER because a BC6OTHER mutant in which BC6OTHER - 776 and BC6ENTC - 779 were substituted with BC6OTHER to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6OTHER mutant.	False
The phosphorylation by BC6OTHER resulted in activation of BC6ENTG because a BC6OTHER mutant in which BC6OTHER - 776 and BC6ENTC - 779 were substituted with BC6OTHER to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6OTHER mutant.	False
The phosphorylation by BC6OTHER resulted in activation of BC6OTHER because a BC6ENTG mutant in which BC6OTHER - 776 and BC6ENTC - 779 were substituted with BC6OTHER to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6OTHER mutant.	False
The phosphorylation by BC6OTHER resulted in activation of BC6OTHER because a BC6OTHER mutant in which BC6OTHER - 776 and BC6ENTC - 779 were substituted with BC6OTHER to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6ENTG and an unphosphorylatable BC6OTHER mutant.	False
The phosphorylation by BC6OTHER resulted in activation of BC6OTHER because a BC6OTHER mutant in which BC6OTHER - 776 and BC6ENTC - 779 were substituted with BC6OTHER to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6ENTG mutant.	False
The neurospecific BC6ENTC 24 - hydroxylase converts excess brain BC6OTHER into BC6OTHER ( BC6OTHER ) which, via the BC6ENTG ( BC6OTHER ), can increase the expression and synthesis of astrocyte BC6OTHER .	False
The neurospecific BC6ENTC 24 - hydroxylase converts excess brain BC6OTHER into BC6OTHER ( BC6OTHER ) which, via the BC6OTHER ( BC6ENTG ), can increase the expression and synthesis of astrocyte BC6OTHER .	False
The neurospecific BC6ENTC 24 - hydroxylase converts excess brain BC6OTHER into BC6OTHER ( BC6OTHER ) which, via the BC6OTHER ( BC6OTHER ), can increase the expression and synthesis of astrocyte BC6ENTG .	False
The neurospecific BC6OTHER 24 - hydroxylase converts excess brain BC6ENTC into BC6OTHER ( BC6OTHER ) which, via the BC6ENTG ( BC6OTHER ), can increase the expression and synthesis of astrocyte BC6OTHER .	False
The neurospecific BC6OTHER 24 - hydroxylase converts excess brain BC6ENTC into BC6OTHER ( BC6OTHER ) which, via the BC6OTHER ( BC6ENTG ), can increase the expression and synthesis of astrocyte BC6OTHER .	False
The neurospecific BC6OTHER 24 - hydroxylase converts excess brain BC6ENTC into BC6OTHER ( BC6OTHER ) which, via the BC6OTHER ( BC6OTHER ), can increase the expression and synthesis of astrocyte BC6ENTG .	False
The neurospecific BC6OTHER 24 - hydroxylase converts excess brain BC6OTHER into BC6ENTC ( BC6OTHER ) which, via the BC6ENTG ( BC6OTHER ), can increase the expression and synthesis of astrocyte BC6OTHER .	False
The neurospecific BC6OTHER 24 - hydroxylase converts excess brain BC6OTHER into BC6ENTC ( BC6OTHER ) which, via the BC6OTHER ( BC6ENTG ), can increase the expression and synthesis of astrocyte BC6OTHER .	False
The neurospecific BC6OTHER 24 - hydroxylase converts excess brain BC6OTHER into BC6ENTC ( BC6OTHER ) which, via the BC6OTHER ( BC6OTHER ), can increase the expression and synthesis of astrocyte BC6ENTG .	False
BC6ENTC also increases BC6ENTG ( BC6OTHER ) deposition and BC6OTHER pathology.	CPR:4
BC6ENTC also increases BC6OTHER ( BC6ENTG ) deposition and BC6OTHER pathology.	CPR:4
BC6ENTC also increases BC6OTHER ( BC6OTHER ) deposition and BC6ENTG pathology.	CPR:4
The neurospecific BC6OTHER 24 - hydroxylase converts excess brain BC6OTHER into BC6OTHER ( BC6ENTC ) which, via the BC6ENTG ( BC6OTHER ), can increase the expression and synthesis of astrocyte BC6OTHER .	False
The neurospecific BC6OTHER 24 - hydroxylase converts excess brain BC6OTHER into BC6OTHER ( BC6ENTC ) which, via the BC6OTHER ( BC6ENTG ), can increase the expression and synthesis of astrocyte BC6OTHER .	False
The neurospecific BC6OTHER 24 - hydroxylase converts excess brain BC6OTHER into BC6OTHER ( BC6ENTC ) which, via the BC6OTHER ( BC6OTHER ), can increase the expression and synthesis of astrocyte BC6ENTG .	False
BC6ENTG , BC6ENTC , BC6OTHER and BC6OTHER were correlated in Alzheimer disease (AD) samples.	False
BC6OTHER , BC6ENTC , BC6ENTG and BC6OTHER were correlated in Alzheimer disease (AD) samples.	False
BC6OTHER , BC6ENTC , BC6OTHER and BC6ENTG were correlated in Alzheimer disease (AD) samples.	False
Excess of BC6ENTC converted into BC6OTHER may up - regulate BC6ENTG synthesis which is a scavenger for BC6OTHER and BC6OTHER .	CPR:3
Excess of BC6ENTC converted into BC6OTHER may up - regulate BC6OTHER synthesis which is a scavenger for BC6ENTG and BC6OTHER .	False
Excess of BC6ENTC converted into BC6OTHER may up - regulate BC6OTHER synthesis which is a scavenger for BC6OTHER and BC6ENTG .	False
Excess of BC6OTHER converted into BC6ENTC may up - regulate BC6ENTG synthesis which is a scavenger for BC6OTHER and BC6OTHER .	CPR:3
Excess of BC6OTHER converted into BC6ENTC may up - regulate BC6OTHER synthesis which is a scavenger for BC6ENTG and BC6OTHER .	False
Excess of BC6OTHER converted into BC6ENTC may up - regulate BC6OTHER synthesis which is a scavenger for BC6OTHER and BC6ENTG .	False
In AD this protective mechanism seems to be inefficient, probably due to the presence of high concentrations of BC6ENTC , microvascular dysfunction and the decreased efficiency of BC6ENTG as lipid transporter and BC6OTHER scavenger.	False
In AD this protective mechanism seems to be inefficient, probably due to the presence of high concentrations of BC6ENTC , microvascular dysfunction and the decreased efficiency of BC6OTHER as lipid transporter and BC6ENTG scavenger.	False
Analysis of side chain BC6ENTC in the CSF is likely to provided useful information about BC6OTHER metabolism and BC6ENTG function in the pathogenesis of AD.	False
Analysis of side chain BC6OTHER in the CSF is likely to provided useful information about BC6ENTC metabolism and BC6ENTG function in the pathogenesis of AD.	False
The BC6ENTC complexes retain potency in BC6ENTG mutant colon cells.	False
In general, antiproliferative activity is greatly enhanced by low levels of the BC6ENTG inhibitor BC6ENTC .	CPR:4
The contrasting activity of BC6ENTC versus BC6OTHER and BC6OTHER anticancer complexes: control of cell selectivity, cross - resistance, BC6ENTG dependence, and apoptosis pathway.	False
The contrasting activity of BC6OTHER versus BC6ENTC and BC6OTHER anticancer complexes: control of cell selectivity, cross - resistance, BC6ENTG dependence, and apoptosis pathway.	False
The contrasting activity of BC6OTHER versus BC6OTHER and BC6ENTC anticancer complexes: control of cell selectivity, cross - resistance, BC6ENTG dependence, and apoptosis pathway.	False
Conversely, BC6ENTG mRNAs increased 100 to 500% at various time points in pregnant and lactating mice and corresponded with enhanced in vitro sulfation of BC6ENTC in liver S9 fractions.	False
Protein expression of BC6ENTG also decreased and corresponded with reduced in vitro glucuronidation of BC6ENTC in S9 fractions from livers of pregnant mice.	CPR:4
Further characterization showed that BC6ENTC suppresses both wild - type and BC6ENTG mutant BC6OTHER activity in vitro.	CPR:4
Further characterization showed that BC6ENTC suppresses both wild - type and BC6OTHER mutant BC6ENTG activity in vitro.	CPR:4
In addition, BC6ENTC demonstrated significant activity against several receptor BC6OTHER kinases involved in neovascularization and tumor progression, including BC6OTHER , BC6ENTG , BC6OTHER BC6OTHER , and BC6OTHER .	CPR:3
In addition, BC6ENTC demonstrated significant activity against several receptor BC6OTHER kinases involved in neovascularization and tumor progression, including BC6OTHER , BC6OTHER , BC6ENTG BC6OTHER , and BC6OTHER .	CPR:3
In addition, BC6ENTC demonstrated significant activity against several receptor BC6OTHER kinases involved in neovascularization and tumor progression, including BC6OTHER , BC6OTHER , BC6OTHER BC6ENTG , and BC6OTHER .	CPR:3
In addition, BC6ENTC demonstrated significant activity against several receptor BC6OTHER kinases involved in neovascularization and tumor progression, including BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER , and BC6ENTG .	CPR:3
In addition, BC6ENTC demonstrated significant activity against several BC6ENTG involved in neovascularization and tumor progression, including BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER , and BC6OTHER .	CPR:3
In addition, BC6ENTC demonstrated significant activity against several receptor BC6OTHER kinases involved in neovascularization and tumor progression, including BC6ENTG , BC6OTHER , BC6OTHER BC6OTHER , and BC6OTHER .	CPR:3
In addition, BC6OTHER demonstrated significant activity against several receptor BC6ENTC kinases involved in neovascularization and tumor progression, including BC6OTHER , BC6ENTG , BC6OTHER BC6OTHER , and BC6OTHER .	False
In addition, BC6OTHER demonstrated significant activity against several receptor BC6ENTC kinases involved in neovascularization and tumor progression, including BC6OTHER , BC6OTHER , BC6ENTG BC6OTHER , and BC6OTHER .	False
In addition, BC6OTHER demonstrated significant activity against several receptor BC6ENTC kinases involved in neovascularization and tumor progression, including BC6OTHER , BC6OTHER , BC6OTHER BC6ENTG , and BC6OTHER .	False
In addition, BC6OTHER demonstrated significant activity against several receptor BC6ENTC kinases involved in neovascularization and tumor progression, including BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER , and BC6ENTG .	False
In addition, BC6OTHER demonstrated significant activity against several receptor BC6ENTC kinases involved in neovascularization and tumor progression, including BC6ENTG , BC6OTHER , BC6OTHER BC6OTHER , and BC6OTHER .	False
BC6ENTC , which belongs chemically to a class that can be described as BC6OTHER , was selected for further pharmacologic characterization based on potent inhibition of BC6ENTG and its favorable BC6OTHER selectivity profile.	CPR:4
BC6ENTC , which belongs chemically to a class that can be described as BC6OTHER , was selected for further pharmacologic characterization based on potent inhibition of BC6OTHER and its favorable BC6ENTG selectivity profile.	CPR:4
BC6OTHER , which belongs chemically to a class that can be described as BC6ENTC , was selected for further pharmacologic characterization based on potent inhibition of BC6ENTG and its favorable BC6OTHER selectivity profile.	CPR:4
BC6OTHER , which belongs chemically to a class that can be described as BC6ENTC , was selected for further pharmacologic characterization based on potent inhibition of BC6OTHER and its favorable BC6ENTG selectivity profile.	CPR:4
To further analyze the mechanism governing the BC6ENTG - BC6ENTC interaction, we examined the effect of BC6OTHER on various recombinant BC6OTHER expressed in mammalian cells from their cloned cDNAs, using BC6OTHER as the permeant ion at physiological concentration.	False
To further analyze the mechanism governing the BC6OTHER channel - BC6ENTC interaction, we examined the effect of BC6OTHER on various recombinant BC6ENTG expressed in mammalian cells from their cloned cDNAs, using BC6OTHER as the permeant ion at physiological concentration.	False
To further analyze the mechanism governing the BC6ENTG - BC6OTHER interaction, we examined the effect of BC6ENTC on various recombinant BC6OTHER expressed in mammalian cells from their cloned cDNAs, using BC6OTHER as the permeant ion at physiological concentration.	False
To further analyze the mechanism governing the BC6OTHER channel - BC6OTHER interaction, we examined the effect of BC6ENTC on various recombinant BC6ENTG expressed in mammalian cells from their cloned cDNAs, using BC6OTHER as the permeant ion at physiological concentration.	False
To further analyze the mechanism governing the BC6ENTG - BC6OTHER interaction, we examined the effect of BC6OTHER on various recombinant BC6ENTC channels expressed in mammalian cells from their cloned cDNAs, using BC6OTHER as the permeant ion at physiological concentration.	False
To further analyze the mechanism governing the BC6ENTG - BC6OTHER interaction, we examined the effect of BC6OTHER on various recombinant BC6OTHER expressed in mammalian cells from their cloned cDNAs, using BC6ENTC as the permeant ion at physiological concentration.	False
To further analyze the mechanism governing the BC6OTHER channel - BC6OTHER interaction, we examined the effect of BC6OTHER on various recombinant BC6ENTG expressed in mammalian cells from their cloned cDNAs, using BC6ENTC as the permeant ion at physiological concentration.	False
BC6ENTC blocked alpha1A and alpha1E with a Kd comparable to that reported for BC6ENTG , but had a lower affinity (approximately 30 - fold) for alpha1C.	CPR:4
BC6ENTC ( BC6OTHER ) belongs to a new chemical class of these molecules which differs from other BC6OTHER antagonists by its ability to potently block BC6ENTG .	CPR:4
Determinants of voltage - dependent inactivation affect BC6ENTC block of BC6ENTG .	CPR:4
BC6OTHER ( BC6ENTC ) belongs to a new chemical class of these molecules which differs from other BC6OTHER antagonists by its ability to potently block BC6ENTG .	CPR:4
Therefore, we conclude that the tissue and sub - cellular localization of BC6ENTG subunits as well as their specific associations are essential parameters to understand the in vivo effects of BC6ENTC .	False
BC6OTHER ( BC6OTHER ) belongs to a new chemical class of these molecules which differs from other BC6ENTC antagonists by its ability to potently block BC6ENTG .	False
To further analyze the mechanism governing the BC6ENTC channel - BC6OTHER interaction, we examined the effect of BC6OTHER on various recombinant BC6ENTG expressed in mammalian cells from their cloned cDNAs, using BC6OTHER as the permeant ion at physiological concentration.	False
BC6ENTC ( BC6OTHER ), an BC6ENTG inhibitor, is currently under evaluation for its anticancer activity in clinical trials.	CPR:4
BC6OTHER ( BC6ENTC ), an BC6ENTG inhibitor, is currently under evaluation for its anticancer activity in clinical trials.	CPR:4
We have demonstrated that BC6ENTC receptor ( BC6ENTG ) is overexpressed in lung adenocarcinoma (AD).	False
Here we investigated whether BC6ENTG plays a role in BC6ENTC - mediated anticancer activity by functioning as a downstream target or by modulating its anticancer efficacy.	False
 BC6ENTG is a target of BC6ENTC and enhances its anticancer activity in lung adenocarcinoma cells.	False
Although treatment with BC6ENTC reduced BC6ENTG levels and BC6OTHER - regulated gene expression in lung AD cells, BC6OTHER expression increased anticancer activity of BC6OTHER .	CPR:4
Although treatment with BC6ENTC reduced BC6OTHER levels and BC6ENTG - regulated gene expression in lung AD cells, BC6OTHER expression increased anticancer activity of BC6OTHER .	CPR:4
Although treatment with BC6ENTC reduced BC6OTHER levels and BC6OTHER - regulated gene expression in lung AD cells, BC6ENTG expression increased anticancer activity of BC6OTHER .	False
Although treatment with BC6OTHER reduced BC6ENTG levels and BC6OTHER - regulated gene expression in lung AD cells, BC6OTHER expression increased anticancer activity of BC6ENTC .	False
Although treatment with BC6OTHER reduced BC6OTHER levels and BC6ENTG - regulated gene expression in lung AD cells, BC6OTHER expression increased anticancer activity of BC6ENTC .	False
Although treatment with BC6OTHER reduced BC6OTHER levels and BC6OTHER - regulated gene expression in lung AD cells, BC6ENTG expression increased anticancer activity of BC6ENTC .	False
In addition, BC6ENTC treatment reduced cell viability, BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER levels in BC6OTHER - expressing lung AD cells.	CPR:4
In addition, BC6ENTC treatment reduced cell viability, BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER levels in BC6OTHER - expressing lung AD cells.	CPR:4
In addition, BC6ENTC treatment reduced cell viability, BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER levels in BC6OTHER - expressing lung AD cells.	CPR:4
In addition, BC6ENTC treatment reduced cell viability, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER levels in BC6OTHER - expressing lung AD cells.	CPR:4
In addition, BC6ENTC treatment reduced cell viability, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG levels in BC6OTHER - expressing lung AD cells.	CPR:4
In addition, BC6ENTC treatment reduced cell viability, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER levels in BC6ENTG - expressing lung AD cells.	False
BC6ENTC : BC6OTHER oxidoreductase ( BC6ENTG ), which is regulated by BC6OTHER , was shown to increase anticancer activity of BC6OTHER in cells.	False
BC6ENTC : BC6OTHER oxidoreductase ( BC6OTHER ), which is regulated by BC6ENTG , was shown to increase anticancer activity of BC6OTHER in cells.	False
BC6OTHER : BC6ENTC oxidoreductase ( BC6ENTG ), which is regulated by BC6OTHER , was shown to increase anticancer activity of BC6OTHER in cells.	False
BC6OTHER : BC6ENTC oxidoreductase ( BC6OTHER ), which is regulated by BC6ENTG , was shown to increase anticancer activity of BC6OTHER in cells.	False
BC6ENTG ( BC6OTHER ), which is regulated by BC6OTHER , was shown to increase anticancer activity of BC6ENTC in cells.	False
BC6OTHER : BC6OTHER oxidoreductase ( BC6ENTG ), which is regulated by BC6OTHER , was shown to increase anticancer activity of BC6ENTC in cells.	False
BC6OTHER : BC6OTHER oxidoreductase ( BC6OTHER ), which is regulated by BC6ENTG , was shown to increase anticancer activity of BC6ENTC in cells.	False
Knockdown of BC6ENTG expression attenuated the reduction of cell cycle regulators by BC6ENTC treatment in BC6OTHER overexpressed cells.	False
Knockdown of BC6OTHER expression attenuated the reduction of cell cycle regulators by BC6ENTC treatment in BC6ENTG overexpressed cells.	False
We demonstrated that BC6ENTG protein not only functions as a downstream target of BC6ENTC , but also enhances anticancer activity of BC6OTHER in lung AD cells.	False
We demonstrated that BC6ENTG protein not only functions as a downstream target of BC6OTHER , but also enhances anticancer activity of BC6ENTC in lung AD cells.	False
Combination chemotherapy with a BC6ENTG antagonist ( BC6ENTC ) and BC6OTHER in a mouse model of human African trypanosomiasis.	CPR:6
Combination chemotherapy with a BC6ENTG antagonist ( BC6OTHER ) and BC6ENTC in a mouse model of human African trypanosomiasis.	CPR:6
In this study we investigated the effects of combination chemotherapy with BC6ENTC and a BC6ENTG antagonist BC6OTHER ( BC6OTHER ) in this mouse model.	False
In this study we investigated the effects of combination chemotherapy with BC6OTHER and a BC6ENTG antagonist BC6ENTC ( BC6OTHER ) in this mouse model.	CPR:6
In this study we investigated the effects of combination chemotherapy with BC6OTHER and a BC6ENTG antagonist BC6OTHER ( BC6ENTC ) in this mouse model.	CPR:6
The rate limiting enzyme of beta - oxidation ( BC6ENTG ) was significantly over - expressed in the liver with BC6ENTC treatment.	CPR:3
These results indicate that BC6ENTC suppresses body weight gain in mice, possibly at least related to the up - regulation of BC6ENTG gene expression.	CPR:3
 BC6ENTG polymorphisms and measures of impulsivity, aggression, and sensation seeking among African - American BC6ENTC - dependent individuals.	False
The findings do not seem to support an association between these polymorphisms in the BC6ENTG gene and impulsive - aggressive traits among BC6ENTC - dependent African - American individuals.	False
Considerable evidence indicates that serotonergic mechanisms, particularly the BC6OTHER transporter ( BC6ENTG ), may mediate central effects of BC6ENTC and may also be involved in impulsive and aggressive behavior.	False
Considerable evidence indicates that serotonergic mechanisms, particularly the BC6ENTG ( BC6OTHER ), may mediate central effects of BC6ENTC and may also be involved in impulsive and aggressive behavior.	False
We investigated whether polymorphisms in the BC6ENTG gene were related to traits of impulsivity, sensation seeking, and aggression among BC6ENTC abusers.	False
Two polymorphisms of the BC6ENTG gene were examined involving the 5' promoter ( BC6OTHER ) region and a 17 base pair BC6OTHER ( BC6OTHER ) marker among BC6ENTC patients.	False
Two polymorphisms of the BC6OTHER gene were examined involving the 5' promoter ( BC6ENTG ) region and a 17 base pair BC6OTHER ( BC6OTHER ) marker among BC6ENTC patients.	False
Two polymorphisms of the BC6OTHER gene were examined involving the 5' promoter ( BC6OTHER ) region and a 17 base pair BC6ENTG ( BC6OTHER ) marker among BC6ENTC patients.	False
Two polymorphisms of the BC6OTHER gene were examined involving the 5' promoter ( BC6OTHER ) region and a 17 base pair BC6OTHER ( BC6ENTG ) marker among BC6ENTC patients.	False
Considerable evidence indicates that serotonergic mechanisms, particularly the BC6ENTC transporter ( BC6ENTG ), may mediate central effects of BC6OTHER and may also be involved in impulsive and aggressive behavior.	False
However, other BC6ENTC , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6ENTG ( BC6OTHER ) and BC6OTHER .	False
However, other BC6ENTC , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6OTHER ( BC6ENTG ) and BC6OTHER .	False
However, other BC6ENTC , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6OTHER ( BC6OTHER ) and BC6ENTG .	False
However, other BC6OTHER , including BC6ENTC , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6ENTG ( BC6OTHER ) and BC6OTHER .	False
However, other BC6OTHER , including BC6ENTC , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6OTHER ( BC6ENTG ) and BC6OTHER .	False
However, other BC6OTHER , including BC6ENTC , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6OTHER ( BC6OTHER ) and BC6ENTG .	False
However, other BC6OTHER , including BC6OTHER , BC6ENTC and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6ENTG ( BC6OTHER ) and BC6OTHER .	False
However, other BC6OTHER , including BC6OTHER , BC6ENTC and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6OTHER ( BC6ENTG ) and BC6OTHER .	False
However, other BC6OTHER , including BC6OTHER , BC6ENTC and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6OTHER ( BC6OTHER ) and BC6ENTG .	False
However, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6ENTC , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6ENTG ( BC6OTHER ) and BC6OTHER .	False
However, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6ENTC , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6OTHER ( BC6ENTG ) and BC6OTHER .	False
However, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6ENTC , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6OTHER ( BC6OTHER ) and BC6ENTG .	False
However, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6ENTC and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6ENTG ( BC6OTHER ) and BC6OTHER .	False
However, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6ENTC and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6OTHER ( BC6ENTG ) and BC6OTHER .	False
However, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6ENTC and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6OTHER ( BC6OTHER ) and BC6ENTG .	False
However, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6ENTC group, also mediate physiological responses through binding to BC6ENTG ( BC6OTHER ) and BC6OTHER .	False
However, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6ENTC group, also mediate physiological responses through binding to BC6OTHER ( BC6ENTG ) and BC6OTHER .	False
However, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6ENTC group, also mediate physiological responses through binding to BC6OTHER ( BC6OTHER ) and BC6ENTG .	False
However, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6ENTC receptor - α ( BC6ENTG ) and BC6OTHER .	False
However, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6ENTC receptor - α ( BC6OTHER ) and BC6ENTG .	False
Moreover, selective BC6ENTC response modulators (SERMs) with diverse structures also regulate transcription of BC6ENTG and BC6OTHER .	False
Moreover, selective BC6ENTC response modulators (SERMs) with diverse structures also regulate transcription of BC6OTHER and BC6ENTG .	False
Further studies of the role of these BC6ENTC and SERMs in regulating responses mediated by BC6ENTG and BC6OTHER a variety of tissues, during different stages of development, are likely to uncover additional estrogenic activities.	False
Further studies of the role of these BC6ENTC and SERMs in regulating responses mediated by BC6OTHER and BC6ENTG a variety of tissues, during different stages of development, are likely to uncover additional estrogenic activities.	False
Crystal structures of E2 in the BC6ENTC receptor ( BC6ENTG ) confirm the importance of the A ring in stabilizing E2 in the BC6OTHER .	False
Crystal structures of E2 in the BC6ENTC receptor ( BC6OTHER ) confirm the importance of the A ring in stabilizing E2 in the BC6ENTG .	False
Ingestion of competitive inhibitors of BC6ENTG such as CHEM and BC6ENTC result in a similar but milder clinical phenotype.	CPR:4
At a pre - receptor level, glucocorticoid action is modulated by BC6ENTC dehydrogenases ( BC6ENTG ).	False
BC6ENTG activates BC6ENTC to BC6OTHER to facilitate BC6OTHER ( BC6OTHER ) - mediated action.	CPR:9
BC6OTHER activates BC6ENTC to BC6OTHER to facilitate BC6ENTG ( BC6OTHER ) - mediated action.	False
BC6OTHER activates BC6ENTC to BC6OTHER to facilitate BC6OTHER ( BC6ENTG ) - mediated action.	False
BC6ENTG activates BC6OTHER to BC6ENTC to facilitate BC6OTHER ( BC6OTHER ) - mediated action.	CPR:9
BC6OTHER activates BC6OTHER to BC6ENTC to facilitate BC6ENTG ( BC6OTHER ) - mediated action.	False
BC6OTHER activates BC6OTHER to BC6ENTC to facilitate BC6OTHER ( BC6ENTG ) - mediated action.	False
 By contrast, BC6ENTG plays a pivotal role in BC6ENTC target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6OTHER to BC6OTHER ) to prevent activation of the BC6OTHER ( BC6OTHER ) by BC6OTHER .	False
 By contrast, BC6OTHER plays a pivotal role in BC6ENTC target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6OTHER to BC6OTHER ) to prevent activation of the BC6ENTG ( BC6OTHER ) by BC6OTHER .	False
 By contrast, BC6OTHER plays a pivotal role in BC6ENTC target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6OTHER to BC6OTHER ) to prevent activation of the BC6OTHER ( BC6ENTG ) by BC6OTHER .	False
 By contrast, BC6ENTG plays a pivotal role in BC6OTHER target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6ENTC to BC6OTHER ) to prevent activation of the BC6OTHER ( BC6OTHER ) by BC6OTHER .	CPR:9
 By contrast, BC6OTHER plays a pivotal role in BC6OTHER target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6ENTC to BC6OTHER ) to prevent activation of the BC6ENTG ( BC6OTHER ) by BC6OTHER .	False
 By contrast, BC6OTHER plays a pivotal role in BC6OTHER target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6ENTC to BC6OTHER ) to prevent activation of the BC6OTHER ( BC6ENTG ) by BC6OTHER .	False
 By contrast, BC6ENTG plays a pivotal role in BC6OTHER target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6OTHER to BC6ENTC ) to prevent activation of the BC6OTHER ( BC6OTHER ) by BC6OTHER .	CPR:9
 By contrast, BC6OTHER plays a pivotal role in BC6OTHER target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6OTHER to BC6ENTC ) to prevent activation of the BC6ENTG ( BC6OTHER ) by BC6OTHER .	False
 By contrast, BC6OTHER plays a pivotal role in BC6OTHER target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6OTHER to BC6ENTC ) to prevent activation of the BC6OTHER ( BC6ENTG ) by BC6OTHER .	False
 By contrast, BC6ENTG plays a pivotal role in BC6OTHER target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6OTHER to BC6OTHER ) to prevent activation of the BC6OTHER ( BC6OTHER ) by BC6ENTC .	False
 By contrast, BC6OTHER plays a pivotal role in BC6OTHER target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6OTHER to BC6OTHER ) to prevent activation of the BC6ENTG ( BC6OTHER ) by BC6ENTC .	CPR:3
 By contrast, BC6OTHER plays a pivotal role in BC6OTHER target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6OTHER to BC6OTHER ) to prevent activation of the BC6OTHER ( BC6ENTG ) by BC6ENTC .	CPR:3
Mutations in the BC6ENTG gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which BC6ENTC activates the BC6OTHER resulting in severe hypertension and hypokalemia.	False
Mutations in the BC6OTHER gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which BC6ENTC activates the BC6ENTG resulting in severe hypertension and hypokalemia.	CPR:3
This manuscript presents the preclinical profile of BC6ENTC , a novel BC6ENTG ( BC6OTHER ) selective inhibitor.	CPR:4
This manuscript presents the preclinical profile of BC6ENTC , a novel BC6OTHER ( BC6ENTG ) selective inhibitor.	CPR:4
Ex vivo, BC6ENTC inhibited BC6ENTG - derived BC6OTHER ( BC6OTHER ) generation with an ID(50) of 33 mg kg( - 1), whereas BC6OTHER - derived production of BC6OTHER ( BC6OTHER ) in the lipopolysaccharide - stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg( - 1).	CPR:4
Ex vivo, BC6ENTC inhibited BC6OTHER - derived BC6OTHER ( BC6OTHER ) generation with an ID(50) of 33 mg kg( - 1), whereas BC6ENTG - derived production of BC6OTHER ( BC6OTHER ) in the lipopolysaccharide - stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg( - 1).	False
Ex vivo, BC6OTHER inhibited BC6ENTG - derived BC6ENTC ( BC6OTHER ) generation with an ID(50) of 33 mg kg( - 1), whereas BC6OTHER - derived production of BC6OTHER ( BC6OTHER ) in the lipopolysaccharide - stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg( - 1).	CPR:9
Ex vivo, BC6OTHER inhibited BC6OTHER - derived BC6ENTC ( BC6OTHER ) generation with an ID(50) of 33 mg kg( - 1), whereas BC6ENTG - derived production of BC6OTHER ( BC6OTHER ) in the lipopolysaccharide - stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg( - 1).	False
Ex vivo, BC6OTHER inhibited BC6ENTG - derived BC6OTHER ( BC6ENTC ) generation with an ID(50) of 33 mg kg( - 1), whereas BC6OTHER - derived production of BC6OTHER ( BC6OTHER ) in the lipopolysaccharide - stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg( - 1).	CPR:9
Ex vivo, BC6OTHER inhibited BC6OTHER - derived BC6OTHER ( BC6ENTC ) generation with an ID(50) of 33 mg kg( - 1), whereas BC6ENTG - derived production of BC6OTHER ( BC6OTHER ) in the lipopolysaccharide - stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg( - 1).	False
Ex vivo, BC6OTHER inhibited BC6ENTG - derived BC6OTHER ( BC6OTHER ) generation with an ID(50) of 33 mg kg( - 1), whereas BC6OTHER - derived production of BC6ENTC ( BC6OTHER ) in the lipopolysaccharide - stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg( - 1).	False
Ex vivo, BC6OTHER inhibited BC6OTHER - derived BC6OTHER ( BC6OTHER ) generation with an ID(50) of 33 mg kg( - 1), whereas BC6ENTG - derived production of BC6ENTC ( BC6OTHER ) in the lipopolysaccharide - stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg( - 1).	CPR:9
Ex vivo, BC6OTHER inhibited BC6ENTG - derived BC6OTHER ( BC6OTHER ) generation with an ID(50) of 33 mg kg( - 1), whereas BC6OTHER - derived production of BC6OTHER ( BC6ENTC ) in the lipopolysaccharide - stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg( - 1).	False
Ex vivo, BC6OTHER inhibited BC6OTHER - derived BC6OTHER ( BC6OTHER ) generation with an ID(50) of 33 mg kg( - 1), whereas BC6ENTG - derived production of BC6OTHER ( BC6ENTC ) in the lipopolysaccharide - stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg( - 1).	CPR:9
Preclinical pharmacology of BC6ENTC : a novel selective inhibitor of BC6ENTG .	CPR:4
However, consistent with its low BC6ENTG inhibitory activity, BC6ENTC at a dose of 100 mg kg( - 1) orally caused no ulcers and was significantly less ulcerogenic than BC6OTHER (P<0.05).	CPR:4
BC6ENTC inhibited purified BC6ENTG and BC6OTHER with K(i) values of 3 and 0.06 microM, respectively.	CPR:4
BC6ENTC inhibited purified BC6OTHER and BC6ENTG with K(i) values of 3 and 0.06 microM, respectively.	CPR:4
However, consistent with its low BC6ENTG inhibitory activity, BC6OTHER at a dose of 100 mg kg( - 1) orally caused no ulcers and was significantly less ulcerogenic than BC6ENTC (P<0.05).	CPR:4
BC6ENTC is a highly selective BC6ENTG inhibitor with anti - inflammatory, analgesic and antipyretic activities comparable with BC6OTHER , the reference NSAID, but with much improved gastrointestinal safety.	CPR:4
BC6OTHER is a highly selective BC6ENTG inhibitor with anti - inflammatory, analgesic and antipyretic activities comparable with BC6ENTC , the reference NSAID, but with much improved gastrointestinal safety.	CPR:4
In cellular assays, BC6ENTC had an IC(50) of 0.14 microM in BC6ENTG - expressing dermal fibroblasts, but caused no inhibition of BC6OTHER at concentrations up to 30 microM (HEK 293 cells transfected with BC6OTHER ).	CPR:4
In cellular assays, BC6ENTC had an IC(50) of 0.14 microM in BC6OTHER - expressing dermal fibroblasts, but caused no inhibition of BC6ENTG at concentrations up to 30 microM (HEK 293 cells transfected with BC6OTHER ).	False
In cellular assays, BC6ENTC had an IC(50) of 0.14 microM in BC6OTHER - expressing dermal fibroblasts, but caused no inhibition of BC6OTHER at concentrations up to 30 microM (HEK 293 cells transfected with BC6ENTG ).	False
In a human whole blood assay, IC(50) values for BC6ENTC were 0.13 microM for BC6ENTG and 67 microM for BC6OTHER ( BC6OTHER / BC6OTHER selectivity ratio 515).	CPR:4
In a human whole blood assay, IC(50) values for BC6ENTC were 0.13 microM for BC6OTHER and 67 microM for BC6ENTG ( BC6OTHER / BC6OTHER selectivity ratio 515).	CPR:4
In a human whole blood assay, IC(50) values for BC6ENTC were 0.13 microM for BC6OTHER and 67 microM for BC6OTHER ( BC6ENTG / BC6OTHER selectivity ratio 515).	CPR:4
In a human whole blood assay, IC(50) values for BC6ENTC were 0.13 microM for BC6OTHER and 67 microM for BC6OTHER ( BC6OTHER / BC6ENTG selectivity ratio 515).	CPR:4
A series of BC6ENTC derivatives were synthesized and evaluated for BC6OTHER inhibition, BC6ENTG expression and suppression of cancer cell growth in vitro.	False
A series of BC6ENTC derivatives were synthesized and evaluated for BC6ENTG inhibition, BC6OTHER expression and suppression of cancer cell growth in vitro.	CPR:4
Structure - based design, synthesis and evaluation of novel BC6ENTC derivatives as BC6ENTG inhibitors and potential for cancer polypharmacology.	CPR:4
Immunocytochemical analyses and function were consistent with BC6ENTG localization to T - tubules intercalated with BC6ENTC and BC6OTHER in slow (soleus) and fast (extensor digitorum longus, EDL) muscles.	False
Immunocytochemical analyses and function were consistent with BC6OTHER localization to T - tubules intercalated with BC6ENTC and BC6ENTG in slow (soleus) and fast (extensor digitorum longus, EDL) muscles.	False
Immunocytochemical analyses and function were consistent with BC6ENTG localization to T - tubules intercalated with BC6OTHER and BC6ENTC receptors in slow (soleus) and fast (extensor digitorum longus, EDL) muscles.	False
During repetitive stimulation of skeletal muscle, extracellular BC6ENTC levels raise, activating BC6ENTG , increasing BC6OTHER influx, and enhancing contractile force, a response called potentiation.	CPR:3
Consistent with two BC6ENTC uptake pathways, induced uptake of BC6OTHER , a fluorescent BC6OTHER derivative, was decreased by inhibition of HCs or BC6ENTG ( BC6OTHER ), and blocked by dual blockade.	CPR:9
Consistent with two BC6ENTC uptake pathways, induced uptake of BC6OTHER , a fluorescent BC6OTHER derivative, was decreased by inhibition of HCs or BC6OTHER ( BC6ENTG ), and blocked by dual blockade.	CPR:9
Consistent with two BC6OTHER uptake pathways, induced uptake of BC6ENTC , a fluorescent BC6OTHER derivative, was decreased by inhibition of HCs or BC6ENTG ( BC6OTHER ), and blocked by dual blockade.	CPR:9
Consistent with two BC6OTHER uptake pathways, induced uptake of BC6ENTC , a fluorescent BC6OTHER derivative, was decreased by inhibition of HCs or BC6OTHER ( BC6ENTG ), and blocked by dual blockade.	CPR:9
Consistent with two BC6OTHER uptake pathways, induced uptake of BC6OTHER , a fluorescent BC6ENTC derivative, was decreased by inhibition of HCs or BC6ENTG ( BC6OTHER ), and blocked by dual blockade.	False
Consistent with two BC6OTHER uptake pathways, induced uptake of BC6OTHER , a fluorescent BC6ENTC derivative, was decreased by inhibition of HCs or BC6OTHER ( BC6ENTG ), and blocked by dual blockade.	False
Consistent with two BC6OTHER uptake pathways, induced uptake of BC6OTHER , a fluorescent BC6OTHER derivative, was decreased by inhibition of HCs or BC6ENTC transporter ( BC6ENTG ), and blocked by dual blockade.	False
BC6OTHER release, BC6ENTC uptake, and potentiation induced by repetitive electrical stimulation were blocked by HC blockers and did not occur in muscles of BC6ENTG knockout mice.	False
BC6ENTC release, BC6OTHER uptake, and potentiation induced by repetitive electrical stimulation were blocked by HC blockers and did not occur in muscles of BC6ENTG knockout mice.	False
The BC6ENTC required for potentiation of skeletal muscle contraction is released via BC6ENTG hemichannels.	CPR:9
During repetitive stimulation of skeletal muscle, extracellular BC6OTHER levels raise, activating BC6ENTG , increasing BC6ENTC influx, and enhancing contractile force, a response called potentiation.	False
MRS2179, a BC6ENTG blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles BC6ENTC activates BC6OTHER but not BC6OTHER .	False
MRS2179, a BC6OTHER blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles BC6ENTC activates BC6ENTG but not BC6OTHER .	CPR:3
MRS2179, a BC6OTHER blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles BC6ENTC activates BC6OTHER but not BC6ENTG .	False
Phosphorylation on BC6ENTC and BC6OTHER residues of BC6ENTG was increased during potentiation, possibly mediating HC opening.	False
Phosphorylation on BC6OTHER and BC6ENTC residues of BC6ENTG was increased during potentiation, possibly mediating HC opening.	False
Opening of BC6ENTG HCs during repetitive activation allows efflux of BC6ENTC , influx of BC6OTHER and possibly BC6OTHER too, which are required for potentiation of contraction.	CPR:9
Opening of BC6ENTG HCs during repetitive activation allows efflux of BC6OTHER , influx of BC6ENTC and possibly BC6OTHER too, which are required for potentiation of contraction.	CPR:9
Opening of BC6ENTG HCs during repetitive activation allows efflux of BC6OTHER , influx of BC6OTHER and possibly BC6ENTC too, which are required for potentiation of contraction.	CPR:9
We found that BC6ENTC appears to be released through BC6ENTG hemichannels ( BC6OTHER HCs).	False
We found that BC6ENTC appears to be released through BC6OTHER hemichannels ( BC6ENTG HCs).	False
Western blot analysis indicated that BC6ENTC inhibits the BC6ENTG / BC6OTHER / BC6OTHER pathway.	CPR:4
Western blot analysis indicated that BC6ENTC inhibits the BC6OTHER / BC6ENTG / BC6OTHER pathway.	CPR:4
Western blot analysis indicated that BC6ENTC inhibits the BC6OTHER / BC6OTHER / BC6ENTG pathway.	CPR:4
 BC6ENTC induces apoptosis through suppression of BC6ENTG signaling pathway in HL - 60 cells.	CPR:4
Taken together, our study suggested, for the first time, that the pro - apoptotic effects of BC6ENTC on HL - 60 cells were mediated through BC6ENTG signaling pathway.	False
BC6ENTG was administered to BC6ENTC - treated rats intraperitoneally at a dose of 300μg / kg / injection from day 8 to day 30 every other day.	False
After the animals were sacrificed on day 15 and 30, BC6ENTC levels, the protein expressions of BC6ENTG / BC6OTHER and BC6OTHER / BC6OTHER signaling, and histopathology in lung tissues were analyzed.	False
After the animals were sacrificed on day 15 and 30, BC6ENTC levels, the protein expressions of BC6OTHER / BC6ENTG and BC6OTHER / BC6OTHER signaling, and histopathology in lung tissues were analyzed.	False
After the animals were sacrificed on day 15 and 30, BC6ENTC levels, the protein expressions of BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER signaling, and histopathology in lung tissues were analyzed.	False
After the animals were sacrificed on day 15 and 30, BC6ENTC levels, the protein expressions of BC6OTHER / BC6OTHER and BC6OTHER / BC6ENTG signaling, and histopathology in lung tissues were analyzed.	False
The BC6ENTC contents in BC6ENTG treated groups were significantly lower than the BC6OTHER groups (P<0.05).	False
The BC6OTHER contents in BC6ENTG treated groups were significantly lower than the BC6ENTC groups (P<0.05).	False
 BC6ENTG inhibits BC6ENTC - induced pulmonary fibrosis in rats.	False
Histopathological results showed BC6ENTG could reduce the progression of BC6ENTC induced fibrosis.	False
Furthermore, the expression of BC6ENTG , a marker of BC6OTHER / BC6OTHER signaling, was significantly up - regulated in BC6OTHER treated groups (P<0.05) compared with the BC6ENTC groups.	False
Furthermore, the expression of BC6OTHER , a marker of BC6ENTG / BC6OTHER signaling, was significantly up - regulated in BC6OTHER treated groups (P<0.05) compared with the BC6ENTC groups.	False
Furthermore, the expression of BC6OTHER , a marker of BC6OTHER / BC6ENTG signaling, was significantly up - regulated in BC6OTHER treated groups (P<0.05) compared with the BC6ENTC groups.	False
Furthermore, the expression of BC6OTHER , a marker of BC6OTHER / BC6OTHER signaling, was significantly up - regulated in BC6ENTG treated groups (P<0.05) compared with the BC6ENTC groups.	False
On the contrary, the expression of BC6ENTG , a marker for BC6OTHER / BC6OTHER signaling, reduced significantly in BC6OTHER - treated groups compared with BC6ENTC groups (P<0.05).	False
On the contrary, the expression of BC6OTHER , a marker for BC6ENTG / BC6OTHER signaling, reduced significantly in BC6OTHER - treated groups compared with BC6ENTC groups (P<0.05).	False
On the contrary, the expression of BC6OTHER , a marker for BC6OTHER / BC6ENTG signaling, reduced significantly in BC6OTHER - treated groups compared with BC6ENTC groups (P<0.05).	False
On the contrary, the expression of BC6OTHER , a marker for BC6OTHER / BC6OTHER signaling, reduced significantly in BC6ENTG - treated groups compared with BC6ENTC groups (P<0.05).	False
In conclusion, the pulmonary fibrosis induced by BC6ENTC in rats was significantly reduced with the therapeutic treatment of BC6ENTG .	False
There is no study to investigate BC6ENTG 's role in the development of pulmonary fibrosis induced by BC6ENTC .	False
In the current study, we used the rat model to explore the potential antifibrotic role of BC6ENTG and its underlying mechanism in BC6ENTC - induced pulmonary fibrosis.	False
Control group received saline, BC6ENTC group received BC6OTHER and BC6ENTG treated group received BC6OTHER and BC6OTHER .	False
Control group received saline, BC6ENTC group received BC6OTHER and BC6OTHER treated group received BC6OTHER and BC6ENTG .	False
Control group received saline, BC6OTHER group received BC6ENTC and BC6ENTG treated group received BC6OTHER and BC6OTHER .	False
Control group received saline, BC6OTHER group received BC6ENTC and BC6OTHER treated group received BC6OTHER and BC6ENTG .	False
Control group received saline, BC6OTHER group received BC6OTHER and BC6ENTG treated group received BC6ENTC and BC6OTHER .	False
Control group received saline, BC6OTHER group received BC6OTHER and BC6OTHER treated group received BC6ENTC and BC6ENTG .	False
We have identified BC6ENTC ( BC6OTHER ) as a novel ZBG that is compatible with BC6ENTG inhibition.	CPR:4
We have identified BC6OTHER ( BC6ENTC ) as a novel ZBG that is compatible with BC6ENTG inhibition.	CPR:4
BC6ENTC inhibits BC6ENTG and BC6OTHER with an IC50 of 681 and 3675 nM, respectively.	CPR:4
BC6ENTC inhibits BC6OTHER and BC6ENTG with an IC50 of 681 and 3675 nM, respectively.	CPR:4
Small molecules bearing CHEM as the BC6ENTC binding group (ZBG) have been the most effective BC6ENTG inhibitors ( BC6OTHER i) to date.	CPR:4
Small molecules bearing CHEM as the BC6ENTC binding group (ZBG) have been the most effective BC6OTHER inhibitors ( BC6ENTG i) to date.	CPR:4
Remarkably, BC6ENTC gives no inhibition of BC6ENTG .	False
Subsequent optimization led to several novel BC6ENTC - based BC6ENTG i that are selective for BC6OTHER and BC6OTHER .	CPR:4
Subsequent optimization led to several novel BC6ENTC - based BC6OTHER i that are selective for BC6ENTG and BC6OTHER .	CPR:4
Subsequent optimization led to several novel BC6ENTC - based BC6OTHER i that are selective for BC6OTHER and BC6ENTG .	CPR:4
 BC6ENTC as Novel BC6OTHER Binding Group for Selective BC6ENTG Inhibition.	CPR:4
 BC6OTHER as Novel BC6ENTC Binding Group for Selective BC6ENTG Inhibition.	CPR:4
This 16.2 - fold (range, 5.5 - 47.9) displacement to the right of the BC6OTHER concentration - response curve by a selective BC6ENTG antagonist emphasizes the central role of BC6ENTC in the airways response to this nucleotide.	False
The effect of BC6ENTG antagonism with BC6ENTC on concentration - related BC6OTHER - induced bronchoconstriction in asthma.	CPR:6
The effect of BC6ENTG antagonism with BC6OTHER on concentration - related BC6ENTC - induced bronchoconstriction in asthma.	False
Selective BC6ENTG antagonists inhibit BC6OTHER ( BC6OTHER ) - induced bronchoconstriction by greater than 80% when expressed as a percentage inhibition of the FEV1 time - response curve following inhalation of the provocation concentration of BC6ENTC required to produce a 20% decrease in FEV1 from baseline (PC20).	False
Selective BC6ENTG antagonists inhibit BC6ENTC ( BC6OTHER ) - induced bronchoconstriction by greater than 80% when expressed as a percentage inhibition of the FEV1 time - response curve following inhalation of the provocation concentration of BC6OTHER required to produce a 20% decrease in FEV1 from baseline (PC20).	False
Selective BC6ENTG antagonists inhibit BC6OTHER ( BC6ENTC ) - induced bronchoconstriction by greater than 80% when expressed as a percentage inhibition of the FEV1 time - response curve following inhalation of the provocation concentration of BC6OTHER required to produce a 20% decrease in FEV1 from baseline (PC20).	False
This 16.2 - fold (range, 5.5 - 47.9) displacement to the right of the BC6ENTC concentration - response curve by a selective BC6ENTG antagonist emphasizes the central role of BC6OTHER in the airways response to this nucleotide.	False
We also rescued BC6ENTC - resistant clones using exogenous BC6ENTG without inhibitory phosphorylation sites, indicating that the mitotic surge of BC6OTHER activity is dispensable for cell proliferation.	False
We also rescued BC6ENTC - resistant clones using exogenous BC6OTHER without inhibitory phosphorylation sites, indicating that the mitotic surge of BC6ENTG activity is dispensable for cell proliferation.	False
The complexity of BC6ENTG regulation has made it difficult to determine whether these different roles require different thresholds of BC6OTHER activity and whether the surge of activity as inhibitory BC6ENTC are removed at mitotic onset is essential for cell proliferation.	False
The complexity of BC6OTHER regulation has made it difficult to determine whether these different roles require different thresholds of BC6ENTG activity and whether the surge of activity as inhibitory BC6ENTC are removed at mitotic onset is essential for cell proliferation.	False
We rescued cells lethally depleted of endogenous BC6ENTG with an exogenous BC6OTHER conferring sensitivity to one BC6ENTC analogue inhibitor ( BC6OTHER ) and resistance to another ( BC6OTHER ).	False
We rescued cells lethally depleted of endogenous BC6OTHER with an exogenous BC6ENTG conferring sensitivity to one BC6ENTC analogue inhibitor ( BC6OTHER ) and resistance to another ( BC6OTHER ).	False
We rescued cells lethally depleted of endogenous BC6ENTG with an exogenous BC6OTHER conferring sensitivity to one BC6OTHER analogue inhibitor ( BC6ENTC ) and resistance to another ( BC6OTHER ).	False
We rescued cells lethally depleted of endogenous BC6OTHER with an exogenous BC6ENTG conferring sensitivity to one BC6OTHER analogue inhibitor ( BC6ENTC ) and resistance to another ( BC6OTHER ).	False
We rescued cells lethally depleted of endogenous BC6ENTG with an exogenous BC6OTHER conferring sensitivity to one BC6OTHER analogue inhibitor ( BC6OTHER ) and resistance to another ( BC6ENTC ).	False
We rescued cells lethally depleted of endogenous BC6OTHER with an exogenous BC6ENTG conferring sensitivity to one BC6OTHER analogue inhibitor ( BC6OTHER ) and resistance to another ( BC6ENTC ).	False
At no BC6ENTC concentration was mitosis in rescued clones prevented without also inducing endoreduplication, suggesting that these two key roles for BC6ENTG are not simply controlled by different BC6OTHER activity thresholds.	False
At no BC6ENTC concentration was mitosis in rescued clones prevented without also inducing endoreduplication, suggesting that these two key roles for BC6OTHER are not simply controlled by different BC6ENTG activity thresholds.	False
On the other hand, peptides modified with BC6ENTC , apart from their moderate antioxytocic activity, turned out to be weak antagonists of the pressor response to BC6ENTG .	CPR:6
Design, synthesis and structure - activity relationship of new BC6ENTG analogues containing BC6ENTC derivatives in position 2.	False
In this study, we present the synthesis and pharmacological properties of new analogues of BC6ENTG modified in the BC6ENTC - terminal part of the molecule with BC6OTHER derivatives: BC6OTHER ( BC6OTHER ) and BC6OTHER .	False
In this study, we present the synthesis and pharmacological properties of new analogues of BC6ENTG modified in the BC6OTHER - terminal part of the molecule with BC6ENTC derivatives: BC6OTHER ( BC6OTHER ) and BC6OTHER .	False
In this study, we present the synthesis and pharmacological properties of new analogues of BC6ENTG modified in the BC6OTHER - terminal part of the molecule with BC6OTHER derivatives: BC6ENTC ( BC6OTHER ) and BC6OTHER .	False
In this study, we present the synthesis and pharmacological properties of new analogues of BC6ENTG modified in the BC6OTHER - terminal part of the molecule with BC6OTHER derivatives: BC6OTHER ( BC6ENTC ) and BC6OTHER .	False
In this study, we present the synthesis and pharmacological properties of new analogues of BC6ENTG modified in the BC6OTHER - terminal part of the molecule with BC6OTHER derivatives: BC6OTHER ( BC6OTHER ) and BC6ENTC .	False
Moreover, the effects of the BC6ENTG agonist BC6ENTC ( BC6OTHER ) - induced locomotor hypoactivity were significantly increased when BC6OTHER proteins were abundant.	CPR:5
Moreover, the effects of the BC6OTHER agonist BC6ENTC ( BC6OTHER ) - induced locomotor hypoactivity were significantly increased when BC6ENTG proteins were abundant.	CPR:5
Moreover, the effects of the BC6ENTG agonist BC6OTHER ( BC6ENTC ) - induced locomotor hypoactivity were significantly increased when BC6OTHER proteins were abundant.	CPR:5
Moreover, the effects of the BC6OTHER agonist BC6OTHER ( BC6ENTC ) - induced locomotor hypoactivity were significantly increased when BC6ENTG proteins were abundant.	CPR:5
The BC6ENTC D3 receptor ( BC6ENTG ) in the ventral striatum is thought to influence motivation and motor functions.	False
The transcription of BC6ENTG was enhanced by the BC6ENTC - related orphan receptor α ( BC6OTHER ), and its activation was inhibited by the BC6OTHER BC6OTHER , an endogenous antagonist of BC6OTHER .	False
The transcription of BC6OTHER was enhanced by the BC6ENTC - related orphan receptor α ( BC6ENTG ), and its activation was inhibited by the BC6OTHER BC6OTHER , an endogenous antagonist of BC6OTHER .	False
The transcription of BC6OTHER was enhanced by the BC6ENTC - related orphan receptor α ( BC6OTHER ), and its activation was inhibited by the BC6ENTG BC6OTHER , an endogenous antagonist of BC6OTHER .	False
The transcription of BC6OTHER was enhanced by the BC6ENTC - related orphan receptor α ( BC6OTHER ), and its activation was inhibited by the BC6OTHER BC6ENTG , an endogenous antagonist of BC6OTHER .	False
The transcription of BC6OTHER was enhanced by the BC6ENTC - related orphan receptor α ( BC6OTHER ), and its activation was inhibited by the BC6OTHER BC6OTHER , an endogenous antagonist of BC6ENTG .	False
The serum or BC6ENTC - induced oscillation in the expression of BC6ENTG in cells was abrogated by the downregulation or overexpression of BC6OTHER , suggesting that BC6OTHER functions as a regulator of BC6OTHER oscillations in the cellular autonomous clock.	False
The serum or BC6ENTC - induced oscillation in the expression of BC6OTHER in cells was abrogated by the downregulation or overexpression of BC6ENTG , suggesting that BC6OTHER functions as a regulator of BC6OTHER oscillations in the cellular autonomous clock.	False
The serum or BC6ENTC - induced oscillation in the expression of BC6OTHER in cells was abrogated by the downregulation or overexpression of BC6OTHER , suggesting that BC6ENTG functions as a regulator of BC6OTHER oscillations in the cellular autonomous clock.	False
The serum or BC6ENTC - induced oscillation in the expression of BC6OTHER in cells was abrogated by the downregulation or overexpression of BC6OTHER , suggesting that BC6OTHER functions as a regulator of BC6ENTG oscillations in the cellular autonomous clock.	False
